[
    "The sample is a clinical trial for HIV-infected individuals with lipoatrophy in at least two areas of their body. The trial is in phase 2/phase 3 and involves the drugs NucleomaxX and NucleomaxX placebo. The eligibility criteria include having a stable ART regimen containing zidovudine or stavudine for at least 12 consecutive weeks prior to study entry, a viral load of 5,000 copies/ml or less within 45 days prior to study entry, and not planning to add or change current vitamin supplementation. Exclusion criteria include having a life expectancy of less than 12 months, currently enrolled in or planning to enroll in an ART interruption study, and having certain abnormal laboratory values. Participants must also be willing to use acceptable forms of contraception.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the corresponding ICD-10 codes, the drugs being used, and the eligibility criteria for patients to participate in the trial. In this particular sample, the trial is in phase 2/phase 3 and is studying three types of cancer: extrahepatic bile duct cancer, gallbladder cancer, and liver cancer. The drugs being used are cisplatin, gemcitabine hydrochloride, and oxaliplatin. The eligibility criteria include a diagnosis of cancer of the biliary tract, unresectable disease, amenable to radiotherapy, and no visceral metastases by imaging, among other requirements. Prior concurrent therapy is also listed as a factor in eligibility.",
    "The sample is a clinical trial for type 2 diabetes, in which the participants are divided into two groups: one receiving the drug dapagliflozin and the other receiving a placebo. The trial is in phase 2/phase 3 and the eligibility criteria include having inadequate glycemic control, receiving insulin and metformin and/or a thiazolidinedione, having a body mass index of 45.0 kg/m2 or less, and having a serum creatinine level below a certain threshold. The exclusion criteria include having type 1 diabetes, elevated levels of certain enzymes, symptoms of severely uncontrolled diabetes, and various other medical conditions.",
    "The sample is a clinical trial for esophageal cancer and adenocarcinoma patients in phase 2/phase 3. The trial involves the use of nimotuzumab, cisplatin, and fluorouracil drugs. The eligibility criteria include being over 18 years old, having histological proof of SCC or esophageal adenocarcinoma, having a life expectancy of over 6 months, and having inoperable superior, medial, or distal third esophageal cancer. Other criteria include having a performance status of 0, 1, or 2, adequate body functions, and adequate calorie ingestion. Exclusion criteria include previous or planned treatment of esophageal carcinoma with surgery, radiotherapy, chemotherapy, or antineoplastic biological therapy, presence of active infection, and pregnancy or lactation.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of generalized anxiety disorder in women between the ages of 18-65. The trial involves the use of three drugs: pexacerfont, escitalopram, and placebo. The eligibility criteria for the trial include meeting the DSM-IV TR criteria for GAD and having either moderate or severe symptoms. The exclusion criteria include being male and having a history of inadequate response to three or more adequate trials of any selective Serotonin reuptake inhibitors (SSRIs) for GAD within the last three years.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the treatment of idiopathic pulmonary fibrosis, a disease with the ICD-10 code J84.112. The trial involves the use of the drugs bosentan and placebo. The eligibility criteria for the trial include being over 18 years old, having a proven diagnosis of IPF within the last 3 years, having a six-minute walk test distance of at least 150 meters but less than 500 meters, and not having certain medical conditions or taking certain medications. The sample also includes a list of exclusion criteria, such as having severe concomitant illness limiting life expectancy, having severe restrictive or obstructive lung disease, or having a recent pulmonary or upper respiratory track infection.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on HIV infections. The trial includes patients who are HIV-1 infected adults with a CD4 count greater than 250 cells/mm3, not currently receiving HIV antiretroviral therapy for more than 6 months or are na\u00efve, and have a viral load greater than 3000 RNA copies/mL. The trial excludes patients with prior retinal eye disease, CD4 count less than 250 cells/\u00b5L, renal failure, active malignancy, corticosteroid therapy, and patients who are either under 18 or over 65 years of age. The trial involves the use of chloroquine phosphate and placebo as drugs.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying the effects of tonapofylline and placebo on patients with renal insufficiency and congestive heart failure. The eligibility criteria for participants include having a previous diagnosis of heart failure and requiring hospitalization for acute decompensated heart failure with clinical evidence of volume overload. There are also exclusion criteria listed, such as a history of allergic reactions to xanthine-containing substances, stroke, or myocardial infarction, and participation in any other investigational study of drugs or devices within 30 days prior to screening.",
    "The sample is a clinical trial for breast cancer patients in phase 2/phase 3. The trial involves the use of two drugs, capecitabine and vinorelbine tartrate. The eligibility criteria include having metastatic breast cancer, prior treatment with taxanes, and no CNS metastases. Patients must also meet certain age, sex, and performance status requirements, as well as have certain hematopoietic, hepatic, renal, and cardiovascular levels within normal ranges. Patients must not be pregnant or nursing, and must not have any pre-existing grade 2 or greater neurotoxicity. The trial also has restrictions on concurrent therapies, including no more than 2 prior chemotherapy lines for metastatic disease and no concurrent biologic therapy or radiotherapy.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 2 diabetes mellitus), the ICD-10 codes associated with the disease, the drugs being used in the trial (alogliptin and glimepiride), and the eligibility criteria for participants. The eligibility criteria include requirements such as having taken a sulfonylurea for at least 4 weeks prior to the observation period, having a glycosylated hemoglobin (HbA1c) level between 7.0% and 10.0%, and receiving specific diet and exercise therapies during the observation period. The exclusion criteria include having taken other diabetic medications besides glimepiride within 12 weeks before the treatment period.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on HIV infections and the associated diseases and icd-10 codes. The drugs being tested include a combination of nrtis, nnrtis, and pis. The eligibility criteria for participants include being HIV infected, not having previously received HAART or anti-HIV drugs for less than 56 consecutive days after birth, and being willing to use acceptable methods of contraception. Exclusion criteria include having grade 3 or 4 clinical or laboratory toxicity, active opportunistic infection or serious bacterial infection, and pancreas, nervous system, blood, liver, or kidney problems that make it impossible to take study medications. Participants cannot be taking any medication that cannot be combined with the study medications in first-line therapy, cannot have received therapy for cancer, and cannot be pregnant or breastfeeding.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on treating patients with colorectal carcinoma and liver metastases. The trial involves the use of drugs such as folfox6 and bevacizumab, and the eligibility criteria include having confirmed adenocarcinoma of the colon or rectum, measurable CT evidence of liver metastases, and an ECOG performance status of 0-1. Exclusion criteria include evidence of ascites, cirrhosis, portal hypertension, and previous radiotherapy to the upper abdomen. The trial aims to assess the efficacy of the drugs in treating the specified conditions.",
    "The sample is a clinical trial that is in phase 2/phase 3 and focuses on cardiovascular disease, aging, endothelial dysfunction, and physical activity. The trial involves the drug alt-711 and has a list of inclusion and exclusion criteria. The inclusion criteria include healthy sedentary elderly individuals who are 65 years or older. The exclusion criteria include individuals with cardiovascular or cerebrovascular disease, changes on ECG indicating cardiomyopathy or ischemia, diabetes mellitus, hypercholesterolemia, BMI greater than 33 kg/m2, and intensive exercise greater than 1 hour a week.",
    "The sample is a clinical trial for a drug called vr506 and a placebo for the treatment of asthma. The trial is in phase 2/phase 3 and the eligibility criteria include having a documented clinical history of asthma for at least 6 months, being between the ages of 12 and 65, having mild or moderate asthma, and being able to use the new inhaler and eDiary correctly. Exclusion criteria include having a history of lung cancer, HIV infection, or drug/alcohol abuse, as well as having any clinically significant abnormalities or findings that may compromise subject safety. The trial also requires subjects to comply with study procedures, including blood sampling, and to be available for all study visits.",
    "The sample is a clinical trial for lupus nephritis, a disease affecting the kidneys in patients with systemic lupus erythematosus. The trial is in phase 2/phase 3 and involves the drugs atacicept, mycophenolate mofetil, placebo, and corticosteroids. The eligibility criteria for the trial include a diagnosis of SLE satisfying at least 4 out of the 11 American College of Rheumatology criteria, and a renal biopsy consistent with active ISN/PRS class III or IV lupus nephritis. Exclusion criteria include a low estimated glomerular filtration rate, severe or progressive central nervous system SLE, recent treatment with certain drugs, and prior treatment with certain B cell modulating agents.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on deep venous thrombosis. The icd-10 codes associated with this disease are listed, as well as the drugs being tested (desirudin and heparin). The eligibility criteria for participants are also listed, including inclusion criteria such as being scheduled for elective cardiac or thoracic surgery and being over 18 years old, and exclusion criteria such as having a history of DVT/PE, requiring anticoagulation during the post-op period, or having a history of HIT.",
    "The sample is a clinical trial for patients with stage IIIB or IV non-small cell lung cancer. The trial is in phase 2/phase 3 and involves the use of the drugs vorinostat, paclitaxel, carboplatin, and placebo. The eligibility criteria include being at least 18 years old, having no prior systemic treatment for lung cancer except for adjuvant therapy at least 12 months prior, having adequate bone marrow, kidney, and liver function, and having an ECOG performance status of 0 or 1. Patients must also agree to use birth control during the study, and women able to have children must have a negative pregnancy test. Exclusion criteria include prior treatment with investigational agents less than 4 weeks before study enrollment, pregnancy or nursing, HIV positivity, Hepatitis A, B, or C, inability to take study medication by mouth, untreated brain cancer, and eligibility for treatment with bevacizumab if it is available.",
    "The sample is a clinical trial for phase 2/phase 3 of lymphoma treatment. The trial is looking for patients with diffuse large B-cell or peripheral T-cell non-Hodgkin's lymphoma who have not received prior treatment and do not have cerebral or meningeal involvement. Patients must have at least one measurable target lesion and meet certain criteria for age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other factors. Patients must also not have a history of concurrent severe disease or other malignancies, and must not be participating in another investigational drug study or taking other concurrent antineoplastic agents. The trial does not specify any particular biologic, chemotherapy, endocrine therapy, radiotherapy, or surgery treatments.",
    "The sample is a clinical trial for tobacco dependence, with a phase 2/phase 3 designation. The trial is looking at the effectiveness of the drugs s-adenosyl-l-methionine and s-adenosyl-l-methionine in helping individuals quit smoking. The eligibility criteria include being at least 18 years old, having smoked more than 10 cigarettes per day for at least 6 months, being willing to make a quit attempt, and being in good health as determined by the physician investigator. There are also exclusion criteria, such as having clinically significant levels of depression or using other tobacco products besides cigarettes. The trial is looking for participants who have not used other treatments for tobacco dependence in the past 30 days and are not currently using an investigational drug or herbal product for tobacco abstinence. Additionally, participants must not have a recent history of alcohol or drug abuse, must not be pregnant or lactating, and must not have a known allergy to SAMe.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (cerebrovascular accident), the ICD-10 codes associated with the disease, the drug being tested (ono-2506), and the eligibility criteria for participants. The eligibility criteria include requirements such as a clinical diagnosis of acute cortical ischemic stroke, a measurable focal neurological deficit for at least 60 minutes, and a pre-stroke mRS scale score of 0 or 1. The exclusion criteria include factors such as a body weight over 125 kg, evidence of non-ischemic mechanisms on CT or MRI, and severe coexisting or terminal systemic disease.",
    "The sample is a clinical trial for a drug called Truvada, which is being tested for its effectiveness in treating patients with hepatitis B and HIV infections. The trial is in phase 2/phase 3 and the eligibility criteria include having a Karnofsky score above 80%, stable ARV treatment for at least 4 months, CD4 count above 200 per mm3, and ARN VIH below 10000 copies per ml. Patients must also have chronic hepatitis B with positive antigenaemia HBe and negative antiHBe, and positive DNA HBV before or under tenofovir treatment. Exclusion criteria include having HIV 2 infection, hepatitis C or D, opportunistic infection, alcohol consumption more than 50g/d, cirrhosis, pregnancy or plan of pregnancy, breastfeeding, immunosuppressive or modulating of the immune response treatment, and other Hepatitis B treatments than tenofovir, lamivudine or emtricitabine since 6 months. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the disease of dry eye and the icd-10 codes associated with it. The drug being tested is carboxymethylcellulose sodium and glycerin. The eligibility criteria for the trial includes having mild, moderate, or severe dry eye symptoms and currently using eye drops, as well as having reduced tear stability or production. There are no exclusion criteria listed for this particular sample.",
    "The sample is a record from a table that contains information about clinical trials. The record includes the phase of the trial, which is a combination of phase 2 and phase 3. The diseases being studied are type 2 diabetes and dyslipidemia, and their corresponding ICD-10 codes are listed. The drugs being tested are fenofibrate, metformin, and placebo. The eligibility criteria for the trial are also provided, including inclusion criteria for patients with type 2 diabetes and dyslipidemia, and exclusion criteria for patients with type 1 diabetes.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on Huntington's disease. The icd-10 code for Huntington's disease is 'G10'. The drugs being tested are minocycline and a matching placebo. The eligibility criteria for participants include being 18 years or older, having clinical features of HD and a confirmatory family history of HD, being able to walk independently and perform daily activities, and being able to take medication by mouth. Exclusion criteria include a history of hypersensitivity or intolerance to minocycline or any tetracycline, vestibular disease, underlying hematologic, hepatic or renal disease, and systemic lupus erythematosus (SLE).",
    "The sample is a clinical trial for the treatment of esophageal cancer in phase 2/phase 3. The trial is looking for patients with localized, nonmetastatic disease that is not suitable for surgery. The patients must meet certain criteria, including having a confirmed diagnosis of esophageal cancer, having a WHO performance status of 0-1, and meeting certain blood count and organ function requirements. Patients must not have had any prior treatment for invasive esophageal carcinoma or gastroesophageal junction carcinoma, and must not have any other prior treatment that would compromise the ability to deliver definitive mediastinal chemoradiotherapy or compromise survival. The trial will use the drugs capecitabine and cisplatin, and patients will be evaluated based on their response to treatment.",
    "The sample is a clinical trial for pancreatic cancer patients in phase 2/phase 3. The trial involves the use of five drugs: fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin. The eligibility criteria for patients include having histologically or cytologically confirmed adenocarcinoma of the pancreas with metastatic disease and measurable disease in an area not previously irradiated. Patients must also meet certain age, performance status, hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, and other medical criteria. Patients cannot have had prior chemotherapy or radiotherapy and cannot be concurrently participating in another clinical trial using therapeutic experimental agents.",
    "The sample is a clinical trial for a drug called indacaterol maleate, which is being tested for the treatment of pulmonary disease, chronic obstructive (COPD) and other obstructive lung diseases. The trial is in phase 2/phase 3 and involves patients aged 40-75 years with a smoking history of at least 10 pack years and symptoms such as cough, sputum production, and shortness of breath. The trial has inclusion criteria such as FEV1 less than 65% of the predicted normal value and at least 0.75 L, and pre-bronchodilator FEV1/FVC less than 70%. Exclusion criteria include a history of asthma or COPD diagnosis before the age of 40, hospitalization for COPD exacerbation within the previous 6 weeks, and use of long-term oxygen therapy. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a clinical trial for a drug called pioglitazone to treat endometriosis. The trial is in phase 2/phase 3 and the eligibility criteria include being a healthy woman between the ages of 18-45 with regular cycles and pelvic pain for at least 3 months. Participants must also have no prior use of hormonal therapy, no history of liver disease, and be scheduled for surgery to confirm the diagnosis of endometriosis. Exclusion criteria include major psychiatric conditions, liver dysfunction, pre-existing malignancy, and known pregnancy. The trial requires participants to consent to participate and to have their surgical specimen evaluated for endometriosis.",
    "The sample is a clinical trial for a drug that is being tested for the treatment of type 2 diabetes. The trial is in phase 2/phase 3 and involves the use of three drugs: rivoglitazone, pioglitazone, and placebo. The trial is looking for male or female patients between the ages of 18 and 75 who have type 2 diabetes and a HbA1c level between 7.5% and 10.5%. The trial has certain exclusion criteria, such as patients who are currently on insulin therapy or have a history of ketoacidosis or therapy with certain drugs. The trial's eligibility criteria are listed in detail under inclusion and exclusion criteria.",
    "The sample is a clinical trial for phase 2/phase 3 of a drug treatment for metastatic non-small cell lung cancer. The trial is for previously untreated patients with an ECOG performance status of 0-1 and normal liver function tests. The drug being tested is chemotherapy +/- disulfiram. The eligibility criteria include being over 18, willingness to abstain from alcohol, not being pregnant, and having no psychiatric history.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on treating multiple sclerosis. The trial involves the drug colecalciferol and has specific eligibility criteria for participants, including having a certain level of disability due to multiple sclerosis and having used the drug Betaferon for at least one month with a positive MxA-response. There are also exclusion criteria, such as having hypercalcaemia, kidney stones, uncontrolled hypertension, hypothyreosis, peanut allergy, severe depression, sarcoidosis, or using other IMD than interferon-beta.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease of arthritis, rheumatoid. The icd-10 codes associated with the disease are listed as well. The trial is testing two drugs, ce-224,535 and placebo. The eligibility criteria for the trial include having active rheumatoid arthritis and an incomplete response to methotrexate, while the exclusion criteria include not being on biologic therapies and having no recent infections.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on three different diseases: chronic myelogenous leukemia, malignant melanoma, and renal cell carcinoma. The diseases are identified by their corresponding ICD-10 codes. The trial is testing two drugs: pegylated interferon alfa-2a and recombinant interferon alfa 2a. The eligibility criteria for participants are listed, including requirements for previous participation in related trials and confirmed response to treatment. There are also exclusion criteria, such as pregnancy or refusal to use adequate contraception.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation, focused on breast neoplasm. The trial involves the use of two different drug combinations, paclitaxel weekly in combination with capecitabine and docetaxel every 3 weeks in combination with capecitabine. The eligibility criteria for the trial include having morphologically proven breast carcinoma, measurable and/or evaluable disease, age 18 years or older, ECOG Performance Status 0-2, and adequate cardiac, hematological, renal, and hepatic functions. Exclusion criteria include having a recurrence-free interval of less than one year if previous adjuvant or neoadjuvant regimen contained a taxane, having a neoplasm other than breast carcinoma, pregnancy or lactation, known brain metastases, preexisting motor or sensory neuropathy \u2265 grade 2, severe hepatic or renal impairment, history of known dihydropyrimidine dehydrogenase (DPD) deficiency, active infection or other serious underlying medical condition, and dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent.",
    "The sample is a clinical trial for a drug called ads-5102, which is being tested for its effectiveness in treating dyskinesia in patients with Parkinson's disease. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The inclusion criteria include having a diagnosis of Parkinson's disease, experiencing troublesome dyskinesia following levodopa dosing, and being able to complete a standardized PD home diary. The exclusion criteria include a history of neurosurgical intervention related to Parkinson's disease, cognitive impairment, and treatment with an investigational drug or device within 30 days prior to screening.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular trial, the phase is a combination of phase 2 and phase 3, and the diseases being studied are gastroesophageal reflux and asthma. The associated ICD-10 codes for these diseases are also listed. The drugs being tested are lansoprazole and placebo. The eligibility criteria for participants include both inclusion and exclusion criteria, such as having chronic cough consistent with bronchoreactivity and gastroesophageal reflux as inclusion criteria, and severe asthmatics who have been hospitalized within the last 6 months or who have required oral steroid use within the last 4 weeks as exclusion criteria.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and focuses on the disease of venous thromboembolism. The trial includes patients who are at least 18 years old and have been admitted to San Francisco General Hospital for injury with at least one risk factor for VTE. The risk factors include age \u2265 40 years, pelvic fracture, lower extremity fracture, spinal cord injury, shock or head injury, major operative procedure, mechanical ventilation > 3 days, and venous injury. The trial excludes prisoners, pregnant patients, patients who are anticipated to have a < 5 day length of stay as determined by the admitting trauma surgeon, and patients who decline to participate in the study. The trial involves the drug fondaparinux sodium.",
    "The sample is a clinical trial with a phase 2/phase 3 designation, focused on Alzheimer's disease and using the drug talsaclidine. The eligibility criteria for participants include having completed a preceding talsaclidine trial within the last four weeks with adequate compliance, being able to understand and provide written informed consent, having a caregiver willing to provide trial-related information, and meeting certain physical and medical requirements. Exclusion criteria include certain medical conditions, drug-related adverse events, and insufficient compliance. The trial also excludes patients using certain medications and undergoing certain therapies.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on systemic lupus erythematosus. The icd-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including the requirement that they meet at least 4 of the 11 classification criteria for systemic lupus erythematosus and have had a renal biopsy indicating active proliferative lupus glomerulonephritis within the past 12 months. There are also exclusion criteria listed, such as a rise in serum creatinine within 1 month prior to the screening visit and having received treatment with cyclophosphamide within 3 months of randomization.",
    "The sample is a clinical trial for a drug called memantine, which is being tested for its effectiveness in treating cognitive dysfunction in patients with multiple sclerosis. The trial is in phase 2/phase 3 and includes patients with relapsing-remitting, secondary progressive, and primary progressive forms of MS who are between the ages of 18 and 65. The trial also has a list of inclusion and exclusion criteria, such as a history of major depression or pregnancy, that determine whether a patient is eligible to participate. The diseases being studied include multiple sclerosis and cognition disorders, and the icd-10 codes associated with these diseases are also listed.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of allergic rhinoconjunctivitis, which is associated with a list of icd-10 codes. The trial involves two drugs, avanz phleum pratense and placebo. The eligibility criteria for the trial include a history of grass pollen allergy, positive skin prick test to grass, and positive Immunoglobulin E test to grass. The exclusion criteria include other allergies overlapping the grass pollen season and severe asthma with a Forced expiratory volume in 1 second (FEV1) below 70% after adequate treatment.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on cytomegalovirus infections and the icd-10 code associated with it is P35.1. The drug being tested is valganciclovir [valcyte]. The eligibility criteria for the trial includes patients between 3 months and 16 years of age who have undergone their first solid organ transplant and are able to tolerate oral medication. Females of childbearing potential must agree to use contraception throughout the study and for 90 days after discontinuing the study drug. Patients who are at risk of developing CMV disease are eligible for the trial, except for those who are D-R- for CMV. Exclusion criteria include patients who have previously participated in the study, those who are participating in another clinical trial (except with the approval of the Sponsor), those with severe, uncontrolled diarrhea (more than 5 watery stools per day), and pregnant or lactating females.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including common criteria for all participants and specific criteria for those completing the core phase 2/3 metformin add-on study. Exclusion criteria are also listed, including clinical manifestations of hepatic or renal impairment, serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (systemic lupus erythematosus), the ICD-10 codes associated with the disease, the drugs being tested (rituximab, placebo, prednisone, acetaminophen, and diphenhydramine), and the eligibility criteria for participants. The inclusion criteria include a diagnosis of SLE, active disease at screening, stable use of one immunosuppressive drug, use of an antimalarial drug, and reliable contraception for subjects of reproductive potential. The exclusion criteria include unstable patients with thrombocytopenia, active moderate to severe glomerulonephritis, and various other medical conditions that would preclude participation.",
    "The sample is a clinical trial for smoking cessation that is in phase 2/phase 3. The trial is focused on individuals who smoke an average of at least 10 cigarettes per day and are willing to take either Chantix or Zyban. The trial is open to Duke employees and their dependents who are enrolled in a Duke Health Plan and intend to remain employed at Duke for the next six months. The trial has a list of inclusion and exclusion criteria that participants must meet. The inclusion criteria include being between 18-65 years old and expressing a desire to quit smoking within the next 30 days. The exclusion criteria include having certain medical conditions, such as hypertension, coronary heart disease, or diabetes treated with insulin, as well as having a history of certain psychiatric conditions or adverse reactions to smoking cessation aids.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on studying allergy. The associated ICD-10 codes for the disease are listed, as well as the drugs being tested, which include a salbutamol inhaler, budesonide/formoterol inhaler, prednisone tablet, desloratadine tablet, and budesonide nasal spray. The eligibility criteria for participants are also listed, including requirements such as a clinical history of house dust mite induced persistent mild to moderate asthma, a positive specific serum IgE test to Dermatophagoides, and willingness to comply with the trial protocol regimen for asthma and/or rhinoconjunctivitis medication. There are also exclusion criteria listed, such as having a mental condition rendering the subject unable to understand the nature of the trial or evidence of an uncooperative attitude.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease of hypertension. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, which are irbesartan and atenolol. The eligibility criteria for participants include being at least 18 years old, having a seated blood pressure diastolic between 90-115 mm Hg, and having a left ventricular mass above a certain threshold. There are also exclusion criteria, such as having significant cardiac or renal disease, drug or alcohol abuse, and uncontrolled diabetes mellitus. The sample includes both inclusion and exclusion criteria for potential participants.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 2/phase 3 and is studying non-small cell lung cancer. The drugs being used are carboplatin, cediranib maleate, and paclitaxel. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. The criteria specify that patients must have histologically or cytologically confirmed non-small cell lung cancer, measurable disease, and meet certain performance and health status requirements. Additionally, patients must not have certain medical conditions or have received certain prior treatments.",
    "The sample is a clinical trial for a drug treatment for chronic sinusitis and nasal polyps. The trial is in phase 2/phase 3 and the table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include requirements such as a confirmed diagnosis of chronic sinusitis, previous surgery, and recurrent sinus obstruction due to polyposis. Patients must also be able to tolerate the use of Nasonex topical intranasal steroid spray and the implant procedure. There are also exclusion criteria, such as recent surgery or evidence of disease that could compromise survival or follow-up assessments. The trial is also excluding patients with certain ocular conditions.",
    "The sample is a clinical trial for acute myeloid leukemia, in phase 2/phase 3. The trial includes patients between the ages of 18-60 who have newly diagnosed AML, excluding acute promyelocytic leukemia. The trial involves the use of drugs such as cytarabine, idarubicin, etoposide, all-trans retinoic acid, and pegfilgrastim. The eligibility criteria include written informed consent, molecular and cytogenetical diagnostics, and exclusion criteria such as bleeding independent of AML, uncontrollable infection, and severe neurological or psychiatric disorder interfering with ability to give informed consent. The trial also excludes patients with insufficiency of the kidneys, liver, severe obstructive or restrictive ventilation disorder, heart failure New York Heart Association (NYHA) III/IV, and those who do not consent for registration, storage, and processing of individual disease-characteristics and course. Additionally, patients with a performance status WHO > 2 and pregnancy are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, atrial flutter), the corresponding ICD-10 codes, the drug being tested (vernakalant injection 20 mg/ml), and the eligibility criteria for participants. The phase of the trial is listed as phase 2/phase 3, indicating that it is in the later stages of testing. The inclusion criteria specify that participants must be 18 years or older, have an atrial arrhythmia with dysrhythmic symptoms lasting between 3 hours and 45 days, and have adequate anticoagulant therapy. The exclusion criteria include having a QRS > 0.14 s or uncorrected QT > 0.440 seconds on a 12-lead ECG, participating in another drug study or having received an investigational drug within 30 days prior to enrollment, having serious diseases/illnesses that could interfere with the study or compromise patient safety, and having received certain IV antiarrhythmic drugs within 24 hours prior to dosing.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on lung cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being used in the trial. The eligibility criteria for participants are also listed, including disease characteristics, patient characteristics, and prior concurrent therapy. The criteria specify that patients must have histologically or cytologically confirmed stage I-III non-small cell lung cancer that is inoperable or that the patient refuses surgery, and that the disease can be encompassed within the radical radiotherapy treatment volume. Additionally, patients must meet certain performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and pulmonary criteria, and must not have certain prior concurrent therapies.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a trial for nicotine dependence and is in phase 2/phase 3. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria for this trial include being between the ages of 14-18, smoking at least 10 cigarettes per day, and having made at least one quit attempt in the previous 6 months. The exclusion criteria include having a current DSM-IV disorder, daily or heavy use of drugs, a positive pregnancy test, currently taking certain medications, currently on NRT, or currently receiving formal treatment for substance abuse, depression, or anxiety.",
    "The sample is a clinical trial for phase 2/phase 3 that involves patients with colorectal cancer and liver metastases, who are also undergoing chemotherapy. The trial includes a list of ICD-10 codes for the diseases, a list of drug names, and eligibility criteria for the patients. The eligibility criteria include having histologically proven adenocarcinoma of the colon or rectum without previous resection, hepatic unresectable metastases, and not optimally resectable metastases. The patients must also have a WHO performance status of 0-1 and a life expectancy of equal or more than 3 months. Adjuvant chemotherapy is allowed, except for oxaliplatin and irinotecan based combination. The exclusion criteria are not specified in the sample.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 2 diabetes mellitus), the corresponding ICD-10 codes, the drugs being tested (alogliptin and metformin), and the eligibility criteria for participants. The eligibility criteria include requirements such as having a stable dose of metformin for at least 12 weeks prior to the trial, having a certain level of glycosylated hemoglobin (HbA1c), and not having a history or symptoms of lactic acidosis. The sample is from a phase 2/phase 3 trial.",
    "The sample is a clinical trial that is in phase 2/phase 3 and focuses on patients with diabetes mellitus, heart failure, and coronary artery disease. The trial involves the use of the drugs telmisartan and bisoprolol, as well as a placebo. The eligibility criteria for the trial include being over 18 years old, having known diabetes mellitus for more than 6 months, and having an increased Nt-proBNP level above 125pg/ml. Exclusion criteria include having a life expectancy below 1 year due to a disease other than diabetes, suffering from chronic infection or malignant disease, being a woman of childbearing age without contraceptive, having a history of cardiac disease, being on systemic cortisone treatment, and being on chronic or acute hemodialysis, ultra filtration or peritoneal dialysis.",
    "The sample is a clinical trial for patients with primary progressive multiple sclerosis. The trial is in phase 2/phase 3 and involves the use of rituximab and a placebo. The eligibility criteria include having a definitive diagnosis of PPMS, a disease duration of at least 1 year, and an EDSS score between 2.0 and 6.5 points. In addition, patients must have a score of at least 2.0 on the Functional Systems (FS) scale for the pyramidal system or gait that is due to lower extremity findings. Patients must also have at least one of the specified CSF specimen results and use reliable contraception during the study treatment and for 1 year following the last dose of study drug. Exclusion criteria include pregnancy or lactation, incompatibility with MRI, history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, and known active bacterial, viral, fungal, mycobacterial, or other infection. Other exclusion criteria include history of cancer, alcohol or drug abuse within 6 months prior to screening, and significant cardiac or pulmonary disease. The trial is expected to last approximately 2.5 years.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on treating depressive disorder, major using the drug sertraline. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include having a diagnosis of depressive disorder, major and a HDRS score greater than 18. Exclusion criteria include having other axis I disorders, any axis II disorders, any serious/life-threatening axis III disorders, and neurological diseases such as stroke or dementia. The icd-10 codes associated with the disease are also listed.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on patients undergoing cardiac surgery with the use of cardiopulmonary bypass. The trial aims to identify the risk factors for postoperative acute kidney injury (AKI) in these patients. The trial includes patients who are over 18 years of age and have at least one risk factor for postoperative AKI. The trial excludes patients who have emergency operations, are pregnant or breastfeeding, have a renal allograft, have preoperative acute renal failure within 6 weeks, have pre-operative end-stage renal disease, or are on chronic moderate to high dose corticosteroid therapy. The trial involves the use of sodium bicarbonate and sodium chloride as drugs. The diseases being studied are cardiac surgery and cardiopulmonary bypass, and the ICD-10 codes associated with these diseases are also included in the table.",
    "The sample is a record of a clinical trial for the treatment of advanced gastric adenocarcinoma. The trial is in phase 2/phase 3 and involves the use of two drugs, s-1 + irinotecan and irinotecan. The eligibility criteria for the trial include having a confirmed diagnosis of inoperable advanced gastric adenocarcinoma or relapse gastric adenocarcinoma, being able to take medication orally, and having a confirmed status of progressive disease after first-line chemotherapy using S-1 alone, S-1 + Cisplatinum or S-1 + taxane, except S-1 + CPT-11. The trial also has exclusion criteria, such as having a history of hypersensitivity to fluoropyrimidines and CPT-11, being pregnant or lactating, and having gastrointestinal bleeding. The sample includes additional details about the eligibility and exclusion criteria, as well as the drugs and diseases involved in the trial.",
    "The sample is a clinical trial for a drug to treat excessive daytime somnolence in patients with Parkinson's disease. The trial is in phase 2/phase 3 and involves the use of caffeine and a placebo. The eligibility criteria include a diagnosis of idiopathic PD and excessive daytime somnolence, while exclusion criteria include certain medical conditions and medication use. The trial also requires that participants have not made changes to their antiparkinsonian medication in the last 3 months or anticipate changes during the study protocol.",
    "The sample is a clinical trial for lupus erythematosus, systemic and lupus nephritis, in which the participants are divided into two groups: one receiving infliximab and the other receiving a placebo. The trial is in phase 2/phase 3 and the eligibility criteria include having SLE with biopsy-proven membranous glomerulonephritis, proteinuria greater than 3 g/day despite adequate therapy with ACE inhibitors and steroids, and meeting certain laboratory test results. Exclusion criteria include having active WHO class IV SLE nephritis, treatment with certain medications within a certain time frame, and having certain medical conditions or histories. The trial also requires participants to use adequate birth control measures and to have a negative tuberculin skin test or have received appropriate treatment for latent TB.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on two diseases, sarcoidosis and pulmonary arterial hypertension, and their corresponding ICD-10 codes. The trial involves the use of two drugs, bosentan and placebo. The eligibility criteria for the trial include patients with known sarcoidosis, age 18 or greater, documented pulmonary hypertension with a PA mean > 25 mm Hg, WHO class II or III, and a six-minute walk distance of between 100 to 500 meters. Patients on stable immunotherapy for their sarcoidosis are also eligible. Exclusion criteria include patients on pulmonary vasodilator drugs, severe airway obstruction, WHO class IV status, pregnancy or breastfeeding, significant left ventricular dysfunction, cardiac index < 2.0 liters and/or right atrial pressure >15 mm Hg, significant liver dysfunction not due to sarcoidosis, severe other organ disease, and patients unable to perform the 6 minute walk study.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (multiple sclerosis), the ICD-10 codes associated with the disease (G35 and C81.18), the drug being tested (mycophenolate mofetil), and the eligibility criteria for participants. The inclusion criteria include being between the ages of 21-45, having clinically definite or laboratory-supported definite relapsing MS of less than or equal to two years in duration, and having had at least one exacerbation in the preceding two years. The exclusion criteria include having primary progressive, secondary progressive, or progressive relapsing MS, having used corticosteroids or plasma exchange within a certain timeframe, having no prior exposure to total lymphoid irradiation or certain immunomodulatory drugs, having had a clinical relapse within a certain timeframe, being pregnant or breastfeeding, having major medical illnesses or cognitive impairment, needing to remain on contraindicated medication, being diabetic, being unable to undergo an MRI scan, being on an intravenous immunoglobulin protocol, or being HIV+ or RPR+. Females of childbearing age who have not undergone a sterilization procedure must be willing to practice effective birth control.",
    "The sample is a clinical trial for patients with major depressive disorder in phase 2/phase 3. The trial includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include patients who have a diagnosis of major depressive episode, have reported an inadequate response to 1 and no more than 1 adequate SSRI or SNRI treatment, have a 17-item Hamilton Rating Scale for Depression score \u2265 18, and have a Body Mass Index of approximately 18-40. The trial also includes exclusion criteria such as patients with unstable medical illness, evidence or history of significant neurological disorder, and patients who demonstrate less than 80% compliance of their antidepressant medication during the Screening Phase.",
    "The sample is a record of a clinical trial for metastatic colorectal cancer. The trial is in phase 2/phase 3 and involves testing two drugs, cmab009 plus irinotecan and irinotecan-only, sequentially with cmab009. The eligibility criteria for the trial include having histologically confirmed metastatic colorectal adenocarcinoma, KRAS wild-type tumors, measurable lesions, and an ECOG performance status of 0 to 1. The exclusion criteria include previous irinotecan or anti-EGFR therapies, abnormal hematologic, liver, or renal function, and symptomatic central nervous system metastases. The diseases are listed as metastatic colorectal cancer, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a clinical trial for the treatment of benign prostatic hyperplasia, a condition that causes lower urinary tract symptoms in males aged 45 years or older. The trial is in phase 2/phase 3 and involves the use of the drug tadalafil and a placebo. The eligibility criteria include having an International Prostate Symptom Score (IPSS) greater than or equal to 13, not using any approved or experimental treatments for benign prostatic hyperplasia or erectile dysfunction during the study, and not having taken certain medications for a specified duration of time prior to the study. The exclusion criteria include a history of urinary retention or lower urinary tract stones, bladder outlet obstruction, certain cardiac or neurological conditions, and nitrate use.",
    "The sample is a clinical trial for a drug called vortioxetine and placebo for the treatment of Major Depressive Disorder. The trial is in phase 2/phase 3 and the diseases being studied are limited to depressive disorder, major. The icd-10 codes associated with the disease are also provided. The eligibility criteria for the trial are listed, including the requirement that participants have a Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score of at least 26 and a Clinical Global Impression Scale-Severity (CGI-S) score of at least 4 at the Screening and Baseline Visits. The exclusion criteria are also listed, including the exclusion of participants with a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR. The sample also includes a list of the inclusion and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on treating multiple myeloma, CLL/SLL, non-Hodgkin's lymphoma, Waldenstroms, and mantle cell lymphoma. The trial involves the use of the drug fludarabine and has a set of inclusion and exclusion criteria for participants. Inclusion criteria include having stage II or III non-progressive disease multiple myeloma, being \u2264 70 years old, having an eligible and willing HLA matched related donor, and meeting certain health criteria such as having a minimum performance score of 70% and platelet count >130 x103 micro L. Exclusion criteria include being over 70 years old, having a performance status <70%, having uncontrolled infections or being HIV positive, and having a history of rapidly growing disease at diagnosis or at any progression or having MDS.",
    "The sample is a clinical trial for the treatment of hepatitis C and liver fibrosis using the drugs ribavirin and ribavirin-placebo. The trial is in phase 2/phase 3 and includes patients over 18 years old with a hepatitis C virus infection who have not responded to previous antiviral treatment. The patients must have an active chronic hepatitis C and a Metavir fibrosis score of at least 2, as well as serum ALT levels above the upper limit of the laboratory on two occasions within 6 months before inclusion. The trial has inclusion and exclusion criteria, including a negative pregnancy test for women, no history of hepatic complications or severe seizures, and no regular alcohol consumption. Patients must also be willing to undergo a liver biopsy at the end of the study and provide written informed consent.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying heart and liver transplantation as well as bone resorption. The icd-10 codes associated with these diseases are listed, as well as the drugs being tested (zoledronic acid and alendronate). The eligibility criteria for participants are also listed, including age range, exclusion criteria such as hyperparathyroidism and cancer, and other factors such as pregnancy or lactation.",
    "The sample is a clinical trial for a drug called melatonin, which is being tested on women between the ages of 30 and 75 with breast cancer who are undergoing surgery at Herlev Hospital. The trial is in phase 2/phase 3 and also includes patients with depression. The table includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being used in the trial. The eligibility criteria for the trial are listed, including inclusion criteria such as no sign of depression and exclusion criteria such as ongoing or previous medically treated depression or bipolar disorder.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of asthma and includes a list of ICD-10 codes associated with the disease. The drug being tested is indacaterol maleate. The eligibility criteria for the trial includes individuals between the ages of 12 and 75 with a diagnosis of persistent asthma who are currently being treated with a bronchodilator and a daily dose of at least 100 \u00b5g beclomethasone dipropionate or equivalent. The FEV1 (forced expiratory volume in one second) at Visit 1 must be at least 50% of the predicted normal value and the FEV1 reversibility must be at least 15%. Exclusion criteria include recent tobacco use, chronic obstructive pulmonary disease (COPD), seasonal allergies likely to worsen asthma during the study period, recent emergency room treatment or hospitalization for asthma, and recent respiratory tract infection. Other exclusion criteria may also apply.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/3 and is focused on type 2 diabetes mellitus. The drugs being tested are a combination of alogliptin and pioglitazone. The eligibility criteria include completing a previous phase of the study, being capable of understanding and complying with the protocol, and signing a written informed consent form. Exclusion criteria include clinical manifestations of hepatic or renal impairment and a history or symptoms of cardiac failure.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on Parkinson's disease and includes a list of ICD-10 codes for the disease. The trial involves testing the effectiveness of three different drugs: cep-1347 10mg, cep1347 25mg, and cep-1347 50mg. The eligibility criteria for the trial are listed, including age, disease severity, and screening procedures for cancer. The exclusion criteria are also listed, including other medical or psychiatric conditions that may compromise participation in the study, history of seizures, and prior treatment with CEP-1347.",
    "The sample is a clinical trial for Parkinson's disease, with a combination of phase 2 and phase 3. The trial involves testing the efficacy and safety of various doses of a drug called tozadenant (syn115) in comparison to a placebo and levodopa. The trial includes a list of inclusion and exclusion criteria for participants, such as meeting the UK PD diagnostic criteria, having a good response to levodopa, and not having a history of hepatitis or cholangitis. The trial also requires participants to complete a Parkinson's disease diary and follow study instructions.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on low-grade B-cell lymphoma, excluding mantle cell lymphoma and histologic transformation to DLBCL. The drugs being tested are rituximab + standard chop and rituximab + bi-weekly chop. The eligibility criteria include factors such as age, lymphoma cell count, ECOG PS, and bidimensionally measurable disease. There are also exclusion criteria, such as CNS involvement, glaucoma, and liver cirrhosis.",
    "The sample is a record of a clinical trial for a drug called tadalafil, which is being tested for its effectiveness in treating pulmonary hypertension in patients with sarcoidosis. The trial is in phase 2/phase 3 and the eligibility criteria include having biopsy-proven sarcoidosis, a mean pulmonary artery pressure greater than 25 mmHg at rest or greater than 30 mmHg with exercise, and a stable sarcoidosis treatment regimen for three months prior to entry into the study. The exclusion criteria include having severe systemic hypertension or hypotension, congestive heart failure, or liver function abnormalities. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a clinical trial for phase 2/phase 3 of treatment for anal cancer. The trial is looking for patients with histologically confirmed squamous cell anal carcinoma, with measurable disease, and who meet certain eligibility criteria. The eligibility criteria include age between 18 to 75, WHO performance status of 0-1, and certain hematopoietic, renal, and cardiovascular requirements. Patients must not have had prior treatment for anal cancer, and must not have any other prior malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix. The trial will use cisplatin, fluorouracil, and mitomycin c as drugs. The table also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, diffuse large B-cell lymphoma), the ICD-10 codes associated with the disease, the drugs being tested (lenalidomide, gemcitabine, oxaliplatin, rituximab, and etoposide), and the eligibility criteria for participants. The eligibility criteria include requirements such as a histologically proven diagnosis of DLBCL, relapse or refractory status to previous chemotherapy treatments, measurable disease by CT/MRI, and an ECOG performance status of 0-2. The exclusion criteria include a diagnosis of lymphoma other than DLBCL, a history of malignancies other than DLBCL, eligibility for autologous stem cell transplant, and certain medical conditions such as HIV, HBV, HCV, and neuropathy grade 4.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of pain, analgesia, and inguinal hernia. The diseases are identified by their ICD-10 codes. The drug being tested is gabapentin. The eligibility criteria for the trial include having elective surgery with open unilateral inguinal herniorraphy, not currently being on gabapentin therapy, not being hypersensitive to gabapentin, not having a history of alcohol or drug abuse, and not being pregnant or nursing.",
    "This sample is a record of a clinical trial for the treatment of colorectal cancer in phase 2/phase 3. The trial involves the use of drugs such as cediranib, bevacizumab, 5-fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria for the trial include a clinical diagnosis of colon or rectal cancer and no prior systemic therapy for metastatic disease. However, patients who have received adjuvant/neoadjuvant oxaliplatin therapy must have done so more than 12 months prior to study entry, and those who have received adjuvant/neoadjuvant 5-FU must have done so more than 6 months prior to study entry. Patients who have previously been treated with a VEGF inhibitor, including bevacizumab and cediranib, or who have poorly controlled hypertension are excluded from the trial.",
    "The sample is a clinical trial for a drug called plecanatide, which is being tested for the treatment of chronic idiopathic constipation. The trial is in phase 2/phase 3 and the eligibility criteria include being between the ages of 18-75, having a body mass index between 18-35 kg/m2, and meeting the modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months. Patients with manual maneuvers required for more than 25% of defecations will not be eligible for participation. The trial also requires patients to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods. Patients must also be willing to maintain a stable diet during the study. The exclusion criteria include loose stool or watery stool in the absence of any laxative or prohibited medicine for more than 25% of bowel movements during the 3 months prior to screening visit or during the 14 day treatment period, meeting the Rome III criteria for Irritable Bowel Syndrome (IBS-C), active peptic ulcer disease not adequately treated or not stable, history of cathartic colon, laxative, enema abuse, or ischemic colitis, fecal impaction within 3 months of screening, and having any diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain. Major surgery within 60 days of screening is also an exclusion criterion.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial (phase 2/phase 3), the disease being studied (rheumatoid arthritis), the ICD-10 codes associated with the disease, the drug being tested (prednisone), and the eligibility criteria for participants. The inclusion criteria include meeting the American College of Rheumatology Criteria for Rheumatoid Arthritis, being between the ages of 18-80, having adequate renal function, and being willing to comply with the study protocol. The exclusion criteria include having an inflammatory arthritis other than RA, having a history of drug or alcohol abuse within the past 6 months, and having any disease or condition that contraindicates the use of an investigational drug or may affect the interpretation of the results.",
    "The sample is a clinical trial that is in phase 2/phase 3 and involves patients with chronic kidney disease, cardiovascular disease, and death. The trial is testing the effectiveness of a high dose multivitamin drug. The eligibility criteria for the trial include being between 35-75 years old, having had a kidney transplant at least 6 months prior, and having a calculated Creatinine Clearance of 25 mL/min or greater. Patients must also be willing to stop taking certain supplements for 4-6 weeks prior to the visit. Exclusion criteria include being pregnant or lactating, having certain medical conditions that limit life expectancy to less than 2 years, and having had certain medical procedures within a certain timeframe. Patients with certain conditions that prevent reliable study participation are also excluded.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on the treatment of multiple sclerosis-related pain. The trial involves the use of two drugs, duloxetine and placebo, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include a diagnosis of MS, age over 17, clinical stability, and daily pain attributed to MS. Exclusion criteria include pain that cannot be differentiated from other causes, certain psychiatric diagnoses, use of certain medications, and various medical conditions. The trial also has a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, pancreatic cancer), the corresponding ICD-10 codes, the drug being tested (rubitecan), and the eligibility criteria for participants. The eligibility criteria include age, cancer stage, previous treatment history, estimated life expectancy, performance status, and adequate organ function. The exclusion criteria include active infections, serious systemic disorders, scheduled surgery, pregnancy or nursing, inability to consistently consume fluids, and recent participation in another clinical trial.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on the disease multiple myeloma. The trial involves the drugs tanespimycin and bortezomib. The eligibility criteria for participants include having a good performance status, histologic evidence of multiple myeloma, having had at least three prior treatment regimens for multiple myeloma that included both bortezomib and lenalidomide, no prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor, no known infections of HAV, HBV, HCV, or HIV, and no chemotherapy, radiation therapy, or immune therapy for three weeks prior to enrollment. The icd-10 codes associated with the disease are also included in the record.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on amyotrophic lateral sclerosis, which is identified in the \"diseases\" field. The icd-10 codes associated with the disease are listed in the \"icdcodes\" field. The trial involves the use of three drugs: memantine (ebixa), riluzole, and placebo, which are listed in the \"drugs\" field. The eligibility criteria for the trial are listed in the \"criteria\" field, including inclusion criteria such as definite or probable disease, normal blood tests, and EMG in accordance with El Escorial criteria, and exclusion criteria such as other diseases, both ADM muscles < 3 on MRC scale, and disease duration > 3 years.",
    "The sample is a phase 2/phase 3 clinical trial for patients with neuroendocrine tumors, including carcinoid tumors, islet cell tumors, and poorly differentiated NETs. The trial is testing the effectiveness of a combination of drugs, including 5-fluorouracil, leucovorin, and oxaliplatin. The eligibility criteria include having confirmed neuroendocrine tumors, measurable disease, and no history of brain or leptomeningeal disease. Patients must also meet certain age, performance status, and health criteria, such as having normal blood counts and liver and kidney function. Prior treatments, such as chemotherapy and radiotherapy, are allowed under certain conditions. The trial is not open to patients with certain types of tumors or those with significant comorbidities.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on patients with diabetes, myocardial infarction, and cardiovascular disease. The icd-10 codes associated with these diseases are also listed. The drug being tested is natural source vitamin e 400iu/day. The eligibility criteria for the trial includes diabetic patients aged 55 and above, while exclusion criteria includes patients who take antioxidant treatment, patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris, Uncontrolled HTN, and those who are allergic to Vitamin E.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on the treatment of post-herpetic neuralgia, a type of nerve pain that occurs after a shingles infection. The trial is testing the effectiveness of a drug called Lamictal in treating this condition. The eligibility criteria for the trial include being over the age of 18, having a diagnosis of post-herpetic neuralgia, and having a minimum score of 4 on the Likert Pain Scale. Patients who are currently taking certain medications or have certain medical conditions are excluded from the trial. The sample includes a list of diseases, ICD-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 2/phase 3 clinical trial that involves patients with various heart-related diseases such as atrial fibrillation, atrial flutter, venous thromboembolic disease, myocardial infarction, and cardiomyopathy. The trial aims to test the effectiveness of two drugs, ati-5923 and coumadin (warfarin), in preventing blood clots. The eligibility criteria for the trial include having one or more of the listed heart-related conditions, being over 18 years old, and being willing to comply with the study requirements. Exclusion criteria include having certain medical conditions or taking certain medications that may interfere with the study, having a life expectancy of less than one year, and being pregnant or nursing.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying chronic lymphocytic leukemia. The icd-10 codes associated with this disease are listed as \"C91.11\", \"C91.12\", and \"C91.10\". The drugs being used in the trial are bendamustine and fludarabine. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\".",
    "The sample is a clinical trial for HIV infections in phase 2/phase 3. The trial is looking for participants who are 18 years or older, HIV-infected, and have measurable HIV Neurocognitive Impairment (HNCI). The participants must also be willing and able to undergo at least 3 lumbar punctures safely during the course of the study. The trial is testing the effectiveness of FDA-approved antiretroviral therapy (see list below) for HIV treatment. The eligibility criteria include having a Karnofsky score of > or = to 60 within 60 days prior to study entry and having a CD4 cell count obtained within 60 days prior to study entry. The exclusion criteria include the presence of serious illness, neurologic disorders other than HIV, active severe psychiatric disorders, active drug or alcohol use or dependence, use of any immunomodulator, vaccine, or investigational therapy including dexamethasone within 30 days prior to study entry, inability to provide informed consent, enrollment in other ARV treatment studies, and a positive serum or urine pregnancy test if female and of reproductive potential.",
    "The sample is a clinical trial for kidney transplantation, in which patients aged 2-21 years with biopsy-proven acute rejection episodes are eligible to participate. The trial is in phase 2/phase 3 and involves the use of rituximab for transplant rejection. The eligibility criteria include a decline in baseline renal function, adequate liver function, negative pregnancy test, and willingness to comply with the study protocol. Exclusion criteria include previous treatment with rituximab, history of severe allergic reactions, ongoing use of high dose steroids, and significant cardiac or pulmonary disease. Patients must also be able to comply with study and follow-up procedures.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on patients with dementia and the icd-10 codes associated with the disease. The trial is testing the effectiveness of megestrol acetate and placebo as treatments for the disease. The eligibility criteria for the trial include patients diagnosed with primary or mixed dementia, weight loss of more than 5% of their habitual weight in the last 6 months, and proteic-caloric malnutrition. The patients must also be outpatients and willing to participate in the study. The exclusion criteria include patients with vascular pure dementia and secondary dementias, those in a terminal phase of dementia, those on concomitant treatment with steroids, androgens or other drugs with progestagens, and those with weight loss secondary to neoplasia.",
    "The sample is a clinical trial for patients with intermediate- or high-grade malignant soft tissue sarcoma that is advanced and/or metastatic and previously untreated. The trial is in phase 2/phase 3 and involves the use of the drugs doxorubicin hydrochloride and trabectedin. The eligibility criteria include confirmed disease progression, measurable disease according to RECIST v 1.1 criteria, and no prior anticancer therapy for this disease. Patient characteristics include a WHO performance status of 0-1, normal blood counts and liver function, and no active or uncontrolled infections or serious illnesses. Prior concurrent therapy is not allowed, and patients must not have concurrent alcohol consumption.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 2/phase 3 trial for the treatment of type 2 diabetes mellitus using the drugs alogliptin and voglibose. The trial includes a list of inclusion and exclusion criteria, such as having completed a previous phase 2 study and not having clinical manifestations of hepatic or renal impairment. The diseases are listed as a single disease name, while the icd-10 codes are listed as a list of codes.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on three diseases: macular degeneration, glaucoma, and regional blood flow. The diseases are identified using ICD-10 codes. The trial involves the use of a drug called moxaverine. The eligibility criteria for the trial include being over 50 years old, having ametropia of less than 6 diopters and anisometropia of less than 2 diopters, and having clear non-lenticular ocular media. The inclusion criteria for AMD patients include having nonexudative AMD and visual acuity in the study eye greater than 20/60. The inclusion criteria for glaucoma patients include having unilateral or bilateral primary open angle glaucoma, at least 3 reliable visual field testings, treated intraocular pressure less than 21 mmHg, and visual field mean deviation MD less than 10 (Humphrey 30-2). The inclusion criteria for healthy control subjects include being age-, gender-, and sex-matched to the two patient groups and matched with regard to smoking habits of the two patient groups, and having no observable eye diseases. The exclusion criteria include having a history or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of the study drug, blood donation during the previous 3 weeks, abuse of alcoholic beverages or drugs, participation in a clinical trial in the 3 weeks preceding the study, known diabetes mellitus, presence of any ocular pathology that interferes with the aims of the present study, intraocular surgery within the last 3 weeks, hypersensitivity to moxaverine, and acute gastric bleeding or massive cerebral hemorrhage related to stroke.",
    "The sample is a clinical trial for asthma treatment in phase 2/phase 3. The trial is looking at the effectiveness of drugs such as rosiglitazone, theophylline, beclomethasone, and inhaled beclomethasone and oral theophylline. The trial is looking for males and females between the ages of 18 and 60 who have a clinical diagnosis of mild or moderate persistent asthma and have had a history of asthma for at least 6 months. The trial is also looking for current cigarette smokers with a minimum five-pack-year smoking history. The trial has inclusion and exclusion criteria, including a baseline FEV1 that is greater than 50% predicted and reversibility of 12% or more at screening, washout or randomisation. The trial is looking for subjects who are capable of providing signed written informed consent and complying with all the specified study procedures. The trial has exclusion criteria, including asthma exacerbation or a respiratory tract infection within four weeks of screening, type 1 or type 2 diabetes mellitus, and women who are lactating, pregnant, or planning to become pregnant. The trial is also looking for subjects who do not have clinically significant renal or hepatic laboratory values, anaemia, or contraindications to treatment as outlined in any of the product labels. The trial is also looking for subjects who do not have a prior history of severe oedema or serious fluid related event associated with any TZD, a history of significant hypersensitivity to study drugs, or presence of unstable or severe angina or congestive heart failure. The trial is also looking for subjects who do not have a history or suspicion of current drug abuse or alcohol abuse within the last 6 months, history suggestive of active infection or non-asthma lung pathology, clinically significant renal disease, metabolic syndrome, cirrhosis, hypertension, or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy. The trial is also looking for subjects who do not have risk factors for HIV, hepatitis B or hepatitis C infection at Screening, are not morbidly obese, and are able to perform spirometry. The trial is also looking for subjects who do not require treatment with certain asthma medications from Screening until study completion and who have not been taking in excess of 1000 \u03bcg daily of beclomethasone within 6 weeks of Screening.",
    "The sample is a clinical trial for breast cancer patients in phase 2/phase 3. The trial is testing the effectiveness of the drug letrozole on patients with estrogen and/or progesterone positive tumors. The trial has specific inclusion and exclusion criteria, such as patients must be postmenopausal and have adequate bone marrow, renal, and hepatic function. Patients who have received prior treatment with aromatase inhibitors or antiestrogens, have tumors in both breasts, evidence of inflammatory breast cancer or distant metastasis, or are eligible for breast conserving surgery are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on HIV infections and the ICD-10 code associated with it is Z21. The trial involves two drugs, kaletra (lopinavir/ritonavir) and kaletra (lopinavir/ritonavir) + combivir (zidovudine/lamivudine). The eligibility criteria for the trial includes being assessed between 20 and 24 months of pregnancy, having a documented HIV-1 infection without indication for ARV therapy, having a CD4 count above or equal to 350 per mm3, having a VL under 30 000 copies per ml, being na\u00efve for PI (except treatment during previous pregnancy), and signing an informed consent. The exclusion criteria includes having HIV2 infection or HIV1 group O infection, having any pathology related to pregnancy, having a contra-indication to study drugs, having unstable hypertension or diabetes, having a known risk of premature delivery, and having resistance mutations on the HIV-1 protease gene by genotyping analysis (1 mutation among V32I et I47A, I50V V82A/F/S/T, I84V, L90 M or more than 3 mutations among L10 F/I/R/V, K20/M/R, L24I, L33F, M46I/L, F53L, I54M/L/T/V, L63P, A71L/V/T).",
    "The sample is a clinical trial for a drug used to treat attention deficit hyperactivity disorder. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The eligibility criteria include age, gender, health status, and other factors that may impact the interpretation of study results or pose a safety concern. The sample also includes exclusion criteria, such as the presence of other psychiatric disorders or substance abuse, that would make a participant ineligible for the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria. In this particular sample, the trial is in phase 2/phase 3 and is focused on atopic dermatitis. The associated ICD-10 codes are \"L20.89\" and \"L20.9\". The drug being tested is fexofenadine/allegra (m016455). The eligibility criteria include being between 6 months and 11 years old and having atopic dermatitis. Exclusion criteria include having low itching scores or only experiencing itching on certain areas of the body.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 1 diabetes), the ICD-10 codes associated with the disease, the drugs being tested (anakinra and saline), and the eligibility criteria for participants. The eligibility criteria include requirements such as a positive GAD auto-antibody test, a certain age range, and a specific C-peptide level. The exclusion criteria include factors such as severe liver or renal disease, a history of heart disease, and pregnancy.",
    "The sample is a clinical trial for acute myocardial infarction, with a phase 2/phase 3 design. The trial involves the use of mesenchymal stem cells and a control group. The eligibility criteria for the trial include being between the ages of 18-70, having ischemic chest pain for more than 30 minutes, being admitted to the hospital within 24 hours of the onset of chest pain, and having electrocardiography that shows ST segment elevation. There are also exclusion criteria, such as having cardiogenic shock, life-threatening arrhythmia, or a history of malignancy. The trial aims to investigate the effectiveness of mesenchymal stem cells in treating acute myocardial infarction.",
    "The sample is a clinical trial for ovarian, fallopian tube, and primary peritoneal cancer patients who have relapsed within 6 months of platinum therapy. The trial is in phase 2/phase 3 and involves the drugs paclitaxel, saracatinib, and a matched placebo. The eligibility criteria include having measurable or evaluable disease, an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2, and adequate haematological and biochemical function. Exclusion criteria include prior administration of weekly paclitaxel, unresolved bowel obstruction, and ongoing active infection or a documented history of HIV infection, Hepatitis B or C.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is focused on hematological malignancies. The trial is testing the effectiveness of darbepoetin alpha (aranesp) and iron saccharate (venofer) on patients who meet certain eligibility criteria, such as being between the ages of 16 and 70 and having adequate iron stores. The sample also includes exclusion criteria, such as HIV positivity and severe iron overload.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying head and neck neoplasms. The icd-10 codes associated with these diseases are listed. The drugs being used in the trial are docetaxel, cisplatin, 5-fluorouracil (5-fu), and radiotherapy, as well as cisplatin, 5-fluorouracil (5-fu), and radiotherapy. The eligibility criteria for participants are also listed, including inclusion criteria such as having locally advanced head and neck cancer without metastasis, being in good health, and having a proven epidermoid carcinoma. Exclusion criteria are also listed, such as having previous treatment for the disease or having other severe clinical diseases.",
    "The sample is a record from a table that contains information about clinical trials. It includes the phase of the trial, which is a combination of phase 2 and phase 3. The diseases being studied are head and neck cancer and squamous cell carcinoma. The icd-10 codes associated with these diseases are also listed. The drug being tested is erlotinib. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which specify the requirements for participants to be included or excluded from the trial.",
    "The sample is a clinical trial with a phase 2/phase 3 design, focused on patients with essential hypertension. The trial includes a list of drugs, diseases, and icd-10 codes, as well as eligibility criteria for inclusion and exclusion. Inclusion criteria include patients with essential hypertension, measured by electronic hemodynamometer, and meeting specific blood pressure criteria at three different visits. Exclusion criteria include patients with secondary hypertension, a history of malignant hypertension, or any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of any drug. The trial also excludes patients with a history of drug or alcohol abuse within the last 2 years of Visit 1 and those who are considered unlikely to comply with the requirements specified in the protocol.",
    "The sample is a record of a clinical trial for the treatment of gastric cancer. The trial is in phase 2/phase 3 and involves the use of two drugs, tegafur/gimeracil/oteracil potassium (s-1) and krestin (psk). The eligibility criteria for the trial include having unresectable advanced or recurrent gastric carcinoma, being 20 years or older, not having received prior treatment, and having certain laboratory values within normal ranges. Patients with certain medical conditions or who are taking certain medications are excluded from the trial. The sample also includes a list of disease names and icd-10 codes associated with the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, prostate cancer), the ICD-10 codes associated with the disease, the drug being tested (celecoxib), and the eligibility criteria for participants. The eligibility criteria include specific requirements related to the diagnosis and progression of prostate cancer, as well as exclusion criteria such as prior hormonal or chemotherapy treatment, allergies to certain medications, and certain medical conditions.",
    "The sample is a clinical trial for a drug called AGI-1067 for the treatment of Type 2 diabetes. The trial is in phase 2/phase 3 and the eligibility criteria include being between 18-75 years old, having Type 2 diabetes for at least 6 months, and having an HbA1c level of at least 7.5%. Participants must not have Type 1 diabetes, severe diabetic neuropathy, or a history of long-term insulin therapy. They must also not be taking certain medications or have certain medical conditions. The trial involves taking either AGI-1067 or a placebo, and participants must provide informed written consent before entering the trial.",
    "The sample is a clinical trial for the treatment of recurrent respiratory papillomatosis using the drug propranolol. The trial is in phase 2/phase 3 and the eligibility criteria include having biopsy-proven recurrent respiratory papillomatosis with appropriate Human Papilloma Virus typing, being under the age of 10, having undergone at least 4 documented surgical interventions in the past year, and providing informed consent. The exclusion criteria include parental or child refusal to participate, heart failure, atrio-ventricular heart block, cardiac anomalies, low resting heart rate, low resting blood pressure, Wolff-Parkinson White Syndrome, unexplained syncope, asthma or reactive airway disease, renal or liver failure, expected long fasting periods (>12 hours), diabetes mellitus, and hypersensitivity to propranolol.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on kidney transplantation and involves the use of the drugs rituximab and placebo. The diseases being studied are listed as kidney transplantation, with corresponding ICD-10 codes provided. The eligibility criteria for the trial are also listed, including inclusion criteria such as being a renal transplant recipient and having signed an IRB-approved informed consent, as well as exclusion criteria such as pregnancy, previous treatment with anti-CD20 antibodies, and active infection with hepatitis B, hepatitis C, or HIV.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3. The trial is focused on heart failure, congestive disease and the icd-10 codes associated with it. The trial involves the use of two drugs, relaxin and placebo. The eligibility criteria for the trial include being hospitalized for acute heart failure, experiencing dyspnea at rest or with minimal exertion, having pulmonary congestion, being able to provide informed consent, having systolic blood pressure greater than 125 mmHg, and having impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2. The exclusion criteria include the use of other IV therapies for acute heart failure, fever or sepsis, recent major neurologic event, recent major surgery, recent acute coronary syndrome, and other recent investigational drug use.",
    "The sample is a clinical trial for patients with metastatic breast cancer and bone metastases. The trial is in phase 2/phase 3 and the drug being tested is zoledronic acid. The eligibility criteria include being a female over 18 years old with confirmed invasive breast cancer and bone metastases, having an ECOG Performance Status of 0 to 2, and a life expectancy of more than 3 months. The patient must also have adequate organ function and have ceased anti-tumor treatment for over 28 days. Exclusion criteria include being pregnant or lactating, having a history of other malignancy, having concurrent diseases or conditions that would make the patient inappropriate for study participation, and having active or uncontrolled infection. The trial also excludes patients with recent dental or jaw surgery, known hypersensitivity to bisphosphonates, and a history of treatment with calcitonin, gallium nitrate or mithracin within 14 days before the study.",
    "The sample is a clinical trial for rheumatoid arthritis, in which patients with a disease duration of more than 5 years and who are RA latex seropositive or IgM RF ELISA >14iu/ml will be selected from a high-risk population of hospital clinic attendees. The trial is a phase 2/phase 3 trial and involves the use of the drugs rosuvastatin and placebo. The eligibility criteria include having both tender and swollen joint counts >4 each and either a CRP >10mg/l, ESR >25mm/h or PV >1.78. Patients on cyclosporine or other medications known to be contraindicated with this form of drug will not be enrolled. The exclusion criteria include evidence of symptomatic vascular disease, those already taking lipid-lowering therapy or those with contraindications to these therapies, and subjects with a total cholesterol level of >7.5mmol/L.",
    "The sample is a clinical trial for influenza, with a phase 2/phase 3 designation. The trial is testing the effectiveness of nitazoxanide and placebo as treatments for influenza in patients between the ages of 12 and 65. The trial has specific inclusion and exclusion criteria, including confirmation of influenza A or B infection, onset of illness no more than 48 hours before presentation, and absence of certain high-risk conditions. The trial also requires patients to be willing and able to comply with protocol requirements and provide informed consent. The sample includes a detailed list of the inclusion and exclusion criteria.",
    "The sample is a clinical trial for advanced cancers in phase 2/phase 3. The trial involves the drug atorvastatin and the eligibility criteria include being in a normal sinus rhythm preoperatively, undergoing planned lobectomy or pneumonectomy, being of a certain age, and having adequate liver function. Exclusion criteria include a history of certain arrhythmias, recent use of certain medications, and allergies to seafood.",
    "The sample is a clinical trial for a drug called lbh589, which is being tested for the treatment of cutaneous t-cell lymphoma. The trial is in phase 2/phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The inclusion criteria include patients with biopsy-confirmed stages IB-IVA mycosis fungoides or S\u00e9zary syndrome, who have been treated with an HDAC inhibitor and had disease progression or an inadequate response to the treatment. The exclusion criteria include patients with a history of visceral disease, impaired cardiac function, and those who have received chemotherapy or any investigational drug or undergone major surgery \u2264 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy. Women who are pregnant or breastfeeding or women of childbearing potential not willing to use a double method of contraception during the study and 3 months after the end of treatment are also excluded.",
    "The sample is a clinical trial for patients with recurrent follicular lymphoma, with a phase 2/phase 3 design. The trial includes patients who have received three or fewer prior regimens of chemotherapy and are beyond their first complete or partial remission. Eligibility criteria include adequate organ function, the ability to receive cyclophosphamide and rituximab mobilization chemotherapy, and the collection of an autologous or allogeneic graft of at least 2.0 * 10^6 CD34+ cells/kg. Patients must also meet certain inclusion criteria for proceeding to hematopoietic stem cell transplant and maintenance therapy. Exclusion criteria include a Karnofsky performance score less than 70%, uncontrolled hypertension, prior autologous or allogeneic HSCT, and known anaphylactic reaction to rituximab.",
    "The sample is a record of a clinical trial for depression treatment. The trial is in phase 2/phase 3 and the disease being studied is depression. The icd-10 codes associated with depression are listed as [\"['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']\"]. The drugs being tested are trazodone and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age, diagnosis of depression, and certain health conditions. The sample also mentions the use of a screening tool called the 17-item HAM-D to assess the severity of depression symptoms.",
    "The sample is a clinical trial for tuberculosis, AIDS, and HIV infections. It is a phase 2/phase 3 trial that involves patients who are HIV infected and aged 18 years or older. The trial requires patients to have never received TB treatment or to have received it for less than a month. Patients must also be receiving rifampicin-based TB treatment for 4 to 6 weeks and have a CD4 cell count of less than 250 cell/mm3 in the 4 weeks following the TB diagnosis. Patients must be na\u00efve of HAART and women of childbearing age must have a negative plasmatic test for pregnancy and accept contraception or declare no wish of pregnancy in the coming year. Exclusion criteria include a positive plasmatic test for pregnancy, Karnofsky score <60%, ALAT > 4N (Hepatitis grade 3 or 4), ongoing psychiatric pathology, and refusal to participate in the study. The amendment includes bilirubin > grade 3 and any grade 4 clinical sign or biological result at the time of inclusion.",
    "The sample is a clinical trial for major depressive disorder, with a phase 2/phase 3 designation. The trial involves the drugs tasimelteon and placebo. The eligibility criteria include a diagnosis of MDD according to DSM-IV TR criteria, a current episode lasting between 4 weeks and 1 year, and a CGI-Severity score of at least 4 at screening and baseline. Exclusion criteria include a history of bipolar disorder, schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder, as well as drug or alcohol abuse/dependence within the past 12 months, and participation in a previous tasimelteon trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 2/phase 3 and is studying chronic hepatitis C. The icd-10 codes associated with the disease are listed, as well as the drugs being tested (nitazoxanide and ribavirin). The eligibility criteria for participants are also listed, including age, duration of hepatitis C infection, liver biopsy results, and exclusion criteria such as previous failed treatment, pregnancy, and other liver diseases.",
    "The sample is a clinical trial for allergic rhinitis, with a combination of phase 2 and phase 3. The trial involves testing the efficacy of three different drugs, including a placebo, on patients who are sensitized to D. pteronyssinus or D. farinae and have been suffering from house dust mite-related allergic rhinitis for at least a year. The trial includes both inclusion and exclusion criteria, such as patients must be between 18 to 50 years old, in general good health, and willing to comply with the protocol. Exclusion criteria include patients with other nasal conditions, pregnant or breastfeeding women, and patients who have received allergy specific immunotherapy for house dust mites in the last 10 years. The trial also prohibits participation from investigators, co-investigators, their children or spouses, and all study collaborators.",
    "The sample is a record from a table that contains information about clinical trials. It is a phase 2/phase 3 trial for chronic kidney disease. The trial is testing the drug \"zemplar\". The trial has eligibility criteria, which includes having an eGFR of 15-59 ml/m2, and exclusion criteria, which includes not currently receiving vitamin D treatment. The table also includes lists of disease names and their corresponding ICD-10 codes.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, type 2 diabetes mellitus), the corresponding ICD-10 codes, the drugs being tested (alogliptin and pioglitazone), and the eligibility criteria for participants. The eligibility criteria include requirements such as a stable dose of pioglitazone for at least 16 weeks prior to the start of the treatment period, a certain level of glycosylated hemoglobin, and adherence to specific diet and exercise therapies. The exclusion criteria include a history or symptoms of cardiac failure and the use of diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period.",
    "The sample is a clinical trial with a combination of phase 2 and phase 3. The trial is focused on diabetes and insulin resistance, and the icd-10 codes for the diseases are provided. The trial involves the use of sitagliptin and placebo drugs. The eligibility criteria for the trial include being HIV-infected, having stable immunologic and virologic status, having a BMI between 18-42kg/m2, and having normal blood chemistry. The trial also has exclusion criteria, including having a history of serious CV disease, moderate to severe renal insufficiency, and known allergy or hypersensitivity to DPPIV-inhibitors. The trial also excludes pregnant or nursing mothers and those with active malignancy or treatment with chemotherapeutic agents or radiation therapy within the past 12 months.",
    "The sample is a clinical trial for renal transplantation, in phase 2/phase 3. The trial is testing the effectiveness of the drug fluvastatin in combination with immunosuppression (Tacrolimus and steroids or Mycophenolat Mofetil) for patients aged 18-65 who have undergone cadaver or living kidney transplantation. The trial has specific inclusion criteria, such as LDL-cholesterol levels and a history of myocardial infarction, and exclusion criteria, such as previous use of statins and elevated liver enzymes. The trial aims to determine the safety and efficacy of the drug in this patient population.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on chronic myeloid leukemia, specifically the Philadelphia chromosome positive accelerated or blast phase. The drug being tested is panobinostat. The eligibility criteria for the trial includes patients who are at least 18 years old, have been diagnosed with the specified type of leukemia, and have demonstrated resistance to at least two BCR-ABL tyrosine kinase inhibitors. Patients must also meet certain laboratory value requirements and not have certain exclusion criteria, such as being a candidate for hematopoietic stem cell transplantation or having impaired cardiac function. The sample also includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a clinical trial that is in phase 2/phase 3 and is focused on the disease of hyperlipidemia. The icd-10 codes associated with this disease are E78.2, E78.49, and E78.5. The drug being tested is simvastatin 20 mg/ezetimibe. The eligibility criteria for the trial include being moderately obese with hyperlipidemia, while exclusion criteria include recent unstable heart or lung conditions, current use of other lipid modifying drugs, hepatic disease, and pregnancy or lactation.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of migraine and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, telcagepant and placebo. The eligibility criteria for participants include having regular menstrual cycles, experiencing headaches during menstrual periods, having a history of migraine with at least two attacks per month, and agreeing to use birth control during the study. Exclusion criteria include having certain types of migraine, taking medication for acute headache too frequently, having certain medical conditions, and consuming excessive amounts of alcohol.",
    "The sample is a clinical trial that is in phase 2/phase 3 and is focused on the treatment of type 2 diabetes. The trial involves the use of the drugs dapagliflozin and placebo. The eligibility criteria for the trial include being male or female, over 18 years old, and having inadequate glycemic control with a clinical diagnosis of moderate renal impairment. The exclusion criteria include having AST and/or ALT levels greater than 3.0 times the upper limit of normal, serum total bilirubin levels greater than 1.5 times ULN, symptoms of severely uncontrolled diabetes, and currently having unstable or serious cardiovascular, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases. The diseases being studied are limited to diabetes mellitus, type 2 and are identified by a list of ICD-10 codes.",
    "The sample is a clinical trial for the treatment of hepatitis C, with a combination of drugs including algeron, pegintron, and ribavirin. The trial is in phase 2/phase 3 and includes patients with confirmed hepatitis C virus infection (genotypes 1a, 1b, 2, 3, 4) and increased ALT levels. The eligibility criteria include age between 18 and 70, BMI between 18 and 30, preserved liver function, and no signs of hepatic encephalopathy or abdominal fluid retention. Exclusion criteria include intolerance to the drugs, infection by hepatitis B virus or HIV, past history of HCV treatment with IFN alfa or pegylated IFN alfa formulations, and various other medical conditions. Patients must agree to use barrier contraception throughout the study and 7 months after its completion.",
    "The sample is a record of a clinical trial for a drug called cx516 (ampakine) for the treatment of schizophrenia. The trial is in phase 2/phase 3 and the disease being studied is schizophrenia. The icd-10 codes associated with the disease are listed as [\"F20.0\", \"F20.1\", \"F20.2\", \"F20.3\", \"F20.5\", \"F20.89\", \"F20.9\"]. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age range, diagnosis of schizophrenia, stable dose of certain medications, and exclusion of serious medical or neurological illnesses, substance abuse, pregnancy, and suicidal or homicidal risk.",
    "The sample is a clinical trial for patients with liver cirrhosis, hepatitis C virus, and HIV infection. The trial is in phase 2/phase 3 and the drugs being tested are pegylated interferon alfa-2a and ribavirin. The eligibility criteria for the trial include being over 18 years old, having compensated liver cirrhosis by HCV genotype 1 or 4 without previous virological response to a standard dose treatment of both drugs, and having the ability to understand and sign a written consent form. The exclusion criteria include having HCV genotypes different to 1 or 4, acute or chronic hepatitis B infection, pregnancy or breast feeding, and other medical conditions such as neutropenia, anemia, thrombocytopenia, and organ or bone marrow transplantation.",
    "The sample is a record of a clinical trial that is in phase 2/phase 3 and is focused on diabetes. The trial includes patients with type 2 diabetes mellitus and a BMI between 25-35 kg/m2. The eligibility criteria also include specific HbA1c levels, and patients must understand the study procedures. The exclusion criteria include patients with type 1 diabetes mellitus, low C-peptide levels, and those who have taken certain oral anti-hyperglycemic agents within the past 12 weeks. Patients who have required insulin therapy within the past 12 weeks are also excluded. The trial involves the use of sitagliptin, metformin, and placebos.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease multiple sclerosis, with icd-10 codes of G35 and C81.18. The drug being tested is hydroxyurea. The eligibility criteria for the trial include being between 18 and 60 years old, having a diagnosis of PP-MS according to McDonald criteria, and having an EDSS score at screening of 2-7 inclusive. Exclusion criteria include hypersensitivity to hydroxyurea, recent treatment with immunosuppressive drugs or steroids, respiratory or urinary infections, history or presence of malignancy, pregnancy or lactation, and low compliance to the therapy.",
    "The sample is a record of a clinical trial with a phase 2/phase 3 designation. The trial is focused on the disease of stroke and includes a list of ICD-10 codes associated with the disease. The drug being tested is propranolol. The eligibility criteria for the trial includes patients with acute ischemic MCA-territory stroke and symptom onset within 18 hours. Patients with suspected stroke in MCA-territory and NIHSS > 3 or imaging evidence of MCA-infarction are also eligible. Exclusion criteria include patients already receiving beta-blockers, anti-arrhythmic, antiinfectious, antiinflammatory or immunosuppressive therapy, and patients with a major heart disease, hypotension, bradycardia or any contraindication to the use of Propranolol.",
    "The sample is a clinical trial for a drug aimed at treating type 2 diabetes. The trial is in phase 2/phase 3 and the diseases being studied are limited to diabetes mellitus, type 2. The icd-10 codes associated with the disease are also listed. The trial involves several drugs, including ly2189265, sitagliptin, placebo solution, placebo tablet, and metformin. The eligibility criteria for participants include having type 2 diabetes for at least 6 months, being able to tolerate metformin at a certain dose, having a specific HbA1c value, having a BMI within a certain range, and not having certain medical conditions or taking certain medications. The trial also has exclusion criteria, such as having type 1 diabetes, using certain medications, or having certain medical conditions.",
    "The sample is a phase 2/phase 3 clinical trial for patients aged 18-65 with moderate to severe ankylosing spondylitis. The trial is testing the effectiveness of rituximab, a drug used to treat certain types of cancer and autoimmune diseases. The eligibility criteria include having an active disease despite concurrent NSAID therapy or intolerance to NSAIDs, stable doses of certain medications for 4 weeks prior to baseline, and willingness to comply with the study. Exclusion criteria include having other chronic inflammatory articular disease or systemic autoimmune disease, any active infection, primary or secondary immunodeficiency, history of cancer with curative treatment not longer than 5 years ago, and lack of peripheral venous access. The trial also has exclusion criteria related to medications, lab findings, and formal aspects.",
    "The sample is a phase 3 clinical trial for patients with cancer who have not yet received chemotherapy. The trial aims to test the effectiveness of a combination of drugs, including aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, and placebo, in reducing nausea caused by chemotherapy. The trial has specific inclusion and exclusion criteria, such as not having symptomatic brain metastases or concurrent bowel obstruction. Patients must also be able to understand English. The trial does not allow certain chemotherapy regimens or concurrent use of certain medications.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on Parkinson's disease. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being used in the study. The eligibility criteria for the trial are also included, with specific inclusion and exclusion criteria listed. Inclusion criteria include completion of previous studies or discontinuation from an open-label study, non-pregnancy and non-nursing status for female patients, and ability to provide written informed consent. Exclusion criteria include recent treatment with investigational agents other than istradefylline, history of psychotic illness, recent treatment with anti-psychotic agents, and clinically significant illness of any organ system that may compromise patient safety or ability to complete the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus and ischemic heart disease who have undergone coronary artery bypass grafting (CABG) with at least one SVG (\u22651 yr & \u226410 yrs). The trial is testing the efficacy of rosiglitazone or placebo. The eligibility criteria include being aged between 40 and 75 years, having no new medication for hyperglycemia and no change in dose of oral hypoglycemic medication within the last 3 months prior to screening, and meeting certain medical requirements. The exclusion criteria include having clinically significant abnormalities at screening tests and exams, type 1 diabetes or history of diabetic ketoacidosis, recent MI or ACS (\u2264 90 days), and other medical conditions that preclude survival. The trial involves IVUS and angiography, and patients must meet certain criteria to be eligible for these procedures.",
    "The sample is a phase 3 clinical trial for the treatment of breast neoplasms. The trial includes patients with histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery. The patients must have either measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST). The tumors must be ER+ and/or PgR+. The trial includes post-menopausal female subjects who are at least 18 years of age and have an ECOG Performance Status of 0 or 1. The trial also requires subjects who had archived tumor tissue available to compare tumor response with intra-tumoral expression of ErbB1 and ErbB2. Adjuvant therapy with an aromatase inhibitor and / or trastuzumab was allowed, however, treatment was to stop more than 1 year prior to the first dose of randomized therapy. The trial has several exclusion criteria, including pre-menopausal, pregnant, or lactating patients, patients who have received prior chemotherapy, hormonal therapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for advanced or metastatic disease, and patients with known history of/clinical evidence of CNS metastases or leptomeningeal carcinomatosis.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The trial involves a combination of drugs including asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, and vindesine. The eligibility criteria for the trial include patients with histologically confirmed acute lymphoblastic leukemia (ALL) and no prior disease that would preclude treatment with chemotherapy. Patients must also not have received chemotherapy or steroids within the past 4 weeks. The icd-10 codes associated with the disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01.",
    "The sample is a phase 3 clinical trial for the treatment of anemia in patients with chronic renal disease. The trial includes patients who have been receiving continuous intravenous maintenance therapy with epoetin alfa for at least a month and have been undergoing regular hemodialysis for at least three months. The trial excludes patients who have received a red blood cell transfusion in the past two months or have poorly controlled hypertension that required interruption of epoetin alfa treatment in the past six months. The trial involves the use of two drugs, methoxy polyethylene glycol-epoetin beta and epoetin alfa. The diseases being studied are not specified beyond anemia. The icd-10 codes associated with the disease are listed as ['D53.2', 'D64.9', 'D46.4', 'D53.0', 'D53.9', 'D61.3', 'D61.9'].",
    "The sample is a phase 3 clinical trial for the treatment of age-related macular degeneration and choroidal neovascularization using the drug ranibizumab. The trial includes patients over 50 years old with active primary or recurrent CNV secondary to AMD, with a total area of CNV encompassed within the lesion of at least 50% of the total lesion area and a total lesion area of no more than 12 disc areas. Patients must also have a BCVA score between 73 and 24 letters in the study eye using ETDRS-like grading charts. Exclusion criteria include a BCVA of less than 34 letters in both eyes, recent treatment with certain therapies, and previous participation in a clinical trial involving anti-angiogenic drugs. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of epilepsy. The trial involves the drug lamotrigine and the patients must have a confirmed diagnosis of epilepsy and be currently treated with one or two antiepileptic medications. They must also be able to complete a seizure diary. Patients with a history of hypersensitivity to lamotrigine or progressive diseases that would interfere with the study objectives are excluded from the trial. The diseases are listed as 'epilepsy' and the icd-10 codes associated with it are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial includes patients who have had RA for more than a year and have an American College of Rheumatology functional class I, II, or III. The patients must have completed the double-blind portion of the IM101064 study and have received an anti-TNF therapy at an approved labeled dose for at least 3 months. The trial excludes patients with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules) and those with a history of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection). The table also includes lists of disease names, ICD-10 codes, drug names, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for patients with locally advanced or metastatic renal cell carcinoma. The trial is testing the effectiveness of two drugs, pazopanib and sunitinib, and the eligibility criteria includes having received no prior systemic therapy for advanced or metastatic RCC, having an ECOG PS of 0 or 1, being at least 18 years old, and having adequate organ system functions. The trial also has exclusion criteria, such as having a history of another malignancy or clinical evidence of CNS metastases. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the treatment of benign prostatic hypertrophy. The record includes the list of diseases and their corresponding ICD-10 codes, the drug being tested, and the eligibility criteria for the trial. The eligibility criteria include inclusion criteria such as having a medical history of benign prostatic hyperplasia, voiding symptoms, and a uroflow rate of 5-15mL/sec. The exclusion criteria include urgent need for prostate surgery, history of allergic reaction to peptide, major organ dysfunction, prior surgical treatment of the prostate or bladder, current or recent treatment with certain drugs, and urologic disorders.",
    "The sample is a phase 3 clinical trial for patients with cystic fibrosis and newly diagnosed diabetes mellitus. The trial involves the use of two drugs, repaglinide and short-acting insulin (actrapid). The eligibility criteria for the trial include being diagnosed with cystic fibrosis, being 10 years or older, and having newly diagnosed diabetes mellitus. Exclusion criteria include having diabetic keto-acidosis, already being treated for diabetes mellitus, and having severe liver insufficiency. The trial also requires patients to provide consent for randomization and participation in the study.",
    "The sample is a phase 3 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. The trial is focused on patients who are new to emetogenic chemotherapy and have confirmed malignant disease. The trial will test the effectiveness of several drugs, including aprepitant, ondansetron, dexamethasone, fosaprepitant dimeglumine, and two unspecified placebos. The eligibility criteria for the trial include a Karnofsky score of 60 or greater, no scheduled dose of cisplatin, no recent abdominal or pelvic radiation, no allergies to study drugs or antiemetics, and no significant medical or mental conditions. Additionally, patients must have normal laboratory values for platelets, absolute neutrophils, AST, ALT, bilirubin, and creatinine.",
    "The sample is a phase 3 clinical trial for patients with locoregionally confined stage III or stage IV squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx. The trial is testing the effectiveness of cisplatin and fluorouracil as a non-operative treatment with curative intent. Patients must meet certain eligibility criteria, including having no evidence of nodal disease below the clavicles or distant hematogenous metastases, and having an ECOG performance status of 0-1. Patients with primary cancer of the nasopharynx, paranasal sinus, or salivary gland, unstable or uncontrolled angina, clinically apparent jaundice, or active infection are ineligible. Patients who have had previous definitive surgery, radiation therapy, chemotherapy, immunotherapy, or EGF receptor inhibition for any disease are also ineligible. Women who are pregnant or breastfeeding are ineligible, and women/men of reproductive potential must be willing to practice acceptable methods of birth control to prevent pregnancy.",
    "The sample is a phase 3 clinical trial for asthma patients. The trial includes patients who are outpatients, aged between 18 and 75 years, and have a confirmed diagnosis of asthma. Patients must have been on maintenance treatment with a medium, stable dose of inhaled corticosteroids for at least 4 weeks prior to the trial. Patients must also be symptomatic with an Asthma Control Questionnaire mean score of at least 1.5. The trial involves the use of tiotropium respimat and placebo respimat drugs. The eligibility criteria include various factors such as age, smoking history, ability to use the Respimat inhaler correctly, and ability to perform all trial-related procedures. The exclusion criteria include patients with significant diseases other than asthma, recent history of myocardial infarction, hospitalization for cardiac failure, lung diseases other than asthma, known active tuberculosis, malignancy, and patients who have taken an investigational drug within 4 weeks prior to Visit 1. The trial also excludes pregnant or nursing women, women of childbearing potential not using a highly effective method of birth control, and patients who have been treated with certain medications within four weeks prior to Visit 1.",
    "The sample is a phase 3 clinical trial for osteoarthritis of the knee. The trial involves the use of ketoprofen in diractin\u00ae and a placebo. The eligibility criteria include being over 45 years old, having class I-III OA of the knee, and meeting the American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee. Exclusion criteria include having skin lesions or dermatological diseases in the treatment area, being involved in the conduct and administration of the study, having received any investigational medicinal product within 30 days prior to screening visit or participation in any previous clinical study with Diractin\u00ae, being pregnant or lactating, having malignancy within the past 2 years, having depressive disorders requiring treatment with tricyclics, having epilepsy, schizophrenia, neuropathic pain, or any other pain condition requiring chronic use of pain medication, having known hypersensitivity or allergy to NSAID\u00b4s including ketoprofen and to ingredients of the IMP, having preexisting asthma or bronchospasm after taking aspirin or other NSAIDs, and being unable to discontinue analgesic therapy including opioids, NSAID\u00b4s, tramadol, muscle relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs approved or used for the treatment of pain for the duration of the study.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of two drugs, human insulin inhalation powder and insulin glargine, for patients who have not previously taken insulin and are currently taking one or more oral antihyperglycemic medications. The trial has specific inclusion and exclusion criteria, including a requirement for a HbA1c level between 8.0% and 10.5%, non-smoking status, and no recent hospitalizations or emergency room visits due to poor diabetic control. Patients with certain medical conditions or taking certain medications are excluded from the trial.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease, with the drug being tested being simvastatin. The eligibility criteria include having mild to moderate Alzheimer's disease, meeting specific diagnostic criteria, having a certain score on a cognitive test, being in stable medical condition, being over 50 years old, living in a community dwelling, having stable doses of certain medications, and being fluent in English or Spanish. Exclusion criteria include having certain medical conditions, taking certain medications, having a history of stroke or head injury, having a major psychiatric disorder, and having a disability that would prevent participation in the study.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of hypertension and includes a list of ICD-10 codes associated with the disease. The trial involves testing multiple drugs, including telmisartan80mg+amlodipine5mg and amlodipine 5mg. The eligibility criteria for the trial include a diagnosis of essential hypertension, failure to respond to six weeks of treatment with amlodipine 5mg, and provision of written informed consent. The exclusion criteria include clinical conditions that would not allow safe completion of the trial or safe administration of the drugs.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on prostate cancer and includes a list of ICD-10 codes related to the disease. The trial involves two drugs, zd4054 and placebo. The eligibility criteria for the trial includes a confirmed diagnosis of prostate cancer that has spread to the bone, increasing PSA levels over a one month period, and no or mild pain from the cancer. Patients currently receiving treatment with surgical or medical castration may also be eligible. Exclusion criteria includes current use of opiates based pain killers, previous treatment with certain chemotherapy drugs, suffering from heart failure or having had a myocardial infarction within the last 6 months, and a history of epilepsy or seizures.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with rheumatoid arthritis for at least 3 months. The patients must have had an inadequate response to methotrexate at a dose of 7.5-25mg/week for at least 12 weeks. The trial will test the effectiveness of methotrexate, ocrelizumab, and a placebo. The trial has inclusion and exclusion criteria, which are listed in the \"criteria\" column. The exclusion criteria include having a different type of autoimmune or inflammatory joint disease, having received biologic therapy for RA in the past, or currently receiving any DMARD other than methotrexate.",
    "The sample is a phase 3 clinical trial for migraine disorders. The trial includes patients between the ages of 18 and 65 who have 1-8 migraines per month and less than 15 total headache days per month. Patients must have recently discontinued the use of certain migraine medications due to nonresponse or intolerable adverse events. Female patients must meet certain criteria for contraception. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial aims to test the efficacy and safety of a combination product (sumatriptan succinate/naproxen sodium) compared to a placebo.",
    "The sample is a phase 3 clinical trial for ulcerative colitis. The eligibility criteria include being at least 21 years old, having endoscopic evidence of UC, and having responded inadequately to corticosteroid treatment. Participants must also be off corticosteroids or on a stable dose for at least 2 weeks prior to enrollment. They must be na\u00efve to infliximab and other tumor necrosis factor-alpha (TNF-\u03b1) antagonists, and either na\u00efve to AZA/6-MP or have not received it for at least 3 months before enrollment. Participants must also meet certain tuberculosis screening criteria and have had UC for more than 10 years. Exclusion criteria include severe extensive colitis, certain symptoms, and various medical conditions. Participants must be willing and able to adhere to the study visit schedule and other protocol requirements, and provide written informed consent. Women of child-bearing potential and all men must agree to use a medically accepted method of contraception.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial is looking for patients who are at least 12 years old, weigh at least 30kg (if they are between 12-15 years old) or 40kg (if they are over 16 years old), and have either had one epileptic seizure with a high risk of relapse or have been newly diagnosed with epilepsy and have had at least 2 unprovoked seizures within the past 3 months. Patients must not be taking more than one anticonvulsant drug at the time of inclusion and must meet other eligibility criteria, such as using contraception if they are fertile women. The trial has exclusion criteria, such as patients with non-epileptic seizures or chronic focal epilepsy in their medical history. The trial is testing the effectiveness of two drugs, lamotrigine and levetiracetam, and patients who have previously taken these drugs are excluded from the trial. Patients must provide informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes participants who are at least 18 years old and have had rheumatoid arthritis for at least 6 months. Participants must have a swollen joint count of at least 4 and a tender joint count of at least 4. They must also have had an inadequate response to current DMARD therapy. The trial includes several drugs, including tocilizumab sc, tocilizumab iv, and disease-modifying antirheumatic drugs (DMARDs). The trial also includes a placebo to tocilizumab sc and a placebo to tocilizumab iv. The eligibility criteria include several inclusion and exclusion criteria, such as no major surgery within 8 weeks prior to screening, no history of inflammatory joint disease other than RA, and no previous treatment with tocilizumab.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on chronic pain and includes a list of ICD-10 codes for related diseases. The trial involves the use of two drugs, tramadol hcl er and celecoxib. The eligibility criteria for the trial include having American College of Rheumatology (ACR) Functional Class I-III OA of the knee or hip, having a pain intensity score of at least 40 mm on the visual analog scale (VAS) at the baseline visit, and being able to discontinue acetaminophen, NSAIDS, COX-2 selective inhibitors, and other analgesics during the washout period and all analgesics other than the study medication throughout the study. The exclusion criteria include having a medical condition other than OA that precludes study participation or interferes with the assessment of chronic pain and other OA symptoms, having a diagnosis of inflammatory arthritis, gout, pseudo-gout or Paget's disease, having a diagnosis of chronic pain syndrome or fibromyalgia, having any other clinically significant form of joint disease or prior joint replacement surgery at the index joint, and having an anticipated need for surgery or other invasive procedure in the index joint.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic obstructive pulmonary disease. The trial involves the use of two drugs, formoterol fumurate inhalation solution 20 mcg and ipratropium bromide 18 mcg and albuterol sulfate 103 mcg. The eligibility criteria for the trial include a diagnosis of COPD, a history of smoking for at least 10 years with at least one pack of cigarettes per day, and meeting certain lung function requirements. The exclusion criteria include a diagnosis of asthma, significant disease other than COPD, and being pregnant or planning to become pregnant.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe chronic kidney disease who are not expected to require dialysis or renal transplant within the next 6 months. The trial is testing the effectiveness of the drugs placebo and ast-120. The eligibility criteria include being 18 years or older, having a certain level of serum creatinine and urinary total protein to urinary total creatinine ratio, and having stable blood pressure. Exclusion criteria include having certain medical conditions or having received any investigational agent or participated in a clinical study within the previous 3 months. The sample includes a list of disease names and icd-10 codes, as well as the eligibility and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial that involves patients with either venous thromboembolism or cancer. The trial includes a list of icd-10 codes for the diseases and a list of drugs, including semuloparin sodium and placebo. The eligibility criteria for the trial include having a metastatic or locally advanced solid tumor of the lung, pancreas, stomach, colon/rectum, bladder, or ovary and initiating a new course of chemotherapy with a minimum intent of 3 months therapy. Exclusion criteria include requiring systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic, high risk of bleeding, severe renal impairment, ECOG performance status 3 & 4, major surgery within 4 weeks before randomization, and known hypersensitivity to unfractionated heparin or low molecular weight heparin.",
    "The sample is a phase 3 clinical trial for patients with ulcerative colitis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require patients to be over 18 years old, confirmed to have ulcerative colitis by histology, in remission, and taking mesalazine or other drugs containing 5-ASA for at least 4 weeks. The exclusion criteria include patients with Crohn's disease, active colitis symptoms, and intolerance to Asacol 400 mg or mesalazine. Patients with other serious medical or psychiatric illnesses that could compromise the study are also excluded.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are at least 18 years old and have essential hypertension with a diastolic blood pressure between 100 and 110 mmHg. The trial also has inclusion and exclusion criteria for female patients, pregnant or nursing women, and patients with a history of cardiovascular disease. The trial involves the use of drugs such as amlodipine, olmesartan medoxomil, amlodipine+valsartan, and hydrochlorothiazide. The eligibility criteria for the core study and extension are also provided.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drug icotinib on patients who have progressed after at least one platinum-based chemotherapy regimen. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and at least one measurable lesion. Patients with symptomatic brain metastases, a malignant tumor within the previous five years, severe infection, congestive heart failure, previous treatment with drugs targeting EGFR, or a history of interstitial lung disease are excluded from the trial. The trial is looking to enroll patients who meet the inclusion criteria and do not meet any of the exclusion criteria.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drugs \"ancrod (viprinex)\" and \"placebo\" in treating patients with acute, ischemic stroke. The trial is looking for patients who have had their first symptoms within 6 hours of beginning treatment and have a baseline NIHSS score greater than 5. The trial has exclusion criteria, including patients with intracranial, extravascular blood on CT, hypertension, low fibrinogen levels, thrombocytopenia, recent or anticipated use of a thrombolytic agent, and recent or anticipated surgery. The diseases being studied in this trial are \"stroke\", \"cerebral ischemia\", and \"brain infarction\", and their corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial involves testing two drugs, mp-376 (levofloxacin solution for inhalation) and tis (tobramycin inhalation solution), on patients with confirmed diagnosis of cystic fibrosis and positive sputum culture for P. aeruginosa within the past 12 months. The trial has inclusion and exclusion criteria, including age, lung function, and previous antibiotic use. Patients who complete the trial are also eligible to participate in an open label extension of the study. The data is organized in a table with columns for phase, diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for bladder cancer. The eligibility criteria include having histologically proven organ-confined transitional cell carcinoma of the bladder, having undergone radical cystectomy and bilateral pelvic lymphadenectomy, and having a pathologic stage from definitive cystectomy specimen of P1, P2a, or P2b and N0, M0 TCC with or without squamous/glandular differentiation. The patient must also have potentially curable disease, no invasive tumor into ureter(s) or urethra, and must register within 9 weeks after surgery. The trial involves the use of drugs such as cisplatin, doxorubicin hydrochloride, methotrexate, and vinblastine. The patient must meet certain patient characteristics such as having a WBC of at least 4,000/mm^3, a platelet count of at least 150,000/mm^3, and no serious arrhythmias or congestive heart disease with New York Heart Association class III or IV status. The patient must not have any other malignancy within the past 5 years except incidental prostate cancer found at cystectomy, basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. The patient must not be pregnant or nursing, and fertile patients must use effective contraception. Prior systemic chemotherapy for bladder cancer is not allowed, but prior intravesical therapy is allowed if administered prior to cystectomy.",
    "The sample is for a phase 3 clinical trial related to diabetes. The diseases being studied are diabetes and the ICD-10 codes associated with it. The drugs being tested are saxagliptin, metformin, and a placebo. The eligibility criteria for the trial include having type 2 diabetes with inadequate blood sugar control, and not having any major heart, liver, or kidney problems. Women who are pregnant or breastfeeding, or those who have previously received treatment for diabetes or are currently taking other medications to lower blood sugar are excluded from the trial.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial is focused on patients who are 66 years or older and have a documented clinical diagnosis of MDD. The trial drug being tested is quetiapine. The eligibility criteria for the trial includes exclusion criteria such as the presence of dementia or mental disorder other than MDD within 6 months of enrollment, uncontrolled hypertension, substance or alcohol abuse, and a current diagnosis of cancer or a current or past diagnosis of stroke.",
    "The sample is a phase 3 clinical trial for congestive heart failure. The trial involves the drugs irbesartan and placebo. The eligibility criteria for the trial include being male or female aged 60 years or older with symptoms of heart failure consistent with NYHA class II-IV, having a left ventricular ejection fraction (LVEF) of 45% or higher, and having been hospitalized for heart failure within the past 6 months or having various abnormalities in electrocardiogram, echocardiogram, or chest x-ray indicating heart disease. Exclusion criteria include recent acute myocardial infarction, heart revascularization procedure, hospitalization for angina, other heart surgery, life-threatening or uncontrolled arrhythmia, recent stroke or surgery of the arteries in the brain, serious lung disease requiring home oxygen, significantly low or high blood pressure, other known diseases that may limit life expectancy to less than 3 years, known or suspected bilateral kidney artery narrowing, and geographic or social factors that make study participation and follow-up impractical.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is testing the effectiveness of nevirapine bid, nevirapine qd, and atazanavir drugs. The eligibility criteria for the trial include having a positive serology confirmed by Western blot, no previous antiretroviral treatment of more than 7 days, and adequate renal function. Exclusion criteria include active drug abuse or chronic alcoholism, hepatic cirrhosis stage Child-Pugh B or C, and active hepatitis B or C disease. The trial also excludes patients with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma, and those receiving systemic treatment for malignant disease.",
    "The sample is for a phase 3 clinical trial for the treatment of allergic rhinitis and asthma. The trial involves two groups, one receiving mometasone furoate nasal spray and the other receiving a placebo nasal spray. The eligibility criteria include being an outpatient between the ages of 18 and 75, having moderate/severe persistent allergic rhinitis with a history of intermittent asthma for at least 2 years, and having actual asthma symptoms in the last 4 weeks. Participants must also have a positive skin prick test or CAP-RAST for at least house dust mite and 1 pollen allergen, and meet other criteria related to medication washout, contraception, and general health. Exclusion criteria include pregnancy or nursing, certain medical conditions, and a history of non-compliance with medication or treatment protocols.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as sitagliptin, pioglitazone, and metformin. The eligibility criteria for the trial include completing a previous study and having at least 75% compliance with study medication during the treatment period. Women of childbearing potential must also comply with the specified contraceptive methods. The diseases are listed as 'type 2 diabetes mellitus' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for atopic dermatitis. The trial is looking at the effectiveness of pimecrolimus and topical corticosteroids as treatments for the disease. The eligibility criteria for participants include being between 3 and 12 months old, having a diagnosis of atopic dermatitis that meets certain criteria, having at least 5% of their body affected by the disease, and having a mild-to-moderate disease severity at baseline. There are also exclusion criteria, such as not having used certain treatments within a certain timeframe, having certain medical conditions, or having a known hypersensitivity to the treatments being studied.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm. The trial involves the use of thalidomide and zoledronic acid as drugs. The eligibility criteria for the trial include a diagnosis of multiple myeloma, measurable or evaluable disease, and a performance status of 0-2. Patients must also meet certain patient characteristics, such as having a platelet count of at least 100,000/mm\u00b3 and not being pregnant or nursing. Prior concurrent therapy is allowed, but certain therapies, such as prior thalidomide or corticosteroids for MM, are not allowed.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus using the drug balaglitazone. The trial includes patients who have been diagnosed with type 2 diabetes for at least 3 months, are over 18 years old, have a BMI of at least 25.0 kg/m2, and have a stable dose of insulin of at least 30 U/day for at least 75 days. The trial excludes patients who have previously used any PPAR-\u03b3 agonist, have used an investigational drug within the last 3 months, have pre-existing medical conditions that could interfere with the study, have contraindications or intolerance to the study medication, or are using any drug that could interfere with glucose levels. Other exclusion criteria include heart failure, recent major cardiovascular events or interventions, uncontrolled blood pressure, diabetic macular oedema, hematuria, high serum creatinine levels, abnormal liver function tests, pregnancy or breastfeeding, mental incapacity or language barriers, substance abuse, and any clinically significant disease or disorder that could interfere with the trial results.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic hepatitis B. The trial includes patients who have not been treated with anti HBV agents with antiproliferative activity against, but previous Interferon (IFN) therapy is permitted. The patients must have a positive serum HBV-DNA >= 1,000,000 copies/mL and ALT level 50-500 U/L. The trial has inclusion and exclusion criteria, and patients must be able to read, understand, and sign the informed consent. Patients with liver cancer, co-infection with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV), autoimmune hepatitis, previous transplantation, or any serious complication, except hepatitis B, are excluded from the trial. The trial involves the use of two drugs, lam group and adv group.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia. The trial includes patients who have been diagnosed with BPH and have a Total International Prostate Symptom Score of at least 13. Patients must also have bladder outlet obstruction of intermediate severity and a prostate volume of at least 20 mL. They must not be using any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and/or overactive bladder (OAB) treatments, including alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase type 5 (PDE5) inhibitors, or herbal preparations at any time during the study. Patients must also meet a number of other inclusion and exclusion criteria, such as not having taken certain treatments within a certain duration, not having certain medical conditions, and not being on certain medications. The study will involve the administration of tadalafil or a placebo, and patients must demonstrate compliance with study drug administration requirements during the placebo lead-in period.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for bacterial infections. The diseases being studied are listed as \"bacterial infections\" and the corresponding ICD-10 codes are provided. The drugs being tested are \"iv vancomycin plus iv aztreonam\" and \"ceftaroline\". The eligibility criteria for the trial are also provided, including inclusion criteria such as having a skin and soft tissue infection that requires surgical intervention or occurs in subjects with diabetes or peripheral vascular disease, and exclusion criteria such as prior treatment with antimicrobials or failure of vancomycin or aztreonam as therapy for the current infection.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the treatment of neuropathic pain. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for the trial. The inclusion criteria require subjects to have been diagnosed with peripheral neuropathic pain for at least 6 months and to have a mean weekly pain score of 4 or higher. The exclusion criteria include several diagnoses, such as cervical or lumbo-sacral radiculopathy, that would make a subject ineligible for the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of major depressive disorder with psychotic features. The trial involves the use of two drugs, mifepristone and placebo. The eligibility criteria for the trial include being between 18 and 75 years old, having a diagnosis of major depressive disorder with psychotic features, and being able to provide written informed consent. The exclusion criteria include having a major medical problem, having previously participated in a Corlux (C-1073, mifepristone) clinical trial, and having a history of an allergic reaction to Corlux (C-1073, mifepristone). The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for complicated intra-abdominal infection. The trial involves the use of two drugs, cxa-201 and metronidazole, and meropenem. The eligibility criteria for the trial include a diagnosis of cIAI and the need for surgical intervention within 24 hours of the first dose of the study drug. Exclusion criteria include certain types of infections, use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first dose of study drug, severe impairment of renal function, and hepatic disease at baseline. Women who are pregnant or nursing are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients who have experienced pain, numbness, or tingling in their hands or feet due to chemotherapy. The trial is testing the effectiveness and safety of a cream containing ketamine and amitriptyline in treating chemotherapy-related peripheral neuropathy (CPN). Patients must have a history of cancer, stable systemic metastases and/or bone involvement, and no preexisting peripheral neuropathy due to any cause other than chemotherapy. They must also meet certain patient characteristics, such as having a Karnofsky performance status of 60-100% and no clinically significant illness that could interfere with the study. Prior concurrent therapy is also taken into account, and patients must not have had prior exposure to a peripheral neurotoxin other than chemotherapy. The cream is applied topically, and patients must not have any open skin lesions in the area where the cream is to be applied. Concurrent medications are also taken into account, and patients must not be taking certain medications known to be associated with sensory neuropathy. However, concurrent opioid analgesics, tricyclic or dual reuptake inhibitor antidepressants, or gabapentin or pregabalin for CPN, or benzodiazepines for sleep are allowed, provided the dose has been stable for at least 2 weeks. Concurrent adjunctive analgesic therapy, such as acupuncture, biofeedback, or herbal preparations, is also allowed provided the dose has been stable for at least 2 weeks.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the use of multiple drugs, including a fixed combination ophthalmic suspension and two other ophthalmic solutions. The eligibility criteria for the trial include being diagnosed with open-angle glaucoma or ocular hypertension, meeting certain IOP criteria, and being willing to sign an informed consent form. There are also various exclusion criteria, such as having certain eye conditions or diseases, being pregnant or breastfeeding, and having a history of severe hypersensitivity to certain medications.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of drugs such as sitagliptin, canagliflozin, metformin, and sulphonylurea. The eligibility criteria for the trial include having a diagnosis of T2DM and currently being treated with metformin and sulphonylurea, having a HbA1c between >=7 and <=10.5% and a fasting plasma glucose (FPG) <300 mg/dL (16.7 mmol/L). Patients with a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening are excluded from the trial. The diseases column lists only one disease, which is diabetes mellitus, type 2, and the icd-10 codes column lists the codes associated with this disease.",
    "The sample is a phase 3 clinical trial for a drug combination of eflornithine and sulindac for the treatment of precancerous conditions. The eligibility criteria for the trial include having a history of surgically resected adenomatous polyps of the colon measuring at least 3mm within the past 5 years, having a screening colonoscopy within the past 6 months, and meeting certain medical requirements such as having normal bilirubin, AST, ALT, and creatinine levels. Patients must also not have a personal or family history of certain types of cancer, not be pregnant or nursing, and not have certain medical conditions or allergies. The trial will last for 36 months and patients must have regional geographic stability during that time.",
    "The sample is a record from a clinical trial table that includes information about a phase 3 trial for the treatment of venous thromboembolism. The table includes the names of the diseases being studied, the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is testing the effectiveness of semuloparin sodium, enoxaparin, and a placebo in patients who have undergone knee replacement surgery or revision of a knee prosthesis at least 6 months prior to the study. The inclusion and exclusion criteria are also listed, which include factors such as recent major orthopedic surgeries, history of deep vein thrombosis or pulmonary embolism, contraindications to venography, high risk of bleeding, allergies to certain medications, and end stage renal disease or dialysis.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial involves the drug quetiapine fumarate. The eligibility criteria for the trial include the patient's ability to provide written informed consent, a documented clinical diagnosis of major depressive disorder, and the ability to understand and comply with the study requirements. Exclusion criteria include a history of non-compliance, lack of response to previous treatment with quetiapine, and participation in a clinical trial within 4 weeks of randomization. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with a diagnosis of cerebral infarction, excluding cardiogenic cerebral embolism. The trial is looking at the effectiveness of the drug Aggrenox capsule in treating this condition. The eligibility criteria include patients who have had an onset of cerebral infarction between 1 week and 6 months before enrollment, are 50 years or older, have stable neurological signs and symptoms, and have at least two of the listed risk factors such as diabetes, hypertension, smoking, obesity, previous vascular disease, end-organ damage, or hyperlipidemia. Exclusion criteria include patients with bleeding risk brain disorders, complications of cardiac disorders, acute coronary syndromes, hypersensitivity to dipyridamole preparations, drug allergy to acetylsalicylic acid or aspirin asthma, history of peptic ulcer, undergone arterial reconstruction after development of cerebral infarction, very severe impairment, bleeding or bleeding tendencies, severe hypertension, complications such as serious cardiac, renal and hepatic disorders, malignant tumor or having had a tumor treatment in the past 5 years, and women who are or may be pregnant or lactating women.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis and Burkholderia infections using the drugs azli and placebo. The trial includes subjects of both genders who are at least 6 years old and have been diagnosed with CF through various methods, including genetic mutations and abnormal nasal potential difference. The trial also requires subjects to have chronic infection with Burkholderia spp. and to have received intermittent or continuous aerosolized antibiotic treatment. The trial includes various inclusion and exclusion criteria, such as the ability to perform pulmonary function tests and the absence of certain medical conditions. Sexually active females of childbearing potential must agree to use a highly effective method of contraception during the study period.",
    "The sample is a phase 3 clinical trial for the treatment of sleep initiation and maintenance disorders and insomnia. The trial involves the use of the drug eplivanserin (sr46349) and a placebo. The eligibility criteria for the trial include a diagnosis of primary insomnia based on DSM-IV-TR criteria, disturbance of sleep maintenance, and impact on daytime functioning associated with sleep maintenance insomnia. Exclusion criteria include pregnancy or lactation, acute or chronic pain resulting in insomnia, current psychiatric disturbances, and various medical conditions that may interfere with the absorption, metabolism, distribution, or excretion of the study drug or affect patient safety. The trial also excludes individuals who consume xanthine-containing beverages, use any over-the-counter or prescription sleep medication, or substances with psychotropic effects or properties known to affect sleep/wake within one week or five half-lives prior to screening. Additionally, night shift workers, individuals who nap three or more times per week over the preceding month, and those with primary hypersomnia, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, or parasomnia are excluded based on medical history and/or nocturnal polysomnography recordings performed at the sleep laboratory during the two screening nights.",
    "This sample is for a phase 3 clinical trial that focuses on treating vasomotor symptoms and hot flashes. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria require postmenopausal women over 40 years of age who experience at least 7 to 8 moderate to severe hot flushes per day or 50 to 60 moderate to severe hot flushes per week. The exclusion criteria include the usual criteria for hormone therapy and the intake of medications other than hormones that affect hot flushes.",
    "The sample is a phase 3 clinical trial for the treatment of attention deficit hyperactivity disorder using methylphenidate HCl. The trial includes patients who have successfully completed earlier ALZA studies without significant drug-related adverse events, whose primary care physician agrees to their participation, and who agree to take only the OROS\u00ae (methylphenidate HCl) supplied and no other methylphenidate dosage form or other medications for the treatment of ADHD during the study. Patients must also be able to comply with the study visit schedule and have normal urinalysis, hematological and blood chemistry values. Exclusion criteria include patients with clinically significant gastrointestinal problems, coexisting medical conditions or taking medication that may interfere with safe administration of methylphenidate, known hypersensitivity to methylphenidate, history of high blood pressure or blood pressure equal to or greater than the 95th percentile for age, gender and height, and female patients who have begun menstruation.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of asthma. The icd-10 codes associated with the disease are listed, along with the drugs being tested, which include montelukast sodium and a placebo comparator. The eligibility criteria for the trial are also listed, including age range and positive skin prick tests to relevant allergens, as well as exclusion criteria such as the absence of any other pulmonary disorders.",
    "The sample is a record from a clinical trial table, containing information about a phase 3 trial for patients with atrial fibrillation and vascular risk. The table includes columns for the trial phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria. The eligibility criteria include requirements for evidence of atrial fibrillation and high risk of vascular events, as well as contraindications for oral anticoagulant treatment. The exclusion criteria include prior intolerance to ASA or clopidogrel, documented peptic ulcer disease, ongoing alcohol abuse, and other factors that may make study participation impractical.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes mellitus. The trial involves testing various drugs, including sitagliptin phosphate, metformin hydrochloride, and pioglitazone, as well as placebos. The eligibility criteria for the trial include patients between the ages of 18 and 78 who have not been on any antihyperglycemic agent in the last 3 months. Patients with a history of type 1 diabetes mellitus or ketoacidosis, or who have previously been treated with sitagliptin or a DPP-4 inhibitor, are excluded from the trial. The diseases and icd-10 codes associated with the trial are also listed.",
    "The sample is a record of a clinical trial for a drug used to treat attention deficit hyperactivity disorder (ADHD). The trial is in phase 3 and the table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include age requirements, a diagnosis of ADHD, a period of time without medication prior to the trial, and the ability to swallow capsules. The exclusion criteria include recent use of unapproved drugs, previous negative reactions to the drug being tested, serious suicidal risk, and pre-existing cardiovascular disease or other conditions that could be worsened by increased heart rate or blood pressure.",
    "The sample is a phase 3 clinical trial for kidney transplantation. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include age, type of donor, written consent, negative pregnancy test for females, and exclusion criteria such as no evidence of graft function, multiple organ transplants, positive HIV/HCV/Hepatitis B surface antigen, abnormal liver profile, and history of malignancy. The extension study inclusion criteria include completion of the core study and written informed consent, while the exclusion criteria include women of childbearing potential who are unwilling to use effective contraception.",
    "The sample is a phase 3 clinical trial that involves children and adolescents with chronic renal failure, hypertension, acquired kidney disease, and congenital kidney disease. The trial aims to test the effectiveness of ace inhibition, intensified blood pressure control, and add-on angiotensin receptor blockade as treatments. The trial has specific inclusion and exclusion criteria, such as age range, renal function, blood pressure, and written informed consent. Patients with certain conditions, such as renal artery stenosis, urological surgery, and secondary renal diseases, are excluded from the trial. Additionally, patients who have not complied with prescribed antihypertensive medication during the run-in period or have received erythropoietin or growth hormone therapy for less than 3 months prior to the run-in period are also excluded. Finally, pregnant women are not eligible for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial is focused on patients with metastatic prostate cancer that is unresponsive or refractory to hormone therapy. The trial includes patients with any Gleason score and detectable metastases, with an ECOG performance status of 0-2. The treatment being tested is chemotherapy using taxotere and prednisone. The eligibility criteria includes a confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate, while the exclusion criteria includes prior treatment with chemotherapy, immunotherapy, gene therapy, and significant cancer-related pain.",
    "The sample is a phase 3 clinical trial for the treatment of thromboembolism. The trial involves the drug \"exanta\" and includes patients who are scheduled for primary elective hip replacement or require surgery for hip fracture. The eligibility criteria include being 18 years or older and providing signed informed consent. The exclusion criteria include a history of heparin-induced thrombocytopenia, conditions associated with increased risk of bleeding, renal impairment, known active liver disease or liver insufficiency, and recent myocardial infarction, ischemic stroke, transient ischemic attack, systemic embolism, or venous thrombo-embolism.",
    "This sample is for a phase 3 clinical trial for the treatment of osteoporosis. The trial is testing the effectiveness of three drugs - lasofoxifene, raloxifene, and placebo. The eligibility criteria for the trial includes postmenopausal women with low bone density and no significant findings in their screening labs, pelvic ultrasound, and mammogram. However, women with metabolic bone disease, fractures, blood clots, recent cancer, or recent use of certain medications are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with coronary artery disease and valvular heart disease. The trial involves the use of intravenous magnesium as a treatment. The eligibility criteria for the trial include patients undergoing coronary artery bypass surgery with or without valve procedure, scheduled for on-pump or cardiopulmonary bypass protocol. The exclusion criteria include patients with existing atrial fibrillation/flutter in the past year or on antiarrhythmic medications, ventricular fibrillation, sustained ventricular tachycardia, 2nd or 3rd degree heart block, paroxysmal supraventricular tachycardia, major aortic repair planned during open-heart procedure, permanent atrial/ventricular pacemaker implanted, dialysis dependent or creatinine clearance < 35 umoles/min or oliguric/anuric renal failure, patient intolerant of beta blockers, patient has reactive airways disease dependent on regular beta-adrenergic agents, and patient is scheduled to undergo off-pump surgical protocol.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial involves the use of the drug LY2216684, as well as a placebo and selective serotonin reuptake inhibitors (SSRIs). The eligibility criteria include being a woman of child-bearing potential who tests negative for pregnancy, being treated with an SSRI for at least 6 weeks prior to the trial, meeting criteria for major depressive disorder, and having a GRID 17-Item Hamilton Depression Rating Scale (GRID-HAMD17) total score greater than or equal to 16 at screening. Exclusion criteria include having any additional ongoing DSM-IV-TR Axis 1 condition other than major depression within 1 year of screening, having a current or previous diagnosis of a bipolar disorder, schizophrenia, or other psychotic disorder, and having a history of substance abuse and/or dependence within the past year.",
    "The sample is a phase 3 clinical trial for liver cancer. The eligibility criteria include having histologically proven hepatoblastoma or hepatocellular carcinoma, with diagnostic surgical biopsy strongly recommended for all patients and mandatory for certain groups. The disease is categorized as standard risk or high risk based on the number of hepatic sections involved and the presence of extrahepatic metastases or abdominal disease. The patient must be 16 years old or younger at diagnosis, with no specified performance status, life expectancy, hematopoietic, hepatic, or renal conditions. Prior concurrent therapy is not specified, but prior surgery is allowed. The trial involves the use of carboplatin, cisplatin, and doxorubicin hydrochloride.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who have been diagnosed with idiopathic PD and have a good response to levodopa. Patients must have predictable motor fluctuations of the wearing OFF type with the presence of at least 2 hrs of OFF time during the waking day. The trial includes patients who are taking optimised levodopa therapy and are able to distinguish their own motor states. Patients must be able to complete the study including the completion of the home diary cards and are capable of giving full written informed consent. The trial excludes pregnant or lactating women, patients with a past or present history of drug or alcohol abuse, patients with a past or present history of psychotic symptoms requiring anti psychotic treatment, and patients with unstable abnormalities of the hepatic, renal, cardiovascular, respiratory, gastro-intestinal, haematological, endocrine or metabolic systems that might complicate assessment of the tolerability of the study medication.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients between the ages of 18 and 65 who have a primary diagnosis of non-psychotic MDD and a MADRS total score of 24. Female patients must have a negative pregnancy test and agree to comply with any applicable contraceptive requirements. The trial involves the drugs spd489 (lisdexamfetamine dimesylate) and placebo. The eligibility criteria include being able to provide written informed consent, being able to swallow a capsule, and not having a current co-morbid psychiatric disorder. Exclusion criteria include having a history of treatment-resistant depression, being considered a suicide risk, having a concurrent chronic or acute illness, and having a known or suspected intolerance to the assigned antidepressant treatments.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease of hyponatremia. The icd-10 codes associated with the disease are \"P74.22\" and \"E87.1\". The trial involves two drugs, lixivaptan and placebo. The eligibility criteria for the trial include being a male or female patient who is 18 years or older and has hyponatremia, and is hospitalized for congestive heart failure.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus and cardiovascular disease. The trial involves the use of the drugs aliskiren and placebo. The eligibility criteria for the trial include having type 2 diabetes and either macroalbuminuria with an eGFR of at least 30 mL/min/1.73 m2, microalbuminuria with a reduced kidney function, or a history of cardiovascular disease with a reduced kidney function. Concomitant treatment must include either an ACEi or an ARB but not both. Exclusion criteria include type 1 diabetes mellitus, recent cardiovascular events or procedures, unstable serum creatinine, hypertension, high serum potassium levels, and previous randomization into the AVOID trial. During the safety follow-up period, aliskiren or aliskiren-containing products must not be used.",
    "The sample is a record of a clinical trial in phase 3, focused on chronic pancreatitis. The trial includes a list of icd-10 codes for the disease, as well as a list of drugs being tested, including triamcinolone and bupivicaine alone. The eligibility criteria for participants are also listed, including age over 18, ability to provide informed consent, and chronic pancreatic-type abdominal pain. Exclusion criteria include pregnancy, malignancy, recent acute pancreatitis, elevated INR or low platelet count, allergy to certain substances, and a Beck's depression score over 20.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes patients who have been treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months and have a HbA1c level between 7.5% - 12.0%. The trial also requires patients to have a Fasting Plasma Glucose level higher than 7.0 mmol/L and a BMI between 23-40 kg/sq.m. The trial excludes patients with metformin contraindications according to local practice and those who have used TZDs (thiazolidinediones) for more than 1 month within 6 months prior to the trial. The trial involves the use of biphasic insulin aspart 30, metformin, and biphasic insulin aspart 50. The diseases included in the trial are diabetes and diabetes mellitus, type 2, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes who have inadequate glycemic control. The trial includes both males and females between the ages of 18 and 77 who are either drug naive or have been treated with anti-diabetic medication for less than 24 weeks since their original diagnosis. In order to be eligible for the trial, participants must have a C-peptide level of at least 1.0 ng/mL, a body mass index of 45.0 kg/m or less, and a serum creatinine level of less than 1.50 mg/dL for men or less than 1.40 mg/dL for women. The trial excludes individuals with symptoms of severely uncontrolled diabetes, as well as those with unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases. The trial will test the effectiveness of the drugs dapagliflozin and metformin xr in treating type 2 diabetes.",
    "The sample is a phase 3 clinical trial for contraception. The trial is open to women aged 16 or older in the UK (except Northern Ireland), 17 or older in Northern Ireland, and 18 or older in Ireland and the US. The trial requires participants to be within 120 hours of unprotected intercourse and have regular menstrual cycles. Participants must not be currently using hormonal contraception and must be willing to abstain from using it until the study is completed. They must have had at least one complete menstrual cycle after a miscarriage, delivery, or abortion. Participants must also be willing to provide informed consent and abstain from further acts of unprotected intercourse until the study is completed. Exclusion criteria include having had unprotected intercourse more than 120 hours prior, current or recent use of hormonal contraception, current pregnancy or breastfeeding, tubal ligation or current use of an IUD, use of hormonal emergency contraception since the last menstrual period, and severe asthma insufficiently controlled by oral glucocorticoid. Participants must also not have hypersensitivity to the active substance levonorgestrel or any of the excipients of the drug products used in the study.",
    "The sample is a phase 3 clinical trial for the treatment of partial epilepsies and partial onset seizures using the drug lacosamide. The trial includes patients who have been diagnosed with epilepsy and have stable doses of 1 to 2 marketed antiepileptic drugs for at least 28 days prior to screening. Patients must have had at least 1 partial seizure with a motor component per 90 days and a maximum allowed seizure frequency of 40 partial seizures of any type during the 28 days prior to screening. The trial has exclusion criteria, including previous use of lacosamide, history of primary generalized seizures, and use of certain medications within 28 days prior to screening. The trial also excludes patients who have had non-epileptic events or have received certain rescue medications. Prior or concomitant use of vigabatrin is also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of partial seizures using the drug zonisamide. The eligibility criteria for the trial include being between the ages of 6 and 18, having completed a previous double-blind study, being in good health, and not having certain medical conditions or a history of non-compliance with treatment. Exclusion criteria include having a body weight less than 20 kg, a history of renal calculi or renal insufficiency, a known diagnosis of HIV or hepatitis B or C, a history of sensitivity to sulfonamide drugs or zonisamide, and a recent history of excessive alcohol use or drug abuse. The trial also excludes subjects who have a history of suicide attempt, clinically significant organic disease, or who are not expected to comply with study procedures. Concomitant use of certain medications is also excluded.",
    "The sample is a phase 3 trial for the treatment of reflux esophagitis. The diseases column lists only one disease, which is reflux esophagitis. The icdcodes column lists the ICD-10 codes associated with the disease. The drugs column lists three different drugs, two of which are esomeprazole and one is omeprazole. The criteria column lists the eligibility criteria for the trial, including inclusion criteria such as having endoscopically verified reflux esophagitis classified into Los Angeles classification Grade A, B, C or D within 1 week before randomisation, and exclusion criteria such as having a gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation and using any PPI from 14 days before EGD performed at the screening visit to the day of randomisation.",
    "The sample is a phase 3 clinical trial for patients who are 18 years or older and require primary orthotopic liver or split liver allograft transplantation. The trial is focused on the drug tacrolimus and the eligibility criteria includes patients receiving a liver transplant from a cadaveric heart-beating donor with compatible AB0 blood type. The exclusion criteria includes patients who have received an auxiliary graft, require initial sequential or parallel therapy with other immunosuppressive antibody preparation(s), require ongoing dosing with corticosteroids, exhibit symptoms of or have a previous history of neoplastic disease, are known to be HIV positive, or are allergic or intolerant to the study medication. The diseases being studied are related to liver transplantation and are identified by their ICD-10 codes.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of hypertension. The trial is focused on patients who have previously been treated with antihypertensive medications but have not reached their blood pressure goal. The trial drug being tested is losartan potassium (+) hydrochlorothiazide. The record includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for inclusion and exclusion from the trial. The inclusion criteria include being 18 years or older and having essential hypertension, while the exclusion criteria include a history of stroke or heart attack, renal or liver disease, uncontrolled diabetes, and sensitivity or intolerance to the study medication.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who are 55 years or older and have a substantially elevated risk of cardiovascular disease. The trial involves the use of two drugs, perindopril-indapamide and gliclazide mr-based glucose lowering. The eligibility criteria include a diagnosis of type 2 diabetes mellitus made at age 30 years or older, a history of major macrovascular or microvascular disease, or another major risk factor for vascular disease. Exclusion criteria include contraindications to treatment with the drugs, specific indications for other treatments, or participation in another trial. Final decisions about eligibility were made at the discretion of the study investigator and the potential study participant, in the light of any requirements or guidance from local ethics committees and other regulatory bodies.",
    "The sample is a phase 3 clinical trial for patients with multiple sclerosis. The trial involves testing the effectiveness of two drugs, dalfampridine-er 5mg and dalfampridine-er 10mg, on MS-related walking impairment. The eligibility criteria include having clinically definite MS, being between 18 and 70 years old, mentally competent, and able to perform all required study procedures. Exclusion criteria include pregnancy or breastfeeding, history of seizures, moderate or severe renal impairment, active urinary tract infection, recent changes in medication regimen, and participation in another investigational trial. The trial requires patients to complete two trials of the Timed 25 Foot Walk (T25FW) at the screening visit and every study visit thereafter. The trial also has specific instructions provided by the National Multiple Sclerosis Society MS Functional Composite Manual.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial includes female patients who are 18 years or older and have symptoms of urinary frequency, urgency, and at least three months of duration. The trial excludes patients with a positive urine culture in the past month, stress or overflow urinary incontinence, pregnancy, seizure disorder, clinically significant renal disease, allergy to lidocaine, uninvestigated hematuria, or history of urinary/reproductive tract malignancy. The trial will test the effectiveness of alkalinized xylocaine and placebo as treatments for overactive bladder.",
    "The sample is for a phase 3 clinical trial for the treatment of moderate to moderately severe chronic active ulcerative colitis. The trial is testing the effectiveness of the drug cobitolimod compared to a placebo. The eligibility criteria include being male or female over 18 years old with a well-established diagnosis of the disease and not responding adequately to currently available therapies. Patients must have tried at least one treatment course with mesalazine or similar drugs, at least one full dose treatment course of corticosteroids, at least one treatment course of azathioprine or mercaptopurine, and/or at least one adequate treatment course of an anti-TNF alpha. Patients must also be on an accumulated stable tolerable GCS dose equivalent to at least 140 mg of prednisolone/prednisone for the last two weeks. The exclusion criteria include patients with suspicion of Crohn's enterocolitis, ischaemic colitis, radiation colitis, diverticular disease associated colitis, as well as microscopic colitis. Patients with disease limited to the rectum (ulcerative proctitis) should also be excluded. Patients with acute fulminant UC and/or signs of systemic toxicity to an extent that requires immediate surgical action should also be excluded. The trial lasts for 52 weeks and women of childbearing potential must use reliable contraceptive methods throughout the duration of the study.",
    "The sample is a phase 3 clinical trial for the treatment of behavioral symptoms and autistic disorder. The trial involves the use of aripiprazole and placebo drugs. The eligibility criteria include meeting the DSM-IV-TR diagnostic criteria for AD, having serious behavioral problems, having a CGI score of at least 4 and an ABC Irritability/Agitation subscale score of at least 18, having a mental age of at least 18 months, and being between 6 and 17 years old. Exclusion criteria include being treatment-resistant to neuroleptic medication, previously not responding to aripiprazole treatment, having another disorder on the autism spectrum, having bipolar disorder, psychosis, schizophrenia, or major depression, having a seizure in the past year, and having a history of severe head trauma or stroke. Non-pharmacologic therapy should be stable prior to screening and consistent throughout the study.",
    "The sample is a phase 3 clinical trial for low back pain. The trial includes patients who have had back pain lasting more than six weeks and have used analgesic medication to treat pain for at least four out of the last seven days and at least 10 days in the last month. Patients must be men or non-pregnant, non-lactating women over the age of 18 and under the age of 75, able to read, understand and sign English-language informed consent, with a diagnosis of back pain and baseline back pain greater than 40 mm out of 100 mm on visual analog scale. Patients taking an NSAID for pain must discontinue use during a washout period based on the attached five (5) half-lives of drug chart. If undergoing physical therapy for back pain, therapy must be stable at least three weeks prior to study and remain the same throughout the study. If using psychoactive medication which might have analgesic effects, (i.e. anti-depressants or anti-convulsants-), treatment must be stable for at least three months prior to study. Patients must be willing to use adequate contraception and not be pregnant or impregnate their partner during the entire time of the study. Patients must be willing to commit to all clinical visits during study-related procedures, including required discontinuation (washout) of analgesic or anti-inflammatory medication prior to Day 1 randomization. The patient must agree to using acetaminophen for rescue medication. Exclusion criteria include patients with back surgery in the past six months, significant neurologic impairment, evidence or history of fracture of the spine in the past year, patients not fluent in English, use of aspirin for non-arthritic conditions, use of controlled substances and/or opiate analgesic for pain, receipt of an oral intramuscular or soft-tissue injection of corticosteroid within one month prior to screening, participation in a clinical trial within the one month prior to screening, history of epidurals in the past 3 months, history of alcohol or substance abuse, uncontrolled or unstable serious cardiovascular, pulmonary, gastrointestinal or urogenital, endocrine, neurologic or psychiatric disorder, and history of gastrointestinal bleed or documented gastric or duodenal ulcer.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of diabetes. The icd-10 codes associated with the disease are listed, along with a list of drugs being tested, including saxagliptin, metformin, pioglitazone, and a placebo. The eligibility criteria for the trial are also listed, including requirements for participants to have type 2 diabetes and inadequate blood sugar control, as well as exclusion criteria such as major heart, liver, or kidney problems, and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for the treatment of central retinal vein occlusion and macular edema using the drug ranibizumab. The trial includes patients who are at least 50 years old and have a history of decreased visual acuity within the past 6 months. Eligible patients must also have a best corrected visual acuity score of 73 or lower and macular edema verified by OCT. The trial has a list of exclusion criteria, including previous treatment with anti-angiogenic drugs, use of other investigational drugs, and history of certain ocular conditions or diseases. Patients must be willing and able to comply with study procedures and give written informed consent.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes and obesity. The trial involves the use of the drugs liraglutide and placebo. The eligibility criteria for the trial include having a BMI of at least 27.0 kg/m^2, being diagnosed with type 2 diabetes and having a stable body weight. The trial also has exclusion criteria, such as having a history of major depressive disorder or suicide attempt, and having uncontrolled hypertension. The diseases being studied are metabolism and nutrition disorder and obesity, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for potentially curable adenocarcinoma of the breast, with a focus on postmenopausal women. The trial requires prior treatment with one of several specified therapies and includes eligibility criteria related to disease stage, hormone receptor status, and patient characteristics such as age and performance status. The trial allows for prior or concurrent adjuvant chemotherapy at the investigator's discretion and prior tamoxifen therapy. The trial also includes requirements for radiotherapy and surgery. The table includes columns for the trial phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for chronic pain, osteoarthritis, and low back pain. The trial involves the use of fentanyl and placebo drugs. The eligibility criteria include having pain due to osteoarthritis or low back pain for at least 12 weeks, taking a non-opioid analgesic at the normal highest dose or more for at least 14 consecutive days, showing insufficient therapeutic efficacy of the non-opioid analgesic currently being used, and requiring a continuous opioid analgesic. Participants must also have an average pain intensity of 50 millimeters or more on the Visual Analog Scale (VAS) in 24-hour daily living prior to informed consent and be able to be hospitalized to the 4th day after the initiation of titration period. Exclusion criteria include having severe pain of lower extremities due to radiculopathy, pain due to compression fracture, having had an operation that may affect the assessment within 30 days before informed consent, having pain considered attributable to psychogenic pain, and having asthma, bradyarrhythmia, and severe respiratory function disorders.",
    "The sample is a phase 3 clinical trial for metastatic breast adenocarcinoma (stage IV) without any prior chemotherapy received. The trial is testing the effectiveness of a combination of drugs including gemcitabine, herceptin, and capecitabine (xeloda). The trial has specific eligibility criteria including HER-2 overexpression, measurable disease, at least one prior chemotherapy regimen, and adequate liver and cardiac function. Exclusion criteria include pregnancy or nursing, concurrent use of certain medications, and other uncontrolled illnesses or invasive malignancies within the past 5 years.",
    "The sample is a phase 3 clinical trial for the treatment of osteoporosis and osteopenia. The trial involves the use of two drugs, alendronate and denosumab. The eligibility criteria for the trial include being an ambulatory postmenopausal woman with a BMD value that corresponds to a T-score of less than or equal to -2.0 at the lumbar spine or total hip within range specific to the study protocol. Exclusion criteria include having any disorder that compromises the ability to give written informed consent or comply with study procedures, as well as various medical conditions such as hyper- or hypothyroidism, hyper- or hypoparathyroidism, and significantly impaired renal function. Additionally, certain medications and treatments are also exclusion criteria.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of sitagliptin 100 mg q.d./metformin \u2265 1500 mg/day and a placebo comparator. The eligibility criteria include poorly controlled patients taking one or two oral antidiabetic medications, while exclusion criteria include patients with a history of type 1 diabetes mellitus or ketoacidosis, those who required insulin therapy within the prior 8 weeks, and those who have been taking certain medications within the prior 12 weeks.",
    "The sample is a phase 3 clinical trial for liver transplantation. The trial includes patients who are 18-70 years old and have received a primary liver transplant from a deceased donor. The patients must have confirmed hepatitis C virus (HCV) status and their allograft must be functioning at an acceptable level. The trial involves the use of various immunosuppressive drugs, including tacrolimus and corticosteroids. Patients must meet certain inclusion criteria, such as having an MDRD eGFR \u2265 30 mL/min/1.73m2 and at least one tacrolimus trough level of \u2265 8 ng/mL in the week prior to randomization. Patients who have received multiple solid organ or islet cell tissue transplants, have a history of malignancy within the past 5 years (other than non-metastatic basal or squamous cell carcinoma of the skin or HCC), or have any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, and excretion of study drug are excluded. Women of child-bearing potential are also excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 3 clinical trial for the treatment of cervical dystonia. The trial is testing the effectiveness of a placebo drug on patients who have not been previously treated with botulinum toxin or have had a minimum interval of 16 weeks since their last injection. Patients must have had cervical dystonia for at least 18 months and meet certain TWSTRS severity, disability, and total score criteria at baseline. Patients with pure anterocollis or pure retrocollis, those in apparent remission from cervical dystonia, those who have had a poor response to the last two botulinum toxin treatments, and those being treated with type B toxin due to lack of efficacy to type A toxin or have known neutralizing antibodies to type A toxin are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial is being conducted in Japan and includes male and female patients over the age of 40 with a smoking history of more than 10 pack years. The trial is testing the effectiveness of tiotropium + olodaterol and olodaterol as treatments for COPD. The eligibility criteria include a diagnosis of COPD, relatively stable airway obstruction, and no significant diseases other than COPD. The exclusion criteria include a history of asthma, clinically relevant abnormal lab values, and a history of certain medical conditions such as thyrotoxicosis and paroxysmal tachycardia. Patients who have undergone certain medical procedures or are taking certain medications are also excluded from the trial. Pregnant or nursing women and patients who are unable to comply with pulmonary medication restrictions are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of the drugs glimepiride and linagliptin, as well as placebos. The trial has specific eligibility criteria, including a minimum age of 18, a BMI of 45 kg/m2 or less, and a signed informed consent. Exclusion criteria include recent myocardial infarction, stroke, or TIA, renal impairment requiring dialysis, and treatment with certain medications. The trial aims to evaluate the effectiveness of the drugs in managing type 2 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for the treatment of deep venous thrombosis. The trial includes patients with confirmed acute symptomatic DVT of the lower limbs and excludes those with severe concomitant diseases, active bleeding or high risk for bleeding, pregnancy or childbearing potential without proper contraceptive measures, breastfeeding, known allergy to idraparinux, SSR126517E, or egg proteins, indication of prolonged anticoagulation for other reason than DVT of the lower limbs, symptomatic pulmonary embolism (PE), and life expectancy less than 6 months. The trial involves the use of drugs such as idrabiotaparinux sodium, idraparinux sodium, avidin, and placebo (for avidin). The diseases are listed as 'deep venous thrombosis' and the icd-10 codes associated with the disease are [\"['I81', 'K64.5', 'I51.3', 'I67.6', 'I74.11', 'I74.5', 'I74.8']\"].",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drug ipragliflozin. The eligibility criteria for the trial include having a HbA1c value between 6.5% and 9.5%, being on a diet and exercise program or having received a single or two antihyperglycemic agents (excluding insulin) with low dose, and having a BMI between 20.0 and 45.0 kg/m2. Exclusion criteria include having type 1 diabetes mellitus, having received insulin within 12 weeks before the study, having proliferative diabetic retinopathy, having a history of clinically significant renal disease, having obvious dysuria caused by a neurogenic bladder or a benign prostatic hypertrophy, having a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, and heart disease (NYHA Class III-IV) within 12 weeks, being pregnant or lactating, having a history of treatment with ASP1941, having participated in another clinical study within 12 weeks before providing written informed consent, having a serum creatinine value higher than upper limit of normal range, having a urinary microalbumin/ urinary creatinine ratio > 300 mg/g in urinalysis, having uncontrolled severe hypertension, or being judged inappropriate for enrollment into the study by the principal investigator or the sub-investigator.",
    "The sample is a phase 3 clinical trial for patients with metastatic colorectal cancer. The trial includes patients with confirmed adenocarcinoma of the colon or rectum, stage IV disease, and an estimated life expectancy of more than 3 months. The trial involves the use of several drugs, including capecitabine, bevacizumab, and irinotecan. The eligibility criteria include adequate hematologic function, effective contraception, and no relevant toxicities due to prior medical treatment. The exclusion criteria include heart failure, prior treatment with bevacizumab or EGFR inhibitors, and known hypersensitivity reactions to any study medication. The trial also excludes patients with certain medical conditions, such as acute or subacute ileus, chronic inflammatory bowel disease, or chronic diarrhea.",
    "The sample is a phase 3 clinical trial for patients with unresectable and/or metastatic, measurable renal cell carcinoma. The trial is testing the effectiveness of sorafenib (nexavar, bay43-9006) as a treatment option. The eligibility criteria include having a life expectancy of at least 12 weeks, having received not more than one prior systemic therapy for advanced disease, having at least one uni-dimensional measurable lesion by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI), and having an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1. The exclusion criteria include having previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, cardiac arrhythmias requiring anti-arrhythmic medication, active clinically serious bacterial or fungal infections, and substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results. The excluded concomitant medications include concurrent anti-cancer chemotherapy, immunotherapy, or hormonal therapy except Bisphosphonates, radiotherapy during study or within 3 weeks of start of study drug, and biological response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CFS) or Granulocyte macrophage colony-stimulating factor (GM-CFS), within 3 weeks prior to study entry or during study.",
    "The sample is a phase 3 clinical trial for lung cancer patients. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel. The eligibility criteria for patients include having unresectable stage IIIA or IIIB non-small cell carcinoma of the lung, being at least 18 years old, having a performance status of ECOG 0-1, and having no significant hepatic or renal insufficiency. Patients must not have had prior systemic chemotherapy or thoracic radiotherapy. The trial requires patients to have measurable or evaluable disease and no distant metastasis or significant pleural effusion. Patients must also not have a history of prior or concurrent malignancy in the past 5 years, except for surgically cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. Fertile patients must use effective contraception during and for 2 weeks after the study.",
    "The sample is a phase 3 clinical trial for kidney transplantation and chronic kidney failure. The trial includes patients who have received a living or deceased donor kidney transplant and are 18 years or older. The trial excludes patients who are receiving an extended criteria donor organ, have a positive cross match, or have completed three years of study treatment. The trial involves the use of three drugs: cyclosporine (csa), belatacept li (less intensive), and belatacept mi (more intensive). The eligibility criteria for the trial include PRA levels and previous graft loss due to acute rejection.",
    "The sample is a phase 3 clinical trial for patients with advanced or recurrent malignant melanoma that cannot be treated with surgery or local therapy. The trial involves the use of dacarbazine, fotemustine, and interferon alfa-2b drugs. The eligibility criteria include having a confirmed diagnosis of malignant melanoma, measurable disease, being between the ages of 18 and 75, having a performance status of 0-2, and a life expectancy of at least 3 months. Patients must also have adequate bone marrow, liver, and renal function, and provide written informed consent. Exclusion criteria include having previous or concurrent malignancies at other sites, prior chemo-immunotherapy, known HIV disease, concurrent treatment with other experimental drugs, and concurrent chemotherapy, immunotherapy, hormonal therapy, or radiation therapy.",
    "The sample is a phase 3 clinical trial for the treatment of non-small cell lung cancer with a primary histology of squamous cell, large cell or adenosquamous carcinoma. The trial involves the use of drugs such as cp 751,871 (figitumumab) and erlotinib. The eligibility criteria for the trial include having at least one measurable lesion as defined by RECIST and not having prior Erlotinib therapy or prior anti IGF IR based investigational therapy. The diseases being studied in the trial include carcinoma, large cell, carcinoma, non-small-cell lung, carcinoma, squamous cell, and carcinoma, adenosquamous cell, which are identified by their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on Crohn's Disease, with a list of ICD-10 codes provided. The trial involves two drugs, infliximab (ifx) placebo infusion and azathioprine (aza) caps. The eligibility criteria for the trial include a diagnosis of Crohn's Disease for at least 6 weeks, moderate to severe disease activity, and no history of certain treatments. The exclusion criteria include recent abdominal surgery, pregnancy or planning pregnancy, and serious simultaneous illness. The sample also includes additional details about the trial's inclusion and exclusion criteria.",
    "This sample is for a phase 3 clinical trial for asthma. The trial is looking at the effectiveness of fluticasone propionate, fluticasone furoate, and a placebo. The eligibility criteria includes being an outpatient at least 12 years of age, having a pre-bronchodilator FEV1 of 40-90% predicted, and having a current asthma therapy that includes an inhaled corticosteroid for at least 4 weeks prior to the first visit. Exclusion criteria includes having a history of life-threatening asthma, respiratory infection or candidiasis, and taking another investigational medication or medication prohibited for use during this study.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on Friedreich's ataxia, a disease that affects the nervous system. The trial is testing the effectiveness of the drug idebenone. The record includes a list of inclusion and exclusion criteria for patients who are eligible to participate in the trial. The criteria include factors such as completion of a previous study, body weight, and absence of certain medical conditions. The record also notes that patients who have experienced adverse effects from idebenone in the past or who are currently participating in another clinical trial are not eligible to participate. Additionally, patients with a history of drug or alcohol abuse, or who are pregnant or breastfeeding, are excluded from the trial.",
    "The sample is a phase 3 clinical trial for human immunodeficiency virus infections. The trial includes patients who are at least 18 years old and are currently receiving an antiretroviral regimen which has not changed for at least 12 weeks. The patients must have plasma HIV-1 ribonucleic acid (RNA) levels greater than 1,000 copies/mL at screening and must not be acutely ill. The trial involves the use of lopinavir/ritonavir (lpv/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (nrtis) as the drug treatment. The eligibility criteria include various inclusion and exclusion criteria such as hemoglobin levels, absolute neutrophil count, platelet count, and liver function tests. Female subjects must be nonpregnant and nonlactating.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with RA based on the 1987 classification criteria of the American College of Rheumatology and have had the disease for at least 6 months. Patients must have been treated with 8 mg/week of MTX for at least 8 weeks prior to enrollment and must have active disease at enrollment. The trial includes a list of drugs, including mra(tocilizumab), mra placebo, mtx, and mtx placebo. The eligibility criteria for the trial are listed, including inclusion and exclusion criteria. The inclusion criteria include having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30 mm/hr and CRP not less than 1.0 mg/dL. The exclusion criteria include being assessed as having Class IV Steinbrocker functional activity in the 4 weeks preceding treatment with the study drug and having received certain therapies in the 2 or 4 weeks preceding treatment with the study drug.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes subjects who are outpatients, aged 40 years or older, with a clinical history of COPD and a current or prior history of at least 10 pack-years of cigarette smoking. The trial involves the use of four different drugs, including a placebo, and the eligibility criteria include various medical and demographic factors, such as gender, pregnancy status, and history of other respiratory disorders. The trial also includes exclusion criteria, such as a history of drug or alcohol abuse, and subjects who are unable to comply with the study procedures.",
    "The sample is a phase 3 clinical trial for lymphoblastic lymphoma, a type of cancer. The trial involves a combination of drugs including asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisolone, thioguanine, and vincristine sulfate. The eligibility criteria for patients include having confirmed lymphoblastic lymphoma, being in stage I-IV of the disease, not being pregnant or nursing, having no known HIV or AIDS infection, and having no prior malignancy or disease that would prevent treatment with chemotherapy. Patients must also not have received prior chemotherapy or radiotherapy, or undergone an organ transplant. Additionally, patients must not have taken systemic corticosteroids for more than 2 months, and must not be participating in another clinical trial.",
    "The sample is a phase 3 clinical trial for postmenopausal osteoporosis. The trial is looking at the effectiveness of two drugs, menatetranone and alfacalcidol, in treating the disease. The eligibility criteria for the trial include postmenopausal women between the ages of 45-75 with a menopause duration of more than 5 years, and a BMD (bone mineral density) more than 2 standard deviations below the young female adult mean. The trial also requires participants to have a BMI between 18-30 kg/m2 and an available anatomic structure of the lumbar spine for DEXA examination. Exclusion criteria include conditions that may affect osteoporosis, recent treatment with certain medications, and certain medical conditions such as cancer or serious renal disease. Participants must also be able to comply with the protocol and return for scheduled visits.",
    "The sample is a phase 3 clinical trial for tobacco dependence and smoking cessation. The trial includes a list of diseases and their corresponding ICD-10 codes. The trial also involves the use of three drugs: nicotine patch, placebo, and varenicline. The eligibility criteria for the trial include being a smoker seeking treatment, being 18 years or older, and consenting to participate. The exclusion criteria include being pregnant or breastfeeding, having end-stage renal disease, being unable to fill in questionnaires in English, and having a previous allergy to varenicline or nicotine patches.",
    "The sample is a phase 3 clinical trial for the treatment of human immunodeficiency virus (HIV) infection. The trial includes patients who are antiretroviral-na\u00efve and have a screening plasma HIV-1 RNA level of at least 1000 c/mL. The trial also requires patients to be over 18 years old, have a negative HLAB*5701 allele assessment, and be willing to use approved methods of contraception to avoid pregnancy (women of childbearing potential only). The trial excludes patients who are pregnant or breastfeeding, have active Center for Disease and Prevention Control (CDC) Category C disease, have hepatic impairment, have HBV co-infection, or have a recent history of upper or lower gastrointestinal bleed. The trial also excludes patients who have allergies or intolerance to the study drugs or their components or drugs of their class, have malignancy within the past 5 years, have received treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening, have received treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening, or have been exposed to an agent with documented activity against HIV-1 in vitro or an experimental vaccine or drug within 28 days of first dose of study medication. The trial also excludes patients with primary viral resistance in the Screening result, verified Grade 4 laboratory abnormality, ALT >5 xULN, ALT \u2265 3xULN and bilirubin \u2265 1.5xULN (with >35% direct bilirubin), or estimated creatinine clearance <50 mL/min.",
    "The sample is a phase 3 clinical trial for the treatment of gastroesophageal reflux disease (GERD) using the drug pantoprazole. The trial includes patients who are outpatients and at least 18 years old (21 years old in Argentina) and have GERD symptoms. The trial has a list of inclusion and exclusion criteria, including not having acute peptic ulcer or ulcer complications, not taking certain medications within a certain time frame, and not being pregnant or breastfeeding. The trial requires written informed consent from the patients. The diseases are listed as a single item in a list, while the icd-10 codes are listed as a list of codes within a string.",
    "The sample is a phase 3 clinical trial for patients diagnosed with type 2 diabetes mellitus. The trial involves the use of the drugs exenatide and placebo. The eligibility criteria for the trial include having suboptimal glycemic control, a stable metformin dose for at least 90 days, and a body mass index between 25 kg/m2 and 45 kg/m2. Exclusion criteria include having participated in a previous study using exenatide or GLP-1 analogs, being treated with excluded medications, and having received systemic glucocorticoid therapy within the 4 weeks preceding the study start. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe rheumatoid arthritis. The trial includes patients who are at least a certain age and have been receiving treatment on an outpatient basis for at least 8 weeks prior to the study start. The trial involves the use of two drugs, tocilizumab 162 mg and placebo. The eligibility criteria include having a certain number of swollen and tender joints, as well as being on a stable dose of disease-modifying anti-rheumatic drugs. The exclusion criteria include having had major surgery within a certain timeframe, having certain autoimmune diseases or inflammatory joint diseases, and having a history of certain medical conditions. The sample also includes other inclusion and exclusion criteria that were applied to the study.",
    "The sample is a phase 3 clinical trial for patients with Type 2 Diabetes. The trial is testing the effectiveness of the drug \"er niacin/laropiprant\" compared to a placebo. The trial includes patients between the ages of 18 to 80 years who have been on a stable dose of antidiabetic medication for at least 3 months. Patients taking certain medications or with certain medical conditions are excluded from the trial. Before starting the trial, patients will undergo a blood test to ensure they meet the eligibility criteria.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are at least 40 years old, have a history of smoking, and have a diagnosis of stable moderate to severe COPD. The trial involves testing the effectiveness of several drugs, including aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate, and placebo. The eligibility criteria include various medical and physical requirements, such as having a negative pregnancy test, being in good health, and being able to perform pulmonary function testing. The exclusion criteria include factors such as recent hospitalization for COPD, respiratory tract infections, and certain cardiovascular conditions. Patients who are pregnant or breastfeeding, have a current diagnosis of cancer, or have a history of drug or alcohol abuse within the past 5 years are also excluded. The trial aims to determine the safety and efficacy of the drugs in treating COPD.",
    "The sample is a record of a clinical trial in phase 3, focused on liver transplantation. The trial involves the drug tacrolimus and includes a list of icd-10 codes for related diseases. The eligibility criteria for the trial are listed, including both inclusion and exclusion criteria. Patients must receive a primary, split liver, or whole liver graft from a cadaveric donor with a compatible ABO blood type to be included. Patients who have previously received an organ transplant, have severe gastrointestinal issues, or have high levels of serum creatinine are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on infections. The ICD-10 codes associated with the diseases being studied are listed. The drugs being tested are daptomycin and vancomycin or semi-synthetic penicillins (ssps). The eligibility criteria for participants include being 65 years or older, having a severe infection that requires hospitalization and parenteral antimicrobial therapy for at least 96 hours, and having a diagnosis of Gram-positive complicated Skin and Soft Tissue Infections (cSSTIs) with or without bacteremia. There are also exclusion criteria listed, such as having conditions that require surgery to cure the infection or remove the infected site, having minor or superficial skin infections, or having medical conditions that may interfere with the evaluation of the trial.",
    "The sample is a phase 3 clinical trial for metastatic breast cancer. The trial includes patients with clinically or pathologically proven metastatic breast cancer and an Eastern Cooperative Oncology Group performance status between 0-2. The trial also requires adequate bone marrow, renal and liver functions within normal limits, and left ventricular ejection fractions more than 45% measured by multiple gated acquisition scan or echocardiogram within 6 weeks of randomization. The trial excludes patients who have had prior chemotherapy for metastatic disease, prior treatment with capecitabine or pegylated liposomal doxorubicin in the adjuvant setting, evidence of brain metastases unless previously treated and asymptomatic for 3 months or greater, history of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure, and anthracycline resistant disease. The trial uses pegylated liposomal doxorubicin and capecitabine as drugs and includes a list of icd-10 codes of diseases.",
    "The sample is a phase 3 clinical trial for seasonal allergic rhinitis and sar. The trial includes subjects between the ages of 6 and 11 who have a documented history of SAR to a relevant seasonal allergen for at least two years and have demonstrated sensitivity to at least one seasonal allergen through a standard skin prick test. The trial involves the use of two drugs, bdp hfa and placebo nasal aerosol. The eligibility criteria include various factors such as the absence of nasal pathology, recent respiratory infections, and active asthma requiring treatment with inhaled or systemic corticosteroids. The trial also includes exclusion criteria such as any conditions that may affect the subject's ability to participate in the clinical trial.",
    "The sample is a phase 3 clinical trial for high-risk, non-cardiovascular surgeries. The trial involves the use of the drug esmolol and has specific eligibility criteria for patients to participate. Inclusion criteria include being male or female, over 40 years old, scheduled for high-risk non-cardiac surgery with anticipated 12-hour post-operative ICU care, and on stable chronic oral beta-blocker therapy. Exclusion criteria include active bleeding, untreated left main disease, active cardiac condition, preoperative positive troponin T, contraindication for esmolol use, previous allergy or intolerance to esmolol, cancer with an expected life expectancy of less than 6 months, pregnancy or lactating or planning to become pregnant, failure to provide informed consent, unable to understand or follow instructions, history of drug allergy or idiosyncrasy to beta-adrenergic drugs, recent history of drug or alcohol abuse, patients with a pacemaker, abnormal liver function Child-Pugh - B, body mass index greater than 45, and reactive airway disease.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis, lung infection, and pseudomonas aeruginosa. The trial involves the use of the drug azli 75 mg three times daily (tid) compared to a placebo. The eligibility criteria for participants include being at least 6 years old, having a documented CF diagnosis, having PA present in sputum or throat swab culture, and exhibiting two or more chronic or intermittent CF symptoms. Participants must also have a FEV1 > 75% predicted and be able to perform reproducible pulmonary function tests. Exclusion criteria include recent administration of investigational drugs or antipseudomonal antibiotics, hypersensitivity to monobactam antibiotics, and history of lung transplantation. Females of childbearing potential must have a negative urine pregnancy test and be practicing an acceptable method of birth control. The trial requires written informed consent/assent prior to any study-related procedures.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of osteoarthritis. The icd-10 codes associated with the disease are listed. The drug being tested is diclofenac sodium gel 1%. The eligibility criteria for the trial are also listed, including key inclusion criteria such as having osteoarthritis of the hand, and key exclusion criteria such as having other rheumatic diseases or known allergies to analgesic drugs.",
    "The sample is a phase 3 clinical trial for patients with Chronic Obstructive Pulmonary Disease (COPD). The trial includes patients who are current or ex-smokers with a smoking history of 10 pack-years and are 40 years of age or older. The trial involves the use of drugs such as Combivent CFC-MDI, Combivent Respimat 20/100 mcg, and Atrovent HFA 42 mcg + Albuterol HFA 200 mcg. The eligibility criteria include signing an informed consent, meeting spirometric criteria, being able to perform study-related procedures, and inhaling medication in a competent manner. The exclusion criteria include having significant diseases other than COPD, recent history of myocardial infarction, being hospitalized or treated for heart failure within the past year, and having a malignancy for which the patient has undergone resection, radiation therapy, or chemotherapy within the last five years. Pregnant or nursing women, women of childbearing potential not using medically approved contraception, and patients with known hypersensitivity to anticholinergic drugs are also excluded.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C infection. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs, and eligibility criteria for participants. The inclusion criteria include being female and practicing specific forms of birth control, having chronic hepatitis C genotype 1a-infection with a certain level of HCV RNA, never having received antiviral treatment for hepatitis C infection, and having no evidence of liver cirrhosis. The exclusion criteria include having significant liver disease with any cause other than HCV as the primary cause, testing positive for hepatitis B surface antigen or anti-human immunodeficiency virus antibody, testing positive for drugs or alcohol, having significant sensitivity to any drug, using contraindicated medications within 2 weeks of dosing, and having abnormal laboratory tests.",
    "The sample is a phase 3 clinical trial for subjects with type 2 diabetes. The trial aims to achieve a median HbA1c of 8.3% and includes subjects with HbA1c levels between 7.0-10.0%. The trial requires subjects to be on a stable dose of 1-2 OADs for at least 90 days prior to screening and have a maximum BMI of 40 kg/m^2. Exclusion criteria include treatment with insulin, GLP-1 receptor agonists, sulphonylurea or DPP-4 inhibitors within 90 days prior to the trial, impaired liver or renal function, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and cardiac disorders. The trial also excludes subjects with severe uncontrolled hypertension, acute treatment required proliferative retinopathy or maculopathy, and history of chronic pancreatitis or idiopathic acute pancreatitis. The trial involves the use of two drugs, insulin degludec/liraglutide and insulin degludec, and liraglutide. The diseases being studied are diabetes and diabetes mellitus, type 2, and the icd-10 codes associated with these diseases are listed in the table.",
    "The sample is a phase 3 clinical trial for the treatment of clostridium infections and diarrhea. The trial includes patients with CDAD who meet certain inclusion criteria, such as signing informed consent and using adequate contraception (for females). However, patients with life-threatening CDAD, toxic megacolon, or who are pregnant are excluded from the trial. Additionally, patients who are concurrently using diarrheal agents or participating in other trials are also excluded. The trial involves the use of two drugs, par-101/opt-80 and vancomycin. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease pneumonia. The trial includes a list of ICD-10 codes associated with pneumonia, as well as a list of drugs being tested, including amoxicillin and benzyl penicillin. The eligibility criteria for the trial are also listed, including clinical signs of severe pneumonia, age between 2 months and 59 months, and exclusion criteria such as clinical signs of very severe pneumonia, diagnosis of meningitis, and severe malnutrition. Other exclusion criteria include chronic conditions that may contribute to respiratory distress, upper airway obstruction, and documented history of treatment with oral amoxicillin. The sample also notes that failure to obtain informed consent and penicillin allergy are exclusion criteria.",
    "The sample is a phase 3 clinical trial for patients with cirrhosis, hepatic encephalopathy, and hyponatremia. The trial involves the drug tolvaptan and has a list of inclusion and exclusion criteria for patient eligibility. Inclusion criteria include a diagnosis of cirrhosis, controlled history of hepatic encephalopathy, and a serum sodium level below 130mg/dl. Exclusion criteria include uncontrolled hepatic encephalopathy, recent alcohol or drug abuse, and contraindications to MRI examination. The table also includes lists of disease names, ICD-10 codes, and drug names.",
    "The sample is a phase 3 clinical trial for patients with cancer and pain. The trial involves the use of the drug modafinil and has specific eligibility criteria for patients to participate. Inclusion criteria include having an Epworth Sleepiness Scale score greater than 10, having sleepiness attributed only to opioids, and being able to give written informed consent. Exclusion criteria include hypersensitivity to modafinil, renal impairment, hepatic dysfunction, known history of cardiovascular disease, and taking certain medications. The trial is not open to pregnant or breastfeeding women or those on hormonal contraception.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial involves the use of several drugs, including atrovent respimat, combivent mdi, combivent respimat, and a placebo for blinding purposes. The eligibility criteria for the trial include being an outpatient of either sex, 40 years or older, with a diagnosis of COPD and a FEV1 of 65% predicted normal and FEV1/FVC of 70%. Patients with significant diseases other than COPD, a history of asthma or allergic rhinitis, or who regularly use daytime oxygen therapy for more than 1 hour per day will be excluded from the trial. Additionally, patients using oral corticosteroid medication at unstable doses or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day will also be excluded.",
    "The sample is a phase 3 clinical trial for patients with chronic heart failure. The trial is testing the effectiveness of the drug olmesartan medoxomil. The eligibility criteria for the trial include patients with NYHA class II through IV chronic heart failure, a history of hypertension or antihypertensive medications, aged 20 years or older and less than 80 years, stable patients who have angiotensin converting enzyme inhibitor and/or beta-blocker, and patients who do not have angiotensin II receptor blocker. Exclusion criteria include patients with renal dysfunction, history of drug hypersensitivity to olmesartan, severe liver dysfunction, history of angioedema, history of malignant tumor or life-threatening illness of poor prognosis, pregnant or possibly pregnant patients, cardiovascular surgery within 6 months prior to the date of the entry, acute myocardial infarction within 6 months prior to the date of the entry, percutaneous coronary intervention or stent implantation within 6 months prior to the date of the entry, and other patients deemed unsuitable as subjects of the study by the treating physician.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder (ADHD) using the drug NRP104. The trial is open to males and non-pregnant females between the ages of 18 and 55 who meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; Text Revision (DSM-IV-TR\u2122) criteria for a primary diagnosis of ADHD. Participants must also have a baseline ADHD-RS score greater than or equal to 28. The trial has a list of inclusion and exclusion criteria, including medical assessments, ECGs, and psychiatric evaluations. Participants must be willing and able to comply with the study procedures and restrictions and have given written informed consent. The trial excludes individuals with certain medical conditions, comorbid psychiatric diagnoses, and a history of drug dependence or substance abuse disorder. The trial also excludes pregnant or lactating females.",
    "The sample is a phase 3 clinical trial for patients with stage III non-small cell lung cancer that cannot be operated on. The trial aims to test the effectiveness of a new experimental drug compared to a control drug. The eligibility criteria for patients include having confirmed stage III NSCLC, being able to tolerate platinum-based chemotherapy and radical radiotherapy, and having certain laboratory values within normal limits. Patients must not have any other medical conditions that could interfere with the treatment or comparisons. Patients must not have received any prior chemotherapy, radiotherapy, or investigational agents.",
    "The sample is a phase 3 clinical trial for the treatment of small cell lung cancer using the drug picoplatin. The eligibility criteria include having a histological or cytological diagnosis of SCLC or combined SCLC/non-small cell lung cancer, having only one prior cisplatin or carboplatin-containing chemotherapy regimen for SCLC within the scope of the National Comprehensive Cancer Network (NCCN) Guidelines, and radiological evidence of SCLC that never responded or progressed within 90 days after completion of first-line therapy (refractory). Other criteria include having a CT scan of the head, chest, and abdomen with contrast, having an ECOG PS of 0, 1, or 2, and having recovered to \u2264 Grade 1 toxicity from all non-hematological adverse effects of prior therapies. Exclusion criteria include having untreated or symptomatic brain or central nervous system (CNS) metastases, having grade 2 or higher peripheral neuropathy, and having significant cardiac disease.",
    "The sample is a phase 3 clinical trial for age-related macular degeneration. The trial is testing the drug bevacizumab. The trial includes patients with na\u00efve subfoveal choroidal neovascularization and best-corrected visual acuity less than 20/200. Patients who have had previous treatments or any other condition that could limit visual improvement are excluded from the trial. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the use of two drugs, brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and brinzolamide ophthalmic suspension, 1%, and brimonidine tartrate ophthalmic solution, 0.2%. The eligibility criteria for the trial include a diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular pressure within protocol-specified range at eligibility visit/s. There are also several exclusion criteria, including severe central vision loss, chronic, recurrent, or severe inflammatory eye disease, and ocular trauma within the preceding 6 months. The trial requires patients to sign an informed consent document and other protocol-specified inclusion criteria may apply.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorders with risperidone oral tablets. The trial is focused on patients with a diagnosis of Bipolar I Disorder, Most Recent Episode Manic, who are voluntarily hospitalized at study initiation for the current manic episode and have a history of at least one documented manic or mixed episode that required treatment prior to study initiation. The patients must also have a total score of >=20 on the Young Mania Rating Scale (YMRS) and total score of <=20 on the Montgomery Asberg Depression Rating Scale (MADRS) at the start of the study. Patients who meet DSM-IV criteria for Schizoaffective Disorder or for rapid cycling, with borderline or antisocial personality disorder, history of substance dependence (excluding nicotine and caffeine) within the 3 months prior to study initiation, with seizure disorder, or females who are pregnant or nursing, or those lacking adequate contraception are excluded from the trial.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients with advanced stage III or stage IV disease who have not received prior chemotherapy treatment. The trial requires patients to have an evaluable or measurable lesion and to be available for detailed follow-up. The trial excludes patients who have had prior malignant tumors, have certain medical conditions such as low platelet or polynuclear cell counts, or have serious medical or psychological factors that may prevent adherence to the treatment schedule. The trial involves the use of drugs such as cisplatin, ifosfamide, gemcitabine, and docetaxel. The eligibility criteria for the trial are listed under both inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of olodaterol (bi 1744) and a placebo. The eligibility criteria include being a current or ex-smoker with a smoking history of more than 10-pack years, having a diagnosis of chronic obstructive pulmonary disease, and being between 40 and 75 years of age. Patients must also be able to perform pulmonary function tests and exercise tests, inhale medication from a metered-dose inhaler and Respimat inhaler, and maintain records. Exclusion criteria include having abnormal baseline haematology, blood chemistry, or urinalysis, a history of asthma, thyrotoxicosis, or paroxysmal tachycardia, and being pregnant or nursing.",
    "The sample is a phase 3 clinical trial for non-Hodgkin's lymphoma, specifically follicular Grade 1-3a NHL. The trial is testing the effectiveness of two drug combinations, galiximab in combination with rituximab and rituximab in combination with placebo. The eligibility criteria include being at least 18 years old, having relapsed or progressive disease after at least one prior chemotherapy treatment, and having measurable disease with at least one lesion of 2.0 cm or larger. The trial also has exclusion criteria, such as having certain types of lymphoma or having received certain types of treatments within a certain timeframe. The trial aims to evaluate the safety and efficacy of the drug combinations in treating non-Hodgkin's lymphoma.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus that is insufficiently controlled with basal insulin with or without metformin. The trial includes the drug lixisenatide (ave0010) as well as a placebo, basal insulin, and metformin. The eligibility criteria for the trial include having type 2 diabetes mellitus for at least 1 year before the screening visit, being between legal age of majority and not pregnant or breastfeeding, and having an HbA1c level between 7% and 10% at screening. There are also several exclusion criteria, such as having a history of hypoglycemia unawareness, having a body mass index less than or equal to 20 kg/m^2, and having a history of unexplained pancreatitis or chronic pancreatitis. The trial also excludes patients with certain laboratory findings, such as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels that are greater than 2 times the upper limit of the normal range, and patients with any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram, or vital signs at the time of screening that precludes safe completion of the study or constrains efficacy assessment.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of asthma. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which include montelukast and a placebo comparator. The eligibility criteria for participants are also listed, including age range, non-smoking status, and a history of asthma exacerbation. There are also exclusion criteria, such as not having any other pulmonary disorders or having been hospitalized for asthma more than three times in the year prior to signing informed consent.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have been taking at least 2 types of oral diabetes medications for at least 12 weeks prior to entering the study and have a Hemoglobin A1c value greater than or equal to 7.0 percent and less than or equal to 11.0 percent if insulin naive. Patients who were previously on Lantus must have a Hemoglobin A1c value less than or equal to 11.0 percent. The trial excludes patients with significant liver, cardiac or gastrointestinal disease, active cancer or have had cancer within the past 5 years (with the exception of basal cell carcinoma or carcinoma in situ), excessive resistance to insulin or hypersensitivity to Lantus, more than one episode of severe low blood sugar within the 6 months before entering the study, taken any other insulin other than Lantus within the past 30 days, or taking any other diabetes medicines that are not allowed in the study or not approved to be taken with insulin.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of two different insulin treatments: insulin degludec/insulin aspart and biphasic insulin aspart 30. The trial includes patients who have been diagnosed with type 2 diabetes for at least 6 months and have a HbA1c level between 7.0-10.0%. Patients must also meet certain inclusion criteria, such as being at least 18 years old and having a maximum BMI of 35.0 kg/m^2. Exclusion criteria include recent treatment with certain medications, cardiovascular disease, and uncontrolled hypertension. The trial is not open to pregnant or breastfeeding women or those with a history of cancer.",
    "The sample is a phase 3 clinical trial for chronic insomnia. The trial includes females of childbearing potential who are sexually active and agree to use adequate contraception. The trial also requires participants to have a body mass index between 18 and 34, and a history of chronic insomnia for at least 3 months. Participants must report a subjective sleep latency greater than or equal to 45 minutes and a subjective total sleep time less than or equal to 6.5 hours. The trial also requires habitual bedtime to be between 10:00 PM and 1:00 AM. Participants must have a mean latency to persistent sleep of greater than 20 minutes on two consecutive screening nights with neither night less than 15 minutes. Also, a mean of 60 minutes of wake time during the 480 minutes in bed across two nights with no night less than 45 minutes. Participants must normally use pharmacological assistance to sleep 0 to 4 times per week in the last 3 months. The trial excludes participants with known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds. Participants who have participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer, are also excluded. The trial also excludes participants who have flown across greater than three time zones within 7 days prior to or during screening, participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of single-blind study medication, or have ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movement syndrome, chronic obstructive pulmonary disease or fibromyalgia. The trial also excludes participants with a history of psychiatric disorder within the past 6 months, history of alcohol abuse within the past 12 months, history of drug abuse within the past 12 months, current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, neurological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication. The trial also excludes participants with an apnea hypopnea index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night, periodic leg movement syndrome with arousal index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night, positive urine drug screen at Screening Visit 1 or any of the polysomnogram assessment visits, positive breathalyzer test on any of the polysomnogram assessment visits, uses tobacco products (including nicotine gum and patch) or any other products that may interfere with the sleep wake cycle during nightly awakenings, used any central nervous system medication or other drugs or supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is longer) prior to the administration of single-blind study medication, intends to continue taking any disallowed medication or any prescription medication or over the counter medication that is known to affect the sleep/wake function or otherwise interfere with evaluation of the study medication, and has any additional condition(s) that in the Investigator's opinion would affect sleep/wake function, prohibit the subject from completing the study, or indicate that continuation in the study would not be in the best interests of the subject. The trial also excludes participants with a history of hepatitis B or hepatitis C.",
    "The sample is a phase 3 clinical trial for the treatment of Lennox-Gastaut syndrome, a type of epilepsy. The trial includes participants who have had at least 90 seizures in the 28 days prior to enrollment and have been on 1-3 anti-epileptic drugs without changing the type or dose. The trial excludes participants who have had a history of generalized tonic-clonic status epilepticus, have received drug therapy for status epilepticus, have had a history of hypoxia, are on a ketogenic diet or have received certain therapies within 6 months prior to the treatment period, have a history of suicide attempt, have an allergy to triazole compound, have clinically significant electrocardiogram abnormalities, or are pregnant, lactating, or wish to be pregnant.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease multiple myeloma and the drug being tested is bortezomib. The eligibility criteria for participants include having a performance status of 0-2, adequate renal function, and having previously documented platelet count and peripheral absolute neutrophil count within a certain time frame. Participants must also sign an informed consent form and agree to use acceptable methods of contraception. Exclusion criteria include hypersensitivity to the drug, being pregnant or breastfeeding, having experienced a recent myocardial infarction, and having received other investigational new drugs or anti-myeloma therapy within a certain time frame. Additionally, participants with serious medical or psychiatric illnesses likely to interfere with participation or who have been diagnosed or treated for another malignancy within a certain time frame are excluded.",
    "The sample is a phase 3 clinical trial for patients with metastatic colorectal neoplasms. The trial includes a list of diseases and their corresponding icd-10 codes, a list of drugs including a placebo, aflibercept, and folfiri, and eligibility criteria for participants. The criteria include having a histologically or cytologically proven adenocarcinoma of the colon or rectum, metastatic disease that is not amenable to potentially curative treatment, and having only one prior line of treatment for metastatic disease. Prior treatment with bevacizumab is permitted, but prior therapy with irinotecan and an Eastern Cooperative Oncology Group performance status greater than 2 are exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of urinary incontinence, detrusor overactivity, urinary urgency, and urge urinary incontinence. The trial involves the use of botulinum toxin a, bladder detrusor muscle injection, and a placebo of vehicle saline. The eligibility criteria for the trial include being an adult woman with detrusor overactivity incontinence confirmed by urodynamic testing, having symptoms that are refractory to standard first- and second-line treatments, experiencing 6 or more urge incontinence episodes on a 3-day bladder diary, and having a normal neurological examination. Exclusion criteria include urinary retention, allergy to Botox, previous bladder treatment with Botox in the past year, pregnancy or planning pregnancy within the next year, and neurologic disease with impaired neurotransmission.",
    "The sample is a phase 3 clinical trial for patients with symptomatic multiple myeloma who are sensitive or refractory to at least one prior line of chemotherapy. The trial involves a list of drugs, including interim/maintenance dexamethasone, induction/consolidation cisplatin, and transplant 1 and 2 melphalan, among others. The eligibility criteria include a Karnofsky performance score > 60%, negative serology for HIV, and adequate pulmonary function studies. Exclusion criteria include severe renal dysfunction, significant neurotoxicity, and poorly-controlled hypertension or diabetes mellitus. The trial does not allow prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least three years. Pregnant or nursing women may not participate, and women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.",
    "The sample is a phase 3 clinical trial for lupus nephritis, a disease affecting the kidneys. The trial involves the use of drugs such as tacrolimus, leflunomide, and prednisone. The eligibility criteria for the trial include a body weight between 40-100kg, a diagnosis of systemic lupus erythematosus, and a diagnosis of type III/IV lupus nephritis by renal biopsy within 6 months. Inclusion criteria also require 24-hour proteinuria of at least 2g and/or active urinary sediments. Exclusion criteria include receiving immunosuppressants, routine treatment of tacrolimus and leflunomide within 1 month, and a history of allergy to tacrolimus and leflunomide. Other exclusion criteria include anticipated maintenance dialysis, planning to receive kidney transplantation, and having a serum creatinine level of 3mg/dl or estimated glomerular filtration rate of less than 30ml/min. Diabetes mellitus patients are also excluded from the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of ulcerative colitis using the drug mesalamine. The trial is open to patients between the ages of 18 and 75 who have a confirmed diagnosis of moderately active flare of ulcerative colitis. Female patients must be postmenopausal or using adequate contraception. Patients with isolated proctitis or comorbidities that could confound the study results or compromise patient safety are excluded from the trial. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of Cushing's disease using the drug pasireotide. The trial is for patients who are 18 years or older and have a confirmed diagnosis of ACTH-dependent Cushing's disease but are not considered candidates for pituitary surgery. The trial has exclusion criteria such as a history of pituitary irradiation in the last 10 years, Cushing's syndrome not caused by a pituitary tumor, active malignant disease in the last 5 years, and pregnancy or lactation in women. The record also mentions that there are other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of lurasidone at different doses (80 mg, 120 mg, and 160 mg). The eligibility criteria for participants include being between 18 and 60 years old, having a diagnosis of schizophrenia or schizoaffective disorder, being female and using an acceptable method of birth control or being surgically sterile or postmenopausal, being able to provide written informed consent, and being able to safely have an MRI. Exclusion criteria include being treatment resistant or intolerant to lurasidone, having had extensive radiation exposure, having tremors or shaking of the limbs, being pregnant or trying to become pregnant or breastfeeding, being colorblind, having a current or past history of a major medical illness or abnormal lab values, taking certain medications, or having a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study.",
    "The sample is a phase 3 clinical trial for the treatment of allergic rhinoconjunctivitis caused by grass pollen. The trial involves the use of two drugs, Grazax and Aerius, and a placebo. The eligibility criteria for participants include being between 18-65 years old, having a clinical history of grass pollen induced allergic rhinoconjunctivitis for at least two years, reporting treatment related allergic reactions after intake of Grazax at screening, and having a positive skin prick test response to Phleum pratense. Exclusion criteria include uncontrolled asthma, FEV1 less than 70% of predicted value, and a history of anaphylaxis or chronic urticaria. Participants must also be willing and able to comply with the protocol.",
    "The sample is a phase 3 clinical trial for patients with solid tumor malignancy of lung, breast, or prostate. The trial includes patients who have received prior oral bisphosphonate therapy and are receiving systemic chemotherapy or hormonal therapy. The trial aims to evaluate the effectiveness of zoledronic acid and sm-153 in treating bone metastases. The eligibility criteria include a minimum diagnostic workup, adequate bone marrow function, and a Zubrod performance status of 0-2 for breast or prostate primaries and 0-1 for lung primaries. Patients with brain metastases and/or spinal cord compression, painful bone metastases, or prior treatment with Strontium-89 or Samarium-153 for bone metastases are excluded. The trial also excludes patients with severe, active co-morbidity, current, active dental problems, or AIDS. Pregnant or lactating patients are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of human immunodeficiency virus (HIV) infection. The trial includes patients who are antiretroviral-na\u00efve and have a screening plasma HIV-1 RNA level of at least 1000 c/mL. The trial also requires patients to be willing to use approved methods of contraception to avoid pregnancy if they are women of childbearing potential. Patients must be at least 18 years old and able to understand and sign a written informed consent form. The trial excludes pregnant or breastfeeding women, patients with moderate to severe hepatic impairment, and those with a recent history of upper or lower gastrointestinal bleed. The trial also excludes patients with certain laboratory abnormalities and those with a history of malignancy within the past 5 years. The trial involves the use of two drugs, gsk1349572 (dolutegravir) and raltegravir.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of type 1 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including human insulin inhalation powder, injectable insulin, and insulin glargine. The eligibility criteria for the trial include being a non-smoker with normal lung function and having type 1 diabetes. Exclusion criteria include having significant pulmonary, hepatic, or renal disease, severe congestive heart failure, active malignancy, or being on systemic glucocorticoid therapy.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis and pseudomonas aeruginosa. The trial involves the drug azli and has specific eligibility criteria for participants, including a diagnosis of CF, a positive lower respiratory tract culture for PA, and no significant respiratory symptoms or chest radiograph findings requiring hospitalization. There are also exclusion criteria, such as recent use of antipseudomonal antibiotics, hypersensitivity to aztreonam or beta-agonists, and history of lung transplantation. The trial requires participants to have stable medication and physiotherapy regimens and normal renal and hepatic function.",
    "The sample is a phase 3 clinical trial for hypoactive sexual desire disorder. The trial is for postmenopausal females who are at least 50 years old and have at least two points of cardiovascular risk. The trial involves the use of testosterone gel and placebo gel. The eligibility criteria include having a clinical diagnosis of HSDD and not having certain medical conditions or a history of certain types of cancer. The exclusion criteria include not having used androgen therapy within 2 months of randomization and not having a history of estrogen-dependent neoplasia or any gynecologic cancer.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes who have inadequate glycemic control. The trial includes both males and females who are 18 years or older and meet certain criteria, such as having a C-peptide level of at least 1.0 ng/mL and a body mass index of 45.0 kg/m\u00b2 or less. The trial also has exclusion criteria, such as having elevated levels of AST and/or ALT, serum total bilirubin, or serum creatinine, as well as having symptoms of severely uncontrolled diabetes or other serious medical conditions. The trial involves the use of drugs such as dapagliflozin and metformin, as well as a placebo.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients who have recurrent MDD as their primary diagnosis according to DSM-IVTR\u2122 criteria and have a confirmed current Major Depressive Episode (MDE) using the Mini International Neuropsychiatric Interview (MINI). Patients must also have a MADRS total score \u226526 and a CGI-S score \u22654, and the reported duration of the current MDE should be \u22653 months. Other inclusion criteria may apply. Patients who meet any of the exclusion criteria listed in the protocol or are unlikely to comply with the protocol or are unsuitable for any reason are excluded from the trial. The trial will test the effectiveness of vortioxetine (lu aa21004) and venlafaxine extended release as potential treatments for major depressive disorder.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of bipolar disorder. The trial involves the drugs asenapine and olanzapine. The eligibility criteria for the trial include having completed previous studies with asenapine for the treatment of manic or mixed episodes without any major protocol violations. Patients with unstable medical conditions or significant laboratory abnormalities are excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed as [\"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", \"I10\"]. The drug being studied is amlodipine. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include patients who completed a preceding study and have a treatment compliance rate of at least 80%. Patients who met the discontinuation criteria in the preceding study are excluded.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia and enlarged prostate. The trial involves the drug lonidamine and has specific eligibility criteria for male participants aged 50-80 years old with lower urinary tract symptoms for at least 3 months, a prostate volume measured by TRUS greater than 30 cc, and a Qmax less than 15 mL/sec when measured by uroflowmetry. In addition, participants must have an International prostate symptom score greater than 12 and a PSA level greater than 1.0 ng/mL. The trial also has exclusion criteria, such as prior treatment with alpha-blockers and/or herbal supplements in the past 2 weeks, active urinary tract infections, and uncontrolled diabetes mellitus. Participants must comply with the prescribed treatment protocol and evaluations and use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential.",
    "This sample is from a phase 3 clinical trial for the treatment of idiopathic restless legs syndrome. The trial involves the drug rotigotine and the eligibility criteria includes completing the Maintenance Period and Taper Period of SP790 or SP794. The exclusion criteria includes having an ongoing serious adverse event related to the trial medication or having a medical or psychiatric condition that could compromise the subject's ability to participate in the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of painful diabetic peripheral neuropathy. The trial involves the drug pregabalin and the patients must have completed a 13-week treatment in a previous study (A0081163). The inclusion criteria require patients to understand and cooperate with study procedures and have signed a written informed consent. The exclusion criteria include patients who experienced serious adverse events or exhibited treatment non-compliance in the preceding study. The diseases are listed as 'diabetic neuropathy, painful' and the icd-10 codes associated with these diseases are also provided.",
    "The sample is a phase 3 clinical trial for heart failure, congestive. The trial includes patients who have a history of heart failure for at least 14 days and have been prescribed diuretic therapy. The patients must have been hospitalized for acute heart failure syndrome requiring IV diuretic therapy and have impaired renal function. The trial excludes patients with acute contrast-induced nephropathy, ongoing or planned IV therapy for heart failure with certain agents, BNP levels below a certain threshold, ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis, severe pulmonary disease, significant stenotic valvular disease, heart transplant recipients or those admitted for cardiac transplantation, clinical evidence of acute coronary syndrome in the 2 weeks prior to screening, heart failure due to significant arrhythmias, acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy, known hepatic impairment, non-cardiac pulmonary edema, including suspected sepsis, allergy to soybean oil or eggs, history of seizure, stroke within 2 years, history of or current brain tumor of any etiology, brain surgery within 2 years, encephalitis/meningitis within 2 years, history of penetrating head trauma, closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years, history of, or at risk for, alcohol withdrawal seizures, advanced Alzheimer's disease, advanced multiple sclerosis, Hgb levels below a certain threshold, and previous exposure to KW-3902. The drugs being tested are rolofylline and a placebo (unspecified).",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drug linagliptin compared to a placebo. The eligibility criteria include having a diagnosis of type 2 diabetes for at least 3 months, having an HbA1c level between 7.5% and 11%, and being treatment-naive or currently being treated with up to one oral antidiabetic medication. Patients must also be between the ages of 18 and 80, have a BMI less than 45 kg/m2, and provide written informed consent. Exclusion criteria include recent myocardial infarction, stroke, or transient ischemic attack, impaired hepatic function, hypersensitivity or allergy to the investigational product or its excipients, recent treatment with insulin or anti-obesity drugs, and a history of alcohol or drug abuse. Women who are pregnant or nursing, not surgically sterile, or not practicing an acceptable method of birth control are also excluded. Patients must be compliant with the dosing regimen during the placebo run-in period.",
    "The sample is a phase 3 clinical trial for the treatment of hyponatremia, dilutional hyponatremia, and inappropriate ADH syndrome. The trial involves the drug tolvaptan and has specific inclusion and exclusion criteria. Inclusion criteria include having clinically euvolemic or hypervolemic states with serum sodium levels below 130 mEq/L, experiencing clinically significant symptoms of hyponatremia, and agreeing to remain abstinent or use double-barrier forms of birth control. Exclusion criteria include being pregnant or breastfeeding, having hyponatremia in hypovolemic states, requiring prolonged hospitalization for reasons other than hyponatremia, and having recent prior treatment for hyponatremia with certain medications. Other exclusion criteria include having certain medical conditions, such as uncontrolled diabetes or anuria, and having a history of drug or medication abuse. The trial also excludes patients who have participated in another investigational drug trial within the past 30 days.",
    "The sample is a phase 3 clinical trial for patients who have received a kidney transplant between 1 month and 5 years prior to the screening date and are experiencing symptomatic drug-induced hand tremor associated with use of Prograf or generic tacrolimus. The trial aims to test the effectiveness of the drugs Prograf and LCP-tacro in reducing tremors. The eligibility criteria include being between 18 and 65 years of age, having at least one complaint of tremor, and maintaining tacrolimus trough levels between 3 to 12 ng/mL. Exclusion criteria include having an estimated glomerular filtration rate (eGFR) <30mL/min, being pregnant or nursing, and having any form of current drug or alcohol abuse. The trial also excludes patients who have essential tremor, Parkinsonism, or tremor from any cause other than tacrolimus-induced tremor, and those who are taking drugs that are likely to affect the PK levels of tacrolimus and are not on a stable dose of those medications.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic obstructive pulmonary disease. The trial involves the use of drugs such as budesonide/formoterol pmdi, budesonide pmdi, and formoterol turbuhaler. The eligibility criteria for the trial include having a clinical diagnosis of COPD with symptoms for more than 2 years, a smoking history of 10 or more pack years, and a history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before the first visit. Patients with a history of asthma, taking oral steroids, or any significant disease or disorder that may jeopardize their safety are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for thromboembolism. The trial includes patients with acute deep vein thrombosis or pulmonary embolism who are 18 years or older and have written informed consent. The trial excludes patients with overt symptoms of VTE for longer than 2 weeks prior to enrollment, contraindications to anticoagulant therapy, and those who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception. The trial involves the use of dabigatran etexilate 150 mg and warfarin (inr 2-3) as drugs. The trial also includes a list of icd-10 codes for diseases and eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients between 18 and 65 years old who have had an inadequate response to no more than three adequate antidepressant treatments. The trial involves the drugs opc-34712 + adt and placebo + adt. The eligibility criteria include a diagnosis of major depressive disorder as defined by DSM-IV-TR criteria, a current depressive episode of at least 8 weeks in duration, and a history of inadequate response to antidepressant treatments. Exclusion criteria include pregnancy, inadequate response to more than three adequate trials of antidepressant treatments, and current diagnoses of certain Axis I and II disorders.",
    "The sample is a phase 3 clinical trial for patients with chronic renal failure who are on hemodialysis for at least 3 months prior to randomization. The trial is testing the effectiveness of peginesatide and epoetin alfa in maintaining hemoglobin levels within a range of 10.0 to 12.0 g/dL. The trial includes patients with anemia and the exclusion criteria include factors such as pregnancy, intolerance to erythropoiesis stimulating agents, bleeding or coagulation disorders, and active malignancy within the past year. The trial also excludes patients with a scheduled kidney transplant or surgery that may lead to significant blood loss. The eligibility criteria include having a mean hemoglobin level within the target range during the screening period and being on intravenous epoetin alfa maintenance therapy for at least 8 weeks prior to randomization.",
    "The sample is a phase 3 clinical trial for HIV infections and acquired immunodeficiency syndrome. The trial involves the use of the drugs vicriviroc and placebo. The eligibility criteria include being infected with HIV-1 virus, having documented plasma HIV-1 RNA >1000 copies/mL within 60 days of Visit 1/Day 1, and being either on a stable regimen of 3 or more antiretrovirals (ART) for at least 4 weeks prior to the screening visit or on no ART agents for at least 4 weeks prior to the screening visit. The subject must also be ART experienced and have documented resistance to at least 2 of the following 3 drug classes: nucleoside reverse transcriptase inhibitor (NRTI); non-nucleoside reverse transcriptase inhibitor (NNRTI); or protease inhibitor (PI). Women of child-bearing potential must agree to use a medically accepted method of contraceptive, and the subject must be willing to initiate CD4+ cell count-guided chemoprophylaxis to prevent opportunistic infection as defined in the protocol. Exclusion criteria include subjects with detectable CXCR4-tropic or dual/mixed CCR5/CXCR4-tropic HIV isolates at Screening, prior history of malignancy (with exceptions of cutaneous Kaposi's sarcoma without visceral or mucosal involvement that resolved with HAART but without systemic anti-cancer treatment, and basal-cell carcinoma of skin), or seizure disorder requiring anti-seizure therapy or with any condition that is likely to increase risk of seizure (CNS malignancy or toxoplasmosis).",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial is testing the effectiveness of infliximab or placebo on patients with single or multiple draining fistulas and Crohn's disease that has lasted for at least 3 months. The inclusion criteria for the trial are having single or multiple draining fistulas and having Crohn's disease for at least 3 months. The exclusion criteria are having Crohn's disease complications that may require surgery and having a positive stool culture. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial that focuses on newborn diseases, sepsis, and puerperal infection. The trial involves the use of chlorhexidine as a drug. The eligibility criteria for the trial include being pregnant, planning to deliver at Chris Hani Baragwanath Hospital or one of its satellite clinics, planning to remain in Soweto for at least two months after delivery, being able to understand and give informed consent, and being at least 15 years old at the time of registration. The exclusion criteria include planned delivery by caesarean section, antenatal ultrasound revealing major fetal congenital anomalies, and having a known or suspected condition in which vaginal exams are contraindicated.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial includes patients who meet specific demographic and procedural inclusion criteria and have completed a previous trial. The patients must also demonstrate an acceptable level of compliance and would benefit from continued treatment according to the investigator. The trial excludes patients with uncontrolled or unstable medical conditions and those who have been judged to be medically noncompliant in managing their disease. The record also includes a list of disease names, icd-10 codes, drug names, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar I disorder. The trial includes patients who are experiencing acute agitation and meet certain inclusion criteria. The trial involves the use of inhaled placebo, inhaled loxapine 5 mg, and inhaled loxapine 10 mg. The eligibility criteria include exclusion of patients with agitation caused by acute intoxication, history of drug or alcohol dependence, and recent use of benzodiazepines or other hypnotics.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of endometriosis. The trial involves the drugs Visanne and placebo. The eligibility criteria for the trial includes female patients with endometriosis-associated pelvic pain, but excludes pregnant or lactating women, those with a history or suspicion of hormone dependent tumor, therapy resistant endometriosis, need for primary surgical treatment, and any other conditions which forbid participation. The diseases are listed as 'endometriosis' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for adults aged 55 and above with moderate to severe osteoarthritis of the knee and symptoms of knee pain for at least 3 months. The trial involves the use of the drug PENNSAID and requires subjects to have radiographic evidence of Kellgren-Lawrence Grade 2-4 within the past 2 years. Subjects must also be currently on a stable dose of anticoagulant therapy and taking oral NSAIDs for at least an average of 25 days per month. The trial has inclusion and exclusion criteria, including a pain score of >40mm on the Patient Pain Visual Analog Scale, ability to comply with the study, and absence of certain medical conditions.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes mellitus. The trial is testing the effectiveness of two drugs, Generex Oral-Lyn\u2122 and regular human insulin. The eligibility criteria include being between the ages of 18 and 75, having a BMI less than 27, and currently managing diabetes with daily insulin injections. Participants must also be willing to follow a specific diet and commit to monitoring their blood glucose levels. Exclusion criteria include having certain medical conditions or a history of drug or alcohol abuse that could interfere with the study.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on venous thromboembolism. The icd-10 codes associated with this disease are listed, as well as the drugs being tested: open-label semuloparin sodium, placebo (for semuloparin sodium), and semuloparin sodium. The eligibility criteria for participants are also listed, including inclusion criteria such as having undergone standard surgery for fracture of the upper third of the femur, and exclusion criteria such as having a high risk of bleeding or known hypersensitivity to heparins.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of bipolar I disorder. The trial involves the drug aripiprazole and the eligibility criteria require patients to have acute symptoms of bipolar disorder. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 3 clinical trial for hypertension. The diseases being studied are limited to hypertension. The icd-10 codes associated with hypertension are listed. The drugs being tested are combinations of valsartan, amlodipine, and hydrochlorothiazide. The eligibility criteria for the trial include a diagnosis of moderate to severe hypertension, with specific blood pressure ranges. Patients on certain numbers of antihypertensive drugs or with arm circumferences over 42 cm are excluded. Other protocol-defined exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of two drugs, lixisenatide and placebo. The eligibility criteria for the trial include having been diagnosed with type 2 diabetes mellitus for at least 2 months and not having been treated with any antidiabetic agent. Exclusion criteria include having an HbA1c level less than 7% or greater than 10%, being pregnant or breastfeeding, having type 1 diabetes mellitus, having a fasting plasma glucose level greater than 250 mg/dL, having a body mass index less than or equal to 20 kg/m^2, and having a history of certain medical conditions such as unexplained pancreatitis or heart failure. The sample also includes additional exclusion criteria at the end of the run-in phase, such as informed consent withdrawal and lack of compliance during the single-blind placebo run-in phase.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder syndrome. The trial includes men aged 40 years and above who have been on a stable and well-tolerated dose of an alpha-blocker for at least 6 weeks prior to screening. The inclusion criteria require participants to have persistent symptoms of OAB with urinary frequency of at least 8 times per day and micturition-related urgency episodes of at least 3 episodes per day. The exclusion criteria include contraindication to fesoterodine, previous history of acute urinary retention requiring catheterization or severe voiding difficulties, and inability to follow the study procedures. The trial will test the efficacy of fesoterodine compared to a placebo.",
    "The sample is a phase 3 clinical trial for chronic kidney disease. The trial is testing the drug eplerenone. The eligibility criteria for the trial includes being between the ages of 18 and 80, having an estimated Glomerular Filtration Rate between 15 and 60 ml/min/1,73 m2, and having a blood pressure of at least 130/80 mmHg or undergoing anti-hypertensive treatment. Exclusion criteria includes having a p-potassium level above 5.0 mM, being allergic to the contents of the drug, being treated with spironolactone or other specific drugs, having certain medical conditions or illnesses, being pregnant or lactating, having dementia or other psychiatric disorders, and having undergone certain types of vascular surgery.",
    "The sample is a phase 3 clinical trial for patients with chronic hepatitis C and liver fibrosis. The trial is testing the effectiveness of the drugs pentoxyphilline and tocopherol. The eligibility criteria include being between 18 and 75 years old, having a positive HCV Ab and HCV RNA test, and histologically proven injuries. Patients must also have a liver biopsy with a size over or equal to 15mm, performed within 3 years of enrollment, with a Metavir score of activity from 0 to 2 and fibrosis score of 2 or 3. Patients who are non long term responders or have contra-indications or intolerance to interferon alfa or ribavirin are also eligible. Exclusion criteria include alcohol consumption over or equal to 40 g/d, allergy to tocopherol or pentoxyphilline, and treatment with certain medications. Patients must not have had anti-viral treatment during the trial and must sign a written informed consent.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder and related disorders. The trial involves the drug Vyvanse (lisdexamfetamine dimesylate) and includes a list of inclusion and exclusion criteria for participants. Inclusion criteria include being between 18-55 years old, having previously met all inclusion/exclusion criteria in a previous study, and having no significant medical abnormalities. Exclusion criteria include having any concurrent chronic or acute illness, a known cardiac structural abnormality, or having taken an investigational drug within 30 days prior to screening. The trial also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes participants with essential hypertension and excludes those with systolic blood pressure greater than 185 mm Hg, recent history of myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, cerebrovascular accident, or transient ischemic attack, and those with moderate to severe heart failure or hypertensive encephalopathy. The trial also excludes participants with clinically significant cardiac conduction defects, secondary hypertension of any etiology, known or suspected unilateral or bilateral renal artery stenosis, and severe renal dysfunction or disease. Female participants of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. The trial includes the use of azilsartan medoxomil, azilsartan medoxomil with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications, and placebo.",
    "The sample is a record of a clinical trial in phase 3, focused on hypertension and high blood pressure. The trial involves the drug combination of ramipril and hydrochlorothiazide. The eligibility criteria for the trial include having a diagnosis of essential hypertension and meeting certain blood pressure requirements. Exclusion criteria include having certain medical conditions or allergies to certain medications. The sample also includes a list of ICD-10 codes associated with the diseases being studied.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on type 2 diabetes and includes a list of ICD-10 codes associated with the disease. The trial involves the use of several drugs, including dapagliflozin and a placebo. The eligibility criteria for the trial include patients with HbA1c levels between 7.5% and 10.5% who are on a stable insulin regimen of at least 30 IU of injectable insulin per day, either without any other oral antidiabetic drug or with a stable dose of oral antidiabetic drugs. Patients with type 1 diabetes, those on more than two additional oral antidiabetic drugs, and those with moderate to severe renal failure or dysfunction are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with solid tumors and weight changes. The trial involves the use of two drugs, megestrol acetate and oxandrolone 20 mg, and has specific eligibility criteria, including confirmed solid tumor, weight loss, ECOG Performance Status of 0-2, and serum creatinine, SGOT, and SGPT levels within certain limits. Patients must also be able to swallow medication and meet their nutritional requirements orally. Exclusion criteria include ongoing or planned treatment with certain medications, recent active thromboembolic disease or recent myocardial infarction, and a BMI of 35 or higher.",
    "The sample is a phase 3 clinical trial for asthma. The trial is looking for patients who have had asthma for at least 12 months and are 12 years or older. The trial is testing the effectiveness of two drugs, fluticasone propionate/formoterol fumarate 100/10 and fluticasone propionate 100, and formoterol fumarate 10. The eligibility criteria include having a documented history of asthma, meeting certain FEV-1 levels, and having symptoms of asthma during the run-in period. Patients must also be otherwise healthy and provide written informed consent. Exclusion criteria include having a history of life-threatening asthma, using certain medications within a certain time frame, having certain diseases or abnormalities, and having a history of alcohol or substance abuse within the past year.",
    "The sample is a phase 3 clinical trial for the treatment of vesicoureteral reflux and urinary tract infections. The trial involves the use of trimethoprim-sulfamethoxazole and a placebo. The eligibility criteria for the trial include being between 2 months and 6 years of age, having been diagnosed with a febrile or symptomatic UTI within 112 days prior to randomization, and having Grade I-IV VUR based on radiographic voiding cystourethrogram. There are also exclusion criteria, such as having a history of more than two UTIs prior to randomization, having co-morbid urologic anomalies, or having a known sulfa allergy. The trial aims to determine the effectiveness of the treatment in reducing the recurrence of UTIs in children with VUR.",
    "The sample is a phase 3 clinical trial for the treatment of diffuse large B-cell non-Hodgkin's lymphoma using the CHOP regimen. The trial is open to patients with CD20+ disease who have been diagnosed within the past 6 weeks and have an International Prognostic Index (IPI) score of 0 or 1. Patients must also meet a number of eligibility criteria related to their disease characteristics, patient characteristics, and prior concurrent therapy. The trial is not open to patients with certain types of lymphoma, prior malignancies, or concurrent diseases that would preclude study treatment. The sample includes a detailed list of eligibility criteria for patients interested in participating in the trial.",
    "This sample is for a phase 3 clinical trial for breast cancer. The trial includes postmenopausal females with histologically or cytologically confirmed estrogen and/or progesterone receptor positive breast cancer, either with local recurrence or metastasis. The trial excludes premenopausal women and those who have previously undergone systemic endocrine therapy for advanced or recurrent disease, or prior fulvestrant therapy. The trial will test the effectiveness of the drugs fulvestrant and anastrozole.",
    "The sample is a phase 3 clinical trial for non-small cell lung carcinoma. The trial is testing the effectiveness of the drugs pemetrexed, gemcitabine, and cisplatin. The eligibility criteria for the trial include a diagnosis of NSCLC Stage IIIB or Stage IV, no prior chemotherapy for lung cancer, and at least one measurable lesion. Patients who have received radiation therapy to less than 25% of bone marrow and completed it at least 4 weeks prior to study enrollment are eligible. Exclusion criteria include recent treatment with unapproved drugs, serious cardiac conditions, medical disorders that would make it difficult to complete the study, inability or unwillingness to take folic acid or Vitamin B12 supplementation, and presence of uncontrolled fluid retention.",
    "The sample is a phase 3 clinical trial for hepatocellular carcinoma, a type of liver cancer. The trial involves the use of drugs such as cni, mmf, steroids, aza, and sirolimus, but without mtor inhibitors. The eligibility criteria for the trial include being 18 years or older, having histologically proven HCC before randomization, and providing signed, written informed consent. Exclusion criteria include having multiple-organ recipients, known hypersensitivity to sirolimus or its derivatives, hyperlipidemia refractory to optimal medical management, evidence of significant local or systemic infection, being HIV-positive, having platelets less than 75,000/cubic mm, and having non-HCC malignancies within the past 5 years, among others. The trial also excludes patients with extrahepatic HCC tumor manifestation, those with a psychologic, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule, and patients under guardianship.",
    "The sample is a phase 3 clinical trial for the treatment of restless legs syndrome. The trial is focused on subjects in North America who are at least 18 years old and have either completed a previous study or have a diagnosis of primary RLS using the International RLS Study Group Diagnostic Criteria. The trial involves the use of ropinirole extended release (xr) as the drug being tested. The eligibility criteria include having a total score of at least 15 on the IRLS Rating Scale at baseline and experiencing RLS symptoms during both the evening and night-time. The trial also has a list of exclusion criteria, including having certain medical conditions, abnormal laboratory or ECG findings, and a history of augmentation or end-of-dose rebound symptoms. Women who are pregnant or not practicing a clinically accepted method of contraception are also excluded. The trial has a detailed list of inclusion and exclusion criteria that must be met for subjects to participate.",
    "The sample is a phase 3 clinical trial for patients with newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum. The trial includes patients who are over 18 years old, have had at least one total colonoscopy in their disease history within the previous 5 years, and have a UC-DAI score from 3 to 8. The trial also includes patients who are men or non-pregnant women, and women with childbearing potential who are using a contraceptive method judged effective by the investigator. Patients who have proctitis, previous colonic surgery, severe/fulminant ulcerative colitis, evidence of other forms of inflammatory bowel disease or infectious disease, allergy to aspirin or salicylate derivatives, or significant hepatic or renal function abnormalities are excluded from the study. The trial also has specific wash-out periods for certain treatments and requires patients to comply with the protocol requirements and fill in diary cards.",
    "The sample is a phase 3 clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial includes patients with a confirmed diagnosis of the disease and measurable disease by radiographic imaging. Patients must also have Child-Pugh class A, ECOG PS 0 or 1, and adequate organ function to be eligible for the trial. The trial excludes patients who have received prior systemic or local treatment for hepatocellular carcinoma, have clinically relevant ascites or severe hemorrhage within 4 weeks of starting the study treatment, have known HIV or serious acute or chronic illness, are currently on another clinical trial, or are pregnant or breastfeeding. The trial will test the effectiveness of two drugs, sunitinib malate and sorafenib, in treating hepatocellular carcinoma.",
    "The sample is a phase 3 clinical trial for obesity. The trial includes patients who are 70 years of age or younger with a body mass index (BMI) between 30 and 45 kg/m2. The trial requires informed consent and adequate contraception for females of child-bearing potential. Patients with a history of stroke, myocardial infarction, unstable cardiovascular disease, clinically significant renal, hepatic or psychiatric disease, unstable thyroid disease or replacement therapy, nephrolithiasis, obesity of known genetic or endocrine origin, participation in a formal weight loss program or lifestyle intervention, glaucoma or elevated intraocular pressure, pregnancy or breastfeeding, drug or alcohol abuse, smoking cessation within previous 3 months or plans to quit smoking during study, eating disorders within past year, cholelithiasis within past 6 months, type 2 diabetes, previous bariatric surgery, bipolar disorder or psychosis, steroid hormone therapy not stable for 3 months, and systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg are excluded from the trial. The trial involves the use of drugs such as vi-0521, topiramate, and phentermine.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic lymphocytic leukemia. The trial involves the drugs idelalisib, rituximab, and a placebo to match idelalisib. The eligibility criteria for the trial include adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy, require therapy for CLL, have experienced CLL progression within the last 24 months since the completion of the last prior therapy, and are currently not fit enough to receive cytotoxic therapy due to chemotherapy-induced bone marrow damage or comorbidities. The icd-10 codes associated with the disease are also included in the record.",
    "The sample is a phase 3 clinical trial for HIV-1 infected adults who are antiretroviral-na\u00efve. The trial involves the use of three drugs - dolutegravir 50 mg oad, darunavir 800mg oad, and ritonavir 100mg oad. The eligibility criteria include having a screening plasma HIV-1 RNA greater than or equal to 1000copies/mL, being non-childbearing potential or using protocol-specified methods of birth control, and having signed and dated written informed consent. Exclusion criteria include being pregnant or breastfeeding, having an active CDC Category C disease, having moderate to severe hepatic impairment, and having a recent history of any upper or lower gastrointestinal bleed.",
    "The sample is a phase 3 clinical trial for patients undergoing elective unilateral total hip replacement or a revision of at least 1 component of a total hip replacement. The trial is testing the effectiveness of enoxaparin and apixaban, along with matching placebos, in preventing deep vein thrombosis and pulmonary embolism. The trial has a list of inclusion and exclusion criteria, including age, medical history, and laboratory values. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial requires patients to undergo bilateral ascending contrast venography.",
    "The sample is a phase 3 clinical trial for epilepsy with partial seizures. The trial is looking for male or female participants who are at least 13 years old and have a confident diagnosis of epilepsy with partial seizures for at least 24 weeks prior to the Baseline Phase. Participants must have a documented history of partial seizures and must have experienced at least 4 partial seizures during an 8-week Baseline Phase. They must also be currently receiving AED monotherapy treatment with a stable regimen of a non-enzyme inducing AED for at least four weeks prior to starting the Baseline Phase. Participants must be able and willing to maintain an accurate, complete, written daily seizure diary, or have a parent/caregiver who is able and willing to maintain an accurate, complete, written daily seizure diary for the entire duration of the study. They must also be able to comply with the dosing of study drugs, background AED, and all study procedures. Female participants of childbearing potential must be using an acceptable form of birth control. The trial has several exclusion criteria, including primary generalized seizures, status epilepticus within the 24 weeks prior to, or during, the Baseline Phase, and taking an enzyme-inducing AED or more than 1 background AED. Participants must not be currently taking lamotrigine or felbamate, using hormone therapy, abusing alcohol and/or other substances, or planning to take an investigational drug anytime during the study. They must not be suffering from acute or progressive neurological disease, severe psychiatric disease or severe mental abnormality that is likely to interfere with the objectives of the study. They must not have any clinically significant cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are aged 40 or older, have stable moderate to severe COPD, and have a post-salbutamol FEV1/FVC ratio of less than 70%. The trial also includes current or ex-smokers of 10 or more pack-years. The trial will test the effectiveness of aclidinium bromide, tiotropium, and placebo as treatments for COPD. The eligibility criteria include no history or current diagnosis of asthma, no evidence of an exacerbation within 6 weeks prior to the screening visit, no evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities, and no contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.",
    "The sample is a phase 3 clinical trial for pain, with a focus on correcting Hallux Valgus Deformity (also known as bunionectomy). The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested (4975 and placebo). The eligibility criteria for the trial include being 18 years or older and planning to undergo the specific surgery for the deformity. Exclusion criteria include certain medical conditions or medications that could interfere with the study or pain assessments, as well as previous participation in a clinical trial with 4975.",
    "The sample is a phase 3 clinical trial for the treatment of graft versus host disease. The trial includes patients who have undergone allogeneic transplantation and are experiencing acute GVHD requiring therapy, specifically skin stage 2 or overall grade II-IV. The trial involves the use of two drugs, methylprednisolone and placebo. The eligibility criteria include signed informed consent and exclusion criteria include mental or emotional contraindications, use of steroids at a dose greater than 1 mg/kg/d, acute GVHD diagnosed solely by virtue of upper GI GVHD, hypersensitivity to Daclizumab or prior therapy with Daclizumab, GVHD from donor lymphocyte infusion, other investigational therapeutics within 30 days of enrollment, and pregnancy or of fertile age without agreeing to use contraception.",
    "The sample is a phase 3 clinical trial for asthma. The eligibility criteria for participants include being at least 12 years old, having a persistent asthma diagnosis for at least 6 months, and being clinically stable for at least 1 month with an ACQ-745 test score of \u2264 3.0. Participants must also have a current use of inhaled corticosteroids and an initial FEV1 of at least 40% of the predicted normal value. Exclusion criteria include recent use of oral or parenteral corticosteroids, severe co-morbidities, recent participation in other clinical studies involving drugs, and intolerance or allergy to any of the drugs assessed in the study. Participants must not be pregnant or lactating and must not have chronic use of \u03b2-blocker medications.",
    "The sample is a phase 3 clinical trial for psoriatic arthritis. The trial is testing the effectiveness of intensive management or tight control compared to standard management (control group). The eligibility criteria include having a diagnosis of psoriatic arthritis with less than 24 months of disease duration, active disease, being at least 18 years old, and having adequate blood count and hepatobiliary function. Women of childbearing potential must use birth control measures during the study and for 6 months after the last dose of treatment. Exclusion criteria include previous treatment with disease modifying drugs, pregnancy or planning pregnancy within 6 months, and use of investigational agents within 4 weeks prior to randomization.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of keratoconjunctivitis sicca, a disease affecting the eyes. The trial involves the drug rebamipide and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having symptoms of dry eye for at least 6 months and being able to provide informed consent. Exclusion criteria include having certain eye conditions, using certain medications, and being pregnant or breastfeeding. The trial also has a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for the treatment of seasonal allergic rhinitis. The trial is looking at the effectiveness of a drug called 0.15% azelastine hydrochloride compared to a placebo. The eligibility criteria for the trial includes patients who are 12 years or older, have a 2 year history of moderate to severe seasonal allergic rhinitis, are in generally good health, and meet minimum symptom requirements as specified in the protocol. Patients must also be willing and able to provide informed consent and participate in all study procedures. Exclusion criteria include the presence of any nasal mucosal erosion, nasal ulceration, or nasal septal perforation, as well as other nasal diseases likely to affect deposition of intranasal medication. Patients with chronic sinusitis, planned travel outside of the study area during the study period, or who have used any investigational drug within 30 days prior to screening are also excluded. Women who are pregnant or nursing, or women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception are also excluded. Other exclusion criteria include respiratory tract infections, asthma, significant pulmonary disease, clinically significant arrhythmia or symptomatic cardiac conditions, a known history of alcohol or drug abuse within the last 2 years, and any surgical or medical condition or physical or laboratory findings that might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that may preclude compliance with the study procedures.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of the drug candesartan in reducing blood pressure in patients with stable diabetic therapy. The inclusion criteria require patients to be between the ages of 37 and 75, have a duration of diabetes for more than 1 year but less than 20 years, and have a mean sitting systolic blood pressure (SBP) of less than 130 mmHg or less than 160 mmHg if treated, and a mean sitting diastolic blood pressure (DBP) of less than 85 mmHg or less than 90 mmHg if treated. Patients must also have a retinal photograph grading level between 20/10 and 47/47 on the ETDRS severity scale. Exclusion criteria include various retinal conditions, positive micral dipstick test, secondary diabetes, pregnancy or lactation, and severe concomitant diseases.",
    "The sample is a phase 3 clinical trial for patients who have received an allogeneic peripheral blood stem cell transplant from either a related or unrelated donor at Washington University Medical Center and have an initial episode of cytomegalovirus (CMV) viremia. The trial is testing the effectiveness of valganciclovir and ganciclovir in treating CMV infections. The inclusion criteria for the trial include having an ANC greater than or equal to 1000, being at least 18 years old, having adequate renal function with creatinine clearance greater than 10 ml/min, and having a total bilirubin less than or equal to 3.0. The exclusion criteria include having current GI graft versus host disease grade III-IV, developing CMV disease prior to or at the time of the first detection of CMV viremia by PCR, having uncontrolled emesis or diarrhea (greater than or equal to 4 episodes per day) for 2 consecutive days, being a pregnant or nursing female patient, or having a known hypersensitivity to ganciclovir.",
    "The sample is a record of a clinical trial in phase 3, which involves the study of the effects of tesamorelin and placebo for tesamorelin on patients with lipodystrophy and HIV infections. The icd-10 codes for the diseases are listed as well. The eligibility criteria for the trial are also included, with specific inclusion and exclusion criteria. In this case, subjects who have completed a previous 26-week treatment period and have signed informed consent are eligible, while those with fasting blood glucose levels above a certain threshold are excluded.",
    "The sample is a phase 3 trial that includes patients with asthma and lung diseases, as well as those with icd-10 codes such as J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40, J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, and M05.122. The trial involves the use of drugs such as albuterol, colchicine, adrenal cortex hormones, and adrenergic-beta agonists. The eligibility criteria for the trial vary for each study.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of various doses and combinations of glimepiride and atorvastatin in reducing cardiovascular risk factors. The eligibility criteria include being an adult with stable metformin monotherapy, having HbA1c levels between 7.0 and 9.5%, and having a fasting blood glucose level above 7.0 mmol/L on 4 days in a week. Exclusion criteria include concomitant treatment with certain medications, significant hypertriglyceridaemia, ongoing cardiovascular disease, and various other health conditions. Female participants must be using highly effective contraception methods.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial involves the drug quetiapine fumarate. The eligibility criteria for the trial include the patient's ability to provide written informed consent, a documented clinical diagnosis of major depressive disorder, and the ability to understand and comply with the study requirements. Exclusion criteria include a history of non-compliance, lack of response to previous treatment with quetiapine, and participation in a clinical trial within 4 weeks of randomization. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating non-Hodgkin's lymphoma using a combination of drugs including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone. The eligibility criteria for the trial include having CD20-positive, follicular Non-Hodgkin's lymphoma grade 1, 2, or 3a, with a tumor biopsy performed within 6 months before study entry. Participants must not have received prior treatment and must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion criteria include having grade 3b follicular lymphoma, transformation to high-grade lymphoma secondary to follicular lymphoma, or any other type of Non-Hodgkin's lymphoma. Participants must not have a history of central nervous system (CNS) disease or have received corticoid therapy during the last 4 weeks, except for prednisone treatment less than (<) 20 milligrams per day (mg per day). Additionally, participants must not have any active bacterial, viral, fungal, or mycobacterial infections or have had any major episode of infections requiring hospitalization or treatment with IV antibiotics within 4 weeks of starting the study medication, or oral antibiotics within 2 weeks prior to starting the study medication.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease thromboembolism. The trial includes patients with acute symptomatic uni- or bilateral Deep Vein Thrombosis (DVT) of the leg involving proximal veins, and/or Pulmonary Embolism (PE). The trial involves the use of two drugs, warfarin and dabigatran etexilate, and has specific inclusion and exclusion criteria for patient eligibility. The inclusion criteria include being 18 years or older and providing written informed consent for study participation. The exclusion criteria include persistent symptoms of VTE, PE requiring urgent intervention, use of vena cava filter, contraindications to anticoagulant therapy, allergy to study medications, elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) > 3x Upper Limit of Normal (ULN) or known liver disease expected to have an impact on survival, severe renal impairment, and patients considered unsuitable for inclusion.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of overactive bladder. The trial involves the drug fesoterodine fumarate and the eligibility criteria include patients who have documented OAB symptoms and are dissatisfied with prior therapy with tolterodine. The exclusion criteria include patients with contraindications to fesoterodine usage, significant hepatic and renal disease, or other significant unstable diseases. Additionally, patients with OAB symptoms caused by neurological conditions or known pathologies of the urinary tract are also excluded. The diseases are listed as 'overactive bladder' and the corresponding ICD-10 code is 'N32.81'.",
    "The sample is a phase 3 clinical trial that involves patients with type 2 diabetes mellitus and moderate or severe renal insufficiency. The trial includes the use of drugs such as sitagliptin, glipizide, and placebos for both drugs. The trial also has a set of inclusion and exclusion criteria, which includes not having type 1 diabetes mellitus or a history of ketoacidosis, not being on a new weight loss program, not having active liver disease, and not being on dialysis or likely to need dialysis during the study. The diseases involved in the trial are diabetes mellitus, type 2, and renal insufficiency, chronic, and their corresponding ICD-10 codes are listed.",
    "This sample is from a phase 3 clinical trial for the treatment of migraine without aura. The trial involves the use of two drugs, sumatriptan succinate / naproxen sodium and a placebo. The eligibility criteria for participants include having a history of at least 6 migraine attacks per month for the past 6 months, being of childbearing potential and using adequate contraception, and not having certain medical conditions or allergies. Exclusion criteria include having a history of certain medical conditions or participating in an investigational drug trial in the previous 4 weeks.",
    "The sample is a phase 3 clinical trial for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-12. The trial involves the use of methylphenidate 20 mg long-acting capsules. The inclusion criteria require a diagnosis of ADHD and current medication with either 20 mg or 40 mg immediate release methylphenidate. The exclusion criteria include concomitant psychiatric disorders requiring pharmacological treatment, severe somatic disorders, eating disorders, addiction disorders, very high or low body weight according to age, known hypersensitivity to methylphenidate, and contraindications for methylphenidate. Other protocol-defined inclusion/exclusion criteria are also applied to the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of refractory partial onset seizures in pediatric patients aged 1 month to less than 4 years old. The trial is testing the drug levetiracetam, and the inclusion criteria require patients to have at least 2 partial onset seizures per week in the two weeks prior to screening, and to have had two partial onset seizures during a 48-hour video EEG at screening. The exclusion criteria include previous exposure to levetiracetam, a ketogenic diet, seizures too close together to count accurately, treatable seizure etiology, current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease, and diagnosis of a terminal illness. The diseases being treated are epilepsy, partial, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a clinical trial in phase 3 for patients with type 2 diabetes mellitus. The trial is testing the drug ipragliflozin. The inclusion criteria for the trial are that patients must have had type 2 diabetes for at least 12 weeks, have an HbA1c value between 6.5 and 9.5%, and have a body mass index (BMI) between 20.0 and 45.0kg/m2. The exclusion criteria include having type 1 diabetes mellitus, having serum creatinine levels above the upper limit of normal, having proteinuria (albumin/creatinine ratio > 300mg/g), having dysuria and/or urinary tract infection, genital infection, having significant renal, hepatic or cardiovascular diseases, having severe gastrointestinal diseases, and having proliferative diabetic retinopathy.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia and acute agitation. The trial involves the use of inhaled loxapine 5 mg, inhaled loxapine 10 mg, and inhaled placebo. The eligibility criteria for the trial include male and female adult patients with schizophrenia and acute agitation, while the exclusion criteria include agitation caused primarily by acute intoxication, history of drug or alcohol dependence, and treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension. The trial involves the use of two drugs, fimasartan/hctz combination and fimasartan. The eligibility criteria for the trial include being an outpatient over 18 years of age, having uncontrolled blood pressure, and agreeing to participate in the study. Exclusion criteria include having severe hypertension, severe renal, gastrointestinal, hematological or hepatic disease, postural hypotension, and a history of myocardial infarction or clinically significant heart failure. Female patients must be post-menopausal or have undergone hysterectomy. Patients must not have participated in another clinical trial within 12 weeks before screening.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients with a clinical diagnosis of rheumatoid arthritis and a subject's global disease assessment of greater than or equal to 20 mm on a visual analog scale. The trial requires patients to discontinue all biologics and disease-modifying antirheumatic drugs except for methotrexate. The inclusion criteria also includes the use of abatacept and methotrexate. The exclusion criteria includes patients who have received treatment with rituximab, immunoadsorption columns, mycophenolate mofetil, cyclosporine A, or other calcineurin inhibitors, or D-Penicillamine. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis. The trial is for Japanese subjects who are at least 20 years old and have a clinical diagnosis of psoriasis vulgaris amenable to topical treatment, involving arms and/or trunk and/or legs. The trial involves the use of three drugs: leo 90105 = calcipotriol + betamethasone dipropionate, dovonex\u00ae = calcipotriol, and rinderon\u00ae - dp = betamethasone dipropionate. The eligibility criteria include having a minimum m-PASI score for extent of 2 in at least one body region, psoriasis vulgaris on the trunk/limbs of not more than 30% body surface area, and a physician's global assessment of disease severity of psoriasis on trunk/limbs of mild, moderate, severe or very severe. The exclusion criteria include current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis, and patients suspected of being unable to comply with the study protocol, e.g. due to alcoholism, drug dependence or psychotic state.",
    "The sample is a phase 3 trial for the treatment of schizophrenia. The trial involves the drug \"ziprasidone oral capsules\" and the eligibility criteria includes having participated in a specific double-blind treatment study, meeting certain duration and safety criteria. Exclusion criteria includes imminent risk of suicide or homicide, serious adverse events related to the study medication in the previous study, and significant prolongation of QT interval in the previous study. The diseases being studied are only limited to schizophrenia and the icd-10 codes associated with it.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of ocular hypertension. The trial involves the use of a drug called bimatoprost/timolol fixed combination. The eligibility criteria for the trial include a clinical diagnosis of glaucoma or ocular hypertension in both eyes and the need for IOP-lowering drug in both eyes. The exclusion criteria include uncontrolled medical conditions and contraindication to beta-adrenoceptor antagonist therapy. The diseases are listed as 'ocular hypertension' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for patients with B-cell chronic lymphocytic leukemia. The trial is testing the effectiveness of a combination of three drugs - rituximab, cyclophosphamide, and fludarabine phosphate. The eligibility criteria for the trial include a diagnosis of CLL, meeting certain disease characteristics such as Binet stage B or C disease, and meeting certain patient characteristics such as having an ECOG performance status of 0-1 and a CIRS score > 6. Patients must not have received previous treatment for CLL and must not have any concurrent disease that requires prolonged therapy involving glucocorticoids.",
    "The sample is a phase 3 clinical trial for acute coronary syndrome. The trial includes patients who are 18 years or older and have been hospitalized for chest pain and potential ACS. Female patients of child-bearing potential must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable contraception. The trial excludes persons with moderate or severe liver disease, persons who have already been treated with an invasive (angioplasty) procedure for the current episode of ACS, and persons who are being treated with blood clotting agents that cannot be stopped. The trial involves the use of ticagrelor and clopidogrel drugs.",
    "The sample is a phase 3 clinical trial for patients with recurrent uterine corpus carcinoma, stage iiia, iiib, iiic, iva, or ivb uterine corpus cancer. The trial involves the use of carboplatin, cisplatin, doxorubicin hydrochloride, and paclitaxel as treatment options. Patients must meet certain eligibility criteria, including having a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2, and not having received prior cytotoxic chemotherapy. Exclusion criteria include having a concomitant malignancy other than non-melanoma skin cancer and having a history of myocardial infarct within 6 months before enrollment. The trial aims to evaluate the efficacy and safety of the treatment options for patients with poor potential for cure by radiation therapy or surgery alone or in combination.",
    "The sample is a phase 3 clinical trial for diabetic macular edema and diabetic retinopathy. The trial is testing the effectiveness of infliximab compared to a placebo. The eligibility criteria include having clinically significant macular edema, with visual acuity less than 0.4 corrected to EDRS scale, which is refractory to at least two sessions of laser photocoagulation. Participants must also have type 1 or type 2 diabetes of at least 1 year duration, and stable diabetic therapy within the last 6 months. Exclusion criteria include vitreoretinal traction, retinal detachment, and proliferative diabetic retinopathy requiring immediate panretinal photocoagulation. Participants must also not have had any previous treatment with monoclonal antibodies or antibody fragments, and must not have a history of alcohol or substance abuse within the preceding 6 months.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients with a documented diagnosis of bipolar disorder, with the most recent episode being manic or mixed. The trial requires inpatient hospital admission for the first 4 days of study treatment. The trial excludes patients with more than 8 mood episodes within the last 12 months, use of prohibited medication, substance or alcohol abuse or dependence, and current suicide risk or suicide attempt within the last 6 months. The trial uses quetiapine fumarate (seroquel) sr as the drug being tested. The diseases being studied include affective psychosis, bipolar, manic disorder, manic-depressive psychosis, mania, and manic state. The icd-10 codes associated with these diseases are F31.10, F31.11, F31.12, F31.13, F31.2, F31.73, and F31.74.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy. The trial is looking for male or female subjects between the ages of 18 and 75 who have untreated, newly diagnosed epilepsy and have had at least two well-documented seizures within the past 12 months. The trial is testing the effectiveness of the drugs zonisamide and carbamazepine. The eligibility criteria include having a documented EEG and CAT or MRI scan, being willing to follow investigational study procedures, and not having any significant or uncontrolled diseases that would interfere with the study. The exclusion criteria include having a history of certain types of seizures, being previously treated with carbamazepine or zonisamide, having a known hypersensitivity to certain medications, and having a history of certain medical conditions.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have undergone surgery. The trial is testing the effectiveness of a combination of four drugs - docetaxel, capecitabine, epirubicin, and cyclophosphamide - as adjuvant chemotherapy. The trial has specific eligibility criteria, including age between 18 and 70, HER2-negative tumors, and no evidence of metastatic disease. Patients must also have normal cardiac and renal function, and meet certain laboratory result requirements. The trial has exclusion criteria, such as prior systemic therapy for breast cancer, prior therapy with anthracyclines or taxanes, and HER2-positive breast cancer. The trial aims to determine the safety and efficacy of the drug combination in preventing recurrence of breast cancer.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients between the ages of 18 and 65 who have a primary diagnosis of non-psychotic MDD and a MADRS total score of 24 or higher. The trial involves two drugs, an antidepressant combined with spd489 (lisdexamfetamine dimesylate) and an antidepressant combined with a placebo. The eligibility criteria include being able to provide written informed consent, having an understanding and ability to comply with study procedures, and being able to swallow a capsule. Exclusion criteria include having a history of treatment-resistant depression, having a current co-morbid psychiatric disorder, being hospitalized for MDD within the last 12 months, having a history of seizures or neurological disease, having known cardiovascular disease, and having a positive urine drug result.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of fibromyalgia. The trial involves the drug pregabalin and the eligibility criteria includes meeting the ACR criteria for fibromyalgia, completing the double-blind study, and not having experienced a serious adverse event related to the study medication in a previous fibromyalgia study. The diseases column lists only fibromyalgia and the icdcodes column lists the corresponding ICD-10 code for fibromyalgia.",
    "The sample is a phase 3 clinical trial for the disease cystic fibrosis. The trial includes the drug tobramycin and has a list of ICD-10 codes associated with the disease. The eligibility criteria for the trial includes successful completion of a core study, being at least 6 years of age, and being either male or female.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients with unresectable Stage IIIA (N2) or Stage IIIB NSCLC. The patients must have histologic or cytologic evidence of NSCLC and multiple and/or bulky N2 mediastinal lymph nodes. The trial involves the use of cisplatin, etoposide, and docetaxel drugs. The eligibility criteria include measurable or evaluable disease documented by CT, MRI, X-ray or physical exam within 28 days prior to study treatment, negative pregnancy test, and completion of chemoradiotherapy per protocol. The exclusion criteria include no prior chemotherapy or radiotherapy for lung cancer, unintended weight loss > 5% body weight in the preceding 3 months prior to study treatment, and no symptomatic peripheral neuropathy prior to entry onto the study.",
    "The sample is a phase 3 clinical trial for patients with atrial fibrillation. The trial is testing the effectiveness of two drugs, sr34006 (idraparinux sodium) injection and vitamin K antagonist (warfarin or acenocoumarol) tablets. The eligibility criteria for the trial include having ECG-documented atrial fibrillation and at least one of the listed risk factors, such as previous ischemic stroke or hypertension requiring drug treatment. Exclusion criteria include legal lower age limitations, indication for VKA other than AF, and uncontrolled hypertension. The trial requires written informed consent and excludes patients who are pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus who are obese and currently taking basal insulin plus at least 2 injections of mealtime insulin daily or pre-mixed insulin. The trial is testing the effectiveness of pramlintide, and participants must have been on a stable insulin dose for at least 3 months. Inclusion criteria also include having an A1c level between 7.0% and 9.0%, being able to perform self-monitoring of glucose, and being willing to attend study visits. Exclusion criteria include having a history of cancer or chemotherapy within 6 months prior to enrollment, being pregnant or nursing, and having a history of acromegaly or Cushing's syndrome.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of acute coronary syndrome. The trial involves the use of drugs such as clopidogrel, prasugrel, and commercially-available aspirin. The eligibility criteria for the trial include having had a recent Unstable Angina/Non-ST-Elevation Myocardial Infarction event, having at least one of four specified high-risk features, and not planning to undergo percutaneous coronary intervention or coronary artery bypass graft. The exclusion criteria include having insignificant coronary artery disease, having had a previous or planned PCI or CABG, having had a STEMI event, and having a history of certain medical conditions such as stroke or bleeding requiring hospitalization.",
    "The sample is a phase 3 clinical trial for patients with prostate cancer. The trial involves a combination of drugs including docetaxel, estramustine phosphate sodium, ketoconazole, and therapeutic hydrocortisone. The eligibility criteria for patients include having histologically confirmed adenocarcinoma of the prostate that was continuously treated with androgen suppression, rising prostate-specific antigen (PSA), Gleason score 7 or higher and/or seminal vesicle involvement at diagnosis, and testosterone less than 50 ng/dL. Patients must also meet certain patient characteristics such as being 18 years or older, having an ECOG performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and cardiovascular criteria. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with moderate to severe COPD who have had symptoms for at least 24 months and have experienced at least two COPD exacerbations requiring oral corticosteroids and/or antibiotics within the past 2-12 months. The trial will test the efficacy of several drugs, including mometasone furoate/formoterol (MF/F) combination, mometasone furoate MDI (MF MDI), formoterol MDI, and placebo. The eligibility criteria include specific lung function measurements, smoking history, and the ability to discontinue current COPD therapy. The exclusion criteria include various medical conditions, allergies, and pregnancy. The trial will also require lab tests and imaging to ensure eligibility.",
    "The sample is a phase 3 clinical trial for the treatment of opioid-induced constipation (OIC). The trial includes men and women between the ages of 18 and 85 who have self-reported active symptoms of OIC and confirmed OIC. Participants must be receiving a stable maintenance opioid regimen for at least 4 weeks prior to screening for non-cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression. Participants must be willing to stop all laxatives and other bowel regimens throughout the 2-week OIC confirmation period and the 12-week treatment period, and to use only bisacodyl as rescue medication if a bowel movement has not occurred within at least 72 hours of the last recorded bowel movement. The trial excludes patients receiving an opioid regimen for the treatment of pain related to cancer, those with a history of cancer within 5 years from the first study visit (with the exception of basal cell cancer and squamous cell skin cancer), those with medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation, and those with other issues to the gastrointestinal tract that could impose a risk to the patient. Pregnant or lactating individuals are also excluded from the trial. The trial will test the efficacy of the drugs nktr-118 and placebo in treating OIC.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C infection. The trial involves the use of multiple drugs, including abt-450/r/abt-267, abt-333, and ribavirin, as well as placebos for each drug. The trial has specific inclusion and exclusion criteria, including previous treatment failure of peg-interferon and ribavirin, no evidence of liver cirrhosis, and no positive screen for drugs or alcohol. Females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control to be eligible for the trial.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients with at least 2 risk factors for metabolic syndrome, which have developed after starting an antipsychotic medication. The inclusion criteria also require that patients are willing to switch to a less metabolically disruptive antipsychotic medication. Exclusion criteria include contraindications to the use of Ziprasidone, treatment resistance, pre-existing medical conditions or taking concomitant medication that may confound the evaluation of the study drug, and a body mass index of 40 or higher at baseline. The trial will test the effectiveness of ziprasidone hcl (oral) in treating bipolar disorder in this patient population.",
    "The sample is for a phase 3 clinical trial that involves patients with hyperparathyroidism and chronic kidney disease. The trial will test the effectiveness of sevelamer carbonate compared to a placebo. The eligibility criteria for the trial include having an eGFR of less than 60 ml/min and being at least 18 years old. The exclusion criteria include having any primary parathyroid disease. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The eligibility criteria include having a life expectancy of at least 10 years, meeting specific staging criteria, having undergone a total mastectomy or lumpectomy with axillary dissection, and having a HER2-positive invasive adenocarcinoma. Patients must also have no clinical or radiologic evidence of metastatic disease and must have adequate hepatic and renal function. Exclusion criteria include prior treatment for breast cancer, prior anthracycline or taxane therapy for any malignancy, and any nonmalignant systemic disease that would preclude treatment or follow-up. Patients must also not have any cardiac disease that would preclude the use of Adriamycin, Taxol, or Herceptin. The trial also has specific guidelines for eligibility of lumpectomy and mastectomy patients regarding irradiation and surgery.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes patients who have been diagnosed clinically with type 2 diabetes for at least 24 weeks prior to randomization and are currently being treated with metformin monotherapy or metformin in combination with one or two other OADs, including an insulin secretagogue, DPP-IV inhibitors, alpha-glucosidase inhibitors, or TZDs. The patients must have an HbA1c level between 7.0-10.0% and a BMI no higher than 45.0 kg/m^2. The trial excludes patients who have been treated with GLP-1 receptor agonists within the last 12 weeks prior to Visit 2, suffer from a life-threatening disease, or are pregnant or not using adequate contraceptive methods. The trial will test the efficacy of insulin degludec as a treatment for type 2 diabetes.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of the drugs nva237 and placebo. The eligibility criteria for the trial include patients who have signed an informed consent form, have a smoking history of at least 10 pack years, and have a post-bronchodilator FEV1 (forced expiratory volume in one second) of 40-70% of the predicted normal, among other criteria. Exclusion criteria include pregnant or nursing women, patients with a recent COPD exacerbation or lower respiratory tract infection, and patients with certain abnormal ECG readings.",
    "The sample is a phase 3 clinical trial that focuses on treating various diseases such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain. The trial involves two drugs, hzt-501 and ibuprofen, and requires participants to meet certain eligibility criteria, such as needing to continue taking an NSAID for at least 6 months and having completed a 24-week treatment period in a previous study. There are also exclusion criteria, such as having malignant disease of the gastrointestinal tract or clinically significant cardiac, renal, or hepatic disease. The study center will determine if participants meet all of the criteria.",
    "The sample is a phase 3 clinical trial for the treatment of advanced or metastatic melanoma that is BRAF mutation positive. The trial is testing the effectiveness of the drugs gsk2118436 and dacarbazine (dtic). The eligibility criteria include being at least 18 years old, having measurable disease according to RECIST 1.1 criteria, and having adequate organ function. Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment and women and men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for a certain period after the last dose of study medication. Exclusion criteria include currently receiving cancer therapy, evidence of active central nervous system disease, and certain cardiac abnormalities.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of HIV infections using the drugs darunavir and ritonavir. The eligibility criteria for the trial include confirmed HIV-1 infection, a documented level of HIV-1 RNA at initiation of antiretroviral treatments, prior antiretroviral regimen, CD4 count of 200 cells per mm3 or greater, viral load below 400 copies per ml within 18 months prior to entry and below 50 copies per mL at entry, and willingness to use acceptable methods of contraception. The exclusion criteria include previous virological failure under prior PI-based regimen, prior therapy in the darunavir, HIV-2 infected patients, absence of documented level of HIV-1 RNA at initiation of antiretroviral treatments, hepatitis B or C infection within 90 days prior to study entry, therapies including interferon, interleukin-2, cytotoxic chemotherapy or immunosuppressors at study entry, serious acute illness requiring systemic treatment or hospitalization in the 14 days prior to study entry, treatment for an active AIDS defining opportunistic infection within 30 days prior to screening, drug or alcohol use or any dependence that would interfere with compliance, and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) and involves the use of the drugs indacaterol and placebo to indacaterol. The trial has eligibility criteria for inclusion and exclusion, including a smoking history of at least 10 pack-years, a post-bronchodilator FEV1 (forced expiratory volume in one second) of less than 80% and greater than or equal to 30% of the predicted normal value, and a post-bronchodilator FEV1/FVC (forced vital capacity) of less than 70%. Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization for in the 6 weeks prior to screening, patients who have had a respiratory tract infection within 6 weeks prior to screening, patients with concomitant pulmonary disease, patients with a history of asthma, patients with diabetes Type I or uncontrolled diabetes Type II, any patient with lung cancer or a history of lung cancer, and patients with a history of certain cardiovascular comorbid conditions are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The trial includes patients who are at an increased risk of developing breast cancer due to certain risk factors such as Gail score \u2265 1.66, age \u2265 60 years, prior atypical ductal hyperplasia, lobular hyperplasia, or lobular carcinoma in situ on breast biopsy, or prior ductal carcinoma in situ (DCIS) treated with total mastectomy with or without tamoxifen. Patients must not have prior DCIS treated with lumpectomy with or without radiation or prior invasive breast cancer, and must not be BRCA1 or BRCA2 carriers. The trial includes female patients who are postmenopausal and have no other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumors with no evidence of disease for \u2265 5 years. Patients must not have uncontrolled hypothyroidism or hyperthyroidism, major medical or psychiatric illness, or substance and alcohol abuse within the past 2 years that would preclude study participation or compliance. Patients must be accessible for treatment and follow-up, and willing to complete quality of life questionnaires in either English or French. The trial includes patients who were randomized to the exemestane arm and are currently receiving exemestane as part of the study and who have not completed 5 years of exemestane, or patients who were randomized to the placebo arm and have either completed 5 years of study drug or who are still receiving placebo. The trial has certain restrictions on prior concurrent therapy, including no concurrent endocrine therapy, no concurrent estrogens, androgens, or progesterones, and no other concurrent medications that may have an effect on study endpoints.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on major depressive disorder. The icd-10 codes associated with the disorder are listed. The drug being tested is vortioxetine (lu aa21004). The eligibility criteria for the trial are also listed, including inclusion criteria such as having completed a short-term treatment study for major depressive episode, and exclusion criteria such as having any current psychiatric disorder other than MDD and using any psychoactive medication. There may be other protocol-defined inclusion and exclusion criteria that apply as well.",
    "The sample is a phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive pathogens. The trial involves the use of single-dose iv oritavancin diphosphate and iv vancomycin. The eligibility criteria for the trial include being 18 years or older, having a confirmed or suspected diagnosis of ABSSSI caused by a Gram-positive pathogen, and presenting with at least 2 signs and symptoms of ABSSSI. Exclusion criteria include prior use of antibacterial therapy with activity against Gram-positive pathogens, severe sepsis or refractory shock, known or suspected bacteremia, and various other conditions that could interfere with the assessment of ABSSSI. The trial aims to evaluate the safety and efficacy of the treatment regimen and assess its potential as a new treatment option for ABSSSI.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as tocilizumab, DMARDs, and a placebo. The eligibility criteria for the trial include being an adult patient over 18 years of age with active RA for more than 6 months and having received permitted DMARDs at a stable dose for at least 8 weeks. The exclusion criteria include having a rheumatic autoimmune disease other than RA, significant systemic involvement secondary to RA, and abnormal levels of certain blood components such as ALT or AST, platelet count, hemoglobin, white blood cells, absolute neutrophil count, and absolute lymphocyte count.",
    "The sample is a phase 3 clinical trial for HIV-associated neuropathic pain. The trial is looking at the effectiveness of pregabalin compared to a placebo. The trial is open to subjects with confirmed diagnosis of HIV infection and moderate to severe pain. However, subjects using street drugs or alcohol abusers during the study, pregnant or breast feeding females, and subjects on anti-diabetic medications are excluded from the trial. Additionally, the use of neuroregenerative agents or neurotoxic chemotherapeutic agents 3 months prior to study start and throughout the study, as well as the use of neurotoxic drugs (other than D-drugs) within a month prior to study start and throughout the study are also exclusion criteria.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of psoriasis. The trial involves the use of drugs such as cp-690,550 and placebo/cp-690,550. The eligibility criteria for participants include being 18 years or older, having a diagnosis of moderate to severe plaque psoriasis for at least 12 months, and having a Psoriasis Area and Severity Index (PASI) score of 12 or higher. Participants must also not have active or latent tuberculosis. Exclusion criteria include having non-plaque or drug-induced forms of psoriasis, being unable to discontinue current psoriasis therapy, and having any uncontrolled significant medical condition.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of insulin degludec/insulin aspart as a treatment option. The eligibility criteria for the trial includes having type 2 diabetes for at least 24 weeks, being insulin na\u00efve, and currently being treated with metformin alone or in combination with one or two other oral anti-diabetic drugs. The patient's HbA1c levels must be between 7.0-10.0%, and their BMI must be below or equal to 45 kg/m^2. The patient must also be willing to adhere to the protocol, including self-measurement of plasma glucose. Exclusion criteria include previous participation in the trial, known or suspected hypersensitivity to trial products, and anticipated significant lifestyle changes during the study.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves two drugs, a fixed combination ophthalmic solution of bimatoprost and timolol. The eligibility criteria for the trial include having ocular hypertension or glaucoma in both eyes and requiring IOP-lowering therapy in each eye. Exclusion criteria include having active or recurrent eye disease, history of eye surgery or laser within 6 months, chronic use of other eye medications during the study, anticipated wearing of contact lenses during the study, and intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days. The diseases are represented as a list of disease names and their corresponding ICD-10 codes are also listed.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, chronic obstructive. The trial is testing the drug tiotropium. The eligibility criteria for participants include being at least 40 years old, having a smoking history of more than 10 pack-years, and having a Forced Expiratory Volume in 1 Second (FEV1) of less than 60% predicted. However, participants with recent history of myocardial infarction, life-threatening cardiac arrhythmia, hospitalization for cardiac failure, history of asthma or allergic conditions, malignancy requiring treatment within the past 5 years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, known active tuberculosis, or known hypersensitivity to anticholinergic drugs are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying hypercholesterolemia and dyslipidemia. The icd-10 codes associated with these diseases are listed as E78.01, E78.00, and Z83.42. The drugs being tested are abt-335 and rosuvastatin calcium, either alone or in combination. The eligibility criteria for participants include having specific fasting lipid results, agreeing to use birth control methods, and adhering to the American Heart Association diet. Participants with certain medical conditions or taking certain medications are excluded from the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial is focused on patients with a current diagnosis of schizophrenia of paranoid, disorganized, catatonic, residual, or undifferentiated subtype with persistent negative symptoms. The trial involves the use of two drugs, asenapine and olanzapine. The eligibility criteria for the trial include having no increase in level of psychiatric care during the past few months due to worsening of symptoms of schizophrenia and requiring a caregiver. The exclusion criteria include having an uncontrolled, unstable clinically significant medical condition or any other psychiatric disorder other than schizophrenia as a primary diagnosis including depression. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of migraine with or without aura. The trial includes patients between the ages of 18-65 who have a history of 1-6 migraine attacks per month in the three months prior to screening and are on a stable dose of medication for migraine prevention. The trial involves the use of drugs such as maxalt 10mg mlt plus caffeine 75mg, maxalt 10mg mlt plus placebo, and placebo + placebo. The eligibility criteria include successful treatment of a migraine attack with a triptan medication, while the exclusion criteria include a history of certain medical conditions such as ischemic heart disease, cerebrovascular disease, and epilepsy, as well as pregnancy or substance abuse.",
    "The sample is a phase 3 clinical trial for renal transplantation. The trial is testing the effectiveness of enteric-coated mycophenolate sodium (ec-mps) as a treatment. The eligibility criteria for the trial include being a recipient of a de novo cadaveric, living unrelated or living related kidney transplant, having a negative serum pregnancy test for females capable of becoming pregnant, and being willing and able to participate in the study. Exclusion criteria include having more than one previous renal transplantation, graft loss due to immunological reasons in the first year after transplantation, being a multi-organ recipient, receiving a kidney from a non-heart beating donor, and being a recipient of A-B-O incompatible transplants. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial is testing the effectiveness of four drugs, including a replication complex inhibitor and a placebo, on participants who are chronically infected with HCV Genotype 4 and have a viral load of at least 10,000 IU/mL. Participants must not have been previously exposed to interferon, RBV, or HCV direct antiviral agents, and must have had a liver biopsy within three years prior to enrollment to demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are permitted. The trial has inclusion and exclusion criteria, including the absence of decompensated liver disease, documented or suspected Hepatocellular carcinoma (HCC), and positive tests for Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus-1 (HIV-1)/HIV-2 antibody at screening.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been diagnosed for at least 1 year and are insufficiently controlled with metformin. The trial involves the drugs lixisenatide, exenatide, and metformin. The eligibility criteria for the trial include having a stable dose of metformin for at least 3 months prior to screening, and having an HbA1c level between 7% and 10% at screening. Exclusion criteria include having a BMI less than or equal to 20 kg/m^2, a weight change of more than 5 kg in the 3 months prior to the study, and a history of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, or inflammatory bowel disease. Other exclusion criteria include having a history of metabolic acidosis, hemoglobinopathy or hemolytic anemia, or a known history of drug or alcohol abuse within 6 months prior to the time of screening. Patients with cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period are also excluded.",
    "The sample is a phase 3 clinical trial for patients undergoing a thoracotomy surgery for non-infectious thoracic conditions. The trial is testing the effectiveness of Exparel 266 mg compared to a placebo in managing postoperative pain. The eligibility criteria include being at least 18 years old, having a scheduled thoracotomy of at least 3 inches, and being in good physical health. Exclusion criteria include being pregnant or nursing, having certain medical conditions or taking certain medications, and having a history of addiction or abuse of drugs or alcohol. The trial aims to assess the efficacy and safety of Exparel in managing postoperative pain in patients undergoing thoracotomy surgery.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B. The trial includes patients who have been positive for hepatitis B surface antigen for at least 6 months, are hepatitis B e antigen positive, and have a plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000 IU/mL. The trial also requires patients to have compensated liver disease with certain minimum hematological and serum biochemical criteria. The trial excludes patients with significant hepatic disease from an etiology other than hepatitis B virus, those who have received antiviral treatment for hepatitis within the previous 6 months, those with a history of severe psychiatric disease, especially depression, those with unstable or significant cardiovascular disease, those who have been exposed to known hepatotoxins such as alcohol or drugs for a prolonged period, and those with any condition that could interfere with their participation in and completion of the study. The trial uses pegylated interferon alpha-2b as a drug for treatment.",
    "The sample is a phase 3 clinical trial for the treatment of iron deficiency anemia. The trial is looking at the effectiveness of two drugs, ferumoxytol and iron sucrose, in participants who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used. The eligibility criteria include being male or female and at least 18 years old, having a hemoglobin level below 10.0 g/dL and a transferrin saturation level below 20%, and not having a history of allergy to IV iron or being on dialysis. Female participants of childbearing potential must be on an effective method of birth control. The exclusion criteria include having a history of allergy to IV iron, being pregnant or intending to become pregnant, having a hemoglobin level below 7.0 g/dL, or having a serum ferritin level above 600 nanogram/mL.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of two different drug combinations for treating two types of kidney diseases: lupus nephritis and membranous glomerulonephritis. The diseases are identified by their ICD-10 codes. The drugs being tested are prednisolone and mycophenolate mofetil, and prednisolone and tacrolimus. The eligibility criteria for the trial include having abnormal urine protein excretion and biopsy-proven membranous lupus nephritis.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are at least 40 years old, have a COPD diagnosis, and have a smoking history of at least 10 pack-years. The trial involves testing the effectiveness of several drugs, including gsk573719/gw642444 125/25, gsk573719/gw642444 62.5/25, gsk573719, and tiotropium bromide. The eligibility criteria include various medical and lifestyle factors, such as a post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and post-albuterol/salbutamol FEV1 of less than or equal to 70% predicted normal values, and a score of greater than or equal to 2 on the Modified Medical Research Council Dyspnea Scale (mMRC). The exclusion criteria include factors such as pregnancy, asthma, and other respiratory disorders.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as folate, methotrexate, methylprednisolone, placebo, and rituximab. The eligibility criteria for the trial include being an adult patient between the ages of 18-80 with RA for at least 2 months, receiving outpatient treatment, and being a candidate for methotrexate treatment. Exclusion criteria include having other rheumatic autoimmune diseases or significant systemic involvement secondary to RA, having inflammatory joint disease or other systemic autoimmune disorder, having had surgery within 12 weeks of the study, and having received previous treatment with any approved or investigational biologic agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy. Concurrent treatment with any biologic agent or DMARD other than methotrexate is also an exclusion criterion.",
    "The sample is a phase 3 clinical trial for partial seizure disorder, epilepsy, and seizures. The trial involves the use of the drug topiramate and a placebo. The eligibility criteria include being between 1-24 months old, receiving regular enteral feedings, weighing between 3.5 and 15 kg, and having clinical or EEG evidence of simple or complex POS. Exclusion criteria include being exclusively breastfed and unable to take medicine by mouth, having a surgically implanted and functioning vagus nerve stimulator, having renal stones, having medically uncontrolled illnesses or conditions, having infantile seizures as a result of a correctable medical condition, or having a progressive neurologic disorder. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 clinical trial for patients with advanced renal cell carcinoma. The trial is testing the effectiveness of a drug called Nexavar (sorafenib, bay43-9006) as a single agent. The eligibility criteria for the trial include having failed at least one prior systemic established therapy for advanced RCC or being unable to tolerate systemic therapy for advanced RCC. Patients must also be at least 18 years old and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Exclusion criteria include having a life expectancy of less than 2 months, metastatic brain or meningeal tumors, and certain medical conditions that could jeopardize their safety while taking an investigational drug. Both male and female patients must use adequate barrier birth control methods during their participation in the trial.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who have been diagnosed with moderate to severe idiopathic Parkinson's disease and have received prior therapy with L dopa for at least one year. Participants must be experiencing motor fluctuations with or without dyskinesias and have a Hoehn & Yahr stage between 2.5 and 4 when in the \"on\" state. The trial will test the efficacy of preladenant, rasagiline, and placebo in treating Parkinson's disease. The eligibility criteria include maintaining an accurate and complete symptom diary, adhering to dose and visit schedules, and using a highly effective method of birth control if sexually active. The exclusion criteria include having a form of drug-induced or atypical parkinsonism, a cognitive impairment, bipolar disorder, untreated major depressive disorder, schizophrenia, or other psychotic disorder. Participants must not have had surgery for their PD, be at imminent risk of self-harm or harm to others, or have sleep attacks or compulsive behavior that would interfere with the integrity of the trial or pose a risk to the subject in participating in the trial.",
    "The sample is a phase 3 clinical trial for breast cancer patients with unresectable, locally recurrent, or metastatic disease. The trial includes patients who have been pre-treated with one anthracyclines containing chemotherapy either in neoadjuvant/adjuvant or 1st line metastatic setting. The trial requires female patients between the ages of 18 to 75 with clinically measurable lesions according to RECIST criteria and a performance status of 70 or higher on the Karnofsky Performance Scale. Patients must also have adequate bone marrow reserve, liver function, and renal function. In addition, patients must provide informed consent and have childbearing potential either terminated by surgery, radiation, or menopause, or use an approved contraceptive method. Exclusion criteria include active infection, known or suspected brain metastases requiring steroid or radiation treatment, pregnancy, breast-feeding, serious concomitant systemic disorders, second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin), bone metastases, pleural effusion, or ascites as the only site of disease, and bone marrow transplantation or autologous stern cell infusion following high-dose chemotherapy for adjuvant or metastatic disease.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs sitagliptin and placebo. The eligibility criteria include being male between 18 and 65 years old, or post-menopausal women under 65 on stable medical therapy for 6 months, having a body mass index between 25.0 and 40.0 kg/m2, and having a baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%. Patients must also have received stable doses of metformin for at least 3 months before randomization. Exclusion criteria include extreme dyslipidemias, type 1 diabetes, secondary form of diabetes, acute metabolic diabetic complications, and taking insulin or a thiazolidinedione within the past 6 months. Patients with cardiovascular disease or taking other medications known to affect lipoprotein metabolism are also excluded. Patients must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule, and phone follow-up assessment.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of breast cancer. The trial involves the use of drugs such as trastuzumab, doxorubicin, paclitaxel, and cmf. The eligibility criteria for the trial include being a female patient over 18 years old with locally advanced breast cancer, and not having received previous therapy for any invasive malignancy. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for bacterial pneumonia. The trial includes patients who require initial hospitalization or treatment in an emergency room or urgent care setting and have an infection that requires initial treatment with IV antimicrobial. The trial excludes patients with community-acquired pneumonia suitable for outpatient therapy with an oral antimicrobial agent, respiratory tract infections not due to community-acquired bacterial pathogens, infections resistant to ceftriaxone, any condition requiring concomitant systemic corticosteroids, and a history of any hypersensitivity or allergic reaction to any \u00df-lactam antimicrobial. The trial will test the effectiveness of ceftaroline fosamil for injection, ceftriaxone, and placebo as treatments for bacterial pneumonia.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have experienced a disease flare after initial response to infliximab, a drug used to treat rheumatoid arthritis. The patients must have received the standard Remicade\u00ae dosing schedule and shown moderate or good improvement according to the DAS28 score. The trial has inclusion and exclusion criteria, including age, pregnancy status, use of investigational medical products, and any clinically significant deviations from normal physical examination or chest X-ray. The trial aims to evaluate the safety and toxicity of the study drug and its excipients.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, ICD-10 codes associated with the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying asthma. The ICD-10 codes associated with asthma are listed, along with the drugs being tested (omalizumab, placebo, and fluticasone). The eligibility criteria for participants are also listed, including age, weight, IgE levels, diagnosis of allergic asthma, positive skin test to allergens, and clinical features of moderate or severe persistent asthma. Exclusion criteria are also listed, including previous use of certain medications, history of severe allergic reactions, and presence of certain medical conditions.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial involves several drugs, including abatacept and infliximab, as well as a placebo. The eligibility criteria for participants include a diagnosis of rheumatoid arthritis, prior treatment with methotrexate, and a certain number of swollen and tender joints. Participants must also not have failed more than three disease modifying anti-rheumatic drugs and must not have a history of cancer or severe bacterial infection. Women of childbearing potential are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial is focused on patients with urinary incontinence caused by neurogenic overactive bladder due to spinal cord injury or multiple sclerosis, who have not responded well to anticholinergic medication. The trial uses normal saline (placebo) as the drug being tested. The eligibility criteria include having respiratory impairment and abnormal pulmonary function test results, while the exclusion criteria include a history or evidence of pelvic or urologic abnormality, previous or current diagnosis of bladder or prostate cancer, and symptomatic or untreated urinary tract infection at the time of enrollment.",
    "The sample is a phase 3 clinical trial for non-small-cell lung carcinoma. The trial includes patients with stage IIIB or stage IV NSCLC who have measurable disease according to response evaluation criteria in solid tumors. The trial involves two groups of patients, one receiving sorafenib, paclitaxel, and carboplatin, and the other receiving a placebo, paclitaxel, and carboplatin. The eligibility criteria include having a performance status of 0 or 1, a life expectancy of at least 12 weeks, and adequate bone marrow, liver, and renal function. Exclusion criteria include prior systemic anticancer therapy, cardiac disease, known brain metastasis, and other medical conditions that may interfere with the patient's participation in the study. Women of childbearing potential must have a negative pregnancy test and agree to use adequate contraception during the study.",
    "The sample is for a phase 3 clinical trial for the treatment of generalized anxiety disorder. The trial includes patients who have a documented clinical diagnosis of the disorder and are able to understand and comply with the requirements of the study. The trial excludes female patients who are pregnant or lactating, as well as those with a current or past diagnosis of stroke or transient ischemic attack. The trial will test the effectiveness of the drugs quetiapine fumarate and escitalopram oxylate. The icd-10 code for generalized anxiety disorder is F41.1. The eligibility criteria for the trial include being able to understand and provide written informed consent.",
    "The sample is a phase 3 clinical trial for the treatment of chronic lymphocytic leukemia. The trial includes patients who are at least 18 years old and have documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL). The patients must also have previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria. The trial involves the use of obinutuzumab, rituximab, and chlorambucil drugs. The eligibility criteria include a Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70 ml/min. The exclusion criteria include prior CLL therapy, transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation), history of other malignancy, positive hepatitis serology (HBV, HCV) or positive HIV or Human T-Cell Leukemia Virus (HTLV) testing, and active infection requiring systemic treatment.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial is testing the effectiveness of clarithromycin and placebo in treating active Crohn's disease in patients who are on a stable dose of azathioprine and 5-ASA preparation. The trial has specific inclusion and exclusion criteria, including a Crohn's Disease Activity Index (CDAI) score of over 200 and a C-reactive protein (CRP) level of over 10 mg/l. Patients must also not have any complications requiring surgery and cannot be on long-term antibiotics or have a known sensitivity to clarithromycin. The trial is not open to patients under 18 or those who are pregnant, postpartum, or breastfeeding.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of restless legs syndrome using the drug rotigotine. The trial is looking for participants with idiopathic RLS and excludes those with secondary RLS, a history of sleep disturbances, and symptomatic orthostatic hypotension. The diseases column lists only one disease, restless legs syndrome, and the icdcodes column lists the corresponding ICD-10 code for that disease.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking for male or female participants between the ages of 6-17 with a documented history of hypertension who are able to swallow a pill and weigh between 18-160 kg. The mean of 3 measurements of their MSSBP must be at or above the 95th percentile for their age, gender, and height. Patients must have written consent from their parent(s)/guardian(s) to participate in the study. Exclusion criteria include renal artery stenosis, heart failure, clinically significant valvular heart disease, and previous solid organ transplantation except for renal, liver, or heart transplantation. Other protocol-defined inclusion/exclusion criteria may also apply. The trial will be testing the effectiveness of the drugs valsartan and enalapril.",
    "The sample is a phase 3 trial for patients with ongoing significant hemorrhage or those at risk of significant hemorrhage within 8 hours of injury. The trial is testing the effectiveness of tranexamic acid and sodium chloride 0.9% as antifibrinolytic agents. Patients who are at least 16 years old and whose responsible doctor is uncertain about using antifibrinolytic therapy are eligible for randomization. Patients with clear indications or contraindications for antifibrinolytic therapy are not eligible. The trial has no other pre-specified exclusion criteria. The diseases being studied are hemorrhage, and the icd-10 codes associated with it are listed.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves patients aged 6 months to 5 years with episodic asthma. The trial includes the use of two drugs, montelukast sodium and a placebo, and has a list of icd-10 codes for asthma. The eligibility criteria for the trial include being in good health and not having persistent asthma symptoms.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of epilepsy and partial seizures using the drug levetiracetam. The trial includes patients between the ages of 4 and 16 years old, with a body weight between 11 and 82 kg. The trial has specific inclusion and exclusion criteria, including a confirmed diagnosis of epilepsy within the last 6 months, a stable anti-epileptic drug treatment for at least 4 weeks prior to baseline, and a minimum of 8 partial seizures during the 8-week prospective baseline period. Exclusion criteria include a treatable seizure etiology, a history of status epilepticus within the last 3 months, and a current diagnosis of Lennox-Gastaut syndrome. The diseases associated with the trial are epilepsy and partial seizures, and the icd-10 codes associated with these diseases are listed.",
    "This sample is for a phase 3 clinical trial for kidney transplantation. The trial is looking at the effectiveness of the drugs tacrolimus, mycophenolate mofetil, and steroids. The eligibility criteria for the trial include patients who are at least 60 years old and undergoing a cadaveric kidney transplant, have end stage kidney disease, and are suitable candidates for primary renal transplantation. Female patients of childbearing age must agree to practice effective birth control during the study. The trial also has exclusion criteria, such as patients with significant, uncontrolled infections or medical conditions that could interfere with the study. Patients must have given written informed consent to participate in the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of epilepsy and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, keppra\u00ae extended release formulation - xr and placebo. The eligibility criteria for the trial includes patients with a confirmed diagnosis of refractory epilepsy who are receiving a stable dose of 1-3 concomitant Anti-Epileptic Drugs (AED). Female patients without childbearing potential are eligible, while those with childbearing potential must use a medically accepted non-hormonal contraceptive method. The exclusion criteria includes patients with seizures occurring in clusters, status epilepticus within 3 months of Visit 1, history of non-epileptic seizures, known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients, pregnant or lactating women, and any woman with childbearing potential who is not using a medically accepted, non-hormonal method of birth control.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes mellitus. The trial involves the use of three different insulin drugs: insulin degludec, insulin detemir, and insulin aspart. The trial has specific inclusion and exclusion criteria, such as having a BMI below or equal to 35.0 kg/m^2 and not having any other antidiabetic drugs than insulin within the last 3 months. The trial is also limited to participants who have had type 1 diabetes mellitus for at least 12 months and are currently being treated with any basal bolus insulin for at least 12 months. The trial is not open to pregnant or breastfeeding women, those with a history of cancer, or those with cardiovascular disease within the last 6 months.",
    "The sample is a phase 3 clinical trial that aims to improve the quality of life for women experiencing menopausal syndrome and libido disorder. The trial involves the use of dehydroepiandrosterone and a placebo drug. The eligibility criteria include being a sexually active woman between the ages of 40 and 65 who is at least 12 months postmenopausal or has had a hysterectomy with one or both ovaries in situ and has a follicle-stimulating hormone (FSH) level greater than 20 IU/L. Participants must also have a body mass index (BMI) between 18-34 kg/m2 and have experienced a significant decrease in their desire or interest in sexual activity. Exclusion criteria include having a BMI less than 18 or greater than 34 kg/m2, severe depression, partnership problems, recent androgen therapy, treatment for depression, and known severe psychiatric illness. Participants must provide written informed consent and meet other clinical requirements to participate in the trial.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C virus (HCV) infection. The trial includes subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral therapy and have a platelet count of less than 75,000/mcL. The trial involves the use of two drugs, eltrombopag and placebo. The eligibility criteria include having evidence of chronic HCV infection, meeting certain blood count and kidney function requirements, and using effective contraception during and after treatment. Exclusion criteria include non-responders to previous treatment with pegIFN and ribavirin, decompensated liver disease, and serious cardiac, cerebrovascular, or pulmonary disease. The trial also excludes subjects with a history of certain psychiatric disorders, bleeding disorders, and other medical conditions.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes the drugs dvs-233 sr and venlafaxine er. The eligibility criteria for the trial include being an outpatient, using medically acceptable contraception if sexually active, and having a primary diagnosis of major depressive disorder. Exclusion criteria include previous treatment with DVS-233 SR or venlafaxine, and known hypersensitivity to venlafaxine. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial involves the drugs talactoferrin and placebo. The eligibility criteria for the trial include having confirmed stage IIIB or IV NSCLC, having failed at least 2 prior systemic anti-cancer regimens for advanced or metastatic NSCLC, having at least one unirradiated and measurable target lesion, having adequate hematologic, renal and hepatic function, having an ECOG score of 0, 1, or 2, and being able to understand and sign an informed consent. Exclusion criteria include having brain metastases, any gastrointestinal tract disease or other medical condition resulting in the inability to take oral medications, history of other malignancies, uncontrolled ischemic heart disease or symptomatic congestive heart failure, serious active infection, psychiatric illness/social situations that would limit study compliance, other uncontrolled serious chronic disease or conditions that could affect compliance or follow-up in the protocol, concurrent radiotherapy to any site or radiotherapy within 4 weeks prior to randomization, known HIV positive or on active anti-retroviral therapy, known Hepatitis B surface antigen positive or hepatitis C positive, receipt of any investigational medication within 4 weeks prior to randomization, pregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and 30 days after completion of treatment, and sexually active male patients unwilling to practice contraception while participating on the study and up to 30 days after completion of treatment. Legal incapacity or limited legal capacity is also an exclusion criterion, unless authorization is granted by a legal guardian.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on asthma and involves children with mild to moderate persistent asthma between the ages of 12 months and 8 years. The trial includes a list of icd-10 codes for the disease, a list of drugs being tested (including a placebo), and eligibility criteria for participants. The inclusion criteria include a documented diagnosis of asthma, at least one major or two minor risk factors, and no significant childhood illness or chronic lung disease. The exclusion criteria include recent respiratory tract infections, severe asthma attacks requiring ICU admission or ventilatory support, and recent use of corticosteroids.",
    "The sample is a phase 3 clinical trial for the treatment of proctitis, a disease affecting the rectum. The trial involves testing the effectiveness of three drugs - mesalamine, canasa, and placebo - on adults between the ages of 18 and 65 with mild to moderate proctitis. The trial has specific eligibility criteria, including a Disease Activity Index (DAI) score between 4 and 10, histological confirmation of proctitis, and negative pregnancy tests for female patients. The trial also has exclusion criteria, such as a history of allergic reactions to certain medications, severe proctitis, and use of certain medications within a certain timeframe. The trial aims to evaluate the safety and efficacy of the drugs and determine their potential as a treatment for proctitis.",
    "The sample is a phase 3 clinical trial for patients with advanced cancer. The trial is testing the effectiveness of the drugs donepezil and placebo in treating sedation caused by opiate use. The eligibility criteria include having drowsiness/sedation caused by opiate for more than 3 days, receiving a regular dose of a strong opioid for cancer pain, having intact cognition, being willing to engage in follow-up visits, being sexually active females at risk of being pregnant with a negative urine pregnancy test, and being 18 years or older. Concurrent radiation treatment and chemotherapy are allowed under certain conditions. Exclusion criteria include major contraindication to donepezil, expected major change in opiate dose or analgesia requirements, treatment with anti-cholinergic agents or Methylphenidate, having tube feeding, and history of ongoing arrhythmia causing a rhythm other than a sinus rhythm.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) with the drugs qva149 and placebo. The trial is for male or female adults aged 40 years or older with a smoking history of at least 10 pack years and a diagnosis of moderate-to-severe COPD as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008. The inclusion criteria also require a post-bronchodilator FEV1 (forced expiratory volume in one second) of less than 80% and at least 30% of the predicted normal value, and a post-bronchodilator FEV1/FVC (forced vital capacity) ratio of less than 70%. The exclusion criteria include recent respiratory tract infection, concomitant pulmonary disease, history of asthma, lung cancer or a history of lung cancer, certain cardiovascular co-morbid conditions, known history and diagnosis of alpha-1 antitrypsin deficiency, active phase of a supervised pulmonary rehabilitation program, and contraindication for inhaled anticholinergic agents and \u03b22 agonists. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug vilazodone. The trial is open to male and female patients between the ages of 18 and 65 who have been diagnosed with MDD according to DSM-IV-TR criteria and have a current Major Depressive Episode of less than two years duration with a minimum duration of at least 4 weeks. Patients must have a HAM-D score of at least 22 and a HAM-D item 1 score of at least 2. Patients must be able to provide written informed consent and speak, read, and understand English. The trial has exclusion criteria including a current or recent history of certain Axis I disorders, substance abuse or dependence, and certain MDD specifiers.",
    "The sample is a phase 3 clinical trial for multiple sclerosis. The eligibility criteria include having undergone a single clinical attack, having a unifocal clinical presentation, and being enrolled within 90 days of the attack. The subject must also have 2 or more cerebral lesions highly suspicious of MS on the screening MRI. The age range for subjects is 18 to 45 years old, and they must not have taken corticosteroids within 30 days prior to the MRI at the baseline visit. Women of child-bearing potential must practice a medically acceptable method of birth control. The exclusion criteria include multifocal clinical presentation, use of experimental or investigational drugs within 6 months prior to study entry, chronic corticosteroid treatment, pregnancy or breast feeding, and a medical or psychiatric condition that affects the subject's ability to give informed consent or complete the study.",
    "This sample is from a clinical trial in phase 3 that focuses on heartburn. The trial includes individuals who are 18 years or older, experience heartburn at least 2 days a week, and have responded to heartburn medication. They must discontinue any current heartburn medications. The trial excludes individuals with a history of erosive esophagitis or GERD diagnosed by a physician, those who are unable to take study medication or complete the study and all study procedures, and those who have required more than one 14-day course of PPI treatment within the past 4 months. The icd-10 code for heartburn is 'R12' and the drug being tested is esomeprazole.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of three drugs, bifeprunox and quetiapine, for patients diagnosed with schizophrenia. The eligibility criteria for the trial includes being between the ages of 18-65 and not having been hospitalized for an exacerbation of schizophrenia within two months prior to screening and during the screening period. The exclusion criteria includes subjects who are acutely psychotic or have a current primary psychiatric diagnosis other than schizophrenia, and those who are at significant risk of suicide or violent behavior based on their history.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial involves the use of two drugs, smc021 oral calcitonin and smc021 placebo. The eligibility criteria for the trial include having a medical history and symptoms of knee osteoarthritis, while exclusion criteria include having any other disease or medication affecting the bone or cartilage, as well as any clinical signs or laboratory evidence of diseases that would prevent the participant from adhering to the protocol or completing the trial. There may be other inclusion/exclusion criteria defined by the protocol. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of intra-abdominal infections. The trial is for hospitalized men and women who are at least 18 years old and expected to receive intravenous antibiotics for at least 5 days but no more than 14 days. The trial requires confirmed or suspected intra-abdominal infections, which are defined by specific criteria. The trial also has exclusion criteria, such as known hypersensitivity to certain antibiotics, pregnancy or lactation, and certain medical conditions. The trial does not allow subjects who have received systemic antibacterial therapy for more than 24 hours within 7 days of enrollment or who require systemic antibacterial therapy with agents other than those described in the study protocol. The trial also excludes subjects with certain medical conditions, such as severe end-stage liver disease, creatinine clearance of less than or equal to 30 mL/min/1.73 m2, and neutropenia caused by immunosuppressive therapy or malignancy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of gastric cancer. The trial includes patients with gastric adenocarcinoma in stage II, IIIa or IIIb who have undergone potentially curative tumor resection within 6 weeks prior to randomization and have not received prior chemotherapy or radiotherapy. The trial involves the use of two drugs, capecitabine and oxaliplatin. The eligibility criteria include being an adult over 18 years of age and having no serious concomitant medical illnesses that would limit life expectancy to less than 5 years. The exclusion criteria include evidence of metastatic disease and unwillingness to practice contraception during the study for sexually active males and females of childbearing potential.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drugs apixaban and enoxaparin in treating venous thrombosis and pulmonary embolism. The trial has a list of inclusion and exclusion criteria for participants, such as being 40 years or older and not having active bleeding or a history of venous thromboembolism. The diseases being studied are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia. The trial is looking at the effectiveness of a placebo drug in patients with heterozygous familial hypercholesterolemia who are already on a stable dose of an approved statin and lipid regulating medication. The inclusion criteria for the trial include being male or female between the ages of 18 and 80, having a diagnosis of heterozygous familial hypercholesterolemia, and having a fasting LDL-C level of at least 100 mg/dL. The exclusion criteria include having homozygous familial hypercholesterolemia, uncontrolled cardiac arrhythmia, uncontrolled hypertension, and poorly controlled type 2 diabetes.",
    "The sample is a phase 3 clinical trial that involves patients with various diseases such as cognitive/functional effects, metastatic cancer, neurotoxicity, and unspecified adult solid tumor. The trial requires patients to have a confirmed diagnosis of a solid tumor malignancy within the past 5 years, with visible brain metastases on contrast-enhanced MRI or CT scan. Patients must also have stable systemic disease and a Karnofsky performance status of 70-100%. The trial involves the use of the drug memantine and has specific eligibility criteria for patients, including serum creatinine levels, total bilirubin levels, and mini-mental status exam score. Patients with severe, active co-morbidities, pregnant or lactating women, and those with prior allergic reactions to memantine hydrochloride are excluded from the trial. The trial also has specific requirements for prior concurrent therapy, including no systemic chemotherapy for 14 days prior, during, or after completion of whole-brain radiotherapy.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension and sickle cell anemia using the drug bosentan. The trial has a list of inclusion and exclusion criteria, including completion of a previous 16-week treatment period, negative pregnancy test for women of childbearing potential, and reliable methods of contraception during the study and for 3 months after treatment. The trial also excludes patients with major protocol violations, hemoglobin concentration less than 6.0 g/dL, pregnancy or breastfeeding, acute liver disease, newly diagnosed cirrhosis or portal hypertension, and newly diagnosed psychotic, addictive, or other disorders that limit the ability to provide informed consent or comply with study requirements. Signed written informed consent is required from the patient or their legal representative prior to any study-related procedure.",
    "This sample is from a clinical trial in phase 3 that focuses on pulmonary embolism. The table includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and the eligibility criteria for participants. The inclusion criteria require confirmation of acute symptomatic proximal PE with or without symptomatic DVT, while the exclusion criteria include legal age limitations, previous thrombectomy or use of fibrinolytic agents, and other indications for VKA. Additionally, the pre-randomization anti-coagulant treatment cannot exceed 48 hours.",
    "The sample is a phase 3 clinical trial for patients with chronic heart failure, iron deficiency, and iron deficiency anemia. The trial involves the use of two drugs, ferinject \u00ae (ferric carboxymaltose) and normal saline (0.9%). The eligibility criteria include being in New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure, having a left ventricular ejection fraction (LVEF) of 40% or lower for patients in NYHA II and 45% or lower in NYHA III, having a screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL, and having a screening ferritin below 100 \u00b5g/L, or below 300 \u00b5g/L when transferrin saturation (TSAT) is below 20%. The exclusion criteria include having a history of acquired iron overload, known active infection, clinically significant bleeding, active malignancy, chronic liver disease, anaemia due to reasons other than iron deficiency, immunosuppressive therapy or renal dialysis, history of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months, unstable angina pectoris, acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months, coronary-artery bypass graft, percutaneous intervention, or major surgery within the last 3 months.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial involves the drugs vildagliptin am, vildagliptin pm, and a placebo. The eligibility criteria include being on metformin for at least three months, having a stable dose of at least 1500 mg daily for four weeks prior to the trial, having a body mass index between 22-40, and meeting certain blood glucose criteria. Patients who are pregnant or lactating, have a history of type 1 diabetes, or have significant diabetic complications are excluded from the trial. Other inclusion/exclusion criteria may also apply. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia in adolescents between the ages of 13 and 17 years. The trial involves the use of the drug risperidone and has a list of inclusion and exclusion criteria for eligible participants. The diseases column lists only one disease, which is schizophrenia, and the icdcodes column contains a list of ICD-10 codes associated with the disease. The criteria column provides detailed information on the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis. The trial is looking for participants of Chinese ancestry who have been diagnosed with plaque-type psoriasis at least 6 months prior to the study start. Participants must have plaque-type psoriasis covering at least 10% of their total body surface area and a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start. They must also be candidates for phototherapy or systemic treatment of psoriasis, either naive or with a history of previous treatment. Exclusion criteria include having nonplaque forms of psoriasis, current drug-induced psoriasis, recent use of investigational drugs or biologics, and being infected with HIV, HBV, HCV, or syphilis.",
    "The sample is a phase 3 clinical trial for patients with acute or primary HIV-1 infection. The trial includes two different drug regimens, both of which include darunavir, ritonavir, and either emtricitabine/tenofovir or tenofovir/emtricitabine, along with raltegravir and maraviroc. The trial has specific inclusion criteria, such as being symptomatic or having a CD4 count less than 500/mm3, and exclusion criteria, such as prior antiretroviral treatment within six months, pregnancy or breastfeeding, and certain abnormal lab values. Patients must also provide written informed consent and be at least 18 years old. The diseases being studied in this trial are limited to HIV-1 infections, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a record of a clinical trial in phase 3, focused on the prevention of venous thromboembolism in patients undergoing unilateral total hip arthroplasty. The trial involves the use of two drugs, edoxaban and enoxaparin sodium. The eligibility criteria for the trial include certain inclusion criteria, such as patients undergoing unilateral total hip arthroplasty, and exclusion criteria, such as subjects with risks of hemorrhage or thromboembolic risks, subjects who weigh less than 40 kg, and subjects who are pregnant or suspect pregnancy or want to become pregnant. The diseases being studied are prevention and venous thromboembolism, and the icd-10 codes associated with these diseases are listed as well.",
    "The sample is a phase 3 clinical trial for patients who have experienced a heart attack within the past 2 to 4 weeks. The trial is testing the effectiveness of omega-3 fatty acids (fish oil supplements) compared to a placebo. The trial is being conducted in the greater Boston area and adjacent regions. The eligibility criteria include having a heart attack within the specified time frame and living within a 50-mile radius of Boston. Exclusion criteria include having metallic implants that prevent undergoing an MRI, active cancer or any other terminal illness with a survival rate of less than 6 months, significant kidney dysfunction, inability to follow study procedures, pregnancy, hemodynamic instability, urgent clinical need for a pacemaker or AICD, and inaccessibility of medical records.",
    "The sample is a phase 3 clinical trial for patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) who have a smoking history of at least 20 pack years. The trial involves the use of several drugs, including indacaterol, salmeterol/fluticasone, and salbutamol, as well as placebos for each drug. The eligibility criteria for the trial include having a post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) of less than 80% and at least 30% of the predicted normal value, as well as a post-bronchodilator FEV1/Forced Vital Capacity (FVC) of less than 70%. Patients with certain medical conditions or who have a history of certain medical conditions are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of attention deficit hyperactivity disorder. The trial involves the use of two drugs, nwp09 and placebo. The eligibility criteria for the trial includes children aged 6 to 12 years who require pharmacologic treatment for ADHD. Patients with other serious illnesses or conditions that could put them at risk or interfere with the treatment or assessment of ADHD are excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial includes patients who are over 18 years old in Senegal and over 21 years old in Cameroon, HIV-1 infected, and have not received any antiretroviral treatment before. The patients must have a CD4 cell count over 50 cells per mm3, use a contraceptive method, and have signed an informed consent. The trial excludes patients with ongoing opportunistic infections or any other serious pathology, ongoing treatment with rifampicine, severe renal or hepatic impairment, HbSAg positive, hemoglobin under 8g/L, neutrophils under 500 cells per mm3, ongoing pregnancy or breastfeeding, and treatment by contra-indicated drugs. The trial uses four different drugs: tenofovir/emtricitabine (truvada) and nevirapine, tenofovir/emtricitabine/efavirenz (atripla), tenofovir (viread) and lopinavir/ritonavir (aluvia), and tenofovir/emtricitabine (truvada) and zidovudine.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on chronic myelogenous leukemia and involves the use of two drugs, nilotinib and imatinib. The eligibility criteria for the trial include a diagnosis of chronic myelogenous leukemia within the first 6 months of diagnosis and confirmation of the Philadelphia chromosome of (9:22) translocations. There are also several exclusion criteria, including previous treatment with a tyrosine kinase inhibitor for more than 2 weeks, impaired cardiac function, and the use of certain medications that have the potential to prolong the QT interval. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drug hycamtin, oral capsules. The trial has specific eligibility criteria, including having at least one measurable cancerous lesion in the brain from primary non-small cell lung cancer, having received previous chemotherapy, being 18 years of age or older, and having adequate bone marrow, renal, and liver capacities. The trial also has exclusion criteria, such as previous whole brain radiation therapy, prior treatment with topotecan, and having a severe concurrent medical condition that could affect compliance. Participants must sign a written informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients with a BMI of 40 kg/m\u00b2 or less and an HbA1c level greater than 7%. Patients must have been treated with basal insulin and at least two other medications, including an insulin secretagogue and metformin, for more than 6 months. The trial excludes patients with type 1 diabetes, those who have only been treated with oral medications, and those with certain medical conditions or who are taking certain medications. The trial also has various other exclusion criteria, including pregnancy, breastfeeding, and a history of drug or alcohol abuse. The eligibility criteria are not intended to include all factors relevant to a patient's potential participation in the trial.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on osteoporosis in postmenopausal women. The trial involves the use of two drugs, denosumab and placebo. The eligibility criteria for the trial include being an ambulatory Indian postmenopausal woman with osteoporosis, being between the ages of 55 and 75, and having a bone mineral density value consistent with a T-score less than -2.5 and greater than -4.0 at either the lumbar spine or total hip. There are also exclusion criteria, such as having certain medical conditions or taking certain medications. The sample provides a detailed list of both inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy. The trial includes subjects between the ages of 16 and 70 with a body weight of at least 40 kg, who have well-characterized focal or generalized epilepsy or epileptic syndrome. The trial allows for 1 to 2 permitted concomitant antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) to be stable and at optimal dosage for the subject from at least 1 month before Visit 1 and expected to be kept stable during the Run-In and Evaluation Periods. The trial excludes subjects with a history or presence of status epilepticus during 1 year preceding Visit 1 or Baseline, subjects on felbamate with less than 18 months continuous exposure before Visit 1, subjects currently on vigabatrin, and subjects taking any drug with possible relevant central nervous system effects except is stable from at least 1 month before Visit 1 and expected to be kept stable during the trial. The trial also excludes subjects with a history of cerebrovascular accident in the last 6 months, severe cardiovascular disease or peripheral vascular disease, any clinical conditions which impair reliable participation in the study or necessitate the use of medication not allowed by protocol, presence of a terminal illness, presence of a serious infection, and subjects with a history of severe adverse hematologic reaction to any drug. Other exclusion criteria include impaired hepatic function, clinically significant deviations from reference range values for laboratory parameters, clinically significant electrocardiogram (ECG) abnormalities, history of suicide attempt, current suicidal ideation or other serious psychiatric disorders requiring or having required hospitalization or medication, known allergic reaction or intolerance to pyrrolidone derivatives and / or investigational product excipients, known multiple drug allergies or severe drug allergy, pregnant or lactating women, known alcohol or drug addiction or abuse within the last 2 years, subject institutionalized under judicial decision, problems of venous accessibility, subject taking part in another clinical / pharmacological study in the month preceding enrollment (Visit 1), investigators, coinvestigators, their spouses or children, or any study collaborators, subjects previously treated with Brivaracetam (BRV), and subject previously screened within this study.",
    "The sample is a phase 3 clinical trial for patients diagnosed with Grade A or Grade B mild reflux oesophagitis. The trial is testing the effectiveness of two drugs, lafutidine and famotidine, in treating heartburn symptoms. The eligibility criteria include being over 20 years old, having complained about heartburn symptoms within the past week, and meeting certain medical requirements such as not having complications from gastric/duodenal ulcers or serious cardiac disorders. Women who are pregnant or breastfeeding are not eligible to participate. The trial also has exclusion criteria, such as patients who have received treatment for cancer or have a medical history of serious hypersensitivity to drugs.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar depression. The trial includes patients aged 18 to 65 who meet the DSM-IV criteria for bipolar disorder I or II with a recent episode of depression. The patients must have a Hamilton Rating Scale for Depression (HAM-D) total score of at least 20 and a HAM-D item 1 score of at least 2. The trial involves the use of two drugs, quetiapine fumarate (seroquel) extended release and placebo. The eligibility criteria include the provision of informed consent, the ability to understand and comply with the requirements of the study, and the absence of certain exclusion criteria such as a current diagnosis of a disorder other than bipolar disorder, a history of non-response to treatment with more than 2 classes of antidepressants, and a current serious suicidal or homicidal risk.",
    "The sample is a phase 3 clinical trial for patients with acute coronary syndromes. The trial involves switching patients from fondaparinux to either bivalirudin or unfractionated heparin. The eligibility criteria include being over 18 years old, presenting with unstable angina or non ST segment elevated myocardial infarction, and being scheduled for angiography. Patients must also be willing to participate in the study and sign an informed consent. However, there are several exclusion criteria, such as having a major or minor stroke within the past 6 months, being pregnant or lactating, or having a platelet count of less than 100,000 cells/mm3.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis vulgaris. The trial is open to both males and females of any race or ethnicity who are at least 18 years old and have a clinical diagnosis of stable plaque psoriasis vulgaris of at least 6 months duration involving the non-scalp regions of the body (trunk and/or limbs) amenable to treatment with a maximum of 100 g of topical medication per week. The trial involves the use of several drugs, including calcipotriol plus betamethasone, betamethasone-17,21-dipropionate, calcipotriene, and topical suspension vehicle. The eligibility criteria include a minimum modified Psoriasis Area and Severity Index (PASI) score for extent of 2 in at least one body region, and females of childbearing potential must have a negative pregnancy test and agree to use a highly effective method of birth control during the study. The exclusion criteria include current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis, and known or suspected severe renal insufficiency or severe hepatic disorders.",
    "The sample is a phase 3 clinical trial for the treatment of vaginal atrophy and related symptoms in menopausal women. The trial involves the use of two drugs, ospemifene 60 mg and placebo. The eligibility criteria for the trial include being naturally or surgically menopausal, having moderate or severe symptoms of vaginal atrophy, having 5% or fewer superficial cells in the maturation index of vaginal smear, having a vaginal pH greater than 5.0, and self-reporting the most bothersome symptom of vaginal dryness or vaginal pain associated with sexual activity with a severity of moderate or severe at randomization. The exclusion criteria include having uterine bleeding of unknown origin, uterine polyps or symptomatic and/or large uterine fibroids, current vaginal infection requiring medication, clinically significant abnormal gynecological findings other than signs of vaginal atrophy, and previous participation in any other ospemifene study.",
    "This sample is from a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis using the drug bosentan. The eligibility criteria for the trial include having completed all assessments from a previous study, providing informed consent, and using reliable contraception for female participants. Exclusion criteria include major protocol violations, pregnancy or breastfeeding, elevated liver enzymes, and known factors or diseases that may interfere with the study. Additionally, participants with a known hypersensitivity to bosentan or any of its components are also excluded. The diseases are listed as a single disease, idiopathic pulmonary fibrosis, and the corresponding ICD-10 code is also provided.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients between the ages of 19 and 75 with confirmed breast adenocarcinoma and evidence of metastatic disease that has progressed after combination treatment of a taxane and an anthracycline. The trial involves the use of three drugs: gemcitabine, capecitabine, and vinorelbine. The eligibility criteria include having measurable disease, no metastatic central nervous system disease, and adequate bone marrow, liver, and renal function. Exclusion criteria include pregnancy or nursing, positive pregnancy test, psychiatric illness or social situation that would preclude study compliance, other concurrent uncontrolled illness, and other invasive malignancy within the past 5 years except nonmelanoma skin cancer.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy. The trial includes subjects between the ages of 16 and 70 with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification. The subjects must have a history of partial onset seizures (POS) and have had at least 2 POS per month during the 3 months preceding Visit 1, and at least 8 POS during the 8-Week Baseline Period. The trial allows for 1 to 2 permitted concomitant antiepileptic drugs (AEDs) and vagal nerve stimulation, but subjects must be uncontrolled while on these treatments. The exclusion criteria include a history or presence of seizures occurring only in clusters and a history or presence of status epilepticus during the year preceding Visit 1 or during Baseline.",
    "The sample is a phase 3 clinical trial for the treatment of Type 2 Diabetes Mellitus using the drugs metformin and cj-30001/cj-30002. The trial has eligibility criteria for subjects, including being between 20 and 69 years old, having a BMI less than 30kg/m2, and having an HbA1c level between 7% and 11%. Exclusion criteria include having Type 1 Diabetes Mellitus, having certain medical conditions such as cardiovascular disease or cancer, and taking certain medications. Subjects must also be willing to adhere to the protocol requirements and sign an informed consent form.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia and enlarged prostate. The trial involves the use of drugs such as tadalafil, placebo, and finasteride. The eligibility criteria for the trial include not having taken any other BPH therapy, overactive bladder therapy, or erectile dysfunction therapy for at least 4 weeks prior to receiving study medication. Participants must also have bladder outlet obstruction and prostate enlargement as measured by ultrasound at screening. Exclusion criteria include having prostate cancer, recent heart attack or surgery, kidney or liver problems, uncontrolled diabetes, stroke, or planned surgery during the study.",
    "The sample is a phase 3 clinical trial for kidney transplantation and transplantation immunology, focusing on the host vs graft reaction. The trial involves administering randomized study drugs to patients who have received a primary or retransplanted cadaveric or non-HLA-identical living kidney transplant. The inclusion criteria include signing an informed consent form, receiving the first oral dose of the study drug within 48 hours of the transplant procedure, and having a negative pregnancy test for female patients of childbearing potential. The exclusion criteria include having received a non-kidney organ transplant, having received a kidney transplant from a non-heart beating donor or an ABO incompatible donor, being seropositive for HIV, having a current or past malignancy (except for non-metastatic basal or squamous cell carcinoma of the skin), having significant liver disease, having an uncontrolled infection or unstable medical condition, taking an investigational drug in the 30 days prior to transplant, receiving everolimus or enteric coated mycophenolic acid at any time during the study, having a known hypersensitivity to certain drugs, being pregnant or lactating, being unlikely to comply with the visits scheduled in the protocol, or having substance abuse or psychiatric disorder.",
    "The sample is a phase 3 clinical trial for obesity. The trial includes patients with a BMI of 35 or higher, who are 70 years old or younger, have a triglyceride level of 200 mg/dL or less with 0 or 1 medication, and have a blood pressure of 140/90 mmHg or less with 0-2 medications for hypertension. The trial excludes patients with a history of stroke, myocardial infarction, or unstable cardiovascular disease within the past 6 months, clinically significant renal, hepatic, or psychiatric disease, unstable thyroid disease or replacement therapy, nephrolithiasis, obesity of known genetic or endocrine origin, participation in a formal weight loss program or lifestyle intervention, history of glaucoma or intraocular pressure, pregnancy or breastfeeding, alcohol abuse, smoking cessation within the previous 3 months or plans to quit smoking during the study, eating disorders, cholelithiasis within the past 6 months, excluded medications, type 2 diabetes, previous bariatric surgery, or a history of bipolar disorder or psychosis. The trial involves the use of the drugs vi-0521 and placebo matched phentermine/topiramate.",
    "The sample is a phase 3 clinical trial for metastatic or locally advanced breast cancer that cannot be treated with surgery or non-systemic treatment. The trial is for postmenopausal women with confirmed estrogen receptor positive and/or progesterone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. The trial involves the drugs exemestane and everolimus (rad001). The eligibility criteria include having at least one accurately measurable lesion or bone lesion, radiological evidence of recurrence or progression on the last systemic therapy prior to enrollment, and written informed consent. The exclusion criteria include HER2-overexpressing patients, previous treatment with mTOR inhibitors, symptomatic brain or other CNS metastases, and patients with Hepatitis B or C.",
    "The sample is a phase 3 clinical trial for prostate cancer. The eligibility criteria include having histologically confirmed prostate cancer, being asymptomatic with a pain score of 0, having a PSA level no more than 100 ng/mL, and having no metastatic disease. Patients must also meet certain age, performance status, and life expectancy requirements, and cannot have had any other malignancy within the past 5 years. The trial does not specify any prior concurrent therapy. The trial will test the effectiveness of the drugs bicalutamide and goserelin acetate on patients who meet these criteria.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for overactive bladder disease. The trial involves the use of three drugs: fesoterodine fumarate, placebo, and tolterodine tartrate. The eligibility criteria for the trial include having OAB symptoms such as urinary frequency and urgency urinary incontinence. However, patients with certain conditions such as hypersensitivity to the active substance or significant hepatic and renal disease are excluded from the trial. Additionally, patients with OAB symptoms caused by neurological conditions or known pathologies of urinary tract are also excluded. The icd-10 code for overactive bladder is N32.81.",
    "The sample is a record from a clinical trial table. It includes information about the phase of the trial, which is phase 3, and the disease being studied, which is rhinitis. The icd-10 codes associated with the disease are also listed. The drugs being tested are levocetirizine, and the eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include age range, symptoms, medical history, laboratory results, and other factors that determine whether a pediatric patient is eligible to participate in the trial. The sample also includes information about the trial's sponsors and investigators.",
    "This sample is for a phase 3 clinical trial focused on osteoporosis. The trial is looking at the effectiveness of three drugs - zoledronic acid, placebo, and teriparatide. The eligibility criteria for participants include being postmenopausal women between the ages of 45 and 89 with a bone mineral density T score of -2.5 or less at femoral neck, total hip, or lumbar spine, or a T score of -2.0 or less with at least one documented osteoporotic vertebral fracture or a previously documented history of an osteoporotic clinical non-vertebral fracture not due to excessive trauma. There are also exclusion criteria, such as prior use of strontium, kidney disease or problems with kidney function, and prior treatment with certain bisphosphonates for longer than 3 months consecutively. The sample also notes that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a record of a clinical trial in phase 3 for chronic obstructive pulmonary disease. The trial includes patients who have been experiencing symptoms for more than 2 years and have a smoking history of 10 or more pack years. They must have had at least one COPD exacerbation requiring oral steroids and/or antibiotics within 1-12 months before the first visit. Patients with a history of asthma or taking oral steroids are excluded, as well as those with any significant disease or disorder that may jeopardize their safety. The trial involves the use of two drugs, budesonide/formoterol pmdi and formoterol turbuhaler. The icd-10 codes associated with the disease are J44.9, J44.1, and J44.0.",
    "The sample is a phase 3 clinical trial that involves patients with atherosclerosis, percutaneous coronary intervention, and acute coronary syndrome. The trial aims to test the effectiveness of three drugs: cangrelor p2y12 (platelet) inhibitor, clopidogrel - 300 or 600 mg (study arm), and clopidogrel 600 mg post cangrelor. The eligibility criteria for the trial include being at least 18 years old, undergoing percutaneous coronary intervention, and providing written informed consent. Patients who have received certain medications or have an increased risk of bleeding are excluded from the trial. The sample also includes a list of icd-10 codes for the diseases and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking for patients who have primary hypertension, either untreated or treated with a maximum of 2 antihypertensive drugs, which the patient and physician are willing to withdraw and replace with a placebo. The trial requires patients to have a mean sitting diastolic blood pressure (DBP) of 90-114 mmHg at visits 1 and 2, and at the end of a 4-week single-blind placebo run-in period. Patients who meet the inclusion criteria will be randomized at visit 4. The trial has a list of exclusion criteria, including pregnancy or lactation, secondary or malignant hypertension, recent myocardial infarction or stroke, chronic use of NSAIDs, and concomitant disease that may interfere with the assessment of the patient.",
    "The sample is a phase 3 clinical trial for seasonal allergic rhinitis. The trial includes patients between the ages of 12 and 70 who have a positive skin prick test and symptoms of the disease. The patients must also give their informed consent and attend the required visits scheduled. The trial has inclusion and exclusion criteria, with patients being excluded if they have a significant nasal abnormality, acute or chronic sinusitis, asthma, or any condition, disease, or hypersensitivity that could be harmed. Patients are also not allowed to take forbidden medications or not comply with the study requirements. Pregnant or breastfeeding women are excluded, and women of childbearing potential must have a pregnancy test done. The trial includes the drugs bilastine, desloratadine, and placebo.",
    "This sample is for a phase 3 clinical trial for the treatment of osteoporosis. The trial includes patients who have previously received 3 infusions in the HORIZON-Pivotal Fracture (PFT) Study. The trial involves the use of two drugs, zoledronic acid and placebo. The eligibility criteria for the trial include having good kidney, eye, and liver health, not using certain therapies for osteoporosis other than the study medication, and having normal calcium levels in the blood. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial includes patients who are insulin naive and have been on oral antidiabetic (OAD) treatment for at least 4 months with metformin, a sulphonylurea or a combination. The patients must have a body mass index (BMI) below or equal to 40.0 kg/m2 and a glycosylated haemoglobin (HbA1c) level between 7.0% and 10%. The trial excludes patients with proliferative retinopathy, recurrent major hypoglycaemia, cardial problems, uncontrolled hypertension, and impaired hepatic or renal function. The trial uses biphasic insulin aspart, insulin detemir, and insulin aspart as the drugs being tested.",
    "The sample is a record of a clinical trial in phase 3, focused on heart failure as the disease being studied. The icd-10 codes associated with heart failure are also listed. The trial involves two drugs, losartan 50 mg and losartan 150 mg. The eligibility criteria for participants include having symptomatic heart failure and a known or recently diagnosed intolerance to first-line medication for heart failure. Participants may or may not be receiving alternative or additional drug treatments.",
    "The sample is for a phase 3 clinical trial for prostate cancer. The trial includes the use of the drugs amg 162 and placebo. The eligibility criteria are not specified in the sample, but it is mentioned that there are other criteria that apply. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for type 2 diabetes mellitus. The trial involves the drugs vildagliptin and placebo. The eligibility criteria include having a confirmed diagnosis of T2DM, receiving a stable dose of SU for at least 12 weeks prior to the trial, having an HbA1c level between 7.5% and 11.0%, being between the ages of 18 and 80, and having a BMI between 20 and 40 kg/m^2. Exclusion criteria include having a FPG level of 270mg/dl or higher and experiencing severe or repetitive hypoglycemia during the run-in period. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of breast cancer. The trial is focused on patients with locally advanced or metastatic HER2-positive breast cancer. The trial involves the use of drugs such as docetaxel, vinorelbine, and trastuzumab. The eligibility criteria for the trial include a WHO performance status of less than 3, and exclusion criteria include recent chemotherapy or adjuvant therapy with the specified drugs, severe dyspnea, and abnormal organ function including cardiac issues. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is testing a combination pill of losartan and hydrochlorothiazide. The eligibility criteria for the trial include being aged 20 years or above, having hypertension defined as blood pressure levels of >/=140/90mmHg or current use of blood pressure lowering drugs, and being able to commence combination therapy of angiotensin receptor antagonists and diuretics. The exclusion criteria include having blood pressure measurements of >/=200/120mmHg, previous serious adverse events due to angiotensin receptor antagonists or diuretics, known or possible pregnancy, known severe liver dysfunction, known severe kidney disease, known contraindication to angiotensin receptor antagonists or diuretics, taking >/=4 tablets except for angiotensin receptor antagonists, ACE inhibitors, thiazide or thiazide-like diuretics in the morning, current participation in another clinical trial, and a high likelihood that the patient is not suitable for the study treatment.",
    "The sample is a phase 3 clinical trial for patients aged 18 to 75 years with a ruptured saccular aneurysm, confirmed by angiography, and successfully secured by surgical clipping. The trial is testing the efficacy and safety of the drugs clazosentan and placebo in treating aneurysmal subarachnoid hemorrhage. The eligibility criteria include specific patient characteristics, such as WFNS grade I-IV, and the presence of a diffuse clot on baseline CT scan. Exclusion criteria include patients with subarachnoid hemorrhage due to causes other than a saccular aneurysm, intraventricular or intracerebral blood, and cerebral vasospasm seen on angiography prior to the clipping procedure. Patients with significant kidney and/or liver disease, as well as those with severe or unstable concomitant conditions or diseases, are also excluded. The trial requires written informed consent from patients or their legal representatives prior to initiation of any study-mandated procedure and randomization.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who are hospitalized and have a minimum PANSS score of 60 when randomized. The trial excludes patients who have planned, regular use of antipsychotics within 1 week of randomization or have had previous treatment with risperidone that resulted in intolerance or lack of response to risperidone. The trial uses two drugs, risperidone and ziprasidone, and the diseases are listed as 'schizophrenia' with corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for ovarian cancer patients who have had platinum-sensitive recurrent cancer at least six months after completing primary standard therapy. The trial is testing the effectiveness of the drug topotecan. Patients must be at least 18 years old, have measurable or assessable lesions or CA-125 levels, and an ECOG performance status of 2 or less. Patients with more than two chemotherapies in their history, progress less than six months after completing primary standard therapy, simultaneous or planned radiation, known hypersensitivity to certain drugs, infection, or who are pregnant or breastfeeding are excluded from the trial. All patients must provide written informed consent.",
    "The sample is a phase 3 clinical trial for patients diagnosed with breast, gastrointestinal, lymphoma, myeloma or lung cancer undergoing chemotherapy or hormonal treatment. The trial is testing the effectiveness of methylphenidate and placebo in reducing fatigue symptoms. The eligibility criteria include being over 18 years old, having a Brief Fatigue Inventory \"fatigue worst\" score of 4 or higher, having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, having a life expectancy of 6 months or more, using acceptable birth control methods, speaking and understanding English, and providing written informed consent. Exclusion criteria include a history of hypersensitivity reaction to methylphenidate, seizure disorder, glaucoma, major psychiatric diagnosis, narcolepsy, Tourette's syndrome, tension or agitation, clinically significant cardiac disease, uncontrolled hypertension, fibromyalgia, use of alcohol or illicit drugs, moderate to severe depression, current use of certain medications or supplements, and any coexisting medical condition or medication likely to interfere with the safe administration of methylphenidate.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who are 18 years or older and have locally advanced, recurrent, or metastatic NSCLC with measurable disease and disease progression during 1-4 cycles of platinum-based chemotherapy. The trial excludes patients with any other malignancies within the last 5 years or unstable systemic disease. The trial will test the effectiveness of two drugs, alimta or taxotere and erlotinib [tarceva]. The table also includes a list of disease names, icd-10 codes of diseases, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are currently being treated with metformin immediate release and have a HbA1c between 7 and 10.5%. Patients must also have a fasting plasma glucose level below 270 mg/dL. The trial involves the use of four drugs: placebo, canagliflozin, sitagliptin, and metformin immediate release. The eligibility criteria include exclusion of patients with a history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes male and female patients aged 40 years or older who have signed an informed consent form. The patients must be outpatients with a smoking history of at least 10 pack years and have used bronchodilators in the previous 2 months. They must also have a post-bronchodilator FEV1 (forced expiratory volume in one second) less than 60% of the predicted normal value and a post-bronchodilator FEV1/FVC (forced vital capacity) less than 0.7. Additionally, they must have a \u2265 5% response to a reversibility test and a Baseline Dyspnoea Index (BDI) focal score less than or equal to 10. Patients with clinically relevant respiratory disorders, current diagnosis of asthma or respiratory disorders other than COPD, clinically significant laboratory and ECG abnormalities, COPD exacerbation in the 2 months prior to screening and during the study period, requiring long term oxygen therapy for chronic hypoxemia, and treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period are excluded from the trial. The drugs being tested are Foster\u00ae 100/6 \u00b5g/unit dose and Seretide Accuhaler\u00ae 500/50 \u00b5g/actuation.",
    "The sample is a phase 3 clinical trial for patients with HIV infection and hyperlipidemia. The trial is testing the effectiveness of atazanavir and the patient's current antiretroviral regimen in reducing LDL cholesterol and triglycerides. The inclusion criteria for the trial include having HIV-1 RNA levels below 500 copies/ml, a CD4 count above 100 cells/mm, and being on a stable antiretroviral regimen for at least 12 weeks that includes a protease inhibitor. The exclusion criteria include a history of heart disease, uncontrolled hypertension, peripheral vascular disease, current use of a non-nucleoside reverse transcriptase inhibitor in the protease inhibitor-containing regimen within 4 weeks, prior or current use of atazanavir, and initiation of treatment with lipid-lowering drugs within 4 weeks prior to study entry.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on the disease of prostatitis. The icd-10 codes associated with the disease are listed as well. The trial involves the drugs alfuzosin and placebo. The eligibility criteria for participants are listed under inclusion and exclusion criteria. Inclusion criteria include being male, at least 18 years old, and experiencing discomfort or pain in the pelvic region for at least six weeks. Exclusion criteria include having certain medical conditions or taking certain medications. Participants must also sign an informed consent document.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The trial includes patients who are 18 years or older and have moderate essential hypertension. The trial excludes patients with severe hypertension, pregnant or nursing women, and those with a history of cardiovascular disease. The trial is testing the effectiveness of the drug combination of valsartan and amlodipine. The eligibility criteria for the trial include specific requirements for age, gender, and health status. The exclusion criteria also include specific health conditions that would disqualify a patient from participating in the trial.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of a combination of three drugs - carboplatin, gemcitabine hydrochloride, and paclitaxel. The eligibility criteria for the trial include having histologically confirmed NSCLC of certain types, evidence of recurrent disease or distant metastases, and measurable or evaluable disease. Patients must also meet certain age, performance status, and hematopoietic, hepatic, and renal function requirements. Prior concurrent therapy is not specified, but patients cannot have had prior chemotherapy for advanced NSCLC. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast cancer and hypercalcemia of malignancy. The trial is testing the effectiveness of three drugs - ibandronate sodium, zoledronic acid, and zolendronic acid - in treating multiple bone metastases. The eligibility criteria include having a histologically proven breast cancer with metastatic disease, newly diagnosed multiple bone metastases within the past 3 months, and meeting certain radiological and medical criteria. Patients must also have an ECOG performance status of 0-2, be able to comply with instructions relating to oral study medications, and have no psychiatric illness or other condition that would preclude giving informed consent. Prior concurrent therapy is also taken into account.",
    "The sample is a phase 3 clinical trial for the treatment of macular edema and retinal vein occlusion. The trial involves the use of drugs such as ranibizumab injection 0.3 mg, ranibizumab injection 0.5 mg, and sham injection. The eligibility criteria include being over 18 years old, having foveal center-involved macular edema secondary to BRVO, and having a mean central subfield thickness of at least 250 \u03bcm on two optical coherence tomography (OCT) measurements. Exclusion criteria include a history of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0, uncontrolled blood pressure, pregnancy or lactation, and any condition that, in the opinion of the investigator, would preclude participation in the study. The study also has ocular inclusion and exclusion criteria, which include a prior episode of retinal vein occlusion, history of radial optic neurotomy or sheathotomy, and history of intraocular corticosteroid use within 3 months prior to Day 0, among others.",
    "The sample is a phase 3 clinical trial for the treatment of spasticity in patients with multiple sclerosis. The trial involves the use of Sativex and a placebo. The eligibility criteria include being diagnosed with MS, having received Sativex for at least 12 weeks prior to screening, and being willing to stop dosing with their own supply for the duration of the study. In addition, participants must be willing to comply with all study requirements and have a stable regimen for all medications and non-pharmacological therapies that may affect spasticity. Exclusion criteria include having any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity, being unable to rate their level of spasticity or distinguish it from other MS symptoms, and having any other significant disease or disorder which, in the opinion of the investigator, may put the subject at risk because of participation in the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of gastric cancer. The trial includes patients between the ages of 18 and 75 with advanced and/or metastatic gastric cancer and at least one measurable lesion. The trial excludes patients with uncontrolled infection, evidence of central nervous system metastases, history of other malignancy within the last 5 years (except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix), radiation therapy or major surgery within 4 weeks of study drug, and previous chemotherapy. The trial involves the use of 5-fluorouracil, capecitabine, and cisplatin as drugs. The icd-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2.",
    "The sample is a phase 3 clinical trial for major depressive disorder (MDD) with inadequate response to no more than one antidepressant. The trial includes patients who are outpatients and have provided signed and dated informed consent. The trial excludes patients with a lifetime history of bipolar disorder, psychotic disorder, or post-traumatic stress disorder, as well as those with a history of suicide attempts in the past year or seen as having a significant history of risk of suicide or homicide. Patients with significant medical conditions that might confound the study or put the patient at greater risk during study participation are also excluded. The trial involves the drugs tc-5214 and placebo. The diseases are listed as major depressive disorder, MDD, and depression, and the icd-10 codes associated with these diseases are also provided.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on breast neoplasms and neoplasms that are hormone-dependent. The trial involves the use of three drugs: atamestane, toremifene, and letrozole. The eligibility criteria for the trial are listed, including requirements for continued treatment and survival follow-up. There are also exclusion criteria, such as subjects who have withdrawn consent or are no longer considered suitable for study participation by the investigator. The icd-10 codes for the diseases are also included in the record.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, which are antidepressant + placebo and antidepressant + aripiprazole. The eligibility criteria for the trial includes being between 18-65 years old, having experienced a current episode of major depressive disorder for at least 8 weeks, and having a treatment history of inadequate response to at least one and no more than three antidepressants.",
    "The sample is a phase 3 clinical trial for patients with various types of ovarian, peritoneal, or fallopian tube cancer. The trial includes patients with any gross residual disease or stage IV cancer, defined surgically, and with appropriate tissue available for histologic evaluation. The trial also includes patients with measurable and non-measurable disease, and those with a GOG Performance Status of 0, 1, or 2. Patients must be entered between 1 and 12 weeks after initial surgery performed for the combined purpose of diagnosis, staging, and cytoreduction. The trial excludes patients with certain medical conditions, such as acute hepatitis or active infection, serious non-healing wounds, or clinically significant cardiovascular disease. Patients who have received prior radiotherapy or chemotherapy for any abdominal or pelvic tumor, or any targeted therapy or hormonal therapy for management of their epithelial ovarian or peritoneal primary cancer, are also excluded. Patients must sign an approved informed consent and authorization permitting release of personal health information.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with a smoking history of at least 10 pack years and a diagnosis of moderate-to-severe COPD. The trial also requires patients to have a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 40% and 80% of the predicted normal value and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) less than 70%. The trial excludes patients who have had a COPD exacerbation requiring treatment with antibiotics or systemic steroids in the last year, patients requiring long-term oxygen therapy, patients with a respiratory tract infection within 4 weeks prior to Visit 1, patients with concomitant pulmonary disease, patients with a history of asthma, patients with lung cancer or a history of lung cancer within the last 5 years, and patients with certain cardiovascular co-morbid conditions. The trial will test the efficacy of three different treatments: indacaterol and glycopyrronium (qva149), placebo to fluticasone/salmeterol, and fluticasone/salmeterol.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients with mild-to-moderate Alzheimer's disease, with a probable diagnosis according to specific criteria. The patients must have a MMSE score between 10-24 and a CT scan or MRI consistent with Alzheimer's disease. The trial also requires a caregiver who cares for the patient at least 5 days per week. Patients who have taken anti-dementia drugs or have other primary psychiatric or neurological disorders are excluded from the trial. Additionally, patients with unstable medical illnesses or significant hepatic or renal disease are also excluded. The trial involves the use of the drugs dimebon and placebo.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves testing the effectiveness of different drugs, including a placebo, in treating the disease. The eligibility criteria for the trial include having a diagnosis of COPD, being between 40 and 75 years old, and having a smoking history of more than 10 pack years. Patients must also meet certain spirometric criteria and sign an informed consent consistent with ICH-GCP guidelines. The exclusion criteria include having a significant disease other than COPD, clinically abnormal baseline haematology, blood chemistry, or urinalysis, and a history of asthma. Other exclusion criteria include having certain medical conditions, such as thyrotoxicosis or paroxysmal tachycardia, and being pregnant or nursing.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer patients who have not progressed after receiving platinum-containing first-line palliative induction chemotherapy. The trial allows patients with brain metastases as long as they are asymptomatic after cranial irradiation completed at least 4 weeks ago. Patients must meet certain eligibility criteria, including having a WHO performance status of 0-2 and no history, signs, or symptoms of clinically active interstitial lung disease. The trial involves the use of the drug gefitinib and prohibits the use of certain drugs, including epidermal growth factor receptor inhibitors and St. John's wort. Patients must not have any other concurrent anticancer therapy or experimental drugs.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients who meet the criteria for manic or mixed episodes according to the DSM-IV-TR and have a diagnosis of \"294.4x Bipolar I Disorder, Most Recent Episode Manic\" or \"296.6x Bipolar I Disorder, Most Recent Episode Mixed\". Patients must also have a total score on the Young Mania Rating Scale (YMRS) of at least 20 at Visit 1 and Visit 2. The trial excludes patients who have received an antidepressant or a psychostimulant within 5 days prior to Visit 1, have a history or a diagnosis of diabetes mellitus, or have received any psychotropic medication within 2 days prior to Visit 2 (except for benzodiazepines). The trial will test the effectiveness of olanzapine, haloperidol, and placebo as treatments for bipolar disorder.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial includes patients who are between the ages of 21 and 80 and have osteoarthritis of the hip or knee. The patients must require therapeutic doses of medication for osteoarthritis pain and have sufficient pain to justify the use of around-the-clock opioids. The trial involves the use of hydrocodone/acetaminophen extended release and a placebo. The eligibility criteria include not being associated with any ongoing research study, not having any serious allergies or reactions to the medication, and not having any significant illnesses or recent injuries. The trial also excludes patients who have a history of drug or alcohol abuse, major psychiatric disorders, or are pregnant or breastfeeding.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the treatment of restless legs syndrome. The record includes the disease name, its corresponding ICD-10 code, the drug name, and the eligibility criteria for the trial. The inclusion criteria require a diagnosis of RLS using the International RLS Study Group Diagnostic Criteria with a total score of 15 or greater on the International RLS Rating Scale. The patient must also have evening and nighttime symptoms of RLS, significant sleep impairment due to RLS symptoms, and symptoms requiring treatment prior to bedtime, but no earlier than 5:00PM. The exclusion criteria include having secondary RLS or any medical conditions that may impact efficacy assessments or present a safety concern.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension in patients who have previously participated in a placebo-controlled study and experienced clinical worsening on placebo or tadalafil. The trial includes patients who have completed Week 16 of the previous study and either had no clinical worsening or became worse on placebo or tadalafil. The inclusion criteria also require females to have a negative urine pregnancy test and use two types of birth control. Patients must be 12 years or older with parental approval. Exclusion criteria include having left-sided heart disease, musculoskeletal disorders that limit mobility, nitrate use, and certain systemic treatments. The trial involves the use of tadalafil as a drug.",
    "The sample is a phase 3 clinical trial for the treatment of systemic lupus erythematosus. The trial involves the use of the drugs premarin and provera. The eligibility criteria for the trial include being a female with an unequivocal diagnosis of SLE, having inactive disease or being stable on 0.5 mg/kg/day or less of prednisone, and having chemical evidence of menopause or having stopped periods for at least 6 months. There are also several exclusion criteria, such as having high blood pressure, a history of blood clots, certain antibody syndromes, gynecologic or breast cancer, and severe disease activity. The trial is looking to enroll women who meet the eligibility criteria and do not have any of the exclusion criteria.",
    "This sample is for a phase 3 clinical trial for the treatment of rheumatoid arthritis. The trial is looking at the effectiveness of methotrexate and tocilizumab in adult patients with moderate to severe RA who have been on methotrexate treatment for at least 12 weeks. The inclusion criteria include being at least 18 years old, having active RA, and having a stable dose of methotrexate for at least 6 weeks. The exclusion criteria include having had major surgery within 8 weeks prior to screening, having a rheumatic autoimmune disease other than RA, and having received treatment with any biologic drug used in the treatment of RA. The trial also has various other criteria for inclusion and exclusion.",
    "The sample is a record of a clinical trial in phase 3, which is focused on two diseases - macular edema, cystoid and retinal vein occlusion. The icd-10 codes associated with these diseases are also listed. The trial involves the use of two drugs - intravitreal triamcinolone injection. The eligibility criteria for the trial include participants with macular edema associated with central retinal vein occlusion or branch retinal vein occlusion, who are 18 years or older and willing to provide consent. The exclusion criteria can be found on the SCORE Study website.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis and par. The trial involves the use of ciclesonide nasal aerosol and a placebo. The eligibility criteria include being a male or premenarchal female between the ages of 6 and 11, weighing at least 20 kg, having a history of perennial allergic rhinitis to a relevant allergen for at least one year, and demonstrating sensitivity to at least one allergen known to induce perennial allergic rhinitis. The trial also has exclusion criteria, such as having a history of certain respiratory infections or disorders, having a known hypersensitivity to corticosteroids, or having any condition that would preclude the subject from completing the protocol.",
    "The sample is a phase 3 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of erlotinib hydrochloride compared to a matched placebo. Patients must have advanced stage IIIB or IV disease and not be suitable for first-line chemotherapy based on certain criteria. They must also meet certain patient characteristics, such as having an estimated life expectancy of at least 8 weeks and not having any severe uncontrolled infections or unstable angina. Patients cannot have had prior chemotherapy or biological anticancer therapy, and cannot be receiving concurrent cyclooxygenase-2 inhibitors. The sample includes detailed eligibility criteria for both disease and patient characteristics.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for type 2 diabetes. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include being diagnosed with type 2 diabetes, currently being treated with dual or triple oral therapy, having an HbA1c between 7.5% and 10.0%, and having a BMI greater than 27. The exclusion criteria include receiving chronic systemic glucocorticoid therapy, participating in an interventional medical, surgical, or pharmaceutical study within 30 days prior to entry into the study, and treatment with certain medications within the last 3 months.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes participants who have been diagnosed with essential hypertension and are being treated with single or dual treatment for hypertension. The trial aims to test the effectiveness of losartan potassium + hydrochlorothiazide + amlodipine besylate (mk-0954e), losartan potassium, amlodipine besylate, and placebos for these drugs. The inclusion criteria for the trial include having a mean trough SiDBP of \u2265 90 mmHg and < 110 mmHg and a mean trough SiSBP of \u2265 140 mmHg and < 200 mmHg. The exclusion criteria include currently taking > 2 antihypertensive medications, having a history of significant multiple and/or severe allergies to certain drugs, being a user of recreational or illicit drugs, being pregnant or breastfeeding, or having participated in a study with an investigational compound or device within 30 days of signing informed consent.",
    "The sample is a phase 3 clinical trial for HIV-1 infections. The trial is testing the effectiveness of two drugs, tmc278 and efavirenz, in treating patients with HIV-1 who have not previously been treated with a therapeutic HIV vaccine or an ARV drug. The trial has inclusion criteria such as the patient having documented HIV-1 infection, a viral load of > 5,000 HIV-1 RNA copies/mL, and sensitivity to the chosen treatment. Exclusion criteria include previous use of any ARV drug, NNRTI resistance associated mutations, and kidney impairment. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of autistic disorder. The trial involves the use of fluoxetine and placebo drugs. The eligibility criteria for the trial include meeting DSM-IV criteria for autistic disorder and having a CYBOCS-PDD score of at least 10 at screening. Patients with certain diagnoses or who have previously taken fluoxetine are excluded from the study. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the use of two drugs, human insulin inhalation powder and insulin. The eligibility criteria for the trial include being insulin-naive, having type 2 diabetes, and being a non-smoker. The exclusion criteria include having significant pulmonary, hepatic, or renal disease, severe congestive heart failure, active malignancy or malignancy within the last 5 years, and systemic glucocorticoid therapy. The icd-10 codes associated with the disease are also provided.",
    "This sample is from a clinical trial in phase 3 and focuses on pulmonary disease, specifically chronic obstructive pulmonary disease. The trial is testing the effectiveness of a drug called tiotropium inhalation solution. The eligibility criteria for participants is not specified in this sample. The icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of epilepsy, specifically the partial form. The trial uses the drug levetiracetam. The eligibility criteria for the trial include patients who completed a previous evaluation period and wish to continue treatment with the investigational drug. Exclusion criteria include patients who did not participate in the previous trial or did not comply with the requirements of the protocol. The sample also includes a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for patients with cancer who have painful sensory chemotherapy-induced peripheral neuropathy (CIPN) resulting from prior treatment with single-agent taxane or platinum agents. The trial is testing the effectiveness of duloxetine hydrochloride in reducing neuropathic pain. Patients must have a diagnosis of cancer and meet certain eligibility criteria, including having CIPN greater than grade 1 and an average neuropathic pain score of at least 4. Patients with certain illnesses known to cause peripheral neuropathy are eligible, provided they have no evidence of neuropathy from these illnesses. The trial excludes patients with a history of seizure disorder, ethanol addiction or dependence within the past 10 years, narrow-angle glaucoma, or serious eating disorders. Prior and concurrent therapy with certain drugs is also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been diagnosed for at least 1 year and are insufficiently controlled with metformin. The trial involves the use of lixisenatide, metformin, and a placebo. The eligibility criteria include exclusion of patients with HbA1c levels below 7% or above 10%, those with a BMI of less than or equal to 20 kg/m^2, and those with a history of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, or metabolic acidosis. Patients with a history of myocardial infarction, stroke, or heart failure requiring hospitalization within the last 6 months prior to screening are also excluded. In addition, patients with uncontrolled or inadequately controlled hypertension, laboratory findings outside of normal ranges, or any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram, or vital signs at the time of screening are excluded. Patients who are considered inappropriate for the study for any reason are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including lc15-0444 25mg bid, lc15-0444 50mg qd, and sitagliptin 100mg qd. The eligibility criteria for the trial include being an adult between 18 and 75 years of age, having an HbA1c between 7% and 11%, and being treated with metformin monotherapy for at least 12 weeks with a dose of 1000 mg/day or higher for at least 4 weeks prior to screening. Exclusion criteria include having type 1 diabetes mellitus, gestational diabetes, or secondary diabetes, taking drugs that may significantly affect blood glucose control, and having certain medical conditions such as congestive heart failure or renal failure.",
    "This sample is for a phase 3 clinical trial for chronic obstructive pulmonary disease. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including aclidinium bromide/formoterol fixed-dose combination, aclidinium bromide, formoterol fumarate, and placebo. The eligibility criteria for the trial include completion of a lead-in study, written informed consent, no medical contraindications, and compliance with study procedures and dosing. There are no specific exclusion criteria listed.",
    "The sample is a phase 3 clinical trial for a drug called IDEA-033. The trial is focused on treating joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation in designated target areas. The trial requires participants to be at least 18 years old and agree to refrain from chronic usage of NSAIDs or any other analgesics or anti-inflammatory drugs other than those provided during the course of the study or documented sporadic concomitant analgesics. Participants must also have healthy skin in the target area(s). The trial has exclusion criteria, including known hypersensitivity to IDEA-033 or other NSAIDs, history of coagulation disorders, history of peptic ulcers or gastric intolerance with NSAIDs, urinary tract infection, clinically significant renal, hepatic, or gastric disease, acute or chronic coexisting illness qualifying for exclusion according to clinical judgement of the investigator, clinical laboratory values outside normal range deemed clinically significant by the investigator, narcotics-containing products within 7 days of administering IMP, and malignancy within the past 2 years.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial involves testing various drugs, including ezetimibe/simvastatin + niacin (er), niacin (er) tablet, and ezetimibe/simvastatin and niacin (er), among others. The eligibility criteria for the trial include having a LDL-C level of 130 through 190 mg/dL and triglycerides less than or equal to 500 mg/dL, as well as being willing to follow a low-cholesterol diet. Exclusion criteria include being pregnant or lactating, having sensitivity or intolerance to certain medications, and having an unacceptable risk associated with discontinuing existing lipid-lowering therapy treatment.",
    "The sample is a clinical trial in phase 3 for the treatment of Parkinson's disease dementia. The trial includes patients who have been diagnosed with idiopathic Parkinson's disease and Parkinson's disease dementia according to specific criteria. The patients must also have a Mini Mental State Examination score between 10 and 26. The trial excludes patients with advanced or severe diseases that may interfere with the evaluation, as well as those with other primary neurodegenerative disorders or treatable dementia. Patients with a history of stereotaxic brain surgery for Parkinson's disease or known hypersensitivity to the drug being tested are also excluded. The trial may have additional inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial in phase 3, which involves the treatment of two types of neoplasms - colorectal and liver - using two different drugs - irinotecan + 5 fu + folinic acid and folinic acid + 5 fu. The eligibility criteria for the trial include having a histologically proven adenocarcinoma of the colon or rectum with complete resection of the primary tumor, complete surgical resection of the liver metastasis(es) within a certain timeframe, and exclusively hepatic metastasis(es) without bone, lung, or brain metastases. The exclusion criteria include prior hepatic radiation or resection, prior radiofrequency ablation or cryoablation, incomplete surgical resection of liver metastasis(es), and prior chemotherapy for metastatic disease. The diseases are represented as a list of names, and the icd-10 codes are represented as a list of strings.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes patients who are inpatients or outpatients at a psychiatric setting and have been diagnosed with recurrent MDD according to DSM-IV-TR\u2122 criteria. The trial also requires patients to have received prescribed treatment for a previous episode of depression and have a MADRS total score \u226526. The trial excludes patients with any current Axis I disorder other than MDD, confirmed using the MINI, and patients with a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder. The trial also excludes patients with physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests, and patients with a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are likely to affect central nervous system functioning. Other protocol-defined inclusion and exclusion criteria may apply.",
    "This sample is for a phase 3 clinical trial that focuses on major depression. The trial includes patients who are currently receiving an adequate trial of an antidepressant and have either major depression or partially remitted depression. However, patients with a diagnosis of bipolar I or bipolar II disorder, psychotic features, or substance dependence or abuse in the past three months are excluded from the trial. The drug being tested in this trial is risperidone. The icd-10 codes associated with major depression are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drugs vortioxetine and placebo. The trial includes eligibility criteria for participants, such as having a primary diagnosis of major depressive episode, a reported duration of the current episode of at least 3 months, and a Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of at least 26. Exclusion criteria include having any current psychiatric disorder other than major depressive disorder, a history of manic or hypomanic episode, schizophrenia, or any other psychotic disorder, and a significant risk of suicide. The trial also includes medical criteria, such as having an alanine aminotransferase, aspartate aminotransferase, or total bilirubin level > 1.5 times the upper limit of normal, and an abnormal electrocardiogram.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes the use of ziprasidone oral capsules as a drug. The eligibility criteria for the trial includes participation in a specific double-blind treatment study, while the exclusion criteria includes imminent risk of suicide or homicide, serious adverse events related to study medication, and significant prolongation of QT interval. The diseases are listed as 'bipolar disorder' and the icd-10 codes associated with it are also provided.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on Parkinson's disease, with the disease name and corresponding ICD-10 code listed. The trial is testing two drugs, carbidopa/levodopa/entacapone and immediate release carbidopa/levodopa. The eligibility criteria for the trial are also listed, including the requirement of a clinical diagnosis of idiopathic Parkinson's disease and a diagnosis of Parkinson's disease for no more than 5 years. The exclusion criteria include a history, signs, or symptoms of atypical or secondary parkinsonism, the presence of drug-related wearing-off symptoms, dyskinesia or other motor complications, and levodopa exposure of more than 30 days or anytime within 8 weeks prior to visit 1. Other inclusion/exclusion criteria may also apply to the study.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension. The trial is looking at the effectiveness of sildenafil citrate (uk-92,480) in treating the disease. The eligibility criteria for the trial includes subjects aged 16 and over who have been diagnosed with pulmonary arterial hypertension and meet certain conditions on right heart catheterization. The trial also has exclusion criteria, such as significant hepatic and/or renal disorder, known hereditary degenerative retinal disorders, and current use of certain medications. The trial will measure the baseline 6-Minute Walk test distance of the subjects and monitor their response to the treatment.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorder using the drug lurasidone hcl. The trial includes patients who are at least 18 years old and meet DSM-IV criteria for the primary diagnosis of schizophrenia or schizoaffective disorder. The eligibility criteria include being an appropriate candidate for switching current antipsychotic medication due to insufficient efficacy and/or safety or tolerability concerns. The exclusion criteria include the presence of an Axis I or Axis II disorder other than schizophrenia or schizoaffective disorder, persistent lack of improvement in psychotic symptoms despite adequate trials of two or more antipsychotic agents in the 12 months prior to screening, and being considered by the investigator to be at imminent risk of suicide or harm to self, others, or property.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have been receiving oral antihyperglycemic medications for at least 3 months and have stable doses of at least 2 of the following medications: Metformin, Sulfonylureas, Dipeptidyl peptidase-IV (DPP-IV) inhibitors, and Thiazolidinediones (TZDs). Patients must also have a hemoglobin A1c (HbA1c) level between 7.5% and 10.0%, a body mass index (BMI) between 25 and 45 kg/meter squared, and be at least 18 years old. Patients who have used insulin therapy in the past 2 years, have taken glucose-lowering medications not included in the inclusion criteria, have had severe hypoglycemia or poor glucose control, or are pregnant or intend to become pregnant during the study are excluded from the trial.",
    "The sample is a phase 3 trial for smoking cessation. The trial includes patients between the ages of 18 and 75 who are current cigarette smokers and motivated to quit. The trial involves the use of varenicline tartrate and a placebo. The eligibility criteria include exclusion of patients with depression, psychosis, panic disorder, bipolar disorder, and severe chronic obstructive pulmonary disease (COPD).",
    "This sample is for a phase 3 clinical trial for the treatment of social anxiety disorder. The trial is testing the drug quetiapine. The inclusion criteria for the trial include having a confirmed consent, meeting the DSM IV criteria for generalized social anxiety disorder, having a score of at least 60 on the LSAS, and being between the ages of 18 and 65. The exclusion criteria include having any primary axis I diagnosis other than social anxiety disorder, having alcohol and/or substance abuse within the last 12 months, having any personality disorder as the primary diagnosis (except for avoidant personality disorder), and being at risk of suicide. The icd-10 codes for the disease are also provided.",
    "This sample is for a phase 3 clinical trial for the treatment of venous thromboembolism. The trial involves the use of two drugs, edoxaban and enoxaparin sodium. The eligibility criteria for the trial includes patients undergoing unilateral total knee arthroplasty, while exclusion criteria includes subjects with risks of hemorrhage or thromboembolic risks, those who weigh less than 40 kg, and those who are pregnant or suspect pregnancy, or want to become pregnant. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking at the effectiveness of a combination of drugs including cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, goserelin acetate, and tamoxifen citrate. The eligibility criteria for the trial includes a diagnosis of primary epithelial invasive carcinoma of the breast, complete resection of the primary tumor within the past 5 weeks, and no distant metastases. Patients must also meet certain age, sex, and health criteria, and cannot have had prior cytotoxic or other antineoplastic therapy. The trial is looking to enroll female patients between the ages of 18 and 70 with a life expectancy of at least 32 weeks.",
    "The sample is a phase 3 clinical trial for acute myeloid leukemia. The trial includes patients with newly diagnosed AML, except for acute promyelocytic leukemia, who are 18 years or older and have given written informed consent. The trial involves the use of drugs such as ara-c, mitoxantrone, daunorubicin, and thioguanin. The eligibility criteria include exclusion of patients with previous or concurrent malignancies other than AML, previous treatment with certain drugs, respiratory insufficiency, heart failure, elevated creatinine or bilirubin levels, pregnancy or lactation, and severe neurologic or psychiatric disease. The trial also requires willingness to record and circulate personal disease-related information as defined in the study protocol.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of diabetic peripheral neuropathy and includes a list of associated ICD-10 codes. The drug being tested is pregabalin. The eligibility criteria for the trial includes being at least 18 years old, having a diagnosis of painful diabetic peripheral neuropathy, and experiencing pain while walking. The exclusion criteria includes being unable to walk 50 feet on a flat surface and experiencing pain while walking due to conditions other than diabetic peripheral neuropathy.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial includes patients with histologically-confirmed prostatic adenocarcinoma in Jewett Clinical Stage A2, B, C or D and TNM* classification cT1b-4, N: any, M: any. The trial requires patients to have a rising PSA following radical prostatectomy or prostate irradiation. The trial involves the use of two drugs, leuprolide acetate - formulation a and leuprolide acetate - formulation b. The eligibility criteria include a pre-trial serum testosterone level >150 ng/dL, Eastern Cooperative Oncology Group (ECOG) Performance status grades 0,1,or 2, and a life expectancy of at least 18 months. The exclusion criteria include a history of clinical hypogonadism, current malignancy or history of malignancy except for prostate cancer or basal or squamous cell carcinoma of the skin, and clinical or laboratory evidence of any severe underlying disease state (excluding prostate cancer) that would place subjects in additional jeopardy by participating in this trial.",
    "The sample is a phase 3 clinical trial for the treatment of diabetes mellitus. The trial includes patients with type 2 diabetes who have not received antidiabetic medication in the 12 weeks prior to screening, have a glycosylated hemoglobin level between 7.5% and 10.0%, and a body mass index less than or equal to 45 kg/m2. The trial involves the use of pioglitazone and metformin, pioglitazone, and metformin as potential treatments. The eligibility criteria include counseling on lifestyle modification, stable condition as determined by a physician, and adequate contraception for sexually active females of childbearing potential. The exclusion criteria include type 1 diabetes, unstable angina or heart failure, history of myocardial infarction or cerebrovascular accident, and various other medical conditions that may compromise safety or affect the evaluation of the study medication.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have operable invasive adenocarcinoma of the breast (T1-T3) and are HER2 negative. The trial involves the use of fluorouracil, doxorubicin, cyclophosphamide, and paclitaxel as adjuvant chemotherapy. Patients must meet certain eligibility criteria, including having at least one high-risk criterion, being free of metastatic disease, and having normal laboratory results. Exclusion criteria include prior systemic therapy for breast cancer, prior therapy with anthracyclines or taxanes, and HER2 positive breast cancer. The trial is only open to female patients between the ages of 18 and 70 who are able to comply with treatment and study follow-up.",
    "The sample is a phase 3 clinical trial for hospital-acquired pneumonia. The trial includes patients who have been hospitalized for at least 72 hours and have at least three of the four following signs: fever, purulent tracheal sputum production/secretion or change in sputum character, total peripheral white blood cell (WBC) count > 12 G/L or < 4.5 G/L or 15% immature neutrophils (bands), and increased plasma or serum C reactive protein (CRP) level. The trial also requires specimens to be collected for microbiological documentation within 24 hours prior to enrollment. Patients with suspected viral or fungal pneumonia, severe HAP, or evidence of severe sepsis with hypotension and/or end-organ dysfunction are excluded from the trial. Patients with any concomitant pulmonary diseases, conditions or complications that could confound the interpretation or evaluation of drug efficacy or safety, including severe bronchiectases, cystic fibrosis, active pulmonary tuberculosis or acute pulmonary embolism, empyema, lung abscess or extra pulmonary extension of the LRTI, are also excluded. Patients with impaired renal function, hepatic cirrhosis with Child-Pugh score > or = B, and immuno-compromised patients are also excluded. Patients with a microbiologically documented infection with a pathogen known prior to inclusion to be resistant to at least one of the study medications, known or suspected hypersensitivity to, or known or suspected serious adverse reaction to levofloxacin and/or piperacillin/tazobactam and/or any other quinolones, beta-lactamase inhibitors, penicillins and/or to cephalosporins, epilepsy or a history of epilepsy or with predisposition to seizures, known or suspected history of tendon disorders unless a potential relationship to fluoroquinolone administration has been excluded, and latent or actual known defects in glucose-6-phosphate dehydrogenase activity are also excluded. Women who are breast-feeding, or are failing to use adequate contraception, patients with a recent history of drug or alcohol abuse, and patients who have received any investigational drug within one month prior to study entry are also excluded.",
    "This is a sample from a clinical trial table for a phase 3 study. The disease being studied is chronic lymphocytic leukemia. The ICD-10 codes associated with the disease are C91.11, C91.12, and C91.10. The drugs being tested are fludarabine and cyclophosphamide. The eligibility criteria for patients include having a diagnosis of B-cell chronic lymphocytic leukemia within the past 12 months, being in Binet stage A disease, having a life expectancy of more than 6 months, having an ECOG performance status of 0-2, and not having received prior chemotherapy, radiotherapy, or antibody treatment. Patients must also be willing to accept contraception if randomized to arm I and have a negative serum pregnancy test. All parameters for risk stratification must also be present.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes patients with fasting LDL-C levels of 75 mg/dL or higher who meet certain LDL-C values on background lipid-lowering therapy. The therapy includes atorvastatin and ezetimibe. Patients with fasting triglycerides of 400 mg/dL or lower are eligible for the trial. However, patients with certain medical conditions such as NYHA II-IV heart failure, uncontrolled cardiac arrhythmia, recent myocardial infarction or stroke, and uncontrolled hypertension are excluded from the trial. The trial requires informed consent from the patients.",
    "The sample is a phase 3 clinical trial for children with pulmonary arterial hypertension. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs, and eligibility criteria for inclusion and exclusion. Inclusion criteria include age, weight, mean pulmonary artery pressure, PCWP, PVRI, and functional capacity. Exclusion criteria include various medical conditions, such as left-sided heart disease, restrictive pulmonary disease, and impaired renal or hepatic function. The trial also requires written informed consent and assent for applicable subjects.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The trial involves the drug rasagiline mesylate and the eligibility criteria includes patients who completed evaluations of week 52 of a previous protocol and require continued rasagiline therapy according to the principal investigator. Patients who suffered adverse effects that were probably drug-related in the previous study are excluded. The sample also includes the ICD-10 code for Parkinson's disease, which is G20.",
    "The sample is a phase 3 clinical trial for patients with acute heart failure or acute decompensation of chronic heart failure. The trial is testing the effectiveness of the drug tezosentan compared to a placebo. The eligibility criteria include being 18 years or older, having dyspnea at rest, and meeting at least two out of four criteria related to heart function. Patients must also have received at least one dose of i.v. diuretic within 24 hours prior to study drug initiation. Exclusion criteria include factors that might interfere with the study conduct or interpretation of the results, such as known drug or alcohol dependence, and concomitant treatment with cyclosporin A or tacrolimus.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes using the drug candesartan. The trial is open to male and female participants aged 18-55 who have been diagnosed with type 1 diabetes before the age of 36 and require continuous insulin treatment within one year of diagnosis. Participants must have had diabetes for more than one year but less than 20 years and have stable diabetic therapy within the last 6 months. They must also have untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85 mmHg and with retinal photograph grading level > 20/10 up to < 47/47 (on ETDRS severity scale). There are several exclusion criteria, including certain eye conditions, positive micral dipstick test, secondary diabetes, pregnancy or lactation, and severe concomitant disease.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed, along with a variety of drugs being tested, including amlodipine and manidipine. The eligibility criteria for the trial are also listed, including age requirements and blood pressure thresholds for inclusion and exclusion. The trial excludes patients with secondary forms of hypertension, severe hypertension, and pregnant or lactating women.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with a smoking history of at least 10 pack-years and a post-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% and greater than or equal to 30% of the predicted normal value. The trial also includes patients with a post-bronchodilator FEV1/FVC (forced vital capacity) of less than 70%. The trial excludes patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to screening, patients who have had a respiratory tract infection within 6 weeks prior to screening, patients with concomitant pulmonary disease, patients with a history of asthma, patients with diabetes Type I or uncontrolled diabetes Type II, any patient with lung cancer or a history of lung cancer, and patients with a history of certain cardiovascular co-morbid conditions. The trial involves the use of indacaterol 75 \u03bcg and placebo to indacaterol.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of hepatitis B. The trial involves the drug lamivudine and has a list of inclusion and exclusion criteria for participants. The diseases are listed as 'hepatitis b' and the icd-10 codes associated with the disease are also provided. The eligibility criteria include written informed consent, liver biopsy acceptance, a certain grade of hepatitis, a certain level of DNA HBV, and a certain level of ALAT. The exclusion criteria include being positive for HCV, HDV, or HIV, being pregnant, having decompensated liver cirrhosis, or being a pretreated patient.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease hepatitis B. The icd-10 codes associated with the disease are listed. The drugs being tested are telbivudine and adefovir dipivoxil. The eligibility criteria for the trial are listed, including requirements for documented chronic hepatitis B, previous or current lamivudine treatment, and evidence of viral breakthrough. There are also exclusion criteria, such as being pregnant or co-infected with other viruses.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. The trial involves testing various drugs, including a placebo and different doses of tamsulosin hydrochloride and solifenacin succinate fixed dose combinations. The eligibility criteria for participants include having LUTS associated with BPH for at least 3 months, a total IPSS score of 13 or higher, and specific urinary flow rate and frequency requirements. Exclusion criteria include having a significant post void residual volume, a prostate estimated to be 75 ml or larger, and evidence of a symptomatic urinary tract infection.",
    "The sample is a phase 3 clinical trial for the treatment of hyperphosphatemia and end-stage renal disease. The trial involves the drug ferric citrate and requires participants to meet certain eligibility criteria, such as being on thrice weekly hemodialysis or peritoneal dialysis for at least three months prior to the screening visit, having serum phosphorus levels within a certain range, and being willing to discontinue current phosphate binders and initiate ferric citrate. There are also exclusion criteria, such as a history of multiple drug allergies or intolerances, a requirement for oral iron therapy, and a psychiatric disorder that interferes with compliance with the study protocol. The trial aims to determine the safety and efficacy of ferric citrate in treating hyperphosphatemia in patients with end-stage renal disease.",
    "The sample is a phase 3 clinical trial for the treatment of low back pain. The trial includes patients with non-specific low back pain with an acute episode of recent onset, defined by average pain within the last 24 hours equal or more than 50 mm on the Visual Analogue Scale (VAS). The trial excludes patients with low back pain due to vertebral collapse or of no mechanical origin, such as neoplasm, infection or inflammatory disorders, and patients with a history of inflammatory arthritis of large joints, seizure disorders, malignant tumor, or treatment with steroidal agents during the two days prior to prospective inclusion. Patients who have received other therapy (physiotherapy, physical manipulations, invasive intervention, acupuncture therapy...) within the last 48 hours are also excluded. The trial drugs used are thiocolchicoside+ketoprofen and thiocolchicoside. Patients who are pregnant, breastfeeding, or women of childbearing potential not using efficient contraception are excluded. Patients with known or suspected hypersensitivity to thiocolchicoside or ketoprofen are also excluded. The eligibility criteria for the trial are listed in detail in the sample.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on breast neoplasms. The icd-10 codes associated with the disease are listed. The trial involves two drugs, exemestane and anastrozole. The eligibility criteria for the trial are also listed, including the requirement that patients have histologically or cytologically confirmed breast cancer and must have metastatic progressive or locally recurrent inoperable breast cancer. The exclusion criteria include having received any hormonal therapy or chemotherapy for advanced/recurrent breast cancer.",
    "The sample is a phase 3 clinical trial for patients with diabetes mellitus type 2. The trial includes the use of two drugs, placebo and taspoglutide, and has a list of inclusion and exclusion criteria. Inclusion criteria include being an adult patient over 18 years of age, having HbA1c levels between 6.5% and 10%, having a BMI of at least 23kg/m2, and having cardiovascular disease with onset at least one month prior to screening. Exclusion criteria include having type 1 diabetes or secondary forms of diabetes, experiencing acute metabolic diabetic complications within the past 6 months, having clinically significant gastrointestinal disease, having a history of chronic or acute pancreatitis, having current NYHA class IV heart failure or post-transplantation cardiomyopathy, and having severely impaired renal function.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease of venous thromboembolism. The icd-10 codes associated with this disease are listed. The trial involves two drugs, rivaroxaban and placebo. The eligibility criteria for the trial are also listed, including inclusion criteria such as having been treated for 6 or 12 months with VKA or rivaroxaban, and exclusion criteria such as being pregnant or having an indication for VKA other than DVT and/or PE.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are 18 years or older and have been diagnosed with RA for at least 6 months. They must be receiving outpatient treatment and have had an inadequate response to methotrexate, which they have been taking for at least 12 weeks with a stable dose for at least 4 weeks. The trial excludes patients with other rheumatic autoimmune diseases or significant systemic involvement secondary to RA, as well as those with inflammatory joint disease or other systemic autoimmune disorders. Patients who have been diagnosed with juvenile arthritis or RA before the age of 16 are also excluded, as are those who have previously been treated with more than one biologic agent or any cell-depleting therapies, or who are currently receiving any biologic agent or DMARD other than methotrexate. The drugs being tested in the trial are rituximab [mabthera/rituxan].",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of pain and the drug being tested is oxycodone naloxone prolonged release tablets (oxn). The trial is looking for male or female subjects who are at least 18 years old and have moderate to severe pain that requires around the clock opioid therapy. The subjects must also report constipation caused or aggravated by opioids. The trial has exclusion criteria which include pregnant or lactating females, subjects with evidence of any clinically unstable disease, impaired liver/kidney function, or significant structural abnormalities of the gastrointestinal tract. The diseases being studied are not specified beyond pain, and the icd-10 codes associated with the disease are listed as [\"['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']\"].",
    "The sample is a phase 3 clinical trial for the treatment of tuberculosis and human immunodeficiency virus infections. The trial involves the use of drugs such as didanosine, lamivudine, and efavirenz, as well as didanosine, lamivudine, and nevirapine. The eligibility criteria for the trial include being over 18 years old, having a positive diagnosis of tuberculosis, being HIV-1 positive with CD4 cell counts less than 250 cells/mm3, and being willing to remain in the same area for at least two years after the start of treatment. The trial also requires participants to stay in the hospital for two weeks during initiation of ART and attend the clinic thrice weekly for the entire period of the study (up to 2 years). Exclusion criteria include pregnancy and lactation, major psychiatric illnesses, and previous antituberculosis or antiretroviral treatment for more than 1 month.",
    "The sample is a clinical trial for phase 3, focused on patients with type 2 diabetes mellitus who have been diagnosed for at least 1 year and are being treated with basal insulin in combination with oral antihyperglycemic drugs for at least 6 months. The trial excludes patients who are under 18 years old, have a BMI of 35 kg/m2 or higher, have an HbA1c level below 7.0% or above 10%, have diabetes other than type 2, have used certain types of insulin or glucose-lowering medications in the past 3 months, have experienced severe hypoglycemia or diabetic retinopathy, or have used an insulin pump in the past 6 months. The eligibility criteria are listed in detail in the sample.",
    "This sample is for a phase 3 clinical trial for seasonal allergic rhinitis. The trial includes patients with a documented history of seasonal allergic rhinitis to mountain cedar or other spring pollen. The trial excludes patients with significant medical conditions, significant nasal abnormalities, significant cardiac conditions, recent infections, use of other allergy medication during the study, and use of asthma medication other than as-needed albuterol. The trial involves testing the effectiveness of four different epinastine nasal sprays with varying concentrations and dose volumes. The diseases are listed as 'seasonal allergic rhinitis' and the corresponding ICD-10 code is 'J30.2'.",
    "The sample is a phase 3 clinical trial for the treatment of sepsis. The trial involves the use of two drugs, drotrecogin alfa (activated) and placebo. The eligibility criteria for the trial include being 18 years or older, having evidence of infection, having systemic inflammatory response syndrome (SIRS), and having vasopressor-dependent septic shock. The exclusion criteria include having received vasopressor therapy for more than 24 hours prior to the start of the study drug, having sepsis-induced organ dysfunction for more than 36 hours prior to the start of the study drug infusion, having single organ dysfunction and recent surgery within 30 days of study entry, having had surgery performed within the 12-hour period immediately preceding the study drug infusion, or being postoperative with evidence of active bleeding, or having planned or anticipated surgery during the infusion period, and not being expected to survive 28 days given their preexisting uncorrectable medical condition. The diseases being treated are sepsis, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 3 clinical trial for patients with pain associated with cancer or cancer treatment. The trial involves the use of the drugs bema\u2122 and placebo. The eligibility criteria include being 18 years or older, having a stable current regimen of oral opioids, regularly experiencing 1-4 breakthrough pain episodes per day, and being able to self-administer the study medication correctly. Exclusion criteria include having psychiatric/cognitive or neurological impairment, recent history or current evidence of alcohol or other drug substance abuse, and being pregnant or not using adequate contraceptive measures. The trial requires patients to complete an electronic diary card with each pain episode.",
    "The sample is a phase 3 clinical trial for patients with atrial fibrillation and inflammation. The trial involves the use of atorvastatin and placebo drugs. The eligibility criteria for the trial include being 18 years or older, having a clinical diagnosis of abnormal heart beat known as atrial fibrillation/flutter, and being able to swallow pill form of drug. Exclusion criteria include being under 18 years of age, enrollment in another ongoing trial, and having certain medical conditions such as severe valvular heart disease or uncontrolled hypertension. The trial also excludes patients who have used statins within the previous 30 days or have implanted devices for active management of arrhythmias by pacing or defibrillation.",
    "The sample is a phase 3 clinical trial for patients with type II diabetes mellitus. The trial involves the use of two drugs, vildagliptin and glimepiride, and requires patients to be on stable metformin. Inclusion criteria include being between 18-70 years old and willing to perform at least 4 capillary blood glucose tests per day. Exclusion criteria include being on any other antidiabetic treatment, being listed in other trials, and having significant diabetic organ disease or complications. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with biliary tract cancer, including intrahepatic or extrahepatic/hilar cholangiocarcinoma or muscle invasive gallbladder cancer or cancer of the distal bile duct. Patients must have undergone a radical surgical approach which includes liver resection, pancreatic resection, or both. The trial involves the drug capecitabine and has eligibility criteria for patient characteristics such as ECOG performance status, urea, creatinine, glomerular filtration rate, hemoglobin, WBC, absolute neutrophil count, platelet count, bilirubin, ALT and AST, surgical biliary drainage, and pregnancy status. Patients must also have no history of other malignant diseases within the past 5 years and no serious co-existing medical condition likely to interfere with protocol treatment. Prior concurrent therapy is also considered. The sample includes detailed eligibility criteria for both disease and patient characteristics.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes using the drugs liraglutide, placebo, and glimepiride. The trial includes patients who have been on a diet and lifestyle changes or metformin monotherapy for at least three months and have a HbA1c level between 6.5-9.0%. Patients with a BMI less than or equal to 40 kg/m^2 are also included. However, patients who have previously been treated with insulin or GLP-1 analogues/mimetics, or have smoked within the past 6 months, are excluded from the trial. Patients with overt cardiovascular disease, abnormal exercise stress ECG test, known retinopathy or maculopathy, known autonomic neuropathy, or have initiated or changed their blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening are also excluded. Additionally, patients with systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg are not eligible for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial involves the use of inhaled mannitol and a placebo comparator. The eligibility criteria for participants include having a confirmed diagnosis of cystic fibrosis, being aged over 6 years old, having FEV1 between 40% and 90% predicted, and being able to perform all the techniques necessary to measure lung function. Exclusion criteria include being terminally ill or eligible for lung transplantation, having had a lung transplant, and having had certain medical conditions or surgeries within the three months prior to enrollment. Participants must also not be pregnant or breastfeeding, and must not have a known allergy to mannitol or be using beta blockers.",
    "The sample is a phase 3 clinical trial for patients with postoperative pain and bunion. The trial involves the use of two drugs, COV795 and placebo. The eligibility criteria include being in good health, aged between 18 and 75 years, having a body mass index of \u226433 kg/m2, and being scheduled for a primary unilateral first metatarsal bunionectomy. Female subjects must not be pregnant or lactating, and male subjects must commit to using a reliable method of birth control. Exclusion criteria include having uncontrolled medical conditions, a history of substance or alcohol abuse, and a positive test for HIV, HBV, or HCV. The trial protocol specifies other criteria for exclusion.",
    "The sample is a phase 3 clinical trial for hypertension. The trial involves the use of the drugs clevidipine and placebo. The eligibility criteria for the trial include being at least 18 years old, scheduled for cardiac surgery, and providing written informed consent. Exclusion criteria include recent cerebrovascular accident, known intolerance to calcium channel blockers, and participation in another therapeutic drug or device trial within 30 days of starting the study. Post-randomization inclusion criteria include being determined to be hypertensive and having the investigator's intent to lower the patient's systolic blood pressure by a minimum of 15% from its baseline value. The trial aims to determine the effectiveness of the drugs in lowering blood pressure in patients undergoing cardiac surgery.",
    "The sample is a phase 3 clinical trial for amyotrophic lateral sclerosis. The trial includes patients aged 18 to 80 years old who have been diagnosed with sporadic or familial ALS and have had their first symptoms within 24 months prior to the start of the trial. Patients must also meet certain criteria, such as having a World Federation of Neurology El Escorial criteria-supported diagnosis and a minimum upright slow vital capacity (SVC) of 65% at screening. Patients taking or not taking Riluzole are eligible for the trial, but there are certain requirements for those currently taking it. Patients must be able to swallow tablets at the time of study entry. There are also exclusion criteria, such as having other medically significant illnesses or abnormal laboratory values, being pregnant or breastfeeding, or having prior exposure to dexpramipexole or currently taking pramipexole or other dopamine agonists. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This sample is for a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis. The trial involves the use of the drugs bosentan and placebo. The eligibility criteria for participants include being 18 years or older, having a proven diagnosis of IPF within the last 3 years with surgical lung biopsy, and not having certain conditions or illnesses that could limit participation in the study. Exclusion criteria include having certain medical conditions, recent use of certain medications, and known hypersensitivity to bosentan or any of its components.",
    "The sample is a phase 3 clinical trial for advanced Parkinson's disease. The trial includes patients who are aged between 30 and 80 years old and have been diagnosed with idiopathic Parkinson's disease for more than 3 years. Patients must have motor fluctuations such as wearing and dyskinesia, and have experienced nocturias for at least 3 nights within 7 days prior to baseline. Patients must also be taking levodopa in combination with benserazide or carbidopa and a non-ergot dopamine agonist. The trial has several exclusion criteria, including patients who are receiving therapy with tolcapone or budipine, have a history of symptomatic orthostatic hypotension, or are pregnant or nursing. The trial also has inclusion and exclusion criteria related to medication use and hypersensitivity.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including placebo, vortioxetine (lu aa21004), and duloxetine. The eligibility criteria for the trial include having recurrent MDD as the primary diagnosis, a MADRS total score of at least 26, a CGI-S score of at least 4, and having the current episode of MDE for more than 3 months. Exclusion criteria include any current anxiety psychiatric disorder, current or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, alcohol or other substance abuse or dependence, and use of any psychoactive medication 2 weeks prior to screening and during the study. The patient must not be at significant risk of suicide or have attempted suicide within 6 months prior to the screening visit. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "This sample is for a phase 3 clinical trial focused on hypertension. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include being an outpatient over 18 years old, having essential hypertension with a msDBP between 90 and 110 mmHg, and not having a history of severe hypertension or secondary forms of hypertension. The exclusion criteria include a history of hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes who have been treated with stable basal insulin analogue dose of minimum 20 U/day with or without stable metformin equal to or above 1500 mg/day for at least 8 weeks prior to screening. The trial is testing the effectiveness of liraglutide compared to a placebo. The inclusion criteria include having a HbA1c level between 7.0-10.0%, a BMI between 20-45 kg/m^2, and being diagnosed with type 2 diabetes for at least 180 days prior to screening. The exclusion criteria include being pregnant, having recurrent severe hypoglycaemic episodes or hypoglycaemic unawareness, having impaired liver or renal function, having uncontrolled hypertension, having any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial, and having known or suspected abuse of alcohol or narcotics.",
    "This sample is for a phase 3 clinical trial for the treatment of painful diabetic neuropathy. The trial is focused on the drug lacosamide. The diseases being studied are limited to painful diabetic neuropathy, and the icd-10 codes associated with this condition are listed. The eligibility criteria for the trial are also provided, including both inclusion and exclusion criteria. Inclusion criteria specify that participants must have painful diabetic neuropathy, while exclusion criteria include factors such as liver enzyme abnormalities, impaired renal function, cardiac abnormalities, and pregnancy or nursing.",
    "The sample is a phase 3 clinical trial for acute schizophrenia. The trial involves the use of er oros paliperidone and olanzapine drugs. The eligibility criteria for the trial include having a DSM-IV diagnosis of schizophrenia, a total PANSS score between 60 and 120, and being capable of self-administering the study drug or having consistent help and support available. Exclusion criteria include having a previous lack of response to any antipsychotic, a significant risk of suicidal or violent behavior, and recent use of certain medications or treatments. The trial requires patients to sign an informed consent document and have a negative urine pregnancy test.",
    "The sample is a phase 3 clinical trial for the treatment of opioid-induced constipation (OIC). The trial involves the use of the drugs nktr-118 and placebo. The eligibility criteria include completing a previous 12-week study, being between the ages of 18 and 85, and continuing to receive a stable maintenance opioid regimen. Participants must also be willing to abstain from all laxatives and other bowel regimens, except for bisacodyl as rescue medication. Exclusion criteria include receiving opioid treatment for cancer-related pain, having a history of cancer within 5 years, and having medical conditions or treatments associated with diarrhea, intermittent loose stools, or constipation. The trial does not allow for pregnant or lactating participants. The diseases listed in the sample are limited to OIC, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial is focused on patients with Pseudomonas aeruginosa infection. The trial is open to male and female subjects between the ages of 6 and 21. The FEV1 at screening must be between 25% and 80% of normal predicted values. The trial will use tobramycin inhalation powder as the drug. The eligibility criteria include confirmed diagnosis of cystic fibrosis, and exclusion criteria include known hypersensitivity to aminoglycosides or inhaled antibiotics.",
    "The sample is a phase 3 clinical trial for men aged 18 years or older with an elevated prostate specific antigen (PSA) level of over 2.5 ng/ml and a normal digital rectal exam. The trial involves the use of ciprofloxacin and a diagnostic 12-core prostate biopsy. The inclusion criteria include having an elevated PSA level and electing to proceed with the biopsy, while the exclusion criteria include a previous prostate biopsy, history of prostate cancer, urinary tract infections or prostatitis within one year of study entry, recent antibiotic use, pyuria or bacteruria on urinalysis, and allergy to fluoroquinolones. The diseases being studied are not specified, but the icd-10 code for elevated PSA is listed as R97.20.",
    "The sample is a record of a clinical trial in phase 3, focused on cardiovascular disease. The trial involves the use of simvastatin at different dosages and a placebo. The eligibility criteria for the trial include having had a prior myocardial infarction and a need for statin therapy, while exclusion criteria include chronic liver disease, severe renal disease, and concurrent treatment with certain medications. The trial is expected to last for 5 years.",
    "The sample is a phase 3 clinical trial for breast cancer patients with locally advanced and/or metastatic disease. The trial includes patients who have received prior neo-adjuvant or adjuvant taxane regimen as long as it has been greater than or equal to 6 months since completion of the regimen. The trial also includes patients who have had 0-1, but no more than one prior course of chemotherapy for metastatic disease. The trial allows patients with either measurable or non-measurable (evaluable) disease and prior radiation therapy allowed of less than 25% of the bone marrow. However, the trial excludes patients with second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence), parenchymal or leptomeningeal brain metastases, peripheral neuropathy greater than or equal to grade 2, prior treatment with gemcitabine and capecitabine, and prior treatment with a taxane in the metastatic setting. The trial also excludes patients with active cardiac disease not controlled by therapy and/or myocardial infarction within the preceding 6 months and concomitant Herceptin is not allowed. The trial uses gemcitabine, docetaxel, and capecitabine as drugs.",
    "The sample is a phase 3 clinical trial for breast cancer patients with stage IV disease. The trial involves the use of lapatinib, paclitaxel, and trastuzumab drugs. The eligibility criteria include having histologically confirmed invasive breast cancer, overexpression of ErbB2, measurable lesion(s) according to RECIST, and being a female of at least 18 years with non-childbearing potential or using adequate contraception. Patients must also have adequate organ function and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. Exclusion criteria include being pregnant or lactating, having received prior chemotherapy or anti-ErbB1/ErbB2 therapy for metastatic disease, having malabsorption syndrome or disease significantly affecting gastrointestinal function, and having unresolved or unstable serious toxicity from prior administration of another investigational drug or prior cancer treatment.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial is looking for male or female participants between the ages of 12 and 20 who have been diagnosed with bipolar spectrum disorder, including bipolar I and bipolar II disorders, cyclothymia, and bipolar NOS. Participants must not have been on any preventive treatment for at least one month prior to enrollment. Female participants of childbearing potential who are sexually active must be using a reliable method of contraception. The trial is testing the effectiveness of the drug quetiapine. The eligibility criteria include being able to understand and comply with the requirements of the study, while the exclusion criteria include known intolerance or lack of response to quetiapine fumarate, pregnancy or lactation, history of substance or alcohol dependence, and use of certain medications within 14 days prior to enrollment.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD) in subjects of Asian ancestry. The trial involves the use of fluticasone furoate/vilanterol and a placebo. The eligibility criteria for the trial include a COPD diagnosis defined by ATS/ERS, being a current or former smoker, having a score of 2 or higher on the modified Medical Research Council Dyspnea Scale at screening, and providing valid informed consent. Exclusion criteria include pregnancy, a current diagnosis of asthma, alpha1-antitrypsin deficiency as the underlying cause for COPD, and other active respiratory disorders. The trial also excludes subjects with a history of hypersensitivity to any of the study medications or components of the inhalation powder, as well as those with a known or suspected history of alcohol or drug abuse within the last 2 years prior to screening. Additionally, subjects who are medically unable to withhold albuterol, ipratropium, or theophylline prior to spirometry testing, or who require long-term oxygen therapy or nocturnal oxygen therapy for greater than 12 hours a day, are excluded. The trial also excludes subjects who have previously used the study medication or other investigational drugs, or who have an affiliation with the investigator site.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is testing the effectiveness of the drugs vaniprevir and ribavirin in Japanese participants diagnosed with compensated CHC GT 1 who have failed to respond to prior IFN-based therapy. The inclusion criteria require participants to have no signs of advanced liver disease or cirrhosis, while the exclusion criteria include co-infection with HIV or active hepatitis B infection. The trial also excludes participants with any condition that may pose additional risk in administering the study drugs.",
    "This sample is from a clinical trial in phase 3 for the treatment of migraine. The trial is focused on pre-menopausal females who have been diagnosed with MRM (migraine with or without aura) and are considered difficult to treat. The trial includes three different drugs: frovatriptan 2.5mg qd, frovatriptan 2.5 mg bid, and a placebo. The eligibility criteria for the trial includes being a pre-menopausal female diagnosed with MRM and meeting the criteria for being difficult to treat.",
    "The sample is a phase 3 clinical trial for osteoarthritis, specifically for osteoarthritis of the hip. The trial involves testing the efficacy of three drugs - naproxcinod, naproxen, and placebo. The eligibility criteria for the trial include being a chronic user of NSAIDs or acetaminophen, being 40 years or older, and having a diagnosis of primary OA of the hip. Exclusion criteria include uncontrolled hypertension or diabetes, hepatic or renal impairment, current or expected use of anticoagulant, clinically relevant abnormal ECG, a history of alcohol or drug abuse, diagnosis of gastric or duodenal ulceration and/or history of significant gastro-duodenal bleeding within the last 6 months, current medical disease that could interfere with the evaluation of efficacy, candidates for imminent joint replacement, and participation in another investigational study within 30 days prior to screening.",
    "The sample is a phase 3 clinical trial for the treatment of post-stroke spasticity and cerebrovascular accident. The trial involves the use of two drugs, gsk1358820 and placebo. The eligibility criteria for the trial include patients with upper limb spasticity who are at least 6 months post-stroke and present with spasticity of both the wrist and fingers. The patients must also have a wrist flexor muscle tone of \u22653 and finger flexor muscle tone of \u22652 on the MAS, and at least one functional disability item with a rating of \u22652 on the Disability Assessment Scale (DAS). The trial is open to male or female patients between 20 and 80 years of age who weigh at least 40kg and are willing to practice contraception during the study period. The trial has exclusion criteria, including patients with bilateral hemiplegia or quadriplegia, fixed contractures of the wrist and/or fingers, and previous surgical intervention, phenol block, ethanol block, or muscle afferent block for wrist and/or finger spasticity. The trial also excludes patients with a diagnosis of systemic neuromuscular disorders, females who are pregnant, nursing, may be pregnant, or planning a pregnancy during the study period, and patients with clinically unstable severe cardiovascular disease or clinically significant severe renal, hepatic or respiratory disease.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who are between 30 and 80 years old and have been diagnosed with Parkinson's disease according to specific diagnostic criteria. The trial involves the use of three drugs: SPM 962, ropinirole, and placebo. Patients must meet certain eligibility criteria, such as having a Total UPDRS Part 3 score over 10 at screening and being on a stable dose of L-dopa for at least 28 days prior to the initial treatment of SPM 962. Patients with certain medical conditions or who have previously participated in a clinical trial of SPM962 are excluded from the trial. The trial also includes a list of exclusion criteria, such as having a history of epilepsy or serious cardiac diseases, being pregnant or nursing, or participating in another trial of IPs.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of the drug brimonidine and the eligibility criteria includes having ocular hypertension or glaucoma in both eyes, currently being treated with brimonidine, and requiring IOP-lowering therapy in both eyes. The exclusion criteria includes having uncontrolled systemic disease or a known allergy or sensitivity to brimonidine. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is looking at the effectiveness of two drugs, erlotinib (tarceva) and pemetrexed (alimta), in patients who have failed prior chemotherapy and have stage IIIB/IV disease. The trial has specific eligibility criteria, including confirmation of adenocarcinoma, presence of measurable disease that has not been irradiated, absence of central nervous system metastatic disease, and a life expectancy of more than 3 months. Patients must also have adequate bone marrow, liver, and renal function, and a reliable caregiver if they are over 65 years old. The trial has exclusion criteria, including psychiatric illness or social situations that would preclude study compliance, other concurrent uncontrolled illness, and other invasive malignancy within the past 5 years except nonmelanoma skin cancer.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on prostate cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being tested - docetaxel, mitoxantrone, and prednisone. The eligibility criteria for participants are also listed, including requirements for documented progressive disease, stable analgesia, and adequate organ function. Exclusion criteria are also listed, such as prior radiotherapy to more than 25% of bone marrow and a history of other cancers within the past five years.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of insulin degludec as a treatment option. The eligibility criteria include having a diagnosis of type 2 diabetes for at least 24 weeks, currently being treated with basal-only insulin, having a HbA1c level between 7.0-10.0%, and having a BMI below or equal to 45 kg/m^2. The trial also requires participants to adhere to the protocol, including self-measured plasma glucose. Exclusion criteria include previous participation in the trial, known or suspected hypersensitivity to trial products, and the receipt of any investigational drug within 4 weeks prior to randomisation.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of major depressive disorder. The trial includes a list of drugs such as quetiapine, amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, and venlafaxine. The eligibility criteria for the trial includes patients aged 18 to 65 years with a documented diagnosis of major depressive disorder. Patients with certain DSM IV Axis I and II disorders are excluded from the trial. The current episode of depression should not exceed 12 months or be less than 4 weeks prior to enrollment.",
    "The sample is a phase 3 clinical trial for chronic lymphocytic leukemia. The trial is testing the effectiveness of obinutuzumab, rituximab, and chlorambucil drugs. The eligibility criteria for the trial include being an adult over 18 years old, having documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL), and having previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria. The exclusion criteria include prior CLL therapy, transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation), history of other malignancy, positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing, and active infection requiring systemic treatment.",
    "The sample is a phase 3 trial for the treatment of fibrocystic disease of breast, fibrocystic changes of breast, fibrocystic mastopathy, and pain. The trial involves the drug \"iogen (molecular iodine)\" and has specific eligibility criteria for premenopausal females between the ages of 18 and 50 with a history of clinical breast pain and documentation of 6 or more sequential days of moderate or severe pain. The trial also has exclusion criteria, including a history of thyroid disease, non-cyclic breast pain, and treatment with certain medications within three months of starting the trial. The trial does not allow for pregnant women or nursing mothers to participate and has other exclusion criteria related to breast implants, hypertension, and history of malignancy.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B. The trial is testing the effectiveness of drugs such as entecavir, tenofovir, adefovir, and lamivudine. The eligibility criteria for the trial includes having evidence of lamivudine resistance, a history of previous LVD treatment, and evidence of at least one LVD resistance substitution. Participants must also have chronic hepatitis B, compensated liver function, and meet certain criteria for INR, serum albumin, and serum total bilirubin levels. Women of childbearing potential must use adequate contraception and have a negative pregnancy test. Exclusion criteria include evidence of decompensated cirrhosis, coinfection with other viruses, pregnancy or breastfeeding, and abnormal laboratory values.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for patients to participate. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. The sample also includes information on the required blood and body fluid analyses and imaging studies prior to randomization.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe scalp psoriasis. The trial involves the use of several corticosteroid drugs and requires participants to meet certain inclusion criteria, such as being 18 years or older and having signed a written informed consent. However, there are also exclusion criteria, such as not being able to use systemic treatment for body psoriasis, being pregnant or nursing, and having a specific washout period for topical or systemic treatments. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for patients with idiopathic Parkinson's disease. The trial includes patients who are Caucasian, aged 35 to 80 years, and have Hoehn & Yahr stages 1 to 4. The patients must have stable medication with anti-parkinsonian medication, including stable treatment with pramipexole or ropinirole, for at least 4 weeks prior to screening. The trial also includes patients who have significant daytime sleepiness and have read and understood the patient information sheet and have provided a signed written informed consent form. The trial has exclusion criteria, including patients with secondary and atypical Parkinson syndrome, depression, dementia, severe disability in extremities, clinically significant disease concerning the lung, liver or kidney, any acute or chronic infection that may influence the outcome of the study, and evidence of clinically active cancer. The trial also excludes patients who are pregnant or lactating, female patients of childbearing potential who do not use a highly effective method of birth control, patients with a mental condition rendering them unable to understand the nature, scope and possible risks of the study, and patients who are employees of the sponsor or patients who are employees or relatives of the investigator.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus who intend to fast during the month of Ramadan. The trial involves the use of sitagliptin, sulfonylurea, and metformin drugs. The eligibility criteria include being Muslim, having a Hemoglobin A1c (HbA1c) level of \u226410%, and being on a stable dose of a SU drug for at least three months with or without metformin therapy. Exclusion criteria include having type 1 diabetes mellitus, being pregnant or breastfeeding, having hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment, and having a history of severe hypoglycemia. The trial also excludes individuals who use insulin or any class of oral antidiabetic therapy other than an SU or metformin, or those currently participating in another interventional study.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypercholesterolemia. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including ezetimibe (+) simvastatin, rosuvastatin calcium, and two unspecified placebos. The eligibility criteria for participants include currently taking a statin medication for high cholesterol and having an LDL-C level between 100 and 190 mg/dl. Exclusion criteria include pregnancy or nursing, and any condition or medication that may pose a risk to the participant or interfere with the study.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes patients who are insulin na\u00efve or have had short-term insulin treatment up to 14 days. Patients must have been diagnosed with type 2 diabetes for at least 6 months and have a HbA1c level between 7.0-10.0%. The trial also requires patients to have a maximum BMI of 45.0 kg/m^2 and be willing to adhere to the protocol, including self-monitoring of plasma glucose. Exclusion criteria include recent use of certain medications, cardiovascular disease, uncontrolled severe hypertension, pregnancy or intention to become pregnant, and a history of cancer. The trial will test the effectiveness of insulin degludec and insulin glargine in combination with metformin or other diabetes medications.",
    "The sample is a phase 3 clinical trial for patients with extensive stage small cell lung cancer. The trial involves the use of cisplatin, etoposide, and irinotecan hydrochloride as treatment options. The eligibility criteria include confirmation of the disease through histology or cytology, measurable or evaluable disease, and a Zubrod performance status of 0-1. Patients must also meet certain hematopoietic, hepatic, and renal requirements, and cannot have any concurrent AIDS-related illness or enzyme inducing antiepileptic drugs. Prior to the trial, patients cannot have received any biologic or systemic chemotherapy for SCLC. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of allergic rhinitis. The trial involves the drug cetirizine and has a list of inclusion and exclusion criteria for children participating in the trial. The inclusion criteria include children without a history of hypersensitivity to cetirizine or other drugs, not pregnant or lactating, and without complications that may affect the trial. The exclusion criteria include children with a history of hypersensitivity to cetirizine or other drugs, pregnant or lactating, and with complications that may affect the trial. The trial also has a list of prohibited concomitant drugs that cannot be taken by the children during the observation period.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on sleep initiation and maintenance disorders. The icd-10 codes associated with the disease are Y93.E9 and Y93.H9. The drugs being tested are volinanserin and placebo. The eligibility criteria include a diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders criteria, disturbances of sleep maintenance criteria, and exclusion criteria such as pregnancy, night shift work, and use of certain medications. The information provided is not exhaustive and is intended to give an overview of the trial.",
    "The sample is a phase 3 clinical trial for gastric cancer. The trial is looking for patients with stage II-IV adenocarcinoma of the stomach, including cardia carcinoma types II and III, who have locally resectable disease and no distant metastases except M1 lymph nodes. Patients must also have no evidence of peritoneal carcinomatosis, no uncontrolled bleeding of the primary tumor, and no gastric outlet syndrome or complete tumor stenosis that would require total parenteral nutrition. Patients must be between the ages of 18 and 69, have a WHO performance status of 0-1, and meet certain hematopoietic, hepatic, renal, and cardiovascular criteria. Patients must not be pregnant or nursing, must have negative pregnancy test, and fertile patients must use effective contraception. Patients must not have any other prior or concurrent neoplasm except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix, no active infection, no allergy to protocol drugs, no dementia or significantly altered mental status, and no other serious medical condition that would prevent compliance. Patients must not have received prior chemotherapy, radiotherapy, or stent implantation, and must not have undergone prior laser therapy. The trial will use cisplatin, fluorouracil, and leucovorin calcium as drugs, and the eligibility criteria include additional details on prior concurrent therapy.",
    "This sample is for a phase 3 clinical trial for the treatment of cystic fibrosis. The trial is testing the effectiveness of two drugs, denufosol tetrasodium inhalation solution and a placebo solution, on patients with confirmed diagnosis of cystic fibrosis. The trial has specific inclusion and exclusion criteria, such as having a FEV1 of greater than or equal to 75% of predicted normal for age, gender, and height, and not being colonized with Burkholderia cepacia. The trial requires patients to be clinically stable for at least 4 weeks prior to screening and to be able to perform spirometry maneuvers. The icd-10 codes for the disease are also included in the table.",
    "The sample is a phase 3 clinical trial for postmenopausal osteoporosis in Korean women aged 60 to 90 years old. The trial includes the drugs denosumab, placebo, and open-label denosumab. The eligibility criteria include having a bone mineral density T-score less than -2.5 and greater than or equal to -4.0, being ambulatory, and not having certain medical conditions or taking certain medications. The trial also has exclusion criteria, such as having a disorder that would prevent the subject from completing the study or interfering with study results.",
    "The sample is a phase 3 clinical trial for prostate cancer. The eligibility criteria include having histologically or cytologically proven adenocarcinoma of the prostate prior to the initiation of radiotherapy, rising prostate-specific antigen levels, and no definite evidence of metastatic disease. Patients must also have a performance status of ECOG 0-1, a life expectancy of more than 5 years, and meet certain hematopoietic, hepatic, renal, and other criteria. Prior concurrent therapies such as biologic therapy and chemotherapy are not allowed, but prior hormonal therapy administered prior to, during, or immediately after radical radiotherapy or prostatectomy is allowed provided duration was no longer than 12 months. The sample includes a list of drugs used in the trial, such as bicalutamide and goserelin, as well as a list of diseases and their corresponding icd-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of open angle glaucoma and ocular hypertension. The trial involves the use of three drugs - xalacom, xalatan, and timolol. The eligibility criteria for the trial include a diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy for at least 4 weeks prior to screening. The exclusion criteria include a closed or barely open anterior chamber angle or a history of acute angle closure glaucoma, as well as a history of ALT or SLT within 3 months prior to screening.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes participants with essential hypertension, defined as having a sitting trough clinic systolic blood pressure between 150 and 180 mm Hg, inclusive at Day -1, and 24-hour mean systolic blood pressure 130-170 mm Hg, inclusive, at Day 1. The trial also includes eligibility criteria for females of childbearing potential who are sexually active, clinical laboratory evaluations, and willingness to discontinue current antihypertensive medication. Exclusion criteria include sitting trough clinic diastolic blood pressure greater than 114 mm Hg, hypersensitivity to angiotensin II receptor blockers, history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, and other serious diseases or conditions that would compromise participant safety. The trial involves the use of azilsartan medoxomil and placebo.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe active rheumatoid arthritis. The trial includes patients who have had an inadequate response to current anti-rheumatic therapies, including methotrexate, and have also had an inadequate response or intolerance to treatment with one or more anti-TNF therapies within one year of entering the study. Patients must have been on stable methotrexate for at least 8 weeks before entering the study. The trial includes the drugs methotrexate, placebo, and tocilizumab [roactemra/actemra]. The eligibility criteria include being at least 18 years old, using reliable methods of contraception if of reproductive potential, and not having had major surgery within 8 weeks before screening or planned major surgery within 6 months after entering the study. Women who are pregnant or breastfeeding are excluded from the trial.",
    "The sample is a phase 3 clinical trial for anxiety disorders. The trial is for male or female patients who are 66 years or older and have a documented clinical diagnosis of Generalised Anxiety Disorder (GAD). The trial includes the drugs quetiapine xr and placebo. The eligibility criteria for inclusion in the trial include the absence of a current episode of major depression. The exclusion criteria include the presence of dementia or other mental disorder than GAD, serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse, and a current diagnosis of cancer or current or past diagnosis of stroke.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease epilepsy and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, usl255 and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of partial-onset seizures, being on a stable dosing regimen of 1 to 3 AEDs for at least 4 weeks prior to the trial, and having a minimum of 8 partial-onset seizures and no more than 21 consecutive seizure-free days during the 8-week baseline. The exclusion criteria include a history of seizure episodes lasting less than 30 minutes, pseudoseizures, or status epilepticus, as well as a history of certain medical conditions and psychiatric illnesses. The trial also excludes individuals who have taken certain medications within a certain timeframe.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of epilepsy with partial-onset seizures. The trial involves the use of two drugs, lacosamide and levetiracetam, and has specific inclusion and exclusion criteria for participants. Inclusion criteria include being a male subject with a diagnosis of epilepsy with partial-onset seizures and only taking levetiracetam in combination with carbamazepine as adjunctive treatment for epilepsy. Exclusion criteria include taking another anti-epileptic drug (AED) than carbamazepine and levetiracetam, taking lipid lowering agents, and taking enzyme inducers. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of macular degeneration and choroidal neovascularization. The trial involves the use of two drugs, verteporfin photodynamic therapy and ranibizumab, as well as two placebo treatments. The eligibility criteria for the trial include being 50 years or older and having subfoveal choroidal neovascularization due to age-related macular degeneration. Exclusion criteria include having choroidal neovascularization due to causes other than AMD and having received prior treatment for neovascular AMD in the study eye. Other protocol-defined inclusion/exclusion criteria may also apply. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease. The trial includes patients who are outpatients and have been diagnosed with mild to moderately-severe, probable or possible Alzheimer's disease according to the criteria defined by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease Related Disorders Association or the Diagnostic and Statistical Manual, Fourth Edition. The patients must also have a responsible caregiver who visits them regularly. The trial excludes patients with neurodegenerative disorders other than Alzheimer's disease, such as Parkinson's Disease, Frontotemporal Dementia or Huntington's disease, as well as patients with specified conditions that may contribute to dementia or coexisting diseases, including significant cardiovascular disease. The trial involves the use of galantamine and placebo drugs.",
    "The sample is a phase 3 clinical trial for breast cancer patients with locally recurrent or metastatic disease. The trial involves the use of bevacizumab (Avastin) and taxane-based chemotherapy. The eligibility criteria include being 18 years or older, having HER-2 negative adenocarcinoma of the breast, and being a candidate for chemotherapy. Exclusion criteria include previous chemotherapy for metastatic or locally recurrent breast cancer, concomitant hormonal therapy, and evidence of CNS metastases. The diseases are listed as breast cancer and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of familial hypercholesterolaemia. The trial involves the use of the drug rosuvastatin calcium and includes children and adolescents between the ages of 6 and 18. The eligibility criteria include not currently taking a statin medicine and not having a history of muscle or sensitivity reactions to any statin medicines. The exclusion criteria include having a current active liver disease or dysfunction, except for a confirmed diagnosis of Gilbert's disease. The diseases are listed as 'familial hypercholesterolaemia', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of a combination of drugs, including an induction dose of infliximab followed by a combination of pegylated interferon alfa-2b and ribavirin. The trial has specific eligibility criteria, including being between 18 and 65 years old, having HCV genotype 1, being naive to interferon and ribavirin, and having a liver biopsy within 24 months of enrollment demonstrating Stage 0-3 fibrosis. The trial also has exclusion criteria, such as being pregnant or nursing, having a history of cirrhosis, or having a known pre-existing psychiatric condition that could interfere with participation in the study. Participants must understand and adhere to the dosing and visit schedules and agree to record medication compliance, concomitant medications, and adverse events accurately and consistently in a daily diary.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease myasthenia gravis and includes a list of associated ICD-10 codes. The trial involves the use of two drugs, tacrolimus and placebo. The eligibility criteria for the trial include a clinical diagnosis of myasthenia gravis, well-controlled symptoms with prednisone treatment, and a specific steroid dose range. Exclusion criteria include a history of thymoma, recent immunosuppressant therapy, and certain medical conditions such as pancreatitis and elevated serum creatinine levels.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on Parkinson's disease. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested, which includes rasagiline and a placebo. The eligibility criteria for the trial are also listed, including inclusion criteria such as patients with idiopathic PD and a Modified Hoehn and Yahr stage <3, and exclusion criteria such as patients with clinically significant medical or surgical conditions, unstable vascular disease, or a history of melanoma. The sample notes that additional inclusion and exclusion criteria may apply.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The trial is testing the effectiveness of the drug rotigotine in treating symptoms of Parkinson's disease. The record includes a list of inclusion and exclusion criteria for participants in the trial, such as having PD for more than 3 years, stable dose of L-dopa but symptoms not adequately controlled, and willingness to complete a diary on specific days. Exclusion criteria include previous use of rotigotine or Neupro, atypical Parkinson's syndrome, and various medical conditions such as dementia, epilepsy, and renal or hepatic dysfunction. The record also includes a list of disease names and ICD-10 codes associated with the trial.",
    "The sample is a phase 3 clinical trial for major depressive disorder using the drug lurasidone. The trial requires subjects to have completed 6 weeks of treatment in previous studies and be judged suitable by the investigator. The eligibility criteria include providing written informed consent, being able to comply with the protocol, and not being at imminent risk of suicide or injury. The exclusion criteria include answering \"yes\" to certain questions on the C-SSRS and being considered at risk by the investigator. The diseases are listed as \"major depressive disorder\" and the icd-10 codes are provided.",
    "This sample is from a clinical trial in phase 3 for the treatment of refractory status epilepticus. The trial is looking at the effectiveness of two drugs, propofol and thiopental/pentobarbital. The eligibility criteria for the trial includes patients who require coma induction for clinical management and do not have cerebral anoxia as the cause of their status epilepticus. Patients who are under 16 years old, pregnant, have epilepsia partialis continua, known intolerance to the study drugs, or have known mitochondrial disorder, hyperlipidemia, or significant rhabdomyolysis are excluded from the trial. The diseases being studied are listed as 'status epilepticus' and the corresponding ICD-10 codes are also provided.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of smoking. The trial includes a list of icd-10 codes related to smoking. The drug being tested is dianicline. The eligibility criteria for the trial includes being an outpatient over the legal age, smoking at least 10 cigarettes per day for at least 2 months, and not having a current psychotic disorder or major depressive disorder. There are also exclusion criteria, such as insufficient motivation or having another participant in the household. The investigator will evaluate whether there are any other reasons why a patient may not be able to participate.",
    "The sample is a phase 3 clinical trial for pulmonary fibrosis. The trial includes patients who are at least 40 years old and have been diagnosed with IPF within the past 5 years according to the most recent IPF guidelines. The diagnosis is confirmed by HRCT pattern and surgical lung biopsy pattern. Patients with Dlco (corrected for Hb) between 30%-79% predicted of normal and FVC>= 50% predicted of normal are eligible for the trial. However, patients with relevant airways obstruction, bleeding risk, thrombotic risk, or certain medications received within a certain time frame are excluded from the trial. The trial includes two drugs, placebo and bibf 1120.",
    "The sample is a phase 3 clinical trial for gastroesophageal reflux disease. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require participants to have experienced symptoms of gastroesophageal reflux disease and to have continued to have reflux symptoms during the pretreatment period. The exclusion criteria include factors such as body weight, coexisting esophageal disease, and use of certain medications. The sample also includes specific details on the eligibility criteria, including the need for stable drug levels and the absence of clinically significant abnormalities in laboratory values.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of rheumatoid arthritis, with a list of specific icd-10 codes provided. The trial involves the use of drugs, including cp-690,550 and disease-modifying antirheumatic drug. The eligibility criteria for the trial are also listed, including the requirement that participants have not been treated with methotrexate and meet specific diagnostic criteria for RA. The exclusion criteria are also listed, including a history of certain medical conditions and recent infections.",
    "The sample is a phase 3 clinical trial for Parkinson's disease, with the drug being tested being rotigotine. The eligibility criteria include being a Korean male or female aged 18 or older with idiopathic Parkinson's disease and not being satisfactorily controlled on a total daily dose of ropinirole from 3mg to 12mg. The exclusion criteria include having previously participated in a trial with rotigotine, having atypical Parkinsonian syndrome(s), dementia, active psychosis, or hallucinations, and having a history of seizures or stroke within 1 year. The trial also has various other criteria and restrictions for enrollment, such as not taking certain medications and having certain laboratory results.",
    "The sample is a phase 3 clinical trial for patients with head and neck cancer, mucositis, oral complications of radiation therapy, and pain. The trial involves the drug doxepin hydrochloride and has eligibility criteria including being over 18 years old, having proof of malignancy currently undergoing radiation therapy, experiencing oral pain related to mucositis, and having an ECOG Performance Status of 0, 1, or 2. Exclusion criteria include allergies to doxepin or tricyclic antidepressants, untreated oral candidiasis or oral HSV infection, and co-morbid systemic illnesses that would interfere with the assessment of safety and toxicity of the drug.",
    "The sample is a phase 3 clinical trial for patients with adenocarcinoma of the prostate that is refractory to hormone therapy and previously treated with a Taxotere-containing regimen. The trial aims to test the effectiveness of cabazitaxel, mitoxantrone, and prednisone in treating the disease. The trial includes patients with at least one visceral or soft tissue metastatic lesion or rising PSA levels. Patients must have undergone surgical or hormone-induced castration and have an ECOG performance status of 0-2. Exclusion criteria include previous treatment with mitoxantrone or <225 mg/m^2 cumulative dose of Taxotere, prior radiotherapy to \u2265 40% of bone marrow, and other concurrent serious illness or medical conditions. The investigator will evaluate whether there are other reasons why a patient may not participate.",
    "The sample is a phase 3 clinical trial for eosinophilic asthma. The trial includes patients who are 12 to 75 years old and have a previous diagnosis of asthma. Patients must have had at least one asthma exacerbation requiring oral, intramuscular, or intravenous corticosteroid use for at least 3 days over the past 12 months before screening. Patients must also have a current blood eosinophil level of at least 400/\u03bcl and airway reversibility of at least 12% to beta-agonist administration. The trial involves the use of the drugs reslizumab and placebo. The eligibility criteria include stable baseline asthma therapy regimen, use of medically accepted contraception for female patients of childbearing potential, and written informed consent. Exclusion criteria include clinically meaningful co-morbidity, known hypereosinophilic syndrome, confounding underlying lung disorder, current smoking, use of systemic immunosuppressive or immunomodulating or other biologic agents, previous receipt of an anti-hIL-5 monoclonal antibody, and aggravating medical factors that are inadequately controlled. Female patients who are pregnant, nursing, or not using a medically accepted, effective method of birth control are also excluded.",
    "The sample is a phase 3 clinical trial that involves patients with chronic hemodialysis, hypertension, and left ventricular hypertrophy. The trial aims to test the effectiveness of lisinopril and atenolol in treating these conditions. The eligibility criteria for the trial include compliance with hemodialysis treatments, hypertension diagnosis, and presence of LVH on echocardiogram. Exclusion criteria include recent vascular events, noncompliance with hemodialysis treatments, and known drug abuse. Patients must also be willing to give informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis using the drug fluticasone furoate. The trial is open to male and eligible female participants between the ages of 2 and 15 who have a clinical history of perennial allergic rhinitis and a positive test response to house dust and/or dust mites on serum antigen-specific IgE antibody test. The trial has a list of inclusion and exclusion criteria, including the absence of seasonal pollen as an allergen, recent participation in a study or exposure to an investigational study drug, and known hypersensitivity to corticosteroids or any excipients in the investigational product. The trial also requires completion of a patient diary and has certain medical requirements, such as ALT < 2xULN and an average of 3TNSS >= 3.0 in the last consecutive 4 days prior to Visit 2.",
    "The sample is a phase 3 clinical trial for the treatment of migraine disorders. The trial involves the use of a sumatriptan iontophoretic transdermal patch called np101 and a placebo. The eligibility criteria for the trial include being an adult between the ages of 18 and 65, having a diagnosis of migraine headache, experiencing moderate to severe headaches during a migraine attack, having at least a one year history of migraine, being in good health, having a negative pregnancy test, having a negative drug screen, being able to read and understand English or Spanish, and having an acceptable patch application site. The exclusion criteria include having started, stopped, or changed treatment with prophylactic anti-migraine treatment or certain medications within 3 months prior to the study, having less than one migraine per month or more than six migraines per month, having suspected or confirmed cardiovascular disease, having a history of epilepsy or conditions associated with a lowered seizure threshold, having Raynaud's disease, having a history of basilar or hemiplegic migraines, having a current diagnosis of a major depressive disorder, having a history or current evidence of drug or alcohol abuse or dependence, being unwilling to discontinue use of certain medications, having a significant allergy or hypersensitivity to any component of the study patch, having any generalized skin irritation or disease, having clinically significant abnormal laboratory parameters, vital signs or ECG parameters, being known to be hepatitis B, hepatitis C or HIV positive, having hepatic dysfunction, being pregnant, breastfeeding, or not using an effective form of contraception, having a known history of failure to respond to sumatriptan, having participated in a clinical study within 30 days of screening, or being electrically sensitive or having electrically sensitive support systems.",
    "The sample is a phase 3 clinical trial for the treatment of human immunodeficiency virus (HIV). The trial includes patients who have had occupational or non-occupational exposure to HIV and require post-exposure prophylaxis (PEP). The trial excludes patients who have a positive HIV rapid test, history of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastro intestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, are pregnant or breastfeeding, or have any condition that would compromise their well-being or prevent them from meeting study requirements. The trial involves the use of drugs such as darunavir/ritonavir, lopinavir in fixed combination with ritonavir, zidovudine, nrtis, and efavirenz. The diseases being treated are HIV and any associated conditions. The icd-10 codes associated with the diseases are also listed.",
    "This sample is for a phase 3 clinical trial for the treatment of stable plaque psoriasis. The trial is testing the effectiveness of desoximetasone spray 0.25% compared to a placebo. The eligibility criteria for participants include being 18 years or older, having a definite clinical diagnosis of stable plaque psoriasis involving at least 10% of the body surface area, and having a combined total lesion severity score of at least 7 for the target lesion. Exclusion criteria include having other types of psoriasis, a history of psoriasis unresponsive to topical corticosteroid therapy, and having other dermatological conditions that may interfere with the clinical assessments. Participants must not have received any biological therapies for psoriasis within 12 weeks prior to the first dose of study drug and must not have used any topical antipsoriatic agents or topical corticosteroids within 2 weeks prior to the first use of study drug.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder (OAB) using the drugs mirabegron and solifenacin succinate. The trial is open to subjects who have experienced OAB symptoms for at least 3 months and have previously received at least one antimuscarinic agent for treatment. The trial has a list of inclusion and exclusion criteria, including restrictions on subjects who are pregnant or have certain medical conditions. The trial will require subjects to complete a micturition diary and questionnaires.",
    "The sample is a phase 3 clinical trial for the treatment of restless legs syndrome. The trial is looking for patients who meet certain eligibility criteria, such as having a history of RLS symptoms and a total RLS severity score of 15 or greater. The trial also has exclusion criteria, such as having a sleep disorder or neurologic disease. The trial is testing the drug xp13512 (gsk1838262) and requires participants to discontinue other treatments for RLS at least 2 weeks prior to the baseline study period. Women of childbearing potential must agree to use birth control during the study.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder using the drug aripiprazole. The trial is open to male and female participants between the ages of 7 and 17 who meet certain criteria, including a diagnosis of bipolar I disorder and a score of >20 on the Y-MRS at baseline. Participants must also have at least normal intelligence and be able to swallow oral medication. Exclusion criteria include a history of certain psychiatric disorders, substance abuse, and hypersensitivity to aripiprazole. Female participants of childbearing potential must be using a reliable form of contraception. The trial is not open to participants who have failed on a previous course of aripiprazole or who have severe renal insufficiency.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of osteoporosis. The trial involves the use of the drug lasofoxifene. The eligibility criteria for the trial include being postmenopausal for at least 5 years and having a screening bone mineral density of at least 2.5 standard deviations below the mean for young adults at the lumbar spine or femoral neck. Exclusion criteria include having a metabolic bone disease other than osteoporosis, taking approved medications for osteoporosis, and having had a recent osteoporotic fracture within the past year or having a bone mineral density of more than 4.5 standard deviations below the mean for young adults at the lumbar spine or femoral neck. The sample also includes a list of icd-10 codes associated with osteoporosis.",
    "The sample is a table that contains information about a clinical trial. It includes the phase of the trial, which is phase 3, a list of diseases being studied, which in this case is cytomegalovirus infections, a list of icd-10 codes associated with the diseases, a list of drugs being used in the trial, which is valganciclovir, and eligibility criteria for participants to be included in the trial. The eligibility criteria are divided into two sections, one for phase I and one for phase II. The criteria include age, risk for CMV, adequate hematological and renal function, use of effective contraception, negative pregnancy, ability to tolerate oral medications, negative baseline CMV PCR, and understanding and signing of informed consent. The exclusion criteria include repeat transplantation, mechanical ventilation, invasive fungal infection, participation in another investigational study, acute CMV infection or disease, anti-CMV therapy within 30 days before enrollment, uncontrolled diarrhea or malabsorption, allergic reaction to study drug, required use of prohibited medications, lactating women, pregnancy, and renal failure. The sample also includes inclusion and exclusion criteria specific to phase II, which include negative serial post-transplant PCRs, negative bronchial cultures for CMV, adequate hematological and renal function, IV ganciclovir for up to 2 weeks post-operation and open label up to day 90, effective contraceptives, negative pregnancy, renal failure, serious adverse events related to study drug, CMV disease, and withdrawal of consent for phase II.",
    "The sample is for a phase 3 clinical trial for the treatment of osteoporosis. The trial is looking at the effectiveness of the drug teriparatide compared to a placebo. The eligibility criteria for the trial includes Japanese patients who are 55 years or older and at high risk for fracture. Patients with a history of metabolic bone disorders or malignant neoplasms in the past 5 years, except for treated skin cancers, are excluded from the trial. Patients with severe or chronically disabling conditions other than osteoporosis are also excluded. The icd-10 codes for osteoporosis are also provided.",
    "The sample is a phase 3 clinical trial for patients with stage I or II thoracic esophageal cancer. The trial is testing the effectiveness of the drugs cisplatin and fluorouracil in treating the disease. The eligibility criteria for the trial include having a tumor no greater than 3 cm with no invasion of mediastinal structures, or a tumor greater than 3 cm with no invasion of mediastinal structures and no adenopathy greater than 1 cm. Patients must also be deemed resectable with curative intent and have no carcinoma in situ, small cell anaplastic carcinoma, or small cell neuroendocrine carcinoma. Additionally, patients must meet certain age, performance status, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other criteria. Prior concurrent therapy is not specified.",
    "The sample is a record of a clinical trial in phase 3, which involves the study of two diseases - respiratory distress syndrome of prematurity (surfactant dysfunction) and bronchopulmonary dysplasia. The trial is focused on the use of two drugs - infasurf (ony inc.) and sham. The eligibility criteria for the trial include a birth weight of less than or equal to 1000 gm, gestational age of less than or equal to 30 weeks, and being intubated and mechanically ventilated at any time between days 7-14 of life. The exclusion criteria include serious congenital malformations, life expectancy less than 7 days from enrollment, previous treatment with iNO, active pulmonary hemorrhage at the time of enrollment, active air leak syndrome at the time of enrollment, bilateral grade IV intracranial hemorrhage prior to enrollment, and less than 48 hours from the last clinical dose of early surfactant.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the drugs saxagliptin and sitagliptin and the eligibility criteria include being diagnosed with type 2 diabetes and having been treated with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks. The exclusion criteria include having type 1 diabetes, a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma, insulin therapy within one year, and previous treatment with DPP-4 inhibitor. The diseases are listed as 'type 2 diabetes' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who have a history of asthma for at least 12 months and have demonstrated FEV-1 of 60-85% of predicted normal values. The trial also includes eligibility criteria for both steroid-requiring and steroid-free patients. The trial will test the efficacy of four drugs, including fluticasone propionate/formoterol fumarate 100/10, fluticasone propionate 100, formoterol fumarate 10, and placebo. The trial has inclusion and exclusion criteria, including no history of systemic corticosteroid medication within 3 months before the screening visit and no upper or lower respiratory infection within 4 weeks prior to the screening visit or during the run-in period. The trial also excludes patients with significant, non-reversible pulmonary disease, known HIV-positive status, and current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.",
    "The sample is a phase 3 clinical trial for cardiovascular disease. The trial includes patients with a waist circumference greater than 102 cm for males and greater than 88 cm for females, who have one coronary heart disease equivalent or two major risk factors for cardiovascular disease. The inclusion criteria include recent documented heart attack, documented symptomatic coronary artery disease, recent ischemic cerebrovascular episode, documented symptomatic peripheral arterial disease, documented type 2 diabetes mellitus, metabolic syndrome, asymptomatic cerebrovascular, renal, or peripheral arterial disease, past abdominal aortic aneurysm repair, elevated high-sensitivity C-reactive protein, and age greater than or equal to 65 years for males and greater than or equal to 70 years for females. The exclusion criteria include obesity of known endocrine origin, pregnant or breastfeeding women, very low calorie diet or weight loss surgery within the past 6 months, presence of any severe medical or psychological condition that would compromise the patient's safe participation, likely cardiovascular intervention within the next 1 month, allergy to rimonabant or excipients, or prior participation in a rimonabant trial. The drugs used in the trial are rimonabant and placebo (for rimonabant).",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of three drugs: telaprevir, pegylated interferon (peg-ifn) alfa-2a, and ribavirin (rbv). The trial has specific eligibility criteria for patients to be included, such as having failed therapy for virologic reasons and completing all assessments in a previous trial. Patients must also be willing to use two effective methods of birth control for up to 7 months after the last dose of study medication. There are also exclusion criteria, such as having received any direct acting anti-viral HCV therapy after discontinuation of a previous trial, having a history of decompensated liver disease or acute or chronic pancreatitis, or having a condition that requires the use of systemic corticosteroids. Patients who prematurely stopped medication for non-compliance or for whom it would be unsafe to repeat treatment are also excluded. Patients with a history of decompensated liver disease or history of cirrhosis with hepatocellular carcinoma are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on major depressive disorder and psychotic disorders, with a list of corresponding ICD-10 codes. The trial involves the use of various doses of mifepristone and a placebo. The eligibility criteria for participants include being between 18 and 75 years old, having a diagnosis of major depressive disorder with psychotic features, and being able to provide written informed consent. Exclusion criteria include having a major medical problem, having previously participated in a CORLUX clinical trial, and having a history of an allergic reaction to CORLUX.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on the disease of venous thrombosis. The icd-10 codes associated with this disease are listed. The trial is testing two drugs, rivaroxaban and enoxaparin followed by vka. The eligibility criteria for the trial are also listed, including inclusion criteria such as confirmed acute symptomatic proximal DVT without symptomatic PE, and exclusion criteria such as legal lower age limitations and use of a fibrinolytic agent to treat the current episode of DVT and/or PE.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients between the ages of 18 and 65 who meet the DSM-IV-TR criteria for a primary diagnosis of schizophrenia and have a PANSS total score of at least 70 at screening. The trial involves the use of two drugs, blonanserin and risperidone. Patients must be willing and able to comply with the study protocol, including treatment in hospital. The trial has a list of exclusion criteria, including recent treatment with other Investigate products or long-acting drugs for schizophrenia, as well as a history of treatment with clozapine or certain other conditions. Patients or their legal guardians must sign a written informed consent form to participate in the trial.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drug pregabalin and a placebo in treating epilepsy with partial onset seizures. The trial is looking for participants who have been diagnosed with epilepsy and are currently taking 1 to 3 anti-epilepsy medicines at stable dosages, and who have taken at least 2 prior (or ongoing) AEDs. The inclusion and exclusion criteria are listed in the \"criteria\" column. The \"diseases\" column lists the specific types of epilepsy being studied, and the \"icdcodes\" column lists the corresponding ICD-10 codes for those diseases.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial is testing the drug atomoxetine on patients who are psychotropic medication naive and between the ages of 8 and 10. The trial has inclusion criteria that require patients to have ADHD and be outpatients, and exclusion criteria that exclude patients with certain disorders or serious suicidal risk. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of breast cancer. The trial includes female patients between the ages of 18 and 70 who have adenocarcinoma of the breast and no evidence of metastatic disease. The trial excludes patients with a history of severe hypersensitivity reaction to Taxotere, previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane, and treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. The trial uses the drugs capecitabine (xeloda), taxotere, and taxotere. The diseases are listed as breast cancer, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B. The trial includes patients who have been HBsAg+ serology for more than 6 months before the beginning of the treatment. The inclusion criteria also include patients with raised serum ALT, significant hepatic necroinflammation and/or fibrosis, or liver stiffness over 7.2 KPa. Patients of both sexes from 18 to 60 years old who have not received specific hepatitis B treatment for at least 6 months prior to the inclusion are eligible to participate. The trial excludes patients with conditions of HBV asymptomatic carrier or cirrhosis, positive serological markers for hepatitis C or HIV, previous specific anti-hepatitis B treatment in the last 6 months, critically ill patient history of heart or renal failure, hypertension, hyperthyroidism, epilepsy, immunodeficiency diseases, malignancies, or any non-controlled systemic disease. The trial also excludes pregnant or nursing women, women in fertile age without any contraceptive methods, patients with severe allergic conditions, severe psychiatric dysfunction, history of autoimmune diseases, history of other hepatic diseases of different etiology, history of immune suppressive disorder or administration of immune suppressive-immune modulator drugs, and very high transaminase levels at the beginning of treatment.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of multiple sclerosis. The trial involves the use of two drugs, interferon beta-1b (betaseron, bay86-5046), and the eligibility criteria include patients who have completed the BENEFIT study either by developing CDMS or by completing 24 months. The exclusion criteria include patients who did not participate in the initial BENEFIT study. The diseases are listed as 'multiple sclerosis', and the icd-10 codes associated with the disease are 'G35' and 'C81.18'.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including placebo and sitagliptin phosphate. The eligibility criteria for the trial includes patients who are currently on diet and exercise therapy and taking glimepiride as monotherapy. Patients with type 1 diabetes mellitus are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with leukemia or lymphoma. The trial involves a list of drugs and eligibility criteria based on disease characteristics, such as histologically confirmed acute lymphoblastic leukemia or precursor B or T lymphoblastic non-Hodgkin's lymphoma. The eligibility criteria also include patient characteristics such as age and prior concurrent therapy. The trial is divided into three risk categories: very low-risk, average risk, and very high-risk, each with their own set of criteria. Patients in the very high-risk category are eligible for stem cell transplantation. The sample includes a detailed list of diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a clinical trial in phase 3 for the treatment of diabetic retinopathy and diabetic macular edema. The trial involves four different drugs: triamcinolone acetonide + laser, ranibizumab + laser, sham injection + laser, and ranibizumab + deferred laser. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of diabetes mellitus, having at least one eye that meets the study eye criteria, having a fellow eye that meets criteria, and being able and willing to provide informed consent. There are also several exclusion criteria, such as significant renal disease, unstable medical status, and participation in an investigational trial within 30 days of randomization. The study eye inclusion criteria include a best corrected electronic Early Treatment Diabetic Retinopathy visual acuity letter score of 78 or lower, definite retinal thickening due to diabetic macular edema involving the center of the macula, and an OCT central subfield of at least 250 microns. The study eye exclusion criteria include macular edema due to a cause other than diabetic macular edema, an ocular condition that might affect macular edema or alter visual acuity during the course of the study, and a history of treatment for diabetic macular edema at any time in the past 4 months.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for metastatic prostate cancer. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include having confirmed adenocarcinoma of the prostate with metastatic bone disease and plans to start or be within 30 days of beginning androgen deprivation therapy. The exclusion criteria include having neuroendocrine, small cell or transitional cell cancer of the prostate, abnormal bone metabolism, previous use of bisphosphonates, major surgery within 4 weeks of registration, adjuvant chemotherapy within 6 months of registration, previous chemotherapy for metastatic disease, hormonal therapy in the adjuvant setting within 12 months of registration, and a prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin. Additionally, there should be no history of allergy or drug reactions to bisphosphonates.",
    "The sample is a phase 3 clinical trial for patients with anemia and chronic kidney disease. The trial involves the drugs darbepoetin alfa and placebo. The eligibility criteria for the trial include patients with stage 3-5 CKD who are not on dialysis, are at least 70 years old, have a hemoglobin level below 110g/L at screening, and have a transferrin saturation of at least 15% at screening. The exclusion criteria include patients with a clinical history of type 2 diabetes mellitus, those anticipating or scheduled to go on renal replacement therapy in the next year, those with uncontrolled hypertension on two separate measurements during screening, and those who have used any erythropoietic protein within 12 weeks of screening.",
    "The sample is a phase 3 clinical trial for the treatment of gout. The trial includes patients with hyperuricemia and gout, as defined by the Chinese Rheumatism Association Criteria, who have not experienced a gout flare in the two weeks prior to the screening period. The trial excludes patients who are pregnant or lactating, have a BMI over 50 kg/m\u00b2, have a history of liver disease, bronchial asthma, renal calculi, or thyroid disease, or have joint diseases induced by rheumatoid arthritis, psoriatic arthritis, or bone tumor. Patients who are intolerant to allopurinol and ibuprofen, have a history of alcohol intake of \u2265 14 drinks/week, or have a clinically significant medical condition are also excluded. The trial will test the efficacy of the drugs febuxostat and allopurinol in reducing serum urate levels in eligible patients.",
    "The sample is a phase 3 clinical trial for the treatment of prostatic hyperplasia. The trial includes male patients who are at least 50 years old and have been diagnosed with BPH. The patients must have an estimated prostate volume of at least 30cc and an I-PSS Symptom Score of at least 8 points. The trial involves the use of dutasteride and placebo drugs. The eligibility criteria include meeting all the inclusion criteria and not meeting any of the exclusion criteria. The exclusion criteria include having a post void residual volume greater than 250mL, a history of AUR within the previous 12 weeks, evidence or history of prostate cancer, PSA levels greater than 10ng/mL, and previous surgery or minimally invasive techniques for BPH. The trial also excludes patients with any unstable, serious co-existing medical conditions, liver function tests greater than 2 times the upper limit of normal, and serum creatinine levels greater than 1.8mg/dL. Patients who have used antiandrogen or a-adrenoceptor blockers within the previous 12 months or other drugs or supplements for relief of BPH symptoms within the previous 4 weeks are also excluded.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial includes a list of inclusion and exclusion criteria for participants, such as achieving clinical response or remission in a previous study, being willing to undergo corticosteroid dose tapering, and not being pregnant or breastfeeding. The trial also involves the use of drugs, including gsk1605786a and placebo. The diseases are listed as Crohn's disease, and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for patients with deep vein thrombosis or pulmonary embolism. The trial involves two drugs, enoxaparin and apixaban, along with a placebo. The eligibility criteria include being 18 years or older and scheduled for knee replacement surgery, while exclusion criteria include bleeding disorders, clotting disorders, and the use of certain medications. The trial aims to evaluate the effectiveness of the drugs in preventing blood clots after surgery.",
    "The sample is a phase 3 clinical trial for kidney diseases. The trial involves the use of enteric-coated mycophenolate sodium (ec-mps), tacrolimus, and corticosteroids as drugs. The eligibility criteria for the trial include having a primary or secondary kidney transplant, being treated with mycophenolic acid and tacrolimus, having a creatinine clearance between 30-60 mL/min, and having stable renal function. Exclusion criteria include being a multi-organ recipient, having had acute rejection within the last 3 months, and having adverse reactions to higher doses of mycophenolate mofetil or mycophenolate sodium. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for ovarian cancer. The trial includes patients with stage III or IV ovarian epithelial carcinoma, including various cellular diagnoses. Patients must have undergone reassessment surgery and have had a partial response to chemotherapy. Eligibility criteria include age under 66, certain hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements, and no prior malignancy in the past 5 years except for certain types of cancer. Patients must have had at least 4 and no more than 6 prior platinum-based combination chemotherapy courses. The trial involves the use of carboplatin, cyclophosphamide, mitoxantrone hydrochloride, and paclitaxel.",
    "The sample is a phase 3 clinical trial for patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer who have undergone only one prior chemotherapy regimen. The trial is testing the effectiveness of tamoxifen citrate and thalidomide as treatments for patients with a biochemical recurrence of the cancer. The eligibility criteria include specific disease stages, absence of measurable and nonmeasurable disease, and normal or normalized CA 125 levels. Patients must also meet certain health criteria, such as having a performance status of GOG 0-1 and no history of brain metastases or significant infections. Additionally, patients must not have a history of certain prior treatments, such as immunotherapy or antiangiogenic agents, and must not be taking certain medications, such as antiseizure medications or bisphosphonates.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on major depressive disorder and includes a list of ICD-10 codes for the disease. The trial involves the use of two drugs, levomilnacipran er and placebo. The eligibility criteria for the trial include being between 18-75 years old, meeting the DSM-IV-TR criteria for Major Depressive Disorder, and having a current depressive episode that has lasted at least 6 weeks. The exclusion criteria include being pregnant or breastfeeding, having a history of suicidal behavior, and having a history of manic or hypomanic episodes, schizophrenia, or obsessive-compulsive disorder.",
    "The sample is a phase 3 clinical trial for male osteoporosis. The trial includes patients with very low bone mineral density in the hip and spine or low bone mineral density in the hip combined with 1-3 mild or moderate fractures of the vertebrae. The trial will test the effectiveness of zoledronic acid 5 mg iv compared to a placebo. The eligibility criteria include exclusion of patients with low Vitamin D, renal insufficiency, previous treatment with certain anti-osteoporotic therapies, chronic use of systemic corticosteroids, history of cancer or metastases within the last 5 years, history of brittle bone disease, multiple myeloma, or Paget's disease, or any other metabolic bone disease, except osteoporosis, and bilateral hip replacements. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for the treatment of dry eye. The record includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and the eligibility criteria for participants. The inclusion criteria include having a history of dry eye, being at least 12 years old, and demonstrating a response to the Controlled Adverse Environment model at Visits 1 and 2. The exclusion criteria include contraindications to the use of the test articles, known allergies or sensitivities to the study medications or their components, ocular infections, active ocular inflammation, preauricular lymphadenopathy, and current contact lens wearers or those who wear contacts during the study.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who have not received prior treatment for metastatic colon or rectal cancer and are scheduled to begin fluoropyrimidine-based chemotherapy as a first line treatment. The trial excludes patients who have received prior chemotherapy for metastatic colon or rectal cancer, planned radiotherapy for underlying disease, central nervous system metastases, or have undergone major surgical procedure, open biopsy, or significant traumatic injury within 28 days before study start. The trial uses bevacizumab and fluoropyrimidine-based chemotherapy as drugs. The diseases are listed as 'colorectal cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3, involving patients with Down syndrome and Alzheimer's disease. The trial is testing the effectiveness of vitamin E, multivitamin, and placebo drugs. The eligibility criteria for the trial include the presence of clinically determined Down syndrome, medical stability, stable medications for at least 3 months, and signed consent form. The trial also has exclusion criteria, such as the presence of any medical or neurological condition other than Alzheimer's disease, low Brief Praxis Test score, high Modified Hachinski score, major depression within 3 months, history of blood coagulation disorder, current use of anti-coagulants, use of experimental medications within 3 months, and regular use of vitamin E greater than 50 units per day during the previous 6 months.",
    "The sample is a phase 3 clinical trial for chemotherapy-induced nausea and vomiting (CINV). The trial includes patients who are at least 18 years old and scheduled to receive their first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher, with a predicted life expectancy of 3 months or greater. Patients must also meet certain inclusion criteria, such as being post-menopausal or using double-barrier contraception if premenopausal. However, there are also exclusion criteria, such as having a symptomatic primary or metastatic CNS malignancy, receiving radiation therapy to the abdomen or pelvis in the week prior to treatment, or having vomited in the 24 hours prior to treatment. Patients who have an active infection, use illicit drugs, have current evidence of alcohol abuse, or are pregnant or breastfeeding are also excluded from the trial. The trial will compare the effectiveness of different drugs, including fosaprepitant dimeglumine, aprepitant, dexamethasone, and ondansetron.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) and involves the use of aclidinium bromide and placebo drugs. The trial has eligibility criteria for inclusion and exclusion of patients, including a diagnosis of stable moderate to severe COPD, current or former cigarette smokers, and no history of asthma or clinically significant respiratory conditions other than COPD or mental illness. Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit, respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1, and those with uncontrolled infection due to HIV and/or active hepatitis are excluded from the trial. Additionally, patients with a history of hypersensitivity reaction to inhaled anticholinergics and clinically significant cardiovascular conditions are also excluded.",
    "The sample is a phase 3 clinical trial for infants who were born small for their gestational age. The trial is testing the effectiveness of two drugs, genotropin (pn-180,307) somatropin and a control with no treatment. The eligibility criteria for the trial includes being a Caucasian male or female between the ages of 19-29 months, having a birth length and/or weight below -2 standard deviations for gestational age, and having a height below -2.5 standard deviations at screening. The trial also excludes individuals with severe intra-uterine growth retardation, severe prematurity, severe familial short stature, and neurological defects or severe neurodevelopmental delay.",
    "The sample is a phase 3 clinical trial for the treatment of complicated urinary tract infection and pyelonephritis. The trial involves the use of two drugs, cxa-201 and levofloxacin. The eligibility criteria for the trial include being at least 18 years old, having pyuria, and clinical signs and/or symptoms of cUTI. Inclusion criteria also require a pretreatment baseline urine culture specimen obtained within 24 hours before the start of administration of the first dose of study drug. Exclusion criteria include having a documented history of any moderate or severe hypersensitivity or allergic reaction to any \u03b2-lactam or quinilone antibacterial, having a concomitant infection at the time of randomization, and having a complete, permanent obstruction of the urinary tract. Women who are pregnant or nursing are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of insulin degludec and sitagliptin in combination with other oral diabetes medications. The eligibility criteria include having a diagnosis of type 2 diabetes for at least 6 months, ongoing treatment with certain oral diabetes medications for at least 3 months prior to the trial, a BMI below or equal to 40.0 kg/m^2, and an HbA1c level between 7.5-11.0%. Exclusion criteria include recent use of certain diabetes medications, cardiovascular disease within the last 6 months, uncontrolled severe hypertension, recurrent severe hypoglycemia, pregnancy or intention of becoming pregnant, and a history of cancer.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia and psychotic disorders. The trial is testing the effectiveness of the drug risperidone in treating these conditions. The inclusion criteria for the trial include a diagnosis of schizophrenia according to the DSM-IV criteria, expected benefit from continuous treatment with risperidone, and a PANSS score between 40 and 120 at the start of the study. The exclusion criteria include having other psychiatric disorders or mental retardation, a history of substance dependence, hypersensitivity or intolerance to risperidone, and extrapyramidal symptoms that are not adequately controlled with medication. The diseases are listed as schizophrenia and psychotic disorders, and the icd-10 codes associated with these diseases are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia and hyperlipidemia using the drugs torcetrapib/atorvastatin and atorvastatin. The trial is looking for participants who have been diagnosed with Heterozygous Familial Hypercholesterolemia and are at least 18 years old. The trial has exclusion criteria for women who are pregnant or lactating, subjects who are taking certain medications, and those with certain medical conditions or laboratory abnormalities. The trial aims to evaluate the safety and effectiveness of the drugs in treating hypercholesterolemia and hyperlipidemia.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease and dyskinesias. The trial is testing the effectiveness of ropinirole controlled-release (requip cr) for restless leg syndrome. The eligibility criteria for the trial include being on 600mg or less of levodopa therapy for two years or less and being on a stable dose of levodopa therapy for at least 4 weeks prior to screening. The exclusion criteria include having a current or past history of dyskinesia and having a state of dementia or a MMSE score less than 26 at screening.",
    "The sample is a phase 3 clinical trial for patients who have undergone surgery for cancer diagnosis or treatment and are experiencing persistent pain for at least 1 month with neuropathic features. The trial is testing the effectiveness of lidocaine patches for pain relief. The trial has eligibility criteria for the patients, including age, performance status, life expectancy, and medical history. Patients must not have pain of multiple etiologies at the proposed treatment site, and the painful area must be no larger than can be covered by 3 lidocaine patches. The trial also has exclusion criteria, including skin disease, breakdown, infection, or extreme thinning at the site of pain, skin or soft tissue malignancy in the painful area, recent history of or concurrent drug or alcohol abuse, and mental or psychiatric condition that would preclude giving informed consent. The trial has prior concurrent therapy restrictions, including no prior neurotoxic chemotherapy with pain in the same area as postsurgical neuropathic pain, no concurrent neurotoxic chemotherapy, and no concurrent radiotherapy to the painful area. The trial also has restrictions on the use of analgesic and adjuvant drugs during study participation.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone er. The trial includes both a double-blind phase and an open-label extension phase. The inclusion criteria for the double-blind phase require participants to have a DSM-IV diagnosis of schizophrenia for at least 1 year, be experiencing an acute episode with a PANSS score between 70 and 120, agree to voluntary hospitalization for at least 14 days, be willing and able to fill out self-administered questionnaires, and be able to comply with self-administration of medication or have consistent help/support available. The open-label extension phase includes patients who completed the 6 weeks of double-blind treatment or at least 21 days of treatment and discontinued due to lack of efficacy, and whose patient and investigator agree that open-label treatment is in the best interest of the patient. The exclusion criteria for the double-blind phase include a DSM-IV axis I diagnosis other than schizophrenia, a diagnosis of substance dependence within 6 months prior to screening evaluation, a history of tardive dyskinesia or neuroleptic malignant syndrome, a history of any severe preexisting gastrointestinal narrowing, previous lack of response to any antipsychotic, and significant risk of suicidal or violent behavior. The open-label phase exclusion criteria include being at significant risk for suicidal or violent behavior and having received an injection of a depot antipsychotic since entry into the preceding double-blind phase.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on asthma and includes a list of ICD-10 codes related to the disease. The trial involves testing multiple drugs, including a placebo, for their effectiveness in treating the disease. The eligibility criteria for participants include having a history of house dust mite induced asthma, using an appropriate amount of inhaled corticosteroid, and having a suitable level of asthma control. Participants must also have a positive skin prick test response to Der pte and/or Der far and positive specific IgE against Der pte and/or Der far. The exclusion criteria include having a clinical history of persistent allergic asthma or rhinitis caused by an allergen other than house dust mites, having intermittent allergic asthma or rhinitis during the period from October to March, and having any clinically relevant chronic disease.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is looking at the effectiveness of consolidation chemotherapy with docetaxel plus cisplatin and ccrt arm without consolidation chemotherapy. The eligibility criteria include having histologically proven non-small cell lung cancer, measurable disease by RECIST, being inoperable Stage IIIA or IIIB, and having an ECOG Performance status of 0-1. Patients must also meet certain blood count and organ function requirements, and must not have had prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy. Exclusion criteria include having any distant metastasis, having a history of another malignancy within the last five years, and having any other morbidity or situation with contraindication for chemotherapy. Pregnant or lactating women, women who have not taken a pregnancy test within 14 days before the first administration, and women and men of childbearing potential who have no willingness to employ adequate contraception are also excluded.",
    "The sample is a phase 3 clinical trial for patients with multiple myeloma. The trial is testing the effectiveness of two different treatments: granulocyte colony-stimulating factor plus plerixafor and granulocyte colony-stimulating factor plus placebo. The eligibility criteria for the trial include a diagnosis of multiple myeloma in first or second complete or partial remission, a certain amount of time since the last cycle of chemotherapy, a certain level of white blood cells, polymorphonuclear leukocytes, and platelets, and a sufficient cardiac and pulmonary status. Patients must also not have certain medical conditions or have received certain treatments in the past.",
    "The sample is a phase 3 clinical trial for patients undergoing knee replacement surgery. The trial is focused on preventing deep vein thrombosis and pulmonary embolism using the drugs enoxaparin and apixaban, as well as matching placebos. The eligibility criteria include being scheduled for the surgery, willingness to undergo venography, and not having certain bleeding or coagulation disorders. Exclusion criteria include recent surgery or trauma, active bleeding, and certain laboratory abnormalities. The diseases being studied are deep vein thrombosis and pulmonary embolism, and their corresponding ICD-10 codes are listed.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial is looking for subjects between the ages of 16 and 75 who have well-characterized focal epilepsy or epileptic syndrome and experience at least 2 but no more than 40 partial onset seizures per 4 weeks during the 8-week baseline period. The subjects must be on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED \u2264 50% of the minimum recommended maintenance dose. The trial is excluding subjects with seizure type IA non-motor as their only seizure type, a history or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline, and other serious uncontrolled diseases. The drugs being tested in the trial are brivaracetam.",
    "The sample is a phase 3 clinical trial for lung cancer. The trial is looking for patients with primary unresectable non-small cell lung cancer, specifically stage IIIA (N2) disease by chest CT scan. The trial is open to any histologic subtype and requires at least one measurable target lesion on chest CT scan. Patients cannot have N3 or metastatic disease, pre-existing pleural or pericardial effusion, or symptomatic CNS involvement. Patients must be over 18 years old with a WHO performance status of 0-2 and physically and mentally fit for study therapy. Patients cannot have prior melanoma, breast cancer, or hypernephroma, or any other primary malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix. Patients cannot have grade 2 or greater pre-existing motor or sensory neurotoxicity, active uncontrolled infection requiring IV antibiotics, or diffuse interstitial pulmonary fibrosis. Patients must not have any psychological, familial, sociological, or geographical condition that would preclude study compliance, and must not be pregnant or nursing. Fertile patients must use effective contraception. Patients cannot have had prior chemotherapy, radiotherapy, or surgery for NSCLC, and cannot have had any other prior therapy for NSCLC.",
    "The sample is a phase 3 clinical trial for treating head and neck cancer using radiotherapy and chemotherapy. The trial includes patients with locally advanced stage head and neck cancer who are not eligible for surgery. The trial involves the use of three drugs: placebo, palifermin, and cisplatin chemotherapy. The eligibility criteria include having squamous cell carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx, and having an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. Patients with a history of any other primary malignancy, except for curatively treated in situ cervical cancer or basal cell carcinoma of the skin without evidence of disease for greater than 3 years, are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with advanced ovarian epithelial, fallopian tube, or primary peritoneal cancer who have undergone an initial exploratory laparotomy with tumor debulking and attained a clinically defined complete remission (CR) following treatment with platinum and paclitaxel based combination chemotherapy regimen. The trial requires patients to have no evidence of cancer on physical examination, CA-125 no greater than 35 units/mL, creatinine no greater than 2.0 mg/dL or creatinine clearance greater than 60 mL/min, bilirubin no greater than 2.0 mg/dL, negative ascites, and no evidence of residual cancer on CT scan of the abdomen/pelvis or chest x-ray. Patients must have received a minimum of 5 and a maximum of 6 courses of chemotherapy prior to the study and must register for the study within 21 to 56 days after prior chemotherapy. The trial also has specific eligibility criteria for age, performance status, life expectancy, hematopoietic, hepatic, renal, and prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have been diagnosed with type 2 diabetes for at least 6 months and have been on premixed human or analogue insulin or self-mixed insulin regimen for at least 3 months before the trial. The trial also requires patients to have a HbA1c level between 7.0-10.0% and a BMI below or equal to 40.0 kg/m^2. The trial excludes patients who have been treated with other insulin regimens or rosiglitazone or glucagon-like peptide-1 (GLP-1) receptor agonists within 3 months prior to the trial. Patients with cardiovascular disease, uncontrolled severe hypertension, pregnancy, breast-feeding, or a history of cancer (except basal cell skin cancer and squamous cell skin cancer) are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for postmenopausal women with estrogen and/or progesterone receptor positive primary invasive breast cancer. The trial is testing the effectiveness of the drug letrozole. The inclusion criteria require the women to have clinical stage T2 or greater tumors that are not eligible for breast-conserving surgery, and to meet certain postmenopausal status requirements. The tumors must also be measurable by clinical examination, mammography, and ultrasound, and the women must have adequate bone marrow function. The exclusion criteria include multifocal disease, bilateral breast tumors, eligibility for breast-conserving surgery, evidence of inflammatory breast cancer or distant metastasis, and simultaneous anti-cancer treatments. The sample also includes additional treatments that are not allowed during the treatment phase of the study.",
    "The sample is a phase 3 clinical trial for newly diagnosed multiple myeloma. The trial includes patients who are at least 65 years old and meet specific diagnostic criteria, including monoclonal plasma cells in the bone marrow, presence of a biopsy-proven plasmacytoma, and myeloma-related organ dysfunction. The trial involves a combination of drugs, including lenalidomide, melphalan, prednisone, aspirin, and placebo. Patients must also meet certain eligibility criteria, such as having a Karnofsky performance status greater than or equal to 60% and being able to adhere to the study visit schedule. The trial has exclusion criteria, such as previous treatment with antimyeloma therapy, serious medical conditions, and pregnancy or lactation.",
    "This sample is for a phase 3 clinical trial for the treatment of ulcerative colitis. The trial includes patients who have been diagnosed with ulcerative colitis and have been in remission for at least 30 days. Female subjects must be post-menopausal, surgically or biologically sterile, or have a negative urine pregnancy test and be on adequate contraception. Patients with proctitis, previous resective colonic surgery, Crohn's disease, hypersensitivity to salicylates, or moderate/severe renal impairment are excluded from the trial. The trial will test the effectiveness of two drugs, spd476 and asacol, on the eligible patients.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of diabetes mellitus. The trial includes a list of icd-10 codes associated with the disease, as well as two drugs, alogliptin and insulin. The eligibility criteria for the trial are listed, including requirements for the subject to be an outpatient and to sign a written consent form. There are also exclusion criteria, such as having serious cardiac or cerebrovascular disorders, or any serious pancreatic or hematological disease. The investigator or subinvestigator may also exclude a subject for any other reason.",
    "The sample is a phase 3 trial for renal transplantation. The diseases involved are listed as 'renal transplantation' and the icd-10 codes associated with them are also provided. The drugs being tested are 'everolimus + cyclosporine', 'everolimus + enteric-coated mycophenolate sodium (ec-mps)', and 'steroids'. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include having completed a previous study and not having experienced acute rejection within the 3 months prior to inclusion. There may be additional criteria that apply as defined by the protocol.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have locally recurrent or metastatic disease that cannot be treated with surgery or radiotherapy. The trial is testing the effectiveness of two drugs, vinflunine plus capecitabine and capecitabine, for patients who have already undergone one, two, or three chemotherapy regimens that included both an anthracycline and a taxane. The trial has inclusion criteria such as being a female patient over 21 years old, having a confirmed diagnosis of breast cancer, and having a Karnofsky performance score of at least 70%. Exclusion criteria include having a history of second primary malignancy, known history of HIV infection, and pregnancy or breastfeeding. The trial also requires patients to have adequate haematological, hepatic, and renal functions, and a normal ECG.",
    "The sample is a phase 3 clinical trial for the treatment of graft versus host disease, leukemia, and lymphoma. The trial involves the use of anti-thymocyte globulin, cyclophosphamide, cyclosporine, methotrexate, and methylprednisolone. The eligibility criteria include specific disease characteristics, age restrictions, performance status, and various medical conditions such as normal liver and kidney function, asymptomatic cardiovascular and pulmonary function, and no prior bone marrow transplantation or radiotherapy that precludes total body irradiation. Patients must also have a suitable donor available and meet specific HLA matching requirements.",
    "The sample is a phase 3 clinical trial for the treatment of generalized anxiety disorder. The trial includes patients who have been diagnosed with GAD and have a HAM-A total score of at least 20 at the screening and randomization visits. The trial excludes patients with certain medical conditions, such as hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, neurologic, active infections, immunological, or allergic disease, as well as those with certain psychiatric disorders, including major depressive disorder, obsessive-compulsive disorder, panic disorder, and others. Patients with antisocial or borderline personality disorder or serious suicidal risk are also excluded. The trial involves the use of the drugs pd 0332334 and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes patients who have been diagnosed with a major depressive episode and have been experiencing symptoms for at least 3 months. The patients must also have a Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of 26 or greater and a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits. The trial involves the use of the drug vortioxetine and a placebo. The eligibility criteria for the trial include exclusion criteria such as having received any investigational compound <30 days before Screening or 5 half-lives prior to Screening, having received Lu AA21004 in a previous clinical study, having a current psychiatric disorder other than MDD, having a diagnosis of alcohol or other substance abuse or dependence, and having a significant risk of suicide. The trial also excludes patients who are currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or planned to initiate such therapy during the study. The trial also excludes patients who have a clinically significant unstable illness or abnormal laboratory values.",
    "The sample is a phase 3 clinical trial for the treatment of Tourette Syndrome. The trial includes subjects between the ages of 7 and 65 who have been diagnosed with Tourette Syndrome for at least 3 months and have a minimum Tic rating scale of > or equal to 19. The trial involves the use of topiramate and a placebo/sugar pill. The eligibility criteria include being in generally good health, having a negative urine drug screening, and being able to take oral medication in tablet form without altering the tablet. The trial also includes exclusion criteria such as having a diagnosis of substance dependence or abuse within the past 3 months, having a significant and unstable major psychiatric disorder requiring treatment, and being pregnant or lactating.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of venous thromboembolism and includes a list of associated ICD-10 codes. The trial involves the use of several drugs, including rivaroxaban and enoxaparin. The eligibility criteria for the trial include patients aged 20 or older who are undergoing elective total hip replacement surgery and have provided written consent. Exclusion criteria include a history of active bleeding, hepatic disease, impaired renal function, ongoing anticoagulant therapy, and other conditions that may interfere with the study.",
    "The sample is a phase 3 clinical trial for the treatment of acute myeloid leukemia (AML). The eligibility criteria include being 18 years or older, having a confirmed diagnosis of AML, having received two or three previous induction/re-induction regimens or being over 65 with adverse cytogenetics and having received 1-3 previous induction/re-induction regimens, and having never attained CR or CRi (primary refractory) or having failed initial induction therapy. Patients must also have recovered from previous bone marrow and/or stem cell transplantation and have an ECOG performance status of 0-2. Exclusion criteria include a history of allergic reactions to egg or cytarabine, persistent clinically significant toxicities from previous chemotherapy, and uncontrolled intercurrent illness. Patients must be capable of understanding and complying with protocol requirements and must be able and willing to sign a written informed consent form.",
    "The sample is a phase 3 clinical trial for patients with brain and central nervous system tumors, cognitive/functional effects, depression, fatigue, and quality of life issues. The trial requires patients to have a confirmed diagnosis of metastatic or primary brain tumor and planned external beam cranial radiotherapy. Patients must also meet certain eligibility criteria, including being 18 years or older, having a Karnofsky performance status of 70-100%, and having a life expectancy of at least 3 months. The trial allows for prior or concurrent chemotherapy and concurrent steroid use, but not concurrent craniospinal axis radiotherapy. Patients must not have a history of steroid psychosis, family history of or active Tourette's Syndrome, or prior or concurrent medications for attention deficit disorder, anxiety disorder, schizophrenia, or substance abuse.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves two drugs, brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution and concurrent brimonidine 0.2% and 0.5% timolol. The eligibility criteria for the trial include a diagnosis of ocular hypertension or glaucoma and a need for IOP-lowering therapy in both eyes. The exclusion criteria include uncontrolled medical conditions and contraindication to \u03b2-adrenoceptor antagonist therapy or brimonidine therapy. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for gastroesophageal reflux disease (GERD) and involves patients who have experienced frequent episodes of heartburn associated with GERD for at least 2-3 days per week during 2-4 weeks before screening and have responded to standard PPI therapy in the past 12 months. The trial includes inclusion and exclusion criteria, such as age restrictions, medication history, and co-existing diseases that may affect the oesophagus. Patients must also be willing and able to complete the entire procedure and comply with study instructions. The trial involves the use of two drugs, zegerid and losec, and requires patients to record their symptoms using an e-diary.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and mood disorders using the drug paliperidone extended-release. The trial includes patients who meet specific inclusion criteria, such as having a history of manic or mixed episodes and meeting certain diagnostic criteria. Patients must also be willing to comply with self-administration of the medication or have support available. Exclusion criteria include a history of substance dependence, certain medical illnesses, and pregnancy or nursing. The trial aims to evaluate the safety and efficacy of the drug in treating bipolar disorder and mood disorders.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial involves the use of three drugs: bifeprunox, placebo, and quetiapine. The eligibility criteria for the trial include having a primary diagnosis of schizophrenia, experiencing clinically significant symptoms, and having medication that remained stable for 8 weeks prior to screening. The trial also has exclusion criteria, such as being at significant risk of suicide, being treatment resistant, and having a current or past history of substance abuse.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying acute coronary syndrome and coronary artery disease. The icd-10 codes associated with these diseases are listed, as well as the drug being tested (atorvastatin). The eligibility criteria for participants are also listed, including inclusion criteria such as having non-ST-segment elevation acute myocardial infarction and angiographic evidence of severe and diffuse coronary artery disease, and exclusion criteria such as having a history of heart failure or renal failure with serum creatinine >2.5 mg/dL.",
    "The sample is a phase 3 clinical trial for the treatment of germ cell tumors, including extragonadal and testicular tumors. The trial involves the use of drugs such as cisplatin, ifosfamide, paclitaxel, and vinblastine. The eligibility criteria include having a confirmed diagnosis of germ cell tumor with evidence of metastatic disease, having previously been treated with only one regimen of etoposide and cisplatin with or without bleomycin, and exhibiting clinical resistance to that treatment. Patients must also meet certain age, performance status, and hematopoietic, hepatic, and renal function requirements. The trial excludes patients who have previously received paclitaxel, docetaxel, or ifosfamide, and those who have received prior dose-intensive therapy with stem cell replacement.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of asthma. The icd-10 codes associated with the disease are listed, along with the drugs being tested, which include montelukast sodium and a placebo comparator. The eligibility criteria for the trial are also provided, including age restrictions and exclusion criteria for other respiratory conditions or acute illnesses that could complicate treatment.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves the use of three drugs: budesonide/formoterol turbuhaler, budesonide turbuhaler (pulmicort), and terbutaline turbuhaler. The eligibility criteria for the trial include a diagnosis of asthma for at least 6 months and prescribed daily use of glucocorticosteroids for at least 3 months prior to the first visit. The exclusion criteria include recent respiratory infection affecting asthma, intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to the study, and any significant disease or disorder that may jeopardize the safety of the patient. The icd-10 codes associated with the disease are also provided.",
    "The sample is for a phase 3 clinical trial for seasonal allergic rhinitis. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include being at least 12 years old, having a documented history of SAR, having a positive skin-prick test response to an appropriate seasonal allergen, and being in good health. The exclusion criteria include having a history of anaphylaxis or severe local reactions to skin testing, requiring chronic use of corticosteroids for asthma, having certain nasal structural abnormalities, and being pregnant or nursing.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are at least 18 years old and have established essential hypertension. The patients must have been treated with either irbesartan 150 mg or amlodipine 5 mg as monotherapy for at least 2 weeks and have uncontrolled systolic blood pressure (\u2265140 mm Hg) assessed by office blood pressure measurements. The trial excludes patients with mean systolic blood pressure \u2265180 mm Hg and/or mean diastolic blood pressure \u2265110 mm Hg, known or suspected causes of secondary hypertension, bilateral artery stenosis, renal artery stenosis in a solitary kidney, renal transplant or only has one functioning kidney, contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination, history of angioedema related to the administration of an angiotensin II receptor antagonist or any combination of the drugs used, severe hepatic impairment, severe renal impairment, concomitant use of any other antihypertensive treatment except of Irbesartan and Amlodipine, administration of any other investigational drug within 30 days before inclusion, presence of any other conditions that would restrict or limit the patient participation for the duration of the study, pregnant or breast feeding women, women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period, and patients who are the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. The trial includes a list of drugs, diseases, and icd-10 codes, and the eligibility criteria for the patients.",
    "The sample is a phase 3 clinical trial for the treatment of plaque psoriasis. The trial includes patients who are at least 18 years old and have been diagnosed with stable plaque psoriasis for at least 6 months. Patients must have failed at least one systemic treatment regimen or have contraindications or tolerability issues with other systemic therapies. The trial involves the use of three drugs: voclosporin, ciclosporin, and placebo. Patients must meet certain inclusion criteria, such as having plaque psoriasis involving at least 10% of the body surface area and a SPGA score of at least 3. Patients must also not be pregnant or nursing and must use reliable forms of birth control during the study. The trial has exclusion criteria, such as having other dermatoses that would interfere with the evaluation of psoriasis, having a current malignancy or history of malignancy within 5 years, or having uncontrolled hypertension. Patients must also not have used any investigational drug or device within 30 days prior to the screening visit and must not be currently participating in another clinical trial of any drug or biological agent.",
    "The sample is a phase 3 clinical trial for patients with rectal cancer that is stage II/III and is either T3 or T4 (excluding anal extension) with no distant metastasis. The trial is testing the effectiveness of the drug Tegafur and Uracil. The eligibility criteria include having confirmed invasive adenocarcinoma of the rectum, meeting certain performance and health status requirements, and having no prior chemotherapy or radiotherapy to the pelvis. Patients must also not have any other concurrent investigational drugs or anticancer treatments. The sample includes a detailed list of eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 3 clinical trial for small cell lung cancer. The trial includes patients with a histological or cytological diagnosis of SCLC, who have either responded to first-line platinum-based chemotherapy or have refractory SCLC. The trial also includes patients with limited or extensive disease, who have radiographically documented progression after first-line treatment with platinum-based chemotherapy and have had no more than one prior chemotherapy regimen. The trial excludes patients who have received chest radiotherapy with curative intent to the primary disease complex within 28 days prior to the first dose, prior anthracycline, topotecan, or irinotecan treatment, and patients with a known history of seropositive human immunodeficiency virus (HIV) or who are receiving immunosuppressive medications that would increase the risk of serious neutropenic complications.",
    "The sample is a phase 3 clinical trial for kidney transplantation. The trial is looking at the use of alemtuzumab and tacrolimus as drugs. The eligibility criteria for the trial includes being between the ages of 18-65, having endstage renal failure with no previous renal transplantation, and having a cadaveric donor. Exclusion criteria includes being pregnant or nursing, having received a multi-organ transplant, having received a live donor transplant, having a panel reactive antibody level greater than 25%, and having a history of anaphylaxis following exposure to humanized monoclonal antibodies.",
    "This sample is for a phase 3 clinical trial for the treatment of invasive candidiasis. The trial is testing the drug caspofungin acetate. The eligibility criteria for the trial includes having clinical and laboratory evidence of blood stream and/or systemic candida infections. However, patients with possible candida contamination, candida colonization, urine, cardiac, bone or brain and prosthetic device infections, acute or moderately severe liver disease, abnormal liver function tests, and abnormal blood clotting for patients on blood thinners are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with chronic liver disease, non-alcoholic steatohepatitis, HCV, HIV infection, and other related conditions. The trial is testing the effectiveness of the drug eltrombopag compared to a placebo. The eligibility criteria include having a Child-Pugh score of 12 or less, a MELD score of 24 or less, and requiring a platelet transfusion to manage the risk of bleeding associated with an elective invasive procedure. The trial also has exclusion criteria, such as a known hypersensitivity to eltrombopag and a history of arterial or venous thrombosis. The sample includes a list of diseases, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of bipolar disorder. The trial involves the use of two drugs, asenapine and olanzapine. The eligibility criteria for the trial include having completed a 3-week study for the treatment of an acute manic or mixed episode with asenapine and not having any major protocol violations. Patients with unstable medical conditions or clinically significant laboratory abnormalities are excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for gastroesophageal reflux disease (GERD) and involves the use of the drugs dexlansoprazole and placebo. The trial includes eligibility criteria for participants, such as having a history of symptomatic GERD and experiencing moderate to severe nocturnal heartburn and GERD-related sleep disturbances. Exclusion criteria include having erosive esophagitis, allergies to certain drugs, and co-existing diseases affecting the esophagus. Participants must also agree to use adequate contraception if sexually active and cannot be pregnant or lactating during the study. The trial aims to evaluate the effectiveness of the drugs in treating GERD symptoms and improving sleep quality.",
    "The sample is a phase 3 clinical trial for the treatment of systemic lupus erythematosus. The trial includes a list of diseases and their corresponding icd-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria include a clinical diagnosis of SLE, active SLE disease, and being on a stable SLE treatment regimen. The exclusion criteria include being pregnant or nursing, having received treatment with any B cell targeted therapy, having received treatment with a biological investigational agent in the past year, and having severe lupus kidney disease or active central nervous system lupus, among others.",
    "The sample is a phase 3 clinical trial for metastatic breast cancer. The trial includes patients with locally recurrent or metastatic disease who are candidates for chemotherapy. The trial drugs include pertuzumab, placebo, trastuzumab, and docetaxel. The eligibility criteria include confirmation of adenocarcinoma of the breast, HER2-positive metastatic breast cancer, LVEF \u226550%, ECOG performance status 0 or 1, and agreement to use contraception. Exclusion criteria include a history of anti-cancer therapy for MBC, history of approved or investigative tyrosine kinase/HER inhibitors for breast cancer, and current peripheral neuropathy of NCI-CTCAE Version 3.0, Grade \u22653 at randomization, among others.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on breast cancer. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, including zd9393 (zoladex) 10.8 mg and zd9393 (zoladex) 3.6 mg. The eligibility criteria for the trial include being a pre-menopausal female with hormone sensitivity (ER positive) of primary or secondary tumor tissue, confirmed diagnosis of breast cancer, and being a candidate for hormonal therapy for advanced breast cancer. Exclusion criteria include having received tamoxifen or other hormonal therapies as adjuvant therapy for breast cancer within 24 weeks before randomization, having received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomization, and having relapsed during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy.",
    "The sample is a phase 3 clinical trial for metastatic pancreatic cancer using the drug bevacizumab (also known as Avastin). The trial has eligibility criteria for adult patients over 18 years old with good liver, kidney, and bone marrow function. Exclusion criteria include previous systemic treatment for metastatic pancreatic cancer, pregnancy or lactation, recent major surgical procedures or traumatic injuries, and current or recent participation in another investigational study or treatment with another investigational drug. The diseases being studied are limited to pancreatic cancer, and the icd-10 code for this disease is C25.3.",
    "The sample is a phase 3 clinical trial for the treatment of liver disease caused by chronic alcoholism. The trial includes patients with established liver disease and a history of chronic alcoholism, as well as those with chronic alcoholism without evidence of liver disease, and healthy subjects without a history of alcoholism or liver disease. The trial involves the use of two drugs, s-adenosylmethionine and placebo, and requires participants to undergo liver biopsies at the start and completion of the study, as well as comply with study medication and required clinic visits and blood sampling. The trial has exclusion criteria that include viral Hepatitis B or C, hemochromatosis, Wilson Disease, sclerosing cholangitis, primary biliary cirrhosis, other chronic diseases, and renal insufficiency.",
    "The sample is a phase 3 clinical trial for patients with coronary heart disease. The trial involves the use of three drugs: dalcetrapib (ro4607381), evidence-based medical care for acute coronary syndrome, and a placebo. The trial has inclusion criteria such as patients being adults over 45 years of age, recently hospitalized for ACS, clinically stable, and receiving evidence-based medical and dietary management of dyslipidemia. Exclusion criteria include uncontrolled diabetes, clinically unstable, severe anemia, uncontrolled hypertension, and concomitant treatment with any other drug raising HDL-C (eg niacin, fibrates). The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for type 2 diabetes. The trial includes patients who have been diagnosed with type 2 diabetes and are currently being treated with metformin immediate release formulation monotherapy at a stable dose of at least 1500 mg/day for at least 10 weeks prior to enrollment. The trial also includes patients with HbA1c levels between 6.7% and 10.5%. The trial excludes patients with a diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of the Young (MODY) or secondary causes of diabetes mellitus, history of diabetic ketoacidosis, symptoms of poorly controlled diabetes, FPG levels above 270 mg/dL, and BMI levels above 45 kg/m2. The trial will test the efficacy of dapagliflozin, metformin, and placebo as treatments for type 2 diabetes.",
    "The sample is a phase 3 clinical trial for the treatment of fallopian tube and ovarian cancer. The trial involves the use of two drugs, TCG and TC. The eligibility criteria for the trial include a confirmed diagnosis of ovarian epithelial cancer, fallopian tube cancer, or extra-ovarian papillary serous tumor, with certain stage requirements. Patients must have had surgery within the past 6 weeks and must meet certain age, performance status, and life expectancy requirements. They must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and must not have certain medical conditions or prior treatments. The trial excludes patients with low malignant-potential ovarian tumors, non-epithelial ovarian tumors, mixed Mullerian tumors, symptomatic brain metastases, or complete bowel obstruction. Patients must not be pregnant or nursing, and must use effective contraception if fertile. The trial also excludes patients with certain prior medical conditions or treatments, and requires that patients be geographically accessible for treatment and follow-up. The trial excludes concurrent immunotherapy, chemotherapy, radiotherapy, antineoplastic agents, investigational drugs, or clinical trial enrollment.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of retinal vein occlusion and macular edema using the drugs Ozurdex. The eligibility criteria for the trial include having a history of central or branch retinal vein occlusion, having received at least two intravitreal anti-VEGF injections but no treatment in the last 45 days, being at least 18 years old, having a visual acuity between 3 and 72 letters, having a central foveal thickness greater than 275 microns or the presence of cystic edema on OCT studies, and being willing to use an appropriate form of contraception (or abstinence) for the duration of the study if a sexually active woman of childbearing potential. The exclusion criteria include having a history of steroid-related glaucoma, having received an intraocular injection of steroid medication within the prior 4 months, having evidence of significant retinal ischemia on fluorescein angiography, having received previous laser photocoagulation within 4 months of the study, having concurrent ocular disease that would limit visual acuity, being pregnant, or being unwilling or unable to follow or comply with all study-related procedures.",
    "The sample is a phase 3 clinical trial for breast cancer. The eligibility criteria include having a life expectancy of at least 10 years, a Zubrod performance status of 0 or 1, and a tumor that is invasive carcinoma of the breast. Patients must have completed either a lumpectomy or a total mastectomy and have had evaluation of pathologic nodal status. Patients must also have no clinical or radiologic evidence of metastatic disease and must have had a baseline left ventricular ejection fraction (LVEF) greater than or equal to the lower limit of normal. Ineligibility criteria include having a tumor that is HER2-positive, having a primary tumor staged as T4, having prior therapy with anthracyclines or taxanes for any malignancy, and having cardiac disease that would preclude the use of anthracyclines.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis B. The trial includes patients between the ages of 18-70 who have been diagnosed with HBeAg-negative chronic hepatitis B for at least 6 months and have liver disease consistent with chronic hepatitis B. The trial excludes patients who have received interferon-based, systemic anti-HBV, antiviral, anti-neoplastic, or immunomodulatory therapy within the past 12 months, non-responders to previous interferon therapy, co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV), hepatocellular cancer, and those with compensated (Child A, score 6) or decompensated liver disease (Child B or C). The trial will test the efficacy of pegylated interferon (peg-ifn) alfa-2a and lamivudine (lam) as potential treatments for chronic hepatitis B.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease asthma. The icd-10 codes associated with the disease are listed. The trial involves two drugs, budesonide/formoterol (symbicort) pmdi and budesonide hfa pmdi. The eligibility criteria for the trial are listed, including age, asthma severity, and diagnosis duration. The exclusion criteria are also listed, including the use of systemic corticosteroids and any significant disease or disorder that may pose a risk to the subject's safety.",
    "This sample is for a phase 3 clinical trial for the treatment of mild to moderate plaque-type psoriasis. The trial is testing two drugs, u0267 foam and vehicle foam. The eligibility criteria include being at least 12 years old, in good general health, and having a diagnosis of psoriasis. Exclusion criteria include having a known allergy or adverse reaction to the drugs being tested, a history of hypercalcemia or vitamin D toxicity, and other serious skin disorders or chronic medical conditions that are not well controlled. Participants cannot have used certain medications or therapies within a certain timeframe before enrollment, and pregnant or breastfeeding women or sexually active women of childbearing potential who are not practicing an acceptable method of birth control are not eligible to participate.",
    "The sample is a phase 3 trial that involves patients with diabetes mellitus, asthma, and chronic obstructive pulmonary disease. The trial uses two drugs, human insulin inhalation powder and injected insulin. The eligibility criteria for the trial include having type 1 or type 2 diabetes and either asthma or COPD. The exclusion criteria include having a current smoking habit.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drug combination of carboplatin and paclitaxel. The eligibility criteria for the trial includes having NSCLC at stages IB, IIA, IIB, or IIIA/T3, having lung function test results that allow for surgery, and being between the ages of 18 and 75. The exclusion criteria includes having poor lung function, a performance status of 3-4, and mediastinal lymph node involvement.",
    "The sample is a phase 3 clinical trial for patients aged 18 to 60 years with a diagnosis of schizophrenia and associated cannabis abuse and/or psychotic disorders. The trial is testing the effectiveness of the drug quetiapine xr. The inclusion criteria include a score of at least 15 on the positive scale of the PANSS, provision of written informed consent, and the ability to understand and comply with the requirements of the study. Exclusion criteria include pregnancy or lactation, known intolerance or lack of response to quetiapine fumarate, and substance or alcohol dependence within 4 weeks prior to enrollment. The trial also excludes patients with medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment, and those with unstable or inadequately treated medical illness.",
    "The sample is a phase 3 clinical trial for lupus erythematosus, systemic and lupus nephritis. The trial involves the use of drugs such as abetimus sodium and phosphate-buffered saline. The eligibility criteria for the trial include a diagnosis of SLE, active SLE renal disease within the past 4 years, and the ability to have weekly intravenous administration of study treatment. Exclusion criteria include recent use of certain therapies and current abuse of drugs or alcohol. The table also includes lists of icd-10 codes for the diseases and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia. The trial involves the use of two drugs, fenofibrate/simvastatin and atorvastatin. The eligibility criteria for the trial include having mixed dyslipidemia, while exclusion criteria include known hypersensitivity to the drugs, pregnancy or lactation, contra-indication to the drugs, and unstable or severe cardiac disease.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, liver transplantation), the corresponding ICD-10 codes, the drugs being used (prograf and mr4), and the eligibility criteria for participants. The eligibility criteria include both inclusion and exclusion criteria, such as negative pregnancy test for female patients of childbearing potential, no history of multi-organ transplant or previous organ transplant, and no substance abuse or psychiatric disorders that may complicate communication with the investigator. The sample also specifies that patients must agree to practice effective birth control during the study and that patients with serum creatinine levels above 1.5mg/Dl are excluded.",
    "The sample is a phase 3 clinical trial for patients with Parkinson's disease who have been diagnosed for at least 5 years. The trial involves the use of the drug safinamide as an add-on therapy to stable doses of levodopa, dopamine agonists, and/or anticholinergics. Patients must have motor fluctuations and at least 1.5 hours of \"off\" time during the day. They must also be able to maintain an accurate diary and meet certain inclusion criteria, such as being between the ages of 30-80 and having a Hoehn and Yahr stage of I-IV during an \"off\" phase. Exclusion criteria include having any indication of forms of parkinsonism other than idiopathic Parkinson's disease, being pregnant or lactating, having a current diagnosis of substance abuse, and having a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C infection. The trial includes patients with HCV genotype 1 who have not received previous treatment for the infection and have a serum HCV RNA level of at least 1000 IU/ml. The trial involves the use of drugs such as alisporivir, peginterferon alfa-2a, ribavirin, and alv placebo. The eligibility criteria include liver evaluation prior to baseline, liver biopsy within 3 years or Fibroscan within 6 months, and exclusion criteria include co-infection with Hepatitis B or HIV, any other cause of relevant liver disease other than HCV, and presence or history of hepatic decompensation. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for psoriasis. The trial includes patients who have had a diagnosis of psoriasis for at least 12 months and have moderate to severe chronic plaque psoriasis. The patients must be candidates for systemic therapy or phototherapy and have active psoriasis despite treatment with topical agents. The trial involves the use of the drugs adalimumab and mtx, as well as a placebo. The eligibility criteria include being 18 years or older, in good health, and willing to self-administer sc injections or have someone available to administer them. Male subjects must have been vasectomized or practicing birth control. Exclusion criteria include previous use of systemic anti-TNF therapy or MTX, known hypersensitivity to adalimumab, and use of certain psoriasis therapies or corticosteroids during the study. Female subjects who are pregnant or breastfeeding or considering becoming pregnant are also excluded.",
    "The sample is a phase 3 clinical trial for patients with stage IIIB or IV non-small cell lung cancer. The trial is testing the effectiveness of three drugs: albumin-bound paclitaxel, paclitaxel, and carboplatin. The eligibility criteria include having measurable disease, no prior chemotherapy for metastatic disease, and expected survival of greater than 12 weeks. Patients must also have certain blood counts and chemistry levels within normal ranges, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion criteria include active brain metastases, pre-existing peripheral neuropathy of Grade 2, 3, or 4, and a history of allergy or hypersensitivity to any of the study drugs. Patients must also not be enrolled in any other clinical protocol or investigational trial involving experimental therapy or therapeutic devices.",
    "The sample is a phase 3 clinical trial for the treatment of acromegaly, a condition characterized by excessive growth hormone production. The trial includes patients who have not responded to maximum doses of octreotide LAR or lanreotide ATG for at least 6 months prior to screening. The trial involves the use of three drugs, pasireotide, octreotide lar 30mg, and lanreotide atg 120mg. The eligibility criteria include having a diagnosis of pituitary micro- or macro adenoma and having a mean GH concentration of a 5-point profile over a 2-hour period > 2.5 \u00b5g/L and sex- and age-adjusted IGF-1 > 1.3 x upper limit of normal (ULN). The exclusion criteria include having received pasireotide prior to enrollment, having compression of the optic chiasm causing acute clinically significant visual field defects, requiring surgical intervention for relief of any sign or symptom associated with tumor compression, having received pituitary irradiation within 10 years prior to screening, having undergone major surgery/surgical therapy for any cause within 4 weeks prior to screening, and being hypothyroid and not adequately treated with a stable dose of thyroid hormone replacement therapy.",
    "The sample is from a phase 3 clinical trial for the treatment of sexual dysfunctions, psychological. The trial involves the use of the drug flibanserin and a placebo. The eligibility criteria for the trial include being a premenopausal woman with HSDD (decreased sexual desire), having regular menstrual periods, and meeting minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress. Patients must also be willing to try to have sexual activity at least once monthly, use an electronic diary on a daily basis, and be in a stable, monogamous, heterosexual relationship for at least 1 year prior to the screening visit. Patients must have used a medically acceptable method of contraception for at least 3 months before the baseline visit and continue to use it during the trial. Exclusion criteria include a history of drug dependence or abuse within the past one year, a history of multiple severe reactions to drugs that affect the brain, and a history of participation in a trial of another investigational medication within one month prior to the screening visit. Patients who are pregnant or have been pregnant within the last 6 months prior to the baseline visit are also excluded.",
    "The sample is a phase 3 clinical trial for patients with osteoarthritis of the knee. The trial includes patients between the ages of 40 and 80 who meet specific criteria, such as having knee pain and radiographically diagnosed osteophytes, and who have received NSAIDs/Cyclooxygenase-2 inhibitors for at least 5 days a week during the 4 weeks prior to screening. The trial also has exclusion criteria, such as patients with a history of surgery or arthroscopy of the study joint within the previous 6 months, or patients with any active GI, cardiovascular, renal, hepatic, neurologic, or psychiatric disease. The trial involves the use of two drugs, pg201 tablet and celebrex capsule.",
    "The sample is a phase 3 clinical trial for patients with gastrointestinal stromal tumors. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for patients to participate. The inclusion criteria include being over 18 years old, having unresectable and/or metastatic GIST, currently receiving imatinib 400 mg per day for a minimum of 4 weeks prior to registration, and having good physical functioning and organ function. The exclusion criteria include disease progression during adjuvant therapy with imatinib, known intolerance of imatinib at a dose of 400 mg/day or higher, prior systemic therapy for advanced GIST with imatinib or those who have been on imatinib for longer than 6 months for unresectable and/or metastatic disease, major surgery within 2 weeks prior to Day 1 of study or who have not yet recovered from prior surgery, use of coumadin derivatives, and patients who have received wide field radiotherapy \u2264 4 weeks or limited field radiation for palliation < 2 weeks or who have not recovered from side effects of this therapy.",
    "The sample is a phase 3 clinical trial for patients with chronic hepatitis C infection (genotype 1) who have failed at least one prior course of standard treatment. The trial involves the use of drugs such as telaprevir, peg-ifn-alfa-2a, ribavirin, and placebo. The eligibility criteria include having an HCV RNA level of at least 1000 IU/mL, willingness to use two effective methods of birth control for up to 7 months after the last dose of study medication, and not having certain conditions such as decompensated liver disease or requiring the use of systemic corticosteroids. The exclusion criteria include being a previous non-responder classified as a viral breakthrough case, having more than one subtype of Hepatitis C virus, or exhibiting co-infection with any other genotype.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes who have inadequate glycemic control despite being on a combination of metformin and sulfonylurea for at least 8 weeks prior to the trial. The trial involves the drugs saxagliptin and placebo. The eligibility criteria include having a BMI of less than or equal to 40 kg/m2 and written informed consent. Exclusion criteria include a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma, current or prior use of certain medications, and certain medical conditions such as CHF and liver disease. The trial also requires an estimated CrCl of at least 60 ml/min at Visit 2 and a creatine kinase level of less than 10 x ULN at Visit 2.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for seasonal allergic rhinitis. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria for the trial are that the participant must be male or female, between 6 and 12 years old, and have a 2-year history of seasonal allergic rhinitis. The exclusion criteria include having a concurrent disease that might interfere with the investigation or evaluation of the study medication, a confirmed diagnosis of chronic rhinosinusitis within the last year, asthma (except for mild intermittent asthma), anatomical nasal deformity, nasal obstruction, being a known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR), chronic or intermittent use of inhaled, oral, intramuscular, intravenous corticosteroids or topical steroids, and having an ocular disorder other than allergic conjunctivitis.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of type 2 diabetes mellitus. The trial involves the drugs linagliptin and placebo. The eligibility criteria for participants include having type 2 diabetes mellitus with an HbA1c level of at least 7.0%, being at least 70 years old, and providing written informed consent. Exclusion criteria include recent myocardial infarction, stroke, or TIA, impaired hepatic function, and current treatment with certain medications.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The trial is testing the effectiveness of a drug called istradefylline (kw-6002). The eligibility criteria for participants include having Parkinson's disease according to UK Parkinson's Disease Society brain bank criteria, being in stages 2-4 of the disease in the OFF state for Modified Hoehn and Yahr Scale, being on a stable dose of levodopa/carbidopa for at least one year, and having predictable end of dose wearing off. Participants must also be able to complete a Parkinson's diary and have an average of 180 minutes of OFF time on two 24 hour diaries. Exclusion criteria include a history of neurosurgical treatment for PD, psychosis, atypical parkinsonism, secondary parkinsonism variant or Parkinson's plus syndromes, cancer diagnosis within 5 years, a Mini-mental status examination score of 25 or less, and a history of seizures or neurologic malignant syndrome.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on Parkinson's disease and the icd-10 code associated with it is G20. The trial involves the use of two drugs, placebo and azilect\u00ae, and has specific eligibility criteria for patients to participate. Inclusion criteria include having idiopathic PD, motor fluctuations averaging at least 1 hour daily in the \"OFF\" state during waking hours, a Modified Hoehn and Yahr stage \u22643 in the \"ON\" state, and taking optimised levodopa or dopa decarboxylase inhibitor (DDI) therapy. Exclusion criteria include having a clinically significant or unstable medical or surgical condition, severe disabling dyskinesias, a clinically significant psychiatric illness, and a Mini Mental State Examination (MMSE) score \u226424. Other inclusion and exclusion criteria may also apply.",
    "This sample is a phase 3 clinical trial for patients with prostate cancer. The trial is testing the effectiveness of zoledronic acid in preventing bone loss in patients undergoing androgen deprivation therapy (ADT) for at least 12 months. The eligibility criteria include a confirmed diagnosis of prostate cancer, a baseline bone mineral density T-score of less than -2.0 in the lumbar spine or total hip, and a life expectancy of at least 12 months. Patients must also have a Zubrod performance status of 0, 1, or 2 and cannot have received bisphosphonate therapy in the past 6 months or have metabolic bone disease, bone metastases, or certain other medical conditions. The trial has exclusion criteria as well.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drugs celecoxib and placebo as palliative chemotherapy for patients with stage IIIB or IV NSCLC. The eligibility criteria include confirmation of NSCLC, age over 18, performance status of 0-2, and no prior chemotherapy for the present disease. The trial also has exclusion criteria, such as regular use of NSAIDs, active duodenal ulcer, serious heart failure or liver disease, and pregnancy or lactation. Participants must provide informed oral and written consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for invasive breast cancer. The trial includes patients who are female and 18 years or older with a primary breast tumor that measures greater than or equal to 2.0 cm by physical exam and is diagnosed as invasive adenocarcinoma made by core needle biopsy. The breast cancer must be HER2-positive and the patient must have an ECOG performance status of 0 or 1. The trial involves the use of drugs such as doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, and lapatinib. The eligibility criteria include various medical tests and assessments, such as LVEF assessment by MUGA scan or ECG, blood counts, and hepatic function. The exclusion criteria include various medical conditions and treatments, such as prior therapy with anthracyclines, taxanes, trastuzumab, or lapatinib for any malignancy, and cardiac disease that would preclude the use of the drugs included in the treatment regimens.",
    "The sample is a phase 3 clinical trial for the treatment of migraine headaches. The trial includes patients between the ages of 18 to 65 years who have been diagnosed with migraine, with or without aura, and have experienced between 1 and 8 migraine attacks per month for the past 12 months. The trial involves the use of the drugs sumatriptan and placebo. The eligibility criteria include being able to distinguish migraine from other types of headaches and not experiencing headaches at a frequency greater than or equal to 15 days per month. The exclusion criteria include a history of resistance to sumatriptan or non-response to 2 or more other triptans, current use of medication for migraine prophylaxis that has not been stable for 30 days prior to screening, and chronic opioid therapy.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of depressive disorder, major. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including desvenlafaxine succinate sustained-release, duloxetine, and a placebo. The eligibility criteria for the trial are also listed, including requirements for a primary diagnosis of major depressive disorder, depressive symptoms for at least 30 days, and being at least 18 years of age. The exclusion criteria are also listed, including a significant risk of suicide, unstable medical conditions, and a history of certain mental health disorders.",
    "The sample is a phase 3 clinical trial for the treatment of breast cancer and osteoporosis. The trial involves the use of drugs such as alendronate sodium, calcium gluconate, and risedronate sodium. The eligibility criteria for the trial include being a postmenopausal female with acceptable quality dual-energy x-ray absorptiometry (DEXA) of the L1-L4 postero-anterior spine and hip within 12 weeks prior to randomization. Patients must also have estrogen receptor- and/or progesterone receptor-positive tumors and meet other patient characteristics such as having no malabsorption syndrome or other bone diseases. Prior concurrent therapy is also taken into consideration, including the use of bisphosphonates and corticosteroids. The sample provides a detailed list of eligibility requirements for patients interested in participating in the trial.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with a smoking history of at least 20 pack-years and a post-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% and greater than or equal to 30% of the predicted normal value. The trial also requires a post-bronchodilator FEV1/FVC (forced vital capacity) of less than 70%. The trial excludes patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period, patients requiring long-term oxygen therapy for chronic hypoxemia, patients with a respiratory tract infection within 6 weeks prior to screening, patients with concomitant pulmonary disease, patients with a history of asthma, patients with diabetes Type I or uncontrolled diabetes Type II, any patient with lung cancer or a history of lung cancer, any patient with active cancer or a history of cancer with less than 5 years disease-free survival time, patients with a history of long QT syndrome or whose QTc interval measured at screening or randomization is prolonged, patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period, and patients unable to successfully use a dry powder inhaler device or perform spirometry measurements. The trial includes the use of indacaterol 300 \u03bcg, placebo to indacaterol, and salmeterol 50 \u03bcg as drugs.",
    "The sample is for a phase 3 clinical trial for the treatment of psoriasis. The trial includes patients who have been diagnosed with psoriasis for at least 6 months, with a BSA (body surface area) of 10%, a PASI (psoriasis area and severity index) score of 12 or above, and a PGA (physician global assessment) score of 3 or above. The trial will test the effectiveness of two drugs, abt-874 and methotrexate. Patients who have previously been exposed to anti-IL 12 will be excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of mixed hyperlipidemia, which is identified by the ICD-10 code E78.2. The trial involves the use of three drugs: mk-0524a, atorvastatin, and simvastatin. The eligibility criteria for participants include being between 18 and 80 years old, having LDL-C levels between 130 and 190 mg/dL, and triglyceride levels between 150 and 500 mg/dL. Exclusion criteria include being pregnant or lactating, having poorly controlled diabetes, being HIV positive, having had a heart attack, stroke, heart bypass surgery, unstable angina, or angioplasty within the past 3 months, and having active or chronic liver disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on kidney transplantation and includes a list of ICD-10 codes for related diseases. The trial involves several drugs, including fk506mr, prograf, mycophenolate mofetil, methylprednisolone, and prednisolone. The eligibility criteria for the trial include obtaining written informed consent, being between 18-70 years old, and receiving the primary kidney. Female patients must have a negative pregnancy test and agree to practice effective birth control during the study. Exclusion criteria include having received an organ transplant other than a kidney, having a PRA>10% in the previous 6 months, needing antibody induction therapy, having significant liver disease, severe infection, severe cardiovascular or respiratory disease, a history of malignancy, or being HIV or HBsAg positive. Patients who are allergic to Prograf or macrolide antibiotics are also excluded.",
    "The sample is a phase 3 clinical trial for individuals with impaired glucose tolerance, impaired fasting glucose, or early type 2 diabetes who are 50 years or older and have at least one cardiovascular risk factor. The trial is testing the effectiveness of insulin glargine, omega-3 polyunsaturated fatty acids, and placebo in reducing cardiovascular events. The eligibility criteria include specific glucose tolerance levels, previous cardiovascular events, and willingness to use a self-glucose-monitoring device and self-inject insulin. Exclusion criteria include type 1 diabetes, uncontrolled hyperglycemia, and certain medical conditions. Participants must provide informed consent and be willing to complete study diaries and questionnaires.",
    "This sample is a record from a clinical trial table and includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. Specifically, this record pertains to a phase 3 trial for ulcerative colitis. The inclusion criteria for participants include being between 18-75 years old, having a diagnosis of ulcerative colitis in active phase, and having a UCDAI score between 4 and 10. Female participants must have a negative pregnancy test and agree to use contraception throughout the study period. Exclusion criteria include having severe ulcerative colitis, infectious colitis, or a history of toxic megacolon, among other conditions.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients who have been diagnosed with major depressive disorder and have been experiencing symptoms for at least 3 months. The patients must have a Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits, and a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits. The trial will test the efficacy of three drugs: vortioxetine, duloxetine, and placebo. The eligibility criteria include exclusion of patients who have previously participated in a Lu AA21004 clinical study, have a current psychiatric disorder other than major depressive disorder, have a history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition. Patients with a diagnosis of any substance abuse or dependence (except nicotine and caffeine) that has not been in sustained full remission for at least 2 years prior to screening are also excluded. Patients with a clinically significant neurological disorder, neurodegenerative disorder, or any Axis II disorder that might compromise the study are also excluded. The trial also excludes patients with abnormal laboratory values, abnormal vital signs, abnormal electrocardiogram, or a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. Patients with a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy are also excluded. Patients with a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma are also excluded. Patients with a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance are also excluded. The trial also excludes patients with a significant risk of suicide according to the investigator's opinion or has a score greater than or equal to 5 on item 10 (suicidal thoughts) of the Montgomery \u00c5sberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic obstructive pulmonary disease. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including budesonide/formoterol (symbicort), budesonide (pulmicort), and terbutaline sulfate (bricasol). The eligibility criteria for the trial are also listed, including age requirements and exclusion criteria such as a history of asthma or significant heart disease.",
    "The sample is a phase 3 clinical trial for acute coronary syndrome. The trial includes patients who are at least 40 years old and have been diagnosed with unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI). The patients must also have at least one risk factor such as diabetes mellitus, metabolic syndrome, history of cerebrovascular disease, peripheral vascular disease, previous CABG, previous documented myocardial infarction, or previous coronary revascularization. The trial involves the use of two drugs, a-002 and varespladib methyl, as well as a placebo. The eligibility criteria for the trial are listed, including exclusion criteria such as severe liver or renal disease, uncontrolled diabetes mellitus, pregnancy or nursing, history of alcohol or drug abuse, and others.",
    "The sample is a phase 3 clinical trial for participants with type 2 diabetes mellitus. The trial involves the use of two drugs, hoe901-u300 (new formulation of insulin glargine) and lantus (insulin glargine). The eligibility criteria for the trial include being over 18 years old, having a HbA1c level between 7.0% and 10% at screening, having type 2 diabetes mellitus, and having been on basal plus mealtime insulin and self-monitoring of blood glucose for at least 1 year. There are also several exclusion criteria, such as having significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period, being pregnant or breastfeeding, and not being willing to use the adaptable injection intervals on at least two days per week.",
    "The sample is a phase 3 clinical trial for advanced non-small cell lung cancer. The trial includes patients with Stage IIIb or Stage IV disease who have had previous chemotherapy with platinum-derivative and have disease in progression. The trial will test the effectiveness of four drugs: docetaxel, vinorelbine, gemcitabine, and capecitabine. The eligibility criteria include written informed consent, age over 18, histological diagnosis of NSCLC, and meeting specific medical requirements. The exclusion criteria include ECOG performance status over 2, age over 75, history of malignant neoplasm within the previous 5 years, previous treatment with docetaxel, presence of symptomatic cerebral metastasis, and other medical conditions that would contraindicate the use of the drugs in the protocol. Pregnant or nursing females are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of drugs, including placebos, and eligibility criteria for inclusion and exclusion. Inclusion criteria include a diagnosis of type 2 diabetes mellitus, being drug-na\u00efve, having a certain level of HbA1c, and being within a certain age and BMI range. Exclusion criteria include uncontrolled hyperglycemia, recent acute coronary syndrome or stroke, liver or renal disease, recent bariatric or GI surgery, cancer, contraindications to sitagliptin, blood disorders, recent treatment with anti-diabetes or anti-obesity drugs, and other uncontrolled endocrine disorders. Pre-menopausal women who are nursing or pregnant or of child-bearing potential and not practicing an acceptable method of birth control are also excluded. The trial aims to evaluate the safety and efficacy of the drugs in treating type 2 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as alogliptin, metformin, and pioglitazone, as well as a placebo. The eligibility criteria include having a historical diagnosis of type 2 diabetes mellitus, a body mass index within an acceptable range, and inadequate glycemic control. Participants must also agree to use adequate contraception if sexually active. Exclusion criteria include having participated in another clinical study within the past 90 days, having a systolic blood pressure beyond the acceptable range, and having New York Heart Association Class III or IV heart failure. Participants with a history of hypersensitivity or allergies to any DPP-4 inhibitor are also excluded.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension who are 65 years or older. The trial involves the use of drugs such as aliskiren, ramipril, hydrochlorothiazide, and amlodipine. The eligibility criteria include having a msSBP between 140 mmHg and 180 mmHg and a msDBP below 110 mmHg, as well as meeting other specific requirements. Patients with certain medical conditions, such as heart failure or a history of myocardial infarction, are excluded from the trial. The trial requires written informed consent from eligible patients.",
    "The sample is a phase 3 clinical trial for chemotherapy-induced nausea and vomiting. The trial includes children between the ages of 6 months and 17 years who are scheduled to receive chemotherapeutic agents associated with moderate, high risk, or very high risk of vomiting for a documented malignancy, or a chemotherapy regimen not previously tolerated due to vomiting. The trial also requires participants to have a predicted life expectancy of at least 3 months and to meet certain inclusion criteria, such as having a Karnofsky score of at least 60 if over 10 years old. The trial involves the use of several drugs, including aprepitant and ondansetron, as well as placebos. The eligibility criteria include exclusion criteria, such as having vomited in the 24 hours prior to treatment, being pregnant or breastfeeding, or having an active infection or uncontrolled disease that might confound the results of the study or pose unwarranted risk in administering study drug to the participant. The trial also has optional cycles 2-6, which have their own inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of sleep initiation and maintenance disorders. The trial involves the use of the drugs volinanserin and placebo. The eligibility criteria for the trial include a diagnosis of primary insomnia based on specific criteria, disturbances of sleep maintenance based on patient information, and specific criteria based on NPSG recordings during screening nights. Exclusion criteria include pregnancy or lactation, night shift work or frequent napping, high consumption of xanthine-containing beverages, recent participation in another trial, high body mass index, use of certain medications or substances, history of certain sleep disorders, and significant medical or surgical disorders. The information provided is not exhaustive and other considerations may be relevant for potential participants.",
    "The sample is a phase 3 clinical trial for head and neck cancer. The trial includes patients who are 18 years or older and have been treated for head and neck squamous cell cancer with T3-T4 and/or N2-N3 pathology. Patients with poor prognosis findings such as extranodal extension, positive resection margins, and perineural or vascular involvement are also included. The trial excludes patients with macroscopic residual disease after surgery and those who have previously been treated with anti-epidermal growth factor receptor (anti-EGFR) targeted therapies. The trial involves the use of two drugs, placebo and erlotinib. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of renal cell carcinoma. The icd-10 codes associated with the disease are listed as [\"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", \"C4A.8\"]. The trial involves the use of four drugs: bevacizumab, temsirolimus, bevacizumab, and interferon-alfa 9mu. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include requirements such as having a confirmed diagnosis of advanced renal cell carcinoma and not having prior systemic treatment for RCC.",
    "The sample is a phase 3 clinical trial for the treatment of atrial fibrillation. The trial includes Japanese male and female patients who are 20 years or older and have non-valvular atrial fibrillation documented by ECG. The patients must also have a risk of stroke and non-CNS systemic embolism. The trial will test the effectiveness of four drugs: rivaroxaban (xarelto, bay59-7939), warfarin, rivaroxaban placebo, and warfarin placebo. The eligibility criteria include exclusion of patients with significant mitral stenosis or those in whom anticoagulants are contraindicated.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have insufficient glycaemic control on diet and exercise alone. The trial involves testing the effectiveness of various drugs, including pioglitazone and linagliptin, in improving glycaemic control. The eligibility criteria include a diagnosis of type 2 diabetes mellitus, age between 18 and 80 years, and a BMI of less than or equal to 45 kg/m2. The trial also has a list of exclusion criteria, including uncontrolled hyperglycaemia, recent myocardial infarction or stroke, active liver disease, and contraindications to pioglitazone. The trial aims to determine the safety and efficacy of the drugs in improving glycaemic control in patients with type 2 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for patients diagnosed with type 2 diabetes and overt nephropathy. The trial is testing the effectiveness of the drug bosentan in treating diabetic nephropathy. The eligibility criteria include being at least 18 years old, having a body weight of at least 40 kg, and being on current treatment with angiotensin II receptor blockers for at least 3 months. Exclusion criteria include having a history of pulmonary chronic obstructive disease, cardiac failure, or coronary artery disease, being pregnant or breastfeeding, and having known hepatic disorders or AST and/or ALT levels above the normal limit. Patients must also provide written informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for infertility. The trial includes female participants between the ages of 35 and 42 who are willing to undergo COS and IVF/ICSI. The participants must have a regular menstrual cycle and meet certain physical criteria. The trial also has exclusion criteria, such as a history of endocrine abnormalities, ovarian hyper-response, or polycystic ovary syndrome. Participants must adhere to the trial schedule and cannot have any contraindications for the use of gonadotropins or gonadotropin releasing hormone antagonists. The trial also excludes participants who have a recent history or presence of alcohol or drug abuse, or known gene defects or genetic abnormalities that could affect the health of the offspring.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating patients with malignancy or cancer using highly emetogenic chemotherapeutic agents. The trial is testing the effectiveness of two drugs, ramosetron and ondansetron, in preventing nausea and vomiting in patients undergoing chemotherapy. The eligibility criteria for the trial include being over 20 years old, having an ECOG performance status of 0-2, and being able to take the study drugs orally. The exclusion criteria include having severe hypertension, heart disease, kidney disease, liver disease, GI obstruction, active gastric ulcer, or other diseases that could provoke nausea and vomiting. Patients who have had nausea and vomiting within 1 week before chemotherapy, those who need radiation therapy during the study period, and those who have known allergies or severe side effects to the study drugs are also excluded. Pregnant or lactating women, or women who wish to become pregnant, are also excluded. The investigator may also exclude others who are deemed inappropriate for the study.",
    "The sample is a phase 3 clinical trial for HIV and Hepatitis C infections. The trial is testing the effectiveness of a combination of drugs including lpv/r, peg-ifna 2a, ribavirin, and nucs. The eligibility criteria for the trial includes being over 18 years old, having a confirmed diagnosis of HIV and HCV infection, being naive for HCV-infection treatment, having chronic hepatitis and/or compensated cirrhosis, having a CD4+ count of > 350 cell/mmc, being HIV-RNA negative during the previous six months, being on stable HAART including r/LPV for > 6 months, having genotype available at baseline and no mutations associated with resistance to PI or no virologic failure on PI treatment, and being free of any clinically significant disease (other than HIV and HCV) that would interfere with study evaluations. The exclusion criteria includes having cirrhosis score Child-Pugh B/C, having HIV-related thrombocytopenia, having neutrophils count < 1500/mmc, having Hb value < 11 g/dL, having creatinine value > 1.5 mg/dL, being pregnant or wishing to become so, having any cause of liver disease other than chronic hepatitis C, status of liver decompensation or any other condition consistent with decompensated liver disease, being an alcohol abuser, having autoimmune hepatitis, prior treatment with PEG-IFN or ribavirin, illicit drugs abuse that in the opinion of the investigator could lead to poor compliance with the terms of the protocol, having active heart disease, having pre-existing severe depression or condition of severe psychiatric disorders, having uncompensated diabetes, having active opportunistic infections or major opportunistic infections during the previous 12 months, having known hypersensitivity or contraindication to study medications, and having any other condition that in the opinion of the investigator will make the subject unsuitable for enrollment or will interfere with the subject participating in or completing the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of fibromyalgia. The trial involves the drug pregabalin and the eligibility criteria includes having met the criteria for a previous fibromyalgia protocol and having received pregabalin or placebo under double-blind conditions. Patients who experienced a serious adverse event during the previous study related to the medication are excluded from participating in this trial. The sample also includes the disease name, icd-10 code, and inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for children aged 6 months to 7 years with Atopic Dermatitis. The trial is testing the effectiveness of the drugs broncho-vaxom and placebo - cap. The eligibility criteria include having a Hanifin-Rajka or Williams et al diagnosis of Atopic Dermatitis with affected body surface area between 15% and 70%, and a SCORAD score between 25 and 70. Exclusion criteria include being under general corticotherapy within one month of study start, having immunodeficiency or malignant disease, having a SCORAD score outside of the range of 25 to 70, and having a known allergy or previous intolerance to the trial drug or any of the corticoids used. Participants must also have written informed consent from their parents or legal guardian.",
    "The sample is a phase 3 clinical trial for asthma. The trial is looking at the effectiveness of a drug called \"elpenhaler active - diskus placebo\". The trial is looking for participants who are between the ages of 18-65 and have been diagnosed with asthma for at least 6 months. Participants must have a FEV1 (forced expiratory volume in one second) of at least 50% and no more than 80% predicted, and must have a reversibility of at least 12%. Participants must also have stable asthma for at least 4 weeks and have been on inhaled steroids (ICS) at a stable dose within the previous 30 days. Other inclusion criteria include having a PIF (peak inspiratory flow) of 30-90 lt/min and providing informed consent. Exclusion criteria include a history of other pulmonary disease, recent asthma exacerbation or respiratory infection, hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral steroid dose increase, heavy smoking, recent change of asthma medication, seasonal asthma alone, history of severe heart disease, pregnancy or lactation, and recent use of a \u03b2-blocker, NSAID or antiallergic/antihistaminic medication.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial involves the use of lapaquistat acetate and stable statin therapy, or stable statin therapy alone. The eligibility criteria include having a low-density lipoprotein cholesterol level within a certain range, having a mean triglyceride level below a certain level, and having clinical laboratory evaluations within the defined reference range. Exclusion criteria include having certain liver or kidney conditions, diabetes, a history of cancer within the past 5 years, and other serious diseases or conditions. Participants must also agree to use acceptable forms of contraception throughout the course of the study.",
    "The sample is a phase 3 clinical trial for advanced gastric adenocarcinoma. The trial is testing three different drugs: s-1, s-1 plus cddp, and 5-fu plus cddp. The eligibility criteria for the trial include being 18 years or older, having a performance status of 0, 1, or 2, and having a life expectancy of at least 3 months. Additionally, certain blood counts and liver and kidney function tests must be within normal limits. Exclusion criteria include having certain medical conditions such as interstitial pneumonia or myocardial infarction within the last 6 months.",
    "The sample is a phase 3 clinical trial for patients with venous thromboembolism. The trial involves the use of two drugs, enoxaparin and dabigatran etexilate. The eligibility criteria for the trial include patients scheduled to undergo primary, unilateral, elective total hip arthroplasty, who are 18 years or older and have given written informed consent. Exclusion criteria include patients weighing less than 40 kg, history of bleeding diathesis, major surgery or trauma within 3 months of enrollment, ongoing treatment for Venous Thromboembolism (VTE), and various other medical conditions. The trial also excludes patients who have participated in a clinical trial within 30 days of randomization and those with a history of alcohol or drug abuse.",
    "The sample is a phase 3 clinical trial for high-risk rhabdomyosarcoma or ectomesenchymoma. The trial includes patients with newly diagnosed disease and metastatic disease. Patients must have undergone an initial surgical procedure within the past 42 days to provide a definitive diagnosis. Patients with parameningeal and paraspinal tumors are allowed, and those with evidence of intracranial extension are eligible. Patients must have a performance status of 0-2, and meet certain blood count, renal function, and cardiac function criteria. Patients must not be pregnant or nursing, and fertile patients must use effective contraception during the study and for at least one month after completion. Patients must not have received prior chemotherapy or radiotherapy, and must not receive certain concurrent therapies during the trial.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial includes patients who have a confirmed diagnosis of MS and are ambulatory with an EDSS score of 0-5.5. Patients must also be in a relapse-free, stable neurological condition and free of corticosteroid treatment for 30 days prior to screening. The trial also has inclusion and exclusion criteria, including age requirements, use of birth control for women of child-bearing potential, and exclusion of patients with progressive forms of MS or who have used certain medications within a certain timeframe. The trial involves the use of glatiramer acetate (GA) and a placebo, and patients must be willing and able to comply with the protocol requirements for the duration of the study.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for breast neoplasms, which is a list of diseases. The icd-10 codes for the diseases are also provided. The trial involves two drugs, capecitabine and sunitinib malate. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. In this case, the inclusion criteria require prior treatment with an anthracycline and a taxane either concurrently or sequentially in the neoadjuvant, adjuvant, and/or advanced disease treatment settings. The exclusion criteria include prior treatment with regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines and taxanes or multiple anthracyclines/taxanes treatments, as well as any prior regimen with capecitabine.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on smoking cessation and the associated diseases and icd-10 codes are listed. The drugs being tested are placebo and varenicline tartarate. The eligibility criteria for the trial are also listed, including requirements for subjects to be current smokers with mild to moderate COPD confirmed by spirometry, and exclusion criteria such as having attempted to quit smoking in the past 3 months or having been previously randomized in a study that included varenicline.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe plaque-type psoriasis. The trial involves the use of the drug secukinumab 150 mg and a placebo. The eligibility criteria for the trial include a diagnosis of moderate to severe plaque-type psoriasis for at least 6 months, a Psoriasis Area and Severity Index (PASI) score of 12 or greater, an Investigator's Global Assessment (IGA) score of 3 or greater, and a Total body surface area (BSA) affected of 10% or greater. Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy is also required. Exclusion criteria include current forms of psoriasis other than chronic plaque-type psoriasis, current drug-induced psoriasis, previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor, significant medical problems such as uncontrolled hypertension or congestive heart failure, and history of lymphoproliferative disease or malignancy within the past 5 years. Pregnant or nursing women are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with inflammatory bowel disease and intestinal fistula. The trial is testing the effectiveness of the drug ast-120. The eligibility criteria include having a documented diagnosis of Crohn's disease, a CDAI score of less than 400, and a platelet count of at least 100,000/uL. Patients must also have at least one draining fistula and be willing to comply with all protocol procedures for the duration of the study. Exclusion criteria include non-response to infliximab or other biological immunosuppressants, symptomatic strictures, and other major physical or psychiatric illnesses within the last 6 months. Patients must be able to attend all visits required by the protocol.",
    "The sample is a phase 3 clinical trial for patients with occasional or recurrent episodes of gastric or intestinal spasm-like pain or discomfort, such as those with irritable bowel syndrome. The trial is testing the effectiveness of hyoscine butylbromide, a drug that helps relieve muscle spasms in the gastrointestinal tract. The eligibility criteria include patients aged 18 to 70 who have experienced the pain for at least 3 months and have a pain intensity score of at least 4 cm on the VAS score. Patients with certain concomitant diseases, severe pain states of organic origin, or taking certain medications are excluded from the trial. Patients who are pregnant or lactating, have known hypersensitivity to N-butylscopolammonium bromide, or have alcohol or drug abuse are also excluded. The trial requires written informed consent from the patient and the ability to complete the entire trial procedure according to the protocol.",
    "The sample is a phase 3 clinical trial for low back pain. The trial includes participants who have been diagnosed with low back pain at least 3 months before the screening or washout period and have taken a stable dose of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Cyclo-Oxygenase 2 (COX-2) selective inhibitors. The trial also includes participants whose average pain intensity is more than or equal to 4.0 centimeters on Visual Analog Scale over the last 48 hours after the completion of screening. Women with childbearing potential must have a negative pregnancy test and must be practicing a highly effective method of birth control. The trial excludes participants who have taken tramadol or tramadol HCl or acetaminophen, or narcotic analgesic tablet within 30 days before investigational product administration. Participants with tumor or infection in meninges or spinal cord, fibromyalgia, reflex sympathetic dystrophy, causalgia, acute spinal cord compression, acute nerve root compression, severe lower extremity weakness or numbness, regional pain syndrome, meningitis, diskitis, back pain because of secondary infection or tumor, or pain caused by a confirmed or suspected neoplasm are also excluded. Participants who have taken analgesic, sedative-hypnotic, or muscle relaxant other than a stable dose of NSAIDs or COX-2 selective inhibitors within 5 times the half-life of the concerned agent before investigational product administration are also excluded. The drugs being tested in the trial are tramadol hcl/acetaminophen extended release and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of persistent bronchial asthma using the drug ciclesonide (xrp1526). The trial is open to males and females aged 12 years or older who have a history of persistent bronchial asthma for at least 6 months and have used bronchodilators or methylxanthines for at least 1 month before screening. Participants must have a FEV1 (forced expiratory volume in one second) of 60 to 90% of predicted and be non-smokers. The trial has a list of exclusion criteria, including a history of life-threatening asthma, other pulmonary diseases, recent upper respiratory infection, use of systemic steroids within 6 months before screening, and pregnancy or breastfeeding. The trial also excludes participants with clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease, abnormal clinical laboratory parameters, history of drug or alcohol abuse, or treatment with any investigational product within 30 days prior to study entry.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial includes patients who are treated as outpatients or inpatients, have a good command of German, score 85 or greater in the IQ test, have a diagnosis of ADHD according to ADHD-CL (DSM IV) and WRI-WRAADDS > 28 points, have had ADHD symptoms since childhood, have a body mass index of 20 or greater, are willing to eat breakfast, are willing and able to come to observation appointments, and have given written consent to participate in the study. Patients who have been treated with psychostimulants in the past 2 weeks, have inconsistencies in the CAARS- S:L >= 8 (Inconsistency Index), work night shifts, have alcohol, medication or drug dependency in the past 6 months or manifest drug abuse, have a diagnosis of a psychosis, have had epileptic attacks in the past, have EEG results which suggest epilepsy, have clinically relevant liver disease, have clinically relevant hyperthyroidism, have an acute depressive episode, illnesses with schizophrenic symptoms, acute manic episode, bipolar disorder, diagnosis of a tic disorder, acute anorexia, acute prominent panic disorder and generalised anxiety, clinically relevant kidney disorders, known high blood pressure, known occlusive arterial disease, known angina pectoris, known coronary heart disease and state after myocardial infarction, known tachycardial arrhythmias, post-stroke status, known elevated intra-occular pressure, known enlarged prostates, have participated in a clinical study within the past 30 days, have participated in this study at an earlier point in time, are simultaneously participating in another clinical trial, are women of child-bearing age without adequate contraception, have terminal illness (e.g. cancer), or are pregnant or in a lactation period are excluded from the trial. The drugs being tested are methylphenidate hydrochloride and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial is testing the effectiveness of the drug LY2216684 (edivoxetine) in combination with selective serotonin reuptake inhibitors (SSRIs) such as escitalopram, citalopram, sertraline, fluoxetine, paroxetine, and fluvoxamine. The eligibility criteria include being an adult who is competent and able to give informed consent, meeting the criteria for major depressive disorder as defined by the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria, and having experienced a minimal clinically meaningful improvement with SSRIs. The sample also includes exclusion criteria such as having another primary psychiatric illness, unstable medical conditions that contraindicate the use of LY2216684, and a history of treatment-resistant depression.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with essential hypertension, defined as having a sitting trough clinic systolic blood pressure between 160 and 190 mm Hg inclusive at Day minus 1 and 24-hour mean systolic blood pressure greater than or equal to 140 mm Hg and \u2264 180 mm Hg at Day 1. The trial also includes eligibility criteria for females of childbearing potential who are sexually active, clinical laboratory evaluations, and willingness to discontinue current antihypertensive medications. The exclusion criteria include sitting trough clinic diastolic blood pressure greater than 119 mmHg at Day minus 1, recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, and other serious diseases or conditions that would compromise subject safety.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who have had asthma for at least 12 months and have used inhaled corticosteroids for at least 4 weeks prior to the screening visit. The trial also requires patients to demonstrate FEV-1 of 40-80% of predicted normal values at the screening and baseline visits, and documented reversibility of 15% within 12 months of the screening visit. The trial includes both males and females aged 12 years and above who are otherwise healthy and provide written informed consent. However, patients with life-threatening asthma within the past year or during the run-in period, history of systemic corticosteroid medication within 3 months before the screening visit, and history of omalizumab use within the past 6 months are excluded from the trial. Other exclusion criteria include patients with significant, non-reversible pulmonary disease, known HIV-positive status, smoking history equivalent to \"10 pack years\", current smoking history within 12 months prior to the screening visit, and current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit. Patients who are confined in an institution are also excluded from the trial. The trial includes a list of drugs, including fluticasone propionate/formoterol fumarate 250/10, placebo, fluticasone propionate/formoterol fumarate 100/10, fluticasone propionate 250, and formoterol fumarate 10.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of HIV infections using the drug Maraviroc. The trial is looking for subjects who are failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA greater than or equal to 1000 copies/ml. The subjects must also have only R5 HIV-1 at screening as verified by the Monogram Biosciences Trofile assay and be at least 16 years old or the minimum adult age as determined by local regulatory authorities or directed by local law. The exclusion criteria include having failed prior treatment with any CCR5 antagonist, being in any ongoing CCR5 trial, or having previously prematurely discontinued Maraviroc in trials. The diseases being studied are HIV infections and the corresponding ICD-10 code is Z21.",
    "The sample is a phase 3 clinical trial that involves patients with coronary artery disease, chronic kidney disease, hypovitaminosis d, and secondary hyperparathyroidism. The trial is testing the effectiveness of paricalcitol compared to a placebo. The eligibility criteria for the trial include being over 18 years old, having a history of established coronary artery disease, having stage 3 or 4 chronic kidney disease, having low levels of serum 25-hydroxyvitamin D, and having evidence of secondary hyperparathyroidism. The trial also has exclusion criteria, such as a history of myocardial infarction, stroke, or cardiac surgery within 6 months of enrollment, uncontrolled blood pressure or diabetes, and a history of malignancy within the past 5 years.",
    "The sample is a record of a clinical trial in phase 3, involving the treatment of graft vs host disease and kidney transplantation. The trial includes the use of drugs such as sirolimus, cyclosporine, mycophenolate mofetil, corticosteroids, and daclizumab. The eligibility criteria for the trial include the requirement for kidney transplantation and the donor must be at least 60 years old. The exclusion criteria include current systemic infection, unstable angina or treatment for serious arrhythmia, and cancer within the previous 5 years.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of glaucoma and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, t2345 and prostaglandin. The eligibility criteria for the trial includes adult patients who have been diagnosed with glaucoma, while the exclusion criteria includes patients under the age of 18.",
    "The sample is a phase 3 clinical trial for non-constipation irritable bowel syndrome. The trial includes a list of icd-10 codes for the disease and two drugs, rifaximin and placebo. The eligibility criteria for the trial include a confirmed IBS diagnosis per Rome II criteria, a colonoscopy within 2 years, and active symptoms of non-constipation IBS at baseline. The exclusion criteria include symptoms of constipation, history of other gastrointestinal diseases, type 1 or 2 diabetes, and lactose intolerance not controlled by lactose-free diet.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on non-valvular atrial fibrillation and includes a list of ICD-10 codes associated with the disease. The trial also involves testing three different doses of a drug called du-176b. The eligibility criteria for the trial are listed, including inclusion criteria for patients with NVAF and SRI or NVAF and Normal/MiRI, and exclusion criteria for patients on hemodialysis, at high risk for bleeding, receiving certain anticoagulant drugs, or with evidence of hepatic function test abnormalities.",
    "The sample is a phase 3 clinical trial for the treatment of synovitis, osteoarthritis, joint diseases, and muskuloskeletal diseases. The trial involves the use of chondroitin sulphate (condrosan) and a placebo drug. The eligibility criteria for the trial include having primary OA of the knee with synovitis criteria, OA of radiological stages 2 and 3 according to Kellgren-Lawrence, minimum joint space width \u22652 mm in the medial femorotibial compartment on standing knee X-ray, and VAS of pain while walking \u226540 mm. The exclusion criteria include having a known allergy to chondroitin sulphate, progressive or serious pathologies, other bone and articular diseases, and having taken certain medications within a certain timeframe. The trial also allows for the use of NSAIDs and acetaminophen as rescue medication.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of pain caused by a nonmalignant condition. The trial involves the drug \"alo-01\" which is a combination of morphine sulfate and naltrexone hydrochloride er. The eligibility criteria for the trial includes being between the ages of 18-70, having a history of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline, and agreeing to refrain from taking any opioid medications other than the study medication during the study period. The exclusion criteria includes having a documented history of allergic reaction or clinically significant intolerance to morphine or other opioids, being pregnant or breast-feeding, receiving chemotherapy, having an active malignancy of any type or having been diagnosed with cancer within the past three years (excluding squamous or basal cell carcinoma of the skin), having a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit, and having a Body Mass Index (BMI)>45kg/m2.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of breast neoplasms. The trial involves the use of two drugs, sunitinib + capecitabine and capecitabine, and the eligibility criteria for the trial are listed. Patients with locally advanced or metastatic disease that can be measured, including those with bone-only disease, are eligible to participate if they have previously been treated with an anthracycline and a taxane in any setting and have progressed on first or second line regimen or adjuvant regimen if disease-free interval is less than 12 months. The exclusion criteria include a history of inflammatory carcinoma if there is no other measurable disease, more than 2 chemotherapy agents in the advanced disease setting, and brain metastases.",
    "The sample is a phase 3 clinical trial for patients aged 40 years or older who are at risk of venous thromboembolic events due to acute medical conditions such as heart failure, active cancer, acute ischemic stroke, acute infectious and inflammatory diseases, acute respiratory insufficiency, or additional risk factors for VTE. The trial includes the use of drugs such as rivaroxaban, enoxaparin, and their placebos. The eligibility criteria include certain inclusion and exclusion criteria, such as not having conditions that contraindicate the use of antithrombotic therapy with the Low Molecular-Weight Heparin (LMWH) enoxaparin, not having conditions that may increase the risk of bleeding, and not having required drugs or procedures that may interfere with the study treatment.",
    "The sample is a phase 3 clinical trial for acute bacterial rhinosinusitis (ABRS) in children aged 3 months to less than 15 years. The trial is investigating the effectiveness of amoxicillin-potassium clavulanate combination (CVA/AMPC) in treating ABRS. The eligibility criteria include having ABRS with inflammation as a bacterial infection, having moderate or severe symptoms, and having a body weight between 6 and 40 kilograms. The trial also has exclusion criteria, such as having a severe infection that requires surgical treatment, having a serious underlying disease, or having a known hypersensitivity to any component of CVA/AMPC or penicillin. The trial requires written informed consent from the child's legally acceptable representative, and if the child is 12 years or older, the child must also provide written informed consent.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is testing the effectiveness of a combination of three drugs: fluorouracil, irinotecan hydrochloride, and leucovorin calcium. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the colon or rectum with metastatic and unresectable disease, measurable disease outside the field of prior irradiation, and no brain metastases. Patients must also have a Karnofsky performance status of 60-100%, certain blood counts within normal ranges, and no contraindications to chemotherapy. Additionally, patients must not have chronic diarrhea or enteropathy, coronary insufficiency or symptomatic cardiac disease, or any other malignancy unless it has been curatively treated. Prior to the trial, patients must not have undergone extensive resection or received any other concurrent anticancer therapy.",
    "The sample is a phase 3 clinical trial for acute coronary syndrome. The trial includes participants who are 18 years or older and have a presumed diagnosis of STE-ACS with onset of symptoms of more than 20 minutes and less than 12 hours. The trial involves the use of two drugs, bivalirudin and heparin. The eligibility criteria include providing written informed consent, undergoing emergent angiography, and meeting certain medical criteria. Exclusion criteria include recent surgery, bleeding diathesis, and allergy to study medications. The trial does not allow participants with a creatinine clearance of less than 30 milliliter/minute or those who have previously enrolled in the study.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast cancer. The trial involves the use of bevacizumab, placebo, and standard chemotherapy. The eligibility criteria include being at least 18 years old, having confirmed breast cancer with measurable or non-measurable metastatic disease that has progressed, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having a life expectancy of at least 3 months. Exclusion criteria include prior hormonal therapy only as treatment for metastatic disease without chemotherapy, HER2-positive status, and inadequate organ function. The trial also has a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for advanced Parkinson's disease. The trial includes participants who have been diagnosed with idiopathic Parkinson's disease and are responsive to levodopa. The participants must also demonstrate severe motor fluctuations despite optimized treatment options. The trial excludes participants who have undergone surgery for the treatment of PD, have contraindications to levodopa, or have any neurological deficits that may interfere with the study assessments. The trial involves the use of levodopa carbidopa intestinal gel, levodopa carbidopa oral encapsulated immediate release tablets, and placebo gel and capsules. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. The trial includes pediatric patients from neonates to under 17 years old who have confirmed malignant disease and are scheduled to receive at least one of the moderately or highly emetogenic chemotherapeutic agents on Study Day 1. The trial involves the use of drugs such as palonosetron, ondansetron, and placebo. The eligibility criteria include written informed consent, patient weight of at least 3.2 kg, and a negative pregnancy test for female patients who have attained menarche. The exclusion criteria include lactating or pregnant female patients, patients with a known history of allergy to any component or other contraindications to any 5-HT3 receptor antagonists, and patients who received any drug with potential anti-emetic effect within 24 hours prior to administration of study treatment.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe low back pain. The trial includes patients who have been diagnosed with low back pain for at least 6 months and are currently being treated with a stable daily maintenance dose of non-opioid analgesic medication. The trial will test the effectiveness of buprenorphine compared to a placebo. Patients must meet certain inclusion criteria, such as having stable health and being willing to comply with all protocol required visits and assessments. Patients who have current cancer related pain, are receiving opioid analgesic medication >10 mg MSE per day, or have a history of other chronic painful conditions are excluded from the trial. Other exclusion criteria include allergy or contraindications to any opioid or acetaminophen, surgical procedure for relief of pain within 6 months, and moderate to severe hepatic or renal impairment.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on breast neoplasms, which are listed in the \"diseases\" field. The \"icdcodes\" field contains a list of ICD-10 codes associated with the diseases. The \"drugs\" field lists the drugs being tested in the trial, which include sunitinib, paclitaxel, and bevacizumab. The \"criteria\" field contains the eligibility criteria for the trial, including inclusion criteria such as a diagnosis of advanced breast cancer and measurable disease, and exclusion criteria such as no prior treatment with cytotoxics in the advanced disease setting and treatment with a taxane in the adjuvant setting unless disease free interval >12 months after end of treatment.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis patients who are intolerant to methotrexate or have an inadequate response to other disease-modifying drugs. The trial is testing the effectiveness of the drug abatacept. The eligibility criteria include completion of a previous phase II study, not receiving other biologics, and meeting certain health requirements. Exclusion criteria include pregnancy, previous use of investigational drugs, and certain medical conditions. The sample includes a list of disease names, corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The trial includes a list of drugs such as dexamethasone, asparaginase, cyclophosphamide, and others. The eligibility criteria for the trial include having histologically confirmed acute lymphoblastic leukemia, not having secondary ALL, and having more than 4 weeks since prior chemotherapy and steroids. The exclusion criteria include having a prior disease that would prevent treatment with chemotherapy. The diseases are listed as 'leukemia' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with essential hypertension, defined as having a sitting trough clinic systolic blood pressure between 150 and 180 mm Hg inclusive at Day minus 1 and a 24-hour mean systolic blood pressure between 130 and 170 mm Hg inclusive at Day 1. The trial also includes female patients of childbearing potential who are sexually active and agree to use adequate contraception. Patients must be willing to discontinue current antihypertensive medications at the Screening Day minus 21 visit. The trial excludes patients with sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1, recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, and other serious diseases or conditions that would compromise subject safety or might affect life expectancy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of breast neoplasm. The trial involves the use of two drugs, taxol and tocosol paclitaxel. The eligibility criteria for the trial include patients with a histologic diagnosis of breast carcinoma, stage IV (M1) disease, and who are 18 years of age or older. Patients who have been treated with a taxane within the past year or whose tumor tissue shows overexpression of HER2/neu are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients between the ages of 18 and 80 who have been diagnosed with active rheumatoid arthritis for at least 6 months and have had an inadequate response to at least one non-biological disease-modifying anti-rheumatic drug (DMARD). The trial involves the use of rituximab and anti-inflammatory drugs. The eligibility criteria include various medical conditions and exclusions, such as a history of cancer, significant cardiac or pulmonary disease, and pregnancy or lactation. The trial is divided into two stages, with different inclusion and exclusion criteria for each stage.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for chronic osteoarthritis of the hip or knee, pain assessment, and arthralgia. The trial involves the use of a drug called cg5503 ir and tapentadol. The table also includes a list of icd-10 codes for the diseases, eligibility criteria for the trial, and exclusion criteria. The inclusion criteria include a clinical diagnosis of chronic osteoarthritis, qualification for joint replacement surgery, and the need for daily analgesic medication. The exclusion criteria include a history of seizure disorder or epilepsy, chronic hepatitis B and C, and current treatment with certain medications.",
    "The sample is a phase 3 clinical trial that involves patients with heart diseases and pulmonary hypertension. The trial is testing the effectiveness of the drug tezosentan compared to a placebo. The eligibility criteria for the trial include patients who are 18 years or older, undergoing complex cardiac surgery on CPB, and have systolic PAP > 40 mmHg or mean PAP > 30 mmHg. Patients with pre-operative pulmonary hypertension due to left heart disease with systolic PAP > 60 mmHg are also eligible. Exclusion criteria include patients with systolic blood pressure < 100 mmHg, significant chronic lung disease, emergency surgery, pregnant/breast-feeding, and severe concomitant illness limiting life expectancy to < 6 months. The trial requires signed written informed consent from all participants.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of venous thromboembolism. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including 15mg du-176b, 30mg du-176b, and fondaparinux. The eligibility criteria for the trial include patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs, while exclusion criteria include patients on hemodialysis or at a high risk for bleeding or thromboembolism, those receiving another antithrombotic therapy and unable to suspend it, and those with evidence of hepatic function test abnormalities.",
    "The sample is a phase 3 clinical trial for the treatment of restless legs syndrome. The trial includes patients who have been diagnosed with RLS according to the diagnostic criteria established by the International RLS Study Group and have an IRLS score of at least 15. Patients who have used dopamine agonists or gabapentin within 1 week before or any anti-RLS treatment within 2 weeks before the start of the pretreatment observation period are excluded from the trial. Patients with an estimated creatinine clearance of less than 60 mL/min, pregnant or lactating women, individuals with serum ferritin levels below 20 ng/mL, and those with movement disorders and/or abnormal neurological findings are also excluded from the trial. The drug being tested is asp8825.",
    "The sample is a phase 3 clinical trial for the treatment of obesity and type 2 diabetes mellitus. The trial involves the use of two drugs, taranabant and a placebo comparator. The eligibility criteria for the trial include having a BMI between 27 kg/m2 and 43 kg/m2 and HbA1c between 7.0% and 10%. However, individuals with a history of major psychiatric disorder, blood pressure greater than 160/100, use of any antihyperglycemic agent other than metformin, or triglycerides greater than 600 mg/dL are excluded from the trial. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for gastric cancer. The trial includes patients with metastatic or locally advanced, unresectable disease who have experienced disease progression during or within 4 months after the last dose of the first-line therapy. The trial involves the use of placebo and paclitaxel drugs. The eligibility criteria include signed informed consent, histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma, good organ function, and good performance status. The exclusion criteria include previous systemic therapy with other anti-angiogenic drugs, uncontrolled high blood pressure, symptomatic or poorly controlled heart disease, and evidence of central nervous system metastasis at baseline.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of ulcerative colitis, with a list of corresponding ICD-10 codes. The trial involves the use of drugs, specifically abatacept and placebo, and includes eligibility criteria for participants such as being 18 years or older, having had ulcerative colitis for at least 3 months, and having moderate to severe active ulcerative colitis with inadequate response or intolerance to standard treatment.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast cancer who are predicted to start chemotherapy for the first time. The trial is testing the effectiveness of the drug epoetin alfa in treating anemia caused by cancer or radiotherapy/chemotherapy. The trial has inclusion and exclusion criteria, including age, weight, medical history, and previous treatments. Patients must also sign an informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial includes patients who have tested positive for hepatitis C virus and have a compatible liver biopsy. Patients must also be treatment naive, between the ages of 18-65, and able to give informed consent. The trial involves the use of two drugs, consensus interferon (interferon alfacon-1) and ribavirin, and consensus interferon alfa (cifn) and ribavirin. Eligibility criteria include having compensated liver disease and meeting certain laboratory result requirements. Exclusion criteria include having liver disease in addition to chronic hepatitis C, decompensated liver disease, and current substance use disorder. Patients with active or uncontrolled psychiatric disease and those with certain medical conditions are also excluded.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who have been regularly treated with systemic corticosteroids and high dose inhaled corticosteroids for at least 6 months prior to the trial. The patients must also be taking an additional controller medication for at least 3 months or have failed an additional controller medication for at least 3 successive months during the prior 12 months. The trial aims to test the effectiveness of mepolizumab compared to a placebo and oral corticosteroids in treating eosinophilic asthma. The eligibility criteria include persistent airflow obstruction, evidence of asthma, and prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma. The exclusion criteria include current or former smokers with a smoking history of >=10 pack years, presence of a clinically important lung condition other than asthma, and a current malignancy or previous history of cancer in remission for less than 12 months prior to screening.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and bipolar I disorder. The trial involves the use of the drug quetiapine fumarate. The eligibility criteria include the patient's ability to provide written assent and the parent or legal guardian's ability to provide written informed consent. The patient must have a documented clinical diagnosis of schizophrenia or bipolar I disorder and must have previously enrolled in either double-blind Study D1441C00149 or D1441C00112. The patient's parent or legal guardian must be able to accompany them to each scheduled study visit. Exclusion criteria include pregnancy or lactation, known intolerance or lack of response to previous treatment with quetiapine, and previous participation in the study.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying chronic kidney disease and insulin resistance. The associated ICD-10 codes for these diseases are listed. The drug being tested is rosiglitazone. The eligibility criteria for participants include having stage 4 CKD, a BMI of 30 or less, and fasting glucose levels below 7 mmol/l. There are also exclusion criteria listed, such as a diagnosis of diabetes mellitus requiring insulin use, significant co-morbidities, and a history of alcohol abuse. Female patients who are pregnant, intend to become pregnant during the study period, or are lactating are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have provided informed consent and currently meet the DSM-IV-TR criteria for schizophrenia. The trial also requires patients to have normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG). Patients with a current psychotic episode (schizophrenia exacerbation) of less than 2 weeks duration at Visit 1 are also included. The trial excludes patients with schizoaffective disorder, schizophreniform disorder, and other psychotic disorders, as well as bipolar I and II disorder, pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders, and women who are pregnant or breast feeding. The trial will test the efficacy of cariprazine, aripiprazole, and placebo.",
    "The sample is a phase 3 clinical trial for patients with esophageal or gastric cancer. The trial involves the use of drugs such as cisplatin, epirubicin hydrochloride, fluorouracil, and leucovorin calcium. The eligibility criteria include having a histologically diagnosed adenocarcinoma of the stomach or gastroesophageal junction, having had en bloc resection of all known tumor, and having tumor extension beyond muscularis propria and/or nodal involvement without evidence of M1 disease. Patients with known unresected cancer, recurrent cancer, microscopic evidence of tumor at the distal or proximal line of stomach resection, noncontiguous resection of tumor, or M1 (metastatic) disease are ineligible. The trial also has requirements for prior therapy, patient characteristics, and initial laboratory values.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The trial includes patients who have consented to participate and meet certain eligibility criteria, such as being female, 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having a diagnosis of invasive adenocarcinoma of the breast made by core needle biopsy. The trial also includes a list of drugs, including capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (adriamycin), and gemcitabine hydrochloride. The eligibility criteria include various medical tests and assessments, such as left ventricular ejection fraction (LVEF) assessment, EKG, and liver imaging. The exclusion criteria include various medical conditions and treatments, such as prior therapy with anthracyclines, taxanes, capecitabine, 5-FU (fluorouracil), gemcitabine, or bevacizumab for any malignancy, and pregnancy or lactation at the time of proposed randomization.",
    "The sample is a phase 3 clinical trial for breast cancer patients who are not suitable for surgery or radiotherapy alone. The trial includes patients with locally advanced or metastatic stage of the disease. The trial involves the use of drugs such as taxane, avastin, and xeloda. The eligibility criteria include having an ECOG performance status of 0-2, histologically confirmed carcinoma of the breast with no overexpression of HER2, and having either measurable or non-measurable target lesions according to RECIST criteria. Patients must have undergone complete staging work-up within 4 weeks prior to registration. The trial also includes exclusion criteria such as known hypersensitivity reaction to the compounds or incorporated substances, previous chemotherapy for metastatic disease, concurrent immunotherapy or hormonal therapy, and life expectancy of less than 3 months.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of diverticulitis. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, including mesalazine and a placebo. The eligibility criteria for the trial are also listed, including a diagnosis of left-sided uncomplicated diverticular disease confirmed by computed tomography, the presence of at least one diverticulum of the left colon, and a recent attack of left-sided uncomplicated diverticulitis responding to antibiotics and/or dietary modification within the last 6 months. The exclusion criteria are also listed, including complicated diverticular disease, right-sided diverticulitis, previous colonic surgery, and various other medical conditions.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B infection. The trial is testing the effectiveness of several drugs, including tdf, ftc/tdf, tdf placebo, and ftc/tdf placebo. The trial is looking for participants who are 18 to 75 years old, have had positive serum HBsAg for at least 6 months, and have HBV DNA levels of at least 10^3 IU/mL. Participants must also be receiving treatment with lamivudine and have confirmation of HBV reverse transcriptase mutation(s) known to confer resistance to lamivudine. The trial has several inclusion and exclusion criteria, including no prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other investigational agents for HBV infection other than lamivudine or adefovir dipivoxil. Participants must also have a calculated creatinine clearance of at least 50 mL/min, hemoglobin levels of at least 10 g/dL, and neutrophil levels of at least 1000 /mm^3. The trial excludes pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study, and males and females of reproductive potential who are not willing to use an effective method of contraception during the study. Other exclusion criteria include decompensated liver disease, interferon or pegylated interferon therapy within 6 months of the screening visit, and significant renal, cardiovascular, pulmonary, or neurological disease.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the treatment of metastatic melanoma. The trial involves the use of two drugs, dacarbazine and temozolomide, and has specific eligibility criteria for potential study participants. These criteria include having confirmed stage 3 or stage 4 melanoma, having at least one melanoma tumor that is 1cm x 1cm or greater in size, and having normal blood chemistries and blood cell counts. There are also exclusion criteria, such as previous chemotherapy treatment for melanoma and melanoma lesions in the brain or liver. The sample includes both inclusion and exclusion criteria for potential study participants.",
    "The sample is a phase 3 clinical trial for patients with partial epilepsy. The trial includes patients who are at least 18 years old and have been on a stable dose of Oxcarbazepine for at least one month prior to screening. Patients must have had at least two partial onset seizures with or without secondary generalization that were refractory to existing anti-epileptic drug therapy during the baseline period. Patients must also have a weight between 50 kg and 100 kg and be of Caucasian ethnicity. The trial excludes patients with epilepsy secondary to progressive metabolic disease, malignant neoplasm, substance abuse, or active infection, as well as those with Lennox-Gastaut syndrome or generalized epilepsy as a primary diagnosis. Patients with severe cardiac, pulmonary, hematological, hepatic, renal, or neoplastic pathology are also excluded. Additionally, patients with a history of clinically relevant psychiatric illness and/or drug abuse, drug addiction, or alcoholism within the last 2 years are excluded. Patients who have taken certain medications, such as psychotropic drugs, anticholinergic drugs, anti-parkinson medication, \u03b11-antagonists, \u03b12-antagonists, carbamazepine, topiramate, felbamate, and vigabatrin, are also excluded. The trial requires patients to comply with study stipulations and provide written informed consent to participate.",
    "The sample is a phase 3 clinical trial that involves patients with coronary artery disease, postprandial hyperglycemia, and vitamin D deficiency. The trial aims to investigate the effects of vitamin D on these conditions. The trial has inclusion criteria such as age between 40-75, angiographically verified coronary artery disease, and serum 25-OH- vitamin D levels below a certain threshold. The trial also has exclusion criteria such as acute coronary syndrome or cerebrovascular event within the previous 1 month, BMI over 40 kg/m\u00b2, and ongoing treatment with certain medications. The trial has a list of diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of sleep initiation and maintenance disorders and insomnia. The trial involves the use of the drugs eplivanserin and placebo. The eligibility criteria for the trial include being an out-patient, having primary insomnia according to DSM-IV-TR-Axis I criteria, complaining of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month, and reporting impact on daytime functioning associated with sleep maintenance insomnia. Exclusion criteria include being pregnant or lactating, having acute or chronic pain resulting in insomnia, having a history of epilepsy or seizures, having a BMI over 32, and having current psychiatric disorders according to DSM-IV-TR criteria, mental retardation, or dementia. The trial also excludes individuals who nap 3 or more times per week over the preceding month and those with a history of primary hypersomnia, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, parasomnia, or dyssomnia.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of seasonal allergic rhinitis. The trial involves the use of two drugs, montelukast and placebo, and the eligibility criteria include a minimum weight and height, ability to record symptoms in a diary, and a history of allergic rhinitis symptoms caused by Japanese Cedar pollinosis. The exclusion criteria include a history of bronchial asthma or allergies other than allergic rhinitis that could worsen due to exposure to JC pollen. The icd-10 code for the disease is J30.2.",
    "The sample is a phase 3 clinical trial for the safety of two drugs, azilsartan medoxomil and chlorthalidone, and olmesartan medoxomil and hydrochlorothiazide, in treating hypertension in patients with moderate renal impairment. The trial includes patients who are treated with 2 or 3 antihypertensive medications and have a mean sitting clinic systolic blood pressure between 135 and 160 mm Hg. The eligibility criteria also include having an estimated glomerular filtration rate (eGFR) in the range of \u226530 to <60 mL/min/1.73 m^2, being a man or woman aged 18 years or older, and having clinical laboratory test results that are not clinically significant in this population. The trial excludes patients who have received any investigational compound within 30 days prior to screening, are currently participating in another investigational study, have secondary hypertension of any etiology, have a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, have clinically significant cardiac conduction defects, have hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease, have severe renal dysfunction or disease, have known or suspected unilateral or bilateral renal artery stenosis, have a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug, have poorly-controlled type 1 or 2 diabetes mellitus, have hypokalemia or hyperkalemia, have an alanine aminotransferase or aspartate aminotransferase level of >2.5 times the upper limit of normal, have any other known serious disease or condition that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow the participant according to the protocol, have a history of hypersensitivity or allergies to ARBs or thiazide-type diuretics or other sulfonamide-derived compounds, have a history of drug abuse or alcohol abuse within the past 2 years, are required to take excluded medications, or if female, are pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study or intending to donate ova during such time period.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of a drug called bi 10773. The eligibility criteria include having a diagnosis of type 2 diabetes, being on a stable treatment regimen of metformin or metformin plus sulfonylurea for at least 12 weeks prior to randomization, having an HbA1c level between 7.0% and 10%, being over 18 years old, having a BMI of 45 kg/m2 or less, and providing written informed consent. Exclusion criteria include uncontrolled hyperglycemia, recent acute coronary syndrome, liver or kidney disease, recent bariatric surgery or other gastrointestinal surgeries that induce chronic malabsorption, recent cancer treatment, contraindications to metformin or sulfonylurea, blood disorders, recent treatment with anti-obesity drugs, current treatment with systemic steroids or uncontrolled endocrine disorders, pre-menopausal women who are pregnant or not practicing an acceptable method of birth control, recent alcohol or drug abuse, participation in another trial with an investigational drug, and any other clinical condition that would jeopardize patient safety.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who have been diagnosed with colorectal adenocarcinoma and meet certain criteria, such as having measurable disease and disease progression after prior therapy. The trial also has eligibility criteria for patient characteristics, such as having a WHO performance status of 0-2 and a life expectancy of at least 12 weeks. The trial involves the use of drugs such as cyclosporine and irinotecan hydrochloride, and the eligibility criteria include restrictions on other medications that patients may be taking. The sample includes detailed information on the eligibility criteria for both disease and patient characteristics, as well as prior and concurrent therapy restrictions.",
    "The sample is a phase 3 trial for patients with anemia caused by lung or gynecologic cancer. The trial involves the use of the drugs epoetin beta and placebo. The eligibility criteria include having a hemoglobin concentration between 8.0 g/dL and 10.0 g/dL, being between 20 and 79 years old, and having a performance status between 0 and 2. Patients who have received a red blood cell transfusion within 4 weeks before treatment or erythropoietin therapy within 8 weeks before treatment are excluded from the trial. The diseases are listed as 'anemia' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for amyotrophic lateral sclerosis (ALS) with the drug MCI-186 and a placebo. The eligibility criteria include patients who meet specific diagnostic criteria for ALS, require assistance in everyday life, and have met certain progress requirements. Exclusion criteria include patients with severe hepatic, heart, or renal disease, as well as those with complications such as Parkinson's disease or dementia. Pregnant or lactating patients, those who cannot agree to contraception, and those who have been administered other investigational products within 12 weeks before consent are also excluded.",
    "The sample is a phase 3 clinical trial for kidney transplantation. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include receiving the first oral dose of the randomized study drug at least one day prior to the transplant procedure and having a negative pregnancy test for female patients of childbearing potential. The exclusion criteria include having previously received an organ transplant other than a kidney, having received a kidney transplant from a non-heart beating or cadaveric donor, having a current or history of malignancy (except for non-metastatic basal or squamous cell carcinoma of the skin), having significant liver disease, having an uncontrolled infection or unstable medical condition, currently or recently taking immunosuppressive agents, having a known hypersensitivity to tacrolimus, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for the treatment of bilateral blepharospasm, a condition characterized by involuntary contractions of the orbicular oculi muscles. The trial involves the use of incobotulinumtoxina (xeomin) and a placebo. The eligibility criteria include being between the ages of 18 and 80, having a Jankovic Rating Scale severity subscore of at least 2, and having a stable satisfactory therapeutic response to previous injections with BOTOX\u00ae. Exclusion criteria include having certain neuromuscular diseases or having received treatment with Botulinum toxins for any indication other than BEB within 4 months prior to the trial.",
    "The sample is a phase 3 clinical trial for patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. The trial is testing the effectiveness of a combination of drugs including cisplatin, docetaxel, fluorouracil, and paclitaxel. The eligibility criteria include having had prior radiotherapy for SCC of the head and neck, being 18 years or older, having a Zubrod performance status of 0-1, and meeting various hematopoietic, hepatic, renal, cardiovascular, pulmonary, immunologic, and other health criteria. Patients must not have had prior systemic chemotherapy for recurrent SCC of the head and neck, and must not have had prior EGFR inhibitors or other targeted agents for recurrent SCC of the head and neck. The trial allows for attempted surgical resection of unresectable disease, provided surgery was performed \u2265 3 months ago, wound is completely healed, and there is no sign of carotid exposure. The sample also includes detailed patient characteristics and prior concurrent therapy information.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on hypercholesterolemia, with a list of associated ICD-10 codes. The trial involves several drugs, including alirocumab, ezetimibe, and placebos for both drugs. The eligibility criteria for participants are listed, including age restrictions, LDL-C levels, and fasting serum triglyceride levels. Participants with a known history of familial hypercholesterolemia are excluded from the trial. The sample notes that the information provided is not exhaustive and that other considerations may be relevant to a participant's potential participation in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of painful HIV-associated distal symmetric polyneuropathy. The trial involves the use of drugs such as ngx-4010 and 0.04% capsaicin patch. The eligibility criteria include documented evidence of HIV-1 infection, diagnosis of painful HIV-associated distal symmetric polyneuropathy, and average NPRS scores during screening period of 3 to 9, among others. The exclusion criteria include recent use of any topically applied pain medication, evidence of another contributing cause for peripheral neuropathy, and recent significant medical-surgical intervention, among others.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel. The eligibility criteria for patients include having histologically or cytologically proven NSCLC and meeting certain staging criteria. Patients must also have a Zubrod performance status of 0 or 1, and meet certain hematopoietic, hepatic, renal, and pulmonary requirements. Patients cannot have had prior systemic chemotherapy or radiotherapy for NSCLC, and cannot be receiving any other concurrent anticancer therapy or investigational therapy.",
    "The sample is a clinical trial in phase 3 for the treatment of apathy and Alzheimer's disease. The trial involves the use of modafinil and a placebo drug. The eligibility criteria for the trial include a diagnosis of mild to moderate stage probable Alzheimer's disease, being on a stable dose of a cholinesterase inhibitor medication for at least 30 days, and clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale. The exclusion criteria include a diagnosis of major depression, a focal brain lesion on neuroimaging, a history of significant substance abuse, and a history of significant head trauma with loss of consciousness for more than 10 minutes.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of aripiprazole im depot compared to a placebo. The eligibility criteria for the trial includes male and female subjects between the ages of 18 and 65 who have been diagnosed with schizophrenia for at least 1 year and have a stable living environment. Subjects must also be experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function. They must have received previous outpatient antipsychotic treatment and have shown a previous good response to such treatment. Exclusion criteria includes subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia, subjects with clinically significant tardive dyskinesia, and subjects with severe akathisia.",
    "The sample is a phase 3 clinical trial for ovarian neoplasms, which includes a list of icd-10 codes for related diseases. The trial involves the use of two drugs, caelyx and paclitaxel hcl. The eligibility criteria for the trial include having a histologically proven epithelial ovarian carcinoma, measurable disease, and recurrence of disease or disease progression after first-line platinum-based chemotherapy. The exclusion criteria include being pregnant or breastfeeding, having a life expectancy of less than 3 months, and having received prior radiation therapy or chemotherapy within a certain timeframe. The sample also includes specific requirements for adequate renal and liver function.",
    "The sample is a phase 3 clinical trial for the treatment of childhood acute lymphoblastic leukemia. The trial includes patients who have relapsed on therapy or within one year of discontinuation of therapy, or greater than 1 year from discontinuation of high-risk intensive therapy (matched sibling donor only). Patients with central nervous system or testicular relapse are also included if it occurred within 18 months of diagnosis or following prophylactic or therapeutic cranial irradiation. Patients in first remission with high-risk features such as t(4,11), t(9,22), or hypodiploidy are also eligible. Patients under 12 months of age in first remission with certain features at diagnosis are also included. The trial has certain eligibility criteria related to age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. The trial does not specify any prior concurrent therapy. The trial requires a genotypically matched sibling or phenotypically matched family member as a donor, or a matched or one antigen mismatched unrelated donor, or cord blood (genotypic or phenotypic match or one antigen mismatch), or matched sibling or phenotypically matched family member peripheral stem cells.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on gastrointestinal stromal tumor and involves the use of two drugs, sunitinib malate and imatinib mesylate. The eligibility criteria for the trial includes patients whose disease has progressed on imatinib 400 mg daily, while exclusion criteria includes current treatment with any chemotherapy other than imatinib and any dose of imatinib other than 400 mg. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of gout. The trial includes patients who meet the American Rheumatism Association criteria for the classification of acute arthritis of primary gout and have a serum uric acid level of at least 6.5 mg/dL. The trial involves the use of the drugs lesinurad and placebo, and patients must be able to take gout flare prophylaxis with colchicine or NSAID. The eligibility criteria include a BMI of less than 45 kg/m2 and a history of intolerance or contraindication to either allopurinol or febuxostat. Exclusion criteria include pregnancy or breastfeeding, kidney stones, drug abuse within the past 5 years, and various medical conditions that may create undue risk or interfere with the subject's ability to comply with the protocol requirements.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes participants who are 50 years or older, reside in the community, and have a Mini-Mental State Examination score of 14-26. The trial involves the use of DHA (docosahexaenoic acid) and a placebo. The eligibility criteria include being fluent in English or Spanish, having corrected vision and hearing, having supervision available for study medication, and having a caregiver/study partner to accompany the participant to all visits. The exclusion criteria include non-AD dementia, residence in a long-term care facility, history of clinically significant stroke, and evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational new drug.",
    "The sample is a phase 3 clinical trial for diabetes mellitus. The trial includes subjects with type 1 or type 2 diabetes mellitus for at least six months, who are between 21 and 70 years old, and have a screening hemoglobin A1c (HbA1c) level of \u2265 7.0 and \u2264 9.0 %. The trial involves the use of insulin glargine and multi-day dosing of insulin glulisine, and subjects must be willing and able to perform self-monitoring of blood glucose (SMBG) four times a day and continuous glucose monitoring (CGMS) for 48 hours at three time periods during the study. The trial has inclusion and exclusion criteria, and subjects must provide informed consent in writing at enrollment.",
    "This sample is from a phase 3 clinical trial for the treatment of pulmonary hypertension. The trial includes the drug bosentan and a placebo. The eligibility criteria for the trial includes having PAH NYHA Class II, significant elevation of mean pulmonary arterial pressure, significant elevation of pulmonary vascular resistance at rest, and limited 6-minute walk distance. Exclusion criteria includes having PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt, restrictive or obstructive lung disease, significant vasoreactivity, and having received treatments for PAH within 4 weeks of randomization. The diseases being studied are limited to pulmonary hypertension and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves two different ICD-10 codes for each disease and two different drugs, brimonidine ophthalmic solution 0.1% and 0.2%. The eligibility criteria for the trial includes having ocular hypertension or glaucoma in both eyes, but excludes individuals with uncontrolled systemic disease or known allergy or sensitivity to brimonidine.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy. The trial includes subjects between the ages of 16 and 70 with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification. The subjects must have a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification) and have had at least 2 POS per month during the 3 months preceding Visit 1 (V1) and at least 8 POS during the 8-Week Baseline Period. The trial allows for 1 to 2 permitted concomitant antiepileptic drug(s) (AEDs) and vagal nerve stimulation (VNS) was allowed and was not counted as a concomitant AED. The exclusion criteria include a history or presence of seizures occurring only in clusters before Visit 3 and a history or presence of status epilepticus during the year preceding Visit 1 or during Baseline. The trial is testing the effectiveness of brivaracetam at 2.5 mg, 10 mg, and 25 mg doses.",
    "The sample is a phase 3 clinical trial for the treatment of sarcoma. The trial involves the use of imatinib mesylate and imatinib drugs. The eligibility criteria for the trial include being 18 years or older, having a histologically documented diagnosis of GIST, having a resectable GIST, having the GIST removed at open surgery, and having immunohistochemical documentation of GIST. Patients must also have a high risk of tumor recurrence, as defined by certain criteria. Exclusion criteria include having inoperable or metastatic GIST, having received any investigational agents within 28 days, and having severe or uncontrolled medical disease. Patients must provide written, voluntary informed consent to participate in the trial.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of psoriasis using the drug etanercept. The eligibility criteria for the trial include being an adult with clinically stable plaque psoriasis involving at least 10% of the body surface and a minimum Psoriasis Area and Severity Index (PASI) score of 10 at screening. The exclusion criteria include previous treatment with etanercept or other TNF inhibitors, as well as having active guttate, erythrodermic, or pustular psoriasis at the time of screening or baseline. The table also includes information on the diseases being studied, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia and mixed dyslipidemia. The trial involves the use of two drugs, niacin er/simvastatin tablets and atorvastatin. The eligibility criteria for the trial include specific laboratory criteria such as HDL-C levels, LDL-C levels, and TG levels, as well as compliance with the Therapeutic Lifestyle Changes (TLC) diet. The exclusion criteria include any medical conditions or abnormalities that would prevent study inclusion.",
    "The sample is a phase 3 clinical trial for the treatment of PTSD and sleep disorders using the drug prazosin. The trial includes patients who are over 18 years old, have been exposed to life-threatening war zone trauma events, have a DSM-IV diagnosis of PTSD, and have a CAPS total score of over 50. Patients must also be capable of giving informed consent and have good general medical health. The trial has a list of exclusion criteria, including acute or unstable chronic medical illness, untreated sleep apnea, allergy or previous adverse reaction to prazosin, and current substance dependence. Patients must also not be on certain medications or therapies, such as prazosin or other alpha-1 antagonists, recent exposure therapy, or other psychotropic medications.",
    "The sample is a phase 3 clinical trial for the treatment of acute, ischemic stroke with first symptoms within 6 hours of beginning treatment. The trial includes patients with baseline NIHSS > 5 and excludes those with intracranial, extravascular blood on CT, hypertension (systolic > 185; diastolic > 105), baseline fibrinogen level < 100 mg/dL, thrombocytopenia (< 100,000 / mm3), recent (< 3 days) or anticipated (< 5 days) use of a thrombolytic agent, and recent (< 14 days) or anticipated surgery. The trial uses a placebo drug and the diseases being studied include stroke, cerebral ischemia, and brain infarction, with corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial in phase 3, which involves testing the effectiveness of a drug called \"estradiol, 25 mcg\" on women who have gone through menopause and are experiencing urogenital aging (UGA) and recurrent urinary tract infections. The trial has eligibility criteria for inclusion, such as having had three or more urinary tract infections in the past year, and exclusion criteria, such as having a known allergy to the trial product or currently having a urinary tract infection. The sample also includes the diseases being studied, which are menopause and urinary infections, and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with rheumatoid arthritis for at least 3 months. The patients must have had an inadequate response to previous or current treatment with at least one anti-TNF-alpha agent. They must also be receiving either leflunomide or methotrexate for at least 12 weeks, with a stable dose for the last 4 weeks. The patients must have a swollen joint count (SJC) of at least 4 (66 joint count) and a tender joint count (TJC) of at least 4 (68 joint count) at screening and baseline. Additionally, their CRP levels must be at least 0.6 mg/dL using a high-sensitivity assay, and they must have a positive rheumatoid factor or positive anti-CCP antibody or both. Patients with rheumatic autoimmune disease or inflammatory joint disease, other than RA, and those who have had any surgical procedure in the past 12 weeks or planned within 48 weeks of baseline are excluded from the trial. The drugs being tested are leflunomide, methotrexate, ocrelizumab, and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of schizoaffective disorder and psychotic disorder. The trial involves the use of the drugs paliperidone er and placebo. The eligibility criteria for the trial include a DSM-IV diagnosis of schizoaffective disorder, a total PANSS score of at least 60, and a score of at least 16 on either the YMRS or HAM-D 21 rating scales. Exclusion criteria include a primary active mental illness diagnosis other than schizoaffective disorder, first episode psychosis, active substance dependence within the previous 6 months, treatment with clozapine within 6 months of randomization, a history of treatment resistance, and pregnancy, breastfeeding, or planning to become pregnant.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who are currently experiencing an acute exacerbation of schizophrenia and require a caregiver. The trial excludes patients who have an uncontrolled or unstable medical condition, as well as those who have any other psychiatric disorder besides schizophrenia as their primary diagnosis. The trial involves the use of three drugs: asenapine, placebo, and olanzapine. The diseases are listed as 'schizophrenia' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of major depressive disorder. The trial involves the use of two drugs, mk0869 and aprepitant, as well as a placebo for comparison. The eligibility criteria for the trial is having major depressive disorder. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are over 18 years old and have been diagnosed with RA for at least 6 months. They must be receiving outpatient treatment and have been on methotrexate for at least 3 months, with stable treatment for at least 1 month. The patients must have had an inadequate response or intolerance to etanercept, infliximab, or adalimumab. The trial excludes patients who have previously been treated with MabThera, are currently receiving any anti-TNF-alpha therapy or biologic therapy, or have previously been treated with any investigational cell-depleting therapies. The trial is testing the effectiveness of rituximab as a treatment for rheumatoid arthritis.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease of type 2 diabetes mellitus. The trial includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, linagliptin and placebo. The eligibility criteria for the trial include patients with insufficient glycemic control, aged 18 to 80 years, and who have not used more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP-1 analogues within 3 months. Patients who have had a myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent are excluded from the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of basal cell carcinoma, a type of skin cancer. The trial involves the use of a drug called imiquimod 5% cream. The eligibility criteria for the trial include having basal cell carcinoma, while exclusion criteria include having psoriasis. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial involves patients who are currently being treated with a serotonin reuptake inhibitor (SRI) antidepressant but have an inadequate response to the treatment. The patients must agree to discontinue the current SRI at the baseline. The trial also requires patients to have a Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score of at least 22 at the screening visit and baseline. Women who participate in the trial must agree not to try to become pregnant during the study and use adequate, highly effective contraception. Patients with any current Axis I disorders other than Major Depressive Disorder (MDD), General Anxiety Disorder (GAD), and Social Anxiety Disorder (SAD) are excluded from the trial, as well as those who are at significant risk of suicide or currently receiving formal psychotherapy or other psychoactive medications. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking for patients with stage I or II primary operable breast cancer who are planning to have surgery within the next 1-4 weeks. Patients must be female, any age, and either premenopausal or postmenopausal. They must also have estrogen receptor positive or unknown hormone receptor status, and no known estrogen receptor negative tumor. Patients must not have any bleeding diathesis not compatible with an IM depot injection, and must not be pregnant. Fertile patients must use effective non-hormonal contraception during and for 2-3 months after the study. Patients must not have any other prior or concurrent malignancy except adequately treated basal cell carcinoma of the skin or cancer of the uterine cervix. The trial is not specifying any performance status or life expectancy requirements. Patients must not have any psychological, familial, sociological, or geographical condition that would preclude study. Prior to the trial, patients must not have received any prior radiotherapy to the primary tumor, and must not have received any other concurrent preoperative therapy for breast cancer. The trial is looking to test the effectiveness of the drug fulvestrant.",
    "The sample is a phase 3 clinical trial for endometrial cancer. The eligibility criteria include having a confirmed grade I, II or III endometrial adenocarcinoma and having undergone a total hysterectomy and bilateral salpingo-oophorectomy within the past 20 weeks. Patients must also have had a normal mammogram or negative breast biopsy within the past year. There are various patient characteristics that are not specified, including age, performance status, and life expectancy. The trial also has specific requirements for hematopoietic, hepatic, renal, and cardiovascular health. Patients cannot have prior or current carcinoma of the breast or any other invasive malignancy within the past 5 years except nonmelanoma skin cancer. The trial does not allow concurrent hormonal therapy and patients must have recovered from prior surgery. There are no specifications for biologic therapy, chemotherapy, or radiotherapy. Concurrent participation on GOG Lap-1 or GOG Lap-2 is allowed.",
    "The sample is a phase 3 clinical trial for patients with gastric adenocarcinoma who have undergone curative D2 lymphadenectomy resection for gastric cancer with no remaining tumor. The trial involves the drugs capecitabine and oxaliplatin. The eligibility criteria include ambulatory patients with a Karnofsky performance status of \u226570%, histologically confirmed gastric adenocarcinoma, and staged pathologically stage II or IIIa or IIIb. Exclusion criteria include pregnant or lactating women, sexually active males and females unwilling to practice contraception during the study, any evidence of metastatic disease, previous cytotoxic chemotherapy, and serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, pain and cancer, which are identified by their respective ICD-10 codes. The trial is testing the effectiveness of a drug called oravescent fentanyl citrate. The eligibility criteria for participants include being between 18-80 years old, having an average of 1-4 breakthrough pain episodes per day, being opioid tolerant, and having a histologically documented diagnosis of a malignant solid tumor or hematological malignancy. Exclusion criteria include primary breakthrough pain not being related to cancer, opioid or fentanyl intolerance, chronic obstructive pulmonary disease (COPD) or heart disease, and sleep apnea or active brain metastases with increased cranial pressure.",
    "The sample is a phase 3 clinical trial for bipolar disorder and mood disorders. The trial includes patients who meet the DSM-IV criteria for Bipolar I Disorder, Most Recent Episode Manic or Mixed (with or without psychotic features) and have a history of at least one previously documented manic or mixed episode requiring medical treatment within 3 years before the screening phase. The patients must also have a total score of at least 20 on the YMRS at screening and at baseline. The trial involves the use of drugs such as placebo, quetiapine, and paliperidone er. The eligibility criteria include being postmenopausal, surgically sterile, abstinent, or agreeing to practice an effective method of birth control if sexually active before entry and throughout the study. The patients must also be able and willing to comply with self-administration of medication or have consistent help or support available. The exclusion criteria include rapid cycling and schizoaffective disorder, significant risk for suicidal or violent behavior during the course of the study, and the use of certain drugs such as cocaine, phencyclidine, and opioids.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, chronic obstructive. The trial includes patients who are current or ex-smokers with a smoking history of at least 10 pack-years and have moderate to severe COPD and are at least 40 years old. The trial involves the use of drugs such as tiotropium+salmeterol, salmeterol, and tiotropium. The eligibility criteria for the trial include exclusion criteria such as recent history of myocardial infarction, life-threatening cardiac arrhythmia, hospitalization for cardiac failure, history of asthma, malignancy requiring treatment within the past 5 years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, known active tuberculosis, pregnant or nursing women, and known hypersensitivity to components of the study medication.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of Crohn's Disease. The trial involves the use of the drugs abatacept and placebo. The eligibility criteria for the trial include being 18 years or older, having had Crohn's Disease for at least 3 months, having moderate to severely active Crohn's Disease, and having had an inadequate response or intolerance to other Crohn's Disease treatments. The diseases column lists only Crohn's Disease, and the icdcodes column lists the ICD-10 codes associated with Crohn's Disease.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of fibromyalgia. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, including a placebo and milnacipran 100mg. The eligibility criteria for the trial are also listed, including specific inclusion and exclusion criteria related to psychiatric illness, depression, substance abuse, and various medical conditions.",
    "The sample is a phase 3 clinical trial for the treatment of hepatocellular carcinoma, which is a type of liver cancer that cannot be surgically removed or has recurred. The trial includes patients with various related diseases and uses a combination of two drugs, abt-869 and sorafenib. The eligibility criteria for the trial include having a histologic or cytologic diagnosis of unresectable or metastatic HCC, being in Child Pugh Class A, having an ECOG performance status of 0-1, and having adequate hematologic, hepatic, and renal function. Patients who have received prior systemic or local therapy for HCC, have untreated brain or meningeal metastases, are currently on another clinical trial, or are pregnant or breastfeeding are excluded from the trial. The icd-10 codes for the diseases included in the trial are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial includes patients between the ages of 7 and 15 who have been diagnosed with the condition and have a mean rhinorrhea and sneezing score of at least 2. The trial involves the use of two drugs, bepotastine besilate and placebo. The eligibility criteria include exclusion of patients with vasomotor or eosinophilic rhinitis, concurrent nasal disease, history of nasal surgical procedures, positive results for certain antigens, drug allergies, and renal function abnormalities.",
    "The sample is a phase 3 clinical trial for the treatment of human immunodeficiency virus infection. The trial involves the use of two drugs, fosamprenavir and ritonavir. The eligibility criteria for the trial include being male or a non-pregnant/non-lactating female aged 13 or older (or 18 or older according to local requirements), and having received fosamprenavir through prior participation in certain studies or other studies deemed appropriate by the project team. Exclusion criteria include having permanently discontinued GW433908 due to intolerance, having an active CDC Class C Event, or having any condition that would preclude participation according to the investigator's opinion.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is looking for male or female patients over 18 years old who have been treated with three classes of drugs (NRTI, NNRTI, and PI) for at least 3 months each, but have developed resistance to more than one PI. The patient's current regimen must contain at least one genotypically active NRTI reported as \"maximal response\" or \"sensitive\" on the screening virtual phenotype report. The trial is testing the effectiveness of tipranavir, darunavir, and ritonavir as part of the patient's optimized background regimen. The patient must have ongoing viral replication and a successful virtual phenotype obtained at screening. The trial has a list of inclusion criteria, including acceptable laboratory values, a Karnofsky performance score of \u2265 70, and willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent opportunistic infections. The trial also has a list of exclusion criteria, including previous use of Tipranavir (TPV) or Darunavir (DRV), full genotypic resistance to TPV or DRV, and any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.",
    "The sample is a phase 3 clinical trial for diabetic retinopathy. The trial involves the use of octreotide acetate in microspheres as a drug. The eligibility criteria for the trial include providing written informed consent, successfully completing a previous study, and willingness to comply with all study requirements. Exclusion criteria include premature discontinuation from the previous study and more than 8 weeks interval since its completion. Other protocol-defined inclusion/exclusion criteria may also apply. The icd-10 codes for the disease are listed as \"H35.23\", \"H35.20\", \"H35.21\", \"H35.22\", \"E10.3553\", \"E11.3553\", and \"E13.3553\".",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of type 2 diabetes mellitus and includes a list of associated ICD-10 codes. The trial involves several drugs, including sitagliptin, rosiglitazone, metformin, and glipizide, as well as a placebo comparator. The eligibility criteria for the trial include having type 2 diabetes mellitus and being inadequately controlled while taking two oral antidiabetic medications. Exclusion criteria include a history of type 1 diabetes mellitus or ketoacidosis, recent insulin therapy, and recent use of Byetta (R) (exenatide).",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of venous thromboembolism and includes a list of associated ICD-10 codes. The trial involves the use of two drugs, fondaparinux and enoxaparin. The eligibility criteria for the trial are listed, including the requirement for informed consent and exclusion criteria such as active or suspected bleeding, low platelet count, and pregnancy. The sample also includes a list of patients who are not eligible for the trial, such as those with an epidural catheter or those who require immediate surgery.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for at least 6 months and have at least 4 swollen and 4 tender joints. The patients must also be on a stable dose of methotrexate for 4 weeks. The trial excludes patients who have been previously exposed to biologic anti-TNFalpha agents, have inflammatory diseases other than rheumatoid arthritis, have been treated with Disease Modifying Anti-rheumatic drug (DMARDs)/systemic immunosuppressives other than methotrexate during the 4 weeks prior to the first administration of study agent, or have a history of, or ongoing, chronic or recurrent infectious disease. The trial will test the effectiveness of golimumab, placebo, and methotrexate (mtx) as treatments for rheumatoid arthritis.",
    "The sample is from a phase 3 clinical trial that focuses on atherosclerosis, hypercholesterolemia, and hyperlipoproteinemia type II. The trial involves two drugs, ezetimibe (plus simvastatin) and placebo (plus simvastatin). The eligibility criteria for the trial include having genotype-confirmed heterozygous familial hypercholesterolemia or clinical diagnosis of heterozygous familial hypercholesterolemia with LDL-C levels above a certain threshold. The trial also has exclusion criteria, such as pregnancy or any other condition that may interfere with optimal participation in the study.",
    "The sample is a phase 3 clinical trial for postmenopausal women with breast cancer and osteoporosis. The trial involves the drugs letrozole and zoledronic acid. The eligibility criteria include a diagnosis of breast cancer, completion of less than 6 years of adjuvant tamoxifen therapy, and a total baseline lumbar spine or femoral neck bone mineral density T-score below -2.0 standard deviation. Other eligibility criteria include age, sex, menopausal status, performance status, life expectancy, hematopoietic, hepatic, renal, and other factors. Prior concurrent therapy is also specified.",
    "The sample is a phase 3 clinical trial for patients with malignant bone disease, moderate to severe pain, and neoplasms metastasis. The trial involves the use of two drugs, ibandronate and zoledronic acid. The eligibility criteria include not having received a bisphosphonate within 3 weeks of signing informed consent, not receiving concurrent or recent investigational therapy, not having untreated esophagitis or gastric ulcers, not having received recent or pre-scheduled radiotherapy to bone, and not being pregnant or breastfeeding.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease of partial epilepsy. The ICD-10 codes associated with the disease are listed. The trial is testing two drugs, pregabalin and lamotrigine. The eligibility criteria for the trial are also listed, including the requirement that patients have experienced at least 2 partial seizures in the past year and have been diagnosed with partial epilepsy. There are also exclusion criteria, such as having treatable causes of seizures or primary generalized seizures.",
    "The sample is a phase 3 clinical trial that involves patients with kidney disease, diabetes mellitus, and anemia. The trial is testing the effectiveness of darbepoetin alfa compared to a placebo. The eligibility criteria for the trial include having a hemoglobin level of 11 g/dL or less, a history of chronic kidney disease, an eGFR between 20 and 60 mL/min/1.73 m2, and a transferrin saturation greater than 15%. Patients with uncontrolled hypertension or who have used erythropoietic protein within 12 weeks of randomization are excluded from the trial. The icd-10 codes for the diseases are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes males and females aged 40 years or older with a clinical diagnosis of moderate to severe stable COPD. The trial involves the use of aclidinium bromide and placebo drugs. The eligibility criteria for the trial include exclusion of individuals with a history or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial is looking at the effectiveness of quetiapine fumarate in treating manic, depressed, or mixed episodes in patients with Bipolar I Disorder. The trial has inclusion criteria such as being 18 years or older, having a diagnosis of Bipolar I Disorder, and having had a manic, depressed, or mixed episode in the last 26 weeks that was treated with quetiapine. Exclusion criteria include pregnancy, substance or alcohol dependence, unstable thyroid function, unstable diabetes, and use of an experimental drug within 30 days of enrollment. Female patients of childbearing potential must be using a reliable method of contraception. The trial requires signed informed consent from all participants.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes subjects aged 19 to 75 years with mild to moderate essential hypertension, measured at more than 90mmHg and less than 110mmHg of sitting diastolic blood pressure (SiDBP) at baseline. The trial excludes patients with severe hypertension, secondary hypertension, abnormal renal or liver function, hypotension, severe insulin dependent or uncontrolled diabetes mellitus, severe heart disease, significant arrhythmia, hypertrophic obstructive cardiomyopathy, severe cerebrovascular disease, wasting disease, autoimmune disease, connective tissue disease, known severe or malignancy retinopathy, hepatitis B or C or HIV positive reaction, history of alcohol or drug abuse within 2 years, allergic reaction to any angiotensin II antagonist, chronic inflammation disease, childbearing and breastfeeding women, and patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial. The trial involves the use of fimasartan 60mg, fimasartan 120mg, and candesartan cilexetil as drugs. The eligibility criteria include subjects who agreed to participate in the study and submitted the written informed consent, considered to understand the study, be cooperative, and able to be followed-up throughout the study period. The trial is judged unsuitable for subjects who are not eligible according to the exclusion criteria.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial is testing the effectiveness of methylphenidate transdermal system (mts) as a treatment for ADHD in adults. The eligibility criteria include meeting DSM-IV-Text Revision criteria for ADHD, being between the ages of 18 and 65, being in general good health, and being able to read and write at a sufficient level to provide written informed consent and complete study-related materials. Exclusion criteria include having other current DSM-IV Axis I Disorders, being at risk for suicide or a risk to harm others, having a history of substance dependence, currently abusing illegal drugs or alcohol, having a positive urine screen for drugs of abuse, having a history of uncontrolled hypertension or significant cardiovascular disease, having any known or suspected significant medical or psychiatric illnesses, and using any medication not considered acceptable by the clinical investigator or the medical monitor during the 7-day period before the start of the study.",
    "The sample is a phase 3 clinical trial for cervical cancer. The eligibility criteria include having invasive cervical carcinoma, being over 18 years old, having a certain stage of cancer, and meeting certain blood count and organ function requirements. Patients who have undergone surgical removal of the cervix and uterus are not eligible. The exclusion criteria include having had prior radiotherapy or chemotherapy, having a pacemaker or implanted defibrillator, and having significant metallic foreign bodies. The trial is testing the effectiveness of cisplatin as a treatment for cervical cancer.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial includes patients with metastatic prostate adenocarcinoma who have documented progression while on androgen ablation therapy. The trial requires patients to be at least 18 years old with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less and adequate hematologic, renal, and hepatic function. The trial excludes patients who have had prior chemotherapy with docetaxel or isotope therapy, as well as those with contraindications to the use of corticosteroids or a history of cancer-related hypercalcemia. The trial will use the drugs calcitriol and docetaxel.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on carpal tunnel syndrome, with a list of associated ICD-10 codes. The drug being tested is gabapentin. The eligibility criteria for the trial are listed, including sensory symptoms over the median nerve distribution for more than three months and confirmatory electrophysiologic results. There are also exclusion criteria, such as evidence of severe CTS or accompanying conditions that could interfere with evaluation. Patients with known epilepsy or who have received previous steroid treatment for CTS are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, osteoarthritis), the corresponding ICD-10 codes, the drugs being tested (buprenorphine transdermal patch and placebo), and the eligibility criteria for participants. The eligibility criteria include requirements for a clinical diagnosis of chronic osteoarthritis, a certain level of pain, and restrictions on the use of certain medications. The record also notes that there may be additional exclusion/inclusion criteria specific to the trial.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The trial is looking for participants who are between 18 and 75 years old, have histologically proven pancreatic cancer stage III or IV, and have no option for resection with curative intent. Participants must also have at least one measurable or not measurable lesion, no previous chemotherapy or other systemic tumor therapy, and no previous radiation. They must have a performance status of 0-2 according to WHO/ECOG, a life expectancy of at least 3 months, and adequate kidney-, liver-, and bone marrow function. Participants must also have the possibility of regular long-term follow-up and must have signed an informed consent before study entry. Exclusion criteria include known secondary cancer other than curatively treated basalioma or carcinoma in situ of the cervix uteri, clinically unstable CNS-metastases, known hypersensitivity against study medication, severe impairment of renal or liver function, clinically relevant disease of the cardiovascular system or other vital organs, known polyneuropathy, known DPD-deficiency, simultaneous treatment with the antiviral agent sorivudin or chemically related agents such as brivudin, pregnancy, lactation or lack of reliable contraception in women at childbearing age, mental disease, drug- or alcohol abuse, participation in another clinical trial within the last 4 weeks, all other diseases which may prevent adequate participation in the trial, and indication of lack of compliance with study regulations.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial involves the use of the drugs bi 10773, placebo, and sitagliptin 100mg. The eligibility criteria for the trial include patients who completed the entire treatment period of a previous double-blind trial and have signed informed consent. Exclusion criteria include patients who meet withdrawal criteria from the previous trial, have liver disease, impaired renal function, contraindications to certain drugs, are pregnant or not practicing an acceptable method of birth control, have a history of alcohol or drug abuse, have participated in another trial with an investigational drug within 30 days prior to informed consent, or have any other clinical condition that would jeopardize their safety while participating in the trial.",
    "The sample is a phase 3 clinical trial for patients with advanced Hepatocellular carcinoma (HCC) that is unresectable and/or metastatic. The trial is testing the effectiveness of sorafenib (nexavar, bay43-9006) compared to a placebo. The eligibility criteria include having a life expectancy of at least 12 weeks, having at least one tumor lesion that meets certain criteria, and having an Eastern Co-operative Oncology Group (ECOG) Performance Status of 0, 1, or 2. Exclusion criteria include having a previous or concurrent cancer that is distinct in primary site or histology from HCC, history of cardiac disease, active clinically serious infections, known history of human immunodeficiency virus (HIV) infection, known central nervous system (CNS) tumors including metastatic brain disease, and clinically significant gastrointestinal bleeding within 30 days prior to study entry.",
    "The sample is a phase 3 clinical trial for sepsis. The trial includes patients with a known or probable source of infection requiring parenteral antimicrobial therapy, who meet at least 3 of the 4 criteria for SIRS, and have sepsis with shock and/or respiratory failure. The trial excludes patients who are pregnant or nursing, receiving immunosuppressive therapy, have a granulocyte count of less than 1000/mm3, have a documented history of moderate to severe chronic heart failure, are positive for human immunodeficiency virus with known CD4 count less than or equal to 50/mm3, have a known history of glucose-6-phosphate dehydrogenase deficiency, have a methemoglobin level greater than 5%, are moribund, classified as \"Do Not Resuscitate\" or \"Do Not Treat\", are not expected to survive for 28 days, have a known esophageal varices, chronic jaundice, cirrhosis, or chronic ascites, are in a chronic vegetative state or have a similar long-term neurological condition, have known portal hypertension or Child-Pugh hepatic impairment class C, have acute third degree burns involving more than 30% of body surface within 120 hours prior to Pretreatment Period, have known hypersensitivity to sulfonamides, have known hypersensitivity to components of resatorvid, or have participated in any other investigational study (drug or device) and/or taken any investigational drug within 30 days or 5 half-lives of the drug. The trial uses resatorvid and placebo as drugs.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone palmitate. The trial includes patients who have been diagnosed with schizophrenia according to the DSM-IV within the past 5 years and have been unsuccessfully treated with an oral antipsychotic due to lack of efficacy, tolerability, safety, compliance, or other reasons. Patients must also be willing and able to fill out self-administered questionnaires during the study. The trial has various exclusion criteria, including substance dependence, hypersensitivity to the drug or its excipients, and history of certain medical conditions. The trial also excludes patients who have received treatment with certain medications or have participated in other investigational drug studies within a certain timeframe.",
    "The sample is a phase 3 clinical trial for patients with hyperlipidemia. The trial includes patients aged between 20 and 75 years old with fasting LDL-C levels above 100 mg/dL. The trial involves the use of pitavastatin and atorvastatin drugs. The eligibility criteria include signing a written informed consent, not having participated in other investigational studies within 3 months, not taking medication or natural health foods known to alter blood lipid profiles within 4 weeks, and not having certain medical conditions such as poorly controlled diabetes mellitus or advanced renal or hepatic disorders. The trial also has exclusion criteria such as being lactating, being pregnant, or planning to become pregnant.",
    "The sample is a phase 3 clinical trial for patients with muscle wasting and non-small cell lung cancer. The trial involves the drugs gtx-024 and placebo. The eligibility criteria include being non-obese, having been diagnosed with Stage III or IV NSCLC, and having a life expectancy of more than 6 months. The trial also has exclusion criteria, such as having a clinically significant concurrent illness or taking certain medications. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for patients with human immunodeficiency virus (HIV) infections. The trial is testing the effectiveness of atazanavir and ritonavir as a treatment for HIV. The eligibility criteria for the trial include being on continued antiretroviral treatment for the previous 6 months, having no evidence of virologic failure on antiretroviral therapy, having only one prior highly active antiretroviral therapy, and having an HIV RNA level below 50 copies/mL in the last 6 months. The exclusion criteria include having a newly diagnosed HIV-related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment, having an active disease condition, having chronic hepatitis B and receiving certain medications, having a CD4 count below 100 cells/mm3, and having certain laboratory values below a certain threshold.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, chronic obstructive. The trial is testing the effectiveness of a drug called fluticasone propionate/salmeterol combination diskus. The eligibility criteria for the trial include a diagnosis of COPD, but exclude individuals with asthma or other uncontrolled medical conditions or respiratory disorders. Additional inclusion and exclusion criteria will be evaluated at the first study visit.",
    "The sample is a phase 3 clinical trial for advanced non-small cell lung cancer. The trial is testing the effectiveness of the drugs gemcitabine and cisplatin. The eligibility criteria for participants include having a confirmed diagnosis of advanced non-small cell lung cancer, not having received prior chemotherapy, having a performance status of 2, being between the ages of 18 and 70, and having normal bone marrow, hepatic, and renal function. Exclusion criteria include having active systemic infections, severe concomitant illness, inadequate hepatic or renal function, ongoing or recent radiation therapy, symptomatic cerebral metastases, previous chemotherapy for advanced disease, and any condition that would limit the patient's ability to provide informed consent or comply with study procedures. Pregnant or nursing females and those with any malignancy within the past 5 years (except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer) are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis. The trial is looking for male or female subjects between the ages of 18 and 75 who have been diagnosed with plaque or guttate psoriasis and have a Psoriasis Area and Severity Index (PASI) score of at least 12 or psoriasis covering at least 10% of their body surface area. The trial is testing the effectiveness of the drug \"alga dunaliella bardawil\" compared to a placebo. The eligibility criteria include signed informed consent, compliance with study requirements, and being a candidate for phototherapy treatment. Exclusion criteria include having an unstable form of psoriasis, receiving any investigational drug within 30 days of randomization, and having a known allergy or sensitivity to the study treatment(s) or any of the participant contained in the study drug formulation.",
    "The sample is a phase 3 trial for the treatment of clostridium infections and diarrhea. The trial includes a list of icd-10 codes for the diseases and a list of drugs, including fidaxomicin, vancomycin, and a matching placebo to fidaxomicin. The eligibility criteria for the trial include being male or female with CDAD, using adequate contraception (for females), and signing informed consent. Exclusion criteria include having life-threatening CDAD, toxic megacolon, being pregnant, using concurrent diarrheal agents, or participating in other trials.",
    "The sample is a phase 3 clinical trial for the treatment of esophageal cancer. The trial is looking at the effectiveness of cisplatin and fluorouracil in treating untreated squamous cell carcinoma or adenocarcinoma of the thoracic esophagus or gastro-esophageal junction. Patients must meet certain eligibility criteria, including having no evidence of distant metastatic disease, having granulocyte counts \u22651,800/mL, platelet count \u2265 100,000/mL, and creatinine clearance \u2265 50 mL/min, and having tumors that are considered surgically resectable. Patients must not have previously received chemotherapy or radiation therapy for this tumor or any radiation therapy that would overlap the radiation fields required for this malignancy. Patients with previous malignancies are eligible if more than 5 years had elapsed from diagnosis without evidence of tumor recurrence. There can be no other serious illness that would limit survival to less than 2 years, or psychiatric condition that would prevent compliance with treatment or informed consent. Pregnant patients are excluded. Informed consent is required for all patients.",
    "The sample is from a clinical trial in phase 3 for the treatment of iron deficiency anemia. The trial involves the use of the drug ferumoxytol. The eligibility criteria include participants who have completed a previous study, female participants who are sexually active must be on birth control, and participants who have not experienced a serious adverse event related to ferumoxytol. The exclusion criteria include female participants who are pregnant, intend to become pregnant, are breastfeeding, or have a positive pregnancy test. The diseases are listed as 'iron deficiency anemia' and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for patients over 40 years old with chronic cough and chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of azithromycin compared to a placebo. The trial includes patients with a history of chronic cough for at least 12 weeks a year in 2 subsequent years and who have been analyzed for bronchiectasis prior to participation by CT-thorax. Patients with a prior history of asthma, use of i.v. or oral corticosteroids and or antibiotics for an exacerbation 3 weeks before inclusion, other relevant lung diseases, clinically relevant abnormal laboratory values suggesting an unknown disease requiring further clinical evaluation, liver disease, pregnancy or lactation, use of macrolides the last 6 weeks prior to inclusion, allergy or intolerance to macrolides, other research medication started 2 months prior to inclusion, or prior randomization in this study are excluded from the trial. The diseases being studied include cough, chronic obstructive pulmonary disease, and chronic bronchitis, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for patients with asthma. The trial includes patients who are at least 18 years old and weigh at least 50 kg. Patients must have physician-diagnosed asthma and either be experiencing an asthma exacerbation or reporting at least mild persistent asthma symptoms. They must also have had asthma symptoms for at least six months prior to randomization and have objective evidence of reversible airway obstruction. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial will test the effectiveness of azithromycin compared to a placebo.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves two doses of cladribine (5.25 mg/kg and 3.5 mg/kg) and has eligibility criteria such as being between 18 and 65 years old, having definite MS according to the McDonald criteria, and having a relapse within 12 months prior to the start of the study. Exclusion criteria include having secondary progressive or primary progressive MS, prior use of disease modifying drugs within the last 3 months, and compromised immune function or infection. The trial requires written informed consent and compliance with study procedures.",
    "The sample is a phase 3 clinical trial for breast cancer patients with metastatic disease. The trial is testing the effectiveness of the drugs docetaxel, lapatinib ditosylate, and paclitaxel. Eligibility criteria include confirmed adenocarcinoma of the breast, HER2/neu overexpressing and/or amplified disease, no CNS metastases, and various other medical requirements. Patients must not have received prior chemotherapy, immunotherapy, biological therapy, or anti-HER2/neu-targeted therapy for recurrent or metastatic breast cancer. The trial also has various exclusion criteria, including serious cardiac illness or condition, serious illness or medical condition that would not allow the patient to be managed according to the protocol, and peripheral neuropathy \u2265 grade 2.",
    "The sample is a phase 3 clinical trial for patients with acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial involves the use of three drugs, nnrti, ftc/tdf, and stribild. The eligibility criteria include having undetectable plasma HIV 1 RNA levels for at least 6 months prior to the screening visit, no previous use of any approved or experimental integrase strand transfer inhibitor (INSTI), and normal ECG and hepatic transaminases. Exclusion criteria include having a new AIDS-defining condition diagnosed within the 30 days prior to screening, receiving drug treatment for hepatitis C, and having an implanted defibrillator or pacemaker.",
    "The sample is a phase 3 clinical trial for patients with moderate persistent asthma. The trial includes patients who have been diagnosed with asthma for at least 6 months and have a forced expiratory volume (FEV1) or peak expiratory flow rate (PEFR) of at least 80% of the predicted normal value. The patients must have been treated with fluticasone 1000 mcg + salmeterol 100 mcg daily for at least 4 weeks at a stable dose and must not have experienced any nocturnal symptoms or awakenings, exacerbations, or limitations of activities in the last 4 weeks. The trial also includes exclusion criteria such as patients with COPD, current smokers or recent ex-smokers with a smoking history of \u226510 pack/years, and patients with a history of near fatal asthma. The trial will not include patients who do not meet the definition of \"controlled asthma\" at the end of the run-in period.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with the diseases of hysterectomy and postoperative conditions, with the corresponding ICD-10 code of \"N99.3\". The trial involves the use of drugs such as morphine, cg5503 ir, and placebo. The eligibility criteria for the trial include being a female between the ages of 18 and 80, scheduled to undergo an abdominal hysterectomy, and experiencing moderate to severe pain following the procedure. The trial also has exclusion criteria, such as a history of alcohol or drug abuse, ongoing or known history of painful endometriosis, and previous abdominal or pelvic open surgery.",
    "The sample is a phase 3 clinical trial for knee osteoarthritis. The trial is looking at the efficacy of various drugs, including glucosamine sulfate/chondroitin sulfate capsules and sachets, and Cosamin DS. The eligibility criteria for the trial include being over 40 years old, having knee osteoarthritis symptoms for at least six months, and meeting specific clinical and radiological criteria. Exclusion criteria include having certain medical conditions, a history of adverse reactions to certain medications, and inability to understand and report the study questionnaire. The trial also requires participants to use medically acceptable forms of contraception if they are of childbearing potential.",
    "The sample is a phase 3 clinical trial for patients with sickle cell disease and symptomatic pulmonary hypertension. The trial is testing the effectiveness of the drug bosentan in treating the condition. The eligibility criteria include having a documented history of sickle cell disease, confirmed pulmonary hypertension, and meeting certain physical requirements such as a 6-minute walk test distance between 150-450 meters. There are also exclusion criteria, such as having certain cardiac or liver diseases, being pregnant or lactating, or having recently undergone bone marrow transplantation. The trial requires signed informed consent from the patient or their legal representative.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is looking for adult male or female patients with compensated liver disease who have not been previously treated with interferon or ribavirin. The trial requires patients to meet certain eligibility criteria, including having a certain hemoglobin level, platelet count, and neutrophil count, as well as having abnormal ALT values and a specific HCV genotype. Female patients must not be pregnant or breastfeeding and must use two methods of birth control. Male patients must practice acceptable methods of contraception. The trial also has exclusion criteria, such as patients with severe renal dysfunction or creatinine clearance, patients with a history of certain liver diseases, and patients with certain preexisting medical conditions.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial involves the use of the drugs mirabegron and placebo. The eligibility criteria for the trial include having symptoms of overactive bladder for at least 3 months, experiencing a frequency of urination of at least 8 times per day, and experiencing at least 3 episodes of urgency with or without incontinence during a 3-day period. Exclusion criteria include having significant stress incontinence, having an indwelling catheter, having diabetic neuropathy, and having a known hypersensitivity to the drugs being used in the trial. The trial also requires patients to complete a micturition diary and questionnaires correctly.",
    "The sample is a phase 3 clinical trial for patients with osteoarthritis and postoperative pain who are undergoing elective total knee arthroplasty under regional anesthesia. The trial is testing the effectiveness of pregabalin and placebo as pain management options. The eligibility criteria include having sufficient psychomotor dexterity and cognitive capacity to use patient-controlled analgesia/epidural analgesia, being graded as American Society of Anesthesiology Class 1 to 3, and not having inflammatory arthritides or other chronic pain syndromes. The exclusion criteria include undergoing revision, unicompartmental, or bilateral total knee arthroplasty, having inflammatory arthritides or Lyme disease, and having fibromyalgia or other chronic pain syndromes.",
    "The sample is a phase 3 clinical trial for the treatment of nausea in patients with Stage I, II, or III breast cancer who are receiving at least four cycles of anthracycline-based chemotherapy. The trial involves the use of the drug esomeprazole and requires participants to meet certain eligibility criteria, such as being female and having adequate renal and liver function. The trial also has exclusion criteria, such as pregnancy or chronic use of steroids. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for patients with mild-to-moderate essential hypertension. The trial includes patients between 18 and 80 years of age who are able to provide written informed consent and have a mean seated diastolic blood pressure (DBP) between 95 and 109 mmHg and systolic blood pressure (SBP) below 180 mmHg. The trial also requires patients to have a 24-hour mean DBP of at least 85 mmHg at visit 3. Patients must be able to stop any current antihypertensive therapy without risk to the patient, as determined by the investigator. The trial has exclusion criteria, including patients taking more than three anti-hypertensive medications at the screening visit, pre-menopausal women who are not surgically sterile or not practicing acceptable means of birth control, and patients with hepatic and/or renal dysfunction or clinically relevant hypokalaemia or hyperkalaemia. The trial also excludes patients with congestive heart failure, stroke, myocardial infarction, or cardiac surgery within the past three months, as well as patients who have previously experienced symptoms characteristic of angiodema during treatment with ACE inhibitor or angiotensin II receptor antagonists.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of chronic hepatitis C. The diseases are listed as a single item in a list. The icd-10 codes for the diseases are also listed in a single item list. The drugs being tested are sofosbuvir, rbv, and peg. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. The inclusion criteria include having HCV genotype 1, 4, 5, or 6, cirrhosis determination, and meeting certain classifications such as being treatment-naive and having screening laboratory values within defined thresholds. The exclusion criteria include prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase, being pregnant or nursing, having a history of clinical hepatic decompensation, having a history of clinically-significant illness or any other major medical disorder that may have interfered with subject treatment, assessment, or compliance with the protocol, and excessive alcohol ingestion or significant drug abuse.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drug dapagliflozin compared to a placebo in treating type 2 diabetes mellitus with high HbA1c levels and inadequate glycaemic control. The trial is looking for participants who are at least 18 years old, have stable doses of metformin and sulfonylurea, and have HbA1c levels between 7.7% and 11.0%. The trial excludes participants with type 1 diabetes mellitus or diabetes insipidus, recent cardiovascular events, kidney or urological disorders, and hepatic disorders. The record includes a list of disease names, ICD-10 codes, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for chronic kidney disease and end-stage renal disease. The trial involves the use of somatropin and placebo drugs. The eligibility criteria for the trial include having a serum albumin value below 40 g/L, being malnourished, and having stable and adequate haemodialysis treatment for at least three months prior to enrolment. Exclusion criteria include having active malignant disease, requiring treatment in an intensive care unit, having uncontrolled hypertension, being on chronic treatment with steroids in doses of more than 10 mg/day prednisolone (or equivalent), being treated with immunosuppressive agents, having known Growth Hormone Deficiency, having any clinically significant disease history, and having severe illness as defined in the protocol.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the efficacy and safety of two inhalation powders, ff/gw642444 and gw642444. The eligibility criteria include being an outpatient, giving informed consent, being male or female, and meeting certain age and COPD diagnosis requirements. Exclusion criteria include pregnancy, asthma, \u03b11-antitrypsin deficiency, and other respiratory disorders. The trial also has specific requirements for pack-year history, lung function, and exacerbation history. The trial will not enroll subjects with certain diseases or abnormalities, including clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities. Subjects must also not have a history of drug or alcohol abuse, be unable to comply with study procedures, or have a questionable validity of consent. The trial will not enroll subjects who have previously been randomized to treatment with GW642444 Inhalation Powder or have participated in certain other studies.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of insulin glargine and ly2189265, along with insulin lispro, in managing blood glucose levels. The trial includes a list of inclusion and exclusion criteria, such as having a BMI between 23 and 45 kg/m^2, being willing to inject subcutaneous medication, and not having a history of heart failure or active malignancy. The trial also requires participants to maintain a study diary and monitor their blood glucose levels.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drug vildagliptin in combination with metformin. The eligibility criteria include being a male, non-fertile female, or a female using a medically approved birth control method, having received metformin for at least three months prior to the trial, and having a stable dose for a minimum of 8 weeks prior to the trial. Patients must also be between the ages of 18-85 and have an HbA1c level between 6.5-8.0%. Exclusion criteria include being pregnant or lactating, having type 1 diabetes or acute metabolic diabetic complications within the past 6 months, and having certain laboratory abnormalities. The trial requires patients to maintain their prior diet and exercise habits and comply with all study requirements.",
    "The sample is a phase 3 clinical trial for lupus nephritis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria for the trial include male or female patients between the ages of 12 and 75 with a diagnosis of systemic lupus erythematosus and a kidney biopsy within 6 months showing histological diagnosis of lupus nephritis. The exclusion criteria include patients on continuous dialysis for more than 2 weeks before randomization, previous or planned kidney transplant, and other clinically significant active medical conditions. The drugs being tested in the trial include mycophenolate mofetil, cyclophosphamide, azathioprine, placebo to azathioprine, placebo to mycophenolate mofetil, and corticosteroid.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial includes patients with genotype 1 hepatitis C infection who have previously received peginterferon-based therapy for at least 24 weeks and relapsed within 1 year of last taking medication. The trial requires patients to have had a liver biopsy within 3 years before screening showing chronic hepatitis C infection. Patients must agree to use 2 forms of effective contraception throughout the study. The trial excludes patients with HIV or non-genotype 1 hepatitis C, liver disease not related to hepatitis C infection, hepatic decompensation, significant laboratory abnormalities or other active diseases, and pregnant or planning to become pregnant. The trial will test the effectiveness of the drugs tmc435, placebo, peginterferon alpha-2a (pegifn alpha-2a), and ribavirin (rbv).",
    "The sample is a phase 3 clinical trial for the treatment of lymphoma. The trial involves the use of multiple drugs, including carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, and vinblastine. The eligibility criteria for the trial include patients with histologically confirmed stage III or IV Hodgkin's disease with specific characteristics, bidimensionally measurable disease, and negative chest x-ray and CT scan of thorax, abdomen, and pelvis. Patients must also meet certain patient characteristics, such as being between the ages of 15 and 65 and having a Zubrod performance status of 0-1. Prior concurrent therapy is limited, with no prior chemotherapy or radiotherapy for Hodgkin's disease allowed.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the use of drugs such as dapagliflozin, glimepiride, metformin hydrochloride, pioglitazone hydrochloride, and rosiglitazone. The eligibility criteria for the trial include having type 2 diabetes, being on a stable sulphonylurea monotherapy dose for at least 8 weeks prior to the study, and having inadequate glycaemic control. The exclusion criteria include having type 1 diabetes, liver impairment, and kidney failure or dysfunction. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients between the ages of 12 to 75 years who have had a history of moderate to severe asthma for at least one year prior to screening. The patients must have had treatment with a stable regimen of salmeterol or formoterol and high-dose inhaled corticosteroids for at least 8 weeks prior to screening. The trial aims to test the effectiveness of omalizumab (xolair) compared to a placebo, corticosteroids, and long-acting beta-agonists. The eligibility criteria include having inadequately controlled asthma and having had at least one asthma exacerbation requiring systemic corticosteroid rescue in the 12 months prior to the screening visit while receiving treatment with high-dose ICS. The trial also requires a positive skin test or a positive, in vitro response to one relevant perennial aeroallergen documented within the 12 months prior to screening. The exclusion criteria include having had an asthma exacerbation requiring intubation within 12 months prior to screening, having active lung disease other than asthma, and requiring chronic immunosuppressive therapy. Female subjects of childbearing potential must use an effective method of contraception from screening through their duration of participation in the study. The trial does not allow patients who have been treated with Xolair within the 12 months prior to screening or have a history of drug or alcohol abuse that may put the subject at risk for being unable to participate fully in the study for the duration of the study.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of ocular hypertension and open-angle glaucoma. The trial involves the drug tafluprost and requires patients to have previously used latanoprost 0.005% as their medication. The eligibility criteria for the trial include having ocular surface related symptoms and/or signs with the prior medication. The diseases are listed as 'ocular hypertension' and 'open-angle glaucoma', and their corresponding ICD-10 codes are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of epilepsy, specifically partial seizures. The trial involves the drug \"lamictal extended-release\" and has eligibility criteria that include a diagnosis of epilepsy with partial seizures for more than 24 weeks, experiencing at least 8 partial seizures during an 8-week baseline phase, and currently receiving treatment with a stable regimen of one or two antiepileptic drugs for at least four weeks. Exclusion criteria include previous treatment with lamotrigine, exhibiting any primary generalized seizures, receiving treatment with felbamate or currently following the ketogenic diet, and being pregnant, breastfeeding, or planning to become pregnant. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the treatment of colorectal cancer. The trial involves a list of drugs, including folfiri regimen, capecitabine, celecoxib, fluorouracil, irinotecan hydrochloride, and leucovorin calcium. The eligibility criteria for the trial include patients with histologically confirmed adenocarcinoma of the colon or rectum, metastatic disease, and measurable disease. Patients who received prior radiotherapy must have measurable or evaluable disease outside the radiotherapy field. The trial also has specific patient characteristics, including age, performance status, and life expectancy. The sample also includes information on hematopoietic, hepatic, renal, and cardiovascular health, as well as other medical conditions that would preclude study compliance and follow-up. The sample also outlines prior concurrent therapy, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery. Finally, the sample includes information on other concurrent treatments that are not allowed during the trial, such as concurrent sorivudine or chemically related analogues, other concurrent investigational drugs, and concurrent prophylactic fluconazole.",
    "The sample is a phase 3 clinical trial for the treatment of proctitis and proctosigmoiditis using the drugs budesonide and placebo. The trial includes patients with confirmed diagnosis of active, mild to moderate UP or UPS, with disease extending at least 5 centimeters (cm) but no further than 40 cm from the anal verge. The eligibility criteria include having a baseline Modified Mayo Disease Activity Index (MMDAI) score between 5 and 10, and not having a history or current diagnosis of Crohn's disease and indeterminate colitis, among other exclusion criteria. Patients must also not be pregnant or lactating, and must have voluntarily signed written informed consent. The trial prohibits the use of certain medications, including laxatives and anti-diarrhea medications, but allows the use of oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements. The trial also has a list of exclusion criteria, including having a history of uncontrolled psychiatric disorders or seizure disorders, recent history of drug or alcohol abuse, and positive stool test for bacterial pathogens, Clostridium difficile toxin, or ovum and parasites.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, asthma), the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants. This particular record is from a phase 3 trial and includes a list of inclusion and exclusion criteria for potential participants, such as having a documented history of asthma for at least 6 months and not having any significant diseases or disorders that may jeopardize their safety. The record also lists the specific drugs being tested, including budesonide/formoterol, budesonide, and theophylline.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes using insulin aspart and glibenclamide. The trial includes patients who have been on diet therapy for at least 12 weeks or diet therapy and oral hypoglycemic agents other than SU agents for at least 12 weeks, and have not been previously treated with insulin and/or SU agents. The patients must have an HbA1c level between 7.5% and 10.0% and a BMI below 30.0 kg/m2. However, patients with proliferative retinopathy or maculopathy requiring acute treatment, impaired hepatic or renal function, cardiac diseases, uncontrolled hypertension, known hypoglycemia unawareness or recurrent major hypoglycemia, or current treatment with systemic corticosteroids are excluded from the trial. The diseases included in the trial are diabetes and diabetes mellitus, type 2, and the corresponding ICD-10 codes are provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of diabetes, specifically type 1 diabetes. The trial involves the use of insulin detemir, insulin aspart, insulin nph, and human soluble insulin. The eligibility criteria for the trial include having type 1 diabetes for at least 12 months, being on a basal/bolus or biphasic insulin treatment for at least 6 months, having a BMI below or equal to 35 kg/m^2, and having an HbA1c below or equal to 12%. The exclusion criteria include having proliferative retinopathy or maculopathy requiring acute treatment, recurrent major hypoglycemia that may interfere with trial participation, and known hypoglycemic unawareness. The diseases associated with the trial are diabetes and diabetes mellitus, type 1, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for pancreatic neoplasms. The trial includes patients with advanced, non-operable, locally recurrent or metastatic disease who have been previously treated with a systemic gemcitabine based regimen. The trial involves the use of larotaxel (xrp9881), 5-fluorouracil, and capecitabine as drugs. The eligibility criteria include adequate bone marrow, kidney, and liver functions, while the exclusion criteria include an ECOG performance status of 2-3-4, prior locoregional radiotherapy for pancreatic cancer, symptomatic brain metastases or leptomeningeal disease, serious intercurrent infections, uncontrolled cardiac or gastro-intestinal diseases, and other concurrent malignancy. Other protocol-defined exclusion/inclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed, along with the drugs being tested - telmisartan/amlodipine 40/5 mg fixed combination and telmisartan/amlodipine 80/5 mg fixed combination. The eligibility criteria for the trial are also listed, including age requirements, diagnosis of essential hypertension, and failure to respond to previous treatment. The exclusion criteria are also listed, including medical conditions that could be worsened by treatment, previous discontinuation from a trial, and high blood pressure levels.",
    "This is a sample from a clinical trial table that includes information about a phase 3 trial for high risk stage III melanoma. The table includes the phase of the trial, a list of diseases, a list of icd-10 codes for the diseases, a list of drugs being tested, and eligibility criteria for participants. The eligibility criteria include age, complete and adequate resection of Stage III melanoma with histologically confirmed melanoma metastatic to lymph node, disease-free status, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1, and randomization within 12 weeks of surgery. The exclusion criteria include prior therapy for melanoma except surgery and auto-immune disease.",
    "The sample is a phase 3 clinical trial for dry eye syndromes. The trial involves testing multiple carboxymethylcellulose based eye drop formulations and preservative-free lubricant eye drops. The eligibility criteria for the trial include having dry eyes and currently using eye drops for dry eye at least twice daily for at least 3 months. Exclusion criteria include recent eye surgeries, wearing contact lenses during the study, and having active ocular allergy.",
    "The sample is a phase 3 clinical trial for non-small-cell lung carcinoma. The trial includes patients who are at least 18 years old and have stage IIIB or IV NSCLC of non-squamous cell carcinoma subtype. Patients must have at least one measurable lesion and a life expectancy of at least 12 weeks. They must also meet certain laboratory requirements for bone marrow, liver, and renal function. Patients with excluded medical conditions such as cardiac disease, HIV infection, or active clinically serious infections are not eligible for the trial. Patients must not have undergone any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for NSCLC. The trial also excludes patients with a history of bleeding diathesis or coagulopathy, undergoing renal dialysis, or with evidence or history of thrombotic or embolic events. Patients must be able to swallow oral medications and not have any malabsorption condition. The trial includes a list of drugs such as sorafenib, placebo, gemcitabine, and cisplatin. The eligibility criteria for the trial are listed in detail, including inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial includes patients who have been diagnosed with prostate adenocarcinoma and have a history of radical prostatectomy. The patients must also demonstrate biochemical progression of the disease based on PSA doubling time. The trial involves the use of three drugs: docetaxel, leuprolide, and bicalutamide. The eligibility criteria include adequate organ function, a Karnofsky performance status of at least 70%, and a serum testosterone level of at least 100 ng/dL. Patients must also be willing to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. The exclusion criteria include clinically significant cardiac disease, uncontrolled serious active infection, and anticipated duration of life less than 2 years. The sample also includes a list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial that involves patients with depression and heart diseases. The trial aims to test the effectiveness of sertraline and placebo pill in treating persistent depressive symptoms. The eligibility criteria for the trial include having a documented history of coronary heart disease and meeting specific criteria for depression. Patients with certain medical conditions, psychiatric disorders, or who are currently using certain medications are excluded from the trial. The trial also excludes patients who are pregnant, planning to get pregnant, or currently participating in psychotherapy or regular aerobic exercise.",
    "The sample is a phase 3 clinical trial that involves patients with bipolar disorder, anxiety, anxiety disorders, and substance use disorders. The trial is testing the effectiveness of quetiapine xr compared to a placebo for quetiapine xr. The eligibility criteria for the trial include being diagnosed with bipolar I or II disorder, currently depressed, and having a lifetime diagnosis of GAD. Patients must also have a Hamilton Depression Rating Scale score of at least 18 and a Hamilton Anxiety Rating Scale score of at least 18. Patients must be between 18 and 65 years old and cannot be pregnant or breastfeeding. There are also several exclusion criteria, including severe medical or neurological problems, severe personality disorder, and a known history of intolerance or hypersensitivity to any of the medications involved in the study.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The trial includes patients who have been newly diagnosed with acute promyelocytic leukemia (APL) and are confirmed to have the disease through cytomorphology and molecular analysis. The patients must be between the ages of 18 and 71, have a WHO performance status of 0-2, and have a white blood cell count at diagnosis of less than or equal to 10 x 109/L. The trial involves the use of several drugs, including arsenic trioxide, idarubicin, and methotrexate, among others. The eligibility criteria include signed written informed consent, confirmation of diagnosis at the genetic level, and meeting certain health requirements such as having a serum total bilirubin level of less than or equal to 3.0 mg/dL and a serum creatinine level of less than or equal to 3.0 mg/dL. The exclusion criteria include having other active malignancies, significant arrhythmias or neuropathy, and being HIV positive, among others. Women who are pregnant or breastfeeding or of child-bearing potential must meet certain criteria to be eligible for the trial. Patients cannot be using other investigational drugs at the time of enrollment or within 30 days before study entry.",
    "The sample is a phase 3 clinical trial for patients with atrial fibrillation. The trial is testing the effectiveness of the drug valsartan compared to a placebo. The eligibility criteria for the trial include being at least 40 years old, having a history of certain cardiovascular diseases or comorbidities, and having written informed consent. Exclusion criteria include having certain medical conditions, being pregnant or lactating, and having received treatment with an investigational agent within the past month. The trial also has specific requirements for blood pressure, ECG episodes, and recent medical procedures.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder, affective disorders, psychotic, mood disorders, and mental disorders. The trial involves the use of topiramate and placebo drugs. The eligibility criteria for the trial include a DSM-IV diagnosis of Bipolar I Disorder, a YMRS score greater than or equal to 20, general good health, ability to swallow tablets, and a fully capable parent or guardian to monitor the patient's disease process and compliance to treatment. The exclusion criteria include diagnoses of autistic disorder, schizophrenia, schizoaffective disorder, or other psychotic disorders not otherwise specified (NOS), alcohol or substance dependence, chronic antidepressant treatment within 4 weeks of randomization, and serious or unstable medical or neurological conditions.",
    "The sample is a phase 3 clinical trial for the treatment of human immunodeficiency virus (HIV) infection using a drug called gw873140. The trial is looking for participants who are HIV-infected, have a screening viral load of at least 5000 copies/mL, and have a R5-tropic only virus at screening. Participants must also have had prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI). Participants must have a stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening and be able to receive a ritonavir-boosted protease inhibitor during treatment studies. Women of childbearing potential must use specific forms of contraception. The trial has exclusion criteria, including acute laboratory abnormalities, history of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Participants with R5/X4-tropic, X4-tropic only, or non-phenotypeable virus at screening are also excluded. Other exclusion criteria include changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment study, pregnancy or breastfeeding women, recent participation in an experimental drug trial, prior use of a CCR5 or CXCR4 antagonist, significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness, and current use of certain medications. Additional qualifying criteria and laboratory test requirements will be assessed by the study physician.",
    "The sample is a phase 3 clinical trial for kidney transplant patients. The trial is testing the effectiveness of two different drug combinations, everolimus and tacrolimus, and mycophenolate mofetil and tacrolimus. The eligibility criteria for the trial includes male or female renal recipients between the ages of 18-70 who have undergone kidney transplantation, either primary or re-transplant. The recipient must have received a cadaveric, deceased donor, living unrelated, or non-HLA identical living related donor kidney, and the graft must be functional at the time of randomization. There are also exclusion criteria, such as a cold ischemic time of more than 30 hours, producing less than 100 ml of urine in the first 24 hours post-transplantation, and having certain medical conditions that may alter the absorption, distribution, metabolism, and/or excretion of study medication.",
    "The sample is a phase 3 clinical trial for individuals with metabolic syndrome and hypertension. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial includes being an outpatient, between the ages of 18 and 75, and having hypertension and metabolic syndrome as defined by specific criteria. Exclusion criteria include being pregnant or lactating, having type 1 or type 2 diabetes, and having certain levels of hypertension or secondary hypertension.",
    "The sample is a phase 3 clinical trial for patients with breast cancer who express HER2-NEU and have visceral metastasis. The trial involves first-line treatment with Trastuzumab in combination with chemotherapy. Patients must be in good general condition, between the ages of 18 and 70, and have a life expectancy of at least 3 months. They must also not have received Trastuzumab for more than 6 months and must not have cerebral metastasis. Women with genital capacities must use effective contraception and all patients must sign a consent form. Exclusion criteria include contraindication to IRM, psychiatric disease, prior cerebral radiotherapy, geographical constraints, infectious or other serious pathology, positive serology for HIV, hBC, or hBS, inclusion in another clinical trial within 4 weeks before inclusion, and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for HIV patients who have a history of drug resistance or antiretroviral failure while receiving each of three drug classes: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and (protease inhibitors) PIs. The trial requires patients to be on a PI containing regimen with enfuvirtide with HIV viral load (VL) < 400 copies/mL for 6 months or longer and continuously using the same PI regimen for 4 months prior to Screening. Patients who decline to continue enfuvirtide or their physician recommends discontinuation due to injection site reactions that persist despite optimal technique and training with available methods of administration or loss of sites for injection due to tissue nodules and hardening are also eligible. The trial excludes patients who have used any drug contraindicated in the current US package insert for PREZISTA (darunavir) or in the investigators brochure for TMC125, have no prior or current therapy with PREZISTA (darunavir) or TMC125, have no prior genotypic results demonstrating 3 or more darunavir resistance-associated mutations associated with diminished response to darunavir, have AST or ALT >5 times ULN, or have calculated CrCl < 30 ml/min.",
    "The sample is a phase 3 clinical trial for patients with end stage renal disease. The trial involves the use of heparin as a drug and has a list of inclusion and exclusion criteria for patient eligibility. The inclusion criteria include being 18 years or older, having a certain level of dialysis flow rate, and having a dialysis catheter of a specific type. The exclusion criteria include having a known allergy to heparin, active bleeding, or a documented infection requiring antibiotics. The trial also has other criteria related to lab results, blood pressure, and the ability to comply with the protocol.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking for male and female patients who are 18 years or older with Stage I or II hypertension. The trial is testing the effectiveness of the drugs telmisartan and ramipril. The eligibility criteria for the trial include having a mean seated cuff diastolic blood pressure between 95 and 119 mmHg. Exclusion criteria include being pregnant, breastfeeding, having secondary hypertension, severe renal dysfunction, hepatic insufficiency, stroke within the last 6 months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months, unstable or uncontrolled diabetes, history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.",
    "The sample is a phase 3 clinical trial for de novo kidney transplant recipients and renal transplantation patients. The trial involves the use of drugs such as everolimus, cyclosporine, and prednison (continuous steroids). The eligibility criteria for the trial include being a recipient of 1st or 2nd single kidney transplant, having a donor age of over 14 years, and being willing and able to participate in the study. Exclusion criteria include having a history of malignancy, severe liver disease, drug or alcohol abuse, and being pregnant or nursing. Additional exclusion criteria post-transplantation include graft not perfused or with thrombosis of the main vessels. The trial also has additional exclusion criteria at randomization, such as unsatisfactory renal function and severe infections requiring hospitalization in the two weeks preceding randomization.",
    "The sample is a phase 3 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. The trial involves the use of two drugs, il13-pe38qqr and prolifespan 20 with carmustine implant (gliadel\u00ae wafer). The eligibility criteria for the trial include being at least 18 years old, having clinical and/or radiographic evidence of first recurrence or progression of supratentorial GBM after a previous resection or biopsy and external beam radiation therapy, having histopathologic documentation of GBM at initial diagnosis, and having had previous cytoreductive surgery or biopsy for GBM. Patients must also have received external beam radiotherapy with a tumor dose of at least 45 Gy, completed at least 4 weeks prior to study entry, and must be in adequate condition as indicated by various hematologic and performance status criteria. Patients must not be receiving concurrent anti-tumor therapy and must have recovered from toxicity of prior therapy. The trial also has exclusion criteria, including patients with contrast-enhancing tumor component crossing the midline, multi-focal tumor not amenable to gross total resection, or tumor dissemination (subependymal or leptomeningeal). Patients who have received any type of stereotactic radiosurgery or brachytherapy, with the exception of the stereotactic radiosurgery boost part of the initial fractionated external beam radiation therapy, are also excluded. Patients who have received prior treatment with IL13-PE38QQR, GLIADEL\u00ae Wafer, or any intracerebral investigational agent, or who have demonstrated a previous hypersensitivity to BCNU or any other component of the GLIADEL\u00ae Wafer, are also excluded. Patients unwilling or unable to follow protocol requirements are also excluded.",
    "The sample is a phase 3 clinical trial for ulcerative colitis. The trial is open to male and female participants between the ages of 5 and 17 who have a documented history of UC that has been successfully maintained in complete remission for at least 1 month prior to study entry. Participants must have a baseline PUCAI score < 10, a body weight between 17 kg and 90 kg, and a history of at least 1 active episode or relapse in the last 12 months. They must have taken a stable maintenance dose of oral mesalamine (or equivalent oral 5-ASA dose) for at least 1 month prior to entry in the study. Participants must also meet certain exclusion criteria, such as having a history of allergy or hypersensitivity to salicylates, aminosalicylates, or any component of the Asacol tablet, or having a significant co-existing illness or other condition(s) that contraindicate(s) administration of the study drug and/or any study procedures. The trial will evaluate the efficacy and safety of Asacol 400 mg in treating ulcerative colitis in children and adolescents.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the use of two drugs, Xalacom and unfixed latanoprost and timolol. The eligibility criteria for the trial include patients with open-angle glaucoma or ocular hypertension, while exclusion criteria include a history of acute angle closure glaucoma, closed or barely open anterior chamber angle, and ocular surgery within the past 3 months. The icd-10 codes associated with the diseases are also provided.",
    "The sample is a record of a clinical trial in phase 3, focused on the diseases Raynaud and scleroderma. The trial involves the drug fasudil and includes a list of eligibility criteria for participants, including both inclusion and exclusion criteria. Inclusion criteria include a diagnosis of scleroderma and definite Raynaud's, while exclusion criteria include factors such as current malignancy, recent surgical procedures, and active alcohol or drug use. The sample also includes a list of icd-10 codes associated with the diseases being studied.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is looking for patients with resectable adenocarcinoma of the rectum, with the tumor located within 15 cm of the anal margin and tethered or partially fixed on digital rectal exam and/or T3-4 on rectal ultrasound. Patients must not have acute or subacute bowel obstruction without colostomy diversion, chronic inflammatory disease of the ileum and/or colon, primary adenocarcinoma of the anal canal, or distant metastasis. Patients must be 80 years old or younger, have a WHO performance status of 0-1, and meet certain hematopoietic, renal, and cardiovascular criteria. Patients must not have had prior biologic, chemotherapy, endocrine, radiotherapy, or surgery for adenocarcinoma of the rectum. The trial is testing the effectiveness of fluorouracil and leucovorin calcium as treatment options.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for patients with metastatic breast cancer who are not eligible for curative surgery or radiotherapy and have received at least two prior chemotherapy regimens. The trial is testing the effectiveness of the drugs vinflunine and an alkylating agent of physician choice registered in cancer. The eligibility criteria include being a female patient between 18 and 75 years old with a Karnofsky performance score of at least 70%, adequate haematological, hepatic and renal functions, and an ECG without clinically relevant abnormality. Exclusion criteria include having a concurrent serious uncontrolled medical disorder, known or clinical evidence of brain metastases or leptomeningeal involvement, pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites, history of second primary malignancy, HIV infection, preexisting neuropathy, pregnancy or breast feeding.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of prostate cancer, specifically hormone refractory prostate cancer. The trial involves the use of two drugs, satraplatin and prednisone. The eligibility criteria for the trial include having stage D2 metastatic prostate cancer, progression after one prior chemotherapy, ECOG performance status equal or less than 2, life expectancy of more than 3 months, surgical or medical castration, adequate bone marrow, hepatic and renal functions, and informed consent. The exclusion criteria include having more than one prior chemotherapy, prior platinum-containing compounds, prior malignancy, prior significant RT/radionuclide therapy, major GI surgery or GI disease affecting absorption, disease with contraindication to steroids, and brain metastases. The diseases are listed as \"prostate cancer\" and \"hormone refractory prostate cancer\" and their corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for pancreatic neoplasms. The trial involves the use of leucovorin, oxaliplatin, and 5-fluorouracil drugs. The eligibility criteria for the trial include having a histologically or cytologically proven pancreatic carcinoma, measurable locally advanced or metastatic disease, and having previously received Gemcitabine-based chemotherapy as 1st line therapy for advanced or metastatic disease. Patients must also have adequate liver and kidney function, as well as adequate hematological function. Exclusion criteria include having peripheral sensory or motor neuropathy > grade 1, serious cardiac arrhythmia, diabetes, or serious active infection or other active illness that would preclude study participation in the opinion of the investigator, and lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome, or inability to take oral medications.",
    "The sample is a phase 3 clinical trial for the treatment of overactive urinary bladder. The trial includes patients who have given written informed consent and meet certain inclusion criteria, such as having symptoms of urgency according to the International Children's Continence Society criteria and experiencing at least 4 episodes of daytime incontinence confirmed by a 7-day participant diary. The trial also has exclusion criteria, such as having a daily voiding frequency less than 5, having a uroflow indicative of pathology other than overactive bladder, and having a post void residual greater than 20 ml. The trial will test the efficacy of solifenacin succinate suspension compared to a placebo.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug quetiapine xr. The trial is open to participants between the ages of 20 and 65 who have been diagnosed with schizophrenia according to the DSM-IV-TR and have a score of 4 or greater on any of the 7 items of the PANSS Positive Symptom Subscale. Participants must also have switched from previous antipsychotics due to insufficient efficacy or tolerability. The trial has several exclusion criteria, including the presence of any DSM-IV-TR Axis I disorder other than schizophrenia, an imminent risk of suicide or danger to self or others, pregnancy or lactation, intolerance or lack of response to quetiapine IR, use of cytochrome P450 3A4 inhibitors or inducers in the 14 days preceding enrollment, administration of a depot antipsychotic injection within one dosing interval before recruitment, and unstable or inadequately treated medical illness as judged by the investigator.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, diabetic neuropathy), the ICD-10 codes associated with the disease, the drug being tested (ranirestat), and the eligibility criteria for participants. The eligibility criteria include age, type of diabetes, general health, and exclusion criteria such as other causes of neuropathic symptoms, significant illness, and drug or alcohol abuse. The record also includes specific inclusion and exclusion criteria for female patients of childbearing potential.",
    "The sample is a phase 3 clinical trial for metastatic hormone-sensitive prostate cancer. The trial includes patients who have been on androgen-deprivation therapy for less than 120 days and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The trial also has a list of inclusion and exclusion criteria, including specific medical conditions, prior treatments, and medication use. The trial involves the use of androgen-deprivation therapy and docetaxel as drugs. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 3 clinical trial for patients with allergic asthma and concomitant seasonal allergic rhinoconjunctivitis. The trial includes patients of any race who are between 12-45 years old, have a body weight between 20-150 kg, and have a total serum IgE level between 30-700 IU/ml. The trial involves the use of depigoid, omalizumab, and placebo drugs. The eligibility criteria include having a positive RAST result for grass pollen and/or rye pollen specific IgE, and having FEV1 greater than 80% of the predicted normal value. The exclusion criteria include pregnancy, breastfeeding, history of significant clinical manifestations of allergy, history of severe anaphylactoid or anaphylactic reaction, and hypersensitivity to any ingredients of the study medication or related drugs.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial involves the use of two drugs, denufosol tetrasodium inhalation solution and a placebo. The eligibility criteria for the trial include having a confirmed diagnosis of cystic fibrosis, having a FEV1 within a certain range, being able to perform spirometry, and being clinically stable for at least 4 weeks before screening. The exclusion criteria include having abnormal renal or liver function, having had a lung transplant, being unable to discontinue use of hypertonic saline, and having participated in a previous trial.",
    "The sample is a phase 3 clinical trial for the treatment of left-sided uncomplicated diverticular disease using mesalazine and placebo drugs. The trial includes patients who have been diagnosed with left-sided uncomplicated diverticular disease confirmed by ultrasonography or computed tomography and have at least one diverticulum of the left colon. The most recent attack of left-sided uncomplicated diverticulitis should have responded to antibiotics and/or dietary modification within the last 6 months, and the patient's C-reactive protein (CRP) should be above the upper limit of normal (ULN) at the start of the most recent attack. Patients with complicated diverticular disease, right-sided diverticulitis, previous colonic surgery, symptomatic organic disease of the gastrointestinal tract, active colorectal cancer or a history of colorectal cancer, hemorrhagic diathesis, active peptic ulcer disease, local intestinal infection, asthma without careful medical monitoring, abnormal hepatic function, or liver cirrhosis, and abnormal renal function are excluded from the trial.",
    "This sample is from a clinical trial in phase 3, which is testing the effectiveness of duloxetine and placebo in treating osteoarthritis knee pain. The trial is looking for male or female outpatients who have this condition and meet certain inclusion criteria. However, there are also exclusion criteria, such as having serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or having a medical or psychiatric condition that could compromise participation or lead to hospitalization during the study. Additionally, individuals who have previously been exposed to duloxetine are not eligible to participate. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for patients diagnosed with type 2 diabetes mellitus. The trial involves the use of the drug exenatide and a placebo. The eligibility criteria for the trial include being treated with metformin and/or a thiazolidinedione, having an HbA1c level between 6.5% and 9.5%, having a body mass index (BMI) between 25 kg/m^2 and 40 kg/m^2, and not having previously received exenatide or glucagon-like peptide-1 analogs. The exclusion criteria include having participated in a medical, surgical, or pharmaceutical study within 30 days of screening, receiving beta blockers or drugs affecting gastrointestinal motility, and having been treated with certain excluded medications within 3 months prior to screening. The trial also excludes patients who have donated blood within 60 days of screening.",
    "The sample is a phase 3 clinical trial for patients with open-angle glaucoma or ocular hypertension who are not sufficiently controlled on monotherapy or are currently on multiple IOP-lowering medications. The trial involves testing the effectiveness of a combination of ophthalmic suspensions and solutions containing brinzolamide and brimonidine tartrate. The eligibility criteria include having a qualifying IOP entry criteria, being able to understand and sign an informed consent form, and meeting other protocol-specified inclusion criteria. Exclusion criteria include having severe central visual field loss, chronic, recurrent or severe inflammatory eye disease, recent use of high-dose salicylate therapy, and other conditions that would make the patient unsuitable for the study.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes who have inadequate glycemic control. The trial includes both males and females between the ages of 18 and 77 who are either drug naive or have been treated with anti-diabetic medication for less than 24 weeks. The trial also has specific inclusion and exclusion criteria, such as a C-peptide level of at least 1.0 ng/mL and a body mass index of no more than 45.0 kg/m\u00b2. Exclusion criteria include elevated levels of AST and/or ALT, serum total bilirubin, and serum creatinine, as well as symptoms of severely uncontrolled diabetes and other serious medical conditions. The trial involves the use of several drugs, including dapagliflozin, metformin, and pioglitazone, as well as a placebo.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of two drugs, exenatide and rosiglitazone, in managing the disease. The eligibility criteria for the trial include having a HbA1c level between 6.8% and 10.0%, and a BMI between 25 kg/m^2 and 40 kg/m^2. Patients who have previously participated in the study or have taken certain medications are excluded from the trial. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who have had an asthma diagnosis for at least 12 months and have been using a low daily dose of inhaled corticosteroid for at least 12 weeks. The trial will test the effectiveness of a combination of drugs including mometasone furoate/formoterol fumarate, mometasone furoate, formoterol fumarate, and placebo. The eligibility criteria include age, asthma diagnosis, medication use, and pulmonary function tests. The trial also includes exclusion criteria such as recent respiratory tract infections, smoking history, and certain medical conditions. The trial requires written informed consent and adherence to schedules.",
    "The sample is a phase 3 clinical trial for patients with rheumatoid arthritis. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs, and eligibility criteria for inclusion and exclusion. Inclusion criteria include being an adult patient between 18-80 years old, having a diagnosis of rheumatoid arthritis for at least 6 months, receiving outpatient treatment for RA, and having a swollen joint count and tender joint count above a certain threshold. Exclusion criteria include having other rheumatic autoimmune diseases or significant systemic involvement secondary to RA, having inflammatory joint disease or other systemic autoimmune disorder, having had surgery within 12 weeks of the study or planned within 24 weeks of randomization, and having received certain types of previous treatments.",
    "The sample is a phase 3 clinical trial for nicotine addiction. The eligibility criteria include being between the ages of 18-65, smoking at least 10 cigarettes per day for the past 6 months, seeking smoking cessation treatment, planning to live in the area for the next 12 months, being a fluent English speaker, and providing written informed consent. Exclusion criteria include regular use of chewing tobacco, snuff or snus, current enrollment or plans to enroll in another smoking cessation or research program in the next 12 months, and current use of other nicotine substitutes or smoking cessation treatments in the next 12 months. Other exclusion criteria include history or current diagnosis of major depression, any suicide risk score, current or past hypomanic/manic episode, history or current diagnosis of Post Traumatic Stress Disorder (PTSD), psychotic disorder, bipolar disorder, schizophrenia, and current use or recent discontinuation of certain medications. Participants must also be able to provide informed consent and complete study tasks.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing remitting multiple sclerosis. The trial involves the use of two drugs, glatiramer acetate (ga) 40 mg and glatiramer acetate 20 mg. The eligibility criteria for the trial include a confirmed diagnosis of MS, relapsing-remitting type, at least one documented relapse in the past 12 months or two documented relapses in the past 24 months, and a stable neurological condition for at least 30 days prior to screening. The exclusion criteria include previous use of Copaxone, treatment with corticosteroids within 30 days prior to screening, and any clinically significant or unstable medical condition.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia and schizoaffective disorder. The trial involves the use of two drugs, asenapine and olanzapine. The diseases are listed along with their corresponding ICD-10 codes. The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. In order to participate, subjects must have completed 12 months of treatment under protocol 25517 and sign a written informed consent. Subjects with uncontrolled, unstable, clinically significant medical conditions are excluded from the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial is focused on patients who have been diagnosed with asthma and have a history of exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization in the previous year. The trial includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial are listed, including requirements such as a clinical diagnosis of asthma, a certain level of FEV1, and current use of inhaled corticosteroid therapy. The exclusion criteria are also listed, which include a history of life-threatening asthma, respiratory infection or oral candidiasis, and taking another investigational medication or prohibited medication.",
    "The sample is a phase 3 clinical trial that involves patients with essential hypertension, left ventricular hypertrophy, and who are overweight. The trial includes the use of drugs such as aliskiren and losartan, as well as placebos. The eligibility criteria for the trial include having a BMI greater than 25 kg/m2 and confirmed LVH by ECHO. Patients who have been treated with an ACE or an ARB within 3 months of study entry and those treated with an ACE and ARB combination at study entry are excluded from the trial. Other protocol-related inclusion and exclusion criteria also apply.",
    "The sample is a phase 3 clinical trial for pneumonia. The trial includes patients between the ages of 18 and 70 who weigh between 40 and 100 kg and have a BMI of at least 18 kg/m2. Patients must have a clinical diagnosis of CAP and chest X-ray showing new or persisting infiltrates. Female patients must not be lactating and must not be at risk of pregnancy. Patients must be able to take the drug orally. Exclusion criteria include severe cases of CAP requiring hospitalization, known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, and other respiratory diseases such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection. Patients with clinically significant conduction or other abnormality on 12-lead ECG, potassium levels below 3.5 mmol/L, any known disease that seriously affects the immune system, active hepatitis or decompensated cirrhosis, and those who have used quinolones or fluoroquinolones within 14 days before enrollment are also excluded. Patients who are being or will be on a long-term medication of steroids are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone er. The trial is looking for participants who have been diagnosed with schizophrenia at least 1 year before screening and are currently experiencing an acute schizophrenic episode with a total PANSS score between 70 and 120. Participants must agree to be hospitalized for a minimum of 14 days at the start of the study and be capable of administering the study medication themselves or have assistance with medication administration consistently available throughout the study. They must also have resided at the same address continuously for at least 30 days prior to screening and be able and willing to fill out self-administered questionnaires. The trial has certain exclusion criteria, such as a diagnosis of substance dependence within 6 months prior to screening and a history of neuroleptic malignant syndrome.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating macular edema and retinal vein occlusion using two drugs, 700 \u00b5g dexamethasone and 350 \u00b5g dexamethasone. The trial has a list of inclusion and exclusion criteria, including age, visual acuity, and medical history. The trial is not open to individuals with certain medical conditions, such as diabetic retinopathy or uncontrolled systemic disease, and those who are using certain medications, such as systemic steroids or warfarin/heparin.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves testing the effectiveness of the drugs asp1941 and placebo. The eligibility criteria for the trial include having type 2 diabetes mellitus, being on a stable diet or one oral hypoglycemic agent, having an estimated GFR value between 30 and 90 mL/min/1.73 m2, having an HbA1C value between 6.5 and 8.5%, and having a body mass index between 29.0 and 45.0 kg/m2. Exclusion criteria include having type 1 diabetes mellitus, proliferative diabetic retinopathy, having received insulin within 12 weeks before the study, having a chronic disease that requires the continuous use of certain medications, having serum creatinine levels above the upper limit of normal, having proteinuria, experiencing dysuria or urinary tract infection, having significant renal, hepatic or cardiovascular diseases, or having severe gastrointestinal diseases.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) and involves the use of aclidinium bromide 200 \u00b5g and 400 \u00b5g. The trial has inclusion criteria such as a diagnosis of stable moderate to severe COPD and current or former cigarette smokers. Exclusion criteria include recent hospitalization for an acute COPD exacerbation, respiratory tract infection or COPD exacerbation in the 6 weeks before the first visit, and clinically significant respiratory conditions other than COPD, cardiovascular conditions, or mental illness. The trial also excludes patients with a history of asthma, chronic use of oxygen therapy greater than or equal to 15 hours per day, uncontrolled infection due to HIV and/or active hepatitis, hypersensitivity reaction to inhaled anticholinergics, and clinically significant cardiovascular conditions.",
    "The sample is a phase 3 clinical trial for the treatment of diabetes mellitus and macular edema. The trial involves the use of two drugs, ranibizumab and sham injection. The eligibility criteria for the trial include being over 18 years old, having diabetes mellitus with retinal thickening involving the center of the fovea, and having a best corrected visual acuity score in the study eye of 20/40 to 20/320. The trial also has exclusion criteria, such as a history of vitreoretinal surgery in the study eye and uncontrolled diabetes mellitus. The trial requires participants to provide written informed consent and to be willing to return for all scheduled visits and assessments.",
    "This is a sample from a clinical trial table that is in phase 3. The trial is focused on the disease asthma, and the icd-10 codes associated with it are listed. The drug being tested is budesonide/formoterol turbuhaler. The eligibility criteria for the trial include having a diagnosis of mild to moderate asthma with a pre-bronchodilator FEV1 of at least 60% of predicted normal values and daily use of inhaled GCS during the last 3 months. The exclusion criteria include regular need of more than 4 inhalations of a short-acting b2-agonist per day, known or suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of any b-blocking agent, and having smoked at least 10 pack-years.",
    "The sample is a phase 3 clinical trial for the treatment of Parkinson's disease in Chinese patients. The trial includes patients who have been diagnosed with Parkinson's disease for at least 2 years and are 30 years of age or older at the time of diagnosis. The patients must have a Modified Hoehn and Yahr stage of 2 to 4 at on-time and must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. The trial involves the use of pramipexole immediate release tablet and pramipexole extended release tablet. The eligibility criteria include various medical and psychiatric exclusions, such as atypical parkinsonian syndromes, dementia, and history of psychosis. Patients who are pregnant or breastfeeding, have clinically significant disease, or have serum levels of certain enzymes above normal limits are also excluded. The trial requires patients to provide signed informed consent before any study procedures are carried out.",
    "The sample is a phase 3 clinical trial for prostate cancer. The eligibility criteria include having biopsy-proven prostate cancer within the last 12 months, meeting certain clinical stage and biopsy Gleason sum requirements, having no evidence of metastatic disease on bone scan or pelvic CT/MRI, and having a Zubrod performance status of less than 2. Patients must also be able to understand and adhere to the protocol and undergo adequate daily trans-abdominal ultrasound localization during radiation treatment. Exclusion criteria include prior androgen suppression therapy, previous or concurrent malignancies other than basal or squamous cell skin cancers, prior pelvic radiation or chemotherapy, prior or planned radical prostate surgery, and certain histologies or Gleason grades on biopsy. Patients who meet the eligibility criteria will be allowed to participate in other protocols if they are eligible and the other protocols do not interfere with participation in this trial.",
    "The sample is a phase 3 trial for the treatment of menorrhagia and heavy menstrual bleeding. The trial includes women between the ages of 18 and 49 who have regularly occurring menstrual periods. The trial involves the use of tranexamic acid tablets and placebo tablets. The eligibility criteria include having no clinically significant disease or abnormalities that may confound the study, no history of bilateral oophorectomy or hysterectomy, and no hormone therapy for birth control.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including placebo and sitagliptin phosphate. The eligibility criteria for the trial include patients who are currently on diet and exercise therapy and metformin as monotherapy, while patients with type 1 diabetes mellitus are excluded.",
    "The sample is a phase 3 clinical trial for pulmonary fibrosis. The trial includes patients who are at least 40 years old and have been diagnosed with IPF within the past 5 years according to the most recent IPF guidelines. The diagnosis is confirmed by HRCT pattern and surgical lung biopsy pattern. Patients with Dlco (corrected for Hb) between 30%-79% predicted of normal and FVC>= 50% predicted of normal are eligible for the trial. However, patients with relevant airways obstruction, likely to have lung transplantation during the study, or with recent myocardial infarction or unstable angina are excluded. Patients with bleeding or thrombotic risk, or who have received certain medications within a certain time frame are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of squamous cell carcinoma of the head and neck using the drug lapatinib. The trial is open to male and female participants between the ages of 18 and 70 who have undergone curative surgery for their cancer and have no evidence of gross residual disease. Participants must also meet certain eligibility criteria, including having a certain pathological stage and high-risk factors, having adequate organ function, and being able to swallow tablets or a suspension of tablets dissolved in water. The trial has exclusion criteria, such as having a history of other malignancies or uncontrolled heart conditions. The trial will evaluate the efficacy and safety of lapatinib compared to a placebo.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing two different diabetes management regimens that involve human insulin inhalation powder. The eligibility criteria include having type 2 diabetes for at least 6 months, having a HbA1c level between 7.0% and 10.5%, and being a candidate for insulin therapy. The exclusion criteria include pregnancy, smoking, a history of severe hypoglycemia, recent pneumonia or glucocorticoid therapy, and certain medical conditions such as renal or lung transplantation or active malignancy.",
    "The sample is a phase 3 clinical trial for patients with persistent asthma that is not optimally controlled on high doses of ICS or medium dose of ICS+LABA. The trial includes patients aged over 18 years with FEV1 >= 40% and < 80% of predicted for the patient normal value and at least 0.9 L. Patients must also have a documented positive response to the reversibility test and not adequately controlled asthma according to GINA 2010 with a score at the Asthma Control Questionnaire (ACQ)> 0.75. The trial excludes patients with a history of near fatal asthma or frequent exacerbations, hospitalization or use of systemic steroids for asthma exacerbation in the 4 weeks prior to screening visit, symptomatic infection of the lower airways in the 4 weeks before the screening visit, current or ex-smokers with total cumulative exposure equal or more than 5 pack-years and /or having stopped smoking one year or less prior to screening visit, and patients with a clinically significant abnormality at 12-lead ECG or presenting a QTcB interval value in ECG > 450 msec in males or > 470 msec in females. The trial involves the use of two drugs, chf1535 200/6 \u00b5g and bdp 100 \u00b5g, and the diseases being studied are asthma.",
    "The sample is a phase 3 clinical trial for patients with refractory multiple myeloma. The trial is testing the effectiveness of the drug plerixafor in combination with stem cell mobilization therapy for possible allogeneic stem cell transplant. The eligibility criteria include a diagnosis of MM, having received at least 2 cycles of lenalidomide therapy, and being in first or second complete or partial remission or stable refractory but not actively progressing myeloma. Patients must also meet certain health requirements and agree to contraception during stem cell mobilization. Exclusion criteria include prior transplantation, radiation therapy to the pelvic area, and current or prior history of other malignancies.",
    "The sample is a phase 3 clinical trial for women with breast cancer and hot flashes. The trial is testing the effectiveness of the drug gabapentin. The eligibility criteria include having a confirmed diagnosis of infiltrating carcinoma of the breast, non-invasive or pre-invasive lesions of the breast, a known breast cancer susceptibility gene or strong family history of breast cancer, and experiencing at least one daily hot flash. Participants must also be able to provide informed consent, be at least 18 years old, have a Karnofsky performance status of over 70%, and have adequate hematopoietic, renal, and hepatic function. Exclusion criteria include a history of secondary cancer within the last 5 years, any residual chemotherapy-induced toxicity, inability to give informed consent or adhere to the protocol, serious medical or psychiatric illness likely to interfere with participation, ongoing or active infection, history of alcohol or drug abuse, allergy to gabapentin, and history of seizure disorder.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have given their written consent and have been diagnosed with schizophrenia according to the DSM-IV criteria. Both inpatients and outpatients are eligible for the trial. The trial includes the drugs er oros paliperidone, placebo, and olanzapine. The eligibility criteria include exclusion criteria such as a diagnosis of a mental disease other than schizophrenia, substance-related disorder within 180 days before the screening test, and a total PANSS score at the screening test <70 or >120. Patients treated with three or more types of antipsychotic within 28 days before the screening test, those with Parkinson's disease, and those with a complication of or a past history of cerebrovascular accident or diabetes mellitus are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for individuals diagnosed with type 2 diabetes mellitus. The trial requires participants to be between 18-75 years old and have been diagnosed with type 2 diabetes for at least six months prior to screening. Participants must also be treated with a stable dose of metformin for at least three months and have not been treated with certain other anti-diabetic therapies within three months prior to screening. The trial also has various inclusion and exclusion criteria related to medical history, medication use, and lifestyle factors. The trial is testing the effectiveness of bromocriptine mesylate as a treatment for type 2 diabetes.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients who have completed a previous study without any serious adverse drug reactions and are physically healthy and ambulatory. Patients must enroll within 3 days of completing the previous study and have well-controlled co-morbid medical conditions. Patients taking certain medications, such as SSRIs and bronchodilators, may be included if doses are within approved ranges. Patients must have a caregiver who is willing and able to provide accurate data and accompany the patient to all visits. Exclusion criteria for patients include no available caregiver, active or clinically-significant conditions affecting absorption, distribution, or metabolism of the study medication, and unwillingness or inability to fulfill study requirements. Exclusion criteria for caregivers include unwillingness or inability to give informed consent or fulfill study requirements.",
    "The sample is a phase 3 clinical trial for eosinophilic asthma. The trial involves the drugs reslizumab and placebo. The eligibility criteria for the trial include being between 18 and 65 years old, having a diagnosis of asthma, having an ACQ score of at least 1.5, and having airway reversibility of at least 12% to beta-agonist administration. Patients must also be currently taking fluticasone at a dosage of at least 440 \u00b5g daily (or equivalent) and have stable asthma therapy regimens for 30 days before screening. Female patients must be surgically sterile, 2 years postmenopausal, or have a negative pregnancy test result. Patients must be in reasonable health and willing to comply with study restrictions. Exclusion criteria include having another confounding underlying lung disorder, a clinically meaningful comorbidity, or a history of use of certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of diffuse large B-cell lymphoma. The trial includes patients aged 60 to 65 years who have not been previously treated and have a minimum life expectancy of 3 months. The trial involves the use of a combination of drugs including rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone. The eligibility criteria include having diffuse large B-cell lymphoma, being in Ann Arbor stage II, III, or IV, having an ECOG performance status of 0 to 2, and having negative HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) serologies test. The exclusion criteria include having T-cell lymphoma, any history of treated or non-treated indolent lymphoma, central nervous system or meningeal involvement by lymphoma, contra-indication to any drug contained in the chemotherapy regimens, and any serious active disease.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves testing the effectiveness of several drugs, including a high and low dose of bi 10773 and placebos. The eligibility criteria include having a diagnosis of type 2 diabetes mellitus, being on a specific treatment regimen for at least 12 weeks prior to randomization, having a certain level of HbA1c, being over 18 years old, and having a BMI of 45 kg/m2 or less. Exclusion criteria include uncontrolled hyperglycemia, recent myocardial infarction, liver or renal disease, recent bariatric surgery, recent cancer treatment, and other medical conditions that could jeopardize patient safety. The trial also requires signed informed consent and periodic pregnancy testing for pre-menopausal women.",
    "The sample is a phase 3 clinical trial for lupus nephritis and systemic lupus erythematosus. The trial involves the use of drugs such as corticosteroids, cyclophosphamide, mycophenolate mofetil, ocrelizumab, azathioprine, and a placebo. The eligibility criteria for the trial include being 16 years or older, having a diagnosis of SLE and active lupus nephritis, and being willing to comply with the protocol requirements. Exclusion criteria include having certain medical conditions, being pregnant or breastfeeding, having a history of drug or alcohol abuse, and having received certain treatments or vaccines prior to the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes and hypertension. The trial involves the use of two drugs, bi 10773 and placebo, and the eligibility criteria includes having a HbA1c level between 7.0% and 10%, and a mean seated systolic blood pressure between 130-159 mmHg and diastolic blood pressure between 80-99 mmHg. Patients with uncontrolled hyperglycemia, known or suspected secondary hypertension, or a recent history of acute coronary syndrome, stroke, or transient ischemic attack are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer (NSCLC) patients with malignant pleural effusion or stage IV disease. The trial is testing the effectiveness of two drug combinations, cetuximab + cisplatin + vinorelbine and cisplatin + vinorelbine, in patients with NSCLC who have evidence of EGFR expression on tumor tissue and at least one measurable index lesion. The eligibility criteria include a diagnosis of histologically or cytologically confirmed NSCLC, while exclusion criteria include previous exposure to monoclonal antibodies or EGFR-targeting therapy, previous chemotherapy for NSCLC, documented or symptomatic brain metastasis, superior vena cava syndrome, and previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have had active RA for at least 3 months. Patients of reproductive potential must be using reliable methods of contraception. The trial excludes patients who have had major surgery within 8 weeks before entering the study or planned major surgery within 6 months after entering the study. Patients who have been treated with methotrexate within 6 months of entering the study or have stopped previous MTX treatment due to toxicity or lack of response are also excluded. Women who are pregnant or breastfeeding are not eligible for the trial. The trial involves the use of methotrexate and tocilizumab [roactemra/actemra].",
    "The sample is a record of a clinical trial in phase 3 for the treatment of dry eye disease. The trial involves the use of two drugs, 3% de-089 ophthalmic solution and 0.1% sodium hyaluronate ophthalmic solution. The eligibility criteria for the trial include having a confirmed keratoconjunctival disorder with abnormal Schirmer score results. Exclusion criteria include having an eye disease that requires therapy other than that for dry eye and needing to wear contact lenses during the study. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for the treatment of erosive esophagitis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require that participants have been treated with standard or higher-than-standard dose PPI, have endoscopically confirmed reflux esophagitis of Grade A to D, and have good compliance with the study medication. The exclusion criteria include participants with esophagus-related complications, a history of surgery or treatment affecting gastroesophageal reflux, acute upper gastrointestinal bleeding, gastric or duodenal ulcer, and Zollinger-Ellison syndrome or other gastric acid hypersecretion disorders.",
    "The sample is a phase 3 clinical trial for the treatment of ulcer. The trial involves the use of two drugs, ibuprofen/famotidine and ibuprofen. The eligibility criteria for the trial include patients who are expected to require daily administration of an NSAID for at least the coming six months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain. Patients who have used an NSAID within the 30 days prior to study entry are excluded. Other exclusion criteria include a history of erosive esophagitis, serious gastrointestinal complications, active cardiac, renal, and/or hepatic disease, current Helicobacter pylori (H. pylori) infection, use of certain medications within the 14 days prior to study entry, uncontrolled diabetes or hypertension, positive pregnancy test, positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, and current participation in an investigational drug study. The study center will determine if patients meet all of the criteria.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The trial is testing the drug cilomilast. The eligibility criteria for the trial include a diagnosis of COPD and a history of cigarette smoking, while exclusion criteria include significant heart or lung disease not associated with COPD, as well as significant stomach or intestinal disease. The sample also includes the ICD-10 codes associated with COPD.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, menopause and postmenopausal vaginal atrophy, which are identified by their corresponding ICD-10 codes. The trial is testing the effectiveness of a drug called estradiol, which is administered in a dose of 10 mcg. The eligibility criteria for the trial includes postmenopausal women who have not had a menstrual cycle for at least two years.",
    "The sample is a phase 3 clinical trial for multiple sclerosis and fatigue. The trial includes a list of diseases and their corresponding icd-10 codes, a list of drugs including high dose aspirin, low dose aspirin, and placebo, and eligibility criteria for participants. The inclusion criteria require confirmed relapsing-remitting or secondary progressive multiple sclerosis, the ability to walk 100 meters without assistance, persistent fatigue for at least 8 weeks, and the ability to complete questionnaires and cognitive testing. Exclusion criteria include untreated depression, significant cognitive impairment, sleep disorders, recent corticosteroid use, and use of certain medications. The trial also has medical contraindications to ASA use, general health concerns, and laboratory exclusions.",
    "The sample is a phase 3 clinical trial for patients with acquired immunodeficiency syndrome (AIDS) and HIV infection who have limited or no approved treatment options due to resistance or intolerance. The trial is testing the drug maraviroc, and the inclusion criteria require subjects to have failed to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA \u2265 1000 copies/ml at screening. Additionally, subjects must have only R5 HIV-1 at screening as verified by the Monogram Biosciences Trofile assay. The exclusion criteria include prior treatment failure with any CCR5 antagonist, ongoing CCR5 trials, or previous discontinuation of Maraviroc in trials. Subjects with potentially life-threatening laboratory abnormalities or medical conditions are also excluded unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who have had disease progression after one prior first-line platinum-based chemotherapy with or without maintenance therapy. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and measurable or nonmeasurable disease. The trial involves the use of placebo (for ramucirumab) and docetaxel as drugs. The eligibility criteria include adequate organ function, urinary protein less than or equal to 1+ on dipstick or routine urinalysis, and life expectancy of greater than or equal to 3 months. Exclusion criteria include disease progression on more than 1 prior chemotherapy regimens, concurrent treatment with other anticancer therapy, and prior therapy with docetaxel.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves testing the effectiveness of various drugs, including placebo, tiotropium, olodaterol, and combinations of these drugs. The eligibility criteria for the trial include patients between 40 and 75 years of age, with a smoking history of more than 10 pack years, and a diagnosis of chronic obstructive pulmonary disease. Patients must also meet certain spirometric criteria. Exclusion criteria include patients with significant diseases other than COPD, abnormal baseline haematology, blood chemistry, or urinalysis, and a history of asthma or other conditions that may put the patient at risk. Pregnant or nursing women and women of childbearing potential not using highly effective methods of birth control are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis. The trial includes patients with plaque-type psoriasis covering at least 10% of their body surface area and a psoriasis area-and-severity index score of 12 or higher. The trial will test the effectiveness of the drug ustekinumab compared to a placebo. The eligibility criteria include being considered a candidate for phototherapy or systemic treatment of psoriasis and having no history of latent or active tuberculosis. The exclusion criteria include having nonplaque forms of psoriasis or drug-induced psoriasis, having had a BCG vaccination within the previous 12 months, and having a history of chronic or recurrent infectious disease or serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months. Patients with certain infections or diseases are also excluded, as well as those with a history of malignancy, except for certain skin cancers and pre-invasive cervical cancer.",
    "The sample is a phase 3 clinical trial for metastatic colorectal cancer. The trial includes patients with adenocarcinoma of the colon or rectum who are over 18 years old and have measurable disease according to RECIST criteria. The trial requires patients to have an expected survival of more than three months and adequate bone marrow, liver, and kidney function. Patients must also have an INR less than 1.5 times the upper limit and adequate contraception for fertile patients. The trial excludes patients who have had earlier chemotherapy for metastatic colorectal cancer, adjuvant treatment within 6 months, surgery or significant trauma within 28 days prior to study entry, planned radiotherapy against target lesions, CNS metastases, prior malignancy within 5 years except ca in situ of cervix and basal cell carcinoma, bleeding diathesis, uncontrolled hypertension, significant cardiovascular disease, treatment with anticoagulant drugs, participation in other clinical trials, and pregnant or lactating patients. The trial uses erlotinib (tarceva) and bevacizumab (avastin) as drugs.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have undergone total mastectomy or lumpectomy followed by an axillary dissection or sentinel node resection. The trial includes patients with histologically confirmed Stage I, IIA or IIB invasive adenocarcinoma of the breast with T1-3, pN0 and M0 classification, and negative axillary lymph nodes or sentinel lymph nodes. The patients must have ER positive tumors and no bone metastases. The trial involves the use of cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, and tamoxifen citrate drugs. The eligibility criteria include various patient characteristics such as age, sex, menopausal status, life expectancy, and performance status, as well as medical history and concurrent therapy.",
    "The sample is a record of a clinical trial in phase 3, which involves patients with atrial fibrillation, stroke, and embolism. The trial is testing the effectiveness of the drugs rivaroxaban and warfarin, as well as matching placebos for each drug. The eligibility criteria for the trial include having documented atrial fibrillation, a history of stroke or embolism, and certain risk factors. Exclusion criteria include significant mitral stenosis, active internal bleeding, and a history of intracranial bleeding or hemorrhagic disorders.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes provided. The trial involves the use of three drugs: Symbicort (listed twice) and Budesonide. The eligibility criteria for the trial are also provided, including age requirements, a clinical diagnosis of asthma, and specific lung function requirements. The exclusion criteria are also listed, including recent hospitalization or emergency treatment for asthma, recent use of certain medications, and recent respiratory infections.",
    "The sample is a phase 3 clinical trial for primary biliary cirrhosis. The trial includes participants who have been diagnosed with PBC and meet certain criteria, such as having elevated alkaline phosphatase levels, positive antimitochondrial antibodies, and a liver biopsy consistent with PBC. Participants must also be taking ursodeoxycholic acid for at least 12 months prior to the trial or be unable to tolerate it. The trial excludes participants with other liver diseases, clinical complications of PBC, severe pruritus, and certain medical conditions. Participants must provide written informed consent and agree to comply with the trial protocol.",
    "The sample is a phase 3 clinical trial for breast cancer. The eligibility criteria include meeting certain risk factors based on age, having certain prior breast conditions, and having no evidence of breast cancer on a mammogram within the past year. Patients must be female, between the ages of 40 and 70, and have a life expectancy of at least 10 years. They must also be psychologically and physically suitable to receive 5 years of anti-estrogen therapy. Prior concurrent therapy with certain drugs is not allowed. The trial involves the drugs anastrozole and placebo.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including lcz696, amlodipine, and placebo. The eligibility criteria for the trial include having a diagnosis of hypertension and meeting specific blood pressure requirements. Patients must also successfully complete ABPM and pass technical requirements. Exclusion criteria include having malignant or severe hypertension, a history of angioedema, or a secondary form of hypertension. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with anemia and cancer. The trial includes the drug epoetin alfa and has eligibility criteria such as being 18 years or older, having a body weight of at least 99lbs, and having a screening hemoglobin level of 11.0 g/dL or lower for men and 10.0 g/dL or lower for women. Exclusion criteria include having a history of or concurrent second malignancy and evidence of primary or metastatic malignancy involving the Central Nervous System. The diseases are listed as anemia and cancer, with corresponding ICD-10 codes provided.",
    "The sample is a phase 3 clinical trial for patients with esophagus cancer. The trial includes the drugs cisplatin and 5-fluorouracil. The eligibility criteria for the trial include having biopsy-proven carcinoma of the esophagus, being unable to undergo radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness, having symptomatic dysphagia scores of \u2265 1, having a performance status ECOG \u2264 2, beginning treatment within 2 weeks of randomization, being at least 18 years old, having adequate hematological and renal function, using adequate contraception if capable of childbearing, and providing written informed consent. Exclusion criteria include previous mega-voltage external beam radiotherapy or brachy-therapy delivered to the region of the chest, synchronous active malignancies, pregnancy or lactation, being unfit for any treatment component, having a tracheo-oesophageal fistula or stents in situ, previous chemotherapy for esophageal cancer, and having a CT scan of thorax and abdomen more than 8 weeks prior to randomization or full blood count, biochemistry (including creatinine), and creatinine clearance more than 2 weeks prior to randomization.",
    "The sample is a phase 3 clinical trial for the treatment of knee pain caused by osteoarthritis. The trial involves the use of the drug duloxetine and a placebo. The eligibility criteria for participants include having knee pain due to osteoarthritis for at least 14 days each month for the 3 months prior to the study, taking nonsteroidal anti-inflammatory drugs (NSAIDs) for knee pain due to osteoarthritis on most days in the 3 months prior to the study, and meeting certain exclusion criteria such as having a history of intolerance or nonresponsiveness to duloxetine, having a history of substance abuse or dependence within the past year, or having a BMI over 40. The trial also excludes participants with certain medical or psychiatric conditions that could compromise participation or lead to hospitalization or a change in medication during the course of the study.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hypertrophy. The trial involves the use of drugs such as cetrorelix 78 mg + 78 mg, cetrorelix 78 mg + 52 mg, and placebo. The eligibility criteria for the trial include having a medical history of benign prostatic hyperplasia and experiencing voiding symptoms. Exclusion criteria include having a urgent need for prostate surgery or prior surgical treatment of the prostate or bladder, major organ dysfunction, and recent treatment with certain drugs. The trial also excludes individuals with certain urologic disorders or a history of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the treatment of schizophrenia. The trial involves the use of drugs such as haloperidol and asenapine, and includes a list of inclusion and exclusion criteria for participants. In order to be eligible for the trial, participants must have completed a previous short-term trial and meet certain demographic and procedural criteria. They must also demonstrate an acceptable level of compliance with trial medication. Exclusion criteria include a high CGI-S score, adverse events, and certain medical or psychiatric conditions.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of painful diabetic neuropathy. The trial involves the use of drugs such as placebo and pregabalin. The eligibility criteria for the trial include having a Visual Analogue Scale (VAS) of pain higher than 40 mm and a diagnosis of type 1 or 2 diabetes mellitus for at least 1 year. The exclusion criteria include having had malignancy within the past 2 years and having neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathy pain. The diseases associated with the trial are diabetic neuropathy, and the icd-10 codes associated with the disease are G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, and H46.3.",
    "This sample is for a phase 3 clinical trial for non-squamous non-small cell lung cancer. The trial is testing the effectiveness of the drugs pemetrexed, gemcitabine, and cisplatin. The eligibility criteria include having a histologically proven or cytological diagnosis of non-squamous non-small cell lung cancer Stage IIIB or IV, no prior systemic chemotherapy for lung cancer, and an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. Participants must also have adequate organ function and an estimated life expectancy of greater than or equal to 12 weeks. Exclusion criteria include having a serious concomitant systemic disorder that would compromise the participant's ability to complete the study, a serious cardiac condition, and being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been diagnosed clinically for at least 24 weeks prior to screening. The trial is testing the effectiveness of insulin degludec/insulin aspart as a treatment option. In order to be eligible for the trial, patients must be insulin na\u00efve and currently receiving metformin monotherapy or metformin in combination with one of the following oral anti-diabetic drugs: insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitor, or alpha-glucosidase inhibitors for at least 12 weeks prior to randomisation. Patients must also have a HbA1c level between 7.0-10.0% and a BMI below or equal to 40.0 kg/m^2. There are several exclusion criteria, including recent treatment with thiazolidinediones (TZDs) or glucagon like peptide 1 (GLP-1) receptor agonists, anticipated significant lifestyle changes during the trial, and any clinically significant disease or disorder that could interfere with the results of the trial.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years of age or older, have a history of smoking, and have a post-albuterol/salbutamol FEV1/FVC ratio of less than 0.70 and a post-albuterol/salbutamol FEV1 of between 35% and 70% of predicted normal. The trial aims to test the efficacy and safety of several drugs, including gsk 573719 +gw642444 125/25, gsk573719 + gw642444 62.5/25, gsk 573719 125, gsk 573719 62.5, gw642444 25, and plb. The eligibility criteria include being an outpatient, having an established clinical history of COPD, and having a score of 2 or higher on the Modified Medical Research Council Dyspnea Scale. The exclusion criteria include pregnancy, asthma, and other respiratory disorders, as well as significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities. The trial also excludes patients with a history of drug or alcohol abuse within 2 years prior to the trial, and those who are affiliated with the investigator site.",
    "The sample is a phase 3 clinical trial for the treatment of skin infections caused by Gram-positive bacteria. The trial includes patients who are at least 18 years old and have been diagnosed with an acute bacterial skin and skin structure infection (ABSSSI) requiring at least 7 days of intravenous therapy. The trial involves the use of two drugs, single-dose iv oritavancin diphosphate and iv vancomycin. The eligibility criteria for the trial include having at least 2 signs and symptoms of ABSSSI, being willing to comply with all required study procedures, and not having any exclusion criteria such as prior use of antibacterial therapy or severe sepsis. The trial aims to evaluate the safety and efficacy of the two drugs in treating ABSSSI caused by Gram-positive bacteria.",
    "The sample is a phase 3 clinical trial for seasonal allergic rhinitis. The trial includes patients who are 12 years of age or older and have a history of seasonal allergic rhinitis during the fall pollen allergy season. The trial involves the use of several drugs, including azelastine hydrochloride 0.15% nasal spray, azelastine hydrochloride 0.15% and placebo, and azelastine 0.1% nasal spray. The eligibility criteria include having a reflective total nasal symptoms score (TNSS) of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Day -7, having taken at least 10 doses of study medication during the lead-in period, and having an instantaneous TNSS of \u2265 8 before beginning the onset of action assessment on Day 1. The trial also has exclusion criteria, such as the use of any investigational drug within 30 days prior to Day -7, the presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose, and the existence of any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of study drug.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar I disorder. The trial involves the use of aripiprazole and placebo drugs. The eligibility criteria include being between the ages of 18 and 65, having the ability to understand and provide informed consent, meeting DSM-IV-TR criteria for manic or mixed episodes of bipolar I disorder, and having completed a previous study with a certain level of drug efficacy. Exclusion criteria include having certain medical conditions or complications, such as schizophrenia or personality disorder, allergy to aripiprazole, or a risk of committing suicide.",
    "The sample is a phase 3 clinical trial for patients with systemic lupus erythematosus. The trial is testing the effectiveness of switching to myfortic or continuing with azathioprine as maintenance therapy. The eligibility criteria include being 18 years or older, meeting the diagnostic criteria for SLE according to ACR guidelines, having a SLEDAI score greater than 6, and being willing to participate in the study. Exclusion criteria include having a creatinine clearance of less than 20ml/min, having a clinically significant infection, having a known hypersensitivity to myfortic or similar drugs, having a history of malignancy within the past 5 years, having active CNS manifestations or a past history of SLE CNS complications, having received prior therapy with mycophenolic acids, having received an investigational drug within four weeks prior to study entry, and being a female of childbearing potential who is planning to become pregnant, who is pregnant and/or lactating, or who is unwilling to use effective means of contraception.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes the drugs bevacizumab, carboplatin, paclitaxel, and a placebo. The eligibility criteria for the trial include having locally advanced or metastatic non-squamous non-small cell lung cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and adequate hematological, renal, and liver function. Exclusion criteria include prior chemotherapy or treatment with another systemic anti-cancer agent for the participant's current stage of the disease, mixed non-small cell and small cell tumors, evidence of tumor invading major blood vessels on imaging, and clinically significant cardiovascular or vascular disease.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cavity cancer using chemotherapy. The trial requires patients to have achieved complete remission with normal CA 125 after first-line platinum-containing chemotherapy and not have participated in MRC-ICON1. Patients must also meet certain age, performance status, hematopoietic, hepatic, renal, and other criteria. Prior participation in certain clinical trials is allowed, but no prior or concurrent malignancy within the past 5 years is allowed except for nonmelanoma skin cancer. The table includes columns for the phase of the trial, the diseases being treated, the corresponding ICD-10 codes, the drugs being used, and the eligibility criteria.",
    "The sample is a phase 3 clinical trial for metastatic breast cancer (MBC) patients. The trial includes the drugs gemcitabine, docetaxel, and paclitaxel. The eligibility criteria for the trial include a histologic diagnosis of MBC, relapsing after receiving one adjuvant/neoadjuvant chemotherapy containing an anthracycline if not clinically contraindicated, and previous hormonal therapy for adjuvant setting or metastatic disease. The exclusion criteria include previous chemotherapy for MBC, previous chemotherapy with gemcitabine in any setting of disease, and patients who are candidates for treatment with trastuzumab. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 clinical trial for non-small-cell lung cancer. The trial is testing the effectiveness of zoledronic acid 4 mg as a treatment. The eligibility criteria for the trial include having a confirmed diagnosis of NSCLC, being newly diagnosed with stage IIIA or IIIB (excluding patients with pleural effusion), and having received primary treatment for the disease with no progression. Patients who have been diagnosed with NSCLC longer than 6 months ago, have been treated with other bisphosphonates in the past 12 months, or have metastases are excluded from the trial. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial includes subjects aged 16 to 70 years with well-characterized localization-related or generalized epilepsy according to the International League Against Epilepsy classification. The inclusion criteria require subjects to have at least 2 or 4 partial-onset seizures or type II-seizure days per month, depending on the type of epilepsy, and to be uncontrolled while treated by 1 to 3 permitted concomitant antiepileptic drugs. The exclusion criteria include a history or presence of seizures occurring only in clusters or as Type IA non-motor, and a history or presence of status epilepticus during the year preceding Visit 1 or during Baseline. The trial involves the use of placebo and brivaracetam as drugs.",
    "The sample is a phase 3 clinical trial for patients with multiple myeloma who have relapsed or progressed after at least one autologous transplant. The trial includes patients with measurable disease and specific criteria for eligibility, such as a performance status of 2 or lower, adequate renal and hepatic function, and a negative pregnancy test for women of childbearing potential. The trial also has exclusion criteria, such as evidence of POEMS Syndrome, significant neurotoxicity, and poorly controlled hypertension or diabetes. The trial involves the use of drugs including velcade, thalidomide, and dexamethasone, and velcade, melphalan, and dexamethasone. The eligibility and exclusion criteria are detailed in the \"criteria\" column of the table.",
    "The sample is a phase 3 clinical trial for gastrointestinal stromal tumors. The trial includes patients who are 18 years or older and have confirmed metastatic and/or unresectable GIST. Patients must have previously undergone treatment with imatinib and sunitinib, with objective disease progression or intolerance to imatinib, as well as disease progression while on sunitinib therapy. The trial allows for prior treatment with other systemic therapies, except for any other vascular endothelial growth factor receptor (VEGFR) inhibitor. Patients must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 is required. Patients must also have adequate bone marrow, liver, and renal function as assessed by laboratory parameters. Recovery to NCI-CTCAE v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure-related toxicity (except alopecia and anemia) is required. The exclusion criteria include major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication, congestive heart failure New York Heart Association (NYHA) class 2, unstable angina or myocardial infarction within the past 6 months before start of study medication, uncontrolled hypertension, arterial thrombotic or embolic events, ongoing infection grade 2 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0, symptomatic metastatic brain or meningeal tumors, evidence or history of bleeding diathesis, any hemorrhage or bleeding event NCI-CTCAE version 4.0 grade 3 or higher within 4 weeks prior to the start of study drug, non-healing wound, ulcer, or bone fracture, and persistent proteinuria of NCI-CTCAE version 4.0 grade 3 or higher. The drugs used in the trial are regorafenib (stivarga, bay73-4506), placebo, and best supportive care.",
    "The sample is a phase 3 clinical trial for HIV-1 infection. The trial is testing the effectiveness of atazanavir/ritonavir monotherapy in HIV-infected patients who are at least 18 years old and have been on treatment with ATV/r plus 2 NRTIs for at least 48 weeks. The patients must have achieved virological suppression (HIV-RNA<50 c/ml) by at least 24 weeks with ATV/r plus 2 NRTIs and must not have experienced virologic failure after the initiation of the first antiretroviral therapy. The trial also requires that the patients have a CD4 cells nadir >100 cells/\u00b5L and are not using proton-pump inhibitors. The trial excludes pregnant and breastfeeding women, patients with AIDS defining events, evidence of active HBV infection (HBsAg positive), previous virological failure, history of resistance to ATV, and use of contraindicated medications.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have had a diagnosis of type 2 diabetes for more than a year, have HbA1c values of not more than 10.5%, and have been on a stable insulin regimen for at least three months. The patients must be between the ages of 30 and 70 and have a body mass index of not more than 45 Kg/m2. The trial excludes patients with type 1 diabetes, those being treated with a thiazolidinedione for less than three months, those with a history of severe hypoglycemia, and those with known hypersensitivity to any of the components in the study medication. Other exclusion criteria include a history of malignancy within the past five years, significant hepatic disease, severe complications of diabetes mellitus, and current drug or alcohol abuse. The trial also excludes pregnant or breastfeeding women and those with abnormal ECG, safety lab, or physical examination results that render their participation in the study inappropriate or unsafe.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients with newly diagnosed Stage IIIb disease or Stage IV disease who have not received prior systemic antineoplastic treatment for Stage IIIb/IV non-small cell carcinoma of the lung. The trial involves the use of drugs such as asa404, placebo, carboplatin, and paclitaxel. The eligibility criteria include having histologically confirmed non-small cell carcinoma of the lung, being at least 18 years old, having a WHO Performance Status of 0-1, and having lab values within a certain range. The trial also has exclusion criteria, such as having CNS metastases, a history of another primary malignancy within the past 5 years, and significant neurologic or psychiatric disorder.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis. The trial includes patients who meet specific eligibility criteria, such as having a maximum Ashworth Score Scale score of \u2265 2 in certain muscle groups, an Expanded Disability Status Scale (EDSS) rating between 3.0-8.0 inclusive, and a Spasticity Disability Rating of 2 or higher at Baseline. Patients must also be willing to discontinue and refrain from using certain drugs for the duration of the study. The trial has exclusion criteria, such as patients with spasticity due to neurological disorder other than MS, clinically evident muscle contractures resulting in irreversible spasticity in lower extremities, and evidence of unstable or severe systemic illness. The trial involves the use of arbaclofen placarbil at different doses and a placebo.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The eligibility criteria for patients include having histologically confirmed adenocarcinoma of the pancreas that is unresectable and locally advanced, with no distant metastases. Patients must also have an ECOG performance status of 0-2, a life expectancy of at least 12 weeks, and meet certain laboratory values for blood counts, bilirubin, creatinine, AST, ALT, alkaline phosphatase, and albumin. Patients must not have certain exclusion criteria, such as severe infection, ophthalmic disease, or untreated gastric or duodenal ulcer. The trial will test the effectiveness of a combination of three drugs: capecitabine, erlotinib hydrochloride, and gemcitabine hydrochloride. Patients must not have received prior radiotherapy or chemotherapy, or anti-epidermal growth factor-receptor therapy.",
    "The sample is a phase 3 clinical trial for the treatment of left ventricular hypertrophy in patients with stage 1 or stage 2 hypertension. The trial involves the use of three drugs - carvedilol mr, atenolol, and lisinopril. The eligibility criteria for the trial include having left ventricular hypertrophy and either stage 1 or stage 2 hypertension. However, patients who are in atrial fibrillation, have uncontrolled diabetes, uncontrollable or symptomatic arrhythmias, unstable angina, second or third degree heart block, history of MI, COPD, liver or kidney disease, use beta-2-agonists, are unable to undergo MRI, or are females of childbearing potential are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the disease osteogenesis imperfecta. The trial includes the drugs risedronate sodium (actonel) and a placebo. The eligibility criteria for the trial includes having an OI diagnosis and an increased risk of fracture, either through a history of at least one radiographically confirmed non-traumatic or low impact fracture with low bone mineral density, or having very low BMD with or without a history of fractures. The exclusion criteria includes any bisphosphonate use within one year of enrollment.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension. The trial includes patients who are at least 12 years old, weigh at least 40 kg, and have a history of pulmonary hypertension established by a resting mean pulmonary artery pressure greater than or equal to 25 mm Hg, pulmonary artery wedge pressure less than or equal to 15 mm Hg, and pulmonary vascular resistance greater than or equal to 3 Wood units via right heart catheterization. The trial also includes patients who have World Health Organization functional class I, II, III or IV status and a qualifying 6-minute walk test distance at screening. The trial excludes patients who are nursing or pregnant, have PAH due to conditions other than those noted in the inclusion criteria, have a history of left-sided heart disease, or have a history of atrial septostomy within 3 months before study entry. The trial also excludes patients who have a history of angina pectoris or other condition that was treated with long-or short-acting nitrates within 12 weeks before administration of study drug, have a history of symptomatic coronary disease, or have had any therapy with a prostacyclin or analogue, L-arginine, phosphodiesterase (PDE) inhibitor, or investigational drug within 4 weeks before administration of study drug. The drugs being tested in the trial are tadalafil and placebo.",
    "The sample is a phase 3 clinical trial for participants with type 2 diabetes mellitus. The trial involves the use of two drugs, lantus (insulin glargine) and hoe901-u300 (new formulation of insulin glargine). The eligibility criteria for the trial include being over 18 years old, having a HbA1c level between 7.0% and 10%, and having been on basal insulin treatment with oral antihyperglycemic drugs and self-monitoring of blood glucose for at least 6 months. Participants must not have used sulfonylurea in the last 2 months before screening and must not have any contraindications to the use of insulin glargine. They must also not have significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period. Pregnant or breastfeeding women or women who intend to become pregnant during the study period are excluded. The trial involves the use of adaptable injection intervals on at least two days per week.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes who are 65 years or older and not controlled with diet and exercise. The trial involves the use of sitagliptin phosphate and a placebo as a comparator drug. The eligibility criteria include having a HbA1c of 7-10% off medication or as a result of a protocol wash-out from oral anti-hyperglycemic agents by the qualifying visit. Exclusion criteria include having type 1 diabetes, a history of ketoacidosis or requiring insulin use, and other medical conditions such as high triglycerides and poorly controlled hypertension.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial includes patients who are 40 years and older, of both genders, and have clinical and radiographic evidence of osteoarthritis. The patients must have been symptomatic for at least six months. The trial involves the use of drugs such as glucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined, and celecoxib. The diseases are listed as 'osteoarthritis' and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial involves the use of two drugs, ivacaftor and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of CF, having at least one allele of the R117H CFTR mutation, and having a percent predicted forced expiratory volume in 1 second (FEV1) between 40% and 90% (for subjects aged 12 years or older) or 40% to 105% (for subjects aged 6 to 11 years) predicted normal for age, sex, and height. The trial also has exclusion criteria, such as having a CFTR gene mutation leading to CFTR channel with gating defect, having abnormal liver function, and ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days before screening.",
    "The sample is a phase 3 clinical trial for upper respiratory tract infection in children aged 1 to 5 years old. The trial involves the drugs muntelukast and placebo. The eligibility criteria for the trial include not having significant health problems, not having a history of wheezing requiring bronchodilators in the last 3 months or more than one treatment in the last year, not having been hospitalized due to reactive airway disease, not using prophylactic montelukast or steroids, not having chronic cardiac or respiratory disease, not having had an acute respiratory tract infection within the 7 days before consideration for the study, not having a history of allergic rhinitis, not receiving chronic medications of any kind, not having a known allergy to montelukast, and being able to provide informed consent from a legal guardian.",
    "The sample is a phase 3 clinical trial for non-small-cell lung carcinoma. The trial is testing the effectiveness of the drugs gemcitabine and cisplatin. The eligibility criteria for the trial include having a histologically or cytologically proven NSCLC, being at clinical stage IB, IIA, IIB, or T3N1, being 18 years or older, having an ECOG performance status of 0-1, having a uni-dimensionally measurable lesion by RECIST criteria, not having received prior chemotherapy or radiotherapy for NSCLC, having adequate bone marrow, liver, and renal function, and providing written informed consent. Exclusion criteria include having a superior sulcus tumor, having a prior malignancy (except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years ago), having uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia, having had a recent myocardial infarction within 6 months, having post-obstructive pneumonia or serious infection, being pregnant or nursing, and having a psychological problem.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on Parkinson's disease and involves the use of drugs such as placebo and pramipexole. The eligibility criteria for the trial include completion of a previous double-blind trial, a diagnosis of early idiopathic Parkinson's disease, and a willingness to comply with scheduled visits and procedures. Exclusion criteria include premature withdrawal from previous trials, atypical parkinsonian syndromes, and any clinically significant disease that could put the patient at risk or prevent compliance with the study. The sample also includes a list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of locally recurrent, locally advanced, or metastatic breast cancer in postmenopausal women. The trial involves the use of several drugs, including atamestane, toremifene, letrozole, aromatase inhibition, and estrogen receptor blocker. The eligibility criteria include women aged 18 years or older, with locally recurrent, locally advanced, or metastatic disease not amenable to radiation therapy or surgery, and with a predicted life expectancy of 12 weeks or more. The trial also requires patients to have at least one tumor localization measurable in 2 dimensions and to be estrogen receptor and/or progesterone receptor positive. The exclusion criteria include prior hormonal therapy or chemotherapy to treat locally recurrent, locally advanced, or metastatic disease, primary diagnosis of disease or progression of disease during therapy with antiestrogens, and other active malignancy.",
    "The sample is a phase 3 clinical trial for allergic rhinitis. The trial includes subjects who are 12 years of age or older, of any race and gender, and have a positive skin prick test response to an appropriate seasonal allergen. The trial aims to evaluate the efficacy of mometasone furoate nasal spray (mfns) compared to a matching placebo nasal spray. The eligibility criteria include having at least a 2-year history of SAR which exacerbates during the study season and being clinically symptomatic at the Screening and Baseline Visits. Exclusion criteria include having a history of severe local reaction(s) or anaphylaxis to skin testing, using any drug in an investigational protocol in the 30 days prior to the Screening Visit, and being a family member of the investigational study staff. Female subjects who are breast-feeding, pregnant, or intend to become pregnant are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of primary insomnia. The trial involves the use of suvorexant high dose, suvorexant low dose, and a placebo as comparators. The eligibility criteria include being at least 18 years old, diagnosed with primary insomnia, in good physical and mental health, and having difficulty with initiating and maintaining sleep. Participants must also be willing to limit alcohol, caffeine, and nicotine consumption, and refrain from napping during the study. Exclusion criteria include pregnancy or breastfeeding, history of another sleep disorder, ongoing depression, substance abuse or dependence, and certain medical conditions.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The eligibility criteria for the trial include having a primary diagnosis of major depressive disorder, meeting certain score requirements on the IVRS HAM-D and IDS-SR assessments, having a CGI-SI score of at least 4, and meeting certain medical criteria such as having a QTc less than 450 msec and normal liver function. The exclusion criteria include having certain medical conditions, a history of substance abuse or dependence, being pregnant or not using contraception, and having a history of non-responsiveness to the drug being tested. The trial involves the use of the drug 323U66 SR and a placebo.",
    "This sample is for a phase 3 clinical trial for the treatment of diabetes mellitus. The trial is testing the effectiveness of inhaled insulin. The eligibility criteria for the trial include having type 2 diabetes and failing two or more oral anti-diabetic agents. The exclusion criteria include having asthma, COPD, or being a smoker. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of osteoporosis, postmenopausal back pain, and spinal fractures. The trial involves the use of drugs such as teriparatide, risedronate, and placebos. The eligibility criteria for the trial include being a postmenopausal woman over 45 years old with a history of back pain and at least one moderate spinal bone fracture. Participants must also have a certain bone mineral density and be able to administer the medication themselves. Exclusion criteria include certain medical conditions, abnormal lab test results, and a history of drug or alcohol abuse.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have measurable or non-measurable, locally advanced or metastatic (stage IV) disease. The trial is testing the effectiveness of a combination of drugs including letrozole, bevacizumab, and fulvestrant. The eligibility criteria include having a functional Eastern Cooperative Oncology Group (ECOG) status of 0 or 1, a life expectancy of at least 24 weeks, and confirmed HER2-negative disease with positive hormone receptors (estrogen receptor [ER] and/or progesterone receptor [PgR]). Patients must also be candidates for receiving first-line treatment with letrozole and have recovered from any previous chemotherapy or radiation therapy. The exclusion criteria include having a history of peripheral neuropathy, impaired liver or kidney function, uncontrolled arterial hypertension, or any other disease or condition that may affect the patient's compliance with the study procedures or place them at a high risk of experiencing complications related to the treatment.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on studying partial seizures. The associated ICD-10 codes for the disease are listed, as well as the drugs being tested (pregabalin and levetiracetam). The eligibility criteria for participants are also listed, including age requirements, diagnosis criteria, and exclusion criteria such as pregnancy or other neurological illnesses that could impair endpoint assessment.",
    "The sample is a phase 3 clinical trial for the treatment of proliferative diabetic retinopathy and diabetic macular edema. The trial involves the use of two drugs, ranibizumab and triamcinolone acetonide, and has specific eligibility criteria for participants, including a diagnosis of diabetes mellitus, presence of severe nonproliferative or proliferative diabetic retinopathy, and diabetic macular edema. The trial also has exclusion criteria, such as significant renal disease, unstable medical status, and participation in another investigational trial within 30 days. The trial involves one or two study eyes and has specific inclusion and exclusion criteria for those eyes. The fellow eye must also meet certain criteria to be eligible for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder using the drug quetiapine. The trial is open to individuals who are 18 years or older and have been diagnosed with bipolar I, II, or not otherwise specified (NOS) disorder. The trial requires participants to have moderate-to-severe hypomanic symptoms or mild manic symptoms that are clinically significant but no worse than moderately severe. Participants must not be receiving mood stabilizing, antidepressant, or antipsychotic medication for more than one week. The trial has inclusion and exclusion criteria, including the requirement for female participants to be postmenopausal, surgically incapable of childbearing, or practicing medically acceptable, effective methods of contraception. The trial also excludes individuals with severe depressive symptoms, psychotic features, or clinically significant suicidal or homicidal ideation, as well as those with a history of neuroleptic malignant syndrome or who have received an experimental drug or used an experimental device within 30 days.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of olanzapine and olanzapine pamoate depot in patients who have not responded well to their current medication or are experiencing negative side effects. The trial has specific inclusion criteria, such as a clinical diagnosis of schizophrenia and a history of clinical worsening of the condition, and exclusion criteria, such as active suicidal ideation and certain medical conditions. The trial is only open to outpatients who have not required hospitalization for at least the past 8 weeks. The diseases being studied are limited to schizophrenia and the icd-10 codes associated with it.",
    "This is a sample from a clinical trial table for a phase 3 trial on schizophrenia. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is testing a placebo and ziprasidone oral capsules. The inclusion criteria for participants include meeting the DSM-IV criteria for schizophrenia, having a Brief Psychiatric Rating Scale - Anchored score of at least 35, and being between the ages of 13 and 17. Exclusion criteria include imminent risk of suicide or homicide and any history of serious or unstable medical illness.",
    "The sample is a phase 3 clinical trial for individuals with hypertension and type 2 diabetes. The trial involves testing the effectiveness of two doses of azilsartan medoxomil compared to a placebo. The eligibility criteria include being over 18 years old, having inadequate glycemic control while on metformin monotherapy, and having a mean sitting clinic systolic blood pressure between 135 and 160 mm Hg. Exclusion criteria include having a mean sitting clinic diastolic blood pressure over 100 mm Hg, having type 1 or poorly controlled type 2 diabetes, and having a history of certain cardiovascular events or conditions. The trial also excludes individuals with certain renal or urinary conditions, as well as those taking certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of ragweed-induced allergic rhinoconjunctivitis. The trial is looking for participants who have a clinical history of the condition for at least 2 years, with or without asthma, and have a positive skin prick test response to Ambrosia artemisiifolia. Participants must also have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value and meet certain clinical laboratory tests, electrocardiogram (ECG) and vital signs criteria. Females of child-bearing potential must agree to use medically accepted methods of contraception. The trial has a list of exclusion criteria, including unstable asthma, history of anaphylaxis with cardio-respiratory symptoms, and participation in any other clinical trial.",
    "The sample is a phase 3 clinical trial for psoriasis vulgaris, a skin disease. The trial includes patients with psoriasis vulgaris on the trunk and/or limbs, excluding psoriasis on the genitals and skin folds, involving 2-30% of the Body Surface Area (BSA). The trial involves the use of two drugs, leo 90100 and vehicle. The eligibility criteria for the trial include a clinical diagnosis of psoriasis vulgaris of at least 6 months duration, an Investigator's Global Assessment of disease severity (IGA) of at least mild, and a modified PASI (m-PASI) score of at least 2. The trial also has exclusion criteria, such as previous treatment with certain therapies and current diagnosis of certain types of psoriasis.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial includes patients who have triple-class drug experience or resistance and are currently on a failing PI-containing regimen that includes 2 other ARVs with no regimen change for 8 weeks prior to study screening. The patients must have an HIV viral load of 1000 copies/ml or more and must be negative for hepatitis B surface antigen within 90 days of study entry. They must also be able to obtain NRTIs and ritonavir and have required ARVs at the time of starting the study intervention. The patients must be willing to use acceptable forms of contraception and have a parent or legal guardian willing to provide consent if applicable. The trial also requires certain abnormal laboratory values. The exclusion criteria include chronic, active hepatitis B virus infection, certain medications, known allergy/sensitivity to components of two or more of the study-provided drugs or their formulations, active drug or alcohol use that may interfere with the study, pregnancy or breastfeeding, use of any immunomodulator, vaccine, or investigational therapy within 30 days prior to study treatment allocation/assignment, require certain medications prohibited with study treatment, and serious illness requiring systemic treatment or hospitalization.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of gastric cancer. The trial involves the drug \"uft (uracil, tegafur)\" and has a list of inclusion and exclusion criteria for participants. The diseases are listed as \"gastric cancer\" and the icd-10 codes associated with it are also provided.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on diabetes mellitus. The icd-10 codes associated with this disease are listed, as well as the drug being tested, alogliptin. The eligibility criteria for participants include being a female of childbearing potential who is not pregnant or lactating, having type 2 diabetes mellitus and having completed one of seven controlled Phase III studies, having certain levels of alanine aminotransferase and serum creatinine, being able and willing to monitor their own blood glucose concentrations, and not having any major illness or debility that would prohibit them from completing the study. There are also exclusion criteria listed, such as having experienced adverse events during the controlled Phase III studies or taking disallowed medications.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on studying prostate cancer. The ICD-10 codes associated with the disease are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including requirements such as previous treatment with hormones, good hematological, liver and kidney function, and recovery from any previous side effects of surgery or radiotherapy. The exclusion criteria are also listed, including previous chemotherapy or radiotherapy, concomitant serious diseases, and contraindications for the treatment with estramustine.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial involves the use of two drugs, phylloquinone (k1) and menatetranone (mk4). The eligibility criteria for participants include being a female who is at least 5 years postmenopausal, ambulatory, community dwelling, able to ingest calcium and vitamin D supplements, willing to restrict vitamin K intake, and having a stable thyroid dose if appropriate. Participants must also have no history of hyperthyroidism, hyperparathyroidism, or other metabolic bone diseases, no hardware in the hip and spine, no history of malignancy within the last five years, not currently using coumadin or warfarin, and vitamin D supplements must be less than 800 IU daily. Additionally, participants must not have used estrogen or other bone-altering medications within the last year, have no history of liver disease or malabsorption, no known allergy to vitamin K, and have not participated in an investigational drug trial within the last month.",
    "The sample is a phase 3 trial for patients with mixed dyslipidemia and qualifying cIMT thickness. The trial includes patients with coronary artery disease, coronary heart disease, and dyslipidemia. The trial involves the drugs abt-335 and placebo. The eligibility criteria for the trial include certain inclusion criteria such as having mixed dyslipidemia and qualifying cIMT thickness, and exclusion criteria such as having certain chronic or unstable medical conditions, unstable dose of medications, being pregnant or lactating, or having poorly controlled diabetes mellitus.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of two drugs, exenatide once weekly and insulin detemir, in improving glycaemic control. Patients must have a suboptimal HbA1c level between 7.1% and 10.0%, a BMI between 25 kg/m2 and 45 kg/m2, and be receiving metformin at a stable dose for at least 3 months prior to the study start. Patients with contraindications for the drugs, allergies to the drugs or their excipients, recent use of weight loss drugs or certain excluded medications, or previous participation in the study or other studies investigating exenatide QW are excluded. The trial also excludes patients who have received treatment with unapproved drugs or devices or are concurrently enrolled in incompatible medical research.",
    "The sample is a phase 3 clinical trial for patients with acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial is testing the effectiveness of a drug called Stribild. The eligibility criteria for the trial include having undetectable plasma HIV-1 RNA levels for at least 6 months, normal ECG, adequate hematologic function, and no known resistance to any of the study agents. Participants must also agree to utilize highly effective contraception methods if they are of childbearing potential. Exclusion criteria include having acute or chronic hepatitis B or hepatitis C co-infection, ongoing malignancy other than cutaneous Kaposi's sarcoma, and receiving ongoing therapy or anticipated to need to initiate drugs or herbal/natural supplements during the study that are contraindicated or not recommended for use.",
    "The sample is a phase 3 clinical trial for patients aged 18-85 with major abscess, surgical site infection, traumatic wound infection, or cellulitis suspected or confirmed to be caused by Gram-positive bacteria. The trial involves two drugs, iv dalbavancin and vancomycin/linezolid, and requires a minimum of 3 days of IV therapy. The eligibility criteria include at least two local signs and symptoms of ABSSSI and at least one systemic sign of infection. Exclusion criteria include a contra-indication to any required study drug, sustained shock, participation in another study of an investigational drug or device within 30 days, and more.",
    "The sample is a phase 3 clinical trial for patients with cardiovascular diseases, peripheral vascular diseases, and atherosclerosis. The trial is testing the effectiveness of the drug cilostazol in treating symptoms of intermittent claudication, such as exercise-induced pain, cramps, fatigue, or other equivalent discomfort, involving large muscle groups of the leg(s) (calf, thigh, buttocks), relieved by rest. The trial has specific eligibility criteria, including positive noninvasive evaluation for significant aortoiliac PAD on the most symptomatic side(s), highest ankle pressure reduced by at least 25 mm Hg after exercise compared to resting pressure, and moderate to severe claudication symptoms. There are also exclusion criteria, such as the presence of critical limb ischemia, poorly-controlled hypertension, and recent major surgery. Participants must attend regular supervised exercise sessions and cannot have a weight greater than 350 lbs or 159 kg.",
    "The sample is a phase 3 trial for the treatment of pain, osteoarthritis, and low back pain using the drug tapentadol (cg5503) extended release (er). The trial includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria for the trial include being a non-lactating female subject, completion of the expected double-blind treatment period of the pivotal Tapentadol (CG5503) Phase 3 trials in osteoarthritis or low back pain, and willingness to take Tapentadol (CG5503) extended release (ER) and the rescue medication supplied for the duration of the trial. The exclusion criteria include a history of alcohol and/or drug abuse, life-long history of seizure disorder or epilepsy, and other medical conditions.",
    "The sample is a phase 3 clinical trial for patients with postoperative pain and bunion. The trial involves the use of two drugs, COV155 and placebo. The eligibility criteria include being between 18 and 75 years old, having a body mass index of 33 or less, and being in good general health. Female subjects must not be pregnant or lactating, and male subjects must be sterile or use reliable birth control during the study. Participants must also be willing to complete pain assessments and clinic visits. There are several exclusion criteria, including uncontrolled medical conditions, history of substance abuse, and certain allergies. The trial also has additional inclusion and exclusion criteria for randomization into the double-blind phase.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on neoplasms of the prostate and involves the use of the drugs dutasteride and placebo. The eligibility criteria for participants include having a single negative prostate biopsy within 6 months prior to enrollment, having a PSA level within a certain range depending on age, and being able and willing to participate in the study for 4 years. Exclusion criteria include a history of prostate cancer, previous prostate surgery, and certain medical conditions or medication use within the past 12 months. The record also includes a list of icd-10 codes associated with the disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease asthma and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, montelukast and salmeterol/fluticasone propionate inhalation powder, and includes eligibility criteria for participants. The inclusion criteria includes a diagnosis of asthma for at least 6 months, a specific range of forced expiratory volume, and a certain level of FEV1 reversibility. The exclusion criteria includes recent hospital admission for asthma, recent respiratory infections, and recent use of oral or parenteral steroid therapy.",
    "The sample is a phase 3 clinical trial for patients with adenocarcinoma of the stomach or gastroesophageal junction. The trial involves two drugs, irinotecan, leucovorin, 5-fluorouracil, docetaxel, cisplatin and leucovorin, 5-fluorouracil. The eligibility criteria include having undergone surgery with curative intent, having a certain extent of nodal involvement, being between 18 and 75 years old, having a good performance status, and having no previous chemotherapy or radiotherapy. The trial also has exclusion criteria, such as having certain systemic diseases or infections, and having certain prior medical conditions or treatments. The trial requires complete staging procedures within 3 months prior to randomization and laboratory requirements within 8 days prior to randomization. Patients must also sign a written informed consent before participating in the trial.",
    "The sample is a phase 3 clinical trial for patients with hypertension and metabolic disorder. The trial is testing the effectiveness of the drug losartan potassium (+) hydrochlorothiazide. The eligibility criteria include being an adult patient with untreated hypertension and meeting the IDF definition of metabolic syndrome. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial is also not open to pregnant women or women of childbearing potential.",
    "The sample is a phase 3 clinical trial for the treatment of neurogenic urinary bladder. The trial includes patients with elevated detrusor Leak Point Pressure (LPP) of neuropathic etiology and Detrusor LPP \u2265 40 cm H2O and < 100 cm H2O. The trial will test the effectiveness of the drugs alfuzosin and placebo. The eligibility criteria include exclusion of patients who have had urological surgery in the last 4 months, urethral dilatation in the last 3 months, \u03b1-blocker therapy in the last 4 weeks, detrusor injections of botulinum toxin in the last 6 months, and other urological diseases/conditions that can lead to upper urinary tract dilatation. Patients with a history of intolerance to \u03b1-blocker therapy, orthostatic hypotension, and risk factors for Torsade de pointes are also excluded. The sample information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial includes patients who have had symptoms of overactive bladder for at least 3 months and experience frequent urination at least 8 times per day. Patients must also have experienced at least 3 episodes of urgency with or without incontinence during a 3-day micturition diary period. The trial includes a list of drugs, including mirabegron, tolterodine, and placebos for both drugs. The eligibility criteria include exclusion criteria such as significant stress incontinence, indwelling catheter, diabetic neuropathy, and evidence of a symptomatic urinary tract infection. Patients must also have normal serum creatinine levels and a clinically normal electrocardiogram.",
    "The sample is a phase 3 clinical trial for patients with colorectal cancer that has spread to the liver. The trial is testing the effectiveness of a combination of drugs (capecitabine, floxuridine, and oxaliplatin) in treating the disease. The eligibility criteria for the trial include having confirmed colorectal adenocarcinoma with no other cellular type, having no more than 6 hepatic metastatic lesions that can potentially be resected or ablated, and being able to undergo surgery and/or ablation within 28 days following randomization. Patients must also meet certain patient characteristics, such as having a life expectancy of at least 5 years and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Prior concurrent therapy is allowed, but certain treatments are not allowed during the trial.",
    "This sample is from a phase 3 clinical trial for the treatment of Major Depressive Disorder (MDD). The trial involves the use of the drug ly2216684, as well as a placebo and a selective serotonin reuptake inhibitor (SSRI). The eligibility criteria for participants include having a clinical diagnosis of MDD, using a reliable method of birth control, having a partial response to SSRI treatment, and meeting certain inclusion scores on pre-defined psychiatric scales. Exclusion criteria include having another primary psychiatric illness, certain medical conditions, and a history of certain treatments or therapies. The trial aims to assess the effectiveness and safety of the drug in treating MDD.",
    "The sample is a phase 3 clinical trial for the treatment of central neuropathic pain after spinal cord injury, stroke, or multiple sclerosis using the drug pregabalin. The trial includes subjects who completed a previous 18-week study for chronic neuropathic pain after spinal cord injury, as well as new participants who meet certain inclusion criteria such as having a pain VAS score of at least 40mm. The table includes information on the diseases being studied, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial in phase 3, focused on liver transplantation. The trial involves the use of two drugs, mycophenolate mofetil and tacrolimus, and has a list of inclusion and non-inclusion criteria for participants. The inclusion criteria include being an adult over 18 years of age, having undergone primary liver transplantation, and being on a low dose immunosuppressive treatment with tacrolimus and steroids. The non-inclusion criteria include pregnancy or ineffective contraception, blood group incompatibility with the donor, autoimmune hepatitis, and other medical conditions. The sample also includes a list of icd-10 codes associated with the diseases being studied.",
    "The sample is a phase 3 clinical trial for hypertension. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria for the trial include being an outpatient who is 18 years or older, having hypertension with specific blood pressure measurements, and giving written informed consent to participate in the entire study. The exclusion criteria are not provided in the sample.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of postmenopausal osteoporosis. The trial involves the drugs arzoxifene and placebo. The eligibility criteria for the trial include being a female between the ages of 60-85 and having at least two years since the last menstrual cycle. Exclusion criteria include a history of certain medical conditions and medications. The diseases are listed as 'osteoporosis, postmenopausal' and the corresponding ICD-10 codes are listed as \"['N95.0', 'N95.2']\".",
    "The sample is a phase 3 clinical trial for obesity and overweight patients. The trial includes two groups, one receiving the drug \"naltrexone sr 32 mg/bupropion sr 360 mg/day\" and the other receiving a placebo. The eligibility criteria include being between 18 and 65 years old, having a body mass index (BMI) between 30 and 45 kg/m\u00b2 for uncomplicated obesity or between 27 and 45 kg/m\u00b2 for obesity with controlled hypertension and/or dyslipidemia, and being normotensive. Other criteria include being free of opioid medication for 7 days prior to randomization, having no clinically significant abnormalities in various blood tests, having a negative urine drug screen, and being able to comply with all required study procedures and schedule. Exclusion criteria include having serious medical conditions, a history of drug or alcohol abuse or dependence, and being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for children between the ages of 2-18 who have undergone resection of a brain tumor with \u2264 1.5 cm2 residual tumor after surgical resection. The trial is open to children regardless of the extent of leptomeningeal or spinal metastasis (M1-3) and who undergo focal or whole brain (\u00b1 spinal) radiation as part of their brain tumor treatment. Patients on any anticonvulsive treatment or concomitant chemotherapy while undergoing radiation are eligible. Patients must be \u2265 24 hours steroid-free prior to starting radiation. The trial is being conducted at one of the 16 tertiary care centers in Canada (CPBTC). The patients' parents/legal guardians must have signed and dated an informed consent to allow study enrollment of their child. Patients > 8 years of age should assent to study participation. Patients less than 10 years of age should have a Lansky Score of >/= 50. Patients 10 years of age or older should have a Karnofsky Score of >/= 50. If ECOG performance scale is used, patient should have a score of 0, 1 or 2. The trial includes a list of diseases such as vomiting and headache, and a list of drugs such as high dose dexamethasone and low dose dexamethasone. The eligibility criteria for enrollment and randomization to a dexamethasone treatment group are also provided.",
    "The sample is a phase 3 clinical trial for smoking cessation. The trial is looking for male or female current cigarette smokers between the ages of 18 and 75 who are motivated to stop smoking. The trial requires participants to have a diagnosis of schizophrenia or schizoaffective disorder and be stable on psychiatric treatment for at least the past 6 months. The trial is testing the effectiveness of placebo and varenicline (cp-526,555) as smoking cessation treatments. The eligibility criteria include a Contemplation Ladder score of 7 or higher at the Screening, Week -1, and Baseline Visits. The exclusion criteria include a PANSS score >70 at Screen or Baseline Visit, recent hospitalization due to suicidal ideation or behavior, active suicidal ideation or behavior, and taking Bupropion.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of osteoarthritis. The icd-10 codes associated with the disease are listed. The drug being tested is diclofenac topical sodium gel 1%. The eligibility criteria for the trial are also listed, including key inclusion criteria such as having osteoarthritis of the knee, and key exclusion criteria such as having other rheumatic diseases or known allergies to analgesic drugs.",
    "The sample is a phase 3 clinical trial for diabetic macular edema. The trial involves the use of two drugs, 1mg and 4mg triamcinolone acetonide, and laser treatment. The eligibility criteria include being over 18 years old, having a diagnosis of diabetes mellitus, and being able to provide informed consent. Exclusion criteria include chronic renal failure, unstable medical status, and participation in an investigational trial within 30 days of study entry. The study eye eligibility criteria include having a best corrected visual acuity score of at least 24 letters, definite retinal thickening due to diabetic macular edema, and mean retinal thickness on two Optical Coherence Tomography (OCT) measurements of at least 250 microns in the central subfield. The fellow eye eligibility criteria include having a best corrected visual acuity score of at least 19 letters and no prior treatment with intravitreal corticosteroids.",
    "The sample is a phase 3 clinical trial for the treatment of diabetic foot. The trial involves the use of two drugs, daptomycin and vancomycin, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having type 1 or type 2 diabetes mellitus, having an MRSA infected foot ulcer Wagner 1-2 without primary surgical intervention, and being between the ages of 18 and 80. Exclusion criteria include having osteomyelitis, severe nephropathy, advanced diabetic retinopathy, or being pregnant or using unsafe contraception. The trial also requires participants to provide written informed consent and comply with the study requirements.",
    "The sample is a phase 3 clinical trial for patients with chronic hepatitis C and evidence of liver transplantation. The trial involves the use of the drug ciclosporin. The eligibility criteria for the trial include being an adult aged 18 or over, having been included in a previous study called Transpeg 1, being a non-responder to previous treatment or having a recurrent disease, having a positive PCR test, having a METAVIR histologic score of 1 or more on the last biopsy, and having been treated with tacrolimus for at least 6 months prior to inclusion. Exclusion criteria include recent treatment with peginterferon or ribavirin, severe hepatocellular failure or decompensated cirrhosis, recent acute graft rejection, treatment with cyclosporin for more than 6 months during the 24 months preceding inclusion, positive serology for HIV or HBV, cancer (except for certain cases), serious concomitant disease or acute or chronic disorder, serious cardiac pathology within the last 6 months, ongoing pregnancy or breast-feeding, serious chronic renal failure, abnormal TSH values, inability to cooperate or communicate with the investigator, and contraindications to ribavirin, peginterferon alfa-2a or cyclosporin.",
    "The sample is a phase 3 clinical trial for patients with stage I or II non-small cell lung cancer who have undergone complete resection of all disease. The trial is testing the effectiveness of bupropion hydrochloride and nicotine in helping current smokers quit smoking. Patients must be willing to establish a quit date within 30 days after registration and be able to read, speak, and understand English. They must also have a Zubrod performance status of 0-2 and no history of seizures or eating disorders. The trial allows concurrent adjuvant chemotherapy and radiotherapy, but no concurrent systemic steroids or monoamine oxidase inhibitors. Patients must not be taking any medications that lower seizure threshold or other nicotine replacement therapy.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia and graft-versus-host disease. The trial involves the use of the drug budesonide and is open to patients who are planning to undergo allogenic stem cell or bone marrow transplantation, have HLA identity with a maximum of one mismatch, and are receiving standard GVHD prophylaxis with cyclosporin A or tacrolimus combined with MTX, +/- ATG or Campath1H. Patients with a history of allogenic transplantation, in vitro T-cell depleted transplant, pretreatment with budesonide within the previous 4 weeks, known intolerance to budesonide, gastrointestinal infections, portal hypertension, concomitant infectious diseases, liver cirrhosis, impaired liver function, severe mental disorder, lack of compliance, drug or alcohol abuse, pregnancy, lactation, or childbearing potential without effective contraception are excluded from the trial.",
    "The sample is a phase 3 clinical trial for Huntington's disease. The trial includes patients who have been diagnosed with Huntington's disease and have a positive family history or have at least 36 CAG repeats in the Huntington gene. The patients must be at least 30 years old, able to take oral medication, and comply with study procedures. They must also be ambulatory and have a caregiver or family member to accompany them. The trial includes both ACR16 and placebo drugs. Patients must meet certain inclusion criteria, such as having a sum of at least 10 points on the mMS at the screening visit, and must not meet any exclusion criteria, such as having a prolonged QTc interval or a history of epilepsy. Females who are pregnant or lactating are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for chronic kidney disease patients on hemodialysis. The trial is testing the effectiveness of the drugs placebo and sevelamer carbonate. The eligibility criteria include being on a hemodialysis regimen for at least 30 days prior to the start of the trial, having a serum iPTH measurement less than 1000 pg/mL, and having a serum phosphorus measurement greater than 5.5 mg/dL. Exclusion criteria include having dysphagia or bowel obstruction, poorly controlled diabetes or hypertension, active vasculitis, HIV infection, or any unstable medical condition. The diseases being studied are chronic kidney disease and chronic kidney disease on hemodialysis, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of insulin glulisine and insulin glargine as treatment options. The eligibility criteria include being between 18 and 70 years old, having a diagnosis of type 2 diabetes for at least six months, and having an A1c level between 7.5% and 10%. Participants must also have been on continuous insulin therapy for at least three months prior to the study and be willing to perform self-monitoring of blood glucose. Exclusion criteria include being treated with certain oral antidiabetic drugs, having certain medical conditions, or being unlikely to comply with the study protocol.",
    "The sample is a phase 3 clinical trial for previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. The trial includes patients with stage III or IV disease, excluding T1N1 and T2N1, and metastatic disease. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2, an absolute neutrophil count of at least 1.5 X 10^9/L, platelet count of at least 100 X 10^9/L, and hemoglobin > 9g/dL. Serum bilirubin must be < 1.25 times upper limit of normal (ULN) and aspartate aminotransferase (AST)/alanine transaminase (ALT) < 2.5 times ULN. Calculated creatinine clearance (Cockcroft-Gault) must be > 55 mL/min. Patients with metastatic disease, primary cancers of the nasal and paranasal cavities and of the nasopharynx, significant intercurrent illness that will interfere with the Chemotherapy or Radiation Therapy during the trial, symptomatic peripheral neuropathy > grade 2, clinically significant hearing impairment, or significant cardiac disease are excluded from the trial. The trial will use tirapazamine and cisplatin as drugs.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial is testing the effectiveness of the drug Risperdal Consta compared to a placebo. The eligibility criteria for participants include having a current diagnosis of bipolar disorder I or II and having at least four episodes of mood disorder in the last year that required psychiatric intervention. Exclusion criteria include being pregnant or breastfeeding, having a psychiatric diagnosis due to substance use or a medical condition, and having received certain medications or treatments within a certain timeframe. The trial requires participants to provide informed consent and agree to receive regular injections.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorder. The trial involves the use of two drugs, lurasidone hcl and risperidone. The eligibility criteria for the trial include being between the ages of 18 and 75, meeting DSM-IV criteria for schizophrenia or schizoaffective disorder, not being pregnant or nursing, and agreeing to participate in the study. Exclusion criteria include having a chronic organic disease of the central nervous system, a history of alcohol or drug abuse, and any condition that might interfere with the study results or the subject's participation.",
    "The sample is a phase 3 clinical trial for the treatment of depression using the drug memantine hcl. The eligibility criteria for the trial include being between 18 and 80 years old, having a level of understanding sufficient to agree to all tests and examinations required by the protocol, and meeting the criteria for major depression, recurrent without psychotic features as defined in DSM-IV based on clinical assessment and confirmed by structured diagnostic interview SCID-P. Exclusion criteria include lack of response to more than 2 antidepressants, serious, unstable illnesses, and current diagnosis of schizophrenia or other psychotic or bipolar disorder as defined in the DSM-IV. The sample also includes a list of icd-10 codes for the disease and a list of inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for breast cancer patients who are eligible for 3-weekly chemotherapy and have an increased risk of febrile neutropenia. The trial involves the use of the drug pegfilgrastim. The eligibility criteria include being over 18 years old, having adequate renal and hepatic function, and having a planned chemotherapy regime with a high risk of febrile neutropenia. Patients must also have an ECOG performance status of 2 or more, grade 2 or higher liver function abnormalities, and be able to comply with the protocol. Exclusion criteria include active uncontrolled infection, inadequate renal or hepatic function, and any evidence or history of hypersensitivity or other contraindications to G-CSF medication.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes male and female participants between the ages of 18 and 80 who have stage 1 or 2 hypertension and are currently receiving 0 or 1 antihypertensive medication. The mean sitting systolic blood pressure must be between 140mmHg and 170mmHg, or the mean sitting diastolic blood pressure must be between 90mmHg and 105mmHg. Participants taking one hypertensive medication had their medication withdrawn and entered a wash-out phase prior to randomization. The trial excludes participants taking two or more antihypertensive medications, those with a known contraindication to angiotensin-converting enzyme (ACE) inhibitors or alpha- or beta-blocker therapy, and those with Type 1 or Type 2 diabetes. The trial includes the drugs carvedilol controlled release/lisinopril and lisinopril + placebo. The diseases included in the trial are hypertension, and the icd-10 codes associated with the disease are I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, and I10.",
    "The sample is a phase 3 clinical trial that involves testing the effects of bifidobacterium lactis (bb-12) and placebo on healthy children aged 1-3 who attend daycare or preschool centers at least 3 days a week. The trial requires that the children refrain from consuming any other yogurts or foods containing probiotics for the duration of the study. The inclusion criteria also specify that the children must be male or female and their parents must speak English or Spanish. However, the trial excludes children with developmental delays, chronic conditions such as diabetes or asthma that require daily medication, birth weight less than 2500 grams, strawberry allergies, active diarrhea, congenital anomalies, failure to thrive, and parental belief of lactose intolerance.",
    "The sample is a phase 3 clinical trial for patients with non-myeloid cancer who are receiving or scheduled to receive chemotherapy and have chemotherapy-related anemia. The trial is testing the effectiveness of sodium ferric gluconate complex in sucrose as a treatment for anemia. Patients must meet certain eligibility criteria, including having a ferritin level above 20 mcg/L and not having anemia caused by gastrointestinal bleeding, hemolysis, vitamin B12 or folic acid deficiency, or chemotherapy-induced myelodysplastic syndromes. Patients must also have an ECOG performance status of 0-2 and meet other patient characteristics criteria. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial includes patients with evidence of chronic hepatitis C who do not have genotype 2 or 3 and have compensated liver disease. The trial excludes patients with genotype 2 or 3, those who have received antiviral therapy for CHC within the last 3 months, and those with hepatitis A, hepatitis B, or HIV infection. Patients with medical conditions associated with chronic liver disease other than CHC are also excluded. The trial uses pegylated-interferon alfa-2a and ribavirin as the drugs for treatment. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 3 clinical trial for a drug called bc1036, aimed at treating persistent cough. The trial is open to both male and female participants aged 18 to 75 years who have been diagnosed with a persistent cough and have a Leicester Cough Questionnaire score of \u2264 17 at baseline. Participants must also have a FEV \u2265 70% of predicted normal at screening and be willing to use effective contraception for the duration of the study. Exclusion criteria include pregnancy or lactation, major surgery within the 30 days preceding the screening visit, and any serious infections within the 30 days prior to the screening visit. Participants must also not have any uncontrolled intercurrent illness, including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, renal or hepatic disease, or psychiatric illness/social situations that would limit compliance with study requirements. Additionally, participants must not have a history of serious adverse allergic reaction to any medication, be currently undergoing treatment with another investigational medicinal product within the 30 days prior to enrollment, or have a history of cancer within the previous five years (excluding carcinoma in situ or nonmelanoma skin cancer treated by surgical excision).",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of ocular hypertension and open-angle glaucoma. The trial involves the drug tafluprost and requires patients to have previously used latanoprost 0.005% as their medication. The record also includes a list of ICD-10 codes for the diseases being treated and eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been treated with insulin for at least 6 months. The trial involves testing the effectiveness of insulin glulisine and insulin glargine in combination with a stable insulin regimen. Patients must meet certain eligibility criteria, such as having a HbA1c between 7.5% and 11.0%, having a full ophthalmologic exam, and being willing to change from a twice daily insulin regimen to a regimen requiring four daily insulin injections. Patients must also not have any exclusion criteria, such as a history of hypoglycemia unawareness or impaired hepatic function. The trial requires patients to perform specified home blood glucose monitoring and comply with study protocol requirements.",
    "The sample is a phase 3 clinical trial for the treatment of colorectal neoplasms. The trial involves the use of two drugs, placebo and xaliproden. The eligibility criteria for the trial include having completed an oxaliplatin-containing chemotherapy regimen post complete surgical removal of primary colon tumor no later than 6 weeks before randomization, having Grade \u2265 1 PSN, as defined by the NCI-CTCAE version 3.0, having an Eastern Cooperative Oncology Group (ECOG) Performance Status \u22642, and meeting certain blood test requirements. The exclusion criteria include pre-existing peripheral neuropathy prior to treatment with oxaliplatin, receiving any further anti-cancer treatment, history of any recent thrombo-embolic events and current clinical evidence of thrombo-embolism, unstable cardiac disease, history of significant neurological or psychiatric disorders including dementia or seizures, active uncontrolled infection, active disseminated intravascular coagulation, other serious underlying medical conditions which could impair the ability of the patient to participate in the study, use of antidepressant/antiepileptic medication (for the treatment of PSN), unless commenced before informed consent form signed, concurrent treatment with any other experimental drugs, pregnant or breast-feeding women, women of childbearing potential must be protected by effective contraceptive methods of birth control, and any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.",
    "This sample is for a phase 3 clinical trial for the treatment of moderate-to-severe Aqueous-Deficient Dry Eye, specifically keratoconjunctivitis sicca. The trial is testing the drug cf101. The eligibility criteria for participants include being 18 years or older, having a positive corneal fluorescein staining score, a Schirmer Test score of at least 1 mm and less than 7 mm/5 min, and an OSDI score of at least 20. Participants must also be willing to forego topical ocular treatments and periocular cosmetic application for the duration of the trial, and must be able to complete the study in compliance with the protocol and provide written informed consent. Exclusion criteria include the presence of certain ocular diseases or conditions, use of certain medications, and recent surgical occlusion of the lacrimal puncta.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as canagliflozin and antihyperglycemic agents, as well as a placebo. The eligibility criteria for the trial include having a diagnosis of type 2 diabetes mellitus, a HbA1c level between 7 and 10.0%, and a fasting plasma glucose level below 270 mg/dL. The exclusion criteria include a history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta cell transplantation, or severe hypoglycemic episodes within 6 months before screening.",
    "The sample is a phase 3 clinical trial for advanced renal cell carcinoma. The trial includes subjects who have undergone prior nephrectomy and have measurable disease per the RECIST criteria Version 1.0. The trial is for treatment-naive subjects or those who have received no more than one prior systemic treatment for metastatic RCC. The trial includes eligibility criteria such as ECOG performance status of 0 or 1, life expectancy of at least 3 months, and ability to give written informed consent and comply with protocol requirements. Exclusion criteria include any prior VEGF-directed therapy, any prior therapy with an agent targeting the mTOR pathway, primary CNS malignancies or CNS metastases, any hematologic or serum chemistry abnormalities, significant cardiovascular disease, non-healing wound, bone fracture, or skin ulcer, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation, serious/active infection or infection requiring parenteral antibiotics, inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug, significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug, significant bleeding disorders within 6 months prior to administration of first dose of study drug, currently active second primary malignancy, pregnant or lactating females, history of genetic or acquired immune suppression disease such as HIV, life-threatening illness or organ system dysfunction compromising safety evaluation, requirement for hemodialysis or peritoneal dialysis, inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of tivozanib or sorafenib, major resection of the stomach or small bowel, or gastric bypass procedure, psychiatric disorder or altered mental status precluding informed consent or necessary testing, and sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study for at least 90 days after the last dose of drug. All fertile male and female subjects and their partners must agree to use a highly effective method of contraception.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been on a basal insulin regimen for at least 3 months and are currently taking metformin with or without other oral antidiabetic drugs. The trial is testing the effectiveness of insulin degludec/insulin aspart and insulin glargine in managing blood sugar levels. The eligibility criteria include having a HbA1c level between 7.0-10.0%, a BMI of maximum 40.0 kg/m^2, and not having certain medical conditions such as cardiovascular disease or uncontrolled severe hypertension. The sample also includes exclusion criteria such as recent use of certain medications and medical history of cancer.",
    "The sample is a phase 3 clinical trial for the treatment of iron deficiency anemia using the drug ferumoxytol. The eligibility criteria include being 18 years or older, having a hemoglobin level below 10.0 g/dL and transferrin saturation below 20%, having a history of unsatisfactory oral iron therapy or being unable to use oral iron, and for female participants of childbearing potential, being on an effective method of birth control. Exclusion criteria include having an allergy to IV iron or two or more classes of drugs, being on dialysis or having a low estimated glomerular filtration rate, being pregnant or intending to become pregnant, having a hemoglobin level below 7.0 g/dL, and having a serum ferritin level above 600 nanograms/mL.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with a clinical diagnosis of COPD, with FEV1 (forced expiratory volume in one second) between 30% and 50% of predicted normal post-bronchodilator, and COPD symptoms for at least 2 years. Patients must have had at least one exacerbation requiring medical intervention within 2-12 months before screening. The trial excludes patients with a current or past diagnosis of asthma, positive FEV1 reversibility test, clinically significant or unstable concurrent diseases, acute COPD exacerbation or lower tract infection, and long-term oxygen therapy. The trial will test the efficacy of three different drugs: beclomethasone 100 \u00b5g plus formoterol 6 \u00b5g (chf1535) pmdi, budesonide 200 \u00b5g plus formoterol 6 \u00b5g dpi, and formoterol 12 \u00b5g dpi.",
    "The sample is a phase 3 clinical trial for the treatment of idiopathic Parkinson's disease. The trial is looking at the effectiveness of safinimide, a drug, compared to a placebo. The trial is open to both male and female participants between the ages of 30 to 80 years who have been diagnosed with idiopathic Parkinson's disease for more than 5 years and have a Hoehn and Yahr stage of I-IV during an \"off\" phase. Participants must also be levodopa-responsive and have been receiving treatment with a stable dose of levodopa for at least 4 weeks. Participants must have motor fluctuations, with >1.5 hours \"off\" time during the day and be able to maintain an accurate and complete diary (18-hour). There are also exclusion criteria, such as having medical conditions or taking concomitant medications that would put them at risk, being in a late stage of Parkinson's disease, having a history of substance abuse, or having a history of allergic response to anticonvulsants, levodopa, or other anti-Parkinsonian agents.",
    "The sample is a phase 3 clinical trial for the treatment of acute coronary syndromes. The trial includes patients with non-ST segment elevation ACS and ST segment elevation ACS who have received optimal reperfusion therapy. The trial excludes patients who have had a previous Q-wave infarct within the last 4 weeks, have CK elevation not caused by myocardial injury, or have uncontrolled hypertension at the time of randomization. The trial will test the effectiveness of two drugs, rosuvastatin calcium and atorvastatin.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on major depressive disorder and includes a list of ICD-10 codes for the disease. The trial involves several drugs, including a placebo and vortioxetine (lu aa21004) and duloxetine. The eligibility criteria for the trial include a primary diagnosis of MDE according to DSM-IV-TR criteria, moderate to severe depression, and a current MDE duration of at least 3 months. The exclusion criteria include any current psychiatric disorder other than MDD, any substance disorder within the previous 6 months, female patients of childbearing potential who are not using effective contraception, and the use of any psychoactive medication 2 weeks prior to screening and during the study. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of soft tissue sarcoma. The trial is open to patients between the ages of 18 and 70 who have histologically proven grade II or III soft tissue sarcoma of a high-risk group. The trial has specific eligibility criteria, including no distant metastases, no severe disease, and no prior chemotherapy. The trial also has patient characteristics requirements, such as a WHO performance status of 0-2 or a Karnofsky score of 60-100%. The trial involves the use of doxorubicin hydrochloride, etoposide, and ifosfamide as treatment options. The sample includes a detailed list of eligibility criteria, patient characteristics, and prior concurrent therapy requirements.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of two drugs, ipragliflozin and a DPP-4 inhibitor. The eligibility criteria for the trial include having a HbA1c value between 6.5 and 9.5%, a BMI between 20.0 and 45.0 kg/m2, and being a type 2 diabetic patient receiving DPP-4 inhibitor mono-therapy for at least 4 weeks. The exclusion criteria include having type 1 diabetes mellitus, serum creatinine levels above the upper limit of normal, proteinuria, dysuria and/or urinary tract infection, genital infection, significant renal, hepatic or cardiovascular diseases, and severe gastrointestinal diseases.",
    "The sample is a phase 3 clinical trial for HIV infection. The trial is testing the effectiveness of lopinavir/ritonavir plus one or two nucleosides as an antiretroviral regimen. The eligibility criteria include being over 18 years old, having documented HIV-1 infection, and being willing to comply with the protocol requirements. Exclusion criteria include evidence of viral resistance against the drugs being tested, active hepatitis B or C, and any active clinically significant disease. Women must use two different methods of birth control and have negative pregnancy tests. The trial aims to enroll subjects who can safely complete the trial and assess the effectiveness of the treatment.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are at least 40 years old and have a clinical history of COPD. The trial involves the use of several drugs, including fluticasone furoate, salmeterol, and a placebo. The eligibility criteria include a signed informed consent, a history of smoking, and specific spirometry criteria. Exclusion criteria include a current diagnosis of asthma, other respiratory disorders, and certain medical conditions. The trial also excludes pregnant or lactating women and those with a history of alcohol or drug abuse.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is looking for patients with localized prostate cancer who are considered to be at high risk for recurrence based on certain adverse prognostic features. The trial is testing the effectiveness of a combination of drugs including bicalutamide, buserelin, flutamide, goserelin, leuprolide acetate, and docetaxel. The eligibility criteria include various disease and patient characteristics such as negative pelvic and para-aortic lymph nodes, ECOG performance status 0-1, and no serious non-malignant disease resulting in a life expectancy of less than 10 years. Prior androgen suppression therapy is allowed, but no prior cytotoxic anticancer therapy or pelvic radiotherapy is allowed. Patients must not have any other serious illness or psychiatric or medical condition that would preclude management of the patient according to the study.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a history of smoking, and have a pre and post-salbutamol FEV1/Forced Vital Capacity (FVC) ratio of less than 0.70 and a post-salbutamol FEV1 of between 30% and 70% of predicted normal values. The trial will test the efficacy of three drugs: umeclidinium/vilanterol, fluticasone propionate/salmeterol, and placebo. The eligibility criteria include being an outpatient, having a signed informed consent, and meeting specific clinical criteria for COPD. The exclusion criteria include pregnancy, asthma, other respiratory disorders, and significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities. The trial also excludes patients with a history of drug or alcohol abuse, those who cannot read, and those who have an affiliation with the investigator site.",
    "The sample is a phase 3 clinical trial for patients diagnosed with a brain tumor, either primary or metastatic. The trial is testing the effectiveness of three drugs - ir methylphenidate, modafinil, and sr methylphenidate - in treating cognitive decline in patients who have had prior radiation treatment to the brain. The eligibility criteria include being over 18 years of age, having a Karnofsky performance status (KPS) performance of 70 at baseline, using acceptable birth control methods, speaking and understanding English or Spanish, and reporting cognitive decline. Exclusion criteria include a history of hypersensitivity reaction to methylphenidate or modafinil, severe headaches, glaucoma, major psychiatric diagnosis, narcolepsy, marked anxiety, tension or agitation, clinically significant pulmonary or cardiac disease, uncontrolled hypertension, uncontrolled seizures, current use of illicit drugs or history of alcohol or drug abuse and/or abuse potential, moderate to severe depression, currently taking psychostimulants, Monoamine oxidase (MAO) inhibitors, or anticoagulants, current use of certain herbals or supplements for fatigue relief, any coexisting medical condition or taking any concomitant medication that is likely to interfere with the safe administration of methylphenidate, and currently taking any erythropoietin type drugs.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of two drugs, gsk573719 and gsk573719, on patients with a history of smoking and a post-bronchodilator FEV1/FVC of less than 0.7. The trial has specific inclusion and exclusion criteria, including a modified Medical Research Council (mMRC) dyspnea score of 2 or greater, and excludes patients with respiratory disorders other than COPD, significant allergies or hypersensitivity to certain medications, and those who have used certain medications within a defined time period prior to the screening visit. The trial also excludes patients with a history of alcohol or drug abuse and those who have previously used GSK573719 or the combination of GSK573719/GW642444.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on prostate cancer and the associated ICD-10 codes include C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being studied are rofecoxib and an unspecified placebo comparator. The eligibility criteria for the trial include regular PSA testing and study biopsies.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial includes Japanese subjects who have been diagnosed with type 2 diabetes for at least 6 months and are currently on monotherapy with an OAD (either glinide, metformin, a-glucosidase inhibitor or thiazolidinedione) in addition to diet and exercise therapy. The trial aims to test the effectiveness of liraglutide and oral anti-diabetic drugs in reducing HbA1c levels in patients with type 2 diabetes. The trial has specific inclusion and exclusion criteria, including a BMI below 40.0 kg/m^2 and no history of malignant tumors or chronic pancreatitis. The trial also requires subjects to perform self-monitoring of plasma glucose (SMPG) and excludes those who have had severe hypoglycemic events or have been hospitalized for diabetic ketoacidosis in the previous 6 months.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of aortic stenosis, which is identified by a list of ICD-10 codes. The trial involves two drugs, ezetimibe (+) simvastatin and a placebo comparator. The eligibility criteria for the trial include patients aged 45 to 85 with mild abnormalities of the aortic valve as confirmed by an echocardiogram. Patients who have previously participated in a trial using the study drug or are currently taking any medications that are not allowed in this study are excluded from participation.",
    "The sample is a phase 3 clinical trial for patients with non-small-cell lung carcinoma, lung cancer, or anemia. The trial involves the use of the drug epoetin alfa and has specific eligibility criteria for inclusion and exclusion. Inclusion criteria include having confirmed non-small cell lung cancer with stage III or IV, or recurrent disease, a hemoglobin level at or below 120 g/L, and being at least 18 years old. Exclusion criteria include having received systemic platinum-based chemotherapy for lung cancer in the previous two months or planning to receive it in the next three months, having a clinically active malignancy other than the underlying lung cancer, and having an expected survival of three months or less. The trial also has additional exclusion criteria related to medical history, blood transfusions, and mental competence.",
    "The sample is a phase 3 clinical trial for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The trial includes patients with stage I, II, or III multiple myeloma who have not been previously treated with chemotherapy. The trial involves a combination of drugs including vincristine sulfate, carmustine, melphalan, cyclophosphamide, and prednisone. The eligibility criteria for the trial are quite strict and include measurable disease, specific laboratory values, and exclusion of certain medical conditions. Patients must also give written informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for infertility. The trial is looking at the effectiveness of two drugs, dr-2011 and crinone 8%, for women aged 18-42 who have experienced infertility due to various reasons such as tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis-linked infertility. The trial has specific inclusion and exclusion criteria, such as not having a BMI over 38 kg/m2 and not having a history of more than 1 failed fresh IVF cycles. The trial is following an FDA-approved protocol and is using frozen sperm, including donor sperm, as long as it meets standard criteria.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease and dementia. The trial includes patients who are 55 years or older and living in the community, have been diagnosed with probable Alzheimer's disease, and have a reliable caregiver who can speak English or Spanish. Female subjects must be surgically sterile or postmenopausal for over a year. The trial excludes patients with evidence of other causes of dementia, active malignancy (except for basal cell carcinoma or squamous cell carcinoma of the skin), chronic or acute renal, hepatic or metabolic disorder, and those who have undergone major surgery within 12 weeks prior to Day 1. The trial also excludes patients who have used any investigational therapy within 30 days or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.",
    "The sample is a phase 3 clinical trial for the treatment of melanoma. The trial is looking at the effectiveness of the drugs gsk1120212 and chemotherapy in patients with unresectable or metastatic cutaneous melanoma that is BRAF V600E/K mutation-positive. Patients must be at least 18 years old and have received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. The trial has specific inclusion and exclusion criteria, including measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), adequate screening organ function, and a negative serum pregnancy test for women of childbearing potential. Patients with a history of interstitial lung disease or pneumonitis, or a history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of attention deficit hyperactivity disorder (ADHD) using methylphenidate hydrochloride extended-release tablets. The trial includes patients who have been diagnosed with ADHD according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and have symptoms present from childhood to adulthood. Patients must also have a minimum weight of 100 lbs and a Global Assessment of Functioning (GAF) Scale score of 41 to 60. Exclusion criteria include non-responsiveness to methylphenidate or other stimulants for the treatment of ADHD, allergy or sensitivity to methylphenidate, and coexisting medical conditions or medications that would interfere with safe administration of methylphenidate.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are at least 18 years old and have a mean seated diastolic blood pressure of 100 mmHg or more for treatment-na\u00efve patients, or 90 mmHg or more for pretreatment patients. The trial also requires a 24-hour mean diastolic blood pressure of 85 mmHg or more at baseline. Patients with mean seated systolic blood pressure of 200 mmHg or more and/or mean seated diastolic blood pressure of 120 mmHg or more, clinically significant hepatic impairment, severe renal impairment, bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant, current treatment with any antihypertensive agents that cannot be safely stopped, or other conditions or situations that could put potential participants at unacceptable risk are excluded from the trial. The drug being tested is a fixed dose combination of telmisartan and amlodipine.",
    "The sample is a phase 3 clinical trial for HIV-1 infections, involving HIV-1 discordant heterosexual couples. The table includes information on the diseases, ICD-10 codes, drugs, and eligibility criteria for the trial. The trial involves two groups of participants: HIV-1 uninfected partners and HIV-1 infected partners. The inclusion criteria for both groups include being in a discordant relationship, planning to remain in the relationship for the duration of the study, and providing written informed consent and locator information. The exclusion criteria for the uninfected partner group include current pregnancy or breastfeeding, concurrent enrollment in another HIV-1 vaccine or prevention trial, and ongoing antiretroviral therapy. The exclusion criteria for the infected partner group include current use of antiretroviral therapy and concurrent enrollment in another HIV-1 treatment trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes using the drug vildagliptin. The trial is focused on patients who are on a stable dose of metformin and have a BMI between 22-45. The inclusion criteria also require that the patient meets certain blood glucose criteria. The exclusion criteria include a history of type 1 diabetes, pregnancy or lactation, significant diabetic complications, serious cardiovascular events within the past 6 months, laboratory value abnormalities, known sensitivity to pioglitazone, and other protocol-defined exclusion criteria. The diseases being studied are limited to diabetes mellitus, type 2, and the icd-10 codes associated with this disease are listed.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes using the drugs liraglutide and exenatide. The trial includes patients with a stable treatment of metformin, sulphonylurea, or a combination of both for at least 3 months, with an HbA1C level between 7.0% and 11.0%, and a BMI of 45.0 kg/m2 or lower. Patients with impaired liver or renal function, a history of significant cardiac events, known retinopathy or maculopathy requiring acute treatment, or recurrent major hypoglycemia or hypoglycemic unawareness are excluded from the trial. The diseases included in the trial are diabetes and diabetes mellitus, type 2, with corresponding ICD-10 codes provided.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma. The trial includes patients with relapsing or progressive disease and requires a Karnofsky performance status of over 50%. Patients must have a life expectancy of at least 3 months and be at least 18 years old. Female patients of child-bearing potential must have a negative pregnancy test and use birth control throughout the study. Male patients must use contraception. The trial excludes patients with non-secretory multiple myeloma, low platelet or neutrophil counts, poor kidney function, peripheral neuropathy, HIV or active hepatitis A, B or C infection, pregnancy or breastfeeding, hypersensitivity to certain drugs, other concurrent malignancies, poorly controlled hypertension, severe cardiovascular disease, or uncontrolled diabetes mellitus. The trial involves the use of velcade (bortezomib), thalidomide, and dexamethasone.",
    "The sample is a phase 3 clinical trial for posttraumatic stress disorder. The trial includes patients who have been diagnosed with PTSD according to the DSM IV-TR criteria, but whose PTSD is not chronic and is a result of a single traumatic event. The trial also includes healthy controls who have experienced a similar traumatic event but have not developed PTSD. The trial excludes patients with a history of epilepsy or significant loss of consciousness, any significant psychiatric or somatic pathology, and those who are pregnant or breastfeeding. The trial also excludes patients who are unable to understand or read the study information, those who refuse to sign the consent form, and those who are left-handed or ambidextrous. The trial involves the use of the drugs avlocardyl and placebo, and patients must meet certain eligibility criteria to participate.",
    "The sample is a record of a clinical trial in phase 3, focused on graft rejection. The trial involves the use of drugs such as everolimus, mycophenolate mofetil, cyclosporine, and corticosteroids. The eligibility criteria for the trial include being a male or female cardiac recipient between the ages of 18 and 70, with a functional graft at the time of randomization. Patients who have previously received multiple solid organ transplants or tissue transplants, or who have received ABO incompatible transplants, are excluded from the trial. Other inclusion and exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hypertrophy. The trial includes patients with voiding symptoms and a medical history of the condition. The trial excludes patients with a history of urgent need for prostate surgery or prior surgical treatment of the prostate or bladder, major organ dysfunction, eczema treated during the last 6 months, current or recent treatment with certain drugs, urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy, and history of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months. The trial involves the use of two drugs, cetrorelix 78+78 and cetrorelix 78 + placebo.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C infection. The trial is testing the effectiveness of peginterferon alfa-2a and ribavirin as a treatment for the disease. The eligibility criteria for participants include having serologic evidence of chronic hepatitis C infection, being previously naive to any therapy, having compensated liver disease, and having quantifiable HCV-RNA. Participants must also have a negative urine or blood pregnancy test and be using two forms of effective contraception during treatment and for 6 months after treatment end. Exclusion criteria include ongoing pregnancy or breastfeeding, low neutrophil or platelet count, low hemoglobin levels, and a history of certain medical conditions or drug abuse.",
    "The sample is a phase 3 clinical trial for patients with sickle cell disease and pulmonary hypertension. The trial is testing the effectiveness of the drug bosentan. The eligibility criteria include having a documented history of sickle cell disease, symptomatic pulmonary hypertension, and a tricuspid regurgitation jet velocity of over 2.9 m/sec. Patients must also have a six-minute walk test distance between 150-450 m and meet specific criteria for pulmonary hypertension confirmed by right heart catheterization. Exclusion criteria include various medical conditions and treatments, as well as pregnancy or lactation. Patients must provide written informed consent before participating in the study.",
    "The sample is a phase 3 clinical trial for diabetic neuropathies. The trial includes patients who have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes, with the pain beginning in the feet and present for at least 6 months. The trial involves the use of duloxetine hydrochloride and placebo drugs. The eligibility criteria include having a score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item, not being pregnant, and agreeing to utilize medically acceptable and reliable means of birth control during participation in the study. The exclusion criteria include having a glycosylated hemoglobin (A1C) > 12%, severe hepatic disease, history of substance abuse or dependence within the past year (excluding nicotine and caffeine), serious or unstable cardiovascular, hepatic, kidney, respiratory, blood disorder, seizure disorder, problems with peripheral vascular disease, or other medical conditions or psychiatric conditions that would hinder participation or likely to lead to hospitalization during the course of the study. Patients who are taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the potential need to take during or within 5 days after discontinuation from the study, treatment of fluoxetine within 30 days of starting the study, or have unstable blood sugar control and uncontrolled or poorly controlled hypertension are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of atherosclerosis and acute coronary syndrome (ACS). The trial involves the use of drugs such as cangrelor, clopidogrel, and placebo, and requires angiography to demonstrate atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation. The eligibility criteria include elevated cardiac markers or ischemic chest discomfort with electrocardiogram changes, age over 65 or diabetes, and exclusion criteria include not being a candidate for PCI, recent trauma or major surgery, and impaired hemostasis. The trial aims to evaluate the safety and efficacy of the drugs in treating atherosclerosis and ACS.",
    "The sample is a phase 3 trial for the treatment of inflammation and pain in patients undergoing routine cataract surgery. The trial involves the use of two drugs, loteprednol etabonate and its vehicle. The eligibility criteria for the trial include being at least 18 years old and a candidate for uncomplicated cataract surgery. Exclusion criteria include known hypersensitivity to the study drugs, severe ocular or medical conditions, elevated intraocular pressure, and poor visual acuity in the non-study eye.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial involves the use of the drugs raltegravir and placebo. The eligibility criteria for the trial include having documented HIV-1 infection, having a sustained HIV RNA level of less than 50 copies/ml, and currently receiving an antiretroviral regimen that has not changed for at least 12 months. Exclusion criteria include having a current diagnosis of acute hepatitis or chronic hepatitis B and/or C with elevated liver enzymes, having a significant history of certain medical conditions, and being pregnant or breastfeeding. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of soft tissue sarcoma. The trial involves the use of two drugs, doxorubicin in combination with palifosfamide-tris and doxorubicin in combination with placebo. The eligibility criteria for patients include being at least 18 years old, having documented soft tissue sarcoma with metastatic disease for which the patient has not received any prior treatment, and having an ECOG Performance Status of 0, 1 or 2. Patients must also have adequate bone marrow and organ function, agree to use a highly reliable method of birth control during the study, and be able to provide informed consent. Patients must not have specific sarcoma histological subtypes, received systemic therapy for the treatment of metastatic sarcoma prior to or during the study, or have any prior anthracycline use. They must also not have a known allergy to any of the study drugs or their excipients, any unstable or clinically significant concurrent medical condition, myocardial dysfunction, documented metastases to brain or meninges, any malignancy other than sarcoma within the last 5 years prior to screening, currently be pregnant or nursing, or have received radiotherapy with curative intent within 4 weeks of the first dose of study drug.",
    "The sample is a phase 3 clinical trial for the treatment of migraine disorders. The trial is open to subjects between the ages of 12 and 17 who have a definitive diagnosis of migraine and experience at least 2 but not more than 8 migraine attacks per month. The trial is testing the effectiveness of a combination tablet of treximet (sumatriptan/naproxen sodium) as a treatment for migraine. The eligibility criteria include being able to distinguish migraine from other headaches, having a negative urine pregnancy test (if female), and having no history of certain medical conditions or drug use. The trial also requires subjects and their parents or legal guardians to provide informed consent and be able to read and write in English or Spanish.",
    "The sample is a phase 3 clinical trial for breast cancer patients with locally recurrent or metastatic disease, suitable for chemotherapy. The trial involves the drugs docetaxel, placebo to bevacizumab, and bevacizumab. The eligibility criteria include female patients over 18 years of age with HER2-negative cancer of the breast, no adjuvant chemotherapy within 6 months before randomization, and an ECOG performance status of 0-1. Exclusion criteria include previous chemotherapy for metastatic or locally recurrent breast cancer, radiotherapy for treatment of metastatic disease, spinal cord compression or brain metastases, inadequate bone marrow, liver, or renal function, and uncontrolled hypertension. The diseases are listed as breast cancer and the icd-10 codes are provided as well.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on non-small cell lung cancer. The trial involves the use of two drugs, docetaxel and carboplatin. The eligibility criteria for the trial include having confirmed NSCLC, a performance status of 0-2, no previous treatment with docetaxel, measurable disease, stable and asymptomatic brain metastases that have been treated with radiotherapy, adequate liver, kidney, and bone marrow function, and the ability to understand the nature of the study and give written informed consent. Exclusion criteria include active cardiac disease, pregnancy or lactation, unknown HIV, chronic hepatitis B or C infections, serious neurologic or psychiatric disease, second primary malignancy within the past 5 years (except nonmelanomas skin cancer or in situ carcinoma of the cervix), and active uncontrolled infection.",
    "The sample is a phase 3 trial for smoking cessation. The diseases being studied are related to smoking cessation. The icd-10 codes associated with the diseases are listed. The drug being tested is nicotine. The eligibility criteria for participants include having a BMI within the range of 19-35 kg/m2, being a current daily smoker for at least a year, and smoking their first cigarette more than 30 minutes after waking up. Exclusion criteria include known or suspected intolerance or hypersensitivity to nicotine or any of the ingredients in the formulation, and participants whose CO level rises during the sequestration period and may have smoked during that time.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial includes patients who are 18 years or older with a CD4 count between 150 and 350 per mm3 (or CD4 percentage between 12.5 and 20 percent) and have not received curative antiretroviral therapy in the past. The trial is conducted in Abidjan and patients must provide informed consent. Patients who are pregnant or have severe renal, hepatic, or neuropsychiatric disease are excluded from the trial. The trial uses a combination of drugs including zidovudine (zdv), lamivudine (3tc), efavirenz (efv), ritonavir (nrv), and indinavir (idv).",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The table includes information on the diseases being treated, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for patients to participate in the trial. The eligibility criteria include a diagnosis of chronic myelogenous leukemia in chronic phase, no previous therapy with homoharringtonine, and no more than six months of prior hydroxyurea therapy. Patients must have failed an adequate trial of alpha-Interferon or IFN/ara-C to be eligible, and must be at least 16 years old. Patients with uncontrolled tachyarrhythmias or who are pregnant or nursing are not eligible.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe pain caused by osteoarthritis in one or more hip or knee joint(s) or persistent moderate to severe low back pain. The trial is testing the effectiveness of a drug called pf-00345439. The eligibility criteria include being between 18 and 75 years old, refraining from taking any opioid medications other than the study drug, and practicing an acceptable method of birth control for females. The exclusion criteria include having a positive urine drug screen, currently being on an opioid regimen with a daily opioid dose equivalent of oxycodone > 160 mg, and having major surgery planned during the study period.",
    "The sample is a phase 3 clinical trial for the treatment of Waldenstr\u00f6m macroglobulinemia, lymphoplasmacytic lymphoma, and splenic marginal zone lymphoma. The trial involves the use of chlorambucil and fludarabine as drugs. The eligibility criteria for the trial include having a confirmed diagnosis of one of the three diseases and needing treatment, having a life expectancy of more than 6 months, and meeting certain medical criteria such as having a creatinine level below 200 \u00b5mol/l and SGPT and SGOT levels below 2x ULN. There are also exclusion criteria such as having had chemotherapy or radiotherapy prior to the study, having a positive HIV serology, or being pregnant or lactating. The trial requires written informed consent and good compliance with the study protocol.",
    "The sample is a phase 3 clinical trial for the treatment of generalized social anxiety disorder. The trial includes patients who are outpatients and over 18 years old, with a primary psychiatric diagnosis of generalized social anxiety disorder as defined by DSM-IV criteria and an LSAS score > 50. The trial involves the use of duloxetine and placebo as drugs. The eligibility criteria include physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities, willingness and ability to comply with the requirements of the study protocol, and exclusion criteria such as a history of intolerance or lack of response to a treatment trial of duloxetine at highest tolerated dose, acute narrow angle glaucoma, and pregnancy. The trial also excludes patients with a history of failure to satisfactorily respond to >2 prior adequate treatment trials, significant personality dysfunction likely to interfere with study participation, serious medical illness or instability for which hospitalization may be likely within the next year, and concurrent psychotherapy initiated within 2 months of baseline. The trial permits entry of patients with major depression, dysthymia, panic disorder, generalized anxiety disorder, post-traumatic stress disorder or obsessive-compulsive disorder if the social anxiety disorder is judged to be the predominant disorder. Patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.",
    "The sample is a phase 3 clinical trial for diabetes mellitus. The trial includes patients between the ages of 40 and 75 who have one or more risk factors for diabetes, such as a high BMI or a family history of the disease. The trial will test the effectiveness of acarbose (glucobay, bayg5421) compared to a placebo. The eligibility criteria include being able to give voluntary informed consent and not having type 2 diabetes or recent cardiovascular events. Exclusion criteria include pregnancy, nursing, major debilitating conditions, and hypersensitivity to acarbose.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial is testing the effectiveness of the drug dexamethasone on patients who have steroid-dependent Crohn's disease and have experienced a relapse in the last 12 months while being treated with at least 10mg of methylprednisone. The trial is open to both male and female patients over the age of 18 who are willing and able to provide written informed consent. However, patients with intestinal sub-occlusion, suspected abdominal abscess, active perianal disease, or a CDAI score greater than 150 are excluded from the trial. Patients who have been on immunosuppressant therapy for less than 4 months, received Infliximab or other anti-TNF in the previous 3 months, have severe concomitant diseases, have elective surgery already scheduled at the start of the study, have chronic use of alcohol or drug addiction, are pregnant, have contra-indications to the use of steroids, or have received investigational treatments in the previous 3 months are also excluded from the trial.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of painful diabetic neuropathy. The trial involves the use of two drugs, pregabalin (lyrica) and a placebo. The eligibility criteria for the trial require patients to have painful diabetic peripheral neuropathy and be receiving treatment for this condition. Patients with other pain conditions are excluded from participating in the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for ovarian cancer. The trial requires patients to have newly diagnosed stage II or III ovarian epithelial cancer and be planning to receive platinum-based chemotherapy. Patients must also be fit for interval debulking surgery and have residual macroscopic disease with the longest dimension of the largest tumor mass greater than 1 cm in diameter documented at primary surgery or postoperatively by imaging. There are no specific age or performance status requirements, and no concurrent or prior malignancy likely to interfere with protocol treatments or comparison. Patients must not have received any prior biologic or endocrine therapy, radiotherapy, or surgery that does not meet the criteria specified in the disease characteristics. The trial will involve chemotherapy treatment.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis. The trial is open to individuals of Chinese origin who have been diagnosed with relapsing remitting or secondary progressive multiple sclerosis. The trial has a list of exclusion criteria, including the presence of any disease other than multiple sclerosis that could better explain the patient's symptoms, HIV infections, hepatitis A, syphilis, immunodeficiency, rheumatic disease or Sjogren syndrome, heart disease, severe depression, pregnancy or lactation, conditions interfering with Magnetic Resonance Imaging (MRI), Gadolinium DTPA (Gadovist, contrast agent) allergy, allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance, and participation in other trials.",
    "The sample is a phase 3 clinical trial for patients with colorectal cancer and liver metastases. The trial involves two drugs, oxaliplatin+capecitabine and oxaliplatin+capecitabine+bevacizumab. The eligibility criteria include having liver metastases that have been radically resected, being at least 18 years old, having an ECOG performance status of 0 or 1, and meeting certain hematology and biochemistry requirements. Exclusion criteria include having extrahepatic metastatic disease, prior non-colorectal malignancies, and certain cardiovascular diseases. The trial also has a list of icd-10 codes for the diseases being studied and a list of eligibility criteria.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on pancreatic cancer. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include requirements such as having a confirmed diagnosis of adenocarcinoma of the pancreas, having unresectable disease, and having measurable or non-measurable disease as determined by CT or MRI. Other requirements include being at least 18 years old, having an ECOG performance status of 0-1, and having adequate bone marrow reserve, liver and renal function. The sample also includes exclusion criteria such as having a candidate for surgical excision based on local extent of disease, having stage M1 disease, and having a history of active collagen vascular disease.",
    "The sample is a phase 3 clinical trial for ovarian cancer. The trial includes patients with stage Ic-IV ovarian cancer who require chemotherapy treatment and are 75 years old or younger with a life expectancy of at least 3 months. The trial excludes patients with previous or concomitant malignant neoplasia, a performance status (ECOG) greater than 2, previous chemotherapy treatment, heart disease, low levels of leukocytes, neutrophils, or platelets, impaired renal or liver function, present or suspected hemorrhagic syndromes, uncooperative or unreliable patients, patients who cannot access the center, or patients who refuse informed consent. The trial will test the effectiveness of liposomal doxorubicin, carboplatin, and paclitaxel as treatments for ovarian cancer.",
    "The sample is a phase 3 clinical trial for diabetes mellitus and hypercholesterolemia. The trial includes patients diagnosed with type 1 diabetes mellitus for at least 1 year, with any HbA1C level, and on stable insulin therapy. The trial also includes patients diagnosed with type 1 diabetes mellitus for at least 3 years, with an HbA1C level greater than 8%, and on stable insulin therapy. Both groups must be between the ages of 10 and 20, have a BMI less than the 85th percentile, and have fasting LDL-C levels greater than 100mg/dl. Patients with severe dyslipidemia, smoking, pregnancy, current use of certain drugs, hypertension, and/or microalbuminuria are excluded from the trial. The trial will use balanced randomization and standardized treatment for patients with hypertension and/or microalbuminuria.",
    "The sample is a phase 3 clinical trial for sepsis. The trial includes patients who have suspected or proven bacterial or fungal infections and are receiving parenteral antimicrobial therapy. Patients must have developed at least 3 of the 4 systemic inflammatory response syndrome criteria within 36 hours prior to the start of study drug administration. Patients must also have septic shock diagnosed within 36 hours prior to study drug administration and have developed respiratory failure within the same time frame. Females of childbearing potential who are sexually active must agree to use adequate contraception and cannot be pregnant or lactating throughout the duration of the study. The trial has various exclusion criteria, including receiving any investigational compound within 30 days prior to the initiation of the study drug infusion, currently receiving any immunosuppressive therapy (excluding glucocorticoids), and having a known history of glucose-6-phosphate dehydrogenase deficiency.",
    "The sample is a phase 3 clinical trial for the treatment of lymphoma. The trial is looking for adult patients over 18 years of age with CD20+ low-grade (indolent) lymphoma of follicular and marginal zone type, small lymphocytic lymphoma without a B-CLL phenotype, or indolent lymphoma not otherwise specified. The lymphoma must be in stage II (with bulky disease), III, or IV. Patients must not have had previous chemotherapy or a maximum of 6 months of chlorambucil or cyclophosphamide. The trial is looking for patients with symptomatic enlarged lymph nodes, spleen or other lymphoma manifestations, progression >6 months of lymphadenopathy or splenomegaly, anemia or thrombocytopenia or decreased hemoglobin or platelets due to lymphoma, general symptoms (weight loss, night sweats or fever), and WHO performance status 0-2. Patients who have had prior treatment with rituximab or an interferon, B-CLL, mantle cell lymphoma, lymphoplasmacytic lymphoma (Waldenstroem's disease), or central nervous system lymphoma are excluded from the trial. Patients with indolent lymphoma transformed into aggressive lymphoma, indolent lymphoma with bulky tumor requiring urgent therapy, prior malignancies (except non-melanoma skin tumors, in situ cervical cancer, or curative surgery >5 years ago), positive for HIV infection, or uncontrolled asthma or allergy requiring corticosteroids are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for asthma patients. The trial includes patients who are between 18 and 75 years old and have had a confirmed diagnosis of asthma for at least 3 months. Patients must have been on a stable dose of inhaled corticosteroids for at least 4 weeks prior to the trial and must be symptomatic with an Asthma Control Questionnaire (ACQ) mean score of at least 1.5. Patients must also have a pre-bronchodilator FEV1 at least 60% and less than or equal to 90% of predicted normal at Visit 1. The trial excludes patients with significant diseases other than asthma, recent history of myocardial infarction or hospitalization for cardiac failure, lung diseases other than asthma, known active tuberculosis, malignancy, significant alcohol or drug abuse, and pregnant or nursing women. Patients must also not have taken certain medications within four weeks prior to Visit 1. The trial aims to test the efficacy of various drugs, including tiotropium respimat\u00ae low dose, tiotropium respimat\u00ae high dose, and 50 mcg salmeterol hfa mdi, compared to placebo.",
    "The sample is a phase 3 clinical trial for patients with metastatic renal cell carcinoma. The trial includes patients who have previously received sunitinib and/or sorafenib within the past 6 months, as well as those who have received cytokines or VEGF-ligand inhibitors. Patients must have at least one measurable lesion and a Karnofsky Performance Status of at least 70%. They must also have adequate bone marrow, liver, and renal function, and a life expectancy of at least 3 months. Women of childbearing potential must have a negative pregnancy test prior to treatment. Patients cannot be currently receiving chemotherapy, immunotherapy, or radiotherapy, and cannot have previously received mTOR inhibitors. Other exclusion criteria include untreated CNS metastases, severe or uncontrolled medical conditions, and a history of another primary malignancy within the past 3 years. Patients must be willing and able to comply with the protocol.",
    "The sample is a phase 3 clinical trial for multiple sclerosis patients with central neuropathic pain. The trial involves the use of two drugs, sativex and placebo. The eligibility criteria include having MS for at least two years, experiencing CNP for at least three months, and having a moderate level of pain. The exclusion criteria include having pain that is not central neuropathic, a history of certain psychiatric disorders or substance abuse, and current use of cannabis-based medications. The trial also requires participants to abstain from cannabis use during the study and prohibits travel outside of the country of residence.",
    "The sample is a phase 3 clinical trial for the treatment of depression. The trial is looking at the effectiveness of the drug risperidone compared to a placebo. The trial is open to individuals between the ages of 19 and 60 who have been diagnosed with severe major depressive disorder and have suicidal thoughts. Participants must also be taking an antidepressant at a therapeutic dose for at least 3 weeks and be in good physical health. Exclusion criteria include having other major psychiatric conditions, substance abuse-induced depression, and unstable major medical illnesses. Female participants who are pregnant, breastfeeding, or unwilling to use birth control measures are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial involves the drugs levomilnacipran er and placebo. The eligibility criteria for the trial include being between 18-80 years old, meeting the DSM-IV-TR criteria for major depressive disorder, and having a current depressive episode that has lasted at least 4 weeks. Exclusion criteria include being pregnant or breastfeeding, having a history of manic or hypomanic episodes, schizophrenia or any other psychotic disorder, or being considered a suicide risk. The diseases are listed as 'major depressive disorder' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for non small cell lung carcinoma. The trial involves the drug \"iressa (gefitinib)\" and requires patients to have previously undergone combined therapy with chemotherapy and surgery or radiotherapy. Chemotherapy with regimens containing cisplatin or carboplatin is mandatory. The eligibility criteria include a confirmed diagnosis of non small cell lung cancer and a positive response to combined therapy. The exclusion criteria include no previous treatment with ZD1839 or any other EGFR-targeted therapy, no progressive disease after combined therapy for locally advanced NSCLC, no presence of metastatic disease, no other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ, and any unresolved chronic toxicity from previous anticancer therapy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of metastatic breast cancer. The trial involves the use of drugs such as ct-p6, herceptin, and paclitaxel. The eligibility criteria for the trial include being a female with Her 2 over-expression and ECOG 0 or 1. Exclusion criteria include having current clinical or radiographic evidence of CNS metastases, current known infection, and being a pregnant or nursing mother. The icd-10 codes associated with the disease are also listed.",
    "This sample is for a phase 3 clinical trial for ovarian cancer. The trial is looking for patients with histologically confirmed ovarian epithelial cancer of specific cell types and who meet certain criteria related to the stage and grade of their cancer, as well as their medical history and physical condition. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel. The sample includes the eligibility criteria for the trial, which includes information about the patient's disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian cancer, primary peritoneal cancer, and fallopian tube cancer using the drugs paclitaxel and carboplatin. The trial is open to patients who have not received prior chemotherapy and meet certain eligibility criteria, including having a confirmed diagnosis of stage II-IV cancer, being at least 20 years old, and having a performance status of ECOG 0-3. The trial also has exclusion criteria, such as patients with ovarian borderline tumor, active infection, or a history of hypersensitivity to polyoxyethylated castor oil. The trial requires written informed consent from all participants.",
    "The sample is a phase 3 clinical trial for diabetes, specifically type 2 diabetes mellitus. The trial includes patients who have been diagnosed clinically with type 2 diabetes for at least 6 months and have an HbA1c level between 7.0-10.0%. The patients must have a BMI below or equal to 35.0 kg/m^2 and be insulin naive, but currently taking one or more oral antidiabetic drugs for at least 12 weeks prior to randomization. The trial excludes patients who have had a change in medication that interferes with glucose metabolism, have used certain medications within the last 12 weeks, or have had cardiovascular disease within the last 6 months. The trial will test the effectiveness of two drugs, insulin degludec/insulin aspart and insulin glargine, on patients who meet the inclusion criteria.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial includes participants who have previously been treated with drugs of 2 or 3 different antiretroviral classes and are currently on highly active antiretroviral treatment (HAART) for more than 4 weeks with a plasma viral load between 1,000 and 300,000 copies of HIV-1 ribonucleic acid per milliliter (RNA/mL). The trial also requires participants to have the possibility of potentially effective OB without enfuvirtide, consisting of 2 to 5 drugs, at least two of which are active from at least two different antiretroviral classes. The inclusion criteria also includes a CD4 cell count greater than 50 cells/cubic millimeter (mm^3) at screening, resistance mutations detected in reverse transcriptase and/or protease genes, and being enfuvirtide-naive. The exclusion criteria includes women of childbearing age not using effective mechanical contraception, pregnant or breastfeeding women, presence of HIV-2 coinfection, participants participating or having participated to another clinical trial during the 30 days prior to selection for this trial, participants having previously been treated with enfuvirtide, presence of active opportunistic infection within 1 month of study entry, existence of Grade 4 clinical or laboratory abnormalities, cirrhosis or severe hepatic failure, uncontrolled diabetes or requiring insulin, and consumption of alcohol and/or narcotics and/or other substances.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who are at least 18 years old and have confirmed colon or rectal cancer with unresectable metastatic disease. Patients must have at least one measurable lesion and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. The trial excludes patients who have previously been treated with Avastin or systemic treatment for advanced or metastatic disease, as well as those with clinically significant cardiovascular disease or who are on daily chronic treatment with high doses of aspirin or non-steroidal anti-inflammatory drugs. The trial involves the use of bevacizumab, capecitabine, and oxaliplatin.",
    "The sample is a phase 3 clinical trial for ovarian cancer. The trial is testing the effectiveness of two drugs, karenitecin and topotecan, on patients with stage III or IV epithelial ovarian cancer that is resistant to platinum/taxane-based chemotherapy regimens and has measurable, progressive disease. The trial has inclusion criteria such as age over 18, confirmed diagnosis of ovarian cancer, and ECOG PS \u2264 2. Exclusion criteria include uncontrolled high blood pressure, uncontrolled diabetes mellitus, or other serious underlying medical condition not compatible with study entry, life expectancy less than 3 months, prior treatment with a camptothecin or any platinum agent other than cisplatin or carboplatin, and prior radiation therapy to greater than one-third of the hematopoietic sites.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have had their primary invasive breast carcinoma resected at the time of original diagnosis. The trial is testing the effectiveness of the drug letrozole. The eligibility criteria include being postmenopausal, having a performance status of ECOG 0-2, and having a life expectancy of at least 5 years. Patients must also meet certain hematopoietic, hepatic, and renal requirements, and must not have any concurrent medical or psychiatric conditions that would preclude study participation. Prior concurrent therapies are allowed in some cases, but not others. The sample includes a detailed list of eligibility criteria for both disease and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial includes patients with a primary diagnosis of Functional Class I-III OA of the hip or knee with documented osteoarthritis flare at baseline, who are chronic users of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain, and have discontinued all analgesic therapy at Screening. The trial excludes patients with a history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDS, including diclofenac, those who require continuous use of opioid or opioid combination products to control OA pain of the knee or hip, and those with clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease. The trial also excludes patients with significant difficulties swallowing capsules or unable to tolerate oral medication, and those who have previously participated in another clinical study of Diclofenac Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening. The trial involves the use of diclofenac and placebo as drugs.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for the trial include a diagnosis of type 2 diabetes mellitus, being drug-na\u00efve or pre-treated with metformin, and having a glycosylated hemoglobin level between 7.0% and 10.5%. Exclusion criteria include uncontrolled hyperglycemia, use of any other antidiabetic drug within 12 weeks prior to randomization (except metformin), and recent acute coronary syndrome, stroke, or TIA.",
    "This sample is for a phase 3 clinical trial for the treatment of endometriosis. The trial is looking at the drug Visanne (also known as sh t00660aa and bay86-5258) and its effectiveness in reducing pelvic pain associated with endometriosis. The eligibility criteria for the trial includes female patients with endometriosis-associated pelvic pain, but excludes pregnant or lactating women, those with a history or suspicion of hormone dependent tumor, therapy resistant endometriosis, or any other conditions that would prevent participation. The diseases are listed as 'endometriosis' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for attention deficit disorder with hyperactivity. The trial involves the use of high dose clonidine hcl sustained release, low dose clonidine hcl sustained release, and a placebo. The eligibility criteria include being between 6 and 17 years old, having a diagnosis of ADHD of the hyperactive or combined inattentive/hyperactive subtypes according to DSM-IV criteria, having a minimum score of 26 on the ADHDRS-IV questionnaire at baseline, having a general good health as judged by the Principal Investigator, having a body mass index \u2265 5th percentile of the subject's age group according to the CDC growth chart, being able to swallow tablets, having a general IQ \u226580 as judged by the Principal Investigator, and being able to sign informed assent or consent form. The exclusion criteria include being pregnant or lactating, having a clinically significant illness or abnormality on physical examination or clinical laboratory evaluations, having a clinically significant abnormality on centrally interpreted Electrocardiogram (ECG) readings, having a concomitant psychiatric disorder requiring psychotropic medication or a severe concomitant Axis I or Axis II disorder that could interfere with study assessments, having a history of concomitant conduct disorder (CD), having a history of seizures, except for a single episode of febrile seizure prior to age 2, having a history of syncopal episodes, having a disorder that would interfere with the absorption, metabolism, or excretion of clonidine, having a history of intolerance to clonidine, including any dermatologic reaction to transdermal clonidine, having a presence or history of alcohol or drug abuse, having a positive drug screen, with the exception of ADHD drugs, and using any investigational drug within 30 days of study start.",
    "The sample is a phase 3 clinical trial for in vitro fertilization. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include being a female of couples with an indication for Controlled Ovarian Stimulation (COS) and in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), being between 18 and 36 years old, having a body weight between 60 and 90 kg and a body mass index (BMI) between 18 and 32 kg/m^2, having a normal menstrual cycle length of 24-35 days, having ejaculatory sperm available, and being willing and able to sign informed consent. The exclusion criteria include a history of or current endocrine abnormality, ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS), more than 20 basal antral follicles <11 mm (both ovaries combined) as measured on ultrasound scan (USS) in the early follicular phase (menstrual cycle day 2-5), less than 2 ovaries or any other ovarian abnormality (including endometrioma > 10 mm; visible on USS), presence of unilateral or bilateral hydrosalphinx (visible on USS), presence of any clinically relevant pathology affecting the uterine cavity or fibroids >=5 cm, more than three unsuccessful IVF cycles since the last established ongoing pregnancy (if applicable), history of non- or low ovarian response to FSH/ human menopausal gonadotropin (hMG) treatment, history of recurrent miscarriage (3 or more, even when unexplained), FSH > 12 IU/L or LH > 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5), any clinically relevant abnormal laboratory value based on a sample taken during the screening phase, contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts), recent history of or current epilepsy, human immunodeficiency virus (HIV) infection, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease, abnormal karyotyping of the patient or her partner (if karyotyping is performed), smoking more than 5 cigarettes per day, history or presence of alcohol or drug abuse within 12 months prior to signing informed consent, previous use of Org 36286, use of hormonal preparations within 1 month prior to randomization, hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol, and administration of investigational drugs within three months prior to signing informed consent.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who have been diagnosed with asthma for more than 6 months and are in good health otherwise. The trial involves the use of two drugs, ciclesonide and placebo. The eligibility criteria include being an outpatient, having written informed consent from parents or legal guardians, and using rescue medication or pretreatment with a controller drug. The exclusion criteria include having concomitant severe diseases, lung diseases causing impairment in pulmonary function, history of life-threatening asthma, and premature birth.",
    "The sample is a phase 3 clinical trial for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The trial includes patients with stage I, II, and III multiple myeloma and requires them to have met certain criteria for the disease, such as bone marrow plasmacytosis or biopsy-proven plasmacytoma, and evidence of end-organ damage. The trial involves the use of three drugs: bortezomib, lenalidomide, and dexamethasone. Patients must have received a minimum of one cycle and a maximum of six cycles of a dexamethasone-based regimen and must not have experienced progressive disease on such therapy. The trial also includes eligibility criteria related to laboratory levels, prior treatment, and contraception use. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial is testing the effectiveness of a drug called ly450139 compared to a placebo. The trial is looking for participants who have mild to moderate Alzheimer's disease with a Mini-Mental State Examination (MMSE) score of 16-26 at Visit 1, a Modified Hachinski Ischemia Scale score of less than or equal to 4, and a Geriatric Depression Scale score of less than or equal to 6. Participants must have had an MRI or CT scan in the last 2 years with no findings inconsistent with a diagnosis of AD. Female participants must be without menstruation for at least 12 consecutive months or have had both ovaries removed. Exclusion criteria include not being able to swallow whole oral medication, having serious or unstable illnesses, not having a reliable caregiver, chronic alcohol or drug abuse within the past 5 years, and having ever had active vaccination for AD.",
    "The sample is a phase 3 clinical trial for the treatment of graft versus host disease. The trial is looking for patients who have newly diagnosed extensive chronic GVHD in at least one organ system, and have at least one typical clinical manifestation of chronic GVHD that differs from acute GVHD. The trial is open to patients aged 1 to 29 with a performance status of Lansky 50-100% or Karnofsky 50-100%, and a life expectancy of at least 2 months. Patients must also meet certain hematopoietic, hepatic, renal, and other criteria. The trial is looking at the effectiveness of cyclosporine, hydroxychloroquine, prednisone, and tacrolimus as treatments for chronic GVHD. Prior treatment for chronic GVHD is limited to topical treatment or adjustments of cyclosporine or tacrolimus doses. No other concurrent systemic or topical immunosuppressants are allowed. Certain medications cannot be taken within 1 hour before or 2 hours after study drug administration.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on Restless Legs Syndrome (RLS) and involves the drug ropinirole. The record includes a list of disease names and their corresponding ICD-10 codes. The eligibility criteria for the trial are also listed, including both inclusion and exclusion criteria. Patients must have a diagnosis of RLS and give written informed consent. Exclusion criteria include other sleep disorders, medical conditions such as diabetes or rheumatoid arthritis, and recent participation in other clinical trials. The record notes that there may be additional inclusion or exclusion criteria evaluated by the physician.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of pulmonary hypertension. The trial involves the drug sitaxentan and includes patients who have a current diagnosis of symptomatic PAH and have 6MWT distances from 150 to 450 meters. The inclusion criteria also specify that patients should not have been previously exposed to an endothelin receptor antagonist. The exclusion criteria include patients with uncontrolled systemic hypertension or hypotension. The diseases are listed as 'hypertension, pulmonary' and the corresponding ICD-10 codes are also provided. The eligibility criteria are listed under both inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and cognition. The trial involves the use of two drugs, sertindole and quetiapine. The eligibility criteria for the trial include having a primary diagnosis of schizophrenia, being between the ages of 18 and 55, and not having previously received antipsychotic drugs for schizophrenia. Exclusion criteria include having a current primary psychiatric diagnosis other than schizophrenia, experiencing acute exacerbation requiring hospitalization within the last 3 months, having clinically significant extrapyramidal symptoms, and having certain cardiovascular or ECG abnormalities. Additionally, participants cannot have hypokalaemia or hypomagnesaemia, be in concurrent treatment with drugs inhibiting the P450 enzymes system CYP3A, or have congenital long QT syndrome or a family history of this disease, or known acquired QT interval prolongation.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of irritable bowel syndrome. The trial involves the use of two drugs, mesalazine and placebo. The eligibility criteria for the trial include patients with a positive diagnosis of IBS based on Rome III criteria, while patients with any organic or metabolic disease are excluded from the trial. The sample also includes a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for the treatment of bacterial skin infections. The trial involves the use of two drugs, retapamulin ointment and placebo ointment. The eligibility criteria for the trial include the subject being aged 2 months or older, having a secondarily-infected traumatic lesion, a negative urine pregnancy test, and a total skin infection rating scale score of at least 8. The trial also has exclusion criteria, such as previous hypersensitivity to pleuromutilin, underlying skin disease, and systemic signs and symptoms of infection. The subject or parent/legal guardian must give written informed consent or assent to participate in the trial.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for rheumatoid arthritis and includes a list of icd-10 codes for the disease. The trial involves the use of drugs such as abatacept and methotrexate, as well as a placebo. The eligibility criteria for the trial include having had rheumatoid arthritis for at least a year and having taken methotrexate for at least three months with a stable dose for 28 days prior to treatment. The exclusion criteria include having evidence of active or latent bacterial or viral infections at the time of potential enrollment.",
    "The sample is a phase 3 clinical trial for patients with metastatic cancer of the colon or rectum that is not amenable to potentially curative treatment. The trial involves the use of drugs such as xaliproden, oxaliplatin, 5-fluorouracil, and leucovorin, as well as a placebo. The eligibility criteria include having measurable disease, no prior chemotherapeutic regimen for metastatic disease, and a disease-free interval from end of adjuvant therapy of at least 6 months. The exclusion criteria include having peripheral neuropathy greater than grade 1, receiving chemotherapeutic agents other than those specified in the trial, and having concurrent active cancer originating from a primary site other than the colon or rectum.",
    "The sample is a phase 3 clinical trial for individuals diagnosed with type 2 diabetes mellitus. The trial is testing the effectiveness of two drugs, exenatide once weekly and liraglutide, in improving glycemic control. The eligibility criteria include having suboptimal glycemic control, a BMI of 45 kg/m^2 or less, and having been treated with lifestyle modification and one of several specified oral antidiabetic agents. Exclusion criteria include contraindications or allergies to the study drugs or other medications, recent use of certain excluded medications, recent blood donation or transfusion, and previous use of certain GLP-1 receptor agonists or GLP-1 analogs.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with type 2 diabetes mellitus who have previously been treated with metformin alone or with metformin and one other oral antidiabetic drug. The trial includes a placebo run-in phase and has specific inclusion and exclusion criteria for patients. The diseases listed in the sample are limited to diabetes mellitus, type 2, and the icd-10 codes associated with the disease. The drugs listed include a placebo identical to bi 1356 5mg, a placebo identical to glimepiride 1mg or 2mg or 3mg or 4 mg, bi 1356, and glimepiride.",
    "The sample is a phase 3 clinical trial for pneumonia. The trial includes hospitalized non-ICU patients who have clinical signs and symptoms of CAP with PSI score IV or V, radiologically confirmed evidence of a new and/or progressive infiltrate(s), and a requirement for initial parenteral therapy. The trial also requires patients to have at least 2 of the following conditions: productive or non-productive cough, dyspnea and/or tachypnea, rigors and/or chills, pleuritic chest pain, auscultatory findings of rales and/or crackles on pulmonary examination and/or evidence of pulmonary consolidation, and fever or hypothermia with a WBC count of >= 10,000 cells/mm3 or >= 15% immature neutrophils bands. Patients must provide written informed consent to participate in the trial. Patients who meet the exclusion criteria, such as those with PSI Class I-III and V with need for ICU admission or hospitalization for > 48 hours before developing pneumonia, are not eligible to participate in the trial.",
    "The sample is a phase 3 clinical trial for patients with chronic kidney disease and anemia. The trial is testing the effectiveness of epoetin alfa, a drug used to increase hemoglobin levels. The inclusion criteria require patients to have a glomerular filtration rate between 15 and 60 mL/min per 1.73 m2, a hemoglobin level between 10.0 and 11.9 g/dL, and a history of increased hemoglobin after the initial dose of epoetin alfa. The exclusion criteria include uncontrolled hypertension, iron deficiency, iron overload, severe congestive heart failure, active infection, recent heart attack, stroke, or blood clot. The diseases being studied are anemia and renal diseases, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for non-metastatic operable primary invasive adenocarcinoma of the breast. The trial is testing the effectiveness of the drug lapatinib in patients with over expression and/or amplification of HER2 in the invasive component of the primary tumor. The trial has eligibility criteria including age, ECOG performance status, axillary node status, hormone receptor status, and completion of necessary baseline laboratory and radiological investigations. Exclusion criteria include a history of any prior invasive breast carcinoma, past or current history of malignant neoplasms, and serious cardiac illness or medical conditions. The trial has specific requirements for randomization and study treatment start dates.",
    "The sample is a phase 3 clinical trial for breast cancer patients with metastatic disease. The trial involves the use of two drugs, pegylated liposomal doxorubicin and capecitabine. The eligibility criteria include being a female patient over 18 years old with confirmed breast cancer, having evaluable disease, having an Eastern Cooperative Oncology Group (ECOG) score of 0-2, having adequate renal, bone marrow, and liver function, and having a sufficient life expectancy to be treated with chemotherapy. Patients with certain medical conditions or who have received certain treatments are excluded from the trial. The trial requires patients to sign an informed consent document and complete study questionnaires.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients with bipolar I disorder who are currently experiencing a manic or mixed episode and are being treated with lithium or valproic acid. The trial involves the drugs asenapine and placebo. The eligibility criteria for the trial include having bipolar I disorder and being treated with lithium or valproic acid, while the exclusion criteria include having an unstable medical condition, clinically significant laboratory abnormality, or a primary diagnosis other than bipolar I disorder.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone palmitate. The trial is looking for participants who have been diagnosed with schizophrenia for at least 1 year and have a total PANSS score of 60 to 120. Participants must also have a BMI of at least 15.0 kg/m\u00b2. Exclusion criteria include having a primary active DSM-IV Axis I diagnosis other than schizophrenia, a decrease of 25% or more in the total PANSS score between screening and baseline evaluations, a DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation, a history of treatment resistance, and being pregnant, breastfeeding, or planning to become pregnant during the study period.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease and dementia of the Alzheimer's type. The trial is testing the effectiveness of the drug \"rivastigmine transdermal patch\". The table includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for participants. Inclusion criteria include a diagnosis of dementia of the Alzheimer's type, being male or surgically sterile or one year postmenopausal, and having a primary caregiver willing to supervise treatment. Exclusion criteria include any condition other than Alzheimer's that could explain the patient's dementia, an advanced or severe disease that may put the patient at special risk, and a current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs anagliptin and sitagliptin. The eligibility criteria for the trial include being diagnosed with type 2 diabetes within the past 3 months, being between the ages of 19 and 75, having a fasting plasma glucose level of no more than 270 mg/dL at the screening visit, and providing written informed consent. Exclusion criteria include having type 1 or secondary diabetes, taking oral anti-hyperglycemic drugs or other medications, having a body mass index outside of the range of 20 to 40 kg/m2, and being deemed inappropriate for the trial by the investigator. The diseases column lists only \"type 2 diabetes mellitus\" and the icdcodes column lists a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for patients with idiopathic Parkinson's Disease who have a good response to levodopa and predictable motor fluctuations of the wearing \"OFF\" type. The trial includes patients who are taking optimized levodopa therapy and have a rating between II-IV on the Hoehn & Yahr scale when in an \"OFF\" state. The trial excludes pregnant or lactating women, women of childbearing potential who are not infertile or not practicing effective contraception, patients with a past or present history of drug or alcohol abuse, patients with a past or present history of suicidal ideation or suicide attempts, and patients with unstable abnormalities of various bodily systems. The trial will test the efficacy and tolerability of 2 mg and 4 mg perampanel compared to a placebo comparator.",
    "The sample is a phase 3 clinical trial for children and adolescents aged 6 to 18 years who have been diagnosed with chronic motor or vocal tic disorder or Tourette's disorder and require drug therapy. The trial involves the use of aripiprazole and placebo as drugs. The eligibility criteria include having a total tic score of more than 22 at baseline, providing an assent form signed by themselves and informed consent form by their legal representatives, and not having secondary tic symptoms accompanied by certain conditions such as mental retardation or autism. Exclusion criteria include having a history of neuroleptic malignant syndrome, antipsychotic or alcohol use disorder, allergy or hypersensitivity reaction to aripiprazole, and having previously taken aripiprazole or participated in a clinical study with aripiprazole.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial involves the use of two drugs, tenofovir df and placebo. The eligibility criteria for the trial include having a documented laboratory diagnosis of HIV infection, prior antiretroviral treatment experience with at least 2 antiretroviral drug classes, and being naive to tenofovir DF. The trial also excludes patients requiring didanosine in the background regimen, those with a prior history of significant renal disease, and those with a prior history of significant bone disease.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of major depressive disorder. The trial involves the use of two drugs, quetiapine fumarate and duloxetine. The eligibility criteria for the trial include having a documented clinical diagnosis of major depressive disorder, being able to understand and comply with the requirements of the study, and being able to provide written informed consent. The exclusion criteria include being pregnant or lactating (for female patients) and having a current or past diagnosis of stroke or transient ischemic attack (TIA). The diseases are listed as 'major depressive disorder' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of non-insulin-dependent diabetes mellitus. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, including sitagliptin phosphate and a comparator drug called voglibose. The eligibility criteria for the trial include patients with type 2 diabetes mellitus who are currently on diet and exercise therapy, while patients with type 1 diabetes mellitus are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with major depressive disorder. The trial is testing the effectiveness of a drug called saredutant succinate (sr48968c). The eligibility criteria include being between 18 and 64 years old, having a confirmed diagnosis of major depressive disorder, and having a minimum total score of 22 on the Montgomery-Asberg Depression Rating Scale (MADRS). Exclusion criteria include having a current depressive episode with psychotic features, a history of substance abuse, or a history of failure to respond to treatment with paroxetine or other antidepressant medications. The trial also excludes patients with certain medical conditions or who are pregnant or breastfeeding. The trial requires written informed consent from the patient and/or legally authorized representative.",
    "The sample is for a phase 3 clinical trial for the treatment of angina pectoris. The trial includes patients with documented coronary artery disease who have previously been treated with atenolol or other beta-blocker agents. The drug being tested is ivabradine. The eligibility criteria include chronic stable angina pectoris, exercise tolerance test positivity and stability, while exclusion criteria include heart rate below 60 bpm and congestive heart failure.",
    "The sample is a phase 3 clinical trial for patients with coronary artery disease who are undergoing on-pump, elective coronary artery bypass grafting with at least 2 free grafts. The trial is testing the effectiveness of aspirin and clopidogrel as drugs for these patients. The eligibility criteria include being 18 years or older, able to give informed consent, and not having any contraindications for the trial. The exclusion criteria include having a planned surgery date less than 5 days from the planned recruitment date, having a clear indication for anticoagulation or ADP receptor antagonist, having an allergy or intolerance to aspirin or clopidogrel, having a history of bleeding diathesis, significant GI bleed, ICH, or liver failure, having known renal failure or contraindication for Cardiac CT Angio, or having had previous cardiac surgery.",
    "The sample is a record of a clinical trial in phase 3, focused on chronic obstructive pulmonary disease. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested, including budesonide/formoterol and formoterol. The eligibility criteria for the trial include a current clinical diagnosis of COPD, documented symptoms for more than 2 years, and a smoking history of at least 10 pack years. The exclusion criteria include a history or current diagnosis of asthma or atopic diseases such as allergic rhinitis.",
    "This sample is from a phase 3 clinical trial for a drug to treat HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain. The trial is looking for men and women who are 18 years or older and have documented evidence of HIV-1 infection and a diagnosis of DSP. The pain should start in the feet. The trial is testing the drug pregabalin against a placebo. The eligibility criteria include exclusion of subjects with untreated vitamin B12 deficiency, diabetes mellitus requiring regular medical treatment, and peripheral neuropathic pain not associated with HIV infection.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus. The trial involves the use of insulin lispro and insulin aspart. The eligibility criteria include having type 2 diabetes, being treated with continuous subcutaneous insulin infusion therapy using a rapid-acting analog for the previous 6 months, having a screening A1C less than or equal to 9.0%, having a body mass index less than 45 kg/m\u00b2 at screening, having a history of stable body weight, and being on a stable dose of oral anti-diabetes medications labeled for use with insulin for at least 3 months prior to study entry. Exclusion criteria include having severe insulin resistance, taking antihyperglycemic medication not approved for use with insulin, having certain medical conditions or receiving certain therapies.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer with a primary histology of predominantly squamous cell, large cell or adenosquamous carcinoma. The trial includes patients with advanced NSCLC with documented Stage IIIB (with pleural effusion) or Stage IV or recurrent disease who have not received prior systemic treatment for NSCLC, except for adjuvant chemotherapy. The trial also includes patients who have completed prior surgery or radiation therapy at least 3 weeks prior to randomization and all acute toxicities have resolved. Patients with symptomatic central nervous system (CNS) metastases, requiring chronic steroid use, or with uncontrolled diabetes are not permitted. The trial includes the drugs cp-751,871 (figitumumab), carboplatin, and paclitaxel. The eligibility criteria for the trial are listed in the \"Inclusion Criteria\" and \"Exclusion Criteria\" sections.",
    "The sample is a phase 3 clinical trial for HIV infections and herpes genitalis. The trial includes participants who are HIV-uninfected and HSV-2 infected, and who plan to stay in the area for the duration of the study. The trial involves the use of acyclovir and acyclovir placebo drugs. The eligibility criteria for the trial include being willing and able to provide consent, undergo clinical evaluations, take study drugs, adhere to follow-up schedule, and provide adequate locator information. Inclusion criteria for MSM and WSM are also specified. Exclusion criteria include current enrollment in another HIV vaccine or prevention trial, history of adverse reaction to acyclovir, current or planned use of famiciclovir, valacyclovir, or acyclovir for genital HSV, and known plans for travel away from study site for more than 2 months. Exclusion criteria for MSM and WSM are also specified.",
    "The sample is a phase 3 clinical trial for patients with defibrillators, implantable and ventricular tachycardia. The trial involves the use of the drug amiodarone and has specific eligibility criteria for patients to be included. Patients must be between 18 and 85 years old, have an ICD implanted for primary or secondary prophylaxis against sudden cardiac death or ventricular arrhythmia, have coronary artery disease with prior myocardial infarction, and have ICD or ECG documentation of ventricular arrhythmia responsible for appropriate ICD therapy. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial also has specific exclusion criteria, including contraindications to contrast media or interventional procedures, recent amiodarone therapy, and certain heart conditions. Females of childbearing potential who are not practicing protocol acceptable method of birth control are also excluded.",
    "The sample is a phase 3 clinical trial for hypertension in children aged 6 months to 5 years. The trial includes patients with a documented history of hypertension, who are able to swallow liquid formulation, and weigh between 6 kg and 40 kg at randomization. The trial also requires patients to have a documented history of mean systolic blood pressure (MSSBP) that is equal to or greater than the 95th percentile for age, gender, and height at randomization. Patients who enter the trial with uncontrolled blood pressure can remain on background antihypertensives with an unchanged dosing regimen. Patients who have had a solid organ transplant more than 1 year ago must be on stable doses of immunosuppressive therapy. The trial excludes patients with background ARB therapy, clinically significant abnormalities or noteworthy abnormal lab values (other than those relating to renal function), AST/SGOT or ALT/SGPT > 3 times the upper limit of the reference range, glomerular filtration rate < 30 mL/min/1.73m\u00b2, serum potassium > upper limit of the reference range, MSSBP \u2265 25% above the 95th percentile, clinically significant ECG abnormalities, and patients that have coarctation of the aorta with a gradient of \u2265 30 mm Hg, or renal artery stenosis. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes, cardiovascular disease, and kidney disease. The trial is testing the effectiveness of olmesartan medoxomil compared to a placebo. The eligibility criteria include having type 2 diabetes, certain cardiovascular risk factors, and normoalbuminuria. Exclusion criteria include severe uncontrolled hyperlipidemia, documented renal or renal-vascular disease, recent myocardial infarction or stroke, history of alcohol or drug abuse, and contraindication to angiotensin receptor blockers or current treatment with an ARB or ACE inhibitor.",
    "This sample is for a phase 3 clinical trial that focuses on inflammation. The trial includes patients with specific icd-10 codes related to inflammation and who are scheduled for unilateral ocular surgery. The drug being tested is difluprednate. The eligibility criteria include not having received any systemic corticosteroid or immunosuppressive drugs in the 2 weeks prior to study enrollment.",
    "The sample is a phase 3 clinical trial for the treatment of ulcerative colitis using encapsulated mesalamine granules (emg). The eligibility criteria include having a confirmed diagnosis of mild to moderate UC in remission for greater than 1 month and less than 12 months, being at least 18 years old, and having the potential for benefit with MP treatment. Participants must also be willing and able to comply with all study procedures. Exclusion criteria include having a history of allergy or intolerance to aspirin, mesalamine, or other salicylates, having an abnormal clinical lab result, or having participated in an investigational drug or device study within the 30 days prior to study screening.",
    "The sample is a phase 3 clinical trial for lupus nephritis, a disease affecting the kidneys in patients with systemic lupus erythematosus (SLE). The trial is testing the effectiveness of two drugs, mycophenolate sodium and cyclophosphamide, in treating lupus nephritis. The eligibility criteria for the trial include being at least 16 years old, having a diagnosis of SLE with at least 4 criteria present, having biopsy-proven active lupus nephritis, and having relapsed or been resistant to previous treatment with intravenous cyclophosphamide. There are also various exclusion criteria related to SLE, treatment, general health, and laboratory findings. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C in children aged 3-17 years old. The trial includes eligibility criteria such as normal hematology and chemistry laboratory results, compensated liver disease, and no significant co-existing psychiatric disease. Exclusion criteria include previous hepatitis C treatment, liver disease not caused by hepatitis C, and known blood disorders. The trial requires patients and partners of patients to use adequate contraception during the course of the study and to abstain from alcohol and any other illicit drugs.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for Parkinson's disease and includes a list of ICDCodes, which is a standardized system of codes used to classify diseases. The trial involves two drugs, Requip PR and Mirapex, and has specific eligibility criteria for participants, including a diagnosis of Parkinson's disease and currently taking pramipexole. There are also exclusion criteria, such as not having significant adverse effects to standard Requip and not having unstable medical conditions. Female patients of childbearing potential must be using an effective method of contraception and cannot be pregnant or lactating. The criteria listed may not be a complete list, and there may be additional criteria that apply.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe non-malignant pain who have not found relief with WHO step I or II analgesics. The trial is testing the effectiveness of oxycodone and naloxone as a WHO step III opioid therapy. Patients must be at least 18 years old and willing to provide written informed consent. They must also be willing to discontinue their current analgesics, like opioids, and pre-study laxative medication. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial will involve attending scheduled clinic visits, completing subjective evaluations, and complying with protocol requirements.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cavity cancer using the drug carboplatin. The eligibility criteria include confirmed diagnosis of the specified cancers, certain disease characteristics such as stage and absence of certain types of tumors, and specific patient characteristics such as age, performance status, and absence of certain medical conditions. Prior concurrent therapies are not allowed, and certain medical tests must be performed before enrollment in the trial.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients with Stage IIIA, IIIB, or IV NSCLC who are not eligible for curative surgery or radiotherapy and have had at least one prior chemotherapy for palliative therapy. The trial involves the drugs pemetrexed and docetaxel. The eligibility criteria include meeting certain disease status assessment criteria, having an ECOG performance status of 0 to 2, and being willing to take folic acid or vitamin B12 supplementation. Exclusion criteria include concurrent administration of any other tumor therapy, pregnancy or breastfeeding, serious concomitant disorders, and unwillingness to take folic acid or vitamin B12 supplementation.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on treating multiple myeloma. The table includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The eligibility criteria include age, prior treatment with anti-myeloma therapy, refractory or relapsed disease, and failure of treatment with lenalidomide and bortezomib. The sample also includes exclusion criteria such as laboratory abnormalities, previous therapy with pomalidomide, and hypersensitivity to certain drugs. The trial requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 and to meet other specific criteria.",
    "The sample is a phase 3 clinical trial for diabetic neuropathy, painful. The trial includes patients with pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus. The patients must have a score of at least 4 on the 24-hour average pain severity score on an 11-point Likert scale. Patients who are currently not receiving treatment for diabetic peripheral neuropathic pain or were receiving treatment for DPNP with a drug other than pregabalin or duloxetine and completed the required washout are eligible for the trial. Patients who have never received treatment with duloxetine or pregabalin are also eligible. The trial requires stable glycemic control, as assessed by a physician investigator, and hemoglobin A1c less than or equal to 12% at screening. The exclusion criteria include known hypersensitivity to duloxetine or pregabalin, uncontrolled narrow-angle glaucoma, and acute liver injury or severe cirrhosis. Patients with serious or unstable cardiovascular, hepatic, renal, respiratory, or hematological illness, symptomatic peripheral vascular disease, a history of seizure disorder, or other medical or psychological conditions that would compromise participation or be likely to require hospitalization during the course of the study are also excluded. The trial requires patients to abstain from non-pharmacological treatment during the study.",
    "The sample is a phase 3 clinical trial for allergic rhinoconjunctivitis with or without mild asthma related to grass pollen. The trial includes subjects who have had allergic symptoms for at least 2 years and have used anti-allergy symptomatic medication in the last pollen season. The trial also requires a positive skin prick test and specific serum IgE-test for grass pollen. The trial excludes subjects with a positive SPT for perennial allergens of house dust mite, chronic asthma or emphysema with a FEV1 < 70 % of predicted value, and use of inhalation corticosteroids outside grass and tree pollen season for more than two episodes and/or longer than fourteen days. The trial also excludes subjects with serious immuno-pathological diseases or malignancies, inflammation and infection of the target organ, severe atopic dermatitis requiring systemic immuno-suppressive medication, and allergen specific immuno-therapy treatment within the last 5 years for a period longer than three months. Additionally, the trial excludes subjects with a history of life threatening anaphylactic events, including anaphylactic food allergy, insect venom anaphylaxis, exercise or drug induced anaphylaxis, a positive pregnancy test, lactation or inadequate contraceptive measures, alcohol- or drug abuse, and lack of co-operation or severe psychological disorders. The trial involves the use of sublivac\u00ae grasses/placebo treatment, sublivac\u00ae grasses treatment, and placebo treatment.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage II or Stage III. The trial includes patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) \u2265 30 % and/or <80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) < 0.70 at screening. The trial also includes current or ex-smokers who have a smoking history of at least 10 pack years and symptomatic patients according to daily diary data. The trial excludes pregnant or nursing women, women of child-bearing potential unless using adequate contraception, patients with Type I or uncontrolled Type II diabetes, patients with a history of long time interval between start of Q wave and end of T wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged, patients with paroxysmal (e.g. intermittent) atrial fibrillation, and patients who have a clinically significant electrocardiogram (ECG) or laboratory abnormality at screening (Visit 2). The trial involves the use of the drugs nva237 50 \u00b5g and indacaterol 150 \u00b5g, as well as a placebo to nva237 and indacaterol 150 \u00b5g. The trial is focused on chronic obstructive pulmonary disease (COPD) and involves a list of icd-10 codes of diseases.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes participants who have a history of mild persistent asthma symptoms and have been treated with a single-controller inhaled corticosteroid or a leukotriene receptor antagonist for the 4 weeks prior to study entry. Participants must also have a forced expiratory volume in one second (FEV1) reversibility of greater than or equal to 12% following bronchodilator administration or a methacholine provocative concentration at 20% (PC20) of less than or equal to 12.5 milligrams per milliliter (mg/ml). The trial will last for 44 weeks, and participants must meet certain criteria during the 8-week screening period to continue in the study. Exclusion criteria include a history of adverse reactions to ICS preparations or any of its ingredients, current or prior use of medications known to significantly interact with corticosteroid disposition, and cigarette smoking or smokeless tobacco use in the year prior to study entry.",
    "The sample is a phase 3 clinical trial for asthma. The trial is looking for participants who have had asthma for at least 12 months and have used inhaled corticosteroids for at least 4 weeks prior to the screening visit. Participants must also demonstrate a FEV-1 of 40-80% of predicted normal values at the screening and baseline visits, and have documented reversibility of 15% within 6 months of the screening visit or at the screening visit. The trial is testing the effectiveness of the drug fluticasone propionate/formoterol fumarate. Participants must be healthy, provide written informed consent, and meet other eligibility criteria. Exclusion criteria include life-threatening asthma within the past year, history of systemic corticosteroid medication within 3 months before the screening visit, and other clinically significant diseases or abnormalities.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of several inhalation powders and a placebo. The eligibility criteria include being an outpatient, giving informed consent, being at least 40 years old, having a clinical history of COPD, and having a certain severity of disease. Exclusion criteria include pregnancy, asthma, other respiratory disorders, and poorly controlled COPD. The trial also excludes subjects with certain medical conditions or who are at risk of non-compliance.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients between the ages of 20 and 75 who have mild to moderate essential hypertension and are outpatients. The drug being tested is aliskiren. The inclusion criteria include age, gender, and outpatient status, while the exclusion criteria include pregnancy or lactation, high blood pressure levels, secondary hypertension, and suspected malignant hypertension. Other protocol-defined criteria may also apply. The diseases being studied are listed as 'hypertension' and the corresponding ICD-10 codes are provided.",
    "The sample is a phase 3 clinical trial for postmenopausal osteoporosis. The trial includes the drugs placebo and ibandronate, and the eligibility criteria includes being postmenopausal for at least 3 years with osteoporosis at certain sites, willingness to take study-supplied calcium and vitamin D supplements, and not having certain medical conditions or taking certain medications. The exclusion criteria includes being pregnant or lactating, participating in another therapeutic trial within 30 days of randomization, having hypersensitivity to any component of ibandronate tablets, and having certain medical conditions.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as ly2189265, placebo, and liraglutide. The eligibility criteria for participants include having a diagnosis of type 2 diabetes mellitus, being Oral Antihyperglycemic Medication (OAM)-na\u00efve or having been taking OAM monotherapy except for thiazolidinedione (TZD) and being willing to discontinue this medication, having a body mass index (BMI) of 18.5 kilograms per meter squared (kg/m^2) to 35.0 kg/m^2, and meeting certain HbA1c value requirements. Exclusion criteria include having a diagnosis of type 1 diabetes, previously being treated with any other glucagon-like peptide-1 (GLP-1) analog, and having certain clinical signs or symptoms of pancreatitis or a history of medullary thyroid carcinoma (MTC).",
    "The sample is a record of a clinical trial for a drug called almotriptan malate, which is being tested for the treatment of migraines. The trial is in phase 3 and the disease being studied is migraine. The icd-10 codes associated with the disease are listed as well. The eligibility criteria for the trial are also provided, including having a history of migraine for at least one year, experiencing an average of 1-14 migraines per month for the 6 months prior to the study, and being able to swallow oral medication. The exclusion criteria are also listed, which include having an allergy to almotriptan malate or experiencing side effects from the drug, having 15 or more headache days per month, experiencing migraine aura without a headache, and having more than 6 non-migraine headaches per month.",
    "The sample is a phase 3 clinical trial for patients aged 12 and above with a history of moderate to severe seasonal allergic rhinitis. The trial involves testing the effectiveness of various drugs, including placebo, azelastine hcl, azelastinehcl/fluticasone propionate, and fluticasone propionate. The eligibility criteria include meeting minimum symptom requirements, being in good health, having a positive skin test to a prevalent spring allergen, and being willing and able to participate in all study procedures. Exclusion criteria include having certain nasal or sinus conditions, recent nasal or sinus surgery, chronic sinus infection, planned travel outside the study area, use of investigational drugs within 30 days of the first visit, hypersensitivity to certain medications, pregnancy or nursing, and certain medical conditions such as asthma, irregular heartbeat, and glaucoma.",
    "The sample is a phase 3 clinical trial for patients with liver metastases secondary to uveal melanoma or metastatic cancer. The trial involves the use of two drugs, fotemustine and isolated perfusion. The eligibility criteria include age 18 and over, WHO performance status of 0-2, no detectable extrahepatic metastases, and various medical conditions within normal ranges. Patients must not be pregnant or nursing, must use effective contraception, and must not have any other uncontrolled severe medical conditions or other malignancies within the past 5 years except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer. The trial excludes patients who have had prior radiotherapy for metastatic disease or concurrent immunologic or biologic therapy.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes mellitus. The trial includes patients who have had diabetes for at least 1 year, have an HbA1c value less than 12%, and a BMI less than or equal to 35.0 kg/m^2. The trial involves the use of glargine, ly2605541, and insulin lispro. The eligibility criteria include adhering to a multiple daily injection regimen, injecting insulin with a prefilled pen, and performing Self-Monitored Blood Glucose (SMBG) and record keeping as required by the protocol. The exclusion criteria include having excessive insulin resistance, receiving any oral or injectable medication (other than metformin for treatment of polycystic ovarian disease) intended for the treatment of diabetes mellitus other than insulins in the 90 days prior to screening, and having had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating patients with either gastric or rectal cancer using preoperative chemotherapy and radiation therapy, followed by surgery. The trial is testing the effectiveness of the drug epoetin alfa. The eligibility criteria for patients include having a confirmed diagnosis of cancer, a life expectancy of greater than 6 months, adequate hematologic, liver, and kidney function, and if female, being postmenopausal, surgically sterile, or practicing an effective method of birth control. The exclusion criteria include having received more than two cycles of chemotherapy, having anemia due to factors other than cancer or chemotherapy, having a history of any other major medical condition or uncontrolled disease, having received prior treatment with epoetin alfa or any investigational forms of erythropoietin within the previous six months, and having had a transfusion of white blood cells or packed red blood cells within one month prior to study entry or administration of androgen therapy within 2 months of study entry. The diseases being studied are stomach and rectal neoplasms, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with hypertension and includes a list of ICD-10 codes for related diseases. The trial involves the use of several drugs, including telmisartan and amlodipine, and has specific eligibility criteria for patients to participate. The inclusion criteria include having essential hypertension and meeting certain blood pressure requirements, while the exclusion criteria include having certain medical conditions or taking certain medications. The trial also excludes pre-menopausal women who are nursing or pregnant.",
    "The sample is a phase 3 clinical trial for patients with unresectable, locally advanced or metastatic gastric cancer. The trial includes patients with measurable or evaluable but non-measurable disease, who have not received prior palliative chemotherapy. The trial involves the use of two drugs, s-1/cisplatin and 5-fu/cisplatin. The eligibility criteria include having given written informed consent, having adequate organ function, being able to take medications orally, and being willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. The exclusion criteria include having had prior palliative chemotherapy or any previous therapy for malignancy within the past 5 years, having a serious illness or medical condition, receiving concomitant treatment with drugs interacting with S-1, 5-FU, or cisplatin, being pregnant or lactating, and having known hypersensitivity to 5-FU or cisplatin.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease asthma and includes a list of ICD-10 codes associated with the disease. The trial involves the drugs ciclesonide and placebo. The eligibility criteria for participants include being outpatients, having symptoms consistent with asthma for at least 12 months, having a Forced Expiratory Volume in one Second (FEV) of at least 80% of predicted, having a history of reversible airway obstruction, and being in good health except for asthma. Exclusion criteria include a history of life-threatening asthma, recent hospitalization for asthma, severe or contraindicated diseases, relevant lung diseases causing alternating impairment in lung function, premature birth, smoking, pregnancy, breastfeeding, or lack of safe contraception for females of child-bearing potential.",
    "The sample is a phase 3 clinical trial for kidney cancer. The trial includes patients who have undergone surgical resection of the primary tumor within the past month and have no evidence of metastatic disease or macroscopic residual disease. The eligibility criteria include specific disease characteristics, patient characteristics such as age and performance status, and hematopoietic, hepatic, renal, cardiovascular, and other health requirements. Patients cannot have prior or other concurrent malignancies or illnesses that would preclude study therapy or comparisons, and cannot be pregnant or nursing. The trial excludes patients who have had prior chemotherapy, radiotherapy, or major organ allografts, and those who are receiving concurrent immunotherapy, corticosteroids, hormonal therapy, or investigational drugs, agents, or devices. The drug being studied is fluorouracil.",
    "The sample is a phase 3 clinical trial for patients with cirrhosis, sepsis, and renal failure. The trial is testing the effectiveness of the drug human albumin. The eligibility criteria for the trial include having cirrhosis, a Child-Pugh score greater than 8, sepsis defined by the presence of infection and two of the four SIRS criteria, creatinine levels below 160 \u00b5mol/L, and written informed consent. Exclusion criteria include spontaneous bacterial peritonitis, difficult to treat infections, heart insufficiency, recent digestive bleeding, septic shock, hepatocellular carcinoma stage D, recent use of antibiotics, and diseases that may affect short-term survival.",
    "The sample is a phase 3 clinical trial for upper limb spasticity in patients who have had a cerebrovascular accident. The trial involves the use of the drug GSK1358820 (botulinum toxin type A) and a placebo. The eligibility criteria include having spasticity in both the wrist and fingers, meeting certain muscle tone and functional disability requirements, being stable on any current medications or physical therapy, and meeting certain age, weight, and liver function requirements. Exclusion criteria include having certain medical conditions or taking certain medications, being pregnant or nursing, having allergies to the study medication, and having certain liver or cardiovascular diseases. The trial requires informed consent and involves a list of exclusion criteria.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on major depressive disorder. The table includes a list of icd-10 codes for the disease and a drug called vortioxetine (lu aa21004). The eligibility criteria for the trial include having completed a short-term treatment study for major depressive episode prior to enrollment, not having any other current psychiatric disorder, using effective contraception if female and of childbearing potential, not using any psychoactive medication, and not having a significant risk of suicide. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for bladder cancer, transitional cell cancer of the renal pelvis and ureter, and urethral cancer. The trial involves the use of drugs such as carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, and vinblastine. The eligibility criteria include having histologically confirmed transitional cell carcinoma of the urothelium, no significant pericardial or pleural effusion or edema, no significant ascites, and no CNS metastases. Patients must also meet certain age, performance status, hematopoietic, hepatic, renal, cardiovascular, and other criteria. Prior concurrent therapy is not allowed, and patients must not be pregnant or nursing. Fertile patients must use effective contraception.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial is looking for postmenopausal women with osteoporosis, as indicated by a low bone mineral density score. The trial is excluding women with certain vertebral abnormalities, those on certain medications, and those with certain medical conditions. The trial is testing the effectiveness of two drugs, osteoform and shelcal, and the eligibility criteria includes specific requirements for vitamin D levels, thyroid function, kidney health, and history of certain diseases.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, hyperglycemia and leukemia, and includes a list of corresponding ICD-10 codes. The trial is testing the effectiveness of therapeutic insulin as a treatment option. The eligibility criteria for participants include a confirmed diagnosis of acute myeloid or lymphoid leukemia, undergoing chemotherapy treatment, and demonstrating high blood sugar levels. Other patient characteristics include a performance status of 0-3, not being pregnant or nursing, and having no known allergy to insulin. The trial allows for concurrent use of corticosteroids but not oral hypoglycemic agents.",
    "The sample is a phase 3 clinical trial for patients with both symptomatic heart failure and type 2 diabetes. The trial is testing the effectiveness of metformin as a treatment option. The inclusion criteria require a physician-diagnosed case of both heart failure and type 2 diabetes, or a new diagnosis of type 2 diabetes during the visit within the heart failure clinic or hospital. Exclusion criteria include subjects currently receiving more than 1500 mg of metformin therapy per day, those unwilling to change their antidiabetic regimens, and those receiving insulin therapy. Other exclusion criteria include serum creatinine levels above 180 \u03bcmol/L, A1c levels below 7.0 percent, inability to communicate, dementia/mental illness, age below 18 years, unwillingness to complete self-monitoring of serum blood sugars during the trial period, participation in another heart failure or diabetes clinical trial involving medication, severe comorbidities or foreshortened life expectancy, and subjects who do not provide written informed consent to participate.",
    "The sample is a phase 3 clinical trial for eosinophilic asthma. The trial includes patients who are 12 to 75 years old and have a previous diagnosis of asthma. Patients must have an ACQ score of at least 1.5 and airway reversibility of at least 12% to beta-agonist administration at screening. They must also be currently taking fluticasone at a dosage of at least 440 \u03bcg daily (or equivalent) and have a blood eosinophil count of at least 400/\u03bcL. Female patients must be surgically sterile, 2 years postmenopausal, or have a negative pregnancy test \u00dfHCG at screening (serum) and baseline (urine). Female patients of childbearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after the end-of-treatment visit. The trial has various exclusion criteria, including patients with clinically meaningful comorbidities, known hypereosinophilic syndrome (HES), or other confounding underlying lung disorders. Patients who are current smokers, have a history of use of systemic immunosuppressive or immunomodulating agents, or are currently using systemic corticosteroids are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of metastatic melanoma, specifically targeting patients with the BRAF V600E mutation. The trial is testing the effectiveness of two drugs, vemurafenib and dacarbazine. The eligibility criteria include being an adult over 18 years old, having stage IIIC or IV metastatic melanoma, and having no prior systemic anticancer therapy. The patient must also have measurable disease by RECIST criteria and a negative pregnancy test. Exclusion criteria include having active central nervous system metastases, a history of carcinomatous meningitis, severe cardiovascular disease within 6 months prior to study drug administration, and previous malignancy within 5 years prior to the study, except for basal or squamous cell carcinoma of the skin, melanoma in-situ, or carcinoma in-situ of the cervix. Effective contraception is required during treatment and for 6 months after completion for fertile men and women.",
    "The sample is a phase 3 clinical trial for patients with knee osteoarthritis and pain. The trial involves the use of three drugs: tapentadol er, matching placebo, and oxycodone cr. The eligibility criteria include a diagnosis of osteoarthritis of the knee, dissatisfaction with current therapy, and a baseline pain score of at least 5 on an 11-point scale. Patients with certain medical conditions or taking certain medications are excluded from the trial. The data is organized in a table with columns for the trial phase, diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who have completed primary chemoradiotherapy and have stable disease or objective response according to Response Evaluation Criteria in Solid Tumors (RECIST). The trial involves the use of single low dose cyclophosphamide and placebo drugs. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, a platelet count > 140 x 10^9/Liter, white blood cells (WBC) > 2.5 x 10^9/Liter, and hemoglobin > 90 gram per liter (g/L). The exclusion criteria include having undergone lung cancer specific therapy other than primary chemo-radiotherapy, receipt of immunotherapy or investigational systemic drugs within 4 weeks prior to randomization, and having metastatic disease or malignant pleural effusion at initial diagnosis and/or at study entry. The sample also includes other exclusion criteria related to disease status, physiological functions, and standard safety.",
    "The sample is a phase 3 clinical trial for generalized anxiety disorder (GAD) and involves the use of duloxetine and placebo drugs. The trial includes both male and female outpatients who are at least 18 years old and have been diagnosed with GAD based on the disease diagnostic criteria. The patients must not suffer from an adjustment disorder or anxiety disorder not otherwise specified (NOS), and their symptoms of GAD should not be situational in nature. Females of childbearing potential must test negative for pregnancy and agree to use a reliable method of birth control during the study and for 1 week following the last dose of study drug. The trial has inclusion and exclusion criteria, including a Clinical Global Impressions of Severity (CGI-Severity) score of greater than or equal to 4 at Visit 1 and Visit 2, a Covi Anxiety Scale (CAS) score of greater than or equal to 9 at Visit 1, and a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of greater than or equal to 10 at Visit 1. Patients with any current and primary DSM-IV Axis I diagnosis other than GAD, the presence of an Axis II disorder or history of antisocial behavior, benzodiazepine use 14 days prior to Visit 2, and patients judged clinically to be at serious suicidal risk are excluded from the trial. Patients who have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the use of two drugs, travoprost ophthalmic solution 0.003% and 0.004%. The eligibility criteria include a diagnosis of open-angle glaucoma or ocular hypertension, qualifying intraocular pressure, and signing an informed consent form. Exclusion criteria include severe central visual field loss, chronic or severe inflammatory eye disease, and hypersensitivity to prostaglandin analogs. Other protocol-defined inclusion and exclusion criteria may also apply. The diseases and their corresponding ICD-10 codes are listed in the table.",
    "The sample is a phase 3 clinical trial for postmenopausal osteoporosis. The trial includes female subjects over 50 years old with lumbar or femoral-neck T-score less than -2.5 and greater than -4. The trial involves the use of disodium clodronate injections with 1% lidocaine. The eligibility criteria include having at least three intact vertebrae between L1 and L4, being treated according to the non-pharmacological standard of care, and having the possibility and willingness to take the injections. The exclusion criteria include having a BMI less than 19 kg/m2, a history of certain medication use, serious diseases of the oral cavity, heart disease, kidney failure or renal insufficiency, and other severe acute or chronic medical or psychiatric conditions.",
    "The sample is a phase 3 clinical trial for the treatment of nocturia, a condition where a person wakes up frequently during the night to urinate. The trial involves the use of two drugs, desmopressin and placebo, and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include being a male over 18 years old and having at least 2 voids every night in a consecutive 3-day period during the screening period based on the patient diary. Exclusion criteria include having severe daytime voiding dysfunction, interstitial cystitis, chronic prostatitis/chronic pelvic pain syndrome, suspicion of bladder outlet obstruction, urinary retention, habitual or psychogenic fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours, and many other medical conditions or abnormalities that may impair participation in the trial.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial is looking for osteopenic, postmenopausal women between the ages of 55 and 75 with a body mass index (BMI) less than 30 kg/m\u00b2. The trial is testing the effectiveness of risedronate and a risedronate placebo. The eligibility criteria includes exclusion criteria such as clinical or radiological evidence of osteoporosis, severe renal impairment, serum 5-hydroxy vitamin D level less than 15 ng/ml, history of recent primary hyperparathyroidism or recent thyroid disorder, history of any generalized bone disease, and current use of certain medications. The sample also includes a disclaimer that the information provided is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "The sample is a phase 3 clinical trial for the treatment of asthma using the drug ciclesonide. The trial is looking for participants who have a history of persistent bronchial asthma for at least 6 months and have a FEV1 (forced expiratory volume in one second) of 50-90% of predicted. The trial has a list of exclusion criteria, including concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids, COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function, respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study, history of life-threatening asthma, premature birth, current smoking, smoking history with either equal or more than 10 pack-years, pregnancy, intention to become pregnant during the course of the study, breast feeding, and lack of safe contraception. The trial is looking to evaluate the effectiveness of ciclesonide in treating asthma in eligible participants.",
    "The sample is a phase 3 clinical trial for Friedreich's Ataxia, a disease affecting the nervous system. The trial includes patients between the ages of 8 and 17 who have a confirmed diagnosis of the disease and a body weight greater than 25 kg/55 lbs. Patients must be able to walk at least 10 meters without assistance and be able to swallow the study medication. Exclusion criteria include recent treatment with idebenone, Coenzyme Q10 or vitamin E, clinically significant abnormalities in hematology or biochemistry, history of drug or alcohol abuse, and participation in a trial of another investigational drug within the last 3 months.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes and diabetes mellitus. The trial involves the use of two drugs, insulin degludec and insulin glargine, and has specific eligibility criteria for participants, including having a HbA1c level below or equal to 8.5% and a BMI below 35 kg/m^2. The trial also has exclusion criteria, such as having had a stroke or heart failure within the past 24 weeks or experiencing recurrent severe hypoglycemia. The diseases and their corresponding ICD-10 codes are listed, and the eligibility and exclusion criteria are provided in detail.",
    "The sample is a phase 3 clinical trial for patients diagnosed with type 2 diabetes. The trial involves the use of the drugs exenatide and placebo. The eligibility criteria include being treated with sulfonylurea alone or in combination with biguanide or thiazolidinedione for at least 90 days prior to the study start, having an HbA1c level between 7.0% and 10%, and having a body weight of at least 50 kg. Exclusion criteria include recent treatment with unapproved drugs, previous participation in a study involving exenatide or GLP-1 analogs, and continuous treatment with drugs affecting gastrointestinal motility for more than 21 days in the 90 days prior to the study start. The combination therapy of sulfonylurea, biguanide, and thiazolidinedione is not allowed.",
    "The sample is a phase 3 clinical trial for the treatment of inflammatory bowel disease and ulcerative colitis using the drug balsalazide disodium. The trial includes patients who are either in remission or have mildly to moderately active symptoms of UC. The eligibility criteria include confirmation of UC diagnosis through past flexible sigmoidoscopy/colonoscopy and willingness to comply with study procedures. Exclusion criteria include a history of allergy or intolerance to aspirin, mesalamine or other salicylates, participation in an investigational drug or device study within 30 days, and prior bowel surgery except appendectomy and cholecystectomy. The trial also excludes patients with unstable cardiovascular, coagulopathy, or pulmonary disease, regular use of nonsteroidal anti-inflammatory drugs (NSAIDS) except cardioprotective ASA, and a history of HIV or hepatitis.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial includes patients between the ages of 35 and 80 who have been diagnosed with knee osteoarthritis based on ACR criteria and have shown stages I to III of Kellgren on radiography. Patients must have suffered from knee osteoarthritis for more than 6 months and scored more than 30 on the total WOMAC scale. The trial involves the use of shinbaro capsule and celebrex. Patients with comorbid orthopedic disease or OA of the index knee from significant trauma or surgery are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of hyperphosphatemia and kidney failure. The trial involves the use of drugs such as ferric citrate, calcium acetate, sevelamer carbonate, and placebo. The eligibility criteria for the trial include being male or non-pregnant, non-breastfeeding female, being at least 18 years old, having serum phosphorus levels of at least 6.0 mg/dL, taking less than 3-18 pills/day of current phosphate binder, and being willing to be discontinued from current phosphate binder(s) and initiated on ferric citrate. Exclusion criteria include having a history of multiple drug allergies or intolerances, intolerance to oral ferric citrate or iron-containing products, and any other medical condition that renders the patient unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the patient.",
    "The sample is a phase 3 clinical trial that involves patients with Parkinson's disease and insomnia. The trial aims to test the effectiveness of the drug eszopiclone in treating insomnia in patients with Parkinson's disease. The eligibility criteria for the trial include having Parkinson's disease by research criteria, sleep maintenance or latency insomnia, being aged between 35-85 years, and being fluent in English. Patients must also not have significant sleep disordered breathing, dementia, or be currently on psychotropic medications other than antidepressants or benzodiazepines. The trial also has exclusion criteria, such as patients who are unable to be maintained on their current dose of PD medications throughout the trial.",
    "The sample is a phase 3 clinical trial for non-Hodgkin's lymphoma and mantle cell lymphoma. The trial includes patients who have not received prior treatment and meet certain eligibility criteria, such as having CD20-positive B cells in lymph node biopsy or other lymphoma pathology specimen, and having adequate hematologic function. The trial involves the use of bendamustine and rituximab drugs. The eligibility criteria include the presence of at least one of the following B-symptoms, large tumor mass, presence of lymphoma-related complications, hyperviscosity syndrome due to monoclonal gammopathy, and bidimensionally measurable disease. The trial excludes patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or grade 3 follicular lymphoma, transformed disease, central nervous system lymphomatous involvement or leptomeningeal lymphoma, prior radiation for non-Hodgkin's lymphoma, active malignancy other than NHL within the past 3 years, and other medical or psychological disorders that would impair the ability of the patient to receive therapy.",
    "The sample is a phase 3 clinical trial that involves testing the effectiveness of a drug called naltrexone sr 32 mg/bupropion sr 360 mg/day versus a placebo in treating obesity, overweight, and type 2 diabetes mellitus. The trial includes participants who are between 18 to 70 years old, have a BMI between 27 and 45 kg/m\u00b2, and are not on injectable antidiabetes medication or inhaled insulin for more than 3 months prior to randomization. Participants must also have taken stable doses of oral single or combination hypoglycemic medications for at least 3 months prior to randomization or not taken medications for the treatment of type 2 diabetes mellitus. The trial has a list of inclusion and exclusion criteria that participants must meet or not meet to be eligible for the study.",
    "The sample is a phase 3 clinical trial for the treatment of primary hypercholesterolemia or combined dyslipidemia. The trial involves the use of two drugs, pitavastatin and atorvastatin. The eligibility criteria include being between the ages of 18-75, not pregnant or lactating, following a restrictive diet, and having a diagnosis of primary hypercholesterolemia or combined dyslipidemia. Exclusion criteria include having certain medical conditions, such as familial hypercholesterolemia or liver injury, and being resistant to lipid-lowering medications. Participants must be available for every clinic visit, which will occur in the morning. The trial requires informed consent and aims to evaluate the safety and efficacy of the drugs in treating the targeted conditions.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The trial is testing the drug eplerenone. The eligibility criteria for the trial includes being between the ages of 6-16 and having a systolic blood pressure greater than or equal to the 95th percentile for age, gender, and height, measured on at least 3 separate occasions. The exclusion criteria includes having chronic kidney disease stage 3 or higher, and having a serum or whole blood potassium level greater than 5.5 mEq/L.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with a clinical diagnosis of moderate to severe COPD, with a smoking history of at least 20 pack years, and post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) less than 80% predicted and greater than or equal to 30% of predicted normal value. The trial also requires post-bronchodilator FEV1/FVC less than 70%. The trial excludes pregnant or nursing women, patients requiring oxygen therapy for chronic hypoxemia, patients with a respiratory tract infection within 6 weeks prior to Visit 1 and during the run-in period, and patients with concomitant pulmonary disease or a history of asthma. The trial also excludes patients with a history of long QTc syndrome or QTc interval greater than 450 ms for males and greater than 470 ms for females, patients who have a clinically significant condition or a clinically relevant laboratory abnormality, and patients with a history of reactions to sympathomimetic amines or inhaled medication. The trial requires patients to be able to use the dry powder devices or perform spirometry and to complete a patient diary. Other protocol-defined inclusion/exclusion criteria may apply. The trial will test the efficacy of drugs such as indacaterol 150 \u03bcg, salmeterol 50 \u03bcg, and placebo to indacaterol and salmeterol.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients who have had at least one exacerbation within the last year and have a post-bronchodilator FEV1/FVC ratio of 70% or less and a post-bronchodilator FEV1 of 50% or less of predicted. The trial involves the drugs roflumilast and placebo. The eligibility criteria include exclusion of patients with unresolved COPD exacerbation at the first baseline visit and those with a diagnosis of asthma or other relevant lung disease.",
    "The sample is a phase 3 clinical trial for patients with breast cancer or bothersome hot flashes. The trial is testing the effectiveness of the drug pregabalin. Eligibility criteria include having a history of breast cancer or a desire to avoid estrogen, experiencing bothersome hot flashes, having an ECOG performance status of 0-1, and a life expectancy of at least 6 months. Patients must also meet certain prior concurrent therapy requirements, such as not having taken gabapentin or pregabalin before and not currently receiving certain types of chemotherapy or hormonal agents. The use of certain other agents for hot flashes is allowed if they have been taken for at least 30 days prior to the study and will be continued throughout the study period.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia using the drug ezetimibe. The trial includes male and female participants between the ages of 18 and 80 who have a National Cholesterol Education Program Adult Treatment Panel III Framingham risk score of 10% or less, fasting LDL-C levels between 100 and 190 mg/dL, and fasting triglycerides levels of 400 mg/dL or less. Participants with a history of coronary heart disease, NYHA III or IV heart failure, uncontrolled cardiac arrhythmia, uncontrolled hypertension, diabetes mellitus, or uncontrolled hypothyroidism or hyperthyroidism are excluded from the trial. The diseases are listed as hyperlipidemia and the corresponding ICD-10 codes are provided. The eligibility criteria are also listed, including both inclusion and exclusion criteria.",
    "The sample is a phase 3 trial for pulmonary disease, chronic obstructive. The icd-10 codes for the disease are J44.9, J44.1, and J44.0. The trial involves several drugs including tiotropium/salmeterol qd, placebo, salmeterol, tiotropium/salmeterol qd+ salmeterol, and tiotropium. The eligibility criteria for the trial include a diagnosis of COPD with post-bronchodilator FEV1<80% predicted and FEV1/FVC<70% predicted. Exclusion criteria include significant other diseases besides COPD, recent MI, unstable or life-threatening arrhythmia requiring intervention or change in drug therapy, hospitalization for cardiac failure in the past year, and a history of asthma.",
    "This sample is for a phase 3 clinical trial for the treatment of major depressive disorder using the drug vortioxetine. The eligibility criteria for participants include having completed a previous double-blind treatment period for the disorder, meeting specific diagnostic criteria, and not having certain exclusion criteria such as other psychiatric disorders or a significant risk of suicide. The table also includes information on the diseases being studied, their corresponding ICD-10 codes, and the drugs being used in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of postherpetic neuralgia, a type of nerve pain that occurs after a shingles infection. The trial includes patients who have been experiencing pain for more than 3 months after the healing of the shingles rash and have a Visual Analogue Scale (VAS) score of pain higher than 40 mm. The trial involves the use of four drugs: placebo, and three doses of pregabalin. The eligibility criteria include exclusion of patients with malignancy within the past 2 years, those who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia, and those with creatinine clearance less than or equal to 30 mL/min. Patients with other severe pain that may impair self-assessment of pain due to postherpetic neuralgia and skin conditions in the affected dermatome that could alter sensation are also excluded.",
    "The sample is a phase 3 clinical trial for patients with invasive breast cancer that has spread to other parts of the body. The trial is testing the effectiveness of two drugs, lapatinib and paclitaxel, in treating the disease. Patients must meet certain eligibility criteria, such as having confirmed amplification of ErbB2 and measurable lesions according to RECIST. They must also have adequate organ function and a life expectancy of at least 12 weeks. Patients who have received certain prior treatments or have certain medical conditions are excluded from the trial. The sample includes both inclusion and exclusion criteria.",
    "The sample is a phase 3 trial for patients with type 2 diabetes mellitus. The trial involves the use of sitagliptin phosphate and a comparator drug, metformin hydrochloride. The eligibility criteria include having inadequately controlled T2DM and not being on insulin or oral antihyperglycemic therapy. The exclusion criteria include a history of type 1 diabetes mellitus or ketoacidosis, and being on antihyperglycemic therapy within the past 4 months. The diseases are listed as 'type 2 diabetes mellitus' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of systemic lupus erythematosus (SLE) using a combination of drugs including rituximab, methylprednisolone, acetaminophen, and diphenhydramine. The trial is open to subjects who have completed a previous study and have active disease as defined by certain criteria. There are also exclusion criteria, such as a history of severe allergic reactions to monoclonal antibodies or recent major surgery. The trial aims to evaluate the safety and efficacy of the treatment in improving clinical outcomes for SLE patients.",
    "The sample is a phase 3 clinical trial for head and neck cancer. The trial includes patients with squamous cell carcinoma in the oral cavity, oropharynx, hypopharynx, or larynx who have undergone surgical resection and are candidates for adjuvant radiation therapy or chemotherapy. The trial aims to test the effectiveness of the drugs placebo and palifermin. The eligibility criteria include having a history of the specified type of cancer, a planned radiation treatment field of at least 50Gy, a performance status of less than or equal to 2, and functional hematopoietic and hepato-renal systems. Exclusion criteria include tumors of the lips, paranasal sinuses, salivary glands, or unknown primary tumors, metastatic disease, presence or history of any other primary malignancy, history of chronic or acute pancreatitis, and prior radiation or chemotherapy to the site of the disease.",
    "The sample is a phase 3 clinical trial for patients with metastatic cancer, pain, and prostate cancer. The trial involves the drug ibandronate sodium and the eligibility criteria include confirmed primary prostate cancer or sclerotic bone metastases, radiologically confirmed bone metastases, clinical diagnosis of metastatic bone pain, and hormone receptor status not specified. Patients must also be male, over 18 years old, have a life expectancy of at least 3 months, and meet certain hematopoietic, hepatic, renal, and other health criteria. Prior concurrent therapy is also specified.",
    "The sample is a phase 3 clinical trial for depressive disorders, including major depression. The trial is focused on the drug risperidone. The trial includes a list of ICD-10 codes for the diseases being studied. The eligibility criteria for the trial includes meeting the DSM-IV criteria for major depressive disorder, having a history of resistance to antidepressant medication, and having a score of at least 20 on the Hamilton Rating Scale of Depression at the start of the study. Exclusion criteria include having a history of schizophrenia, bipolar disorder, or manic episode, substance dependence, and cognitive disorders. Pregnant or nursing females or those lacking adequate contraception are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of osteoporosis. The trial is looking for ambulatory men who are 25 years of age or older and have a bone mineral density of at least 1.5 standard deviation below the corresponding normal young adult men average BMD. The trial is also looking for men who have received glucocorticoid therapy at an average dose of at least 5.0 milligrams per day of prednisone or its equivalent for a minimum of 3 consecutive months immediately preceding screening. The trial is excluding patients with a history of unresolved skeletal diseases that affect bone metabolism other than glucocorticoid-induced osteoporosis, history of malignant neoplasms in the 5 years prior to Visit 2, abnormal thyroid function not corrected by therapy, and past and/or current treatment with certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of diverticulitis. The trial includes patients who are over 18 years old and have had an episode of acute diverticulitis that resolved without colonic resection. The trial excludes patients who have had previous colorectal surgery, active peptic ulcer disease, history of or current presence of inflammatory bowel disease (IBD), active irritable bowel syndrome (IBS) requiring ongoing medication, allergy or hypersensitivity to aspirin or related compounds, allergy to radiologic contrast agents, use of another investigational product within 30 days of baseline, use of antibiotic therapy within 4 weeks of baseline, use of prebiotic, probiotic or 5-ASA medications within 14 days of baseline, use of systemic or rectal steroids within 6 weeks of baseline, use of anti-inflammatory drugs (NSIADs, COX-2 inhibitors) including aspirin (except for cardiac prophylaxis) and ibuprofen, on a regular and ongoing basis, history of alcohol or other substance abuse within the previous year, active or recent history of endometriosis or dysmenorrhoea within 6 months prior to baseline, and lactating females. The trial involves the use of drugs such as spd476, mmx\u2122 mesalazine, and placebo. The diseases being treated are listed as diverticulitis, and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who are at least 30 years old and have been diagnosed with idiopathic Parkinson's Disease. The patients must also be demonstrating lack of control with L-dopa therapy. The trial involves the use of two drugs, Requip PR and placebo. The eligibility criteria include various medical and personal factors, such as stable liver function, absence of drug abuse or alcoholism, and willingness to comply with study procedures. The exclusion criteria include factors such as late stage advanced Parkinson's disease, significant psychiatric or cardiovascular disease, and recent use of dopamine agonists.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of multiple sclerosis. The trial involves the use of two drugs, fampridine-sr and placebo. The eligibility criteria for the trial include patients with clinically defined multiple sclerosis who are able to complete two trials of a timed 25 foot walk. However, female patients who are pregnant or breastfeeding are excluded from the trial. The icd-10 codes associated with the disease are also included in the record.",
    "The sample is a phase 3 trial for the treatment of narcolepsy and cataplexy. The trial is testing the efficacy of a drug called BF2.649 (Pitolisant). The inclusion criteria for the trial include patients aged 18 years and over, with a diagnosis of narcolepsy according to the International Classification of Sleep Disorders (ICSD-2) criteria, and an excessive daytime sleepiness (EDS) score of at least 12. Patients who have previously participated in and completed a Bioprojet narcolepsy study assessing BF2.649 efficacy or narcoleptic patients who cannot participate in a double-blind study against placebo but could benefit from testing a new therapy such as BF2.649 in an open-label study are also eligible. The exclusion criteria include patients who have discontinued study treatment during previous studies due to adverse events related to BF2.649, patients with an untreated sleep apnea syndrome or any other cause of daytime sleepiness, patients working in an occupation requiring variable shift work or routine night shifts, and patients with psychiatric and neurological disorders or other problems that would preclude their participation in the trial. Patients with a current or recent history of substance abuse or dependence disorder, including alcohol abuse, are also excluded. Other exclusion criteria include patients with other active clinically significant illnesses, including unstable cardiovascular or neoplastic pathology, known history of long QTc syndrome, syncope or arrhythmia, severe hepatic or renal impairment, known hypersensitivity to the tested treatment, and participation in another study in the 30 days prior to the entry in this study.",
    "The sample is a phase 3 clinical trial for the treatment of spasticity in patients with multiple sclerosis. The trial involves the use of the drug Sativex\u00ae compared to a placebo. The eligibility criteria include being diagnosed with any disease sub-type of MS for at least six months, having spasticity due to MS for at least three months which is not wholly relieved with current anti-spasticity therapy, and being willing to comply with all study requirements. The exclusion criteria include having any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject's level of spasticity, currently receiving a prohibited medication, and having any other significant disease or disorder which may put the subject at risk because of participation in the study.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed as [\"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", \"I10\"]. The drug being tested is valsartan/amlodipine. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include factors such as uncomplicated essential hypertension being an inclusion criteria, while severe hypertension, history of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm, liver, kidney, or pancreas disease, insulin dependent diabetes, and allergy to certain medications used to treat high blood pressure being exclusion criteria. The sample also notes that there may be other protocol-defined exclusion criteria that apply.",
    "The sample is a phase 3 clinical trial for osteoarthritis of the knee. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including placebo, hyruan plus, and lbsa0103. The eligibility criteria for the trial include being over 40 years of age, having Kellgren & Lawrence grade I-III, and experiencing weight-bearing pain of at least 40mm on at least one knee. Participants must also be willing to discontinue certain medications and therapies for the duration of the study. Exclusion criteria include having a body mass index over 32, rheumatoid arthritis, certain medical conditions, and Kellgren & Lawrence Grade IV.",
    "The sample is a phase 3 clinical trial for non-CF bronchiectasis. The trial involves the use of the drugs azli and placebo. The eligibility criteria for the trial include being 18 years or older, having chronic sputum production on most days, and a positive sputum culture for gram-negative organisms. Exclusion criteria include a history of CF, hospitalization within 14 days prior to joining the study, previous exposure to AZLI, pregnancy or breastfeeding, and other serious medical conditions. The trial also requires participants to meet lung, liver, and kidney function requirements.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of sitagliptin phosphate, acarbose, glimepiride, and a placebo as a comparator drug. The eligibility criteria include being at least 18 years old, having T2DM and being on a stable dose of acarbose for at least 10 weeks, and not having a history of type 1 diabetes mellitus. Exclusion criteria include having cardiovascular disorders, liver or kidney disease, cancer, or any clinically significant disease or disorder. The trial aims to evaluate the efficacy and safety of the drugs in treating T2DM.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of growth hormone deficiency. The trial includes both males and females between the ages of 18 and 65 who have isolated growth hormone deficiency. The trial involves the use of two drugs, placebo and somatropin. The eligibility criteria for the trial include having isolated growth hormone deficiency and not having diabetes mellitus type 1 or 2. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for patients with mild-to-moderate Alzheimer's disease. The trial is looking at the effectiveness of galantamine hydrobromide as a treatment. The trial includes patients living in residential homes for the elderly or day patients, who have a Mini-Mental Status Examination (MMSE) score of 10 - 24, and a score of at least 18 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog-11) with an onset between ages 40 and 90. Patients must also have a history of at least 6 months of gradual and progressive cognitive decline and a consistent informant to accompany them on scheduled visits. Patients with neurogenerative disorders such as Parkinson's disease, cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation or a brain tumor, dementia caused by small strokes or cerebrovascular disease, epilepsy, significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders, or heart disease are excluded from the trial. Females of childbearing potential without adequate contraception are also excluded.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of venous thromboembolism. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, including du-176b (edoxaban) and enoxaparin sodium 20mg. The eligibility criteria for the trial are also listed, including inclusion criteria such as subjects scheduled for surgery within 10 days for a fracture of the inner or outer femoral neck, and exclusion criteria such as subjects with risks of hemorrhage or thrombolic risks, those who weigh less than 40 kg, and those who are pregnant or suspect pregnancy.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on treating chemotherapy-induced neutropenia. The disease is identified by its name and its ICD-10 code, which is D61.810. The drug being tested is chemotherapy, specifically the AT regimen (doxorubicin/docetaxel). The eligibility criteria for the trial are listed, including inclusion criteria (breast cancer patients scheduled to receive the AT regimen) and exclusion criteria (subjects who have received more than 1 prior chemotherapy regimen, including adjuvant therapy within the last 12 months).",
    "The sample is a phase 3 clinical trial for the treatment of bipolar I disorder using the drug aripiprazole. The trial is open to men and women between the ages of 18 and 65 who meet specific DSM-IV-TR criteria for manic or mixed episodes of bipolar I disorder. Participants must have completed or withdrawn from a previous study and meet certain criteria related to their condition. There are also exclusion criteria, such as having certain medical conditions or allergies to the drug being tested. The eligibility criteria are outlined in detail in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug quetiapine fumarate sustained release. The trial includes patients who have been clinically diagnosed with MDD according to the DSM-IV criteria and have either a single episode or recurrent episodes. Patients with other Axis I disorders or Axis II disorders that significantly impact their psychiatric status are excluded from the trial. Additionally, patients whose current episode of depression is either longer than 12 months or shorter than 4 weeks from enrollment are also excluded. The diseases and their corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial involves two drugs, mk0653a and a comparator drug, atorvastatin, and the treatment duration is 6 weeks. The eligibility criteria include currently being treated with atorvastatin for at least 6 weeks, having stable weight for more than 6 weeks, and having type 2 diabetes. The exclusion criteria include consuming more than 14 alcoholic drinks per week, being pregnant or lactating, having taken another investigation drug within 3 months of starting the study, having a history of congestive heart failure, heart attack, or coronary artery bypass surgery, having uncontrolled high blood pressure, being HIV positive, and having a history of cancer in the last 5 years. The diseases involved in the trial are limited to diabetes mellitus, type 2, and the icd-10 codes associated with the disease are provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of small cell lung cancer. The trial involves the drugs pemetrexed, etoposide, and carboplatin. The eligibility criteria for the trial include a clinical diagnosis of extensive stage small cell lung cancer, the ability to perform self-care but not work activities, and no prior anticancer therapy for SCLC. The exclusion criteria include previous participation in a study involving pemetrexed and recent treatment with a drug that has not received regulatory approval for any indication. The diseases are listed as 'small cell lung cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of acromegaly, a disease characterized by excessive growth hormone production. The trial is testing the effectiveness of octreotide acetate 30 mg suspension in patients who have been receiving somatostatin-analogues in a conventional treatment regimen for at least 6 months but have uncontrolled disease. The eligibility criteria include a written voluntary informed consent, a baseline GH level above 2 \u00b5g/L, and IGF-I levels above the upper limits of normal for age and gender. Other protocol-defined inclusion/exclusion criteria also apply to the study.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of gastroesophageal reflux and includes a list of associated ICD-10 codes. The drug being studied is pantoprazole. The eligibility criteria for the trial includes written informed consent, hospitalization for the entire study period, and symptoms of heartburn, acid regurgitation, or dysphagia for at least one day since admission to the hospital. The trial excludes individuals with certain conditions such as Zollinger-Ellison syndrome, previous acid-lowering surgery, and inflammatory bowel diseases. The sample includes both main inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of various types of female genital neoplasms, including ovarian, fallopian tube, and peritoneal cancers. The trial involves the use of three drugs - gemcitabine, paclitaxel, and carboplatin - administered intravenously. Patients must have had surgery to confirm the diagnosis and be enrolled within 12 weeks postoperatively. The eligibility criteria include specific stage and histologic diagnosis requirements, as well as exclusion criteria such as prior radiotherapy or chemotherapy for abdominal or pelvic tumors. Patients with certain other types of cancer within the last 5 years are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of Major Depressive Disorder (MDD) using extended-release bupropion hydrochloride. The trial includes patients with a primary diagnosis of MDD lasting between 12 weeks and 2 years, who engage in sexual activity leading to orgasm at least once every two weeks, and have normal orgasmic function. The trial excludes patients with arousal or orgasm dysfunction, those who have previously failed to respond to two adequate trials of antidepressants in the past 2 years, those with other unstable medical disorders, and those with a positive urine test for illicit drug use at screening. The sample also includes a list of icd-10 codes associated with MDD.",
    "The sample is a phase 3 clinical trial for narcolepsy. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include requirements such as a diagnosis of narcolepsy, good health, and the ability to comply with study restrictions. Patients are excluded if they have certain medical or psychiatric conditions, consume too much caffeine, have a history of drug abuse, or are pregnant or lactating. The trial involves the use of armodafinil and a placebo.",
    "The sample is a phase 3 clinical trial for the treatment of follicular lymphoma, a type of cancer. The trial is for patients who have not received any prior treatment and have certain symptoms such as bulky disease, B symptoms, elevated serum LDH or beta2-microglobulin, involvement of at least 3 nodal sites, symptomatic splenic enlargement, compressive syndrome, or pleural/peritoneal effusion. The trial involves the drug rituximab and has specific eligibility criteria, including age over 18, adequate hematological function, and a performance status of less than 2 on the ECOG scale. The trial also has exclusion criteria, such as the presence of CNS disease, poor renal or hepatic function, and known sensitivity or allergy to murine products. Patients must have previously signed a written informed consent form to participate in the trial.",
    "The sample is for a phase 3 clinical trial for the treatment of gastroesophageal reflux disease (GERD) using the drug pantoprazole. The trial is open to participants between the ages of 12 and 16 who have been clinically diagnosed with GERD and are able to swallow tablets. However, individuals with gastrointestinal or malabsorption disorders, those who chronically use warfarin, or those who have a positive pregnancy test are excluded from the trial. The sample also includes the ICD-10 codes associated with GERD.",
    "The sample is a phase 3 clinical trial for non-seminomatous germ cell tumors (NSGCT) with a poor prognosis. The trial is looking for patients with NSGCT that have either been histologically confirmed or have clinical evidence of the disease with high serum human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) levels. The patients must have clinical stage II-III disease and a primary site in the testicular, retroperitoneal, or mediastinal area. The trial is testing a combination of drugs including cisplatin, etoposide, ifosfamide, oxaliplatin, and paclitaxel. The eligibility criteria include age over 16, specific hematopoietic and renal levels, no prior chemotherapy or other malignancies except basal cell skin cancer, and no HIV positivity. The trial does not specify performance status or life expectancy.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have failed diet and exercise therapy or oral monotherapy and have a body mass index between 23 and 45 kg/m2. The trial involves the use of two drugs, alogliptin and glipizide. The eligibility criteria include having a stable dose of non-excluded medications, monitoring blood glucose concentrations, and agreeing to use contraception if sexually active. Exclusion criteria include having high blood pressure, low hemoglobin levels, abnormal liver or kidney function, and a history of certain medical conditions or treatments. The trial aims to evaluate the safety and efficacy of alogliptin in treating type 2 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of the drugs ipragliflozin and alpha glucosidase inhibitor. The eligibility criteria for the trial include patients who have been receiving \u03b1-glucosidase inhibitor mono-therapy for at least 4 weeks, have an HbA1c value between 6.5 and 9.5%, and have a BMI between 20.0 and 45.0 kg/m2. The exclusion criteria include patients with type 1 diabetes mellitus, serum creatinine levels above the upper limit of normal, proteinuria (albumin/creatinine ratio > 300mg/g), dysuria and/or urinary tract infection, genital infection, significant renal, hepatic or cardiovascular diseases, and severe gastrointestinal diseases.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are 18 years or older and have been diagnosed with essential hypertension with inadequate control of blood pressure. The trial also includes patients who have failed to respond to four weeks of treatment with telmisartan 40mg. The trial excludes patients with severe heart disease, cerebrovascular disease, diabetes with poor glucose control, severe or malignant retinopathy, hepatic or renal dysfunction, acute or chronic inflammatory status, and those who require additional antihypertensive drugs or concomitant medications known to affect blood pressure. The trial also excludes patients with a history of drug or alcohol dependency, any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of investigational products, and those who have received other study drugs within 30 days prior to randomization. The trial also excludes premenopausal women who are not using adequate contraception, pregnant or breastfeeding, and those with a history of malignancy including leukemia and lymphoma within the past 5 years.",
    "The sample is a record from a clinical trial table that includes information about a phase 3 trial for breast cancer. The record lists the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria include having histologically confirmed breast cancer, a primary tumor of at least 2 cm, and no systemic metastasis. Participants must also be between the ages of 18 and 65, have adequate organ function, and provide written consent to participate. The exclusion criteria include multicentricity in various quadrants, known allergies to certain medications, pre-existing treatment-resistant cardiac disease, and uncontrolled hypertension, among others.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on studying breast cancer and metastases. The ICD-10 codes associated with the diseases being studied are listed. The drugs being tested are larotaxel and capecitabine. The eligibility criteria for participants include having a diagnosis of breast cancer that has metastasized or recurred and cannot be removed by surgery, having received previous treatment with anthracyclines and taxanes, being at least 18 years old, not taking other treatments for cancer at the time of the trial, and not being pregnant. Additional criteria and clinical assessments may also be required.",
    "The sample is a record of a clinical trial in phase 3, focused on diabetes and diabetes mellitus type 2. The trial involves the use of drugs such as liraglutide, glibenclamide, and placebos. The eligibility criteria for the trial include having type 2 diabetes, undergoing diet and exercise therapy for at least eight weeks, having an HbA1c level between 7.0% and 10.0%, and having a BMI less than 35 kg/m2. The exclusion criteria include recent treatment with insulin or any drug that could affect glucose levels, having a serious medical condition, and being pregnant or breastfeeding for females. The icd-10 codes for the diseases are also included in the record.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis and pancreatic insufficiency. The trial involves testing the effectiveness of the drug Pancrecarb\u00ae (pancrelipase) compared to a placebo. The eligibility criteria for participants include being at least 7 years old, having a confirmed diagnosis of CF, having adequate nutritional status, and currently receiving pancreatic enzyme replacement therapy. Exclusion criteria include a history of fibrosing colonopathy, significant bowel resection, and being refractory to pancreatic enzyme replacement therapy. Participants must also be able to understand and sign a written informed consent and comply with the requirements of the study.",
    "This sample is from a clinical trial in phase 3 for the treatment of melanoma and metastatic neoplasm. The trial is testing a drug called cc-5013. The eligibility criteria for participants include having stage IV metastatic malignant melanoma that has relapsed or is refractory to standard metastatic therapy, being able to adhere to the study visit schedule and other protocol requirements, and signing an informed consent form. Women of childbearing potential must have a negative pregnancy test within 7 days of starting the study drug. Patients with active brain disease or newly diagnosed brain metastases within 4 weeks prior to the start of study treatment are excluded. The icd-10 codes for the diseases are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of major depressive disorder. The trial involves the drug quetiapine fumarate and has a list of inclusion and exclusion criteria. The diseases are listed as 'major depressive disorder' and the icd-10 codes associated with it are also provided. The eligibility criteria include having a documented clinical diagnosis of major depressive disorder, being able to understand and comply with the requirements of the study, and being able to provide written informed consent. The exclusion criteria include being pregnant or lactating (for female patients) and having a current or past diagnosis of stroke or transient ischemic attack (TIA).",
    "The sample is a phase 3 clinical trial for patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with airflow obstruction of level 2 and 3. The trial includes patients with Forced Expiratory Volume in one second (FEV1) \u2265 30% and <80 % of the predicted normal, and FEV1/FVC < 0.70 when measured 45 min after the inhalation of 84 \u00b5g ipratropium bromide. The trial involves the drugs nva237 and placebo. The eligibility criteria include being a current or ex-smoker with at least 10 cigarette pack years smoking history. The exclusion criteria include patients with a history of long QT syndrome, with a prolonged QTc measured during screening, or patients who have a clinically significant ECG abnormality at screening. Additionally, patients with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases are excluded. Pregnant or nursing (lactating) women are also excluded, as well as women of childbearing potential unless using an effective method of contraception. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves the use of drugs such as budesonide/formoterol, budesonide, and formoterol. The eligibility criteria for the trial include being at least 12 years of age, having a diagnosis of asthma, and having received treatment with inhaled corticosteroids and/or lung treatments specified in the protocol within the required timeframe and doses. The exclusion criteria include having received treatment with non-inhaled corticosteroids within the previous 4 weeks, having sensitivity to drugs specified in the protocol, requiring treatment with beta-blockers, having had cancer within the previous 5 years, or currently having any other significant disease or disorder as judged by the investigator. The diseases are listed as 'asthma' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with metastatic colorectal cancer who have previously received a thymidylate synthase inhibitor. The trial aims to test the effectiveness of the drug brivanib alaninate in treating the disease. Eligible patients must have confirmed K-Ras wild type tumors and meet certain criteria related to their disease characteristics and patient characteristics. The trial excludes patients with certain medical conditions or who have received certain prior treatments. The trial requires patients to complete quality of life and health utilities questionnaires and provide tumor tissue and blood samples.",
    "The sample is a phase 3 clinical trial for cancer patients with breakthrough pain. The trial involves the use of the drug fentanyl and has a set of inclusion and exclusion criteria that patients must meet in order to participate. The inclusion criteria include having given informed consent, being a cancer patient with breakthrough pain, being at least 18 years old, having received certain opioids for the past month, and experiencing severe pain that requires additional analgesics. The exclusion criteria include recent substance abuse, pregnancy or nursing, neurological or psychiatric impairment, severe hepatic impairment, recent therapy that could alter pain or response to analgesics, and hypersensitivity to fentanyl or other opioids. The trial also requires patients to use adequate contraceptive precaution and have a negative pregnancy test.",
    "The sample is for a phase 3 clinical trial for juvenile rheumatoid arthritis. The diseases being studied are listed as 'arthritis, juvenile rheumatoid'. The icd-10 codes associated with the disease are also provided. The drugs being tested are 'celecoxib' and 'naproxen'. The eligibility criteria for the trial include being between the ages of 2-18 with active JRA, while exclusion criteria include taking other experimental medications or recent changes in arthritis medications.",
    "The sample is a phase 3 clinical trial for diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including tak-875 and placebo. The eligibility criteria for the trial include being an outpatient and signing a written informed consent form. Exclusion criteria include having serious cardiac, cerebrovascular, pancreatic, or hematological disease, or being considered ineligible by the investigator or sub-investigator.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) and involves the use of two drugs, aclidinium bromide/formoterol fumarate and formoterol fumarate. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include being a current or former smoker with a history of at least 10 pack-years, having a diagnosis of stable moderate to severe COPD, and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines. Exclusion criteria include recent hospitalization for an acute COPD exacerbation, respiratory tract infection or COPD exacerbation in the six weeks prior to the trial, clinically significant respiratory conditions other than COPD, chronic use of oxygen therapy for 15 hours or more per day, clinically significant cardiovascular conditions, uncontrolled infection that may place the patient at risk resulting from HIV, active hepatitis and/or diagnosed active tuberculosis, history of hypersensitivity reaction to inhaled anticholinergics, Stage II hypertension, and current diagnosis of cancer other than basal or squamous cell skin cancer.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes subjects who have demonstrable hypertension, defined as mean sitting trough cuff blood pressure \u2265 140/100 mmHg or mean sitting trough cuff BP \u2265 160/90 mmHg. The trial includes male or female newly diagnosed hypertensive subjects or those currently on hypertension medication. The trial has inclusion and exclusion criteria, including negative urine pregnancy test at screening, not lactating, and not planning to become pregnant during the study. The trial also requires birth control throughout the study. The trial excludes subjects with uncontrolled hypertension taking multiple antihypertensive therapies, signs or symptoms which could exacerbate the occurrence of hypotension, history of hypertensive encephalopathy, stroke or transient ischemic attack (TIA), and participation in another clinical trial involving an investigational drug within one month prior to screening. The trial also excludes subjects with a history of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina within the past 6 months, and any history of New York Heart Association Class III or IV congestive heart failure (CHF). The trial also excludes subjects with a history of secondary hypertension including renal disease, pheochromocytoma, or Cushing's syndrome, uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a solitary kidney, evidence of symptomatic resting bradycardia, evidence of hemodynamically significant cardiac valvular disease, presence of heart block greater than first degree atrioventricular block, chronic atrial fibrillation or flutter, uncontrolled Type I or Type II diabetes defined as HbA1c >9.0%, evidence of liver disease as indicated by ALT and AST and/or total bilirubin >3 times the upper limit of normal, severe renal insufficiency defined as a creatinine clearance (based on the Cockcroft-Gault formula) of <30 mL/min, clinically significant laboratory elevations at Visit 1 that compromise subject safety, based on the investigator's judgment, positive for any one of the following tests: hepatitis B surface antigen, hepatitis C antibody (confirmed by radio immunobinding assay, RIBA) or HIV antibody (confirmed by western blot assay), subjects with malignancy during the past 2 years excluding squamous cell or basal cell carcinoma of the skin, known allergy to any of the medications used in the study, subjects who require or are taking any concomitant medication, which may interfere with the objectives of the study, pregnant or lactating females, current history of drug or alcohol abuse, and any medical condition, which in the judgment of the Investigator would jeopardize the evaluation of efficacy or safety and/or constitute a significant safety risk to the subject.",
    "The sample is a phase 3 clinical trial for chronic heart failure. The trial includes patients with symptomatic chronic heart failure, left ventricular systolic dysfunction, sinus rhythm, and resting heart rate of at least 70 bpm. The trial will test the effectiveness of ivabradine and placebo drugs. The eligibility criteria include stable condition, no recent myocardial infarction or coronary revascularization, no recent stroke or transient cerebral ischemia, no congenital heart disease, no severe valvular disease, no active myocarditis, and no permanent atrial fibrillation or flutter.",
    "This sample is for a phase 3 clinical trial for the treatment of migraine. The trial is focused on patients who have a history of migraine for more than a year and experience 1-4 migraine attacks per month. The inclusion criteria also require that the attacks start off mild and progress to moderate or severe. The exclusion criteria include having more than 15 headache days per month, heart disease, and uncontrolled high blood pressure. The trial will be comparing the effectiveness of two drugs, rizatriptan benzoate and a placebo. The diseases being studied are only related to migraine. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking for patients with metastatic breast cancer or multiple sites of new disease that is clinically obvious metastatic disease. The patients must have measurable or nonmeasurable disease and no known brain or CNS metastases. The trial is looking for female patients who are postmenopausal, with a Zubrod performance status of 0-2, and HIV negative. The patients must not have any bleeding diathesis, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission. The trial is not looking for patients who have had prior immunotherapy or chemotherapy for recurrent or metastatic disease. The patients must have had prior adjuvant hormonal therapy, but no prior hormonal therapy for recurrent or metastatic disease. The patients must not be on long-term anticoagulant therapy (except antiplatelet therapy). The trial is testing the effectiveness of anastrozole and fulvestrant as treatments for breast cancer.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients who have completed a 12-week lead-in trial and are currently being treated with lithium or valproic acid. The trial involves the drugs asenapine and placebo. The eligibility criteria for inclusion in the trial include having bipolar I disorder with a current episode of manic or mixed symptoms. Exclusion criteria include having an unstable medical condition or clinically significant laboratory abnormality, as well as having a primary diagnosis other than bipolar I disorder.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on bladder cancer and the icd-10 codes associated with the disease are listed. The drug being tested is mitomycin c (mmc). The eligibility criteria for the trial are listed, including age requirements and confirmation of non-muscle invasive urothelial bladder carcinoma. The inclusion criteria also specify that patients must have a documented past history of Ta or T1 non-muscle invasive urothelial bladder tumors. The exclusion criteria include recent intravesical therapy, radiation treatment, or surgery for bladder cancer, as well as treatment with any chemotherapeutic agent during the study.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes. The trial is testing the effectiveness of insulin lispro protamine suspension and insulin levemir. The eligibility criteria include having a clinical diagnosis of type 1 diabetes for at least one year, being 18 years or older, having a BMI less than or equal to 35 kg/m2, and having a hemoglobin A1c level within a certain range. Patients must also be willing and able to perform self-monitoring of blood glucose, use insulin injection devices, and comply with study visits. Exclusion criteria include recent use of oral antihyperglycemic medications, multiple episodes of severe hypoglycemia, pregnancy or intent to become pregnant, and recent use of certain medications.",
    "The sample is a phase 3 clinical trial for HIV infections, using the drug raltegravir. The eligibility criteria for participants include being over 18 years old, having a documented laboratory diagnosis of HIV-1 infection, having a stable antiretroviral regimen for at least 6 months, and having a plasma HIV-1 RNA level of less than 75 copies/ml by branched deoxyribonucleic acid (bDNA) assay or less than 50 copies/ml by Ultrasensitive Polymerase Chain Reaction (PCR) for at least 6 months prior to the screening visit. Exclusion criteria include any prior therapy with MK-0518 or any other HIV-1 integrase inhibitor, any HIV-1 viral load above the specified limits, any previous known hypersensitivity to components of the study drug formulation, and various other medical conditions. Female participants must have a negative serum pregnancy test and be willing to use an adequate method of contraception throughout the study.",
    "The sample is a phase 3 clinical trial for lupus erythematosus, systemic. The trial includes a list of icd-10 codes for the disease and a list of drugs, including atorvastatin and placebo atorvastatin. The eligibility criteria for the trial include meeting the American College of Rheumatology diagnostic guidelines for SLE, being an outpatient, having a weight of 25 kg or more, and being able to complete self-report questionnaires in either English or Spanish. Exclusion criteria include drug-induced lupus, liver disease, myositis, and inability to obtain adequate-quality IMT images, among others. Participants must also be willing to comply with a recommended diet and use acceptable methods of contraception.",
    "The sample is a phase 3 clinical trial for patients diagnosed with type 2 diabetes mellitus. The trial requires patients to have been treated with diet and exercise and a stable, maximally tolerated dose of metformin for at least 3 months prior to screening. The trial also requires patients to have an HbA1c level between 6.5% and 9.0% and a BMI between 25 kg/m^2 and 40 kg/m^2. The trial will test the effectiveness of the drugs exenatide and glimepiride. The eligibility criteria include various inclusion and exclusion criteria, such as not having participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening and not receiving drugs that directly affect gastrointestinal motility.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial is looking at the effectiveness of fluticasone furoate (ff)/gw642444 inhalation powder. The eligibility criteria include being at least 40 years old, having a clinical history of COPD, and having a post-albuterol/salbutamol FEV1/FVC ratio of \u22640.70. Exclusion criteria include pregnancy, asthma, \u03b11-antitrypsin deficiency, and other respiratory disorders. Participants must also be able to comply with the study procedures and give their informed consent to participate.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia, schizophrenic disorders, psychotic disorders, and dementia praecox. The trial is testing the drug paliperidone er. The eligibility criteria for inclusion in the trial include meeting the DSM-IV criteria for schizophrenia, being physically healthy, weighing at least 63.9 pounds, not being a danger to oneself or others, having family support available, and having a responsible adult available to accompany the patient to the investigational site at each visit. Exclusion criteria include having a history of certain mental disorders, substance dependence, pregnancy, and a history or presence of circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death in association with the use of drugs that prolong the QTc interval.",
    "The sample is a phase 3 clinical trial for chemotherapy-induced nausea and vomiting. The trial is looking for patients who are 20 years or older, diagnosed with malignant disease, and have not received chemotherapy before or have been treated with low emetogenicity anti-tumor drugs. The trial is testing the effectiveness of palonosetron and granisetron hydrochloride in preventing nausea and vomiting. The eligibility criteria include specific requirements for white blood cell count, liver function, and kidney function, as well as performance status. The exclusion criteria include severe complications, symptomatic brain metastases, ongoing emesis or nausea, and certain medical conditions. Additionally, participants must not have any allergies to the study drugs or dexamethasone, and must be willing to practice adequate contraception during the study period.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves testing the effectiveness of the drugs asp1941 and metformin, as well as a placebo. The eligibility criteria include being diagnosed with type 2 diabetes mellitus at least 12 weeks before the study, having a stable diet and exercise program for at least 8 weeks before the study, and having a BMI between 20.0 and 45.0 kg/m2. In addition, the patient must have a HbA1c value between 7.0 and 10.0% at screening and not meet any of the discontinuation criteria on fasting plasma glucose. Exclusion criteria include having type 1 diabetes mellitus, proliferative diabetic retinopathy, receiving insulin within 12 weeks prior to the study, and having a history of clinically significant renal disease(s). The sample also includes a list of icd-10 codes for the disease and eligibility and exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease small cell lung carcinoma, which is identified through histological or cytological testing. The trial includes two drugs, etoposide + cisplatin and irinotecan + cisplatin, and lists the eligibility criteria for participants. Inclusion criteria include a WHO performance status of 0 or 1, while exclusion criteria include no previous radiotherapy except for bone metastases and no prior surgery on the primary tumor except for palliative purposes.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary disease, chronic obstructive. The trial involves the use of two drugs, fluticasone furoate/vilanterol and tiotropium. The eligibility criteria for the trial include being an outpatient, giving written informed consent, being male or female, being at least 40 years old, having a clinical history of COPD, having a smoking history of at least 10 pack-years, having a measured post-albuterol/salbutamol FEV1 less than 70% of predicted, having a measured post-albuterol/salbutamol FEV1/FVC ratio of less than or equal to 0.70, having a history of hospitalization or treatment with oral corticosteroids or antibiotics for COPD within the last 3 years, and having a measured aPWV greater than 12.0 m/s. The only exclusion criterion is having a body mass index of less than or equal to 35.",
    "The sample is a phase 3 clinical trial for patients aged 35 to 65 years with a diagnosis of rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria for at least 1 year and no more than 10 years prior to start of therapy. The trial involves the use of DMARDs (methotrexate, chloroquine, leflunomidum, cyclosporin a, sulfasalazine, om 89) and patients must have active disease (Disease Activity Score [DAS] 28 >2.8 and <3.5), with changes in the DAS 28 score <0.6 within the 6 weeks before inclusion. Patients must have stable RA basic therapy according to standard criteria for at least 3 months, a chest X-ray within 1 month prior to first infusion with no evidence of malignancy, infections, or fibrosis, and screening laboratory test results that meet prespecified criteria. Patients must have at least one swollen joint and evidence of erosive disease by x-ray at baseline. The trial has exclusion criteria such as women who are pregnant, nursing, or planning pregnancy within 15 months after screening, use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, history of any other therapeutic agent targeted at reducing tumor necrosis factor (TNF), and history of previous administration of infliximab. Other exclusion criteria include serious infection in the previous 3 months, active tuberculosis (TB) or evidence of latent TB, hepatitis B surface antigen or Hepatitis C (HCV) antibody positive, documented Human Immunodeficiency Virus (HIV) infection, and current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, psychiatric, neurologic, or cerebral disease. Patients with a history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location, or splenomegaly are also excluded. Known recent substance abuse (drug or alcohol) is also an exclusion criterion.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients with a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features. The trial excludes patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder NOS. Patients with other DSM-IV TR Axis I or Axis II disorder are also ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening. The trial involves the use of placebo and geodon (ziprasidone) as drugs. The icd-10 codes associated with the disease are [\"['F31.81', 'F31.89', 'F31.9', 'F25.0', 'F31.0', 'F31.31', 'F31.32']\"].",
    "The sample is for a phase 3 clinical trial for the treatment of persistent allergic rhinitis. The trial includes subjects who have had at least a 2-year history of allergic rhinitis and are currently experiencing symptoms. The trial requires subjects to be at least 12 years old, of any race and gender, and have a positive skin-prick test to one or more allergens. The trial involves the use of two drugs, 5-mg desloratadine and a placebo tablet. The eligibility criteria include various medical and non-medical factors, such as symptom severity, disease history, and birth control use. The exclusion criteria include factors such as a history of anaphylaxis, pregnancy, and noncompliance with medication or treatment protocols.",
    "The sample is a phase 3 clinical trial for breast cancer patients with negative axillary lymph nodes and high risk criteria according to St. Gallen consensus criteria. The trial involves the use of drugs such as docetaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide. The eligibility criteria include written informed consent, histologically proven breast cancer, age between 18 and 70 years, adequate hepatic, renal and heart functions, and negative pregnancy test. Exclusion criteria include prior systemic anticancer therapy for breast cancer, prior radiation therapy for breast cancer, and other serious illness or medical condition. The trial does not include male patients.",
    "The sample is a phase 3 clinical trial for the treatment of small cell lung cancer. The trial involves two drugs, carboplatin, etoposide & thalidomide and carboplatin, etoposide & placebo. The eligibility criteria include having histologically or cytologically confirmed small cell lung cancer, being over 18 years old, having an ECOG performance status of 0-3, and having a life expectancy of at least 8 weeks. Patients must not have symptomatic brain metastases requiring immediate radiotherapy and must meet certain hematopoietic, hepatic, and renal criteria. They must also not be pregnant or nursing, have negative pregnancy test results, and use effective contraception during and for 4 weeks after the study. Patients must not have had prior chemotherapy or radiotherapy, and must not have any significant medical condition or laboratory finding that would preclude study participation.",
    "The sample is a phase 3 clinical trial for the treatment of follicular lymphoma. The trial is looking at the effectiveness of rituximab, a drug used in first-line induction therapy. The eligibility criteria include being over 18 years old, having confirmed follicular lymphoma Grade 1, 2, or 3a, and having no previous anti-lymphoma treatment before induction chemotherapy. Participants must also have achieved complete or partial remission after first-line induction therapy including rituximab. Exclusion criteria include having Grade 3b follicular lymphoma, transformation to high-grade lymphoma, presence of central nervous system lymphoma, acquired immunodeficiency syndrome-related lymphoma, or any other primary malignancy for which the participant has not been disease-free for at least 5 years.",
    "The sample is a phase 3 clinical trial for the treatment of colorectal cancer and neurotoxicity. The trial involves patients who have undergone curative resection for stage II or III disease and are scheduled to receive 6 months of adjuvant treatment with either FOLFOX4 or Modified FOLFOX6 chemotherapy regimens. The trial has eligibility criteria for patient characteristics such as platelet count, hemoglobin, and creatinine levels, as well as prior concurrent therapy restrictions. The table includes columns for the phase of the trial, diseases being treated, icd-10 codes of the diseases, drugs being used, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before the trial. Patients must have blood pressure that is not adequately controlled on existing treatment before entry to the trial. The trial drug is telmisartan 80 mg + hydrochlorothiazide 25 mg. The eligibility criteria include essential hypertension, failure to respond to six weeks run-in treatment with T80/H12.5 in a preceding trial, and willingness to provide written informed consent. The exclusion criteria include women of child-bearing potential not practicing acceptable means of birth control, known or suspected secondary hypertension, clinically significant change in ECG reported as adverse event in preceding trial, and any medical condition developing in preceding trial that could be worsened by telmisartan/HCTZ (80/25).",
    "The sample is a phase 3 clinical trial for non-Hodgkin lymphoma. The trial includes patients who have relapsed after two or more prior regimens of chemotherapy and have an ECOG performance status of 0, 1, or 2. The trial also requires patients to have adequate hematologic, renal, and hepatic function, and a left ventricular ejection fraction (LVEF) of at least 50% determined by MUGA scan. The trial excludes patients who have received a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m\u00b2, have had a prior allogenic stem cell transplant, have a histological diagnosis of Burkitt lymphoma, lymphoblastic lymphoma, or Mantle cell lymphoma, have active CNS lymphoma or HIV-related lymphoma, have received any chemotherapy, radiotherapy, or other anticancer treatment within the 2 weeks before randomization, or are pregnant or nursing. The trial will test the efficacy of several drugs, including pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, vinorelbine, oxalplatin, ifosfamide, etoposide, mitoxatrone, gemcitabine, or rituximab.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The trial is testing the drug tiotropium. The eligibility criteria for participants include a diagnosis of COPD according to the European Respiratory Society, stable moderate to severe airway obstruction, and a baseline FEV1/SVC ratio of less than 70%. Participants must also have a smoking history of more than 10 pack-years and have experienced an exacerbation in the past year. The sample also includes a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for newly diagnosed advanced anaplastic large cell lymphoma. The trial is looking for patients under the age of 21 who have a CD30+ diagnosis and are in Murphy stage III or IV. Patients with B-cell large cell lymphoma or skin-limited disease are not eligible. The trial requires patients to have a bilirubin level no greater than 1.5 times the upper limit of normal and an AST or ALT level less than 2.5 times the ULN (unless due to lymphoma). Patients must also have a shortening fraction of at least 27% by echocardiogram or an ejection fraction of at least 50% by radionuclide angiogram. Prior concurrent therapy is not specified, but prior limited-dose radiotherapy or steroids for management of a mediastinal mass are allowed. Patients must not be pregnant or nursing, must have a negative pregnancy test, and fertile patients must use effective contraception.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are either treatment naive or treated with one antidiabetic medication. The inclusion criteria require patients to have a diagnosis of type 2 diabetes prior to informed consent, a glycosylated haemoglobin A1 (HbA1c) level between 7.0 to 10.0%, and a BMI of 45 kg/m2 or less. Exclusion criteria include recent myocardial infarction, stroke or TIA, impaired hepatic function, uncontrolled hyperglycaemia, known hypersensitivity or allergy to the investigational product or its excipients, and treatment with certain antidiabetic drugs or anti-obesity drugs within 3 months prior to informed consent. Pre-menopausal women who are nursing or pregnant, or are of child-bearing potential and not practicing an acceptable method of birth control, are also excluded. The trial requires signed and dated written informed consent in accordance with GCP and local legislation.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The trial includes a list of ICD-10 codes related to hypertension and a list of drugs being tested, including carvedilol phosphate modified release formulation and metoprolol succinate. The eligibility criteria for the trial include having a documented history of hypertension, triglycerides within a certain range, and LDLc levels not requiring lipid lowering medication. The exclusion criteria include having a known contraindication to alpha- or beta-blocker therapy, having taken non-ocular beta-blockers within three months before screening, having Type I or II diabetes, and taking lipid lowering medications.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have undergone surgery within the past 12 weeks and have no known clinical residual locoregional disease. The trial requires patients to have histologically confirmed breast cancer confined to the breast and axillary nodes, with no distant metastatic disease. Patients must have undergone a total mastectomy with or without adjuvant radiotherapy or breast-conserving surgery followed by radiotherapy. Patients with microscopically positive axillary sentinel nodes are allowed provided they were evaluated on a clinical trial evaluating microscopically positive lymph nodes. Patients with locally advanced, inoperable breast cancer, including inflammatory breast cancer, supraclavicular node involvement, or enlarged internal mammary nodes, are not eligible. Patients must also be premenopausal females with estrogen receptor and/or progesterone receptor positive tumors. The trial has various patient characteristics and prior concurrent therapy requirements. The drugs being tested in the trial are chemotherapy, exemestane, tamoxifen, and triptorelin.",
    "The sample is a phase 3 clinical trial for psoriatic arthritis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria includes being at least 18 years old, having a diagnosis of psoriatic arthritis for at least 6 months, meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria, and having been inadequately treated by disease-modifying antirheumatic drugs (DMARDs). The exclusion criteria includes being pregnant or breastfeeding, having a history of allergy to any component of the investigational product, and having therapeutic failure on more than 3 agents for PsA or more than 1 biologic tumor necrosis factor (TNF) blocker.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are at least 40 years old, have a history of COPD, and have a post-albuterol spirometry criteria of FEV1/FVC ratio \u2264 0.70 and FEV1 \u2264 70% of predicted normal. The trial excludes patients with other respiratory disorders, poorly controlled COPD, and certain medical conditions. The trial involves the use of two drugs, fluticasone furoate 100mcg/vilanterol 25mcg and fluticaosne propionate 500mcg/salmeterol 50mcg, and requires patients to meet specific eligibility criteria.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes who have had the disease for at least 24 months. The trial is testing the effectiveness of three different insulin treatments: human insulin inhalation powder, injectable insulin, and insulin glargine. The trial has specific inclusion criteria, such as having an HbA1c less than or equal to 11% and being a non-smoker, as well as exclusion criteria, such as having a daily total insulin dosage greater than 150 U at screening and having a history of lung transplantation or lung cancer. The trial is designed to determine the safety and efficacy of these insulin treatments for patients with type 1 diabetes.",
    "This sample is a phase 3 clinical trial for the treatment of gastrointestinal stromal tumor. The trial requires patients to have a confirmed diagnosis of gastrointestinal stromal tumor expressing CD117+ or with a documented mutation of the KIT or PDGFRA gene, with metastatic disease in the liver and/or abdominal cavity but no extra-abdominal metastases. Patients must have achieved complete response, partial response, or stable disease without progression since the start of imatinib mesylate therapy, and undergone 6-12 months of treatment with imatinib mesylate as a standard of care or within other clinical studies. Patients must also have surgically resectable residual disease as assessed by CT scan and/or MRI within the past 14 days. The trial has various patient characteristics that must be met, including WHO performance status 0-1, ANC > 1,500/mm^3, platelet count > 100,000/mm^3, and more. Prior concurrent therapy is also outlined in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia. The trial includes patients who are male or female between the ages of 18 and 80, not on a statin or on a low dose statin with a stable dose for at least 4 weeks, have a history of intolerance to at least 2 statins, and are not at LDL-C goal. The lipid lowering therapy has been stable prior to enrollment for at least 4 weeks and fasting triglycerides are less than or equal to 400 mg/dL. The trial excludes patients with NYHA III or IV heart failure, uncontrolled cardiac arrhythmia, uncontrolled hypertension, type 1 diabetes, poorly controlled type 2 diabetes, uncontrolled hypothyroidism or hyperthyroidism. The trial includes a placebo to evolocumab, ezetimibe, and a placebo to ezetimibe as drugs.",
    "The sample is a phase 3 clinical trial for psoriasis. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require participants to have been diagnosed with psoriasis at least 6 months prior to registration, have plaque type psoriasis covering at least 10% of their body, and have a PASI score of 12 or higher. Female participants of childbearing potential or males with partners who can become pregnant must agree to use appropriate contraception for 1 year. The exclusion criteria include participants with guttate, erythrodermic, or pustular psoriasis, a history of tuberculosis or chronic infection, current or past history of malignant tumors (except for certain types), and current serious infections.",
    "The sample is a record of a clinical trial in phase 3, focused on graft rejection disease. The trial involves the drug everolimus and includes a list of icd-10 codes for the disease. The eligibility criteria for the trial include being an adult with an established cardiac allograft vasculopathy, being on statins at study entry, and being more than 12 months post-transplant. Exclusion criteria include having a serum creatinine value greater than 2.0 mg/dL, having a biopsy-proven acute rejection episode within 6 months prior to study entry, and having received any investigational drug within 4 weeks prior to study entry.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying non-Hodgkin's lymphoma. The icd-10 codes associated with the disease are listed, as well as the drug being used (rituximab). The eligibility criteria for participants are also listed, including requirements such as being in remission for 5-6 months post-autologous stem cell transplant, having a certain level of neutrophils and platelets, and having a Zubrod performance status of 2 or less. There are also exclusion criteria listed, such as having uncontrolled active infection or severe medical or psychiatric illness.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of osteoporosis and includes a list of ICD-10 codes associated with the disease. The trial involves the use of several drugs, including ed-71, alfacalcidol, ed-71 placebo, and alfacalcidol placebo. The eligibility criteria for the trial include various conditions related to osteoporosis, such as fragility fractures and low bone mineral density. The trial also has exclusion criteria, such as certain medical disorders and recent use of certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes patients who are male or female and over 18 years old, have a fasting LDL-C level greater than 2mmol/L at both visit 1 and visit 2, have established cardiovascular disease, diabetes, or are at high risk of cardiovascular disease, have taken simvastatin 40mg continuously for the past 6 weeks, have a fasting triglyceride level of less than 3.7mmol/L, have HbA1c less than 9% at visit 1, and are 75% compliant with medication between visit 1 and visit 2. Patients who are hypersensitive to any of the study medications or their components, have a history of or active liver disease, are pregnant, lactating, or a female patient of childbearing potential not using adequate contraception, have severe renal impairment, uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, a recent history of or current alcohol abuse, CK greater than 10 x ULN at visit 1 or visit 2, fasting LDL-C greater than 4.2mmol/L, or any acute or serious condition or history suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis are excluded from the trial. The trial includes the use of ezetimibe (+) simvastatin, atorvastatin, and rosuvastatin as comparators.",
    "The sample is a phase 3 clinical trial for patients with invasive breast cancer in stage IIIb, stage IIIc with T4 lesion, or stage IV disease. The trial requires documentation of ErbB2 overexpression and progressive advanced or metastatic breast cancer. Patients must have refractory breast cancer and have received prior treatment with trastuzumab for at least 6 weeks. Hormone receptor positive tumors must have disease progression following hormonal therapy. Patients with stable central nervous system metastases are eligible. The trial excludes pregnant or lactating females, patients with malabsorption syndrome or ulcerative colitis, and those with concurrent disease or condition that would make them inappropriate for study participation. Patients with unresolved or unstable serious toxicity from prior administration of another investigational drug, active or uncontrolled infection, dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent are also excluded.",
    "The sample is a phase 3 clinical trial for psoriatic arthritis. The trial includes patients who have had a documented diagnosis of psoriatic arthritis for at least 6 months and have active psoriatic arthritis at the time of entry into the study. The patients must have started treatment with methotrexate at a dose not to exceed 25 milligrams per week at least 3 months prior to the beginning of the study and should have no serious toxic side effects attributable to methotrexate. The route of administration and doses of methotrexate should be stable for at least 4 weeks prior to the first administration of the study agent. Patients who are not currently using methotrexate must have not received methotrexate for at least 4 weeks prior to the first administration of the study agent. The trial excludes patients with other inflammatory diseases, those who have used any therapeutic agent targeted at reducing interleukin (IL)-12 or IL-23, and those who have used any biologic agents that are targeted for reducing tumor necrosis factor-alpha. Patients with a medical history of latent or active granulomatous infection or any known malignancy or a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years of the beginning of the study) are also excluded from the trial. The trial includes a placebo group and two groups receiving different doses of ustekinumab.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial is for male or female outpatients who are at least 12 years old but have not yet reached their 18th birthday and have a diagnosis of ADHD with normal intelligence. The trial excludes patients who weigh less than 30 kg or more than 85 kg, have other relevant psychiatric diagnoses, are at serious suicidal risk, have a history of severe allergies, have had alcohol or drug abuse within the past 3 months, or are pregnant or breastfeeding. Sexually active females must use a medically acceptable method of contraception. The trial will be testing the drug atomoxetine.",
    "The sample is a phase 3 clinical trial for the treatment of basal cell carcinoma using the drug imiquimod. The trial is looking for participants who have a primary tumor of superficial BCC with a minimum tumor area of 0.5cm2 and a maximum diameter of 2.0cm. Female participants of childbearing potential must have a negative pregnancy test and be willing to use a medically acceptable method of contraception. The trial has exclusion criteria, including evidence of clinically significant, unstable medical conditions, Gorlin syndrome, metastatic tumor, or other malignant cancers of the skin at the target tumor site within the last 5 years. Participants who have received defined treatments in the tumor site or surrounding area, any dermatological disease in the target tumor site or surrounding area, or a systemic bacterial or viral infection within 2 weeks prior to study initiation are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of glioblastoma and anaplastic astrocytoma. The trial involves the use of the drug temozolomide and has specific eligibility criteria, including confirmation of the disease, age over 65, and certain blood counts and lab values within normal limits. Exclusion criteria include serious medical or neurological conditions, HIV infection, and previous chemotherapy or radiotherapy to the brain. Patients must provide written consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of irritable bowel syndrome with diarrhea. The trial involves the use of drugs called rezular and placebo. The eligibility criteria for the trial include fulfilling the Rome III criteria for IBS-D, and exclusion criteria include major cardiovascular disease, psychiatric illness except mild or moderate depression, pregnancy, presence of other GI disease that could explain IBS-like symptoms, and history of major gastric, hepatic, pancreatic or intestinal surgery or perforation. The icd-10 codes associated with the disease are K58.0 and K58.9.",
    "The sample is a phase 3 clinical trial for the treatment of attention-deficit/hyperactivity disorder. The trial is testing the efficacy and safety of extended-release guanfacine hydrochloride. The eligibility criteria include being between the ages of 13-17, having a primary diagnosis of ADHD, and meeting certain score requirements on diagnostic tests. Exclusion criteria include having certain comorbid psychiatric diagnoses, abnormal laboratory values, and a history of certain cardiac abnormalities. The sample also includes a list of inclusion and exclusion criteria for the trial.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, ICD-10 codes associated with the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on ventilator-associated pneumonia. The ICD-10 code associated with this disease is J95.851. The drugs being tested are doripenem, imipenem-cilastatin, and placebo. The eligibility criteria for participants include having new or worsening radiographic infiltrates consistent with ventilator-associated pneumonia, having been on mechanical ventilation for at least 48 hours, and having a baseline Clinical Pulmonary Infection Score (CPIS) of 6 or higher and an Acute Physiology and Chronic Health Evaluation (APACHE) II score between 8 and 35. There are also exclusion criteria, such as having received antibiotics for more than 24 hours before study medication administration and having certain medical conditions like lung cancer or severe liver disease.",
    "This sample is for a phase 3 clinical trial for the treatment of hyponatremia using the drug tolvaptan. The eligibility criteria include being 18 years or older, able to provide informed consent, and having previously participated in a tolvaptan hyponatremia trial with evidence of continued need or desire for therapy. The exclusion criteria include having a medical condition where long-term treatment with an aquaretic agent may present a risk, having hyponatremia that is acute, reversible, artifactual, or due to conditions not associated with vasopressin excess or likely to respond to aquaretic therapy, having conditions associated with an independent imminent risk of morbidity and mortality, and having conditions that may confound the assessment of endpoints. The diseases listed are only hyponatremia, and the icd-10 codes associated with it are P74.22 and E87.1.",
    "The sample is a phase 3 clinical trial for patients with cerebrovascular accident. The trial involves administering rt-pa 0.9 mg/kg verum or placebo intravenously to patients who meet certain eligibility criteria. These criteria include being an inpatient between the ages of 18 and 80 with a clinical diagnosis of ischemic stroke causing measurable neurological deficits. The onset of symptoms must have been between 3 and 4 hours prior to the administration of the study drug, and symptoms must have been present for at least 30 minutes and not significantly improved before treatment. Patients must also be willing to participate voluntarily and comply with the protocol. Exclusion criteria include evidence of intracranial hemorrhage, minor neurological deficits, severe stroke, and a history of central nervous system damage.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are non-smokers and have been diagnosed with type 2 diabetes for at least 6 months. Patients must have a stable regimen of metformin and a secretagogue, with a maximum dose of half the manufacturer-recommended daily dose, for at least 6 weeks. The trial also requires patients to have an HbA1c level between 7.5% and 11.0%, a BMI of 40kg/m2 or less, and certain pulmonary function test results. Patients who have been treated with any type of anti-diabetic therapy other than metformin and secretagogues within the past 12 weeks, have high serum creatinine levels, or have a history of certain pulmonary diseases or complications of diabetes are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with sepsis and hypotension. The trial involves the use of the drug drotrecogin alfa (activated) and a placebo. The eligibility criteria for the trial include severe sepsis patients who have been treated with a 96-hour infusion of commercial Drotrecogin Alfa (Activated) and require continued vasopressor support after the infusion. Exclusion criteria include patients who require extensive surgical procedures within the next 3 days, have a platelet count below 30,000/mm3, are receiving therapeutic heparin of 15,000 units/day or more, are not expected to survive 24 days, or are contraindicated as per country-specific registration. The diseases in the trial are sepsis and hypotension, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for patients with unresectable metastatic melanoma and concurrent visceral/soft tissue metastases. The trial is testing the effectiveness of the drug temozolomide. Eligibility criteria include having asymptomatic brain metastasis that is not amenable to surgery or stereotactic radiosurgery, at least one site of measurable disease, and documented evidence of disease progression. Patients must also meet certain age, performance status, and hematopoietic, hepatic, and renal function requirements. They cannot have other prior or concurrent malignancies, uncontrolled infections, or psychological, familial, sociological, or geographical conditions that would preclude study. Prior and concurrent therapies are also restricted. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is looking for subjects who are 18-70 years old, diagnosed with chronic hepatitis C genotype 1, and have not responded to prior treatment. The trial is testing the effectiveness of the drug Rebetol (ribavirin). The eligibility criteria include normal or elevated liver function tests, certain hematologic and biochemical criteria, and a negative pregnancy test for female subjects. The trial also requires the use of contraception for female subjects and sexually active male subjects. The exclusion criteria include pregnancy, involvement in another clinical trial, and certain medical conditions such as severe depression and poorly controlled diabetes mellitus.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying hyperuricemia. The associated ICD-10 code is E79.0. The drugs being used in the trial are rasburicase and allopurinol. The eligibility criteria for participants include being at high risk of malignancy and/or chemotherapy-induced hyperuricemia, having a performance status less than 3 on ECOG scale or more than 30% KPS scale, having uric acid concentrations \u2265 8.0mg/dL, and suffering from non-Hodgkin's lymphoma Stage more than III, or acute lymphoblastic leukemia with peripheral with blood cell count more than 25,000/mm3, or any lymphoma or leukemia. There are also exclusion criteria listed, such as not having been treated with an investigational drug at any time during the 14-day study period (except for agents that are permitted by the Sponsor), not being pregnant or lactating, and not having a history of significant atopic allergy problems or documented history of asthma.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who are 18 years or older and have locally advanced, recurrent, or metastatic NSCLC with measurable disease. Patients must not have had disease progression after 4 cycles of platinum-based chemotherapy. The trial involves the drugs erlotinib (tarceva) and placebo. The eligibility criteria include exclusion of patients with unstable systemic disease or any other malignancies in the last 5 years.",
    "The sample is a phase 3 clinical trial for recurrent and/or metastatic head and neck cancer. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for participants. The inclusion criteria include being at least 18 years old, having confirmed metastatic and/or recurrent squamous cell carcinoma of the head and neck, and having measurable and non-measurable disease. The exclusion criteria include a history of CNS metastases, prior systemic treatment for metastatic and/or recurrent SCCHN, and clinically significant cardiovascular disease.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients who have been diagnosed with possible or probable Alzheimer's disease and have a caregiver who can assist with medication compliance and attend all visits. The patients must also have a minimum MMSE score between 12 and 26 and have been taking a maintenance dosage of certain drugs for at least 4 weeks prior to randomization. The trial excludes patients with non-Alzheimer primary dementia, major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia, or delusional disorder. Patients with uncontrolled systemic illness or a life expectancy of less than one year are also excluded. Pregnant women or those intending to become pregnant, patients enrolled in another interventional clinical trial, and those with certain prescriptions or medical conditions are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation and a focus on breast cancer. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including \"tab premarin (ethinyl estradiol)\" and a placebo. The eligibility criteria for the trial include patients with histological or cytologic proof of breast cancer, operable breast cancer, and who are candidates for adjuvant chemotherapy according to the standard policy. Patients who have no contraindication to anthracycline based chemotherapy and who give informed consent to participate in the study are also eligible. The exclusion criteria are not specified in the sample.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial is looking for male and female patients between the ages of 12 and 80 who have been diagnosed with epilepsy with partial-onset seizures. The patients must have non-controlled partial seizures despite having been treated with at least two different antiepileptic drugs for at least two years. The trial is testing the effectiveness of the drugs placebo and rufinamide. The eligibility criteria include having at least six seizures during the prospective Baseline Phase with no 21-day seizure-free periods, using a maximum of three approved antiepileptic drugs, and having a stable dose of the same AED(s) for one month prior to screening. The exclusion criteria include having a history of drug abuse, alcohol abuse in the past two years, or a diagnosis of Congenital Short QT Syndrome.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension who are at least 55 years old. The trial involves the use of three drugs: valsartan 160 mg capsules, amlodipine 5 mg capsules, and a placebo. The eligibility criteria include having a measured systolic blood pressure between 130 and 160 mmHg, not having peripheral edema, and not having any contraindications or secondary forms of hypertension. Exclusion criteria include having a history of heart failure, significant valvular heart disease, or renal impairment, among others. Patients must provide written informed consent to participate in the study.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes patients who have been diagnosed clinically with type 2 diabetes for at least 24 weeks prior to the randomization visit and are currently being treated with insulin glargine and up to three oral antidiabetic drugs. The patients' glycosylated hemoglobin levels should be between 7.0-10.0% and their body mass index should be below or equal to 40 kg/m^2. The trial excludes patients who have been treated with glucagon-like peptide 1 receptor agonists or thiazolidinediones within the last 12 weeks prior to the randomization visit, have had a stroke, heart failure New York Heart Association class III or IV, myocardial infarction, unstable angina pectoris, or coronary arterial bypass graft or angioplasty within the last 24 weeks prior to the randomization visit, have uncontrolled or untreated severe hypertension, have had more than one severe hypoglycemic event during the last 12 months, have hypoglycemic unawareness, or have a life-threatening disease such as cancer.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on diabetes, specifically type 2 diabetes, and involves two drugs, insulin detemir and insulin nph. The trial has a list of inclusion and exclusion criteria, including a requirement that participants have an HbA1C level between 7.5% and 11.0% and have been on an oral antidiabetic drug for at least three months. Exclusion criteria include previous treatment with insulin for more than 7 days and proliferate retinopathy or maculopathy that has required acute treatment within the last year. The trial is designed to evaluate the effectiveness of the two drugs in treating type 2 diabetes.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial includes patients who have been diagnosed with Crohn's disease for more than 4 months and have small bowel and/or colonic involvement. The trial aims to test the effectiveness of the drugs GSK1605786A and placebo. The eligibility criteria include being 18 years or older, having a confirmed diagnosis of Crohn's disease, and having moderately-to-severely active disease. The trial also requires stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn's disease. The trial has exclusion criteria, including pregnancy, diagnosis of coeliac disease, and chronic use of narcotics for chronic pain. The trial also has a list of prohibited medications and medical conditions that would exclude patients from participating.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients who have not been treated with interferon before and have compensated liver disease. The trial involves the use of albumin interferon alfa-2b, peginterferon alfa-2a, and ribavirin. The eligibility criteria include having a liver biopsy within 2 years of Day 0 or during screening, being infected with hepatitis C virus genotype 1, and not having any other causes of chronic liver disease. The trial also requires subjects to be willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin. The exclusion criteria include having decompensated liver disease, a history of moderate, severe or uncontrolled psychiatric disease, being positive for HIV-1 or hepatitis B surface antigen, and having a history of immunologically mediated disease.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the efficacy and safety of two inhalation powders, ff/gw642444 and gw642444. The eligibility criteria include being an outpatient, giving informed consent, being male or female, and meeting certain age and COPD diagnosis requirements. Exclusion criteria include pregnancy, asthma, \u03b11-antitrypsin deficiency, and other respiratory disorders. The trial also has specific requirements for pack-year history, lung function, and exacerbation history. The trial will not enroll subjects with certain diseases or abnormalities, including clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities. Subjects must also not have a history of drug or alcohol abuse, be unable to comply with study procedures, or have a questionable validity of consent. The trial will not enroll subjects who have previously been randomized to treatment with GW642444 Inhalation Powder or have participated in certain other studies.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients who have a diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria and a clinical diagnosis of probable AD according to NINCDS/ADRDA criteria. The patients must also have an MMSE score of > or = 10 and < or = 20. The trial involves the use of rivastigmine transdermal patch and placebo. The eligibility criteria include exclusion of patients with a current DSM-IV diagnosis of major depression, those who have taken rivastigmine in the past, and those with a score of > 5 on the Modified Hachinski Ischemic Scale (MHIS). Other protocol-defined inclusion/exclusion criteria may also apply. The extension phase eligibility criteria include patients who have completed the Double-blind Treatment Phase on study medication, while exclusion criteria include patients who have any important protocol deviations until the completion of the Double-blind Treatment Phase.",
    "The sample is a phase 3 clinical trial for the treatment of diabetic peripheral neuropathy. The trial includes patients with Type 1 or 2 diabetes mellitus who have been experiencing painful peripheral neuropathy symptoms for at least 6 months. The trial involves the use of tapentadol extended release (er) and a placebo. Patients must meet certain inclusion criteria, such as having controlled blood glucose levels and having taken analgesic medications for at least 3 months prior to screening. Patients must also meet certain exclusion criteria, such as having a history of significant pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders.",
    "The sample is a phase 3 clinical trial for seasonal allergic rhinitis. The trial includes patients who have had SAR to Mountain Cedar for at least two years and have a demonstrated sensitivity to Mountain Cedar through a standard skin prick test. The trial involves the use of ciclesonide hfa 160 \u03bcg, ciclesonide hfa 80 \u03bcg, and a placebo. The eligibility criteria include being in good health, having a negative pregnancy test for females, possessing an educational level and degree of understanding of English, and agreeing to avoid pregnancy during the study. The exclusion criteria include a history of physical findings of nasal pathology, participation in any investigational drug trial within the 30 days preceding the Screening Visit, and plans to travel outside the study area for more than 24 hours during the Run-in period. The trial also excludes patients with a known hypersensitivity to any corticosteroid or any of the excipients in the formulation of ciclesonide, a history of a respiratory infection or disorder, and plans to travel outside the study area for 2 or more consecutive days between Randomization Visit and the final Treatment Visit.",
    "The sample is a phase 3 clinical trial for HIV-1 infection. The trial is testing the effectiveness of two drug combinations, abacavir/lamivudine/atazanavir/ritonavir and abacavir/lamivudine/atazanavir, in antiretroviral-na\u00efve patients with plasma HIV-1 RNA levels of at least 1,000 copies/mL. The trial has inclusion criteria such as being at least 18 years old, having documented evidence of HIV-1 infection, and being willing and able to provide written informed consent. Exclusion criteria include having certain mutations associated with atazanavir resistance, being pregnant or breastfeeding, having certain medical conditions, and requiring treatment with certain medications. The trial also has eligibility criteria for a treatment extension phase from weeks 84 to 144.",
    "The sample is a phase 3 clinical trial for patients with locally advanced, recurrent, or metastatic colorectal adenocarcinoma. The trial includes patients with various stages of colon and rectal cancer, and the eligibility criteria include measurable or evaluable disease, no known brain or leptomeningeal disease, and a performance status of Zubrod 0-2. Patients must also meet various medical criteria, such as having no history of hemorrhagic or thrombotic disorders, and having a platelet count greater than 100,000/mm^3. The trial involves the use of drugs such as oxaliplatin, leucovorin calcium, capecitabine, and fluorouracil. The trial has various exclusion criteria, such as no prior bevacizumab or oxaliplatin, and no concurrent therapeutic anticoagulation.",
    "The sample is a phase 3 clinical trial for patients with systemic sclerosis and ulcers. The trial involves the use of macitentan 3mg, macitentan 10mg, or a placebo. The eligibility criteria include being at least 18 years old, having a diagnosis of systemic sclerosis according to the American College of Rheumatology's classification criteria, and having at least one visible, active ischemic digital ulcer at baseline. Exclusion criteria include having ulcers due to a condition other than systemic sclerosis, having symptomatic pulmonary arterial hypertension, having a body mass index less than 18 kg/m^2, and having abnormal liver function or low hemoglobin levels. Patients who are pregnant or breastfeeding, have substance or alcohol abuse or dependence, or are on certain medications are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who are either treatment naive or have been previously treated with any oral hypoglycaemic agent. The trial involves two drugs, placebo + pioglitazone (30 mg) and linagliptin + pioglitazone (30 mg). The eligibility criteria include having a signed and dated written informed consent, a diagnosis of type 2 diabetes mellitus, unchanged antidiabetic therapy for ten weeks prior to informed consent, HbA1c levels between 7.5-11%, and a BMI of less than or equal to 40 kg/m2. The exclusion criteria include recent myocardial infarction, stroke or Transient Isquemic Atack (TIA), impaired hepatic function, known hypersensitivity or allergy to the investigational product or its excipients, recent treatment with Glucagon-like peptide-1 (GLP-1) analogue / agonist or insulin, alcohol or drug abuse, recent participation in another trial with an investigational drug, fasting blood glucose levels above 240 mg/dl, pre-menopausal women who are nursing or pregnant or not practicing an acceptable method of birth control, recent treatment with systemic steroids or change in the dosage of thyroid hormone, heart failure New York Heart Asociation (NYHA) class I-IV, history of heart failure, diabetic ketoacidosis within 6 months prior to informed consent, hemodialyzed patients, and any other clinical condition that would not allow safe completion of the protocol and safe administration of the drugs.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C virus (HCV) infection. The trial includes subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral therapy, have a platelet count of less than 75,000/mcL, and meet other eligibility criteria. The trial involves the use of the drugs eltrombopag and placebo. The inclusion and exclusion criteria are listed in detail, including factors such as history of psychiatric disorders, bleeding disorders, and previous treatment with investigational drugs or IFN. The trial excludes pregnant or nursing women and males with a pregnant partner. The sample is described in a structured format with clear headings for inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar I disorder. The trial is evaluating the effectiveness of injectable risperidone (consta) or oral antipsychotic drugs. The eligibility criteria include a DSM-IV-TR diagnosis of bipolar disorder, age between 18 and 70 years, and willingness to receive treatment at specific medical centers. The trial also requires that the eligible individual is clinically appropriate for antipsychotic treatment for at least 15 months and that it is clinically appropriate to switch to one of the second-generation antipsychotic agents being evaluated in the study. The exclusion criteria include pregnancy or lactation, current participation in another study that would confound the present study objectives, and treatment resistance to either risperidone or more than two of the other antipsychotic agents in this trial.",
    "The sample is a phase 3 clinical trial for the treatment of rheumatoid arthritis. The trial is testing the effectiveness of the drugs ofatumumab and placebo in patients who have not responded well to previous methotrexate treatment. The eligibility criteria include having active disease with a certain number of swollen and tender joints, as well as a certain level of C-Reactive Protein or Erythrocyte Sedimentation Rate. Patients must have been on a stable dose of methotrexate for at least 4 weeks. Exclusion criteria include having other autoimmune diseases or significant systemic involvement due to rheumatoid arthritis, previous exposure to certain treatments, and various medical conditions. Patients who are pregnant or breastfeeding, or who are unable to comply with the study protocol, are also excluded.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast cancer. The trial is testing the effectiveness of the drug ixabepilone in combination with calcium gluconate and magnesium sulfate. The trial includes patients who have not previously been treated with ixabepilone and have had no more than two prior chemotherapy regimens for metastatic disease. Patients must also meet certain eligibility criteria, such as having a certain performance status and life expectancy, and must not have certain medical conditions or be taking certain medications. The trial excludes pregnant or nursing women, those with certain medical conditions, and those taking certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of prostatic hyperplasia. The trial includes males aged 50 years or older with a clinical diagnosis of BPH, a prostate volume of at least 30cc, and a total serum PSA of at least 1.5ng/mL. The trial involves the use of dutasteride and tamsulosin for a period of 4 years. The eligibility criteria include being able to give written informed consent, being fluent and literate in the local language, and being able to swallow and retain oral medication. The exclusion criteria include a total serum PSA of over 10.0ng/mL, a history or evidence of prostate cancer, and a history of unsuccessful treatment with tamsulosin or finasteride. The trial also excludes individuals with certain medical conditions or who have participated in other drug trials within the past 30 days.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia. The trial includes subjects who are male or female between the ages of 18 and 80. Subjects not taking a statin must have a fasting LDL-C level of at least 150 mg/dL, while those already on a non-intensive or intensive statin must have fasting LDL-C levels of at least 100 mg/dL and 80 mg/dL, respectively. Fasting triglycerides must be less than or equal to 400 mg/dL. The trial excludes subjects with statin intolerance, NYHA III or IV heart failure, uncontrolled hypertension or cardiac arrhythmia, poorly controlled diabetes, and uncontrolled hypothyroidism or hyperthyroidism. The trial will test the efficacy of several drugs, including ezetimibe, atorvastatin, rosuvastatin, simvastatin, and placebos.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for the treatment of locally advanced or metastatic medullary thyroid cancer. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The eligibility criteria include requirements such as age, performance status, and previous diagnosis of the disease. The sample also includes exclusion criteria, such as recent major surgery or radiation therapy, and certain medical conditions that may increase the risk of ventricular arrhythmia.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of prostate cancer using the drug triptorelin (decapeptyl\u00ae). The trial is for patients who have not yet received androgen deprivation therapy and have an estimated survival time of at least twelve months. The inclusion criteria also require a performance status score of \u2264 2 according to the World Health Organisation criteria. The exclusion criteria include previous surgical castration, previous or planned curative prostate cancer therapy, and previous hormone therapy. Patients with a risk of serious complications in the case of tumour flare are also excluded. The diseases are listed as 'prostate cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The eligibility criteria include men and women with confirmed idiopathic PD, with at least two cardinal signs without any other known or suspected cause of parkinsonism. The trial is for subjects with a diagnosis of early idiopathic PD of less than 1\u00bd years duration from time of documented diagnosis. The clinical condition of the subjects at the time of enrollment should not require anti-PD treatment and will not require for the next 9 months. The trial excludes subjects younger than 30 or older than 80 years, subjects with loss of postural reflexes, UPDRS Tremor score of 3 or greater in any limb, Hoehn &Yahr Stage III or greater at screening, freezing while walking, and other features that tend to exclude PD as the cause of Parkinsonism. The trial also excludes subjects who have had previous use of rasagiline or selegiline, and those who have used other anti-PD medication basis at any time prior to baseline. The trial includes other exclusion criteria related to medical or surgical conditions, hypertension, melanoma, cognitive impairment, psychiatric illness, alcohol or substance abuse, experimental medications, and use of certain medications within a specific time frame. Women who are not postmenopausal, surgically sterilized, or using adequate birth control are also excluded.",
    "The sample is a phase 3 clinical trial for patients with primary non-small cell lung cancer. The trial is looking at the effectiveness of the drugs cisplatin and docetaxel in combination with surgery for patients with stage IIIA disease. Patients must have measurable disease by chest x-ray and/or contrast-enhanced CT scan and be candidates for surgery. They must also meet certain eligibility criteria, including having a confirmed diagnosis of NSCLC within the past 3 months and having no distant metastases. The trial is also looking at various patient characteristics, such as age, performance status, and hematopoietic, hepatic, renal, cardiovascular, pulmonary, and immunologic status. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 3 clinical trial for diabetes, specifically type 2 diabetes. The trial includes patients who have been on stable diabetes treatment for at least 90 days prior to the screening visit. The patients must have a HbA1c level between 7-10%, moderate renal impairment, and a BMI between 20-45 kg/m^2. The trial will test the effectiveness of the drug liraglutide compared to a placebo. The eligibility criteria includes various factors such as exclusion of patients with impaired liver function, history of chronic pancreatitis, and recent cardiovascular events. Patients with proliferative retinopathy or maculopathy requiring acute treatment are also excluded.",
    "The sample is a phase 3 clinical trial for obesity. The trial includes patients with a body mass index (BMI) between 30 kg/m\u00b2 and 43kg/m\u00b2 who have maintained a stable weight for at least 3 months prior to the study start. Patients must be between 18 and 65 years old, able to understand the study procedures and alternative treatments available, and able to read, understand, and complete study questionnaires. Exclusion criteria include a history or presence of a major psychiatric disorder, recent history of stroke, TIA or neurological disorder, history of seizures or high risk of developing seizures, systolic blood pressure >160mm Hg or diastolic blood pressure > 100 mm Hg, and diabetes mellitus as defined by medical history. The trial will test the effectiveness of the drug taranabant compared to a placebo.",
    "The sample is a phase 3 trial for patients with cancer and breakthrough pain. The disease being studied is pain and the icd-10 codes associated with it are N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, and R52. The drug being tested is nasal fentanyl. The eligibility criteria for the trial include being an adult in- or out-patient with cancer and breakthrough pain, using a stable, chronic opioid treatment for background pain, having a minimum of three breakthrough pain episodes per week and a maximum of four per day, having a life expectancy of at least three months, and having received no previous randomization in previous studies with NF, i.e. FT-016-IM, FT-017-IM or FT-018-IM, but previous use of Actiq is accepted.",
    "The sample is a phase 3 clinical trial for pulmonary hypertension. The trial is looking at the effectiveness of inhaled iloprost, inhaled placebo, sildenafil, and bosentan as treatments for idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH). The trial is open to individuals between the ages of 12 and 85 of any gender who have a confirmed diagnosis of PAH and a 6-minute walk distance (6-MWD) between 100-450 meters at screening. Participants must also be on a stable dose of sildenafil, with or without bosentan. Exclusion criteria include recent treatment with certain medications for PAH, pulmonary hypertension due to conditions other than IPAH or FPAH, and recent addition of other PAH medications.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of drugs such as bg00012, placebo, and glatiramer acetate. The eligibility criteria for participants include having a confirmed diagnosis of RRMS according to McDonald criteria #1-4, having a baseline EDSS between 0.0 and 5.0, and having a relapsing-remitting disease course. Participants with other chronic diseases of the immune system, malignancies, urologic, pulmonary, or gastrointestinal disease, as well as pregnant or nursing women, are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been previously treated with metformin alone or with metformin and one other oral antidiabetic drug. The trial involves the drugs linagliptin and placebo. The eligibility criteria include a stable dose of at least 1500 mg/day of metformin for at least 8 weeks prior to randomization, a diagnosis of type 2 diabetes prior to informed consent, and a glycosylated haemoglobin A1 (HbA1c) level between 7.0% and 10.0%. Exclusion criteria include recent myocardial infarction, stroke, or TIA, impaired hepatic function, uncontrolled hyperglycemia, known hypersensitivity or allergy to the investigational product or its excipients, and current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent. Pre-menopausal women who are nursing or pregnant, or are of child-bearing potential and not practicing an acceptable method of birth control, are also excluded.",
    "The sample is a phase 3 clinical trial for Tourette's Disorder and Tic Disorder. The trial involves the use of Aripiprazole and a placebo drug. The eligibility criteria include being between 7 to 17 years old, meeting DSM-IV-TR diagnostic criteria for Tourette's Disorder, and having tic symptoms that cause impairment in normal routines. Females of childbearing potential must have a negative pregnancy test and practice acceptable double-barrier methods of contraception. The trial also has exclusion criteria, such as having a history of schizophrenia or bipolar disorder, being sexually active without using two approved methods of contraception, and having abnormal laboratory test results, vital signs, and ECG results.",
    "The sample is a phase 3 clinical trial for the treatment of erosive esophagitis. The trial includes participants who have endoscopically confirmed erosive esophagitis of Grade A to D, as defined by the LA classification grading system. The trial aims to enroll at least 30% (120 participants) of the total participants who are clearly Grade C or D. The trial includes the drugs tak-438, lansoprazole, and placebos. The eligibility criteria include being an outpatient (including inpatient for examination) and not having certain esophagus-related complications, a history of certain treatments affecting gastroesophageal reflux, acute upper gastrointestinal bleeding, gastric or duodenal ulcer within 30 days prior to Visit 1, or certain gastric acid hypersecretion disorders.",
    "The sample is a phase 3 clinical trial for the treatment of cervical dystonia, a condition characterized by involuntary muscle contractions in the neck. The trial involves the use of three different treatments: incobotulinumtoxina (xeomin) at two different doses and a placebo. The eligibility criteria for participants include being between the ages of 18 and 75, having a clinical diagnosis of cervical dystonia with a need for injection, and meeting certain scores on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Participants must also be on a stable dose of medications for at least 3 months prior to the trial and have a stable therapeutic response to previous Botulinum Toxin injections. Exclusion criteria include certain types of torticollis, neuromuscular diseases, and recent treatment with Botulinum Toxins for any indication other than cervical dystonia.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including a placebo. The eligibility criteria for the trial are also listed, including age requirements, blood pressure levels, and medication adherence. There are also exclusion criteria, such as certain medical conditions and recent participation in other clinical studies.",
    "The sample is a phase 3 clinical trial for type 1 diabetes. The trial involves daily intranasal administration of insulin. The eligibility criteria for the trial includes children who carry HLA-conferred genetic risk for developing type 1 diabetes and have had at least two types of autoantibodies of ICA, IAA, GADA and IA-2A in at least two consecutive blood samples drawn at least 3 months apart. The age requirement for the trial is at least one year. The exclusion criteria includes severe other disease and age above 15 years.",
    "The sample is a phase 3 clinical trial for neuropathic pain. The trial includes subjects with either diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) who have had pain for at least 3 months. The trial will test the effectiveness of topical analgesics and oral intake of medication for pain relief. The inclusion criteria for the trial include being over 18 years old, having intact skin in the area of treatment, and having a creatinine clearance of at least 30 mL/min. The exclusion criteria include a history of alcohol or drug abuse, psychiatric illness, pregnancy or breastfeeding, severe cardiac or hepatic impairment, and severe renal failure. Additionally, subjects cannot be undergoing active treatment for cancer or be infected with HIV. The trial also has specific exclusion criteria for each type of neuropathic pain. The trial will not allow the use of other drugs for neuropathic pain or transcutaneous electrical nerve stimulation (TENS) during the trial.",
    "The sample is a phase 3 clinical trial for the treatment of hemodialysis and hyperphosphatemia. The trial involves the use of two drugs, pa21 and sevelamer hydrochloride. The eligibility criteria for the trial include patients who are 20 years or older and receiving stable maintenance hemodialysis three times a week. Patients must not have changed their phosphate binder agent dose for at least four weeks before the observation period starts. The exclusion criteria include patients with a history of pronounced brain or cardiovascular disorders, severe gastrointestinal disorders, or severe hepatic disorders.",
    "The sample is a phase 3 clinical trial for chronic primary insomnia in individuals who are at least 65 years old. The trial includes patients with a regular sleep pattern and a documented diagnosis of primary insomnia. The trial excludes patients with other sleep disorders, significant medical or psychiatric illnesses, substance abuse or addiction within the last year, and those who use psychotropic drugs affecting sleep within two weeks prior to randomization. The trial involves the use of esmirtazapine and placebo drugs, and patients must meet specific eligibility criteria to participate.",
    "The sample is a phase 3 trial for the treatment of venous thrombosis. The trial includes patients who have been diagnosed with deep vein thrombosis or pulmonary embolism and have completed anticoagulant treatment without recurrence of venous thromboembolism. The trial involves the use of the drugs apixaban and placebo. The eligibility criteria for the trial include being 18 years or older, having no indications for long-term treatment with a vitamin K antagonist, and not having active bleeding or high risk for serious bleeding. Exclusion criteria include having a short life expectancy, uncontrolled high blood pressure, or impaired kidney or liver function.",
    "The sample is a phase 3 clinical trial for non-small-cell lung cancer. The trial includes patients who have not received prior chemotherapy and have measurable disease that has not been irradiated. Patients must also have a life expectancy of more than 3 months, be over the age of 70, have a performance status of less than 3, and be \"non-frail\" according to a comprehensive geriatric assessment. Adequate bone marrow, liver, renal, and cardiac function are also required. Patients must provide informed consent to participate in the trial. Exclusion criteria include psychiatric illness or social situations that would prevent study compliance, other concurrent uncontrolled illness, other invasive malignancy within the past 5 years (except nonmelanoma skin cancer), no presence of a reliable caregiver, and other concurrent investigational agents.",
    "The sample is a phase 3 clinical trial for the treatment of low back pain. The trial includes patients who are ambulatory, between the ages of 18 and 70, with a body mass index between 18 and 30 kg/m\u00b2, and normal blood pressure. The trial will test the effectiveness of acetylsalicylic acid (aspirin, baye4465), ibuprofen, and placebo as treatments for low back pain. The eligibility criteria include having low back pain localized below the costal margin and above the inferior gluteal folds, either as acute low back pain, or as chronic or intermittent low back pain. The exclusion criteria include hypersensitivity to acetylsalicylic, salicylates, or other Non Steroidal Anti-inflammatory drugs, serious physical illness, pregnancy or lactation period, and abuse of alcohol or addictive substances.",
    "The sample is a phase 3 clinical trial for the treatment of seasonal allergic rhinitis. The trial involves participants who have good general health and a diagnosis of seasonal allergic rhinitis. The trial requires participants to have a positive skin test reaction to mountain cedar pollen and to reside in an area where exposure to mountain cedar pollen is significant. The trial involves the use of fluticasone propionate and a placebo. The eligibility criteria include having moderate to severe symptoms of allergic rhinitis and understanding and willingness to participate in the trial. The exclusion criteria include intolerance or hypersensitivity to the study materials, nasal disorders, uncontrolled diseases, active bacterial or viral infections, and cataracts.",
    "The sample is a phase 3 clinical trial for patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of aclidinium bromide compared to a placebo. The eligibility criteria for the trial include having a post-levalbuterol FEV1 between 30% and 80% predicted, being a current or former cigarette smoker, having a Functional Residual Capacity (FRC) measured by body plethysmography of at least 120% of predicted value, and having a Baseline Dyspnea Index (BDI) focal score of 7 or less at Visit 4. The exclusion criteria include having a history of asthma, allergic rhinitis, or atopy, being hospitalized for acute COPD exacerbation in the 3 months prior to study entry, having a respiratory tract infection or COPD exacerbation in the 6 weeks prior to study entry, having clinically significant respiratory conditions other than COPD, and chronic use of oxygen therapy for 15 or more hours a day.",
    "The sample is a phase 3 clinical trial for the treatment of ocular hypertension and open-angle glaucoma. The trial involves two drugs, timolol and tafluprost, and a fixed dose combination of tafluprost and timolol. The eligibility criteria include being 18 years or older, having a diagnosis of ocular hypertension or open-angle glaucoma, meeting specific IOP levels and visual acuity scores, being willing to follow instructions, and providing written informed consent. Exclusion criteria include pregnancy or planning pregnancy, IOP greater than 36 mmHg, diagnosis of angle-closure or secondary glaucoma, contraindication or hypersensitivity to study medications, recent ocular surgery or use of contact lenses, and any abnormality or illness that could interfere with the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of transitional cell carcinoma of the urothelial tract and bladder cancer using the drug vinflunine and best supportive care. The trial includes patients who have progressed after 1st line platinum-chemotherapy and are at least 18 years old with adequate hematologic, hepatic, and renal function. Patients with CNS disease, moderate neuropathy, or more than 1 previous chemotherapy are excluded from the trial. The diseases are listed with their corresponding ICD-10 codes, and the eligibility criteria are provided in the inclusion and exclusion criteria sections.",
    "The sample is a phase 3 clinical trial for patients with metastatic colorectal cancer. The trial includes patients who have confirmed wild type KRAS and have experienced disease progression on first line chemotherapy with bevacizumab plus either FOLFOX, OPTIMOX, or XELOX. Patients must have measurable or nonmeasurable disease and must not have received prior treatment with irinotecan. The trial also includes eligibility criteria related to performance status, blood counts, liver function, kidney function, and cardiovascular health. Patients must not have a history or known presence of brain metastasis, nephrotic range proteinuria from prior bevacizumab therapy, or other concurrent anticancer treatments. Women and men of reproductive potential must agree to use an effective contraceptive method. Patients must not be pregnant or nursing. All patients must be informed of the investigational nature of the study and must sign and give written informed consent.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of small cell lung cancer. The trial involves the use of two drugs, intravenous topotecan/cisplatin and intravenous etoposide/cisplatin. The eligibility criteria for the trial include having evaluable extensive small cell lung cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of less than 2, a life expectancy of more than 3 months, and being fit to receive any of the treatments. Exclusion criteria include having extensive disease treatable with radiotherapy, a past or current history of other malignant disease, prior chemotherapy, pregnancy, lactation, lack of effective contraception, concurrent severe medical problems other than small cell lung cancer, and having central nervous system metastases receiving more than 12 mg/day dexamethasone or equivalent to control symptoms.",
    "The sample is a phase 3 clinical trial for patients with locally advanced, metastatic, or locally recurrent gastric, esophageal, or gastro-esophageal junction adenocarcinoma that is ErbB2 (HER2) positive. The trial involves the use of lapatinib, capecitabine, and oxaliplatin, as well as a placebo. The eligibility criteria include signed informed consent, adequate organ function, and measurable or non-measurable but radiologically evaluable disease according to RECIST. Exclusion criteria include pregnancy or lactation, uncontrolled infection, and concurrent anti-cancer therapy.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of lymphoma. The trial involves a combination of drugs including doxorubicin, bleomycin, vinblastine, dacarbazine, vincristine, mechlorethamine, etoposide, prednisone, and cyclophosphamide. The eligibility criteria for the trial include having previously untreated classical Hodgkin's lymphoma, being at least 16 years old, having an ECOG performance status of 0-2, and having measurable or evaluable disease. The exclusion criteria include being pregnant or nursing, having prior radiotherapy or chemotherapy, and being HIV positive.",
    "The sample is a phase 3 clinical trial for the treatment of immune thrombocytopenic purpura. The eligibility criteria include meeting the ASH guidelines for diagnosis, being within 30 days of diagnosis, having a platelet count of 30,000/\u03bcl or less at diagnosis or at some point before study entry, and having a platelet count of 150,000/\u03bcl or less at randomization. Participants must be at least 15 years old and have the ability to provide informed consent. Exclusion criteria include recent rituximab therapy or splenectomy, known HIV or HCV infection, systemic lupus erythematosus, pregnancy or breastfeeding, insulin-requiring diabetes mellitus, previous exposure to prednisone at a high dose, ongoing use of platelet-inhibiting treatments, and anything that may interfere with participation in the study. Participants must not have been previously enrolled in the ITP^2 study or currently enrolled in other interventional clinical trials. Additionally, they must not have been exposed to thrombopoietic agents or dexamethasone at a high dose for the treatment of ITP prior to study entry.",
    "The sample is a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough. The trial involves the use of thalidomide and a placebo drug. The eligibility criteria for the trial include having idiopathic pulmonary fibrosis for more than 3 months but less than 5 years, having a high resolution CT scan of the chest consistent with IPF within the previous 12 months, and having a chronic cough for more than 8 weeks. Participants must also be over the age of 50 and not able to bear children. Exclusion criteria include being pregnant or lactating, having a known cause of lung fibrosis other than IPF, significant respiratory toxin exposure, collagen vascular disease, and a history of seizures or poorly controlled diabetes. Participants must also not have an allergy to thalidomide.",
    "The sample is a phase 3 clinical trial for major depressive disorder and depression. The trial includes patients who have had an inadequate response to no more than one antidepressant and are out-patients at enrollment and randomization. The trial excludes patients with a lifetime history of bipolar disorder, psychotic disorder, or post-traumatic stress disorder, as well as those with a history of suicide attempts in the past year or with a significant history of risk of suicide or homicide. Additionally, patients with a history of renal insufficiency or impairment or conditions that could affect absorption or metabolism of the investigational product in this patient population are excluded. The trial involves the drugs tc-5214 and placebo, and the eligibility criteria include provision of signed and dated informed consent before initiation of any study-related procedures.",
    "This sample is for a phase 3 clinical trial for the treatment of ulcerative colitis using the drug mesalazine. The eligibility criteria for participants include having active ulcerative colitis confirmed by endoscopy and histology, a Clinical Activity Index (CAI) greater than 4 and an Endoscopic Index (EI) greater than or equal to 4. Participants must not have Crohn's disease, toxic megacolon, colorectal cancer, or other serious secondary diseases. They must also not have taken immunosuppressants within 3 months or corticosteroids within 1 month prior to baseline. Additionally, their serum creatinine and transaminase levels must be within certain limits.",
    "The sample is a phase 3 trial for contraception. The diseases being studied are only related to contraception. The icd-10 codes associated with the diseases are Z92.0, Z30.012, and Z30.09. The drugs being tested are flexible (extended) treatment of ee20/drsp (yaz, bay86-5300), fixed extended treatment of ee20/drsp (yaz, bay86-5300), and standard 24+4 treatment of ee20/drsp (yaz, bay86-5300). The eligibility criteria for the trial include healthy women who desire contraception and smokers who are 30 years old or younger. The exclusion criteria include those who have a contraindication against the use of hormonal contraceptives.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for kidney transplantation. The diseases column lists only one disease, which is kidney transplantation. The icdcodes column contains a list of ICD-10 codes related to the disease. The drugs column lists the drugs used in the trial, which include mycophenolate mofetil, anti-IL-2R, methylprednisolone, and cyclosporine. The criteria column contains the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria include being an adult aged 18-75 years, receiving a first donor kidney, eligible for immunosuppressive treatment, and eligible for oral treatment from the first day post-transplantation. The exclusion criteria include receiving a second or subsequent kidney transplant, having a history of malignancy in the last 5 years (except for successfully treated squamous cell or basal cell cancer and cervical cancer in situ), and having active hepatitis B and/or hepatitis C or HIV infection.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The eligibility criteria include having histologically confirmed adenocarcinoma of the pancreas, being at stage T1-4, N0-1 (stage I-IVA), and having no M1 or NX staging. The primary tumor of the pancreas (pancreatic head, neck, uncinate process, or body/tail) and maximum diameter/dimension and tumor status at surgical margin must be known. Prior potentially curative gross resection within 3-8 weeks before the study is required, and non-adenocarcinomas, adenosquamous carcinomas, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct carcinoma, or ampullary carcinoma are not allowed. Patients must be 18 years or older, have a Karnofsky performance status of 60-100%, and a post-resection CA-19-9 level required. Other eligibility criteria include meeting certain hematopoietic, hepatic, renal, and other health requirements, not having significant nausea or vomiting, and being able to maintain adequate nutrition. Patients must not have had prior malignancy within the past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix, and must not be pregnant. Fertile patients must use effective contraception. Prior concurrent therapy with biologic therapy, chemotherapy, endocrine therapy, radiotherapy, or surgery is not allowed.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients with a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features. The trial excludes patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder not otherwise specified. Patients with other DSM-IV TR Axis I or Axis II disorder are also ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening. The trial involves the use of geodon (ziprasidone) and placebo as drugs. The icd-10 codes associated with the disease are [\"['F31.81', 'F31.89', 'F31.9', 'F25.0', 'F31.0', 'F31.31', 'F31.32']\"].",
    "The sample is a phase 3 clinical trial for the treatment of interstitial cystitis using the drug adalimumab. The trial is open to both male and female participants between the ages of 18 and 65 who have been previously diagnosed with interstitial cystitis and are currently experiencing symptoms such as urinary urgency, frequency, or pain for more than 6 months. Participants must also be post-menopausal or surgically sterile or willing to use an adequate form of birth control, and must be capable of voiding independently. The trial has a list of exclusion criteria, including having symptoms that are presently relieved on other medications for interstitial cystitis, having a body mass index (BMI) of >39 kg/m2, and having uncontrolled hypertension. Participants must also not have had previous exposure to Humira\u00ae (adalimumab) and must not have taken investigational medication within 30 days of screening. The trial requires participants to provide informed consent and comply with protocol requirements.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of non-small-cell lung carcinoma. The trial involves the drugs kd019 and erlotinib. The eligibility criteria for the trial include having failed one or two previous courses of therapy, having no active brain metastasis (although treated non-active brain metastasis are acceptable), not having received an Epidermal Growth Factor Receptors inhibitor (such as Tarceva or Iressa) in the past, and having demonstrated progressive disease. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial that involves patients with a history of migraine disorders, heart disease, cerebrovascular accident, TIA (transient ischemic attack), vascular diseases, and peripheral vascular diseases. The trial includes the use of drugs such as telcagepant, acetaminophen/paracetamol, and placebos. The eligibility criteria for the trial include being 18 years or older with a history of migraine with or without aura and having stable coronary artery disease for 3 months or more. Exclusion criteria include being pregnant, having other pain syndromes that might interfere with study assessments, uncontrolled psychiatric conditions, dementia, or significant neurological disorders (other than migraine).",
    "This sample is for a phase 3 clinical trial for psoriasis. The trial is looking at the effectiveness of the drugs u0267 and vehicle. The eligibility criteria for the trial include being at least 12 years old, having mild to moderate plaque-type psoriasis, and being in good general health. Exclusion criteria include having a known allergy or adverse reaction to calcipotriene or other vitamin D analogs, a history of hypercalcemia or vitamin D toxicity, and having a diagnosis of generalized pustular or erythrodermic exfoliative psoriasis. Other exclusion criteria include having a serious skin disorder or chronic medical condition that is not well controlled, using non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment, and using topical therapies that have a known beneficial effect on psoriasis within two weeks of enrollment. Additionally, participants cannot have used systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment, used any investigational therapy within four weeks of enrollment, or be pregnant, breastfeeding, or sexually active women of childbearing potential who are not practicing an acceptable method of birth control.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial involves the use of the drug ziprasidone at doses of 80-160 mg/d and 160 mg/d, as well as a placebo. The eligibility criteria include having a diagnosis of schizophrenia or schizoaffective disorder, being between the ages of 18-65, having been treated with ziprasidone at a dose of 160 mg/d for at least 3 weeks with adequate compliance, and having a score of 4 or greater on any of the 7 items of the PANSS Positive Symptom Subscale. The trial also has exclusion criteria, such as past or current intolerance of ziprasidone side effects, significant cardiac disease, and alcohol or substance dependence within the past 12 months. Women who are pregnant or breastfeeding are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for chronic kidney disease. The trial includes patients with an eGFR between 30-60 ml/min, who are over 18 years old, have no known allergies or adverse effects from NAC, no scheduled radio-contrast procedures, and are not taking any medications known to affect creatinine secretion. The trial involves two drugs, n-acetylcysteine and placebo. The diseases are listed as 'chronic kidney disease' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for amyotrophic lateral sclerosis (ALS) with the drug MCI-186 and a placebo. The trial has a list of inclusion and exclusion criteria for patients, including not having complications such as Parkinson's disease or renal failure, not being pregnant or lactating, and not participating in other clinical trials. Patients who completed drug administration without discontinuation in a previous confirmatory study are eligible to participate. The trial also includes a list of disease names and ICD-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of diffuse large b-cell lymphoma and follicular nhl grade 3b. The trial involves the use of the drug rituximab and requires patients to have undergone 4 to 8 cycles of R-CHOP/like treatment and achieved CR or CRu. Patients must also have an ECOG score of 0.1 or 2, be over 18 years old, and have a negative pregnancy test. Men must agree not to father a child during the therapy. Exclusion criteria include transformed lymphoma, secondary malignancy, evidence of CNS involvement, significant cardiac disease, creatinine levels above 2.0 mg/dl, and positive HIV or Hepatitis status.",
    "The sample is a phase 3 clinical trial for patients with fever and sepsis. The trial includes a list of icd-10 codes for the diseases, a list of drug names, and eligibility criteria for inclusion and exclusion. Inclusion criteria include being over 18 years old, hospitalized to an internal medicine department or ICU, having a body temperature over 38 degrees Celsius, and meeting one or more of the following conditions: a pulse rate over 90 bpm, a respiratory rate over 20/min or PaCO2<32 mmHg, or a WBC count over 12000 or under 4000. Patients must also have hypotension or disturbed end-organ perfusion (confusion, oliguria, lactic acidosis, etc.). Exclusion criteria include acute or chronic liver disease, acute CNS disorder, current isoniazid treatment, alcoholism, active malignancy, pregnancy, and TPN or PPN.",
    "This sample is for a phase 3 clinical trial for constipation. The trial is testing the drug \"n-methylnaltrexone bromide (moa-728)\" on adult outpatients who have opioid-induced constipation and chronic non-malignant pain. The patients must be taking oral, transdermal, intravenous, or subcutaneous opioids and be willing to discontinue all pre-study laxative therapy and use only study permitted rescue laxatives. The inclusion criteria also includes a list of specific requirements. The exclusion criteria includes patients with a history of chronic constipation before the initiation of opioid therapy, other GI disorders known to affect bowel transit, and women who are pregnant, breastfeeding, or plan to become pregnant.",
    "The sample is a phase 3 clinical trial for patients with chronic hepatitis C and HIV infections. The trial is testing the effectiveness of peg interferon plus ribavirin as a treatment. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The inclusion criteria include having hepatitis C genotype 1 infection, detectable plasma HCV-RNA, chronic liver disease consistent with CHC infection, and other specific requirements. The exclusion criteria include previous use of certain therapies, evidence of active hepatitis B infection, and abnormal bloodwork.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial includes patients who have completed a previous study or have chronic pain for at least 3 months associated with certain conditions. The drug being tested is hydrocodone er. The eligibility criteria include being able to self-administer the drug, complying with study restrictions, and returning for scheduled visits. Exclusion criteria include substance abuse, pregnancy, active malignancy, and certain medical conditions. The trial requires written informed consent and a negative pregnancy test for women of childbearing potential.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone palmitate. The trial includes patients who have signed an informed consent and meet the diagnostic criteria for schizophrenia. Female patients must be postmenopausal for at least 2 years or have a negative pregnancy test result at screening. The trial has inclusion and exclusion criteria, including no primary, active diagnosis other than schizophrenia, no psychiatric inpatient hospitalization for relapse of symptoms of schizophrenia in the past 90 days, no change in antipsychotic medication in the past 45 days, no active substance dependence within 3 months, no history of treatment resistance, and no history of concurrent significant or unstable diseases such as heart, lung, or liver diseases. Patients must also be able to perform study requirements such as answering questionnaires.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease. The trial involves testing the effectiveness of three drugs - bapineuzumab 0.5 mg/kg, placebo control, and bapineuzumab 1.0 m/kg. The eligibility criteria for the trial include a diagnosis of probable AD, age between 50 and 89, a Mini-Mental Status Exam score of 16-26, and a brain MRI scan consistent with the diagnosis of AD. The patient must also have stable doses of medications, and the caregiver must be able to attend all clinic visits. The exclusion criteria include significant neurological disease other than AD, major psychiatric disorder, significant systemic illness, history of stroke or seizure, smoking more than 20 cigarettes per day, and use of certain medications. Women of childbearing potential and those with pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body are also excluded.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who have essential hypertension and meet certain blood pressure criteria. Patients must be able to stop taking their current antihypertensive drugs without risk, and cannot be taking three or more antihypertensive drugs at the time of signing the informed consent form. Patients with known or suspected secondary hypertension, clinically relevant cardiac arrhythmia, congestive heart failure with NYHA functional class III-IV, recent cardiovascular events, or a history of stroke or transient ischaemic attack within the last 6 months are excluded from the trial. Patients with a history of sudden deterioration of renal function with ARBs or ACE inhibitors, post-renal transplant or post-nephrectomy, or who have previously experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors are also excluded. Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs, as well as those with hepatic and/or renal dysfunction, and pre-menopausal women who are nursing or pregnant are also excluded. The trial involves the use of two drugs, telmisartan and amlodipine, or telmisartan alone.",
    "The sample is a phase 3 clinical trial that involves patients with dyslipidemia, coronary heart disease, and mixed dyslipidemia. The trial will test the effectiveness of the drugs abt-335, simvastatin, and placebo. The eligibility criteria for the trial include having mixed dyslipidemia and agreeing to use adequate birth control methods and adhere to the American Heart Association diet. Exclusion criteria include having unstable medical conditions, taking certain medications, being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for non-small cell lung carcinoma. The trial includes patients with Stage IIIB (with effusion) or Stage IV NSCLC of any histology who have not received prior chemotherapy and have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. The trial involves two drugs, nexavar (sorafenib, bay43-9006) + carboplatin + paclitaxel and carboplatin plus paclitaxel. The eligibility criteria include adequate bone marrow, liver and renal function, life expectancy of at least 12 weeks, and age greater than or equal to 18 years. The exclusion criteria include prior systemic anti-cancer therapy, known brain metastasis, pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug, thrombotic or embolic events including Transient ischemic attack (TIA) within the past 6 months, uncontrolled hypertension, any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug, major surgery within 4 weeks, and evidence or history of bleeding diathesis or coagulopathy.",
    "The sample is a phase 3 clinical trial for breast cancer, cardiac toxicity, and perioperative/postoperative complications. The trial requires patients to have histologically confirmed invasive breast cancer that is HER2-negative and meet certain criteria related to tumor size and lymph node involvement. Patients must also meet certain eligibility criteria related to their health status, including having a normal LVEF and no evidence of metastatic disease. The trial involves the use of cyclophosphamide, docetaxel, epirubicin hydrochloride, and fluorouracil. Patients must not have received prior neoadjuvant endocrine therapy, chemotherapy, or radiotherapy, and must not be taking certain medications or have certain medical conditions.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, which are aripiprazole+ adt and placebo+ adt. The eligibility criteria for the trial includes men and women between the ages of 18-65 who have experienced single or recurrent, non-psychotic episodes of Major Depressive Disorder for at least 8 weeks. Additionally, participants must have a treatment history of an inadequate response to at least one and no more than three adequate antidepressant trials.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have had the disease for at least 1 year and are at least 18 years old. Patients must have been receiving oral antihyperglycemic medications for at least 3 months prior to the study and have been on stable doses of at least 2 of the following medications: Metformin, Sulfonylureas, Dipeptidyl peptidase-intravenous (DPP-IV) inhibitors, or Thiazolidinediones (TZDs). Patients must also have a hemoglobin A1c (HbA1c) level between 7.5% and 10.0%, a body mass index (BMI) between 25 and 45 kilograms per square meter (kg/m2), and must not have used insulin therapy (outside of pregnancy) in the past 2 years, except for short-term treatment of acute conditions. Patients must not have taken any glucose-lowering medications not included in the inclusion criteria in the past 3 months before the study. Patients must also not have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study or be currently diagnosed as having hypoglycemia unawareness. Patients with a history of renal transplantation or currently receiving renal dialysis or creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dL) or obvious clinical signs or symptoms, or laboratory evidence, of liver disease are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder using the drug Lamictal. The trial is for male and female subjects between the ages of 10 and 17 who are currently experiencing a manic/hypomanic, depressed, or mixed mood episode and have a stable treatment regimen. The subjects must be living with their custodial parent(s) or legal guardian(s) and have daily contact with them. The trial has a list of inclusion and exclusion criteria, including the absence of certain disorders, a history of rash related to Lamictal use, and a negative test for illicit drug use. The trial also excludes subjects who pose a current homicidal or serious suicidal risk or have made a suicide attempt within the past twelve months.",
    "The sample is a phase 3 clinical trial for the treatment of venous thrombosis. The trial involves the use of drugs such as enoxaparin, warfarin, and apixaban, as well as placebos for these drugs. The eligibility criteria for the trial include being 18 years or older and having a clinical diagnosis of DVT or PE. However, individuals with contraindications for enoxaparin or warfarin, active bleeding or high risk for serious bleeding, short life expectancy, uncontrolled high blood pressure, or significantly impaired kidney or liver function are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of migraine. The trial involves the use of drugs such as telcagepant and rizatriptan, as well as placebos. The eligibility criteria for the trial include having a history of migraine, being in good health, and using acceptable contraception for females of childbearing potential. Exclusion criteria include having a history of stroke, heart disease, or other significant cardiovascular diseases, as well as major depression or other pain syndromes that may interfere with the study. The trial also excludes individuals with a history of cancer within the last 5 years.",
    "The sample is a phase 3 clinical trial for the treatment of ulcerative colitis using the drug mesalamin. The trial is open to male and non-pregnant, non-lactating females who are 18 years of age or older and have a documented diagnosis of UC with disease extending at least 15 cm from the anal verge. The trial requires active UC defined by a modified UC-DAI score of 4-10 with sigmoidoscopy component score \u2265 2 and rectal bleeding component score \u2265 1. The trial has a list of exclusion criteria, including severe UC, previous failed treatment with a mesalazine dose of > 2.0 g/day, and treatment with systemic or rectal steroids within 4 weeks prior to randomization. The trial also requires written informed consent from participants.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The eligibility criteria include being between the ages of 55 and 90, having a diagnosis of probable Alzheimer's disease, and having a study partner who can accompany the participant to all visits. Exclusion criteria include having non-Alzheimer's dementia, being a female of child-bearing potential, and having a history of clinically significant stroke or major psychiatric disorder. The trial involves the use of the drug valproate and a placebo, and participants must be able to ingest oral medication. The trial also includes a list of excluded medications and medical contraindications.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial involves the use of three drugs: bifeprunox, placebo, and quetiapine. The eligibility criteria for the trial include having a primary diagnosis of schizophrenia, experiencing clinically significant symptoms, and having medication that remained stable for 8 weeks prior to screening. The trial also has exclusion criteria, such as being at significant risk of suicide, being treatment resistant, and having a current or past history of substance abuse.",
    "The sample is a phase 3 clinical trial for amyotrophic lateral sclerosis. The trial includes patients between the ages of 18-80 who are legal residents of the United States or Canada and have a history of a chronic onset of a progressive motor weakness of less than 24 months duration. Patients must fulfill El Escorial criteria of probable or definite ALS and have a manual muscle testing score of less than 8 and a forced vital capacity by pulmonary function testing of at least 60% predicted. Patients must also meet certain exclusion criteria, such as not having any clinically significant abnormalities on the prestudy laboratory evaluation, physical examination, ECG, chest x-ray or ophthalmologic exam, and not having any clinically significant medical condition that would compromise their safety. The trial involves the use of insulin-like growth factor, type 1 and a placebo, and patients must be able to comply with protocol requirements and provide written informed consent.",
    "The sample is a phase 3 clinical trial for the drug Sativex\u00ae on patients with peripheral neuropathic pain. The trial includes patients who have previously participated in a GW clinical study and have shown tolerability to the study medication. The inclusion criteria also require patients to be expected to gain clinical benefit from receiving Sativex\u00ae therapy and to be willing to comply with all study requirements. The exclusion criteria include a history of schizophrenia, substance abuse, epilepsy, and hypersensitivity to cannabinoids. Other exclusion criteria include significant psychiatric disorders, cardiac dysfunction, impaired renal or hepatic function, and pregnancy or lactation. The trial also requires patients to use effective contraception if they or their partner are of childbearing potential.",
    "The sample is a record of a clinical trial in phase 3, which involves patients with both Heterozygous Familial Hypercholesterolemia (HeFH) and Coronary Artery Disease (CAD). The trial is testing the effectiveness of two drugs, mipomersen sodium and placebo, in reducing cholesterol levels. The eligibility criteria for the trial include a stable lipid-lowering therapy for 12 weeks, being on maximally tolerated statin therapy with at least 1 statin at a dose greater than zero, per Investigator judgment, a stable low-fat diet for 8 weeks, and a stable weight for 6 weeks. The exclusion criteria include significant health problems in recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, orthostatic hypotension, uncontrolled hypertension, blood disorders, liver disease, cancer, or digestive problems, and receiving apheresis treatment or last apheresis treatment within 8 weeks.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of HIV infection. The trial involves the use of three drugs: efavirenz, tenofovir, and abacavir/lamivudine. The eligibility criteria for participants include having documented HIV-1 infection, not having received more than 14 days of prior treatment with antiretroviral drugs, meeting laboratory test criteria, and being able to take study medications as directed and complete all study visits and evaluations during the 48 week study. Women of childbearing potential must abstain from sexual intercourse or use acceptable contraception. The exclusion criteria include being enrolled in other HIV treatment studies, and being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for the treatment of hyperlipidemia. The trial involves the drug ezetimibe (+) simvastatin. The eligibility criteria for the trial include patients who voluntarily agree to participate and have no contraindications for the use of statins. Exclusion criteria include hypersensitivity to any of the active ingredients, increased serum hepatic enzymes, severe hepatic insufficiency, and pregnancy or potential pregnancy in women.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have no evidence of metastatic disease and overexpression of HER2 receptor. The trial involves the use of parenteral chemotherapy and eligibility criteria include receiving or scheduled to receive neoadjuvant or adjuvant chemotherapy, hormone receptor status known, and adequate bone marrow, hepatic, and renal function. Patients must also meet certain patient characteristics such as having an ECOG performance status of 0-1 and no clinically significant cardiac abnormalities. Prior concurrent therapy is not allowed, but concurrent radiotherapy is allowed. The sample includes detailed disease and patient characteristics, as well as prior concurrent therapy information.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who have completed previous REQUIP studies or at least 12 weeks of randomized treatment in study 169. Patients must not have a break in medication between completing the feeder study and beginning treatment in study 248. Women of child-bearing potential must be practicing a clinically accepted method of contraception during the study and for one month following completion of the study. Patients must provide written informed consent and be willing and able to comply with study procedures. Exclusion criteria include ongoing clinically significant adverse events, severe conditions other than Parkinson's disease, clinically significant abnormalities in laboratory or ECG tests, severe dizziness or fainting due to postural hypotension on standing, withdrawal or change in dose of certain medications within 7 days prior to enrollment, pregnancy or breastfeeding, and use of an investigational drug throughout the treatment period.",
    "The sample is a phase 3 clinical trial for patients with relapsed or refractory indolent non-Hodgkin's lymphoma, including follicular lymphoma grade I and II. The trial is testing the effectiveness of rituximab and pixantrone (bbr 2778) as treatments. The inclusion criteria require patients to have had 1-5 prior treatments with either radiation, chemotherapy, or rituximab and to be presenting with an episode of progressive disease. The exclusion criteria include patients who failed to respond to previous rituximab treatment or relapsed within 6 months of the first rituximab infusion, as well as patients known to have an allergic reaction to rituximab or murine derived proteins. The icd-10 codes for the diseases being studied are also provided.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, secondary hyperparathyroidism and chronic kidney disease, and includes a list of corresponding ICD-10 codes. The trial involves two drugs, cinacalcet and placebo. The eligibility criteria for the trial include being at least 18 years old, having a PTH level of at least 300 pg/mL, a serum calcium level of at least 8.4mg/dL, and a Ca x P level of at least 45 mg2*/dL2. The exclusion criteria include recent parathyroidectomy or cinacalcet therapy, recent hospitalization for certain conditions, history of seizure, scheduled kidney transplant, and anticipated parathyroidectomy.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, Hodgkin's lymphoma), the ICD-10 codes associated with the disease, the drugs being tested (panobinostat and placebo), and the eligibility criteria for participants. The eligibility criteria include factors such as age, history of confirmed classical HL, complete response to treatment, and risk for relapse. The exclusion criteria include prior treatment with certain therapies and failure to recover from reversible toxicity due to prior therapies.",
    "The sample is a phase 3 trial for hypertension. The trial includes patients who have been treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1 and have systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1. The trial excludes patients with a history of angina pectoris that has not been stabilized in the past 6 weeks, clinically significant abnormal lab results or diseases, myocardial infarction within the past 6 months, and stroke in the past 6 months. The drug being tested is mk0954, losartan potassium, and the duration of treatment is 12 weeks.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking for patients who have nonmetastatic, unilateral adenocarcinoma of the breast, with no clinically or radiologically suspicious metastases, and no positive sentinel lymph nodes. The patients must have undergone complete surgical resection within the past 42 days, with at least 8 lymph nodes removed, and the tumor must be at least 1 cm with no residual disease. Patients must also have at least one factor of poor prognosis, such as a tumor greater than 2 cm, hormone receptor negative tumor, grade II or III, or be 35 years old or under. The trial is looking for female patients between the ages of 18 and 65, with a WHO performance status of 0-1, and a life expectancy that is not specified. Patients must also meet certain hematopoietic, hepatic, renal, pulmonary, and other criteria. The trial is not looking for patients who have had prior chemotherapy, radiotherapy, or anticancer hormone therapy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the drugs vildagliptin and gliclazide. The eligibility criteria for the trial include not currently being on drug therapy for type 2 diabetes, having a body mass index (BMI) between 22 and 45, and meeting certain blood glucose criteria. The exclusion criteria include pregnancy or lactation, having type 1 diabetes, evidence of significant diabetic complications or serious cardiovascular conditions, laboratory value abnormalities as defined by the protocol, and other protocol-defined exclusion criteria that may apply. The diseases associated with the trial are listed as 'diabetes mellitus, type 2' and the corresponding ICD-10 codes are also provided.",
    "The sample is from a phase 3 clinical trial for HIV and HIV infections. The trial involves the use of drugs such as stribild, atv, ritonavir, and ftc/tdf, as well as placebos for these drugs. The eligibility criteria for the trial include having a plasma HIV-1 RNA level of at least 5,000 copies/mL, not having used any approved or investigational antiretroviral drug before, having a normal electrocardiogram and adequate renal and hematologic function, and agreeing to use highly effective contraception methods. Exclusion criteria include having a new AIDS-defining condition, receiving treatment for hepatitis C, having decompensated cirrhosis, and having a history of malignancy within the past 5 years.",
    "The sample is a phase 3 clinical trial for contraception. The trial is for females who are generally healthy, under 18 years of age, and require contraception. The trial involves the insertion of a levonorgestrel intrauterine contraceptive system (LCS12). The inclusion criteria include having regular menstrual cycles without hormonal contraceptive use, suitable uterine conditions for the insertion of LCS12, and normal safety laboratory results. The exclusion criteria include known or suspected pregnancy, recent delivery or abortion, history of ectopic pregnancies, and various other conditions. The trial requires the subject to attend scheduled study visits and comply with study procedures.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The eligibility criteria include being between 18 and 65 years old, having a clinical diagnosis of schizophrenia according to the DSM-IV criteria, being dissatisfied with current antipsychotic treatment, and being able to read and write in English or French at a grade 7 proficiency level. Exclusion criteria include having substance/alcohol dependence or abuse, requiring treatment with another antipsychotic agent, having a history of idiopathic or drug-induced agranulocytosis, and having laboratory test results outside the reference range considered clinically significant. The trial is investigating the efficacy and safety of quetiapine fumarate extended-release as a monotherapy for at least 7 days prior to initiating treatment.",
    "The sample is a phase 3 clinical trial for the treatment of acute viral pharyngitis using the drugs ambroxol and placebo. The trial is open to both male and female patients between the ages of 18 and 65 who have a sore throat rated as at least severe on the VRS (PI) scale. Patients must also provide written informed consent and be compliant with the trial requirements. However, patients with symptoms of primarily bacterial pharyngitis or bacterial secondary infection, a white blood cell count exceeding 10?109/L, or a history of acute viral or bacterial pharyngitis in the past 4 weeks are not eligible to participate. Patients with broncho-motor disorders or concomitant diseases with relatively large quantities of secretion, known hypersensitivity to Ambroxol or to auxiliary substances contained in the tablet, previous and/or existing tumour condition, pregnancy and/or breast-feeding, alcohol and/or drug abuse, or simultaneous participation in another clinical trial are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes two drugs, linagliptine 5 mg and a combination of linagliptine 5 mg and pioglitazone 30 mg. The eligibility criteria for the trial include signed and dated written informed consent, completion of the entire treatment period of a previous trial, and exclusion of patients who meet the withdrawal criteria of the previous trial. Pre-menopausal women who are nursing or pregnant, or are of child-bearing potential and not practicing an acceptable method of birth control, are also excluded. Additionally, patients with alcohol or drug abuse within the past 3 months, or any other clinical condition that would not allow safe completion of the protocol and safe administration of the trial medication, are excluded.",
    "The sample is a phase 3 clinical trial for metastatic colorectal cancer. The trial includes patients who have not received previous therapy for metastatic colorectal disease but for whom FOLFIRI treatment is clinically indicated. The trial involves the use of drugs such as 5 fluorouracil, irinotecan, levo-leucovorin, sunitinib, and placebo. The eligibility criteria for the trial include confirmed colorectal adenocarcinoma with metastatic disease, adequate organ function, and no history of another primary cancer in the last 3 years. The exclusion criteria include a history of brain metastasis, spinal cord compression carcinomatous meningitis, or leptomeningeal disease, as well as previous full field radiotherapy within the last 4 weeks or limited field radiotherapy within 2 weeks of enrolling into the study.",
    "The sample is a phase 3 clinical trial for the treatment of macular degeneration using the drug ranibizumab. The trial is looking for men and women over the age of 50 with active primary or recurrent subfoveal CNV lesions secondary to AMD. The trial has specific inclusion and exclusion criteria, including a minimum visual acuity score and a maximum lesion size. Participants must be willing and able to attend all clinic visits and complete all study-related procedures. The trial is not open to individuals with a history of certain ocular or systemic treatments or surgeries, or with certain retinal conditions.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on macular degeneration, with a list of associated ICD-10 codes provided. The drug being tested is ranibizumab. The eligibility criteria for the trial are listed, including age requirements and specific characteristics of the macular degeneration being studied. The exclusion criteria are also listed, which include prior or concurrent treatments for subfoveal CNV, previous radiation therapy to the eye, head or neck, and a diagnosis of Type 1 or Type 2 Diabetes Mellitus.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of preservative-free tafluprost or vehicle and preservative-free timolol maleate. The eligibility criteria include a diagnosis of primary open-angle glaucoma, pigmentary glaucoma, capsular glaucoma/pseudoexfoliation, or ocular hypertension, stable use of ocular hypotensive medication for at least 30 days prior to screening, and willingness to discontinue all topical and/or systemic ocular hypotensive medication during the washout period. Participants must also have a best-corrected early treatment of diabetic retinopathy study (ETDRS) visual acuity of 20/80 or better in each eye, be willing and able to avoid wearing contact lenses, and self-administer or have an able person available on a daily basis to assist with administration of study medications. Exclusion criteria include mean IOP >36 mmHg in either eye at screening, history of any inflammatory ocular surface disease or a history of anterior or posterior uveitis in either eye within 6 months prior to screening, and history of retinal detachment, proliferative diabetic retinopathy, or any progressive retinal disease.",
    "This sample is a phase 3 clinical trial for patients with confirmed acute symptomatic proximal deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE). The trial includes a list of drugs, such as rivaroxaban (xarelto, bay59-7939), unfractionated heparin, and warfarin, and a list of diseases with their corresponding icd-10 codes. The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. Inclusion criteria include men and women who are 20 years of age or older, while exclusion criteria include factors such as thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT, and subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with moderate to severe COPD who are current or ex-smokers with a smoking history of at least 10 pack years. The trial also requires patients to have a qualifying FEV1 at Visit 2. The trial excludes patients with a history of asthma or high blood eosinophil count, concomitant pulmonary disease, lung lobectomy or lung volume reduction or lung transplantation, \u03b1-1 antitrypsin deficiency, and those who have had live attenuated vaccinations within 30 days prior to screening visit or during run-in period. Other protocol-defined inclusion/exclusion criteria may also apply. The trial involves several drugs, including nva237 50\u00b5g once daily, tiotropium 18\u00b5g once daily, flu/sal, and nva237 placebo + tiotropium placebo.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of insomnia. The icd-10 codes associated with the disease are listed as well. The trial involves two drugs, zolpidem tartrate sublingual tablet and placebo. The eligibility criteria for the trial include being an adult with a history of sleeplessness, while exclusion criteria include being allergic to the investigational drug or having any conditions or medications that may interfere with the study drug evaluation.",
    "The sample is a phase 3 clinical trial for patients with myocardial ischemia or acute coronary syndrome. The trial involves the use of two drugs, eptifibatide (integrilin) and placebo. The eligibility criteria include being willing and able to give informed consent, planning to undergo an invasive strategy after receiving the study drug, experiencing symptoms of cardiac ischemia at rest, and meeting certain age and medical history requirements. Exclusion criteria include pregnancy, recent renal dialysis, certain serious illnesses or conditions, history of certain hematologic problems, and recent therapy with certain related drugs.",
    "This sample is for a phase 3 clinical trial for the treatment of pneumonia using the drug prednisone. The trial is looking for patients who have clinical symptoms of community-acquired pneumonia, such as fever, cough, sputum, pleural pain, and dyspnea, as well as radiological symptoms of pneumonia. Patients who have conditions that require corticosteroid therapy, are pregnant or lactating, have malignancy, are immune-compromised, or have been pre-treated with macrolide for more than 24 hours are excluded from the trial. The sample also includes the ICD-10 codes for the diseases being studied.",
    "The sample is a phase 3 clinical trial for the treatment of retinal vein occlusion using the drug ranibizumab. The trial includes patients who have completed 12 months in previous trials and are within 90 days of enrollment in the HORIZON extension study. The eligibility criteria include being at least 18 years old and providing informed consent. Exclusion criteria include pregnancy or lactation, inadequate contraception, any condition that may pose a hazard to the subject, inability to comply with study procedures, and participation in another medical investigation or trial. The diseases are listed as 'retinal vein occlusion' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes, chronic kidney disease, hyperlipidemia, and microalbuminuria or proteinuria less than 3.5 g/d. The trial is testing the effectiveness of extended release niacin as a treatment option. The inclusion criteria require patients to have a diagnosis of type 2 diabetes, chronic kidney disease stage 2 or 3, and hyperlipidemia currently treated with a \"statin\" drug. The exclusion criteria include not meeting the inclusion criteria, elevated transaminases, unstable type 2 diabetes, and known seropositivity for Hepatitis B, C, or HIV, among others. Patients must also be over 18 years old and not pregnant or nursing.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are aged 40 or older, have stable moderate to severe COPD, and are current or ex-smokers of at least 10 pack-years. The trial involves the use of aclidinium bromide and placebo drugs. The eligibility criteria include specific lung function measurements and exclude patients with asthma or certain respiratory and cardiovascular conditions. Patients who have just started or finished pulmonary rehabilitation within 3 months prior to the screening visit are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on HIV infections and the drug being tested is lopinavir/ritonavir. The eligibility criteria for participants include being over 18 years old, having confirmed HIV-1 seropositivity, and having stable antiretroviral treatment for at least 3 months. Participants must also have an HIV-1 ARN load of less than 50 copies/mL for at least 6 months, and must have no history of treatment failure or opportunistic infections in the previous 6 months. The exclusion criteria include low levels of neutrophils, hemoglobin, or platelets, high levels of creatinine, SGOT, or SGPT, current IL-2 treatment, HBV infection treated or not by lamivudine or tenofovir, pregnancy or feeding, and enrollment in another study not compliant with KALESOLO Study group assignment.",
    "The sample is a phase 3 clinical trial for type 2 diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including a placebo. The eligibility criteria for the trial include having type 2 diabetes mellitus, being drug na\u00efve or willing to wash-out from existing oral therapy, having a BMI between 25 to 48 kg/m2, having an HbA1c level between 7.0% to 10.0%, and being between the ages of 18 to 75 years. The exclusion criteria include currently being on 3 or more oral antidiabetic drugs or insulin and having type 1 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes and uncontrolled hypertension. The trial is testing the effectiveness of dapagliflozin and a placebo-matching dapagliflozin. The eligibility criteria include being between the ages of 18 and 89, having a hemoglobin A1c between 7% and 10.5%, and having a seated systolic blood pressure of 140 to 165 mm Hg and seated diastolic blood pressure 85 to 105 mm Hg. Participants must also have a stable dose of oral antidiabetic agent or insulin and a stable dose of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker. Exclusion criteria include a history of diabetic ketoacidosis or hyperosmolar nonketotic coma, myocardial infarction, and unstable congestive heart disease.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial involves the use of drugs such as bevacizumab, erlotinib hcl, and placebo. The eligibility criteria for the trial include having confirmed NSCLC, clinical or radiographic progression during or after first-line chemotherapy or chemoradiotherapy for NSCLC, and an ECOG performance status of 0, 1, or 2. Exclusion criteria include having squamous cell carcinoma, prior treatment with an investigational or marketed inhibitor of the Epidermal Growth Factor Receptor (EGFR) pathway or anti-angiogenesis agent, and systemic chemotherapy, radiotherapy, or investigational treatment within 28 days prior to randomization.",
    "The sample is a phase 3 clinical trial for the treatment of generalized anxiety disorder. The trial includes patients who have a primary diagnosis of generalized anxiety disorder according to the DSM-IV-TR criteria and have a Hamilton Anxiety Scale total score of at least 20, with a score of at least 2 on both item 1 (anxious mood) and item 2 (tension). The trial involves the use of three drugs: placebo, vortioxetine, and duloxetine. The eligibility criteria include exclusion of patients who have received any investigational compound within 30 days before screening, have a history of certain psychiatric disorders, have a known sensitivity to duloxetine, or are taking excluded medications. The trial also excludes patients who have a significant risk of suicide, have previously failed to respond to adequate treatment with selective serotonin reuptake inhibitor and/or serotonin-norepinephrine reuptake inhibitors, or have received electroconvulsive therapy within 6 months prior to screening. The trial also excludes patients who have a clinically significant unstable illness or have laboratory values outside the normal range.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs ipragliflozin and placebo. The eligibility criteria for the trial include being a type 2 diabetic patient for at least 12 weeks, having an HbA1c value between 7.0 and 10.0%, having a body mass index (BMI) between 20.0 and 45.0 kg/m2, and being able to safely discontinue currently taking hypoglycemic agents during treatment. Exclusion criteria include being a type 1 diabetes mellitus patient, having serum creatinine levels above the upper limit of normal, having proteinuria (albumin/creatinine ratio > 300mg/g), having dysuria and/or urinary tract infection, genital infection, having significant renal, hepatic or cardiovascular diseases, and having severe gastrointestinal diseases.",
    "The sample is a phase 3 clinical trial for non-CF bronchiectasis. The trial involves the use of the drugs azli and placebo. The eligibility criteria for the trial include being 18 years or older, having chronic sputum production on most days, and a positive sputum culture for gram-negative organisms. Exclusion criteria include a history of CF, hospitalization within 14 days prior to joining the study, previous exposure to AZLI, pregnancy or breastfeeding, and other serious medical conditions. The trial also requires participants to meet lung, liver, and kidney function requirements.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial includes patients with acute hepatitis C who meet certain eligibility criteria, such as having ALT levels over 3x normal values and a clear history of exposure within 2 months prior to diagnosis. Patients without chronic liver disease, HBsAg negative, and meeting certain blood and medical criteria are also eligible. The trial excludes patients with co-infection with hepatitis B, liver cirrhosis, and other medical conditions. Patients must also provide signed informed consent and use effective contraception during the treatment period. The trial aims to test the effectiveness of pegylated interferon alpha2a as a treatment for hepatitis C.",
    "The sample is a phase 3 clinical trial for the treatment of autism using the drug paliperidone er. The trial is for males and females between the ages of 12 and 21 who have a DSM-IV-TR diagnosis of autism and are outpatient. The inclusion criteria include being able to swallow pills, being antipsychotic medication-free for at least 2 weeks, having a score of 4 or more on the Clinical Global Impressions Severity Scale, having a score of 18 or higher on the Aberrant Behavior Checklist Irritability Scale, having a mental age of 18 months or greater based on testing, and being in good physical health. The exclusion criteria include having Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise Specified (PDD NOS), Rett's Disorder, childhood disintegrative disorder, schizophrenia, bipolar disorder, Fragile X Syndrome, Tuberous Sclerosis, having a significant medical condition, having an active seizure disorder, being pregnant, having evidence of a prior adequate trial of paliperidone ER, having a history of neuroleptic malignant syndrome, and being hypersensitive to paliperidone ER. The icd-10 code for autism is Z13.41.",
    "The sample is a phase 3 clinical trial for essential hypertension. The trial includes patients with a mean sitting clinic systolic blood pressure between 160 and 190 mm Hg. The trial drugs include azilsartan medoxomil and chlorthalidone, as well as olmesartan medoxomil and hydrochlorothiazide. The eligibility criteria include having clinical laboratory test results within the reference range, being willing to discontinue current antihypertensive medications, and not having any serious diseases or conditions that would compromise safety. The exclusion criteria include having a mean sitting clinic diastolic blood pressure greater than 119 mm Hg, having a recent history of myocardial infarction or other serious conditions, and having a history of drug or alcohol abuse.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the disease hypercholesterolemia. The trial includes a list of icd-10 codes for the disease and a list of drugs that will be used in the trial. The eligibility criteria for the trial are also provided, including inclusion criteria such as having a cholesterol level of 130 mg/dL or greater and being at moderate high risk or high risk for coronary heart disease, and exclusion criteria such as having an allergy to the drugs being used or weighing less than 100 lbs.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, chronic obstructive. The trial involves the drug salmeterol 50mcg/ fluticasone propionate 500mcg. The eligibility criteria for the trial include patients with COPD and FEV1 <60% of predicted normal and baseline (pre-bronchodilator) FEV1/FVC ratio <70%, as well as current or ex-smokers with a smoking history of at least 10 pack-years. The exclusion criteria include a diagnosis of other respiratory disorders (including asthma) and a requirement for long term oxygen therapy. The icd-10 codes associated with the disease are J44.9, J44.1, and J44.0.",
    "The sample is a phase 3 clinical trial for colorectal neoplasms. The trial involves laparoscopic colorectal resection and the use of cefmetazole and kanamycin/metronidazole drugs. The eligibility criteria for the trial include having colorectal tumor (cancer, adenoma, and suspected cases) and not having certain conditions such as ECOG Performance Status >=2, age less than 20, any organ dysfunction, ileus, preoperative infectious disease, antibiotic or steroid administration before surgery, neo-adjuvant radiation and/or chemo therapy, severe diabetes mellitus, pregnancy/lactational woman, and severe allergy.",
    "The sample is a record of a clinical trial in phase 3 for renal transplantation. The diseases involved are listed as 'renal transplantation' and are associated with a list of ICD-10 codes. The drugs being tested are 'enteric-coated mycophenolate sodium (ec-mps)' and 'prednisone'. The eligibility criteria for the trial are listed under 'criteria', including inclusion criteria such as primary donor kidney transplant and a panel reactive antibody (PRA) of less than or equal to 20%, and exclusion criteria such as multi-organ transplantation and non-compatible donors. The sample also notes that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of idiopathic Parkinson's disease. The trial involves the drug rotigotine and the eligibility criteria includes subjects who have completed treatment in one of the SP824, SP825, or SP826 trials. The exclusion criteria includes subjects who had an ongoing serious adverse event from the previous OLE trial that was assessed as related to study medication. The icd-10 code for idiopathic Parkinson's disease is G20.",
    "The sample is a phase 3 clinical trial for patients with non-small cell lung cancer and metastases. The trial is testing the effectiveness of the drug lonafarnib (sarasar). The eligibility criteria include being 18 years or older, having an ECOG performance status of 0 to 1, and meeting certain laboratory requirements. Patients must also have no prior chemotherapy for NSCLC and cannot have bone metastases as the only site of disease. The trial excludes patients who have had prior surgery or radiation therapy within the last 2 weeks, are pregnant or nursing, have significant QTc prolongation at baseline, or have medical conditions that would interfere with taking oral medications.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of fibromyalgia. The trial includes patients who meet the ACR criteria for fibromyalgia and have a score of 40 mm or higher on the Pain Visual Analog Scale, as well as an average score of 4 or higher on 4 daily pain diaries. Patients with other severe pain conditions, severe depression, or taking excluded medications are excluded from the trial. The trial involves the use of pregabalin and a placebo. The diseases column lists only fibromyalgia, and the icdcodes column lists the ICD-10 code for fibromyalgia (M79.7).",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis. The trial includes participants who have been diagnosed with plaque-type psoriasis for at least 6 months and have a Psoriasis Area Severity Index (PASI) score of 12 or higher. The trial will test the effectiveness of two drugs, placebo and infliximab, on participants who are candidates for systemic treatment of psoriasis. The eligibility criteria include having a body weight of 80 kilograms or less, using adequate birth control measures, and not having received previous treatment with infliximab or any biologic treatment within the previous 3 months. The exclusion criteria include having nonplaque forms of psoriasis, being pregnant or nursing, and having used any investigational drug within the previous 4 weeks or 5 times the half-life of the investigational agent, whichever is longer.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of open-angle glaucoma using the drug memantine. The trial includes patients with glaucoma damage on examination of visual field and optic disc, who also have good visual acuity with glasses if needed. The diseases are listed as 'open-angle glaucoma' and the corresponding ICD-10 codes are provided. The eligibility criteria for the trial are also listed under the 'criteria' column.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The trial is looking at the effectiveness of rasagiline mesylate compared to a placebo. The trial is open to both men and women who are 35 years or older and have been diagnosed with Parkinson's disease based on at least two of the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without any other known or suspected cause of parkinsonism. The trial excludes subjects with unstable systemic medical problems or clinically significant malignancy, with particular attention to clinically significant or unstable vascular disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease psoriasis, which is identified in the 'diseases' field. The 'icdcodes' field lists the ICD-10 codes associated with psoriasis. The trial involves two drugs, etanercept and placebo, which are listed in the 'drugs' field. The 'criteria' field outlines the eligibility criteria for patients participating in the trial, including restrictions on certain psoriasis medications during the study.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial is looking for subjects who have well-characterized epilepsy according to the 1989 International League Against Epilepsy classification and who are currently receiving Levetiracetam (LEV) at the recommended therapeutic dose. The trial is specifically looking for subjects who the investigator expects will benefit from LEV but for whom the investigator has decided to discontinue due to nonpsychotic behavioral side effects following the introduction of LEV. The trial is also looking for female subjects without childbearing potential or female subjects with childbearing potential who use a medically accepted contraceptive method. The trial has a list of inclusion and exclusion criteria that must be met for subjects to participate.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus, hypercholesterolemia, and pre-diabetes. The trial involves testing the effectiveness of various drugs, including metformin hcl and colesevelam, on patients with these conditions. The eligibility criteria for the trial include age between 18 and 79 years, specific glucose and LDL-C levels, and being drug-na\u00efve. Women may also be enrolled if they meet certain criteria. Exclusion criteria include a history of type 1 diabetes, chronic use of insulin therapy, and certain medical conditions that could interfere with the study.",
    "This sample is a record of a clinical trial in phase 3 for heart failure. The trial includes patients with chronic systolic heart failure of ischemic or non-ischemic etiology for at least 4 weeks, who are currently in New York Heart Association (NYHA) functional Class II and on optimal dose or maximally tolerated dose of standard heart failure medicines (including ACE-I/ARBs, beta-blockers) and diuretics if indicated for fluid overload. The trial also requires patients to have participated in the double-blind phase of the EMPHASIS-HF trial. Patients with severe chronic systolic heart failure symptomatic at rest despite optimal medical therapy and estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2 are excluded from the trial. The drug being tested in this trial is eplerenone.",
    "The sample is a phase 3 clinical trial for patients with mild-to-moderate essential hypertension. The trial includes patients who are either untreated or currently taking antihypertensive therapy. The trial involves the use of three drugs: lcz696, olmesartan, and placebo. The eligibility criteria for the trial include specific blood pressure ranges and an absolute difference of \u226415 mmHg in msSBP between visits. Exclusion criteria include severe hypertension, history of angioedema, and evidence of a secondary form of hypertension. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for advanced colorectal cancer. The trial includes patients who are not eligible for curative surgery and have measurable disease. The trial involves two drugs, 21capecitabine + bevacizumab + oxaliplatin and 1capecitabine + oxaliplatin + bevacizumab + cetuximab. The eligibility criteria include having histologically proven advanced colorectal cancer, being 18 years or older, having a WHO performance status of 0-1, and having adequate bone marrow, hepatic, and renal function. The exclusion criteria include having prior chemotherapy for advanced disease, previous radiotherapy for rectal cancer or for symptomatic treatment of distant metastases, and serious non-healing wounds or ulcers.",
    "The sample is a phase 3 clinical trial that involves patients with major depression, bipolar depression, and schizoaffective disorder. The trial includes the drugs razadyne and placebo. The eligibility criteria for the trial include males and females between the ages of 18-90 with a DSM-IV diagnosis of the aforementioned disorders. Exclusion criteria include patients with dementia, substance use disorder, organic mental disorders, unstable physical disorders, and physical disorders that significantly affect the central nervous system function. Additionally, patients with certain heart conditions, coronary artery disease, liver and renal function impairment, and certain gastrointestinal disorders are excluded. Female patients who are pregnant or not using acceptable forms of contraception are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the disease of osteoporosis. The icd-10 codes associated with the disease are listed as [\"M81.6\", \"Z82.62\", \"Z13.820\", \"M81.8\", \"Z87.310\", \"M81.0\", \"M80.80XS\"]. The trial involves two drugs, placebo and denosumab. The eligibility criteria for the trial are listed, including age requirements and bone mineral density T-score thresholds. The exclusion criteria are also listed, including severe or multiple moderate vertebral fractures.",
    "The sample is a phase 3 clinical trial for the treatment of chronic genotype 2 or 3 hepatitis C infection using the drugs sofosbuvir, peg, and rbv. The trial includes patients who have not received any previous HCV antiviral treatment and have certain inclusion criteria, such as not having any other clinically significant chronic liver disease. However, there are also exclusion criteria, such as having a positive test for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab, or having a history of psychiatric illness, cancer, or poorly controlled diabetes. The trial also requires that patients have not participated in any other clinical study within 3 months prior to the first dose.",
    "The sample is a phase 3 clinical trial for patients with bronchial asthma. The trial includes the use of several drugs, including berodual\u00ae via respimat\u00ae, high dose, berodual\u00ae via respimat\u00ae, low dose, berodual\u00ae via mdi, high dose, placebo respimat\u00ae, and placebo mdi. The eligibility criteria for the trial include a diagnosis of bronchial asthma, age between 18 and 65 years, and a screening FEV1 between 40% and 80% of predicted normal. Patients must also be non-smokers or ex-smokers with a smoking history of \u2264 10 pack-years and cessation of smoking \u2265 1 year prior to the screening visit. In addition, patients must be able to be trained in proper use of MDI and RESPIMAT\u00ae devices and perform technically satisfactory pulmonary function tests. Exclusion criteria include significant disease other than asthma, history of myocardial infarction within the last year, tuberculosis with indication for treatment, and history of cancer within the last five years, among others. Patients who need more than 8 puffs of salbutamol (100 \u00b5g per puff) rescue medication on 3 or more consecutive days during the run-in period are also excluded.",
    "The sample is a phase 3 clinical trial for patients with newly diagnosed multiple myeloma. The trial includes patients with bone marrow plasmacytosis and Durie-Salmon Stage IIA-B or IIIA-B. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3, be at least 18 years old, have a signed informed consent form, and an expected survival of greater than 8 weeks. Patients must also be capable of swallowing study medication tablets and following directions regarding taking study medication, or have a daily care provider who will be responsible for administering study medication. Patients will be eligible for the study even if they lack socioeconomic access to autologous transplantation. The trial includes a list of drugs such as zoledronic acid, dexamethasone, thalidomide, vincristine, and adriamycin. The eligibility criteria include exclusion criteria such as elevated direct bilirubin, ongoing radiation therapy, prior treatment for multiple myeloma, and concurrent uncontrolled serious infection. Women of childbearing potential who are not utilizing birth control or who are pregnant or nursing will be excluded from the study. Patients with comorbid conditions that would contraindicate the use of vincristine, doxorubicin, dexamethasone, thalidomide, or zoledronate will also be excluded.",
    "The sample is a record of a clinical trial for a drug called Perampanel, which is being tested for its effectiveness in treating Parkinson's disease. The trial is in phase 3, and the record includes a list of inclusion and exclusion criteria for potential participants. The criteria cover a range of medical and lifestyle factors, such as pregnancy, drug or alcohol abuse, and previous or planned surgeries. The record also includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being used in the trial.",
    "This sample is a phase 3 clinical trial for the treatment of juvenile idiopathic arthritis. The trial includes patients aged 2-17 years with systemic juvenile idiopathic arthritis and persistent activity for at least 6 months. The trial involves the use of drugs such as tocilizumab, placebo, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The eligibility criteria include the presence of active disease and inadequate clinical response to NSAIDs and corticosteroids. Exclusion criteria include previous treatment with tocilizumab, intravenous long-acting corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with essential hypertension and includes a list of icd-10 codes for the disease. The trial involves the use of three drugs: olmesartan, placebo, and lcz696. The eligibility criteria for the trial include patients with a mean sitting systolic blood pressure between 150 mmHg and 180 mmHg, good medication compliance, and the ability to communicate and comply with all study requirements. Exclusion criteria include patients with severe hypertension, a history of stroke or myocardial infarction, and women of child-bearing potential who do not use adequate birth control methods. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria. In this particular sample, the trial is in phase 3 and is focused on studying perennial allergic rhinitis in children between the ages of 2-5 years. The trial is testing the drug triamcinolone. The eligibility criteria include having a history of at least 1 year of perennial allergic rhinitis, meeting a certain symptom score, not having any other clinically relevant diseases, not having been recently exposed to rhinitis medications, and not having a history of hypersensitivity to glucocorticoids or any excipients of the formulation. There are also exclusion criteria listed, such as having asthma or using certain medications within a certain timeframe. Any waiver of these criteria must be approved by the investigator and sponsor on a case-by-case basis.",
    "The sample is a phase 3 clinical trial for allergic rhinitis. The trial includes subjects who are 12 years of age or older, of any race and gender, and have a positive skin prick test response to an appropriate seasonal allergen. The trial aims to evaluate the efficacy of mometasone furoate nasal spray (mfns) compared to a matching placebo nasal spray. The eligibility criteria include having at least a 2-year history of SAR which exacerbates during the study season and being clinically symptomatic at the Screening and Baseline Visits. Exclusion criteria include having a history of severe local reaction(s) or anaphylaxis to skin testing, using any drug in an investigational protocol in the 30 days prior to the Screening Visit, and being a family member of the investigational study staff. Female subjects who are breast-feeding, pregnant, or intend to become pregnant are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of septic shock and sepsis-associated hypotension. The trial involves the use of two different drugs, hypertonic saline and terlipressin, and normal saline and norepinephrine. The eligibility criteria for the trial include meeting certain criteria for Systemic Inflammatory Response Syndrome (SIRS), having a known or highly probable source of sepsis that is controlled, and having a MAP (mean arterial pressure) less than 70 mm Hg. Exclusion criteria include having certain medical conditions such as intracranial hypertension or liver disease, being pregnant, or having a \"do not resuscitate\" order.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis using Sativex\u00ae and placebo drugs. The trial is looking for participants who are 18 years or older, have been diagnosed with Secondary-Progressive or Primary-Progressive MS for at least 12 months, and have been relapse-free for at least 3 months before the screening visit. Participants must also have lower limb spasticity, an EDSS score between 3.0 and 6.5, and moderate to severe spasticity due to MS for at least 6 months with stable drug treatment not able to relieve symptoms as a whole, deserving a specific add-on treatment. Immunomodulatory or immunosuppressant therapies must not have been modified during the study and 6 months before starting the study, and stable doses of anti-spasticity agents must have been taken for at least 2 months prior to the screening visit. Participants must also have given written informed consent. Exclusion criteria include any concomitant disease that may cause spasticity or that could interfere with the subject's spasticity, Botulinum Toxin injection for spasticity in the 4 months prior to the screening visit, any known or suspected history of psychotic illness, alcohol or substance abuse, epilepsy, hypersensitivity to cannabinoids, significant cardiac, renal or hepatic disease, female subjects of childbearing potentials and male subjects whose partner is childbearing potential, unless willing to ensure that they or their partner use contraception during the study, female subjects who are pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter, and Sativex\u00ae SmPC contraindications.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients between 18 and 65 years old who have had an inadequate response to no more than three adequate antidepressant treatments. The trial involves the drugs opc-34712 + adt and placebo + adt. The eligibility criteria include a diagnosis of major depressive disorder as defined by DSM-IV-TR criteria, a current depressive episode of at least 8 weeks in duration, and a history of inadequate response to antidepressant treatments. The exclusion criteria include pregnancy or breastfeeding, a history of inadequate response to more than three adequate trials of antidepressant treatments, and current diagnoses of certain Axis I and Axis II disorders. The diseases and icd-10 codes associated with the trial include depressive disorder, depression, depressive disorder major, mood disorders, and mental disorders.",
    "The sample is a phase 3 clinical trial for patients with chronic kidney disease and hyperkalemia. The trial is testing the effectiveness of the drug patiromer compared to a placebo. The eligibility criteria include being between the ages of 18 and 80, having an eGFR of 15 to <60 mL/min/1.73m2, and having a serum potassium value of 5.1 to <6.5 mEq/L. Participants must also be taking either an ACE inhibitor, an ARB, or an aldosterone antagonist medication. Exclusion criteria include having certain autoimmune-related kidney diseases, uncontrolled Type 1 diabetes, severe heart failure, recent major surgery or cardiovascular/cerebrovascular events, and a BMI \u2265 40 kg/m2.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for liver cancer, with megestrol acetate as the drug being tested. The eligibility criteria for the trial include a diagnosis of hepatocellular carcinoma (HCC) or meeting certain radiological or serum alpha-fetoprotein level criteria. Patients must also have a performance status of ECOG 0-3, bilirubin no greater than 5.8 mg/dL, and creatinine less than 1.7 mg/dL. They must not be pregnant, have clinical encephalopathy, or have had any other malignancy within the past 5 years. Prior concurrent therapy is not specified, but patients cannot have had prior chemoembolization or systemic chemotherapy for HCC, prior surgery for HCC, or prior percutaneous injection for HCC.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of overactive bladder symptoms in patients who have been experiencing these symptoms for at least 12 weeks. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, including ym178, placebo, and tolterodine er. The eligibility criteria for the trial are also listed, including requirements for the frequency and urgency of micturition, as well as exclusion criteria such as the presence of stress urinary incontinence or a history of urinary tract infections.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of drugs such as sitagliptin phosphate, pioglitazone hydrochloride, and metformin. The eligibility criteria for the trial include patients who are unlikely to conceive and meet certain categories based on their current medical regimen and screening A1c levels. Exclusion criteria include patients with a history of type 1 diabetes mellitus, previous treatment with certain medications, and those on a weight loss program or with active liver disease. The trial also excludes patients who have undergone surgery within the prior 30 days or have received treatment with an investigational product within 12 weeks prior to Visit 1.",
    "The sample is a phase 3 clinical trial for patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. The trial aims to evaluate the effectiveness of cisplatin in treating head and neck cancer, mucositis, pain, and radiation toxicity. The trial includes patients with at least 2 mucosal sites of the oral cavity/oropharynx mucosa assessable by visual transoral inspection that will receive at least 66 Gy. Patients must be able to eat at least soft solids and not require a feeding tube for nutrition or hydration at study entry. The trial has inclusion and exclusion criteria, and patients must sign a study-specific informed consent prior to study entry.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of the drug natalizumab and a placebo. The eligibility criteria for participants include a diagnosis of MS, being between the ages of 18 and 50, having a baseline EDSS score between 0.0 and 5.0, and having experienced at least one relapse within the 12 months prior to randomization. Participants must also have given written informed consent to participate in the study. Exclusion criteria include progressive forms of MS, recent relapses, significant medical conditions, severe allergies or drug hypersensitivity, and abnormal blood tests.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder mania. The trial includes patients who have been diagnosed with bipolar I disorder mania, manic or mixed episode, with or without psychotic features, and are currently undergoing lithium or valproate treatment. The trial aims to investigate the effectiveness of aripiprazole as an adjunctive treatment to lithium or valproate. The trial also includes a placebo group. The eligibility criteria include having therapeutic serum levels of lithium or valproate and a Young Mania Rating Total Score of 16 or higher at screening and baseline. The exclusion criteria include a diagnosis of delirium, dementia, amnesia, or other cognitive disorder, or a psychotic disorder, as well as a significant risk of suicide based on history, mental status exam, or investigator judgment. Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of investigational product are also excluded.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of obesity. The icd-10 codes associated with the disease are listed, along with the drugs being tested - taranabant and a placebo comparator. The eligibility criteria for the trial are also listed, including a body mass index range for inclusion and exclusion criteria related to medical conditions.",
    "The sample is a phase 3 clinical trial for patients with non-small-cell lung carcinoma who have failed previous treatments with erlotinib or gefitinib. The trial involves two parts, with the first part requiring patients to have received and failed at least one line of cytotoxic chemotherapy and have progressive disease following at least 12 weeks of treatment with erlotinib or gefitinib. The second part of the trial requires patients to have shown clinical benefit of 12 weeks duration in Part A of the trial determined on the second tumour assessment. The trial has a list of inclusion and exclusion criteria, including age, performance score, life expectancy, and various medical conditions. The trial also has a list of prohibited concomitant medication.",
    "The sample is a phase 3 clinical trial for chronic constipation. The trial includes patients who have completed a colonoscopy and other protocol procedures with no significant findings. Patients must report less than 3 bowel movements per week and experience straining, lumpy or hard stools, and/or incomplete evacuation during more than 25% of bowel movements. Patients must also demonstrate continued chronic constipation during the pretreatment period and be compliant with IVRS. Exclusion criteria include a history of loose or watery stools, symptoms or diagnosis of Irritable Bowel Syndrome (IBS), structural abnormalities of the gastrointestinal tract, or any medical or surgical history that could confound the study assessments. The trial involves the use of matching placebo and linaclotide drugs.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial includes patients who have had symptoms of Crohn's disease for at least 3 months and have been diagnosed through endoscopic and histological or radiological criteria. The disease must be located in the terminal ileum, ascending colon, or ileocolitis and must be in an active phase. The trial excludes patients with known Crohn's lesions in the upper GI-tract, CD in the rectum, short bowel syndrome, septic complications, abscess, perforation, or active fistulas, among other criteria. Patients must not have received certain treatments within a specified time frame before the study. The trial will test the effectiveness of budesonide and mesalazine.",
    "This sample is for a phase 3 clinical trial for the treatment of osteoporosis. The trial includes patients with involutional osteoporosis who have experienced fragility vertebral fractures. The trial will test the effectiveness of three drugs: denosumab, placebo, and alendronate sodium hydrate. The eligibility criteria for the trial includes having involutional osteoporosis with prevalent fragility vertebral fractures, while exclusion criteria includes having any underlying condition that might have resulted in abnormal bone metabolism. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of two drugs, olanzapine and paliperidone er, on patients who meet the DSM-IV criteria for schizophrenia and have a PANSS total score between 60 and 100. The trial has inclusion criteria such as patients being healthy on the basis of a physical examination and vital signs at screening, and exclusion criteria such as patients with abnormal fasting plasma glucose or fasting triglycerides levels at screening, and pregnant or breastfeeding females. The trial also requires patients to have never been treated with an antipsychotic before or to have not been treated with paliperidone ER, olanzapine, or clozapine within the past 6 months.",
    "The sample is a phase 3 clinical trial for patients with non-squamous, non-small-cell lung cancer. The trial is testing the effectiveness of the drugs tivantinib and erlotinib, as well as a placebo. The eligibility criteria include having measurable disease and documented disease progression following last prior therapy, having received one or two prior lines of systemic anti-cancer therapy, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The trial also requires adequate bone marrow, liver, and renal functions, and the availability of a biopsy tissue sample for biomarker determination. Exclusion criteria include prior therapy with an EGFR inhibitor and/or ARQ 197, receipt of any systemic anti-tumor treatment for NSCLC within 3 weeks prior to randomization, and significant co-morbid conditions that would impair study participation or cooperation.",
    "The sample is a phase 3 clinical trial for the treatment of mesothelioma and lung cancer. The trial involves the use of the drugs vorinostat and placebo. The eligibility criteria include being 18 years or older with a confirmed diagnosis of malignant pleural mesothelioma, having received no more than 2 prior systemic therapy regimens, and having a Karnofsky performance scale status of \u226570. The trial also has exclusion criteria, such as having an active infection or uncontrolled brain metastases. The trial has an extension phase for participants who are receiving treatment with vorinostat and have not experienced progression of mesothelioma.",
    "This is a sample from a table that contains information about a clinical trial. The trial is in phase 3 and is focused on chronic obstructive pulmonary disease. The table includes a list of icd-10 codes for the disease, as well as a list of drugs being used in the trial (indacaterol, tiotropium, and placebo). The eligibility criteria for the trial are also included, with specific requirements for patients' smoking history and lung function. Patients who have received corticosteroids in the three months prior to screening are excluded from the trial.",
    "The sample is from a phase 3 clinical trial for major depressive disorder. The eligibility criteria include patients who have a diagnosis of major depressive episode, have reported an inadequate response to at least one and no more than three adequate antidepressant treatments, and have a HAM-D17 score of at least 18 at the end of the screening phase. Patients must also be able to comply with the prescribed dosage regimens, report for regularly scheduled office visits, and communicate to study personnel about adverse events and concomitant medication use. The exclusion criteria include patients with a current need for involuntary commitment, a history of antidepressant-induced hypomania, and those who have participated in any clinical trial with an investigational drug or device within the past month.",
    "The sample is a phase 3 clinical trial for patients with acute heart failure, either ischemic or non-ischemic. The trial is testing the effectiveness of the drug tezosentan in treating acute heart failure. The eligibility criteria include being 18 years or older, having dyspnea at rest and breathing rate of at least 24/min, and meeting at least two out of four criteria related to elevated BNP or N terminal pro-BNP levels, clinical evidence of pulmonary congestion/edema, evidence of pulmonary congestion on chest X-ray, or left ventricular systolic dysfunction. Patients must also be in need of i.v. therapy for acute heart failure and have received at least one dose of i.v. diuretic within 24 hours prior to study drug initiation. Exclusion criteria include factors that might interfere with the study conduct or interpretation of the results, such as known drug or alcohol dependence, and concomitant treatment with cyclosporin A or tacrolimus.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients with schizophrenia who sign a written consent form. The trial excludes patients with clinically significant heart, kidney, liver, or gastrointestinal diseases, as well as those with psychiatric disorders other than schizophrenia. The trial involves the use of iloperidone, an active comparator, and a placebo. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients who have had an inadequate response to no more than one antidepressant and are currently outpatient. The trial excludes patients with a history of bipolar disorder, psychotic disorder, post-traumatic stress disorder, suicide attempts in the past year, or significant risk of suicide or homicide. Patients with renal insufficiency or impairment or conditions that could affect absorption or metabolism of the investigational product are also excluded. The trial involves the drugs tc-5214 and placebo. The eligibility criteria include providing signed and dated informed consent before initiation of any study-related procedures.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of allergy. The trial includes a list of icd-10 codes related to the disease. The trial involves two drugs, namely '300 ir grass pollen allergen extract tablet' and 'placebo tablet'. The eligibility criteria for the trial include being an outpatient aged between 5 to 17 years, having grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons, being sensitized to grass pollen, and having a total symptom score on the Retrospective RTSS during the previous pollen season of greater than or equal to 12. Patients who have received any desensitization treatment for grass pollen are excluded from the trial.",
    "The sample is a phase 3 clinical trial for acute bacterial sinusitis. The trial includes patients who are at least 12 years old, weigh at least 40 kg, and have a clinical diagnosis of acute bacterial sinusitis. The trial requires patients to have radiographic evidence of sinusitis on CT scans taken at screening and be symptomatic at the screening and baseline visits. Patients must also be in general good health and free of any clinically significant disease (other than sinusitis) that would interfere with the study schedule or procedures, or compromise the subject's safety. The trial includes a list of inclusion and exclusion criteria, such as a history of chronic sinusitis, allergy to corticosteroids or penicillins, and a concurrent need for antibiotic therapy other than the study drug. The trial also requires female patients of child-bearing potential to have a negative serum pregnancy test at screening and agree to use a medically accepted method of contraception throughout the entire study period.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial involves the use of several drugs, including olodaterol and tiotropium, as well as placebos. The eligibility criteria for the trial include being 40 years of age or older, having a 10 pack year smoking history, and being able to perform pulmonary function tests and use both a Dry powder inhaler (DPI) and Respimat device. Exclusion criteria include having significant other diseases, abnormal hematology, chemistry, or urinalysis, a history of asthma or thyrotoxicosis, and several other factors. Participants cannot be enrolled in another study or taking investigational products, and pregnant or nursing women must be willing to use two methods of birth control.",
    "The sample is a phase 3 clinical trial for gastroesophageal reflux disease. The trial includes patients who have a history of frequent episodes of GERD-related symptoms and meet certain criteria, such as having heartburn as their main symptom and experiencing it at least three days a week. The trial also has exclusion criteria, such as patients with a history of drug or alcohol abuse, recent significant weight loss, or other gastrointestinal diseases. Patients who have taken certain medications or antibiotics within a certain timeframe are also excluded. The trial involves testing the effectiveness of sodium alginate double action tablets compared to a placebo.",
    "The sample is a phase 3 clinical trial for the treatment of metastatic melanoma of cutaneous origin. The trial involves the drugs elesclomol (sta-4783) and paclitaxel. The eligibility criteria for the trial include having a confirmed diagnosis of metastatic melanoma, a performance status of 2 or less, measurable disease according to modified RECIST, a life expectancy of greater than 12 weeks, LDH levels within normal range, and being at least 18 years old and able to provide informed consent. Exclusion criteria include having received previous cytotoxic chemotherapy treatment for melanoma, having received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy, vaccine or investigational non-chemotherapeutic treatment for melanoma, having brain metastases, having a history of a second malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ within the past 5 years, and being pregnant or nursing if female.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of breast cancer. The trial is testing the effectiveness of two drugs, sunitinib malate and taxotere, on patients with unresectable locally recurrent or metastatic breast cancer that is Her-2 negative. The eligibility criteria for the trial include having breast cancer with evidence of the disease and not being contraindicated for docetaxel. The exclusion criteria include having inflammatory carcinoma with no other measurable disease. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 3 clinical trial for colorectal neoplasms. The trial includes patients with pathologically proven colorectal cancer, excluding those with synchronous colorectal cancer that invades muscularis propria or deeper. The trial requires tumor resection with D2 or D3 lymph node dissection and pathological determination of curability of tumor resection is cur A. Patients must be above 20 and below 75 years old with an ECOG Performance status of 0 or 1 and no prior chemotherapy or radiation therapy. Adjuvant chemotherapy can be started within 9 weeks after surgery. The trial has exclusion criteria such as active co-existing malignancy, severe postoperative complications, and certain medical conditions. Patients must provide written informed consent to participate in the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of ankylosing spondylitis. The trial involves the use of drugs such as meloxicam suppository, meloxicam tablet, and indomethacin. The eligibility criteria for the trial include having active ankylosing spondylitis with a pain rating of at least 40 mm on a VAS and an increase of at least 30% after nonsteroidal anti-inflammatory drugs (NSAIDs) wash-out. The trial excludes individuals with peripheral arthritis and inflammatory bowel disease.",
    "The sample is a phase 3 clinical trial for the treatment of erosive esophagitis using the drugs tak-438. The trial includes participants who have successfully completed a preceding phase 3 double-blind study and have endoscopically healed EE. The inclusion criteria require participants to have endoscopically confirmed EE of Grade O as defined by the Los Angeles (LA) Classification Grading System. The exclusion criteria include participants with esophagus-related complications, a history of radiotherapy or cryotherapy of the esophagus, or a caustic or physiochemical trauma. Participants who have received surgery or treatment affecting gastroesophageal reflux or who have a history of surgery of stomach or duodenum are also excluded. Participants with acute upper gastrointestinal bleeding, gastric or duodenal ulcer within 30 days prior to the study drug administration are also excluded. Participants with a previous or current history of Zollinger-Ellison syndrome or other gastric acid hypersecretion disorder are also excluded.",
    "The sample is a phase 3 clinical trial for patients with stage IV non-small cell lung cancer. The trial is testing the effectiveness of observation, gemcitabine, and erlotinib as treatments. The eligibility criteria include having histologically documented NSCLC, measurable disease according to the RECIST criteria, and normal hepatic function. Patients must also have a life expectancy of more than 12 weeks and be between the ages of 18 and 70. Exclusion criteria include having small cell lung cancer, prior therapy with EGFR inhibitor, and any unstable systemic disease. Patients must provide written informed consent to participate in the study and use of tumor samples.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying hypertension. The icd-10 codes associated with hypertension are listed, as well as the drugs being tested. The eligibility criteria for participants include having essential hypertension, being between the ages of 20 and 80, being an outpatient, and being able to provide written informed consent. There are also exclusion criteria listed, such as having certain medical conditions or taking certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension. The trial is looking for participants between the ages of 12 and 75 who weigh at least 40 kg and have a Body Mass Index of less than 45. The trial is open to those with idiopathic/heritable PAH, PAH associated with repaired congenital systemic-to-pulmonary shunts (repaired \u2265 5 years), PAH associated with collagen vascular disease, or PAH associated with HIV. Participants must have previously undergone testing consistent with the diagnosis of PAH and have a baseline 6-minute walk distance between 200 and 425 meters. The trial requires participants to be reliable and cooperative with protocol requirements. Exclusion criteria include nursing or pregnancy, current use of certain medications, PAH due to conditions not included in the inclusion criteria, history of certain medical conditions, and use of an investigational drug within 30 days of baseline.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes mellitus. The trial requires male or female patients between the ages of 18 and 70 who have had an established diagnosis of type 1 diabetes for more than 1 year and have HbA1c values of not more than 10.5%. Patients must also have been on a stable insulin regimen for at least three months that includes at least two daily insulin injections and meets the current standard of care. The trial excludes patients with type 2 diabetes mellitus, a history of frequent severe hypoglycemia within the prior six months, and other medical conditions such as significant hepatic disease or severe complications of diabetes mellitus. Patients must also not have a history of drug or alcohol abuse, be pregnant or breastfeeding, or have abnormal ECG, safety lab, or physical examination results.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for hypertension. The diseases column lists only one disease, which is hypertension. The icdcodes column contains a list of ICD-10 codes related to hypertension. The drugs column lists two drugs, valsartan and irbesartan, which are being tested in the trial. The criteria column contains the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria include having mild or moderate hypertension, being on chronic hemodialysis for at least 6 months, and having a stable hematocrit if treated with epoetin. The exclusion criteria include being unable to discontinue angiotensin II receptor blockers safely, being treated with more than 3 different compounds for hypertension, and having atrial fibrillation. There may be other exclusion criteria defined by the protocol.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for type 2 diabetes. The trial includes patients who have been treated with metformin, sulfonylurea, thiazolidinedione, or a combination of these for at least three months prior to screening. The patients must have an HbA1c level between 7.1% and 10.0%, a BMI greater than 25 kg/m^2 and less than 45 kg/m^2, and must not have used any prescription drug to promote weight loss within 3 months prior to screening. The trial excludes patients who have participated in any interventional, medical, surgical, or pharmaceutical study within 30 days prior to screening, have characteristics contraindicating metformin, sulfonylurea, or thiazolidinedione use, are receiving chronic systemic glucocorticoid therapy, or have used any excluded medications.",
    "The sample is a phase 3 clinical trial for the treatment of acute ischemic stroke using the drug saline or placebo. The trial has eligibility criteria for inclusion and exclusion, including a NIH stroke scale score of greater than 5, age between 18 and 83, and the ability to administer the drug within 5 hours of symptom onset or within 60 minutes of Tissue Plasminogen Activator (tPA) administration in the thrombolysis group. Exclusion criteria include recent episodes of congestive heart failure, severe aortic or mitral stenosis, recent cardiac surgery, acute myocardial infarction, suspicion of aortic dissection, and other serious medical conditions. The trial also requires signed informed consent and a negative pregnancy test for women of childbearing age.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is focused on Chinese subjects aged 18-65 who meet the ICD-10 criteria for schizophrenia. The trial involves the use of two drugs, intramuscular ziprasidone mesylate and intramuscular haloperidol. The eligibility criteria include being in the acute phase of schizophrenia and being appropriate to receive intramuscular medication for at least 3 days. The exclusion criteria include a history of clinically significant physical illness, recent use of investigational agents, and recent use of antipsychotic agents or parenteral benzodiazepines.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis and exocrine pancreatic insufficiency. The trial involves the use of the drug Ultrase\u00ae MT20 and a placebo. The eligibility criteria for participants include having a confirmed diagnosis of CF, requiring pancreatic enzyme supplementation, being clinically stable, having an adequate nutritional status, and being able to swallow capsules and eat a high-fat diet. Exclusion criteria include having a known contraindication or allergy to Ultrase or any porcine protein, using narcotics or bowel stimulants, having acute pancreatitis or acute exacerbation of chronic pancreatic disease, and having certain medical conditions. Female participants must be premenarcheal, surgically sterile, or postmenopausal, or must practice an acceptable method of contraception. Participants must also be able and willing to complete the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial is focused on patients with a current diagnosis of schizophrenia of paranoid, disorganized, catatonic, residual, or undifferentiated subtype with persistent negative symptoms. The trial involves the use of two drugs, asenapine and olanzapine. The eligibility criteria for the trial include having no increase in level of psychiatric care during the past few months due to worsening of symptoms of schizophrenia and requiring a caregiver. The exclusion criteria include having an uncontrolled, unstable clinically significant medical condition or any other psychiatric disorder other than schizophrenia as a primary diagnosis including depression. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of metastatic castration-resistant prostate cancer. The trial involves the use of drugs such as prednisone, sunitinib, and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of adenocarcinoma of the prostate, having failed docetaxel chemotherapy, and having progressive disease based on PSA progression, RECIST, or positive bone scan. Exclusion criteria include prior treatment with sunitinib and/or more than one prior chemotherapy regimen in the metastatic disease setting, ongoing urinary obstruction, and cardiac dysfunction.",
    "The sample is a phase 3 clinical trial for patients with advanced liver cancer who have previously been treated with sorafenib and experienced disease progression or intolerance to the treatment. The trial is testing the effectiveness of everolimus and everolimus placebo as potential treatments. The eligibility criteria include having an ECOG performance status of \u2264 2 and Child-Pugh A, as well as meeting specific radiological confirmation and intolerance criteria. The exclusion criteria include active bleeding in the last 28 days, prior therapy with mTOR inhibitors, and prior liver or other organ transplantation that requires systemic immunosuppression. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of depression in patients with bipolar I disorder. The trial involves the use of the drugs armodafinil and placebo, and the eligibility criteria includes having a diagnosis of bipolar I disorder, experiencing a major depressive episode, having had at least one previous manic or mixed episode, and having no more than six mood episodes in the last year. Other criteria include being in good health, using a medically accepted method of contraception if sexually active, and being willing to comply with study restrictions and attend regularly scheduled clinic visits. Exclusion criteria include having any Axis I disorder apart from bipolar I disorder, having psychotic symptoms, having current active suicidal ideation, having a history of an eating disorder or substance abuse, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of vildagliptin and placebo drugs. The eligibility criteria include confirmed diagnosis of T2DM, C-peptide levels above 0.6 ng/ml, HbA1c levels between 7.5% and 11%, and stable treatment with basal insulin or pre-mixed insulin for at least 12 weeks prior to the trial. Patients receiving metformin must be on a stable dose for at least 12 weeks prior to the trial. The trial excludes patients with fasting plasma glucose levels above 240 mg/dl, pregnant or lactating women, acute metabolic diabetes complications, congestive heart failure, recent myocardial infarction, and liver disease. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of Restless Legs Syndrome in patients with End-Stage Renal Disease who require hemodialysis. The trial involves the use of the drug Rotigotine and a placebo. The eligibility criteria include meeting specific hematology parameters, having a diagnosis of Restless Legs Syndrome based on specific clinical features, having a moderate to severe score on the IRLS and RLS-DI assessments, and having a certain number of Periodic Limb Movements per hour on the Periodic Limb Movement Index. Exclusion criteria include having certain concomitant diseases, a history of psychotic episodes, and previous treatment with certain drug classes. Women of childbearing potential must use effective contraception.",
    "The sample is a phase 3 clinical trial for patients with malignant diseases who are scheduled to receive a single day of moderately or highly emetogenic chemotherapy regimen. The trial aims to test the effectiveness of a combination of drugs, including apf530, dexamethasone, and palonosetron hydrochloride, in preventing nausea and vomiting caused by chemotherapy. The eligibility criteria include having no head and neck cancer or upper gastrointestinal cancer, being able to receive standardized doses of dexamethasone, and having an ECOG performance status of 0-2. Patients must also meet certain patient characteristics, such as having a QTc interval \u2264 500 ms and no recent history of alcohol or drug abuse. Prior concurrent therapy is also taken into consideration, and patients must not have received radiotherapy 7 days prior to, during, and 5 days after completion of study treatment. The use of certain medications is also prohibited during the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial requires patients to be at least 18 years old and less than 75 years old, and to have been taking exenatide 10 micrograms twice a day for at least 3 months. Patients must also be taking one of three oral diabetes medication regimens for at least 3 months, and have a hemoglobin A1C level between 7.0% and 10.0%. Patients who have used insulin regularly in the past 2 years, taken glucose-lowering medications not included in the inclusion criteria in the past 3 months, had more than one episode of severe hypoglycemia in the past 6 months, or have clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease are excluded from the trial. Pregnant patients or those who intend to get pregnant during the course of the study are also excluded.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of osmotic-release methylphenidate and placebo in treating ADHD and smoking. The trial has eligibility criteria for participants, including a clinical diagnosis of ADHD, smoking for at least 3 months, and an interest in quitting. Exclusion criteria include allergies to OROS-MPH, pregnancy or breastfeeding, abnormal ECG, and taking certain medications. The sample also includes a list of disease names, icd-10 codes, and eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chronic plaque psoriasis. The trial includes patients who have been diagnosed with moderate to severe plaque psoriasis for at least 12 months prior to screening. The trial involves the use of the drug apremilast, as well as topical treatments or phototherapy, and a placebo. The eligibility criteria include being at least 18 years old, meeting laboratory criteria, and having a negative pregnancy test for females of childbearing potential. The exclusion criteria include having a history of substance abuse, active tuberculosis, or a history of malignancy (except for treated skin carcinomas and cervical intraepithelial neoplasia). The trial also excludes patients who have used certain medications within a certain timeframe prior to randomization.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of psoriasis. The trial is testing the effectiveness of the drugs cp-690,550 and placebo/cp-690,550. The trial is looking for participants who are 18 years or older, have been diagnosed with moderate to severe plaque psoriasis for at least 12 months, have a Psoriasis Area and Severity Index (PASI) score of 12 or greater, and are considered candidates for systemic or light therapy. Participants must also have no evidence of active or latent tuberculosis. Exclusion criteria include non-plaque or drug-induced forms of psoriasis, inability to discontinue current oral, injectable or topical therapy for psoriasis, and any uncontrolled significant medical condition.",
    "The sample is a phase 3 clinical trial for chronic pain associated with osteoarthritis or lower back pain. The trial includes participants who have been experiencing chronic pain for at least 3 months and have not been able to control it with oral NSAIDs at a usual maximum dose. The trial involves the use of tramadol hydrochloride plus acetaminophen and placebo, and participants must meet certain inclusion criteria, such as being outpatients and ambulatory without the need for any supportive device or assistance during daily life. However, there are also exclusion criteria, such as having conditions for which opioids or acetaminophen are contraindicated, a history of convulsion or the possibility of convulsive seizure, concurrent, previous, or possible alcohol dependence, drug dependence, or narcotic addiction, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients between the ages of 18 and 70 who have been diagnosed with bipolar I or II and are currently experiencing depression. The trial involves the use of divalproex sodium er and a placebo. Patients must meet certain inclusion criteria, such as having a baseline Montgomery-Asberg Depression Scale (MADRS) score of >19 and Young Mania Rating Scale (YMRS) score of <12, and must not be using any concomitant psychotropic medications during the acute phase except prn benzodiazepines. Patients who lack the capacity to provide informed consent, have previously used divalproex or Dvpx-ER, are a serious suicide risk, or have medically unstable conditions are excluded from the trial. Additionally, patients who have any alcohol, cocaine, or cannabis dependence within 3 months of study entry or have abused cocaine, hallucinogens, opiates, crystal methamphetamine, or MMDA within 3 months of study entry are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of proteinuria, a condition associated with chronic kidney disease. The trial involves the use of two drugs, losartan potassium and amlodipine besylate, as well as enalapril maleate as a comparator. The trial is open to participants between the ages of 1 and 17 who are able to provide a first-morning urine sample each day during the study. The eligibility criteria also include a documented history of proteinuria and a signed consent of parent and/or legal guardian. Exclusion criteria include pregnancy or nursing, requiring more than 2 medications to control high blood pressure, having undergone major organ transplantation, known sensitivity to losartan or other similar drugs, known sensitivity to amlodipine or other calcium channel blocker, and requiring cyclosporine to treat renal disease.",
    "The sample is a phase 3 clinical trial for asthma. The eligibility criteria include being a Chinese male or female outpatient aged between 17 and 70 years, having a documented clinical history of asthma for at least 12 weeks prior to the study, and demonstrating a certain level of reversibility of FEV1. The subjects must also be on a stable dose of high or moderate dose ICS or LABA for at least 2 weeks. Exclusion criteria include having a history of life-threatening asthma, bacterial or viral infection of the respiratory tract, or any other respiratory abnormalities other than asthma. The trial also excludes patients who are pregnant or lactating, have evidence of alcohol abuse, or have a pre-planned surgery operation in 6 months. The trial involves the use of fluticasone propionate inhalation solution and budesonide suspension as drugs.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with hypercholesterolemia and metabolic syndrome, and the table includes a list of diseases and their corresponding ICD-10 codes. The trial involves the use of three drugs: ezetimibe (+) simvastatin, atorvastatin calcium, and an unspecified placebo. The eligibility criteria for the trial are also included, with a list of inclusion and exclusion criteria. The inclusion criteria specify that patients must be between 18 and 79 years old and have high risk for coronary heart disease with LDL-C above 70 mg/dL or 100 mg/dL depending on their CHD risk category. The exclusion criteria include a variety of conditions that could pose a risk to the patient or interfere with participating in the study, such as chronic medical conditions, unstable doses of medications, and pregnancy or lactation.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial includes patients between the ages of 18 and 75 who have undergone a liver biopsy within the past 18 months and have a fibrosis score of F2, F3, or F3+ in the Metavir classification. Patients must not have received antiviral therapy and must be non-responders or relapsers to past antiviral treatment. The trial involves the drugs irbesartan and placebo. The eligibility criteria include several inclusion and exclusion criteria, such as the absence of hepatocellular carcinoma, HIV, cirrhosis, and anti-fibrotic treatment, as well as not being an alcohol abuser and not being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for chronic kidney disease, dialysis, and hyperphosphatemia. The trial involves the use of the drugs MCI-196 (colestilan, colestimide, cholebine) and a placebo. The eligibility criteria include being between 18 and 80 years old, having stable phosphate control using calcium-based phosphate-binding medication only, undergoing regular dialysis treatment, being on a stabilized phosphorus diet, and meeting certain requirements for pregnancy and contraception. Exclusion criteria include having certain medical comorbidities, having a BMI outside of a certain range, having gastrointestinal motility problems, testing positive for certain viruses, having a history of substance or alcohol abuse, having seizure disorders, using certain phosphate binder medications, having certain allergies, and having participated in a clinical study with experimental medication or biological products within a certain timeframe.",
    "The sample is a phase 3 clinical trial for the treatment of proctitis and proctosigmoiditis using the drugs budesonide and placebo. The trial includes patients with confirmed diagnosis of active, mild to moderate UP or UPS, with disease extending at least 5 centimeters but no further than 40 cm from the anal verge. The eligibility criteria include having a baseline MMDAI score between 5 and 10, not having a history or current diagnosis of Crohn's disease and indeterminate colitis, and not having certain medical conditions such as uncontrolled diabetes or abnormal thyroid function. The trial also excludes patients with a history of drug or alcohol abuse, recent vaccination, or allergies to budesonide or any other items used in its preparation. The trial prohibits certain medications to treat UP/UPS, including laxatives and anti-diarrhea medications, but allows oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes subjects who are aged between 35 to 80 years and have a mean systolic blood pressure of at least 130 mmHg if they have diabetes and/or chronic kidney disease, or at least 140 mmHg for all other subjects. The trial requires subjects to be receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic. Female subjects must be of non-childbearing potential. The trial has exclusion criteria such as average sitting systolic blood pressure of at least 180 mmHg or diastolic blood pressure of at least 110 mmHg, and subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (CVA) within 6 months. The trial also excludes subjects with implanted pacemakers or implanted cardioverter defibrillator (ICD), symptomatic congestive heart failure requiring treatment, hemodynamically significant valvular heart disease, type I diabetes mellitus, hemodialysis or peritoneal dialysis, diagnosis or recurrence of malignancy within the past 3 years, sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation greater than or equal to 90%, subjects who perform alternating shift or night work, and subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening.",
    "The sample is a phase 3 trial for congestive heart failure. The trial includes the drugs candesartan and placebo. The eligibility criteria for the trial includes being 18 years or older, having symptoms of congestive heart failure for more than 4 weeks before starting the study, and providing informed consent. The exclusion criteria includes having current low blood pressure with symptoms, significant liver disease, and being pregnant or lactating.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the drug CP-690,550 and the eligibility criteria include having completed a previous study on the drug. The record also includes a list of ICD-10 codes for the disease and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease pharyngitis and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, placebo and flurbiprofen. The eligibility criteria for the trial include having a complaint of sore throat, providing written informed consent, and meeting certain medical requirements. The exclusion criteria include a history of upper gastrointestinal ulcer, hepatic disease, renal dysfunction, or chronic analgesic use.",
    "The sample is a phase 3 clinical trial for patients with oral complications and a complaint of dry mouth attributed to opioid use. The trial is testing the effectiveness of pilocarpine hydrochloride compared to a placebo. Eligible patients must be receiving routine dosing of certain opioids and have a severity rating of at least 20 mm on a visual analog scale. Patients must also meet certain age, performance status, life expectancy, and medical criteria. They cannot have certain medical conditions or be taking certain medications. The trial excludes patients who have had prior radiotherapy to the parotid glands or concurrent use of tricyclic antidepressants. The trial will also collect quality of life data from patients in either English or French.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves two drugs, sitagliptin phosphate (+) metformin hydrochloride and pioglitazone, with the former being the experimental drug and the latter being the comparator. The eligibility criteria for the trial include patients who are inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy. The exclusion criteria include patients with a history of type 1 diabetes mellitus or ketoacidosis, those who were on antihyperglycemic agent therapy within the prior 12 weeks, and those who were on more than 4 weeks of antihyperglycemic therapy over the prior 3 years. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is for adults who are at least 18 years old and have been treated with three classes of antiretroviral drugs, including nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), for at least three months. The patients must have resistance to more than one PI, and those who are NNRTI-na\u00efve but have genotypically documented NNRTI-resistance mutations on past or screening resistance testing are also eligible. The CD4+ T lymphocyte count must be at least 50 cells/mm3, and the HIV-1 viral load must be at least 1,000 copies/mL at screening. The antiretroviral study treatment regimen must consist of tipranavir (TPV)/ritonavir (RTV) in combination with an optimized background regimen (OBR) of 2-4 agents, including N(t)RTIs (NRTI or NtRTI), enfuvirtide (ENF), and/or, where available, a trial approved expanded access program (EAP) investigational agent. The patients must have acceptable screening laboratory values that indicate adequate baseline organ function, acceptable medical history with a chest X-ray without evidence of active disease and an electrocardiogram (ECG) without clinically important abnormalities within one year of the study, and a reliable method of barrier contraception will be used by all female patients who are of childbearing potential. The exclusion criteria include known hypersensitivity to TPV or RTV, ARV medication na\u00efve, genotypic resistance to TPV, recent drug holiday, prior tipranavir use, inability to adhere to the requirements of the protocol, prior history of hemorrhagic stroke or intracranial aneurysm, history of ischemic stroke, neurosurgery or skull trauma within 4 weeks prior to screening, history of Progressive Multifocal Leukoencephalopathy, Visceral Kaposi's Sarcoma, and/or any malignancy, and any acquired immunodeficiency syndrome (AIDS) defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease fibromyalgia, which is identified by the presence of widespread pain for at least 3 months and pain in at least 11 of 18 specific tender point sites. The trial includes a list of icd-10 codes associated with the disease. The drugs being tested in the trial include [s,s]-reboxetine, placebo, and [s,s]-reboxetine. The eligibility criteria for the trial include being at least 18 years old and meeting the ACR criteria for fibromyalgia. Exclusion criteria include having other severe pain, autoimmune rheumatic disorder, non-focal rheumatic disease, active infection, untreated endocrine disorder, a recent diagnosis or episode of major depressive disorder, dysthymia, uncontrolled depression, history of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features.",
    "The sample is a phase 3 clinical trial for ovarian cancer and fallopian tube cancer. The trial involves the use of pegylated liposomal doxorubicin, carboplatin, and paclitaxel as drugs. The eligibility criteria include patients aged over 18 with a histologically proven diagnosis of cancer of the ovary, the fallopian tube, or extra-ovarian papillary serous tumors. Patients should have measurable disease or cancer antigen assessable disease, and disease in progression for more than 6 months after a first or second platinum-based line. Patients should have previously received a taxane derivative, have an ECOG performance status of less than 2, and a life expectancy of at least 12 weeks. Adequate bone marrow, renal, and hepatic function is also required. Exclusion criteria include ovarian tumors of low malignant potential, non-epithelial ovarian or mixed epithelial/non-epithelial tumors, previous radiotherapy, prior diagnosis of malignancy, bowel obstruction, sub-occlusive disease, or presence of symptomatic brain metastases, pre-existing motor or sensory neurologic pathology or symptoms, history of congestive heart failure, severe active infection, severe hypersensitivity to products containing Cremophor EL and/or to compounds chemically related to paclitaxel, carboplatin or Caelyx, fertile women not using adequate contraceptive methods, and pregnant or breastfeeding women.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes mellitus. The trial involves two drugs, insulin glargine new formulation (hoe901) and insulin glargine (hoe901) (lantus). The eligibility criteria include being over 18 years old, having an HbA1c level between 7.0% and 10.0%, and being on a stable insulin dose in the last 30 days. Patients using pre-mix insulins, human regular insulin as mealtime insulin, or any glucose-lowering drugs other than basal insulin and mealtime rapid-insulin analogue in the last 3 months are excluded. The trial also excludes patients with severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit, unstable proliferative diabetic retinopathy, or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment during the study period.",
    "The sample is a phase 3 clinical trial for patients diagnosed with type 2 diabetes. The trial involves the drugs saxagliptin and placebo. The eligibility criteria for the trial include being drug na\u00efve, having an HbA1c level between 7.2% and 10.0% at enrollment, and not having received insulin therapy within one year of enrollment. Patients with type 1 diabetes, a history of ketoacidosis, or hyperosmolar non-ketonic koma are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of two diseases, primary open angle glaucoma and ocular hypertension, and includes a list of corresponding ICD-10 codes. The trial is testing the effectiveness of a specific drug, a fixed combination of latanoprost 0.005% and timolol 0.5%. The eligibility criteria for the trial includes patients who are 18 years or older, have an IOP of 21 mmHg or higher, and are currently being treated with ophthalmic beta-blockers monotherapy but require a change in medication due to insufficient response to treatment. The exclusion criteria includes patients who have received any ophthalmic hypotensive agent other than a beta-blocker within the last month, have a contraindication to latanoprost or timolol, have a history of certain medical conditions, or have known intolerance to certain excipients contained in the trial treatment.",
    "The sample is a phase 3 trial for two types of diabetes mellitus: non-insulin dependent type 2 diabetes and non-insulin-dependent diabetes mellitus. The trial involves the use of sitagliptin, glimepiride as a comparator, and open-label metformin. The eligibility criteria for the trial include being 18 years or older, diagnosed with type 2 diabetes, and on a stable dose of metformin of at least 1500 mg per day. Exclusion criteria include a history of type 1 diabetes, pregnancy, HIV positivity, being on a weight loss program or medication, and having a history of blood disorder, certain cancers, heart, liver, or kidney disease. The icd-10 codes for the diseases being studied are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug duloxetine. The trial requires participants to be at least 18 years old and diagnosed with major depressive disorder. They must also be able to visit the doctor's office once a week to once every 2 weeks for a total of 8 weeks. Exclusion criteria include being pregnant or breastfeeding, having a current or previous major psychiatric disorder other than depression, a history of alcohol or drug dependence or abuse within the past 6 months, being allergic to the study drug or experiencing allergic reactions when taking several medications at once, and having a serious medical illness.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of fibromyalgia. The trial includes patients who meet the ACR criteria for fibromyalgia and have a score of over 40 mm on the Visual Analog Scale. The trial excludes patients with other musculoskeletal or rheumatic diseases, active infections, or untreated endocrine disorders. The trial involves the use of two drugs, pregabalin and placebo. The sample also includes the ICD-10 code for fibromyalgia, which is M79.7.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial includes patients who are chronically infected with HCV-1b and have a viral load of at least 100,000 IU/mL at screening. The patients must be between the ages of 20 and 75 and must have previously been non-responders to interferon plus ribavirin therapy or have been excluded from or intolerant to this therapy. The trial excludes patients with hepatocellular carcinoma, co-infection with Hepatitis B virus or Human Immunodeficiency Virus, and those with severe or uncontrollable complications. The trial will test the effectiveness of two drugs, bms-790052 (daclatasvir) and bms-650032 (asunaprevir), and will evaluate the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of drugs such as aripiprazole, olanzapine, quetiapine, or risperidone. The eligibility criteria for the trial includes having a clinical diagnosis of schizophrenia and experiencing symptoms that are not well controlled or not tolerating antipsychotic medication well. Patients with a diagnosis of schizoaffective disorder or who are treatment-resistant to antipsychotics are excluded from the trial. The icd-10 codes associated with schizophrenia are also included in the table.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed as [\"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", \"I10\"]. The drug being tested is a combination of valsartan and amlodipine. The eligibility criteria for the trial include successful completion of a previous core trial, and specific blood pressure measurements. Patients who experienced serious and drug-related adverse events in the previous trial are excluded, as well as those who meet other protocol-defined exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug vilazodone. The trial is open to both male and female participants between the ages of 18 and 70 who meet the DSM-IV-TR criteria for major depressive disorder and have a Hamilton Depression Rating Scale score of at least 18. Participants must not have a history of schizophrenia, schizoaffective disorder, or bipolar I or II disorder, and must not have a history of substance abuse or dependence within the past year. They must also not pose a serious suicidal or homicidal risk, and must not be taking psychotropic drugs or migraine medications with a serotonergic mechanism of action. Other exclusion criteria include hypersensitivity to SSRIs or 5-HT1a agonists, previous treatment with vilazodone, and taking Chantix or St. John's Wort. Participants must not have any significant acute or chronic medical disorders, seizure disorders, or prior history of malignancy with less than 5 year survival or completed treatment less than 1 year prior to enrollment and currently without evidence of recurrence. Female participants must not be pregnant, lactating, or planning to become pregnant during the study, and must be using adequate and reliable contraception throughout the trial. Participants must not have clinically significant ECG abnormalities, abnormal laboratory findings, or a positive drug screen. They must also be willing to comply with the visit schedule and study procedures.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of three drugs - thalidomide, dexamethasone, and doxil. The eligibility criteria for the trial include having previously untreated, histologically confirmed multiple myeloma, having an Eastern Cooperative Oncology Group (ECOG) status of 0-2, and having adequate blood counts and serum calcium levels. Exclusion criteria include not having received treatment with dexamethasone for multiple myeloma, not having peripheral neuropathy of Grade 2 or higher, and not having a Left Ventricular Ejection Fraction (LVEF) of less than 45 percentage, among others.",
    "The sample is a phase 3 clinical trial for lung transplantation patients. The trial is testing the effectiveness of the drugs everolimus and mycophenolatmofetil as immunosuppressive agents. The eligibility criteria include being a recipient of a single or bilateral lung transplantation, providing informed consent, being able to receive everolimus at week 3 after transplantation, having a negative pregnancy test for women of childbearing potential, and using appropriate contraceptive methods during the study. The exclusion criteria include systemic infection of the donor or recipient, HIV positivity, and participation in another investigational drug trial within 30 days before study start. The trial aims to determine the safety and efficacy of the drugs in lung transplantation patients.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on restless legs syndrome and includes a list of icd-10 codes associated with the disease. The trial involves the use of two drugs, pramipexole and levodopa in combination with benserazide. The eligibility criteria for the trial are listed, including age range, diagnosis, and symptoms. The exclusion criteria are also listed, including contraindications to the study medications and other health conditions that may put the patient at risk. The sample also notes that pregnant or nursing women or women of childbearing age who are not willing to use adequate contraceptive methods during the study period are excluded from participation.",
    "The sample is a phase 3 clinical trial for the treatment of renal cell carcinoma. The trial is testing the effectiveness of two drugs, pazopanib and sunitinib, on patients with locally advanced or metastatic renal cell carcinoma. The eligibility criteria include a diagnosis of renal cell carcinoma with clear-cell component histology, no prior systemic therapy for advanced or metastatic RCC, measurable disease by CT or MRI, and a Karnofsky performance scale status of >=70. In addition, patients must meet several other criteria related to age, organ function, and serum calcium concentration. The exclusion criteria include pregnancy or lactation, history of another malignancy, and several other medical conditions. Patients must also not be taking any prohibited medications or undergoing any cancer therapy at the time of enrollment.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of juvenile idiopathic arthritis. The trial involves the use of drugs such as infliximab plus methotrexate, combination of dmards, and methotrexate alone. The eligibility criteria for the trial include having arthritis lasting for at least 6 weeks but not more than 6 months, having polyarticular disease with at least 5 active joints with at least 3 joints with pain or tenderness and limitation of motion, and not having previous treatment with DMARDs. The exclusion criteria include having systemic JIA, any abnormality in the hematopoietic or lymphatic system, any major concurrent medical condition, inadequate psychosocial situation, pregnancy, and being a non-abstinent female with reproductive capacity without regular contraceptive use.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have had rheumatoid arthritis for at least 6 months. The patients must have also failed to respond to 1-5 DMARDs or biological agents and must be rheumatoid factor positive. The trial excludes patients with other chronic inflammatory articular disease or systemic rheumatic disease, those who have had joint or bone surgery within 8 weeks prior to randomization, and those who have previously been treated with any cell-depleting therapy. The trial will test the effectiveness of methotrexate and rituximab (mabthera/rituxan) as treatments for rheumatoid arthritis.",
    "The sample is a phase 3 clinical trial for the smallpox vaccine cj-50300. The trial is looking for healthy Korean male and female subjects below 60 years of age and born before 1979 who have been vaccinated with smallpox vaccines. The trial has a list of inclusion and exclusion criteria, including having good general health, without clinically skin diseases history, physical examination or laboratory test results, and not having diseases or conditions that cause immunodeficiency. The trial also excludes subjects who have taken corticosteroid within 3 months of vaccination or who are taking oral or parenteral corticosteroid, and subjects who have been taken immunosuppressive therapy including interferon within 3 months of vaccination or are taking immunosuppressive therapy. The trial has a total of 24 exclusion criteria, including being born after 1980, having a history or present of eczema or atopic dermatitis, and being allergic or sensitive to any known components of the vaccine or other medicines. The trial also excludes subjects who work in medical institutions, have household contacts with women who are pregnant or breast-feeding, or have a known history of cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis. The sample also includes a list of icd-10 codes of diseases associated with smallpox.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial includes patients who have failed treatment with diet and exercise for at least 2 months prior to screening and have inadequate glycemic control. The trial will test the efficacy of the drugs alogliptin and pioglitazone compared to a placebo. The eligibility criteria include a historical diagnosis of type 2 diabetes, a body mass index between 23 and 45 kg/m2, and a fasting C-peptide greater than or equal to 0.8 ng per mL. The trial also has exclusion criteria, such as a history of cancer, major illness, or debility that would prohibit the subject from completing the study. Participants must be willing and able to monitor their blood concentrations with a home glucose monitor and agree to use adequate contraception if they are sexually active.",
    "The sample is a phase 3 clinical trial for patients with visual impairment caused by macular edema secondary to either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). The trial is testing the effectiveness of the drug ranibizumab. The eligibility criteria include a diagnosis within 12 months prior to the trial, specific visual acuity scores, and exclusion criteria such as pregnancy, history of stroke, and use of certain medications. Other protocol-defined inclusion/exclusion criteria may also apply. The table includes columns for the trial phase, diseases being studied, ICD-10 codes for those diseases, the drug being tested, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for locally advanced or metastatic non-small cell lung cancer. The trial includes patients who have had disease progression after one prior platinum-based anticancer therapy. The trial involves the use of drugs such as aflibercept, placebo, docetaxel, and dexamethasone. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and adequate renal, liver, and bone marrow functions. Exclusion criteria include prior docetaxel treatment, uncontrolled hypertension, and prior treatment with radiotherapy, surgery, or chemotherapy within 28 days of randomization. The table also includes information on the diseases being studied, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of arthritis, specifically rheumatoid arthritis. The trial is being conducted in Japan and is open to Japanese individuals between the ages of 20 and 75 who have been diagnosed with the disease within the past 10 years. The trial involves the use of the drugs etanercept and methotrexate. The eligibility criteria include being Japanese and living in Japan, as well as not having received certain previous treatments or having other rheumatic diseases or conditions that could increase the risk of infection. Pregnant or lactating women are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have completed a short-term trial and meet certain demographic and procedural inclusion criteria. The patients must also demonstrate an acceptable degree of compliance with trial medication. The trial involves the use of two drugs, olanzapine and asenapine. The eligibility criteria include both inclusion and exclusion criteria, such as a CGI-S score of less than 6 and not having any clinically significant findings that would prohibit continuation. The trial also excludes patients who have met certain medical/psychiatric status criteria in the short-term trials, except for antidepressants and mood stabilizers.",
    "This sample is for a phase 3 clinical trial focused on hypertension. The trial is testing the effectiveness of the drug combination valsartan and amlodipine. The eligibility criteria for participants include being 18 years or older and having moderate to severe high blood pressure. Exclusion criteria include a history of allergies to certain medications, inability to stop prior blood pressure medications safely, and various medical conditions such as kidney impairment or autoimmune diseases. Women of child-bearing potential must be using acceptable methods of contraception or be post-menopausal or surgically sterile to participate. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with non-small cell lung cancer or radiation toxicity. The trial involves the use of carboplatin and paclitaxel as treatment. The eligibility criteria include having a pathologically proven diagnosis of Stage IIIA or IIIB NSCLC, being considered unresectable or inoperable, and having measurable or evaluable disease. Patients must also meet certain medical criteria, such as having a Zubrod Performance Status of 0-1 and adequate bone marrow function. Exclusion criteria include having N3 supraclavicular disease, prior systemic chemotherapy for the study cancer, and uncontrolled neuropathy grade 2 or greater regardless of cause.",
    "The sample is a phase 3 clinical trial for the treatment of plaque psoriasis. The trial includes subjects who are between 4 and 18 years old, weigh at least 13 kg, and have failed to respond to topical therapy. The trial also includes subjects who need systemic treatment to control their disease and meet certain criteria, such as having a Physician's Global Assessment (PGA) score of at least 4 or a Body Surface Area (BSA) involved of more than 20%. The trial excludes subjects who have previously used certain treatments, such as biologics or methotrexate, or who have certain types of psoriasis or infections. The trial will test the effectiveness of methotrexate and a placebo to methotrexate.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of two drugs, exenatide twice daily and premixed insulin aspart twice daily. The eligibility criteria for the trial include having been treated with diet and exercise and a stable dose of metformin or metformin with sulfonylurea/meglitinides for at least 3 months prior to the study start, having an HbA1c between 6.5% and 10.0%, and having a body mass index (BMI) between 25 kg/m^2 and 40 kg/m^2. Exclusion criteria include having type 1 diabetes, receiving chronic systemic glucocorticoid therapy, receiving treatment for gastrointestinal disease with a drug affecting gastrointestinal motility, using any prescription drug to promote weight loss within 3 months prior to the study start, having received treatment within 30 days prior to the study start with a drug that has not received regulatory approval, or having previously completed or withdrawn from this study or any other study investigating exenatide or GLP-1 analogs.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who are experiencing inadequate glycemic control on their current medication regimen. The trial is testing the effectiveness of liraglutide as a potential treatment option. The inclusion criteria require patients to have a BMI between 20 and 45 kg/m2, fasting C-peptide levels of at least 0.8 ng/mL, and HbA1c levels between 7.0% and 10.0%. Female subjects of childbearing potential must be practicing adequate contraception. The exclusion criteria include a history of cancer, treated diabetic gastroparesis, biliary disease or pancreatitis, significant GI surgery, recent clinically significant cardiovascular and/or cerebrovascular disease, hypertension, HIV infection, liver disease or acute symptomatic infection with hepatitis B or hepatitis C, alcohol or substance abuse, pregnancy, lactation, or being less than 6 weeks postpartum, known allergy to any GLP 1 analogue, liraglutide, other study medications' excipients, excipients of albiglutide, or Baker's yeast, history of type 1 diabetes mellitus, contraindications for the use of either background or potential randomized study medications, receipt of any investigational drug or liraglutide within the 30 days or 5 half lives before screening, or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies.",
    "The sample is a record of a clinical trial in phase 3, which involves the study of the effectiveness of two drugs, pegintron and intron a, in treating two types of cancer: melanoma and neoplasm metastasis. The diseases are identified by their names and icd-10 codes. The eligibility criteria for the trial are also listed, including the requirement for patients to have histologically proven cutaneous melanoma, a tumor thickness of at least 1.5 mm, and no evidence of distant metastasis. The exclusion criteria include any prior chemo-, immuno-, hormonal or radiation therapy, as well as macroscopic disease.",
    "The sample is a phase 3 trial for the treatment of advanced hepatocellular carcinoma. The trial includes the drugs sorafenib and placebo. The eligibility criteria for the trial includes being male or female, aged 18 or over, and having advanced hepatocellular carcinoma. Exclusion criteria includes a history of prior systemic chemotherapy and failure in vital organ. The diseases are listed as 'carcinoma, hepatocellular' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for subjects with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or other medical conditions expected to require daily NSAID therapy for at least 6 months. The trial involves two drugs, pn 200 tablets (500 mg naproxen and 20 mg omeprazole) and naproxen 500 mg tablets (pn 200 minus omeprazole). The eligibility criteria include having a history of a documented, uncomplicated gastric or duodenal ulcer within the past 5 years or being 50 years of age and older. Female subjects must have a negative pregnancy test and meet certain criteria for contraception. Exclusion criteria include a history of hypersensitivity to omeprazole or NSAIDs, participation in any study of an investigational treatment in the 4 weeks before screening, and presence of uncontrolled acute or chronic medical illness.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial is comparing the effectiveness of fentanyl buccal tablets to immediate-release oxycodone. The eligibility criteria include having chronic pain for at least 3 months associated with certain conditions, currently using a specific amount of opioid therapy, and being willing to provide written informed consent. Exclusion criteria include uncontrolled or rapidly escalating pain, recent history of substance abuse, known allergies to study drugs, and certain medical or psychiatric conditions. Participants must be willing and able to self-administer the study drug, comply with study restrictions, complete an electronic diary, and return to the clinic for scheduled visits.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients with HCV genotype 2 or 3 and cirrhosis determination who are unwilling, ineligible, or intolerant to IFN. The trial involves the use of drugs such as sof, rbv, placebo to match sof, and placebo to match rbv. The eligibility criteria include screening laboratory values within defined thresholds, no prior treatment with any investigational drug or device within 30 days of the screening visit, and the use of highly effective contraception methods if female of childbearing potential or sexually active male. The exclusion criteria include prior exposure to a direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase, pregnant or nursing female or male with pregnant female partner, current or prior history of clinical hepatic decompensation, history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol, excessive alcohol ingestion, or significant drug abuse.",
    "The sample is a phase 3 clinical trial for patients with stage IIIB or IV non-small cell lung cancer who require first-line chemotherapy. The trial is testing the effectiveness of tariquidar and vinorelbine compared to a placebo and vinorelbine. The eligibility criteria include having a WHO performance status of 2 or greater, being 18 years or older, having certain blood levels within normal ranges, and not having certain medical conditions or receiving experimental therapies within the last 4 weeks. The trial excludes patients who are eligible for curative radiotherapy or surgery, have had previous chemotherapy for NSCLC, have a WHO performance status less than 2 or greater than 2, have bronchoalveolar carcinoma, have previous or current primary malignancies at other sites within the last 5 years (with some exceptions), have poor medical risk due to other nonmalignant systemic diseases or active uncontrolled infections, have symptomatic brain metastases, have other medical or surgical conditions that would contraindicate chemotherapy, or have known hypervitaminosis or known sensitivity to certain vitamins.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic hepatitis B. The trial involves two drugs, entecavir and pegylated interferon \u03b1-2a, administered sequentially, and pegylated interferon \u03b1-2a administered alone. The trial has eligibility criteria for inclusion and exclusion. Inclusion criteria include having HBeAg positive, HBsAg positive, HBV DNA > 100,000 copies/ml, and anti-HBs negative, with serum ALT exceeding 2 X ULN but less than 10 X ULN. Exclusion criteria include being infected concurrently with HCV, HDV, and HIV, having a history of antiviral treatment for Hepatitis B, or having hepatic decompensation.",
    "The sample is a phase 3 clinical trial for patients diagnosed with rheumatoid arthritis. The trial includes patients who have been treated with MTX therapy for at least 4 weeks before the first administration and have at least 4 swollen and tender joints. The trial excludes patients with a history of hypersensitivity to human immunoglobulin proteins or other ingredients of golimumab, as well as patients with other collagen diseases, latent or active granulomatous infections, Felty syndrome, or severe, advanced, or poorly controlled diseases in any of the kidney, liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system, psychiatric system, and brain.",
    "The sample is a phase 3 clinical trial for the treatment of seasonal allergic rhinitis. The trial includes male and female subjects who are 12 years of age or older and have a 2-year history of moderate to severe seasonal allergic rhinitis. The trial involves the use of drugs such as mp29-02, azelastine hcl, fluticasone propionate, and placebo. The eligibility criteria include meeting minimum symptom requirements, being in generally good health, having a positive skin test to a prevalent Texas Mountain Cedar allergen, and being willing and able to provide informed consent and participate in all study procedures. The exclusion criteria include having nasal mucosal erosion, nasal ulceration, or nasal septal perforation, having other nasal diseases likely to affect deposition of intranasal medication, having had nasal or sinus surgery within the previous year, having chronic sinusitis, having planned travel outside of the study area during the study period, having used any investigational drug within 30 days prior to Day screening, having hypersensitivity to drugs similar to azelastine hydrochloride or fluticasone propionate, being pregnant or nursing, having respiratory tract infections within 14 days prior to Day screening, having respiratory tract infections requiring antibiotic treatment 14 days prior to screening, having asthma (with the exception of mild, intermittent asthma), having significant pulmonary disease including COPD, having clinically significant arrhythmia or symptomatic cardiac conditions, having a known history of alcohol or drug abuse within the last 2 years, having any surgical or medical condition or physical or laboratory findings that might significantly alter the absorption, distribution, metabolism, or excretion of study drug, that might significantly affect the subject's ability to complete this trial, or their safety in this trial, and having clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures.",
    "The sample is a phase 3 clinical trial for hypertension, with a list of icd-10 codes for related diseases. The trial involves four drugs: hydrochlorothiazide (+) losartan potassium, losartan potassium, placebo for losartan, and placebo for losartan/hctz. The eligibility criteria for the trial include being between 6 and 17 years old, having hypertension, and being able to swallow tablets. Females of childbearing potential must use contraception throughout the trial. Exclusion criteria include a history of heart, metabolic, or kidney disease, known disorders in various body systems, pregnancy or nursing, and participation in another clinical trial within the last 28 days.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma, a type of cancer. The trial involves the use of drugs such as cisplatin, cyclophosphamide, dexamethasone, etoposide, and thalidomide. The eligibility criteria for the trial include confirmation of stage I, II, or III multiple myeloma with specific protein criteria present, having received no more than 4 prior treatment regimens, and meeting certain health requirements such as having a certain level of blood cells and no preexisting peripheral neuropathy. Patients must also not be pregnant or nursing and must use effective contraception during the study. The trial allows for prior biologic therapy and chemotherapy, but not concurrent therapy. The sample does not specify the duration of the trial or the number of participants.",
    "The sample is a phase 3 clinical trial for women with invasive breast cancer who have undergone surgical treatment. The trial is testing the effectiveness of tibolone, a drug used to treat climacteric symptoms, compared to a placebo. The trial includes women who have experienced menopause or have had their ovaries or uterus removed, and who are experiencing vasomotor symptoms. The trial has specific inclusion and exclusion criteria, including age restrictions, history of cancer, and use of certain medications. Participants must provide informed consent and be willing to comply with all trial requirements.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of pain and includes a list of ICD-10 codes for the diseases being studied. The trial involves the use of three drugs, including a placebo, and has specific eligibility criteria for patients to participate. Patients must be at least 18 years old, scheduled to have a bunionectomy, and willing to stay at the study site for at least 48 hours after receiving the initial dose of medication. There are also exclusion criteria, such as having a current or previous disease that could impact the study or using prohibited medications. The sample includes both inclusion and exclusion criteria for patients.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of mania and bipolar I disorder using the drugs cariprazine and placebo. The trial includes a list of inclusion and exclusion criteria for patients, such as meeting the DSM-IV-TR criteria for bipolar I disorder and being voluntarily hospitalized for a current manic episode. The table also includes a list of icd-10 codes for the diseases being studied.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, which are antidepressant + placebo and antidepressant + aripiprazole. The eligibility criteria for the trial includes being between 18-65 years old, having experienced a current episode of major depressive disorder for at least 8 weeks, and having a treatment history of inadequate response to at least one and no more than three antidepressants.",
    "The sample is a phase 3 clinical trial for the treatment of various types of melanoma, including mucosal melanoma, recurrent melanoma, and stage II-IV skin melanoma. The trial involves the use of three drugs: carboplatin, paclitaxel, and sorafenib tosylate. The eligibility criteria for the trial include having a confirmed diagnosis of melanoma that is metastatic or unresectable, having measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST), and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients must also meet various laboratory and medical criteria, such as having a white blood count of at least 3,000/mm^3 and not having a serious intercurrent illness. Women who are pregnant or breastfeeding are excluded from the study, and all females of childbearing potential must have a blood test or urine study to rule out pregnancy before participating in the trial. Patients who have received prior systemic cytotoxic chemotherapy for treatment of melanoma are ineligible, but patients who have received immunotherapy or one prior investigational therapy may be eligible. Patients must not have ocular melanoma or a history or clinical evidence of brain metastasis. Patients must not be taking certain medications, such as cytochrome P450 enzyme-inducing antiepileptic drugs, rifampin, or St. John's Wort. HIV-positive patients are also excluded from the study.",
    "The sample is a phase 3 clinical trial for stress disorders, specifically post-traumatic stress disorder. The trial is testing the effectiveness of the drug Zoloft (sertraline) on children and adolescents between the ages of 6 and 17 who have been diagnosed with PTSD according to DSM-IV criteria and determined by the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL). The inclusion criteria require that subjects are within the specified age range and have a diagnosis of PTSD. The exclusion criteria exclude subjects who are currently experiencing ongoing trauma or living with their abuser, as well as those who are expected to participate in litigation related to their trauma during the study. Additionally, subjects who are likely to or at high risk for experiencing re-exposure to their index trauma are also excluded.",
    "The sample is a phase 3 clinical trial that focuses on metabolism and nutrition disorder and obesity. The trial involves the use of the drugs liraglutide and placebo. The eligibility criteria for the trial include having a BMI of 30.0 kg/m^2 or above, or a BMI of 27 kg/m^2 or above with co-morbidities of treated or untreated dyslipidemia and/or hypertension. Participants must also have stable body weight and have had a failed dietary effort in the past. Exclusion criteria include having type 1 or type 2 diabetes, a high HbA1c or FPG level, a screening calcitonin of 50 ng/L or above, a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma, and a history of acute or chronic pancreatitis. Participants must not have obesity induced by drug treatment, use approved weight lowering pharmacotherapy, or have had previous surgical treatment of obesity. Additionally, participants must not have a history of major depressive disorder or suicide attempt, or uncontrolled hypertension.",
    "The sample is a phase 3 clinical trial for HIV infections using Kaletra tablets as the drug. The eligibility criteria include being HIV and HCV positive, having an undetectable viral load for the last 6 months on HAART therapy, having serum AST and ALT levels less than 5 times normal, and having a Karnofsky Score of 70 or greater. Female participants must have a negative pregnancy test and agree to use a reliable form of birth control during the study. Exclusion criteria include active hepatitis B, substance abuse or psychiatric illness, abnormal laboratory test results, pregnancy or lactation, recent use of investigational drugs, resistance to lopinavir, receiving systemic chemotherapy, and being unsuitable for any other reason.",
    "The sample is a phase 3 clinical trial for patients with chronic renal anemia. The trial includes patients who are at least 18 years old and have been on regular hemodialysis for at least 12 weeks. The patients must also have been on maintenance therapy with subcutaneous epoetin alfa at the same administration interval for 4 weeks. The trial excludes patients who have received a red blood cell transfusion in the previous 2 months, have poorly controlled hypertension requiring interruption of epoetin alfa in the previous 6 months, have acute or chronic bleeding, or have active malignant disease (except non-melanoma skin cancer). The trial will test the effectiveness of methoxy polyethylene glycol-epoetin beta [mircera] and epoetin alfa as treatments for chronic renal anemia.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have been inadequately controlled on a stable dose of metformin and pioglitazone or on a combination therapy including metformin and another oral antidiabetic agent. The trial excludes patients with certain medical conditions, such as a history of cancer or heart failure, and those who have received investigational drugs within a certain timeframe. Patients must meet certain eligibility criteria, such as having a BMI between 23 and 45 kg/m^2 and a fasting plasma C-peptide concentration greater than or equal to 0.8 ng/mL. The trial includes the drugs alogliptin, pioglitazone, metformin, and placebo.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is focused on babies who are breastfed by their mothers and have received antiretroviral therapy as part of PMTCT. The inclusion criteria include being a singleton, having a negative HIV-1 DNA PCR test result at day 7, and meeting certain requirements for the mother such as being HIV-1 infected and not eligible for HAART or not taking HAART. The exclusion criteria include presenting with clinical symptoms or biological abnormalities, having serious congenital malformations, having a birth weight lower than 2.0 kg, and participating in another clinical trial on the day of enrollment.",
    "The sample is a phase 3 clinical trial for HIV and infectious diseases. The trial involves the use of two drugs, darunavir and ritonavir. The eligibility criteria for the trial include having documented HIV infection with a plasma HIV-RNA level of at least 1000 copies/mL, being able to comply with protocol requirements, and not having prior use of certain drugs. Exclusion criteria include not currently using an investigational drug, not being pregnant or breastfeeding, and having no Grade 3 or 4 laboratory abnormality as defined by DAIDS. The diseases are represented by a list of disease names and their corresponding ICD-10 codes.",
    "This is a sample from a clinical trial table that includes information about a phase 3 trial for prostate cancer. The table includes the phase of the trial, a list of diseases (in this case, only prostate cancer), a list of icd-10 codes for the disease, a list of drugs being used in the trial (lupron and casodex), and the eligibility criteria for participants. The inclusion criteria include specific PSA levels, Gleason scores, and clinical stages, as well as requirements for imaging and lab tests. Exclusion criteria are limited to those who do not meet the eligibility criteria.",
    "The sample is a phase 3 clinical trial that includes a list of childhood acute leukemia types, myelodysplastic syndromes, and other myeloid malignancies. The trial involves the use of drugs such as asparaginase, daunorubicin hydrochloride, cytarabine, thioguanine, and etoposide. The eligibility criteria for the trial include a diagnosis of DS or DS mosaicism by karyotype or chromosomal analysis, a diagnosis of MDS with < 30% blasts or AML, and no prior chemotherapy, radiotherapy, or any antileukemic therapy. Other criteria include specific age-related creatinine levels, no evidence of dyspnea at rest, and pulse oximetry > 94%. Patients with a history of transient myeloproliferative disorder (TMD) are also eligible under certain conditions.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have a documented history of RA in agreement with ACR criteria and have been on DMARD treatment for RA for at least 6 months with a stable dose for at least 6 weeks prior to the screening visit. Patients must also have a duration of morning stiffness greater than or equal to 45 minutes, and at least 4 swollen and tender joints out of 28. The trial excludes patients who suffer from another disease that requires glucocorticoid treatment during the study period, have had synovectomy within 4 months prior to study start, or have used glucocorticoids within a certain time frame prior to the screening visit. Patients who have used biologicals such as tumor necrosis factor \u03b1 (TNF\u03b1) inhibitors and other compounds within 5 serum half lives prior to screening visit, are pregnant or nursing are also excluded from the trial.",
    "The sample is for a phase 3 clinical trial for prostate cancer. The trial includes patients who are 18 years or older and have histologically proven prostate cancer of all stages where endocrine treatment is indicated. The patients must have a baseline testosterone level of over 1.5 ng/mL and a life expectancy of at least 12 months. The trial involves the use of drugs such as degarelix and leuprolide 7.5 mg. The diseases are listed as 'prostate cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes using the drug MP-513 and a placebo. The trial is open to subjects who are at least 18 years old and have had a documented diagnosis of type 2 diabetes for at least 6 months. The subject's diabetes must be managed by metformin monotherapy and their HbA1c must be between 7.0% and 10.0%. The trial has a list of inclusion and exclusion criteria, including BMI, FPG, and medical history. Female subjects must agree to use a double barrier method of contraception during the study. The trial aims to evaluate the safety and efficacy of MP-513 in treating type 2 diabetes.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who meet the DSM-IV-TR criteria for schizophrenia, are between 18 and 65 years old, and have a PANSS total score between 60 and 100 at screening and baseline. The trial excludes patients with a current, predominant Axis I psychiatric disorder other than schizophrenia, a current or history of substance dependence or abuse, significant risk of harming themselves or others, resistance to antipsychotic treatment, hospitalization for acute exacerbation within the past 3 months, or treatment with risperidone or paliperidone within the past 6 months. Other inclusion and exclusion criteria may also apply. The trial involves the use of zicronapine and risperidone as drugs.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of uncontrolled asthma. The trial involves a fixed combination of budesonide and formoterol, as well as budesonide. The eligibility criteria for the trial include a diagnosis of uncontrolled asthma, age between 18 and 77 years, and being a non-smoker. Exclusion criteria include the use of certain medications, certain medical conditions such as diabetes and neuropsychiatric diseases, and recent hospitalization for asthma or respiratory infection.",
    "This sample is for a phase 3 clinical trial for hypertension. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. In this particular sample, the drug being studied is aliskiren and the eligibility criteria includes patients who are at least 65 years old and have essential hypertension. However, patients with severe hypertension, a history or evidence of a secondary form of hypertension, or a history of hypertensive encephalopathy or cerebrovascular accident are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm. The trial involves the use of drugs such as dexamethasone, doxorubicin hydrochloride, valspodar, and vincristine sulfate. The eligibility criteria for the trial include confirmation of multiple myeloma, measurable disease, and objective evidence of progression. Patients must also have adequate prior chemotherapy and meet certain patient characteristics such as age, performance status, and hematopoietic, hepatic, renal, cardiovascular, neurologic, and gastrointestinal function. Prior concurrent therapy is also taken into consideration.",
    "The sample is a phase 3 clinical trial for patients with non-small-cell lung carcinoma. The trial is testing the effectiveness of two drugs, placebo and bibw 2992, on patients who have failed at least one but not more than two lines of cytotoxic chemotherapy. The trial has specific inclusion criteria, such as patients with pathologic confirmation of NSCLC Stage III-B or Stage IV adenocarcinoma, and exclusion criteria, such as patients with active brain metastases or significant or recent acute gastrointestinal disorders with diarrhea. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2 and a life expectancy of at least three months. The trial requires written informed consent consistent with ICH-GCP guidelines.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy using the drug eslicarbazepine acetate. The trial is for patients who are 65 years or older and have had a documented diagnosis of epilepsy for at least 12 months. Patients must have had at least 2 partial-onset seizures in the 4 weeks prior to screening and be currently treated with 1 or 2 antiepileptic drugs (except oxcarbazepine) in a stable dosage regimen for at least 4 weeks prior to screening. Patients must also be willing and able to comply with all trial requirements. The trial has inclusion and exclusion criteria, which are listed in detail. The diseases column lists only one disease, which is epilepsy, and the icdcodes column lists the ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for influenza and other viral respiratory diseases. The trial involves testing the effectiveness of the drug Ingavirin (imidazolyl ethanamide pentandioic acid) versus a placebo oral capsule. The trial includes participants who have had continuous contact with an ill person during the influenza/other acute viral respiratory disease season and have been exposed to the ill person's symptoms within 48 hours. Participants must also have signed an informed consent form and agree to use contraception throughout the study. Exclusion criteria include recent intake of interferone or interferone inducers, anti-virals (other than the investigational drug), vaccination for influenza within the past year, and pregnancy or lactation. The diseases being studied include influenza, acute respiratory infection, common cold, flu, and viral infection, and the corresponding ICD-10 codes are listed. The eligibility criteria for the trial are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial includes patients with overactive bladder symptoms for at least 3 months and who have reported an average of 1 urge incontinence episode per day in the 3-day bladder diary prior to the randomization/baseline visit. The trial also includes patients with a mean urinary frequency of at least 8 micturitions per day as verified by the 3-day bladder diary. The trial excludes patients with conditions that would contraindicate the usage of fesoterodine, clinically significant hepatic or renal disease, or other significant unstable diseases. Additionally, patients with OAB symptoms caused by neurological conditions or known pathologies of the urinary tract are excluded. Patients with a previous history of acute urinary retention requiring catheterization or severe voiding difficulties are also excluded.",
    "The sample is a phase 3 clinical trial for patients with unresectable Stage III or Stage IV non-small cell lung cancer and cachexia. The trial is testing the effectiveness of anamorelin hcl compared to a placebo. The eligibility criteria include a documented diagnosis of the disease, involuntary weight loss of at least 5% body weight within 6 months prior to screening, and a body mass index of 30 kg/m2 or less. Patients must also have a life expectancy of more than 4 months, an ECOG performance status of 2 or less, and adequate hepatic and renal function. Exclusion criteria include other forms of lung cancer, pregnancy or breastfeeding, and major surgery within 4 weeks prior to randomization. Patients must also not be taking prescription medications intended to increase appetite or treat weight loss, and must not have an active, uncontrolled infection or untreated clinically relevant hypothyroidism.",
    "The sample is a phase 3 clinical trial for the treatment of osteoporosis. The trial involves the drug alendronate and has eligibility criteria that include having non-metastatic adenocarcinoma of the prostate, a life expectancy of more than 12 months, and a requirement for treatment with LHRH agonists for at least 12 months. The trial also has exclusion criteria that include bone metastases, previous use of bisphosphonate within the past 12 months, and known hypersensitivity to LHRH. The trial requires the subject to sign an informed consent form before any study-specific procedures can be performed.",
    "The sample is a phase 3 clinical trial for patients with various types of cancer who have received or are currently receiving neurotoxic chemotherapy. The trial is testing the effectiveness of a gel containing baclofen, amitriptyline, and ketamine in treating pain and symptoms of peripheral neuropathy caused by the chemotherapy. Patients must meet certain eligibility criteria, including having a neuropathic pain score of at least 4 out of 10 and no pre-existing peripheral neuropathy due to any cause other than chemotherapy. The trial also has various patient characteristics and prior concurrent therapy requirements.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients who have had COPD for at least 12 months and chronic productive cough for 3 months in each of the 2 years prior to the baseline visit. The patients must have a FEV1/FVC ratio (post-bronchodilator) of \u2264 70% and a FEV1 (post-bronchodilator) between \u2265 40% and \u2264 70% of predicted. They must have been treated with tiotropium for at least 3 months before enrollment and have used at least 28 puffs of rescue medication during the last week prior to randomization. The trial will test the effectiveness of roflumilast and placebo as treatments for COPD. The sample also includes a list of ICD-10 codes for COPD and the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of erosive esophagitis, and the table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria require participants to have endoscopically confirmed erosive esophagitis of Grade A to D, and the target number of participants who are clearly Grade C or D is 15% or more of the total participants. Participants must have successfully completed the treatment period and have endoscopically healed EE at Week 2, 4, or 8 in the treatment period. The exclusion criteria include participants with an esophagus-related complication, a history of radiotherapy or cryotherapy of the esophagus, or a caustic or physiochemical trauma. Participants with Schatzki's ring or Barrett's esophagus are allowed to be included. Participants who have received surgery or treatment affecting gastroesophageal reflux or who have a history of surgery of stomach or duodenum are excluded. Participants with acute upper gastrointestinal bleeding, gastric or duodenal ulcer within 30 days prior to initiation of study drug administration, or a previous or current history of Zollinger-Ellison syndrome or other gastric acid hypersecretion disorder are also excluded.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the use of saxagliptin, metformin, and a placebo. The eligibility criteria for the trial include being diagnosed with type 2 diabetes, being on a stable dose of metformin greater than 1500 mg/day, and having an HbA1c level between 7.0% and 10.0%. The exclusion criteria include having used insulin therapy within one year of enrollment (except for hospitalization or gestational diabetes), having type 1 diabetes, a history of ketoacidosis, or hyperosmolar non-ketonic koma. The icd-10 codes associated with the disease are also provided.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for renal transplantation. The diseases column lists only one disease, which is renal transplantation. The icdcodes column contains a list of ICD-10 codes related to the disease. The drugs column lists three drugs that are being used in the trial, namely sirolimus, tacrolimus, and cyclosporine a. The criteria column contains the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria include age greater than or equal to 13 years, receiving CsA or tacrolimus from the time of transplantation or within 2 weeks thereafter, and having a functioning allograft and a Nankivell GFR greater than or equal to 20 mL/min within 2 weeks before randomization. The exclusion criteria include biopsy-confirmed acute rejection within 12 weeks before randomization that required antirejection treatment and patients who have undergone kidney-pancreas or other multiple organ transplants.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed as [\"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", \"I10\"]. The drug being tested is valsartan/amlodipine. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include factors such as uncomplicated essential hypertension being an inclusion criteria, while severe hypertension, history of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm, liver, kidney, or pancreas disease, insulin dependent diabetes, and allergy to certain medications used to treat high blood pressure being exclusion criteria. The sample also notes that there may be other protocol-defined exclusion criteria that apply.",
    "The sample is a record from a clinical trial table and includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular trial, it is a phase 3 study focused on non-small cell lung cancer and lung cancer. The drugs being tested are vandetanib and pemetrexed. The eligibility criteria include factors such as age, disease stage, previous treatment, performance status, and various medical conditions. The sample also includes exclusion criteria, such as certain medical conditions, medications, and previous or current malignancies.",
    "The sample is a phase 3 clinical trial for prostate cancer patients who have decided to undergo a prostatectomy or brachytherapy. The trial is testing the effects of vitamin E on the patients. The eligibility criteria include having localized prostate cancer, not taking supplemental vitamin E, being over 18 years old, having a life expectancy of greater than 6 months, and having normal organ and marrow function. Patients must also have the ability to understand and sign a written informed consent document. Exclusion criteria include having metastatic prostate cancer, receiving any other investigational agents, having a known bleeding diathesis or being on therapeutic anticoagulation, having a history of allergic reactions to compounds of similar chemical or biologic composition to vitamin E, and not being able to comply with study requirements due to uncontrolled intercurrent illness. Only men are eligible for this trial, and members of all races and ethnic groups are eligible.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorders using the drug quetiapine. The trial includes men and women between the ages of 18 and 65 with persistent positive or negative symptoms and a PANSS total score of at least 70 and less than 110, as well as a Clinical Global Improvement (CGI)- Severity of Illness score of at least 4 (moderately ill) at screening. The trial has inclusion and exclusion criteria, including the exclusion of subjects with other psychiatric, medical, or behavioral comorbid disorders that may interfere with study conduct or interpretation, and subjects with alcohol or psychoactive-substance dependence not in full remission or with significant alcohol or substance abuse in the past 3 months. The trial also requires subjects to respect the visit schedule and not have known intolerance to quetiapine at 800mg/day.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking for patients with histologically confirmed invasive breast cancer, with a tumor size of at least 3 cm by ultrasound, and no evidence of metastatic disease. The trial is open to female patients of any age and menopausal status, with no specified performance status or life expectancy. Patients must not be pregnant or nursing, must have a negative pregnancy test, and must use effective contraception if fertile. The trial is testing the effectiveness of a combination of cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride, and paclitaxel. There are no specified prior concurrent therapies.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes. The trial is testing two drugs, fluticasone furoate/gw642444 inhalation powder and fluticasone furoate inhalation powder. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of asthma for at least 6 months prior to screening, and having a best FEV1 of at least 50% of the predicted normal value at screening. The trial also has exclusion criteria, such as a history of life-threatening asthma, respiratory infection or oral candidiasis, and taking another investigational medication or medication prohibited for use during the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves the use of two drugs, fluticasone furoate/gw642444 and fluticasone propionate. The eligibility criteria for the trial include having a clinical diagnosis of asthma, a reversible FEV1 of 12% or greater, and currently using moderate to high dose inhaled corticosteroid therapy. The exclusion criteria include a history of life-threatening asthma, respiratory infection or oral candidiasis, asthma exacerbation, uncontrolled disease or clinical abnormality, allergies, and taking another investigational medication or prohibited medication. The diseases associated with the trial are asthma, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 3 clinical trial for constipation. The trial is open to male and non-pregnant, non-breastfeeding females who are at least 18 years old and have a history of constipation. The eligibility criteria include having two or fewer spontaneous bowel movements per week, with hard stools, incomplete evacuation, or straining during defecation. Subjects who never have spontaneous bowel movements are also eligible. Exclusion criteria include drug-induced constipation, endocrine, metabolic, or neurologic disorders, megacolon/megarectum, pseudo-obstruction, constipation resulting from surgery, known or suspected organic disorders of the large bowel, severe and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders, cancer or AIDS, and other gastrointestinal or endocrine disorders. Females of child-bearing potential must have adequate contraceptive protection during the trial. The trial will test the effectiveness of prucalopride.",
    "The sample is a phase 3 clinical trial for the treatment of impetigo, a skin infection. The trial involves testing three different drugs: ozenoxacin placebo, retapamulin 1% ointment, and ozenoxacin 1% cream. The eligibility criteria for participants include having a clinical diagnosis of bullous or non-bullous impetigo with a total affected area between 1-100 cm2, a Total Skin Infection Rating Scale (SIRS) score of at least 8, and no bacterial infection that cannot be treated with a topical antibiotic. Participants with systemic signs and symptoms of infection, such as a fever, are excluded from the trial.",
    "The sample is a phase 3 clinical trial for fibromyalgia. The trial includes patients who meet the American College of Rheumatology criteria for fibromyalgia and have completed at least 4 pain diaries within the last 7 days with an average pain score of at least 4. Patients must also have a score of at least 40 mm on the Visual Analogue Scale of the SF-MPQ at screening and randomization. Patients with other severe pain that may confound assessment or self-evaluation of the pain associated with fibromyalgia, any inflammatory muscle or rheumatologic disease other than fibromyalgia, active infections, or untreated endocrine disorders, and severe depression are excluded from the trial. The trial will test the efficacy of pregabalin and placebo as treatments for fibromyalgia.",
    "The sample is a phase 3 clinical trial for asthma, with the inclusion criteria being outpatients of Asian ancestry who are 12 years or older (or 18 years or older if local regulations or regulatory status of study medication permit enrolment of adults only) and have been diagnosed with asthma at least 12 weeks prior to the first visit. The trial requires subjects to have a best FEV1 of 40%-90% of the predicted normal value at the screening visit, and to demonstrate \u226512% and \u2265200mL reversibility of FEV1 within 10-40 minutes following 2-4 inhalations of albuterol/salbutamol inhalation aerosol (or one nebulized treatment with albuterol/salbutamol solution) at the screening visit. All subjects must be using an ICS, with or without LABA, for at least 12 weeks prior to the first visit. The trial also has exclusion criteria, including a history of life-threatening asthma, respiratory infection, asthma exacerbation requiring oral corticosteroids within 12 weeks of the first visit, and other concurrent diseases/abnormalities that would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of metastatic colorectal cancer. The trial involves the use of chemotherapy and bevacizumab as drugs. The eligibility criteria for the trial include being an adult patient over 18 years of age, having metastatic colorectal cancer with disease progression, and having been previously treated with first-line chemotherapy plus Avastin. The exclusion criteria include having a diagnosis of progression of disease more than 3 months after last Avastin administration, having first-line patients with progression-free survival in first-line of less than 3 months, and having patients receiving less than 3 consecutive months of Avastin in first-line therapy. Additionally, patients with a past or current history of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix, clinically significant cardiovascular disease within 6 months prior to start of study treatment, and known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol, are also excluded from the trial.",
    "The sample is a phase 3 clinical trial that focuses on the treatment of osteoporosis, vascular calcification, and inflammation. The trial involves the use of vitamin K as a drug. The eligibility criteria for the trial include being an ambulatory general population with a dietary intake of vitamin K below 120 mcg. Exclusion criteria include having a terminal illness, renal or liver disease requiring treatment, kidney stone in the past 5 years, and treatment with certain medications for osteoporosis in the previous 3 months. The trial also excludes individuals with known coronary disease, prior open heart surgery, and atrial fibrillation.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of chronic hepatitis C, and the table includes a list of diseases and their corresponding ICD-10 codes. The trial involves the use of two drugs, peginterferon alfa-2a and ribavirin, and includes eligibility criteria for patients to participate in the trial. The inclusion criteria include being an adult patient with serological evidence of chronic hepatitis C, having genotype 2 or 3, and receiving PEGASYS + Copegus according to local standard of care with no rapid viral response. The exclusion criteria include having received pegylated interferon, standard interferon, or ribavirin therapy prior to the current therapy, coinfection with hepatitis A or B or HIV, and a history or other evidence of decompensated liver disease.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients who are above 18 years old and have had an affective episode requiring hospitalization or outpatient drug treatment. The episode can be a manic episode, a depressive episode of at least moderate degree, or a mixed manic state. The trial requires that no more than 12 months have passed between the onset of the index episode and the date of randomization. Patients must have had at least one previous episode within the last five years that meets the criteria mentioned above. The trial also requires that patients have had at least one manic episode or mixed manic episode within the last five years. Patients who have contraindications to the protocol drugs, severe somatic disease, or are pregnant are excluded from the trial. Patients who have previously received prophylactic treatment with lithium or lamotrigine and experienced a definite lack of prophylactic effect are also excluded. Patients with an ICD-10 diagnosis of abuse within the last year with a subsequent risk of protocol violation are excluded as well. Patients who are anticipated to violate the protocol for other reasons, have not given written informed consent, or have previously been randomized in the study are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on prostate cancer and involves the use of two drugs, doxorubicin hydrochloride and methylprednisolone. The eligibility criteria for patients include having symptomatic prostate cancer with bone pain or urethral compression, and having metastatic disease. Patients must also have a neutrophil count greater than 1500/mm3, a platelet count greater than 100,000/mm3, and a hemoglobin level greater than 9 g/dL. They must not have any contraindications to anthracycline treatment and must not have had any prior primary cancer except basal cell skin cancer. The trial does not allow for concurrent chemotherapy or strontium treatment.",
    "The sample is a phase 3 trial for chronic obstructive pulmonary disease (COPD). The trial includes a list of ICD-10 codes for the disease and two drugs, roflumilast and placebo. The eligibility criteria for the trial include having a history of COPD for at least 12 months prior to the baseline visit, having a FEV1/FVC ratio (post-bronchodilator) of \u2264 70%, and having a FEV1 (post-bronchodilator) between \u2265 40% and \u2264 70% of predicted. The main exclusion criteria include having a COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to the baseline visit.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features. The trial involves the use of aripiprazole and placebo drugs. The eligibility criteria for the trial include certain inclusion and exclusion criteria, such as patients with certain other psychological disorders or a co-morbid serious, uncontrolled systemic illness. Patients with a significant risk of committing suicide are also excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial includes participants who have been experiencing chronic pain due to conditions such as Osteo Arthritis, Low Back Pain, Rheumatoid Arthritis, Neck Shoulder Arm Syndrome, Diabetic Neuropathy, Post herpetic Neuralgia, or other conditions for at least 3 months. The trial drug is tramadol hydrochloride (hcl) plus acetaminophen (jns013). The eligibility criteria include participants whose pain cannot be controlled sufficiently with at least 14-day continuous treatment with identical oral non steroid anti-inflammatory drugs (NSAIDs) at a usual maximum dose during 3 months prior to this study, ambulatory participants without need for any supportive device or assistance during daily life, outpatients, and participants who do not plan to change the therapeutic policy and content of the medications for underlying disease during screening period to the end of Treatment Period I. The exclusion criteria include participants with conditions for which opioids are contraindicated, participants with conditions for which APAP are contraindicated, participants with history of convulsion or the possibility of convulsive seizure, participants with concurrent, previous, or possible alcohol dependence, drug dependence, or narcotic addiction, pregnant participants or those who may be pregnant, lactating mothers, and participants who wish pregnancy during the study period.",
    "The sample is a phase 3 clinical trial for pain management after inguinal hernia repair surgery. The trial includes patients who have elective open unilateral inguinal herniorraphy using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local anesthetic infiltration at the conclusion of surgery. The trial aims to test the effectiveness of pregabalin and placebo in pain management. The eligibility criteria include the ability to use and tolerate non-steroidal anti-inflammatory drugs, tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery. The exclusion criteria include non-elective or emergency surgery, hernia with incarceration, and the planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery with general anesthesia.",
    "The sample is a phase 3 clinical trial for patients with idiopathic Parkinson's disease. The trial is testing the effectiveness of pramipexole extended release and pramipexole immediate release drugs. The eligibility criteria include being diagnosed with Parkinson's disease within the last 5 years, being at least 30 years old at the time of diagnosis, having a Modified Hoehn and Yahr stage of 1 to 3, and receiving pramipexole immediate release for at least three months prior to the baseline visit. The trial also has exclusion criteria, such as having motor complications under levodopa therapy, having dementia, or having a history of drug abuse. Patients must comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. The trial requires patients to provide signed informed consent before any study procedures are carried out in accordance with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines and local legislation.",
    "This is a sample from a clinical trial table that is in phase 3. The trial is focused on asthma and the icd-10 codes associated with it. The drugs being tested are budesonide/formoterol (symbicort) pmdi and budesonide hfa pmdi. The eligibility criteria for the trial include being African American, at least 12 years old, having moderate to severe asthma requiring treatment with an inhaled corticosteroid, and having a diagnosis of asthma for at least 6 months. The exclusion criteria include subjects requiring treatment with systemic corticosteroids and any significant disease or disorder that may jeopardize a subject's safety.",
    "This sample is for a phase 3 clinical trial focused on obesity. The trial is looking for obese adults with a BMI between 30 to 45 kg/m2 or overweight adults with a BMI between 27 to 29.9 kg/m2 and at least one obesity-related comorbidity such as hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, or sleep apnea. The trial requires participants to be able to complete a 2-year study. Exclusion criteria include diabetes, pregnancy, history of heart valve disease, and serious or unstable current or past medical conditions. The trial will test the effectiveness of lorcaserin 10 mg bid and a matching placebo bid.",
    "The sample is a phase 3 clinical trial for the treatment of head and neck cancer. The trial is looking at the effectiveness of a combination of drugs including cisplatin, docetaxel, and 5-fluorouracil. The eligibility criteria for the trial includes having histologically confirmed squamous cell carcinoma of the oropharynx, being in stage III or IV disease, and having no T1-2, N1 disease or T4b disease. Patients must also have no other primary tumor sites or unknown primary tumor sites and must not have received any prior treatment for head and neck cancer. The trial is looking for patients with measurable or non-measurable disease by clinical exam, CT scan or MRI, and the disease must be considered curatively resectable. Patients must also have a Zubrod performance status of 0-1 and meet certain medical criteria such as having no myocardial infarction within the past 3 months and no active systemic infection. Prior concurrent therapy is not allowed.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes mellitus. The trial involves the use of three different drugs, including technosphere\u00ae insulin with medtone c inhaler, technosphere \u00aeinsulin with gen2 inhaler, and insulin aspart in combination with a basal insulin. The eligibility criteria for the trial include being at least 18 years old, having a clinical diagnosis of type 1 diabetes mellitus for at least 12 months, having a body mass index (BMI) of 38 kg/m2 or less, having a stable dose of basal/bolus insulin therapy for at least 3 months with an FPG consistently < 220 mg/dL, having an HbA1c level between 7.5% and 10.0%, having a fasting C-peptide level of 0.30 pmol/mL or higher, and being willing to not use CGM during the entire course of the trial. The exclusion criteria include having a total daily insulin dose of 2 IU/kg/day or higher, having a history of inhaled insulin use in the previous 6 months, having two or more unexplained severe hypoglycemic episodes within 3 months of screening, having any hospitalization or emergency room visit due to poor diabetic control within 6 months of screening, having an allergy or known hypersensitivity to insulin or to any of the drugs to be used in the study, having a history of recent blood transfusions, hemoglobinopathies, or any other conditions that affect HbA1c measurements, having a history of COPD, asthma, or any other clinically important pulmonary disease, having any clinically significant radiological findings on screening chest x-ray, having active respiratory infection within 30 days before screening, having major organ system diseases, including seizure disorder, systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine, cancer (other than excised cutaneous basal cell carcinoma) or any history of lung neoplasms, having current or previous chemotherapy or radiation therapy that may result in pulmonary toxicity, having clinically significant abnormalities on screening laboratory evaluation or chest x-ray, having severe complications of diabetes, being pregnant, lactating, or planning to become pregnant during the clinical study period, having current drug or alcohol abuse or a history of drug or alcohol abuse, exposure to any investigational medications or devices within the previous 30 days before study entry, being unable to read or write, or unlikely to comprehend and follow the study protocol procedures, lack of compliance with medication or procedures that may affect the study data or subject safety and that precludes the subject from participation in the study, or any other concurrent medical or major psychiatric condition that makes the subject unsuitable for the clinical study or could limit the validity of the informed consent or impair the subject's safety.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of psoriasis, with a list of icd-10 codes provided. The drugs being tested are cp-690,550, and the eligibility criteria for participants include being 18 years or older with a diagnosis of plaque-type psoriasis for at least 12 months prior to the first dose of the study drug. Participants must also have a Psoriasis Area and Severity Index (PASI) score of 12 or greater, and a Physician's Global Assessment (PGA) score of 3 (moderate) or 4 (severe), with psoriasis covering at least 10% of their body surface area. Exclusion criteria include non-plaque or drug-induced forms of psoriasis, inability to discontinue current oral, injectable, or topical therapy for psoriasis, and any uncontrolled significant medical condition.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on rheumatoid arthritis and includes a list of ICD-10 codes associated with the disease. The trial involves several drugs, including a placebo, methylprednisolone, methotrexate, and folic acid or folate. The eligibility criteria for the trial include being an adult between the ages of 18 and 80 with active rheumatoid arthritis for at least 3 months and no more than 10 years, evidence of erosive disease and/or clinical synovitis in a signal joint, and inadequate response to 12.5-25 mg/week methotrexate for at least 12 weeks. The exclusion criteria include having a rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis, having had any surgical procedure within 12 weeks prior to baseline, and having previous treatment with a biologic agent or with a B cell modulating or cell depleting therapy.",
    "The sample is a phase 3 clinical trial for patients suffering from chronic bronchitis and lung diseases. The trial involves two drugs, avelox (moxifloxacin, bay12-8039) and placebo. The eligibility criteria for the trial include being a male or female out-patient aged 45 years or older, having FEV1 (forced expiratory volume in one second) of 70% or less and FEV1/FVC (forced vital capacity) of 70% or less predicted from age, height, and sex, having a smoking history of at least 20 pack-years, and having presented with at least two documented acute exacerbation episodes during the last 12 months. The exclusion criteria include having a known history of chronic colonization of pathogenic organisms resistant to moxifloxacin, requiring home ventilatory support for COPD, or having a tracheostomy in situ.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes patients who are over 18 years old and have been admitted to a hospital for a heart problem and are currently taking an approved medication to lower cholesterol. The trial excludes patients with congestive heart failure, uncontrolled high blood pressure, poorly controlled blood sugar, impaired kidney function, or HIV. The trial will test the effectiveness of the drug mk0653a (ezetimibe [+] simvastatin) compared to several other cholesterol-lowering medications, including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. The icd-10 codes associated with hypercholesterolemia are E78.01, E78.00, and Z83.42.",
    "The sample is a phase 3 clinical trial for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) using methylphenidate hydrochloride. The trial is looking for adults who have been diagnosed with ADHD according to DSM-IV criteria and have had symptoms from childhood to adulthood. The inclusion criteria also require that some symptoms were present before the age of 7 and continue to meet DSM-IV criteria at the time of assessment. The exclusion criteria include patients who are non-responders to methylphenidate or have been treated with any methylphenidate-containing medication within 1 month of starting the study. Patients with clinically unstable psychiatric conditions, family history of schizophrenia or affective psychosis, motor tics or a history of Tourette's syndrome, substance abuse or dependence disorder, eating disorder, or mental retardation are also excluded. Additionally, patients using any medications that may affect the evaluation of study results are not eligible for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of venous thromboembolism. The trial involves patients who have been treated for 6 to 18 months with therapeutic dosages of an oral VKA or RE-COVER study medication. The trial includes inclusion and exclusion criteria, such as written informed consent, no indication for VKA other than DVT and/or PE, no active liver disease or liver disease decreasing survival, and no acute bacterial endocarditis. Patients with active bleeding or high risk for bleeding, uncontrolled hypertension, intake of another experimental drug within the 30 days prior to randomization into the study, life expectancy less than 6 months, childbearing potential without proper contraceptive measures, pregnancy or breastfeeding are excluded from the trial. The drugs being tested are dabigatran etexilate 150 mg twice daily (bid) and matching placebo twice daily (bid).",
    "The sample is a phase 3 clinical trial for patients with CD20-positive diffuse large B-cell lymphoma who have experienced relapse after complete remission or partial response to first-line treatment. The trial includes a list of drugs, such as rituximab and etoposide, and eligibility criteria, including age between 18 and 65, ECOG performance status of 0 to 2, and a minimum life expectancy of 3 months. Exclusion criteria include Burkitt, mantle-cell, and T-cell lymphoma, documented infection with HIV and hepatitis B virus, and poor renal or hepatic function. The trial requires signed written informed consent prior to randomization.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes patients who meet the DSM-IV-TR criteria for major depressive disorder and have a confirmed diagnosis through the MINI interview. The trial excludes patients with a history of bipolar or psychotic disorders, alcohol/substance dependence or abuse, and those who have used certain medications within a specified time frame. The trial will evaluate the effectiveness of saredutant, escitalopram, and a placebo. The eligibility criteria include a minimum score on the MADRS and HAM-D assessments, as well as a minimum duration of the current depressive episode. The investigator will also evaluate other reasons why a patient may not be eligible for the trial.",
    "The sample is a phase 3 clinical trial for patients with documented atrial fibrillation for more than 72 hours. The trial aims to investigate the effectiveness of cardioversion and antiarrhythmic treatment in these patients who are under oral anticoagulation. The trial includes a list of inclusion and exclusion criteria, such as contraindications to oral anticoagulation, previous use of amiodarone, and severe congestive heart failure. The trial also lists the diseases, icd-10 codes, and drugs involved in the study. The eligibility criteria are not exhaustive and may not include all relevant considerations for a patient's potential participation in the trial.",
    "The sample is a phase 3 clinical trial for patients with tumor lysis syndrome, cancer, and hyperuricemia. The trial involves the use of two drugs, rasburicase and allopurinol. The eligibility criteria for the trial include having a high risk or potential risk for tumor lysis syndrome, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, being at least 18 years old, having a life expectancy of more than 3 months, and having a negative pregnancy test (for females of childbearing potential) and using an effective contraceptive method (for both males and females). The inclusion criteria for high risk or potential risk for tumor lysis syndrome are also specified in detail. Patients must provide signed written informed consent to participate in the trial.",
    "The sample is a phase 3 trial that focuses on the treatment of neural tube defects and contraception using oral contraceptives. The trial includes a list of icd-10 codes for the diseases being studied and a list of drugs being tested, which are drospirenone/ethinylestradiol/methyltetrahydrofolate and drospirenone/ethinylestradiol (yaz). The eligibility criteria for the trial include healthy women between the ages of 18 and 40 who are seeking oral contraception. The exclusion criteria include the use of steroidal oral contraceptives or any drug that could alter oral contraception metabolism during the study.",
    "The sample is a phase 3 clinical trial for primary insomnia. The trial includes subjects who meet DSM-IV criteria for primary insomnia and report sleeping no more than 6.5 hours per night and/or taking more than 30 minutes each night to fall asleep for at least one month prior to screening. The trial includes male and female subjects between 21 and 64 years of age, inclusive, at the time of consent. Female subjects of childbearing potential must sign the Women of Childbearing Potential Addendum to the informed consent form. The trial excludes subjects with any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems. The trial also excludes subjects with a history of cancer within the past 5 years, or current malignancy except for non melanomatous skin cancer, and subjects with a psychiatric diagnosis with psychosis, dementia or delirium. Subjects with Sexual and Gender Identity Disorders or other non-psychotic disorders will be considered on a case-by-case basis. The trial also excludes subjects with one of the following Personality Disorders: schizotypal, schizoid, or borderline personality disorder. The trial also excludes subjects with difficulties in sleep initiation or maintenance associated with known medical diagnosis (e.g. sleep apnea, restless leg syndrome (RLS), or periodic leg movement syndrome (PLMS), or has any condition that has or may affect sleep (e.g., chronic pain, BPH, etc.). The trial also excludes subjects who have participated in a previous eszopiclone clinical trial, have a known sensitivity to racemic zopiclone, any benzodiazepine, any sedative hypnotic, any substance that is contained in the formulation, or have been hospitalized for any allergic conditions (e.g. recurrent dermatitis, drug hypersensitivity, drug allergy, etc.). The trial also excludes subjects with a history of substance abuse in the past 10 years or substance dependence at any time or positive urine drug test at screening. The trial also excludes subjects who test positive at screening for hepatitis B surface antigen, hepatitis C antibody or have a history of a positive result, and subjects who are known to be seropositive for HIV. Female subjects who are pregnant, lactating or within 6 months post partum are also excluded. The trial also excludes subjects who self-report consumption of more than two alcoholic beverages daily, 14 or more alcoholic beverages weekly, or five or more alcoholic beverages on any given day. The trial also excludes subjects who have taken any psychotropic medications or other medications known to affect sleep within the 3 days prior to screening visit or is anticipated to need any of these types of medications during double-blind treatment. The trial also excludes subjects who have participated in any investigational study within 30 days prior to screening. The trial also excludes subjects who have taken herbal supplements, purported to have central nervous system effects,(tablets, powders, extracts or tinctures) or combination products with herbs or melatonin within 14 days prior to screening or St. John's Wort within 30 days prior to screening. The trial also excludes subjects who are a rotating or third/night shift worker and subjects who are a staff member or relative of a staff member.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes participants who have been on a stable dose of statin for at least 3 months prior to screening and have a mean low density lipoprotein cholesterol level greater than or equal to 100 mg/dL and less than or equal to 190 mg/dL for 2 consecutive samples. The trial involves the use of lapaquistat acetate and stable statin therapy or stable statin therapy alone. The eligibility criteria include being a sexually active female of childbearing potential who agrees to use adequate contraception, having a mean triglyceride level greater than or equal to 400 mg/dL for 2 consecutive samples, and being willing and able to comply with the recommended, standardized diet. The exclusion criteria include having active liver disease or jaundice, having a previous history of cancer that has been in remission for less than 5 years prior to the first dose of study medication, and having type 1 or 2 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for the treatment of neurogenic orthostatic hypotension, non-diabetic autonomic neuropathy, multiple system atrophy, and dopamine beta hydroxylase deficiency. The trial involves the use of the drug droxidopa and a placebo. The eligibility criteria for the trial include having participated in a previous droxidopa protocol, providing written informed consent, and not currently taking certain medications. Exclusion criteria include having certain medical conditions, taking certain medications, and being pregnant or breastfeeding. The trial also requires the use of acceptable contraception for women of childbearing potential.",
    "The sample is a phase 3 clinical trial for the treatment of rheumatoid arthritis. The trial includes patients who have been diagnosed with active rheumatoid arthritis after the age of 16 and have been treated with one of the following disease modifying anti-rheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine. Patients must have at least 4 swollen joints and 4 tender/painful joints, and either an Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or a C-Reactive Protein (CRP) blood result of 10mg/L or more. Additionally, patients must have at least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, or presence of serum anti-cyclic citrullinated peptide antibodies (blood test). Patients who are pregnant or breastfeeding, have poorly controlled hypertension, liver disease or significant liver function test abnormalities, certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders, recent or significant cardiovascular disease, significant active or recent infection including tuberculosis, previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent, severe renal impairment, or neutropenia are excluded from the trial. The drugs being tested are fostamatinib and placebo, fostamatinib.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients with a clinical diagnosis of asthma, who have a reversible airway obstruction of at least 12% and 200mLs following 2-4 inhalations of albuterol, and have an FEV1 of 40-85% predicted normal. The patients must also be currently using inhaled corticosteroid therapy. The trial excludes patients with a history of life-threatening asthma within the previous 5 years, respiratory infection or oral candidiasis, asthma exacerbation requiring oral corticosteroids or overnight hospitalization, uncontrolled disease or clinical abnormality, allergies, taking another investigational medication or prohibited medication, night shift workers, and current smokers or subjects with a smoking history of at least 10 pack years. The trial will test the efficacy of several drugs, including fluticasone furoate/vilanterol inhalation powder, fluticasone propionate/salmeterol inhalation powder, and two placebos.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesteremia and hyperlipidemia. The trial involves the use of three drugs - mk-0524a, er niacin, and placebo. The eligibility criteria for the trial include having a certain level of LDL-C, TG, and no unstable doses of medications. Pregnant or lactating women, women intending to become pregnant, and patients with certain medical conditions are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of diabetic macular edema. The trial includes patients with Type 1 or Type 2 diabetes mellitus with stable treatment for at least 3 months and glycosylated hemoglobin (HbA1c) \u2264 12.0%. Patients must have visual impairment due to DME in at least one eye and be eligible for laser treatment. The study eye must have BCVA \u2265 39 and \u226478 letters using ETDRS-like visual acuity testing charts at a testing distance of 4 meters. Patients with certain ocular and systemic conditions or prior treatments are excluded. The trial will use ranibizumab as the drug treatment.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. The trial involves the use of drugs such as amg 386 and paclitaxel, along with a placebo. The eligibility criteria include being a female over 18 years old, having a Gynecologic Oncology Group (GOG) Performance Status of 0 or 1, and having undergone surgery for one of the specified cancers. The trial also requires radiographically documented disease progression and adequate organ and hematological function. Exclusion criteria include having received more than 3 previous regimens of anti-cancer therapy, having received paclitaxel as consolidation therapy, and having primary platinum-refractory disease. The trial also excludes subjects with a history of arterial or venous thromboembolism within 12 months prior to randomization, and those who have not yet completed a 21 day washout period prior to randomization for any previous anti-cancer systemic therapies.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a history of smoking, and have a pre and post-albuterol/salbutamol FEV1/FVC ratio of less than 0.70 and a pre and post-albuterol/salbutamol FEV1 of less than or equal to 70% of predicted normal values. The trial will test the efficacy of umeclidinium bromide and fluticasone propionate/salmeterol in treating COPD. The eligibility criteria include being an outpatient, providing informed consent, having an established clinical history of COPD, and meeting certain smoking history and disease severity criteria. Exclusion criteria include pregnancy, asthma, other respiratory disorders, and certain medical conditions. The trial will not include patients who are unable to read or have a history of drug or alcohol abuse.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for Crohn's disease, a type of inflammatory bowel disease. The trial involves the drug adalimumab and has a list of inclusion and exclusion criteria for eligible patients. The inclusion criteria include having moderate to severe Crohn's disease and having failed prior infliximab therapy. The exclusion criteria include previous treatment with adalimumab and being considered an unsuitable candidate by the investigator for any reason. The table also includes lists of disease names, ICD-10 codes, and drug names.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs, and eligibility criteria for inclusion and exclusion. Inclusion criteria include a diagnosis of type 2 diabetes mellitus, being on a diet and exercise regimen, pre-treatment with metformin, having an HbA1c level between 7.0% and 10%, being 18 years or older, and having a BMI of 45Kg/m2 or less. Exclusion criteria include uncontrolled hyperglycemia, use of any other antidiabetic drug except metformin, recent acute coronary syndrome, indication of liver disease, moderate to severe renal impairment, recent bariatric surgery, medical history of cancer or treatment for cancer, blood disorders causing haemolysis or unstable red blood cell, hypersensitivity to concomitant drugs, and treatment with anti-obesity drugs.",
    "The sample is a record of a clinical trial in phase 3 for kidney transplantation. The diseases involved are only related to kidney transplantation. The icd-10 codes for the diseases are listed. The drugs used in the trial are fty720 5 mg + reduced-dose neoral (rdn) + corticosteroids, fty720 2.5 mg + full dose neoral (fdn) + corticosteroids, and mmf 2 g + full-dose neoral (fdn) + corticosteroids. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include age range and exclusion of patients in need of multiple organ transplants.",
    "The sample is a phase 3 clinical trial for the treatment of vasomotor symptoms in postmenopausal women. The trial includes the use of desvenlafaxine succinate sustained release and placebo drugs. The eligibility criteria include being generally healthy and meeting certain menopausal criteria. Exclusion criteria include a history of seizure disorder, clinically important hepatic or renal disease, and certain mental health disorders.",
    "The sample is a phase 3 clinical trial for patients with high-grade gliomas, specifically glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma, in their first relapse. The trial requires patients to have had prior local radiotherapy and less than 1.5 cm of residual gadolinium-enhancing tumor in maximal cross-sectional diameter by MRI. Patients must also meet certain eligibility criteria related to age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. The trial excludes patients with primary brainstem or spinal cord gliomas or secondary glioblastomas arising after prior treatment for a non-glial tumor. The trial involves a combination of drugs including carboplatin, etoposide, isotretinoin, and thiotepa. The sample provides a detailed list of eligibility criteria and prior concurrent therapy requirements.",
    "The sample is a phase 3 clinical trial for the treatment of narcolepsy using the drug sodium oxybate. The trial is open to individuals who are 16 years of age or older and have a history of excessive daytime sleepiness and cataplexy. Participants must also have valid PSG & MSLT scores within the last five years and a current diagnosis of narcolepsy. The trial has a list of inclusion and exclusion criteria, including the use of birth control for females of child-bearing potential and the absence of certain medical conditions or medications. The trial also requires participants to have adequate support and transportation to and from the trial site.",
    "The sample is a phase 3 clinical trial for the treatment of nausea and vomiting induced by chemotherapy. The trial includes patients with colorectal cancer who are scheduled to receive oxaliplatin at a dose between 85 mg/m\u00b2 and 130 mg/m\u00b2 in their first cycle of therapy. The trial involves a combination of drugs including casopitant, dexamethasone, placebo, and ondansetron. The eligibility criteria include being at least 18 years of age, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and meeting certain hematologic and metabolic criteria. The trial also includes exclusion criteria such as having received cytotoxic chemotherapy prior to the first study cycle of chemotherapy, being pregnant or lactating, and having a known hypersensitivity or contraindication to certain drugs.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on major depressive disorder and the drug being tested is escitalopram. The eligibility criteria for the trial include meeting DSM-IV diagnostic criteria for major depressive disorder and having a current depressive episode that has lasted at least 12 weeks. Exclusion criteria include being pregnant or breastfeeding, having certain mental health disorders, being at risk for suicide, and having a history of seizure disorder or other conditions that increase the risk of seizure. The diseases and icd-10 codes associated with the trial are also listed.",
    "The sample is a phase 3 clinical trial for alcohol dependence. The trial includes males and females who are at least 18 years old and weigh between 40 and 140 kg. Participants must be in good physical health and have a current DSM-IV diagnosis of alcohol dependence. They must also be currently drinking at least 14 alcohol units per week for women and 21 alcohol units per week for men in the last 30 days. Participants must be literate in English and willing to participate in behavioral treatments for alcoholism. Exclusion criteria include severe alcohol withdrawal symptoms, serious medical co-morbidity, and severe or life-threatening adverse reactions to ondansetron or similar medication. Participants must also be free of certain drugs before double-blind randomization.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of embolism and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, certoparin and heparin. The eligibility criteria for the trial include hospitalization due to an acute non-surgical disease and a significant decrease in mobility. Exclusion criteria include indications for anticoagulant or thrombolytic therapy, major surgical or invasive procedures within the 4 weeks prior to randomization, and immobilization due to cast or fracture of lower extremity, among others. The sample also notes that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is from a phase 3 clinical trial for a drug aimed at treating sexual dysfunctions, specifically HSDD (hypoactive sexual desire disorder) in premenopausal women. The trial includes patients who are 18 years or older and have been diagnosed with HSDD according to DSM IV-TR criteria. Patients must have a score of 15 or higher on the Female Sexual Distress Scale-Revised (FSDS-R) and must be willing to try to have sexual activity at least once a month. Patients must also be in a stable, monogamous, heterosexual relationship for at least 1 year prior to the screening visit. The trial has exclusion criteria, including patients who have taken certain medications within 30 days before the screening visit, patients with a history of drug dependence or abuse within the past year, and patients with certain sexual disorders or medical conditions.",
    "The sample is a phase 3 clinical trial for patients with various types of cancer, including fallopian tube, ovarian, and primary peritoneal cancer. The trial is testing the effectiveness of a combination of chemotherapy drugs, including carboplatin and paclitaxel, in treating the cancer. The trial also involves the use of glutathione therapy to prevent neurotoxicity caused by the chemotherapy. Patients must meet certain eligibility criteria, such as having a life expectancy of at least 6 months and a negative pregnancy test for women of childbearing potential. Patients with pre-existing peripheral neuropathy or certain medical conditions are excluded from the trial.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied, the ICD-10 codes associated with the disease, the drug being tested, and the eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying acute graft versus host disease. The ICD-10 codes associated with the disease are D89.810 and D89.812. The drug being tested is etanercept (enbrel). The eligibility criteria for participants include having undergone HCT with either a myeloablative or nonmyeloablative preparative regimen, being any age, and having biopsy-proven Grade I acute GVHD. There are also exclusion criteria, such as being pregnant or nursing, having active infections unresponsive to antibiotics, or having a history of Grade II-IV GVHD.",
    "The sample is a phase 3 clinical trial for essential hypertension. The trial includes participants with grade 2-3 hypertension that is not adequately controlled and who are willing to discontinue current antihypertensive medications. The eligibility criteria include having clinical laboratory test results within the reference range, being capable of understanding and complying with protocol requirements, and signing a written informed consent form. The trial also includes exclusion criteria such as having received any investigational compound within 30 days prior to screening, having a history of cancer that has not been in remission for at least 5 years, and having a history of drug abuse. The trial involves a post-placebo run-in period and a post-single-blind TAK-491 40 mg treatment period. The study aims to evaluate the efficacy and safety of TAK-491 40 mg monotherapy in reducing blood pressure in participants with essential hypertension.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C virus. The trial is testing the effectiveness of four drugs - asunaprevir, daclatasvir, peg-interferon alfa-2a, and ribavirin. The trial is looking for eligible participants who are males and females over the age of 18, have HCV genotype 1 or 4, and have previously failed treatment with Peginterferon alfa-2a or peginterferon alfa-2b and Ribavirin. The trial also requires that participants have HCV RNA levels of at least 10,000 IU/mL and are seronegative for HIV and Hepatitis B surface antigen. The trial allows for subjects with compensated cirrhosis, but they are capped at approximately 25% of the treated population. The exclusion criteria include prior treatment of HCV with HCV direct-acting antiviral (DAA), evidence of a medical condition contributing to chronic liver disease other than HCV, evidence of decompensated liver disease, diagnosed or suspected hepatocellular carcinoma or other malignancies, uncontrolled diabetes or hypertension, and other criteria that would exclude the subject from receiving P/R.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of metastatic renal cell cancer. The trial involves the use of drugs such as bevacizumab and interferon alfa 2a, as well as a placebo. The eligibility criteria for the trial include having clear cell type metastatic renal cell cancer, having undergone nephrectomy, and not having proteinuria. Exclusion criteria include having received prior systemic treatment for metastatic renal cell cancer, having undergone major surgical procedures or significant traumatic injury within 28 days prior to the start of the study treatment, having brain metastases or spinal cord compression, needing full dose anticoagulants, having uncontrolled hypertension, and having clinically significant cardiovascular disease. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and eligibility criteria for participants. The inclusion criteria include having a specific HbA1c level, BMI range, and being on a stable treatment regimen of metformin. The exclusion criteria include previous exposure to exenatide once weekly, recent blood donation, and current or recent use of certain medications. Participants must not have received any investigational drugs within a month of the study start and must not have experienced adverse events related to certain medications in the past.",
    "The sample is a phase 3 clinical trial for the treatment of esophagitis, both reflux and peptic. The trial involves the use of dexlansoprazole MR and a placebo. The eligibility criteria for the trial include having successfully completed a previous phase 3 study and having healed esophageal erosions proven by endoscopy. Exclusion criteria include the use of certain medications, chronic use of NSAIDs or COX-2 inhibitors, and evidence of uncontrolled systemic disease. Subjects who have participated in certain maintenance studies or who are unable to comply with the requirements of the study are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on postmenopausal women with osteoporosis. The diseases listed are postmenopause and osteoporosis, and the icd-10 codes associated with these diseases are also provided. The drug being tested is bazedoxifene bza-20. The eligibility criteria for the trial are also listed, including age, postmenopausal status, and specific osteoporosis risk factors. The exclusion criteria are also provided, including a history of osteoporotic vertebral fractures or a BMD T-score below -2.5.",
    "The sample is a phase 3 clinical trial for the treatment of pharyngitis. The trial includes patients between the ages of 6 months and 12 years who have been diagnosed with acute tonsillitis and/or pharyngitis and have clinical signs and symptoms such as sore throat, difficulty feeding or swallowing, and irritability. The trial requires patients to have a positive rapid screening test for S. pyogenes and be an appropriate candidate for oral antibiotic therapy. Females must be non-lactating and meet certain requirements for birth control. The trial has exclusion criteria, including chronic or recurrent odynophagia, hospitalization or IV antimicrobial therapy, and previous allergy or intolerance to penicillin or beta-lactam antimicrobials. Patients with certain medical conditions or who are taking certain medications are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking for patients who have been diagnosed with schizophrenia for 1 to 5 years and have a history of treatment with antipsychotics. Patients must have experienced two or more relapses requiring psychiatric hospitalization in the preceding 24 months, including the current acute episode. They must also be experiencing an acute schizophrenic episode with a Positive And Negative Syndrome Scale (PANSS) total score at screening between 70 and 120, inclusive. Patients must be healthy on the basis of physical examination, medical history, and vital signs performed at screening. Women must be postmenopausal, surgically sterile, abstinent, or practicing an effective method of birth control, and must have a negative urine pregnancy test at screening. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug. Patients who have never been treated with antipsychotics before, treatment-resistant patients, and those currently treated with clozapine are excluded from the trial. Patients with substance dependence within 6 months prior to entry and current intravenous drug use or abuse, allergies, hypersensitivity, or intolerance to risperidone or paliperidone or excipients, treatment with a long-acting injectable antipsychotic within three injection cycles prior to screening, newly started psychotherapy program within the two months preceding the treatment phase baseline, evidence of clinically significant hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances in the past 6 months, history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome, involuntarily hospitalized patients, and pregnant or breastfeeding females are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of genotype 1 chronic hepatitis C in treatment-naive patients. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs used in the trial, and eligibility criteria for inclusion and exclusion. Inclusion criteria include having chronic HCV infection genotype 1 with HCV RNA level > 1,000 IU/mL, not having had any previous treatment for hepatitis C, and having documentation of a liver biopsy within 2 years before the screening visit or agreeing to have a biopsy performed within the screening period. Exclusion criteria include being infected or co-infected with HCV of another genotype than genotype 1, having a pre-existing psychiatric condition, having history of decompensated liver disease or showing evidence of significant liver disease in addition to hepatitis C, having HIV or HBV co-infection, and having active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma).",
    "The sample is a phase 3 trial that involves patients with dyslipidemia, coronary heart disease, and mixed dyslipidemia. The trial uses icd-10 codes to identify the diseases. The drugs used in the trial are abt-335, rosuvastatin calcium, and placebo. The eligibility criteria for the trial include patients with mixed dyslipidemia, while the exclusion criteria include patients with unstable medical conditions, those taking certain medications, and women who are pregnant or lactating.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is looking for patients with histologically proven prostate cancer at high risk for relapse, with a PSA level between 20-100 ng/mL and a Gleason score of at least 7, or a clinical stage of at least T2, Gleason score of at least 8, and PSA no greater than 100 ng/mL. Patients must have negative lymph nodes and no metastatic disease. Patients must also have a Zubrod performance status of 0 or 1, and meet certain hematopoietic, hepatic, renal, and other criteria. Patients must not have had any other invasive cancer within the past 5 years except superficial nonmelanomatous skin cancer, and must not have any major medical or psychiatric illness that would preclude study participation. Fertile patients must use effective contraception. The trial excludes patients who have had prior radical prostatectomy, cryosurgery for prostate cancer, or orchiectomy. The trial also excludes patients who have had pelvic radiotherapy or concurrent intensity-modulated radiotherapy, and patients who have had chemotherapy within the past 5 years. Patients who have had finasteride for prostatic hypertrophy must have had it at least 60 days prior to the trial, and patients who have had testosterone must have had it at least 90 days prior to the trial. Patients who have had pharmacologic androgen ablation for prostate cancer must have had it no more than 30 days prior to the trial. The trial does not specify any biologic therapy.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with non-valvular atrial fibrillation and stroke, and the icd-10 codes associated with these diseases are listed. The trial is testing the effectiveness of three drugs: warfarin, dabigatran dose 1, and dabigatran dose 2. The eligibility criteria for the trial are listed, including inclusion criteria such as having at least one additional risk factor for stroke and exclusion criteria such as severe, disabling stroke within the previous 6 months or any stroke within the previous 14 days. The sample also includes a list of contraindications for the trial, such as active liver disease or known hypersensitivity to galactose.",
    "The sample is a phase 3 clinical trial for the treatment of opioid-induced constipation. The trial includes patients with a confirmed neoplasm causing pain and requiring management with opioids. The inclusion criteria require patients to have active symptoms of OIC and be receiving a stable maintenance opioid regimen for at least 4 weeks prior to screening. The exclusion criteria include patients with cancer-related pain due to ovarian cancer, leukaemia, or lymphoma, and those requiring radiation therapy between the diaphragm and pelvis. Patients who are pregnant or lactating are also excluded. The trial involves the use of the drugs nktr-118 and placebo. The eligibility criteria include the provision of written informed consent and being aged 18 or older.",
    "The sample is a phase 3 clinical trial for the treatment of insomnia related to Major Depressive Disorder. The trial involves the drug eszopiclone and includes eligibility criteria such as being between 21 and 64 years old, having a primary diagnosis of Major Depressive Disorder, and experiencing symptoms of insomnia related to MDD. Exclusion criteria include having a history of drug or alcohol abuse, having a disorder that may interfere with drug absorption, and being pregnant or lactating. The trial also includes a list of diseases and their corresponding ICD-10 codes, as well as a list of eligibility criteria and exclusion criteria.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes subjects of any race and gender who are at least 12 years old and have been diagnosed with asthma for at least 12 months. The subjects must have been using a medium or high daily dose of inhaled corticosteroids (ICS) for at least 12 weeks prior to screening and have been on a stable regimen for at least 2 weeks prior to screening. The trial includes several drugs, including mometasone furoate combination mdi 200/10 mcg bid, mometasone furoate combination mdi 400/10 mcg bid, fluticasone/salmeterol 250/50 mcg bid, and fluticasone/salmeterol 500/50 mcg bid. The eligibility criteria include showing evidence of reversibility within the last 12 months or during the screening period, having an FEV1 of at least 50% predicted, and having normal blood count, blood chemistries, urinalysis, and ECG. The trial also requires female subjects of childbearing potential to use a medically acceptable form of birth control and have a negative serum pregnancy test at screening. The exclusion criteria include a change in absolute FEV1 of more than 20%, requiring the use of more than 12 inhalations per day of short-acting beta-agonist (SABA) MDI or more than 2 nebulized treatments per day of 2.5 mg salbutamol, experiencing a clinical asthma exacerbation, requiring ventilator support for respiratory failure secondary to asthma, and having a smoking history of more than 10 pack-years.",
    "The sample is a phase 3 clinical trial for the treatment of sleep initiation and maintenance disorders. The trial involves the use of two drugs, eplivanserin and lormetazepam. The eligibility criteria for the trial include having primary insomnia according to DSM-IV-TR criteria, experiencing at least 1 hour of wakefulness for at least 3 nights per week during the month preceding inclusion, and having disturbances of sleep maintenance criteria based on the patient's sleep questionnaire during the run-in period. Exclusion criteria include being pregnant or breastfeeding, being a night shift worker or napping 3 or more times per week, consuming more than 5 cups or glasses of xanthine-containing beverages per day, and having insomnia secondary to a general medical condition.",
    "The sample is a phase 3 clinical trial for patients with locally advanced or metastatic non-small cell lung cancer. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs including erlotinib, sunitinib, and placebo, and eligibility criteria for inclusion and exclusion. Patients must have had no more than 2 prior chemotherapy regimens, including a platinum-based regimen, and must not have a history of or known brain metastases. Patients who have previously been treated with certain types of inhibitors are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with diabetic neuropathy and pain. The trial is testing the effectiveness of Sativex compared to a placebo. The eligibility criteria include being diagnosed with Type 1 or 2 diabetes mellitus and neuropathic pain due to distal symmetrical diabetic neuropathy of at least six months duration. The exclusion criteria include uncontrolled diabetes, history of schizophrenia or other significant psychiatric disorder, history of alcohol or substance abuse, and impaired renal or hepatic function. Participants must also be willing to comply with all study requirements and maintain a stable dose of regular pain medication and non-pharmacological therapies throughout the study.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial includes patients who are 40 years of age or older, have a smoking history of more than 10 pack-years, and have moderate to severe airway obstruction. The trial involves the use of drugs such as tiotropium and salmeterol, as well as placebos. The eligibility criteria include the ability to perform pulmonary function tests, the ability to inhale medication from the HandiHaler and inhalation aerosol, and a ventilatory limitation of maximal exercise capacity. Exclusion criteria include significant diseases other than COPD, recent history of myocardial infarction, and known active tuberculosis. Patients with a history of asthma or allergic rhinitis or who have a total blood eosinophil count \u2265600 /mm3 are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease epilepsy, with a list of associated ICD-10 codes. The trial involves the use of two drugs, both of which are versions of Keppra XR. The eligibility criteria for the trial include being between the ages of 12 and 75, having inadequately controlled partial onset epilepsy, and experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard AED(s). The exclusion criteria include a history of status epilepticus in the 6 months preceding randomization, significant medical, psychiatric or neurological illness, intake of benzodiazepines on more than an occasional basis, and a history of previous treatment with levetiracetam or sensitivity to levetiracetam.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial includes patients who have failed treatment with diet and exercise or have been receiving a stable dose of certain medications for more than 3 months. The trial involves the use of alogliptin and pioglitazone, alogliptin, or a placebo. The eligibility criteria include a diagnosis of type 2 diabetes, adequate contraception for sexually active females, and specific glycemic and triglyceride levels. Exclusion criteria include a history of type 1 diabetes, drug or alcohol abuse, and certain medical conditions such as liver disease and heart failure.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease and related conditions such as dementia, mental disorders, and brain diseases. The trial is testing the effectiveness of galantamine hydrobromide as a treatment. The inclusion criteria for the trial include a diagnosis of probable Alzheimer's disease, mild to moderate impairment of thinking, reasoning, and judgment, and signed informed consent forms. The exclusion criteria include patients with Parkinson's Disease, Pick's Disease, Huntington's Chorea, Creutzfeld-Jacob disease, Down's syndrome, brain cancer, mental retardation, epilepsy, psychiatric disease, liver, kidney or heart failure, significant heart, lung, digestive, hormone or mental disease or Vitamin B deficiency, previous severe head injury or blood clot in the brain, patients who are hospitalized, living in nursing homes or residential care facilities, patients with brain infections such as abscess, meningitis, encephalitis, and patients with a history of drug or alcohol abuse.",
    "This sample is from a clinical trial in phase 3 that focuses on heartburn. The trial includes individuals who are 18 years or older, experience heartburn at least 2 days a week, and have responded to heartburn medication. They must discontinue any current heartburn medications. The trial excludes individuals with a history of erosive esophagitis or GERD diagnosed by a physician, those who are unable to take study medication or complete the study and all study procedures, and those who have required more than one 14-day course of PPI treatment within the past 4 months. The icd-10 code for heartburn is 'R12' and the drug being tested is esomeprazole.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes patients who have a DSMIV diagnosis of bipolar I disorder with a current episode of manic or mixed symptoms. The trial excludes patients with unstable medical conditions, clinically significant laboratory abnormalities, or those who have had four or more mood episodes in the past 12 months. Patients with any other psychiatric disorder as a primary diagnosis are also excluded. The trial involves the use of asenapine, olanzapine, and placebo as potential treatments.",
    "The sample is a phase 3 clinical trial for patients with colorectal cancer. The trial includes patients who have undergone curability A or B surgeries and have been evaluated as lymph node metastasis positive. The patients must be between the ages of 20 and 80, have a performance status of 0 to 2, and have not received preoperative cancer therapy. They must also have no diarrhea, no severe impairment of renal, hepatic, or bone marrow functions, and no serious concurrent complications. Patients must give written informed consent to participate in the study. Exclusion criteria include patients graded as curability C, patients with stenosis not capable of oral intake, and patients with fresh hemorrhage from the gastrointestinal tract. Other exclusion criteria include patients with poorly controlled diabetes, a history of ischemic heart disease, or concurrent psychiatric disease or psychotic symptoms. Patients who have experienced serious drug allergy in the past or are judged by the investigator or subinvestigator to be inappropriate as subjects are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been hospitalized for an ACS event. The trial is testing the effectiveness of a drug called aleglitazar compared to a placebo. The inclusion criteria for the trial include being an adult over 18 years of age with type 2 diabetes mellitus and having been hospitalized for an ACS event within 8 weeks prior to randomization. The exclusion criteria include having an estimated glomerular filtration rate below 45 mL/min/1.73m2, being on concomitant treatment with a thiazolidinedione and/or fibrate, having triglycerides above 400 mg/dL, having anemia, and having symptomatic congestive heart failure classified as NYHA class II-IV (or NYHA class I-IV in France and Germany).",
    "The sample is a record of a clinical trial in phase 3 for the treatment of melanoma. The trial involves the use of drugs such as ipilimumab, placebo, and dacarbazine. The eligibility criteria for the trial include having measurable disease, being in Eastern Cooperative Oncology Group (ECOG) 0 or 1, and meeting certain lab and imaging requirements. Participants must also test negative for HIV, Hepatitis B, and C, and be over 18 years old (16 years old is allowable). There are also certain restrictions on prior therapy. Exclusion criteria include being pregnant or nursing, having inadequate contraception, having brain metastasis, or having primary ocular or mucosal melanoma.",
    "The sample is a phase 3 clinical trial for subjects with type 2 diabetes and a HbA1c level between 7.5-10.0%. The trial requires subjects to be on stable daily doses of basal insulin and either metformin or metformin and SU or metformin and glinides for at least 90 days prior to the trial start. The trial also requires subjects to have a BMI of 27 kg/m^2 or higher. The trial has exclusion criteria such as treatment with GLP-1 receptor agonists, impaired liver or renal function, screening calcitonin equal to or above 50 ng/l, personal or family history of MTC or MEN 2, cardiac disorders, severe uncontrolled hypertension, acute treatment required proliferative retinopathy or maculopathy, and history of chronic pancreatitis or idiopathic acute pancreatitis.",
    "The sample is a phase 3 clinical trial for patients who have had a myocardial infarction and have left ventricular systolic dysfunction. The trial is testing the effectiveness of the drugs aliskiren and placebo. The eligibility criteria include being 18 years or older, having left ventricular systolic dysfunction associated with the qualifying acute myocardial infarction, and being on stable doses of certain concomitant medications for at least 2 weeks prior to the trial. The trial also has exclusion criteria, such as refractory hypertension, cardiogenic shock, and stroke or transient ischemic event within 6 months of the study visit. The trial has an extension study with its own inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of overactive bladder. The trial involves the drug fesoterodine fumarate and the eligibility criteria include having OAB symptoms such as frequent urination and urinary urgency. The exclusion criteria include known hypersensitivity to the drug or its components, neurological diseases affecting bladder function, and complications of lower urinary tract pathology.",
    "The sample is for a phase 3 clinical trial that focuses on treating vasomotor symptoms. The trial includes a list of icd-10 codes for the disease. The trial will test the effectiveness of two drugs, desvenlafaxine succinate (dvs) sr and placebo. The eligibility criteria for the trial include generally healthy postmenopausal women with a BMI less than or equal to 34 kg/m^2. The exclusion criteria include hypersensitivity to Venlafaxine, a history of myocardial infarction and/or unstable angina within 6 months of screening, and a history of seizure disorder.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of diabetic macular edema, which is associated with specific ICD-10 codes. The drug being tested is ranibizumab. The eligibility criteria for the trial include having stable Type 1 or Type 2 diabetes mellitus and visual impairment due to focal or diffuse DME in at least one eye. There are also exclusion criteria, such as having active conditions in the study eye that could prevent the improvement of visual acuity on study treatment, active eye infection or inflammation, and a history of stroke, renal failure, or uncontrolled hypertension. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients with active clinical synovitis in at least 2 joints, with onset of symptoms within the last 2 years. Patients must also have a positive test result for anticyclic citrullinated peptides 2 and a Disease Activity Score 28 based on C-reactive protein score \u22653.2 at screening. Patients must be methotrexate naive or have minimal exposure to methotrexate, and biologic naive. The trial involves the use of abatacept and methotrexate, as well as their respective placebos. Patients must meet certain inclusion and exclusion criteria, such as not having other rheumatic diseases, not having received certain treatments within a certain timeframe, and not having certain infections or illnesses.",
    "The sample is a phase 3 clinical trial for patients with prostate cancer who may benefit from medical androgen deprivation therapy. The trial includes eligibility criteria such as being male and over 18 years old, having a life expectancy of at least 1 year, and having a WHO/ECOG performance status of 0, 1, or 2. Exclusion criteria include evidence of brain metastases, spinal cord compression, severe urinary tract obstruction, or any tumor in the immediate vicinity that could cause spinal cord compression. Patients must also not have received certain previous treatments or have certain medical conditions. The trial involves the drug leuprolide acetate 22.5 mg depot, gp-pharm sa.",
    "The sample is a phase 3 clinical trial for bipolar I disorder. The trial includes men and women between the ages of 18 and 65 who meet DSM-IV-TR criteria for manic or mixed episodes and have a YMRS total score of 20 or more. The trial involves the use of aripiprazole and placebo drugs. The eligibility criteria include the ability to provide informed consent, absence of certain medical conditions, and not having received certain treatments during the screening period. The exclusion criteria include patients with certain medical conditions, those experiencing their first manic or mixed episode, and those who have received certain treatments during the screening period. Patients with a diabetic blood glucose level or a history or complication of diabetes are also excluded.",
    "The sample is a phase 3 clinical trial for patients with chronic hepatitis B and HIV infections. The trial includes a list of diseases, icd-10 codes, drugs, and eligibility criteria. The inclusion criteria include having documented chronic hepatitis B infection, detectable HBV DNA, HBe-Ag positive, anti-HBe negative, and a liver biopsy consistent with chronic hepatitis B. Patients must also have documented HIV-infection, CD4-cell count above 200 cells/\u00b5l, and elevated serum ALT. The exclusion criteria include being older than 65 years of age, pregnant or lactating, having hypersensitivity to study medication, and having received any systemic anti-neoplastic treatment. The trial also excludes patients with ongoing hepatitis A, C or Delta infection, autoimmune hepatitis, liver cirrhosis, and other medical conditions associated with chronic liver disease. Patients with severe psychiatric conditions, severe seizure disorder, severe cardiac disease, and immunologically mediated disease are also excluded.",
    "The sample is a phase 3 clinical trial for breast cancer. The eligibility criteria include having a histologically proven breast cancer with negative HER2 neu proto-oncogene overexpression by FISH, and having undergone definitive surgical treatment either by mastectomy or breast conserving surgery with axillary lymph node dissection. The patient must have a Karnofsky Performance status index > 80%, normal cardiac function, and meet certain laboratory requirements. The patient must also have a complete staging work-up within 3 months prior to registration. Exclusion criteria include prior systemic anticancer therapy for breast cancer, prior anthracycline therapy or taxoids for any malignancy, and pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI-CTC. Other serious illnesses or medical conditions, past or current history of neoplasm other than breast carcinoma, and concurrent treatment with other experimental drugs or any other anti-cancer therapy are also exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of macular degeneration. The trial involves the use of two drugs, bevasiranib and ranibizumab. The eligibility criteria for the trial include being 50 years or older, having certain types of macular degeneration, and having a specific level of visual acuity. Patients must also be willing to attend monthly follow-up visits for two years. Exclusion criteria include having received certain previous treatments for AMD, recent intraocular surgery, previous posterior vitrectomy, and having advanced glaucoma or high intraocular pressure.",
    "The sample is a phase 3 clinical trial for non-Hodgkin's lymphoma. The trial is testing the effectiveness of rituximab, a drug used to treat cancer. The eligibility criteria for the trial includes adult patients between the ages of 60-75 with B-cell follicular NHL who have not received previous treatment and have active disease with rapid progression. The exclusion criteria includes patients with other cancers within 3 years of the study, long-term use of systemic corticosteroids, central nervous system involvement, history of significant cardiovascular disease, and positive test results for HIV, or hepatitis B or C.",
    "This sample is from a phase 3 clinical trial for the treatment of insomnia. The trial involves the drug \"org 50081\". The eligibility criteria for participants include providing written informed consent, completing previous protocols, and passing safety and efficacy assessments. Exclusion criteria include abnormal ECG or laboratory values, relevant adverse events, and non-compliance with previous protocols. The diseases being studied are listed as \"insomnia\" and the associated ICD-10 codes are provided.",
    "The sample is a phase 3 clinical trial for the treatment of depression and depressive disorders. The trial involves the use of desvenlafaxine administered as a succinate salt in a sustained-release form (dvs sr) and a placebo. The eligibility criteria include being a peri- and postmenopausal woman between the ages of 40 and 70 years with a primary diagnosis of MDD, single or recurrent episode, without psychotic features. The Montgomery-Asberg Depression Rating Scale (MADRS) total score must be greater than or equal to 22 at the screening and baseline visit. Exclusion criteria include the use of certain drug products, current psychoactive substance abuse or dependence, and a history or active presence of clinically important medical disease. Additional criteria also apply. The diseases included in the trial are depression, depressive disorder, and depressive disorder, major, and the icd-10 codes associated with these diseases are provided.",
    "The sample is a phase 3 clinical trial for the treatment of sleep initiation and maintenance disorders and insomnia. The trial involves the use of the drug eplivanserin (sr46349) and a placebo. The eligibility criteria for the trial include having primary insomnia according to DSM-IV-TR-Axis I criteria, spending at least 6.5 hours and not more than 9.0 hours in bed each night over the preceding two weeks, complaining of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month, and reporting impact daytime functioning associated with sleep maintenance insomnia. Exclusion criteria include being pregnant or lactating, having acute or chronic pain resulting in insomnia, having a history of epilepsy or seizures, having a BMI >32, having current psychiatric disorders according to DSM-IV-TR criteria, and being unable to complete the study questionnaires.",
    "The sample is a phase 3 clinical trial for dry eye syndrome. The trial includes three different drugs: bromfenac ophthalmic solution a, bromfenac ophthalmic solution b, and a placebo comparator. The eligibility criteria for the trial require participants to be 18 years or older, of any gender or race, and not have any local or systemic diseases that could interfere with the assessment of safety or efficacy or result in early discontinuation from the study.",
    "The sample is a phase 3 clinical trial for the treatment of arthritis, rheumatoid using the drug abatacept. The trial includes participants who have completed two previous studies by Bristol-Myers Squibb and meet certain eligibility criteria, such as maintaining stable doses of concomitant medications and being willing to self-inject or allow a caregiver to inject the study medication. Exclusion criteria include severe or uncontrolled medical conditions, abnormal laboratory test results, and imprisonment or involuntary incarceration. The trial requires adherence to a study visit schedule and compliance with other protocol requirements.",
    "The sample is a phase 3 clinical trial for patients with breast cancer who will receive their first cycle of non-cisplatin moderately emetogenic chemotherapy. The trial is testing the effectiveness of the drug dexamethasone in reducing nausea and vomiting caused by chemotherapy. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for patients to participate in the trial. The inclusion criteria include being diagnosed with breast cancer, being over 18 years old, having a performance status of 0-2 on the ECOG performance scale, and having full recovery from any post-operative sequelae. The exclusion criteria include having previously received chemotherapy, having received or will receive radiation therapy to the abdomen or pelvis in the week prior to treatment, and having an active infection or any uncontrolled disease that might confound the results of the study or pose unwarranted risk. Patients with controlled diabetes are eligible. The sample also includes a list of drugs that are eligible for the trial and the eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 3 clinical trial for multiple myeloma patients who are scheduled to receive high-dose Melphalan followed by autologous peripheral blood progenitor cell (PBSCT). The trial is testing the effectiveness of palifermin, a growth factor, before and after the treatment. The eligibility criteria include having a BMI of 35 or less, a good performance status, and functional hematopoietic, hepato-renal, and pulmonary systems. The trial also requires a minimum baseline best corrected visual acuity (BCVA) of 20/40 or better in one eye, and a LOCS III score at baseline of P < 1.0, C < 2.0 and NO < 2.0 in at least one eye. Exclusion criteria include having any other malignancy, prior autologous or allogeneic transplants, and prior treatment with palifermin or other growth factors. The trial also excludes patients with certain ocular diseases or scheduled to undergo cataract surgery, as well as those with active oral mucositis infection, positive for HIV, hepatitis B or C, or unable or unwilling to follow study procedures. Women in childbearing potential must have a negative pregnancy test and agree to use adequate contraceptive precautions.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is testing a combination of pegylated interferon alfa-2b and ribavirin. The eligibility criteria include being between 18 and 70 years old, having genotype-1 hepatitis C virus, and having a liver biopsy confirming the diagnosis of chronic hepatitis or liver cirrhosis. Other criteria include having certain hematological, biochemical, and serological criteria within normal limits, practicing adequate contraception, and not having any preexisting medical conditions that could interfere with the study. The exclusion criteria include being pregnant or breastfeeding, having previously been treated for chronic hepatitis C with certain medications, and having any other condition that could interfere with the subject's participation in the study.",
    "The sample is a phase 3 clinical trial for generalized anxiety disorder. The trial includes adult male and female subjects who have a primary DSM-IV diagnosis of GAD and have previously failed to respond optimally to a GAD treatment. The trial excludes subjects with certain DSM-IV diagnoses such as major depressive disorder, social phobia, and schizophrenia, as well as those with cognitive disorders or factitious disorder. The trial involves the use of two drugs, pregabalin and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with essential hypertension, with a sitting systolic blood pressure between 150 and 180 mm Hg, and a 24-hour mean systolic blood pressure between 130 and 170 mm Hg. The trial involves the use of drugs such as azilsartan medoxomil, valsartan, olmesartan, and placebo. The eligibility criteria include being capable of understanding and complying with protocol requirements, not being pregnant or lactating, having clinical laboratory evaluations within the reference range, and being willing to discontinue current antihypertensive medications. The exclusion criteria include having a sitting diastolic blood pressure greater than 114 mm Hg, taking or expected to take an excluded medication, being hypersensitive to angiotensin II receptor blockers, having a history of myocardial infarction, heart failure, or other serious diseases or conditions that would compromise the participant's safety.",
    "The sample is a phase 3 clinical trial for patients with chronic hepatitis B and C. The trial is testing the effectiveness of peginterferon alfa-2a plus ribavirin as a treatment for the disease. The eligibility criteria for the trial include being at least 18 years old, having elevated serum ALT levels, and having adequate liver reserve. Patients must also be treatment na\u00efve or have had treatment failure to previous interferon monotherapy or treatment failure to previous lamivudine therapy. Exclusion criteria include drug addiction, alcohol abuse, and any history of major organ transplantation with an existing functional graft. Patients must not be pregnant, lactating, or not practicing two adequate forms of birth control. The trial aims to determine the safety and efficacy of the treatment for patients with chronic hepatitis B and C.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial involves the use of two drugs, paclitaxel and carboplatin, and a new drug called nov-002 injection in combination with carboplatin. The trial has specific eligibility criteria, including a diagnosis of Stage IIIb or Stage IV NSCLC, an ECOG performance score of 0 or 1, adequate bone marrow, hepatic, and renal function, and a life expectancy of at least 12 weeks. Patients must also be able to self-administer daily subcutaneous injections or have a caregiver who can do so. There are also exclusion criteria, such as prior chemotherapy for advanced NSCLC, CNS metastases, and chronic use of systemic corticosteroids in pharmacological doses. Patients must provide written informed consent and agree to abide by the trial restrictions and return for required assessments. Pregnant or nursing women are excluded from the trial.",
    "The sample is a phase 3 clinical trial for breast cancer and osteoporosis. The trial is testing the effectiveness of zoledronic acid as an adjuvant chemotherapy treatment for localized breast cancer in women aged 18 to 50 who are premenopausal or perimenopausal. The trial has eligibility criteria related to the patient's disease characteristics, age, sex, menopausal status, performance status, life expectancy, hematopoietic, hepatic, renal, and other factors. The trial also has prior concurrent therapy requirements related to biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other factors. The sample includes a list of disease names, icd-10 codes, drug names, and eligibility criteria.",
    "The sample is a record of a clinical trial in phase 3, involving patients with pain and a fracture of the neck of the femur. The trial includes a list of ICD-10 codes for the diseases, a list of drug names, and eligibility criteria for patients to participate in the trial. The inclusion criteria include patients of either sex who are over 18 years old and undergoing surgical correction of a unilateral fracture of the hip. The exclusion criteria include participation in another clinical trial within 4 weeks prior to enrollment, refusal to give verbal consent to telephone interviews, inability to comply with the study protocol, previous major surgical procedure on the same hip, current use of analgesics for any other reason, a history of chronic pain syndrome, abused legal or illicit drug use, hypersensitivity to botanicals of the Compositae family, and known sensitivity to paracetamol, codeine or tramadol.",
    "The sample is a phase 3 clinical trial for individuals with human immunodeficiency virus (HIV) infection. The trial involves the use of three drugs: lopinavir/ritonavir (lpv/r), emtricitabine/tenofovir disoproxil fumarate (ftc/tdf), and raltegravir (ral). The eligibility criteria for participants include providing written consent, being naive to antiretroviral treatment with HIV RNA greater than or equal to 1,000 copies/mL at screening, and requiring antiretroviral therapy. Participants must also not exhibit evidence of acute illness, not have been treated for an active acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within 45 days of initiating study drug, and not require any drugs that are contraindicated or have significant pharmacokinetic interactions with study drugs during the course of the study. Female participants must be either postmenopausal for at least one year, surgically sterile, or must use a non-hormonal method of birth control that is acceptable to both the participant and investigator. The exclusion criteria include having a history of an allergic reaction or significant sensitivity to the study drugs, having an ongoing history of substance abuse or psychiatric illness that could preclude protocol adherence, having resistance to lopinavir/ritonavir, tenofovir, or emtricitabine based on the HIV-1 drug resistance genotypic test results at the screening visit, having significant medical history of concomitant illness or disease that would adversely affect participation in the study, having received any investigational drug or investigational vaccine within 30 days prior to study drug administration, and having abnormal screening results for hemoglobin, absolute neutrophil count, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), calculated creatinine clearance, or hepatitis B surface antigen (HBsAg). The investigator must also consider the participant to be a suitable candidate for the study.",
    "The sample is a phase 3 clinical trial for asthma. The trial is open to adult and adolescent subjects of either sex and any race, who have been diagnosed with asthma for at least 12 months. The trial will test the efficacy of a combination of drugs, including mometasone furoate/formoterol fumarate, mometasone furoate, formoterol fumarate, and placebo. To be eligible for enrollment, subjects must meet certain inclusion criteria, such as using a medium daily dose of inhaled glucocorticosteroid for at least 12 weeks and having a FEV1 of at least 60% and no more than 90% predicted. They must also meet none of the exclusion criteria, such as experiencing a decrease in AM or PM PEF below the Screening Period stability limit on any 2 consecutive days prior to Randomization. The trial will also require subjects to use a medically acceptable form of birth control if they are of childbearing potential.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been on insulin therapy for at least 12 weeks prior to the trial start. The trial includes the drugs liraglutide and placebo, and the eligibility criteria include having a stable insulin therapy, a glycosylated haemoglobin level between 7.5 and 11.0%, and a body mass index below 45.0 kg/m^2. Exclusion criteria include having proliferative retinopathy or maculopathy, recent treatment with glucagon-like peptide-1 receptor agonist or any oral antidiabetic drugs, and recurrent severe hypoglycaemia or hypoglycaemic unawareness.",
    "The sample is a phase 3 clinical trial for patients with advanced idiopathic Parkinson's disease. The trial involves the use of pramipexole and placebo drugs. The eligibility criteria for the trial include completion of a double-blind trial, a Modified Hoehn and Yahr stage of 2 to 4 at on-time, and concomitant treatment with standard or controlled release L-Dopa+ or a combination of L-Dopa+ and entacapone. Patients must also be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion criteria include premature withdrawal from the double-blind trial, atypical parkinsonian syndromes, any psychiatric disorder that could prevent compliance or completion of the study, history of psychosis, deep brain stimulation, clinically significant ECG abnormalities, clinically significant hypotension and/or symptomatic orthostatic hypotension, malignant melanoma or history of previously treated malignant melanoma, any other clinically significant disease that could put the patient at risk or could prevent compliance or completion of the study, pregnancy or breast-feeding, sexually active female of childbearing potential not using a medically approved method of birth control, serum levels of AST, ALT, AP or bilirubin > 2 upper limit normal at baseline, creatinine clearance < 50 mL/min at baseline, any medication with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit, any of the following drugs within 4 weeks prior to baseline visit: methylphenidate, cinnarizine, amphetamines, flunarizine within 3 months prior to baseline, known hypersensitivity to pramipexole or its excipients, drug abuse within 2 years prior to baseline, participation in investigational drug studies other than the trial 248.525, or use of other investigational drugs within one month or five times the half-life of the investigational drug (whichever is longer) prior to baseline.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who have been treated with antipsychotics for at least 3 months. The trial aims to test the effectiveness of switching patients from their current antipsychotic medication to aripiprazole. Patients must also have a confirmed diagnosis of metabolic syndrome and not be receiving treatment specifically for any of the parameters related to metabolic syndrome at the time of randomization. The trial has a list of inclusion and exclusion criteria, including a clinical global impression-severity scale score of 4 or lower at baseline, no risk of suicide, and no diagnosis of type 1 or 2 diabetes mellitus. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and up to 4 weeks after the last dose of investigational product. The trial also has a list of drugs that patients must have been treated with for at least 3 months, including olanzapine, risperidone, or quetiapine. The sample includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients who have been diagnosed with chronic hepatitis C and have undergone a liver biopsy within 2 years of Day 0 or during screening. The patients must be infected with hepatitis C virus genotype 2/3 and have never been treated with an interferon product. The trial involves the use of albumin interferon alfa-2b, peginterferon alfa-2a, and ribavirin. Patients must meet certain eligibility criteria, such as having compensated liver disease and not being pregnant or nursing. There are also exclusion criteria, such as having a history of moderate, severe, or uncontrolled psychiatric disease, or having a clinical diagnosis of other causes of chronic liver disease. The trial does not include patients who have had cancer within the last 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix. Patients who have had drug or alcohol addiction within the last 6 months are also excluded, except for those in a supervised methadone treatment program.",
    "This sample is from a phase 3 clinical trial for obesity. The trial is testing the effectiveness of the drug taranabant compared to a placebo. The eligibility criteria for participants include being 18 years or older with a BMI between 30 and 43 kg/m2 (or between 27 and 43 kg/m2 for those with obesity-related comorbidities such as hypertension, dyslipidemia, or sleep apnea). Participants must also have had stable weight for at least 3 months prior to the study start. Exclusion criteria include a history of diabetes mellitus, major psychiatric disorder, significant cardiovascular disease, stroke, TIA, neurological disorder, or non-febrile seizures. Additionally, participants with a screening systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar depression. The trial is looking at the effectiveness of the drugs lurasidone and placebo. The eligibility criteria for participants include being between the ages of 18 and 75, meeting DSM-IV-TR criteria for bipolar I disorder, having a lifetime history of at least one bipolar manic or mixed manic episode, and currently being treated with lithium or divalproex or willing to begin treatment with them. Participants must also be in good physical health and not pregnant or nursing. Exclusion criteria include being at imminent risk of suicide or injury, having any chronic organic disease of the CNS, hospitalization for a manic or mixed episode within the past two months, and having a clinically significant history of alcohol or substance abuse within the past 3 months or alcohol or substance dependence within the past 12 months.",
    "The sample is a phase 3 clinical trial for the treatment of peripheral neuropathic pain syndrome, including diabetic peripheral neuropathy, postherpetic neuralgia, or post-traumatic neuropathic pain. The trial involves the use of the drugs pregabalin and placebo. The eligibility criteria for the trial include a confirmed diagnosis of the aforementioned conditions by a qualified pain specialist, completion of at least 4 daily pain diaries with an average pain score of \u22654 over the 7 days prior to randomization, and absence of neurologic disorders unrelated to the conditions being studied. The exclusion criteria include the presence of severe pain associated with conditions other than the ones being studied and a creatinine clearance of less than 30 mL/min.",
    "The sample is a phase 3 clinical trial for chronic bronchitis. The trial is testing the effectiveness of two drugs, moxifloxacin and azithromycin sr, on patients with chronic bronchitis who have experienced at least two exacerbations of acute bacterial exacerbations of chronic bronchitis (AECB) in the past 12 months. The trial includes patients who have been diagnosed with chronic bronchitis and have clinical evidence of AECB, as well as a documented FEV1 less than 80% of predicted. The eligibility criteria include specific symptoms and the exclusion criteria include recent treatment with systemic antibiotics or a chest radiograph consistent with pneumonia.",
    "The sample is a phase 3 clinical trial for the treatment of uterine fibroids and anemia. The trial involves the use of drugs such as proellex 25 mg, proellex 50 mg, and placebo. The eligibility criteria for the trial include being a female between the ages of 18 and 48 with a BMI between 18 and 39, being anemic with hemoglobin levels less than or equal to 10.5 g/dL and experiencing uterine fibroid-associated symptoms, and planning or anticipating surgical interventions for uterine fibroids. The trial also requires compliance with all study procedures, including endometrial biopsies and blood draws. Exclusion criteria include post-menopausal women, those with a history of uterine arterial embolization or endometrial ablation therapy, and those with a diagnosis or suspected diagnosis of carcinoma of the breast or reproductive organs. The use of certain concomitant medications is also prohibited.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is looking for patients who have been diagnosed with adenocarcinoma of the prostate and have failed local treatments such as surgery and/or radiotherapy and/or brachytherapy. The patients should have a rising prostate-specific antigen level of at least 2.0 ng/mL (confirmed by 2 measurements at least 2 weeks apart) and a doubling time of 32 weeks or less. The patients should not have any clinical or radiographic evidence of disease and should have an original Gleason score of at least 7 OR Gleason score of 6 with capsular penetration or positive seminal vesicles or lymph nodes. The patients should not have any metastases. The trial is looking for patients who are 18 years or older, have a Zubrod performance status of 0-1, and have a life expectancy that is not specified. The patients should have an absolute granulocyte count of at least 1,500/mm^3, a platelet count of at least 100,000/mm^3, and a hemoglobin level of at least 10 g/dL. The patients should not have any history of bleeding disorders that would contraindicate warfarin, including clotting factor defects. The patients should have a bilirubin level no greater than 1.5 mg/dL and AST/ALT no greater than 1.5 times upper limit of normal. The patients should have a creatinine level no greater than 1.5 mg/dL and a blood urea nitrogen (BUN) no greater than 1.2 times normal. The patients should not have any symptomatic heart disease, history of myocardial infarction, or history of thromboembolic events (e.g., deep vein thrombosis, symptomatic cerebrovascular events, or pulmonary embolism). The patients should not have any other major medical or psychiatric illness that would preclude study entry and should not have any other prior or concurrent invasive malignancy within the past 5 years except superficial skin cancer. The patients should not have any history of esophageal varices and fertile patients must use effective contraception. The trial allows concurrent warfarin and bisphosphonate therapy initiated prior to or after randomization. The trial has certain criteria for prior concurrent therapy such as at least 6 weeks since prior vaccine therapy, at least 5 years since prior chemotherapy, prior adjuvant or neoadjuvant hormonal therapy of less than 8 months duration allowed, at least 1 year since prior androgen therapy, and at least 5 years since prior radiotherapy to sites other than prostate. The trial also has certain criteria for surgery.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of metastatic prostate cancer using the drug oral satraplatin. The trial includes patients who have progressed after unlimited prior cytotoxic chemotherapy regimens and have an ECOG performance status of equal or less than 2. Patients must also have undergone surgical or medical castration and have adequate bone marrow, liver, and renal function. The trial has inclusion and exclusion criteria, which are listed in the record. The diseases associated with the trial are listed as 'prostate cancer' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial that involves patients with coronary heart disease or risk equivalents that place them at high risk for cardiovascular disease events, as well as patients with diabetes mellitus. The trial is testing the effectiveness of two drugs, torcetrapib/atorvastatin and atorvastatin, in treating these conditions. The eligibility criteria for the trial include a diagnosis of coronary heart disease or risk equivalents, while exclusion criteria include pregnancy or lactation, use of certain medications, and other medical conditions that could affect subject safety or evaluation of response.",
    "The sample is a phase 3 clinical trial for patients with multiple myeloma who have received between 1 and 3 prior lines of treatment for their disease and require therapy due to disease progression. The trial includes patients with secretory MM with measurable levels of monoclonal protein in serum or urine, excluding those with Waldenstrom's macroglobulinemia. Patients must have an ECOG performance status of 0, 1, or 2 and a life expectancy of more than 3 months. Women of child-bearing potential must agree to use 2 methods of contraception, and men must use barrier contraception during the treatment period and for 4 weeks after the last dose. The trial has inclusion and exclusion criteria, including laboratory abnormalities, medical conditions, and prior treatments that may prevent patients from participating.",
    "The sample is a record of a clinical trial in phase 3, which involves the treatment of metastatic germ cell cancer of the testes using the drugs cisplatin and etoposide. The eligibility criteria for the trial include having a good-prognosis disease, being eligible for treatment with bleomycin, etoposide, and cisplatin, having a creatinine clearance of at least 60 mL/min, having no prior or concurrent malignancy except basal cell skin cancer, having no major systemic illness, and having no impaired respiratory function. The sample also includes a list of disease names and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis (RA) patients who are considered methotrexate inadequate responders. The trial involves the use of subcutaneous (sc) and intravenous (iv) abatacept drugs. The eligibility criteria include having 10 or more swollen joints and 12 or more tender joints, while exclusion criteria include having failed one or multiple anti-tumor necrosis factor (TNF) therapies, having a diagnosis of any other rheumatic disease, having active vasculitis of a major organ system, having severe chronic or recurrent bacterial infections, and having received treatment with rituximab. The sample also includes information about an Anti-TNF Failure Sub-study that was initiated separately from the main study to assess immunogenicity and safety in the Anti-TNF Failure population, but was terminated due to low recruitment.",
    "The sample is a phase 3 clinical trial for the treatment of juvenile rheumatoid arthritis. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested (abatacept and placebo), and eligibility criteria for participants. The inclusion criteria require a diagnosis of juvenile rheumatoid arthritis or juvenile idiopathic arthritis, current active arthritis, and failed treatment with at least one disease modifying anti-rheumatic drug. The exclusion criteria include the presence of infection or history of frequent acute or chronic infections, joint replacement surgery required during the study or history of surgery on more than 5 joints, live vaccines within 3 months of the first dose of study medication, unresolved serious bacterial infection or chronic bacterial infection, and subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash, hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.",
    "The sample is a phase 3 clinical trial for patients with coronary artery disease, myocardial ischemia, and myocardial infarction. The trial involves the use of intravenous infusion of saline as a drug. The eligibility criteria for the trial include patients who have undergone surgery for unstable coronary artery disease, accepted for surgery within 2 weeks after STEMI, and have undergone coronary surgery with or without cardiopulmonary bypass or simultaneous valve procedure. The exclusion criteria include patients who are unable to provide informed consent, have preoperative use of inotropes or mechanical circulatory assist, preoperative dialysis, redo-procedure, unexpected intraoperative finding/event that increases the dignity of the procedure, body weight over 125 kg, and food allergy known to have caused flush, rash or asthma.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of the drugs alogliptin and metformin, as well as placebos for both drugs. The eligibility criteria for participants include having a historical diagnosis of type 2 diabetes mellitus, being treated with diet and exercise for at least 2 months prior to screening, having a specific range of Glycosylated Hemoglobin concentration, having a body mass index within a certain range, and regularly using non-excluded medications. Exclusion criteria include having certain medical conditions or histories, using certain medications, and having allergies to certain drugs. Participants must also agree to use adequate contraception and monitor their own blood glucose concentrations throughout the study.",
    "The sample is a phase 3 clinical trial for patients aged 50 years or older with probable Alzheimer's disease. The trial involves the drugs memantine er and placebo, and the eligibility criteria include confirmatory MRI or CT scan within the prior 12 months, Mini-Mental State Examination (MMSE) scores between 3 and 14, and ongoing daily acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for at least 3 months prior to screening. Exclusion criteria include patients with a modified Hachinski Ischemia Score greater than 4, patients who have taken memantine within one month of screening, and patients with a known hypersensitivity to memantine, neramexane, rimantadine, or amantadine. Other exclusion criteria include patients with other neurological disorders, dementia complicated by other organic disease, and dementia complicated by the presence of predominant delusions.",
    "The sample is a record from a clinical trial database and contains information about a completed trial. The trial was a phase 3 trial and focused on the disease cystic fibrosis. The trial tested two drugs, tobramycin inhalation powder and tobramycin solution for inhalation. The eligibility criteria for the trial included a confirmed diagnosis of cystic fibrosis, a certain level of lung function, and the presence of a specific type of bacteria in a recent culture. The sample also includes a list of ICD-10 codes for the disease, SMILES codes for the drugs, and detailed inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for diabetes, specifically type 1 and type 2. The trial involves two drugs, technosphere\u00ae insulin inhalation powder and usual care. The eligibility criteria for the trial includes being a non-smoker, having a body mass index less than 42 kg/m2, and having no abnormalities in screening pulmonary radiology. For subjects with diabetes, they must have had the disease for at least 2 years and have an HbA1c level between 6.6% and 12.0%. Subjects without abnormalities in glucose control must have no history of diabetes and normal results from a formal glucose tolerance test. Exclusion criteria includes a history of chronic obstructive pulmonary disease, asthma, or other significant pulmonary disease, significant renal, hepatic, or cardiac disease, being pregnant or lactating, having participated in studies of other investigational drugs within the previous 3 months, and evidence of severe complications of diabetes.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug ziprasidone. The eligibility criteria for the trial include having successfully completed a previous ziprasidone clinical study, not being hospitalized in an acute psychiatric service, providing written informed consent, and using an adequate method of contraception for female patients at risk of pregnancy. Exclusion criteria include immediate risk of harm to self or others, requiring concurrent treatment with non-study antipsychotic agents, requiring treatment with antidepressants or mood stabilizers, and having a history of certain medical conditions or diseases. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "This is a sample entry from a clinical trial table. The trial is in phase 3 and is focused on the disease of multiple sclerosis. The icd-10 codes associated with the disease are 'G35' and 'C81.18'. The trial is testing the drugs fampridine-sr and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of multiple sclerosis and being able to walk with or without an assistive device. Exclusion criteria include pregnancy, breastfeeding, or not using adequate birth control, participating in other investigational drug trials, having a medical history or clinical findings that preclude entry into the study, having a medication history that precludes entry into the study, and having previously been treated with 4-aminopyridine (4-AP).",
    "The sample is a record of a clinical trial in phase 3, focused on the disease pneumonia. The trial involves the use of the drugs simvastatin and placebo. The eligibility criteria for the trial include a duration of mechanical ventilation of more than 48 hours, suspicion of VAP with a Clinical Pulmonary Infection Score modified of 5 or more, and the performance of certain cultures prior to antibiotic administration. There are also exclusion criteria, such as statin treatment received under mechanical ventilation, age less than 18 years, and pregnancy. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma. The trial includes patients with active multiple myeloma stage II or III Durie Salmon and measurable levels of myeloma paraprotein in serum or urine. The trial involves two drugs, a combination of thalidomide and dexamethasone and a placebo with dexamethasone. The eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and the use of contraception for women of childbearing potential and barrier contraception for men. The exclusion criteria include pregnant or lactating females, peripheral neuropathy, prior history of malignancy, and lab abnormalities such as low ANC or platelet count, high serum creatinine or bilirubin, and high SGOT/AST or SGPT/ALT.",
    "The sample is a phase 3 clinical trial for patients with metastatic adenocarcinoma of the pancreas, chemotherapeutic agent toxicity, and thromboembolism. The trial is testing the effectiveness of dalt\u00e9parine and chemotherapy at the investigator's discretion. The eligibility criteria include having measurable disease, a WHO performance status of 0-2, and meeting certain laboratory values. Patients must also not have certain medical conditions or prior treatments. The trial is looking for patients who are not pregnant or nursing, have no contraindications to the study drugs, and have no psychological, familial, social, or geographical conditions that would prevent them from participating.",
    "The sample is a phase 3 clinical trial for patients with hypertension and hyperlipidemia. The trial involves the use of drugs such as valsartan and rosuvastatin, as well as placebos. The eligibility criteria include being between the ages of 20-80, having hypertension and hyperlipidemia, and signing an informed consent form. Exclusion criteria include having high blood pressure or high levels of LDL-C or TG, having a significant difference in blood pressure between arms, and experiencing orthostatic hypotension symptoms.",
    "The sample is a phase 3 clinical trial for chronic insomnia. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested, including ramelteon and a placebo. The eligibility criteria for the trial include having primary insomnia for at least 3 months, meeting specific sleep latency and total sleep time requirements, having a habitual bedtime between 8:30 p.m. and 12:00 a.m., and having a body mass index between 18 and 34. Exclusion criteria include a history of seizures, sleep apnea, chronic obstructive pulmonary disease, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder, as well as a history of drug addiction or drug abuse within the past 12 months. The trial also includes a list of disallowed medications and substances, including anxiolytics, hypnotics, and antidepressants.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with type 2 diabetes mellitus and involves the use of several drugs, including linagliptin and metformin. The eligibility criteria for the trial include a diagnosis of type 2 diabetes and treatment with one antidiabetic drug. However, patients with a history of myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism, impaired hepatic function, or treatment with anti-obesity drugs are excluded from the trial. Additionally, patients with renal failure or impairment are excluded based on their estimated glomerular filtration rate.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease. The trial involves the drug semagacestat and the eligibility criteria include meeting the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease, having completed a previous study on semagacestat, having a reliable caregiver, being capable of swallowing whole oral medication, and agreeing not to participate in other investigational compounds for the duration of the study. The exclusion criteria include meeting the discontinuation criteria of a previous study. The diseases are listed as \"Alzheimer's disease\" and the icd-10 codes associated with it are [\"G30.8\", \"G30.9\", \"G30.0\", \"G30.1\"].",
    "The sample is a phase 3 clinical trial for kidney neoplasms. The trial involves the use of two drugs, axitinib and sorafenib, and the eligibility criteria includes having confirmed renal cell cancer with a component of clear cell subtype and evidence of measurable disease. Patients must have failed one prior systemic first-line regimen for metastatic renal cell cancer. Exclusion criteria includes prior treatment for metastatic renal cell cancer with more than one systemic first-line therapy and major surgery or radiation within 4 weeks or 2 weeks of starting the study drug.",
    "The sample is a phase 3 clinical trial for patients with hypercholesterolemia. The trial involves the use of ezetimibe 10 mg, atorvastatin, and a comparator drug called rosuvastatin. The eligibility criteria for the trial include being at high cardiovascular risk, never having taken lipid-lowering therapy or being off such therapy for at least 6 weeks, or currently taking a stable dose of certain lipid-lowering agents. Patients must also be willing to maintain a cholesterol-lowering diet during the study. There are several exclusion criteria, including being Asian, routinely having more than 2 alcoholic drinks per day, being pregnant or breastfeeding, having congestive heart failure, and having had a myocardial infarction, coronary bypass surgery, angioplasty, or acute coronary syndrome within 3 months of screening. Patients with uncontrolled cardiac arrhythmias, kidney disease, any disease known to influence blood lipid levels, or any disorders of the blood, digestive system, or nervous system are also excluded. Patients with poorly controlled or newly diagnosed diabetes, known to be HIV positive, or with a history of cancer in the last 5 years (except certain skin and cervical cancers) are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of melanoma and skin cancer. The trial involves the use of drugs such as cisplatin, dacarbazine, and vinblastine. The eligibility criteria include being diagnosed with malignant melanoma with regional lymph node metastases, having undergone complete lymph node dissection and being free of any residual tumor, and having no distant or resected in-transit metastases. Patients must also meet certain age, performance status, life expectancy, hematopoietic, hepatic, renal, and other criteria. Prior concurrent therapy is also taken into consideration. The trial does not allow prior chemotherapy or immunotherapy with interferon or IL-2, and no concurrent immunomodulators or steroids are allowed. The trial also has restrictions on concurrent nonsteroid anti-inflammatory drugs or other prostaglandin synthetase inhibitors.",
    "The sample is a phase 3 clinical trial for women with menorrhagia or heavy menstrual bleeding. The trial involves the use of tranexamic acid tablets and placebo tablets. The eligibility criteria include being a woman between the ages of 18-49 with regularly occurring menstrual periods. Exclusion criteria include a history or presence of clinically significant disease or abnormalities that may confound the study, a history of bilateral oophorectomy or hysterectomy, and hormone therapy. The icd-10 codes associated with the diseases are also provided.",
    "The sample is a phase 3 trial that focuses on patients with critical limb ischemia, peripheral vascular disease, foot ulcers, and rest leg pain. The trial uses the drug Remodulin\u00ae (treprostinil sodium) injection. The eligibility criteria for the trial are patients with Stage III or IV critical limb ischemia due to documented peripheral arterial disease with no planned interventional vascular procedures. The sample also includes a list of ICD-10 codes associated with the diseases being studied.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of the drug lurasidone hcl. The eligibility criteria for the trial includes being between the ages of 18 and 75, meeting DSM-IV criteria for schizophrenia, being in good physical health, and agreeing to comply with the protocol. Exclusion criteria includes a history of alcohol or drug abuse, use of an investigational compound within the last 30 days, and being considered at imminent risk of suicide or injury to self or others.",
    "The sample is a phase 3 clinical trial for patients with non-malignant lower back pain who have been taking analgesic medications for at least 3 months or are dissatisfied with their current therapy. Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to < 160 mg of oral morphine. The trial includes the drugs tapentadol (cg5503) er, oxycodone cr, and placebo. The eligibility criteria include a baseline score of =5 on an 11-point numerical rater scale, calculated as the average pain intensity during the last 3 days prior to randomization. The exclusion criteria include a history of alcohol and/or drug abuse, significant liver insufficiency, chronic hepatitis B or C, or HIV, life-long history of seizure disorder or epilepsy, history of malignancy within past 2 years (with exception of basal cell carcinoma that has been successfully treated), uncontrolled hypertension, severely impaired renal function, and moderate to severely impaired hepatic function or with laboratory values reflecting inadequate hepatic function.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and bipolar disorder. The trial is focused on the drug aripiprazole. The eligibility criteria for the trial includes adolescent patients with schizophrenia or child and adolescent patients with bipolar I disorder, manic or mixed episode. Patients with a co-morbid serious, uncontrolled systemic illness or a significant risk of committing suicide are excluded from the trial. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 clinical trial for patients with advanced non-small-cell lung cancer. The trial is testing the effectiveness of the drugs docetaxel and cisplatin. The eligibility criteria include having a histologic or cytologic diagnosis of advanced NSCLC, having at least one evaluable tumor lesion, and having adequate bone marrow and hepatic function. Patients must not have received prior chemotherapy or radiation therapy within 4 weeks, and must not have any serious concomitant systemic disorders. The trial also has exclusion criteria, such as having symptomatic central nervous system metastases or a history of hypersensitivity to any of the study medication.",
    "The sample is a phase 3 clinical trial for patients with HIV-1 infection who have been receiving highly active antiretroviral therapy (HAART) for at least 24 weeks. The trial aims to evaluate the efficacy and safety of changing the current HAART regimen to simplify or reduce toxicity. The trial includes patients with a plasma viral load of less than 50 copies/mL for at least 24 weeks prior to screening and a CD4 count of over 100/mm3 at the start of HAART and over 200/mm3 at screening. Patients with a history of virological failure, primary PI mutations, co-infection with hepatitis B, or active clinically significant or life-threatening diseases are excluded from the trial. The trial involves the use of darunavir (DRV, TMC114) as the drug of interest.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus and coronary heart disease. The trial is testing the effectiveness of the drugs pioglitazone and glimepiride in reducing the risk of cardiovascular events. The eligibility criteria include having a glycosylated hemoglobin level within a certain range, having angiographic evidence of coronary heart disease, and not having certain medical conditions or taking certain medications. The exclusion criteria include having type 1 diabetes mellitus, participating in another investigational study, having uncontrolled hypertension, and having a history of drug or alcohol abuse.",
    "The sample is a phase 3 clinical trial for ovarian cancer. The trial includes patients who have documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred and have not received prior chemotherapy in the recurrent setting. The trial involves the use of drugs such as carboplatin, gemcitabine, bevacizumab, and placebo. The eligibility criteria for the trial include signed informed consent form, age of 18 years or older, measurable disease, and recovery from prior radiation therapy or surgery. The exclusion criteria include prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian tube carcinoma, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess, and inadequate control of hypertension.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial includes patients who have been diagnosed with type 2 diabetes and have been treated with one or more oral antidiabetic drugs for the last 3 months. The trial also has specific inclusion and exclusion criteria, such as a BMI less than 45.0 kg/m^2 and no treatment with insulin within the last 3 months prior to the trial. The trial will test the effectiveness of drugs such as liraglutide, glimepiride, and metformin, as well as a placebo. The trial will exclude patients with impaired liver or renal function, significant cardiovascular disease, known retinopathy or maculopathy, and recurrent major hypoglycemia or hypoglycemic unawareness.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial involves the use of drugs such as boceprevir, peginterferon alfa-2b, ribavirin, and erythropoietin. The eligibility criteria for participants include having previously documented chronic hepatitis C genotype 1 infection, a liver biopsy with histology consistent with CHC and no other etiology, and a weight between 40 kg and 125 kg. Participants must also agree to use acceptable methods of contraception and attend frequent site visits for the duration of the trial. Exclusion criteria include co-infection with HIV or hepatitis B virus, prior treatment for hepatitis C, and participation in any other clinical trial within 30 days of the screening visit. Participants must not have any contraindications for the use of erythropoietin and must not have any known pre-existing medical condition that could interfere with their participation in and completion of the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis B. The trial includes patients with a biopsy performed within one year prior to screening or during screening, with ALT levels greater than 1.5 times the upper limit of normal, and HBV DNA levels greater than 10E5 copies/ml. The trial also includes patients who are HBeAg negative and anti-HBeAg positive, between the ages of 18-70, and have written informed consent. Patients must not have evidence of HCC on hepatic imaging and must be using two forms of effective contraception if fertile. The trial excludes patients who have received antiviral therapy against HBV within the previous 6 months, have severe hepatitis activity as documented by ALT levels greater than 10 times the upper limit of normal, have advanced liver disease, pre-existent leucopenia or thrombopenia, co-infection with HCV, HDV or HIV, other acquired or inherited causes of liver disease, alpha fetoprotein levels greater than 50 ng/ml, evidence of severe renal disease, hyper- or hypothyroidism, significant cardiovascular or pulmonary dysfunction, malignancy, immunodeficiency syndromes, immune suppressive treatment within the previous 6 months, contra-indications for alpha-interferon therapy, pregnancy or breast-feeding, any medical condition requiring chronic systemic administration of steroids, substance alcohol or drug abuse, clinically significant retinal abnormalities, clinically significant hearing abnormalities, or hemoglobinopathies. The trial involves the use of ribavirin and peginterferon alpha 2a as drugs.",
    "The sample is a phase 3 clinical trial for chronic lymphocytic leukemia. The trial is testing the effectiveness of a combination of drugs including fludarabine, cyclophosphamide, and mitoxantrone. The eligibility criteria for patients include having confirmed relapsed and advanced CLL, with Binet stage B or C disease and rapid disease progression, enlarged lymph nodes and organs, or severe B-symptoms. Patients must also have an ECOG performance status of 0-3, a life expectancy of more than 6 months, and no severe organ dysfunction or other prior or concurrent neoplasm, autoimmune hemolytic anemia, or thrombocytopenia. Additionally, patients must have had no more than three previous treatment regimens for CLL, with fludarabine being the only exception.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of seasonal allergic rhinitis. The trial is testing the effectiveness of a drug called gw685698x aqueous nasal spray. The record includes a list of inclusion and exclusion criteria for participants, such as being an outpatient, having a diagnosis of seasonal allergic rhinitis, and not having significant medical conditions or allergies to the investigational product. The record also includes the icd-10 code for the disease and a list of other diseases that may be included in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of anemia. The trial includes patients with non-myeloid malignancy and a baseline hemoglobin value between 11 and 12 g/dL. Female patients with reproductive potential must have a negative pregnancy test and all patients must have signed an informed consent. The trial excludes patients with uncontrolled hypertension, a history of cardiac arrhythmias or thrombotic events, recent transfusions, or planned myelosuppressive chemotherapy or radiation. The drug being tested is epoetin alfa. The diseases being studied are not specified beyond anemia, and the icd-10 codes listed are for various types of anemia.",
    "This sample is for a phase 3 clinical trial for the treatment of heart defects, congenital. The trial includes the use of two drugs, clopidogrel (sr25990) and placebo. The eligibility criteria for the trial includes having cyanotic congenital heart disease treated by any palliative systemic-to-pulmonary artery shunt. The exclusion criteria includes having active bleeding or an increased risk of bleeding, being allergic to two or more classes of drugs, being unable to receive the drug orally or enterically, and having current clinically significant or persistent thrombocytopenia, neutropenia, severe hepatic or renal failure.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the use of the drugs abatacept and placebo. The eligibility criteria for the trial include having active rheumatoid arthritis and failing or having failed anti-TNF therapy in the past. The exclusion criteria include being pregnant or breastfeeding, having current symptoms of serious medical disease, a history of cancer in the last 5 years (other than non-melanoma skin cancer), chronic serious infection, active TB requiring treatment in the last 5 years, herpes zoster in the last 2 months, any active viral infection including HIV, and serious side effects associated with previous anti-TNF therapy. The icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have moderate to severe active RA for at least 6 months. Patients must have had an inadequate response to a stable dose of MTX. The trial includes the drugs tocilizumab, placebo, and methotrexate. Patients of reproductive potential must be using reliable methods of contraception. Exclusion criteria include major surgery within 8 weeks before entering the study, prior treatment failure with an anti-tumor necrosis factor agent, and women who are pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B patients who are HBeAg negative. The trial is testing the effectiveness of peginterferon alfa-2a [pegasys] as a treatment. The eligibility criteria include being between 18-55 years old, having liver disease consistent with chronic hepatitis, and having participated in study ML18253. Exclusion criteria include having received interferon-based or any systemic anti-HBV therapy within the past 12 months, having co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV), and having hepatocellular cancer or compensated or decompensated liver disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of venous thromboembolism and includes a list of associated ICD-10 codes. The trial involves the use of three drugs: semuloparin sodium, enoxaparin sodium, and placebo. The eligibility criteria for the trial include patients undergoing major abdominal surgery and those under 60 years of age with additional risk factors for VTE. Exclusion criteria include recent major surgery, clinical signs or symptoms of DVT or PE, and high risk of bleeding, among others. The sample also includes a disclaimer that the information provided is not exhaustive and other considerations may be relevant for potential participants in the trial.",
    "The sample is a phase 3 clinical trial for patients with idiopathic pulmonary fibrosis, lung disease, and pulmonary fibrosis. The trial involves the use of interferon gamma-1b (\"actimmune\") as a treatment. The eligibility criteria include having clinical symptoms consistent with IPF, a diagnosis of IPF within 48 months before randomization, and a high-resolution computed tomographic scan (HRCT) showing definite IPF. Patients must also have a forced vital capacity (FVC) of at least 55% of predicted value and a hemoglobin (Hb)-corrected carbon monoxide diffusing capacity/carbon monoxide transfer capacity (DLCO/TLCO) of at least 35% of predicted value. Patients must also have evidence of IPF disease progression within the past year. There are several exclusion criteria, including a history of malignancy likely to result in death, significant disability, or likely to require significant medical or surgical intervention within the next 3 years, and any condition other than IPF which, in the opinion of the Principal Investigator, is likely to result in the death of the patient within the next 3 years.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of gastric cancer. The trial is testing the effectiveness of a combination of drugs, including trastuzumab, fluorouracil, cisplatin, and capecitabine, on patients with inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or gastro-esophageal junction. The trial is specifically targeting patients with HER2-positive tumors. The record includes the eligibility criteria for the trial, which includes being an adult patient over 18 years of age with adenocarcinoma. The record also lists the exclusion criteria, which includes a history of previous chemotherapy for advanced/metastatic disease, lack of physical integrity of the upper gastrointestinal tract, history of cardiac disease, and dyspnoea at rest due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy.",
    "The sample is a phase 3 clinical trial for kidney transplantation and graft rejection. The trial involves the use of drugs such as everolimus, mycophenolic acid (mpa), cyclosporine a (csa), basiliximab, and corticosteroids. The eligibility criteria for the trial include patients between 18 to 70 years old who have given written informed consent. Exclusion criteria include recipients of multi-organ transplantation, primary cadaveric or primary non-human leucocyte antigen (HLA) identical living donor kidney transplantation, and graft cold ischemia time greater than 40 hours. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with relapsed ovarian cancer. The trial involves the use of the drugs treosulfan and has eligibility criteria that include measurable or evaluable tumor lesions or progression defined as CA-125 more than or equal to 100 U/ml, age greater than or equal to 70 years, and ECOG 0-2. Exclusion criteria include pretreatment with treosulfan, no measurable or evaluable tumor lesions or CA-125 more than or equal to 100 U/ml, inadequate bone marrow function, creatinine and bilirubin levels outside of the reference laboratory's normal range, and simultaneous radiotherapy.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The trial is testing the effectiveness of two drugs, erlotinib and gemcitabine, on patients with locally advanced, unresectable, or metastatic adenocarcinoma. The eligibility criteria include having no prior systemic treatment for metastatic disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, and adequate hematologic, hepatic, and renal function. Exclusion criteria include unstable systemic disease, prior systemic human epidermal growth factor receptor 1 (HER1) or epidermal growth factor receptor (EGFR) inhibitors, and other malignancy within 5 years prior to study entry. The sample also includes additional criteria related to ophthalmologic abnormalities, ability to take oral medication, and nursing mothers.",
    "This sample is for a phase 3 clinical trial for the treatment of vasomotor symptoms in postmenopausal Chinese women. The trial includes two drugs, estradiol/drsp (angeliq, bay86-4891) and a placebo. The eligibility criteria for the trial include being a Chinese postmenopausal woman with moderate to severe vasomotor symptoms, and exclusion criteria include a history of steroid hormone dependent malignant disease, known or suspected malignant or premalignant disease, current or history of severe heart, liver, renal, psychiatric disease, and hyperlipemia.",
    "The sample is a phase 3 clinical trial for the treatment of fallopian tube cancer, ovarian cancer, and primary peritoneal cavity cancer using erlotinib hydrochloride. The trial has eligibility criteria for patients with confirmed histology of the specified cancers who have completed first-line therapy within the past 6 weeks and achieved complete response, partial response, or stabilization of disease after therapy. Patients must also meet certain patient characteristics, such as having a performance status of ECOG 0-1 and meeting certain hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, and other criteria. The trial excludes patients with adenocarcinoma of unknown origin, known brain metastases or leptomeningeal disease, and certain medical conditions or psychiatric disorders. Prior concurrent therapy is also restricted, including no prior therapy targeting epidermal growth factor receptor and no concurrent immunotherapy or chemotherapy. Interval debulking surgery after 3 courses of chemotherapy and second-look surgery at the end of chemotherapy are allowed. Concurrent participation in another study is also allowed.",
    "The sample is for a phase 3 clinical trial for postmenopausal osteoporosis. The trial includes patients who are 50 years of age or older, have not had a menstrual cycle for more than 5 years, and have low bone mineral density in the lumbar spine or total hip. Patients with at least one prevalent vertebral body fracture are also eligible. The trial excludes patients with a history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia, a BMI over 32 kg/m, or who have used medications that impact bone metabolism within 3 months of starting the study drug. Patients with hypocalcemia or hypercalcemia of any cause or markedly abnormal clinical laboratory measurements are also excluded. The study drug being tested is risedronate.",
    "The sample is a phase 3 clinical trial for the treatment of breast cancer. The trial includes patients with invasive breast cancer who have a primary tumor greater than 2 cm in diameter and no evidence of metastasis. The trial drugs are lapatinib and paclitaxel, and patients must have overexpression and/or amplification of HER2 in the invasive component of the primary tumor. The eligibility criteria include various medical and demographic factors, such as age, gender, performance status, and hematology and hepatic status. Patients must also have signed an informed consent form and agree to make available tumor samples for submission to a central laboratory for translational studies. The exclusion criteria include prior treatment for primary invasive breast cancer, previous or current history of malignant neoplasms, and various medical conditions that would make the subject inappropriate for study participation.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drugs Rozerem and placebo in treating insomnia and obstructive sleep apnea in patients over the age of 60. The trial has a list of inclusion and exclusion criteria, which determine who is eligible to participate in the trial. The inclusion criteria include having obstructive sleep apnea, insomnia, and being over the age of 60. The exclusion criteria include having cognitive impairment, active alcohol or substance abuse, active use of other sedative-hypnotic agents, active use of fluvoxamine, evidence of hepatic dysfunction, presence of Periodic Limb Movement Disorder or Restless Legs Syndrome, and severe Chronic Obstructive Pulmonary Disease. The trial also has a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for stroke patients. The trial involves the use of candesartan cilexetil and placebo drugs. The eligibility criteria for the trial include having a clinical stroke syndrome with limb paresis, systolic blood pressure of at least 140 mm Hg, and being able to receive trial treatment within 30 hours of symptom onset. Patients must also be over 18 years old and provide consent. Exclusion criteria include reduced consciousness, already receiving AT1 receptor blocker, contraindications to treatment with AT1 receptor blocker, and other serious or life-threatening diseases. Patients who are severely mentally or physically disabled, have a life expectancy of less than 12 months, are unavailable for follow-up, or are pregnant or breastfeeding are also excluded.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is testing a fixed dose combination of telmisartan and amlodipine, as well as amlodipine alone. The eligibility criteria for participants include having a diagnosis of essential hypertension with inadequately controlled blood pressure, failure to respond to six weeks of treatment with amlodipine, and being able to stop any current antihypertensive therapy without unacceptable risk. Exclusion criteria include pregnancy, breast-feeding, known or suspected secondary hypertension, and various other medical conditions. Participants must also be willing and able to provide written informed consent.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of asthma. The icd-10 codes associated with the disease are listed. The trial involves several drugs, including montelukast sodium, a placebo, and fluticasone. The eligibility criteria for participants include being chronic asthma sufferers who smoke between 0.5 and 2 packs of cigarettes per day. Participants with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or emphysema are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the disease of hypertension. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, which are aliskiren and ramipril. The eligibility criteria for the trial are also listed, including requirements for blood pressure levels and exclusion criteria such as a history of certain medical conditions or allergies to the study medications. The sample also notes that there may be additional inclusion/exclusion criteria defined by the trial protocol.",
    "The sample is a phase 3 clinical trial for patients with chronic myeloid leukemia or acute lymphoblastic leukemia who have primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of it. The trial involves the use of the drugs dasatinib and has eligibility criteria that include being 18 years or older, having adequate hepatic and renal function, and having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Exclusion criteria include being pregnant or breastfeeding, having a serious uncontrolled medical disorder or active infection, and having a history of significant bleeding disorder unrelated to CML. The trial is not open to prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.",
    "The sample is a phase 3 clinical trial for the treatment of hyperphosphatemia, end stage renal disease, and ESRD. The trial involves the use of ferric citrate as a phosphate-binding agent. The eligibility criteria for the trial include being over 18 years old, being on a three-times per week hemodialysis regimen, having a stable dose of a phosphate-binding agent for at least one month prior to study entry, and having a serum calcium level of 8 mg/dL to 10.5 mg/dL. Exclusion criteria include being pregnant or lactating, having a clinically significant GI disorder, having tertiary hyperparathyroidism or being immediately post-operative from a parathyroidectomy, having a ferritin level above 800 ng/mL, having an unstable medical condition unsuitable for the study, having been treated with an investigational agent within 30 days of enrollment, or having a history of documented iron allergy or hemochromatosis.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease. The trial involves the drug rosiglitazone and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include a clinical diagnosis of probable Alzheimer's disease, a MMSE score between 10 and 23, and not having taken an approved Alzheimer's therapy in the last 30 days. Exclusion criteria include a diagnosis of vascular dementia, type I or secondary diabetes mellitus, and a history of significant psychiatric illness or major depressive disorder.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma and plasma cell neoplasm using the drugs dexamethasone and lenalidomide. The eligibility criteria include having previously untreated multiple myeloma with measurable M-protein levels, being 18 years or older with a Zubrod performance status of 0-3, and having certain hematopoietic, hepatic, renal, and cardiovascular conditions. Patients must not be pregnant or nursing, have uncontrolled active infections, or have other serious medical conditions or psychiatric illnesses that would preclude study participation. Prior concurrent therapies such as interferon or thalidomide are not allowed, but prior high-dose dexamethasone and localized radiotherapy are allowed. Patients must be able to take aspirin or enoxaparin as a form of thrombotic prophylaxis.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is looking at the effectiveness of two drugs, bevacizumab and bevacizumab with erlotinib. The eligibility criteria for the trial includes having a histologically proven metastatic adenocarcinoma of colon or rectum, having inoperable disease, having a measurable lesion as assessed by CT scan or MRI, and not having received previous therapy for metastatic disease. Other criteria include having an ECOG performance status of 0-2, certain blood counts and levels within normal ranges, no peripheral sensory neuropathy, and no clinically significant cardiovascular disease. Additionally, patients must have no evidence of bleeding diathesis or coagulopathy, no serious, non-healing wound, ulcer, or bone fracture, and no significant ophthalmologic abnormality. Patients must also have had more than 28 days since prior major surgical procedure or open biopsy. Fertile patients must use effective means of contraception.",
    "The sample is a phase 3 clinical trial for the treatment of migraine disorders and acute migraines. The trial includes patients aged 18 to 65 who have had at least 2 migraine attacks per month in the three months prior to screening and have documented use of Butalbital-containing Combination Medication (MCM) to have treated at least one migraine. The trial excludes patients with certain medical conditions, such as cardiovascular or cerebrovascular disease, impaired hepatic or renal function, and bleeding disorders, as well as those who have taken certain medications within a certain timeframe. The trial involves the use of treximet\u00ae, butalbital-containing combination medications (bcm), and placebo. The eligibility criteria include cognitive assessments and all other questionnaires programmed in an electronic diary, and written informed consent.",
    "The sample is a phase 3 clinical trial for ocular inflammation. The trial includes patients who are at least 18 years old and are candidates for routine, uncomplicated cataract surgery. The trial excludes patients with known hypersensitivity or contraindication to the study drug or its components, chronic systemic diseases that may increase the risk to the subject or compound the result of the study, severe/serious ocular conditions, elevated intraocular pressure, uncontrolled glaucoma, or being treated for glaucoma in the study eye. Women who are pregnant or breastfeeding are also excluded. The trial requires patients to comply with all treatment and follow-up procedures.",
    "The sample is a phase 3 clinical trial for the treatment of lymphoma using the drugs bexarotene and methoxypsoralen. The eligibility criteria include having histologically confirmed mycosis fungoides at stage IB or IIA, being over 18 years old with a Karnofsky performance status of 60-100%, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must also not be pregnant or nursing, have negative pregnancy test results, and use effective contraception during and for at least 3 months after study participation. Additionally, patients must be willing and able to avoid prolonged exposure to the sun and limit sun exposure on the day of PUVA therapy. Prior concurrent therapies are also taken into consideration.",
    "This sample is for a phase 3 clinical trial for the treatment of schizophrenia. The trial is focused on the drug risperidone. The eligibility criteria for the trial include having a responsible person available to accompany the patient to each visit and meeting the DSM-IV criteria for schizophrenia. Exclusion criteria include having a history of substance dependence, being under 35kg in weight, and being unable to swallow oral tablets. The diseases being studied are limited to schizophrenia and the corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 3 clinical trial for the treatment of Generalized Anxiety Disorder. The trial involves the use of the drugs vortioxetine and placebo. The eligibility criteria for participants include having a primary diagnosis of Generalized Anxiety Disorder, a Hamilton Anxiety Scale total score of at least 20, and a Montgomery-\u00c5sberg Depression Rating Scale total score of no more than 16. Exclusion criteria include having any current psychiatric disorder other than Generalized Anxiety Disorder, a history of certain mental disorders or substance abuse, and a significant risk of suicide. Participants must also not be currently receiving certain types of therapy and must not have certain medical conditions or abnormal test results.",
    "The sample is a phase 3 clinical trial for the treatment of post-stroke spasticity and cerebrovascular accident. The trial involves the use of two drugs, gsk1358820 and placebo. The eligibility criteria for the trial include patients with lower limb spasticity who are at least 6 months post-stroke and present with equinus deformity (plantar flexion of the ankle) at the start of the double-blind phase. Patients must also have a MAS ankle score of \u22653 at the start of the double-blind phase and be between 20 and 80 years of age. Exclusion criteria include patients with bilateral hemiplegia or quadriplegia, presence of fixed contractures of the ankle, and previous surgical intervention, phenol block, ethanol block, or Muscle Afferent Block (MAB) for ankle spasticity. The trial also excludes patients with a diagnosis of systemic neuromuscular disorders, females who are pregnant, nursing, may be pregnant, or planning a pregnancy during the study period, and those with clinically unstable severe cardiovascular disease or clinically significant severe renal or hepatic disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of allergy, specifically grass pollen-related allergic rhinoconjunctivitis. The icd-10 codes associated with the disease are listed. The trial involves testing three different drugs: 300 ir (4m), 300 ir (2m), and placebo. The eligibility criteria for participants are listed, including age range, specific allergy test results, and symptom severity. Exclusion criteria are also listed, including other allergies and previous desensitization treatments.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C genotype 1 infection. The trial includes patients between the ages of 18 and 70 who have confirmed prior virological failure with an approved dose of PegIFN/RBV and have a HCV RNA level of at least 1,000 IU/mL at screening. The trial excludes patients with HCV infection of mixed genotype, Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV) co-infection, evidence of acute or chronic liver disease due to causes other than chronic HCV infection, decompensated liver disease, body weight less than 40 or greater than 125 kg, clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary disease, history or evidence of retinopathy or clinically significant ophthalmological disorder, pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study, laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD deficit), and patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection including and not restricted to protease or polymerase inhibitors. The trial includes the drugs bi 201335, pegylated interferon-alpha (ifn), ribavirin (rbv), and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of pseudobulbar affect (PBA) in patients with Amyotrophic Lateral Sclerosis (ALS) or multiple sclerosis. The trial includes three drugs: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, and a placebo. The eligibility criteria include a diagnosis of ALS or multiple sclerosis, clinical history and symptoms of PBA, and a CNS-LS score of 13 or greater. Exclusion criteria include myasthenia gravis, personal or family history of heart block or QTc prolongation, and sensitivity to the drugs being tested.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who have had a complete tumor resection and are eligible for randomization to either treatment arm within 8 weeks after surgery. Patients should never have had any evidence of metastatic disease. The trial includes patients with a life expectancy of at least 5 years. The trial excludes pregnant or lactating women, sexually active males and females unwilling to practice contraception during the study, patients who have had previous cytotoxic chemotherapy, radiotherapy or immunotherapy for the currently treated colon cancer, and patients who have not completely recovered from surgery. The trial uses capecitabine, oxaliplatin, leucovorin (lv), and 5-fluorouracil (5-fu) as drugs. The eligibility criteria include histologically confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C).",
    "This sample is for a phase 3 clinical trial for the treatment of diabetes. The trial includes patients who have been treated with a sulfonylurea for at least 2 months and have inadequate blood sugar control. The patients cannot be on any other medications to lower blood sugar and cannot have major heart, liver, or kidney problems. Women who are pregnant or breastfeeding are not eligible for the trial. The trial will test the effectiveness of saxagliptin, glyburide, metformin, and a placebo. The diseases included in the trial are only diabetes and the icd-10 codes associated with it.",
    "The sample is a phase 3 clinical trial for the treatment of narcolepsy. The trial includes patients who are 18 years or older and have been diagnosed with narcolepsy according to the International Classification of Sleep Disorders criteria. Patients must also be taking stable doses of modafinil for at least three months prior to the trial. The trial involves the use of drugs such as xyrem, xyrem placebo, modafinil at established dose, and modafinil (placebo). Patients must meet certain inclusion criteria, such as having adequate support for the duration of the trial and using a medically accepted method of birth control if of child-bearing potential. Patients who have received gamma-hydroxybutyrate in the last 30 days or have taken any investigational therapy within the 30-day period prior to the initial screening visit are excluded from the trial. Other exclusion criteria include having sleep apnea syndrome, taking certain medications, having certain illnesses or disorders, and having a history of substance use disorder or seizure disorder.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial includes patients with genotype 1 hepatitis C infection who have not received any prior treatment for the disease. Participants must have had a liver biopsy within 3 years before screening showing chronic hepatitis C infection. The trial involves the use of drugs such as placebo, tmc435, peginterferon alpha-2a or peginterferon alpha-2b (pegifn\u03b1-2a/b), and ribavirin (rbv). Inclusion criteria also require participants to agree to use 2 forms of effective contraception throughout the study. Exclusion criteria include infection with HIV or non-genotype 1 hepatitis C, liver disease not related to hepatitis C infection, hepatic decompensation, significant laboratory abnormalities or other active diseases, and pregnancy or planning to become pregnant.",
    "This sample is for a phase 3 clinical trial for chronic myeloid leukemia. The trial includes patients who have been diagnosed with chronic phase Ph+ CML within the last 6 months and have confirmed diagnosis of CML chronic phase. Patients must have adequate hepatic and renal function and be able to take oral tablets. Exclusion criteria include Philadelphia negative CML, prior anti-leukemia treatment, and prior stem cell transplant. The trial will test the effectiveness of two drugs, bosutinib and imatinib.",
    "The sample is a phase 3 clinical trial for the treatment of infection. The trial involves the use of two drugs, omiganan 1% gel and povidone-iodine 10%, and the eligibility criteria include the insertion of a noncuffed temporary central venous catheter, being at least 13 years old, and having a negative pregnancy test. Exclusion criteria include prior treatment with certain antibiotics, requirement for topical antibiotic use near the catheterization site, and severe neutropenia. Patients with suspected or known bloodstream infections, burn patients, and those with allergies to adhesive tape or bandages are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of childhood acute lymphoblastic leukemia. The trial includes patients with B-cell acute lymphoblastic leukemia who have not received prior cytotoxic chemotherapy, except for steroids and intrathecal cytarabine. The trial also includes patients with Down syndrome. The eligibility criteria include specific disease characteristics, such as initial white blood cell count and cytogenetics, as well as age and language requirements for parents or legal guardians. The trial involves a combination of drugs, including doxorubicin hydrochloride, cytarabine, dexamethasone, pegaspargase, methotrexate, leucovorin calcium, mercaptopurine, cyclophosphamide, thioguanine, and vincristine sulfate. The trial is being conducted at specific institutions and all institutional, FDA, and NCI requirements for human studies must be met.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of atrial fibrillation. The trial involves the use of two drugs, omega-3-acid ethyl esters and placebo. The eligibility criteria for the trial include being 18 years or older, having a history of symptomatic atrial fibrillation, and providing written informed consent. Exclusion criteria include having permanent atrial fibrillation, being on certain antiarrhythmic drug therapy, having a history of unsuccessful cardioversion, and having certain cardiovascular conditions or surgeries within the prior 6 months. The sample also lists other medical conditions that would exclude a participant from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of two drugs, bimatoprost/brimonidine tartrate/timolol ophthalmic solution and fixed combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution. The eligibility criteria for the trial include having ocular hypertension or primary open-angle glaucoma in both eyes and requiring treatment with IOP-lowering medication in both eyes. Exclusion criteria include chronic use of ocular medications other than study medication, use of corticosteroids within 30 days, history of prior eye surgery within 6 months, and anticipated wearing of contact lenses during the study. The icd-10 codes for the diseases being treated are also provided.",
    "The sample is a phase 3 clinical trial for epilepsy and generalized tonic-clonic seizures. The trial includes patients who have been on a stable dose of 1 or 2 anti-epileptic drugs for the last 4 weeks. The trial excludes patients with signs of a progressive brain lesion/disease, a diagnosis of Lennox-Gastaut Syndrome, confirmed focal epilepsy, or a history of convulsive or nonconvulsive status epilepticus while taking concomitant anti-epileptic drugs for the last 3 months prior to Visit 1. The drug being tested in the trial is levetiracetam. The diseases being studied are epilepsy and generalized tonic-clonic seizures, and their corresponding ICD-10 codes are listed.",
    "The sample is a phase 3 clinical trial for allergic rhinitis. The trial includes subjects who are 12 years of age or older, of any race and gender, and have a positive skin prick test response to an appropriate seasonal allergen. The trial aims to evaluate the efficacy of mometasone furoate nasal spray (mfns) compared to a matching placebo nasal spray. The eligibility criteria include having at least a 2-year history of SAR which exacerbates during the study season and being clinically symptomatic at the Screening and Baseline Visits. Exclusion criteria include having a history of severe local reaction(s) or anaphylaxis to skin testing, using any drug in an investigational protocol in the 30 days prior to the Screening Visit, and being a family member of the investigational study staff. Female subjects who are breast-feeding, pregnant, or intend to become pregnant are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of opioid-induced constipation (OIC). The trial includes patients who have reported active symptoms of OIC and have confirmed OIC with less than 3 bowel movements per week. Patients must also be receiving a stable maintenance opioid regimen for at least 4 weeks prior to screening for non-cancer-related pain. The trial will last for 12 weeks and patients will be required to stop all laxatives and other bowel regimens, except for bisacodyl as rescue medication. Patients with a history of cancer within 5 years, medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation, and other gastrointestinal tract issues that could impose a risk to the patient are excluded from the trial. Patients who are pregnant or lactating are also excluded. The trial will include the drug NKTR-118 and a placebo.",
    "The sample is a phase 3 clinical trial for patients with atherosclerosis. The trial is testing the effectiveness of the drugs glipizide and rosiglitazone maleate in treating type 2 diabetes mellitus (T2DM) in patients who are also undergoing coronary angiography for evaluation of suspected or previously diagnosed coronary artery disease or who are undergoing PCI. The trial has specific inclusion and exclusion criteria, including age range, established diagnosis of T2DM, prior anti-hyperglycemic diabetic therapy, left ventricular ejection fraction, and contraceptive measures for female subjects. Exclusion criteria include type 1 diabetes, exposure to a TZD or other PPAR-g agonist within the 6 months prior to screening visit, and recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months. The trial aims to determine the safety and efficacy of the drugs in treating T2DM in this patient population.",
    "The sample is a phase 3 trial for the treatment of scalp psoriasis. The trial includes subjects who are 18 years or older and have moderate to severe scalp psoriasis. The trial excludes subjects who need systemic treatment for their body psoriasis and those who have recently used certain topical or systemic treatments. The trial involves two drugs, clobex shampoo 0.05% and clobex shampoo placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for female subjects with polycystic ovarian syndrome who are suitable for IVF/ICSI and undergoing their first or second attempt. The trial includes eligibility criteria such as age between 18-35 years old, BMI less than or equal to 32, normal FSH value, and normal thyroid function. The trial also has exclusion criteria such as ongoing pregnancy, uterine malformation, and history of major thromboembolic disease. The trial involves the use of drugs such as cetrorelix acetate, recombinant human choriogonadotropin, and recombinant human follicle stimulating hormone. The criteria for inclusion and exclusion are clearly defined in the sample.",
    "The sample is a phase 3 clinical trial for diabetes and diabetes mellitus, type 1. The trial involves the use of insulin detemir and insulin aspart as drugs. The eligibility criteria include obtaining informed consent, having completed 52 weeks of treatment with insulin detemir in a previous trial, and using adequate contraception for fertile females. The exclusion criteria include having significant concomitant diseases, being pregnant or intending to become pregnant, and having previously participated in the trial. The diseases are identified by their ICD-10 codes.",
    "The sample is a record of a clinical trial in phase 3, focused on essential hypertension. The trial includes patients of both genders who are at least 18 years old. The trial involves the use of the drugs aliskiren/amlodipine and aliskiren/amlodipine/hctz. The eligibility criteria for the trial include having stage II essential hypertension, while exclusion criteria include severe hypertension, poorly controlled diabetes mellitus or type 1 DM, history of myocardial infarction or stroke, and presence of heart failure. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of prostate cancer. The trial includes a list of drugs, such as degarelix and leuprolide, and a list of eligibility criteria, including a requirement for patients to have completed a previous study and to have signed informed consent. The diseases are specified as only prostate cancer, and the icd-10 codes associated with the disease are also listed.",
    "The sample is a phase 3 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of the drugs capecitabine and bevacizumab as first-line treatment. The eligibility criteria include having measurable disease, a performance status of 0-1, and adequate bone marrow, renal, and liver function. Exclusion criteria include a history of CNS metastases, second malignancy within the past 5 years (with some exceptions), and intolerance to the study drugs. The trial also has specific criteria for randomization and follow-up.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of multiple myeloma. The trial involves the drugs thalidomide and placebo. The eligibility criteria for the trial include patients with multiple myeloma who have not received previous treatment, do not require high dose chemotherapy with autologous stem cell support, are not women of fertile age, do not have psychiatric disease or mental reduction leading to lack of cooperation, have given consent, have a life expectancy of at least 3 months, and do not have active cancer of other etiology. The icd-10 codes associated with multiple myeloma are also included in the record.",
    "The sample is a record of a clinical trial in phase 3, which is focused on postmenopausal women with osteoporosis. The trial involves two groups of drugs, a test group and a reference group. The eligibility criteria for the trial include being a female over 40 years old and in postmenopausal, while the exclusion criteria include having a history of malignant cancer.",
    "The sample is a phase 3 clinical trial for the treatment of idiopathic Parkinson's disease. The trial is looking at the effectiveness of safinamide as an add-on therapy for patients who have been diagnosed with the disease for less than 5 years and have a Hoehn and Yahr stage of I-III. The trial is open to patients between the ages of 30 and 80 who are willing to participate and have provided written informed consent. The trial has a list of exclusion criteria, including patients with other forms of Parkinsonism, pregnant or lactating females, those with a history of substance abuse, and those with certain medical conditions such as uncontrolled hypertension or congestive heart failure. The trial also has a list of inclusion criteria, including patients who have been receiving treatment with a single dopamine agonist at a stable dose for at least 4 weeks prior to the screening visit. The trial has a list of drugs that are permitted and not permitted during the trial, and a list of diseases and conditions that would exclude patients from participating.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on non-small cell lung carcinoma and the icd-10 codes associated with it. The trial is testing the effectiveness of three drugs: zoledronic acid, taxotere, and carboplatin. The eligibility criteria for the trial include being at least 18 years old, having non-small cell lung cancer that cannot be treated by surgery, and being willing to sign an informed consent form. The exclusion criteria include having cancer that has spread to the bone or brain, having kidney disease, or being treated with other investigational drugs.",
    "The sample is a phase 3 clinical trial for patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection. The trial involves the use of darunavir (drv) and ritonavir (rtv) drugs. The eligibility criteria for the trial include having a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL, stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at screening, and non-nucleoside reverse transcriptase inhibitors (NNRTIs) not being a valid treatment option. The exclusion criteria include having any currently active conditions that fit the definition of the World Health Organization (WHO) Clinical Stage 4, previous or current use of enfuvirtide (ENF), tipranavir and/or DRV, and life expectancy of less than 12 months. Pregnant or breast-feeding females are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug amibegron (sr58611a). The trial includes patients who have been diagnosed with Major Depressive Disorder and meet the criteria for a recurrent Major Depressive Episode. The trial has specific severity assessments for depression that patients must meet. Patients who are at immediate risk for suicidal behavior or have an unstable medical condition are excluded from the trial. Patients with psychotic features, catatonic features, seasonal pattern or postpartum onset are also excluded. Patients who have taken concomitant treatment that may interfere with valid collection or interpretation of study data or have been treated with non-pharmacologic therapy intended to treat depression in the past 6 months are also excluded. Patients who have been treated with paroxetine (Paxil) within the previous 6 months, are pregnant or breastfeeding, or likely to become pregnant during the course of the study are also excluded.",
    "The sample is a phase 3 clinical trial for locally advanced and metastatic breast cancer. The trial is testing the effectiveness of two drugs, fulvestrant and exemestane, in postmenopausal women who have already received treatment with an aromatase inhibitor and have evidence of hormone sensitivity. The eligibility criteria include biopsy confirmation of breast cancer, written informed consent, and no previous treatment with Faslodex or Aromasin. The exclusion criteria include previous treatment with Faslodex or Aromasin, treatment with an investigational or non-approved drug within one month, and existing serious diseases or allergies to the active or inactive ingredients of the drugs.",
    "The sample is a record of a clinical trial for the treatment of multiple myeloma in phase 3. The trial involves the use of drugs such as velcade, thalidomide, and dexamethasone. The eligibility criteria for the trial include a confirmed diagnosis of symptomatic MM, no prior or current systemic therapy for MM, and the presence of quantifiable M protein in serum or urine. Patients must also have a Karnofsky performance status of at least 60%, be willing and able to comply with the protocol requirements, and have adequate organ function. Exclusion criteria include a diagnosis of asymptomatic MM or of MGUS, a previous history of thrombosis or venous thromboembolism, and poorly controlled hypertension or diabetes mellitus. The sample also includes a list of diseases, icd-10 codes, and inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for Crohn's disease, IBD, colitis, and inflammatory bowel disease. The trial involves three groups of participants who will receive either ustekinumab, a placebo, or a different dose of ustekinumab. The eligibility criteria for the trial include having active Crohn's disease, confirmed by radiography, histology, or endoscopy, and having received infliximab, adalimumab, or certolizumab pegol without responding initially or losing response with continued therapy, or being intolerant to the medication. The trial also has exclusion criteria, such as having had bowel resection within 6 months, being pregnant or planning pregnancy, and having certain complications of Crohn's disease.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease. The trial is testing the effectiveness of the drug memantine hcl. The eligibility criteria for the trial include having moderate to severe Alzheimer's disease with a score of 4 or higher on the agitation/aggression domain of NPI, and having a stable dose of donepezil for 3 months. The exclusion criteria include having evidence of other psychiatric disorders, an oncologic diagnosis, or significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease.",
    "The sample is a phase 3 clinical trial for the treatment of hepatocellular carcinoma. The trial is testing the effectiveness of the drugs thermodox and 5% dextrose solution in treating the disease. The eligibility criteria for the trial include being diagnosed with hepatocellular carcinoma, having no more than 4 lesions with at least one being 3.0 cm or larger, and being an appropriate candidate for receiving RFA as a medically indicated treatment. The trial also has exclusion criteria, such as having serious medical illnesses, being pregnant or breastfeeding, and having any known allergic reactions to the drugs or liposomal components. The trial requires subjects to have a life expectancy of at least 4 months and to be willing to return to the study site for their study visits.",
    "The sample is a phase 3 clinical trial for HIV-1 infection. The trial is testing the effectiveness of the drugs ftc/rpv/tdf, pi, rtv, and nrtis. The eligibility criteria for participants include being on antiretroviral therapy with a ritonavir-boosted PI and two NRTIs for at least 6 months, having undetectable levels of HIV-1 RNA for at least 6 months, and having no previous use of any approved or experimental nonnucleoside reverse transcriptase inhibitor (NNRTI) drug. Participants must also meet various health criteria, such as having normal ECG, hepatic transaminases, and total bilirubin levels, as well as adequate hematologic and renal function. Participants must agree to utilize highly effective contraception methods and be at least 18 years old with a life expectancy of at least 1 year. Exclusion criteria include having a new AIDS-defining condition diagnosed within 30 days prior to screening, being a breastfeeding female, having a positive serum pregnancy test (female of childbearing potential), and having a history of malignancy within 5 years prior to study entry or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma.",
    "The sample is a phase 3 clinical trial that focuses on patients who have undergone elective total hip or knee replacement surgery and are currently prescribed enoxaparin for venous blood clot prevention. The trial aims to study the effects of rivaroxaban, a drug used for blood thinning, on these patients. The trial has a list of diseases and their corresponding icd-10 codes, including arthritis, osteoarthritis of the knee and hip, and thromboembolism. The eligibility criteria for the trial include having undergone the surgery, receiving postoperative venous blood clot prevention therapy within 24 hours of the surgery, and being committed to remaining in the subacute unit for the duration of the study. The exclusion criteria include having a platelet count below 90,000/\u00b5L, active internal bleeding or high risk of bleeding, and a history of increased bleeding risk. The trial also excludes patients with clinically significant kidney or liver disease, anemia, known allergies or intolerance to rivaroxaban, and those with drug addiction or alcohol abuse within 3 years prior to screening.",
    "The sample is a phase 3 clinical trial for relapsing remitting multiple sclerosis (RRMS) using a new formulation of Rebif - human interferon beta-1a and interferon beta-1b as drugs. The trial has eligibility criteria for subjects, including being between 18 and 60 years old, having a diagnosis of RRMS according to McDonald criteria or Poser, and being willing to follow study procedures. Exclusion criteria include having had prior interferon beta therapy, receiving any other approved disease modifying therapy for MS, or having any chronic pain syndrome. The trial also excludes subjects with inadequate liver function or bone marrow reserve, current autoimmune disease (other than RRMS), or major medical or psychiatric illness that could affect compliance with the study protocol. Female subjects must not be pregnant or breastfeeding and must lack childbearing potential. The trial requires written informed consent from all subjects.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial is testing the effectiveness of four different drugs: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid, and placebo. The trial is looking for men and women who are 40 years or older and have a diagnosis of primary OA of the knee. Participants must be current chronic users of NSAIDS or acetaminophen and must discontinue all analgesic therapy at screening. There are several exclusion criteria, including uncontrolled hypertension or diabetes, hepatic or renal impairment, current or expected use of anti-coagulant, clinical relevant abnormal ECG, a history of alcohol or drug abuse, candidates for imminent joint replacement, and participation within 30 days prior to screening in another investigational study.",
    "This sample is from a clinical trial in phase 3 that focuses on pain. The trial includes patients with a history of osteoarthritis and who can communicate in English. The trial excludes patients who are younger than 55 or older than 75 years, have an American Society of Anesthesiologists physical status IV, or are currently enrolled in another investigational study. Prior use of pregabalin or gabapentin is not an exclusionary criterion, but patients must have stopped taking these medications at least 14 days before surgery. The trial involves the use of pregabalin, placebo, and another dose of pregabalin. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of skin diseases and soft tissue infections caused by Gram-positive bacteria. The trial involves the use of three drugs - daptomycin, vancomycin, and teicoplanin. The eligibility criteria for the trial include hospitalization of the subjects with clinical evidence of infected ulcers, major abscess, deep or extensive cellulitis, or post-surgical/post-traumatic wound infection. The trial excludes subjects with certain categories of cSSTIs, documented bacteraemia, shock or hypotension, and those who have received certain antibiotics within the past 48 hours. Other exclusion criteria include subjects diagnosed with pneumonia, severe renal impairment, or hepatic disease, and those with a previous history of hearing loss.",
    "The sample is a phase 3 clinical trial for the treatment of idiopathic pulmonary fibrosis. The trial includes patients between the ages of 40 and 80 who have been diagnosed with the disease and meet certain criteria related to lung function and oxygen saturation. The trial involves the use of the drugs pirfenidone and placebo. The eligibility criteria include factors such as lung function, ability to walk a certain distance, and absence of certain medical conditions. Patients who are unable to undergo pulmonary function testing, have certain medical conditions, or are pregnant or lactating are excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial that involves patients with primary hypercholesterolemia or mixed dyslipidemia. The trial includes a list of icd-10 codes for the diseases, a list of drug names, and eligibility criteria for patients to be included or excluded from the trial. The eligibility criteria include age range, LDL-C values, and other entry criteria. The sample also includes exclusion criteria for patients whose LDL-C values are not within the protocol specified range.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar I disorder using the drug cariprazine. The trial includes patients who have provided informed consent and meet the DSM-IV-TR criteria for bipolar I disorder, as confirmed by the Structured Clinical Interview for DSM-IV. Patients must have experienced a manic or mixed episode requiring treatment within the past 12 months and must have normal physical examination, laboratory, vital signs, and ECG results. Patients with a diagnosis of an axis I disorder other than bipolar I disorder are excluded from the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of generalized anxiety disorder. The trial involves the drug quetiapine fumarate and has a list of inclusion and exclusion criteria. The inclusion criteria include having a documented clinical diagnosis of generalized anxiety disorder, being able to understand and comply with the requirements of the study, and being able to provide written informed consent. The exclusion criteria include being pregnant or lactating (for female patients) and having a current or past diagnosis of stroke or transient ischemic attack (TIA). The sample also includes the ICD-10 code for generalized anxiety disorder, which is F41.1.",
    "The sample is a phase 3 clinical trial for patients with atrial fibrillation who are 50 years or older and have at least one risk factor for stroke. The trial is testing the effectiveness of the drugs apixaban and acetylsalicylic acid in preventing stroke in these patients. The eligibility criteria include having documented atrial fibrillation, not currently receiving vitamin K antagonist therapy, and meeting certain risk factor requirements. Exclusion criteria include pregnancy or breastfeeding, reversible causes of atrial fibrillation, valvular disease requiring surgery, and severe comorbid conditions with a life expectancy of less than one year. Participants must also not have had serious bleeding in the last 6 months or be at high risk for bleeding.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes patients who are over 18 years old and have primary hypercholesterolemia with a cardiovascular risk of more than 20% in 10 years, type 2 diabetes, a history of coronary heart disease, or other established atherosclerotic disease. The trial involves the use of the drug rosuvastatin and includes eligibility criteria such as written informed consent, willingness to follow study procedures, and specific LDL-C levels. Exclusion criteria include known familial hypercholesterolemia, secondary hypercholesterolemia, serious adverse effects or hypersensitivity reactions to other HMG-CoA reductase inhibitors, and uncontrolled diabetes or hypertension.",
    "The sample is a phase 3 clinical trial for patients with unresectable non-small cell lung cancer that is considered incurable with other therapies. The trial is testing the effectiveness of the drug docetaxel. The eligibility criteria include age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. Patients must not have prior anaphylactic reaction to any taxane, no known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting, no infection or chronic debilitating illness that would increase the risk of chemotherapy administration, no grade 2 or greater peripheral neuropathy of any etiology, no edema, and no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer. Prior concurrent therapy is also specified.",
    "The sample is a phase 3 clinical trial for patients with gastrointestinal or lung cancer who have experienced involuntary weight loss of 5% or more within the last 6 months and anorexia. The trial is testing the effectiveness of melatonin versus a placebo in improving appetite and weight gain. The eligibility criteria include being over 18 years old, having a Karnofsky score of 40 or higher, being able to maintain oral food intake during the study period, and not currently taking melatonin. The trial also has exclusion criteria, such as having dementia or delirium, being unable to take oral food, or having unstable secondary cachexia caused by certain symptoms. Patients who meet the criteria and sign informed consent can continue all medications including complementary therapies or antineoplastic therapy while on-study other than melatonin if they have been on a stable dose for at least 2 weeks. Pregnant females or females who are lactating/nursing are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and depression. The trial involves the use of two drugs, quetiapine extended release and risperidone. The eligibility criteria for the trial include a diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR, baseline depressive symptoms, and provision of written informed consent. Exclusion criteria include the use of certain medications, significant clinical disorders, and an ANC of \u22641.5 x 109 per liter. Patients who pose an imminent risk of suicide or a danger to self or others are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone palmitate. The trial is looking for patients who have been diagnosed with schizophrenia for at least 1 year and have a PANSS total score of 60 to 120. Patients must also have a documented history of exposure to either a risperidone or paliperidone formulation and known to be tolerated before baseline. Women of childbearing potential must have a negative pregnancy test. Patients must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Exclusion criteria include a primary active DSM-IV-TR Axis I diagnosis other than schizophrenia, a DSM-IV-TR diagnosis of active substance dependence within 3 months before screening, and relevant history of or current presence of any significant or unstable cardiovascular, respiratory, neurological, renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease. Patients with a history or current presence of neuroleptic malignant syndrome or tardive dyskinesia, or known or suspected hypersensitivity or intolerance to risperidone, paliperidone, or any of their excipients are also excluded.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial is looking at the effectiveness of atomoxetine and other standard therapies for ADHD. The eligibility criteria for the trial include being between 6 and 16 years old, having a diagnosis of ADHD according to DSM IV confirmed by SADS PL, being pharmacological na\u00efve, having normal intelligence, and signing an informed consent document. Exclusion criteria include a history of bipolar disorder, psychosis, or autism spectrum disorder, any seizure disorder, significant prior or current medical conditions, history of alcohol or drug abuse within the past 3 months, and taking any excluded medications during the trial.",
    "The sample is a phase 3 clinical trial for patients with symptomatic multiple myeloma who have not received any previous chemotherapy treatment for the disease. The trial involves two drugs, melphalan/prednisone/velcade and thalidomide/prednisone/velcade, and has a list of eligibility criteria for patients to meet in order to participate. These criteria include being over 65 years old, having measurable disease, having a certain performance status, and meeting certain laboratory values. The sample also lists exclusion criteria, such as having received previous treatment for multiple myeloma, having non-secretor myeloma, or having certain medical conditions.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes patients who have been diagnosed with type 2 diabetes for at least 6 months and are insulin na\u00efve. The patients must be currently treated with metformin monotherapy or metformin in combination with insulin secretagogues, DPP-4 inhibitor, or alpha-glucosidase-inhibitor with unchanged dosing for at least 3 months prior to visit 1. The patients must have an HbA1c level between 7.0-10.0% and a BMI below or equal to 45.0 kg/m^2. The trial excludes patients who have used Thiazoledinediones (TZDs), Exenatide or Liraglutide within the last 3 months prior to Visit 1, have cardiovascular disease within the last 6 months prior to visit 1, have uncontrolled treated/untreated severe hypertension, are pregnant, breastfeeding, intend to become pregnant, or have a medical history of cancer.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy using the drug retigabine ir. The trial is looking for participants who are 18 years or older and have a confident diagnosis of epilepsy with partial-onset seizures. Participants must have experienced at least 4 partial-onset seizures during an 8-week prospective baseline phase and be receiving a stable dose of one of the specified antiepileptic drugs. They must also be able and willing to maintain an accurate daily seizure calendar and functional status diary. The trial has a list of exclusion criteria, including a history of generalized epilepsy, substance abuse, and certain medical conditions. Female participants must have a negative pregnancy test and agree to use contraception during the study. French participants must be affiliated with or a beneficiary of a social security category.",
    "The sample is a phase 3 clinical trial for the treatment of diabetes mellitus using inhaled insulin. The trial includes patients with type 2 diabetes who have been on a stable dose of drugs for the past two months. The eligibility criteria include being a type 2 diabetic and not smoking, while the exclusion criteria include having type 1 diabetes or being a smoker. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have been diagnosed with schizophrenia according to the DSM-IV and have experienced an acute episode with a PANSS total score between 70 and 120. The trial involves the use of the drugs paliperidone and placebo. Patients must meet certain inclusion criteria, such as being willing and capable of completing questionnaires and taking oral medications independently, and must not have certain exclusion criteria, such as a history of neuroleptic malignant syndrome or significant risk of suicide or homicidal behavior. The trial also includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for women and men.",
    "This sample is a phase 3 clinical trial for hypertension. The trial includes both newly diagnosed/untreated patients and previously treated patients with essential hypertension. The patients must be 18 years or older and meet certain blood pressure criteria. The trial involves the use of three drugs: aliskiren, valsartan, and hydrochlorothiazide (hctz). The eligibility criteria include exclusion of patients with severe hypertension, women of child-bearing potential who are not using contraception, and those with a history of secondary hypertension or hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The eligibility criteria for the trial include having histologically or cytologically confirmed adenocarcinoma of the pancreas, no neuroendocrine or other histologies, no extra-abdominal metastases, and nonresectable disease meeting certain criteria. Patients must also have a WHO performance status of 0-2, bilirubin and creatinine levels within certain ranges, and no major organ disorders. Prior adjuvant or palliative chemotherapy or radiotherapy is not allowed, but prior surgical diversion of the biliary and/or digestive tract is allowed. The trial will involve the use of fluorouracil, gemcitabine hydrochloride, and liposomal cisplatin.",
    "The sample is a phase 3 clinical trial for kidney transplantation. The trial is looking for patients between the ages of 18 and 60 who have end-stage kidney disease and are undergoing primary renal transplantation or retransplantation. Patients who receive a kidney transplant from a cadaveric or living donor with a compatible AB0 blood type can be included. The trial is testing the drug tacrolimus. The eligibility criteria include exclusion criteria such as high immunological risk, cold ischemia time greater than 30 hours, significant liver disease, severe hypercholesterolemia, allergy or intolerance to study medication, ongoing dosing with corticosteroids, known HIV positivity, and malignancy or history of malignancy.",
    "The sample is a phase 3 clinical trial for HIV infections caused by human immunodeficiency virus type 1. The trial involves the drugs tmc278 and efavirenz. The eligibility criteria for the trial include having documented HIV-1 infection, never having been treated with a therapeutic HIV vaccine or an ARV drug prior to screening, having a plasma viral load of over 5,000 HIV-1 RNA copies/mL, and having a virus that is sensitive to TDF and FTC. The exclusion criteria include previous use of any ARV drug, documented evidence of NNRTI resistance associated mutations in the patient's HIV, and various medical conditions such as active TB and kidney impairment. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of thrombosis, venous disease. The trial involves the use of fondaparinux 2.5mg or placebo. The eligibility criteria for the trial include having acute symptomatic superficial thrombophlebitis of the lower limbs at least 5 cm long, diagnosed by compression ultrasound. Exclusion criteria include having superficial thrombophlebitis that is within 3 cm from the sapheno-femoral junction, deep vein thrombosis or pulmonary embolism within the last 6 months, treatment for cancer during the last 6 months, anticoagulant medication for more than 48 hours prior to inclusion, need for oral non-steroidal anti-inflammatory drugs during the study, significant bleeding event during the past month, major surgery within the last 3 months, low platelet count (below 100\u00d7109/L), kidney disease (Calculated creatinine clearance < 30 mL/min), and being a woman of child-bearing potential not using a reliable contraceptive method.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease melanoma, and the icd-10 codes associated with it. The trial involves the use of drugs such as dacarbazine, cp-675,206, and temozolomide. The eligibility criteria for the trial include having surgically incurable melanoma, either Stage IV or IIIC with N3 status for regional lymph nodes and in-transit or satellite lesions, a serum lactic acid dehydrogenase (LDH) <= 2 x ULN, and an ECOG performance status of 0 or 1. The exclusion criteria include having received any systemic therapy for metastatic melanoma except post-surgical adjuvant treatment with cytokines (eg, alpha-interferon or GM-CSF) or with vaccines after complete resection of melanoma, and having a history of brain metastases.",
    "The sample is a phase 3 clinical trial for patients with gastrointestinal stromal tumor. The trial requires patients to have a histologic diagnosis of primary GIST, express Kit protein by immunohistochemistry, and have a tumor size of at least 3cm in maximum dimension. Patients must have undergone complete gross resection of a primary GIST within 70 days prior to registration. The trial also has various inclusion and exclusion criteria, including specific laboratory values and prior treatments. Patients must provide written informed consent and authorization for the use and disclosure of their protected health information. The trial does not allow for the use of full dose warfarin or breastfeeding while taking STI571.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) with a list of drugs including ff/vi 100/25 inhalation powder ndpi, fluticasone propionate/salmeterol 250/50 inhalation powder accuhaler/diskus, and salbutamol as needed. The eligibility criteria include being a male or female over 40 years old, having a clinical history of COPD, and having a measured post-albuterol FEV1/forced vital capacity ratio of <=0.70 at screening. Exclusion criteria include having a current diagnosis of asthma, other respiratory disorders, and significant cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities. Women who are pregnant or lactating or are planning on becoming pregnant during the study are also excluded.",
    "The sample is a phase 3 clinical trial for patients with Waldenstr\u00f6m macroglobulinemia, splenic lymphoma with villous lymphocytes (SLVL), or non-IgM lymphoplasmacytic lymphoma. The trial involves the use of chlorambucil and fludarabine phosphate as therapeutic intervention for previously untreated disease. Eligibility criteria include a performance status of 0-2, life expectancy of more than 6 months, and negative pregnancy test. Patients with severe or life-threatening cardiac, pulmonary, neurological, psychiatric, or metabolic disease, concurrent malignancy, AIDS or AIDS-related complex, or active hepatitis C infection are not eligible. Prior plasmapheresis for control of clinically significant hyperviscosity and prior splenectomy for SLVL are allowed.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients who meet specific inclusion criteria, such as having a Mini-Mental Status Examination (MMSE) score between 14 and 26, being medically stable for at least 3 months, and having a Modified Hachinski score equal to or less than 4. Patients must also be fluent in English or Spanish, have a study partner to accompany them to all scheduled visits, and be able to ingest oral medication. Exclusion criteria include having B12 or folate deficiency, renal insufficiency, active neoplastic disease, and a history of clinically significant stroke or major psychiatric disorder. The trial will test the effectiveness of folate, vitamin B6, and vitamin B12 as potential treatments for Alzheimer's disease.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the use of three drugs - vildagliptin, gliclazide, and metformin. The eligibility criteria for the trial include being on a stable dose of metformin, meeting blood glucose criteria, and having a body mass index (BMI) between 22 and 45. Exclusion criteria include pregnancy or lactation, type 1 diabetes, significant diabetic or cardiovascular complications, abnormal laboratory values, and other protocol-defined exclusion criteria. The diseases being studied are limited to diabetes mellitus, type 2, and the icd-10 codes associated with the disease are listed as well.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial includes patients with osteophytes or sclerosis at the carpometacarpal (CMC) joint who experience unacceptable pain despite modification of activity and a therapeutic dose of nonsteroidal anti-inflammatory drugs (NSAIDS), if tolerated. The trial excludes patients with previous traumatic dislocation, ligament tear, or fracture of the thumb in the affected hand, known hand comorbidities, systemic rheumatic disease, bleeding diatheses or anti-coagulation, allergies to steroids, chicken products, bupivicaine, or adhesive, current use of oral or intravenous steroids, active systemic malignancies, hyaluronan injection in the target CMC joint in the last 6 months, steroid or hyaluronan injection in any other joint in the last 6 months, insulin dependent diabetes mellitus (IDDM), active infection, pain in the index joint that is more than 40 out of 100 on a VAS Pain scale, end stage CMC osteoarthritis, equivalent to bone on bone, Kellgren and Lawrence Stage IV, grade 3 or 4 Eaton and Litter (E+L) Classification, E+L 3: Advanced joint distraction, subchondral cysts, and sclerosis, and E+L 4: Involvement of several joint surfaces. The trial involves the use of synvisc (hylan g-f20; hyaluronan injection), bupivicaine (local anesthesia injection), and kenalog (triamcinolone; corticosteroid injection) as drugs.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is for patients with locally advanced or metastatic NSCLC that is not curable. Patients must have previously received one platinum-containing chemotherapy regimen for locally advanced or metastatic disease, or one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence. No more than two prior systemic anti-cancer therapies are allowed. Prior radiation therapy is allowed to less than 25% of the bone marrow. The trial has inclusion and exclusion criteria, which are listed in detail.",
    "The sample is a phase 3 clinical trial for male subjects with chronic constipation. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested (placebo and prucalopride). The eligibility criteria for the trial include being a male out-patient over 18 years of age with a history of constipation, agreeing to stop current laxative treatment, and being willing to adhere to all trial requirements. Exclusion criteria include subjects with drug-induced constipation, secondary causes of chronic constipation, significant history of cancer, and known serious illnesses. The trial also requires subjects to complete questionnaires and an e-diary.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease lupus nephritis and includes a list of associated ICD-10 codes. The trial involves the use of several drugs, including mycophenolate mofetil, cyclophosphamide (both induction and maintenance phases), and prednisone. The eligibility criteria for the trial include being an adult patient over 18 years of age with a diagnosis of systemic lupus erythematosus and lupus nephritis (class III, IV or V). Exclusion criteria include having received cytotoxic drugs in the previous 8 weeks, having systemic infections, or having hepatitis B or C, or HIV.",
    "The sample is a phase 3 clinical trial for the treatment of metabolic syndrome X. The trial involves the drug telmisartan (Micardis\u00ae) versus a placebo. The eligibility criteria for participants include being between 30 and 70 years old, having abdominal obesity, and meeting certain criteria for the metabolic syndrome such as high triglycerides and low HDL cholesterol. Participants must also be willing to complete dietary and activity diaries and questionnaires. Exclusion criteria include taking certain medications, having certain medical disorders, and having contraindications to MRI. Women who are pre-menopausal and not practicing acceptable methods of birth control are also excluded. Participants must be able to reduce their total fat consumption and saturated fat consumption during the run-in period.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial includes postmenopausal women or men over 60 years old with a DXA T-Score at lumbar spine, total hip or femur neck less than -2.0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral density. The trial requires pretreatment with bisphosphonates for at least four years and a risk for hip and vertebral fractures of at least 30% according to DVO-guideline for osteoporosis 2009. The trial includes the drugs alendronate and placebo. The eligibility criteria include exclusion of other pharmacological treatment of osteoporosis during the last 48 months, other bone diseases, malabsorption syndromes, renal insufficiency with a calculated creatinine clearance less than 35 ml/min, diseases of the esophagus, delayed esophageal clearance, inability to realize the intake instructions, and hypocalcemia. The trial requires signed informed consent.",
    "The sample is a phase 3 clinical trial for a drug called vi-0521, aimed at treating obesity and type 2 diabetes. The trial includes patients who are 70 years old or younger and have a BMI of 27 or higher, along with two or more obesity-related co-morbid conditions. The trial also requires patients to meet certain metabolic criteria, such as having a fasting blood glucose level above 100 mg/dL or a diagnosis of type 2 diabetes. Patients must also have a waist circumference of at least 102 cm for men or 88 cm for women. The trial has exclusion criteria, such as a history of stroke or heart attack within the past 6 months, clinically significant renal or hepatic disease, and drug or alcohol abuse.",
    "The sample is a phase 3 clinical trial for the treatment of unresectable or metastatic melanoma. The trial includes patients with confirmed melanoma who have progressed after receiving at least one cycle of DTIC or TMZ containing regimen. The trial also requires patients to have an ECOG PS of 0 or 1 and measurable disease as per the modified RECIST criteria. The trial excludes patients with primary ocular or mucosal melanoma, previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, history of cardiac disease, and known history of human immunodeficiency virus (HIV) infection. The trial involves the use of drugs such as sorafenib, carboplatin/paclitaxel, and placebo.",
    "The sample is a phase 3 clinical trial for patients with recurrent or persistent advanced ovarian, fallopian, or primary peritoneal carcinoma of epithelial origin. The trial involves the use of three drugs - phenoxodiol, carboplatin, and placebo. The eligibility criteria include having measurable disease, having undergone at least two courses of therapy with a platinum drug, and having responded to the first course of therapy. Patients must also have relapsed within 6 months of completing the second or greater course of platinum therapy and have a platinum-free interval of no greater than 6 months at the time of enrollment. Other criteria include adequate physiological and hematological function, a Karnofsky performance score of at least 60%, and being able to understand the risks and benefits of the study and give written informed consent to participation. Exclusion criteria include patients with mucinous histological type of ovarian cancer, patients who have failed to show a clinical response to at least one prior course of platinum therapy, and patients with active infection or concurrent severe and/or uncontrolled medical disease.",
    "The sample is a phase 3 clinical trial for the treatment of opioid-induced constipation (OIC). The trial includes patients who have provided written informed consent and meet certain eligibility criteria, such as experiencing symptoms of OIC and having confirmed OIC. Patients who are already enrolled in other NKTR-118 studies and receiving a stable maintenance opioid regimen may also be eligible. The trial involves the use of the drug NKTR-118 and usual care, with patients being required to stop all laxatives and other bowel regimens except for bisacodyl as rescue medication. Patients with certain medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation, as well as those with other gastrointestinal tract issues that could pose a risk, are excluded from the trial. Patients who are pregnant or lactating are also excluded.",
    "The sample is a phase 3 clinical trial for type 2 diabetes. The trial includes participants who have been receiving metformin at a total daily dose of at least 1500 mg per day for at least 8 weeks, with inadequate glycemic control. The trial also requires participants to have a C-peptide level of at least 1.0 ng/mL, a body mass index of no more than 45.0 kg/m^2, and a serum creatinine level of less than 1.50 mg/dL for men or less than 1.40 mg/dL for women. The trial excludes participants with symptoms of severely uncontrolled diabetes, as well as those with unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases. The trial will test the efficacy of dapagliflozin and metformin compared to a placebo.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is focused on the drug paliperidone er and the eligibility criteria includes meeting the Diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia, being previously non-acute and having been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time prior to enrollment, and being healthy on the basis of a physical examination and vital signs at screening. Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or agree to practice an effective method of birth control before entry and throughout the study. The exclusion criteria includes participants on clozapine, any conventional depot neuroleptic or risperidone long-acting injection during the last 3 months, participants with serious unstable medical condition, history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome, judged to be at high risk for adverse events, violence or self-harm, and current use or known history of substance dependence according to Diagnostic and Statistical Manual of Mental Disorders criteria.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease asthma, with a list of associated ICD-10 codes. The trial involves several drugs, including vilanterol, salmeterol inhalation powder, and placebo inhalation powder. The eligibility criteria for the trial include being an outpatient at least 12 years of age, having a clinical diagnosis of asthma for at least 12 weeks, and having a best pre-bronchodilator FEV1 of 40%-90% predicted. The trial also has exclusion criteria, such as a history of life-threatening asthma and allergies to study drugs. The sample includes detailed inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial includes patients with genotype 1 hepatitis C infection who have not received any prior treatment for the disease. Patients must have had a liver biopsy within 3 years before screening showing chronic hepatitis C infection. The trial involves the use of four drugs: placebo, tmc435, peginterferon alpha-2a (pegifn alpha-2a), and ribavirin (rbv). Patients must agree to use two forms of effective contraception throughout the study. The trial has exclusion criteria, including infection with HIV or non-genotype 1 hepatitis C, liver disease not related to hepatitis C infection, hepatic decompensation, significant laboratory abnormalities or other active diseases, and pregnancy or planning to become pregnant.",
    "The sample is a phase 3 clinical trial for patients with squamous cell carcinoma of the thoracic esophagus. The trial is testing the effectiveness of neoadjuvant chemotherapy using cisplatin and 5-fluorouracil. The eligibility criteria include being above 18 years old, having a Karnofsky performance status of >70, and having normal circulatory, pulmonary, bone marrow, renal, and liver function. Patients with metastatic disease, synchronous malignancy, history of other cancer within 5 years prior to esophageal cancer treatment, allergic reaction to cisplatin or 5-fluorouracil, systemic infection, or pregnancy are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, atherosclerosis and kidney failure, and includes a list of corresponding ICD-10 codes. The trial involves several drugs, including tacrolimus, mycophenolate mofetil, prednisone, and sirolimus. The eligibility criteria for the trial includes a history of dialysis for at least 3 years, a history of diabetes for at least 5 years, hypertension or ischemic nephropathy as a cause of end-stage renal disease or loss of the first transplant, and a history of coronary artery disease, stroke, myocardial infarction, or amputation for vascular disease. The exclusion criteria includes a history of malignancy within the last 5 years (except adequately treated skin cancer), recipients of non-renal organ transplant, active gastrointestinal disease that may interfere with drug absorption, active HIV, hepatitis B or C infection, and women who are pregnant or breastfeeding.",
    "The sample is a clinical trial in phase 3 for patients with type 2 diabetes mellitus. The trial involves the use of glimepiride and metformin hydrochloride combination or glimepiride alone as a treatment. The eligibility criteria include being a Chinese patient with type 2 diabetes mellitus, diagnosed for at least 1 year and inadequately controlled with metformin. The patient must also have a signed written informed consent. Exclusion criteria include having type 1 diabetes mellitus, HbA1c levels below 7% or above 10%, fasting plasma glucose levels above 250 mg/dL, age below 18 years or above 80 years, not being on a stable daily dose of at least 1500 mg metformin within 3 months prior to screening, and currently receiving or having received anti-diabetic drugs other than metformin within 3 months prior to screening.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of two drugs, bg00012 and placebo. The eligibility criteria for participants include having a confirmed diagnosis of RRMS according to McDonald criteria #1-4, having a baseline EDSS between 0.0 and 5.0, and having a relapsing-remitting disease course. Exclusion criteria include having other chronic diseases of the immune system, malignancies, acute urologic, pulmonary, or gastrointestinal disease, and being pregnant or nursing. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for obesity. The trial includes patients with a body mass index (BMI) of 27-45 kg/m(2) or a BMI of 25-27 kg/m(2) with a waist circumference of at least 102 cm in males or 88 cm in females. Patients must also have a medical history positive for preexisting cardiovascular disease or type 2 diabetes mellitus with at least one other risk factor. Exclusion criteria include recent myocardial infarction, heart failure symptoms greater than New York Heart Association Functional Class II, and hemodynamically significant valvular or left ventricular tract obstruction. Patients with certain medical conditions such as hyperthyroidism, chronic liver disease, or end-stage renal disease are also excluded. Additionally, patients cannot have had recent non-hemorrhagic stroke or transient ischemic attack, or have a history of hemorrhagic stroke. Patients must be able to perform regular physical activity and cannot be taking certain medications such as monoamine oxidase inhibitors or drugs that increase levels of serotonin in the brain. The trial will test the effectiveness of sibutramine hydrochloride compared to a placebo in treating obesity.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial is focused on patients with mild to moderate asthma who are currently receiving inhaled corticoid-steroid medicine and require a review of their current asthma treatment. The trial has inclusion criteria such as being over 18 years old and having a confirmed diagnosis of asthma by a doctor. The exclusion criteria include patients who are pregnant, breastfeeding, or planning pregnancy, patients with a history of chronic obstructive pulmonary disease, patients using any beta blocker therapy, and patients receiving steroid tablets or steroid injections. The sample also includes a list of diseases (only asthma in this case), a list of icd-10 codes associated with the disease, a list of drugs being used in the trial (budesonide/formoterol in this case), and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe chronic kidney disease who are not expected to require dialysis or renal transplant within the next 6 months. The trial is testing the effectiveness of the drugs placebo and ast-120. The eligibility criteria include being 18 years or older, having a certain level of serum creatinine and urinary total protein to urinary total creatinine ratio, and having stable blood pressure. Exclusion criteria include having certain medical conditions or having received any investigational agent or participated in a clinical study within the previous 3 months. The purpose of the trial is to collect safety and efficacy data.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of the drug Rebif\u00ae new formulation (ifn-beta-1a, rnf) and a placebo. The eligibility criteria include being between 18 and 60 years old, having a diagnosis of relapsing-remitting multiple sclerosis according to the revised McDonald criteria 2005, having brain and/or spinal MRI with findings typical of multiple sclerosis, having disease duration for more than 12 months, having disease activity characterized by at least one clinical event and one or more Gadolinium-enhancing MRI lesions within the 6 months prior to randomization, having a score of <=5.5 on the Expanded Disability Status Scale (EDSS), and being willing and able to comply with the protocol for the duration of the study. Exclusion criteria include having any disease other than MS that could better explain signs and symptoms, having complete transverse myelitis or bilateral optic neuritis, having received or used monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy, or total lymphoid irradiation, having received within 3 months prior to baseline any approved disease-modifying therapy for MS, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure, and having received within 30 days prior to baseline oral or systemic corticosteroids or ACTH.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy. The trial is looking at the effectiveness of the drug lacosamide in reducing the number of seizures in patients with simple partial seizures or complex partial seizures. The inclusion criteria for the trial include having a stable dose of 1 or 2 marketed antiepileptic drugs and experiencing 2 to 40 seizures per 28-day period. The exclusion criteria include having a history of primary generalized or unclassified seizures, seizures that are uncountable due to clustering, and taking certain medications such as Benzodiazepines, Phenobarbital or Primidone. The trial is also excluding patients with significant medical or psychiatric conditions, a history of alcohol or drug abuse, and those who have used certain medications in the past.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug cariprazine. The trial is looking for patients who meet the DSM-IV-TR criteria for schizophrenia and have normal physical examination, laboratory, vital signs, and electrocardiogram (ECG). Patients with other psychotic disorders or bipolar disorder are excluded from the trial. The sample includes the list of diseases, icd-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of osteoporosis. The trial is focused on postmenopausal women between the ages of 60 and 85 who have a screening bone mineral density (BMD) of the total hip and/or spine equal to or lower than 2.5 standard deviation (SD) T-score for subjects without an asymptomatic fracture or equal to or lower than -2.0 SD T-score for subjects with an asymptomatic fracture. The trial involves the use of the drugs tibolone and placebo. The eligibility criteria for the trial include voluntary written informed consent, willingness to observe all clinical trial requirements, and a body mass index (BMI) of 34 kg/m^2 or less. The exclusion criteria include recent acute vertebral fracture, more than two prevalent asymptomatic vertebral fractures at baseline, screening BMD of the total hip or spine lower than -4 SD T-score, and various other conditions such as bone disease other than osteoporosis, treatment with certain medications within a certain timeframe, and history or presence of certain types of cancer.",
    "This sample is a phase 3 clinical trial for asthma. The trial is looking for males and females who are 12 years or older and have a history of persistent bronchial asthma for at least 6 months. Participants must have used an inhaled steroid or a combination of an inhaled steroid/long-acting beta 2 agonist for at least 1 month before screening. At screening, participants must have an FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or ICS/LABA use respectively, with reversibility of FEV1 by at least 12% and 200 ml post-bronchodilator. Participants must be able to use oral inhalers and be non-smokers. Exclusion criteria include a history of life-threatening asthma, other pulmonary diseases, use of systemic steroids within 1 month before screening or more than 3 times in previous 6 months, beta-adrenergic blocking agent use, more than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening, pregnant or breast-feeding females, females of child-bearing potential not using adequate means of birth control, clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease, abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results, history of drug or alcohol abuse, and treatment with any investigational product within 30 days prior to study entry. The drug being tested is ciclesonide (xrp1526).",
    "The sample is a phase 3 clinical trial that focuses on two diseases, atrophy and vaginal diseases. The trial includes a list of icd-10 codes for the diseases. The trial involves two drugs, ospemifene 60 mg and placebo. The eligibility criteria for the trial include being naturally or surgically menopausal, having an intact uterus, having a vaginal pH greater than 5.0, and having 5% or fewer superficial cells in the maturation index of vaginal smear. The exclusion criteria include having evidence of endometrial hyperplasia, cancer or other pathology, an abnormal Pap smear, uterine bleeding of unknown origin or uterine polyps, current vaginal infection requiring medication, use of hormonal medications, and clinically significant abnormal gynecological findings other than signs of vaginal atrophy.",
    "The sample is a phase 3 clinical trial for locally advanced or metastatic breast cancer patients who have received prior anthracycline therapy. The trial includes eligibility criteria such as a 12-month disease-free interval since the end of their last cytotoxic therapy, normal cardiac function, and no more than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer. Exclusion criteria include prior treatment with certain chemotherapy regimens, recent use of hormonal therapy, and history of congestive heart failure. The table includes columns for the trial phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of low back pain. The trial includes both males and females who are 20 years or older and have been diagnosed with low back pain for at least 4 weeks with non-malignant pain etiology. The trial involves the use of two drugs, placebo and buprenorphine transdermal system. The eligibility criteria include having a clinical diagnosis of low back pain, while the exclusion criteria include having a current chronic disease or a past history of chronic diseases that require frequent analgesic therapy, in addition to low back pain.",
    "The sample is a phase 3 clinical trial for subjects with type 2 diabetes mellitus who have been using a stable combination oral antidiabetic therapy of 2 or 3 agents in different therapeutic classes for at least 3 months. The trial aims to test the effectiveness of insulin glulisine as a treatment option. The eligibility criteria include being 18 to 79 years old, having a diagnosis of type 2 diabetes mellitus for at least 6 months, having a stable dose of 2 oral antidiabetic agents, and having an HbA1c level of at least 8.0%. The trial also requires subjects to perform self-monitoring of blood glucose up to 4 times a day and adhere to the study protocol. Exclusion criteria include insulin use within the previous year, impaired renal function, and any disease or condition that may interfere with the completion of the study.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have at least 4 involved axillary and/or intramammary lymph nodes and have undergone breast conserving surgery or modified radical mastectomy plus axillary lymph node dissection. The trial includes a list of drugs such as carboplatin, cisplatin, and paclitaxel, and eligibility criteria for patients including age, sex, menopausal status, performance status, and various medical conditions. Patients must not have had prior chemotherapy or hormonal therapy for breast cancer, and must not have had a second malignancy within the past 5 years except for certain types of cancer. Fertile patients must use effective contraception and patients must not be pregnant or nursing.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone er. The trial includes patients who have been diagnosed with schizophrenia for at least 1 year and are experiencing an acute episode with a total PANSS score between 70 and 120. Patients must agree to voluntary hospitalization for a minimum of 14 days. The trial also has exclusion criteria, such as a history of substance dependence or neuroleptic malignant syndrome. The trial has both a double-blind phase and an open-label phase, with specific requirements for eligibility in each phase.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial includes patients with any subtype of ADHD and comorbidities. The trial involves the use of dexmethylphenidate, mixed amphetamine salts, er, and placebo drugs. The eligibility criteria include a signed informed consent, a Clinical Global Impressions - Severity for ADHD (CGI-S-ADHD) rating of greater than or equal to 4, normal physical exam, laboratory studies, vital signs, and ECG, and the ability to complete study instruments and swallow capsules. Exclusion criteria include previous diagnosis of mental retardation, non-responder to either medication at the doses offered in the study in an adequate trial, and any other medical condition which represents a contraindication for either treatment. Females of childbearing age who are sexually active must use acceptable birth control (double protection method) and after counseling, must be willing to do so.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of several drugs, including gsk573719/gw642444 125/25, gsk573719/gw642444 62.5/25, gw642444, and tiotropium bromide. The eligibility criteria for the trial include being 40 years of age or older, having a COPD diagnosis, and having a post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and post-albuterol/salbutamol FEV1 of less than or equal to 70% predicted normal values. The trial also has a list of exclusion criteria, including pregnancy or lactation, current diagnosis of asthma, and other respiratory disorders other than COPD. The trial is not open to anyone affiliated with the investigator site or anyone with a history of alcohol or drug abuse within 2 years prior to Visit 1.",
    "The sample is a phase 3 clinical trial for HIV and HIV infections. The trial involves the use of drugs such as cobi, rtv, atv, and ftc/tdf, as well as placebos. The eligibility criteria for the trial include having a plasma HIV-1 RNA level of at least 5,000 copies/mL, not having used any approved or investigational antiretroviral drug before, having a normal ECG, and meeting certain renal, hepatic, hematologic, and amylase function requirements. Participants must also agree to use highly effective contraception methods throughout the duration of the study treatment and for 30 days following the last dose of study drug. Exclusion criteria include having a new AIDS-defining condition, receiving drug treatment for Hepatitis C, having an implanted defibrillator or pacemaker, and having a history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.",
    "The sample is a phase 3 clinical trial for psoriatic arthritis. The trial includes patients who have been diagnosed with active psoriatic arthritis for at least 6 months and have at least 5 tender and 5 swollen joints at baseline. Patients may have previously received certain types of anti-TNF therapy or have proven inability to tolerate it. If the patient is using methotrexate, they should have started treatment at a dose not to exceed 25 mg/week at least 3 months prior to the beginning of the study and should have no serious toxic side effects attributable to methotrexate. The trial excludes patients with other inflammatory diseases, those who have used any therapeutic agent targeted at reducing IL-12 or IL-23, those who have used certain types of anti-TNF therapy within a certain time frame, those with a medical history of latent or active granulomatous infection, and those with any known malignancy or history of malignancy. The trial includes a placebo group and two groups receiving different doses of ustekinumab. The eligibility criteria and exclusion criteria are listed in detail.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with moderate to severe COPD who have been experiencing symptoms for at least 24 months and have a prebronchodilator FEV1/FVC ratio of <=70%. The trial involves testing the efficacy of several drugs, including mometasone furoate/formoterol (mf/f) combination, mometasone furoate mdi (mf mdi), formoterol mdi, and placebo. The eligibility criteria include being an ex- or current smoker with a smoking history of at least 10 pack years, having acceptable lab tests and chest x-rays, and being willing to discontinue current COPD therapy. The exclusion criteria include having certain medical conditions, allergies/sensitivities to certain drugs, being pregnant or breastfeeding, and having previously participated in an MF/F trial. The trial also includes specific inclusion and exclusion criteria related to female subjects of childbearing potential.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast cancer who have responded or have stable disease after six to eight courses of first line induction chemotherapy treatment. The trial requires patients to have measurable and/or evaluable disease and a performance status of ECOG 0, 1, or 2. Patients must also have normal cardiac function confirmed by left ventricular ejection fraction (LVEF) and provide written informed consent. The trial involves the drug paclitaxel and has a list of exclusion criteria, including the presence of peripheral neuropathy greater than grade 2 by NCI Common Toxicity Criteria (NCI-CTC) following induction chemotherapy and adjuvant taxane-based therapy.",
    "The sample is a phase 3 clinical trial that involves patients with childhood cancer, aplastic anemia, and metabolic disorders. The trial requires the use of a single lumen Broviac or double lumen Hickman-type CVC for chemotherapy, blood product support, or hematopoietic stem cell transplantation. The CVC is planned to remain in place for 6 months from study entry. Patients with thrombophilia, bleeding disorders, or previous complications with a CVC are excluded from the trial. The drugs used in the trial are heparin and normal saline. The diseases are identified by their names and ICD-10 codes, and the eligibility criteria are listed as inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for patients with painful diabetic peripheral neuropathy. The trial includes patients with Type 1 or Type 2 diabetes mellitus who have been experiencing symptoms and signs for at least 6 months, and pain present at the time of screening. Patients must have their blood glucose controlled by diet, hypoglycemics, or insulin for at least 3 months prior to enrolling in the study. Patients must have been taking analgesic medications for the condition for at least 3 months prior to screening. Patients currently requiring opioid treatment must be taking daily doses of an opioid-based analgesic equivalent to <=160 mg of oral morphine. The trial excludes patients with significant pulmonary, gastrointestinal, endocrine, metabolic, neurological, psychiatric disorders, or any other clinically significant disease that may affect efficacy or safety assessments or may compromise patient's safety during trial participation. The trial also excludes patients with severely impaired renal function, laboratory values above or below limits of normal, significant cardiac disease, significant vascular disease, life-long history of seizure disorders or epilepsy, and those with moderate to severe hepatic impairment.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is for patients who are infected with only genotype 3 of hepatitis C and have not received any prior treatment. The treatment involves a combination of peginterferon alfa-2b (pegetron) and ribavirin (rebetol). The eligibility criteria include a positive HCV RNA test result at Week 4 and a negative HCV RNA test result at Week 12, as well as a recent liver biopsy. Patients with cirrhosis or other signs of advanced liver disease may not need a biopsy. The exclusion criteria include co-infection with HIV or Hepatitis B, evidence of decompensated liver disease, and pre-existing psychiatric conditions. Patients with diabetes and/or systemic hypertension will need to have ocular examinations prior to treatment.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone er. The trial includes patients who are 65 years or older and have been diagnosed with schizophrenia for at least 1 year. The patients must have a total PANSS score between 70 and 120 at screening and baseline. They must also agree to hospitalization for a minimum of 14 days and for the duration of the study if clinically indicated. Patients who have completed 6 weeks of the double-blind treatment phase or finished at least 21 days of treatment and discontinued because of lack of efficacy are eligible for the open-label treatment phase. The trial excludes patients with a DSM-IV Axis I diagnosis other than schizophrenia, substance dependence within the 6 months before screening, history of tardive dyskinesia or neuroleptic malignant syndrome (NMS), severe preexisting severe gastrointestinal narrowing, or previous history of a lack of response to any antipsychotic.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking for male or female outpatients between the ages of 18 and 79 who have had Stage I/II hypertension for at least 2 years. The trial requires participants to meet certain blood pressure criteria and be willing to adhere to dietary compliance and protocol procedures. Participants must also have a lifestyle that allows them to attend all evaluations, including those conducted on consecutive days. Exclusion criteria include having any form of secondary hypertension, clinically significant respiratory or cardiovascular disease, a history of coronary artery disease or peripheral vascular disease, diabetes mellitus, Type I or II, or a history of hypersensitivity to nebivolol, metoprolol, or any beta-blocker. The trial will be testing the effectiveness of nebivolol and metoprolol er (tm) as treatments for hypertension.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial that involves two types of dementia - vascular and mixed. The trial is focused on the drug donepezil. The eligibility criteria for the trial include meeting DSM-IV-TR criteria for the clinical diagnosis of vascular dementia or dementia due to multiple etiologies, and having a reliable caregiver or family member who agrees to accompany the subject to all scheduled visits and provide information about the subject as required. The exclusion criteria include having any current primary psychiatric diagnosis other than dementia of the Alzheimer's type or vascular dementia. The table also includes lists of disease names, ICD-10 codes, and drugs.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying essential hypertension. The associated ICD-10 codes for the disease are listed, along with the drugs being tested, which include xoma 985, amlodipine besylate, and perindopril erbumine. The eligibility criteria for participants are also listed, including inclusion criteria such as having essential hypertension and being able to provide written informed consent, and exclusion criteria such as having certain medical conditions or being pregnant.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial is open to both men and women who are at least 18 years old and have not been treated with DVS SR in the past. The trial requires participants to have a primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), single or recurrent episode, without psychotic features. Participants must also have a HAM D17 total score of at least 20 at the screening and baseline visit. The trial excludes individuals who have a significant risk of suicide, any unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic, neurologic, or any other medical condition that might confound the study or put the subject at greater risk during study participation.",
    "The sample is a phase 3 clinical trial for the management of moderate to severe malignant or nonmalignant pain in male and female patients aged 6 to 17 years. The trial involves the use of oxycodone hydrochloride controlled-release tablets as the study drug. The eligibility criteria include having completed a 4-week study drug treatment in a previous trial, having tolerated the oxycodone HCl CR therapy, and being willing and able to swallow the tablets whole. Exclusion criteria include ongoing adverse events, pregnancy or lactation, allergy to oxycodone or other opioids, contraindication for opioid use, maintenance on methadone for pain, abnormal vital signs or laboratory testing, planned surgery during the study, and use of any other investigational medication/therapy. Other protocol-specific inclusion/exclusion criteria may also apply.",
    "This sample is for a phase 3 clinical trial for the treatment of ulcerative colitis. The trial is testing the effectiveness of two drugs, colal-pred\u00ae and prednisolone. The eligibility criteria for participants include having a confirmed diagnosis of ulcerative colitis, a score of 6-10 on the Disease Activity Index, and moderate to severe mucosal appearance. Exclusion criteria include previous colonic surgery, unstable medical conditions such as diabetes or heart failure, and a history of tuberculosis. The icd-10 codes associated with the disease are also included in the table.",
    "The sample is a phase 3 clinical trial for multiple sclerosis. The trial includes patients who have experienced a neurological event consistent with demyelination within the past 90 days and have at least 2 T2 lesions on an MRI scan. The trial involves the drugs teriflunomide and placebo. The eligibility criteria include not having any major systemic diseases, impaired bone marrow function, pregnancy or nursing, alcohol or drug abuse, and not having used certain immunosuppressant agents before enrollment. The sample also includes exclusion criteria for any known condition or circumstance that would prevent compliance or completion of the study.",
    "The sample is a phase 3 clinical trial for multiple sclerosis. The trial includes patients with a relapsing-remitting disease course who are ambulatory with a converted Kurtzke EDSS score of 0-5.5. The trial requires patients to have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria. Patients must be between 18 and 55 years of age and have a disease duration of at least 6 months. The trial involves the use of drugs such as laquinimod, placebo, and interferon \u03b2-1a (avonex\u00ae). The eligibility criteria include having experienced at least one documented relapse in the 12 months prior to screening or at least two documented relapses in the 24 months prior to screening. The exclusion criteria include having received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening, and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for amyotrophic lateral sclerosis (ALS) with the drug MCI-186 and a placebo. The trial has eligibility criteria for patients who have been diagnosed with definite, probable, or probable-laboratory-supported ALS according to the revised EL Escorial for Airlie House diagnostic criteria, can eat, excrete, or move without assistance, and have had ALS for less than 3 years. The trial also has exclusion criteria for patients with severe hepatic, heart, or renal disease, respiratory difficulties, complications such as Parkinson's disease or dementia, and those who are pregnant or lactating. Patients who have participated in other trials within 12 weeks before consent or are currently participating in other clinical trials are also excluded.",
    "The sample is a phase 3 clinical trial for small cell lung cancer with extensive disease in the first-line treatment. The trial includes two drugs, topotecan + cisplatin and etoposide + carboplatin. The eligibility criteria for the trial include confirmation of SCLC, extensive stage, no prior chemotherapy, WHO PS 0-3, adequate organ function (liver, kidney), adequate hematology (bone marrow), and informed consent. The exclusion criteria include PS 4, inadequate organ function, uncontrolled infection, and concomitant major medical contraindications.",
    "This sample is for a phase 3 clinical trial for rheumatoid arthritis. The trial is testing the effectiveness of a combination of drugs including rituximab, methotrexate, and methylprednisolone. The eligibility criteria for the trial includes adult patients between the ages of 18-80 who have rheumatoid arthritis and have not responded well to at least one DMARD treatment. The patients must also have active disease and have stopped taking DMARDs other than methotrexate for at least 4 weeks prior to the start of the study treatment. The exclusion criteria includes patients with autoimmune diseases other than rheumatoid arthritis, those who have had bone or joint surgery within 8 weeks prior to screening or have joint surgery planned within 24 weeks of MabThera infusion, those who are receiving concurrent treatment with any DMARD or antiTNF-alfa, and those who have received intra-articular or parenteral corticosteroids within 4 weeks prior to screening.",
    "This sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves the use of two drugs, montelukast sodium and a placebo comparator. The eligibility criteria for the trial includes adult patients with acute asthma attacks, while exclusion criteria includes patients with other pulmonary symptoms or diseases, a smoking history of more than 15 years, and other severe diseases affecting the cardiovascular, hepatic, renal, or hematologic systems. The diseases are listed as 'asthma' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder (ADHD). The trial includes patients who meet the DSM-IV-TR criteria for a primary diagnosis of ADHD and have a baseline ADHD-RS-IV score of at least 28. The patients must also have blood pressure within the 95th percentile for their age, gender, and height. The trial will test the effectiveness of three different doses of ldx (30 mg, 50 mg, and 70 mg) and a placebo. The eligibility criteria include exclusion of patients with controlled or uncontrolled comorbid psychiatric diagnosis, conduct disorder, suicidal tendencies, and those who are under or overweight. Patients with concurrent chronic or acute illness that might confound the results are also excluded.",
    "The sample is a phase 3 clinical trial for patients with newly diagnosed multiple myeloma. The trial involves the use of various drugs such as lenalidomide/low dose dex, bortezomib/lenalidomide/low dose dex, and lenalidomide. The eligibility criteria for the trial include being at least 18 years old, having a Zubrod Performance Status of 0-3, having adequate marrow function, not having received prior chemotherapy or radiotherapy to a large area of the pelvis, not having received prior treatment with bortezomib or lenalidomide, and not having certain medical conditions such as uncontrolled active infection, psychiatric illness, or Hepatitis B, Hepatitis C, or HIV. Additionally, females of childbearing potential must have a negative pregnancy test and patients must be offered participation in genetic studies.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on non-small cell lung cancer and includes a list of ICD-10 codes for the disease. The trial is testing the effectiveness of three drugs: gefitinib, carboplatin, and paclitaxel. The eligibility criteria for the trial include having locally advanced Stage IIIB or Stage IV NSCLC with adenocarcinoma histology, and being a never smoker or light ex-smoker. The exclusion criteria include having had prior chemotherapy, biological or immunological therapy, and having pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline.",
    "The sample is a phase 3 clinical trial for the treatment of renal cell cancer. The trial includes patients with confirmed metastatic disease and surgically removed primary tumors. Patients must have a Karnofsky-Performance Status of over 70%, be between the ages of 19-75, and have a life expectancy of at least 3 months. They must also have adequate bone marrow and organ function, and a negative pregnancy test for female patients. The trial excludes patients with untreated or uncontrolled brain metastases, second neoplasia, or major concomitant diseases of the cardiovascular, respiratory or renal systems, as well as active systemic infections. Patients with severe renal disease or liver insufficiency or myeloid dysfunction, drug addiction, or a history of severe psychiatric disease are also excluded. Patients unwilling or unable to give informed consent, pregnant or breastfeeding patients, and patients with evidence of allergy or hypersensitivity against recombinant Interferon alfa-2a or other components of preparation are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of two drugs, ckd-501 0.5mg and pioglitazone 15mg. The eligibility criteria for the trial include being between 18 and 80 years old, having type 2 diabetes mellitus, having a BMI between 21kg/\u33a1 and 40kg/\u33a1, and having a C-peptide level over 1.0 ng/ml. The trial also has a list of exclusion criteria, including having type 1 diabetes or secondary diabetes, having a history of drug abuse or alcoholism, and having participated in another trial within 4 weeks.",
    "The sample is a phase 3 clinical trial for the treatment of liver cancer, specifically hepatocellular carcinoma. The trial involves the drugs pi-88 and placebo. The eligibility criteria include having undergone curative resection for primary hepatocellular carcinoma within the past 4-6 weeks, having an ECOG performance status of 0-2, and being classified as Child Pugh A or B. Exclusion criteria include evidence of tumor metastasis or co-existing malignant disease, prior recurrence of HCC or any liver resection prior to the most recent procedure, and history of prior HCC therapy. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have undergone prior preoperative chemotherapy. The trial requires patients to have completely resected primary carcinoma of the breast with histologically detectable tumor residuals and/or involvement of axillary nodes. Patients must also meet certain eligibility criteria, such as having a Karnofsky index of at least 70%, a life expectancy of at least 10 years, and no clinical evidence of local recurrence or distant metastases. The trial involves the use of zoledronic acid and has a list of exclusion criteria, such as known hypersensitivity reaction to the investigational compound, prior postoperative chemotherapy, and concurrent treatment with other experimental drugs or any other anti-cancer therapy. The trial is not open to male patients.",
    "The sample is a phase 3 clinical trial for patients with colorectal cancer. The trial includes patients with advanced and/or metastatic disease who are not eligible for hepatic resection after first-line combination chemotherapy. The trial involves the use of drugs such as capecitabine, fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria include age 18 and over, WHO performance status of 0-2, unidimensionally measurable disease, and no brain metastases. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and must not have any preexisting neuropathy > grade 1 or known hypersensitivity reaction to any of the components of study drugs. Prior concurrent therapy is also specified.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian cancer and primary peritoneal cavity cancer. The trial involves the use of two drugs, cisplatin and paclitaxel. The eligibility criteria for patients include having confirmed primary ovarian epithelial cancer or primary peritoneal cancer, suboptimal residual disease within 6 weeks of laparotomy with maximum resection, and stage III or IV disease. Patients must also meet certain age and health requirements, such as having a WBC count of at least 3,000/mm3 and no history of congestive heart failure. Patients cannot have received prior cytotoxic chemotherapy or radiotherapy. The trial requires cytologic confirmation of malignant pleural effusion if it is the sole basis of entry. The sample includes a list of disease names and corresponding ICD-10 codes, as well as eligibility criteria for patients.",
    "The sample is a phase 3 clinical trial for the treatment of iron-deficiency anemia in patients with indolent non-Hodgkin's lymphoma, multiple myeloma, or chronic lymphocytic leukemia who are on any chemotherapy excluding anthracycline containing. The trial requires subjects to be at least 18 years old with a life expectancy of at least 6 months and to have received at least 12 weeks of treatment in the current course of chemotherapy before starting iron therapy. The trial also requires subjects to have a hemoglobin level between 8.5 g/dL and 10.5 g/dL at the time of randomization and to meet certain criteria for iron-restricted erythropoiesis. The trial has a list of exclusion criteria, including recent anaemia treatment, subjects weighing less than 35 kg, ongoing haemolysis, and ongoing significant neurological or psychiatric disorders. The trial also requires signed informed consent from subjects and adequate contraceptive precautions for female subjects.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of two drugs, paliperidone palmitate and risperidone. The eligibility criteria for participants include having a diagnosis of schizophrenia for at least one year, a specific score on the Positive and Negative Syndrome Scale, and a minimum body mass index. Female participants must also be postmenopausal, surgically sterile, abstinent, or using an effective method of birth control. Participants must be able to self-administer the medication or have assistance available. Exclusion criteria include having a primary diagnosis other than schizophrenia, a decrease in PANSS score, previous participation in the study, active substance dependence, and a history of treatment resistance.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are outpatients and over 18 years old with a diagnosis of Stage II hypertension, defined as mean sitting Systolic Blood Pressure (msSBP) \u2265 160 mmHg and < 180 mmHg at Visit 2. The trial excludes patients with severe hypertension, secondary form of hypertension, current diagnosis of heart failure, current angina pectoris requiring pharmacological therapy, second or third degree heart block without a pacemaker, concurrent potentially life-threatening arrhythmia or symptomatic arrhythmia, clinically significant valvular heart disease, previous history of hypertensive encephalopathy or stroke, Transcient Ischemic Attack (TIA), heart attack, coronary bypass surgery or any PCI, known Keith-Wagener grade III or IV hypertensive retinopathy, patients on combination antihypertensive therapy that includes more than 2 classes of antihypertensive medications in the month prior to Visit 1, patients with Type 1 diabetes mellitus, patients with Type 2 diabetes mellitus not well controlled, elevated Serum potassium (over 5.3 mEq/L (mmol/L)), any surgical or medical condition or the use of any medication which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs. The trial involves the use of two drugs, aliskiren/hydrochlorothiazide (hctz) (300/25 mg) and aliskiren (300 mg).",
    "The sample is a record of a clinical trial in phase 3 for the treatment of cervical cancer. The trial involves the use of three drugs - cisplatin, gemcitabine hydrochloride, and paclitaxel. The eligibility criteria for the trial include a diagnosis of primary carcinoma of the cervix that meets certain staging criteria, measurable disease, and a Zubrod performance status of 0-1. Patients must also meet certain age, renal, and other health criteria, and cannot have had prior systemic therapy or concurrent antitumor therapy. The sample also includes information on prior concurrent therapy, such as chemotherapy and radiotherapy.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, associated ICD-10 codes, drugs being used, and eligibility criteria for patients. In this particular sample, the trial is in phase 3 and is studying bone marrow disease and pain. The associated ICD-10 codes for these diseases are listed. The drugs being used in the trial are fentanyl, emla, l.m.x4, and propofol. The eligibility criteria for patients include being between the ages of 2 and 17, having acute lymphoblastic leukemia or lymphoblastic lymphoma in remission or on the day of anticipated remission procedures, and having three anticipated bone marrow aspirates and lumbar punctures with intrathecal chemotherapy remaining in their treatment. There are also exclusion criteria listed, such as being newly diagnosed, having low platelet count, or having neurological impairment that would increase susceptibility to opioids.",
    "The sample is a phase 3 clinical trial for the treatment of gastroesophageal reflux disease. The trial includes patients who have completed a previous trial or have been diagnosed with the disease. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include exclusion criteria such as the use of certain medications, evidence of uncontrolled systemic disease, and a history of certain medical conditions. The trial aims to test the effectiveness of dexlansoprazole MR in treating the disease.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of osteoporosis in postmenopausal women. The trial involves the drugs arzoxifene and raloxifene. The eligibility criteria for the trial include having osteoporosis, being between 50 and 75 years old, having at least two back bones that can be x-rayed, and not having had a period in at least two years. Exclusion criteria include having a bone disease other than osteoporosis, a history of estrogen dependent cancer, stroke or certain heart problems, and certain abnormal lab values. Participants must also be willing to have blood tests.",
    "The sample is a phase 3 clinical trial for the treatment of Major Depressive Disorder (MDD). The trial involves testing the effectiveness of the drug ly2216684, as well as a placebo and a selective serotonin reuptake inhibitor (SSRI), on patients who have a partial response to SSRI treatment. The trial has specific inclusion and exclusion criteria, including a clinical diagnosis of MDD, meeting certain psychiatric scale scores, and not having any other primary psychiatric illnesses or medical conditions that could be exacerbated by noradrenergic agents. Participants must also be reliable and able to keep all scheduled appointments. The trial excludes participants who have a history of substance abuse, bipolar disorder, schizophrenia, or other psychotic disorders, as well as those who have received certain types of therapy or are at serious risk for harm to themselves or others.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who have been diagnosed with idiopathic PD and have predictable motor fluctuations of the wearing OFF type. Patients must be taking optimised levodopa therapy and must be able to distinguish their own motor states and the absence or presence of troublesome or non-troublesome dyskinesias. The trial has inclusion and exclusion criteria, including restrictions on medication use and medical conditions that could interfere with the evaluation of symptoms caused by the study drug. The trial aims to evaluate the tolerability of the study medication and its effectiveness in treating Parkinson's disease.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of gastroesophageal reflux. The trial includes the drug esomeprazole and lists the ICD-10 codes associated with the disease. The eligibility criteria for the trial include a history of chronic reflux esophagitis or symptomatic GERD, and subjects who are considered suitable for surgical treatment and long-term management of esomeprazole. The exclusion criteria include a history of esophageal, gastric, or duodenal surgery that may negatively impact subsequent treatment, contraindication to the study drug, and pregnancy, lactation, or child-bearing potential.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial is looking for patients with locally advanced disease or at high risk for relapse, but with no clinically or radiologically suspected metastases. Patients must have a confirmed diagnosis of adenocarcinoma of the prostate and meet at least one of the following criteria for poor prognosis: Gleason score greater than 7, T3 or T4 disease, prostate-specific antigen greater than 20 ng/mL, or N1 disease. Patients must also meet certain eligibility criteria related to age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other factors. Patients cannot have had prior chemotherapy or hormonal therapy, and cannot be receiving concurrent immunotherapy or other anticancer therapy. The trial will be testing the effectiveness of a combination of drugs including bicalutamide, goserelin acetate, docetaxel, estramustine phosphate sodium, and acetylsalicylic acid.",
    "The sample is a phase 3 clinical trial for atrial fibrillation. The trial includes patients who have permanent AF and meet certain eligibility criteria, such as having a 12-lead ECG showing AF or atrial flutter within 14 days prior to randomization, having documentation of being in AF or atrial flutter at least 6 months prior to randomization, and having no evidence of sinus rhythm between these two documentations. Patients must also have at least one of the specified risk criteria, such as coronary artery disease or symptomatic heart failure. Exclusion criteria include paroxysmal AF and heart failure of NYHA class IV or recent unstable NYHA class III. The trial involves the use of the drugs dronedarone and placebo (for dronedarone).",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of type 2 diabetes and hyperlipidemia. The trial involves the use of three drugs: colesevelam hcl, rosiglitazone maleate, and sitagliptin phosphate. The eligibility criteria for the trial include having an HbA1C level between 7.0% and 10.0% while on metformin monotherapy, and being withdrawn from other non-metformin drugs if the HbA1C level is between 6.5% and 9.5% at screening. Subjects currently treated with a thiazolidinedione are excluded from the trial. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is looking for previously untreated adults with HCV genotype 1, who have compensated liver disease and pretreatment liver biopsy slides available. The trial is testing the effectiveness of two drugs, Rebetol and Copegus, on eligible patients. The eligibility criteria include factors such as age, weight, and hematology and chemistry laboratory results. The trial also has exclusion criteria, such as previous hepatitis C treatment, pregnancy, and liver disease not caused by hepatitis C. The sample provides a detailed list of both inclusion and exclusion criteria for the trial.",
    "The sample is for a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes males and females aged 40 years or older who are current or ex-smokers with a clinical diagnosis of severe stable COPD. The trial excludes individuals with a history or current diagnosis of asthma, allergic rhinitis, or atopy, those who have had a respiratory tract infection or acute COPD exacerbation in the last 6 weeks, those who have been hospitalized for an acute COPD exacerbation in the last 3 months, and those with evidence of contraindicated use of anticholinergic drugs. The trial involves the use of aclidinium bromide, placebo tiotropium, tiotropium, and placebo las34273.",
    "The sample is a record of a clinical trial in phase 3, focused on the diseases of impaired glucose tolerance and diabetes. The icd-10 codes associated with these diseases are listed. The drug being tested is avandamet, which is a combination of rosiglitazone and metformin, and it is being administered twice daily. The eligibility criteria for the trial are also listed, including age range, residency, and medical history. The exclusion criteria are also provided, which include prior use of certain medications and certain medical conditions.",
    "The sample is a phase 3 clinical trial for the treatment of dementia and Alzheimer's disease using galantamine hydrobromide. The trial includes patients with a diagnosis of Alzheimer's type dementia rated as severe, with progressive worsening of memory and other cognitive functions, and who have had a brain imaging (CT or MRI scan) within the last 3 years. Patients must also be able to be mobile (aided or unaided) with sufficient vision and hearing to comply with testing. Exclusion criteria include dementia caused by cerebrovascular disease, disturbances of consciousness, delirium, psychosis, severe aphasia, major sensorimotor impairment, cognitive impairment due to acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency, infections, primary or metastatic cerebral neoplasia, endocrine or metabolic disease, mental retardation, pregnant or nursing women, or those without adequate contraception.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of lorazepam in treating status epilepticus and convulsions. The trial is looking for children who have acute generalized seizures lasting for at least 5 minutes and have not received any anti-convulsant therapy within 1 hour of presentation. The trial excludes children who have received anticonvulsant treatment within 1 hour prior to assessment, those whose seizures stop after correcting hypoglycemia, and those with a known adverse reaction to lorazepam. The sample also includes the list of icd-10 codes associated with the diseases being studied.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of interferon beta-1b (betaseron, bay86-5046) as the drug. The eligibility criteria for the trial include completion of a previous study, medical assessment, and agreement to practice adequate contraception methods for females of child-bearing potential. Exclusion criteria include severe heart diseases, severe depression or suicide attempt history, epilepsy not adequately controlled by treatment, known allergy to IFNs, human albumin or mannitol, and medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study. The diseases are listed as 'multiple sclerosis, relapsing-remitting' and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of anagliptin and a placebo of anagliptin. The eligibility criteria include having type 2 diabetes, inability to control blood glucose with diet and exercise, fasting plasma glucose levels of less than or equal to 270mg/dL, and written consent to participate. Exclusion criteria include having type 1 or secondary diabetes, requiring insulin therapy, recent use of oral anti-hyperglycemic drugs, having a body mass index outside of the range of 20-40kg/m2, and being deemed inappropriate for the trial by the investigator. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for non-constipation irritable bowel syndrome. The trial includes a list of icd-10 codes for the disease and two drugs, rifaximin and placebo. The eligibility criteria for the trial include a confirmed IBS diagnosis per Rome II, a colonoscopy within 2 years, and active symptoms of non-constipation IBS at baseline. The exclusion criteria include symptoms of constipation, history of other gastrointestinal diseases, type 1 or 2 diabetes, and lactose intolerance not controlled by lactose-free diet.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes who have inadequate glycemic control. The trial is testing the effectiveness of the drugs dapagliflozin and metformin, as well as a placebo for dapagliflozin. The eligibility criteria include being between the ages of 18 and 77, having a hemoglobin A1c level between 7% and 12%, being drug naive, having a C-peptide level of at least 1.0 ng/mL, and having a body mass index of 45.0 kg/m^2 or less. The exclusion criteria include various medical conditions and recent medical procedures, as well as the use of certain medications.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus and renal insufficiency. The trial involves the drugs bi 10773 and placebo, and the eligibility criteria include a diagnosis of type 2 diabetes mellitus, an estimated glomerular filtration rate of less than 90 ml/min, and being on the maximum tolerated dose of antidiabetic therapy for 12 weeks prior to randomization. Exclusion criteria include uncontrolled hyperglycemia, impaired renal function, liver disease, and a history of cancer. Women who are pregnant or nursing or of child-bearing potential and not practicing an acceptable method of birth control are also excluded.",
    "The sample is a phase 3 clinical trial for painful diabetic neuropathy. The trial is open to male and female outpatients aged 18 years or older who have been diagnosed with Type 1 or Type 2 diabetes mellitus and are experiencing pain due to bilateral peripheral polyneuropathy caused by diabetes. The trial requires stable glycemic control and a mean score between 4.0 and 9.0 on the 24 hour average pain intensity assessment. The trial involves the use of eslicarbazepine acetate (bia 2-093) or a placebo. The eligibility criteria include various medical and demographic factors, such as the absence of significant skin lesions, a negative serum pregnancy test for female subjects of childbearing potential, and the absence of a history of drug abuse or dependence within the past year. The exclusion criteria include various medical factors, such as a history of chronic hepatitis B or C within the past 3 months or human immunodeficiency virus infection.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients who have had definitive surgery for operable breast cancer and have at least one axillary lymph node showing evidence of tumor. The trial involves the use of multiple drugs, including doxorubicin and docetaxel, doxorubicin and cyclophosphamide, and their combinations. The eligibility criteria include normal cardiac function, laboratory requirements, and complete staging work-up within 3 months prior to registration. Patients must be accessible for treatment and follow-up, and negative pregnancy test is required for women of childbearing potential. Exclusion criteria include prior systemic anticancer therapy for breast cancer, prior radiation therapy for breast cancer, and other serious illnesses or medical conditions.",
    "The sample is a phase 3 clinical trial for the treatment of head and neck cancer. The trial includes patients with squamous cell carcinoma of the head and neck, with stage III or IV disease, and with primary tumors in the oral cavity, oropharynx, hypopharynx, or larynx. Patients with tumors in the nasal cavity, paranasal cavity, or nasopharynx are excluded. The trial involves the use of carboplatin, cisplatin, docetaxel, and fluorouracil as treatment options. The eligibility criteria include various medical and health-related factors, such as age, performance status, hematopoietic, hepatic, renal, cardiovascular, pulmonary, neurologic, and other factors. Patients must not have active drug addiction, other malignancies within the past 5 years, or other serious illnesses or medical conditions. The trial excludes patients who are pregnant or nursing, have HIV, or have unhealed or clinically active peptic ulcer disease. Prior concurrent therapy is not allowed, and patients must not have had prior chemotherapy or radiotherapy. Biopsy is allowed, but not prior surgery for this cancer.",
    "The sample is a phase 3 clinical trial for the treatment of clostridium infections. The trial involves patients who are at least 18 years old and have new onset of disease evidenced by diarrhea and one or more symptoms of CDAD. The patients must have C. difficile toxin A or B detected in a stool specimen obtained within 3 days before enrollment by enzyme immunoassay. The trial involves the use of nitazoxanide and vancomycin as drugs. The eligibility criteria include avoiding certain medications during the study and meeting certain inclusion criteria. The exclusion criteria include having other known causes of diarrhea or colitis, severe lactose intolerance, and more than 1 recurrence of CDAD during the 6 months prior to enrollment. Females of childbearing age who are either pregnant, breastfeeding, or not using birth control and are sexually active are also excluded. Patients who are clinically unstable or unlikely to live throughout the 31-day duration of the study due to underlying illness are also excluded. Patients with a history of hypersensitivity to nitazoxanide or vancomycin or any active ingredient in the formulations are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have been diagnosed clinically with diabetes for at least 6 months and are currently being treated with monotherapy or combination therapy of insulin secretagogues and metformin, with or without addition of alfa-glucosidase-inhibitors or a DPP-4 inhibitor. The trial also requires patients to have a HbA1c level between 7.0-10.0% and a BMI no higher than 35.0 kg/m^2. Patients who have used TZDs, exenatide or liraglutide within the last 3 months prior to visit 1, have cardiovascular disease, uncontrolled severe hypertension, are pregnant or breastfeeding, or have a history of cancer (except basal cell skin cancer or squamous cell skin cancer) are excluded from the trial. The trial is being conducted in Japan and Thailand, and the eligibility criteria may vary slightly based on local requirements.",
    "The sample is a phase 3 clinical trial for the treatment of keratoconjunctivitis sicca and dry eye disease. The trial involves the use of the drugs lifitegrast and placebo. The eligibility criteria for the trial include being at least 18 years old, having a patient-reported history of dry eye in both eyes, and demonstrating a positive response to the Controlled Adverse Environment model. Exclusion criteria include having any ocular condition that could affect study parameters, using any topical ophthalmic preparations 72 hours prior to Visit 1 and during the study, and having a history of alcohol and/or drug abuse. The trial requires subjects to avoid wearing contact lenses for 7 days prior to and during the study period.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial involves the use of two drugs, duloxetine and placebo. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of depression with previous episodes, and signing informed consent. Exclusion criteria include being pregnant or breastfeeding, having a history of bipolar disorder or other psychotic disorders, having a serious medical illness, and having taken certain medications within a certain timeframe.",
    "The sample is a phase 3 clinical trial for the treatment of gout. The trial includes patients who meet the American Rheumatism Association criteria for the diagnosis of gout and have a serum urate level greater than or equal to 8.0 mg/dL. The trial excludes patients with severe, unstable, or life-threatening medical conditions, a known body reaction to certain drugs, a history of xanthinuria, alcohol consumption greater than 14/week, significant concomitant illness, active liver or peptic ulcer disease, rheumatoid arthritis requiring treatment, estimated creatinine clearance less than 30 mL/min, and those requiring therapy with certain drugs. The trial involves the use of febuxostat, allopurinol, and naproxen. Females of childbearing potential who are sexually active must agree to use adequate contraception and cannot be pregnant or lactating throughout the duration of the study.",
    "The sample is a phase 3 clinical trial for patients with diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs used in the treatment, including lantus, metformin, glyburide, and thiazolidinedione. The eligibility criteria for the trial include patients between 18-79 years of age with diagnosed type 2 diabetes for at least a year and treated with stable doses of two oral antidiabetic drugs, one of which must be either Avandia or Actos for at least three months. The exclusion criteria include major cardiovascular events. The information provided is not intended to cover all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus using a combination of alogliptin and metformin. The trial is looking for participants who have been treated with metformin alone for at least 3 months but are experiencing inadequate glycemic control. The participants must meet certain eligibility criteria, including having a BMI between 23 and 45 kg/m2, a fasting C-peptide concentration of at least 0.8 ng/mL, and a glycosylated hemoglobin concentration between 7.0% and 10.0%. The trial also has exclusion criteria, such as a history of cancer or heart failure, and participants must not be taking certain medications. The trial requires participants to monitor their own blood glucose concentrations and to provide written informed consent.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of venous thromboembolism and includes a list of associated ICD-10 codes. The trial involves the use of three drugs: semuloparin sodium, enoxaparin sodium, and a placebo. The eligibility criteria for the trial include elective total hip replacement surgery or a revision of at least one component of a prosthesis implanted at least 6 months prior to study entry. Exclusion criteria include recent major orthopedic surgery, a history of deep vein thrombosis or pulmonary embolism, high risk of bleeding, known allergy to heparin or enoxaparin, contra-indications to the performance of venography, and end stage renal disease or patient on dialysis. The information provided is not intended to be a comprehensive list of all considerations relevant to a patient's potential participation in the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including metformin, sulphonylurea, and saxagliptin. The eligibility criteria for the trial include being diagnosed with type 2 diabetes, being treated with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1, and having an HbA1c level between 6.5% and 10.0%. Exclusion criteria include having type 1 diabetes, a history of diabetic ketoacidosis or hyperosmolar non-ketonic coma, and insulin therapy within one year of enrollment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes).",
    "The sample is a phase 3 clinical trial for the treatment of metastatic colorectal cancer. The trial involves the use of two drugs, regorafenib and placebo, and requires subjects to have failed at least two lines of prior treatment. The eligibility criteria include having histological or cytological documentation of adenocarcinoma of the colon or rectum, measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1, and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 1. The trial also has exclusion criteria, such as prior treatment with regorafenib, previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization, and arterial or venous thrombotic or embolic events.",
    "The sample is a phase 3 clinical trial for diabetes mellitus. The trial includes a list of icd-10 codes for the disease and a list of drugs, including syr-472, alogliptin 25 mg, and placebo. The eligibility criteria for the trial include being an outpatient and signing a written informed consent form. Exclusion criteria include having serious cardiac, cerebrovascular, pancreatic, or hematological disease, or being considered ineligible by the investigator or subinvestigator.",
    "The sample is a phase 3 clinical trial for psoriasis. The trial is looking for male or female subjects who are at least 12 years old and in good general health, and have moderate plaque-type psoriasis on their body (excluding the scalp and face). The trial also requires the involvement of at least 10% of the total scalp surface area with clinical signs rated as moderate. The trial is testing the effectiveness of calcipotriene foam and vehicle foam as treatments for psoriasis. The eligibility criteria include being able to complete the study and comply with study instructions, negative urine pregnancy test for females of childbearing potential, and not having participated in any previous calcipotriene foam clinical trials. The exclusion criteria include having a history of hypercalcemia or vitamin D toxicity, having a serious skin disorder or any chronic medical condition that is not well-controlled, and using nonbiologic systemic anti-psoriatic therapy within 4 weeks prior to enrollment.",
    "The sample is a phase 3 clinical trial for patients with locally advanced, recurrent, and metastatic non-squamous cell carcinoma of the lung who have not received prior systemic treatment. The trial is specifically for patients who have a positive translocation or inversion event involving the ALK gene locus. The trial includes inclusion criteria such as a signed informed consent document, willingness to comply with scheduled visits and treatment plans, and being 18 years or older (except in India where the upper age limit is 65 years old). Exclusion criteria include current treatment on another therapeutic clinical trial, prior therapy directly targeting ALK, and various medical conditions or laboratory abnormalities that would make the patient inappropriate for the study. The trial involves the use of drugs and has a list of eligibility criteria that must be met for patients to participate.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of canagliflozin, metformin, sulphonylurea, and a placebo. The eligibility criteria for the trial include having a diagnosis of T2DM and currently being treated with metformin and sulphonylurea, having a HbA1c between >=7 and <=10.5%, and having a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L). Patients with a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening are excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking for patients who have ductal carcinoma in situ (DCIS) of the breast detected by mammogram at the time of diagnosis, with lesions \u2264 2.5 cm, low nuclei grade (NG1) or intermediate nuclei grade (NG2) with necrosis in < one third of the involved ducts, inked margins \u2265 3 mm, clinically node negative, and non-palpable. Patients must also have no suspicious areas on post-operative mammogram taken within 12 weeks after final surgery, no bloody nipple discharge, and no more than 12 weeks since prior final surgery (arm II only). The trial is looking for female patients who are 26 years or older, not pregnant or nursing, and have no active connective tissue disorders. Patients must not have had prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. The trial is not looking for patients who have had prior chemotherapy, radiotherapy, or other concurrent hormonal therapy.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed as well. The drug being tested is vildagliptin. The eligibility criteria for the trial are listed, including a requirement of being diagnosed with type 2 diabetes for at least 6 months, meeting certain blood glucose criteria, and having a BMI in the range of 22-40. There are also exclusion criteria listed, such as a history of type 1 diabetes or the use of certain medications within 3 months prior to screening. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of infection. The trial includes patients with a fever caused by an uncomplicated acute viral or bacterial infection, with an oral temperature between 100 to 104 degrees Fahrenheit and an onset of fever within 3 days. The trial will test the effectiveness of ibuprofen and placebo drugs. The eligibility criteria include being in good health, while the exclusion criteria include having a chronic underlying medical condition or serious infection, taking antibiotics or antivirals, taking medication that may interfere with fever assessment, being pregnant or breastfeeding, and having any serious medical or psychiatric disorder.",
    "The sample is a phase 3 clinical trial for essential hypertension. The trial includes patients who are 18 years or older and have a certain range of blood pressure readings. Patients must be able to discontinue all prior antihypertensive medications safely for a period of 1 week to 4 weeks as required by the protocol. Pregnant or nursing women are excluded from the trial. The trial involves the use of the drug aliskiren/amlodipine/hydrochlorothiazide. The eligibility criteria and exclusion criteria are listed in detail.",
    "The sample is from a phase 3 clinical trial for obesity and overweight patients. The trial includes two groups, one receiving the drug \"naltrexone sr 32 mg/ bupropion sr 360 mg/ day\" and the other receiving a placebo. The eligibility criteria for the trial include being between 18 and 65 years old, having a body mass index (BMI) between 30 and 45 kg/m\u00b2 for uncomplicated obesity or between 27 and 45 kg/m\u00b2 for controlled hypertension and/or dyslipidemia, being a non-smoker, having normal blood pressure and lipid levels, and not having any significant medical or psychiatric conditions. The trial also excludes patients with certain medical conditions, those taking certain medications, and those who have recently undergone weight loss interventions or have gained or lost a significant amount of weight. Participants must be able to comply with all study procedures and speak and read English.",
    "The sample is a phase 3 clinical trial for patients with symptomatic pulmonary arterial hypertension (PAH) in modified World Health Organization (WHO) functional class II to IV. The trial includes patients with idiopathic (IPAH), familial (FPAH), or related PAH belonging to groups 1.1 to 1.3 of the Venice classification. The diagnosis of PAH is confirmed by hemodynamic evaluation showing specific criteria. The trial has inclusion and exclusion criteria, including age, 6-minute walk distance, and various medical conditions. The trial involves the use of macitentan (act-064992) and a placebo.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients with a clinical diagnosis of rheumatoid arthritis and a Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score between 3.2 and 5.1. Patients must have been on background methotrexate for at least 3 months and be able to self-inject or have a caregiver do it for them. Participants must discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate. Exclusion criteria include prior exposure to abatacept or CTLA-4 Ig, treatment with rituximab, leflunomide within 1 year of screening, treatment with immunoadsorption columns, mycophenolate mofetil (Cellcept\u00ae), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial involves the drugs memantine and a placebo pill. The eligibility criteria include being between 50-95 years old, having a diagnosis of dementia by DSM-IV criteria, having a MMSE score between 7-28, being conversant in English, having a caregiver or study partner willing to participate, and being able to ingest oral medication. Exclusion criteria include a history of stroke without substantial recovery, neurological or medical conditions causing significant disability independent of dementia, Parkinson's disease, history of major psychiatric disorders, dementia due to certain infectious diseases, sensory impairment, significant clinical disorders or laboratory findings, clinical contraindication to the use of memantine, history of seizure within the past 5 years, platelet count below 100,000/mm3, history of claustrophobia, and presence of certain metallic implants.",
    "The sample is a phase 3 clinical trial for renal transplantation. The trial involves the use of drugs such as cyclosporine, daclizumab, mycophenoate mofetil, prednisolone, and sirolimus. The eligibility criteria for the trial include the receipt of a first cadaveric kidney graft, antilymphocyte antibodies and panel reactive antibodies less than 30%, and cold ischaemia time less than or equal to 36 hours. Exclusion criteria include kidney from a living donor, known hypersensitivity to any of the drugs in the study, history of cancer or malignancy during the previous 5 years, and severe refractory hyperlipidaemia. The exclusion criteria for the follow-up phase include acute rejection greater than or equal to grade I, estimated creatinine clearance less than 40 mL/min, serum creatinine variations greater than 30%, and proteinuria greater than 1 gram/24 hour or mean mycophenolate mofetil dose less than 1.5 gram/day during the week before randomization.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary arterial hypertension using the drug ambrisentan. The eligibility criteria for the trial include completing a previous study or receiving placebo, being able to understand and sign the informed consent form, and using reliable contraception for the duration of the study. Exclusion criteria include receiving certain medications, being pregnant or breastfeeding, having certain medical conditions, and recent history of substance abuse or participation in another clinical trial. The diseases and corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease and Down syndrome. The trial involves the use of alpha-tocopherol and a sugar pill as drugs. The eligibility criteria for the trial include having clinically determined Down syndrome, being 50 years or older, being medically stable, having stable medications for more than a month, and having the involvement/cooperation of an informant/caregiver. Exclusion criteria include having a medical/neurological condition other than Alzheimer's disease associated with dementia, inability to perform the Brief Praxis Test adequately, having a modified Hachinski score greater than 4 at the screening visit, having major depression within 3 months, having a history of coagulopathy, using anticoagulants, using experimental medications within 2 months, having regular use of vitamin E greater than 50 units per day during the previous 6 months, and having an allergy to vitamin E.",
    "The sample is a phase 3 clinical trial for menopause and postmenopausal vaginal atrophy. The trial involves the use of estradiol, 10 mcg as a drug. The eligibility criteria for the trial include being a postmenopausal woman with at least one urogenital symptom and being generally healthy. The exclusion criteria include exposure to exogenous sex steroid hormones within the past 3 months. The icd-10 codes associated with the diseases are E28.310 and E28.319.",
    "This sample is from a clinical trial in phase 3 that focuses on the disease candidiasis. The icd-10 codes associated with the disease are listed. The trial involves testing the effectiveness of three drugs: vfend\u00e2\u00ae i.v., oral, conventional amphotericin b, and diflucan iv, oral. The eligibility criteria for the trial are also listed, including the inclusion criteria of patients with candidemia and the exclusion criteria of patients with neutropenia.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients with moderate-to-severe COPD as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007. The trial requires patients to have a post-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% and greater than or equal to 30% of the predicted normal value, and a post-bronchodilator FEV1/FVC (Forced Vital Capacity) of less than 70%. Patients must also be currently receiving COPD bronchodilator treatment that includes a LABA bronchodilator or a fixed dose combination of LABA and Inhaled Corticosteroid (ICS). Exclusion criteria include patients with a history of asthma, patients currently being treated for COPD with tiotropium (Spiriva\u00ae), patients with diabetes Type I or uncontrolled diabetes Type II, and patients with a history of certain cardiovascular comorbid conditions. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with liver cirrhosis and chronic hepatitis C. The trial involves the use of drugs such as peginterferon alfa-2a and ribavirin. The eligibility criteria for the trial include patients aged 20 to 75 years-old with quantifiable serum HCV-RNA, elevated serum alanine aminotransferase activity, and proven CHC with compensated LC on liver biopsy. However, patients with certain conditions such as neutropenia, thrombocytopenia, anemia, hepatitis B co-infection, decompensated liver disease, organ transplant, and poorly controlled psychiatric disease are excluded from the trial. Additionally, patients with poorly controlled diabetes, malignant neoplastic disease, severe cardiac or chronic pulmonary disease, immunologically mediated disease, and retinopathy are also excluded.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial involves the use of drugs such as cyclophosphamide, epirubicin hydrochloride, fluorouracil, and paclitaxel. The eligibility criteria for the trial include having histologically confirmed primary breast cancer with at least one involved axillary or internal mammary node, having undergone radical surgery within the past 7 weeks, and not having any metastatic disease or inflammatory carcinoma. The trial is open to female patients with an ECOG performance status of 0-1, and who meet certain medical criteria such as having a platelet count of at least 100,000/mm\u00b3 and not having any serious medical illness requiring medication. Prior to the trial, patients must not have received any chemotherapy or cytotoxic regimens, and must not have undergone any radiation therapy except for intraoperative radiation therapy.",
    "The sample is a phase 3 clinical trial for patients with advanced biliary tract cancer that cannot be treated with conventional surgery. The trial includes patients who are 18 years or older, have a life expectancy of at least 12 weeks, and have an Eastern Cooperative Oncology Group (ECOG) Performance Status score less than 3. Patients must also be willing and able to sign informed consent and use an accepted and effective method of contraception if sexually active. Women of child-bearing age must have a negative pregnancy test. The trial excludes patients who have had prior chemotherapy, unstable angina, class III or IV New York Heart Association heart disease, central nervous system metastases, uncontrolled diabetes mellitus, uncontrolled seizure disorder, major surgery, chemotherapy, immunotherapy, or radiotherapy during the 28 days preceding the first study treatment, need for concomitant anticancer therapy or other investigational agents during study participation or 28 days prior to study participation, pregnant or breast-feeding, or a known history of human immunodeficiency virus (HIV) infection.",
    "The sample is a phase 3 clinical trial for HIV patients. The trial is testing the effectiveness of the drug tenofovir/emtricitabine/rilpivirine. The eligibility criteria for the trial include being 18 years or older, having documented HIV-1 infection, and having a viral load of less than 50 copies/mL. Patients must also have been on Atripla or Kivexa plus efavirenz for at least 12 weeks, have a CD4 cell count of more than 50 cells/mm3, and an estimated glomerular filtration rate of more than 50 ml/min. Patients with symptomatic CNS related toxicity associated with efavirenz are also eligible. Women of childbearing potential must be using effective birth control methods and willing to continue using them during the trial and for at least 30 days after the end of the trial. Heterosexually active males must also be using effective birth control methods. Patients infected with HIV-2, using any disallowed concomitant therapy, having acute viral hepatitis, or having chronic hepatitis B and/or C with AST and/or ALT >5 x ULN are excluded from the trial. Patients who have received rilpivirine in the past, have any clinical evidence of baseline resistance mutations, or have known allergies to certain substances are also excluded. Patients with severe hepatic impairment, moderate or severe renal impairment, or any condition or laboratory results that may interfere with assessments or completion of the trial are also excluded.",
    "The sample is a phase 3 clinical trial that focuses on patients with type 2 diabetes mellitus, cardiovascular disease, hypertension, and inadequate glycaemic control. The trial involves the use of the drug dapagliflozin and a placebo. The eligibility criteria for the trial include having type 2 diabetes mellitus, cardiovascular disease, and hypertension, while exclusion criteria include having type 1 diabetes or diabetes insipidus, poorly controlled diabetes, and any clinically significant illness that could compromise the patient's safety and participation in the study. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes and end-stage kidney disease. The trial involves the drugs sitagliptin and glipizide. The eligibility criteria include being on dialysis, having a hemoglobin A1c level between 7% and 9%, and being compliant with study medication and other treatments during the run-in period. Exclusion criteria include a history of type 1 diabetes or ketoacidosis, significant cardiovascular disorder, and hypersensitivity or contraindication to glipizide. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 3 clinical trial for patients with pulmonary hypertension. The trial is testing the effectiveness of inhaled treprostinil compared to a placebo inhalation solution. The eligibility criteria for the trial include having clinically stable pulmonary arterial hypertension diagnosed as either idiopathic or familial PAH, collagen vascular disease associated PAH, HIV PAH, or PAH induced by anorexigens, being on a stable dose of 125 mg twice daily (bid) of bosentan OR any stable dose of sildenafil for at least three months prior to study start, having an unencouraged six minute walk test (6MWT) of between 200 and 450 meters at screening, and meeting certain cardiac catheterization criteria. Patients must also be willing and able to follow all study procedures. Exclusion criteria include pregnancy or lactation, having PAH due to conditions other than those listed in the inclusion criteria, having had any change in or discontinued any PAH medication within the last three months, and having received any prostanoid within the 30 days before screening or scheduled to receive any during the course of the study. Patients with known intolerance to any drug, especially to treprostinil sodium or prostanoids, an increased risk of hemorrhage, or any musculoskeletal disease or any other disease that would limit ambulation are also excluded.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial includes patients between the ages of 18-70 who have clinically active mild to moderate small bowel CD and no stricture on previous examinations. The trial excludes patients with evidence of other forms of inflammatory small bowel bowel disease, idiopathic proctitis or infectious disease, known small bowel strictures from previous examinations, pacemaker, swallowing disorders, planned or actual pregnancy or lactation, chronic use of non-steroidal anti-inflammatory drugs, intake of corticosteroids, any immunosuppressive agents, any Crohn specific biological agents, any other disease or condition which may interfere with study assessments, alcoholism or drug addiction, severe renal/hepatic impairment, allergy to salicylate or 5-ASA derivatives, unlikely to comply with the protocol, and any patient who has previously taken part in this study. The trial drug being tested is mesalazine (mesalamine).",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy. The trial is looking for participants who have been diagnosed with partial epilepsy and have a medical history of seizures. Participants must have had at least 4 partial onset seizures during the 8 weeks prior to screening with no 28-day seizure-free period. They must also have a documented EEG recording consistent with focal onset epilepsy and a CT or MRI scan conducted within 10 years prior to screening showing the absence of a structural abnormality. Participants must be on stable treatment with 1-2 AEDs during the last 4 weeks prior to screening. The trial has inclusion and exclusion criteria that participants must meet. Participants must give written informed consent prior to participation in the study. The trial is testing the effectiveness of eslicarbazepine acetate 1600 mg and eslicarbazepine acetate 1200 mg.",
    "The sample is a phase 3 clinical trial for patients with recurrent or metastatic head and neck cancer. The trial is testing the effectiveness of the drugs docetaxel and gefitinib. The eligibility criteria include having a confirmed diagnosis of squamous cell carcinoma of the head and neck, being considered incurable by local therapies, and having no prior systemic EGFR inhibitors. Patients must also have fully recovered from any prior surgery, chemotherapy, or radiation therapy and meet certain health requirements. The trial has exclusion criteria, such as prior therapy with docetaxel, unstable systemic disease, and pregnancy or breastfeeding. The trial is designed to evaluate the safety and efficacy of the drugs and to assess the response to therapy.",
    "The sample is a phase 3 clinical trial for primary myelofibrosis and MPN-associated myelofibrosis. The trial involves the use of drugs such as pomalidomide and placebo. The eligibility criteria include being at least 18 years old, having RBC-transfusion-dependence, having a hemoglobin level of 130 g/L or less, and having an ECOG performance status of 2 or less. The exclusion criteria include prior blood cell or bone marrow allotransplant, use of drugs to treat MPN-associated myelofibrosis within 30 days before starting study drug, and anemia due to reasons other than MPN-associated myelofibrosis. The trial also requires participants to follow pregnancy precautions and not donate blood or semen.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who are currently being treated with insulin alone (with or without metformin) and are inadequately controlled. The trial is testing the effectiveness of a combination of alogliptin and insulin compared to insulin alone. The eligibility criteria include a stable metformin dose for at least 8 weeks prior to randomization, a body mass index between 23 and 45 kg/m2, and a fasting C-peptide concentration greater than or equal to 0.8 ng per mL. The trial also requires participants to have a glycosylated hemoglobin concentration greater than or equal to 8.0% at screening and to be using a stable dose of insulin of at least 15 units but not more than 100 units per day for at least 8 weeks prior to randomization. The exclusion criteria include a history of cancer, heart failure, or infection with hepatitis B, hepatitis C, or human immunodeficiency virus. Participants must also not be taking any medications, including over-the-counter products, without first consulting with the investigator.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating sexual dysfunctions, psychological in women with HSDD (hypoactive sexual desire disorder) using the drug flibanserin flexible dose. The eligibility criteria for the trial include having a primary diagnosis of HSDD, being willing to continue in the study, and using a medically acceptable method of contraception for at least 3 months before the screening visit. Exclusion criteria include a history of MDD (major depressive disorder) within 6 months prior to the screening visit, clinically significant ECG abnormalities, and findings of certain pelvic or vaginal conditions at the screening visit. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of glaucoma and ocular hypertension. The diseases are listed as 'glaucoma, primary open angle (poag)' and 'ocular hypertension', and their corresponding ICD-10 codes are also provided. The drugs being tested are Xalacom (KP2035) and Xalatan. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include a minimum intraocular pressure requirement and exclusion of patients with certain medical histories.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial includes male and female subjects between the ages of 6 and 12 who have a history of PAR and are willing to comply with the study requirements. The trial involves testing the effectiveness of three drugs: azelastine hydrochloride nasal spray 0.15%, azelastine hydrochloride nasal spray 0.10%, and placebo. The eligibility criteria include having a positive response to skin prick testing for dust mite, cockroach, mold, cat or dog dander, and having a 12-hour reflective TNSS of at least 6 out of a possible 12 and a congestion score of \u22652 or a rhinorrhea score of \u22652 on Visit 1. The trial also has exclusion criteria, such as having significant pulmonary disease including asthma, chronic obstructive sleep apnea syndrome, or any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the disease psoriasis. The trial involves the drug adalimumab and includes a list of ICD-10 codes for psoriasis. The eligibility criteria for the trial include being 18 years or older, having a stable medical history, and having previously participated in an adalimumab psoriasis study. Exclusion criteria include being considered unsuitable for the study by the investigator and being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients between the ages of 50 and 85 with a diagnosis of probable Alzheimer's disease and a baseline Mini-Mental State Examination (MMSE) score of 10-24. The trial also requires a primary caregiver to supervise treatment and provide input into efficacy assessments. The trial involves the use of several drugs, including rivastigmine patches and placebos. The eligibility criteria include exclusion criteria for patients with severe or unstable cardiovascular disease, cerebrovascular disease, and other medical or neurological conditions that could interfere with efficacy and safety assessments. The trial also has other protocol-defined inclusion/exclusion criteria that may apply.",
    "The sample is a phase 3 clinical trial for patients with stage IIIA non-small cell lung cancer who have undergone complete surgical resection. The trial is testing the effectiveness of the drugs carboplatin and paclitaxel in preventing the recurrence of the cancer. The eligibility criteria include factors such as age, performance status, and hematopoietic and renal function. Patients must not have received prior chemotherapy for non-small cell lung cancer and must not be pregnant or nursing. The trial also excludes patients who have received prior radiotherapy for non-small cell lung cancer.",
    "The sample is a phase 3 trial for two diseases, acquired bleeding disorder and trauma. The icd-10 codes for these diseases are listed. The trial involves two drugs, eptacog alfa (activated) and placebo. The eligibility criteria for the trial include having a trauma injury with evidence of active hemorrhage that is refractory to blood component therapy and surgical haemostatic procedures at the time of randomisation.",
    "The sample is a phase 3 clinical trial for the treatment of bladder cancer using the drug eflornithine. The trial is for patients with low grade, superficial transitional cell carcinoma of the bladder that has been newly diagnosed or has recurred. Patients must have had all visible tumors removed within the past 12 weeks and must not have any prior upper tract TCC or history of grade 3 TCC, carcinoma in situ, non-TCC histology, or TCC greater than or equal to T2. Patients must also have had an abdominal CT scan, IVP, or retrograde pyelogram within the past 3 months to rule out upper urinary tract tumor. The trial is open to patients 18 years and older with no significant medical or psychiatric conditions, and who are not pregnant or nursing. Patients must have had no prior malignancy within the past 5 years and no concurrent malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix. The trial has specific criteria for prior concurrent therapy, including no prior systemic chemotherapy for bladder cancer, no concurrent intravesical therapy, and at least 4 weeks since prior chemotherapy.",
    "The sample is a phase 3 clinical trial for the treatment of hyperkalemia, a condition characterized by high levels of potassium in the blood. The trial involves the use of two different doses of zirconium silicate and two different doses of placebo, administered during both the acute and subacute phases of the condition. The eligibility criteria for the trial include being over 18 years of age, having mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, and being able to have repeated blood draws or effective venous catheterization. Women of childbearing potential must be practicing a highly effective method of birth control. Exclusion criteria include having pseudohyperkalemia signs and symptoms, being treated with certain medications within the last 7 days, having a life expectancy of less than 3 months, being HIV positive, and having certain medical conditions or allergies.",
    "The sample is a phase 3 clinical trial for the treatment of postherpetic neuralgia, complex regional pain syndromes (CRPS), and postoperative pain. The trial involves the use of the drugs fentanyl and placebo. The eligibility criteria include having pain for at least 12 weeks prior to informed consent, taking a non-opioid analgesic at the normal highest dose or more for at least 14 consecutive days prior to informed consent, showing insufficient therapeutic efficacy of the non-opioid analgesic currently being used, and having an average pain intensity of 50 millimeter or more on the Visual Analog Scale in 24-hour daily living prior to informed consent. The exclusion criteria include having an operation that may affect the assessment within 30 days before informed consent, having psychogenic pain, having asthma, bradyarrhythmia, severe respiratory function disorders, hepatic dysfunction, renal impairment, or a history of hypersensitivity to fentanyl and other opioid analgesics.",
    "The sample is a phase 3 clinical trial for obsessive compulsive disorder. The trial includes patients who have been diagnosed with OCD and have undergone at least 12 weeks of treatment with SSRI or clomipramine. The trial excludes patients who have substance abuse or dependence, are pregnant or lactating, have known intolerance or lack of response to quetiapine, or are using antihypertensive medication with changing doses. The trial will test the effectiveness of quetiapine fumarate and SSRI/clomipramine as treatments for OCD.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus. The trial includes a list of inclusion and exclusion criteria, such as being between the ages of 18 and 80 (or 65 for participants in India), having a stable regimen of insulin for at least 10 weeks, and not having been treated with certain medications within the past 12 weeks. The trial also includes a list of drugs being used, including sitagliptin and metformin, as well as a placebo comparator. The trial aims to target a fasting glucose level of 72-100 mg/dL and participants must agree to remain abstinent or use birth control during the study.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B virus infection. The trial includes participants who are nucleoside- and nucleotide-naive, have compensated liver function, and meet certain HBV DNA and alanine aminotransferase level criteria. The trial excludes participants with decompensated cirrhosis, coinfection with certain viruses, and laboratory values outside of the protocol-specified range. The table includes columns for the trial phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of Myelodysplastic Syndrome (MDS). The trial includes patients who have been diagnosed with MDS denovo or secondary, with a French-American-British (FAB) and International Prognostic Scoring System (IPSS) greater than or equal to 0.5. The trial involves the use of two drugs, decitabine at 15 mg/m2 and decitabine at 20 mg/m2. The eligibility criteria include having an Eastern Oncology Cooperative Group (ECOG) performance status of 0-2, adequate hepatic and renal function, and having recovered from all toxic effects of prior therapy. The exclusion criteria include not having a diagnosis of acute myeloid leukemia, not having received radiotherapy within 14 days before the first dose of study drug, not having any other prior cancer, and not having associated autoimmune hemolytic anemia or immune thrombocytopenia and inaspirable bone marrow. Patients with mental illness or any other condition that could prevent full cooperation with the study requirements are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of acute myeloid leukemia (AML). The trial is for patients aged 61 to 75 with a WHO performance status of 0-2 and a life expectancy that is not specified. The trial involves the use of drugs such as cytarabine, etoposide, gemtuzumab ozogamicin, idarubicin, and mitoxantrone hydrochloride. The eligibility criteria include a diagnosis of AML with bone marrow blasts of at least 20%, FAB subtypes M0-M2 and M4-M7, and no acute promyelocytic leukemia (FAB subtype M3). Patients must also not have blast crisis of chronic myelogenous leukemia, no AML supervening after other myeloproliferative diseases, and no active CNS leukemia. The sample also includes various patient characteristics such as hematopoietic, hepatic, renal, cardiovascular, and pulmonary conditions, as well as prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial is testing capsules containing carbidopa, levodopa, and entacapone as a treatment for Parkinson's disease. The eligibility criteria for the trial include being between the ages of 30 and 80 at the time of Parkinson's disease diagnosis, having at least 2 cardinal signs of the disease, and having Parkinson's disease impairment that warrants treatment with a levodopa formulation according to the investigator's assessment. The exclusion criteria include having a history, signs, or symptoms suggesting the diagnosis of atypical or secondary Parkinsonism due to drugs, metabolic disorders, encephalitis, or other neurodegenerative diseases, having a diagnosis of Parkinson's disease for more than 5 years prior to screening, and having previous use of levodopa in any formulation, entacapone, or tolcapone for more than 30 days or anytime within 4 weeks (28 days) prior to baseline. Additionally, the use of a dopamine agonist within 4 weeks (28 days) prior to baseline is also an exclusion criterion.",
    "The sample is a phase 3 clinical trial for seasonal allergic rhinitis. The trial includes patients who are 12 years of age or older and have a history of SAR for at least 2 years. The patients must have a 12-hour reflective TNSS of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Day -7. They must also have taken at least 10 doses of study medication during the lead-in period. The trial involves the use of 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, or placebo. The eligibility criteria include general good health, absence of any disease or concomitant treatment that could interfere with the interpretation of the study results, and willingness to comply with the study requirements. The exclusion criteria include the presence of any nasal mucosal erosion, nasal ulceration, or nasal septal perforation, other nasal diseases, planned travel outside of the study area during the study period, and the use of any investigational drug within 30 days prior to Day -7. Women who are pregnant or nursing, women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception, and patients with clinically significant arrhythmia or symptomatic cardiac conditions are also excluded.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of seizures. The trial involves the drug pregabalin and the eligibility criteria include having completed a previous study and showing a significant clinical response. However, individuals with a treatable cause of seizure or a progressive neurological or systemic disorder are excluded from the trial. The diseases are listed as 'seizures' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with leukemia or myelodysplastic syndromes. The trial involves the use of drugs such as cytarabine, daunorubicin hydrochloride, and gemtuzumab ozogamicin. The eligibility criteria include a confirmed diagnosis of AML or RAEB, a certain age range and performance status, and no prior induction therapy for AML or myelodysplastic syndromes. The trial also has specific requirements for the patient's hematopoietic, hepatic, renal, and cardiovascular health, as well as their medical history.",
    "This is a sample from a clinical trial table that includes information about a phase 3 trial for the treatment of pulmonary arterial hypertension. The table includes columns for the phase of the trial, the diseases being studied, the ICD-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. In this particular sample, the drug being studied is bosentan and the eligibility criteria includes requirements such as signed informed consent, completion of a previous study, and age restrictions. There are also exclusion criteria listed, such as intolerance to the drug and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for contraception. The eligible participants are healthy females between the ages of 18 and 35 who are in need of contraception and have a history of regular menstrual cycles. The trial excludes pregnant or lactating women, those who have had a vaginal or cesarean delivery or abortion within 6 weeks prior to the screening visit, and those with certain medical conditions such as liver tumors or a history of venous or arterial thrombotic/thromboembolic events. The trial also prohibits the use of certain contraceptive methods during treatment. The sample includes a list of diseases, icd-10 codes, drugs, and eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of gastric cancer and neoplasm metastasis. The trial involves the use of two drugs, 5-fu continuous infusion and mtx + 5-fu sequential therapy. The eligibility criteria for the trial include having histologic confirmation of gastric adenocarcinoma, inoperable or recurrent metastatic disease, peritoneal metastasis, being between 20 and 75 years old, having a performance status of 2 or less, and not having received prior treatment for gastric carcinoma except for surgery and adjuvant chemotherapy. The trial also has exclusion criteria, such as having massive pleural effusion, brain metastasis with symptoms, severe diarrhea, and other severe medical conditions or active malignancies.",
    "The sample is a phase 3 clinical trial for non hodgkin lymphoma. The trial involves the drugs enzastaurin and placebo. The eligibility criteria for the trial include having a clinical diagnosis of diffuse large B cell lymphoma, recently completing R-CHOP therapy and achieving remission, having an International Prognostic Index (IPI) score of 3, 4, or 5, being at least 18 years of age, and agreeing to the study follow-up schedule. The exclusion criteria include having received therapy other than R-CHOP for lymphoma, having a serious medical condition such as infection, second cancer, or heart disease, having received radiation to more than one lesion, and being unable to swallow tablets.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia who are experiencing a psychotic episode. The trial is testing the effectiveness of intramuscular olanzapine depot compared to a placebo. The eligibility criteria include having a sufficient level of understanding to complete all tests and examinations required by the protocol, not having participated in a clinical trial of another investigational drug within 1 month prior to the study entry, and not being pregnant or breastfeeding. The exclusion criteria include being previously treated with olanzapine and considered treatment-resistant, having one or more seizures without a clear and resolved etiology, and having a DSM-IV or DSM-IV-TR substance dependence within the past 30 days.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis for more than 6 months and less than 15 years, have been regularly using methotrexate for the past 12 weeks with a stable dose for the past 8 weeks, have at least 8 tender and swollen joints, and have at least one erosion of a hand or foot joint observed on an X-ray. The trial also requires patients to have an abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR), and to be positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibody. Women who are pregnant, breastfeeding, or planning to become pregnant during the study are excluded. The trial also has a list of exclusion criteria, including the use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6 weeks, steroid injection or intravenous (iv) infusion in the last 6 weeks, and use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks. Patients with a history of an inadequate response to a biologic disease-modifying anti-rheumatic drug (DMARD), serious reaction to other biological DMARDs, or use of DMARDS other than MTX, hydroxychloroquine, or sulfasalazine within the last 8 weeks are also excluded. The trial also excludes patients with active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA. Patients with cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years, and those who have received a live vaccine within the past 12 weeks are also excluded. Patients with hepatitis or human immunodeficiency virus (HIV), a serious bacterial infection, symptoms of herpes zoster or herpes simplex within the last month, active or latent tuberculosis (TB), current symptoms of a serious disorder or illness, use of an investigational drug within the last month, or history of the use of rituximab, any other B cell targeted biotherapy, or denosumab are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial includes patients with LDL-C levels above 100 mg/dL who are on a stable dose of atorvastatin 20 mg. The trial compares the effectiveness of four different drugs: atorvastatin, placebo, ezetimibe, and placebo. The eligibility criteria include being a non-pregnant and non-lactating woman who is not intending to become pregnant, having no sensitivity or intolerance to ezetimibe or atorvastatin, and not having diabetes or coronary heart disease.",
    "The sample is a phase 3 clinical trial for newly diagnosed stage IV squamous cell lung cancer. The trial includes patients with disseminated metastases and those with a malignant pleural or pericardial effusion. Patients who have received prior adjuvant therapy for early-stage lung cancer are eligible if at least 12 months have elapsed from that treatment. The trial requires patients to have histologically confirmed squamous cell bronchogenic carcinoma, with mixed non-small cell histologies being acceptable as long as squamous carcinoma is the predominant histology. Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the recurrence is outside the original radiation therapy port. The trial requires patients to have an ECOG Performance Status of 0 or 1 and laboratory values within certain ranges. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Patients must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. The trial excludes patients with prior treatment with gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib, past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences, a history of cardiac disease, active brain metastases, women who are pregnant or lactating, any serious, active infection (> Grade 2) at the time of treatment, a serious underlying medical condition that would impair the ability of the patient to receive protocol treatment, a major surgical procedure, or significant traumatic injury \u226428 days of beginning treatment, or anticipation of the need for major surgery during the course of the study, uncontrolled or intercurrent illness, history of any medical or psychiatric condition or laboratory abnormality that may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results, and known or suspected allergy/hypersensitivity to any agent given in the course of this trial.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the efficacy of four different drugs, including a placebo. The eligibility criteria include being an outpatient, being 40 years or older, having a clinical history of COPD, and having a pre and post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and a pre and post-albuterol/salbutamol FEV1 of \u226470% of predicted normal values. Exclusion criteria include pregnancy, asthma, other respiratory disorders, and significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or hematological abnormalities. The trial also excludes subjects with a history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, corticosteroid, lactose/milk protein or magnesium stearate, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that contraindicates study participation or use of an inhaled anticholingeric.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial is looking at the effectiveness of oxymorphone extended release as a treatment for moderate to severe chronic non-neuropathic low back pain. The trial is open to males and females who are 18 years or older and in good health. Participants must have been on a stable around-the-clock opioid pain medication for the management of moderate to severe chronic lower back pain for at least three months prior to screening. The trial has specific inclusion and exclusion criteria, including not being pregnant or lactating, not having certain medical conditions, and not having a history of substance abuse or alcohol abuse. Participants must also provide written informed consent.",
    "The sample is a phase 3 clinical trial for patients with end-stage, C-peptide-negative, Type 1-diabetic nephropathy. The trial involves a primary simultaneous pancreas/kidney (SPK) cadaveric transplant, with either intestinal or bladder and either portal or systemic venous drainages. The trial compares the effectiveness of sirolimus versus mycophenolate mofetil as treatments. The inclusion criteria for the trial include being a male or female patient between 18 and 55 years of age, having signed the Patient Informed Consent Form, and receiving the SPK transplant. The exclusion criteria include being pregnant or breastfeeding, having a positive T-cell crossmatch, having active liver disease, having a history of malignancy (with some exceptions), being included in another clinical trial protocol for any investigational drug within 4 weeks prior to randomisation, having any form of substance abuse or psychiatric disorder, receiving a SPK transplant from a living donor or receiving segmental pancreatic transplant or a previous kidney transplant alone, having pancreatic duct occlusion technique, and having a donor who is older than 55 years of age.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are current or ex-smokers with a smoking history of at least 10 pack-years and have a relatively stable airway obstruction with a post-bronchodilator FEV1 \u2264 70% of predicted normal and post-bronchodilator FEV1 / FVC \u226470%. The trial involves the use of tiotropium at different doses and patients must be able to inhale from the HandiHaler\u00ae and the Respimat\u00ae devices. The eligibility criteria include signing an informed consent, being 40 years of age or older, and meeting specific medical criteria. Exclusion criteria include significant diseases other than COPD, recent history of myocardial infarction, and known active tuberculosis, among others.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is related to upper respiratory tract infection. The icd-10 codes associated with the disease are listed. The drug being tested is azithromycin sr. The eligibility criteria for the trial are also listed, including the inclusion and exclusion criteria. In this case, patients with Laryngopharyngitis, Tonsillitis, or Acute Bacterial Rhinosinusitis are eligible for the trial, while patients with severe underlying diseases or confounding diseases are excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have inadequate glycemic control on metformin monotherapy or on metformin in combination with an SU at protocol-specified doses and having HbA1c >=7.0% and <=10.5% at Week -2. The trial excludes patients with a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy. Patients with repeated fasting plasma glucose (FPG) and/or fasting self-monitored blood glucose (SMBG) measurements >=270 mg/dL (15 mmol/L) during the pre-treatment phase, despite reinforcement of diet and exercise counseling, are also excluded. Additionally, patients with a history of a severe hypoglycemic episode within 6 months before screening or a history of or current illness considered to be clinically significant by the investigator are excluded. The trial includes a list of drugs, including placebo, canagliflozin 100mg, canagliflozin 300mg, metformin, and sulphonylurea, and a list of icd-10 codes of diseases.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis B. The trial is looking at the effectiveness of two drugs, tenofovir disoproxil fumarate (tdf) tablets and adefovir dipivoxil (adv) tablets, in treating HBeAg positive/negative CHB with blood HBVDNA\u226510^5 copies/mL and elevated ALT. The trial is only open to nucleoside and nucleotide na\u00efve CHB subjects, with previous lamivudine treatment allowed in less than 10% of the total study population. The inclusion criteria also specify that subjects must not have hepatocellular carcinoma (HCC) potential or decompensated liver disease, acute liver disease due to other causes, or a medication history of immunosuppressive therapy, immunomodulatory therapy, systemic cytotoxic agents, chronic antiviral agents including Chinese herbal medicines known to have activity against HBV (e.g., lamivudine, hepatitis B immunoglobulin (HBIg)) within the previous 6 months prior to randomisation into this study.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is testing the effectiveness of several drugs, including abacavir/lamivudine, atazanavir, efavirenz, emtricitabine/tenofovir disoproxil fumarate, ritonavir, and their respective placebos. The eligibility criteria for participants include being HIV-infected, antiretroviral naive, having a viral load greater than 1,000 copies/ml, and meeting certain laboratory values. Participants must also be willing to use acceptable forms of contraception and have a negative hepatitis B surface antigen. Exclusion criteria include having received certain types of therapy within 30 days prior to study entry, having known allergies/sensitivities to study drugs, and having active alcohol or drug use that would interfere with adherence to study requirements. Women who become pregnant during the study will be required to permanently discontinue their study regimens.",
    "The sample is a phase 3 clinical trial for contraception. The trial is looking for sexually active women who are at risk for pregnancy and not planning to use condoms. The women must be in need of contraception and willing to use an oral contraceptive for 12 months. They must be between 18 and 50 years old, have a body mass index between 17 and 35, and be in good physical and mental health. The trial has inclusion and exclusion criteria, including contraindications for contraceptive steroids and additional contraindications related to the antimineralocorticoid activity of drospirenone. Women with certain medical conditions, abnormal cervical smears, or abnormal laboratory results are excluded from the trial. Women who have used certain drugs or participated in another clinical trial within 2 months prior to the start of the trial medication or during the trial period are also excluded. There is an endometrial biopsy substudy for some of the participants.",
    "The sample is a clinical trial in phase 3 for the treatment of prostatic hyperplasia using the drug alfuzosin. The trial includes Japanese patients who have been diagnosed with symptomatic BPH within the last 6 months and have been suffering from lower urinary tract symptoms related to BPH for at least 6 months. The trial has certain inclusion and exclusion criteria, such as patients with mental disorders or who cannot comply with the treatment regiment are excluded. The investigator will also evaluate other reasons why a patient may not participate. The diseases are listed as a single disease name, while the icd-10 codes are listed as a list of codes. The eligibility criteria are also listed as inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients with a confirmed diagnosis of schizophrenia and a history of antipsychotic treatment. The trial involves the drugs ly2140023 and placebo. The eligibility criteria include being moderately ill, willing to participate in a minimum of 2 weeks of inpatient hospitalization, and having experienced an exacerbation of illness within the 2 weeks prior to entering the study. Exclusion criteria include a history of inadequate clinical response to antipsychotic treatment, substance dependence or abuse, and participation in any clinical trial involving an investigational product or unapproved use of a drug or device within 6 months prior to study entry.",
    "The sample is a phase 3 clinical trial for chemotherapy-induced nausea and vomiting. The trial is for patients who are receiving their first course of cytotoxic chemotherapy with cisplatin, either alone or in combination with other chemotherapeutic agents. The trial includes patients with a malignant solid tumor and who are naive to cytotoxic chemotherapy. The trial also includes patients with an ECOG Performance Status of 0, 1, or 2, and who have adequate hematologic and metabolic status based on laboratory criteria. The trial excludes patients who are pregnant or lactating, have a history of alcohol abuse or current use of illicit drugs, have received or are scheduled to receive radiation therapy to the abdomen or pelvis within 1 week prior to Day 1 or between Days 1 to 5, have any vomiting, retching, or mild nausea within 24 hours prior to Day 1, have symptomatic primary or metastatic CNS malignancy, have active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection, or any uncontrolled medical conditions (other than malignancy) that may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks in administering the study drugs to the patient. The trial also excludes patients who have known hypersensitivity or contraindication to 5-HT3 receptor antagonists or dexamethasone, are participating in a clinical trial involving palonosetron, have taken any investigational drugs (other than those given in this study) within 4 weeks prior to Day 1, and/or are scheduled to receive any investigational drug during the study. The trial also excludes patients who are scheduled to receive bone marrow transplantation and/or stem cell rescue therapy, and any medication with known or potential antiemetic activity within 24 hours prior to Day 1.",
    "The sample is a phase 3 clinical trial for ovarian cancer, fallopian tube cancer, and peritoneal neoplasms. The trial involves the drugs epo906 (patupilone) and doxorubicin. The eligibility criteria for the trial include being 18 years or older, having a confirmed diagnosis of one of the specified cancers, having no more than three previous chemotherapy regimens, and having the most recent regimen be platinum-based. Exclusion criteria include having an unresolved bowel obstruction, having had previous chemotherapy within 3 weeks, and recovering from any surgery for any cause. Other protocol-defined inclusion/exclusion criteria will also apply. The table also includes lists of disease names, ICD-10 codes, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for patients with fever, neutropenia, and cancer. The trial involves the use of ciprofloxacin and amoxicillin, as well as i.v. antibiotics. The eligibility criteria include severe neutropenia, fever, and the ability to swallow oral medication. Patients must also provide written informed consent. Exclusion criteria include certain diagnoses, comorbidities requiring hospitalization, and allergies to the drugs being used. The trial also excludes patients who have received certain treatments or therapies.",
    "The sample is a record of a clinical trial in phase 3 for Alzheimer's disease. The trial involves testing the effectiveness of three drugs - bapineuzumab 0.5 mg/kg, placebo control, and bapineuzumab 1.0 m/kg. The eligibility criteria for the trial include a diagnosis of probable AD, age between 50 and 89, a Mini-Mental Status Exam score of 16-26, and a brain MRI scan consistent with the diagnosis of AD. The patient must also have stable doses of medications, and the caregiver must be able to attend all clinic visits. The exclusion criteria include significant neurological disease other than AD, major psychiatric disorder, significant systemic illness, history of stroke or seizure, smoking more than 20 cigarettes per day, and use of certain medications. Women of childbearing potential and those with pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body are also excluded.",
    "The sample is a phase 3 clinical trial for kidney transplantation. The trial is looking at the effectiveness of the drugs tacrolimus, mycophenolate mofetil, daclizumab, and steroids. The eligibility criteria for the trial include being a male or female patient younger than 18 but not younger than 2 years of age, having end stage kidney disease, and having a negative serum pregnancy test for female patients of childbearing potential. Exclusion criteria include having a most recently measured panel reactive antibody (PRA) grade of > or = 50%, being allergic to or intolerant of study medication, and having significant liver disease. The trial is not open to patients who have previously received or are receiving an organ transplant other than kidney, have been previously enrolled in this study, or have the relapsing and non-diarrhoeal form of haemolytic uraemic syndrome.",
    "The sample is a phase 3 clinical trial for patients with nerve pain after spinal cord injury. The trial is testing the effectiveness of the drugs placebo and pregabalin. The eligibility criteria for the trial includes having chronic pain for at least 3 months or intermittent pain for at least 6 months, with a pain score of at least 4 in 4 of the 7 days prior to treatment. Exclusion criteria includes recent use or intolerance to pregabalin, low creatinine clearance, low white blood cell count, drug or alcohol abuse, unstable medical conditions, abnormal electrocardiogram, and severe pain associated with conditions other than spinal cord injury. The diseases being studied are neuralgia and spinal cord injuries, with corresponding ICD-10 codes provided.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves two drugs, bimatoprost 0.03% formulation b ophthalmic solution and bimatoprost 0.03% ophthalmic solution. The eligibility criteria for the trial include having ocular hypertension or glaucoma in both eyes and requiring IOP-lowering therapy in each eye. Exclusion criteria include having active or recurrent eye disease, history of eye surgery or laser within 6 months, chronic use of other eye medications during the study, anticipated wearing of contact lenses during the study, and intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days. The diseases are represented as a list of disease names and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes and diabetic nephropathy. The trial involves the use of olmesartan medoxomil and placebo tablets. The eligibility criteria include a clinical diagnosis of diabetic nephropathy, a certain level of albumin-to-creatinine ratio in the first morning urinalysis, and a specific range of serum creatinine levels. Exclusion criteria include type 1 diabetes, non-diabetic nephropathy, and a history of certain medical procedures or conditions. The diseases involved in the trial are diabetic nephropathy, type 2 diabetes mellitus, and proteinuria, and their corresponding ICD-10 codes are listed.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial is testing the effectiveness of creatine as a treatment for PD. The eligibility criteria include being willing to give informed consent and commit to long-term follow-up, having been diagnosed with PD within the past 5 years, and having been treated with dopaminergic therapy for at least 90 days but not more than 2 years. The exclusion criteria include having used creatine within 14 days prior to baseline or during the study, having a known hypersensitivity or intolerability to creatine, having any unstable or clinically significant condition that would impair the subject's ability to comply with long-term study follow-up, and having any other known or suspected causes of parkinsonism or any significant features suggestive of a diagnosis of atypical parkinsonism.",
    "The sample is a phase 3 clinical trial for individuals with metabolic syndrome and type 2 diabetes. The trial is testing the effectiveness of the drug topiramate. The eligibility criteria include a diagnosis of metabolic syndrome, a BMI of 30 or higher, and meeting at least three of five specific criteria related to triglycerides, cholesterol, blood pressure, waist circumference, and blood glucose levels. Participants must also be able to give informed consent, have well-controlled diabetes and hypertension, and be willing to take oral medication. Exclusion criteria include renal insufficiency, taking medication with known serious interactions with topiramate, and a history of certain medical conditions. Family members of employees or investigators and employees of the investigator or study center may participate but may not serve any staff role for themselves.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of hypercholesterolemia. The trial involves the use of two drugs, rosuvastatin and atorvastatin. The eligibility criteria for the trial include having been diagnosed with hypercholesterolemia or being at high risk for it, having specific levels of LDL-C and fasting triglycerides, and not having a history of statin-induced myopathy or certain cardiovascular diseases. The exclusion criteria include having familial dysbetalipoproteinemia or unstable/uncontrolled cardiovascular diseases. The sample also includes the icd-10 codes associated with hypercholesterolemia.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of diabetic retinopathy. The trial involves the use of two drugs, ruboxistaurin and placebo. The eligibility criteria for the trial include having type 1 or type 2 diabetes mellitus, being 18 years or older, meeting specific requirements for diabetic retinopathy, and having a hemoglobin A1c (HbA1C) level of \u226413.0%. Exclusion criteria include a history of panretinal photocoagulation for diabetic retinopathy, presence of eye disorders that may affect the progression of diabetic retinopathy or cause vision loss, and presence of medical disorders or cancer that could represent a safety risk during the study. Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually active without using an acceptable method of birth control are also excluded from the trial. The diseases and icd-10 codes associated with the trial are also listed.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C genotype 1. The trial involves the use of drugs such as boceprevir, placebo, and ribavirin. The eligibility criteria for the trial include having a body weight between 40 kg and 125 kg, a previous diagnosis of CHC genotype 1 infection, and a liver biopsy with histology consistent with CHC and no other etiology. Participants must also agree to use acceptable methods of contraception with their partner. Exclusion criteria include co-infection with HIV or hepatitis B virus, previous discontinuation of interferon or ribavirin regimen due to adverse events, and treatment with any investigational drug within 30 days of the screening visit in this trial. Participants with decompensated liver disease, clinically significant ocular examination findings, clinical diagnosis of substance abuse, or any known pre-existing medical condition that could interfere with their participation in and completion of the trial are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of metastatic colorectal cancer. The trial involves the use of two drugs, panitumumab and folfox regimen. The eligibility criteria include being at least 18 years old, having a diagnosis of metastatic colorectal cancer, having at least one measurable lesion of at least 20 mm per modified RECIST, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. The trial excludes individuals with a history or known presence of central nervous system (CNS) metastases, prior chemotherapy or systemic therapy for the treatment of metastatic colorectal carcinoma, prior oxaliplatin therapy, and prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors. Additionally, individuals with clinically significant cardiovascular disease, interstitial lung disease, active inflammatory bowel disease, or peripheral sensory neuropathy with functional impairment are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for postmenopausal osteoporosis. The trial is looking at the effectiveness of the drug odanacatib compared to a placebo. The trial is open to postmenopausal women who are at least 65 years old and have low bone mineral density. Participants must be able to walk and cannot be currently taking osteoporosis therapy or have a metabolic bone disorder other than osteoporosis. Additionally, participants cannot have had a hip fracture and cannot be currently participating in another drug study. The eligibility criteria for the trial are listed in the \"criteria\" column.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of type 1 diabetes using insulin glulisine. The trial has specific eligibility criteria, including a range for HbA1c levels and a maximum BMI. The trial excludes patients with type 2 diabetes. The record also includes the icd-10 codes for the disease and a list of the disease names.",
    "The sample is a phase 3 clinical trial for advanced Parkinson's disease. The trial is looking at the effectiveness of levodopa-carbidopa intestinal gel for patients with severe motor fluctuations. The inclusion criteria require patients to have idiopathic Parkinson's disease according to UKPDS Brain Bank Criteria, be levodopa-responsive, and have recognizable off and on states confirmed by diary. The exclusion criteria include unclear diagnosis or suspicion of other parkinsonian syndromes, previous surgery for PD treatment, and contraindications to levodopa such as narrow angle glaucoma. The diseases column lists only \"advanced Parkinson's disease\" and the icdcodes column lists the corresponding ICD-10 code \"G20\".",
    "The sample is a phase 3 clinical trial for breast cancer patients with locally advanced or metastatic stage of the disease that is not suitable for surgery or radiotherapy alone. The trial involves the use of the drugs capecitabine and trastuzumab. The eligibility criteria include having a confirmed diagnosis of breast cancer, HER2-overexpression of the primary or metastatic tumor tissue, and disease progression during or after previous chemotherapy and trastuzumab treatment. Patients must also meet certain medical criteria, such as having a Karnofsky performance status evaluation of at least 60% and a left ventricular ejection fraction of at least 50%. Exclusion criteria include known hypersensitivity reaction to the compounds or incorporated substances, concurrent immunotherapy or hormonal therapy, and history of congestive heart failure or other significant uncontrolled cardiac disease.",
    "The sample is a phase 3 clinical trial for the treatment of Major Depressive Disorder (MDD) using extended-release bupropion hydrochloride. The trial includes patients with a primary diagnosis of MDD lasting between 12 weeks and 2 years, who engage in sexual activity leading to orgasm at least once every two weeks, and have normal orgasmic function. The trial excludes patients with arousal or orgasm dysfunction, those who have previously failed to respond to two adequate trials of antidepressants in the past 2 years, those with other unstable medical disorders, and those with a positive urine test for illicit drug use at screening. The sample also includes a list of icd-10 codes associated with MDD.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on treating major depressive disorder in patients who are at least 60 years old. The trial is testing the effectiveness of the drug paroxetine cr. The table also includes a list of diseases and their corresponding icd-10 codes, as well as eligibility criteria for the trial. The inclusion criteria include a diagnosis of major depressive disorder and a current major depressive episode lasting at least 2 months. The exclusion criteria include patients with a primary diagnosis other than MDD, a history of schizophrenia, bipolar disorder, or dementia, and patients who have received certain types of therapy or have a history of seizure disorders.",
    "The sample is a phase 3 clinical trial for individuals with impaired glucose tolerance and type 2 diabetes. The trial involves the use of the drugs pioglitazone and placebo. The eligibility criteria for the trial include being 18 years or older, having impaired glucose tolerance, and meeting at least one of several additional criteria such as having a family history of type 2 diabetes or being of a minority ethnic background. Exclusion criteria include having type 2 diabetes, previously being treated with certain medications, and having certain medical conditions such as cardiovascular disease or renal disease. The trial aims to evaluate the effectiveness of pioglitazone in treating impaired glucose tolerance and type 2 diabetes.",
    "The sample is a phase 3 clinical trial for the treatment of myelodysplastic syndromes. The trial is testing the effectiveness of lenalidomide 5 mg, lenalidomide 10 mg, and placebo drugs. The eligibility criteria for the trial include being 18 years or older, having a documented diagnosis of MDS that meets certain criteria, being RBC transfusion dependent, and being able to adhere to the study visit schedule and other protocol requirements. Exclusion criteria include being pregnant or lactating, having prior therapy with lenalidomide, and having certain medical conditions or illnesses that would prevent the subject from participating in the study.",
    "The sample is a phase 3 clinical trial for acute otitis media. The trial involves testing the effectiveness of xylitol syrup and placebo as treatments. The eligibility criteria for participants include being between six months and five years old, having a history of at least three episodes of AOM in the previous 12 months, and being English or Spanish speaking. Exclusion criteria include having a history of tympanostomy tubes, intestinal malabsorption or chronic diarrhea, diabetes mellitus, any inborn error of metabolism, and known allergies to any of the study solution components.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis and exocrine pancreatic insufficiency. The trial involves the use of the drugs liprotamase and placebo. The eligibility criteria for the trial include a diagnosis of CF based on specific criteria, clinical stability, and the ability to take pancreatic enzyme supplementation. Inclusion criteria also require females of childbearing potential to use birth control. Exclusion criteria include pregnancy, breastfeeding, and certain medical conditions that may interfere with the study. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying hypertension. The icd-10 codes associated with hypertension are listed. The drugs being tested are valsartan and lisinopril. The eligibility criteria for participants include having mild to moderate hypertension, a positive urine spot test for albumin concentration, and confirmation of microalbuminuria. There are also exclusion criteria, such as evidence of renal impairment and serum potassium values outside of a certain range.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who are at least 12 years old and have been diagnosed with asthma at least 12 weeks prior to the first visit. The trial requires patients to have a pre-bronchodilator FEV1 of at least 60% predicted and FEV1 reversibility of at least 12% and 200ml. Patients must also be currently receiving asthma therapy that includes a non-corticosteroid controller and/or short-acting beta-agonist. The trial has various exclusion criteria, including a history of life-threatening asthma exacerbation within the past 10 years, current or recent respiratory infection, and known or suspected allergy to study medication or materials. The trial will test the efficacy of fluticasone furoate 50mcg, fluticasone propionate 100mcg, and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer using the drugs docetaxel and prednisone. The eligibility criteria include having confirmed adenocarcinoma of the prostate that has metastasized, hormone-refractory disease, and a PSA level above 10 \u00b5g/L that is rising between two sequential measurements. Patients must also have a performance status of WHO 0-2, a life expectancy that is not specified, and meet certain hematopoietic, hepatic, renal, cardiovascular, pulmonary, and immunologic criteria. Prior concurrent therapy is also listed, including restrictions on prior radiotherapy and surgery, and allowances for certain biologic, endocrine, and radiotherapy treatments.",
    "The sample is a phase 3 clinical trial for patients who have undergone kidney transplantation and are at risk of graft rejection or kidney failure. The trial involves the use of either cyclosporin or tacrolimus as a treatment option. The eligibility criteria for the trial include being over 18 years of age, having mild to moderate renal insufficiency, and currently being treated with a calcineurin inhibitor. Patients who have experienced acute rejection or received a transplant more than 10 years ago are excluded from the trial. The diseases involved in the trial include graft rejection, kidney failure, and various conditions related to kidney transplantation, which are identified by their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for patients with major depressive disorder. The trial is testing the effectiveness of duloxetine compared to a placebo. The trial has specific inclusion and exclusion criteria, including a minimum score on the Montgomery-Asberg Depression Rating Scale, a history of depression, and the absence of certain medical conditions or medication use. Patients must also be willing and able to comply with the study protocol. The trial will exclude patients who have previously been treated with duloxetine or have participated in another clinical trial within 30 days prior to screening. The trial will also exclude patients who are pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial involves the drugs erlotinib and placebo. The eligibility criteria include having a confirmed diagnosis of Stage IB-IIIA NSCLC, being able to start the drug within a certain timeline after surgery, and having primary tissue that is EGFR-positive. Exclusion criteria include a history of prior radiotherapy for NSCLC, poorly controlled gastrointestinal disorders, and tumors with mixed histology of NSCLC and SCLC. Patients who have had other cancer are eligible if they have remained disease-free for at least 5 years.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes patients between the ages of 18 and 70 who have been diagnosed with MDD according to DSM-IV-TR criteria and have a current Major Depressive Episode of less than two year's duration with a minimum duration of at least 4 weeks. The trial involves the use of the drug vilazodone and a placebo. Patients must meet certain inclusion criteria, such as having a HAM-D score \u2265 22 on the first 17 items of the 21-item HAM-D and being able to provide written informed consent. Patients must also meet certain exclusion criteria, such as having a current or recent history of certain disorders or being noncompliant with the visit schedule or study procedures. Female patients must not be pregnant, lactating, or planning to become pregnant during the time of study participation.",
    "The sample is a phase 3 clinical trial for the treatment of ankylosing spondylitis, a type of inflammatory arthritis that affects the spine. The trial involves the drugs tocilizumab and placebo, and the eligibility criteria include being an adult patient over 18 years old with active disease and inadequate response to previous non-steroidal anti-inflammatory drugs (NSAIDs) or tumor necrosis factor (TNF) antagonist therapy. The trial also has exclusion criteria, such as a history of severe allergic reactions to monoclonal antibodies or a body weight over 150 kg. The trial requires patients to meet certain inclusion criteria and not meet any of the exclusion criteria to participate.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have undergone surgery to remove the tumor. The trial is looking for patients who have hormone receptor-negative disease and are not candidates for endocrine therapy or standard chemotherapy. The trial is also looking for postmenopausal female patients with an ECOG performance status of 0-2 and specific blood counts and organ function. Patients must not have any other nonmalignant, uncontrolled systemic diseases, psychiatric illness, or addictive or cognitive disorder that would preclude study participation or compliance. The trial excludes patients with certain medical conditions, recent falls, spontaneous bone fractures, neglect, or abuse. The trial also excludes patients who have received certain prior therapies or concurrent therapies. The trial allows concurrent trastuzumab (Herceptin\u00ae) and bisphosphonates for the treatment of osteoporosis. The trial requires patients to meet specific criteria for cumulative doses of prior anthracyclines if they have received them.",
    "The sample is for a phase 3 clinical trial for the treatment of pulmonary hypertension using sildenafil citrate. The trial includes patients who have completed a 12-week pivotal study for PAH and excludes any other patients with PAH who were not included in the pivotal study. The diseases are listed as 'pulmonary hypertension' and the icd-10 codes associated with it are also provided. The eligibility criteria are listed under inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial is looking at the effectiveness of three drugs: placebo, czp, and methotrexate (mtx). The eligibility criteria for the trial includes subjects who have developed RA within one year after onset, have never received MTX before, have moderate or higher disease activity, and satisfy at least two of the three criteria for poor prognostic factors. The exclusion criteria includes patients with other types of inflammatory arthritis, secondary non-inflammatory arthritis, NYHA Class III or IV congestive heart failure, current or history of tuberculosis, high risk of infection, current or history of malignant tumor, and female patients who are breastfeeding or pregnant or of childbearing potential.",
    "The sample is a phase 3 clinical trial for patients with muscle wasting and non-small cell lung cancer. The trial involves the drugs gtx-024 and placebo. The eligibility criteria include being non-obese, having been diagnosed with stage III or IV NSCLC, and having a life expectancy of more than 6 months. Other criteria include having a serum creatinine level of less than or equal to 2.0 mg/dL, an ECOG score of less than or equal to 1, and a baseline stair climb time of less than 30 seconds. Exclusion criteria include having a clinically significant concurrent illness, uncontrolled hypertension, congestive heart failure or angina, and active cancer other than NSCLC or non-melanoma carcinoma of the skin within the previous two years.",
    "This sample is for a phase 3 clinical trial for the treatment of newly diagnosed chronic myelogenous leukemia in chronic phase. The trial is looking for patients who are positive for the Philadelphia chromosome and/or BCR/ABL, and who have not shown any signs of acceleration or blastic disease. The trial is testing a combination of drugs including busulfan, cytarabine, etoposide, hydroxyurea, and idarubicin. Patients must be between the ages of 15 and 65, have no major organ impairment, and must not be pregnant. Fertile patients must use effective contraception. Prior interferon alfa is not allowed, but prior hydroxyurea is allowed.",
    "The sample is a phase 3 clinical trial for patients with asthma and lung diseases. The trial is testing the effectiveness of GERD treatment for these patients. The trial includes patients who are 18 years or older, have physician-diagnosed asthma, and are currently on a stable dose of daily inhaled steroids for asthma control. Patients must also have poor asthma control, as indicated by a score of 1.5 or greater on the Juniper Asthma Control Questionnaire or two or more episodes of asthma symptoms in the past 12 months requiring medical attention. Patients must not have had previous anti-reflux or peptic ulcer surgery, severe reflux, or other major chronic illnesses. They must also not be taking certain medications or have certain allergies. Females of childbearing potential must be willing to practice an adequate birth control method. Patients must be able to provide consent and perform baseline measurements. They must also complete at least 10 of the last 14 days of the screening period diary entry and not have an intention to move out of the area within 6 months.",
    "The sample is a phase 3 trial for the treatment of partial onset seizures in pediatric patients with 1 to 2 anti-epileptic drugs. The trial is focused on the drug levetiracetam (lev). The eligibility criteria include previous participation in levetiracetam pediatric studies or direct enrollment, and exclusion criteria include patients on a ketogenic diet, seizures too close together to accurately count, pseudoseizures, status epilepticus 1 month prior to Visit 1, and current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease. The diseases being studied in this sample are limited to epilepsy, partial, and the icd-10 codes associated with these diseases are provided.",
    "The sample is a phase 3 clinical trial for patients with hypertension and dyslipidemias. The trial is testing the effectiveness of the drugs telmisartan and simvastatin in reducing blood pressure and cholesterol levels. The eligibility criteria include being 18 years or older, having hypertension with a mean seated cuff DBP of 95-109 mmHg, and hypercholesterolemia with a fasting LDL-C level of 100-250 mg/dL for groups I and II, and 100-160 mg/dL for group III. Patients must also meet certain CV risk factors and have no exclusion criteria, such as being pregnant or having a history of drug or alcohol dependency. The trial aims to determine the safety and efficacy of the drugs in reducing cardiovascular risk in patients with hypertension and dyslipidemias.",
    "The sample is a phase 3 clinical trial for the treatment of plaque psoriasis. The trial is testing a drug called placebo. The eligibility criteria for the trial include being at least 18 years old, having a clinical diagnosis of psoriasis for at least 6 months, and having moderate to severe plaque psoriasis. Exclusion criteria include previous exposure to systemic anti-IL 12 therapy, inability to discontinue systemic or topical therapies for psoriasis, taking or requiring oral or injectable corticosteroids, and being diagnosed with certain types of psoriasis. Female subjects who are pregnant or breastfeeding or considering becoming pregnant are also excluded. The trial is being conducted under the supervision of a principal investigator.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the use of two drugs, brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and brinzolamide ophthalmic suspension, 1%, and brimonidine tartrate ophthalmic solution, 0.2%. The eligibility criteria for the trial include a diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular pressure within protocol-specified range at eligibility visit/s. There are also several exclusion criteria, including severe central vision loss, chronic, recurrent, or severe inflammatory eye disease, ocular trauma or infection within the preceding months, and other ocular pathology that may preclude the administration of study product. The trial requires the subjects to sign an informed consent document and other protocol-specified inclusion criteria may apply.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of hepatitis C virus infection using drugs such as daclatasvir, asunaprevir, ribavirin, and telaprevir. The trial includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial are also listed, including age requirements, HCV RNA levels, and previous exposure to interferon-based therapy. The exclusion criteria are also listed, which include the presence of hepatocellular carcinoma, co-infection with HBV or HIV, and severe or uncontrollable complications.",
    "The sample is a phase 3 clinical trial for the treatment of stage IV breast cancer in patients with HER2 overexpression. The trial involves the use of trastuzumab, vinorelbine, paclitaxel, and docetaxel. The eligibility criteria include having measurable disease, being 18 years or older, having a life expectancy of greater than 6 months, and meeting certain health requirements such as having a certain ANC count and platelet count. The exclusion criteria include having prior chemotherapy or trastuzumab therapy for metastatic breast cancer, being pregnant or lactating, having known brain metastases or leptomeningeal carcinomatosis, and having certain pre-existing conditions.",
    "The sample is a phase 3 clinical trial that involves testing the effectiveness of a gel called \"pro 2000/5\" versus a placebo in preventing the transmission of HIV, gonorrhea, chlamydial infections, and genital herpes. The trial is conducted in multiple locations and involves women aged 16 or 18 years and above, who are likely to be sexually active and willing to undergo regular HIV testing and use the study gel as instructed. The eligibility criteria include being HIV negative at screening, willing to receive the HIV result before randomization, and willing to undergo regular speculum examinations and genital infection screens. The exclusion criteria include being pregnant or within 6 weeks postpartum at enrollment, having Grade 3 clinical or laboratory abnormalities, and participating in a clinical trial of an unlicensed product or any other intervention likely to impact the outcome of this trial.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of irritable bowel syndrome. The icd-10 codes associated with the disease are listed as well. The drug being tested is called renzapride. The eligibility criteria for the trial are also listed, including inclusion criteria such as having constipation predominant IBS and exclusion criteria such as having diarrhea predominant or alternating symptom IBS or other gastrointestinal diseases that affect bowel transit.",
    "The sample is a phase 3 clinical trial for dry eye disease. The trial includes male and female adults aged 18 years and over who have a documented history of dry eye syndrome, keratoconjunctivitis sicca (KCS), or Sj\u00f6gren syndrome. Participants must agree to discontinue all artificial tears and not wear contact lenses during the study. The trial will test the effectiveness of sodium hyaluronate and a vehicle as treatments for dry eye disease. The eligibility criteria include signed informed consent and exclusion criteria include pregnancy or lactation, ocular surgery or trauma within the past 4 months, and any active inflammation of the eye not due to KCS. Participants must not have participated in a previous clinical trial of Vismed\u00ae and must not have participated in any other clinical trial within 30 days prior to screening.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of drugs for sleep initiation and maintenance disorders. The diseases being studied are nonorganic insomnia associated with schizophrenia and manic-depressive psychosis. The icd-10 codes associated with these diseases are \"Y93.E9\" and \"Y93.H9\". The drugs being tested are zolpidem mr, nitrazepam, and placebo. The eligibility criteria for the trial include patients who have nonorganic insomnia associated with schizophrenia and manic-depressive psychosis, while the exclusion criteria include patients who have allergic reactions to zolpidem or nitrazepam, serious cardiac disorders, serious hepatic impairment, or serious renal diseases.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on the treatment of multiple myeloma. The trial involves the drug Velcade and includes a list of eligibility criteria for participants, such as being under 65 years of age, having a measurable monoclonal spike, and not having certain medical conditions. The record also includes a list of exclusion criteria, such as having a history of cancer other than basal cell carcinoma or cervical cancer in situ, or having clinical signs of heart failure or coronary heart disease.",
    "The sample is a phase 3 clinical trial for HIV infections and hepatitis C. The trial involves the use of drugs such as lpv/r, nucleoside reverse transcriptase inhibitors, peg-ifna 2a, and ribavirin. The eligibility criteria for the trial include being over 18 years old, having serologic evidence of HIV and HCV infection, being naive for HIV and HCV therapy, having active chronic hepatitis or compensated cirrhosis, having a CD4+ count between 200 and 500 cell/mm3, having no mutations associated with resistance to antiretroviral drugs, and using effective contraceptive methods. Exclusion criteria include having HbsAg positive, having cirrhosis score Child-Pugh B/C, having HIV-related thrombocytopenia, having neutrophils count below 1500/mmc, having Hb value below 9 g/dL at screening and below 11 g/dL at randomization, having creatinine value above 1.5 mg/dL, being on a HAART regimen included ddI and/or AZT, being pregnant or wishing to become so, having any cause of liver disease other than chronic hepatitis C, being an alcohol abuser, having prior treatment with PEG-IFN/ribavirin, having illicit drugs abuse, having active heart disease, and having pre-existing severe depression or severe psychiatric disorders.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on osteoarthritis of the knee. The icd-10 codes associated with this disease are listed, as well as the drug being tested (gw406381). The eligibility criteria for participants are also provided, including inclusion criteria such as having a primary diagnosis of osteoarthritis of the knee with symptom duration of at least 3 months and using pain medication at least 5 days per week, and exclusion criteria such as a history of hypersensitivity or intolerance to pain medications, history of gastroduodenal perforations and/or obstructions, and history of uncontrolled hypertension.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C infection. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs, and eligibility criteria for participants. The inclusion criteria include being a female practicing specific forms of birth control, having chronic hepatitis C genotype 1b-infection with an HCV RNA level greater than or equal to 10,000 IU/mL at screening, never having received antiviral treatment for hepatitis C infection, and having no evidence of liver cirrhosis. The exclusion criteria include having significant liver disease with any cause other than HCV as the primary cause, testing positive for hepatitis B surface antigen or anti-human immunodeficiency virus antibody, testing positive for drugs or alcohol, having significant sensitivity to any drug, using contraindicated medications within 2 weeks of dosing, and having abnormal laboratory tests.",
    "The sample is a phase 3 clinical trial for asthma, with the drug being tested being gw685698/gw642444 (fluticasone furoate/vilanterol trifenatate) compared to a placebo. The trial is for outpatients of Asian ancestry who are 12 years of age or older (or 18 years or older if local regulations or the regulatory status of study medication permit enrolment of adults only) and have been diagnosed with asthma as defined by the Global Initiative for Asthma at least 12 weeks prior to Visit 1. The trial has inclusion and exclusion criteria, including informed consent, a best FEV1 of 40%-90% of the predicted normal value at the Screening visit, and demonstrated \u226512% and \u2265200mL reversibility of FEV1 within 10-40minutes following 2-4 inhalations of albuterol/salbutamol inhalation aerosol (or one nebulised treatment with albuterol/salbutamol solution) at the Screening Visit. The trial also has exclusion criteria, including a history of life-threatening asthma, respiratory infection, asthma exacerbation requiring oral corticosteroids within 12 weeks of Visit 1, and other concurrent diseases/abnormalities that would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.",
    "This is a sample from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on contraception. The icd-10 codes associated with the disease are Z92.0, Z30.012, and Z30.09. The drugs being tested are nomac-e2 and levonorgestrel and ethinyl estradiol. The eligibility criteria for participants include being a sexually active woman at risk for pregnancy, being willing to use an oral contraceptive for 6 months, being between the ages of 18 and 50, having a body mass index between 17 and 29 kg/m^2, being in good physical and mental health, and being willing to give informed consent in writing. There are also exclusion criteria, such as not being able to use hormonal treatments, having a history of alcohol or drug abuse, and having abnormal laboratory results or cervical smears.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with rheumatoid arthritis within the last 2 years and have not been treated with methotrexate or have taken a maximum of 10mg per week for up to 3 weeks. Patients must have a C-Reactive Protein (CRP) level of at least 4.5 mg/L and test positive for rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP). Patients must also have at least 12 tender joints and 10 swollen joints. Exclusion criteria include patients who are not willing to use birth control, have been diagnosed with another rheumatic disease, have a history of cancer within the last 5 years, have active tuberculosis, are currently being treated with another investigation drug within the last 28 days, or have an active bacterial or viral infection. The trial will test the effectiveness of abatacept and methotrexate compared to a placebo.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial requires patients to have histologically confirmed colorectal carcinoma, either stage II or III, and to have received potentially curative therapy within the past 12 weeks. Patients must also meet certain eligibility criteria, including being 18 years or older, having a WHO performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients must not be pregnant or nursing, must use effective contraception if fertile, and must not have certain medical conditions or sensitivities. The trial involves the drug rofecoxib and has specific prior concurrent therapy requirements.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, macular edema and retinal vein occlusion, and includes a list of corresponding ICD-10 codes. The trial involves two drugs, both of which contain dexamethasone in different dosages. The eligibility criteria for the trial include being 18 years or older with macular edema resulting from retinal vein occlusion, a decrease in visual acuity in at least one eye, and having visual acuity in the other eye no worse than 20/200. The exclusion criteria include a known anticipated need for ocular surgery within the next 12 months, a history of glaucoma or current high eye pressure requiring more than one medication, diabetic retinopathy, uncontrolled systemic disease, being a known steroid-responder, and the use of systemic steroids or warfarin/heparin.",
    "The sample is a phase 3 clinical trial for patients who have suffered from ischemic stroke and have not been treated with statins for the past 3 months. The trial is testing the effectiveness of the drug rosuvastatin in reducing the risk of stroke recurrence. The eligibility criteria include being over 20 years of age, having undergone an MRI within 48 hours of symptom onset, and having any degree of stenosis on the relevant artery of atherothrombotic origin appearing on DWI through MRA or CTA. Exclusion criteria include a history of hemorrhagic stroke, presence of high-risk potential cardiac sources of embolism, and known major hematologic, neoplastic, metabolic, gastrointestinal or endocrine dysfunction. The sample also includes a list of prohibited medications and medical conditions that would make a patient ineligible for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy with the drug lacosamide. The trial is looking for male or female participants who are at least 18 years old and have a diagnosis of epilepsy with partial-onset seizures. Participants must be taking levetiracetam in combination with one sodium channel blocking antiepileptic drug as adjunctive treatment for epilepsy. The trial requires a minimum seizure frequency during the 8-week retrospective seizure baseline and at least one seizure during the 4-week prospective seizure baseline. Participants must have been maintained on a stable dose of levetiracetam and a sodium channel blocking antiepileptic drug for at least 4 weeks prior to the screening visit. The trial has exclusion criteria, including previous use of lacosamide, history of alcohol or drug abuse, and history of any medical or psychiatric condition that could jeopardize the subject's health or compromise their ability to participate in the study.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on type 1 diabetes and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, diapep277 and placebo. The eligibility criteria for the trial include a diagnosis of type 1 diabetes for up to 3 months, insulin dependency, fasting C-peptide levels of at least 0.22 nmol/L, and the presence of at least one diabetes-related autoantibody. The exclusion criteria include pregnancy or intent to conceive in the next 2 years, significant diseases that could affect response to treatment, immune deficiency, or the use of immuno-suppressive or cytotoxic drugs.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of bipolar disorder using the drug risperidone. The trial is open to individuals between the ages of 10 and 17 who have a primary diagnosis of bipolar I disorder, mania or mixed type, and have a Young Mania Rating Scale score greater than or equal to 20 at screening and baseline. The record includes a list of icd-10 codes associated with the disease, as well as eligibility criteria for inclusion and exclusion from the trial. Exclusion criteria include a history of substance dependence, significant risk for suicidal or violent behavior, recent electroconvulsive treatment or depot antipsychotic use, inability to swallow medication in tablet form, positive urine drug screen, known or suspected seizure disorder, and history of hypersensitivity or intolerance to risperidone.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia and dyslipidemia. The trial involves the use of two drugs, pitavastatin and simvastatin. The eligibility criteria for the trial include being between 18-75 years old, having at least two cardiovascular disease risk factors, following a restrictive diet, and having a diagnosis of primary hypercholesterolemia or combined dyslipidemia. The exclusion criteria include having homozygous familial hypercholesterolemia, conditions that may cause secondary dyslipidemia, uncontrolled diabetes mellitus, abnormal pancreatic, liver or renal function, and abnormal serum creatine kinase (CK) above the pre-specified level.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, osteoarthritis of the knee and pain. The icd-10 codes associated with these diseases are also listed. The trial involves three drugs, oxycodone, placebo, and tapentadol (cg5503). The eligibility criteria for the trial are also listed, including requirements for patients' diagnoses, current medication use, and pain levels. The exclusion criteria are also listed, including factors such as a history of alcohol or drug abuse, significant liver insufficiency, and uncontrolled hypertension.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is testing the effectiveness of the drug mk-0518, as well as several comparator drugs including efavirenz, truvada, and placebos for both mk-0518 and efavirenz. The eligibility criteria for participants include being at least 18 years old, being HIV positive, and having never received antiretroviral therapy. Exclusion criteria include having received previous antiretroviral agents, having resistance to certain drugs, and having acute hepatitis. Participants with chronic hepatitis may still be eligible if they have stable liver function tests.",
    "The sample is a phase 3 clinical trial for osteoarthritis of the knee. The trial involves the use of drugs such as ketoprofen in diractin\u00ae, celecoxib, and a placebo. The eligibility criteria for the trial include being over 45 years old, having class I-III OA of the knee, and meeting the American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee. There are also exclusion criteria, such as having skin lesions or dermatological diseases in the treatment area, being involved in the conduct and administration of the study, and having received any investigational medicinal product within 30 days prior to the screening visit. The sample also includes a list of icd-10 codes for the diseases being studied and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for aggressive B-cell non-Hodgkin's lymphoma that has failed prior combination chemotherapy with an anthracycline-containing regimen. The trial is looking for patients with diffuse large cell, small non-cleaved cell/Burkitt's lymphoma who are experiencing their first relapse or have primary refractory disease. Patients must have documented CD20 antigen expression and measurable disease, but no clinical evidence of CNS involvement by lymphoma. Patients must also meet certain eligibility criteria, including being over 18 years old, having a Zubrod performance status of 0-2, and not having any other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix. The trial is testing the effectiveness of carboplatin, etoposide, and ifosfamide as treatment options. Patients must have recovered from toxic effects of all prior therapy and cannot be receiving any other concurrent therapy unless disease progression occurs.",
    "The sample is a phase 3 clinical trial for patients with liver metastases secondary to cutaneous or ocular melanoma. The trial allows for limited unresectable extrahepatic disease, as long as the life-limiting component of progressive disease is in the liver. The patients must have measurable disease by CT scan and/or MRI, and meet certain patient characteristics such as having a life expectancy of at least 3 months, ECOG performance status 0-2, and meeting certain laboratory values. The trial involves the use of melphalan, regional chemotherapy, and systemic chemotherapy. Patients must not have certain medical conditions or prior treatments, and must have recovered from any prior chemotherapy, radiotherapy, or biologic therapy for this cancer.",
    "The sample is a phase 3 clinical trial that involves patients with various diseases such as heart failure, anemia, cardiovascular disease, ventricular dysfunction, and congestive heart failure. The trial includes a list of ICD-10 codes for each disease. The drugs being tested are darbepoetin alfa and placebo. The eligibility criteria for the trial include having heart failure for at least 3 months, a hemoglobin level between 9.0 g/dL and 12.0 g/dL, and a left ventricular ejection fraction of 40% or less. The exclusion criteria include having a transferrin saturation level below 15%, high blood pressure, heart failure primarily due to valvular heart disease, having received a major organ transplant or receiving renal replacement therapy, and having a serum creatinine level above 3.0 mg/dL.",
    "The sample is a phase 3 clinical trial for the treatment of attention deficit hyperactivity disorder (ADHD) using methylphenidate hydrochloride extended release capsules. The trial is open to males and females aged 6 to 18 who have been diagnosed with ADHD and have ADHD-RS-IV scores in the 90th percentile or higher. Participants must be in need of treatment for ADHD and able to have a 2-day washout from previous medication. Females of child-bearing potential must not be pregnant and must practice birth control. The trial has a list of exclusion criteria, including an IQ less than 80, current primary psychiatric diagnosis of other listed disorders, chronic medical illnesses, use of psychotropic central nervous system (CNS) meds having effect exceeding 14 days from screening, planned use of prohibited drugs, pregnancy or breast-feeding, significant ECG or laboratory abnormalities, experimental drug or medical device within 30 days prior to screening, hypersensitivity to methylphenidate, inability or unwillingness to comply with protocol, well controlled on current ADHD treatment, and inability to take oral capsules.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The trial includes patients with a primary diagnosis of Functional Class I-III OA of the hip or knee who are chronic users of nonsteroidal anti-inflammatory drugs (NDAIDs) and/or acetaminophen for OA pain. Patients must have discontinued all analgesic therapy at Screening. Women of child-bearing potential must be practicing an acceptable method of birth control and not pregnant or nursing. Exclusion criteria include a history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDs, including meloxicam, continuous use of opioid or opioid combination products to control OA pain of the knee or hip, clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease, significant difficulties swallowing capsules or unable to tolerate oral medication, and previous participation in another clinical study of Meloxicam Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening. The drugs being tested are meloxicam test capsules and placebo capsules.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients between the ages of 10 and 17 who meet the DSM-IV criteria for Bipolar I disorder (manic or mixed). The trial involves the use of ziprasidone oral capsules and placebo oral capsules. The eligibility criteria include exclusion of patients with an imminent risk of suicide or homicide, as judged by the site investigator, and any history of serious or unstable medical illness, including risk for QT prolongation.",
    "The sample is a phase 3 clinical trial for asthma in children between the ages of 4-12. The trial includes patients with a known history of mild to moderate reversible asthma for at least 6 months prior to the screening visit. The trial also requires patients to demonstrate a FEV1 of \u226560% to \u226480% of predicted normal values during the screening phase. The trial medication is flutiform\u00ae (formoterol fumarate / fluticasone propionate). The eligibility criteria include various factors such as no beta agonist use on the day of screening, documented reversibility of \u2265 15% in FEV1 during the screening phase, and satisfactory technique in the use of the pressurized MDI and spacer device. The exclusion criteria include life-threatening asthma within the past year, history of systemic (injectable) corticosteroid medication within 1 month before the Screening Visit, and current evidence or history of any clinically significant disease or abnormality. The trial requires written informed parental consent and informed assent from the patient where possible.",
    "The sample is for a phase 3 clinical trial for the treatment of migraine. The trial is focused on the drug topiramate. The eligibility criteria for the trial include a diagnosis of migraine with or without aura, having successfully finished a previous study, being in generally good health, and being able to take medicine orally. Female participants must also be using birth control. Exclusion criteria include having a more painful condition than the headache pain, taking any other medications not allowed by the study, having abnormal liver tests, not being compliant with study medication during a previous study, and being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for patients with non-small-cell lung carcinoma. The trial is testing the effectiveness of two drug combinations, gemcitabine/eloxatin and carboplatin/paclitaxel, on patients who have not received any previous chemotherapy or systemic therapy. Patients must have a measurable lesion and an ECOG Performance Status of 0 or 1, with no peripheral neuropathy greater than Grade 1. Patients with stable brain metastases may also be eligible. Patients must have recovered fully from any previous surgical procedures and cannot have a history of acute cardiac or CNS events within the past 6 months. Patients who are pregnant or lactating, have a hypersensitivity to any of the study drugs, or have a serious uncontrolled medical or psychiatric illness are excluded from the trial. Patients who have had other malignancies within the past 5 years, except for certain types of skin and bladder cancers, are also excluded.",
    "The sample is a phase 3 clinical trial for attention-deficit hyperactivity disorder. The trial includes patients who meet the criteria of ADHD based on Conners' Adult ADHD Diagnostic Interview for DSM-IV, have a DSM-IV Total ADHD Symptoms score of = 24 as determined by the investigator or co-investigator at baseline, are healthy based on physical examination, medical history, vital signs, 12-lead ECG and clinical laboratory tests performed at screening, and have signed an informed consent form. Patients with co-morbid psychiatric diagnoses per DSM-IV-TR criteria of bipolar I disorder, schizophrenia, schizoaffective disorder, or severe obsessive compulsive disorders, pervasive developmental disorder (including autistic disorder or Asperger's disorder), suicidality, or any other diagnosis that in the judgment of the investigator or co-investigator would exclude the patient from the study, as well as those with motor tics, history of Tourette's disorder, or family history of Tourette's disorder, and those with known or suspected mental retardation are excluded from the trial. The trial involves the use of two drugs, jns001 and placebo.",
    "The sample is a phase 3 clinical trial for children who have received a kidney transplant and have experienced one or more episodes of acute or chronic rejection. The trial is testing the effectiveness of cyclosporine, sirolimus, and tacrolimus in stabilizing kidney function. The trial has specific inclusion and exclusion criteria, such as being 20 years of age or younger, having written informed consent from a parent or guardian if under 18, and not having a history of cancer or an active infection. The trial also requires participants to use birth control during the study and for 3 months following treatment.",
    "This sample is for a phase 3 clinical trial for breast cancer. The trial is looking for patients with metastatic or locally advanced breast carcinoma who demonstrate HER2 3+ positivity on IHC or 2+ over-expression and FISH test demonstrating C-erB2 gene amplification. Patients must not have any known or suspected brain metastases or CNS disease, and hormone receptor status is not specified. The trial is looking for female patients with an ECOG performance status of 0 or 1 who are suitable for trastuzumab (Herceptin\u00ae) +/- chemotherapy in terms of bone marrow, hepatic, and renal function. Patients must not have a prior history of cerebrovascular disease or neurological disorder including seizures, and must not have had prior cranial radiotherapy or neurosurgery.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are 18 years or older and have had rheumatoid arthritis for no more than 2 years. The patients must have a Disease Activity Score 28 (DAS28) greater than 3.2, and a swollen joint count (SJC) of at least 4 out of 66 joints and a tender joint count (TJC) of at least 6 out of 68 joints. They must also be Rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) positive. Patients with an Erythrocyte sedimentation rate (ESR) of at least 28 mm/h or C-reactive protein (CRP) of at least 10 mg/L at screening are also eligible. Patients who have previously been treated with tocilizumab or methotrexate or biologic agent, have a rheumatic autoimmune disease other than rheumatoid arthritis, have a history of or current inflammatory joint disease other than RA, or are classified as functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in RA are excluded from the trial. The trial will test the effectiveness of tocilizumab, methotrexate, and placebos for both drugs.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes mellitus. The trial is testing the effectiveness of three different drugs: ly2963016, lantus, and insulin lispro. The eligibility criteria for the trial include having type 1 diabetes for at least one year, a Hemoglobin A1c level of 11.0% or less, and a body mass index of 35 kg/m\u00b2 or less. Patients must also be on basal-bolus insulin therapy for at least one year. Exclusion criteria include having had more than one episode of severe low blood sugar or diabetic ketoacidosis within the six months prior to the study, having known hypersensitivity or allergy to any of the study insulins, and having significant renal, cardiac, gastrointestinal, or liver disease. Patients with active cancer or cancer within the past five years are also excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of idiopathic restless legs syndrome. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The eligibility criteria include age range, diagnosis criteria for restless legs syndrome, and exclusion criteria such as pregnancy, certain medical conditions, and other sleep disorders.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for breast cancer patients with bone metastasis. The trial involves the use of zoledronic acid and placebo drugs. The eligibility criteria for the trial include being a female patient over 18 years of age with confirmed breast cancer and bone metastasis, having received a minimum of 9 doses of Zometa or Aredia, and not having abnormal kidney function or dental problems. Exclusion criteria include recent or planned dental or jaw surgery, diagnosis of metabolic bone disease other than osteoporosis, known hypersensitivity to Zometa, and treatment with other investigational drugs within 30 days prior to randomization.",
    "The sample is a phase 3 clinical trial for patients with brain tumors or metastatic disease. The trial involves the use of donepezil hydrochloride and placebo drugs. The eligibility criteria include being over 18 years old, having a life expectancy of at least 30 weeks, and having received a prior course of at least 30 Gy fractionated whole or partial brain irradiation for treatment of a primary brain tumor or metastatic disease to the brain. Patients must have completed radiation more than 6 months prior to enrollment and have no radiographic evidence of brain disease, or stable brain disease defined as no evidence of tumor progression in the 3 months prior to enrollment. Patients who have undergone one or more treatments with single fraction stereotactic radiosurgery (SRS) in addition to whole or partial brain irradiation are eligible, as long as the SRS was completed more than 6 months prior to registration if NED or stable disease. Patients must have a Karnofsky Performance Status of more than 60 or ECOG 0-2. The exclusion criteria include hypersensitivity to donepezil, arrhythmias including bradycardia or heartblock, and patients who have received GliaSite or other type of brain brachytherapy, convection enhanced delivery of immunotoxins, and/or any other investigational modalities for treatment of their brain tumor. Women who are currently breastfeeding or pregnant are not eligible for the study.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves testing the effectiveness of various drugs, including tiotropium, olodaterol, and a combination of the two, as well as a placebo. The trial has specific inclusion and exclusion criteria, including a diagnosis of COPD, a smoking history of more than 10 pack years, and the ability to perform pulmonary function tests. Exclusion criteria include significant disease other than COPD, history of asthma, and pregnancy or nursing. The trial aims to determine the safety and efficacy of the drugs in treating COPD.",
    "The sample is from a phase 3 clinical trial for obesity and overweight patients. The trial includes three drugs: naltrexone sr 16 mg/bupropion sr 360 mg /day, naltrexone sr 32 mg/bupropion sr 360 mg /day, and placebo. The eligibility criteria include having a BMI of \u226530 and \u226445kg/m\u00b2 for subjects with uncomplicated obesity, and BMI of \u226527 and \u226445kg/m\u00b2 for subjects with obesity and controlled hypertension and/or dyslipidemia. The trial also has exclusion criteria, such as a history of drug or alcohol abuse, serious medical conditions, and serious psychiatric illness. The sample includes the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for chronic constipation. The eligibility criteria include female patients aged 18 to 75 years with a history of self-reported chronic constipation for at least 6 months and not satisfied with laxatives in the past. The trial also requires patients to have less than 3 successful bowel movements during the last week of the run-in period. Patients must be willing and able to follow the entire procedure and comply with study instructions. Exclusion criteria include a history or evidence of organic disease in the large bowel, intestinal perforation or obstruction, drug or alcohol abuse, and pregnancy or lactation. The trial also excludes patients with certain medical conditions such as hypothyroidism, diabetes mellitus, and neurological diseases. Patients must not have participated in another clinical study of drugs or devices parallel to or less than 90 days before study entry or previous participation in this study. Women of childbearing potential must use medically reliable methods of contraception for the entire study duration.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia and prostatic hyperplasia. The trial involves the use of dutasteride 0.5mg capsule and a matched placebo. The eligibility criteria for the trial include a clinical diagnosis of BPH, a minimum AUA-SI score of 12, a Qmax between 5ml/sec and 15ml/sec, a minimum voided volume of 125ml, and a prostate volume of at least 30cm(3). Exclusion criteria include a post void residual volume greater than 250ml, a history or evidence of prostate cancer, a total serum PSA level below 1.5ng/ml or above 10.0ng/ml, previous prostatic surgery or other invasive procedures to treat BPH, and a history of AUR within 3 months. Other exclusion criteria include a history of hepatic impairment or abnormal liver function tests, use of certain medications within the past 6 months, and participation in any other drug trial within 30 days of the current trial.",
    "The sample is a phase 3 clinical trial for chemotherapy-induced nausea and vomiting. The trial is for children and adolescents between the ages of 5-18 years who have a confirmed diagnosis of malignancy and are receiving highly emetogenic chemotherapy for the first time. The trial involves the use of the drugs aprepitant and placebo. The eligibility criteria include having a caregiver who can understand Hindi or English, not having significant organ dysfunction or active infection, not being pregnant, and not having uncontrolled medical conditions other than malignancy. The exclusion criteria include having received or receiving chemotherapy other than VAC, ABVD, and CDDP/Doxorubicin, having received treatment with another investigational drug within 4 weeks of study start or prior Aprepitant use, and having abnormal lab values.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of the common cold. The trial involves the drug xylometazoline and includes a list of icd-10 codes for the disease. The eligibility criteria for the trial include being over 18 years old and having moderate common cold symptoms for less than 36 hours. Exclusion criteria include having a congested or runny nose for more than two continuous weeks in the previous 12 months, having a deviated septum or nasal polyps, recent use of antibiotics, and recent sinusitis. There may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a phase 3 clinical trial for patients with inoperable, locally advanced, or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. The trial involves the use of drugs such as bevacizumab, capecitabine, cisplatin, placebo, and 5-fluorouracil. The eligibility criteria include being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and having a life expectancy of at least 3 months. Patients must also have measurable or evaluable disease and not be receiving anticoagulant medication with an INR \u2264 1.5 and aPTT \u2264 1.5 x Upper Limit of Normal (ULN) within 7 days prior to randomisation. The exclusion criteria include previous chemotherapy for locally advanced or metastatic gastric cancer, previous platinum or anti-angiogenic therapy, and inadequate bone marrow, liver, or renal function. Patients with CNS metastasis at baseline or a history of another malignancy that could affect compliance with the protocol or interpretation of results are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of opioid-induced constipation. The trial involves the use of methylnaltrexone and placebo drugs. The eligibility criteria include having a history of chronic non-malignant pain, taking opioids for at least a month, and not having a history of chronic constipation. Participants must also be willing to discontinue all laxative therapy and use only study-permitted rescue laxatives. Exclusion criteria include prior treatment with oral or subcutaneous MNTX, pregnancy or breastfeeding, and certain gastrointestinal disorders.",
    "The sample is a phase 3 clinical trial for breast cancer. The eligibility criteria include having histologically or cytologically confirmed breast adenocarcinoma, absence of lymph node involvement, and absence of any clinical or radiological evidence of local or metastatic disease. The trial is open to premenopausal or postmenopausal women with certain tumor characteristics, and postmenopausal women with tumors measuring 1-2 cm if the tumor has at least 2 of the adverse prognostic tumor criteria. The trial also requires adequate bone marrow, liver, renal, and cardiac function, as well as a negative pregnancy test and informed consent. Exclusion criteria include other invasive malignancy within the past 5 years, other concurrent uncontrolled illness, psychiatric illness or social situation that would preclude study compliance, pregnant or nursing women, history of allergic reaction attributed to docetaxel, and other concurrent investigational agents. The drugs being tested in the trial are docetaxel and epirubicin.",
    "The sample is a phase 3 clinical trial for psoriasis. The trial includes patients with stable moderate to severe plaque psoriasis for at least 6 months, with involved BSA \u2265 10% and PASI \u2265 10 at screening and at baseline. The patients are candidates for systemic therapy or phototherapy in the opinion of the investigator. The trial has inclusion and exclusion criteria, which are listed in the sample. The trial will test the effect of etanercept and clobetasol propionate foam on psoriasis.",
    "The sample is a phase 3 clinical trial for kidney stones. The trial includes patients between the ages of 18 and 70 who are non-diabetic and have normal white blood cell count and serum creatinine levels. Patients must also have a urine analysis consistent with the absence of infection, a negative urine culture, and no subjective or objective fever. They must be able to tolerate oral fluids and pain medication, have a unilateral ureteral calculus less than 10mm visible on CT scan within the ureter, and be able to make informed medical decisions regarding consent. Patients must also be willing to follow up in the urology office. Exclusion criteria include individuals who are unable to consent, not yet adults (infants, children, teenagers), pregnant women, prisoners, those who have had prior treatment for this particular stone, those who have received medical therapy only for stone disease, those who use chronic narcotics, and those who are currently on alpha blocker therapy.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes and coexisting vascular disease or hypertension. The trial involves the drug rosiglitazone and requires patients to have initiated statin and fibrate therapy at least 6 months prior to screening. Patients must also meet certain inclusion criteria, such as being between 30 and 75 years old, having an HbA1c value < 10% at screening, and having evidence of at least one atheromatous plaque causing narrowing of internal carotid artery between 10 and 95%. However, there are also exclusion criteria, such as having taken >2 concomitant oral anti-hypertensive agents within the 3 months prior to screening or having a history of gangrene or transient ischaemic attack. Patients must give their signed informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial includes patients who are able to speak English and provide written informed consent, are willing and able to self-administer the study drug, comply with study restrictions, complete an electronic diary, and return to the clinic for scheduled visits. Women of childbearing potential must use a medically accepted method of contraception and have a negative pregnancy test at screening. Patients must have pain of at least 3 months' duration associated with osteoarthritis or low back pain and report an average pain intensity score of 5 or more on the 11-point numerical rating scale. Patients must not participate in other studies involving an investigational agent while enrolled in this study. Exclusion criteria include known or suspected hypersensitivities or allergies to any ingredient in the study drug, recent history or current evidence of alcohol or substance abuse, medical or psychiatric disease that would compromise collected data, taking more than 135 mg/day of oxycodone or equivalent during the 14 days prior to screening, history of suicidality, expected surgery during the study, primary painful condition related to any source of chronic pain other than osteoarthritis or low back pain, pregnancy or lactation, active malignancy, HIV, clinically significant deviation from normal in physical examination and/or clinical laboratory test values, cardiopulmonary disease that would significantly increase the risk of treatment with opioids, participation in a study involving an investigational drug in the previous 30 days, receipt of a monoamine oxidase inhibitor within 14 days before the first treatment with study drug, any other medical condition or receiving concomitant medication/therapy that would compromise the patient's safety or compliance with the study protocol, or involvement in active litigation in regard to the pain currently being treated. The investigator may exclude patients who are not suitable for the study for any reason.",
    "The sample is a phase 3 clinical trial for the treatment of fibromyalgia using the drug Savella. The trial is open to both male and female patients who are 65 years or older and have been diagnosed with fibromyalgia according to the ACR 1990 criteria. Patients must have a pain score of at least 10 on the Gracely scale at both screening and baseline assessments. Patients must also have discontinued other dual-acting antidepressant medications for a period not less than 4.5 times the drug half-life as of the baseline evaluation. The trial has a list of exclusion criteria, including uncontrolled hypertension, baseline orthostasis, psychosis, active suicidality, current episode of major depression or other severe psychiatric illness, current alcohol/substance abuse or dependence, significant cardiovascular disease, uncontrolled narrow angle glaucoma, history of seizures, use of MAO inhibitor drugs within the last 14 days, abnormal baseline liver or renal function tests, dementia or other syndrome of cognitive impairment that could interfere with the subject's ability to participate fully in the assessment protocol, and obstructive uropathy in males.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The trial is for patients with cytologically confirmed acute promyelocytic leukemia (APL) or the variant form of APL who have not received any prior treatment. The trial involves the use of drugs such as mercaptopurine, methotrexate, and tretinoin. Eligibility criteria include confirmation of low- or intermediate-risk disease, PML-RAR\u03b1 fusion gene positivity, and no recurrent disease. Patients must also have a Zubrod performance status of 0-3, not be pregnant or nursing, and have no unstable cardiac arrhythmia or unstable angina. Prior concurrent therapy is limited to no more than 1 prior dose of intrathecal chemotherapy for acute leukemia and no prior systemic chemotherapy, hydroxyurea, or leukapheresis for acute leukemia. Prior tretinoin at a dose of \u2264 45 mg/m^2/day is allowed provided it was received \u2264 5 days prior to study registration.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of rapid acting intramuscular olanzapine and isotonic sodium chloride solution in treating clinically agitated patients with schizophrenia. The trial has specific inclusion and exclusion criteria, including patients meeting DSM-IV-TR criteria for schizophrenia, being between 20 and 65 years old, and having a minimum total score on the Positive and Negative Syndrome Scale-Excited Component. Patients who have previously been treated with oral olanzapine and are considered treatment-resistant, have a history of allergic reaction or intolerance to study medication, or have certain medical conditions are excluded from the trial. The trial also has restrictions on concomitant treatment and prohibited concomitant medicines. Patients must sign an informed consent document and be able to cooperate with all study procedures.",
    "The sample is a phase 3 clinical trial for the treatment of acute hepatitis C virus (HCV) using the drug ribavirin. The trial is open to individuals between the ages of 18 and 65 who have been diagnosed with HCV and have normal or elevated serum alanine transferase (ALT) levels and positive serum HCV-RNA. Participants must also have negative pregnancy tests (for women of childbearing potential) and use reliable contraception during the study and for a period of time after treatment completion. The trial has a list of exclusion criteria, including liver disease unrelated to HCV infection, low hemoglobin or white blood cell counts, ongoing pregnancy or breastfeeding, severe psychiatric or neurologic disease, and other severe illnesses or conditions that would make the participant unsuitable for the study.",
    "The sample is a phase 3 clinical trial for patients with renal failure. The trial includes a list of icd-10 codes for the disease and a list of drugs, including 10mg rosuvastatin and a placebo. The eligibility criteria for the trial includes male or female subjects aged 50-80 years who have received regular haemodialysis treatment for at least 3 months. Exclusion criteria include having an underlying condition that is expected to limit survival to less than 1 year and having received statin therapy within the past 6 months.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of HIV-1. The trial involves the use of drugs such as maraviroc, emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, as well as placebos for emtricitabine/tenofovir and maraviroc. The eligibility criteria for the trial include having a plasma HIV-1 RNA level of at least 1,000 copies/mL, a CD4 count of at least 100 cells/mm3, and only R5 HIV 1 at screening. Exclusion criteria include prior treatment with any other HIV antiretroviral therapy for more than 14 days, evidence of genotypic/phenotypic resistance to darunavir, tenofovir, and emtricitabine, and CXCR4 using virus detected using randomized tropism determination or repeated failure to obtain an interpretable tropism result.",
    "The sample is a phase 3 clinical trial for the treatment of non-melanomatous skin cancer using the drug imiquimod. The trial is looking for patients with primary basal cell skin carcinoma located in low-risk areas and with no genetic or nevoid conditions. Patients of any age and performance status are eligible, as long as they have no bleeding disorder, are not pregnant or nursing, and have no life-threatening disease. Patients must be available for study follow-up for up to 3 years and have access to a telephone. There are no concurrent participation in any other experimental trial. The eligibility criteria are listed in detail under \"DISEASE CHARACTERISTICS\" and \"PATIENT CHARACTERISTICS\".",
    "The sample is a phase 3 clinical trial for patients with non-small cell lung cancer who are not candidates for combined modality therapy. The trial includes patients with stage IIIB or IV disease who have received one chemotherapy regimen and achieved a complete response, partial response, or stable disease. The trial involves the use of the drug sunitinib malate. The eligibility criteria include having measurable or non-measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meeting certain medical requirements such as having granulocytes and platelet counts within a certain range and having no ongoing cardiac dysrhythmias or history of certain medical conditions. Patients must also meet certain exclusion criteria, such as having a history of pulmonary hemorrhage or bleeding diathesis.",
    "The sample is a record of a clinical trial in phase 3, which is focused on studying the effects of the drug pitavastatin on patients with hypercholesterolemia and dyslipidemias. The trial has a list of inclusion and exclusion criteria, which includes being over 65 years of age, having primary hypercholesterolemia, combined dyslipidemia, and having completed a previous study. The trial also has a list of icd-10 codes associated with the diseases being studied.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic migraine using the drug topiramate. The trial is looking for participants who have successfully completed the double-blind portion of the CAPSS-276 study or discontinued the study after a minimum of 4 weeks maintenance treatment due to lack of effect of study drug. The inclusion criteria include a diagnosis of chronic migraine, being in generally good health, able to take medicine orally, and using birth control if female. The exclusion criteria include having a more painful condition than the headache pain, taking any other medications not allowed by the study protocol, having abnormal liver tests, not being compliant with study medication during the CAPSS-276 study, and being pregnant or breast-feeding. The diseases being studied are limited to migraine, and the icd-10 codes associated with the disease are listed.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of ulcerative colitis, a disease that affects the colon and rectum. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested, which includes tacrolimus and a placebo. The eligibility criteria for the trial are also listed, including the requirement that patients have moderate to severe refractory UC and have not responded to steroid treatment. The exclusion criteria are also listed, which include patients with mild or fulminant type UC, renal or hepatic failure, and those taking certain immunosuppressants.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes males and females aged 40 years or older with a clinical diagnosis of moderate to severe stable COPD. The trial involves the use of aclidinium bromide and placebo drugs. The eligibility criteria for the trial include exclusion of individuals with a history or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of diabetes, specifically type 1 diabetes. The trial involves the use of three different insulin drugs: insulin detemir, insulin nph, and insulin aspart. The eligibility criteria for the trial include being insulin detemir naive, having type 1 diabetes for at least 12 months, and having an HbA1c level of less than or equal to 11.0%. The exclusion criteria include having significant concomitant diseases. The diseases and their corresponding ICD-10 codes are also listed in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of osteoporosis and multiple sclerosis. The trial involves the use of zoledronic acid and a placebo drug. The eligibility criteria for participants include having a definite diagnosis of multiple sclerosis, a specific subtype of the disease, a certain level of disability, and a bone mineral density T-score within a specific range. Participants must also be able to read, write, and communicate well, and must not have received certain types of immunomodulatory treatment within the last 30 days. Exclusion criteria include contraindications against certain medications, certain medical conditions, and pregnancy or breastfeeding. Other protocol-defined criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of three different drugs: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, concurrent brimonidine 0.2% and timolol 0.5% ophthalmic solution, and brimonidine 0.2% ophthalmic solution. The trial has specific eligibility criteria, including a diagnosis of ocular hypertension or glaucoma and a need for IOP-lowering therapy in both eyes. There are also exclusion criteria, such as uncontrolled medical conditions and contraindications to \u03b2-adrenoceptor antagonist therapy or brimonidine therapy. The diseases are represented as a list of disease names, and the icd-10 codes are listed for each disease.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial is testing the effectiveness of the drug \"smc021 oral calcitonin\" compared to a placebo. The trial is looking for postmenopausal women with osteoporosis who are in good health and not taking any medication that affects bone metabolism. The inclusion criteria include having a BMD T-score above -4.0 and no more than 2 prevalent vertebral fractures. Participants with a BMD T-score lower than -2.5 and a severe vertebral fracture will be excluded from the study. The trial also excludes participants with evidence of any clinical osteoporotic fracture or a history of a clinical osteoporotic fracture (excluding wrist fractures). Additionally, participants with a BMD T-score above -1.5 in all of the following regions: Lumbar spine, femoral neck or total hip will be excluded. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for contraception. The trial is looking for healthy women between the ages of 18 and 45 who are at risk for pregnancy and have a history of regular cycles. The trial is testing the drug norethindrone acetate/ethinyl estradiol. The inclusion criteria for the trial are being a healthy woman between the ages of 18 and 45 who is at risk for pregnancy and has a history of regular cycles. The exclusion criteria are having contraindications for the use of hormonal contraception, conditions that affect the absorption or metabolism of steroid hormones, and having a BMI over 35. The icd-10 codes associated with the disease are Z92.0, Z30.012, and Z30.09.",
    "This sample is a phase 3 clinical trial for the treatment of B-cell chronic lymphocytic leukemia. The trial is testing the effectiveness of the drugs cyclophosphamide and fludarabine. The eligibility criteria for participants include a diagnosis of B-cell chronic lymphocytic leukemia, meeting specific criteria such as Binet classification stages B or C, Del 17 p (FISH) negative, and Matutes score 4 or 5. Participants must also meet certain exclusion criteria, such as having a life expectancy of less than 6 months, having certain medical conditions, or being pregnant or breastfeeding. Prior chemotherapy, radiotherapy, or immunotherapy for CLL is not allowed, but corticosteroids within the past month are allowed.",
    "This sample is a record of a clinical trial with a phase 3 designation. The trial is focused on HIV infections and the associated symptoms. The table includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being used in the trial. The eligibility criteria for participants are also included, with specific requirements for CD4+ T-cell count, prior use of rIL-2, and willingness to receive further dosing. There are also exclusion criteria, including allergies to certain drugs and recent use of other pain medications.",
    "The sample is a phase 3 clinical trial for epilepsy. The trial is looking for subjects who have been diagnosed with epilepsy within the past year and have had at least two unprovoked seizures in the past two years, with at least one occurring in the last six months. Female subjects without childbearing potential are eligible, and those with childbearing potential must use a medically accepted contraceptive method. The trial is excluding subjects who have previously been allocated to a trial treatment used in this trial, those who have participated in another clinical trial with an investigational drug or device within 12 weeks of the selection visit, pregnant or lactating women, those with known pseudoseizures within the last year, those with uncountable seizures or a history of convulsive status epilepticus, those with any disorder or condition that may interfere with the absorption, distribution, metabolisation or excretion of drugs, those with a history of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous five years, those with progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors, and those with a terminal illness or any medical condition that might interfere with the subject's trial participation. The trial is testing the effectiveness of three drugs: levetiracetam, carbamazepine controlled release (cbz-cr), and valproate extended release.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is testing the effectiveness of the drug paliperidone palmitate. The eligibility criteria for the trial include meeting the DSM-IV criteria for schizophrenia, being on an adequate dose of antipsychotic medication, and having a baseline PANSS score of at least 80 and a baseline CGI-S score of at least 4. Women must be postmenopausal, surgically sterile, abstinent, or using a highly effective method of birth control. Men must use a double barrier method of birth control and not donate sperm during the study and for 3 months after receiving the last dose of the study drug. Patients with a psychiatric diagnosis due to direct pharmacological effects of a substance or a general medical condition, those who have never been treated with antipsychotics before, and those on clozapine during the last 3 months are excluded from the trial. Patients with serious unstable medical conditions or clinically relevant laboratory abnormalities are also excluded.",
    "The sample is a phase 3 clinical trial for patients with advanced Parkinson's disease. The trial is testing the effectiveness of a drug called istradefylline (kw-6002). The patients must be at least 30 years old and have been diagnosed with Parkinson's disease according to UK Parkinson's Disease Society criteria and the Modified Hoehn and Yahr Scale. They must have been receiving levodopa treatment for at least one year and have an average of at least three hours OFF time as recorded in two 24-hour ON/OFF diaries. Female patients must be non-pregnant and non-nursing. Patients cannot be enrolled if they are taking certain excluded medications, have been treated with any investigational drug within 30 days prior to randomisation, have ever received istradefylline or been treated with a COMT inhibitor, are psychotic, have clinically significant illness or laboratory values at screening, have insufficient mental capacity to comply with protocol requirements or certain psychiatric or neurological conditions.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on post-menopausal osteoporosis and includes a list of ICD-10 codes for the disease. The trial involves the use of the drug ibandronate, which is listed multiple times. The eligibility criteria for the trial includes women between the ages of 55-80 who have been post-menopausal for at least 5 years and are ambulatory. The exclusion criteria includes a history of malignant disease within the previous 10 years (with the exception of successfully removed basal cell cancer), breast cancer within the previous 20 years, allergy to bisphosphonates, previous treatment with an intravenous bisphosphonate at any time, and previous treatment with an oral bisphosphonate within the last 6 months, >1 month of treatment within the last year, or >3 months of treatment within the last 2 years.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as methotrexate, ocrelizumab, and placebo. The eligibility criteria for the trial include being at least 18 years old, having had rheumatoid arthritis for 3 months to 5 years, and being new to methotrexate. The exclusion criteria include having other rheumatic autoimmune diseases or inflammatory joint diseases, having received biologic therapy for RA in the past, and receiving concurrent treatment with any DMARD. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on two types of esophagitis: reflux and peptic. The diseases are identified by their ICD-10 codes. The trial involves three drugs: dexlansoprazole mr, dexlansoprazole mr, and lansoprazole. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Inclusion criteria require that the subject has endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D). Exclusion criteria include a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori, use of certain medications, history of certain medical conditions, and recent upper gastrointestinal hemorrhage.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on studying the effects of contraception on pregnancy. The icd-10 codes associated with the disease are listed as well as the drugs being tested, which are c31g and nonoxynol-9 (n-9). The eligibility criteria for participants are also listed, including age range, negative pregnancy test, normal menstrual cycle, willingness to engage in heterosexual intercourse, and willingness to use the study product as the primary method of contraception. There are also exclusion criteria listed, such as a history of allergy to spermicides or products containing N-9, a history of infertility, or a current diagnosis of cervical cancer.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe plaque-type psoriasis. The trial includes adult male and female subjects with a Baseline Psoriasis Area and Severity Index (PASI) score of 12 or greater and at least 10% of their total body surface area (BSA) involved at Baseline. The trial involves the use of two drugs, infliximab and methotrexate, and subjects must meet specific eligibility criteria, including negative diagnostic TB test results, no history of latent or active TB, and no signs or symptoms suggestive of active TB. Subjects with poor health, including concomitant congestive heart failure (CHF), history of chronic or recurrent infectious disease, and other specified conditions, are excluded from participation in the study. Additionally, subjects who have used any investigational drugs within 4 weeks of Screening, who are participating in other clinical studies, staff or family members of study staff are excluded from participation in the study.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The trial includes patients who are female and 18 years or older, have histologically confirmed invasive breast cancer, and are at high risk of breast cancer recurrence. The trial involves the use of two drugs, capecitabine and docetaxel. The eligibility criteria include providing written informed consent, having a high risk of breast cancer recurrence, and meeting certain medical criteria. The exclusion criteria include being over 65 years of age, having certain types of breast cancer, having certain medical conditions, and being unable to comply with the protocol.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial includes patients with probable Alzheimer's disease, as diagnosed by NINCDS/ADRDA and DSM IV criteria. Patients must have a Mini-Mental Status Examination Score (MMSE) between 13 and 25 to be eligible for the trial. The drug being tested is atorvastatin. The eligibility criteria includes exclusion of patients with dementia due to causes other than Alzheimer's disease, and any condition that may increase the risk to the patient or decrease the reliability of the data required for the study.",
    "The sample is a phase 3 clinical trial for the treatment of hepatocellular carcinoma. The trial includes patients who have undergone surgical resection or local ablation for treatment of HCC with curative intent within 4 months from staging to potentially curative treatment. The trial also includes patients who have confirmed CR (absence of residual tumor after curative treatment) on the eligibility scan by independent radiological review. The trial has inclusion and exclusion criteria, including adequate bone marrow, liver and renal function, Child-Pugh score 5-7 points, ECOG Performance Status of 0, and no history of cardiovascular disease or HIV infection. The trial also excludes patients with recurrent HCC, low risk of recurrence after curative treatment, and previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study. The trial compares the effectiveness of the drug Nexavar (sorafenib, bay43-9006) to a placebo.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the drug muraglitazar. The patients must have been receiving stable metformin therapy for at least 6 weeks prior to screening and have an HbA1c level between 7% and 10%. They must also have a fasting c-peptide level of at least 1.0 umol, a body mass index of 41 kg/m2 or less, and mean serum triglycerides of 600 mg/dl or less. The diseases being studied are limited to diabetes mellitus, type 2 and the corresponding ICD-10 codes are listed as well.",
    "The sample is a phase 3 clinical trial for gastrointestinal stromal tumors. The trial is testing the drug nilotinib. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being tested, and the eligibility criteria for the trial. The eligibility criteria include age, confirmation of disease progression or intolerance to previous therapies, measurable disease, normal organ function, and physical fitness. There are also exclusion criteria, such as previous treatment with nilotinib or other targeted therapies, impaired cardiac function, and pregnancy or lactation. The sample also includes criteria for the extension phase of the trial.",
    "The sample is a phase 3 clinical trial for chronic myeloid leukemia. The trial is testing the effectiveness of the drug imatinib on patients who have previously been treated with other drugs for the disease, except for imatinib. The trial has specific eligibility criteria, including patients being over 18 years old, having a confirmed diagnosis of BCR-ABL positive CML in chronic phase, and having adequate end organ function. Patients must also agree to use effective birth control during the trial. Exclusion criteria include patients who are pregnant or breastfeeding, have a history of non-compliance with medical regimens, or have known chronic liver disease. The trial requires written informed consent from all participants.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with type 2 diabetes mellitus and includes a list of icd-10 codes associated with the disease. The trial involves the use of two drugs, sitagliptin phosphate and a placebo, and includes eligibility criteria for patients to participate in the trial. The inclusion criteria require patients to have poorly controlled diabetes while on insulin or insulin and metformin, while the exclusion criteria include a history of type 1 diabetes or ketoacidosis, recent use of oral antidiabetic agents other than metformin, and current treatment with daily use of pre-prandial short-acting or rapid-acting insulin.",
    "The sample is a phase 3 clinical trial for patients with relapsing remitting multiple sclerosis. The trial involves testing the effectiveness of three drugs - bg00002 (natalizumab), interferon beta-1a, and glatiramer acetate. The eligibility criteria for the trial include having a diagnosis of relapsing remitting multiple sclerosis, having been treated with a stable regimen of either glatiramer acetate or interferon beta-1a for 6 to 18 months prior to randomization, and having had disease activity within 12 months prior to screening while on therapy. Patients must also be na\u00efve to natalizumab and have a documented Expanded Disability Status Scale (EDSS) score between 0.0 and 5.5. The exclusion criteria include having a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS, known intolerance or contraindication to the use of glatiramer acetate or interferon beta-1a, and having had an MS exacerbation (relapse) within 30 days prior to randomization. Other exclusion criteria include being immunocompromised, having contraindicated implanted metal devices, having a history of malignant disease, and having a positive test result for hepatitis C virus or hepatitis B virus.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial involves the use of the drugs escitalopram and placebo. The eligibility criteria for the trial include meeting the DSM-IV-TR diagnostic criteria for major depressive disorder and having a current depressive episode that has lasted at least 8 weeks. Exclusion criteria include being pregnant or breastfeeding, having a history of manic or hypomanic episodes, schizophrenia or other psychotic disorders, obsessive-compulsive disorder, being considered a suicide risk, and having a history of seizures, stroke, significant head injury, central nervous system tumors, or any other condition that predisposes patients to a risk for seizure.",
    "The sample is a phase 3 clinical trial for patients with ovarian or primary peritoneal carcinoma. The trial includes patients with either optimal or suboptimal residual disease following initial surgery. The trial also includes patients with specific histologic epithelial cell types. Patients must be within 12 weeks after initial surgery and be a candidate for first-line chemotherapy. They must also meet certain criteria for bone marrow, hepatic, renal, and neurologic function, as well as have a negative urine pregnancy test. The trial excludes patients with certain types of tumors, prior therapy for ovarian or primary peritoneal carcinoma, and prior biological response modifier therapy within the previous 5 years. Pregnant or nursing women are also excluded. The trial aims to evaluate the safety and efficacy of interferon gamma-1b.",
    "The sample is a phase 3 clinical trial for chronic myeloid leukemia. The trial includes patients who are 18 years or older and have a Philadelphia Chromosome-positive chronic myeloid leukemia. The trial involves the drugs dasatinib and imatinib. The eligibility criteria include having an Eastern Cooperative Oncology Group Performance Status score of 0-2 and not having pleural effusion, uncontrolled cardiovascular disease, significant bleeding disorder unrelated to CML, or prior treatment with interferon/imatinib/dasatinib/anti-CML systemic treatments except anagrelide/hydroxyurea.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for patients with type 2 diabetes mellitus. The trial is testing the drug vildagliptin. The eligibility criteria for the trial includes patients who have not been treated with oral antidiabetic agents for at least 12 weeks prior to study entry, are at least 18 years old, have a body mass index between 22-35 kg/m2, and have an HbA1c level of no more than 7.5%. Patients with type 1 diabetes, acute metabolic diabetic complications, evidence of significant diabetic complications, or who have received insulin treatment within the past 6 months are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for participants with type 2 diabetes mellitus. The trial involves the use of two drugs, lixisenatide and metformin. The eligibility criteria include having a stable metformin dose for at least 3 months prior to screening, and a diagnosis of type 2 diabetes mellitus for at least 1 year before the screening visit. Exclusion criteria include having a screening HbA1c below 7.0% or above 10.0%, fasting plasma glucose above 250 mg/dL, and a BMI below 20 kg/m^2 or above 40 kg/m^2. Other exclusion criteria include previous use of insulin, history of pancreatitis or medullary thyroid cancer, and any contraindication related to metformin or previous treatment with lixisenatide. The provided information is not exhaustive and other considerations may be relevant for potential participants.",
    "The sample is a phase 3 clinical trial for major depressive disorder and depression. The trial includes patients who have had an inadequate response to no more than one antidepressant and are currently outpatient. The trial excludes patients with a history of bipolar disorder, psychotic disorder, post-traumatic stress disorder, suicide attempts in the past year, or significant risk of suicide or homicide. Patients with renal insufficiency or impairment or conditions that could affect absorption or metabolism of the investigational product are also excluded. The trial involves the drugs tc-5214 and placebo. The eligibility criteria include providing signed and dated informed consent before initiation of any study-related procedures.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of ulcerative colitis. The trial involves the use of two different doses of mesalamine, a drug used to treat inflammatory bowel disease. The eligibility criteria for the trial include having a documented history of ulcerative colitis, experiencing at least one flare in the past 18 months, and being on a stable dose of oral Asacol for the past 3 months. The exclusion criteria include a history of renal or hepatic disease, allergy or hypersensitivity to certain medications, and recent treatment with immunomodulatory therapy, biologic therapy, or corticosteroids.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is for males and females who are at least 18 years old and have been treated with three classes of drugs for at least 3 months, but have developed resistance to more than one protease inhibitor. The trial involves a new drug called tipranavir, which is to be taken in combination with 2-4 other agents. Patients must have a CD4+ T lymphocyte count of at least 50 cells/\u00b5l and HIV-1 VL of at least 1000 copies/mL at screening. Patients with chronic hepatitis C or B are also eligible. The trial has a list of inclusion and exclusion criteria, including acceptable medical history, adequate baseline organ function, and the use of reliable barrier contraception for female patients of reproductive potential. Patients with a history of certain illnesses or conditions, such as PML or alcohol abuse, are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with hypercholesterolemia or combined hyperlipidemia. The trial is testing the effectiveness of the drug policosanol. The inclusion criteria for the trial include having high LDL values, being between the ages of 18 and 80, and having no communication problems with the investigator. Exclusion criteria include known hypersensitivity to the drug, recent myocardial infarction or PTCA/CABG, unstable angina pectoris, and other serious diseases or circumstances that would prevent participation in the trial. The sample also includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes patients who have been diagnosed with major depressive disorder according to DSM-IV criteria and have a HAM-D17 total score of 22 or higher at screening and baseline. Patients with a CGI-Severity score of 4 or higher at screening and baseline are also eligible. The trial involves the use of the drug agomelatine and a placebo. Patients who complete the core protocol are eligible to participate in the Open-Label Extension Phase. However, patients with a history of bipolar disorder, schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder are excluded from the trial. Patients with any current Axis I disorder other than major depressive disorder, substance or alcohol abuse in the last 30 days, dependence in the last 6 months, concomitant psychotropic medication, including herbal preparations and melatonin, psychotherapy of any type, and female patients of childbearing potential who are not using effective contraception are also excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who have progressed while on or following a first-line chemotherapy regimen for Stage IIIb disease or Stage IV disease. Patients who have received bevacizumab and/or EGFR inhibitors in first-line will also be eligible. The trial has a list of eligibility criteria, including age, performance status, laboratory values, and life expectancy. The trial also has a list of exclusion criteria, including patients with CNS metastases, concurrent malignancy, recent radiotherapy or surgery, and certain medical conditions. Patients who are pregnant or breastfeeding, have significant neurologic or psychiatric disorders, or are unwilling or unable to comply with the protocol are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying pulmonary arterial hypertension and hypertension, pulmonary. The drug being tested is GSK1325760A. The eligibility criteria for participants include completing the 24-week administration of the Phase II/III study, being assessed as appropriate for the long-term extension administration of the drug, and agreeing to sign a new informed consent form. Exclusion criteria include being withdrawn from the Phase II/III study, wishing to become pregnant, needing treatment with other PAH medication, experiencing a worsening of WHO Functional Classification or right ventricular failure during the Phase II/III study, or having rapidly progressing cardiac, hepatic, or renal failure. The decision to participate in the long-term extension study is at the discretion of the investigator or subinvestigator.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is looking at the effectiveness of the drugs bevacizumab and capecitabine in treating metastatic colorectal cancer in patients who are 70 years or older and have been diagnosed with metastatic disease within the past 6 months. The trial has specific inclusion and exclusion criteria, including not having received prior chemotherapeutic treatment for metastatic colorectal cancer and not having a history of other malignancies. Additionally, patients with clinically significant cardiovascular disease or who are currently taking certain medications are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, esophagitis reflux and esophagitis peptic, which are identified by their respective ICD-10 codes. The trial involves the use of three drugs: dexlansoprazole mr, dexlansoprazole mr, and placebo. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which include having successfully completed a previous phase 3 study, not using certain medications during the trial, and not having a need for continuous anticoagulant therapy.",
    "The sample is a phase 3 clinical trial that involves patients with various diseases such as cardiovascular disease, peripheral arterial disease, diabetes mellitus, and coronary heart disease. The trial aims to test the effectiveness of three drugs, namely er niacin/laropiprant, simvastatin, and ezetimibe/simvastatin. The eligibility criteria for the trial include having a history of myocardial infarction, cerebrovascular atherosclerotic disease, peripheral arterial disease, or diabetes mellitus with evidence of symptomatic coronary heart disease. Patients who are less than 50 or more than 80 years old, have a history of chronic liver disease, severe renal insufficiency, or active inflammatory muscle disease, and those who are taking certain medications are excluded from the trial. The trial also requires patients to be compliant with clinic visits and prescribed medication for the duration of the study.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is testing the effectiveness of a combination of drugs, including celecoxib, fluorouracil, and leucovorin calcium. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the colon, being at least 18 years old, having a WHO performance status of 0-1, and having undergone curative radical resection within the past 6 weeks. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, pulmonary, gastrointestinal, and other health criteria. They must not be pregnant or nursing, must use effective contraception if fertile, and must not have any other severe acute or chronic medical condition or laboratory abnormality that would preclude study participation. The trial also has restrictions on prior concurrent therapy, including no concurrent sargramostim or molgramostim, no more than 4 weeks of concurrent orally/nasally inhaled steroids over a 6-month period, and no prior systemic anticancer treatment for colon cancer. Patients must not be concurrently participating in any other clinical study and must not be taking any other experimental agents.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes using insulin degludec, placebo, and liraglutide. The trial includes patients who are insulin na\u00efve and currently being treated with metformin or metformin in combination with other medications. The inclusion criteria require a specific range of glycosylated haemoglobin levels, while the exclusion criteria exclude patients with certain medical conditions or recent use of certain medications. The diseases being studied are diabetes and diabetes mellitus, type 2, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying diabetes mellitus type 2. The icd-10 codes associated with this disease are listed. The drugs being used in the trial are vildagliptin and thiazolidinedione (tzd). The eligibility criteria for participants include having a stable dose of metformin for at least four weeks prior to the trial, being between the ages of 18-80, having a BMI between 22-40 kg/m2, and having an HbA1c level between 7.0 to 10%. There are also exclusion criteria, such as having a history of type 1 diabetes or liver disease, and not having been treated with insulin or any oral anti-diabetic other than metformin within 8 weeks prior to the trial.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial includes the drugs asenapine, olanzapine, and a placebo. The eligibility criteria for the trial require participants to have a current manic or mixed episode and a diagnosis of bipolar I disorder according to the DSM-IV. Participants with unstable medical conditions, clinically significant laboratory abnormalities, or other psychiatric disorders as a primary diagnosis are excluded from the trial. The icd-10 codes associated with bipolar disorder are also included in the table.",
    "The sample is a phase 3 clinical trial for the treatment of adenocarcinoma of the colon, specifically stage III colon cancer. The trial involves the use of drugs such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, and locally directed therapy. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the colon, stage III disease, no resected stage IV disease, and no rectal cancer. Other criteria include having at least one pathologically confirmed positive lymph node, no distant metastatic disease, and meeting certain health requirements such as having a performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 and meeting certain blood count and organ function criteria. Additionally, participants cannot have certain medical conditions or have received certain prior treatments.",
    "The sample is a phase 3 clinical trial for dyslipidemia and kidney disease. The trial involves two drugs, abt-335 plus rosuvastatin and rosuvastatin, and has a list of inclusion and exclusion criteria. Inclusion criteria include dyslipidemic participants with Chronic Kidney Disease Stage 3 and specific laboratory criteria for estimated glomerular filtration rate and fasting lipid results. Exclusion criteria include participants with certain chronic or unstable medical conditions, unstable dose of medications, pregnant or lactating women, poorly controlled diabetes mellitus, and participants of Asian ancestry. The diseases are dyslipidemia and kidney disease, and the icd-10 codes associated with them are listed.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, irritable bowel syndrome with constipation and chronic constipation, which are identified by their corresponding ICD-10 codes. The trial is testing the drug linaclotide. The eligibility criteria for the trial include having completed a pre-treatment period or a previous study, being sexually active and agreeing to use birth control, having a negative pregnancy test, and meeting the protocol criteria for either chronic constipation or IBS-C. The exclusion criteria include not using prohibited medicine, not planning to receive an investigational drug during the study, and not having any unresolved adverse events or clinically significant findings on physical examination, electrocardiogram, or clinical laboratory test.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is testing the effectiveness of the drugs capecitabine and oxaliplatin in treating the disease. The eligibility criteria for patients include having histologically confirmed adenocarcinoma of the rectum, being between the ages of 18 and 80, having a performance status of ECOG 0-2, and having no contraindication to study treatment. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular requirements, and cannot have a history of other cancer except basal cell skin cancer or carcinoma in situ of the cervix, peripheral neuropathy, uncontrolled diabetes, or other uncontrolled severe disease. Patients must not be pregnant or nursing, and fertile patients must use effective contraception. The trial does not allow patients who have had prior chemotherapy or radiotherapy for cancer, or who are participating in another clinical trial of an experimental medical treatment.",
    "The sample is a phase 3 clinical trial for the treatment of macular edema and retinal vein occlusion. The trial involves the use of sham injection, ranibizumab injection 0.3 mg, and ranibizumab injection 0.5 mg. The eligibility criteria include being over 18 years old, having foveal center-involved macular edema secondary to CRVO, and having a BCVA using ETDRS charts of 20/40 to 20/320. The trial also has exclusion criteria, such as a history of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0, uncontrolled blood pressure, and pregnancy or lactation. The study eye must not have a history of retinal vein occlusion, brisk afferent pupillary defect, or any anti-VEGF treatment in the study eye within 3 months prior to Day 0. The trial also has ocular exclusion criteria, such as a history of laser photocoagulation for macular edema within 4 months prior to Day 0 and a substantial cataract that is likely to be decreasing visual acuity by 3 lines or more.",
    "The sample is a phase 3 clinical trial for Crohn's disease. The trial involves the use of methotrexate and placebo drugs. The eligibility criteria for the trial include being 18 years or older, having established Crohn's disease with active symptoms requiring prednisone therapy, and not being pregnant or lactating. Exclusion criteria include intolerance or hypersensitivity to certain medications, being pregnant or planning pregnancy, having had a serious infection or opportunistic infection in the recent past, and having certain medical conditions such as cirrhosis, lung disease, or diabetes mellitus. The trial also excludes individuals who have had certain surgeries or have certain bowel conditions. Additionally, individuals with certain impairments in cardiac, liver, or renal function, as well as those with current or recent malignancy, are excluded from the trial.",
    "The sample is from a clinical trial in phase 3, focused on patients with chronic obstructive pulmonary disease. The trial involves the use of drugs such as tiotropium and olodaterol, as well as a placebo. The eligibility criteria for patients include being a current or ex-smoker with a smoking history of more than 10 pack years, having a diagnosis of COPD, and meeting certain spirometric criteria. Patients must also be able to perform pulmonary function tests and maintain records. There are several exclusion criteria, including having a significant disease other than COPD, a history of asthma, and a diagnosis of thyrotoxicosis or paroxysmal tachycardia. Pregnant or nursing women and patients who have previously been randomized in this study or are currently participating in another study are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on prostate cancer. The trial includes a list of ICD-10 codes for the disease, as well as a list of drugs being tested (zd4054 and placebo). The eligibility criteria for the trial are also listed, including requirements such as a confirmed diagnosis of prostate cancer, increasing PSA levels, and current treatment with surgical or medical castration. The exclusion criteria are also listed, including factors such as current use of opiate-based painkillers, previous chemotherapy treatment, recent heart failure or myocardial infarction, and a history of epilepsy or seizures.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease sepsis and includes a list of associated ICD-10 codes. The trial involves two drugs, drotrecogin alfa (activated) and a placebo. The eligibility criteria for the trial includes adult patients with recent onset of severe sepsis or presence of a suspected or proven infection, and at least one induced organ dysfunction. The exclusion criteria includes patients who are indicated for the treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country, patients who are contraindicated for treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country, and patients with a platelet count less than 30,000/mm3.",
    "The sample is a phase 3 clinical trial for patients who have undergone liver transplantation due to end-stage or fulminant hepatitis C, or liver cirrhosis. The trial is testing a combination of pegylated interferon alfa-2b and rebetol as a treatment. The eligibility criteria include being between 18-70 years old, having persistent HCV viremia after OLT, and being on stable doses of immunosuppression for at least 1 month. The trial also requires that patients have compensated liver disease with minimum hematologic, biochemical, and serologic criteria. Exclusion criteria include being pregnant or breastfeeding, having used any investigational product within 30 days prior to screening, and having received a positive hepatitis C core antibody or HCV positive donor liver graft.",
    "The sample is from a clinical trial in phase 3 and involves patients with lower urinary tract symptoms and benign prostatic hyperplasia. The diseases are identified by their ICD-10 codes. The trial is testing two drugs, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) and tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg). The eligibility criteria for the trial include completion of 12 weeks of double-blind treatment in a previous study, while exclusion criteria include having a significant post-void residual volume of over 150 mL.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with RA for more than 6 months and less than 15 years, have at least 8 tender and swollen joints, and have an abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR). Patients must also be positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibody and have previously been treated with biologic TNF-\u03b1 inhibitor therapy but stopped due to insufficient efficacy or intolerance. Patients must also be regularly using at least 1 conventional disease-modifying anti-rheumatic drug (DMARD) with a stable dose for at least 8 weeks prior to the study start. The trial has various exclusion criteria, including recent use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS), steroid injection or intravenous (IV) infusion, and history of serious reaction to other biological DMARDs. Patients with certain conditions such as fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA are also excluded. Patients must not have had cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years, and must not have received a live vaccine within the past 12 weeks. Patients with hepatitis or human immunodeficiency virus (HIV), a serious bacterial infection, symptoms of herpes zoster or herpes simplex within the last month, active or latent tuberculosis (TB), or current symptoms of a serious disorder or illness are also excluded. Patients who have used an investigational drug within the last month are also excluded.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have been diagnosed with RA for at least 6 months and have had an inadequate response to previous treatments. The trial involves the use of drugs such as rituximab and methotrexate, as well as a placebo. The eligibility criteria include being between the ages of 18-80, having moderate to severe active RA activity, and using MTX for at least 12 weeks prior to the trial. The trial also requires patients to use reliable contraception if they are of reproductive potential. The exclusion criteria include having other rheumatic autoimmune diseases or significant systemic involvement secondary to RA, having a history of cancer or significant cytopenias, and having received certain types of previous treatments.",
    "The sample is a phase 3 clinical trial for the treatment of painful diabetic neuropathy. The trial includes participants who have pain caused by Type 1 or Type 2 diabetes mellitus and have been experiencing daily pain for at least 6 months. The trial involves the use of duloxetine and placebo drugs. The eligibility criteria include confirmation of diagnosis by a score of at least 3 on the Michigan Neuropathy Screening Inventory (MNSI), stable glycemic control, and a score of greater than or equal to 4 on the Brief Pain Inventory (BPI) 24-hour average pain item at Screening. The exclusion criteria include current enrollment in or discontinuation from a clinical trial involving an investigational drug or device, serious or unstable cardiovascular, hepatic, renal, respiratory, or hematologic illness, and prior exposure to drugs known to cause neuropathy.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of olodaterol (bi 1744) and a placebo. The eligibility criteria include being a current or ex-smoker with a smoking history of more than 10-pack years, having a diagnosis of chronic obstructive pulmonary disease, and having a post-bronchodilator FEV1 (Forced Expiratory Volume in 1 sec) of less than 80% of predicted normal and post-bronchodilator FEV1/FVC of less than 70%. Patients must also be able to perform pulmonary function tests and exercise tests, inhale medication from a metered-dose inhaler and Respimat inhaler, and meet other criteria. Exclusion criteria include having certain medical conditions or taking certain medications, having undergone thoracotomy with pulmonary resection, and being pregnant or nursing.",
    "The sample is a phase 3 clinical trial for the treatment of venous thrombosis using the drug arixtra (fondaparinux sodium). The trial is open to patients undergoing open laparotomy gynecologic surgery who are competent to self-administer injections or have caregivers or nurses who can perform injections. Patients must have signed an approved informed consent. However, patients with a medical history that requires chronic anticoagulation, contraindications to anticoagulation, contraindications to placement of ICDs, receiving low molecular weight heparin or unfractionated heparin for prophylaxis post-operatively, unable to receive injections as an outpatient and/or unable to undergo a doppler ultrasound of the lower extremities, renal insufficiency, body weight less than 50 kg, hypersensitivity to low molecular weight heparin, pregnant or have a positive pregnancy test, or receiving continuous (indwelling) epidural are excluded from the trial.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of idiopathic Parkinson's disease. The diseases column lists only one disease, which is idiopathic Parkinson's disease. The icdcodes column lists the ICD-10 code for the disease, which is G20. The drugs column lists the drugs being used in the trial, which are safinamide, safinamide, and placebo. The criteria column lists the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include patients with a diagnosis of idiopathic Parkinson's disease of less than 5 years duration, and a Hoehn and Yahr Stage of I to III, who were receiving treatment with a single dopamine agonist at a stable dose for at least 4 weeks prior to Visit 1 (Screening). Exclusion criteria include patients with medical conditions and/or taking concomitant medications that would have put them at risk, interfered with the study evaluations, or made them unable to complete the requirements of the study, patients with a diagnosis or recent history of substance abuse, a history of psychosis, who were depressed, had evidence of dementia or cognitive dysfunction, or who were experiencing end of dose wearing-off, female patients of childbearing potential, and patients who have previously received safinamide.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes. The trial is testing the effectiveness of insulin glargine, insulin lispro protamine suspension (ilps), and insulin lispro in combination with metformin and at least one other oral antihyperglycemic medication (sulfonylurea or thiazolidinedione). The trial has specific inclusion criteria, such as a hemoglobin A1C (HbA1c) level between 7.5% and 11.0%, a body mass index (BMI) between 25 and 45 kg/m^2, and the ability to follow the protocol. Exclusion criteria include taking any glucose-lowering agents other than those listed in the inclusion criteria, a history of severe hypoglycemia in the past 6 months, pregnancy or breastfeeding, significant cardiac, renal, or liver disease, undergoing therapy for a malignancy, contraindications to the study medications, an irregular sleep/wake cycle, or any serious disease or condition considered exclusionary by the investigator.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for the treatment of ulcerative colitis. The record includes the list of diseases and their corresponding ICD-10 codes, the list of drugs being tested, and the eligibility criteria for the trial. The eligibility criteria include age range, disease severity, and exclusion criteria such as allergies or co-existing illnesses that may contraindicate the administration of the study drug or any study procedures.",
    "The sample is a phase 3 clinical trial for patients with cancer and thromboembolism. The trial involves the use of the drug \"arixtra alone\". The eligibility criteria include documentation of cancer, age over 18, and an acute, radiographically confirmed, de novo Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Exclusion criteria include patients who have received therapeutic doses of any heparin for more than 72 hours before randomization, severe renal impairment, platelet count of less than 50,000 per cubic millimeter, bleeding from the gastrointestinal tract that requires blood transfusion, intracranial bleeding or retroperitoneal bleeding, and allergy to iodine. Patients with brain metastasis secondary to melanoma, choriocarcinoma, renal cell and medullary thyroid carcinoma will also not be included in the study.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial includes patients who have been experiencing overactive bladder symptoms for at least 3 months, with a mean urinary frequency of 8 or more micturitions per 24 hours and a mean number of urgency episodes of 3 or more per 24 hours. The trial involves the drugs fesoterodine and placebo. Patients who have a contraindication to fesoterodine, a known etiology of OAB, a history of acute urinary retention requiring catheterization or severe voiding difficulties, or are unable to follow the study procedures are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia and hyperlipidemia. The trial involves two drugs, laropiprant/niacin (mk0524a) and a placebo comparator. The eligibility criteria include being between 18 and 70 years old, agreeing to use contraception if female, and not having a history of being unable to take niacin or niacin-containing products. Exclusion criteria include consuming more than 2 alcoholic beverages per day, having poorly controlled diabetes, and engaging in vigorous exercise or an aggressive diet regimen. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). The trial includes patients who are current or ex-smokers with a smoking history of at least 10 pack years and have a post-bronchodilator FEV1 (forced expiratory volume in one second) of at least 30% and less than 80% of the predicted normal, and postbronchodilator FEV1/FVC (forced vital capacity) ratio less than 0.7 at Visit 2. The trial excludes pregnant or nursing women, patients requiring long term oxygen therapy, patients with a lower respiratory tract infection within 6 weeks prior to Visit 1, patients with concomitant pulmonary disease, patients with a history of asthma, lung cancer or certain cardiovascular comorbid conditions, patients with a known history and diagnosis of alpha-1 antitrypsin deficiency, patients in the active phase of a supervised pulmonary rehabilitation program, and patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents.",
    "The sample is a phase 3 clinical trial for the treatment of diabetes, specifically type 2 diabetes. The trial involves two drugs, a combination of repaglinide and metformin, and a combination of rosiglitazone and metformin. The trial also includes a list of diseases and their corresponding ICD-10 codes. The eligibility criteria for the trial includes having type 2 diabetes for at least 3 months, having an HbA1c level between 7.5-11.0% on monotherapy or between 7.0-10.0% on dual therapy, and having a maximum BMI of 45 kg/m2. The exclusion criteria includes having any clinically significant disease history, severe heart disease, or being pregnant.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of HIV infection. The trial involves the use of two drugs, tenofovir df and lopinavir/ritonavir with 2 nucleoside rtis. The eligibility criteria for the trial include being HIV positive, over 18 years of age, having an HIV RNA count of over 400 copies/mL, having any CD4 cell count, being antiretroviral na\u00efve, and not having any acute illness. There are no exclusion criteria listed in the sample. The icd-10 code for HIV infection is also included in the record as ['Z21'].",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of several drugs, including gsk573719/gw642444 125/25mcg, gsk573719 125mcg, gw642444 25mcg, and a placebo. The eligibility criteria for the trial include a diagnosis of COPD, a history of smoking, a post-bronchodilator FEV1/FVC ratio of less than 0.7, a predicted FEV1 of 70% or less, and a Modified Medical Research Council (mMRC) dyspnea score of 2 or greater. Exclusion criteria include pregnancy, lactation, or plans to become pregnant, respiratory disorders other than COPD, clinically significant non-respiratory diseases or abnormalities, significant allergy or hypersensitivity to certain medications, recent hospitalization for COPD or pneumonia, recent lung volume reduction surgery, abnormal ECG or laboratory findings, recent use of certain medications, long-term oxygen therapy, regular use of nebulized treatment with short-acting bronchodilators, participation in the acute phase of a pulmonary rehabilitation program, a history of alcohol or drug abuse, affiliation with the investigational site, and previous use of certain medications.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with stage 1 or stage 2 essential hypertension and includes a list of diseases and corresponding ICD-10 codes. The trial involves the use of various drugs, including nebivolol and valsartan, as well as a placebo. The eligibility criteria for the trial include being an outpatient over the age of 18 with normal physical examination findings, ECG results, and chest x-ray. Exclusion criteria include secondary hypertension, clinically significant cardiovascular or respiratory disease, and a medical contraindication to discontinuing current antihypertensive therapy. The sample also includes specific inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial includes patients who have a screening plasma HIV-1 RNA of at least 1000 copies/mL and are ART-experienced, INI-experienced, and DTG na\u00efve. The patients must also have current virological failure on a raltegravir or elvitegravir regimen and their HIV-1 must show genotypic resistance to RAL or ELV at screening. Additionally, the patients must have been on stable ART for at least one month prior to screening and through day 1, with exceptions for ETV, EFV, and NVP that can be interrupted within 14 days of day 1. The trial also requires that the patients have documented resistance to at least one drug from each of two or more of any approved classes of ART other than integrase inhibitors and be able to receive at least one fully active drug as part of the OBR from day 8. Women capable of becoming pregnant must use appropriate contraception during the study. The trial excludes women who are pregnant or breastfeeding, patients with an active AIDS-defining condition at screening (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ <200c/mm3), and patients with moderate to severe hepatic impairment as defined by Child-Pugh classification. Other exclusion criteria include recent history (less than or equal to 3 months) of any upper or lower gastrointestinal bleed, allergy or intolerance to the study drugs or their components or drugs of their class, malignancy within the past 6 months, treatment with an HIV-1 therapeutic vaccine within 90 days of screening, treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of screening, and exposure to an experimental drug or vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP. The trial also excludes patients with any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4 lipids) at screening, ALT> 5 times the upper limit of normal (ULN) at screening, and ALT \u2265 3X ULN and bilirubin > 1.5 X ULN (with 35% direct bilirubin) at screening.",
    "The sample is a phase 3 clinical trial for the treatment of gastric ulcer. The trial involves the use of two drugs, pn400 (vimovo) and pn 400 (vimovo), and the eligibility criteria includes having a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical conditions expected to require daily NSAID therapy for at least 12 months. In addition, male or non-pregnant female subjects who are 18-49 years of age and have a history of a documented, uncomplicated gastric or duodenal ulcer within the past 5 years, or those who are 50 years of age and older are eligible to participate. Female subjects must meet certain criteria related to their potential for pregnancy. Exclusion criteria include a history of hypersensitivity to esomeprazole or to another PPI, participation in any study of an investigational treatment in the 4 weeks before screening, and presence of uncontrolled acute or chronic medical illness that would endanger the subject if they were to participate in the study.",
    "The sample is a phase 3 clinical trial for the treatment of esophageal metaplasia using the drugs ranitidine and pantoprazole. The trial includes patients with dyspeptic symptoms, upper abdominal pain, heartburn, and regurgitation, and who have endoscopically normal appearing GE junction, irregular z-line, or erosive esophagitis up to Grade 2. Patients with Barrett's esophagus, severe esophagitis Grade 3 or 4, documented active duodenal or gastric ulcer, presence of esophageal varices, history of gastric surgery altering normal anatomy, or who are pregnant or nursing are excluded from the trial. The icd-10 codes for the diseases are also provided.",
    "This sample is for a phase 3 clinical trial for the treatment of acute myeloid leukemia. The trial is open to patients who are newly diagnosed with AML, excluding acute promyelocytic leukemia, and are over 60 years old. The trial involves the use of drugs such as cytarabine, idarubicin, all-trans retinoic acid, mitoxantrone, and etoposid. The eligibility criteria include informed consent, molecular and cytogenetical analyses, and exclusion criteria such as uncontrolled infection, kidney or liver insufficiency, and severe neurological or psychiatric disorders. The performance status of the patients should be WHO > 2.",
    "The sample is a phase 3 clinical trial for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. The trial involves the use of extended-release guanfacine hydrochloride, atomoxetine hydrochloride, and a placebo comparator. The eligibility criteria include meeting DSM-IV-TR criteria for a primary diagnosis of ADHD, having a minimum ADHD-RS-IV total score of 32 at baseline, and functioning at an age-appropriate level intellectually. Exclusion criteria include having a current or uncontrolled co-morbid psychiatric diagnosis, a known history or presence of structural cardiac abnormalities, and a history of alcohol or other substance abuse or dependence within the last 6 months.",
    "The sample is a phase 3 clinical trial for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial involves the drugs ofatumumab and ibrutinib. The eligibility criteria include having an ECOG performance status of 0-1, a diagnosis of CLL or SLL that meets IWCLL 2008 criteria, active disease meeting at least 1 of the IWCLL 2008 criteria for requiring treatment, having received at least one prior therapy for CLL/SLL, and being considered not appropriate for treatment or retreatment with purine analog based therapy. The trial also has exclusion criteria, such as a history of certain medical conditions or prior exposure to the study drugs.",
    "The sample is a phase 3 clinical trial for the treatment of allergic rhinoconjunctivitis to grass, with or without asthma, in children between the ages of 5 and 18. The trial involves testing the effectiveness of various drugs, including a placebo, loratadine syrup, olopatadine, mometasone furoate, albuterol, fluticasone, and prednisone. The eligibility criteria include having a clinical history of significant allergic rhinoconjunctivitis to grass, a positive skin prick test response to Phleum pratense, and positive specific IgE against Phleum pratense. Participants must also have an FEV1 of at least 70% of predicted value and meet various other criteria related to safety and willingness to participate. Exclusion criteria include a history of severe asthma, anaphylaxis with cardiorespiratory symptoms, chronic urticaria and angioedema, and various other conditions that could interfere with the study evaluations or optimal participation.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves the use of drugs such as tiotropium and olodaterol. The eligibility criteria for the trial include a diagnosis of COPD, relatively stable airway obstruction, a smoking history of more than 10 pack years, and being 40 years of age or older. Exclusion criteria include significant diseases other than COPD, clinically relevant abnormal lab values, a history of asthma, and a diagnosis of thyrotoxicosis, among others. Patients who are pregnant or nursing, unable to comply with pulmonary medication restrictions, or not using a highly effective method of birth control are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of two drugs, paliperidone extended release (er) and aripiprazole. The eligibility criteria for participants include meeting the DSM-IV criteria for schizophrenia for at least 1 year, having a PANSS score between 60 and 120, and having received treatment with at least 1 antipsychotic before participation in the study. Participants must also have a weight of equal to or greater than 29 kilograms and must not be a danger to themselves or others. Exclusion criteria include a history of substance dependence, certain neurological disorders, and having received a depot injectable antipsychotic within 2 treatment cycles before the screening visit. Female participants must be incapable of pregnancy or must agree to use an acceptable method of contraception for the duration of the study.",
    "The sample is a phase 3 clinical trial for the treatment of pneumonia caused by Pneumocystis jiroveci in individuals with documented or presumptive HIV infection. The trial involves the use of two drugs, pafuramidine maleate and trimethoprim-sulfamethoxazole, and has specific eligibility criteria for inclusion, such as the presence of signs and symptoms of PCP for at least 5 days and a suitable candidate for oral therapy. Exclusion criteria include severe PCP, active illicit drug use, and pregnancy or lactation. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for attention-deficit/hyperactivity disorder. The trial includes subjects who have had an inadequate response to methylphenidate treatment and are aged between 6-17 years. The trial involves the use of two drugs, lisdexamfetamine dimesylate and atomoxetine hydrochloride. The eligibility criteria include meeting the DSM IV TR criteria for a primary diagnosis of ADHD, having a baseline ADHD-RS-IV total score of 28, and not having taken more than one MPH treatment. The exclusion criteria include having failed to respond to more than one previous course of MPH treatment, having previously been exposed to STRATTERA or amphetamine therapy, and having a current or uncontrolled comorbid psychiatric diagnosis with significant symptoms. Conduct disorder is also an exclusionary criterion.",
    "The sample is a phase 3 clinical trial for mood disorders in male and female patients aged 12-18 years. Patients must have a diagnosis of a DSM-IV mood disorder and currently display symptoms of depression/dysthymia or mania/hypomania. The drug being tested is quetiapine. Patients must meet certain inclusion criteria, such as having a legal guardian who understands the study and providing written informed consent. Patients who are pregnant or lactating, have certain medical conditions, or have a history of hypersensitivity to or intolerance to quetiapine are excluded from the study.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer, osteoporosis, and fractures. The trial involves the drug toremifene citrate and has specific eligibility criteria for participants, including being male and over 50 years old, having a documented history of prostate cancer, and meeting certain bone density thresholds. Participants must also have adequate bone marrow, liver, and renal function, and agree to complete a daily diary of medication intake. Exclusion criteria include taking certain medications, having certain medical conditions, and having received prior treatment with toremifene.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who are outpatients and at least 12 years old, with a pre-bronchodilator FEV1 of 40-90% predicted normal and a reversibility FEV1 of at least 12% and 200mL. The trial also requires that the patients have been using inhaled corticosteroids for at least 12 weeks prior to the first visit. The trial excludes patients with a history of life-threatening asthma in the last 10 years, respiratory infection or oral candidiasis, asthma exacerbation requiring oral corticosteroids or overnight hospitalization, uncontrolled disease or clinical abnormality, allergies to study drugs or excipients, taking another investigational medication or prohibited medication, night shift workers, and current smokers or subjects with a smoking history of at least 10 pack years. The trial includes three drugs: fluticasone furoate/vilanterol inhalation powder, fluticasone furoate inhalation powder, and placebo inhalation powder.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial is testing the effectiveness of a combination of alogliptin and glyburide in patients who have been treated with sulfonylurea alone but are experiencing inadequate glycemic control. The trial has eligibility criteria that include a BMI between 23 and 45 kg/m2, fasting C-peptide concentration greater than or equal to 0.8 ng/mL, and glycosylated hemoglobin concentration between 7.0% and 10.0%. Exclusion criteria include a history of cancer, heart failure, or infection with hepatitis B, hepatitis C, or human immunodeficiency virus. The trial also has specific medication and treatment exclusions.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of myocardial infarction, which is identified by a list of ICD-10 codes. The trial involves the use of two drugs, abciximab and abciximab placebo. The eligibility criteria for the trial are listed, including age requirements, time since infarct, and specific symptoms and ST segment elevation. The exclusion criteria are also listed, including various medical conditions and treatments that would make a patient ineligible for the trial. The sample also includes a signed informed consent form.",
    "The sample is a phase 3 clinical trial for asthma. The trial is testing two drugs, mometasone furoate/formoterol (mf/f) mdi and fluticasone propionate/salmeterol (f/sc) dpi. The eligibility criteria for participants include having a diagnosis of asthma for at least 12 months, using a medium daily dose of inhaled glucocorticosteroids for at least 12 weeks, and having a history of asthma-related unscheduled visits to a physician or emergency room. Participants must also have used a total of 12 or more inhalations of SABA rescue medication during the last 10 days of run-in. Exclusion criteria include experiencing a clinical asthma exacerbation or requiring the use of greater than 8 inhalations per day of SABA MDI or 2 or more nebulized treatments per day of 2.5 mg SABA on any 2 consecutive days between the Screening and Baseline Visits.",
    "The sample is a phase 3 clinical trial for patients with refractory epilepsy and simple or complex partial onset seizures. The trial is testing the effectiveness of the drugs retigabine and placebo. The inclusion criteria require patients to have a 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase and be currently treated with up to three established AEDs. The exclusion criteria include existing medical or psychiatric conditions that could affect the patient's health or ability to participate in the study, clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests, impaired renal function, evidence of progressive central nervous disease, lesion, or encephalopathy, history of primary generalized seizures, and history of clustering or flurries or status epilepticus within 12 months of study entry.",
    "The sample is a phase 3 clinical trial for previously-untreated acute myeloid leukemia. The trial is testing the effectiveness of cytarabine plus daunorubicin as a treatment. The eligibility criteria include being 15 years old or older but 65 years or younger, having a Karnofsky score of 50 or more, and having adequate hepatic, renal, and cardiac function. Patients with certain types of leukemia, prior chemotherapy for leukemia or anthracycline treatment for any malignancy, significant active infection, uncontrolled bleeding, significant cardiovascular disease, any coexisting major illness or organ failure, psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlikely, and nursing or pregnant women are excluded from the trial. Patients with a diagnosis of prior malignancy are also excluded unless they have been disease-free for at least 5 years following therapy with curative intent. Signed and dated informed consent must be obtained from all participants.",
    "The sample is a clinical trial in phase 3 for the treatment of breast cancer. The trial is looking at the effectiveness of three drugs: tamoxifen, anastrazole (arimidex), and goserelin acetate (zoladex). The trial is open to premenopausal women who are 20 years or older and have operable and measurable breast cancer. The women must also be estrogen receptor positive and have provided written informed consent. The trial excludes women with a medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Additionally, women who are unwilling to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)) are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of peptic ulcer. The trial involves the use of two drugs, hzt-501 and ibuprofen, and requires patients to meet certain eligibility criteria. Inclusion criteria include the expectation of requiring daily administration of a nonsteroidal anti-inflammatory drug for at least six months, and not having used a NSAID within the 30 days prior to study entry. Exclusion criteria include a history of erosive esophagitis or serious gastrointestinal complications, active cardiac, renal, or hepatic disease, current Helicobacter pylori infection, use of certain medications within 14 days prior to study entry, uncontrolled diabetes or hypertension, positive pregnancy test, positive test for HIV, hepatitis B, or hepatitis C, and participation in an investigational drug study within 30 days prior to study entry. The study center will determine if patients meet all of the criteria.",
    "The sample is a phase 3 clinical trial for kidney transplantation. The trial is looking for patients who are at least 60 years old and have end-stage kidney disease, and are suitable candidates for primary renal transplantation or retransplantation. Patients who have received a kidney transplant from a cadaveric or living donor with compatible ABO blood type can also be included. The trial is testing the drug tacrolimus. The eligibility criteria include exclusion criteria such as patients with immunological high risk, cold ischemia time greater than 30 hours, significant liver disease, allergies or intolerance to study medication, known HIV positive status, malignancy or history of malignancy, and significant, uncontrolled concomitant infections.",
    "The sample is a phase 3 clinical trial for the treatment of autistic disorder. The trial includes children between the ages of 3 and 12 who have been diagnosed with autistic disorder according to the DSM-IV and Autism Diagnostic Interview-Revised (ADI-R). The trial involves the use of two drugs, d-cycloserine and placebo. The eligibility criteria for the trial include a minimum score on the Aberrant Behavior Checklist (ABC) Lethargy Subscale, and exclusion criteria include severe to profound mental retardation, weight below 11 kilograms, and the presence of certain psychiatric or medical conditions. Females of childbearing potential are required to use a suitable form of birth control during the study.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients between the ages of 18 and 75 who have had RA for more than 6 months and are able to receive outpatient treatment. The patients must have been on a stable dose of methotrexate for at least 12 weeks before entering the study. Oral corticosteroids and non-steroidal anti-inflammatory drugs are permitted if the patient has been on a stable dose for 4 weeks before the study. The trial excludes patients who have had major surgery within 8 weeks prior to screening, have a history of or current inflammatory joint disease or rheumatic autoimmune disease other than RA, have had an inadequate response to anti-tumor necrosis factor agents, or have initiated treatment with lipid lowering agents within 12 weeks prior to baseline. The trial will test the effectiveness of tocilizumab, methotrexate, and a placebo.",
    "The sample is a phase 3 trial for the disease glaucoma. The trial includes a list of icd-10 codes associated with the disease. The drugs being tested are dorzolamide hydrochloride (+) timolol maleate, as well as two comparators: timolol maleate and dorzolamide hydrochloride. The eligibility criteria for the trial includes patients with glaucoma and ocular hypertension, but excludes those with a history of ocular surgery within the past 3 months or who have a contradiction to timolol and dorzolamide.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on thyroid cancer. The icd-10 codes associated with the disease are listed, as well as the drugs being tested (lenvatinib and placebo). The eligibility criteria for participants are also listed, including requirements for disease confirmation, measurable disease, and prior treatment history. Additionally, there are exclusion criteria listed, such as having received multiple prior VEGF/VEGFR-targeted therapies or having received any anticancer treatment within a certain timeframe prior to the study. The sample also includes inclusion criteria for a specific treatment period within the trial.",
    "The sample is a phase 3 clinical trial for breast cancer patients with metastatic or locally-recurrent and inoperable cancer. The trial is testing the effectiveness of the drug docetaxel in combination with ramucirumab. The eligibility criteria include having confirmed adenocarcinoma of the breast, being HER2-negative, and not having received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer. Participants must also meet various health criteria, such as having normal liver and kidney function, and must not have any concurrent active malignancy other than breast adenocarcinoma. Exclusion criteria include having a known sensitivity to docetaxel or other drugs formulated with polysorbate 80, having brain metastases or carcinomatous meningitis, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the drugs vildagliptin and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of T2DM, being on a stable dose of insulin and metformin (if applicable), being between the ages of 18 and 80, having an HbA1c level between 7.5 and 11.0%, and having a BMI between 22 and 40 kg/m2. Exclusion criteria include having type 1 diabetes, being pregnant or lactating, having serious diabetic or cardiovascular complications, and having laboratory value abnormalities as defined by the protocol. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for bacterial skin and skin structure infections. The trial includes patients who are 18 years or older and require hospitalization and initial parenteral therapy for at least 48 hours. The trial includes patients with abscesses, wound infections, diabetic foot, and ulcers. The trial also includes patients with infected ischemic ulcers and those with major abscesses associated with extensive cellulitis. The trial excludes patients with certain skin and skin structure infections, known hypersensitivity to certain antibiotics, severe life-threatening diseases, and immunosuppression. The trial also excludes patients with certain medical conditions such as severe hepatic insufficiency, renal impairment, and clinically relevant heart failure. The trial requires written informed consent and a specimen obtained for culture from the infected area. The duration of treatment is anticipated to be at least 7 days.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes mellitus. The trial involves the use of insulin degludec, insulin detemir, and insulin aspart. The eligibility criteria include being diagnosed with type 1 diabetes mellitus, ongoing daily treatment with insulin for at least 3 months prior to screening, and having a maximum HbA1c of 11%. Exclusion criteria include known hypersensitivity to trial products, previous participation in the trial, pregnancy or intent to become pregnant, and significant concomitant disease that could interfere with the trial. The trial requires informed consent and child assent if applicable, and the trial physician will judge if a participant has hypoglycemic unawareness or recurrent severe hypoglycemic events.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating patients with pain, bone neoplasm, and neoplasm metastasis. The trial involves the use of two drugs, ibandronate and zoledronic acid. The eligibility criteria for the trial include patients with malignant bone disease and moderate to severe pain. Exclusion criteria include patients who have received a bisphosphonate within 3 weeks of signing the informed consent, patients receiving concurrent investigational therapy, untreated esophagitis or gastric ulcers, recent or pre-scheduled radiotherapy to bone, and patients who are pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for early rheumatoid arthritis. The trial is looking at the effectiveness of methotrexate as a treatment option. The eligibility criteria for the trial includes having a diagnosis of rheumatoid arthritis with a disease duration of less than 1 year, meeting certain disease activity and joint swelling/tenderness criteria, and being in good health as determined by medical history, laboratory profile, physical examination, chest x-ray, and electrocardiogram. Exclusion criteria includes previous exposure to certain therapies, joint surgery within the preceding two months, chronic infections, and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus. The trial includes eligibility criteria such as having a HbA1c level between 7.1% to 11.0%, a BMI between 25 kg/m2 to 45 kg/m2, and a stable body weight. Participants must have been treated with metformin for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening. Exclusion criteria include a history of cardiac disease, liver disease, renal transplantation, active or untreated malignancy, and contraindications for the oral antidiabetic agent being used. Participants must not have had greater than three episodes of major hypoglycemia within 6 months prior to screening and must not have any known allergies or hypersensitivities to the drugs being used. Additionally, participants must not have been treated with certain excluded medications within 3 months prior to screening and must not be currently enrolled in any other clinical study.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients who are 18 years or older and have operable primary invasive breast cancer. The patients must have completed definitive loco-regional surgery and their primary tumor must be confirmed as triple negative. The trial excludes patients with locally advanced breast cancers, previous breast cancer history, and clinically significant cardiovascular disease. The trial will test the effectiveness of bevacizumab and standard adjuvant chemotherapy as treatments for breast cancer. The diseases column lists only one disease, which is breast cancer, and the icdcodes column lists several ICD-10 codes related to breast cancer.",
    "The sample is a phase 3 clinical trial for the treatment of choroidal neovascularization and age-related macular degeneration. The trial involves the use of intravitreal ranibizumab and photodynamic therapy. The eligibility criteria include patients over 50 years old with subfoveal CNV of any type secondary to AMD, with no recent macula treatment, and a best corrected visual acuity score between 24-73 letters. Exclusion criteria include prior treatment with certain medications or participation in a clinical trial involving anti-angiogenic drugs, ocular disorders that may confound interpretation of the study results, and history of certain eye surgeries or complications.",
    "The sample is a phase 3 clinical trial for patients with HIV infections and chronic hepatitis C. The trial is testing the effectiveness of ribavirin and HIV antiretroviral therapy in treating the diseases. The eligibility criteria for the trial include having a positive Western Blot for HIV, RNA viral hepatitis C, and chronic active C hepatitis on liver histological score METAVIR. Patients must have previously undergone treatment for C hepatitis for at least 3 months, including peg-interferon and ribavirin or peg-interferon alone if counterindication for ribavirin occurred, and failed to eradicate the C hepatitis virus. The trial also requires regular follow-up in an outpatient clinic for HIV and unchanged antiretroviral treatment for the last 3 months before inclusion. Exclusion criteria include a history of transplantation or clinical hepatic failure, opportunistic infection in the past three months before inclusion, any hepatic disease not related to HCV, diabetes mellitus, immunocompromised treatment, active intravenous drug addiction, alcohol consumption of more than 50 g per day, and counterindication for the use of interferon.",
    "The sample is a phase 3 clinical trial for acute myeloid leukemia. The trial is for patients who are not medically fit for combination induction chemotherapy and have newly diagnosed or re-lapsing AML with pathologic confirmation of AML. The trial requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. The trial excludes patients who have had previous cytotoxic or biologic treatment for AML, acute promyelocytic leukemia (APL), central nervous system leukemia, uncontrolled systemic infection, uncompensated disseminated intravascular coagulation, symptomatic neuropathy of grade 2 or worse, or known allergy to imidazole drugs. The drugs being tested in the trial are tipifarnib, zarnestra, and r115777.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial is looking for male and female adults aged 40 years or older who have signed an informed consent form. The patients must be cooperative outpatients with a smoking history of at least 20 pack years and a diagnosis of moderate to severe COPD, as classified by the GOLD Guidelines (2006). The patients must also have a post-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% and at least 30% of the predicted normal value, as well as a post-bronchodilator FEV1/forced vital capacity (FVC) of less than 70%. The trial is testing the effectiveness of two drugs, indacaterol 300 \u03bcg and placebo. The eligibility criteria include exclusion criteria such as pregnant or nursing women, patients requiring oxygen therapy, and patients with a history of lung cancer or a history of cancer with less than 5 years disease-free survival time. The sample also includes other protocol-defined inclusion/exclusion criteria applied to the study.",
    "The sample is a phase 3 clinical trial for kidney transplant recipients who are at least 6 months post-surgery and have a single organ kidney. The trial aims to modify the immunosuppressive regimen of the patients to reduce cardiovascular risk factors. The patients must be at least 30 years old and have a Framingham risk factor score that exceeds the low comparative 10-year CHD risk. The trial involves the use of mycophenolate mofetil as an immunosuppressant and patients must meet certain criteria to be eligible for the trial. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for psoriasis vulgaris, a skin disease. The trial involves the use of various topical treatments, including calcipotriol plus hydrocortisone ointment vehicle, tacalcitol ointment, and calcipotriol plus hydrocortisone ointment. The eligibility criteria for the trial include having a clinical diagnosis of psoriasis vulgaris involving the face, clinical signs of psoriasis vulgaris on the trunk and/or limbs, and an extent of psoriatic involvement of the face of at least 10 cm2. The trial also has exclusion criteria, such as recent use of certain systemic treatments and topical treatments, as well as the presence of certain skin conditions and disorders of calcium metabolism.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of a drug called bi 10773 in treating patients with type 2 diabetes and obesity. The trial includes patients who have been diagnosed with type 2 diabetes and are currently on a diet and exercise regimen, as well as multiple daily injections of insulin and metformin. The patients must have a stable metformin therapy with a daily dose of at least 1500 mg/day or maximum tolerated dose, and their HbA1c levels must be between 7.5% and 10% at screening. The trial excludes patients with uncontrolled hyperglycemia, contraindications to metformin, or who have had acute coronary syndrome, stroke, or TIA within 3 months prior to informed consent. The diseases included in the trial are diabetes mellitus, type 2, and obesity, and their corresponding ICD-10 codes are listed. The eligibility criteria for the trial are also provided.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as saxagliptin, pioglitazone, rosiglitazone, and metformin, as well as a placebo. The eligibility criteria for the trial include having a stable dose of TZD monotherapy for at least 12 weeks prior to screening, a hemoglobin A1c level between 7.0% and 10.5%, a body mass index of 45kg/m2 or less, and a fasting C-peptide level of at least 1 ng/mL. Exclusion criteria include poorly controlled diabetes, recent cardiac or cerebrovascular events, and a serum creatinine level of 2.0 mg/dL or higher.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast cancer. The trial includes patients who are female, have received up to three prior chemotherapy regimens, and have a life expectancy of at least 3 months. The trial involves the drugs eribulin mesylate and capecitabine. The eligibility criteria include having a confirmed diagnosis of breast cancer, resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, and adequate renal, bone marrow, and liver function. Patients must also be willing and able to comply with the study protocol and complete quality of life questionnaires. Exclusion criteria include having received more than three prior chemotherapy regimens, having received capecitabine as a prior therapy, and having significant cardiovascular impairment or pre-existing neuropathy greater than Grade 2.",
    "The sample is from a clinical trial for a drug called zonisamide, which is being tested for its effectiveness in treating partial seizures. The trial is in phase 3 and the eligibility criteria include being between 16 and 70 years old, having a definite diagnosis of partial seizures that are refractory to current anti-epilepsy drug therapy, and having at least 4 partial seizures per month within 12 weeks prior to entry. In addition, participants must be on a stable dose of at least 1-2 concomitant anti-epilepsy drugs for the 3 months prior to enrollment. The trial also has exclusion criteria, such as having a history of alcohol or drug abuse within 2 years, being pregnant or lactating, or having a history of kidney stone. Participants must sign a written informed consent and agree to comply with the protocol.",
    "This sample is for a phase 3 clinical trial for the treatment of prostate cancer using the drug triptorelin pamoate 11.25mg. The eligibility criteria for the trial include having locally advanced or metastatic prostate cancer, being male and over 18 years old, having a screening testosterone level of >125 ng/dL, having a life expectancy of greater than 12 months, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, being willing to give signed informed consent, and being able to adhere to the study visit schedule and other protocol requirements. Exclusion criteria include prior hormonal therapy for prostate cancer, prior surgery or radiotherapy of prostate cancer with curative intent unless disease is verified by a rising prostate specific antigen (PSA) concentration on follow up, presence or history of any other malignancy except for non melanoma skin cancer adequately treated at least 2 years before study entry, and various medical conditions that could confound the ability to interpret data from the study or place the patient at unacceptable risk if they participate in the study.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of sitagliptin, metformin, and a placebo. The eligibility criteria include being currently treated with diet/exercise and on a stable dose of sitagliptin for a certain period of time, having a specific HbA1c level, and not having type 1 diabetes mellitus, secondary diabetes mellitus, or gestational diabetes mellitus.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B. The trial is testing the effectiveness of two drugs, gsk548470 300 mg tablet and etv 0.5 mg capsule. The eligibility criteria for participants include being between 16 and 69 years old, having chronic HBV infection, and meeting certain health requirements such as having a certain level of serum ALT and creatinine clearance. Exclusion criteria include having certain medical conditions or taking certain medications. Participants must also be able to understand and sign a written informed consent form.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with essential hypertension, with a sitting trough clinic systolic blood pressure between 150 and 180 mm Hg, and a 24-hour mean systolic blood pressure between 130 and 170 mm Hg. The trial involves the use of drugs such as azilsartan medoxomil and olmesartan, as well as a placebo. The eligibility criteria include having normal clinical laboratory evaluations, being willing to discontinue current antihypertensive medications, and not having any serious diseases or conditions that would compromise subject safety. The exclusion criteria include having a history of myocardial infarction, heart failure, or other serious medical conditions, as well as being noncompliant with study medication during the placebo run-in period.",
    "The sample is a phase 3 clinical trial for chronic noncancer pain patients who require continuous opioid therapy. The trial is testing the effectiveness of two drugs, oros hydromorphone hcl and oxycodone, for pain control. The inclusion criteria require patients to have never received an opioid or currently be treated with a weak opioid, and to have insufficient pain control. The exclusion criteria include patients who have been treated with strong opioids within the last 4 weeks, patients who will undergo any treatment that may abruptly alter the degree or nature of pain experienced within the next 6 months, patients with a history of disease(s) or current illness that would preclude them from participation, and pregnant or nursing patients.",
    "The sample is a phase 3 clinical trial for patients with stage IIB-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. The trial involves the use of drugs such as carboplatin, cisplatin, paclitaxel, and topotecan hydrochloride. The eligibility criteria include factors such as age (18-75), performance status (ECOG 0-1), and life expectancy (at least 12 weeks). Patients must also meet certain hematopoietic, renal, and cardiovascular requirements, and cannot have any concurrent serious illnesses or medical conditions that would preclude study participation. Prior concurrent therapies are also restricted. The trial allows for concurrent enrollment on CAN-NCIC-OV13/EORTC 55971.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial involves testing the effectiveness of tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), and placebo to tiotropium+olodaterol. The eligibility criteria include patients between 40 and 75 years of age, with a smoking history of more than 10 pack years, and relatively stable airway obstruction. Patients must be able to perform pulmonary function tests and inhale medication from the RESPIMAT inhaler and a metered dose inhaler. Exclusion criteria include patients with significant diseases other than COPD, abnormal baseline haematology, blood chemistry, or urinalysis, a history of asthma, thyrotoxicosis, paroxysmal tachycardia, myocardial infarction within 1 year of screening visit, and other conditions. Patients who have undergone thoracotomy with pulmonary resection, being treated with any oral \u00df-adrenergics, and regularly use daytime oxygen therapy for more than one hour per day are also excluded. Pregnant or nursing women and women of childbearing potential not using a highly effective method of birth control are also excluded.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes associated with those diseases, drugs being used, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on intra-abdominal infections. The icd-10 codes associated with these infections are listed, as well as the two drugs being used in the trial: metronidazole and ceftriaxone sodium. The eligibility criteria for participants are also listed, including age requirements, diagnosis requirements, and exclusion criteria such as known hypersensitivity to the drugs being used or severe underlying diseases.",
    "The sample is a phase 3 clinical trial for chronic low back pain. The trial includes the drug duloxetine and a placebo. The eligibility criteria include being an outpatient over 18 years old, having chronic low back pain, and not having certain medical conditions or psychiatric conditions that could affect participation. Exclusion criteria include having a BMI over 40, major depressive disorder, requiring daily narcotics, and having suicidal risk. The trial aims to measure the effectiveness of duloxetine in treating chronic low back pain.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of colorectal cancer. The trial involves the use of drugs such as bevacizumab, irinotecan, leucovorin, and fluorouracil. The eligibility criteria for the trial include being an adult patient over 18 years of age with histologically confirmed adenocarcinoma of the colon or rectum with metastatic disease, having at least one measurable lesion, and having an ECOG performance status of 1 or less. Exclusion criteria include prior systemic therapy for advanced or metastatic disease, adjuvant or neo-adjuvant treatment for non-metastatic disease in the past 6 months, other malignancy within the past 5 years (except cured basal cell cancer of skin or cured cancer in situ of cervix), and clinically significant cardiovascular disease in the past 6 months. The diseases are listed as 'colorectal cancer', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of atopic dermatitis. The trial involves the use of two drugs, v0034cr01b and desonide 0.1% cream, as well as a vehicle cream. The eligibility criteria for the trial include having atopic dermatitis with a dry skin and an objective SCORAD score of less than 15, as well as xerosis on the body with a score of at least 2 on the anterior part of the lower limbs. The exclusion criteria include having an acute phase or severe form of atopic dermatitis. The diseases column lists only one disease, atopic dermatitis, and the icdcodes column lists the corresponding ICD-10 codes for the disease.",
    "The sample is a phase 3 clinical trial for psoriasis vulgaris, a skin disease. The trial involves the use of a specific drug called calcipotriol plus hydrocortisone (leo 80190) and has eligibility criteria for inclusion and exclusion. Inclusion criteria include having a clinical diagnosis of psoriasis vulgaris involving the face, clinical signs of psoriasis vulgaris on the trunk and/or limbs, and an extent of psoriatic involvement of the face of at least 10 cm2. Exclusion criteria include recent use of certain systemic treatments or biological treatments for psoriasis vulgaris, recent use of certain therapies such as PUVA or UVB therapy, and the presence of certain skin conditions or diseases. The trial also excludes patients with known or suspected severe renal insufficiency or severe hepatic disorders, or known or suspected disorders of calcium metabolism associated with hypercalcaemia.",
    "The sample is a phase 3 clinical trial for primary insomnia. The trial includes patients with a habitual bedtime between 9:00 pm and 1:00 am, and who do not have a history or evidence of restless leg syndrome, periodic limb movement disorder, or sleep apnea. The trial drugs are vec-162 20 mg, placebo, and vec-162 50 mg. The eligibility criteria include a diagnosis of primary insomnia as defined in DSM-IV, and patients must sign a written consent form. The exclusion criteria include a history of drug or alcohol abuse, psychiatric disorders, chronic obstructive pulmonary disease, seizures, sleep apnea, narcolepsy, circadian-rhythm sleep disorder, parasomnia, or any sleep disorder other than chronic insomnia. Recent history of shift work or jet lag is also an exclusion criterion.",
    "The sample is a phase 3 clinical trial for the treatment of binge eating disorder and obesity. The trial involves the use of the drug lamotrigine and a placebo. The eligibility criteria include meeting DSM-IV-TR criteria for BED for at least the last 6 months, having a body mass index greater than 30 kg/m2, and being between the ages of 18 and 65. Exclusion criteria include having a current body mass index less than 30 kg/m2, being pregnant or lactating, displaying clinically significant suicidality or homicidality, and having a history of seizures or a personality disorder that might interfere with assessment or compliance with study procedures. The trial also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial that involves patients with mixed dyslipidemia, coronary heart disease, and dyslipidemia. The trial will test the effectiveness of the drugs abt-335, atorvastatin, and placebo. The eligibility criteria for the trial include subjects with mixed dyslipidemia who agree to use adequate birth control methods and adhere to the American Heart Association diet. Exclusion criteria include patients with unstable medical conditions, those taking certain medications or unstable doses of specific medications, and women who are pregnant or lactating.",
    "The sample is a phase 3 clinical trial that aims to test the effectiveness of the drugs vorapaxar and placebo in treating various diseases such as atherosclerosis, ischemia, myocardial infarction, cerebrovascular accident, and peripheral arterial disease. The trial involves patients who are at least 18 years old and have a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems. The trial has inclusion and exclusion criteria that determine the eligibility of the patients to participate. The inclusion criteria include having a history of myocardial infarction, ischemic stroke, or peripheral arterial disease, while the exclusion criteria include having a bleeding disorder, sustained severe hypertension, or valvular heart disease, among others.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of generalized anxiety disorder. The trial involves the use of two drugs, quetiapine fumarate and paroxetine. The eligibility criteria for participants include being between the ages of 18 and 65, having a diagnosis of generalized anxiety disorder, and not currently experiencing a major depressive episode. Exclusion criteria include a history of schizophrenia or other psychotic disorders, hypertension, and a current diagnosis of cancer unless in remission for at least 5 years. The sample also includes the ICD-10 code for generalized anxiety disorder, which is F41.1.",
    "This is a sample from a clinical trial table for a phase 3 study on schizophrenia. The trial is testing the effectiveness of paliperidone palmitate and placebo drugs. The eligibility criteria for participants include meeting the diagnostic criteria for schizophrenia, having a PANSS total score between 60 to 120, and having a documented history of exposure to either a risperidone or paliperidone formulation. Women of childbearing potential must have a negative pregnancy test and must be using a highly effective method of birth control throughout the study. Exclusion criteria include having a primary active diagnosis other than schizophrenia, a diagnosis of active substance dependence within 3 months before screening, and a history or current presence of any significant or unstable systemic disease.",
    "The sample is a phase 3 clinical trial for acute stroke and cerebral infarction patients. The trial involves the use of citicoline and placebo drugs. The eligibility criteria include being over 18 years old, having a measurable focal neurological deficit lasting for at least 60 minutes, having a CT scan and/or conventional MRI compatible with the clinical diagnosis of acute ischemic stroke, and having an acute ischemic stroke referable to the middle cerebral artery territory. The trial also has exclusion criteria, such as patients in a coma, history of ventricular dysrhythmias, and pre-existing medical conditions that may interfere with the patient's suitability and participation in the study.",
    "The sample is for a phase 3 clinical trial and focuses on the disease of dyspepsia. The trial includes patients between the ages of 18 and 65 who have mild to moderate symptoms of dyspepsia, such as early satiety or discomfort after meals. Patients with gastrointestinal malignancy, peptic ulcer, liver, gallbladder, and pancreas diseases are excluded. The trial involves the administration of two drugs, cinitapride and domperidone. The eligibility criteria include signing an informed consent form, while the exclusion criteria include patients with gastroesophageal reflux, irritable bowel syndrome, acid regurgitation, a history of gastric or duodenal ulcer, depression, anxiety neurosis, arrhythmia, hepatic and renal insufficiency, pathological lactorrhea, alcohol abuse, drug dependence, neuropsychiatric disorders, pregnancy, lactation, and allergies to cinitapride. Patients who require other therapy to change gastrointestinal mobility or who are participating or have participated in other drug clinical trials within 3 months prior to entry are also excluded. The investigators may also exclude patients who are considered inappropriate to participate.",
    "The sample is a phase 3 trial for individuals with elevated high-sensitivity c-reactive protein (hscrp). The trial includes men who are 50 years or older and women who are 60 years or older with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130mg/dL) and elevated levels of C-Reactive Protein (CRP) > 2.0 mg/L. The trial excludes individuals with a history of cardiovascular or cerebrovascular events, active liver disease, diabetes mellitus, uncontrolled hypertension or hypothyroidism, history of certain malignancies, chronic inflammatory conditions, and history of alcohol or drug abuse. The trial involves the use of the drug rosuvastatin.",
    "The sample is a phase 3 clinical trial for patients with chronic neuropathic low back pain. The trial is testing the effectiveness of the drug ralfinamide in treating this type of pain. The inclusion criteria for the trial include having chronic neuropathic low back pain with a minimum intensity of \"40 mm\" or greater on the Visual Analogue Scale (VAS; 100-mm) at screening, and an average of \"40 mm\" or more at baseline (based on prior 7 days). Patients must also have a clear neuropathic component to their pain, as indicated by a rating on the Pain Detect Questionnaire (PD-Q) of greater than 18. The trial is open to patients between the ages of 18 and 85 who are willing and able to understand and sign an approved Informed Consent Form. The exclusion criteria include patients with any other cause of peripheral or central neuropathic pain, pain due to metabolic (including diabetes), infectious or proliferative diseases, or pain due to any condition that is as severe as the neuropathic pain. Patients with severe trophic changes, severe swelling, joint deformities or stiff joint with limited passive movement, or patients who may be candidates for back surgery within 52 weeks after baseline are also excluded. Additionally, patients with clinically significant, uncontrolled gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, asthma, uncompensated chronic obstructive pulmonary disease (COPD), severe uncontrolled diabetes, or second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, significant ECG abnormalities or QTc \u2265 450 msec (males) or \u2265 470 msec (females), where QTc is based on Bazett's correction method, are excluded from the trial.",
    "The sample is a phase 3 clinical trial for chronic plaque psoriasis. The trial includes patients who are 18 years or older and have achieved disease remission with only cyclosporine as systemic therapy for 8-16 weeks. The trial will test the effectiveness of cyclosporine a microemulsion compared to a placebo. The eligibility criteria include specific age range, disease remission status, and PASI score. The exclusion criteria include abnormal renal function, severe chronic degenerative diseases, severe uncontrolled hypertension, body weight over 110 kg, abnormal liver function, hyperkalemia or hyperuricemia, clinically significant impairment of hematopoietic and cardiovascular function, concomitant therapy with nephrotoxic medications, malignancy or a history of malignancy, females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception, clinically significant uncontrolled bacterial, viral or fungal infection, and evidence of drug and/or alcohol abuse.",
    "The sample is a phase 3 clinical trial for infertility. The trial includes women who have undergone controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up, and ICSI. The trial involves embryo transfer on day 3 and the use of two drugs, triptorelin acetate and nacl %0.9. The eligibility criteria include certain conditions that must be met for a woman to participate in the trial, while the exclusion criteria include conditions that would prevent a woman from participating.",
    "The sample is a phase 3 clinical trial for the treatment of antibiotic-associated diarrhea and clostridium difficile. The trial involves the use of saccharomyces boulardii and a placebo. The eligibility criteria for the trial include being an adult patient who is hospitalized and receiving systemic antibiotic treatment, being contractually capable and able to follow study procedures, and providing informed consent. Exclusion criteria include having an allergy to yeast or the study medication, having a central venous catheter, being immunosuppressed, having diarrhea or chronic diarrhea, and having taken certain medications within a certain timeframe. The trial does not allow for simultaneous participation in other clinical trials and requires protection against conception, pregnancy, or lactation.",
    "The sample is a phase 3 clinical trial for patients aged 18-85 with major abscess, surgical site infection, traumatic wound infection, or cellulitis suspected or confirmed to be caused by Gram-positive bacteria. The trial involves two drugs, dalbavancin and vancomycin/linezolid, and requires a minimum of 3 days of IV therapy. The eligibility criteria include having at least two local signs and symptoms of ABSSSI and at least one systemic sign of infection, and being willing and able to comply with study procedures. Exclusion criteria include contra-indications to the study drugs, sustained shock, participation in another study of an investigational drug or device within 30 days, and various other conditions that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.",
    "The sample is a phase 3 clinical trial for patients aged 3 to 18 years who have cerebral palsy, mental retardation, or any other neurological impairment or condition, and suffer from chronic drooling. The trial is testing the effectiveness of oral glycopyrrolate liquid as a treatment for drooling. Patients must meet certain inclusion criteria, such as having a Modified Teacher's Drooling Scale score of at least 5, and must not meet any of the exclusion criteria, such as having a contraindication to the study medication or being pregnant or breastfeeding. The trial requires reliable parents/caregivers who are willing and capable of administering medications, and patients must provide written informed consent and assent if mentally capable.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia. The trial involves the use of dutasteride (avodart) and placebo drugs. The eligibility criteria for the trial include being a male at least 50 years of age, having a peak urinary flow rate between 4-15 ml/sec, a voided volume of at least 125 ml, and a prostate volume greater than 30 grams. The patient must also have an AUA-SI score of 9 or higher and be scheduled for a Laser TURP or eligible for one. Exclusion criteria include prior surgical intervention for BPH, receiving any intervention for prostate disease, or having a previous hypersensitivity to dutasteride. The patient must also not have taken certain medications within a certain timeframe, have certain medical conditions, or have had certain surgeries or procedures.",
    "The sample is a phase 3 clinical trial for type 2 diabetes mellitus. The trial includes patients who are male or female, between the ages of 18 and 77, and have a pre-randomization A1C level between 7.0 and 10.0%. Patients must also have a C-peptide level of at least 1.0 ng/mL, a body mass index of 45 kg/m\u00b2 or less, and be able to perform self-monitoring of blood glucose. The trial involves the drugs dapagliflozin and placebo. The eligibility criteria include exclusion criteria such as abnormal levels of AST and/or ALT, high levels of serum total bilirubin, high levels of creatinine kinase, and high levels of serum creatinine. Patients with unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases are also excluded.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The trial includes patients with histologically confirmed invasive carcinoma of the female breast, with 0-3 positive axillary lymph nodes. The trial also includes patients with estrogen-receptor and/or progesterone receptor negative, positive, or unknown tumors, and HER2 positive, negative or unknown disease. Patients must have undergone either modified radical mastectomy or lumpectomy, and all primary breast and axillary node surgery must be completed prior to enrollment on the study. Patients must be disease-free from prior malignancies for > 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix. The trial includes a list of drugs, eligibility criteria, and a list of diseases and icd-10 codes.",
    "The sample is a phase 3 clinical trial for the treatment of allergic rhinitis. The trial is open to male and female subjects between the ages of 4 and 12 who have a history of allergic rhinitis. The trial requires the use of Dymista Nasal Spray and fluticasone propionate nasal spray. The eligibility criteria include being in good health, free of any disease or concomitant treatment that could interfere with the interpretation of the study results, and willing and able to comply with the study requirements. The exclusion criteria include having certain nasal diseases, hypersensitivity to certain drugs, respiratory tract infections within two weeks prior to the visit, and certain surgical or medical conditions that might significantly alter the absorption, distribution, metabolism, or excretion of the study drug. The trial also excludes family members of research center or private practice personnel who are directly involved in the study and members of the same family cannot enroll in the study at the same time.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease acromegaly and includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, c2l-oct-01 pr and octreotide acetate prolonged release, both at a dose of 30 mg. The eligibility criteria for the trial include a diagnosis of active acromegaly, a stable treatment regimen for at least 12 weeks prior to entry, and normal IGF-1 levels for subjects treated with a 30 mg dose of a depot formulation of a somatostatin analogue. The exclusion criteria include pregnancy or lactation in women of childbearing potential, previous treatment with a growth hormone receptor antagonist within 12 weeks of study entry, and intolerance or allergy to the test article or its non-active ingredients.",
    "The sample is a phase 3 clinical trial for fibromyalgia. The trial includes male and female subjects who are 18 years or older and meet the American College of Rheumatology diagnostic criteria for fibromyalgia. The trial involves the drugs xyrem\u00ae and placebo. The eligibility criteria for inclusion include meeting the ACR diagnostic criteria for fibromyalgia, while exclusion criteria include having a history of rheumatic disease or other disorders that may compromise reliable representation of subjective symptoms, as well as any other condition that may cause a risk to subjects if they participate in the trial.",
    "The sample is a phase 3 clinical trial for Attention Deficit Hyperactivity Disorder (ADHD) patients. The trial includes patients who have been diagnosed with one of the three subtypes of ADHD and have taken methylphenidate in the past without any significant adverse experiences. The patients must agree to take only the supplied study drug as treatment for ADHD during the three-week treatment phase of the study. The trial also includes inclusion and exclusion criteria, such as being able to comply with the study visit schedule and not having clinically significant gastrointestinal problems or glaucoma. Female patients who have begun menstruation are also excluded from the trial. The table includes columns for the phase of the trial, diseases, icd-10 codes, drugs, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis C. The trial is testing the effectiveness of the drugs telaprevir and ribavirin on patients with genotype 1 chronic hepatitis C. The eligibility criteria includes being between 18 and 70 years old, having detectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA), and having acceptable screening laboratory values, tests, and physical exam results. Patients must also be willing to follow contraception requirements and sign an informed consent form. Exclusion criteria includes having contraindications to Pegasys\u00ae or Copegus\u00ae therapy, evidence of hepatic decompensation in cirrhotic subjects, history of organ transplant, or any current medical condition that could impact the safety of the subject in participation in the study.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug desvenlafaxine succinate. The trial includes outpatients who have completed a previous short-term study for MDD with no major protocol violations or study events that would prevent their entry into the long-term study. Sexually active participants must use contraception during the trial and for 15 days after the last dose of the study drug. Exclusion criteria include clinically significant abnormalities on physical examination or previous test results, significant risk of suicide, and presence of other medical conditions that could compromise the study or be detrimental to the subject.",
    "The sample is a record of a clinical trial in phase 3, focused on cytomegalovirus infections. The trial involves the use of valganciclovir as a treatment option. The eligibility criteria for the trial include being at least 16 years old, having received a renal allograft from a seropositive donor, having adequate hematological and renal function, and agreeing to maintain effective birth control for 90 days following cessation of study medication. Exclusion criteria include having CMV disease or receiving anti-CMV therapy within 30 days prior to screening, being a multi-organ transplant recipient, being positive for hepatitis B, hepatitis C, or HIV, and being pregnant or lactating.",
    "The sample is a phase 3 trial for the treatment of mania and bipolar disorder. The trial includes patients with specific icd-10 codes and requires written informed consent from the patient's legal guardian. Patients must have a YMRS total score of at least 20 at both screening and randomization. The trial involves the use of two drugs, quetiapine fumarate and lithium. Patients who have a known intolerance or lack of response to these drugs or have a known or suspected hypersensitivity to them are excluded from the trial.",
    "The sample is a phase 3 clinical trial for pediatric subjects with severe forms of sickle cell anemia who have had a completed overt clinical stroke after the age of one year with documented infarction on brain CT or MRI. The trial requires at least 18 months of chronic monthly erythrocyte transfusions since primary stroke and transfusional iron overload. The drug being tested is hydroxyurea. The eligibility criteria include age range of 5.0-18.9 years, inclusive, and adequate monthly erythrocyte transfusions with average HbS less than or equal to 45%. The exclusion criteria include inability to receive or tolerate chronic RBC transfusion therapy, inability to take or tolerate daily oral hydroxyurea, and clinical and laboratory evidence of hypersplenism. The trial requires compliance with study-related treatments, evaluations, and follow-up.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of erosive esophagitis. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, including lafutidine, famotidine, and omeprazole. The eligibility criteria for the trial are also included, with specific inclusion and exclusion criteria listed. In order to be included in the trial, patients must have symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification. Patients with gastric or duodenal ulcers, concurrent presence of Barrett's esophagus, a history of poor response to H2RA or PPI, or other conditions that may affect the assessment of efficacy and safety are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with chronic kidney disease and hyperphosphatemia. The trial involves testing the effectiveness of three different drugs, including mci-196, placebo, and sevelamer, in controlling phosphate levels. The eligibility criteria for the trial include being 18 years or older, having stable phosphate control, being on a stabilized phosphorus diet, and having no significant medical comorbidities that would make the subject unsuitable for inclusion in the study. Exclusion criteria include having a BMI below 16.0 kg/m2 or above 40.0 kg/m2, having significant gastrointestinal motility problems, testing positive for HIV 1 and 2 antibodies, having a history of substance or alcohol abuse within the last year, having seizure disorders, having a history of drug or other allergy, having a temporary catheter as a vascular access, or having participated in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent.",
    "The sample is a phase 3 clinical trial for bipolar disorder and depression. The trial includes patients who meet the DSM-IV criteria for Bipolar I disorder, with or without rapid cycling and without psychotic features. Patients must have received a therapeutic dose of lithium, valproate or lamotrigine for at least 4 weeks prior to randomization. The trial involves the drugs ziprasidone and placebo. The eligibility criteria include exclusion of patients with ultra-fast rapid cycling, significant heart disease, and psychotic symptoms.",
    "The sample is a phase 3 clinical trial for patients with multiple myeloma who require second, third, or fourth-line therapy due to disease progression. The trial is testing the drug bortezomib. The eligibility criteria include having measurable disease, a Karnofsky performance status of at least 60%, and a life expectancy of more than 3 months. Patients must also meet certain laboratory value requirements and have not previously received treatment with VELCADE. Exclusion criteria include previous refractory treatment with high-dose dexamethasone, recent chemotherapy or radiation therapy, and certain medical conditions such as poorly controlled hypertension or diabetes. Female patients must not be pregnant or breastfeeding. Patients must also not be enrolled in another clinical research study or receiving an investigational agent.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, prostate cancer), the ICD-10 codes associated with the disease, the drugs being used in the trial (antiandrogen therapy and releasing hormone agonist therapy), and the eligibility criteria for patients to participate in the trial. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy. The sample also includes detailed information about the disease characteristics, patient characteristics, and prior concurrent therapy requirements.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes female patients between the ages of 18 and 70 with histologically proven, core-biopsied, invasive breast cancer of any clinical and/or radiological T-stage (except for T4d). The trial involves the use of the drugs epirubicin, docetaxel, capecitabine, and trastuzumab. The eligibility criteria include normal cardiac function, no prior or current neoplasm except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, and no distant disease/secondary carcinoma judged clinically and at least by chest X-ray, liver sonography, and bone scan upon randomization. The exclusion criteria include stage T4d/inflammatory breast cancer, pregnant or lactating patients, pre-existing motor or sensory neurotoxicity of a severity \u2265 WHO grade 2, preoperative local treatment for breast cancer, prior or concomitant systemic antitumor therapy, and other serious illness or medical condition.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of type 2 diabetes mellitus. The icd-10 codes associated with the disease are listed as E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The trial involves the drugs vildagliptin and placebo. The eligibility criteria for the trial include a history of type 2 diabetes mellitus and moderate or severe renal impairment. The exclusion criteria include a glucose level above 270 mg/dL or 15 mmol/L. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with cystic fibrosis who have had their first or early lower respiratory tract infection with Pseudomonas aeruginosa. The trial is testing the effectiveness of tobramycin solution for inhalation 300 mg as a treatment. The eligibility criteria include being at least 6 months old, having a confirmed diagnosis of cystic fibrosis, and meeting specific criteria for Pseudomonas infection. Exclusion criteria include hypersensitivity to aminoglycosides, signs of acute pulmonary disease, recent use of investigational drugs or loop diuretics, and abnormal hearing or pregnancy. The trial requires written informed consent from patients or their legal guardians.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on pain. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which are oxycodone cr and r331333 (also known as jns024 er or cg5503). The eligibility criteria for participants are also listed, including a documented clinical diagnosis of any type of cancer, chronic malignant tumor-related cancer pain with an average score for pain intensity in the past 24 hours of >=4 on the 11-point numerical rating scale, and not having received treatment with opioid analgesics within 28 days before screening. There are also exclusion criteria listed, such as having complicated uncontrolled/clinically significant arrhythmia, previous or concurrent presence of any disease which may develop increased intracranial pressure, and history of alcohol and/or drug abuse.",
    "The sample is a phase 3 clinical trial for patients with chronic renal insufficiency and type 2 diabetes. The trial is testing the effectiveness of bardoxolone methyl, a drug, compared to a placebo. The eligibility criteria include having a screening eGFR between 15.0 and 30.0 mL/min/1.73 m2, a history of type 2 diabetes, and being at least 18 years old. Patients must also be taking an ACE inhibitor and/or an ARB for at least 6 weeks prior to and during screening. The trial also has exclusion criteria, such as having type 1 diabetes, ongoing clinical evidence suggesting non-diabetic renal disease, and a history of a renal transplant. Patients must be willing to practice methods of birth control during the entire study period and for at least 30 days after the last dose of the study drug is ingested. The trial requires patients to give written informed consent for study participation and provide consent for access to medical data according to appropriate local data protection legislation, allowing authorization to access medical records and describe events captured in the endpoints.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease diabetes mellitus, type 2. The icd-10 codes associated with the disease are listed. The trial involves testing the effectiveness of different drug combinations, including valsartan 160 mg + nateglinide 60 mg, valsartan 160 mg + nateglinide placebo, nateglinide 60 mg + valsartan placebo, and valsartan placebo + nateglinide placebo. The eligibility criteria for the trial are listed, including age and glucose tolerance requirements, as well as exclusion criteria, which includes having frank diabetes. Contact information is provided for more detailed information about the trial.",
    "The sample is a phase 3 clinical trial for patients with hypercholesterolemia. The trial is looking at the effectiveness of ezetimibe and several other statin drugs as compared to a placebo. The eligibility criteria include being male or female over 18 years of age, having a diagnosis of primary hypercholesterolemia and being defined as \"high risk\" with a diagnosis of CAD or diabetes, having a serum LDL-C > 2.0 mmol/L while on any statin at below maximum daily dose for a minimum of four weeks prior to the baseline visit, and being of South Asian descent. The exclusion criteria include having any condition that would render the patient unable to complete the study or for which study participation would produce significant risk or not be in the best interests of the patient, having cancer within the past 5 years (except for successfully treated basal and squamous cell carcinoma), and having disorders of the hematologic, digestive, or central nervous system that would limit study evaluation or participation.",
    "The sample is a record of a clinical trial in phase 3 for chronic obstructive pulmonary disease. The trial involves the use of two drugs, budesonide/formoterol (symbicort) pmdi and formoterol turbuhaler. The eligibility criteria for the trial include having a current clinical diagnosis of COPD with symptoms for more than 2 years, being a current smoker or having a smoking history of 10 or more pack years, and having a history of at least 1 COPD exacerbation requiring a course of steroids and/or antibiotics within 1-12 months before the first visit. The exclusion criteria include having a history of asthma or allergic rhinitis at or after 18 years of age, taking oral steroids, or having any significant disease or disorder that may jeopardize the subject's safety.",
    "This sample is for a phase 3 clinical trial for the treatment of hyperlipidemia. The trial involves the use of drugs such as fenofibrate/simvastatin and simvastatin. The eligibility criteria for the trial includes having mixed dyslipidemia, while exclusion criteria includes known hypersensitivity to the drugs, pregnancy or lactation, contra-indication to the drugs, and unstable or severe cardiac disease.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes participants who have had one of the specified induction therapies for treatment of Stage IIIB or IV NSCLC and have received only one chemotherapeutic doublet lasting precisely 4 cycles. The trial requires documented evidence of a tumor response of complete response, partial response, or stable disease. Participants who have received prior systemic anticancer therapy or any systemic treatment for any other cancer will not be included. The trial also excludes participants who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Participants must be able to comply with the protocol and study procedures and not have a serious concomitant systemic disorder that would compromise their ability to complete the study. Additionally, participants with a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV, will be excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease pharyngitis and includes a list of associated ICD-10 codes. The trial involves testing the effectiveness of three drugs: placebo, flurbiprofen, and acetaminophen 650mg. The eligibility criteria for participants include having a complaint of sore throat, providing written informed consent, and meeting certain medical requirements. Exclusion criteria include a history of upper gastrointestinal ulcer, hepatic disease, renal dysfunction, or chronic analgesic use.",
    "The sample is a phase 3 clinical trial for eczema. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria require subjects to have a diagnosis of eczema with specific symptoms, less than 10% body surface area involvement, and a score of 3 or higher on the investigators global assessment of eczema severity. The exclusion criteria include any systemic disorder or active skin disease that could interfere with the study results, recent exposure to certain therapies, and a history of allergies or anaphylaxis.",
    "The sample is a phase 3 clinical trial for the treatment of melanoma. The trial is looking for patients with Stage IIIC (unresectable) or Stage IV (metastatic) melanoma that is determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay. The patients must have a radiologically measurable tumor and be able to carry out daily life activities without significant difficulty. They must also be able to swallow and retain oral medication and use acceptable methods of contraception during the course of the study if sexually active. The trial has certain exclusion criteria, such as prior treatment with a BRAF or a MEK inhibitor, prior systemic anti-cancer treatment for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma, and current use of prohibited medication listed in the protocol. The trial also excludes patients with certain medical conditions, such as left ventricular ejection fraction less than the lower limit of normal, uncontrolled blood pressure, and history or current evidence of retinal vein occlusion or central serous retinopathy. Patients with brain metastases are eligible if they have been previously treated with surgery or stereotactic radiosurgery and the disease has been stable for at least 12 weeks. The trial does not allow pregnant or nursing patients to participate.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension. The trial is testing the effectiveness of two drugs, telmisartan+amlodipine and amlodipine, in treating hypertension. The eligibility criteria for the trial include being an outpatient, being able to provide written informed consent, and having essential hypertension. Exclusion criteria include having certain medical conditions such as congestive heart failure or a history of stroke, being pregnant or nursing, having drug or alcohol dependency, and not being compliant with the study requirements. The trial is being conducted in accordance with Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.",
    "The sample is a phase 3 clinical trial for the treatment of common cold and pharyngitis. The trial involves the use of drugs such as acetylsalicylic acid (aspirin complex, baye4465) + pseudoephedrine, acetylsalicylic acid (aspirin, baye4465), pseudoephedrine, and placebo. The eligibility criteria for the trial include being between 18 and 65 years of age, having onset of cold symptoms within 96 hours before study participation, and having a current complaint of at least moderate sore throat and nasal congestion at baseline. The trial also has exclusion criteria such as pregnancy or lactation, uncontrolled chronic diseases, and history of hypersensitivity to certain drugs. Participants must agree to comply with the study requirements and provide written informed consent prior to enrollment.",
    "The sample is a phase 3 clinical trial for multiple sclerosis. The eligibility criteria include having a single, first clinical event suggestive of MS within 60 days prior to study Day 1, at least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 millimeter (mm), at least one of which is ovoid or periventricular or infratentorial, EDSS 0 - 5.0 at least one time point during the screening period before start of treatment, being between 18 and 50 years old, willing to follow study procedures, and providing written informed consent. Exclusion criteria include having a diagnosis of MS, any other disease that could better explain the subject's signs and symptoms, complete transverse myelitis or bilateral optic neuritis, using or having used any other approved MS disease-modifying drug (DMD), any investigational drug or undergone an experimental procedure within 12 weeks prior to study Day 1, and more.",
    "The sample is a phase 3 clinical trial for osteoarthritis. The eligibility criteria include being 50 years or older, having a diagnosis of OA of the hip as defined by the American College of Rheumatology criteria, having symptomatic OA with daily hip pain for at least 1 month, having hip pain of > or equal to 3 and < or equal to 9 on a 10-point Visual Numerical Scale in the index hip, being functional class I, II or III according to the Steinbrocker criteria, being eligible for pharmacologic treatment to control arthritis symptoms, and providing written informed consent before undergoing any study procedures. The exclusion criteria include having bilateral hip OA with contralateral hip more severe symptomatically or radiologically than the index hip, having evidence of secondary hip OA, having a concomitant inflammatory rheumatic condition, which may interfere with the assessment of OA, or acute joint trauma at the index hip, and having received oral, intramuscular, intravenous, or soft tissue injection of corticosteroids within 4 weeks prior to the screening visit. The study drug being tested is celecoxib.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves testing multiple IOP-lowering medications, including brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, brinzolamide 1% ophthalmic suspension, and brimonidine tartrate 0.2% ophthalmic solution. The eligibility criteria for the trial include being diagnosed with open-angle glaucoma or ocular hypertension and being insufficiently controlled on monotherapy or currently on multiple IOP-lowering medications. Other inclusion criteria include meeting qualifying IOP entry criteria, being able to understand and sign an informed consent form, and meeting other protocol-specified inclusion criteria. Exclusion criteria include severe central visual field loss, BCVA score worse than 55 ETDRS letters, chronic, recurrent or severe inflammatory eye disease, recent ocular trauma or infection, clinically significant or progressive retinal disease, recent intraocular or ocular laser surgery, and any other conditions that would make the subject unsuitable for the study. Other protocol-specified exclusion criteria may also apply.",
    "This sample is for a phase 3 clinical trial for the treatment of osteoporosis using the drug bazedoxifene acetate. The trial is looking for postmenopausal women who either have osteoporosis without vertebral fracture but meet bone mineral density criteria, or have osteoporosis with vertebral fracture. The inclusion and exclusion criteria are listed in the \"criteria\" column. The \"diseases\" column lists only osteoporosis, and the \"icdcodes\" column lists the ICD-10 codes associated with osteoporosis.",
    "The sample is a phase 3 clinical trial for the treatment of heavy menstrual bleeding. The trial is open to non-pregnant, non-lactating, non-menopausal females who are at least 18 years old and have been diagnosed with functional Menorrhagia in the last 6 months. The trial involves the use of two drugs, levosert-20 and mirena. The eligibility criteria include various medical conditions and factors, such as abnormal liver function, renal insufficiency, and a BMI over 30. The exclusion criteria include a history of endometrial ablation or dilatation, abnormal uterine bleeding caused by organic factors, and known or suspected pregnancy. The trial requires written consent from participants after they have been informed about the purpose and nature of the investigation.",
    "The sample is a phase 3 clinical trial for patients with adenocarcinoma of the lung, with or without BAC features, but not combined with other histology such as small cell carcinoma or squamous carcinoma. The trial is testing the drug gefitinib. Patients must be between the ages of 18-75, have an ECOG performance status of 0-2, and have never smoked more than 100 cigarettes in their lifetime. They must also meet certain laboratory criteria and have no prior invasive malignancies within the past 5 years, except for adequately treated cutaneous basal cell carcinoma or uterine cervix in situ cancer. Patients with CNS metastases are not excluded as long as their symptoms are well-controlled with corticosteroids. Exclusion criteria include pregnancy or breastfeeding, major surgery other than biopsy within the past two weeks, severe hypersensitivity to gefitinib or any of its excipients, clinically active interstitial lung disease, and other significant clinical disorders or laboratory findings that make it undesirable for the subject to participate in the study. Concomitant use of certain drugs is also excluded.",
    "The sample is a record of a clinical trial in phase 3, which is focused on chronic low back pain. The trial involves the use of two drugs, duloxetine and placebo, and includes a list of inclusion and exclusion criteria for participants. The diseases associated with the trial are listed as \"back pain without radiation,\" and the icd-10 codes associated with these diseases are also provided. The table also includes the phase of the trial, the list of drugs being tested, and the eligibility criteria for participants.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking at the effectiveness of candesartan cilexetil and hydrochlorothiazide in treating primary hypertension. Patients must have untreated or treated hypertension with a maximum of 2 antihypertensive drugs, which they and their physician are willing to withdraw and change to candesartan monotherapy. Patients must also have a mean sitting diastolic blood pressure (DBP) between 90-114 mmHg. The trial has inclusion and exclusion criteria, including not being involved in the planning or conduct of the study, not being pregnant or lactating, not having secondary or malignant hypertension, and not having certain medical conditions or taking certain medications. Patients must also have a certain level of compliance with the study medication during the run-in phase.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with type 2 diabetes mellitus and involves the use of drugs such as canagliflozin and sitagliptin, as well as a placebo. The trial includes eligibility criteria for patients to be included, such as having an HbA1c between 7% and 10% and a fasting plasma glucose level below 270 mg/dL. There are also exclusion criteria, such as a history of diabetic ketoacidosis or severe hypoglycemic episodes within the past 6 months. The sample also includes a list of ICD-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial includes patients who have undergone curative surgery not less than 4 and not more than 8 weeks prior to randomization. The trial aims to test the effectiveness of a combination of drugs including capecitabine, 5-fluorouracil (5-fu), leucovorin calcium, and oxaliplatin. The eligibility criteria for the trial include patients who are willing and able to comply with the protocol, age \u2265 18 years-of-age, and have histologically confirmed colon carcinoma, American Joint Cancer Committee/Union Internationale Contre le Cancer (AJCC/UICC) Stage II or Stage III. The trial also has exclusion criteria, including patients with macroscopic or microscopic evidence of remaining tumor, history of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for oral drug intake, and clinically significant (ie, active) cardiovascular disease.",
    "The sample is a phase 3 clinical trial for metastatic breast cancer patients with confirmed amplification of the ErbB2 gene. The trial is testing the effectiveness of the drug lapatinib. The eligibility criteria include having previously received taxane and anthracycline-containing regimens, as well as trastuzumab plus cytotoxic chemotherapy or anti-hormonal regimen in the metastatic setting. The trial also requires archived tumor tissue available for testing and at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors. The exclusion criteria include concurrent cancer therapy, active or uncontrolled infection, and unresolved or unstable serious toxicity from prior administration of another investigational drug or prior cancer treatment.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the disease cystic fibrosis. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including pancrelipase delayed release and a placebo comparator. The eligibility criteria for the trial are listed, including requirements for a confirmed diagnosis of cystic fibrosis, pancreatic enzyme insufficiency, and stable treatment with a pancreatic enzyme product. The criteria also include exclusion factors such as a history of fibrosing colonopathy or use of immunosuppressive drugs. Females of child-bearing potential must agree to continue using a medically acceptable method of birth control.",
    "The sample is a phase 3 clinical trial for attention deficit disorder with hyperactivity. The trial involves patients who have completed a previous study and have been diagnosed with ADHD according to the DSM-IV and confirmed by the CAADID. Patients must be healthy and able to comply with the study visit schedule and assessments. They must also have completed at least 52 weeks of open-label treatment and must have been on a stable daily dose of (PR) OROS methlyphenidate prior to inclusion in this phase. The trial involves the use of double-blind placebo and double-blind pr oros methylphenidate, as well as open label pr oros methylphenidate. The eligibility criteria include a written informed consent and exclusion criteria include non-responsiveness to methylphenidate, allergy or hypersensitivity to methlyphenidate, clinically unstable psychiatric conditions, use of other anti-depressants or mood stabilizers, and any medication likely to interfere with safe administration of methylphenidate.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial is looking at the effectiveness of a combination of drugs including docetaxel, trastuzumab, epirubicin, cyclophosphamide, 5-fluoruracil, and granulocyte-colony stimulating growth factor. The trial is open to premenopausal or postmenopausal women aged 18-75 years old who have histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma with HER2/c-neu over expression. Participants must have had surgical excision of the primary tumor with tumor-free operation margins and at least 10 axillary lymph nodes removed. They must also have tumor involvement of at least one axillary lymph node and no clinical or radiological evidence of local or metastatic disease. Participants must have adequate bone marrow, liver, renal, and cardiac function, and must provide written informed consent. Exclusion criteria include a positive pregnancy test, psychiatric illness or social situation that would preclude study compliance, other concurrent uncontrolled illness, prior or concurrent antineoplastic therapy, and previous history of other invasive malignancy other than non-melanomatous skin cancer.",
    "The sample is a phase 3 clinical trial for patients with visual impairment caused by macular edema following branch retinal vein occlusion (BRVO). The trial is testing the effectiveness of the drug ranibizumab. The eligibility criteria include a diagnosis of BRVO within the past 6 months, a BCVA (best corrected visual acuity) of 20/40 to 20/400 in the study eye, and no prior episode of RVO in the study eye. Exclusion criteria include insufficient media clarity for fundus photographs, central retinal thickness less than 250 \u00b5m in the study eye, and active formation of new vessels in the study eye. Other protocol-defined inclusion/exclusion criteria may also apply. The diseases included in the trial are visual impairment, macular edema, and branch retinal vein occlusion, and their corresponding ICD-10 codes are listed.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic obstructive pulmonary disease. The trial involves the use of a drug called formoterol fumarate inhalation solution. The eligibility criteria for the trial include a medical diagnosis of COPD and a current or prior history of cigarette smoking. However, individuals with a medical diagnosis of asthma or any significant condition or disease other than COPD are excluded from the trial. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for breast cancer and osteoporosis. The trial involves the drug risedronate sodium and is open to premenopausal women who are scheduled to undergo adjuvant or neoadjuvant chemotherapy for primary breast cancer (stages I-IIIB) and are at least 18 years old with an ECOG performance status of 0 or 1. The trial has a list of eligibility criteria, including no prior bilateral oophorectomy, not on estrogen replacement therapy, and having premenopausal estrogen levels \u2264 1 month of study entry. There are also contraindications, such as hypercalcemia, hypocalcemia, and inability to stand or sit upright for at least 30 minutes. The trial involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown, so pregnant and nursing women and women of childbearing potential who are unwilling to employ adequate contraception are excluded. Additionally, patients with a bone mineral density T score of \u2264 -2.0 at the hip or lumbar spine are ineligible, except for those with a T score of -1.9. Patients with a history of vertebral compression fracture are also ineligible, except for those with a traumatic fracture of the coccyx. Patients with diseases affecting bone metabolism, severe renal impairment, creatinine > 2.0 mg/dL, malabsorption syndrome, corticosteroids at doses > 5 mg daily of prednison or equivalent for > 2 weeks in the past 6 months, previous treatment with bisphosphonates, estrogen replacement therapy, oral contraceptive use, or prior bilateral oophorectomy are also excluded. Dental extraction, root canal, or implants \u2264 3 months prior to registration or planned during study treatment are also contraindications.",
    "The sample is a phase 3 clinical trial for non-Hodgkin's lymphoma. The trial involves the use of a combination of drugs, galiximab and rituximab, and the eligibility criteria include having demonstrated a response to the drugs in a previous study and then relapsing or progressing with a TTP of at least 6 months. The disease must be bidimensionally measurable with at least one lesion of 2.0 cm in a single dimension, and the patient must have acceptable hematologic, hepatic, and renal function. There are also several exclusion criteria, including having received any lymphoma therapy between the previous study and the current one, being transfusion-dependent, having CNS lymphoma, or having another primary malignancy requiring active treatment. Additionally, the patient must not have serious nonmalignant disease or active uncontrolled bacterial, viral, or fungal infections, or other conditions that would compromise the protocol objectives. Finally, the patient must not have New York Heart Association Class III or IV cardiac disease or have had a myocardial infarction within 6 months prior to the start of the study.",
    "The sample is a phase 3 trial for the treatment of partial epilepsies and partial onset seizures. The trial is focused on the drug lacosamide. The eligibility criteria includes having participated in a previous study for treatment of partial-onset seizures, while exclusion criteria includes receiving any other study drug or experimental device, meeting withdrawal criteria for the previous study, or experiencing any ongoing serious adverse event. The icd-10 codes associated with the diseases are also provided.",
    "The sample is a phase 3 clinical trial for HIV infections and AIDS. The trial is looking at the effectiveness of three drugs - enfuvirtide, emtricitabine/tenofovir, and lopinavir or efavirenz - in treating antiretroviral na\u00efve HIV-1 infected patients with a CD4 cell count below 100 per mm3, or CD4 cell count below 200/mm3 and past history or presence of B or C(AIDS defining)event. The trial has inclusion and exclusion criteria, including no pregnancy or breastfeeding, no coinfection with HIV-2 or infection with HIV-1 subtype O, no previous antiretroviral treatment, no neoplasia disease currently treated with chemotherapy or radiotherapy, no severe liver failure, no treatment with cytokines or HIV vaccine trial, and no biological abnormalities such as hemoglobin below 10 g/dl, neutrophils below 750 per mm3, thrombocytopenia below 50000 per mm3, creatinine clearance below 60 ml per min, or liver function tests over 3 Upper Limit of Normal. Participants must also sign informed consent to participate in the trial.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for kidney transplantation. The diseases listed are only related to kidney transplantation. The icd-10 codes are also related to kidney diseases. The drug being tested is tacrolimus. The eligibility criteria for the trial are listed under inclusion and exclusion criteria. Patients between the ages of 5 and 65 who are receiving a kidney transplant from a cadaveric donor or a living non HLA identical donor with compatible ABO blood type are eligible. Patients with end stage kidney disease who are suitable candidates for primary renal transplantation or re-transplantation are also eligible, unless the graft was lost due to immunological reasons within 12 months. Patients who have received an organ transplant other than a kidney, have a high immunological risk, or have a donor kidney with a cold ischaemia time of more than 30 hours are excluded from the trial.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes participants who have previously documented CHC genotype 1 infection and have a liver biopsy with histology consistent with CHC and no other etiology. Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the Screening Visit with no findings suspicious for hepatocellular carcinoma (HCC). The trial involves the use of ribavirin (rbv), placebo, and boceprevir as drugs. The eligibility criteria include being at least 18 years of age, weighing between 40 kg and 125 kg, and agreeing to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after the last dose of study drug, or longer if dictated by local regulations. The exclusion criteria include coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive), prior treatment for hepatitis C, treatment with any investigational drug within 30 days of the randomization visit in this study, and evidence of decompensated liver disease. There are also other exclusion criteria related to pre-existing medical conditions, psychiatric conditions, substance abuse, and pregnancy or nursing.",
    "The sample is a phase 3 clinical trial for the treatment of chronic kidney disease using the drug paricalcitol. The trial is open to Chinese male and female participants who are at least 20 years old and have been on maintenance hemodialysis for at least 2 months prior to the screening visit. The inclusion criteria include specific levels of intact parathyroid hormone, serum calcium, and calcium-phosphorus product. Exclusion criteria include a history of allergic reactions to vitamin D or related compounds, recent partial parathyroidectomy, New York Heart Association Class III or IV, current malignancy (except for basal or squamous cell carcinoma of the skin), clinically significant liver disease, history of drug or alcohol abuse, known HIV positivity, and evidence of poor compliance with diet, medication, or hemodialysis.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease osteoarthritis, specifically in the knee or hip. The trial includes a list of ICD-10 codes associated with the disease. The trial involves two drugs, mk0663 and etoricoxib, as well as a comparator drug, celecoxib. The eligibility criteria for the trial includes having osteoarthritis that requires medication for pain relief, while exclusion criteria includes any known allergies to the study drugs.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of myocardial infarction. The trial involves the use of drugs such as enoxaparin, tenecteplase, and clopidogrel. The eligibility criteria for the trial include being 18 years or older, experiencing symptoms for less than 3 hours prior to randomization, having a 12-lead ECG indicative of an acute STEMI, and providing informed consent. The exclusion criteria include a medical history, procedures, medication administration, or the presence of factors that would generally predispose to bleeding events or the inability to evaluate the study's primary endpoint. The icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension that is not adequately controlled. The trial is testing the effectiveness of a fixed dose combination of telmisartan and amlodipine, as well as amlodipine alone. The eligibility criteria include being at least 18 years old, having a diagnosis of essential hypertension, and having failed to respond to six weeks of treatment with amlodipine 5 mg monotherapy. Patients must also be able to stop any current antihypertensive therapy without unacceptable risk and provide written informed consent. Exclusion criteria include not practicing acceptable means of birth control, having known or suspected secondary hypertension, and having clinically significant hepatic or renal impairment.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia, schizoaffective disorders, and psychotic disorders. The trial involves the use of the drug quetiapine ir (immediate release). The eligibility criteria for the trial includes men and women between the ages of 18 and 65 who require treatment for an acute episode of schizophrenia/schizoaffective disorder as determined by their doctor. Exclusion criteria includes significant and unstable conditions of the heart, circulation, blood, liver, or kidney, malignancies (cancer), diabetes (mellitus), history of fits or fainting, resistance to antipsychotic medication, current alcohol/drug abuse, and pregnant/breastfeeding women. The icd-10 codes for the diseases being treated are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of sexual dysfunctions, psychological. The trial involves the drug flibanserin and includes a list of icd-10 codes for the diseases being treated. The eligibility criteria for the trial includes women over 18 and pre-menopausal, with a FSDS-R score above 14, willingness to try to have sexual activity at least monthly, and a stable, monogamous, heterosexual relationship for at least one year. Exclusion criteria includes clinically relevant conditions that might interfere with the patient's ability to participate in the trial, specified medications, drug dependence or abuse, and pregnancy, among others.",
    "The sample is a phase 3 clinical trial for age-related macular degeneration. The trial includes patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, with various lesion types. Patients must have a BCVA score between 73 and 24 letters in the study eye. The trial excludes patients who have received certain prior treatments or surgeries for AMD or glaucoma. The trial involves the use of various doses of ranibizumab administered monthly or quarterly. The eligibility criteria include additional protocol-defined criteria.",
    "The sample is a phase 3 clinical trial for patients with type 1 diabetes. The trial is testing the effectiveness of two insulin treatments, insulin glulisine / insulin glargine and insulin glulisin / insulin detemir. The eligibility criteria include being covered by a social security scheme, having type 1 diabetes for at least 5 years, and being treated with intensive insulin treatment for at least 6 months. Patients must also have an HbA1c level of <= 8.5% and be capable of checking their blood glucose concentration using the provided materials. Exclusion criteria include recent severe hypoglycemia, proliferating retinopathy, altered hepatic or renal function, acute infection, and history of drug or alcohol abuse. The sample also includes a disclaimer that the information provided is not exhaustive and other considerations may be relevant for potential participants.",
    "This sample is from a phase 3 clinical trial for asthma. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used in the trial, and the eligibility criteria for participants. The inclusion criteria require a diagnosis of asthma and recent use of asthma maintenance therapy, while the exclusion criteria include severe asthma, sensitivity to certain drugs, and recent use of non-inhaled corticosteroids or beta-blockers.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of insomnia. The trial involves the use of two drugs, esmirtazapine and placebo. The eligibility criteria for participants include having difficulty falling asleep, maintaining sleep, or experiencing early morning awakenings. However, individuals with significant medical or psychiatric illnesses causing sleep disturbances, a history of bipolar disorder or family history of suicide, sleep disorders such as sleep-related breathing disorder or narcolepsy, significant other medical illnesses such as acute or chronic pain, heart, kidney or liver disease within the last year, currently diagnosed or meeting the criteria for Major Depressive Disorder (MDD) or having been treated for MDD within the last 2 years, and substance abuse, excessive use of alcohol or drug addiction within the last year are excluded from the trial. The diseases being studied are not specified, but a list of ICD-10 codes associated with insomnia is provided.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are on a diet and exercise regimen and have been pre-treated with pioglitazone alone or in combination with metformin for at least 12 weeks prior to randomization. The trial aims to test the efficacy of the drug bi 10773 compared to a placebo. The eligibility criteria include a diagnosis of type 2 diabetes mellitus, HbA1c levels between 7.0% and 10.0%, age over 18, and a BMI of less than or equal to 45 kg/m2. The exclusion criteria include uncontrolled hyperglycemia, use of any other antidiabetic medication within 12 weeks prior to randomization, recent myocardial infarction, stroke or transient ischaemic attack, liver disease, impaired renal function, recent bariatric surgery or other gastrointestinal surgeries that induce chronic malabsorption, medical history of cancer or treatment for cancer within the last 5 years, blood dyscrasias or any disorders causing haemolysis or unstable red blood cells, contraindications to pioglitazone or metformin, treatment with anti-obesity drugs, current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent, pre-menopausal women who are nursing or pregnant or are of childbearing potential and not practicing an acceptable method of birth control, alcohol or drug abuse within the 3 months prior to informed consent, participation in another trial with an investigational drug within 30 days prior to informed consent, and any other clinical condition that would jeopardize patient safety while participating in this clinical trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients with a primary diagnosis of schizophrenia who have had at least one prior episode of acute schizophrenia in the 3 years preceding screening and have been on continuous antipsychotic treatment for at least 1 year. Patients must also be clinically stable for at least 4 weeks prior to entry. The trial excludes patients with uncontrolled medical conditions, a history of suicide attempt or violence towards others in the past 2 years, substance-induced psychotic disorder or behavioral disturbance due to substance abuse, current substance abuse/dependence, or concurrent psychiatric disorders other than schizophrenia. The trial will test the efficacy of asenapine and placebo in a double-blind study.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as pioglitazone, placebo, and rivoglitazone hcl. The eligibility criteria for the trial include a diagnosis of type 2 diabetes, being at least 18 years old, having an A1C level between 7% and 8.5%, and having a non-fasting C-peptide level greater than 0.5ng/mL. The trial also has exclusion criteria, such as a history of type 1 diabetes or ketoacidosis, a BMI greater than 45 kg/m2, and a history of prior treatment failure with or intolerance of a TZD.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the disease fibromyalgia. The trial involves the drugs pregabalin and placebo. The eligibility criteria for the trial include having fibromyalgia as an inclusion criteria and having other painful conditions as an exclusion criteria. The icd-10 code for fibromyalgia is also included in the record.",
    "The sample is a record of a clinical trial in phase 3, focused on essential hypertension. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, including olmesartan medoxomil, amlodipine, and hydrochlorothiazide. The eligibility criteria for the trial are also listed, including inclusion criteria such as a mean seated blood pressure greater than 160/100 mmHg without antihypertensive pre-treatment or pre-treatment with amlodipine 5 or 10 mg with a mean seated blood pressure greater than or equal to 140/90 mmHg. Exclusion criteria include secondary hypertension and any serious disorder that may limit the ability to evaluate the efficacy or safety of the test drugs.",
    "The sample is a phase 3 clinical trial for HIV infection. The trial is testing the effectiveness of several drugs, including elvitegravir, raltegravir, and a placebo, in combination with a fully-active ritonavir-boosted-PI and an allowed second agent. The eligibility criteria include having plasma HIV-1 RNA levels of at least 1,000 copies/mL, documented resistance or at least six months experience with two or more different classes of antiretroviral agents, and normal ECG, renal function, hepatic transaminases, total bilirubin, hematologic function, and serum amylase. Participants must also be over 18 years old, have a life expectancy of at least 1 year, and be able to understand and sign a written informed consent form. Exclusion criteria include having a new AIDS-defining condition diagnosed within the 30 days prior to screening, prior treatment with any HIV-1 integrase inhibitor, and ongoing therapy with any disallowed medication.",
    "The sample is for a phase 3 clinical trial that involves subjects with vomiting and nausea. The trial is testing the effectiveness of two drugs, ramosetron and granisetron, in preventing vomiting in cancer patients who are scheduled to receive chemotherapy. The eligibility criteria include age between 20-74 years old, absence of vomiting symptoms for at least one week before the trial, ECOG performance status scale no greater than 2, and signed informed consent form. Exclusion criteria include recent radiotherapy or chemotherapy, known heart failure or myocardial infraction, concurrent diseases that may cause vomiting, recent use of medications that could influence the outcome of the study, history of allergy or intolerance to the drugs being tested, pregnancy or breastfeeding, life expectancy less than 3 months, and participation in other investigational drug trials within 1 month before entering this study.",
    "The sample is a phase 3 clinical trial for patients with myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasms and leukemia. The trial is testing the effectiveness of the drug decitabine. The eligibility criteria include specific disease characteristics such as bone marrow blast count and cytogenetic risk factors, as well as patient characteristics such as age and performance status. Patients must also meet certain prior concurrent therapy requirements. The sample includes a detailed list of eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial that focuses on dyslipidemias, coronary heart disease, combined (atherogenic) dyslipidemia, and mixed dyslipidemia. The trial involves the use of drugs such as abt-335, placebo, atorvastatin, and ezetimibe. The eligibility criteria for the trial include having mixed dyslipidemia with specific levels of triglycerides, HDL-C, and LDL-C, as well as agreeing to use adequate birth control methods and adhere to the American Heart Association (AHA) Diet. Exclusion criteria include having unstable or uncontrolled medical conditions, taking certain medications, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for the treatment of psoriasis vulgaris. The trial is looking at the effectiveness of three different drugs: calcipotriol and betamethasone (leo 80185 gel), leo 80185 vehicle, and tacalcitol ointment. The eligibility criteria for the trial include having a clinical diagnosis of psoriasis vulgaris involving the trunk and/or arms and/or legs, with a minimum PASI score for extent of 2 in at least one body region. The trial is open to both males and females of any ethnic origin who are 18 years or older and attending a hospital outpatient clinic or the private practice of a dermatologist. There are also exclusion criteria, such as having received certain treatments within a certain time frame, having certain skin conditions, or being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of dermatitis, specifically atopic dermatitis. The icd-10 codes associated with the disease are listed as \"L20.89\" and \"L20.9\". The trial involves two treatments, tacrolimus ointment and a placebo ointment. The eligibility criteria for the trial include being at least 16 years old and having a Rajka/Langeland score of at least 3. Patients with genetic epidermal barrier defects or clinically significant skin infections on the affected area are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. The trial is for patients who are receiving their first course of an anthracycline and cyclophosphamide containing moderately emetogenic chemotherapy regimen for the treatment of a solid malignant tumor. The trial is testing the effectiveness of netupitant and palonosetron, palonosetron, and dexamethasone as treatments for nausea and vomiting. The eligibility criteria include being naive to cytotoxic chemotherapy, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, and having adequate hematologic and metabolic status based on laboratory criteria. The exclusion criteria include being pregnant or lactating, having current evidence of alcohol abuse, and having any uncontrolled medical condition that may confound the results of the study or pose unwarranted risks in administering the study drugs to the patient. The trial also has a Multiple-Cycle Extension, which has its own set of inclusion and exclusion criteria.",
    "The sample is a record from a clinical trial table that includes information about a phase 3 trial for the treatment of melanoma. The record includes the list of diseases and their corresponding ICD-10 codes, as well as the list of drugs being tested. The eligibility criteria for the trial are also included, with specific requirements for the patient's medical history, disease stage, and organ function. The inclusion criteria require a histologically confirmed diagnosis of melanoma, measurable disease, and an ECOG performance status of 1 or less. The exclusion criteria include prior cytotoxic chemotherapy, primary ocular or mucosal melanoma, and significant medical disease other than cancer.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including a placebo and vortioxetine (lu aa21004). The eligibility criteria for the trial include having a primary diagnosis of Major Depressive Episode (MDE) according to DSM-IV TR criteria, having at least one other MDE before the current one, and having moderate to severe depression. Exclusion criteria include having any current psychiatric disorder other than MDD, any substance disorder within the previous 6 months, being a female patient of childbearing potential who is not using effective contraception, and using any psychoactive medication 2 weeks prior to screening and during the study. Patients in remission (MADRS total score <=10) at both Week 10 and Week 12 are eligible for randomisation. Other protocol-defined inclusion and exclusion criteria may also apply.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying chronic prostatitis with chronic pelvic pain syndrome and prostatitis. The associated ICD-10 codes for these diseases are listed. The trial is testing botulinum toxin type A and a placebo. The eligibility criteria for participants include specific inclusion and exclusion criteria related to medical history, medication use, and other health conditions.",
    "The sample is a phase 3 clinical trial for diabetic macular edema. The trial includes patients who are 18 years or older with type 1 or 2 diabetes mellitus and have a decrease in vision primarily due to DME in the study eye. The patients must have a BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye. The trial excludes patients who have had laser photocoagulation or previous use of intraocular or periocular corticosteroids in the study eye within a certain time frame, as well as those who have had previous treatment with anti-angiogenic drugs in the study eye within a certain time frame. Patients with active proliferative diabetic retinopathy (PDR), uncontrolled diabetes mellitus, or only one functional eye are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of venous thromboembolism. The trial involves the use of three drugs: enoxaparin sodium, semuloparin sodium, and placebo. The eligibility criteria for the trial include standard surgery for fracture of the upper third of the femur, while exclusion criteria include factors such as major orthopedic surgery in the 3 months prior to study start, deep vein thrombosis or pulmonary embolism within the last 12 months, and high risk of bleeding. The sample also includes a disclaimer that the information provided is not exhaustive and other factors may be considered for a patient's potential participation in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes participants who have been diagnosed with schizophrenia according to the DSM-IV criteria and have received a full course of treatment with Risperdal, Zyprexa, or Seroquel before enrollment but had to change medication due to unsatisfying efficacy, tolerability, or safety issues. Participants must also be in a non-acute phase and have received treatment with any of the above three antipsychotics within 4 weeks before enrollment. Female participants must be postmenopausal, surgically sterile, abstinent, or using an effective method of birth control. The trial has exclusion criteria, including participants who have received treatment with clozapine or risperidone microspheres for injection within 3 months before screening, have a history of seizure except febrile convulsion, have refractory schizophrenia, have received electric shock treatment within 1 month before screening, or have serious, unstable physical diseases.",
    "The sample is a phase 3 clinical trial for bladder cancer. The trial is looking for patients with cytologically confirmed solitary primary or recurrent papillary transitional cell carcinoma of the bladder, with a tumor no greater than 2 cm in diameter, and who have negative urine cytology and no suspicious lesions in the bladder requiring biopsy. Patients must also meet certain age, performance status, and health criteria, and cannot have a prior history of certain types of tumors or other medical conditions. The trial is testing the effectiveness of the drug mitomycin c, and patients must not have received this drug within the past year. The sample also includes information on prior concurrent therapies that patients must not have received within certain time frames.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of advanced or metastatic soft tissue sarcoma. The trial involves the use of two drugs, doxorubicin hydrochloride and ifosfamide, and has specific eligibility criteria for patients, including age range, performance status, and medical history. The record also includes information on the diseases being studied, the ICD-10 codes associated with them, and the eligibility criteria for patients to participate in the trial. Additionally, the record outlines the prior concurrent therapies that are not allowed for patients participating in the trial.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C infection. The trial is testing the effectiveness of the drug peginterferon alfa-2a. The eligibility criteria for participants include having quantifiable HCV RNA, a liver biopsy consistent with chronic hepatitis C infection, and compensated liver disease without cirrhosis. Participants must also have a negative pregnancy test and use effective contraception during treatment. Exclusion criteria include previous interferon therapy, liver cirrhosis, and signs of hepatocellular carcinoma. The trial also excludes participants with certain medical conditions and those who have received certain treatments within the past 6 months.",
    "The sample is a phase 3 clinical trial for diabetes, specifically type 2 diabetes. The trial involves two drugs, insulin degludec and insulin glargine, and the eligibility criteria includes being insulin na\u00efve or having had short term insulin treatment up to 14 days, having a current treatment of metformin monotherapy or metformin in combination with other drugs, having a HbA1c level between 7.0-10.0%, and having a BMI below or equal to 45.0 kg/m^2. Exclusion criteria includes recent use of certain drugs, cardiovascular disease within the last 6 months, uncontrolled severe hypertension, pregnancy or intention of becoming pregnant, and a history of cancer. The diseases included in the trial are diabetes and diabetes mellitus, type 2, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for the treatment of kidney cancer. The trial requires patients to have histologically confirmed renal cell carcinoma with advanced metastatic disease that requires treatment and measurable disease (single bone lesions not included). Patients must also meet certain criteria such as being between the ages of 18 and 81, having a WHO performance status of 0-1, and having a life expectancy of more than 12 weeks. Additionally, patients must meet certain hematopoietic, hepatic, renal, and cardiovascular requirements. Patients cannot be pregnant or nursing, and fertile patients must use effective contraception during and for at least 6 months after study participation. Patients cannot have any other concurrent disease or prior malignancy that would preclude study treatments or comparisons, and cannot have a concurrent active infection requiring antibiotics. Prior to the trial, patients cannot have received any biologic therapy, chemotherapy, or endocrine therapy, and cannot be on concurrent corticosteroids. Patients must have had at least 4 weeks since prior radiotherapy and prior resection of the primary tumor is recommended but not required. Prior major organ allografts are not allowed. The drug being tested in the trial is fluorouracil.",
    "The sample is a phase 3 clinical trial for postmenopausal osteoporosis. The trial includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested (alendronate and denosumab), and eligibility criteria for participants. Inclusion criteria include being a postmenopausal female over 55 years old, having received alendronate therapy for at least 6 months prior to the study, and having a lumbar spine or total hip bone mineral density corresponding to a T-score of -2 or lower but not lower than -4. Exclusion criteria include vitamin D deficiency, administration of certain medications (intravenous bisphosphonate, fluoride, or strontium ranelate), administration of parathyroid hormone or derivatives within the last year, and administration of any bisphosphonate other than alendronate within 1 year of screening.",
    "The sample is a phase 3 clinical trial for relapsing multiple sclerosis. The trial involves administering Rebif 44 mcg three times a week for at least 6 months prior to study enrollment, along with either prophylactic ibuprofen or ibuprofen as needed. The eligibility criteria include having an Expanded Disability Status Scale (EDSS) score of less than 5.5, being between 18 and 60 years old, and not having any contra-indication to taking ibuprofen during the 4 weeks of the study. Exclusion criteria include having secondary progressive multiple sclerosis without superimposed attacks, using any other injectable medications during the week prior to the screening period, and having a history of chronic pain syndrome. The trial also has various other exclusion criteria related to medical conditions, investigational drugs, and pregnancy.",
    "The sample is a record of a clinical trial in phase 3, focused on exercise-induced asthma. The trial involves several drugs, including montelukast sodium, salmeterol xinafoate, and fluticasone propionate, as well as matching placebos for each drug. The trial is open to children between the ages of 6 and 14 who have a history of asthma for at least 12 months and demonstrate airway constriction brought on by exercise. The trial excludes participants who are taking any medications that are not allowed in the study.",
    "The sample is a phase 3 clinical trial for essential hypertension. The trial includes patients with a mean sitting blood pressure of 140/90-115 mmHg and mean 24h diastolic blood pressure greater than or equal to 80 mmHg with at least 30% of daytime readings greater than 85 mmHg prior to randomization. The trial drugs are olmesartan medoxomil and amlodipine. The eligibility criteria include exclusion of patients with secondary hypertension of any aetiology, serious disorders that may limit the ability to evaluate the efficacy or safety of the test drugs, and history of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, congestive heart failure, hypertensive encephalopathy, stroke or TIA within the last 6 months.",
    "The sample is a phase 3 clinical trial for chronic malignant tumor-related pain. The trial includes subjects who are opioid-na\u00efve or have been pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment. The trial involves the use of tapentadol extended release, morphine sulphate controlled release, and a matching placebo after tapentadol in the titration phase. The trial also has inclusion and exclusion criteria, including age, gender, medical history, and current medication use. The diseases being studied are tumors and pain, and the icd-10 codes associated with them are listed.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial is testing the effectiveness of a drug called saredutant succinate (sr48968c). The eligibility criteria for the trial include being between 18 and 64 years old, having a confirmed diagnosis of major depressive disorder, and having a minimum total score of 22 on the Montgomery-Asberg Depression Rating Scale (MADRS). Exclusion criteria include having a current depressive episode with psychotic features, a history of substance abuse, and severe or unstable cardiovascular, renal, hepatic, respiratory, hematological, endocrinological, neurological, or other somatic disease that might interfere with the evaluation of study medication. The trial is looking to enroll both inpatients and outpatients who are able to comply with the protocol and follow written and verbal instructions.",
    "The sample is a phase 3 clinical trial for allergic rhinitis. The trial includes subjects who are 6-11 years old and have a documented history of PAR to a relevant perennial allergen for at least 12 months. The trial involves the use of two drugs, bdp and placebo. The eligibility criteria include informed consent, general good health, and other specific criteria. The exclusion criteria include pregnancy, nursing, previous participation in a BDP nasal aerosol study, and a known hypersensitivity to any corticosteroid or any of the excipients in the study medication formulation, among others. The trial also prohibits the use of certain concomitant medications and tobacco products.",
    "The sample is a phase 3 clinical trial for schizoaffective disorder. The trial includes patients who are experiencing an acute exacerbation of psychotic symptoms and meet certain criteria, such as having a DSM-IV diagnosis of schizoaffective disorder and scoring a certain level on the PANSS, YMRS, and/or HAM-D-21 assessments. Patients must also be healthy based on physical examinations, ECG, laboratory tests, medical history, and vital signs measurements. The trial excludes patients with certain conditions, such as a primary active mental illness diagnosis other than schizoaffective disorder, a history of hypersensitivity to certain medications, and those who are pregnant or planning to become pregnant. The trial involves the use of two drugs, placebo and paliperidone palmitate.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial is for males and females who are at least 18 years old and have not received antiretroviral treatment before. The trial requires participants to have a CD4+ count within a certain range, adequate renal function, and a Karnofsky score above 70. Participants must also have an HIV-1 viral load of 1,000 copies/mL and be willing to initiate CD4+ cell count-guided chemoprophylaxis to prevent opportunistic infections. The trial excludes individuals with active drug abuse or chronic alcoholism, active hepatitis B or C disease, and laboratory parameters above DAIDS Grade 2. Participants must also not have a hypersensitivity to any ingredients of the test products and must not have previously used Viramune\u00ae or any other antiretroviral agents. The trial also excludes individuals who are receiving other concomitant treatments which are not permitted, as described in the prescribing information, and those who have been diagnosed with malignant disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating lymphoma, and the icd-10 codes associated with the disease are listed. The trial involves the use of three different drugs, including temsirolimus (cci-779) and investigator's choice. The eligibility criteria for the trial are also listed, including the requirement that participants have received 2 to 7 prior therapies and have confirmed mantle cell lymphoma. The exclusion criteria are also listed, including the exclusion of subjects who have received investigational therapy within 3 weeks of the first dose and those with active central nervous system metastases.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug duloxetine. The trial requires participants to be at least 18 years old and diagnosed with major depressive disorder. They must also be able to visit the doctor's office once a week to once every 2 weeks for a total of 14 weeks. However, women who are pregnant or breastfeeding, those with a current or previous major psychiatric disorder other than depression, those with a primary diagnosis of an anxiety disorder within the past 6 months, and those with a history of alcohol or drug dependence or abuse within the past 6 months are excluded from the trial. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for patients with hypercholesterolemia and coronary heart disease or a CHD risk equivalent, clinical evidence of atherosclerosis, or a Framingham 10-year CHD risk score of >20. The trial involves the use of rosuvastatin (Crestor), ezetimibe, and simvastatin as cholesterol-lowering medications. The eligibility criteria include patients being 18 years or older, signing an informed consent, and stopping any current cholesterol-lowering medications. The exclusion criteria include the use of lipid-lowering drugs and other prohibited concomitant medications, a history of statin-induced myopathy or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors, and patients considered to be unstable by their physician after certain events. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "This sample is a phase 3 clinical trial for breast cancer. The trial is looking at the effectiveness of a combination of drugs including docetaxel, epirubicin, cyclophosphamide, 5-fluoruracil, and granulocyte-colony stimulating growth factor. The trial is open to premenopausal or postmenopausal women aged 18-75 years old who have histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma, with tumor involvement of at least one axillary lymph node, and no clinical or radiological evidence of local or metastatic disease. Participants must have had surgical excision of the primary tumor with tumor-free operation margins within 60 days prior to enrollment, and at least 10 axillary lymph nodes must have been removed. They must also meet certain criteria for bone marrow, liver, renal, and cardiac function, and provide written informed consent. Exclusion criteria include a positive pregnancy test, psychiatric illness or social situation that would preclude study compliance, other concurrent uncontrolled illness, prior or concurrent antineoplastic therapy, and previous history of other invasive malignancy other than non-melanomatous skin cancer.",
    "The sample is a phase 3 clinical trial for the treatment of primary insomnia. The trial involves the use of suvorexant high dose, suvorexant low dose, and a placebo as comparators. The eligibility criteria include being at least 18 years old, diagnosed with primary insomnia, in good physical and mental health, and having difficulty with initiating and maintaining sleep. Participants must also be willing to limit alcohol, caffeine, and nicotine consumption, and refrain from napping during the study. Exclusion criteria include pregnancy or breastfeeding, history of another sleep disorder, ongoing depression, substance abuse or dependence, and certain medical conditions.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD) in male and female adults aged 40 years or older. The trial includes patients with a smoking history of at least 10 pack years and a post-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% and greater than or equal to 30% of the predicted normal value. The trial also includes patients with a post-bronchodilator FEV1/Forced vital capacity (FVC) of less than 70%. The trial excludes patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period, patients requiring long-term oxygen therapy for chronic hypoxemia, patients with concomitant pulmonary disease, patients with a history of asthma, patients with diabetes Type I or uncontrolled diabetes Type II, any patient with lung cancer or a history of lung cancer, any patient with active cancer or a history of cancer with less than 5 years disease-free survival time, patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at Visit 1 or randomization is prolonged, patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period, and patients unable to successfully use a dry powder inhaler device, MDI or perform spirometry measurements.",
    "The sample is a phase 3 clinical trial for various mental health disorders such as oppositional defiant disorder, conduct disorder, ADHD, and bipolar disorder. The trial is testing the effectiveness of the drug Risperdal in treating severe conduct problems in children aged 4 to 14 years old. The inclusion criteria for the trial includes having received Risperdal treatment for at least 4 months, being capable of discontinuing the drug for up to 14 days, and having a reliable adult carer who can report on the subject's behavior and attend scheduled assessments. The exclusion criteria includes having certain mental health disorders, being pregnant, having a history of neuroleptic malignant syndrome, and not being able to discontinue other psychotropic medications.",
    "The sample is a phase 3 clinical trial for the treatment of severe persistent asthma using the drugs omalizumab and placebo. The trial is looking for patients who have uncontrolled asthma according to the Global Initiative for Asthma guidelines and have had at least two exacerbations requiring systemic corticosteroids or at least one hospitalization or emergency room visit in the past year. Patients must also be treated with high-dose inhaled corticosteroids and inhaled long-acting \u03b22 agonists. Patients who are non-atopic, meaning they have negative blood multiallergic testing and negative Aspergillus-specific IgE-radio allergosorbent blood test and negative skin prick tests to a battery of common aeroallergens, are eligible for the trial. Patients who are current smokers or have a smoking history of less than 3 years or more than 10 pack years, have had an asthma exacerbation in the 4 weeks prior to randomization, have active lung disease other than non-atopic asthma, have an active cancer or a history of cancer with less than 5 disease-free years, or are pregnant or nursing are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a record of a clinical trial in phase 3 for patients with type 2 diabetes. The trial is testing the effectiveness of a drug called kad-1229. The eligibility criteria for the trial include patients who have inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy, are 20 years or older, and have an HbA1c level between \u2265 6.5 to < 9%. Patients with type 1 diabetes mellitus or serious diabetic complications and other serious complications are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of rheumatoid arthritis using the drug adalimumab. The eligibility criteria include being at least 18 years old, meeting the American College of Rheumatology criteria for diagnosis of rheumatoid arthritis for at least 6 months, having an unsatisfactory response or intolerance to prior disease modifying anti-rheumatic drugs, and being able and willing to administer subcutaneous injections. The trial also has exclusion criteria, such as a history of cancer or lymphoproliferative disease, uncontrolled diabetes, and active peptic ulcer disease. The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma. The trial includes patients who meet the Durie and Salmon criteria for initial diagnosis of MM and have stage II or III MM at diagnosis or anytime thereafter. Patients must also have symptomatic MM requiring treatment and have received at least three cycles of initial systemic therapy within 2-10 months of initiation of the initial therapy (excluding the time for mobilization therapy). Patients must be able to receive high-dose melphalan between 2 and 8 weeks after the initiation of mobilization therapy if receiving chemotherapy-based mobilization regimens. Adequate organ function is required, including cardiac, hepatic, renal, and pulmonary function. Patients must have an adequate autologous graft containing at least 4.0 x 106 CD34+ cells/kg patient weight. Patients who have never advanced beyond Stage I MM since diagnosis, have non-secretory MM, plasma cell leukemia, or a Karnofsky performance score less than 70% are excluded from the trial. Other exclusion criteria include uncontrolled hypertension, infections, prior malignancies, pregnancy or breastfeeding, seropositivity for HIV, unwillingness to use contraceptive techniques during and for 12 months following treatment, prior allograft or prior autograft, and prior organ transplant requiring immunosuppressive therapy.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on diabetes mellitus and includes a list of ICD-10 codes associated with the disease. The trial involves the use of three drugs: insulin glulisine, lispro, and insulin glargine. The eligibility criteria for the trial include having type 1 or type 2 diabetes, having an HbA1c measurement between 6.5% and 11.0% at visit 1, and having more than 3 months of continuous insulin treatment prior to study entry. Pregnant women are excluded from the trial. The sample also includes a disclaimer that the information provided is not exhaustive and other considerations may be relevant for potential participants.",
    "The sample is a phase 3 clinical trial for Parkinson's disease, with the drug E2007 being tested. The eligibility criteria for the trial include male or female patients with idiopathic PD who have completed a previous study with the drug and have not withdrawn prior to the final efficacy visit. Patients with ongoing or severe adverse events related to the drug are not eligible. Exclusion criteria include pregnant or lactating women, patients with a history of drug or alcohol abuse, and those with certain medical conditions or taking certain medications. The trial also excludes patients who have undergone previous stereotactic surgery for Parkinson's disease or are currently taking pergolide.",
    "The sample is a phase 3 clinical trial for patients with submassive pulmonary embolism. The trial is testing the effectiveness of unfractionated heparin as a treatment. The eligibility criteria for the trial include having acute PE symptoms for less than 14 days, having a filling defect by contrast-enhanced chest CT in at least one main or proximal lower lobe pulmonary artery, and having right ventricular dysfunction confirmed by echocardiography where the RV/LV end diastolic diameter ratio is \u2265 1.0. Exclusion criteria include age less than 18 years or greater than 80 years, known significant bleeding risk, recent administration of thrombolytic agents, active bleeding, and other conditions that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.",
    "The sample is a phase 3 clinical trial for breast cancer patients. The eligibility criteria include having histologically confirmed invasive adenocarcinoma of the breast, being at stage I, II, or IIIA, having at least one axillary lymph node with evidence of tumor on histologic exam, and having undergone either a prior total mastectomy and axillary dissection or prior lumpectomy and axillary dissection. Patients must receive radiotherapy after randomization and after chemotherapy. The trial excludes patients with metastatic disease, nonmalignant systemic diseases that would preclude study participation, and psychiatric or addictive disorders that would preclude informed consent. The trial also excludes patients who have had prior chemotherapy, hormonal therapy, or radiotherapy for breast cancer, and those who have had other concurrent investigational chemotherapy.",
    "The sample is a phase 3 clinical trial for male osteoporosis. The trial includes the use of the drugs ibandronate and placebo. The eligibility criteria for the trial includes ambulatory men who are at least 30 years old and diagnosed with primary, idiopathic or hypogonadal osteoporosis. The trial also has exclusion criteria, which includes significant medical conditions or laboratory abnormalities, malignant disease diagnosed within the previous 5 years, disease/disorder known to influence bone metabolism or cause of secondary osteoporosis, hypersensitivity to any component of ibandronate, inability to stand or sit in an upright position for at least 60 minutes, and many others. The trial also has inclusion criteria, which includes subjects who, in the opinion of the investigator, are willing and able to comply with the protocol requirements and subjects who have signed an informed consent.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of arthritis, specifically gouty arthritis. The icd-10 codes associated with the disease are listed. The trial involves the use of several drugs, including indomethacin and celecoxib. The eligibility criteria for the trial are also listed, including requirements for pain intensity and exclusion criteria for other types of arthritis or acute trauma to the index joint.",
    "This sample is for a phase 3 clinical trial for the treatment of bipolar disorder using the drug aripiprazole. The trial is looking for participants who have a clinical diagnosis of bipolar I disorder with a manic or mixed episode. The inclusion criteria also specify that this cannot be the participant's first manic or mixed episode. The exclusion criteria include being allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole, as well as having participated in a previous clinical trial within the past month or ever participated in a trial with aripiprazole. The icd-10 codes associated with bipolar disorder are also listed.",
    "The sample is a phase 3 clinical trial for advanced, incurable, squamous cell carcinoma of the head and neck. The trial is testing the effectiveness of methotrexate and paclitaxel as treatments for the disease. The eligibility criteria include having measurable or evaluable disease, an ECOG performance status of 0-1, and being unable to tolerate cisplatin-based therapy for various reasons. Patients must also meet certain age, health, and prior treatment requirements. The trial does not allow for concurrent, active, invasive malignancies or significant detectable infections. Patients must not be pregnant or nursing and must use effective contraception. The trial does not specify the duration of treatment or follow-up.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial involves the use of the drugs vortioxetine and placebo. The eligibility criteria for participants include having a primary diagnosis of major depressive disorder, a reported duration of the current depressive episode of at least 3 months, and a Montgomery \u00c5sberg Depression Rating Scale total score greater than or equal to 30. Exclusion criteria include having received any investigational compound less than 30 days before screening, having a current or past history of certain psychiatric disorders or substance abuse, and taking certain disallowed medications. Participants must also not have a significant risk of suicide and must not be currently receiving formal cognitive or behavioral therapy. The trial aims to evaluate the safety, tolerability, and efficacy of the study medication.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on two diseases, open-angle glaucoma and ocular hypertension, which are identified by their respective ICD-10 codes. The trial involves two drugs, brinzolamide 10 mg/ml + timolol 5 mg/ml eye drops, suspension and dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops, solution (cosopt). The eligibility criteria for the trial include being 18 years or older, having a diagnosis of open-angle glaucoma or ocular hypertension, and meeting any other protocol-defined inclusion criteria. Exclusion criteria include being under 18, pregnant, or meeting any other protocol-defined exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of Major Depressive Disorder. The trial includes patients who are outpatients and have a clinical diagnosis of MDD. They must be using a reliable method of birth control and taking a selective serotonin reuptake inhibitor (SSRI) approved for MDD treatment within their country. The patients must have had a partial response to SSRI treatment and meet inclusion scores on pre-defined psychiatric scales to assess diagnosis of depression, disease severity, and response to SSRI treatment. They must also be reliable and able to keep all scheduled appointments and have had at least 1 previous episode of MDD prior to the current episode within the past 5 years. The trial excludes patients who have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other than major depression within 1 year of screening, a current or any previous diagnosis of a bipolar disorder, schizophrenia, or other psychotic disorder, a history of substance abuse and/or dependence within the past 1 year, and any diagnosed medical condition which could be exacerbated by noradrenergic agents. The trial also excludes patients who have initiated or discontinued hormone therapy within the previous 3 months prior to enrollment, have a lifetime history of vagal nerve stimulation, transcranial magnetic stimulation, or psychosurgery, have received electroconvulsive therapy in the past year, have a serious or unstable medical condition, have a history of seizure disorders, have initiated psychotherapy or other nondrug therapies within 6 weeks prior to enrollment or any time during the study, and participants who are judged to be at serious risk for harm to self or others. Pregnant or breastfeeding patients are also excluded, as well as those who meet criteria for treatment-resistant depression.",
    "The sample is a phase 3 clinical trial for patients with ulcerative colitis of mild to moderate severity. The trial is testing the effectiveness of the drug budesonide. The eligibility criteria include being between 18 and 74 years old, having completed a previous study without achieving clinical remission, and having a UCDAI score of 10 or less. Patients must also not have certain medical conditions or be taking certain medications. The trial requires patients to provide written informed consent and to comply with study requirements.",
    "The sample is a phase 3 clinical trial for the treatment of ankylosing spondylitis, a type of arthritis that affects the spine. The trial is testing the effectiveness of a placebo drug on adult patients who have had the disease for at least 3 months and have not responded well to previous non-steroidal anti-inflammatory drugs (NSAIDs). The trial has specific inclusion and exclusion criteria, including stable doses of certain medications for at least 4 weeks prior to baseline and no history of severe allergic reactions to certain types of antibodies. The trial is not open to patients who have had major surgery within 8 weeks prior to screening or who have a body weight over 150 kg.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients who have been anti-HCV positive for more than 6 months, have had elevated ALT and/or AST levels in the previous 6 months, and have positive HCV-RNA. Patients must have had a liver biopsy within one year before the start of therapy in non-cirrhosis cases, and in the case of known cirrhosis, a liver biopsy is not necessary. Patients must also have the intention to be treated and participate in the treatment, and have given written informed consent. The trial has exclusion criteria, including patients under 18 years old, pregnant or intending to get pregnant within the 12 months period of treatment and up to 6 months after discontinuation of therapy, and patients with a life expectancy of less than 1 year. Other exclusion criteria include patients with Child Pugh B or C, creatinine levels above 150 \u03bcmol/L or > 1.70 mg/dl, and haemoglobulin levels below 6.5 mmol/l or < 10.5 g/dl. Patients with white blood cell counts below 2.5 x 109/L, neutrophil counts below 1.5 x 109/L, and platelet counts below 70 x 109/L are also excluded. Patients with HIV positivity, chemotherapy, systematical antiviral treatment during the 6 months prior to study entry, other serious diseases, active uncontrolled psychiatric disorders and suicidal leanings, a history of uncontrolled seizure or other significant CNS dysfunction, and any condition which might interfere with the evaluation of the study objectives are also excluded.",
    "The sample is a phase 3 clinical trial for patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic deep vein thrombosis (DVT). The trial includes a list of drugs such as rivaroxaban, unfractionated heparin, and warfarin. The eligibility criteria for the trial includes age, exclusion criteria such as thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE, and other medical conditions such as hepatic disease, active bleeding, and high blood pressure. The table also includes information on the diseases being studied and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for type 2 diabetes. The trial includes patients who have inadequate glycemic control, with a pre-randomization A1C level between 7.0% and 10.5%. The trial also requires patients to have a C-peptide level of at least 1.0 ng/mL and a body mass index of no more than 45.0 kg/m\u00b2. The trial excludes patients with certain conditions such as severely uncontrolled diabetes, high levels of AST and/or ALT, high levels of serum total bilirubin, and low levels of serum creatinine. The trial involves the use of drugs such as dapagliflozin, placebo matching dapagliflozin, and thiazolidinedione (pioglitazone).",
    "The sample is a phase 3 clinical trial for the treatment of diabetes mellitus and macular edema. The trial involves the use of two drugs, ranibizumab and sham injection. The eligibility criteria for the trial include being over 18 years old, having diabetes mellitus with retinal thickening involving the center of the fovea, and having a best corrected visual acuity score in the study eye of 20/40 to 20/320. The trial also has exclusion criteria, such as a history of vitreoretinal surgery in the study eye and uncontrolled diabetes mellitus. The trial requires participants to provide written informed consent and to be willing to return for all scheduled visits and assessments.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, ICD-10 codes associated with those diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying ocular hypertension and open-angle glaucoma. The ICD-10 codes associated with these diseases are listed, as well as the drugs being tested. The eligibility criteria for participants are also listed, including age, prior use of certain medications, specific IOP levels and visual acuity scores, willingness to follow instructions, and written informed consent. The exclusion criteria are also listed, which include factors such as pregnancy, certain medical conditions, and recent participation in another clinical trial.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis in children aged 15 years or younger. The trial involves testing the effectiveness of several drugs, including wal801cl dry syrup, ketotifen fumarate dry syrup, and their respective placebos. The eligibility criteria for the trial include having a body weight of 14 kg or more, typical symptoms of perennial allergic rhinitis, and a serum specific immunoglobulin E (IgE) score of 2 or higher caused by house dust or mite within the past year. Patients must also be classified as \"moderate\" or \"severe\" in the Allergic Rhinitis Severity Classification during the observation period. The trial excludes patients who have a history of drug allergy, clinically significant renal, hepatic or cardiac disease, or other complications. Additionally, patients who have participated in any other clinical trial study within the past month or six times the half-life of the investigational drug, whichever is longer, are not eligible for inclusion.",
    "The sample is a phase 3 clinical trial for chronic pain, specifically low back pain and analgesia. The trial involves the drug alo-02 and a placebo. The eligibility criteria for participants include having moderate-to-severe chronic low back pain for at least 3 months and requiring a continuous around-the-clock opioid analgesic for an extended period of time. Participants must also refrain from taking other opioid and non-opioid medications during the study. Exclusion criteria include a history of lumbosacral radiculopathy or chronic low back pain due to other underlying disorders, ongoing pain due to other chronic pain conditions, and a history of alcohol or drug abuse. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 3 clinical trial for the treatment of human immunodeficiency virus infections. The trial includes patients who are HIV-1 positive and have not received antiretroviral therapy for more than 7 days. The trial involves the use of lopinavir/ritonavir with nucleoside reverse transcriptase inhibitors. The eligibility criteria include specific laboratory values and exclude patients who are pregnant or lactating.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of asthma and includes a list of ICD-10 codes associated with the disease. The trial involves the use of two drugs, formoterol and budesonide/formoterol. The eligibility criteria for the trial includes a diagnosed history of asthma for at least 6 months, mild and stable asthma, and a FEV1 value greater than 70% of predicted normal value. The trial also includes exclusion criteria such as any significant respiratory disease other than asthma, recent upper or lower respiratory tract infection, and use of certain medications.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of the drug doripenem in treating complicated lower urinary tract infections or pyelonephritis. The trial is looking for participants who meet certain inclusion criteria, such as having a diagnosis of the specified conditions, and excluding those who are pregnant or have a history of severe reactions to antibiotics. The diseases are listed along with their corresponding ICD-10 codes, and the eligibility criteria are provided in the \"criteria\" field.",
    "The sample is a phase 3 clinical trial for the treatment of pseudomonas aeruginosa infection in patients with cystic fibrosis. The trial involves the use of two different drugs, liposomal amikacin for inhalation (arikayce\u2122) using the pari investigational eflow\u00ae nebulizer and tobramycin inhalation solution using a pari lc\u00ae plus nebulizer. The eligibility criteria for the trial include a confirmed diagnosis of cystic fibrosis, a history of chronic infection with Pseudomonas aeruginosa, and a sputum culture positive for Pseudomonas aeruginosa at screening. The trial also has exclusion criteria, such as a history of major complications of lung disease within 8 weeks prior to screening and a history of lung transplantation.",
    "The sample is a phase 3 clinical trial for an oral contraceptive. The trial is looking for healthy female subjects between the ages of 18 and 35 who are currently using a low-dose EE containing oral contraceptive and suffering from at least two hormone withdrawal associated symptoms. The trial also requires a history of regular cyclic menstrual periods. The exclusion criteria include a history of thrombotic/thromboembolic events, migraine with focal neurological symptoms, diabetes mellitus with vascular involvement, obesity, moderate to severe hypertension, pancreatitis, severe hepatic disease, jaundice and/or pruritus related to cholestasis, severe renal insufficiency or acute renal failure, and presence or history of liver tumors or known or suspected sex-steroid influenced malignancies or premalignant disease.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of multiple drugs, including sitagliptin, liraglutide, glimepiride, and metformin. The eligibility criteria for the trial include having type 2 diabetes mellitus, being on a stable dose of metformin monotherapy for at least 12 weeks, and having a hemoglobin A1C level between 7.0% and 11.0%. Patients must also be capable of using a liraglutide pen device. Exclusion criteria include having a history of type 1 diabetes mellitus, recent cardiovascular disorders, impaired liver or kidney function, a history of malignancy or hematological disorder, pregnancy or breastfeeding, and participation in another study with an investigational drug or device within 12 weeks prior to screening.",
    "The sample is a phase 3 clinical trial for chronic nephropathy, proteinuria, and hypertension. The trial involves the use of fluvastatin and standard therapy as drugs. The eligibility criteria for the trial include being over 16 years old, having hypertension with a systolic or diastolic blood pressure above 140 or 90 mmHg respectively, having a creatinine clearance above 20 ml/min/1.73m2, having a urinary protein excretion rate persistently above 1 g/24 hours, and providing written informed consent. Exclusion criteria include having a specific contraindication to statin therapy, chronic treatment with certain drugs, recent acute myocardial infarction or cerebrovascular accident, severe uncontrolled hypertension, evidence or suspicion of certain diseases, elevated serum aminotransferase concentrations, history of poor tolerance or allergy to certain drugs, drug or alcohol abuse, pregnancy, breast feeding, ineffective contraception, legal incapacity, and/or other circumstances rendering the patient unable to understand the nature, scope, and possible consequences of the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of non-small-cell lung carcinoma using the drug zd6474 (vandetanib). The trial has eligibility criteria for patients to be included, such as having exhausted standard cancer treatments, and exclusion criteria, such as having had recent chemotherapy or significant cardiovascular events. The diseases are listed as non-small-cell lung carcinoma, and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The eligibility criteria include being diagnosed with idiopathic Parkinson's disease, being at least 30 years old at the time of diagnosis, currently being treated with carbidopa/levodopa/entacapone (CLE) and on a stable regimen of conventional LD for at least 4 weeks, requiring a total daily levodopa (LD) dose of at least 400 mg, having a minimum dosing frequency of four times per day, and having predictable \"off\" periods. The trial also allows the use of certain medications as long as the doses and regimens have been stable for at least 4 weeks prior to screening. The exclusion criteria include being diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome, nonresponsiveness to LD therapy, and having received certain medications within 4 weeks of screening or planning to take them during participation in the clinical study. Other exclusion criteria include having certain medical conditions or allergies, being pregnant or breastfeeding, and being unable to complete a symptom diary.",
    "The sample is a record of a clinical trial in phase 3, focused on pulmonary disease, specifically chronic obstructive airways disease. The trial involves the drug salmeterol/fluticasone propionate 50/500mcg diskus. The eligibility criteria for participants include having a clinical history of chronic obstructive airways disease, being current or ex-smokers with a smoking history of at least 10 pack-years, and having reduced lung function. The exclusion criteria include having a diagnosis of any other serious disease and must have a chest X-ray to eliminate a diagnosis other than COPD.",
    "The sample is a phase 3 clinical trial for systemic lupus erythematosus. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including a placebo and two different doses of belimumab. The eligibility criteria for the trial include a clinical diagnosis of SLE, active SLE disease, and being on a stable SLE treatment regimen. There are also several exclusion criteria, such as being pregnant or nursing, having received certain types of treatment in the past, and having certain medical conditions or infections.",
    "This sample is for a phase 3 clinical trial focused on cardiovascular diseases. The trial is testing the effectiveness of two drugs, fenofibrate/simvastatin and simvastatin, on patients with mixed dyslipidemia. The eligibility criteria for the trial include having mixed dyslipidemia, while exclusion criteria include having diabetes, known hypersensitivity to the drugs, being pregnant or lactating, having a contra-indication to the drugs, or having unstable or severe cardiac disease.",
    "The sample is a phase 3 clinical trial for the treatment of migraines using frovatriptan 2.5 mg. The trial is open to females aged 15 years and over with a documented history of experiencing migraines according to IHS criteria, including confirmation of a 3 month diary based documented history of MAM. The trial requires participants to have an average frequency of MAM in at least two out of three menstrual cycles within the previous 12 months, regular and predictable menstrual periods, and MAM headaches occurring between Day -2 and day +4 of menses. Participants must be able and willing to sign informed consent and to comply with study procedures, including completion of the diary cards. Exclusion criteria include more than three migraine attacks per month that were not MAM attacks, a history of myocardial infarction, ischemic heart disease, coronary vasospasm or peripheral vascular disease, significant cerebrovascular disease, uncontrolled hypertension, severe hepatic or renal insufficiency, more than 15 headache days per month, exclusive of migraine headache, any other condition or serious illness which, in the opinion of the investigator, would interfere with optimal participation in the study, a history of clinically relevant allergy, including that to frovatriptan or other triptans, pregnant or breast-feeding, or intending to become pregnant or breast-feed during the study period, treatment with another investigational drug within 30 days or 5 half-lives before the screening visit, any change in their oral contraceptive medication (if applicable) in the 2 months prior to screening, or anticipation of any change during study participation, any change in the type or dose of any prophylactic migraine medication in the 2 months prior to screening, or anticipation of any change during study participation, and a history of migraine with aura, according to IHS criteria, and currently treated with a combined oral contraceptive (South Africa only).",
    "This sample is for a phase 3 clinical trial for the treatment of fibromyalgia using the drug Xyrem\u00ae. The eligibility criteria include having completed a previous study, being able to take the drug for approximately 9-1/2 months, and not having experienced any serious adverse events related to the drug in the previous studies. The exclusion criteria include early termination from the previous studies or experiencing adverse events that may prevent safe participation in this study. The diseases being studied are limited to fibromyalgia and the corresponding ICD-10 code is M79.7.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug risperidone. The trial includes patients between the ages of 18-65 who have been diagnosed with major depressive disorder and have shown a sub-optimal response to a single antidepressant. The patients must be healthy based on a physical exam and willing to maintain a stable dose of the same antidepressant throughout the study. The trial has inclusion and exclusion criteria, with exclusion criteria including the presence of other serious medical illnesses.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of rheumatoid arthritis using drugs such as golimumab, methotrexate, and placebo. The eligibility criteria for participants include having a diagnosis of active rheumatoid arthritis with at least 4 swollen and 4 tender joints for at least 3 months prior to screening, having been treated with and tolerated methotrexate at a dose of at least 15 mg per week for at least 3 months prior to screening, and being on a stable methotrexate dose of greater than or equal to 15 mg per week and less than or equal to 25 mg per week for at least 4 weeks prior to screening. Exclusion criteria include having known hypersensitivity to human immunoglobulin proteins or other components of golimumab, having a known clinically serious adverse reaction to a biologic anti-TNF agent, and having a history of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to screening.",
    "The sample is a phase 3 clinical trial for patients with atrial fibrillation and atrial flutter. The trial involves the use of warfarin and apixaban drugs. The eligibility criteria for the trial include being male or female over the age of 18 with atrial fibrillation and at least one risk factor for stroke, such as age over 75, previous stroke, transient ischemic attack, systemic embolism, symptomatic congestive heart failure, left ventricular dysfunction with LVEF of 40% or less, or diabetes mellitus or hypertension requiring pharmacological treatment. The diseases are listed as atrial fibrillation and atrial flutter, and the icd-10 codes associated with these diseases are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorder. The trial includes patients with specific ICD-10 codes for these diseases and involves the use of two drugs, d-serine and placebo. The eligibility criteria for the trial includes a diagnosis of schizophrenia or schizoaffective disorder, while exclusion criteria includes being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD). The trial includes patients who are current or ex-smokers with a smoking history of at least 10 pack years. The trial aims to test the efficacy of four drugs: qva149, nva237, tiotropium, and salbutamol/albuterol. The eligibility criteria include having a post-bronchodilator Forced Expiratory Volume in one second (FEV1) <50% of the predicted normal value, and post-bronchodilator FEV1/Forced Vital Capacity (FVC) <0.70 at Visit 2 (day -14). Patients must also have a documented history of at least 1 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticosteroids and/or antibiotics. The exclusion criteria include patients with concomitant pulmonary disease, uncontrolled hypo- or hyperthyroidism, narrow-angle glaucoma, symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention, and patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm3 (at visit 2), or onset of symptoms prior to 40 years.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of osteoporosis. The trial involves the use of drugs such as zoledronic acid, alendronate, and calcium/vitamin D. The eligibility criteria for the trial include low bone mineral density in postmenopausal women with a \"t-score\" of -2.0 or lower. The exclusion criteria include previous use of certain medications such as bisphosphonates, parathormone, strontium ranelate, and sodium fluoride. Other protocol-defined inclusion/exclusion criteria also apply to the study.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on the disease gout. The icd-10 codes associated with the disease are listed. The drugs being tested are febuxostat and allopurinol. The eligibility criteria for the trial are also listed, including requirements for participants to be receiving thiazide diuretic therapy and to have a serum urate level less than 8.0 mg/dL. Females of childbearing potential who are sexually active must agree to use adequate contraception and cannot be pregnant or lactating throughout the duration of the study. There are also exclusion criteria, such as having any other significant medical condition that would interfere with the treatment or safety of the protocol, or being intolerant of allopurinol.",
    "The sample is a phase 3 clinical trial for bladder cancer patients who meet certain criteria. The trial involves the drug gefitinib and requires patients to have undergone TUR of all visible bladder lesions within the past 21 to 60 days with biopsy of the underlying bladder wall for all tumors and cold-cup biopsy of all suspicious areas. Patients must also have no metastatic disease and meet a variety of other eligibility criteria related to their health and medical history. The trial excludes patients with certain medical conditions or who have taken certain medications. The schema includes columns for the phase of the trial, diseases being studied, icd-10 codes of those diseases, drugs being used, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for the treatment of bacterial pneumonia. The trial is looking at the effectiveness of ampicillin sodium/sulbactam sodium in patients who are 16 years or older and have been diagnosed with moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization. The trial has inclusion criteria such as age and diagnosis, and exclusion criteria such as known or suspected hypersensitivity or intolerance to the drug, hepatic dysfunction, severe renal dysfunction, and severe underlying disease. The diseases are listed as 'pneumonia, bacterial' and the icd-10 codes associated with the disease are 'J15.9' and 'P23.6'.",
    "The sample is a phase 3 clinical trial for the treatment of non-valvular atrial fibrillation. The trial involves the use of drugs such as idrabiotaparinux sodium, warfarin, and avidin, as well as placebos for these drugs. The trial has a list of inclusion and exclusion criteria, which determine who can participate in the trial. The inclusion criteria include having a history of ischemic stroke, transient ischemic attack, or systemic embolism, as well as having at least two risk factors such as hypertension, impaired left ventricular function, congestive heart failure, age over 75, or diabetes. The exclusion criteria include having a stroke or TIA within the previous 5 days, having a reversible disorder causing transient AF, planning major surgery or cardioversion within 30 days, having an INR over 3 at baseline, having active bleeding or high risk of bleeding, having uncontrolled hypertension, being pregnant or having childbearing potential without proper contraceptive measures, or breastfeeding.",
    "The sample is a phase 3 clinical trial for the treatment of renal cell carcinoma. The trial includes patients with primary-intact renal cell carcinoma who are eligible for nephrectomy with curative intent. The trial also includes patients with tumors that are at least 4 cm in size or have macroscopic fully resectable nodes, surgically resectable renal vein thrombus, or surgically resectable inferior vena caval thrombus by radiologic criteria to be clinically >= pT1bNany (resectable) M0 disease. Patients must have no history of distant metastases and no prior anti-cancer therapy for renal cell carcinoma is permitted in either the adjuvant or neoadjuvant setting. The trial also includes eligibility criteria for patients who have undergone radical or partial nephrectomy. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and an absolute baseline left ventricular ejection fraction (LVEF) of >= 50% by multigated acquisition (MUGA) scan within 4 weeks prior to randomization. Patients must have paraffin-embedded tumor specimen available for central core review of tumor histology and other correlative studies. The trial also includes various exclusion criteria, such as serious intercurrent illness, ongoing ventricular cardiac dysrhythmias of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 grade >= 2, and hypertension that cannot be controlled by medications (>= diastolic blood pressure 100 mm Hg despite optimal medical therapy).",
    "This sample is a phase 3 clinical trial for a microbicide gel to prevent HIV infections, gonorrhea, and chlamydia infections. The trial is looking for female participants between the ages of 18 and 35 who have had more than one male sexual partner in the last 3 months and are willing to use the study product as directed. Participants must also be willing to adhere to a follow-up schedule, report any self-medication during the study, and provide various samples for testing. Exclusion criteria include being pregnant, having a history of adverse reactions to the study product, and having any condition that would make study participation unsafe or complicate data interpretation.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on pulmonary disease, specifically chronic obstructive pulmonary disease (COPD). The trial includes a list of ICD-10 codes for COPD and a list of drugs being tested, including a placebo. The eligibility criteria for the trial are listed, including a diagnosis of COPD, a history of cigarette smoking, and specific lung function measurements. The exclusion criteria are also listed, including pregnancy, other respiratory disorders, and certain medication use. The sample also includes a list of drugs that participants cannot have used prior to the trial.",
    "The sample is a phase 3 clinical trial for patients with perennial allergic rhinitis. The trial includes patients of both sexes aged between 12 and 70 years with a documented clinical history of PAR for at least 2 years prior to the study inclusion. The patients must have a positive skin prick test for at least one of the following perennial allergens (house-dust mites, Dermatophagoides pteronyssinus or D. farinae, animal danders, dogs or cats, molds, etc.). The patients must also have a sum in the previous 6 assessments of the reflective nasal symptoms score equal to or greater than 30 (\u226530 over 72). Additionally, at the time of randomization, patients must have positive symptomatology in instantaneous nasal symptoms equal or greater than 5 (\u22655 over 12). Women of childbearing potential must have a negative pregnancy test and must use an effective contraceptive method. The trial includes both inclusion and exclusion criteria. The inclusion criteria include provision of written informed consent to participate and willingness to attend the required visits scheduled in the protocol. The criteria to continue with the open label period included previous participation in the double-blind period, eligibility for a long-term symptomatic treatment according to the investigator assessment, and patient willingness to follow the treatment for one year. The exclusion criteria include patients who have non-allergic rhinitis, negative skin prick test, patients with nasal polyps or a significant deviation of the nasal septum, any other nasal illness that can interfere with the aim of the study, patients who have acute or chronic sinusitis, patients who are also diagnosed with SAR, immunotherapy, patients who are taking or have taken specified medications prior to randomisation in the study and have not complied with the specified washout period, and severe concomitant disease that could interfere with treatment response (hepatic, renal, cardiovascular), electrocardiographic abnormalities, arrhythmia, recent acute myocardial infarction or neoplastic diseases. The drugs used in the trial are bilastine, cetirizine, and placebo.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the treatment of Restless Legs Syndrome. The record includes the disease name, icd-10 codes, drug name, and eligibility criteria for the trial. The eligibility criteria include specific requirements for patients to be included in the trial, as well as exclusion criteria for patients who cannot participate. The physician will evaluate any additional inclusion or exclusion criteria.",
    "The sample is a phase 3 clinical trial for bladder and urethral cancer patients who have undergone radical cystectomy and pelvic lymph node dissection within 12 weeks prior to randomization. The trial aims to test the effectiveness of various drugs such as carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, and vinblastine sulfate. The eligibility criteria include having histologically confirmed transitional cell carcinoma of the bladder or mixed histologies containing a component of transitional cell carcinoma, no evidence of distant metastatic disease, and no positive surgical margins in the cystectomy specimen. Patients must also meet certain age, performance status, and hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapies are not allowed, except for prior intravesical therapy for superficial bladder cancer.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of hypertension. The icd-10 codes associated with the disease are listed, along with the drug being tested, which is aliskiren/hctz. The eligibility criteria for the trial are also listed, including age requirements and the diagnosis of hypertension. Additionally, exclusion criteria are listed, such as a history of heart failure or previous cardiovascular events. Other criteria may also apply.",
    "The sample is a phase 3 clinical trial for the treatment of polycythemia vera, a disease characterized by an overproduction of red blood cells. The trial includes patients who have been newly diagnosed with PV according to WHO 2007 diagnostic criteria, as well as those with an old diagnosis confirmed with JAK-2 positivity and clinical course of the disease. The drug being tested is hydroxyurea. The eligibility criteria include being 18 years or older, ability and willingness to comply with all study requirements, and written informed consent. Exclusion criteria include pregnancy or lactation, known hypersensitivity or contraindication to study treatments, significant liver or renal disease, presence of any life-threatening condition or disease likely to significantly shorten life expectancy, history of active substance or alcohol abuse within the last year, and any condition that would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of three different treatments: 125/25 mcg once-daily gsk573719/gw642444, 125mcg once-daily gsk573719, and placebo once-daily. The eligibility criteria for the trial include being 40 years of age or older, having a COPD diagnosis, and having at least a 10 pack-year smoking history. Exclusion criteria include having other respiratory disorders, being pregnant or lactating, and having abnormal ECG or Holter monitor findings. Participants must also not have used certain medications within a certain timeframe prior to the trial. The trial is being conducted on an outpatient basis and participants must provide signed informed consent.",
    "The sample is a phase 3 clinical trial for anxiety disorders. The trial is testing the drug quetiapine sr. The eligibility criteria for the trial includes patients who are between 18 to 65 years old and have been diagnosed with GAD according to DSM-IV criteria 300.02 as assessed by the MINI. Patients with depressive symptoms, defined as having a Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score of 17 or more at the enrolment visit, will be excluded from participation in this study. The diseases are listed as anxiety disorders and the icd-10 codes associated with these disorders are also provided.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the diseases being studied, the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying the effects of paricalcitol and maxacalcitol on patients with secondary hyperparathyroidism and undergoing hemodialysis. The inclusion criteria for participants include being adult chronic kidney disease stage 5 patients undergoing dialysis with stable dialysate calcium and phosphate binders, and having intact parathyroid hormone (iPTH) greater than or equal to 300 pg/mL, adjusted normalized serum total calcium (Ca) greater than or equal to 8.4 to less than 10.2 mg/dL, and serum phosphorus (P) less than or equal to 6.5 mg/dL. The exclusion criteria include recent severe cardiovascular or hepatic disease, uncontrolled hypertension or diabetes, recent parathyroidectomy or ethanol infusion, taking drugs that affect iPTH, calcium or bone metabolism, and being pregnant or breastfeeding.",
    "The sample is a record of a clinical trial in phase 3, which involves heart, liver, and kidney transplantation. The trial is testing the drug FK506E. The diseases are listed along with their corresponding ICD-10 codes. The eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. Patients who had previously participated in the phase II pharmacokinetic or phase III studies with FK506E are eligible to participate. Pregnant or nursing women and those unwilling or unable to use adequate contraception during the study are excluded.",
    "The sample is a record of a clinical trial in phase 3, which involves testing the effectiveness of two drugs, ivabradine and placebo, on patients with two specific diseases: coronary disease and ventricular dysfunction, left. The diseases are identified by their corresponding ICD-10 codes. The eligibility criteria for the trial are listed under inclusion and exclusion criteria, which specify the medical conditions that patients must meet or avoid to participate in the trial.",
    "The sample is a phase 3 clinical trial for prostate cancer. The trial includes patients with confirmed prostate adenocarcinoma and metastatic disease, with measurable or evaluable disease and no brain metastases. Patients must be 18 years or older with an ECOG performance status of 0-2 and a life expectancy of at least 3 months. They must also meet certain hematopoietic, hepatic, renal, and cardiovascular criteria, and have no severe peripheral neuropathy, active infection, or other malignancy within the past 5 years except basal cell skin cancer. Patients must not have any familial, social, geographical, or psychological situation that would preclude study compliance and follow-up, and no other serious disease that would preclude study participation. Prior concurrent therapy is allowed for hormonal therapy within the past 2 months, but not for surgical castration. No other concurrent investigational drugs are allowed. The trial includes antiandrogen therapy, docetaxel, and goserelin acetate as drugs.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug paliperidone palmitate. The trial is looking for participants who have been diagnosed with schizophrenia for at least 1 year and have a total PANSS score of 70 to 120. Participants must also have a BMI of more than 17.0 kg/m\u00b2. The trial has exclusion criteria, including a primary active diagnosis other than schizophrenia, a decrease of 25% or more in the total PANSS score between screening and baseline evaluations, and a history of treatment resistance. Women who are pregnant, breastfeeding, or planning to become pregnant during the study period are also excluded.",
    "The sample is a phase 3 clinical trial for children and teenagers between the ages of 4 and 17 who have been diagnosed with type 1 diabetes mellitus and have been on uninterrupted insulin therapy for at least a year. The trial is testing the effectiveness of multiple daily injections of insulin glulisine, insulin lispro, insulin glargine, and NPH insulin. The trial has specific inclusion and exclusion criteria, including a glycated hemoglobin level between 6.0% and 11.0%, no history of primary seizure disorders, and no treatment with anti-diabetic oral agents or investigational drugs in the month before the trial. The trial also excludes subjects with active proliferative diabetic retinopathy, diabetes other than type 1 diabetes mellitus, and those who have had pancreas and/or islet cell transplants. The trial requires subjects to be willing and able to do blood glucose monitoring using a sponsor-provided glucometer and subject diary.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of the drug tiotropium compared to a placebo. The eligibility criteria for the trial include being 40 years or older, having a smoking history of at least 10 pack years, and having a diagnosis of COPD with a post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1<70% of FVC while on stable respiratory medication. There are also exclusion criteria, such as having significant diseases other than COPD, recent myocardial infarction or unstable arrhythmia, and known hypersensitivity to anticholinergic drugs or components. The trial requires written informed consent from the patients.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic myelogenous leukemia. The trial involves the drug peginterferon alfa-2a and has specific eligibility criteria for participants, including previous participation in certain studies. The record also includes exclusion criteria, such as being a major protocol violator in a previous study. The diseases are listed as 'myelogenous leukemia, chronic' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of soft tissue sarcoma. The trial is open to patients with locally advanced unresectable or metastatic disease, and the disease must be histologically confirmed. The trial is limited to patients with high-grade (grade 2-3) disease according to the FNLCC grading system. Patients must have a measurable lesion with clinical evidence of progression within the past 6 weeks. Patients with known or symptomatic CNS metastases are not eligible. The trial is open to patients between the ages of 18 and 60 with a WHO performance status of 0-1. Patients must have no history of cardiovascular disease and no other severe medical illness. Patients must not be pregnant and must use effective contraception if fertile. The trial is not open to patients with prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell skin cancer. The trial has specific eligibility criteria for hematopoietic, hepatic, renal, and other patient characteristics. The trial does not allow prior chemotherapy for advanced or metastatic disease, but prior adjuvant chemotherapy is allowed provided there was no disease progression within 6 months after completion of treatment. The trial does not allow prior radiotherapy to the sole index lesion, and the surgery is not specified.",
    "The sample is a phase 3 clinical trial for patients with unresectable hepatocellular carcinoma. The trial is testing the effectiveness of two drugs, oxaliplatin and doxorubicin, on patients who have not received previous palliative systemic chemotherapy for metastatic disease. The eligibility criteria include having at least one measurable lesion, a Karnofsky Performance Score of at least 70, and adequate organ and marrow function. Patients must also have progressed after previous local treatment and meet certain medical criteria. Exclusion criteria include allergies to the study drugs, previous liver transplantation, and concomitant use of other anti-cancer therapies. Pregnant or lactating women or women of childbearing potential without proper contraceptive methods are also excluded. The sample is not intended to contain all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample is a phase 3 clinical trial for the treatment of Generalized Anxiety Disorder. The trial involves the use of the drugs vortioxetine and placebo. The eligibility criteria for the trial include having a primary diagnosis of Generalized Anxiety Disorder, having a Hamilton Anxiety Scale total score greater than or equal to 20 at Screening and Baseline, and having a Montgomery-\u00c5sberg Depression Rating Scale total score less than or equal to 16 at Screening and Baseline. Exclusion criteria include having any current psychiatric disorder other than Generalized Anxiety Disorder, having a history of certain mental disorders or substance abuse, and having a significant risk of suicide. The trial also excludes individuals who have previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors, and those who are currently receiving formal cognitive or behavioral therapy.",
    "The sample is a phase 3 trial for pulmonary hypertension. The icd-10 codes associated with the disease are listed. The drug being tested is bosentan. The eligibility criteria for the trial include having completed a previous 16-week treatment period and signing an informed consent. Exclusion criteria include any major violation of the previous protocol and being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for patients with moderate essential hypertension. The trial is testing the effectiveness of the drug combination valsartan and amlodipine. The eligibility criteria for the trial include being 18 years or older, having untreated MSSBP (mean systolic blood pressure) between 160 and 180 mmHg or treated MSSBP below 180 mmHg, and not having severe hypertension or a history of cardiovascular disease. Pregnant or nursing women and patients with controlled hypertension under current therapy are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have not responded to previous anti-estrogen hormonal treatments. The trial is testing the effectiveness of the drug fulvestrant. Inclusion criteria include being postmenopausal, having positive estrogen receptor hormone sensitivity, and giving written informed consent. Exclusion criteria include having a serious illness or allergy to the drug's ingredients, and having received multiple regimens of chemotherapy or hormonal treatment for advanced breast cancer. The trial's eligibility criteria are listed in detail.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus using a combination of alogliptin and pioglitazone drugs. The trial is open to individuals who have been diagnosed with type 2 diabetes mellitus and are currently being treated with a thiazolidinedione either alone or in combination with metformin or a sulfonylurea but are experiencing inadequate glycemic control. The trial has a set of inclusion and exclusion criteria that must be met by the participants. The inclusion criteria include having a body mass index between 23 and 45 kg/m2, fasting C-peptide concentration greater than or equal to 0.8 ng per mL, and glycosylated hemoglobin concentration between 7.0% and 10.0%, among others. The exclusion criteria include a history of cancer, heart failure, coronary angioplasty, and substance abuse, among others. Participants must not take any medications, including over-the-counter products, without first consulting with the investigator.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C infection. The trial involves the use of multiple drugs, including abt-450/r/abt-267, abt-333, and ribavirin, as well as placebos for each drug. The trial has specific inclusion and exclusion criteria, such as having never received antiviral treatment for hepatitis C infection and no evidence of liver cirrhosis. Females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control to be eligible for the trial. The trial also excludes individuals with a positive screen for drugs or alcohol, significant sensitivity to any drug, or certain predefined abnormal laboratory tests. Additionally, individuals with a positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody are excluded from the trial.",
    "The sample is a phase 3 clinical trial for metastatic breast cancer. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria includes female patients over 18 years old with histologically proven breast cancer, menopausal patients, and those with measurable lesions and adequate biological values. The exclusion criteria includes patients previously treated with hormonotherapy in metastatic phase, those with a history of treatment with aromatase inhibitors, and those with certain types of metastatic lesions. Patients must have given their consent prior to participation.",
    "The sample is a phase 3 clinical trial for patients with metastatic breast or colorectal cancer who are scheduled to receive capecitabine with an initial dose in the range of 750-1500 mg/m2 twice daily alone or in combination with one or more other agents. The trial also includes patients who have received any number or type of prior treatment regimens for metastatic disease or have received no prior treatment for metastatic disease. The trial involves the use of capecitabine, celecoxib, and placebo drugs. The eligibility criteria include adequate organ and bone marrow function, controlled brain metastasis, and the ability to understand and provide written informed consent. The exclusion criteria include allergies to certain medications, serious illnesses or medical conditions, and active infections.",
    "The sample is a phase 3 clinical trial for asthma patients. The trial includes patients who are between 18 and 75 years old and have had a diagnosis of asthma for at least 3 months. Patients must have a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 60% and 90% of predicted normal at Visit 1. Patients must also be symptomatic despite their current maintenance treatment with low doses of inhaled corticosteroids. The trial includes a list of exclusion criteria, such as patients with significant diseases other than asthma, recent history of Acute Coronary Syndrome, and known active tuberculosis. Patients must also be able to use the Respimat\u00ae inhaler correctly and perform all trial-related procedures. The trial includes a list of drugs, including placebo and tiotropium at 2.5 mcg and 5 mcg doses. The eligibility criteria include a list of 25 inclusion and exclusion criteria.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on major depressive disorder and the drug being tested is escitalopram. The eligibility criteria for the trial include meeting DSM-IV diagnostic criteria for major depressive disorder and having a current depressive episode that has lasted at least 12 weeks. Exclusion criteria include being pregnant or breastfeeding, having certain mental health disorders, being at risk for suicide, and having a history of seizure disorder or other conditions that increase the risk of seizure. The diseases and icd-10 codes associated with the trial are also listed.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of two drugs, risperdal consta and paliperidone palmitate. The eligibility criteria for the trial include having a diagnosis of schizophrenia for at least 1 year, having a total PANSS score between 60 and 120, and having a BMI of at least 17 kg/m2. Female patients must be postmenopausal, surgically sterile, abstinent, or practicing an effective method of birth control. Exclusion criteria include having a primary, active diagnosis on Axis I other than schizophrenia, having a history of treatment resistance, and having a significant risk of suicidal or violent behavior. Women who are pregnant or breastfeeding or planning to become pregnant during the study are also excluded.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of leukemia, and the icd-10 codes associated with the disease are listed. The trial involves the use of multiple drugs, including cyclophosphamide, cytarabine, and doxorubicin hydrochloride. The eligibility criteria for the trial include a diagnosis of B-precursor acute lymphoblastic leukemia, a white blood cell count above a certain threshold, and enrollment in a classification study. The patient characteristics include an age range of 1 to under 31, no specified performance status or life expectancy, and no specified hepatic or renal conditions. The prior concurrent therapy is not specified for biologic therapy, radiotherapy, or surgery, but there are restrictions on chemotherapy and endocrine therapy.",
    "The sample is a phase 3 clinical trial for patients with CD20 and CD22-positive, follicular lymphoma who have received 1 or 2 prior regimens, at least 1 of which should have contained administration of rituximab. The trial involves the use of multiple drugs including inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, and dexamethasone. The eligibility criteria include age 18 years or older, ECOG performance status <= 2, ANC >= 1.5 x 10^9/L (1500/mL) and platelets >= 75 x 10^9/L (75,000/mL), and at least 1 measurable disease lesion that is >= 1.5 cm x 1.5 cm by CT or MRI. The exclusion criteria include clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3b follicular lymphoma, and rituximab refractory disease.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorder. The trial includes two drugs, asenapine and olanzapine, and the eligibility criteria require subjects to have either schizophrenia or schizoaffective disorder and to sign a written informed consent. Exclusion criteria include having an uncontrolled, unstable, clinically significant medical condition or any other psychiatric disorder other than schizophrenia as a primary diagnosis, including depression. The icd-10 codes for the diseases are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis using the drug rituximab. The trial is looking for adult patients between the ages of 18 and 80 who have moderate to severe active rheumatoid arthritis and have not responded well to a previous or current treatment with an anti-TNF agent. The patients must have been taking methotrexate for at least 12 weeks at a stable dose over the past 4 weeks. The trial has exclusion criteria, including previous treatment with MabThera, recent use of an anti-TNF agent, concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate, and active or chronic infection.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have previously been treated with metformin alone or with metformin and one other oral antidiabetic drug. The trial involves the use of the drugs linagliptin and placebo. The eligibility criteria include having a diagnosis of type 2 diabetes prior to informed consent, a certain level of glycosylated haemoglobin A1 (HbA1c), being between the ages of 18 and 80, having a BMI less than 40 kg/m2, and providing written informed consent. Exclusion criteria include recent myocardial infarction, stroke, or transient ischemic attack, impaired hepatic function, known hypersensitivity or allergy to the investigational product or its excipients, and current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent. Pre-menopausal women who are nursing or pregnant, or are of child-bearing potential and not practicing an acceptable method of birth control, are also excluded.",
    "The sample is a phase 3 clinical trial for breast cancer patients who have locally recurrent or metastatic disease and have received at least two prior chemotherapeutic regimens for breast cancer. The trial is testing the effectiveness of two drugs, E7389 and \"physician's choice,\" as a treatment option. The eligibility criteria include having a confirmed diagnosis of breast cancer, refractory to the most recent chemotherapy, and having resolved all chemotherapy or radiation-related toxicities to Grade 1 severity or lower. Patients must also have adequate renal, bone marrow, and liver function, and be willing and able to comply with the study protocol. The exclusion criteria include having received certain treatments within a specified period before the trial, having brain or subdural metastases, and having other significant diseases or disorders that would exclude the patient from the study.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial includes participants who are male and 18 years or older, with a confirmed diagnosis of prostate adenocarcinoma and radiograph-documented metastatic disease. The trial involves the use of drugs such as orteronel, prednisone, and orteronel placebo. The eligibility criteria include having a life expectancy of 6 months or more, meeting certain laboratory values, and having a stable medical condition. Participants must also practice effective barrier contraception during the entire study treatment period or abstain from heterosexual intercourse. The exclusion criteria include having a known hypersensitivity to the drugs used in the trial, having received prior therapy with certain drugs, and having uncontrolled cardiovascular conditions or gastrointestinal diseases that could interfere with oral absorption or tolerance of orteronel.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension and renal impairment. The trial involves the use of three drugs: olmesartan medoxomil, losartan, and furosemide oral tablets. The eligibility criteria for the trial include having a mean sitting blood pressure within a certain range and having mild to moderate renal impairment. Exclusion criteria include having malignant hypertension, severe heart failure or renal disease, recent history of myocardial infarction or stroke, and other underlying diseases that may interfere with participation in the trial. Pregnant or breastfeeding females or those with a history of drug and/or alcohol abuse are also excluded.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The eligibility criteria include requirements for the stage and type of cancer, as well as patient characteristics such as age and medical history. Prior concurrent therapies are also specified. The trial requires complete en bloc resection by laparotomy and does not allow laparoscopic colectomy without prior surgery on protocol SWOG-9411. Patients must not have distant peritoneal metastases or extrapelvic nodal metastasis unless resected en bloc with the primary tumor. Patients must also meet certain hematopoietic, hepatic, renal, and other health criteria. Effective contraception is required for fertile patients.",
    "The sample is a phase 3 clinical trial for patients aged 40 years or older with moderate to severe chronic obstructive pulmonary disease (COPD) and a 20 pack-year smoking history. The trial involves the use of the drug indacaterol 150 \u03bcg and a placebo to indacaterol. The eligibility criteria include a post-bronchodilator forced expiratory volume in 1 second (FEV1) of \u2265 30% and < 80% predicted FEV1/FVC (forced vital capacity) < 70%. Exclusion criteria include a history of asthma, prior exposure to indacaterol, active cancer or history of cancer, concomitant pulmonary disease, diabetes Type I or uncontrolled diabetes Type II, a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged, and patients unable to successfully use a dry-powder inhaler device or perform spirometry measurements. Other protocol-defined inclusion/exclusion criteria applied to the study.",
    "The sample is a phase 3 clinical trial for patients with pathologically confirmed malignancy involving certain sites in the head and neck region. The trial is testing the effectiveness of benzydamine hydrochloride 0.15% oral rinse in preventing oral and/or oropharyngeal mucositis caused by radiation therapy. The eligibility criteria include a Karnofsky performance scale of at least 60%, high risk for developing mucositis due to radiation, and planned to receive a continuous course of radiation with or without chemotherapy. Exclusion criteria include hypersensitivity to benzydamine HCl, presence of mucositis at the time of entry, and use of certain medications.",
    "The sample is a phase 3 trial for HIV infections. The trial involves two groups of patients, one group will immediately switch to atazanavir/ritonavir and two nrtis, while the other group will delay or have the option to switch to lpv/r and two nrtis. The eligibility criteria for the trial include being HIV positive, having been on LPV/RTV-based HAART for at least 6 months, having HIV-1 RNA less than 50c/mL, having a non-HDL higher than 160 mg/dL, and having a CD4 count of at least 50 cells/mL. The exclusion criteria include the use of lipid-lowering agents.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, primary Sj\u00f6gren's syndrome), the ICD-10 codes associated with the disease, the drugs being tested (hydroxychloroquine and placebo), and the eligibility criteria for participants. The inclusion criteria include being diagnosed with primary Sj\u00f6gren's syndrome, being 18 years or older, having undergone a clinical examination, and being able to provide informed consent. The exclusion criteria include having other autoimmune diseases, retinopathy or severe cataracts, previous treatment with hydroxychloroquine, and various other medical conditions.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on major depressive disorder. The icd-10 codes associated with this disorder are listed, as well as the drugs being tested (saredutant and placebo). The eligibility criteria for participants are also listed, including requirements for diagnosis, exclusion criteria, and other factors that may disqualify a patient from participating in the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chronic plaque psoriasis. The trial includes patients who are at least 18 years old and have been diagnosed with moderate to severe plaque psoriasis for at least 6 months. Patients must have failed to respond to or have a contraindication to at least two different systemic therapies, one of which must be cyclosporine, methotrexate, or oral PUVA. The trial involves the use of calcipotriol/betamethasone ointment and a placebo (vehicle ointment). The eligibility criteria include being in generally good health as determined by the principal investigator, while the exclusion criteria include previous exposure to adalimumab, inability to discontinue systemic therapies and/or topical therapies for the treatment of psoriasis, and taking or requiring oral or injectable corticosteroids. Female subjects who are pregnant or breastfeeding or considering becoming pregnant are also excluded. Additionally, patients with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis are excluded, as well as those with a calcium metabolism disorder.",
    "The sample is a phase 3 clinical trial for the treatment of chronic genotype 2 or 3 hepatitis C virus (HCV) infection. The trial involves the use of drugs such as sof, rbv, and placebos to match them. The eligibility criteria for the trial include being over 18 years old, having HCV RNA levels above 10,000 IU/mL, and being treatment naive or experienced. The trial also requires subjects to be healthy except for their HCV diagnosis and to agree to use two forms of highly effective contraception for the duration of the study and 6 months after the last dose of study medication. The exclusion criteria include prior use of any other inhibitor of the HCV NS5B Polymerase, history of any other clinically significant chronic liver disease, evidence of or history of decompensated liver disease, HIV or chronic hepatitis B virus (HBV) infection, hepatocellular carcinoma (HCC) or other malignancy, chronic use of immunosuppressive agents or immunomodulatory agents, and history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study or not be in the best interest of the subject in the opinion of the investigator.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial includes adults of both genders who meet the diagnostic criteria for ADHD according to the DSM-IV-TR. The trial involves two drugs, atomoxetine hydrochloride and placebo. The eligibility criteria include exclusion of patients with major psychiatric disorders, significant medical conditions, current alcohol/drug abuse/dependence, and those taking excluded medications.",
    "The sample is a phase 3 clinical trial for individuals with mood disorders who have difficulty swallowing lamotrigine IR compressed tablets. The trial requires participants to have a documented diagnosis of a mood disorder and a person willing to complete a Companion/Caregiver Preference Question. Participants must have been taking a stable dose of currently marketed compressed tablet formulation of lamotrigine IR for at least 4 weeks prior to the study and must be adherent to the prescribed dosing regimen. The trial also has various inclusion and exclusion criteria, including age, gender, and medical history. Participants must provide informed consent and read, write, and comprehend English at a level sufficient to complete study-related assessments.",
    "The sample is a phase 3 clinical trial for the treatment of psoriatic arthritis. The trial is testing the effectiveness of apremilast 20mg, apremilast 30mg, and a placebo. The eligibility criteria for participants include being at least 18 years old, having a documented diagnosis of psoriatic arthritis for at least 3 months, and meeting certain laboratory criteria. Participants must not have been previously treated with disease-modifying antirheumatic drugs (DMARDS) and must be receiving treatment on an outpatient basis. The trial also has a list of exclusion criteria, including a history of certain diseases or conditions, active substance abuse, and prior treatment with certain medications.",
    "The sample is a phase 3 clinical trial for chronic HIV-1 infection. The trial includes patients who have been on a well-tolerated combination of antiretroviral drugs for at least 3 months, including enfuvirtide, and have no uncontrolled opportunistic diseases. Patients must also have plasma HIV-1 RNA levels below 400 copies per ml for at least 3 months and no restrictions on CD4 lymphocyte levels. Women of childbearing age must use mechanical contraception during any sexual intercourse and have a negative pregnancy test. The trial excludes patients with HIV-2 infection, poor compliance with antiretroviral therapy, current treatment with an investigational drug, or previous treatment with an integrase inhibitor in the context of a clinical study. Patients with certain conditions, such as acute hepatitis or significant biological abnormalities, are also excluded. Concomitant treatments with certain compounds are also not allowed.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the drug certolizumab pegol and the patients must have moderate to severe RA with at least two swollen and tender joints in one of the hand/wrist. They must have also failed at least one non-biologic or biologic DMARDs and currently receiving MTX therapy. The inclusion and exclusion criteria are also listed. The icd-10 codes for the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of severe sepsis. The trial includes patients who are at least 18 years old and have confirmed early-onset severe sepsis, as well as at least 3 of 4 systemic inflammatory response syndrome (SIRS) criteria and sepsis-associated organ dysfunction. The trial also requires patients to have a Baseline Acute Physiology and Chronic Health Evaluation II (Apache II) Score of 21 to 37 and to receive the study drug within 12 hours of the onset of the first qualifying organ dysfunction. Patients must also be committed to full patient support. Exclusion criteria include pregnancy or breastfeeding, extensive third-degree burns, weight over 150 kg, imminent death from sepsis, pre-existing medical conditions that cannot be corrected, severe congestive heart failure, immunosuppressive therapy, low granulocyte counts, recent cardiopulmonary resuscitation, HIV-positive patients with low CD4 counts, significant hepatic impairment, portal hypertension, esophageal varices, treatment with endotoxin-removal devices, active cancer, and treatment with polymyxin B or colistin.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for epilepsy with the specific type of epilepsy being tonic-clonic. The icd-10 codes associated with the disease are listed. The drug being tested is levetiracetam. The eligibility criteria for the trial are also listed, including the requirement for a confirmed diagnosis of epilepsy and having experienced unprovoked seizures in the past. The sample also includes exclusion criteria, such as not needing an additional antiepileptic drug.",
    "The sample is a phase 3 clinical trial for metastatic colorectal cancer. The trial involves the use of two drugs, panitumumab and folfiri, and has specific eligibility criteria for participants, including having only received one chemotherapy regimen for mCRC and having radiologically documented disease progression. The trial also has exclusion criteria, such as a history of central nervous system metastases and known allergies to certain drugs. The sample includes the phase, diseases being studied, icd-10 codes, drugs being used, and eligibility and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves the use of preservative-free tafluprost and a comparator drug called timolol. The eligibility criteria for the trial include having a diagnosis of primary open-angle glaucoma, pigmentary glaucoma, capsular glaucoma/pseudoexfoliation, or ocular hypertension, having a stable dose of prescribed ocular hypotensive medication for 30 days prior to screening, or being drug-naive, having vision corrected to 20/80 or better in each eye, and being willing and able to avoid wearing contact lenses and self-administer or have an able person available on a daily basis to assist with administration of study medications. The exclusion criteria include having a history of inflammatory ocular surface disease or anterior or posterior uveitis in either eye, having a history of retinal detachment, diabetic retinopathy, or other progressive retinal disease, having experienced significant visual field loss within the last year, having had intraocular surgery in either eye in the last 4 months, having a history of glaucoma surgery or refractive surgery in either eye, currently taking two or more anti-glaucoma medications (except Cosopt\u2122 or its generic formulation), having previously used tafluprost, having a history of cardiovascular disorder within 6 months prior to screening, having a history of bronchial asthma, wheezing, pneumonia, COPD, other pulmonary disease, or abnormal chest x-ray, and having a mean (or median) IOP >36 mmHg in either eye at the Screening Visit or at any time point (0800 hours, 1000 hours, and 1600 hours) of the Baseline Visit.",
    "The sample is a phase 3 clinical trial for HIV and HIV infections. The trial involves the use of drugs such as Stribild, Atripla, and their placebos. The eligibility criteria for the trial include having a plasma HIV-1 RNA level of at least 5,000 copies/mL, not having used any approved or investigational antiretroviral drug before, having a normal electrocardiogram, and having adequate renal and hematologic function. Exclusion criteria include having a new AIDS-defining condition, receiving treatment for hepatitis C, having decompensated cirrhosis, and having a history of malignancy within the past 5 years. The trial is open to individuals who are at least 18 years old and have a life expectancy of at least 1 year.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who have given written informed consent and have been on a stable regimen of levodopa plus at least one other antiparkinsonian agent and who have OFF state. Patients who meet stage 4 or 5 while in the OFF state and stage 0 to 3 while in the ON state on the Modified Hoehn and Yahr Scale are also included. The trial requires patients to have experienced a 30% or more improvement in Unified Parkinson's Disease Rating Scale (UPDRS) part\u2162 score when tested for responsiveness to levodopa during the baseline period. Patients who have at least one OFF state per day and can understand the expression of OFF state, ON state, and dyskinesia are also included. Patients or their families must have a desire for self-injection of KW-6500. The trial excludes patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic, metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system (excluding Parkinson's disease), orthostatic hypotension, a history of intolerance to morphine or its derivatives, sulfur, sulfur-containing pharmaceutical products, or sulfite, a history of malignant syndrome, a diagnosis of cancer or evidence of continued disease, a positive pregnancy test, or a history of mental disease (excluding psychiatric symptoms associated with Parkinson's disease). Patients who are taking antipsychotics or central dopamine antagonists (excluding domperidone), receiving methyldopa or 5-HT3 receptor antagonists, receiving reserpine or papaverine, have had a neurosurgical operation for Parkinson's disease, have had transcranial magnetic stimulation, or have a history of drug or alcohol abuse or dependence are also excluded.",
    "The sample is a phase 3 clinical trial for advanced Parkinson's disease. The trial includes patients who are at least 30 years old and have been diagnosed with idiopathic Parkinson's disease for more than 3 years. The patients must have a stable dose of L-dopa and be able to differentiate between the \"on\" and \"off\" state. They must also have clinical symptoms of gastrointestinal dysfunction and complete 6 Parkinson's diaries over a period of 6 days. The trial includes both inclusion and exclusion criteria, such as not having participated in another study of an investigational medicinal product within the last 30 days and not having a history of chronic alcohol or drug abuse within the prior 6 months. The trial will test the effectiveness of the drug rotigotine compared to a placebo.",
    "The sample is a phase 3 clinical trial for patients with metastatic colorectal cancer. The trial involves the use of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin as treatment options. The eligibility criteria include confirmation of metastatic colorectal adenocarcinoma, bidimensionally measurable disease, adequate hematologic and renal functions, and no previous chemotherapy other than adjuvant chemotherapy or concomitant chemoradiotherapy completed at least 6 months before inclusion. Exclusion criteria include pregnancy or breastfeeding, severe cardiac, respiratory, renal or hepatic failure, active coronary heart disease, and a history of psychological illness or condition that may interfere with the patient's ability to understand the requirements of the study.",
    "The sample is a phase 3 clinical trial for patients with chronic schizophrenia. The trial is looking at the effectiveness of the drug escitalopram. The patients must be under 60 years old, medicated, and clinically stable with a Positive and Negative Syndrome Scale (PANSS) score of 50 or above. The trial includes both inpatients and outpatients who have been on stable doses of antipsychotic medications for at least one month before the study entry. The eligibility criteria also includes being free of any additional axis I diagnosis or significant medical illnesses before enrollment into the study. The exclusion criteria includes comorbidity with mania or major depression, pregnancy, lactation, impaired renal or hepatic function, history of sensitivity to cipramil or to other drugs from the selective serotonin reuptake inhibitor (SSRI) group, mental retardation, organic conditions (brain tumors, drug abuse), and severe exacerbation of the psychiatric condition. Patients will also be excluded during the study if they remove their informed consent.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma. The trial includes patients who are 18 years or older and have been diagnosed with measurable, secretory multiple myeloma. The patients must have experienced relapse or progression of myeloma following prior systemic antineoplastic therapy. The trial excludes patients who have previously been treated with VELCADE, have had more than 3 previous lines of therapy, or have peripheral neuropathy or neuropathic pain of NCI CTCAE Grade \u22652. Additionally, patients who have received antineoplastic or experimental therapy, corticosteroid use above 10mg a day, or plasmapheresis within 3 weeks prior to randomization, or radiation therapy or major surgery within 2 weeks prior to randomization are also excluded. Patients with prior malignancy other than multiple myeloma diagnosed or treated within the last 2 years, with the exception of completely resected carcinoma in situ or basal/squamous carcinoma of the skin are also excluded. The trial involves the use of velcade administered by subcutaneous injection or intravenous infusion.",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes patients who have had at least one exacerbation within the last year and have a post-bronchodilator FEV1/FVC ratio of 70% or less and a post-bronchodilator FEV1 of 50% or less of predicted. The trial involves the drugs roflumilast and placebo. The eligibility criteria include both main inclusion and exclusion criteria. The main exclusion criteria include unresolved COPD exacerbation at the first baseline visit and a diagnosis of asthma or other relevant lung disease.",
    "This sample is for a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients between the ages of 18 and 75 who meet DSM-IV criteria for a primary diagnosis of schizophrenia and are in good physical health. Patients must also be willing to comply with the protocol, including inpatient requirements and outpatient visits. Exclusion criteria include a history of alcohol or drug abuse, use of investigational compounds within the last 30 days, and chronic organic disease of the CNS. The trial will test the effectiveness of drugs such as lurasidone and olanzapine, as well as a placebo comparator.",
    "The sample is a phase 3 clinical trial for chemotherapy-induced nausea and vomiting. The trial includes patients who are naive to cytotoxic chemotherapy and have been diagnosed with a malignant tumor. The trial allows for the use of certain chemotherapy agents on Day 1, depending on their emetogenic potential. Patients must have an ECOG Performance Status of 0, 1, or 2 and meet certain laboratory criteria. Exclusion criteria include pregnancy or lactation, current use of illicit drugs or alcohol abuse, and certain medical conditions that may pose risks in administering the investigational product. The trial involves the use of multiple drugs, including netupitant and palonosetron, aprepitant, palonosetron, and dexamethasone. The eligibility criteria and exclusion criteria are listed in detail.",
    "The sample is a phase 3 clinical trial for asthma. The trial includes children between the ages of 6 and 11 who have been diagnosed with asthma and have been treated for at least 6 months. The trial will test the effectiveness of two drugs, budesonide/formoterol pmdi 40/2.25ug + spacer and budesonide/formoterol pmdi 40/2.25 ug. The eligibility criteria for the trial include having a pre-bronchodilator PEF of 50% of predicted normal value and not currently using systemic glucocorticosteroids or having a respiratory infection. Participants with any significant disease or disorder as judged by the investigator will be excluded from the trial.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the treatment of perennial allergic rhinitis. The table includes a list of diseases and their corresponding ICD-10 codes, a list of drugs being tested, and the eligibility criteria for participants. The inclusion criteria include completing a previous study, giving written consent, being in good health, and using a reliable form of birth control if female. The exclusion criteria include being pregnant or lactating, having nasal polyps, or having any condition that would prevent completion of the study.",
    "The sample is a phase 3 clinical trial for postmenopausal women with early breast cancer who have previously been treated with tamoxifen for 2.5 to 3.5 years. The trial involves the use of letrozole treatment and zoledronic acid. The eligibility criteria include a Karnofsky performance status of at least 70, life expectancy of at least 16 weeks, no clinical or radiologic evidence of distant metastases, and no prior treatment with an aromatase inhibitor. Exclusion criteria include pregnancy or lactation, other malignancies, active infection or serious underlying medical conditions, evidence of pathological fracture, abnormal renal function, and known hypersensitivity to zoledronic acid. The trial also requires compliance with treatment and scheduled follow-up visits.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial is looking for male and female subjects between the ages of 30 and 83 who have been diagnosed with idiopathic PD for at least 3 years and have a disease severity of stages I-III. The subjects must have been treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement and be on a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks before screening. The trial is looking for subjects who have signs of \"wearing-off\" phenomenon for a minimum of 4 weeks before screening. The trial has exclusion criteria, including non-idiopathic PD, dyskinesia disability score >3, severe and/or unpredictable OFF periods, and treatment with prohibited medication. The trial also excludes subjects who have had previous or planned deep brain stimulation or stereotactic surgery for PD.",
    "The sample is a phase 3 clinical trial for cancer patients who are opioid-tolerant and experiencing moderate or lesser intensity pain related to cancer or its treatment. The trial is testing the effectiveness of fentanyl sublingual spray compared to a placebo. The eligibility criteria include being at least 18 years old, having a diagnosis of cancer, experiencing breakthrough cancer pain episodes, and being able to evaluate and record pain relief. Exclusion criteria include intolerance to opioids or fentanyl, uncontrolled hypertension, and inability to assess pain or response to pain medications for any reason. The trial requires informed consent and women of childbearing potential must practice reliable contraception.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on prostate cancer. The trial includes a list of ICDCodes, which are codes used to classify diseases, and a list of drugs being tested, including flutamide, zoladex, and lupron. The eligibility criteria for the trial are also listed, including requirements such as a confirmed diagnosis of locally confined adenocarcinoma of the prostate, negative nodes evaluated by imaging methods or surgical sampling, and a Karnofsky performance status of at least 70. The exclusion criteria are also listed, including stage T1a or \u2265 T2c disease, lymph node involvement, and evidence of distant metastasis.",
    "The sample is a phase 3 clinical trial for relapsing-remitting multiple sclerosis. The trial includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs used in the trial. The eligibility criteria for the trial include being between 18 and 65 years old, having normal laboratory hematologic parameters, and having no medical history or evidence of latent tuberculosis infection or tuberculosis. Exclusion criteria include not being enrolled in the trial, having moderate to severe renal impairment, and having received certain types of therapy or treatment within a certain timeframe.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of pulmonary hypertension. The trial includes patients with primary PAH, connective tissue disease, or those who have undergone surgical repair of a congenital heart lesion. The drug being tested is sildenafil citrate. The eligibility criteria for the trial include specific inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial includes patients who have a documented history of PAR to a relevant perennial allergen and require treatment with an INCS throughout the entire study period. The trial involves the use of two drugs, ciclesonide and mometasone, and has a list of inclusion and exclusion criteria. The inclusion criteria include being in general good health, having a demonstrated sensitivity to at least one allergen known to induce PAR, and possessing a degree of understanding of written English. The exclusion criteria include having a history of physical findings of clinically significant nasal pathology, having a known hypersensitivity to any corticosteroid or any of the components in the formulations of ciclesonide or mometasone, and having any condition that would preclude the subject from completing the protocol with completion of the assessments as written.",
    "The sample is a phase 3 clinical trial for aggressive non-Hodgkin's lymphoma. The trial includes patients with various subtypes of the disease, including diffuse large cell lymphoma, peripheral T-cell lymphoma, and anaplastic large cell lymphoma. Patients must have measurable or evaluable disease and have been previously treated with only one chemotherapy regimen that did not include cisplatin, cytarabine, or gemcitabine. Patients must also meet certain eligibility criteria, including age between 16 and 65, ECOG performance status of 0-3, and no uncontrolled CNS involvement by lymphoma. The trial also includes various patient characteristics and prior concurrent therapies that are allowed or not allowed. The purpose of the trial is to evaluate the safety and efficacy of the treatment regimen.",
    "The sample is a phase 3 clinical trial for the treatment of anemia. The trial includes patients with NDD-CKD or HD-CKD and the eligibility criteria include age between 18 to 85 years, TSAT and Hgb levels below certain thresholds, and Ferritin levels below certain thresholds. The trial involves two drugs, ferric carboxymaltose and standard medical care (smc). The exclusion criteria include previous participation in a FCM trial, known hypersensitivity to FCM, history of anemia other than anemia due to chronic renal failure, current history of GI bleeding, received IV Iron within the last 30 days, anticipated need for surgery, malignancy history, AST or ALT greater than normal, received an investigational drug within 30 days of screening, and pregnant or sexually active females who are not willing to use an effective form of birth control.",
    "The sample is a phase 3 clinical trial for patients with essential diastolic hypertension. The trial is testing the effectiveness of three different drugs: valsartan/amlodipine 80/5 mg, valsartan 80 mg, and valsartan 160 mg. The trial has specific inclusion and exclusion criteria for patients to participate. Inclusion criteria include being an outpatient between the ages of 18 and 86 with a mean sitting diastolic blood pressure between 95 and 110 mmHg. Exclusion criteria include severe hypertension, contraindications to the drugs being tested, and various medical conditions such as heart failure and renal impairment. The trial is testing the safety and efficacy of the drugs and may have additional exclusion criteria not listed in the sample.",
    "The sample is a phase 3 clinical trial for aggressive non-Hodgkin's lymphoma. The trial includes patients between the ages of 18 and 60 who have confirmed lymphoma and at least two risk factors. The trial involves a combination of drugs including chop regimen, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, melphalan, methotrexate, methylprednisolone, mitoxantrone hydrochloride, prednisone, therapeutic hydrocortisone, and vincristine sulfate. The eligibility criteria include various patient characteristics such as no CNS involvement, no significant heart failure, and no severe active acute or chronic infection. Prior concurrent therapy is also specified.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, ulcerative colitis), the corresponding ICD-10 codes, the drugs being tested (asacol 800 mg and asacol 400 mg), and the eligibility criteria for participants. The eligibility criteria include age range, confirmed diagnosis of ulcerative colitis, and current demonstration of moderately active disease. There are also exclusion criteria, such as a history of allergy or hypersensitivity to certain medications, current renal or hepatic disease, and recent participation in other clinical studies. The sample also includes specific restrictions on medication use, such as avoiding certain doses of mesalamine-containing compounds and avoiding antibiotics and NSAIDs within a certain timeframe. Finally, the sample notes that female participants must have a negative pregnancy test and not be lactating.",
    "The sample is a phase 3 clinical trial for patients with breast cancer who are eligible for neoadjuvant or adjuvant myelosuppressive chemotherapy. The trial is testing the effectiveness of two drugs, ep2006 and filgrastim, in treating chemotherapy-associated neutropenia. The eligibility criteria include having histologically proven breast cancer, being a woman over 18 years old, and having an estimated life expectancy of more than six months. The exclusion criteria include having a previous or concurrent malignancy, any serious illness or medical condition that may interfere with safety or compliance, and other protocol-defined criteria.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have been diagnosed with schizophrenia for at least 1 year and have a total PANSS score between 70 and 120. Patients must also have a BMI greater than 17.0 kg/m2 and be willing to meet study requirements. Patients with a primary diagnosis other than schizophrenia, those who are unable to provide their own consent or are involuntarily committed to psychiatric hospitalization, and those with a history of treatment resistance are excluded from the trial. Additionally, patients with significant or unstable cardiovascular, respiratory, neurological, renal, hepatic, hematologic, endocrine, immunologic, or other systemic diseases are excluded. Patients must also not have a history of severe preexisting gastrointestinal narrowing or inability to swallow the oral tolerability medication whole. The trial also excludes patients with a history of neuroleptic malignant syndrome, significant risk of suicidal, homicidal or violent ideation or behavior, or a history of life-threatening allergic reaction to any drug. Patients who are pregnant, breastfeeding, or planning to become pregnant during the study period are also excluded. The trial includes a list of allowed and disallowed therapies, and patients must not have been exposed to experimental drugs, experimental biologics, or experimental medical devices within 6 months before screening or prior randomization into the study.",
    "The sample is a phase 3 clinical trial for bipolar disorder in outpatients aged 4-9 years. The trial involves the use of aripiprazole and placebo drugs. The eligibility criteria include meeting DSM-IV criteria for bipolar disorder type 1 or 2, cyclothymia, or bipolar disorder not otherwise specified, and having a Young Mania Rating Scale score of 15 or higher at baseline. Exclusion criteria include a history of intolerance to aripiprazole, experiencing a manic episode with a documented aripiprazole dose as monotherapy treatment of 0.2 mg/kg/day, and having an active neurological/medical disorder for which treatment with aripiprazole would be contraindicated. Patients taking psychotropic agents (other than psychostimulants) within one week of baseline are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who have been diagnosed with schizophrenia for at least 1 year before screening and have a PANSS score of less than 120. The patients must also have a body mass index of at least 15.0 kg/m2 and have resided at the same address for at least 30 days. The trial excludes patients who are unable to provide their own consent, have been involuntarily committed to psychiatric hospitalization, have a primary, active diagnosis other than schizophrenia, have a history of treatment resistance, have a history of any severe preexisting gastrointestinal narrowing or inability to swallow the medication whole with water, have a history of neuroleptic malignant syndrome, are at significant risk of suicidal or violent behavior, have a current presence of any significant or unstable medication condition, are being treated with any protocol disallowed therapies, or have a clinically significant result from screening laboratory or ECG. The trial will test the effectiveness of placebo and paliperidone palmitate as treatments for schizophrenia.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy with tonic-clonic seizures. The trial includes patients who are at least 13 years old and have a confirmed diagnosis of epilepsy with PGTC seizures for more than 24 weeks prior to the Baseline Phase. The trial also requires patients to have electroencephalogram (EEG) evidence of either spike-and-wave discharges consistent with PGTC, or at least 2 EEGs with no indication of focal abnormalities. Patients must have a documented history of PGTC seizures with or without other generalized seizure type(s) with no focal onset, and at least 1 PGTC seizure during the eight consecutive weeks prior to starting the 8-week Baseline Phase. The trial includes patients who are currently treated with a stable regimen of one or two AED(s) for at least four weeks prior to starting the Baseline Phase (historical or prospective). Patients must be able and willing to maintain an accurate and complete daily written seizure diary, or have a parent/caregiver who is able and willing to maintain an accurate and complete daily written seizure diary for the entire duration of the study. The trial also requires patients to be able to comply with dosing of study drugs, background AEDs and all study procedures. Patients must have given written informed consent, or have a parent/legally authorized representative who has given written informed consent, prior to the performance of any study assessments. The trial excludes patients who have a history of partial seizures or interictal expression of partial seizures as evidenced by EEG, have had status epilepticus within the 24 weeks prior to, or during, the Baseline Phase, are taking three or more background AEDs chronically, have Lennox-Gastaut syndrome, are currently using or have previously used lamotrigine, are currently taking felbamate, are abusing alcohol and/or other substance(s), have taken an investigational drug within the previous 30 days or plans to take an investigational drug anytime during the study, are receiving chronic treatment with any medication that could influence seizure control, are currently following the ketogenic diet, are planning surgery to control seizures during the study, are suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormality that are likely to interfere with the objectives of the study, have any clinically significant cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs, or are pregnant, breastfeeding, or planning to become pregnant during the study or within the three weeks after the last dose of study drug.",
    "The sample is a phase 3 clinical trial for the treatment of multiple myeloma using the drug bortezomib. The trial has eligibility criteria for inclusion and exclusion, including a requirement for symptomatic myeloma diagnosis and recent autologous stem cell transplantation. Exclusion criteria include prior exposure to bortezomib, neuropathy, and uncontrolled cardiovascular disease. The sample also includes a list of icd-10 codes for the disease and a description of the eligibility criteria.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, the disease being studied (in this case, fibromyalgia), the ICD-10 codes associated with the disease, the drugs being tested (pregabalin and placebo), and the eligibility criteria for participants. The eligibility criteria include requirements such as being at least 18 years old, having a diagnosis of fibromyalgia and stable depression, and having taken an antidepressant for at least 3 months. Exclusion criteria include having failed pregabalin treatment, having severe or unstable depression, having other types of pain or conditions that may interfere with evaluating fibromyalgia symptoms, and being at risk of suicide or self-harm.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder. The trial is open to men and women aged 18 to 65 years who have been diagnosed with bipolar I or II disorder, with the most recent episode being manic, hypomanic, mixed or depressive with Rapid Cycling. The trial involves the use of either quetiapine fumarate or valproate. The eligibility criteria include signed informed consent, while the exclusion criteria include substance or alcohol dependence, pregnancy or risk of pregnancy, schizophrenia or borderline personality disorder, history of seizure disorder, acute suicidal or external aggressive behavior, legal incapacity, or indication for treatment against the will of the patient by law. The icd-10 codes for the disease are also provided.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis. The trial involves the use of drugs such as tocilizumab, placebo, and permitted DMARDs. The eligibility criteria for the trial include being an adult patient over 18 years of age, having active rheumatoid arthritis for more than 6 months, and having received permitted DMARDs at a stable dose for at least 7 weeks prior to baseline. The exclusion criteria include having other rheumatic autoimmune diseases or inflammatory joint diseases, having undergone major surgery within 8 weeks prior to screening or planned within 6 months following randomization, having unsuccessful treatment with a biologic agent, including an anti-TNF agent, and having previous treatment with tocilizumab.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and depression using the drug Seroquel (quetiapine fumarate) tablets. The trial includes patients who have given written informed consent and have been diagnosed with bipolar disorder with their most recent episode being depressed. Patients must also be outpatients. Exclusion criteria include patients with a current Axis I disorder other than bipolar disorder within 6 months of screening, and patients whose current episode of depression exceeds 12 months or is less than 4 weeks. The diseases being studied are bipolar disorder and depression, and their corresponding ICD-10 codes are listed.",
    "The sample is a phase 3 clinical trial for various types of cancer, including endometrial, kidney, ovarian, and sarcoma. The trial involves the use of two drugs, doxorubicin hydrochloride and ifosfamide, and has eligibility criteria for patients with soft tissue sarcoma with pulmonary metastases. The criteria include age, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as prior concurrent therapy. The trial requires reevaluation of metastases before randomization. The table also includes lists of disease names, icd-10 codes, and drugs.",
    "The sample is a phase 3 clinical trial for patients with exocrine pancreatic insufficiency, steatorrhea, malabsorption syndromes, and cystic fibrosis. The trial involves the use of the drugs pancrease mt 10.5 or mt 21 and a placebo for those drugs. The eligibility criteria for the trial include having a diagnosis of CF, requiring pancreatic enzyme replacement therapy, having excess fat in the feces, and being on a stable diet and dose of pancreatic enzyme supplementation. The exclusion criteria include no extreme physical wasting, no severe pulmonary disease unrelated to complications of CF, no use of certain drugs, no known congenital abnormalities of the gastrointestinal tract, heart, or liver, and no distal intestinal obstruction syndrome.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial includes patients who are 12 years of age or older and have a 2-year history of PAR. The trial involves the use of three drugs: 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, and placebo. The eligibility criteria include meeting minimum symptom requirements, having a positive skin test to cockroach, dust mite, mold or cat/dog dander, and being in generally good health. Exclusion criteria include having nasal diseases likely to affect deposition of intranasal medication, respiratory tract infections within 2 weeks of screening, and significant pulmonary disease including COPD. The trial also excludes patients with a known history of alcohol or drug abuse, and those who received prohibited medications within specified timepoints in the protocol.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial is testing the effectiveness of a combination therapy of either nateglinide or mitiglinide calcium hydrate (rapid-acting insulin secretagogues) and another antidiabetic drug. The eligibility criteria include being diagnosed with type 2 diabetes mellitus, having an HbA1c of \u2265 6.5% and < 10.0%, receiving specific diet and exercise therapies, and being suitable for combination therapy. Exclusion criteria include severe renal dysfunction, obvious clinical manifestations of hepatic impairment, serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease. Participants must be capable of understanding and complying with protocol requirements and must sign informed consent documents prior to the start of any study procedures.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of epilepsy. The trial is focused on patients who have new-onset epilepsy or a relapse of untreated epilepsy and have experienced at least one but not more than 20 unprovoked seizures within the past 3 months. The patients must weigh more than 110 pounds and be considered a good candidate for rapid initiation of anti-seizure medication. They must also be able to swallow a tablet whole without crushing it. The trial excludes patients who have not taken anti-seizure medications within the past 30 days, have provoking factors for seizures, have active liver disease or serious kidney disease, are pregnant or breastfeeding, or are not using birth control. The trial will test the effectiveness of the drugs topiramate and phenytoin.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of aripiprazole depot compared to a placebo depot. The eligibility criteria for the trial includes subjects who are able to provide written informed consent, are between 18 to 60 years of age, have a current diagnosis of schizophrenia, and require chronic treatment with an antipsychotic medication. Exclusion criteria includes subjects with a current diagnosis of other mental disorders, substance dependence, and those with a history of seizures or other medical conditions that would interfere with the study assessments. The trial also requires subjects to wash-out from prohibited concomitant medications during screening and/or Phase 1.",
    "The sample is a phase 3 clinical trial for diabetes and diabetes mellitus type 2. The trial involves the use of insulin degludec, insulin aspart, and liraglutide as drugs. The eligibility criteria for the trial include obtaining informed consent, completing a previous trial with insulin degludec once daily + metformin, and willingness to adhere to the protocol. Exclusion criteria include previous treatment with GLP-1 receptor agonists, impaired liver or renal function, and participation in a previous trial with insulin glargine. The diseases and their corresponding ICD-10 codes are also listed.",
    "The sample is a phase 3 clinical trial for patients with hypertension, type 2 diabetes, and albuminuria. The trial involves the use of two drugs, ramipril and ramipril-telmisartan. The eligibility criteria for the trial include being over 18 years old, having a diastolic blood pressure between 80 and 104 mmHg, having type 2 diabetes with a hemoglobin A1C less than 0.080, and having a UA ratio albumin:creatinine between 2.0 and 25 mg/mmol. There are also exclusion criteria, such as having a DBP greater than 104 mmHg, having hepatic or renal dysfunction, or having a history of drug or alcohol dependency. The sample includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves the use of drugs such as montelukast sodium and aminophylline hydrate. The eligibility criteria for the trial includes adult participants with acute asthma attacks, while exclusion criteria includes participants with other pulmonary symptoms, smoking habits, and other severe diseases. The diseases are listed as 'asthma' and the icd-10 codes associated with the disease are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian, peritoneal, and fallopian tube cancers using the drugs carboplatin and cisplatin. The eligibility criteria include having histologically proven stage IIIC or IV cancer, a tumor greater than 2 cm, and no brain or leptomeningeal metastases. Patients must also meet certain age, performance status, and hematopoietic, hepatic, and renal function requirements. They cannot have any other serious disabling diseases or prior primary malignancies, and must be able to comply with the protocol and follow-up. There are no prior concurrent therapies allowed except for diagnostic biopsy. The table also includes lists of disease names, ICD-10 codes, and eligibility criteria.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who have completed the week 24 visit of a previous trial (ML19070) and are eligible for re-treatment. The inclusion criteria require patients to have a DAS28 score greater than 2.6, swollen joint count of at least 4, and tender joint count of at least 4. The exclusion criteria include patients who withdrew from treatment before week 16 of the previous trial, those who had a previous response to MabThera after week 16, and those receiving concurrent treatment with certain medications. The trial involves the use of rituximab (mabthera/rituxan).",
    "The sample is a phase 3 clinical trial for asthma. The trial includes patients who have been diagnosed with asthma at least 12 weeks before the first visit and are at least 12 years old. The trial requires patients to have a pre-bronchodilator FEV1 of at least 60% predicted and FEV1 reversibility of at least 12% and 200mls. Patients must also be currently receiving asthma therapy that includes a non-corticosteroid controller and/or short-acting beta agonist. The trial excludes patients with a history of life-threatening asthma exacerbation within the past 10 years, asthma exacerbation requiring treatment with oral corticosteroids within the last 3 months or that required overnight hospital stay within 6 months, current or recent respiratory infection or current oral candida infection, presence of another significant respiratory disease or medical condition that is not controlled or that could affect subject safety or study outcome, known or suspected allergy to study drug or materials, taking another investigational medication or prohibited medication during the study, previous treatment with inhaled fluticasone furoate in a phase II or III study, current smokers or former smokers with significant tobacco exposure, and children in care. The trial will test the effectiveness of fluticasone furoate 50mcg compared to a placebo.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes patients who were previously randomized to the No-Treatment Arm in the IRHC-001 protocol and did not have a significant reduction in plasma HCV RNA level by bDNA assay at Week 24 compared to baseline or detectable plasma HCV RNA by bDNA or TMA assays at Week 48. The trial involves the use of daily infergen (interferon alfacon-1, cifn) (9 or 15 \u00b5g) + ribavirin (1000-1200 mg, based on body weight) po daily for up to 48 weeks. The eligibility criteria include signed informed consent, use of effective contraception, and exclusion of patients who experienced hepatic decompensation during IRHC-001 or show laboratory, clinical, or physiologic evidence of hepatic decompensation at screening for IRHC-002. The trial excludes pregnant or lactating women, male partners of pregnant women, and patients who were on any experimental protocols or therapy while participating in IRHC-001.",
    "The sample is a phase 3 clinical trial for the treatment of prostate cancer. The trial includes participants who have been diagnosed with adenocarcinoma of the prostate and meet certain eligibility criteria, such as having a predicted probability of 5-year freedom from progression \u2264 60% and no evidence of metastasis. The trial involves the use of several drugs, including docetaxel (taxotere\u00ae) chemotherapy and leuprolide acetate (eligard\u00ae) hormonal therapy. The trial also has exclusion criteria, such as participants who have received prior systemic treatment for prostate cancer with hormonal therapy, chemotherapy, or any other anticancer therapy. The eligibility criteria and exclusion criteria are detailed in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of obsessive-compulsive disorder and generalized anxiety disorder. The trial involves the drug memantine and includes a list of eligibility criteria for participants. Inclusion criteria include being between 18-64 years old, meeting DSM-IV criteria for GAD or OCD, and having a total score of 20 or more on the HARS or YBOCS at screening. Exclusion criteria include having a psychiatric condition that would require inpatient or partial psychiatric hospitalization, being pregnant or nursing, and having a history of poor compliance or attempted suicide within the past twelve months. The sample also includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of metastatic colorectal cancer. The trial involves the use of drugs such as oxaliplatin, leucovorin, and 5-fluorouracil. The eligibility criteria for the trial include having documented colorectal cancer that is EGFR-positive and metastatic, and having received prior irinotecan as first-line treatment for metastatic disease. Exclusion criteria include having a serious uncontrolled medical disorder, known dihydropyrimidine dehydrogenase deficiency, known metastases in the central nervous system, symptomatic sensory or peripheral neuropathy, and having received prior oxaliplatin therapy, cetuximab, or other therapy that targets the EGF pathway.",
    "The sample is a phase 3 clinical trial for metastatic breast cancer. The trial includes patients with locally recurrent or metastatic disease who have confirmed adenocarcinoma of the breast. The trial involves the use of bevacizumab, placebo, and chemotherapy drugs. The eligibility criteria include being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and having the ability to comply with study and follow-up procedures. Exclusion criteria include prior chemotherapy for locally recurrent or metastatic disease, prior hormonal therapy less than 1 week prior to Day 0, and prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0. The trial also has various other exclusion criteria related to medical history and laboratory values.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The trial is looking at the effectiveness of the drug galantamine hbr in treating mild to moderate Alzheimer's disease in out-patients. The trial has specific inclusion criteria, such as a diagnosis of probable Alzheimer's disease, a MMSE score of 10-24, and having a responsible caregiver. There are also exclusion criteria, such as having other neurodegenerative disorders or evidence of multi-infarct dementia or clinically active cerebrovascular disease. The trial requires patients to sign an informed consent form and have their caregiver sign an assent form. The diseases are listed as 'alzheimer disease' and the icd-10 codes are listed as [\"['G30.8', 'G30.9', 'G30.0', 'G30.1']\"].",
    "The sample is a phase 3 clinical trial for patients with heart disease, arrhythmia, and atrial fibrillation. The trial is testing the effectiveness of the drug olmesartan. The eligibility criteria for the trial include having documented paroxysmal atrial fibrillation, being over 18 years old, and providing written informed consent. Exclusion criteria include having certain medical conditions or taking certain medications, being pregnant or breastfeeding, and having a history of drug addiction or chronic alcohol abuse. The trial also requires participants to have a cooperative attitude.",
    "The sample is a phase 3 clinical trial for the treatment of seasonal allergic rhinitis. The trial is looking at the effectiveness of the drugs act-129968, placebo, and cetirizine. The eligibility criteria for participants include having a documented clinical history of symptomatic seasonal allergic rhinitis associated with mountain cedar pollen for the last 2 years, and having an evening reflective Total Nasal Symptom Score (p.m.rTNSS) of at least 42 out of a maximum potential score of 84 over the 7-day run-in period, or > or = 6 out of a maximum score of 12 on each of the last 4 consecutive days during the run-in period. Exclusion criteria include having non-allergic rhinitis, severe physical nasal obstruction, acute or significant chronic sinusitis, bacterial or viral infection of the upper or lower respiratory tract, nasal sinuses, or middle ear, ongoing chronic respiratory disorders, asthma requiring use of short-acting beta2-agonists > 2 times a week or any asthma treatment other than inhaled short-acting beta2-agonists, diagnosis of aspirin or non-steroidal anti-inflammatory drug (NSAID)-induced asthma, nasal biopsy or surgery, sinus surgery, or perforation within the 8 weeks prior to the Screening Visit, ocular surgery within the 8 weeks prior to the Screening Visit, ocular infections (bacterial or viral) within the 4 weeks before screening, use of forbidden medications (prescribed or over-the-counter [OTC]), congenital or acquired severe immunodeficiency or known Human immunodeficiency virus (HIV) infection.",
    "The sample is a phase 3 clinical trial for chronic pain. The trial is looking for subjects who have been taking opioids for at least 3 months and have a moderate to severe chronic pain condition. The trial will last for 6 to 12 months and female subjects of childbearing potential must use contraception throughout the study period. The trial has certain exclusion criteria such as uncontrolled blood pressure, high BMI, and clinically significant abnormalities in clinical chemistry, hematology or urinalysis. The trial requires subjects to provide written informed consent.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes patients who are currently experiencing an acute exacerbation of schizophrenia and require a caregiver. The trial excludes patients who have an uncontrolled or unstable medical condition, as well as those who have any other psychiatric disorder other than schizophrenia as a primary diagnosis. The trial involves the use of drugs such as asenapine and haloperidol. The diseases are listed as 'schizophrenia' and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for the treatment of epilepsy using the drug Lamictal. The trial is looking for subjects with newly diagnosed or recurrent epilepsy who have had at least 2 seizures in the previous 6 months with at least 1 seizure in the previous 3 months. The trial has inclusion criteria such as age \u226516 years, confident diagnosis of epilepsy uncomplicated by pseudoseizures, and ability to comply with dosing of investigational products and all study procedures. Exclusion criteria include subjects with seizure types other than partial seizure or generalized tonic-clonic seizures with or without myoclonus, history of treatment with AEDs during 6 months before the start of treatment with the investigational product, and subjects with a history of rash associated with other AED treatment. The trial also has exclusion criteria for subjects with acute or chronic illnesses likely to impair drug absorption, distribution, metabolism or excretion or with any unstable physical symptoms likely to require hospitalization during participation in the study. Female subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study are also excluded.",
    "The sample is a phase 3 clinical trial for Crohn's disease with anorectal involvement. The trial is testing the effectiveness of 10% metronidazole ointment as a treatment option. The eligibility criteria include having a PCDAI score of 5 or above, perianal symptoms for longer than 3 months, and being on stable medication for at least a certain period of time. Patients must also be 18 years or older and provide written informed consent. Exclusion criteria include recent surgery, perianal abscess, stoma of less than 6 months, allergy to metronidazole, and participation in an experimental drug study in the preceding three months.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of hypercholesterolemia. The trial involves the use of two drugs, atorvastatin and ezetimibe, and the eligibility criteria include having LDL-C levels above 70 mg/dL and being on a stable dose of atorvastatin 40 mg. The exclusion criteria include being pregnant or lactating, or having sensitivity or intolerance to either of the drugs. The diseases are listed as a single disease, hypercholesterolemia, and the icd-10 codes associated with it are E78.01, E78.00, and Z83.42.",
    "The sample is a phase 3 clinical trial for breast cancer patients with ErbB2-overexpressing invasive carcinoma. The trial includes patients who have undergone adequate excision of tumor and have tumors that overexpress ErbB2. Patients must have Stage I through Stage IIIc disease according to the American Joint Committee on Cancer staging criteria for breast cancer and meet certain criteria related to lymph node status. Patients must have received and completed treatment with a neoadjuvant or adjuvant chemotherapy regimen containing either an anthracycline or a taxane, or any cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimen. Patients may continue to receive endocrine therapy while taking study medication, if endocrine therapy was initiated as either adjuvant therapy for treatment of the initial diagnosis of invasive breast cancer or for ovarian function suppression. Patients must have clinical and radiologic assessments that are negative for local or regional recurrence of disease or metastatic disease at the time of study entry. Patients must meet certain laboratory and organ function criteria and must have signed the informed consent form. There are also exclusion criteria, such as having clinical and radiologic evidence of local or regional recurrence of disease or metastatic disease at the time of study entry, having a prior history of other breast cancer malignancies, and having unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.",
    "The sample is a record from a table that contains information about clinical trials. The trial is in phase 3 and is focused on Alzheimer's disease. The icd-10 codes associated with the disease are listed as \"G30.8\", \"G30.9\", \"G30.0\", and \"G30.1\". The drug being tested is a rivastigmine transdermal patch. The eligibility criteria for the trial include having completed the double-blind treatment phase without significant protocol violations.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of two drugs, interferon-alfa and su011248, on patients with renal cell carcinoma. The trial is looking for patients with clear cell histology and metastases, who have measurable disease by radiographic technique and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients who have had prior systemic therapy for RCC, have a history of or known brain metastases, or have serious acute or chronic illness or recent history of significant cardiac abnormality are excluded from the trial. The sample also includes the ICD-10 codes for the disease and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients with confirmed diagnosis of NSCLC, non-epidermoid, stage IV or IIIB with pleural effusion, or N3 tumors not candidate for thoracic radiotherapy, harboring deletions in the exon 19 or mutation in the exon 21 in the TK of the EGFR. The trial involves the use of erlotinib (tarceva), carboplatin, gemcitabine, docetaxel, and cisplatin as drugs. The eligibility criteria include informed consent, age over 18, ECOG performance status less than 2, adequate bone marrow, renal, and hepatic function, and patients must be accessible for treatment and follow-up. The exclusion criteria include pregnant or lactating women, patients with prior chemotherapy for metastatic disease, prior treatment with EGFR targeted therapies, and any other severe disease or clinical conditions.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of rheumatoid arthritis using the drugs pelubiprofen and celebrex. The trial is open to adult males and females aged 18 to 80 who are currently taking NSAIDs for their condition and belong to ACR functional class 1, 2, or 3. Patients who belong to ACR functional class 4, are hypersensitive to the trial medicines or excipient, or have a history of cerebrovascular bleeding or bleeding disorder are excluded from the trial. The diseases associated with the trial are pelubiprofen, celebrex, and rheumatoid arthritis, and the icd-10 codes associated with the diseases are listed as well.",
    "This sample is for a phase 3 clinical trial for the treatment of anemia in patients with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) who require red blood cell transfusions. The drug being tested is lenalidomide. The eligibility criteria include being 18 years or older, having a diagnosis of MDS with any chromosome karyotype except del 5q[31], being resistant to erythropoiesis stimulating agents (ESAs) or having a blood erythropoietin level > 500 mU/mL, having an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \u2264 2, and agreeing to follow pregnancy precautions and counseling related to teratogenic and other risks of lenalidomide. Exclusion criteria include having previously received immunomodulating or immunosuppressive agents, having an allergic reaction to thalidomide, having renal insufficiency, having a prior history of cancer other than MDS, having low levels of absolute neutrophil count or platelets, having high levels of AST or ALT, having uncontrolled hyperthyroidism or hypothyroidism, having significant neuropathy, having had a prior stem cell transplantation, having anemia due to reasons other than MDS, having a history of deep venous thrombosis or pulmonary embolus within the past 3 years, having significant active cardiac disease within the past 6 months, or having a known HIV or Hepatitis C infection or active Hepatitis B infection. Participants must also be willing to consent to two or more bone marrow aspirate procedures to be completed during the study.",
    "The sample is a phase 3 clinical trial for low-grade Non-Hodgkin's lymphoma. The trial includes patients with Stage III-IV disease and requires baseline measurements and evaluations to be obtained within 4 weeks prior to registration. Patients must have at least one objective measurable disease parameter, which can be determined through radiographic findings or a clearly defined, bidimensionally measurable defect or mass measuring at least 2 cm in diameter on a radionuclide or a CT scan. Patients must also have a tissue diagnosis of low-grade malignant lymphoma obtained within 12 months prior to registration. Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of birth control. Patients must not have had prior chemotherapy, radiotherapy, or immunotherapy, and must have an ECOG performance status of 0-1. Lab values must be obtained within 4 weeks prior to protocol entry, and patients with documented marrow involvement at the time of registration are not required to meet the hematologic parameters above. Patients must give signed informed consent. The trial involves the use of cyclophosphamide, fludarabine phosphate, vincristine sulfate, and prednisone.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who have confirmed NSCLC with advanced stage (IIIb/IV) and have received 1 or 2 chemotherapy treatments before, with at least one being platin-based. The trial excludes patients who have previously used EGFR-TKI or antibody to EGFR, such as gefitinib, erlotinib, herceptin, or erbitux. The table also includes information on the icd-10 codes of the diseases, the drugs being used in the trial, and the eligibility criteria for inclusion and exclusion.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of hypercholesterolemia and hyperlipidemia using niacin and laropiprant. The eligibility criteria for the trial are listed, including inclusion criteria such as being at risk for heart disease and having triglycerides below 500 mg/dL, and exclusion criteria such as having a history of cardiovascular events or diabetes with high LDL-C levels. The sample also includes the icd-10 codes for the diseases being treated.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of the drugs exenatide and placebo. The eligibility criteria for the trial include being diagnosed with type 2 diabetes for at least 6 months, having a stable dose of certain medications for at least 6 weeks prior to screening, having an HbA1c level between 6.6% and 10.0%, and having a BMI between 25 kg/m^2 and 39.9 kg/m^2. The exclusion criteria include being treated with certain excluded medications, having conditions that contraindicate the use of certain medications, having had a change in lipid-lowering agents within 6 weeks of screening, having received certain other medications, or having received treatment with an unapproved drug within the last 30 days.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of type 2 diabetes. The trial involves the use of two drugs, human insulin inhalation powder and injectable insulin. The eligibility criteria for the trial include having type 2 diabetes, being a non-smoker, and having normal lung function. The exclusion criteria include having pulmonary, hepatic, or renal disease, congestive heart failure, active malignancy, or being on systemic glucocorticoid therapy. The diseases are listed as 'diabetes mellitus, type 2' and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for generalized anxiety disorder (GAD) and involves the use of duloxetine, venlafaxine, and placebo drugs. The trial includes eligibility criteria for male and female outpatients who are at least 18 years old and have GAD. Exclusion criteria include having any other primary DSM-IV Axis I diagnosis, a history of antisocial behavior, previous completion or withdrawal from the study, and a history of alcohol or psychoactive substance abuse or dependence within the past 6 months. The trial also lists the icd-10 codes for the diseases being studied.",
    "The sample is a phase 3 trial that focuses on three diseases: hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. The icd-10 codes associated with these diseases are also provided. The trial involves the drug ezetimibe (+) simvastatin. The eligibility criteria for the trial include individuals between the ages of 18-79 with high cholesterol and high triglycerides. The exclusion criteria include individuals who do not meet specific cholesterol or triglyceride levels required by the study.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The trial is looking for patients with morphologically confirmed acute myeloid leukemia (AML) who are between the ages of 18 and 60 and have a Zubrod performance status of 0-3. The trial is testing the effectiveness of a combination of drugs including gemtuzumab ozogamicin, cytosine arabinoside, and daunomycin. The eligibility criteria include various medical and health factors such as liver function, renal function, and cardiovascular health. Patients must not have had prior systemic chemotherapy and must not have any other malignancy within the past 5 years. The sample also includes information on the prior concurrent therapy that is allowed during the trial.",
    "The sample is a phase 3 clinical trial for the treatment of primary insomnia. The trial is looking at the effectiveness of the drug circadin compared to a placebo. The eligibility criteria for participants include being between the ages of 18-80, having a diagnosis of primary insomnia according to DSM-IV criteria, and not having used benzodiazepines or non-BZD hypnotics for at least 2 weeks. Participants must also be willing to take a 6-SMT level evaluation test and sign a written informed consent. Exclusion criteria include the use of benzodiazepines or other hypnotics during the study, severe neurological or psychiatric disorders, and pregnancy or breastfeeding.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of sulfonylurea and placebo drugs. The eligibility criteria for the trial include having type 2 diabetes and receiving sulfonylurea mono-therapy for at least 4 weeks, having an HbA1c value between 7.0 and 9.5%, and having a body mass index (BMI) between 20.0 and 45.0 kg/m2. The exclusion criteria include having type 1 diabetes mellitus, having serum creatinine levels above the upper limit of normal, having proteinuria (albumin/creatinine ratio > 300mg/g), having dysuria and/or urinary tract infection, genital infection, having significant renal, hepatic or cardiovascular diseases, and having severe gastrointestinal diseases.",
    "The sample is a phase 3 clinical trial for bipolar I disorder in male and female patients aged 12-18 years. Female patients of menarche must be using a medically accepted means of contraception. The patients must have a diagnosis of DSM-IV BP, type I and currently display an acute depressive episode as determined by K-SADS. They must also have a baseline CDRS score of at least 40 and be fluent in English. Patients with certain medical conditions, neurological disorders, mental disorders, or substance dependence within the past 3 months are excluded from the trial. Patients who were treated with carbamazepine at any point during the month prior to screening are also excluded. The trial is testing the effectiveness of quetiapine as a treatment for bipolar I disorder.",
    "The sample is a phase 3 clinical trial for patients with essential hypertension. The trial is testing the efficacy of two drugs, valsartan/amlodipine 80/5 mg and amlodipine 5 mg. The eligibility criteria include being an outpatient between the ages of 18 and 86, having essential hypertension, and meeting specific blood pressure requirements at different visits. Exclusion criteria include severe hypertension, contraindications to the drugs being tested, and various medical conditions that could affect the absorption, distribution, metabolism, or excretion of the drugs. Women who are pregnant or nursing or of child-bearing potential must use reliable contraception throughout the study. The trial also excludes patients with a history of heart failure, certain types of heart block, angina pectoris, valvular heart disease, and secondary forms of hypertension. Patients with certain types of diabetes, moderate or malignant retinopathy, hepatic or renal impairment, or chronic inflammatory conditions are also excluded. The trial requires patients to discontinue all prior antihypertensive medications safely for up to 28 days prior to Visit 2. The trial lasts for a certain period, and patients must comply with all study requirements.",
    "The sample is a phase 3 clinical trial for the treatment of migraine disorders. The trial includes subjects between the ages of 18 and 65 who have 1-8 migraines per month and less than 15 total headache days per month. The trial is testing a combination product of sumatriptan succinate and naproxen sodium versus a placebo. The eligibility criteria include having recently discontinued the use of certain migraine medications due to nonresponse or intolerable adverse events, and meeting certain requirements for contraception for female subjects. Exclusion criteria include having certain medical conditions or taking certain medications, as well as having participated in another investigational drug trial within the previous four weeks.",
    "The sample is a phase 3 clinical trial for the treatment of ovarian cancer using the drug cediranib. The eligibility criteria include being a female aged 18 or older with a previous diagnosis of epithelial ovarian carcinoma, fallopian tube carcinoma, or primary serous peritoneal carcinoma requiring treatment with further platinum-based chemotherapy. Other criteria include having measurable or non-measurable relapsed disease, an ECOG performance status of 0-1, and adequate bone marrow, liver, and renal function. Exclusion criteria include having non-epithelial ovarian cancer, poorly controlled hypertension, a history of inflammatory bowel disease, and other malignancies within 5 years prior to randomization. Patients must also be willing to use adequate contraception for the duration of the trial treatment and at least 6 months after.",
    "The sample is a phase 3 clinical trial for the treatment of autistic disorder. The trial involves the use of aripiprazole and placebo drugs. The eligibility criteria for the trial include meeting the DSM-IV diagnostic criteria for AD, having serious behavioral problems, having a CGI score of at least 4 and an ABC Irritability/Agitation subscale score of at least 18, having a mental age of at least 18 months, and being between 6 and 17 years old. Exclusion criteria include being treatment-resistant to neuroleptic medication, previously not responding to aripiprazole treatment, having another disorder on the autism spectrum, having bipolar disorder, psychosis, or schizophrenia, having a seizure in the past year, and having a history of severe head trauma or stroke. Patients undergoing non-pharmacologic therapies must have started at least 2 months prior to the initial screening visit and must remain in a consistent treatment program for the duration of the study.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of type 2 diabetes. The trial includes a list of icd-10 codes associated with the disease, as well as a list of drugs being tested, including dapagliflozin, glipizide, and metformin hydrochloride. The eligibility criteria for the trial include being treated with oral anti-diabetic drug therapy, including Metformin, for at least 8 weeks prior to enrollment, having an HbA1c level between 6.5% and 10%, and not having type 1 diabetes, insulin therapy within one year of enrollment, or renal failure or dysfunction. The exclusion criteria include having type 1 diabetes, insulin therapy within one year of enrollment, or renal failure or dysfunction.",
    "The sample is a phase 3 clinical trial for head and neck cancer patients. The trial requires patients to have histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, with stage III or IV cancer. Patients must not have metastases below the clavicle or more distant by clinical exam or radiology. Patients must be 18 years or older with a Zubrod performance status of 0-1 and a life expectancy that is not specified. Patients must also meet certain hematopoietic, hepatic, renal, and cardiovascular criteria. Patients must not have had prior chemotherapy or radiotherapy to the head and neck, except for radioactive iodine therapy. The sample does not specify the duration of the trial or the number of patients involved.",
    "The sample is a phase 3 clinical trial for asthma. The trial is comparing the effectiveness of budesonide/formoterol turbuhaler versus conventional best asthma therapy. The eligibility criteria for the trial includes a diagnosis of asthma for at least 3 months and prescribed daily use of glucocorticosteroids at a dose greater than 320 mcg/day for at least 3 months prior to the start of the trial. The exclusion criteria includes a smoking history of more than 10 pack-years, recent asthma exacerbation requiring change in treatment, and any significant disease or disorder that may jeopardize the safety of the patient. Additional inclusion and exclusion criteria will be evaluated by the investigator.",
    "The sample is a phase 3 clinical trial for chronic kidney disease, dialysis, hyperphosphatemia, and dyslipidemia. The trial is testing the effectiveness of two drugs, mci-196 and placebo, on patients who are clinically stable on haemodialysis or peritoneal dialysis and have stable phosphate control. The trial has specific inclusion and exclusion criteria, such as age, serum albumin level, PTH level, body mass index, LDL-C level, triglycerides level, and medical comorbidities. Patients with a history of substance or alcohol abuse, seizure disorders, drug or other allergies, or who have participated in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent are excluded from the trial.",
    "The sample is a phase 3 clinical trial for HIV infections. The trial includes patients who are at least 18 years old and have a plasma HIV RNA level of at least 1000 copies/mL and a CD4 cell count of at least 50 cells/mm3. The patients must be currently receiving a NNRTI-containing HAART regimen or have not been treated with an alternative regimen since the documented virologic failure. The failing NNRTI-containing regimen must be the patient's first virologic failure on treatment and contain a NNRTI and at least 2 NRTIs. The regimen must have been administered for at least 24 weeks and the patient must have documented virologic response to the regimen (HIV RNA < 400 c/mL). The trial excludes patients who are pregnant or breastfeeding, have reported virologic failure to two or more antiretroviral regimens, have an active AIDS-defined opportunistic infection or disease, or have had proven or suspected acute hepatitis within 30 days prior to study entry. The trial is testing the effectiveness of atazanavir+ritonavir and lopinavir+ritonavir as treatments for HIV infections.",
    "The table contains information about clinical trials for different phases of drug testing. Each trial includes a list of diseases, their corresponding ICD-10 codes, and the drugs being tested. Additionally, there is eligibility criteria for each trial, including age, diagnosis, medical history, and medication use. The sample provided is for a phase 3 trial for the treatment of schizophrenia with the drug lurasidone. The eligibility criteria include having a primary diagnosis of schizophrenia, a PANSS Total score \u2265 80, and a CGI-S score of \u2265 4. The trial also requires subjects to be in good physical health, not pregnant or nursing, and willing to comply with the protocol assessments and visits. Exclusion criteria include having a history of alcohol or substance abuse, being homeless, or having poor peripheral venous access.",
    "The sample is a phase 3 clinical trial for depression. The trial is looking for healthy men and women between the ages of 18 to 55 who have been nonsmokers for at least a year. The trial has inclusion and exclusion criteria, which include medical history, physical examination, laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). The trial is testing the effectiveness of three drugs: desvenlafaxine sr, desipramine, and paroxetine. The icd-10 codes for the disease are listed as [\"['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']\"].",
    "The sample is for a phase 3 clinical trial for juvenile rheumatoid arthritis. The trial includes the use of the drugs etanercept and placebo. The eligibility criteria for the trial includes being between the ages of 2 and 18, having stable systemic features of SOJRA for at least 3 months, and taking prednisone at a stable dose. Exclusion criteria includes being pregnant or nursing, having clinically significant abnormal laboratory test results, having previously received any tumor necrosis factor (TNF) inhibitor, and having any serious medical or psychiatric condition or history of alcohol or drug abuse.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes and high blood sugar using the drug dapagliflozin. The trial includes patients who have been diagnosed with type 2 diabetes and have a blood sugar level between 6.5% and 10% one week before treatment starts. The trial has inclusion criteria such as providing informed consent and being at least 20 years old, and exclusion criteria such as having type 1 diabetes, having a fasting blood sugar level above 240 mg/dL before treatment starts, having unstable or rapidly progressing renal disease, having severe hepatic insufficiency or significant abnormal liver function, and having a significant cardiovascular history.",
    "The sample is a phase 3 clinical trial for lung cancer. The trial is testing the effectiveness of two drugs, amrubicin hydrochloride and etoposide-cisplatin combined chemotherapy. The eligibility criteria for the trial include having histologically/cytologically proven small cell lung cancer, extensive disease, no prior chemotherapy regimen, being 18 years or older, and having an ECOG performance status of 0-1. The exclusion criteria include having brain metastasis requiring treatment, having undergone treatment (surgical or radiotherapy) of the primary tumor, having interstitial pneumonia or pulmonary fibrosis, and having abnormal cardiac function or myocardial infraction within 6 months before study enrollment.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of two drugs, atorvastatin and a sugar pill, on patients with obesity and dyslipidemia. The diseases are listed along with their corresponding ICD-10 codes. The eligibility criteria for the trial are also provided, including inclusion criteria such as abnormal triglyceride and HDL-C levels, and exclusion criteria such as untreated abnormal thyroid function and diabetes.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial includes patients who have been diagnosed with major depressive disorder according to DSM-IV criteria and have a HAM-D17 total score of 22 or higher at screening and baseline. Patients with a CGI-Severity score of 4 or higher at screening and baseline are also eligible. The trial involves the use of the drug agomelatine and a placebo. Patients who complete the core protocol are eligible to participate in the Open-Label Extension Phase. There are several exclusion criteria, including a history of bipolar disorder, schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder, substance or alcohol abuse in the last 30 days, dependence in the last 6 months, and concomitant psychotropic medication or psychotherapy of any type. Female patients of childbearing potential who are not using effective contraception are also excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial is looking at the effectiveness of the drugs nva237 and placebo. The eligibility criteria include being a male or female adult aged 40 or older, having a smoking history of at least 10 pack years, and having a post-bronchodilator FEV1 (forced expiratory volume in one second) between 30% and 80% of the predicted normal. Patients must also be symptomatic according to daily electronic diary data and meet certain criteria related to their lung function. Exclusion criteria include a history of malignancy, asthma, or other pulmonary diseases, as well as recent COPD exacerbations or respiratory tract infections.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of four drugs - insulin glargine, metformin, taspoglutide, and taspoglutide. The eligibility criteria for the trial include being an adult patient between 18-75 years of age, having type 2 diabetes mellitus, and being treated with a stable dose of metformin and sulfonylurea for at least 12 weeks prior to screening. Other criteria include having a stable body weight, fasting C-peptide level of at least 1ng/ml, and being treatment-na\u00efve for insulin. Exclusion criteria include having a history of type 1 diabetes mellitus or secondary forms of diabetes, acute metabolic diabetic complications, clinically symptomatic gastrointestinal disease, and other medical conditions.",
    "The sample is a phase 3 clinical trial for the treatment of breast cancer and metastasis. The trial involves the use of two drugs, temsirolimus (cci-779) and letrozole, for a duration of 34 months. The trial has eligibility criteria for women aged over 18 years who are postmenopausal and have a confirmed diagnosis of locally advanced or metastatic breast cancer. The trial excludes subjects with extensive visceral disease, bone as the only site of disease, and those who have received prior radiation therapy to the site of measurable disease for subjects with a solitary measurable lesion. The diseases are listed as breast neoplasms and neoplasm metastasis, and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for non-erosive gastroesophageal reflux disease. The trial includes participants with grade N or M in the modified LA classification system confirmed by endoscopy, repeated acid reflux symptoms for 2 days or more in one week in the 3 weeks before the trial, and severity of moderate or higher for acid reflux symptoms in the 3 weeks before the trial. The trial excludes participants with esophagus-related complications, a history of surgery or treatment affecting gastroesophageal reflux, acute upper gastrointestinal bleeding, acute gastritis or acute exacerbation of chronic gastritis as a complication, a previous or current history of the Zollinger-Ellison syndrome or other gastric acid hypersecretion disorders, and a history of chest pain due to heart disease or with chest pains suspected of being caused by heart disease within one year before the trial. The trial involves the drugs tak-438 and placebo.",
    "The sample is a record of a clinical trial in phase 3, which involves testing the drug topiramate on patients with alcohol dependence and borderline personality disorder. The trial has specific inclusion and exclusion criteria, such as a diagnosis of AD and BPD, and the absence of serious medical conditions or opiate dependence. Patients with major Axis I disorders or those taking mood stabilizers and antipsychotic medications are also excluded. Additionally, patients with liver function test abnormalities that exceed 3 times normal values are not eligible for the trial. The icd-10 codes for alcohol dependence are F10.20, F10.24, F10.27, F10.280, F10.281, F10.282, and F10.288, while the icd-10 code for borderline personality disorder is F60.3.",
    "This is a sample from a clinical trial table. The trial is in phase 3 and is focused on hypoactive sexual desire disorder. The icd-10 code for this disorder is F52.0. The trial involves two drugs, testosterone gel and placebo gel. The eligibility criteria for the trial include being between the ages of 30 to 65 years and having undergone hysterectomy and bilateral salpingo-oophorectomy. Exclusion criteria include a history of allergic reactions to androgens, any systemic skin diseases or local skin abnormalities in the area of application, and being diagnosed with another primary female sexual dysfunction. Additionally, participants with a medical condition that could affect or interfere with sexual function or using a systemic topical gel or cream estrogen therapy are also excluded.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying pulmonary arterial hypertension. The ICD-10 code associated with this disease is I27.21. The drugs being tested are iloprost (5 \u00b5g) and a placebo. The eligibility criteria for participants include having symptomatic idiopathic or familial pulmonary arterial hypertension or pulmonary hypertension associated with HIV or drugs/toxins in NYHA functional class II to IV. Women of childbearing potential must have a negative urine pregnancy test and use adequate contraception during the study and for 28 days after discontinuation of the study drug. There are also exclusion criteria, such as having pulmonary arterial hypertension related to any condition other than those specified in the inclusion criteria, having moderate to severe obstructive or restrictive lung disease, or being pregnant or breastfeeding.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial involves the drug atorvastatin and has specific eligibility criteria for participants. Inclusion criteria include being between the ages of 30 and 79, having a triglyceride level of 6.8 mmol/L and an LDL-C level of 5.7 mmol/L at screening. Exclusion criteria include being pregnant or lactating, using certain types of contraception, having blood cholesterol levels controlled with statins other than atorvastatin, receiving high doses of certain statins, and receiving multiple lipid-lowering agents.",
    "The sample is a phase 3 clinical trial for the treatment of attention-deficit/hyperactivity disorder. The trial is testing the efficacy and safety of extended-release guanfacine hydrochloride. The eligibility criteria include being between 6-17 years old, meeting DSM-IV-TR criteria for ADHD, having a minimum ADHD-RS-IV total score of 32, and having a minimum CGI-S score of 4. The trial also requires subjects to be able to swallow intact tablets and have a supine and standing BP measurement within the 95th percentile for age, gender, and height. Exclusion criteria include having a current, controlled or uncontrolled, comorbid psychiatric diagnosis, known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems, and other conditions or illnesses that could represent an inappropriate risk to the subject or confound the interpretation of the study. The trial also excludes subjects who are significantly overweight, have a known or suspected allergy or hypersensitivity to guanfacine hydrochloride, or have a history of alcohol or other substance abuse or dependence within the last 6 months.",
    "The sample is a phase 3 clinical trial for type 1 diabetes. The trial is testing the effectiveness of technosphere insulin and an active comparator drug. The eligibility criteria for participants include having a clinical diagnosis of type 1 diabetes for at least 1 year, being a non-smoker for the prior 6 months, having a BMI less than or equal to 35kg/m2, having an HbA1c level between 7% and 11%, having a serum creatinine level less than or equal to 1.8 mg/dL for females and less than or equal to 2.0 mg/dL for males, having FEV1, DLco, and TLC levels within certain ranges, maintaining a treatment regimen of insulin less than or equal to 1.4 iu/kg/day, and having a urine cotinine level less than or equal to 100 ng/mL. Exclusion criteria include a history of certain pulmonary diseases, evidence of severe complications of diabetes, and elevated levels of certain liver enzymes.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial includes patients with a documented diagnosis of cystic fibrosis and/or a genotype with two identifiable mutations. Patients must be at least 5 years old and able to perform acceptable spirometric maneuvers. They must also have a pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) greater than 25% of predicted values and no evidence of respiratory tract infection or pulmonary exacerbation requiring antibiotics or corticosteroids within 2 weeks of screening. Patients must have completed at least 2 cycles of TOBI\u00ae administration prior to the screening visit if they are on a cycling TOBI\u00ae regimen, and must be stabilized for at least 6 weeks prior to Visit 1 if they are on daily inhaled antibiotic use. Patients who have previously participated in study 205.339 can also be selected. Exclusion criteria include known hypersensitivity to the study drug, participation in another study with an investigational drug within one month preceding the screening visit, current participation in another trial, known substance abuse, pregnancy or lactation, and clinically significant disease or medical condition other than CF or CF-related conditions that would compromise patient safety or data quality.",
    "This sample is from a phase 3 clinical trial for cardiovascular diseases. The trial is testing the effectiveness of atorvastatin, a drug used to lower cholesterol levels, on subjects with measurable carotid plaque with lipid who are eligible for statin therapy. The inclusion criteria for the trial are that the subjects must have measurable carotid plaque with lipid and be eligible for statin therapy. The exclusion criteria are that the subjects must have a screen LDL-cholesterol greater than 120 mg/dL, be currently on high dose statin, or have contraindications for MRI or statin therapy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of restless legs syndrome. The trial involves the drug xp13512 (gen) and the eligibility criteria include having completed one of four previous studies. The exclusion criteria include subjects who may not comply with the study procedures or medication administration. The diseases are listed as 'restless legs syndrome' and the corresponding ICD-10 code is 'G25.81'.",
    "The sample is a phase 3 trial for congestive heart failure. The trial includes the drugs candesartan and placebo. The eligibility criteria for the trial includes being 18 years or older, having symptoms of congestive heart failure for more than 4 weeks before starting the study, and providing informed consent. The exclusion criteria includes having current low blood pressure with symptoms, significant liver disease, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for the treatment of non-small cell lung cancer using the drug marimastat. The trial is open to patients with stage IIIA/B disease who have minimal residual disease after incomplete surgical resection, radical radiotherapy, or documented complete or partial tumor response following at least 2 courses of cytotoxic chemotherapy. Patients must meet certain eligibility criteria, including being 18 years or older, having a performance status of ECOG 0-2, and having no major medical illness that precludes prolonged marimastat administration. Patients must also have no second malignancy within 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. The trial excludes patients who have had prior marimastat, batimastat, bleomycin, or busulphan, and those who have had more than 1 cytotoxic chemotherapy regimen for non-small cell lung cancer. The trial requires at least 4 weeks since any investigational drug therapies.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of diabetes, specifically type 1 diabetes. The trial involves the use of three drugs: insulin detemir, nph insulin, and insulin aspart. The eligibility criteria for the trial include being treated with insulin for at least 12 months, planning to become pregnant with a screening HbA1c level of less than or equal to 9.0%, or being pregnant with an intrauterine singleton living fetus and a HbA1c level of less than or equal to 8.0%. The exclusion criteria include known or suspected hypersensitivity to the trial products or related products, untreated hyperthyroidism or hypothyroidism, known or suspected abuse of alcohol or narcotics, cardiac problems, impaired kidney or liver function, uncontrolled hypertension, proliferative retinopathy or maculopathy requiring acute treatment, and being HIV, Hepatitis B, or Hepatitis C positive. Additionally, any concomitant medication contraindicated in pregnancy is also an exclusion criterion. The diseases associated with the trial are diabetes and diabetes mellitus, type 1, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of two drugs, tiotropium and salmeterol, either alone or in combination, in treating COPD. The trial has specific eligibility criteria, including a diagnosis of COPD, a smoking history of at least 10 pack-years, and the ability to perform pulmonary function tests and inhale medication properly. Patients with significant diseases other than COPD, recent myocardial infarction, or a history of asthma or life-threatening pulmonary obstruction are excluded from the trial. Pregnant or nursing women and patients currently participating in another study are also excluded.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for the treatment of ulcerative colitis. The record includes the list of diseases and their corresponding ICD-10 codes, the list of drugs being tested, and the eligibility criteria for the trial. The inclusion criteria include patients who are 18-75 years old, have been diagnosed with ulcerative colitis for at least 6 months, and have a UCDAI score between 4 and 10. Female patients of child-bearing potential must have a negative pregnancy test and agree to use contraception throughout the study period. The exclusion criteria include patients with severe ulcerative colitis, infectious colitis, or other medical conditions that would make the administration of the study drug or procedures hazardous.",
    "The sample is a phase 3 clinical trial for the treatment of generalized anxiety disorder (GAD) using drugs such as duloxetine, venlafaxine, and placebo. The trial is open to male and female outpatients who are at least 18 years old and have been diagnosed with GAD based on the disease diagnostic criteria. The symptoms of GAD should not be situational in nature. The trial has inclusion and exclusion criteria, which are listed in the \"criteria\" column. The exclusion criteria include any current and primary DSM-IV Axis I diagnosis other than GAD, the presence of an Axis II disorder or history of antisocial behavior, which, in the judgement of the investigator, would interfere with compliance with the study protocol.",
    "The sample is a phase 3 clinical trial for HIV-1 infection. The table includes information on the diseases, icd-10 codes, drugs, and eligibility criteria for the trial. The inclusion criteria include having a certain level of HIV-1 RNA, not having used any anti-HIV drugs before, and meeting certain health requirements. Participants must also agree to use effective contraception during the study period. Exclusion criteria include having certain medical conditions or undergoing certain treatments, as well as having a history of substance abuse or participating in other clinical trials.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes and postprandial lipemia. The trial involves the drugs sitagliptin and placebo. The eligibility criteria include having a body mass index between 25.0 and 40.0 kg/m2, a baseline HbA1c between 6.5 and 8.5%, and a baseline fasting plasma glucose < 15.0 mmol/L. Patients must also have received stable doses of metformin for at least 3 months before randomization and be generally healthy without elevations in hepatic transaminases or abnormal renal function or coagulation. Exclusion criteria include patients with extreme dyslipidemias, type 1 diabetes, or acute metabolic diabetic complications. Patients with cardiovascular disease or taking other medications known to affect lipoprotein metabolism will also be excluded.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis, chronic hepatitis B, and cirrhosis. The trial involves the use of telbivudine, lamivudine, and a placebo. The eligibility criteria for the trial include documented decompensated chronic hepatitis B, evidence of hepatic cirrhosis or portal hypertension, and a Child-Turcotte-Pugh score of more than 7 points. Patients who are pregnant or breastfeeding, coinfected with hepatitis C virus, hepatitis D virus, or Human immunodeficiency virus, or have previously received certain treatments for HBV infection are excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with locally advanced, unresectable, or metastatic adenocarcinoma of the biliary tree (intra- and extra-hepatic biliary ducts or gallbladder). The trial involves the use of two drugs, capecitabine and gemcitabine hydrochloride. The eligibility criteria include having evidence of disease, but measurable disease is not required, and having a minimum life expectancy of 12 weeks. Patients must also meet certain medical criteria, such as having a stable liver function and no other active medical conditions that would render the protocol treatment dangerous. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record from a clinical trial table. It pertains to a phase 3 trial for patients with atrial fibrillation who are scheduled for direct current cardioversion. The trial involves the drug candesartan. The record includes a list of diseases and their corresponding ICD-10 codes, as well as eligibility criteria for inclusion and exclusion from the trial. The inclusion criteria include a diagnosis of atrial fibrillation lasting more than 48 hours, while the exclusion criteria include a history of hypersensitivity to angiotensin II receptor blockers or ACE inhibitors, current use of antiarrhythmic medication, and certain medical conditions such as severe hepatic dysfunction or pregnancy.",
    "The sample is a phase 3 clinical trial for the treatment of essential hypertension. The trial is open to male and female Europeans aged 18 years or older with moderate to severe hypertension. The trial involves the use of two drugs, olmesartan medoxomil (om)+ hydrochlorothiazide (hctz) tablets and olmesartan medoxomil (om)/ hydrochlorothiazide (hctz) 20mg/25mg. The eligibility criteria for the trial include exclusion of female patients who are pregnant, lactating, or planning to become pregnant during the trial period. Patients with serious disorders that may limit the ability to evaluate the efficacy or safety of the study medication are also excluded. Additionally, patients with a history of certain medical conditions within the last six months, clinically significant abnormal laboratory values at screening, or secondary hypertension are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of benign prostatic hyperplasia. The trial involves the use of the drugs finasteride and alfuzosin. The eligibility criteria for the trial include being a male at least 50 years of age, having an AUA symptom severity score of at least 10, and meeting certain requirements for prostate size and volume. There are also several exclusion criteria, such as having had prior surgical intervention for BPH, being enrolled in another treatment trial, or having a bleeding disorder or taking anticoagulation medication. The sample includes both inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for patients with nausea and neoplasms. The trial involves the drugs olanzapine and haldol. The eligibility criteria for the trial include being over 18 years old, having significant nausea/vomiting, having failed previous treatments, having adequate cognitive function, and being able to communicate well. The exclusion criteria include having a partial/complete bowel obstruction, currently taking Haldol or olanzapine, having drug-induced extrapyramidal symptoms, having Parkinson's disease, or undergoing chemotherapy or radiotherapy to the brain, abdomen, stomach, or esophagus. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 trial for two types of esophagitis - reflux and peptic. The trial involves the use of dexlansoprazole MR and a placebo. The eligibility criteria for the trial include having successfully completed a previous phase 3 study and having healed esophageal erosions proven by endoscopy. Exclusion criteria include the use of certain medications and the need for continuous anticoagulant therapy.",
    "The sample is a phase 3 clinical trial for non-insulin-dependent diabetes mellitus. The trial is testing the drug rosiglitazone and has a list of inclusion and exclusion criteria for participants. Inclusion criteria include having type 2 diabetes, co-existing vascular disease, and at least 6 months of statin or fibrate therapy. Exclusion criteria include having more than 2 concomitant oral anti-hyperglycaemic agents within 3 months of screening, previous exposure to a thiazolidinedione, and a history of chronic insulin use. The trial also has criteria for blood pressure, angina, and various medical histories.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with mild to moderate hypertension, between the ages of 20 to 80, who are able to provide written informed consent. The trial excludes patients who are still taking more than three anti-hypertensives at the screening visit, pre-menopausal women, and those with known or suspected secondary hypertension. Other exclusion criteria include hepatic and/or renal dysfunction, known bilateral renal artery stenosis, and clinically significant hyperkalemia. The trial involves the use of two drugs, telmisartan 40 mg/hydrochlorothiazide 12.5 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg. The eligibility criteria include specific blood pressure measurements and exclude patients with certain medical conditions or who are taking certain medications.",
    "The sample is a phase 3 clinical trial for diabetic nephropathy. The trial includes patients with type 2 diabetes, microalbuminuria, and controlled blood pressure. The trial will test the effectiveness of sulodexide compared to a placebo. The eligibility criteria include age, HbA1C levels, obesity, and certain medical conditions. Patients must also be able to tolerate oral medication and not have a history of drug abuse or noncompliance with medical regimens. The trial excludes patients with certain medical conditions, including non-diabetic renal disease, cardiovascular disease, and liver dysfunction. Patients must not have been previously exposed to sulodexide.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves two drugs, sitagliptin phosphate (+) metformin hydrochloride and metformin. The eligibility criteria for the trial include being between 18 and 78 years old, having an Hb1Ac level of at least 7.5%, and not having taken any antihyperglycemic agent in the last 4 months. The trial is open to male patients and female patients who are unlikely to conceive. Patients with type 1 diabetes mellitus or a history of ketoacidosis are excluded from the trial.",
    "The sample is from a phase 3 clinical trial for the treatment of sexual dysfunctions, psychological. The trial is testing the effectiveness of drugs such as flibanserin and placebo. The eligibility criteria for the trial includes being a premenopausal woman with HSDD (decreased sexual desire), having a regular menstrual cycle, and meeting minimum cut-off scores on questionnaires relating to sexual functioning and distress. Patients must also be in a stable, monogamous, heterosexual relationship for at least 1 year and have used a medically acceptable method of contraception for at least 3 months prior to the trial. Exclusion criteria includes patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening, patients with a history of drug dependence or abuse within the past one year, and patients who have entered the menopausal transition or menopause or have had a hysterectomy.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients with a diagnosis of MDD, single or recurrent episode, according to DSM-IV criteria. The trial requires patients to have a current episode of at least 4 weeks and a CGI-Severity score of at least 4 at Screening and Baseline. Patients with a history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder (current or during previous one year), obsessive-compulsive disorder, any other current Axis I disorder other than MDD which is the focus of treatment, substance or alcohol abuse in the last 30 days, dependence in the last 6 months, concomitant psychotropic medication, including herbal preparations and melatonin, psychotherapy of any type, prior exposure to agomelatine, and female patients of childbearing potential who are not using effective contraception are excluded from the trial. Other protocol-defined inclusion/exclusion criteria may also apply. The trial involves the use of agomelatine and placebo as drugs.",
    "The sample is a phase 3 clinical trial for the treatment of venous thromboembolism. The trial involves the use of drugs such as rivaroxaban and enoxaparin. The eligibility criteria for the trial include patients aged 20 years or above who are undergoing elective TKR (the first replacement of the applicable knee joint) and have given written informed consent. Exclusion criteria include a history of clinically significant active bleeding, hepatic disease associated with coagulopathy, severe impaired renal function, and ongoing anticoagulant therapy that cannot be stopped. The trial also prohibits the use of planned intermittent pneumatic compression during the treatment period.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of perennial allergic rhinitis. The trial includes a list of ICD-10 codes associated with the disease, as well as a list of drugs being tested, including gw685698x and mometasone furoate. The eligibility criteria for the trial include a history of the disease for at least 2 years, a positive allergen test, and female patients of child-bearing potential must use birth control. Patients who require certain medications for their allergy or have serious medical problems are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis. The trial is looking at the effectiveness of two drugs, megadose oral methylprednisolone and IV methylprednisolone, in treating acute symptomatic exacerbation of MS. The trial is open to individuals between the ages of 18 and 50 who have been diagnosed with a relapsing form of multiple sclerosis and have an Expanded Disability Status Scale (EDSS) score between 2 and 6.5. The trial has a list of inclusion and exclusion criteria that participants must meet in order to be eligible to participate. The inclusion criteria include having new or worsening symptoms of MS for greater than 24 hours and less than or equal to 7 days, and having signs referable to the symptoms. The exclusion criteria include having been treated with systemic corticosteroid use within one month of the index episode at screening, and having a history of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes and uncontrolled hypertension. The trial is testing the effectiveness of the drug dapagliflozin compared to a placebo. The eligibility criteria include being between 18 and 89 years old, having a mean 24-hour blood pressure of at least 130/80, and having a stable dose of oral antidiabetic medication or insulin for a certain period of time. Exclusion criteria include having certain medical conditions or abnormal levels of certain substances in the body. Participants must provide written informed consent to participate in the trial.",
    "The sample is a phase 3 clinical trial for participants with type 2 diabetes mellitus. The trial is testing the effectiveness of a combination of drugs, including ly2189265, insulin glargine, sulfonylureas (su), and biguanide (bg). The eligibility criteria include having a stable dose of sulfonylurea and/or biguanide for at least 8 weeks before screening, a qualifying glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0%, and a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m^2). Exclusion criteria include having type 1 diabetes, previously being treated with any other glucagon-like peptide 1 (GLP-1) analog, and having received therapy with certain other drugs within 3 months before screening. Participants with clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis are also excluded. Additionally, participants with self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC) are excluded.",
    "This sample is from a phase 3 clinical trial for obesity. The trial includes patients with a body mass index (BMI) greater than 25 kg/m\u00b2 and excludes those with unstable weight, untreated diabetes, high blood pressure, or any severe medical or psychological conditions that could compromise their safety or successful participation in the study. The trial also excludes patients with a history of cancer within the past five years, except for adequately treated localized basal cell skin cancer or in situ uterine cervical cancer. The trial involves the use of the drug rimonabant (sr141716) and a placebo. The eligibility criteria include various medical and laboratory findings, such as abnormal TSH levels, positive tests for hepatitis B or C, and positive urine pregnancy tests.",
    "The sample is a phase 3 clinical trial for individuals diagnosed with type 1 diabetes for at least 24 months and treated with continuous subcutaneous insulin infusion therapy for the previous 6 months. The trial aims to test the effectiveness of insulin lispro and insulin aspart, both administered over a 6-day period. The trial has specific inclusion and exclusion criteria, including a maximum baseline body mass index of 35.0 kg/m2 and a baseline glycated hemoglobin A1c level between 5% and 9%. Participants with impaired renal function, legal blindness, hypoglycemic coma, seizures, or disorientation in the 12 months prior to screening, or any other serious disease considered exclusionary by the investigator are excluded from the trial. Additionally, participants who are pregnant, breastfeeding, or sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable are also excluded. The trial requires participants to comply with the use of a data collection device to directly record data.",
    "The sample is a phase 3 clinical trial for the treatment of ulcerative colitis. The trial includes patients between the ages of 18 and 75 who have been diagnosed with active mild or moderate UC and are experiencing a flare despite a therapeutic dose of an oral 5-ASA. The trial will test the effectiveness of budesonide mmx\u00ae and 5-ASA compared to a placebo. The eligibility criteria include various medical conditions that may affect the evaluation of the study, and participants must be willing to use an acceptable form of contraception. The trial also has exclusion criteria, including severe UC, infectious colitis, active malignancy, and liver cirrhosis. Participants must be able to comprehend the full nature and purpose of the study, including possible risks and side effects, and also able to comply with all requirements of the study.",
    "The sample is a phase 3 clinical trial for children between the ages of 5 and 12 with moderate to severe persistent reversible asthma. The trial includes the use of three drugs - flutiform, seretide, and flixotide - and requires subjects to have a documented reversibility of at least 15% in FEV1 during the screening period. Inclusion criteria also include the use of an inhaled corticosteroid for asthma at a stable dose for at least 4 weeks prior to the screening visit and inadequate asthma control on an ICS alone at a dose of \u2264 500 \u00b5g fluticasone equivalents/day, OR controlled asthma on an ICS-LABA combination at a ICS dose of \u2264 200 \u00b5g fluticasone equivalents/day. The trial requires subjects to be able to perform spirometry adequately and to attend all study visits. Exclusion criteria include near fatal or life-threatening asthma within the past year, hospitalization or an emergency visit for asthma within the past 6 months, and current or prior non-response or partial response only to an ICS-LABA combination.",
    "The sample is a phase 3 clinical trial for chronic kidney disease, dialysis, and hyperphosphatemia. The trial involves the drugs mci-196 and placebo. The eligibility criteria include being over 18 years old, having stable phosphate control, being on a stabilized phosphorus diet, and undergoing regular dialysis treatment. Female participants must have a negative pregnancy test and male participants must agree to use appropriate contraception. Exclusion criteria include having certain medical conditions, low serum albumin levels, high PTH levels, low hemoglobin levels, gastrointestinal motility problems, liver dysfunction, positive tests for hepatitis B, hepatitis C, or HIV, lactose intolerance, substance or alcohol abuse, seizure disorders, drug or other allergies, using certain medications, being scheduled for a kidney transplant within the next 6 months, or participating in a clinical study with experimental medication or biological products within a certain timeframe.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular record, the trial is in phase 3 and is focused on studying HIV infections. The ICD-10 code associated with this disease is \"Z21\". The drugs being tested are abacavir sulfate, lamivudine, and zidovudine, lamivudine/zidovudine, and lopinavir/ritonavir. The eligibility criteria for mothers to participate in the trial include being HIV infected, between the 12th and 30th week of pregnancy, having a viral load less than 55,000 copies/ml, and a CD4 count greater than 350 cells/ml within 30 days of study entry, among other requirements. There are also exclusion criteria, such as having certain medical conditions or taking certain medications, that would prevent someone from participating in the trial.",
    "The sample is a phase 3 clinical trial for asthma. The trial is looking for male or female outpatients who are at least 18 years old and have uncontrolled or partly controlled asthma. The patients must have remained in the same severity class for the past 14 days and had no acute exacerbations by investigator judgment. The trial requires patients to have a positive result of Brocho-provocation test or an improvement of at least 12% reversibility in FEV1 or FVC following administration of an inhaled \u03b22-agonist before the study. Patients who have hypersensitivity to \u03b22-agonist or lactose, hospitalization due to asthma during the previous 3 months, respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks, oral or systemic corticosteroids in the previous 4 weeks, inadequately controlled hyperthyroidism, or any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory disease other than asthma are excluded from the trial. Patients who have received an investigational drug within 30 days prior to admission to the study, significant alcohol, drug or medication abuse, females who are pregnant or breast-feeding, and heavy smokers (more than 10 packs year) or who are smoking within previous 6 months are also excluded from the trial. The trial is testing the effectiveness of meptin swinghaler and berotec as treatments for asthma.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C virus. The trial includes patients who are over 18 years old and have chronic genotype 1 HCV infection. The patients must be HCV treatment-naive and have HCV RNA levels greater than 10,000 IU/mL at screening. The trial also requires patients to have screening laboratory values within defined thresholds and use two effective contraception methods if female of childbearing potential or sexually active male. The exclusion criteria include pregnant or nursing females or males with pregnant female partners, presence of cirrhosis, coinfection with HIV or hepatitis B virus (HBV), current or prior history of clinical hepatic decompensation, chronic use of systemic immunosuppressive agents, and history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. The trial uses the drugs ldv/sof and rbv.",
    "The sample is a phase 3 clinical trial for sleep disorder. The trial includes patients over the age of 18 and below age 65 who have a history of sleep disturbance with non-restorative sleep. The trial excludes subjects who have previously taken GABAdone, SentraPM or trazadone, those who are currently taking tricyclic anti-depressants, pregnant or lactating females, and subjects with implanted pacemakers or other implanted electrical devices. The trial involves the use of trazodone, sentra pm and trazodone (copack kit trazamine), and placebo trazodone and placebo sentra pm. The icd-10 codes associated with the disease are ['G47.9', 'G47.21', 'G47.22', 'G47.23', 'G47.52', 'G47.29', 'G47.20'].",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder using the drug lamotrigine. The trial is looking for patients who have been diagnosed with Bipolar I Disorder and are currently depressed for a minimum of 8 weeks. Patients must have been hospitalized for mood disorder or incarceration related to mania behavior. The trial has certain inclusion and exclusion criteria, such as patients must not be suicidal, must not have a history of non-response to antidepressant treatment, and must not have a clinical history of substance dependence in the past year or abuse within the 4 weeks prior to study entry. Patients must also not have had epilepsy or hypothyroidism.",
    "The sample is a phase 3 clinical trial for the treatment of overactive bladder. The trial involves the use of drugs such as mirabegron and tolterodine, as well as placebos. The eligibility criteria for the trial include experiencing symptoms of overactive bladder for at least 3 months, having a frequency of urination of at least 8 times per day, and experiencing at least 3 episodes of urgency with or without incontinence during a 3-day period. Exclusion criteria include having significant stress incontinence, having an indwelling catheter, having diabetic neuropathy, and having a known hypersensitivity to certain drugs. Participants must also be willing and able to complete a micturition diary and questionnaires correctly.",
    "The sample is a record of a clinical trial in phase 3, focused on diabetes and diabetes mellitus type 2. The trial involves the use of drugs such as sulfonylurea and liraglutide. The eligibility criteria for the trial include having type 2 diabetes, undergoing diet and exercise therapy with sulfonylurea for at least eight weeks, having an HbA1c level between 7.0% and 10.0%, and having a BMI less than 35 kg/m2. The exclusion criteria include recent treatment with insulin or any drug that could interfere with glucose levels, having any serious medical condition, and being pregnant or breastfeeding for females. The icd-10 codes for the diseases involved in the trial are also listed.",
    "The sample is a phase 3 clinical trial for patients aged 18 to 75 years with a ruptured saccular aneurysm that has been successfully secured by endovascular coiling. The trial is testing the efficacy and safety of clazosentan 5 mg/h and 15 mg/h compared to a placebo. The eligibility criteria include confirmation of the aneurysm by angiography, a World Federation of Neurological Surgeons (WFNS) grade I-IV, and the presence of any thick clot on baseline CT scan. Exclusion criteria include subarachnoid hemorrhage due to causes other than saccular aneurysm, giant aneurysms, intraventricular or intracerebral blood, and several other conditions. Patients must provide written informed consent to participate in the study.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial is testing the efficacy of the drugs alogliptin and placebo. The eligibility criteria include having inadequate glycemic control and receiving no current antidiabetic therapy, having a body mass index between 23 and 45 kg/m2, and having a fasting C-peptide concentration greater than or equal to 0.8 ng per mL. Other criteria include having a glycosylated hemoglobin concentration between 7.0% and 10.0%, having a systolic blood pressure less than or equal to 180 mm Hg and diastolic pressure less than or equal to 110 mm Hg, and having no major illness or debility that would prohibit participation in the study. Exclusion criteria include a history of cancer, heart failure, or infection with hepatitis B, hepatitis C, or human immunodeficiency virus. The trial also has a list of excluded medications, including antidiabetic agents and weight-loss drugs.",
    "The sample is a phase 3 clinical trial for the treatment of colorectal cancer. The trial involves the use of drugs such as cetuximab, 5-fu, irinotecan, leucovorin, and oxaliplatin. The eligibility criteria for the trial include having locally advanced or metastatic colorectal cancer, not having received prior treatment for advanced or metastatic colorectal cancer, and meeting certain laboratory values. Patients must also not have certain medical conditions or prior exposure to certain medications. The trial requires patients to have at least one paraffin block available or appropriate number of unstained slides for analysis of EGFR status.",
    "The sample is a phase 3 clinical trial for patients with advanced idiopathic Parkinson's disease. The trial includes patients who have been diagnosed with Parkinson's disease for at least 2 years and are 30 years of age or older at the time of diagnosis. The trial involves the use of pramipexole extended release, pramipexole immediate release, or placebo as treatment options. The eligibility criteria for the trial include the presence of at least two of the following signs: resting tremor, bradykinesia, rigidity, a Modified Hoehn and Yahr stage of 2 to 4 at on-time, and motor fluctuations with at least 2 cumulative hours of off-time every day during waking hours. Patients must also be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. The trial has exclusion criteria, including atypical parkinsonian syndromes, dementia, any psychiatric disorder that could prevent compliance or completion of the study, history of psychosis, clinically significant Electrocardiogram abnormalities, and any other clinically significant disease that could put the patient at risk or could prevent compliance or completion of the study.",
    "The sample is a phase 3 clinical trial for individuals with a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or other medical conditions that require daily NSAID therapy for at least 6 months. The trial focuses on the treatment of gastric ulcers and involves the use of drugs such as pn400 (vimovo) and diclofenac/misoprostol. The eligibility criteria include being 18 years or older, having a documented history of an ulcer-related serious upper gastrointestinal event, and being able to understand and comply with study procedures. Exclusion criteria include a history of hypersensitivity to esomeprazole or another proton-pump inhibitor, a positive test result for H. pylori, and a recent history of alcohol or drug abuse or dependence.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug lamotrigine. The trial is looking for participants who have been diagnosed with schizophrenia and have persistent positive symptoms for at least 3 months prior to screening. Participants must also be taking 1-2 specific atypical antipsychotics for at least 3 months and be on a stable dose for at least 1 month prior to entering the study. The trial has inclusion and exclusion criteria, including a requirement that the participant or legal guardian is able to understand and sign the consent form. Exclusion criteria include a history of other Axis I disorders, significant medical disorders or treatments that would interfere with the study, and use of certain medications within 1 month of screening.",
    "This sample is for a phase 3 clinical trial and focuses on the disease \"pulmonary disease, chronic obstructive\". The ICD-10 codes associated with this disease are \"J44.9\", \"J44.1\", and \"J44.0\". The trial will be testing the drugs \"tiotropium\" and \"salmeterol\". There is no information provided about the eligibility criteria for participants in this trial.",
    "The sample is a phase 3 clinical trial for the treatment of multiple sclerosis. The trial includes patients who are at least 18 years old and have a definite diagnosis of multiple sclerosis. The patients must have an Expanded Disability Status Scale (EDSS) rating between 3.0-8.0 and meet other eligibility criteria, such as having a normal ECG and blood pressure, and being willing to wash out current medication with anti-spasticity activities. The trial involves the use of several drugs, including ipx056 and encapsulated baclofen, as well as a placebo. The patients must comply with the protocol and be available for all scheduled clinic visits. The trial also has exclusion criteria, such as a history of allergic or severe intolerance to baclofen, and any medical condition that would interfere with the interpretation of the study results or the safety of the patient.",
    "The sample is a phase 3 clinical trial for patients with multiple myeloma who are receiving high-dose chemotherapy and autologous peripheral stem cell transplantation. The trial is testing the effectiveness of the drugs emend and placebo. The eligibility criteria include being 18 years or older, having signed informed consent, and not having suffered from nausea and vomiting in the last 12 hours prior to the planned chemotherapy. Exclusion criteria include taking certain medications, having a history of hypersensitivity to the investigational product or any similar drugs, being pregnant or nursing, and having a mental condition that would prevent understanding of the trial. The trial also requires compliance with completing a diary and FLIE-score.",
    "The sample is a phase 3 clinical trial for major depressive disorder. The trial includes patients with a diagnosis of MDD, single or recurrent episode, according to DSM-IV criteria. The patients must have a current episode of at least 4 weeks and a CGI-Severity score of at least 4 at Screening and Baseline. The trial excludes patients with a history of bipolar disorder, schizophrenia, schizoaffective disorder, eating disorder, obsessive-compulsive disorder, substance or alcohol abuse in the last 30 days, dependence in the last 6 months, concomitant psychotropic medication, psychotherapy of any type, prior exposure to agomelatine, and female patients of childbearing potential who are not using effective contraception. The trial involves the use of agomelatine and placebo as drugs.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial includes patients of both genders between the ages of 18 and 55 who have been diagnosed with RRMS and have an EDSS score of 0 to 5.0. The trial is looking at the effectiveness of interferon beta-1b and copaxone, and patients must be treatment-naive to these drugs. The trial has a list of inclusion and exclusion criteria, including no neurological progression at disease onset or between relapses, no serious or acute heart diseases, no history of severe depression or suicide attempt, and no serious or acute liver, renal or bone marrow dysfunction. Patients with monoclonal gammopathy or known allergies to certain substances are also excluded. Pregnant or lactating patients are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for HIV infection. The trial involves the use of cellulose sulfate gel (6%) as a drug. The eligibility criteria for participants include being at least 18 years old, having an average of at least three vaginal sex acts per week with at least three different partners in the last three months, and being HIV negative. Participants must also be willing and able to comply with the protocol. Exclusion criteria include pregnancy, allergy to latex or spermicides, and being an intravenous drug user.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of different drugs in treating vaginal atrophy and other related diseases. The trial is looking at the drugs ospemifene 30 mg, ospemifene 60 mg, placebo, and nonhormonal vaginal lubricant. The eligibility criteria for participants include being naturally or surgically postmenopausal, experiencing moderate or severe symptoms of vaginal atrophy, having a vaginal pH greater than 5.0, and having 5% or fewer superficial cells in the maturation index of a vaginal smear. The exclusion criteria include having evidence of endometrial hyperplasia, endometrial cancer, or other abnormal endometrial pathology, having an abnormal Pap smear, experiencing uterine bleeding of unknown origin or having uterine polyps, and having a current vaginal infection requiring medication.",
    "The sample is a phase 3 clinical trial that involves patients with various diseases such as arthralgia, bunion, hallux valgus, and pain. The trial includes a list of icd-10 codes for each disease and a list of drugs used in the trial, including tapentadol, oxycodone, and placebo. The eligibility criteria for the trial include undergoing primary unilateral first metatarsal bunionectomy, having moderate to severe pain, and meeting certain requirements for female patients. The exclusion criteria include a history of seizure disorder or epilepsy, recent malignancy, alcohol or drug abuse, active infections, severe renal insufficiency, and certain medications being taken.",
    "The sample is a phase 3 clinical trial for patients with orthostatic hypotension associated with primary autonomic failure, dopamine beta hydroxylase deficiency, or non-diabetic autonomic neuropathies. The trial is testing the effectiveness of the drug droxidopa compared to a placebo. The eligibility criteria include being 18 years or older, having a documented fall in blood pressure upon standing, and not taking certain medications or having certain medical conditions. Patients must also provide written informed consent to participate in the study. The sample includes a list of diseases, their corresponding ICD-10 codes, and the eligibility criteria for the trial.",
    "The sample is a phase 3 clinical trial for patients who have undergone allogeneic stem cell transplantation and have tested positive for CMV-PCR or pp65 antigenemia assay within 100 days after the transplantation. The trial is testing the effectiveness of valganciclovir and ganciclovir drugs in treating the patients. The eligibility criteria include having a certain level of absolute neutrophil count and creatinine clearance, and not having gastrointestinal graft-versus-host disease above grade 2. The exclusion criteria include having suspected or diagnosed CMV disease, receiving syngeneic SCT, or having received an investigational medicinal product within the last 30 days prior to screening. The patient's body weight should be between 50 kg and 95 kg, and they should not have received anti-CMV therapy within the past 30 days prior to screening. The patient should not have participated in this study before and should not have neutropenia, thrombocytopenia, or anemia within 10 days before or at the time point of randomization.",
    "The sample is a phase 3 clinical trial for psoriatic arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with psoriatic arthritis for at least 6 months. Patients must meet the Classification Criteria for Psoriatic Arthritis (CASPAR) PsA at the time of screening and have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs). Patients must have at least 3 swollen and 3 tender joints. The trial allows concurrent treatment with methotrexate, leflunomide, or sulfasalazine, and patients must use contraception. The trial excludes pregnant or breastfeeding patients, those with a history of allergy to any component of the investigational product, and those who have therapeutic failure on more than 3 agents for PsA or more than 1 biologic tumor necrosis factor (TNF) blocker.",
    "The sample is a phase 3 clinical trial for the treatment of obesity. The trial includes overweight and/or obese men and women with a body mass index (BMI) of 30 to 45 kg/m2 with or without a comorbid condition such as hypertension, dyslipidemia, CV disease, glucose intolerance, or sleep apnea. Participants with a BMI of 27 to 29.9 kg/m2 with at least one comorbid condition are also eligible. The trial will last for 1 year and pregnant women, those with diabetes mellitus, history of symptomatic heart valve disease, or serious or unstable current or past medical conditions are excluded. The trial will test the effectiveness of lorcaserin, which will be administered in two different doses, and a matching placebo.",
    "The sample is a phase 3 clinical trial for the treatment of migraine. The trial includes patients with at least 1 year history of migraine, with or without aura. Females of childbearing years must use acceptable contraception throughout the trial. Patients who are pregnant or breastfeeding, have uncontrolled diabetes or HIV disease, uncontrolled cardiovascular disease, major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine), have a history of gastric or small intestinal surgery or have a disease that causes malabsorption, or have a history of cancer within the last 5 years are excluded from the trial. The trial involves the use of drugs, including mk0974 at 50 mg, 150 mg, and 300 mg doses, as well as a comparator placebo. The diseases being studied are listed as 'migraine', and the corresponding ICD-10 codes are provided as well.",
    "The sample is a phase 3 clinical trial for gastrointestinal stromal tumors. The trial includes patients who are at least 18 years old and have confirmed metastatic and/or unresectable GIST. The trial requires measurable disease on CT or MRI as defined by RECIST, documented radiographic progression or intolerance to imatinib and sunitinib, and clinical failure of the most recent prior therapy for GIST. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meet certain hemoglobin, neutrophil count, platelet, ALT, AST, alkaline phosphatase, bilirubin, PT, PTT, and serum creatinine levels. Patients who have previously received other known heat shock protein 90 (Hsp90) inhibitors, have had surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease, or have initiated or discontinued concurrent medication that is a potent CYP3A inhibitor less than 2 weeks prior to administration of IPI-504 or placebo are excluded from the trial. Patients with certain medical conditions or diseases, such as acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any other significant co-morbid condition or disease which, in the judgment of the investigator, would place the patient at undue risk or interfere with the study, are also excluded. Women who are pregnant or lactating are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of schizoaffective disorder and psychotic disorder. The trial involves the use of drugs such as placebo and paliperidone er. The eligibility criteria for the trial include a DSM-IV diagnosis of schizoaffective disorder, a total PANSS score of at least 60, and a score of at least 16 on either the YMRS or HAM-D 21 rating scales. Exclusion criteria include a primary active mental illness diagnosis other than schizoaffective disorder, first episode psychosis, active substance dependence within the previous 6 months, treatment with clozapine within 6 months of randomization, a history of treatment resistance, and pregnancy, breastfeeding, or planning to become pregnant.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is focused on bacterial infections. The icd-10 codes associated with the diseases are listed as [\"['A49.9', 'A04.9', 'A04.8', 'A49.8']\"]. The trial involves the use of three drugs: ceftaroline, vancomycin plus aztreonam, and a placebo. The eligibility criteria for the trial are listed, including specific requirements for the type of infection and exclusion criteria such as prior treatment with certain antimicrobials or failure of previous therapies.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with adult-onset RA for at least six months but not longer than fifteen years. Patients must have active RA disease, as defined by 9 tender joints and 9 swollen joints at screening and baseline, and fulfilling 1 of the following 2 criteria during the screening period: 30 mm/hour ESR (Westergren), or CRP >15 mg/L. Patients must have received treatment with MTX (with or without folic acid) for at least 6 months prior to the baseline visit. The dose of MTX and route of administration must have been stable for at least 2 months prior to the baseline visit. The minimum stable dose of MTX allowed is 10 mg weekly. Patients must be willing to complete an X-ray of the hands and feet 24 weeks after randomization even if they are no longer receiving study treatment in the present study, provided they have not withdrawn their informed consent. Exclusion criteria include patients with a diagnosis of any other inflammatory arthritis, a secondary, non-inflammatory type of arthritis, female patients who are breast feeding, pregnant, or plan to become pregnant during the trial or for three months following last dose of study drug, patients with a history of tuberculosis or positive chest X-ray for tuberculosis, patients at a high risk of infection, patients with known human immunodeficiency virus (HIV) infection, patients with an active malignancy of any type or a history of malignancy (except basal cell carcinoma of the skin that has been excised prior to study start), patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the trial, and patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis).",
    "The sample is a phase 3 clinical trial for patients with chronic pain lasting at least 3 months, associated with various conditions such as diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, complex regional pain syndrome, back pain, neck pain, fibromyalgia, chronic pancreatitis, or osteoarthritis. The trial is testing the effectiveness of a drug called OraVescent fentanyl for alleviating breakthrough pain (BTP) episodes, which are temporary flares of severe or excruciating pain. To be eligible for the trial, patients must be using a stable dose of opioid therapy for at least 30 days prior to enrollment, have an average pain intensity score of 6 or less, and experience 1 to 4 BTP episodes per day with each episode lasting less than 4 hours. Patients must also be able to effectively self-administer the study drug and complete an electronic diary. There are various exclusion criteria, such as uncontrolled or rapidly escalating pain, known or suspected hypersensitivities or allergies to any ingredient in the study drug, recent history or current evidence of substance abuse, and medical or psychiatric disease that could compromise collected data.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial includes patients with a diagnosis of this condition who are literate and willing to comply with study procedures. The trial excludes patients with significant medical conditions, those using corticosteroids or allergy medications, current or recent tobacco use, exposure to investigational drugs in the past year, and those with abnormal ECG or laboratory results. The trial involves the use of two drugs, ff and placebo. The diseases are listed as 'rhinitis, allergic, perennial' and the corresponding ICD-10 codes are provided.",
    "The sample is a phase 3 clinical trial for hypoactive sexual desire disorder. The trial involves women who are one year post-menopausal, between the ages of 40-70, and in good health while on transdermal HRT. The women must also be in a stable monogamous sexual relationship and experiencing low sexual desire causing distress. The trial will test the effectiveness of testosterone and placebo drugs. The eligibility criteria and exclusion criteria are also provided.",
    "The sample is a phase 3 clinical trial for attention deficit disorder with hyperactivity. The trial involves the use of neutral salts of dextroamphetamine sulfate, usp, amphetamine sulphate, usp, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. The eligibility criteria for the trial include a primary diagnosis of ADHD, a baseline ADHD-RS-IV score of at least 32, and compliance with contraceptive restrictions for non-pregnant females of childbearing potential. Exclusion criteria include being significantly underweight or morbidly obese, having comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or severe Axis I disorders, having a history of seizure, tic disorder, or a current diagnosis and/or family history of Tourette's Disorder, and being pregnant or lactating for females.",
    "This sample is for a phase 3 clinical trial for the treatment of multiple myeloma. The trial is focused on patients who have newly diagnosed multiple myeloma and require treatment. The trial excludes patients with a life expectancy of less than 3 months, another active malignant disease, those who have been treated with bisphosphonates for more than 3 months within the last 6 months, patients with creatinine levels above 400 \u00b5mol/l 4 weeks after starting chemotherapy, patients who cannot cooperate for monthly infusions, and those who do not give their informed consent. The drug being tested in this trial is pamidronate.",
    "The sample is a phase 3 clinical trial for acute myeloid leukemia (AML). The trial is looking for patients between the ages of 40 and 65 who have been diagnosed with AML in complete remission and have an HLA compatible sibling or unrelated donor. The trial is testing the effectiveness of two drugs, busulphan plus cyclophosphamide and busulphan plus fludarabine. The eligibility criteria include having a performance status of Eastern Cooperative Oncology Group (ECOG)<3, written and signed informed consent, and central venous access secured through an indwelling catheter. The exclusion criteria include having poorly controlled arterial hypertension, a history of acute myocardial infarction within the last 12 months, positive HIV serology, any major organ dysfunction, and severe psychiatric illness or any disorder that compromises the ability to give truly informed consent for participation in the study.",
    "This sample is from a phase 3 clinical trial for the drug vortioxetine, which is being tested for the treatment of major depressive disorder. The trial is looking for participants who have completed a previous study with LuAA21004 and have been diagnosed with recurrent major depressive episodes according to DSM-IV-TR criteria. Participants must also have been recommended for continuation treatment with LuAA21004 by their investigator. Females of childbearing potential who are sexually active with a nonsterilized male partner must agree to use adequate contraception throughout the study. Exclusion criteria include having other psychiatric disorders, a significant risk of suicide, or being unlikely to comply with the study protocol. Participants must not have any clinically significant adverse events related to study medication from the prior study and must not be using disallowed concomitant medication.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia using the drug aripiprazole im depot. The trial is open to male and female subjects between the ages of 18 and 65 who are able to provide written informed consent or have consent from a legally acceptable representative. Subjects must have completed previous studies or be new to the trial and require chronic treatment with an antipsychotic medication. Exclusion criteria include a current diagnosis of a disorder other than schizophrenia, resistance to antipsychotic treatment, a significant risk of violent behavior or suicide, substance dependence, allergy or intolerance to aripiprazole or other quinolinones, and a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia.",
    "The sample is a phase 3 clinical trial for breast cancer patients with HER2-overexpression. The trial is testing the effectiveness of a combination of drugs including bibw 2992, trastuzumab, and vinorelbine. The eligibility criteria include having stage IV metastatic disease, having progressed on one prior trastuzumab treatment, and having received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer. Patients must also have at least one measurable lesion and an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. Exclusion criteria include prior treatment with certain drugs, known pre-existing interstitial lung disease, active brain metastases, and clinically relevant cardiovascular abnormalities. Patients must also have adequate hepatic, renal, and hematologic organ function.",
    "The sample is a phase 3 clinical trial for patients with metastatic or advanced renal cell carcinoma who are not suitable for cytokine therapy. The trial is testing the effectiveness of two drugs, sunitinib (sutent) and sorafenib (nexavar), as first-line therapy. The eligibility criteria include having a measurable lesion, adequate bone marrow, liver, and renal function, and a life expectancy of at least 12 weeks. Patients with certain medical conditions, such as cardiac disease or HIV infection, are excluded from the trial. The trial also excludes patients who have received certain types of treatments in the past, such as chemotherapy or radiotherapy.",
    "The sample is a phase 3 clinical trial for the treatment of restless legs syndrome. The trial involves the drug rotigotine and has eligibility criteria for inclusion and exclusion. Inclusion criteria include having idiopathic restless legs syndrome, while exclusion criteria include ongoing serious adverse events from a previous trial medication, pregnancy or nursing, and any medical or psychiatric conditions that could compromise the subject's ability to participate in the trial. The diseases column lists only restless legs syndrome, and the icdcodes column lists the corresponding ICD-10 code for the disease.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B, specifically targeting patients who are HBeAg-positive. The trial involves the use of two drugs, entecavir and telbivudine. The eligibility criteria for the trial include being between 18-70 years old, able to comply with the study regimen, and providing written informed consent. Exclusion criteria include being pregnant or breastfeeding, co-infected with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus, having received hepatitis B therapy in the past, and having a history of or symptoms of hepatic decompensation or pancreatitis. Other protocol-defined inclusion/exclusion criteria may also apply. The diseases and their corresponding ICD-10 codes are listed, and the eligibility criteria are also provided.",
    "The sample is a phase 3 clinical trial that involves patients with bipolar I disorder and alcohol dependence. The trial includes the use of drugs such as quetiapine fumarate, lithium, and divalproex. The eligibility criteria for the trial include meeting the criteria for bipolar I disorder with alcohol dependence, being an outpatient, and having a recent history of heavy drinking. The exclusion criteria include having unstable medical illness, recent antipsychotic use, and poorly controlled diabetes mellitus or diabetes-related illness.",
    "The sample is from a clinical trial in phase 3 for the treatment of pulmonary hypertension in patients who have completed a previous study. The trial is testing the drug sitaxentan. The eligibility criteria include having controlled blood pressure and not having hypotension. The diseases being treated are hypertension and pulmonary disease, and the icd-10 codes associated with these diseases are listed.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of epilepsy. The trial involves the drug \"lamotrigine extended-release\" and the eligibility criteria include having a confirmed diagnosis of epilepsy and currently being on LAMICTAL and up to 2 other anti-epileptic drugs. However, females of childbearing potential cannot be on hormonal contraceptives or hormone replacement therapy. The diseases are listed as \"epilepsy\" and the corresponding ICD-10 codes are also provided.",
    "The sample is a phase 3 clinical trial for ocular inflammation. The trial includes patients who are candidates for routine cataract surgery and have the potential for postoperative pinholed Snellen visual acuity of at least 20/200 in the study eye. The trial excludes patients who require concurrent ocular therapy with certain medications, have known hypersensitivity or contraindication to the study drug(s) or their components, are monocular or have poor visual acuity in the non-study eye, or have had recent ocular surgery. The trial involves the use of 0.5% loteprednol etabonate ophthalmic ointment and its vehicle as the study drugs.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes and renal insufficiency. The trial involves the drugs canagliflozin and placebo. The eligibility criteria include patients with type 2 diabetes who are not on any AHA or on any AHA in monotherapy or combination therapy, and patients with reduced kidney function. Exclusion criteria include a history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy. Patients with proliferative diabetic retinopathy for which treatment is planned during the course of the study, kidney disease that required treatment with immunosuppressive therapy, history of dialysis or kidney transplant, presence of nephrotic syndrome, or inflammatory kidney disease are also excluded. Patients receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen, or with a history of a severe hypoglycemic episode within 6 months before screening are also excluded.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of seasonal allergic rhinitis and hay fever. The trial involves the use of beclomethasone dipropionate and a placebo nasal aerosol. The eligibility criteria for the trial include being 12 years or older, having a documented history of season allergic rhinitis to mountain cedar pollen, being in general good health, and meeting other criteria. The exclusion criteria include having a history of nasal pathology, participating in any investigational drug study within 30 days prior to the screening visit, having a respiratory infection/disorder within 14 days prior to the screening visit, using any prohibited concomitant medications, and meeting other criteria.",
    "The sample is a phase 3 clinical trial that focuses on treating inflammation and pain. The trial involves using a vehicle of loteprednol etabonate and loteprednol etabonate drugs. The diseases being targeted are inflammation and pain, and their corresponding ICD-10 codes are listed. The eligibility criteria for the trial include being at least 18 years old, a candidate for routine cataract surgery, and having potential postoperative pinholed Snellen visual acuity of at least 20/200 in the study eye. Exclusion criteria include having a known hypersensitivity or contraindication to the study drug or components, having a severe/serious ocular condition or any other unstable medical condition that may preclude study treatment or follow-up, having elevated intraocular pressure, uncontrolled glaucoma, or being treated for glaucoma in the study eye, and being monocular or having pinholed Snellen VA 20/200 or worse in the non-study eye.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the use of four drugs: exenatide once weekly, metformin, sitagliptin, and pioglitazone. The eligibility criteria for the trial include being at least 18 years old, having a BMI between 23 kg/m2 and 45 kg/m2, and having a history of stable body weight. However, patients with a history of cardiac disease, renal transplantation, active or untreated malignancy, severe GI disorder, acute or chronic pancreatitis, active proliferative retinopathy, or who have been treated with drugs that promote weight loss or any antidiabetic agent for more than 7 days within 3 months prior to screening are excluded from the trial. Additionally, patients who have had an organ transplant, previously completed or discontinued study drug in this study, withdrawn from this study or any other study investigating exenatide once weekly, received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry, or are currently enrolled in any other clinical study are also excluded.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for patients with type 2 diabetes. The trial is testing the effectiveness of vildagliptin and metformin as treatments. The eligibility criteria for the trial include being between the ages of 65 and the upper age limit for metformin, having a BMI between 22 and 40 kg/m2, and having an HbA1c level between 7 and 9%. Patients must also be drug naive and have a fasting plasma glucose level of less than 270 mg/dL. Exclusion criteria include a history of type 1 diabetes, significant diabetic complications, and treatment with insulin or other oral antidiabetic agents. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for type 2 diabetes. The trial includes patients who are drug naive and have a Hemoglobin A1c (HbA1c) level between 6.0% and 8.0%. The trial also requires patients to have a fasting C-peptide level of at least 1.0 ng/mL and a body mass index of no more than 40 kg/m\u00b2. The trial drugs include saxagliptin, placebo, metformin (blinded), and metformin (open-label). The eligibility criteria for the trial include exclusion criteria such as recent cardiac or cerebrovascular events and elevated serum creatinine.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the disease of branch retinal vein occlusion and includes a list of associated ICD-10 codes. The trial is testing the effectiveness of the drug intravitreal aflibercept injection (iai;eylea\u00ae;bay86-5321) in treating macular edema secondary to BRVO. The record includes a list of inclusion and exclusion criteria for participants in the trial.",
    "The sample is a phase 3 clinical trial for HIV infections. The eligibility criteria include being between 18-35 years old, at higher risk of becoming HIV infected, willing to participate in all aspects of the study, and not having any medical conditions that would make study participation unsafe. Participants must also be willing to use a study-approved effective non-barrier method of contraception for the duration of the study, take study product as directed, and adhere to the follow-up schedule. They must not be pregnant or breastfeeding, and must not have received or be receiving an experimental HIV vaccine or participating in any other clinical trial with a biomedical intervention. Additionally, they must not be taking certain medications and must have adequate renal and hepatic function.",
    "The sample is a phase 3 clinical trial for patients with HIV. The trial is testing the effectiveness of switching from tenofovir to abacavir as part of the current HAART treatment. The eligibility criteria include being an adult with a diagnosis of HIV-1 infection, having a T-score of \u2264-2 measured by DEXA within the last 6 months, and maintaining undetectable plasma HIV-1 RNA for at least 12 months. The exclusion criteria include a history of intolerance, toxicity or virological failure to abacavir, being HLA B*5701 positive, having secondary osteoporosis/osteopenia, and therapy with biphosphonates within the last 12 months.",
    "The sample is a phase 3 clinical trial for acute bacterial sinusitis. The trial includes patients who are at least 18 years old and have been experiencing symptoms for at least 7 days but less than 28 days. The trial involves the use of two drugs, moxifloxacin and placebo. The eligibility criteria for the trial include radiographic and clinical criteria, such as the presence of air-fluid levels or opacification on a radiographic paranasal sinus film, and the presence of major and minor symptoms such as purulent nasal discharge, facial pain, headache, and fever. Patients with a history of chronic sinusitis, sinus surgery, or symptoms suggestive of allergic rhinitis or other infections are excluded from the trial.",
    "The sample is a phase 3 clinical trial for gastroesophageal reflux disease. The trial includes patients who are 18-70 years old and have at least one of the two symptoms, heartburn and reflux. Patients must also have photographically documented erosive esophagitis confirmed by esophagogastroduodenoscopy (EGD) and graded according to the Los Angeles (LA) Classification (A-D), within 5 days before randomization to treatment. Female patients are required to be nonpregnant, nonlactating, postmenopausal, surgically sterilized, or using a medically acceptable form of birth control. The trial excludes patients with cancerous or peptic ulcers, Zollinger-Ellison syndrome, varices of esophagus or fundus of stomach, a known history of gastric acid suppression operation, esophageal operation or peptic operation other than simple closure of perforation, severe complications, severe other diseases of digestive tract such as Crohn's disease and ulcerative colitis, and severe other systemic diseases. Patients who have taken proton pump inhibitors within the 5 days or for more than three consecutive days within the two weeks immediately preceding start of study drug, participated in a clinical trial with an investigational drug or device within the past three months, have hypersensitivity or idiosyncratic reaction to ilaprazole, esomeprazole or any other benzimidazole, have alcoholic intemperance, drug addiction or any other improper habits are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD) using drugs called gsk573719/vi 62.5/25, gsk573719/vi 125/25, and placebo. The trial includes outpatient subjects who are 40 years of age or older, have a history of COPD, and have a post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and a post-albuterol/salbutamol FEV1 of less than or equal to 70% of predicted normal values. The trial has inclusion and exclusion criteria, including exclusion of subjects with asthma, alpha-1 antitrypsin deficiency, active lung infections, lung cancer, and other significant respiratory conditions in addition to COPD. The trial also excludes subjects with significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine, or haematological abnormalities, and those with a history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate. The trial has a list of medications that subjects are not allowed to take prior to screening, and subjects must be able to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit. The trial also excludes subjects who are participating in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1, and those with a known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1. Finally, the trial excludes subjects who are affiliated with the investigator site.",
    "The sample is a phase 3 clinical trial for the treatment of short bowel syndrome. The trial includes patients who have undergone major intestinal resection resulting in at least 12 months of intravenous feeding and require parenteral nutrition (PN) treatment at least 3 times weekly. The trial involves the use of three drugs: placebo, teduglutide 0.05 mg/kg/d, and teduglutide 0.1 mg/kg/d. The eligibility criteria include being 18 years or older, having a body weight less than 90 kg, having a BMI between 18 to 27 kg/m2, and having adequate hepatic and renal function. Exclusion criteria include a history of cancer or clinically significant lymphoproliferative disease, alcohol or drug abuse within the previous year, and participation in another clinical study within 30 days prior to signing the informed consent form. The sample also includes a list of diseases and their corresponding ICD-10 codes, as well as the eligibility and exclusion criteria for the trial.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of asthma. The trial involves the use of drugs such as budesonide/formoterol, fluticasone/salmeterol, and albuterol. The eligibility criteria for the trial include being at least 18 years old, having a diagnosis of asthma, and having received inhaled corticosteroids within a specified timeframe and dose. The exclusion criteria include having severe asthma or asthma that is affected by seasonal factors, having received non-inhaled corticosteroids within the previous 4 weeks, having sensitivity to drugs specified in the protocol, or requiring treatment with beta-blockers. The diseases are listed as ['asthma'] and the icd-10 codes associated with the disease are [\"['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']\"].",
    "The sample is a phase 3 clinical trial for chronic obstructive pulmonary disease (COPD). The trial includes male and female adults aged 40 years or older with a smoking history of at least 10 pack years and a diagnosis of moderate-to-severe COPD as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines. The trial also requires that the post-bronchodilator FEV1 (forced expiratory volume in one second) be less than 80% and greater than or equal to 30% of the predicted normal value, and the post-bronchodilator FEV1/FVC (forced vital capacity) be less than 70%. The trial excludes patients who have had a respiratory tract infection within 4 weeks prior to Visit 1, patients with concomitant pulmonary disease, patients with a history of asthma, patients with lung cancer or a history of lung cancer, patients with certain cardiovascular co-morbid conditions, patients with a known history and diagnosis of alpha-1 antitrypsin deficiency, patients in the active phase of a supervised pulmonary rehabilitation program, and patients contraindicated for inhaled anticholinergic agents and \u03b22 agonists. The trial will test the efficacy of several drugs, including indacaterol and glycopyrronium (qva149), glycopyrronium (nva237), indacaterol (qab149), tiotropium, and placebo.",
    "The sample is a phase 3 clinical trial for patients with non-small cell lung cancer. The trial is testing the effectiveness of a combination of drugs including docetaxel, vinorelbine, carboplatin, and gemcitabine. Patients must have confirmed NSCLC and be willing to undergo a biopsy to customize their chemotherapy. They must also have stage IV or IIIB NSCLC, measurable or evaluable disease, and a performance status of 0 or 1. Patients with stable brain metastases may also enroll. The trial has a list of inclusion and exclusion criteria, including adequate bone marrow and liver function, normal laboratory ranges for PT and APTT, and a negative pregnancy test for women of childbearing potential. Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80, or those receiving concurrent treatment with other investigational drugs, are excluded.",
    "The sample is a record of a clinical trial in phase 3, focused on the disease of obesity. The trial includes a list of icd-10 codes associated with the disease and a drug called mk0557. The eligibility criteria for the trial includes obese men and non-pregnant women who are at least 18 years old and meet a specific body mass index requirement. Patients with uncontrolled high blood pressure and/or diabetes mellitus are excluded from the trial.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients with histologically confirmed adenocarcinoma of the breast, with certain pathologic stage criteria. Patients must have undergone modified radical mastectomy or lumpectomy prior to entry, and must not have certain clinical characteristics such as skin involvement or axillary nodes fixed to chest wall. Patients must also meet certain eligibility criteria related to age, menopausal status, performance status, and other health factors. The trial involves the use of two drugs, fenretinide and tamoxifen citrate, and includes eligibility criteria related to prior chemotherapy or hormonal therapy. The sample includes detailed eligibility criteria for the trial, including disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for heart failure. The trial includes patients who are over 18 years old and have confirmed written informed consent. The patients must have acute decompensated heart failure and require intravenous therapy for HF, such as diuretic or vasodilator. They must also have COAD and meet at least 2 of the following criteria: history of smoking > 20 pack years, prior history of PFTs within last 1 year consistent with COAD, history of chronic cough and sputum production, or progressive dyspnea, episodes of acute bronchitis over at least 2 yrs. The trial excludes women who are lactating, pregnant, or of childbearing potential not using 2 reliable contraceptive methods, patients who had received an investigational new drug within the last 4 weeks, patients with a history of a psychological illness or condition that interferes with their ability to understand the requirements of the study, patients with SBP <90mmHg, creatinine >0.25mmol/L, or Sp02 < 80% on supplemental oxygen or known cor pulmonale with TR. The trial will test the effectiveness of nesiritide compared to placebo.",
    "The sample is a phase 3 clinical trial for patients with schizophrenia or schizoaffective disorder. The trial involves the use of three different doses of risperidone long-acting injectable (lai) and requires patients to have been on stable antipsychotic therapy for at least one month prior to enrollment. The trial has specific inclusion and exclusion criteria, including no recent use of clozapine, no participation in other drug trials, and no serious medical conditions. Female patients of childbearing potential must be using adequate contraception. The trial requires written informed consent from patients or their legal representatives.",
    "The sample is a phase 3 clinical trial for patients with acute myeloid leukemia (AML) who are in their first relapse after achieving a first complete response (CR) or CRp that lasted between 3 and 24 months after completion of the initial induction regimen. The trial is testing the effectiveness of the drugs cytarabine and laromustine. The eligibility criteria include having at least 10% blasts by bone marrow aspirate and/or biopsy, being 18 years or older, having an ECOG performance status of 0-2, and meeting various medical requirements related to liver, kidney, cardiovascular, pulmonary, and immunologic health. Patients must not be pregnant or nursing, must use effective contraception during and for 3 months after completion of study treatment, and must not have any other active malignancy or severe medical condition that would preclude study treatment. Prior concurrent therapy is not specified, but patients must not have received any other treatment while in their first relapse except hydroxyurea, and must not receive any other concurrent standard or investigational treatment for AML. Patients must also not take concurrent disulfiram (Antabuse\u00ae).",
    "The sample is a phase 3 clinical trial for patients with hypertension and hypercholesterolemia. The trial includes patients who are between 20 and 80 years old and have a systolic blood pressure between 140 and 180 mmHg, and LDL cholesterol levels between 140 and 250 mg/dL. The trial involves the use of four different drugs, each containing a combination of amlodipine and atorvastatin. The eligibility criteria include exclusion of patients who have experienced coronary artery disease, myocardial infarction, or have undergone coronary artery bypass grafting or percutaneous coronary intervention. Additionally, patients with clinically meaningful valvular disease or a history of cerebrovascular diseases such as stroke or transient ischemic attack within the past 3 months are excluded.",
    "The sample is a phase 3 clinical trial for the treatment of pain. The trial includes the use of drugs such as buprenorphine, fentanyl, and placebo. The eligibility criteria for the trial includes men over the age of 18 who have provided written informed consent. Exclusion criteria includes women, individuals with known allergies to the drugs being investigated, those currently participating in other experiments or who have participated in experiments within the past 14 days, individuals with previous pain or psychiatric conditions, those using painkillers, those with a history of drug addiction or family members with drug addiction, chronic constipation, ileus, inflammatory bowel syndrome, and those who have had abdominal surgery within the last three months.",
    "The sample is a phase 3 clinical trial for individuals with type 2 diabetes mellitus who are experiencing inadequate glycemic control despite being treated with metformin. The trial includes eligibility criteria such as having a stable dose of metformin, a specific body mass index range, and regular use of other non-excluded medications. Exclusion criteria include a history of certain medical conditions, infections, or allergies to certain drugs. Participants must also agree to use adequate contraception if sexually active and monitor their own blood glucose concentrations with a home glucose monitor.",
    "The sample is a phase 3 clinical trial for the treatment of allergic rhinitis, both seasonal and perennial. The trial involves two drugs, 5-mg desloratadine and a placebo. The eligibility criteria for the trial include having a 2-year history of allergic rhinitis, being at least 12 years old, having a positive skin-prick test to one or more allergens, and being free of any clinically significant disease other than allergic rhinitis. Exclusion criteria include a history of anaphylaxis or severe local reactions to skin testing, intolerable symptoms, chronic use of corticosteroids for asthma, and current evidence of other significant diseases. The trial requires written informed consent and adherence to dose and visit schedules.",
    "The sample is a phase 3 clinical trial for the treatment of various ear and respiratory conditions, including serous otitis media, negative middle ear pressure, rhinitis, and otitis media with effusion. The trial involves the use of triamcinolone acetonide nasal spray and a placebo nasal spray. The eligibility criteria for the trial include being between the ages of 0-18 and having a diagnosis of serous otitis media and/or negative middle ear pressure. There are also several exclusion criteria, such as having a history of otologic surgery or radiation therapy to the head and neck region, as well as having certain medical conditions like cystic fibrosis or immunodeficiency.",
    "The sample is a phase 3 clinical trial for patients with both hepatitis C and human immunodeficiency virus (HIV). The trial is testing the effectiveness of the drugs Sofosbuvir (Sof) and Ribavirin (Rbv) in treating the patients. The eligibility criteria for the trial include being over 18 years old, having a confirmed chronic HCV and HIV-1 infection, having a certain level of HCV RNA, and meeting certain HIV antiretroviral therapy criteria. The trial also has exclusion criteria, such as having a non-genotype 1/2/3 or mixed genotype, having prior treatment for HCV, or having chronic liver disease of a non-HCV etiology. The trial requires liver imaging within 6 months of baseline/Day 1 in cirrhotic patients only, to exclude hepatocellular carcinoma (HCC). The sample includes a detailed list of inclusion and exclusion criteria for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of leukemia. The trial is open to patients between the ages of 16 and 60 who have been diagnosed with acute myeloid leukemia (AML) and meet certain criteria, including having a sibling donor match for those undergoing allogeneic transplantation. The trial involves the use of several drugs, including busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (go), and daunorubicin. The eligibility criteria include various medical and demographic factors, such as negative pregnancy test, HIV negative, and Eastern Cooperative Oncology Group (ECOG) performance status 0-4. The exclusion criteria include certain types of leukemia, prior biologic therapy, and prior cytotoxic chemotherapy or radiotherapy for any malignancy.",
    "The sample is a phase 3 trial for patients with Parkinson's disease and severe motor fluctuations. The trial is looking at the effectiveness of levodopa-carbidopa intestinal gel. The inclusion criteria require patients to have idiopathic Parkinson's disease and be responsive to levodopa, as well as having completed a previous protocol study. The exclusion criteria include patients with abnormal findings in labs, ECG, physical examination, adverse events, psychiatric, neurological or behavioral disorders, etc. at the end of the double-blind phase of the previous study. The diseases listed in the sample include dyskinesias and Parkinson's disease, and the icd-10 code listed is G20.",
    "The sample is a phase 3 clinical trial for non-squamous cell type non-small cell lung cancer (NSCLC) using the drugs taxotere and pemetrexed. The trial includes patients with Stage IV or Stage IIIB NSCLC who cannot be treated with curative intent or have relapsed after surgery or radiation therapy. Patients must meet certain eligibility criteria, including having measurable lesions and meeting certain blood test results. Patients who are pregnant or lactating, have certain comorbidities, or are currently receiving other anticancer chemotherapy or investigational drugs are excluded from the trial. The trial also excludes patients with certain genetic mutations.",
    "The sample is from a phase 3 clinical trial for hypoactive sexual desire disorder. The trial involves the use of testosterone gel and placebo gel. The eligibility criteria include being between the ages of 30 to 65 years and having undergone hysterectomy and bilateral salpingo-oophorectomy. The exclusion criteria include a history of allergic reactions to androgens, any systemic skin diseases or local skin abnormalities in the area of application, and being diagnosed with another primary female sexual dysfunction. Additionally, participants with a medical condition that could affect or interfere with sexual function or using a systemic transdermal gel or cream estrogen therapy are also excluded.",
    "The sample is a phase 3 clinical trial for rheumatoid arthritis. The trial is testing the effectiveness of golimumab therapy compared to placebo injections and capsules, as well as methotrexate capsules. The eligibility criteria for participants include having a diagnosis of rheumatoid arthritis for at least 3 months, being methotrexate-na\u00efve, having active RA with at least 4 swollen and 4 tender joints, and meeting at least 2 of the 4 specified criteria. Participants must also be on a stable dose of oral corticosteroids equivalent to <= 10 mg of prednisone/day for at least 2 weeks prior to the trial. Exclusion criteria include having other inflammatory diseases, no treatment with DMARDs/systemic immunosuppressives in the 4 weeks prior to the trial, no prior treatment with biologic anti-TNF drugs, and no history of or ongoing chronic or recurrent infectious disease. Participants must not have had a serious infection within 2 months prior to the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who are currently being treated with PPAR gamma agents (pioglitazone or rosiglitazone) and another anti-diabetes agent (metformin). Patients must have a HbA1c between >=7 and <=10.5% and a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L). Patients with a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening are excluded from the trial. The trial includes a placebo group and several drug groups, including canagliflozin, sitagliptin, metformin, and pioglitazone.",
    "The sample is a phase 3 clinical trial for various types of childhood acute lymphoblastic leukemia, including B-cell and T-cell leukemia, as well as graft versus host disease. The trial involves the use of drugs such as thiotepa, cyclophosphamide, tacrolimus, methotrexate, and sirolimus. The eligibility criteria include being in second complete remission, meeting certain risk criteria, and having completed required study therapy. Patients must also meet various health criteria, such as having a certain performance status, normal liver and kidney function, and no evidence of active CNS or other extramedullary disease. Patients must not have had a prior stem cell transplantation or be taking certain medications.",
    "The sample is a phase 3 clinical trial for the treatment of restless legs syndrome. The trial includes patients with a diagnosis of primary RLS according to RLS Diagnostic Clinical Interview and International Restless Legs Syndrome Study Group Diagnostic Criteria, who have disturbed sleep with both evening and night time symptoms requiring treatment. The trial excludes patients with signs of secondary RLS, primary sleep disorder or movement disorder other than RLS, unstable medical conditions, inability to tolerate dopamine agonists or dopamine antagonists, and unwillingness to discontinue any medications currently being taken to treat RLS symptoms. The trial will be testing the effectiveness of ropinirole extended release (xr) as a treatment for RLS.",
    "The sample is a phase 3 trial for obesity. The trial includes a list of icd-10 codes for the disease. The trial will compare the drugs taranabant and placebo. The eligibility criteria for the trial includes having a BMI between 30-43 kg/m2, and excludes individuals with a history of major psychiatric disorder, seizures, high blood pressure, high fasting blood glucose, and high triglycerides.",
    "The sample is a phase 3 clinical trial for the treatment of hepatitis B. The trial includes patients with specific icd-10 codes for hepatitis B and requires them to have a Child-Pugh score of 7 or higher and HBV viremia to be eligible. Patients with ALT levels greater than 15 times the upper limit of normal or co-infection with HIV, HCV, or HDV are excluded. The trial will test the effectiveness of two drugs, entecavir (etv) and adefovir (adv), on eligible patients.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and affective psychosis. The trial is testing the effectiveness of the drug paliperidone er. The inclusion criteria for the trial include meeting the DSM-IV criteria for Bipolar I Disorder, having a history of at least one manic or mixed episode requiring medical treatment within the past 3 years, and taking lithium or valproate for at least 2 weeks before screening. The exclusion criteria include having a history of rapid cycling or schizoaffective disorder, being at significant risk for suicidal or violent behavior, and having used certain drugs or benzodiazepines at high doses for a prolonged period of time. Women must be postmenopausal or use effective birth control throughout the study.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves the use of two drugs, dorzolamide hydrochloride (+) timolol maleate and a comparator drug, dorzolamide hcl/timolol maleate + prostaglandin. The eligibility criteria for the trial include patients who have been recently diagnosed and are presently untreated for open-angle glaucoma or ocular hypertension with an IOP of at least 27 mmHg in at least one eye, or patients who have already been diagnosed with open-angle glaucoma or ocular hypertension and have been untreated for at least 30 days with an IOP of 27 mmHg or more in at least one eye. Exclusion criteria include patients with a history of any illness that might confound the results of the study or pose additional risk by administering the drugs, the presence of any fundus pathology likely to change during the study or to influence IOP, and any contraindication to the use of the drugs. Patients on certain medications or with certain medical conditions are also excluded. Pregnant women or women of childbearing potential who are not using an acceptable method of contraception are also excluded. Severe renal impairment is also an exclusion criterion.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients who have had prior treatment with at least one and no more than two systemic therapy regimens, with at least one being standard chemotherapy for advanced NSCLC. Adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses. Patients must have adequate renal, hematologic, liver function and an ECOG PS of 0-2. The trial excludes patients with small cell histology, symptomatic brain mets or known leptomeningeal mets, prior therapy with agent known or proposed to be active by action on EGFR tyrosine kinase or other HER family proteins, and uncontrolled medical disorders. The drugs being tested are dacomitinib (pf-00299804), active comparator (erlotinib), placebo erlotinib, and placebo pf00299804.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial is testing the drug ropinirole xl (formerly cr). The eligibility criteria for the trial includes being at least 30 years old, having a diagnosis of idiopathic Parkinson's disease, and having completed either Study 167 or Study 164. Exclusion criteria includes having uncontrolled psychiatric, hematological, renal, hepatic, endocrinological, neurological, cardiovascular disease, or active malignancy, experiencing dizziness or fainting due to orthostatic hypotension on standing, having a significant sleep disorder, or having a history of drug abuse or alcoholism.",
    "The sample is a phase 3 clinical trial for chronic hepatitis B virus (HBV) infection. The trial is testing the effectiveness of tenofovir disoproxil fumarate (TDF) compared to a placebo. The trial is open to male and female participants between the ages of 12 and 17 who have documented chronic HBV infection and meet certain eligibility criteria, such as having a certain level of HBV DNA and ALT, and being able to swallow oral tablets. The trial has exclusion criteria, such as pregnancy, breastfeeding, and certain medical conditions or prior therapies that would make the participant unsuitable for the study. The trial is looking to enroll participants who have not received prior TDF therapy.",
    "The sample is a phase 3 clinical trial for the treatment of ulcerative colitis using the drug adalimumab. The trial is open to both male and female participants over the age of 18 who have been diagnosed with active ulcerative colitis for at least 90 days prior to the start of the trial. Participants must have a Mayo score of 6 to 12 points and an endoscopy subscore of 2 to 3 points, despite concurrent treatment with at least one of the following: oral corticosteroids, immunosuppressants, or both. Participants must be able to self-administer subcutaneous injections or have a caregiver who can reliably administer them. The trial has a list of exclusion criteria, including previous treatment with adalimumab or participation in an adalimumab clinical study, and a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC or planning bowel surgery. Participants must be able and willing to give written informed consent and comply with the requirements of the study protocol.",
    "The sample is a phase 3 clinical trial for patients with congestive heart failure. The trial is testing the effectiveness of two drugs, carvedilol controlled release and carvedilol immediate release. The eligibility criteria include being at least 18 years old, having stable chronic heart failure, and having an LVEF (left ventricular ejection fraction) of less than 40 as measured by 2-D echocardiography. The trial also has exclusion criteria, such as being on beta-blocker therapy for more than 42 days prior to consent and having a history of drug or alcohol abuse within the past year. The trial requires written informed consent from participants.",
    "The sample is a phase 3 clinical trial for newly diagnosed acute myeloid leukemia (AML) patients, including those with cytopenia or myelodysplastic syndromes. Patients with <20% bone marrow blasts are eligible if they have a karyotypic abnormality characteristic of de novo AML or an unequivocal presence of megakaryoblasts. Infants <1 month of age with progressive disease, and patients with Down syndrome \u22654 years of age are also eligible. Patients with certain bone marrow failure syndromes or promyelocytic leukemia (M3) are not eligible. The trial involves a list of drugs, including asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, and mitoxantrone hydrochloride. The eligibility criteria include not being pregnant or nursing, having negative pregnancy test results, and using effective contraception if fertile. Prior chemotherapy, radiation therapy, or any antileukemic therapy is not allowed, except for topical or inhalation steroids for other conditions and intrathecal cytarabine given at diagnosis. Concurrent peripheral blood stem cell transplantation is not allowed in patients with matched family donors.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C virus. The trial includes patients who have previously failed a nonstructural protein (NS)3/4A protease inhibitor plus pegylated interferon (PEG)/RBV regimen. The trial requires patients to have HCV RNA levels greater than 10,000 IU/mL at screening and a cirrhosis determination, which may require a liver biopsy. Patients must also meet certain screening laboratory values within defined thresholds and use two effective contraception methods if female of childbearing potential or sexually active male. The trial excludes pregnant or nursing females or males with pregnant female partners, patients with coinfection with HIV or hepatitis B virus, patients with current or prior history of clinical hepatic decompensation, patients with hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers), patients with chronic use of systemic immunosuppressive agents, and patients with a history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.",
    "The sample is a phase 3 clinical trial for the treatment of nocturia, a condition characterized by frequent urination at night. The trial involves the use of two drugs, desmopressin and placebo, and has eligibility criteria for female participants who are 18 years or older and have at least two voids every night in a consecutive 3-day period during the screening period. The exclusion criteria include various medical conditions, such as severe daytime voiding dysfunction, interstitial cystitis, urinary retention, and urologic malignancies, as well as lifestyle factors that may interfere with regular nighttime sleep, such as shift work. The trial requires written informed consent from participants and documentation of a reliable method of contraception for those of reproductive age.",
    "The sample is a phase 3 clinical trial for the treatment of restless legs syndrome using the drug ropinirole. The trial is focused on patients with moderate to severe idiopathic restless legs syndrome and requires a confirmed diagnosis of the condition with a score of at least 11 on the RLS Diagnostic Index. Patients must also have a certain severity of symptoms, as measured by a score of at least 15 on the International Restless Legs Score (IRLS), and have experienced RLS symptoms for at least 15 nights in the last four weeks. Other inclusion criteria include having less than 6 hours of sleep on nights with RLS symptoms and a MADRS score of at least 12 at baseline. Exclusion criteria include having any other sleep disorder that might interfere with RLS symptoms or sleep, secondary RLS due to certain medical conditions, significant psychiatric disorders, current or past suicidality, medication known to trigger or interfere with RLS symptoms, and various medical conditions that could affect assessments of efficacy. Women of childbearing potential must use adequate contraception and subjects taking medication known to induce drowsiness or affect sleep are also excluded.",
    "The sample is a phase 3 clinical trial for patients with stage III or IV non-small cell lung cancer (NSCLC) who have not received chemotherapy before. The trial includes patients between the ages of 18 and 70 with an ECOG performance status of 1 or less, a body weight of at least 45kg, and specific blood counts and liver function tests within normal ranges. The trial involves the use of pegylated rhg-csf and placebo, and patients must meet certain inclusion criteria and not have certain exclusion criteria. The diseases being studied in the trial also include neutropenia and febrile neutropenia, and the icd-10 codes associated with these diseases are listed. The eligibility criteria for the trial are also provided.",
    "The sample is a record of a clinical trial in phase 3, which is testing the effectiveness of vitamin D supplements in treating diabetes mellitus and vitamin D deficiency. The trial is being conducted in the Riyadh area and the participants must meet certain eligibility criteria, such as being type II diabetics who consume no more than one serving of milk per day, not taking vitamin supplements, and having less than 10 hours of sun exposure per week. The trial is also excluding participants who suffer from granulomatous conditions, liver disease, or kidney disease, or who take anticonvulsants, barbiturates, or steroids. The trial is measuring the effects of vitamin D supplements, including vitamin D3 2000 IU, vitamin D3 5000 IU, and a placebo. The trial is looking for stable glycemic control and a current HA1c between 6.5 and 8%, and a current total 25 OH vitamin D level between 10-30 nmol/L.",
    "The sample is a phase 3 clinical trial for advanced Parkinson's disease. The trial includes participants who have been diagnosed with idiopathic Parkinson's disease and are responsive to levodopa. The participants must also demonstrate severe motor fluctuations despite optimized treatment options. The trial excludes participants who have undergone surgery for the treatment of PD, have contraindications to levodopa, or have any neurological deficits that may interfere with the study assessments. The trial involves the use of levodopa carbidopa intestinal gel, levodopa-carbidopa oral encapsulated immediate release tablets, and placebo capsules. The trial also includes eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 3 clinical trial for asthma. The table includes information on the diseases being studied, the icd-10 codes associated with those diseases, the drugs being used, and the eligibility criteria for participants. The inclusion criteria includes being male or female over the age of 18 with a clinical history consistent with asthma, and meeting certain FEV1 and methacholine PC20 criteria. The exclusion criteria includes being a smoker with a total smoking history of more than 10 pack years, having a significant unstable medical condition other than asthma, having a history of life-threatening asthma requiring intubation and mechanical ventilation in the past 10 years, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for attention deficit disorder. The trial includes male or female participants aged 6-17 years who meet DSM-IV-TR criteria for primary diagnosis of ADHD and have a minimum ADHD-RS-IV total score of 32 at enrollment/visit 2. The trial also includes a placebo group. The inclusion criteria require that the subject is able to swallow intact tablets. The exclusion criteria include a current controlled or uncontrolled, co-morbid psychiatric diagnosis, a known history or presence of structural cardiac abnormalities, orthostatic hypotension or a known history of controlled or uncontrolled hypertension, current use of any prohibited medication or other medications that affect blood pressure, or heart rate or that have CNS effects or affect cognitive performance, significant overweight based on Centre for disease control and prevention BMI for age gender-specific charts, and currently considered a suicide risk in the opinion of the investigator. The trial also excludes participants with a history of failure to respond to an adequate trial of an alfa2-agonist for the treatment of ADHD.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic hepatitis B. The trial is focused on patients who have received a liver transplant due to end-stage liver disease caused by chronic HBV infection. The patients must have detectable hepatitis B surface antigen (HBsAg) at screening and for at least 24 weeks prior to screening, and their HBV-DNA levels must be less than 172 IU/mL (approximately less than 1000 copies/mL) prior to the transplant. The trial is testing the effectiveness of the drug entecavir. The record also includes the eligibility criteria for the trial, including inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for the treatment of non-Hodgkin's lymphoma. The trial is testing the effectiveness of two drugs, bortezomib and rituximab, on patients with follicular B-NHL. The eligibility criteria for the trial include being 18 years or older, having a documented relapse or progression following prior antineoplastic treatment, and having at least one measurable tumor mass. Exclusion criteria include having received certain types of prior treatment, having peripheral neuropathy or neuropathic pain of Grade 2 or worse, and being pregnant or breastfeeding. The trial requires participants to sign an informed consent document and, in some countries, a separate consent for genetic and protein testing.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of pulmonary disease, chronic obstructive. The trial involves the drugs zileuton and placebo. The eligibility criteria for the trial include being admitted to the hospital for a COPD exacerbation, having an FEV1 less than 60% of predicted level, and having at least 10 pack years of smoking. The exclusion criteria include having any uncontrolled systemic disease, known hypersensitivity to zileuton, asthma, lobar pneumonia or pulmonary edema, interstitial lung disease, medical condition that is likely to limit survival to less than 30 days at the time of study entry, history of liver disease, current use of theophylline, participation in another clinical trial in the COPD Clinical Research Network, incarceration, institutionalization, being pregnant, history of a suicide attempt, prior inpatient admission for a psychiatric disorder, and bipolar disorder.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes participants who have been diagnosed with essential hypertension and are being treated with a single or dual combination treatment for hypertension. The trial aims to test the effectiveness of the drugs \"l50/h12.5/a5\", \"l50/h12.5\", and \"placebo to l50/h12.5/a5\" compared to \"placebo to l50/h12.5\". The trial has specific inclusion and exclusion criteria, such as having a mean trough SiDBP of \u2265 90 mmHg and < 110 mmHg and not currently taking more than two antihypertensive medications. The trial also excludes participants who have a history of significant multiple and/or severe allergies to certain medications or are currently using recreational or illicit drugs.",
    "The sample is a phase 3 clinical trial for lupus nephritis, a disease affecting the kidneys in patients with systemic lupus erythematosus (SLE). The trial includes a list of drugs, including rituximab, mycophenolate mofetil, and methylprednisolone, as well as a placebo. The eligibility criteria for the trial include a diagnosis of SLE and ISN/RPS 2003 Class III or IV lupus nephritis, proteinuria, and age between 16 and 75 years. Exclusion criteria include various medical conditions, such as retinitis, poorly controlled seizure disorder, and significant or uncontrolled medical disease in any organ system not related to SLE or LN. The trial also excludes patients with a history of cancer, alcohol or drug abuse, and those who have received certain treatments within a certain timeframe.",
    "The sample is a phase 3 clinical trial for the treatment of multiple system atrophy. The trial is testing the effectiveness of rifampicin compared to a placebo. The eligibility criteria for participants include being between the ages of 30-80 with a diagnosis of possible or probable MSA of the parkinsonian or cerebellar subtype, being less than 4 years from the time of diagnosis, having an anticipated survival of at least 3 years, having \"normal\" cognition as assessed by the Mini-Mental State Examination (MMSE), and being able to swallow capsules whole. Exclusion criteria include being pregnant or lactating, having a UMSARS score >17, having a clinically significant or unstable medical or surgical condition, having taken any investigational products within 60 days prior to baseline, and taking certain medications. The trial also requires participants to practice an acceptable method of birth control and to have a score on the MMSE >24.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial includes male patients between the ages of 30 and 85 who have osteoporosis due to hypogonadism, past steroid use, or idiopathic causes. Patients with stable testosterone replacement therapy for at least 18 months can also be included. The trial involves the use of drugs such as risedronate, teriparatide, placebo teriparatide, and placebo risedronate. The eligibility criteria include having a bone mineral density of 2 or more standard deviations below the young adult peak for men at the lumbar spine, hip, or radius, as well as normal renal and liver function. Exclusion criteria include a history of specific osteoporosis drugs in the previous 6 months, known or suspected metabolic bone diseases, hypercalcemia, Paget's disease of bone or fibrous dysplasia, and a history of malignancy. Patients with certain medical conditions or laboratory abnormalities are also excluded. The trial involves a total of 29 exclusion criteria.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The trial includes patients with locally advanced or metastatic adenocarcinoma of the pancreas and measurable disease. Patients must have a WHO performance status of 0-2, absolute neutrophil count > 1,500/mm^3, platelet count > 100,000/mm^3, creatinine < 1.5 times normal, transaminases < 2 times normal (5 times normal if liver metastases), and total bilirubin < 1.5 times normal. Fertile patients must use effective contraception. Exclusion criteria include brain metastases, pregnancy or nursing, intestinal occlusion, prior inflammatory intestinal disease, Crohn's disease, hemorrhagic rectal colitis, peripheral neuropathy > grade 2, and other severe illnesses. Patients must not have received prior therapy for advanced disease, inhibitors of kinase signaling (e.g., ras/raf, MEK, AKT, mTOR, or farnesyl transferase), inhibitors of angiogenesis (e.g., bevacizumab), organ graft or allogeneic transplantation, or concurrent participation in another therapeutic study. Prior chemotherapy or radiochemotherapy must have been at least 6 months prior, and prior radiotherapy and/or surgery must have been at least 4 weeks prior. Concurrent inductors of CYP3A4 (e.g., barbiturates, anti-epileptics, or rifampicin) are also excluded.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, the disease being studied (cervical dystonia), the corresponding ICD-10 codes, the drug being tested (placebo), and the eligibility criteria for participants. The inclusion criteria include having dystonia for at least 18 months, not having received previous treatment with Botulinum toxin-A or -B, and having a certain score on the TWSTRS scale. The exclusion criteria include known hypersensitivity to Botulinum toxin, certain types of dystonia, previous poor response to BTX treatment, and previous surgeries involving the neck or shoulder region.",
    "The sample is a phase 3 clinical trial for patients with stage IIIB or IV non-small cell lung cancer who require first-line chemotherapy. The trial is testing the effectiveness of tariquidar plus paclitaxel/carboplatin compared to a placebo plus paclitaxel/carboplatin. The eligibility criteria include having a WHO performance status of 1 or 0, being 18 years or older, having certain blood levels within normal ranges, and not having certain medical conditions or previous treatments. Patients must also be able to give written informed consent and comply with the protocol. Exclusion criteria include being eligible for curative radiotherapy or surgery, having had previous chemotherapy for NSCLC, having a WHO performance status greater than 1, and having certain medical or surgical conditions that would contraindicate chemotherapy.",
    "The sample is a phase 3 clinical trial for chronic hepatitis C. The trial includes participants who have previously been diagnosed with genotype 1 infection and have liver biopsy results consistent with CHC and no other etiology. Participants must have completed a qualifying regimen of pegylated interferon alfa-2a plus ribavirin or pegylated interferon alfa-2b plus ribavirin for a minimum of 12 weeks. The trial involves the use of drugs such as boceprevir and ribavirin, as well as a placebo. The eligibility criteria include age, weight, and willingness to use contraception. Exclusion criteria include coinfection with HIV or hepatitis B virus, discontinuation of previous interferon or ribavirin regimen due to adverse events, and evidence of decompensated liver disease. The trial also has specific hematologic, biochemical, and serologic criteria that participants must meet.",
    "The sample is a phase 3 clinical trial for attention deficit/hyperactivity disorder (ADHD). The trial includes patients who have been diagnosed with ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV) and confirmed by the Conners' Adult ADHD Diagnostic Interview for DSM IV. The patients must have a chronic course of ADHD symptomatology from childhood to adulthood, with some symptoms present before age 7 years and continue to meet DSM-IV criteria at the time of assessment. The trial involves the use of prolonged release (PR) OROS methylphenidate 54 mg, PR OROS methylphenidate 72 mg, and placebo as treatment for ADHD. Patients must agree to take only the supplied study drug as treatment for ADHD during the study and not to initiate a new behavioral modification program during the study or if currently using a behavioral modification program agrees not to change this program during the study. The trial has exclusion criteria, including patients who are known to be a non-responder to methylphenidate, have been treated with any methylphenidate-containing medication within 1 month of screening visit, have participated in and prematurely withdrawn from 42603ATT3002, CR002479 or 42603ATT3004, CR011068 study, have a known allergy or hypersensitivity to methylphenidate, or components of PR OROS methylphenidate, and have any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, borderline personality disorder.",
    "The sample is a phase 3 clinical trial for the treatment of migraine. The trial includes the use of drugs such as telcagepant potassium 150 mg, telcagepant potassium 300 mg, and zolmitriptan 5 mg, as well as placebos and rescue medication. The eligibility criteria for the trial include having at least 1 year history of migraine, using acceptable contraception for females of childbearing potential, and not having certain medical conditions such as stroke, heart disease, or uncontrolled hypertension. Exclusion criteria include being pregnant or breastfeeding, having major depression or other pain syndromes, or having a history of cancer within the last 5 years.",
    "The sample is a phase 3 clinical trial for HIV infection. The trial includes patients who are at least 18 years old and have documented HIV RNA levels below 50 copies/mL for at least 3 months while on a KALETRA based regimen. Patients must have been on the KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy and have no documentation of HIV RNA levels above 50 copies/mL for at least 3 months while on the KALETRA based regimen. The trial excludes patients who are pregnant or nursing, receiving Stavudine as a component of the background antiretroviral therapy, currently receiving a second protease inhibitor in addition to KALETRA, currently receiving or have received in the past twelve weeks treatment for the management of elevated lipids, used another experimental HIV-integrase inhibitor, have a current diagnosis of acute hepatitis due to any cause, or have used systemic immunosuppressive therapy within one month prior to treatment in this study. The trial includes several drugs, including mk0518 (raltegravir), kaletra\u2122 (lopinavir (+) ritonavir), and placebos.",
    "The sample is a phase 3 clinical trial for HIV infection. The trial includes patients who are at least 18 years old, HIV positive, and have had documented HIV RNA levels below 50 copies/mL for at least 3 months while on a KALETRA based regimen. Patients must have been on the KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy and have no documentation of HIV RNA levels above 50 copies/mL for at least 3 months while on the KALETRA based regimen. The trial excludes patients who are pregnant or nursing, receiving Stavudine as a component of the background antiretroviral therapy, currently receiving a second protease inhibitor in addition to KALETRA, currently receiving or have received in the past twelve weeks treatment for the management of elevated lipids, used another experimental HIV-integrase inhibitor, or have a current diagnosis of acute hepatitis due to any cause. The trial includes a comparator group receiving raltegravir and a placebo group receiving lopinavir (+) ritonavir.",
    "The sample is a phase 3 clinical trial for allergic rhinitis, specifically for perennial and intermittent allergic rhinitis. The trial involves the use of fluticasone furoate nasal spray and a placebo. The eligibility criteria include being a Chinese adolescent or adult with a confirmed diagnosis of allergic rhinitis, being symptomatic at screening, and being able to comply with study procedures. Exclusion criteria include having complications of nasal disease or upper respiratory tract infection, significant systemic diseases, hypersensitivity to steroids and ingredients, being pregnant or lactating, and having participated in another study within 4 months before screening. Patients who cannot withdraw from certain medications during the screening period are also excluded.",
    "The sample is a phase 3 clinical trial for newly diagnosed chronic-graft-versus host disease (GVHD) in patients who have undergone prior transplantation with any type of donor, hematopoietic stem cell graft, or conditioning regimen. The trial is testing the effectiveness of mycophenolate mofetil compared to a placebo. The eligibility criteria include various patient characteristics such as age, performance status, and hematopoietic, hepatic, renal, pulmonary, immunologic, and gastrointestinal health. Prior concurrent therapy is also taken into consideration. The sample includes a detailed list of eligibility criteria for patients to participate in the trial.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes a placebo group and a group taking lc15-0444 50mg qd. The eligibility criteria for the trial include being an adult between 18 and 75 years old, having an HbA1c between 7% and 11%, and not having received any diabetic medications within 6 weeks from screening. Exclusion criteria include having type 1 diabetes mellitus, gestational diabetes, or secondary diabetes, taking drugs that may significantly affect blood glucose control, and having certain medical conditions such as congestive heart failure or renal failure. Patients with a history of hypersensitivity to metformin or biguanides, or who took certain medications within the last 6 weeks or 6 months prior to Visit 1, are also excluded. The investigator may also exclude patients for other reasons.",
    "The sample is a phase 3 clinical trial for breast cancer patients with T2-3 (greater than 2 cm), N0-1, M0. The trial includes patients with histologic confirmation of invasive, but non-inflammatory carcinoma of the breast. Patients with T1N1 (after histological confirmation of nodal disease) are also eligible. The trial requires patients to have adequate bone marrow, liver, and renal function, as well as a normal cardiac ejection fraction. Patients with multicentric disease and extensive Ductal Carcinoma in Situ (DCIS) are also eligible. The trial excludes patients with T1N0 disease, history of other invasive malignancies (except non-melanoma skin cancer and non-invasive cervical cancer), history of congestive heart failure, and those who had surgical therapy prior to referral. The trial requires patients to sign an informed consent indicating that they are aware of the investigational nature of the study.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with type 2 diabetes mellitus and includes a list of associated ICD-10 codes. The trial involves the use of several drugs, including sitagliptin phosphate, pioglitazone, and a placebo. The eligibility criteria for the trial include patients who are currently on diet and exercise therapy and pioglitazone as monotherapy, while exclusion criteria include patients with type 1 diabetes mellitus.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The trial includes patients who have been diagnosed with idiopathic PD for at least 3 years and have a disease severity of stages I-III. The patients must have been treated with L-DOPA/DDCI for at least 1 year and have clear clinical improvement as per the investigator's judgment. The trial involves the use of drugs such as bia 9-1067, entacapone, placebo, levodopa, carbidopa, and benserazide. The eligibility criteria include being able to comprehend and sign an informed consent form, keeping reliable diaries of motor fluctuations, and having a minimum of 1.5 hours of \"wearing-off\" phenomenon despite optimal anti-PD therapy. The exclusion criteria include non-idiopathic PD, severe and/or unpredictable OFF periods, treatment with prohibited medication, and any medical condition that might place the subject at increased risk or interfere with assessments. The trial involves two phases: screening and randomization. The patients must meet certain criteria during both phases to be eligible for the trial.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial involves the use of drugs such as ly2189265, liraglutide, and metformin. The eligibility criteria for the trial include having type 2 diabetes, not being optimally controlled on diet and exercise, having a stable dose of metformin for at least 3 months prior to the first study visit, and having a glycosylated hemoglobin (HbA1c) level between 7.0% and 10.0%. Participants must also be willing to continue treatment with metformin throughout the trial, be aged 18 or older, have a stable weight, and have a body mass index (BMI) of 45 kg/m^2 or less. Exclusion criteria include having type 1 diabetes, having used any antihyperglycemic medications other than metformin within the past 3 months, having used insulin therapy (except for short-term treatment of acute conditions) within the past 2 years, and having used drugs that promote weight loss within the past 3 months. Other exclusion criteria include having certain cardiovascular conditions, gastric emptying abnormalities, liver disease, pancreatitis, and certain genetic conditions. Participants must also have a serum creatinine level and serum calcitonin level within certain ranges to be eligible for the trial.",
    "The sample is a record of a clinical trial in phase 3, focused on the treatment of hypertension. The trial includes patients who meet certain eligibility criteria, such as being essential hypertensive patients who satisfy non-responder criteria, being male or female, and being 20 years or older. The trial also has exclusion criteria, such as patients taking four or more anti-hypertensive medications, having secondary hypertension, or having sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias. The trial involves the use of two drugs, telmisartan+amlodipine and telmisartan, and has a list of diseases and icd-10 codes associated with it. The eligibility and exclusion criteria are listed in detail in the \"criteria\" column.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The eligibility criteria include having memory complaints and difficulties, abnormal memory function, a Mini-Mental Exam score between 24 and 30, and a Clinical Dementia Rating of 0.5. The trial also requires good general health and no significant neurologic or systemic illnesses. Exclusion criteria include a history of alcohol or substance abuse, major depression or other major psychiatric disorders, and use of certain medications. The trial will involve the use of donepezil and vitamin E, and an informant must be available to monitor the subject's administration of the study drug and accompany them to all clinic visits.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating hormone refractory prostate cancer with bone metastases. The diseases are listed as \"hormone refractory prostate cancer\" and \"bone metastases\" and the icd-10 codes associated with these diseases are also provided. The drugs being tested in the trial are \"radium-223 dichloride (xofigo, bay88-8223)\", \"placebo\", and \"best standard of care (bsoc)\". The eligibility criteria for the trial are also listed, including requirements for confirmed adenocarcinoma of the prostate, known hormone refractory disease, multiple skeletal metastases, and no intention to use cytotoxic chemotherapy within the next 6 months. The exclusion criteria are also provided, including restrictions on treatment with investigational drugs, eligibility for first course of docetaxel, treatment with cytotoxic chemotherapy within the previous 4 weeks, and history of visceral metastasis.",
    "The sample is a phase 3 clinical trial for patients with a malignant solid tumor who are scheduled to receive their first course of cytotoxic chemotherapy with cisplatin. The trial is testing the effectiveness of a combination of drugs, including oral and IV casopitant, IV ondansetron hydrochloride, and oral dexamethasone, in reducing nausea and vomiting caused by chemotherapy. The eligibility criteria include being at least 18 years old, having an ECOG Performance Status of 0, 1, or 2, and meeting certain hematologic and metabolic criteria. The trial also has exclusion criteria, such as having previously received cytotoxic chemotherapy or having a known hypersensitivity to certain drugs.",
    "The sample is a phase 3 clinical trial for active rheumatoid arthritis. The trial includes patients with specific disease activity criteria, such as a Disease Activity Score 28-C-Reactive Protein (CRP) greater than 3.2 or more than 6 swollen and 6 tender joints with CRP greater than the upper limit of normal. Participants must also have at least 1 erosion in hands/wrists or positive anticyclic citrullinated peptides or rheumatoid factor, and clinically detectable synovitis of at least 1 wrist/ankle at screening and baseline. Additionally, participants must have been treated with methotrexate for at least 3 months before screening, with a weekly dose of at least 15 mg or a maximum tolerated dose for at least 28 days prior to the first study dose. The trial includes the use of abatacept and placebo as drugs.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves testing various drugs, including sitagliptin phosphate, pioglitazone, glimepiride, gliclazide, and metformin. The eligibility criteria for the trial include having a stable dose of metformin and either glimepiride or gliclazide for at least 10 weeks prior to the study start, and having a hemoglobin A1C level between 7.5% and 10.5%. The trial excludes patients with type 1 diabetes, those taking certain medications, and those with a history of certain medical conditions. The trial is open to male patients and females who are highly unlikely to conceive.",
    "The sample is a phase 3 clinical trial for the treatment of bipolar disorder and anxiety disorder using the drug risperidone. The trial includes subjects who are 18 years or older and have lifetime bipolar I, II, or NOS disorder, as well as lifetime panic disorder or generalized anxiety disorder. The trial has inclusion and exclusion criteria, including the requirement that subjects' bipolar symptoms be no more than moderately severe and their anxiety symptoms be at least moderately severe. Subjects must not be receiving certain medications for more than one week prior to baseline. Women who are pregnant or nursing are excluded from the trial. The trial aims to determine the effectiveness of risperidone in treating bipolar disorder and anxiety disorder.",
    "The sample is a phase 3 clinical trial for breast neoplasms, which includes a list of icd-10 codes for related diseases. The trial involves several drugs, including fec-docgemzar adjuvant chemotherapy, fec-doc adjuvant chemotherapy, zoledronic acid i.v. 2 years, and zoledronic acid i.v. 5 years. The eligibility criteria for the trial include having primary epithelial invasive carcinoma of the breast, histopathological proof of axillary lymph node metastases, complete resection of the primary tumor, being female and over 18 years of age, having a performance status of \u2264 2 on Eastern Cooperative Oncology Group (ECOG) Scale, and having adequate bone marrow reserve. The exclusion criteria include having inflammatory breast cancer, previous or concomitant cytotoxic or other systemic antineoplastic treatment, history of treatment or disease affecting bone metabolism, and severe renal insufficiency. The sample also includes a detailed list of inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for patients with Lennox-Gastaut Syndrome (LGS), a type of epilepsy. The trial is testing the effectiveness of different doses of clobazam and a placebo. The trial includes patients who are under 11 years old and have been diagnosed with LGS, and are currently taking at least one anti-epileptic drug. Patients must have a caregiver who can keep an accurate seizure diary. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial also has other protocol-defined inclusion and exclusion criteria that may apply.",
    "The sample is a phase 3 clinical trial for type 2 diabetes. The trial includes participants who are between 40 and 70 years old and have been diagnosed with type 2 diabetes according to WHO criteria and are being treated with metformin and/or sulfonylureas or diet. The trial excludes participants with kidney disease, liver disease, macroalbuminuria, heart failure, severe neuropathy, neutropenia, anemia, alcohol or drug abuse, severe organic or metabolic diseases including cancer, C-peptide levels below 0.3 pmol/l, medication interactions, treatment with insulin, PPI or other medications for ulcus diseases, treatment with warfarin or other coumarin derivations, pregnant or breastfeeding women, allergy to medication used in the study, and participants who are already participating in another clinical intervention trial. The trial includes a list of icd-10 codes for the disease and a list of drugs being used in the trial, including nexium and placebo. The eligibility criteria for the trial are also listed.",
    "The sample is a phase 3 clinical trial for the treatment of pulmonary hypertension using the drug ambrisentan. The trial is open to participants who are 18 years or older and have been diagnosed with pulmonary hypertension due to various etiologies, including PAH, lung diseases, chronic thromboembolic obstruction, and sarcoidosis. Participants must have a stable regimen of certain therapies and meet specific criteria for right heart catheterization. Female participants must have a negative pregnancy test and use reliable contraception during the study and for four weeks after the final visit. Male participants must be informed of potential risks associated with the drug. Exclusion criteria include previous participation in a clinical study with ambrisentan, recent use of certain medications, abnormal liver function, and contraindications to treatment with endothelin receptor antagonist. Participants who have had certain malignancies or are pregnant or breastfeeding are also excluded.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial includes patients who have been diagnosed clinically with type 2 diabetes for at least 6 months and are currently being treated with oral anti-diabetic drugs, basal insulin, or a combination of both. The trial also includes patients with a body mass index (BMI) below or equal to 40.0 kg/m^2 and HbA1c levels within a certain range. However, patients with a history of cancer, cardiovascular disease, uncontrolled severe hypertension, or who are pregnant or breastfeeding are excluded from the trial. The trial involves the use of insulin degludec and insulin glargine as drugs. The eligibility criteria for the trial are listed in detail under inclusion and exclusion criteria.",
    "The sample is a phase 3 clinical trial for Parkinson's disease. The eligibility criteria for participants include having a diagnosis of idiopathic PD for less than 5 years, being on a stable regimen of treatment for at least 5 weeks if receiving amantadine and/or anticholinergics, having a UPDRS Part 3 score of at least 10, a Hoehn and Yahr Stage of 3 or less, being between 30 and 85 years old, and meeting certain clinical laboratory test results. Exclusion criteria include having drug-induced or atypical Parkinsonism, cognitive impairment, bipolar disorder, untreated major depressive disorder, schizophrenia, or other psychotic disorder, having had surgery for PD, having a history of repeated strokes with stepwise progression of Parkinsonism or head injuries, or a stroke within 6 months of screening, and having certain medical conditions or taking certain medications. Participants must also agree to use a highly effective method of birth control if sexually active or planning to be sexually active.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is looking for participants who have locally advanced or metastatic disease that is of non-squamous histology and are \"light ex-smokers\" or \"never-smokers\" of East Asian ethnicity. The trial is excluding participants with clinically significant third-space fluid collections, clinically active interstitial lung disease, and those whose Epidermal Growth Factor Receptor (EGFR) mutation status is known prior to study entry. The trial is testing the effectiveness of a combination of drugs including pemetrexed, cisplatin, and gefitinib. The eligibility criteria for the trial include a histological diagnosis of NSCLC, no prior systemic therapy for lung cancer, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
    "The sample is a phase 3 clinical trial for the treatment of metastatic melanoma. The trial involves the use of two drugs, tasisulam-sodium and paclitaxel. The eligibility criteria for the trial include having a histologic and/or cytologic diagnosis of metastatic melanoma, having the presence of evaluable disease, having a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) Scale, having progressed after 1 previous systemic treatment containing dacarbazine or temozolomide for metastatic melanoma, and having discontinued all previous therapies for cancer for at least 30 days before study enrollment. The trial also has exclusion criteria, such as having received greater than or equal to 2 previous chemotherapy-containing systemic treatment regimens for metastatic melanoma, having active central nervous system (CNS) or leptomeningeal metastasis, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease. The trial is testing the effectiveness of various drugs, including tiotropium and olodaterol, in treating the disease. The eligibility criteria for the trial include a diagnosis of COPD, relatively stable airway obstruction, a smoking history of more than 10 pack years, and being 40 years of age or older. Exclusion criteria include significant disease other than COPD, clinically relevant abnormal lab values, and a history of asthma or other conditions. Patients who are pregnant or nursing, unable to comply with medication restrictions, or have a known hypersensitivity to certain drugs are also excluded.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial includes patients with unresectable stage 111B with pericardial or pleural effusion or stage IV or recurrent non-squamous NSCLC. The trial involves the use of drugs such as amg 706, placebo, paclitaxel, and carboplatin. The eligibility criteria include measurable or non-measurable disease per modified RECIST criteria, ECOG performance status of 0 or 1, life expectancy of greater than or equal to 3 months, ability to take oral medications, and competency to give written informed consent. The exclusion criteria include untreated or symptomatic central nervous system metastases, prior chemotherapy for advanced non-squamous NSCLC, and any prior targeted therapies. The trial also has various other exclusion criteria related to medical conditions, surgeries, and pregnancy.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of epilepsy. The trial involves the drug lacosamide and the eligibility criteria include a diagnosis of epilepsy and completion of a double-blind trial. The exclusion criteria include taking any other investigational drug besides lacosamide and meeting withdrawal criteria from the double-blind trial. The diseases are listed as 'epilepsy' and the icd-10 codes associated with it are also provided.",
    "The sample is a phase 3 clinical trial for colorectal cancer. The trial is testing the effectiveness of the drugs folfox and cetuximab. The eligibility criteria for the trial includes having histologically confirmed stage III adenocarcinoma of the colon, having undergone curative resection within the past 28-56 days, and having a carcinoembryonic antigen (CEA) level that is no more than 1.5 times the upper limit of normal (ULN) after surgery. Patients must also have a performance status of WHO 0-1, a life expectancy of at least 5 years, and meet certain hematopoietic, hepatic, renal, and cardiovascular criteria. Patients must not have had prior chemotherapy or abdominal or pelvic irradiation, and must not have any other significant disease that would preclude study participation.",
    "The sample is a phase 3 clinical trial for chronic lymphocytic leukemia. The trial is testing the effectiveness of obinutuzumab, rituximab, and chlorambucil drugs. The eligibility criteria for the trial include being an adult over 18 years old, having documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL), and having previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria. The exclusion criteria include prior CLL therapy, transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation), history of other malignancy, positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing, and active infection requiring systemic treatment.",
    "The sample is a phase 3 clinical trial for the treatment of interstitial cystitis and painful bladder syndrome. The trial involves testing the effectiveness of mycophenolate mofetil and mycofenolate mofetil (mmf) compared to a placebo. The eligibility criteria for participants include being at least 18 years old, having a confirmed diagnosis of PBS/IC, experiencing symptoms of urinary frequency and pain/discomfort, and having failed at least 24 weeks of active treatment with a minimum of 3 standard forms of therapy. Exclusion criteria include a history of cancer or pre-malignant conditions, bladder calculus, tuberculous cystitis, neurologic disease affecting bladder function, and current immunocompromised conditions. Women with child-bearing potential must agree to use two reliable/medically approved methods of birth control. Men with chronic bacterial prostatitis or suspicious prostate exam are excluded, while women who are lactating, pregnant, or experiencing symptoms only during menses are also excluded.",
    "The sample is a phase 3 clinical trial for breast neoplasms, with a list of icd-10 codes for related diseases. The trial involves two drugs, epirubicin, cyclophosphamide and docetaxel, and docetaxel, cyclophosphamide. The eligibility criteria include being younger than 35 but at least 18 years old, having a hormone receptor-negative tumor and being between 35 and 75 years old, or having a hormone receptor-positive tumor and being between 35 and 59 years old with certain characteristics. Inclusion criteria include having signed informed consent, having histologically confirmed invasive breast carcinoma, and having a TOP2A normal tumor. Exclusion criteria include pregnancy or breast-feeding, previous medical cancer treatment with certain drugs, distant metastases or bilateral breast cancer, other active malignancies, a comorbidity score greater than 3, treatment with a non-approved product or test product in the last 30 days, and known severe hypersensitivity to certain drugs or auxiliary agents.",
    "The sample is a phase 3 clinical trial for the treatment of Restless Legs Syndrome. The trial is open to male and female out-patients aged 18-80 years who have been diagnosed with idiopathic Restless Legs Syndrome (IRLS) according to the clinical Restless Legs Syndrome (RLS) criteria of the International Restless Legs Syndrome Study Group (IRLSSG). The trial requires participants to have a Restless Legs Syndrome (RLS) rating scale for severity total score >15 and RLS symptoms present at least 2 to 3 days per week during the last 3 months. The trial involves the use of the drugs pramipexole and placebo. The eligibility criteria and exclusion criteria are listed in detail in the sample.",
    "The sample is a phase 3 clinical trial for the treatment of melanoma. The trial includes patients with stage III or IV melanoma with one or more metastatic tumors for which surgery is not a curative option. The trial uses drugs such as allovectin-7, allovectin-7/dacarbazine, and dacarbazine. The eligibility criteria include having at least one measurable tumor between 1 cm2 and 100 cm2, no history of brain metastases, and no prior chemotherapy. Patients must also meet certain age, performance status, and health criteria, such as having normal liver and kidney function and no active infections or psychiatric disorders.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of acute coronary syndrome. The trial involves the use of two drugs, rosuvastatin and atorvastatin, and requires patients to meet certain eligibility criteria, such as having been admitted to the hospital for ACS with chest pain or discomfort occurring during rest or with minimal exertion, and evidence of coronary artery disease. The trial also has exclusion criteria, such as hypersensitivity to statins and sustained ST-segment elevation on ECG. The diseases are listed as 'acute coronary syndrome' and the corresponding ICD-10 code is 'I24.0'.",
    "The sample is a phase 3 clinical trial for patients with ovarian cancer or peritoneal cavity cancer. The trial involves the use of carboplatin and pegylated liposomal doxorubicin hydrochloride drugs. The eligibility criteria include confirmed ovarian epithelial carcinoma, stage III or IV disease, no borderline ovarian tumors, and disease progression or recurrence after a progression-free and platinum-free interval of 6-24 months after completion of first-line platinum-based chemotherapy. Patients must also meet certain patient characteristics such as having a Zubrod performance status of 0-1 and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. Prior concurrent therapy is also taken into consideration.",
    "The sample is a record of a clinical trial in phase 3 for chronic obstructive pulmonary disease. The trial includes a list of ICD-10 codes for the disease and a list of drugs being tested, including Symbicort Turbuhaler and any other available COPD treatment as decided by the investigator. The eligibility criteria for the trial include a current clinical diagnosis of COPD, documented COPD symptoms for more than 2 years, and specific lung function measurements. Exclusion criteria include a history or current diagnosis of asthma or atopic diseases, significant or unstable cardiovascular disorders, and recent COPD exacerbations requiring hospitalization or systemic steroids.",
    "The sample is a phase 3 clinical trial for prostate cancer patients who have undergone radical prostatectomy and are considered at high risk for recurrent disease. The trial involves the drug docetaxel and has eligibility criteria related to disease characteristics, patient characteristics, and prior concurrent therapy. The diseases are listed as 'prostate cancer' and the icd-10 codes associated with the disease are also provided. The eligibility criteria include requirements such as negative lymph nodes, a preoperative PSA level of at least 10.0 ng/mL, and no metastatic disease. Patient characteristics include a WHO/ECOG performance status of 0-1, normal hemoglobin, neutrophil count, platelet count, creatinine, bilirubin, AST and ALT levels, and alkaline phosphatase. The sample also specifies that patients should not have any active untreated infectious disease, gastric ulcer, known hypersensitivity to polysorbate 80, symptomatic peripheral neuropathy \u2265 grade 2, myocardial infarction within the past 6 months, other unstable cardiovascular disease within the past 6 months, other serious illness or medical condition, or altered psychological or physical state that would preclude study compliance. Prior concurrent therapy requirements include no prior hormonal therapy affecting prostate cancer cells, no prior radiotherapy to the pelvis, no prior chemotherapy, and no other concurrent anticancer therapy or investigational drugs.",
    "The sample is a phase 3 clinical trial for patients with Alzheimer's disease who have symptoms of delusions or hallucinations. The trial involves two treatment groups: one receiving aripiprazole and the other receiving a placebo. The eligibility criteria include a diagnosis of Alzheimer's disease, a Mini Mental State Examination (MMSE) score of 6 to 24 points, and the ability to self-locomote or use an assistive device. Patients must also have an identified caregiver or proxy. The trial has an extension phase for eligible patients who completed the 10-week acute phase and were deemed suitable for participation in the long-term trial. The exclusion criteria include various psychiatric and medical conditions, substance use disorders, and refractory response to neuroleptics.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients who are 18 years or older with a mean seated systolic blood pressure greater than or equal to 140 mm Hg but less than or equal to 199 mm Hg or a mean seated diastolic blood pressure greater than or equal to 90 mm Hg and less than or equal to 109 mm Hg, following a period of taking only placebo. Patients must also have a mean daytime systolic blood pressure greater than or equal to 135 mm Hg and less than or equal to 199 mm Hg and a mean daytime diastolic blood pressure less than or equal to 109 mm Hg as measured by an ambulatory blood pressure monitoring device (ABPM), after a period of taking only placebo. Female patients must have a negative serum pregnancy test at screening and must practice approved measures of birth control throughout the study. Patients with a history of stroke or transient ischemic attack (TIA) within the last one year, myocardial infarction, coronary angioplasty, coronary artery bypass graft, or heart failure within the past 6 months, secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome, type I diabetes, hemodynamically significant cardiac valvular disease, clinically significant cardiac conduction defects, including second or third degree AV block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication are excluded from the trial. The drugs being tested are amlodipine and olmesartan medoxomil plus amlodipine.",
    "The sample is a phase 3 clinical trial for patients with colorectal cancer who have undergone curative resection and are considered to have stage II or III disease or completely resected stage IV disease with no evidence of residual tumor. The trial involves the use of oxaliplatin-based adjuvant chemotherapy with 85 mg/m^2 oxaliplatin every 2 weeks, along with the drugs calcium gluconate, magnesium sulfate, and oxaliplatin. The eligibility criteria include various disease and patient characteristics, such as ECOG performance status, blood counts, and serum levels, as well as the absence of certain medical conditions and prior treatments. Patients must also be willing to provide a blood sample for research purposes and able to comply with study treatment.",
    "The sample is a phase 3 clinical trial for the treatment of relapsing-remitting multiple sclerosis. The trial involves the use of the drugs natalizumab and placebo. The eligibility criteria for participants include a diagnosis of MS, being between the ages of 18 and 55, having a baseline EDSS score between 0.0 and 5.0, having been treated with Avonex for at least 12 months prior to randomization, and having experienced at least one relapse while on Avonex within the 12 months prior to randomization. Participants must also have given written informed consent to participate in the study. Exclusion criteria include primary progressive, secondary progressive, or progressive relapsing MS, recent MS relapse, significant infectious illness, abnormal lab results, severe allergic reactions or drug hypersensitivity, inability to perform certain tests, and abnormal blood tests at the screening visit.",
    "The sample is a phase 3 clinical trial for osteoarthritis of the knee. The trial includes patients who are able to provide written informed consent, willing to comply with study requirements, and are between the ages of 40 and 85. The index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence. Patients must have moderate to moderately-severe OA pain in the index knee and no analgesia taken 12 hours prior to an efficacy measure. Patients with certain medical conditions or taking certain medications are excluded from the trial. The trial includes the use of low dose ampion, high dose ampion, placebo low dose 4 ml, and placebo 10 ml.",
    "The sample is a phase 3 clinical trial for asthma patients. The trial includes patients who are between 18 and 75 years old and have had a confirmed diagnosis of asthma for at least 3 months. Patients must have been on a stable dose of inhaled corticosteroids for at least 4 weeks prior to the trial. The trial involves the use of various drugs, including a placebo, tiotropium respimat\u00ae low and high doses, and salmeterol hfa mdi. Patients must be able to use the Respimat\u00ae inhaler and metered dose inhaler correctly and perform all trial-related procedures, including pulmonary function tests and the use of electronic diary/peak flow meter. The trial has a list of exclusion criteria, including patients with significant diseases other than asthma, recent history of myocardial infarction, and known active tuberculosis. Pregnant or nursing women and women of childbearing potential not using a highly effective method of birth control are also excluded. Patients who have taken an investigational drug within four weeks prior to the trial and those who have been treated with certain medications within four weeks prior to the trial are also excluded. Patients who have previously been randomized in this trial or in the respective twin trial (205.419) or are currently participating in another trial are also excluded.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial is testing the effectiveness of the drug ranolazine compared to a placebo. The eligibility criteria for participants include being 18 to 75 years old, having a documented history of T2DM, being treatment-naive or having received no prior treatment with antihyperglycemic therapy for at least 90 days, having a BMI between 25 kg/m2 to 45 kg/m2, and having an HbA1c between 7% to 10%. Exclusion criteria include having a history of type 1 diabetes mellitus, severe hypoglycemia, or any clinically significant cardiovascular or cerebrovascular event within the past 3 months. Participants must also be able and willing to comply with all study procedures and use highly effective contraception methods if female and of child-bearing potential.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying the treatment of metastatic prostate cancer. The diseases being studied are \"prostatic neoplasms\" and \"neoplasm metastasis\" and their corresponding ICD-10 codes are listed. The drugs being tested are \"aflibercept\", \"placebo (for aflibercept)\", \"docetaxel\", and \"prednisone or prednisolone\". The eligibility criteria for participants are also listed, including inclusion criteria such as having confirmed prostate adenocarcinoma and metastatic disease, and exclusion criteria such as having prior cytotoxic chemotherapy for prostate cancer or an ECOG performance status greater than 2.",
    "The sample is a phase 3 clinical trial for diabetic retinopathy and diabetic macular edema. The trial involves the use of the drug triamcinolone acetonide and has eligibility criteria for patients with diabetes mellitus, age 18 or older, and at least one eye meeting specific criteria. The trial also has exclusion criteria, such as chronic renal failure, poor glycemic control, and certain ocular conditions. The study eye must have retinal thickening due to diabetic macular edema and meet other specific criteria, while the fellow eye must meet separate inclusion criteria. The trial involves randomization of eyes to receive either intravitreal triamcinolone acetonide or laser treatment.",
    "The sample is a phase 3 clinical trial for patients with myocardial infarction or STEMI. The trial involves the use of two drugs, prasugrel and clopidogrel, and requires patients to meet certain eligibility criteria, such as being between the ages of 18 and 75, having a planned percutaneous coronary intervention, and providing informed consent. However, there are also exclusion criteria, such as being over the age of 75, having a history of stroke or TIA, or being pregnant or nursing. The trial also has specific requirements for the patient's medical history and current health status, such as not having uncontrollable hypertension or a contraindication to prasugrel or clopidogrel.",
    "The sample is a phase 3 clinical trial for the drug flibanserin, aimed at treating HSDD (decreased sexual desire) in premenopausal women who have regular menstrual periods and meet DSM IV-TR criteria. The trial requires patients to meet certain eligibility criteria, such as being in a stable, monogamous, heterosexual relationship, using a medically acceptable method of contraception, and being willing to use an electronic diary on a daily basis. Patients must also meet certain exclusion criteria, such as having a history of drug dependence or abuse, being pregnant or breastfeeding, or having a history of major depressive disorder. The trial aims to evaluate the safety and efficacy of flibanserin in improving sexual function and reducing sexual distress in women with HSDD.",
    "The sample is a phase 3 clinical trial for epilepsy patients who are receiving a stable dose of oral carbamazepine (CBZ) of 1200 mg/day to 2000 mg/day. The trial aims to test the safety and efficacy of intravenous carbamazepine (iv cbz) as a treatment for epilepsy. The eligibility criteria include being at least 18 years old, having a negative pregnancy test, and being diagnosed with any of the approved epilepsy indications for CBZ. The exclusion criteria include having a known hypersensitivity to CBZ, being pregnant or lactating, having a history of drug or alcohol abuse within the past year, and having previously participated in the study. The patients must comply with all study procedures, including complying with protocol-determined dosing intervals, confinement at the investigative site for up to 6 nights and 7 days, and agreeing to participate in the entire study.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are at least 40 years old, have a history of COPD, and are current or former smokers. The trial involves two drugs, fluticasone furoate/vilanterol 100/25mcg and tiotropium bromide 18mcg. The eligibility criteria include various cardiovascular risk factors and exclude patients with other respiratory disorders, abnormal liver or heart function, and certain medical conditions. The trial also excludes patients who are pregnant or lactating, have a history of alcohol or drug abuse, or are unable to comply with study procedures.",
    "The sample is a phase 3 clinical trial for patients with stomach cancer or metastatic neoplasm. The trial involves the use of two drugs, ECC and FOLFIRI, and has specific eligibility criteria for patients to participate. These criteria include being 18 years or older, having a histologically proven adenocarcinoma of the stomach or cardia, having a locally advanced tumor that cannot be treated surgically or a metastatic tumor, and having measurable lesions according to RECIST criteria. Patients must also have a general state WHO score of less than 2 and meet certain laboratory values. Exclusion criteria include disphagy or intestinal obstruction, pregnancy or nursing, previous cardiac toxicity to certain drugs, recent radiotherapy, and other cancers threatening short-term life. Regular follow-up is required for psychological, social, family, or geographical reasons.",
    "The sample is a phase 3 clinical trial for the treatment of thyroid cancer using the drugs XL184 and placebo. The eligibility criteria for the trial include having a confirmed diagnosis of MTC that cannot be removed by surgery, being at least 18 years old, having an ECOG performance status \u2264 2, and having documented worsening of disease at screening compared to a previous CT scan or MRI image done within 14 months of screening. Other criteria include adequate organ and bone marrow function, using medically accepted methods of contraception during the study and for 3 months following discontinuation of study treatments, and having no other diagnosis of cancer unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed \u2265 2 years previously. Exclusion criteria include having received prior treatment for cancer within 4 weeks of randomization, having received radiation to \u2265 25% of bone marrow, having received treatment with other investigational agents within 4 weeks of randomization, having received treatment with XL184, having brain metastases or spinal cord compression, having a history of clinically significant episodes of vomiting blood or a recent history of vomiting > 2.5 mL of red blood, having serious illness other than cancer, being pregnant or breastfeeding, having an active infection requiring ongoing treatment, and being incapable of understanding and complying with the protocol or unable to provide informed consent.",
    "The sample is a phase 3 clinical trial for bipolar disorder. The trial includes patients who have been diagnosed with bipolar 1 disorder and are currently experiencing a mixed or manic episode or are stable. The patients must have had two or more bipolar mood episodes in the last 2 years, excluding the current episode, and must have a negative pregnancy test. The trial excludes patients who have had more than 4 mood episodes a year during the last two years, patients experiencing a depressive episode, patients with a history of antisocial or borderline personality illness, patients with unstable or serious general medical illness, and patients who have received medications disallowed by the study criteria. The trial involves the use of two drugs, risperdal consta and placebo.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer patients who are medically inoperable or unresectable. The trial is testing the effectiveness of cisplatin and gemcitabine hydrochloride as a treatment. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The trial is not allowing concurrent immunotherapy or other experimental medications. The sample also includes detailed requirements for various medical factors such as hematopoietic, hepatic, renal, cardiovascular, and pulmonary conditions. The trial is also limiting the maximum length of the esophagus receiving radiotherapy and excluding 25% of the heart from the boost volume.",
    "The sample is a phase 3 trial for congestive heart failure. The trial includes the drugs candesartan and placebo. The eligibility criteria for the trial includes being 18 years or older, having symptoms of congestive heart failure for more than 4 weeks before starting the study, and providing informed consent. The exclusion criteria includes having current low blood pressure with symptoms, significant liver disease, and being pregnant or lactating.",
    "The sample is a phase 3 clinical trial for patients with rheumatoid arthritis. The trial is testing the effectiveness of a drug called golimumab compared to a placebo. The inclusion criteria for the trial include having a diagnosis of rheumatoid arthritis for at least 3 months, having active RA with at least 4 swollen and 4 tender joints, and having been previously treated with at least one dose of etanercept, adalimumab, or infliximab. Patients must also meet certain criteria for tuberculosis screening and have been on a stable dose of certain medications for a certain amount of time. The exclusion criteria include having other inflammatory diseases, a history of certain treatments or diseases, ongoing infectious disease, and serious infection within 2 months prior to the trial.",
    "The sample is a phase 3 clinical trial for newly diagnosed non-small cell lung carcinoma patients in stage IIIB or stage IV. The trial is testing the effectiveness of the drugs pemetrexed and carboplatin. The eligibility criteria include being over 18 years old, having no prior chemotherapy for NSCLC, having a confirmed non-squamous histological type of NSCLC, and having an ECOG performance status of 2. Patients must also have measurable disease and adequate organ function. Exclusion criteria include having a performance status other than 2, prior chemotherapy for NSCLC, and serious uncontrolled medical or psychiatric illness. Patients must sign an informed consent form and be able to comply with the study's requirements and procedures.",
    "The sample is a phase 3 clinical trial for the treatment of intermittent claudication and peripheral vascular disease using niacin extended release and lovastatin tablets. The trial is open to men and women over the age of 40 who have a history of IC of the lower extremities for at least 6 months with no change in symptoms in the previous 3 months prior to screening. Participants must also have LDL-C of < 160 mg/dL and Triglycerides < 800mg/dL. However, individuals with severe neuropathy, gross obesity, critical limb ischemia, recent surgical or endovascular interventions, documented CAD taking any cholesterol-modifying agent, high blood pressure, clinically significant laboratory test abnormalities for liver or renal function tests or HgbA1C, or a history of alcohol abuse or currently drinks alcohol in excess are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of open-angle glaucoma and ocular hypertension. The trial involves two drugs, travoprost ophthalmic solution 0.004% with sofzia\u00ae preservative system (travatan z\u00ae) and latanoprost ophthalmic solution 0.005% (xalatan\u00ae). The eligibility criteria include being 18 years or older, having a diagnosis of open-angle glaucoma or ocular hypertension in at least one eye, having controlled intraocular pressure with latanoprost 0.005% (XALATAN\u00ae) for at least one continuous month prior to Visit 1, and having a best corrected visual acuity of -0.6 logarithm of the Minimum Angle of Resolution (logMAR) or better in each eye. The exclusion criteria include any medical condition that may preclude safe administration of the test article, use of contact lenses within 30 days of Visit 1, participation in an investigational drug or device study within 30 days of entering this study, and other protocol-defined exclusion criteria may apply.",
    "The sample is a record from a table that contains information about clinical trials. It pertains to a phase 3 trial for the treatment of type 2 diabetes mellitus. The table includes columns for the trial phase, diseases being studied, ICD-10 codes for those diseases, drugs being tested, and eligibility criteria for participants. The sample includes information on the inclusion and exclusion criteria for the trial, such as the requirement for a diagnosis of type 2 diabetes mellitus prior to informed consent and the exclusion of patients with uncontrolled hyperglycemia or liver disease. It also lists the specific drugs being tested, including metformin and bi 10773, as well as placebos at low and high doses.",
    "The sample is a phase 3 clinical trial for asthma. The eligibility criteria include being at least 12 years old, having a diagnosis of asthma for at least 12 months, using a high dose of inhaled glucocorticosteroid for at least 12 weeks prior to screening, and having experienced at least one severe exacerbation requiring a course of oral glucocorticosteroid 2 to 12 months prior to screening. The trial involves testing the effectiveness of three different drugs: mometasone furoate/formoterol (mf/f) combination, mometasone furoate mdi (mf mdi), and a placebo. The trial also includes a list of exclusion criteria, such as having a history of significant QTC prolongation, being a smoker or ex-smoker with a cumulative smoking history >10 pack-years, and having a history of significant medical illness or disorder that could interfere with the study.",
    "The sample is a phase 3 clinical trial for chronic myeloid leukemia. The trial includes patients who have been diagnosed with CP CML within 6 months and have no evidence of extramedullary disease except hepatosplenomegaly. The patients must also have a BCR-ABL fusion demonstrated by the presence of the t(9;22) Philadelphia chromosome. The trial excludes patients who have received prior imatinib, dasatinib, or nilotinib therapy, as well as those who have undergone major surgery within 28 days prior to initiating therapy. Patients with uncontrolled hypertriglyceridemia, uncontrolled hypertension, ongoing or active infection, or a history of human immunodeficiency virus (HIV) are also excluded. The trial requires patients to have adequate hepatic, renal, and pancreatic function, as well as an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. The eligibility criteria also exclude patients with any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the drug.",
    "The sample is a phase 3 clinical trial for arthritis, arthritis rheumatoid, and autoimmune diseases. The trial involves the use of drugs such as golimumab and methotrexate, as well as placebos. The eligibility criteria for participants include having inadequate RA disease control despite treatment with certain medications, receiving a stable dose of methotrexate for at least 4 consecutive weeks, and having a negative tuberculosis test. Exclusion criteria include having a history of certain infections or inflammatory diseases, demonstrating improvement in disease activity before the trial, and having a history of malignancy or lymphoproliferative disease.",
    "The sample is a phase 3 clinical trial for Major Depressive Disorder. The trial includes patients who have a recurrent Major Depressive Episode with a Montgomery and Asberg Depression Rating Scale (MADRS) total score of 30 or higher. The trial excludes patients who are at immediate risk for suicidal behavior, have psychotic features, catatonic features, seasonal pattern or postpartum onset, have a current depressive episode secondary to a general medical disorder, have a lifetime history or presence of bipolar disorder, psychotic disorder, panic disorder and antisocial personality disorder, have severe or unstable concomitant medical conditions, are pregnant, breastfeeding, or likely to become pregnant during the study, or have been treated with escitalopram within 6 months before the study or have had an adverse reaction to escitalopram. The investigator will evaluate whether there are other reasons why a patient may not participate. The trial will test the efficacy of sr58611a, escitalopram, and placebo.",
    "The sample is a phase 3 clinical trial for the treatment of chronic hepatitis C. The trial is testing a combination of pegylated interferon alfa-2b and ribavirin. The eligibility criteria include being diagnosed with chronic hepatitis C, being between 18 and 65 years old, having a certain level of HCV and being suitable for treatment with Pegetron. Participants must also meet certain laboratory values and agree to use contraception during the study. Exclusion criteria include previous interferon-based therapy, active hepatitis B virus infection, HIV positive status, cirrhosis, severe depression or psychoses, epilepsy, illicit drug use, non-compliance with medical regimens, liver disease other than chronic hepatitis C, participation in other clinical studies, recent use of investigational drugs, and being pregnant or planning to become pregnant.",
    "The sample is a phase 3 clinical trial for the treatment of homozygous familial hypercholesterolemia. The trial includes eligibility criteria for participants, such as being at least 18 years old, having a diagnosis of functional homozygous FH, and having stable concurrent lipid lowering medication/apheresis for at least 6 weeks before the baseline visit. Exclusion criteria include uncontrolled hypertension, chronic renal insufficiency, and a history of chronic hepatitis B or C. Participants must also be willing to comply with all study-related procedures. The trial involves the drug aegr-733 and has a list of diseases and icd-10 codes associated with it.",
    "The sample is a phase 3 clinical trial for patients with intracerebral hemorrhage and hypertension. The trial is testing the effectiveness of the drug clevidipine in reducing systolic blood pressure. The eligibility criteria include having a CT evidence of intracerebral hemorrhage, being 18 years or older, having a baseline systolic blood pressure greater than 160 mmHg, and requiring antihypertensive therapy to achieve a systolic blood pressure of 160 mmHg or less. Exclusion criteria include having a Glasgow coma score of less than 5, known liver failure or pancreatitis, and participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment.",
    "The sample is a phase 3 clinical trial for the treatment of bladder neoplasms. The trial involves the use of gemcitabine and placebo drugs. The eligibility criteria for the trial include having clinical evidence of superficial transitional cell carcinoma of the bladder, being at least 18 years old, having a Karnofsky Performance Status greater than or equal to 70%, and being able to comply with the study requirements. Female patients with reproductive potential must use a reliable contraceptive method and have a negative serum pregnancy test within 7 days of study enrollment. Exclusion criteria include having clinical evidence of muscle-invasive or locally advanced bladder cancer, distant metastases, or other serious concomitant disorders that would compromise the safety of the patient or their ability to complete the study according to the protocol.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe hypertension in European patients. The trial involves the use of multiple drugs, including olmesartan medoxomil/hydrochlorothiazide tablets, and a placebo. The eligibility criteria for the trial include being 18 years or older, having moderate to severe hypertension, and not having any serious disorders that may limit the ability to evaluate the efficacy or safety of the study medication. Exclusion criteria include being pregnant or lactating, having a history of certain medical conditions within the last six months, having clinically significant abnormal laboratory values at screening, and having secondary hypertension.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial includes male and female subjects between the ages of 18 and 60 who have been diagnosed with schizophrenia for at least 3 years and require chronic treatment with an anti-psychotic medication. The trial involves the use of several drugs, including aripiprazole depot and aripiprazole orally, as well as placebo treatments. The eligibility criteria include the ability to provide written informed consent, understanding of the study and protocol requirements, and the absence of certain medical conditions or drug dependencies. The exclusion criteria include a history of certain mental disorders, substance dependence, and allergies or hypersensitivity to certain medications.",
    "The sample is a phase 3 clinical trial for asthma patients between the ages of 12 and 17. The trial involves testing the effectiveness of two different doses of tiotropium respimat inhaler compared to a placebo respimat inhaler. The eligibility criteria for the trial includes having a confirmed diagnosis of asthma, being on a stable medium dose of inhaled corticosteroids for at least 4 weeks prior to the trial, and having a pre-bronchodilator FEV1 between 60% and 90% of predicted normal. Patients must also be symptomatic and have an Asthma Control Questionnaire mean score of 1.5 or higher. Exclusion criteria includes having a significant disease other than asthma, clinically relevant abnormal screening haematology or blood chemistry, and a history of congenital or acquired heart disease. Patients must also be able to use the Respimat inhaler correctly and perform all trial-related procedures.",
    "The sample is a phase 3 clinical trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD). The trial includes male and female adults aged 40 years or older with a smoking history of at least 10 pack years. The trial involves the use of drugs such as qva149, tiotropium, and formoterol, as well as placebos. The trial has inclusion criteria such as post-bronchodilator FEV1 < 80% and \u226530% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) <70%, and exclusion criteria such as patients with a history of long QT syndrome, Type I or uncontrolled Type II diabetes, and patients with any history of asthma. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for patients with non-small cell lung cancer and brain metastases. The trial is testing the effectiveness of two drugs, erlotinib hydrochloride and temozolomide, in treating the disease. The eligibility criteria for the trial include having one to three intraparenchymal brain metastases, no prior complete resection of all known brain metastases, and no clinical or radiographic evidence of progression (other than study lesion[s]) within the past month. Patients must also meet certain medical criteria, such as having a performance status of Zubrod 0-1 and hemoglobin levels of at least 8 g/dL. The trial excludes patients with liver metastases, leptomeningeal metastases, or clinically active interstitial lung disease. Patients must not be pregnant or nursing, and must use effective contraception if fertile. The trial also excludes patients with a history of allergic reaction to compounds of similar chemical or biologic composition to erlotinib or temozolomide, and those who are taking certain medications or undergoing certain therapies.",
    "The sample is a phase 3 clinical trial for the treatment of plaque psoriasis. The trial includes patients who have been diagnosed with psoriasis for at least 6 months and have a BSA (body surface area) of 10%, a PASI (psoriasis area and severity index) score of 12 or above, and a PGA (physician global assessment) score of 3 or above. The trial excludes patients who have previously been exposed to either etanercept or ABT-874. The trial uses a placebo as the drug being tested.",
    "The sample is a phase 3 clinical trial for the treatment of attention deficit hyperactivity disorder (ADHD) using methylphenidate hydrochloride extended release capsules and a placebo. The trial is for males and females between the ages of 6 and 12 who have been diagnosed with ADHD and have ADHD-RS-IV scores in the 90th percentile or higher. Participants must be able to have a 2-day washout from previous medication and females of child-bearing potential must not be pregnant and practice birth control. The trial has inclusion and exclusion criteria, including IQ requirements, medical illnesses, and use of certain medications. Participants must be willing to comply with the protocol and provide signed consent and assent. The trial is looking to determine the effectiveness of the treatment and any potential side effects.",
    "The sample is a phase 3 clinical trial for Alzheimer's disease. The eligibility criteria include having a clinical diagnosis of probable Alzheimer's disease, mild to moderate Alzheimer's disease as defined by a MMSE score of 10 to 26, and at least 6 months of ongoing acetylcholinesterase inhibitor therapy for Alzheimer's disease. The trial also requires a brain CT or MRI scan showing no evidence of any other potential cause of dementia other than Alzheimer's disease. In addition, the subject must have a regular caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on the subject's status. The exclusion criteria include a diagnosis of possible, probable, or definite vascular dementia, history or evidence of any other CNS disorder that could be interpreted as a cause of dementia, and history or presence of gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.",
    "The sample is from a phase 3 clinical trial for the treatment of migraine disorders. The trial includes a list of diseases and their corresponding icd-10 codes, as well as a list of drugs being tested (map0004 and placebo). The eligibility criteria for the trial include being between 18 and 65 years old and having a history of episodic, acute migraine. Exclusion criteria include allergies or contraindications to the study drugs, as well as a history of certain medical conditions such as chronic pulmonary disease, coronary artery disease, and major psychiatric conditions. The final decision on suitability for study participation is left to the discretion of the Investigator.",
    "The sample is a phase 3 clinical trial for patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with airflow obstruction of level 2 and 3. The trial includes patients with Forced Expiratory Volume in one second (FEV1) \u2265 30% and <80 % of the predicted normal, and FEV1/ Forced Vital Capacity (FVC) < 0.70 when measured 45 min after the inhalation of 84 \u00b5g ipratropium bromide. The trial excludes patients with a history of long QT syndrome, with a prolonged QTc measured during screening, or patients who have a clinically significant ECG abnormality at screening. Pregnant or nursing (lactating) women are also excluded, as well as women of childbearing potential unless using an effective method of contraception. Patients with a body mass index (BMI) of more than 40 kg/m2 are also excluded. Other protocol-defined inclusion/exclusion criteria may apply.",
    "The sample is a record from a clinical trial table. It is a phase 3 trial for the treatment of multiple sclerosis. The record includes the list of diseases and their corresponding ICD-10 codes, the list of drugs being tested, and the eligibility criteria for the trial. The inclusion criteria include patients between the ages of 18-55 with a diagnosis of relapsing-remitting multiple sclerosis and an Expanded Disability Status Scale (EDSS) score of 0-5.5. The exclusion criteria include patients with other chronic diseases of the immune system, malignancies, acute pulmonary disease, cardiac failure, pregnant or nursing women, and patients who cannot tolerate treatment with an interferon. There are also other protocol-defined inclusion/exclusion criteria applied to the study.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves two drugs, insulin degludec/insulin aspart and insulin glargine, and requires participants to be insulin na\u00efve and have a diagnosis of type 2 diabetes mellitus for at least 6 months. Participants must also have a glycosylated haemoglobin (HbA1c) level between 7.5 - 11.0% and a body mass index (BMI) no higher than 40.0 kg/m^2. The trial has both inclusion and exclusion criteria, including not having been treated with glucagon like peptide-1 (GLP-1) receptor agonists and/or thiazolidinedione(s) within the last 3 months prior to trial start and not having been diagnosed with cardiovascular disease within 6 months before trial start. The trial also has an extension period, which requires participants to have completed the 26-week treatment period in the main trial and not have any anticipated significant lifestyle changes during the trial.",
    "This is a sample from a table that contains information about clinical trials. The trial is in phase 3 and is related to in vitro fertilization. The table includes a list of diseases and their corresponding ICD-10 codes, a list of drugs used in the trial, and eligibility criteria for participants. The eligibility criteria include age, body weight and mass index, menstrual cycle length, availability of ejaculatory sperm, and willingness to sign informed consent. Exclusion criteria include a history of endocrine abnormalities, ovarian hyper-response or hyperstimulation syndrome, polycystic ovary syndrome, and other ovarian abnormalities. The sample also includes criteria related to laboratory values, contraindications for the use of gonadotropins, and previous use of corifollitropin alfa or hormonal preparations.",
    "The sample is a phase 3 clinical trial for the treatment of type 1 diabetes mellitus. The trial includes male and female patients between the ages of 10 and 20 who have been diagnosed with insulin-dependent type 1 diabetes mellitus within the previous 3 months and have a fasting C-peptide level above 0.1 nmol/L and elevated GAD65 antibodies. The trial excludes patients who have been treated with immunosuppressants or any anti-diabetic medications other than insulin, have a history of certain diseases or conditions, have received any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, are participating in other clinical trials with a new chemical entity within the previous 3 months, are pregnant or planning to become pregnant within 1 year after the last Diamyd dose, or have associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study. The trial involves the use of rhgad65, rhgad65, and placebo drugs.",
    "The sample is a phase 3 clinical trial for diabetes, specifically type 1 diabetes. The trial includes patients who have been diagnosed with type 1 diabetes for at least 12 months and have been using injection-based therapies for the last 3 months. The patients must also be currently using any basal insulin and at least three daily meal-time insulin injections. The trial also requires patients to have a maximum HbA1c level of 10.0% and a body mass index (BMI) below or equal to 35.0 kg/m^2. Patients must be able to self-manage their insulin therapy and adhere to the protocol, including performing self-measured plasma glucose (SMPG) profiles and adjusting their insulin doses. Exclusion criteria include recent use of any antidiabetic glucose lowering drug other than insulin, cardiovascular disease within the last 6 months, uncontrolled severe hypertension, pregnancy or intention of becoming pregnant, and a history of cancer (except basal cell skin cancer or squamous cell skin cancer).",
    "The sample is a phase 3 trial for the treatment of gastroesophageal reflux. The trial includes infants who are beyond the neonatal period and are between 28 days and 11 months old, with a weight between 2.5 kg and 15 kg. The trial involves the use of pantoprazole and placebo drugs. The eligibility criteria for the trial include a clinical diagnosis of GERD and the absence of upper GI anatomic disorders, acute life-threatening medical conditions, and clinically significant medical conditions or laboratory abnormalities.",
    "The sample is a phase 3 trial for the treatment of type 2 diabetes and high blood sugar. The trial involves the use of the drugs dapagliflozin and placebo. The eligibility criteria for the trial include providing informed consent, being at least 20 years old, having a diagnosis of type 2 diabetes with a blood sugar level between 6.5% and 10% at 1 week before randomization. Exclusion criteria include having type 1 diabetes, having a fasting blood sugar level above 240 mg/dL before randomization, having a history of unstable or rapidly progressing renal disease, having severe hepatic insufficiency and/or significant abnormal liver function, and having a significant cardiovascular history.",
    "The sample is a phase 3 clinical trial for head and neck cancer patients. The trial includes patients with squamous cell carcinoma of the oropharynx, hypopharynx, or larynx, who have stage III or IV disease. The trial involves the use of cetuximab and cisplatin drugs. The eligibility criteria include various medical tests and assessments, such as physical examination, chest x-ray, CT scan or MRI of the head and neck, and echocardiogram. Patients must also meet certain health requirements, such as adequate bone marrow and hepatic function, and must not have any severe active co-morbidities. The trial has exclusion criteria, such as prior invasive malignancy, prior systemic chemotherapy for the study cancer, and prior severe infusion reaction to a monoclonal antibody.",
    "The sample is a phase 3 clinical trial for the treatment of metabolism and nutrition disorders, obesity, and obstructive sleep apnoea. The trial involves the use of the drug liraglutide and a placebo. The eligibility criteria for the trial include having a body mass index of 30 kg/m^2 or above, a stable body weight, and a diagnosis of moderate or severe obstructive sleep apnoea. Participants must also be unwilling or unable to use continuous positive airway pressure treatment and must be willing to comply with all protocol procedures. Exclusion criteria include a history of diabetes, certain medications, and certain medical conditions.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying chronic constipation and constipation. The ICD-10 codes associated with these diseases are listed. The drugs being tested are linaclotide 290 micrograms, linaclotide 145 micrograms, and a matching placebo. The eligibility criteria for participants are also listed, including requirements such as having completed a colonoscopy and meeting specific criteria for chronic constipation. There are also exclusion criteria listed, such as having a history of loose or watery stools or a disease that could affect gastrointestinal motility.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus. The trial involves the drugs vildagliptin and placebo. The eligibility criteria include being at least 70 years old, having a confirmed diagnosis of T2DM, having an HbA1c level between 7% and 10%, and having a BMI between 19 and 45kg/m2. Exclusion criteria include having a FPG level of 270 mg/dL or higher, previous participation in a vildagliptin clinical study, hypersensitivity to DPP-4 inhibitors, and having a concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample is a phase 3 clinical trial for gastric cancer. The trial includes patients with unresectable advanced or metastatic disease who have confirmed adenocarcinoma of the stomach or gastroesophageal junction. The trial involves the use of three drugs: cetuximab, capecitabine, and cisplatin. The eligibility criteria include written informed consent, age greater than or equal to 18 years, measurable lesions, and Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The exclusion criteria include prior chemotherapy, brain metastasis, and active Hepatitis B or C. The trial also has other medical and psychological conditions that would exclude the subject from the study.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial includes patients who are 40 years or older, have a history of smoking, and have a pre and post-salbutamol FEV1/FVC ratio of less than 0.70 and a post-salbutamol FEV1 of between 30% and 70% of predicted normal values. The trial aims to test the efficacy of several drugs, including umeclidinium bromide/vilanterol and fluticasone propionate/salmeterol, compared to placebo. The eligibility criteria include being an outpatient, having a signed informed consent, and meeting certain medical criteria. The exclusion criteria include pregnancy, asthma, and other respiratory disorders, as well as other medical conditions that may put the patient at risk or affect the efficacy or safety analysis of the trial.",
    "The sample is a phase 3 clinical trial for women who have a history of stage 0-II breast cancer with no more than 4 involved axillary nodes, and no current evidence of disease. The trial is testing the effectiveness of norethindrone acetate in treating menopausal symptoms in women with breast cancer. The eligibility criteria include being female, menopausal or perimenopausal, and having a positive, negative, or unknown hormone receptor status. Patients must also meet certain health requirements, such as having no active liver disease, no prior or concurrent deep vein thrombosis, and no prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix. Prior hormone replacement therapy is allowed if stopped no more than 4 weeks after breast cancer diagnosis and at least 3 months prior to the study. No concurrent chemotherapy or radiotherapy is allowed, and no prior randomization into trials comparing effects of chemotherapy and bilateral oophorectomy in premenopausal women.",
    "The sample is a phase 3 clinical trial for attention deficit hyperactivity disorder. The trial is focused on the drug atomoxetine. The eligibility criteria for the trial includes being an outpatient between the ages of 6 and 12, having a diagnosis of ADHD, and having normal intelligence. Exclusion criteria includes having a weight less than 20 kg or more than 60 kg, having other relevant psychiatric diagnoses, being at serious suicidal risk, having a history of severe allergies, and having alcohol or drug abuse within the past 3 months.",
    "The sample is a phase 3 clinical trial for adults aged 18 and above with primary hypercholesterolemia and a plasma LDL-C level between 145 mg/dL and 250 mg/dL, and plasma TG level below 350 mg/dL after adequate drug washout. The trial involves the use of drugs such as ezetimibe + simvastatin, simvastatin, and placebo. The eligibility criteria include refraining from drinking alcohol or caffeine-containing beverages for 12 hours prior to each study visit, being minimally active, and observing the NCEP Step I diet. The exclusion criteria include pregnancy, smoking, excessive alcohol consumption, and underlying diseases that may interfere with optimal participation in the study. The trial also excludes individuals with certain concomitant illnesses and those using certain drugs, foods, or other agents known to alter lipid levels or cause interactions with either ezetimibe or simvastatin.",
    "The sample is a phase 3 clinical trial for patients with non-ST-segment elevation Acute Coronary Syndrome (NSTE-ACS). The trial involves the use of various drugs, including otamixaban, ufh, and eptifibatide, as well as placebos for each drug. The eligibility criteria for the trial include having ischemic symptoms at rest for at least 10 minutes within 24 hours of randomization, having new ST-segment depression or transient ST-segment elevation in at least 2 contiguous leads on the electrocardiogram, and planned to have a coronary angiography as early as possible and within 36 hours. Patients must also provide informed consent in writing. Exclusion criteria include having already undergone a revascularization procedure for the qualifying event Acute ST-segment elevation MI, having received curative dose of anticoagulant treatment for more than 24 hours prior to randomization, and having an allergy to otamixaban.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe cancer pain. The trial includes participants who are currently receiving strong oral or transdermal opioid analgesics with inadequate pain control or who are expected to require between 40 mg and 184 mg of oral morphine or morphine equivalents every 24 hours for the chronic management of cancer pain. The trial excludes participants with neuropathic pain or pain of unknown origin, acute pain, or a recent history of drug or alcohol abuse. Female participants must use a medically acceptable method of contraception throughout the study. The trial will test the efficacy of hydromorphone hcl, oxycodone hcl cr, and placebo as study medications.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on breakthrough pain and cancer, with a list of associated ICD-10 codes. The drug being tested is fentanyl ethypharm. The eligibility criteria for the trial include written informed consent, a malignant solid tumor or hematological malignancy causing cancer-related pain, and a stable dose of background opioid treatment for at least a week. The trial also requires participants to have one to four episodes of breakthrough pain per day. The main exclusion criteria include hypersensitivity to fentanyl or any of the excipients, intrathecal opioids, recent history of substance abuse, recent or planned therapy that would alter pain, and moderate or severe hepatic or renal disease.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on treating patients with depression, HIV infections, and hepatitis C. The diseases are identified by their ICD-10 codes. The trial involves the use of citalopram and placebos as drugs. The eligibility criteria for the trial include being an HIV-positive adult with chronic HCV infection requiring therapy and having no contraindications to PEG-IFN/ribavirin. The exclusion criteria include having a prior suicide attempt, active depression, treatment with antidepressants within 6 months of study entry, or other psychiatric disorders.",
    "The sample is a phase 3 clinical trial for Parkinson's disease and idiopathic Parkinson's disease. The trial includes participants who have completed a 12-week treatment period of a parent trial and are willing and able to provide written informed consent. Participants must be able to adhere to dose and visit schedules and must be taking L-dopa. They may also be taking additional adjunct PD medications. The trial has inclusion and exclusion criteria, including normal clinical laboratory test results, normal physical examination results, and the use of highly effective birth control for sexually active participants. Exclusion criteria include a history of poorly controlled diabetes or abnormal renal function, elevated liver-related withdrawal criteria, and elevated blood pressure withdrawal criteria. Participants must not have a history of primary or recurrent malignant disease within the past 5 years, and must not have received certain prespecified medications or ingested high tyramine-containing aged cheeses. The trial also excludes participants with allergies or sensitivities to the investigational products or their excipients, and those with any clinically significant condition or situation that would interfere with the trial evaluations or optimal participation.",
    "The sample is from a phase 3 clinical trial for infertility. The trial involves the use of several drugs, including corifollitropin alfa, recfsh, gonadatropin releasing hormone antagonist, human chorion gonadatropin, and placebos. The eligibility criteria for the trial include being a female of couples with an indication for COS and IVF or ICSI, being between 18 and 36 years old, having a body weight of no more than 60 kg and a BMI between 18 and 32 kg/m^2, having a normal menstrual cycle length of 24-35 days, and having ejaculatory sperm available. There are also several exclusion criteria, including a history of endocrine abnormality, ovarian hyper-response or ovarian hyperstimulation syndrome, polycystic ovary syndrome, and other conditions affecting the uterine cavity or ovaries. The sample also includes a list of diseases and their corresponding icd-10 codes.",
    "The sample is a phase 3 clinical trial for osteoporosis. The trial includes a list of icd-10 codes for the disease and a list of drugs being tested, including odanacatib and a placebo for odanacatib. The eligibility criteria for the trial include being a male between 40 and 95 years of age, having osteoporosis, having suitable anatomy for a dual energy x-ray absorptiometry (DXA) scan of the lumbar spine and hip, and being ambulatory. Exclusion criteria include currently being on oral bisphosphonates or other treatment for osteoporosis, having had a previous hip fragility fracture and being a candidate for standard of care therapy, having had a fragility fracture within 12 months, having been diagnosed with metabolic bone disorder other than osteoporosis, being Vitamin D deficient, having a history of renal stones, having active parathyroid disease, having a history of thyroid disease not well controlled by medication, being diagnosed with secondary osteoporosis, having a daily calcium intake of less than 1,200 mg and being unwilling to take study prescribed supplements or increase dietary intake, having a history of malignancy within the past 5 years, and being diagnosed with hypogonadism due to causes that affect multiple organ and body systems.",
    "The sample is a phase 3 clinical trial for the treatment of glaucoma. The trial involves patients who have been diagnosed with glaucoma and have an intraocular pressure (IOP) of 22 mmHg or above in at least one eye. The trial will test the effectiveness of two drugs, timolol and latanoprost. The eligibility criteria for the trial include being 18 years of age or older and not having had prior cyclodestructive procedures or ocular trauma or surgery within 3 months of the baseline visit. The trial will exclude patients who require surgery for acute angle closure.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder using the drug Lu AA21004. The trial includes patients who have completed the double-blind treatment period of a preceding study and have shown improvement in their CGI-S score. The eligibility criteria include signing a written informed consent form, appearing to benefit from long-term treatment with Lu AA21004, and not having any current psychiatric or substance-related disorders, clinically significant neurological or neurodegenerative disorders, or any DSM-IV-TR axis II disorder that might compromise the study. Patients who are at significant risk of suicide or have attempted suicide during the preceding study are excluded from the trial. The diseases are listed as 'major depressive disorder', and the icd-10 codes associated with the disease are also provided.",
    "The sample is a record from a clinical trial table that includes information about the trial's phase, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is focused on chronic obstructive pulmonary disease (COPD). The icd-10 codes associated with COPD are listed as J44.9, J44.1, and J44.0. The drugs being tested are glycopyrronium bromide and a placebo. The eligibility criteria for participants include a diagnosis of moderate-to-severe COPD, a smoking history of at least 10 pack-years, and specific lung function measurements. There are also exclusion criteria, such as recent lower respiratory tract infections, concomitant pulmonary disease, and a history of asthma or lung cancer.",
    "The sample is a phase 3 clinical trial for the treatment of depression. The trial includes patients with chronic hepatitis C infection who have not received antiviral treatment and are over 18 years old. The trial excludes patients who have received antidepressive treatment within the last 3 years, have a history of psychiatric diseases including major depressive disorders, have a history of substance abuse, are pregnant or lactating, have hepatitis B or HIV-coinfection, have decompensated liver disease, hepatocellular carcinoma, or a history of bleeding esophageal varices, have neutropenia, thrombocytopenia, or anemia, have a history of autoimmune disease, have a history of organ transplantation, concomitant liver disease, severe cardiopulmonary disease, hemolytic anemia, or malignant disease. The trial involves the use of escitalopram, placebo, peginterferon alfa-2a, and ribavirin as drugs.",
    "The sample is a phase 3 clinical trial for psoriatic arthritis. The trial includes patients who are at least 18 years old and have been diagnosed with psoriatic arthritis for at least 6 months. Patients must meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at the time of screening and have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs). Patients must have at least 3 swollen and 3 tender joints. The trial allows concurrent treatment with methotrexate, leflunomide, or sulfasalazine, and patients must use contraception. Patients with a history of allergy to any component of the investigational product, hepatitis B surface antigen and/or hepatitis C antibody positive at screening, or therapeutic failure on more than 3 agents for PsA or more than 1 biologic tumor necrosis factor (TNF) blocker are excluded from the trial.",
    "The sample is a phase 3 clinical trial for the treatment of Hepatitis C. The trial is looking at the effectiveness of daclatasvir, peg-interferon alfa-2a, and ribavirin in participants who have not been previously treated with interferon, ribavirin, or HCV direct antiviral agents. The trial is specifically looking at participants who are chronically infected with HCV genotype 1 and have a viral load of at least 10,000 IU/mL at screening. The trial is also looking at participants who are self-described as Black-African American, Latino, or White-Caucasian and have had a liver biopsy obtained \u226436 months prior to first treatment. The trial is excluding participants who have evidence of decompensated liver disease, documented or suspected Hepatocellular carcinoma (HCC), or are positive for Hepatitis B or HIV 1/HIV 2 antibody at screening.",
    "The sample is a phase 3 clinical trial for patients with acquired immunodeficiency syndrome (AIDS) and HIV infections. The trial involves the use of a combination of drugs including pi, rtv, ftc/tdf, and stribild. The eligibility criteria for the trial include being on a stable antiretroviral regimen for at least 6 months, having undetectable plasma HIV 1 RNA levels for at least 6 months, and having no previous use of any approved or experimental integrase strand transfer inhibitor (INSTI). Other criteria include having normal ECG, hepatic transaminases \u2264 5 \u00d7 the upper limit of the normal range (ULN), and adequate hematologic function. The trial also has exclusion criteria such as having a new AIDS-defining condition diagnosed within the 30 days prior to screening, receiving drug treatment for hepatitis C, or having an implanted defibrillator or pacemaker.",
    "The sample is a record from a clinical trial table that includes information about the trial phase, diseases being studied, corresponding ICD-10 codes, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying myelodysplastic syndromes and anemia. The ICD-10 codes associated with these diseases are also listed. The drugs being tested are placebo and epoetin alfa. The eligibility criteria for participants include a diagnosis of MDS via bone marrow studies within 12 weeks before randomization, no prior or concurrent treatment with epoetin alfa or any other approved or experimental erythropoietin stimulating agents within the previous 12 months before randomization, and no history of deep venous thrombosis or arterial thrombosis within the past 12 or 6 months, respectively. Additionally, participants must not have secondary MDS or anemia caused by factors other than MDS and must not have uncontrolled disease or dysfunction deemed clinically significant by the investigator not attributable to MDS.",
    "The sample is a phase 3 clinical trial for patients with cancer and thrombosis. The trial involves the administration of the drugs bemiparin and placebo through a central venous catheter (CVC) for anti-tumoral treatment or any other treatment related to the neoplastic process. The inclusion criteria for the trial include patients over 18 years old who have given their informed consent, have a platelet count above 30,000/mm3, and have no hemorrhagic symptomatology at the time of their inclusion. The exclusion criteria include patients with a history of clinically evident hemorrhagic episodes, major surgery in the past two months, known hypersensitivity to LMWH, heparin or substances of porcine origin, congenital or acquired bleeding diathesis, damage to or surgical interventions of the central nervous system, eyes and ears within the past 6 months, acute bacterial endocarditis or slow endocarditis, history of heparin-associated thrombocytopenia, severe renal failure or hepatic insufficiency, severe arterial hypertension, suspected inability/or inability to comply with treatment and/or complete the study, participation in another clinical trial or have done so in the past 30 days, life expectancy less than 3 months, women who are pregnant or breast-feeding, or with the possibility of becoming pregnant during the study, patients on treatment with anticoagulants or who have been on treatment during the week previous to insert the CVC, and patients diagnosed with acute leukemia or awaiting a transplant from hematopoietic progenitors during the 90 days of the study.",
    "The sample is a record of a clinical trial in phase 3, which is focused on studying the effects of the drug cilnidipine on patients with hypertension and stroke. The diseases being studied are hypertension and stroke, and their corresponding ICD-10 codes are listed. The eligibility criteria for the trial are also provided, including inclusion criteria for ischemic stroke patients with hypertension and exclusion criteria for cardioembolic stroke patients, severe hypertensive patients, and secondary hypertensive patients.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on the treatment of depressive disorder, major. The icd-10 codes associated with the disease are listed as well. The drug being tested is bupropion xl. The eligibility criteria for the trial are also listed, including inclusion criteria such as a primary diagnosis of Major Depressive Disorder with DSM-IV criteria for their current episode for at least 8 weeks, and exclusion criteria such as a history of seizure disorder or brain injury, anorexia or bulimia within the past 12 months, and a past or current DMS-IV diagnosis of schizophrenia or any other psychotic disorder(s). Additionally, patients who have had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for patients with brain edema or brain tumor. The trial involves the use of the drugs hcrf and placebo hcrf. The eligibility criteria include a confirmed diagnosis of a primary malignant brain tumor or documentation of the primary source of cancer if metastatic, the presence of steroid-associated side effects, and the requirement of dexamethasone to control symptoms of peritumoral edema for at least 30 days. Patients must also have a stable dexamethasone dose and a Karnofsky score of >50. Exclusion criteria include ongoing or anticipated need for surgery, radiosurgery or radiation therapy, and serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine metabolic disease. Women of childbearing potential must have a negative serum pregnancy test at screening and must practice birth control during the study.",
    "The sample is a phase 3 clinical trial for the treatment of moderate to severe atopic dermatitis using tacrolimus ointment. The trial is open to both male and female patients of any ethnic group between the ages of 2 and 15 years old. Patients must have a Rajka/Langeland score of at least 4.5 and be known to be responsive to topical steroids. Patients must also meet certain wash-out criteria and not take any medication or therapy prohibited by the protocol during the study period. Exclusion criteria include having a genetic epidermal barrier defect, being pregnant or breastfeeding, having a skin infection on the affected area, having a known hypersensitivity to macrolides or tacrolimus, and having any form of substance abuse or psychiatric disorder that may invalidate communication with the investigator. Patients must also not be HIV positive.",
    "The sample is a phase 3 clinical trial for heart failure, congestive. The trial includes patients who have a history of heart failure for at least 14 days and have been prescribed diuretic therapy. The patients must have also been hospitalized for acute heart failure syndrome requiring IV diuretic therapy and have impaired renal function. The trial excludes patients with acute contrast induced nephropathy, ongoing or planned IV therapy for heart failure with positive inotropic agents, vasopressors, vasodilators, or mechanical support with the exception of IV nitrates, BNP <500pg/mL or NT-pro-BNP <2000 pg/mL, ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis, severe pulmonary disease, significant stenotic valvular disease, heart transplant recipient or admitted for cardiac transplantation, clinical evidence of acute coronary syndrome in the 2 weeks prior to screening, heart failure due to significant arrhythmias, acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy, known hepatic impairment, non-cardiac pulmonary edema, including suspected sepsis, allergy to soybean oil or eggs, history of seizure, stroke within 2 years, history of or current brain tumor of any etiology, brain surgery within 2 years, encephalitis/meningitis within 2 years, history of penetrating head trauma, closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years, history of, or at risk for, alcohol withdrawal seizures, advanced Alzheimer's disease, advanced multiple sclerosis, Hgb <8 g/dL, Hct <25%, or the need for a blood transfusion, and previous exposure to KW-3902. The drugs being tested are rolofylline and a placebo (unspecified).",
    "The sample is a phase 3 clinical trial for patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). The trial includes patients who are current or ex-smokers with a smoking history of at least 10 pack years. Patients must have a post-bronchodilator forced expiratory volume in one second (FEV1) of at least 30% and less than 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) less than 0.7 at Visit 2. The trial excludes pregnant or nursing women, patients requiring long term oxygen therapy, patients with a lower respiratory tract infection within 4 weeks prior to Visit 1, patients with concomitant pulmonary disease, patients with a history of asthma, patients with a history of malignancy of any organ system within the past 5 years, patients with certain cardiovascular comorbid conditions, patients with a known history and diagnosis of alpha-1 antitrypsin deficiency, patients in the active phase of a supervised pulmonary rehabilitation program, and patients contraindicated for treatment with, or having a history of reactions/hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, sympathomimetic amines. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "This sample is for a phase 3 clinical trial for the treatment of venous thromboembolism. The trial involves patients who are scheduled for elective total knee replacement surgery. The trial includes four drugs: rivaroxaban (xarelto, bay59-7939), enoxaparin, and two placebos (one for rivaroxaban and one for enoxaparin). The eligibility criteria for the trial include being 18 years or older and not having active bleeding or a high risk of bleeding that would contraindicate treatment with Low Molecular Weight Heparin (LMWH). The exclusion criteria include having conditions that would prohibit bilateral venography or preclude subject treatment with enoxaparin or require dose adjustment.",
    "This sample is from a clinical trial in phase 3 that is studying the use of the drug amiodarone in patients with either atrial fibrillation or lung cancer. The trial is looking for patients with resectable lung nodules or masses who meet certain inclusion criteria and do not have any of the exclusion criteria, such as allergies to amiodarone or documented atrial fibrillation within the past 12 months. The diseases are listed along with their corresponding ICD-10 codes.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of chronic low back pain using the drug OROS hydromorphone slow release. The trial includes patients who have successfully completed a short-term study with the same drug and require at least 8 mg of hydromorphone HCI every 24 hours for pain management. The record also includes a list of inclusion and exclusion criteria for patient eligibility, such as intolerance to opioids, pregnancy or breastfeeding, gastrointestinal disorders, and CNS disorders.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus. The trial involves the use of drugs such as sitagliptin 50 mg, metformin 500 mg, sitagliptin 100 mg, and placebo, as well as metformin 850 mg. The eligibility criteria for the trial include having type 2 diabetes mellitus, being male or a female who cannot have children or agrees to use birth control during the study, and not being on an antihyperglycemic agent. The exclusion criteria include having type 1 diabetes mellitus or ketoacidosis, taking a dipeptidyl peptidase-4 (DPP-4) inhibitor, being on a weight loss program or medication, having a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer, being HIV positive, or being pregnant.",
    "The sample is a phase 3 clinical trial for liver transplantation and transplantation immunology, focusing on the host vs graft reaction. The trial involves the use of drugs such as prograf-xl, prograf, and mmf. The eligibility criteria for the trial include being a primary liver transplant recipient, receiving the first dose of the drug within 48 hours of transplantation, and having no previous organ transplant other than a liver. Exclusion criteria include having a current malignancy or a history of malignancy within the past 5 years, being pregnant or lactating, and having any form of substance abuse or psychiatric disorder. The trial requires patients to comply with scheduled visits and protocol biopsies.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of relapsing multiple sclerosis. The trial involves the drug fty720 and has eligibility criteria for patients between the ages of 18 and 65 who have relapsing MS. The exclusion criteria include patients with a type of MS that is not relapsing, a history of chronic immune disease, certain cancers, diabetic patients with certain eye disorders, patients on certain immunosuppressive or heart medications, patients with certain heart or lung conditions. There may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a phase 3 clinical trial for the treatment of hypercholesterolemia. The trial is looking for participants who are at least 8 years old and weigh at least 30 kg, and who have homozygous FH (as confirmed by genetic testing or clinical criteria). Participants must also be taking a stable, approved lipid-lowering drug regimen for at least 8 weeks prior to the screening visit and must continue that treatment for the duration of the study. Female participants cannot be pregnant, lactating, planning to become pregnant, and must agree to use adequate contraception throughout the study. The trial has exclusion criteria, including liver or kidney disease, positive hepatitis B or C status, HIV status, inability or unwillingness to discontinue excluded medications, and a history of cancer that had been in remission for less than 5 years prior to the first dose of study drug. Participants must also not have a history of fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain, and must not have any other serious disease or condition that might reduce life expectancy or impair successful management according to the protocol.",
    "The sample is a phase 3 clinical trial for the treatment of squamous cell carcinoma of the head and neck. The trial is testing the effectiveness of two drugs, tegafur-gimeracil-oteracil potassium and tegafur-uracil, in patients who have completed definitive treatment for the disease within the past 3 months. The eligibility criteria include specific disease characteristics, such as the stage and location of the primary tumor, as well as patient characteristics, such as performance status and blood counts. Prior concurrent therapy is also taken into consideration. The sample provides detailed information on the eligibility criteria for the trial, including disease and patient characteristics, as well as prior concurrent therapy.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer patients in stages IIIA, IIIB, and IV. The trial involves the drug carboxyamidotriazole and has two tracks. Track I includes patients who have already undergone standard chemotherapy (with or without TRT) for a minimum of 3 or a maximum of 6 months and have stable or responding disease. Track II includes patients who have not undergone prior chemotherapy for NSCLC and have a life expectancy of at least six months. The eligibility criteria for both tracks include various medical conditions such as ANC, PLT, HgB, and creatinine levels, as well as expected survival of at least three months. The exclusion criteria include untreated brain metastases, planned concurrent chemotherapy, immunotherapy, or radiotherapy, and pregnancy or nursing.",
    "The sample is a record of a clinical trial in phase 3 for the treatment of schizophrenia. The trial includes patients who have completed a previous trial and have demonstrated compliance with the treatment. The trial involves the use of two drugs, asenapine and olanzapine. The eligibility criteria for the trial include meeting demographic and procedural requirements, as well as being judged medically compliant by the investigator. Patients with uncontrolled medical conditions or who have been deemed medically noncompliant are excluded from the trial. The icd-10 codes for the disease are also included in the record.",
    "The sample is a phase 3 clinical trial for the treatment of diabetic macular edema. The trial includes patients who are at least 18 years old and have been diagnosed with diabetes mellitus types 1 or 2. The patients must have a best corrected visual acuity of 19-68 letters and a retinal thickness greater than 250 micron by OCT. The trial involves the use of two drugs, fluocinolone acetonide, and the same drug again. The eligibility criteria include exclusion criteria such as glaucoma, ocular hypertension, IOP >21 mmHg, and prior intravitreal, subtenon, or periocular steroid therapy within 6 months. The trial also excludes patients who have had any ocular surgery within the last 3 months, retinal laser treatment within the last 3 months, a history of uncontrolled IOP elevation with steroid use that did not respond to topical therapy, and any lens opacity that impairs visualization of the posterior pole.",
    "The sample is a phase 3 clinical trial for the treatment of malignant mesothelioma. The trial involves the use of two drugs, doxorubicin hydrochloride and ranpirnase. The eligibility criteria for the trial include having histologically confirmed malignant pleural or peritoneal mesothelioma, measurable or evaluable disease, and meeting certain patient characteristics such as being 21 years or older with an ECOG performance status of 0-1. Patients must also meet certain hematopoietic, hepatic, renal, cardiovascular, metabolic, and other criteria. Prior to the trial, patients must not have received more than one prior systemic chemotherapy regimen and no prior doxorubicin. Prior surgical resection is allowed, and prior radiotherapy for progressive or recurrent disease is also allowed except for myocardium radiotherapy.",
    "The sample is a phase 3 clinical trial for the treatment of cystic fibrosis. The trial involves the use of two drugs, mp-376 (levofloxacin solution for inhalation) and a placebo. The eligibility criteria for the trial include being at least 12 years old, having a confirmed diagnosis of cystic fibrosis, having a positive sputum culture for P. aeruginosa at screening and within the past 12 months, being able to elicit an FEV1 >/= 25% but </= 85% of predicted value at screening, having received at least 3 courses of inhaled antimicrobials over the preceding 12 months, being clinically stable with no changes in health status within the last 28 days, and being able to reproducibly produce sputum and perform spirometry. The exclusion criteria include the use of any nebulized or systemic antibiotics within 28 days prior to baseline, a history of hypersensitivity to fluoroquinolones or intolerance with aerosol medication, evidence of respiratory infections within 14 days prior to dosing, and a CrCl < 20ml/min or < 20ml/min/1.73 m2 at Screening.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia and schizoaffective disorder using the drug ziprasidone. The trial includes patients who are not currently being treated with antipsychotic medication and have been diagnosed with schizophrenia or schizoaffective disorder. Patients who have been treated with antipsychotic medication for less than 5 years are also included. However, patients who are at immediate risk of harming themselves or others, have been treated with clozapine within 3 months prior to baseline, have a history of neuroleptic treatment, or are currently receiving antipsychotic treatment are excluded from the trial. The icd-10 codes for the diseases are also provided.",
    "The sample is a phase 3 trial for the treatment of neuropathic pain using the drug pregabalin. The trial is open to Chinese outpatients between the ages of 18 and 75 who have a score of greater than 40 mm on the visual log scale of SF-MPQ at screening and baseline. The inclusion criteria also specify that the patient must have neuropathic pain. The exclusion criteria state that patients with neurologic disorders unrelated to neuropathic pain or with a serum creatinine clearance greater than 60 ml/min will not be eligible for the trial. The icd-10 codes associated with the disease are also provided.",
    "This is a sample from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria. In this particular sample, the trial is in phase 3 and is focused on asthma. The icd-10 codes associated with the disease are listed, as well as the drugs being tested, which include fluticasone propionate inhalation solution, oral prednisone, placebo inhalation solution, placebo tablet, and salbutamol. The eligibility criteria for the trial include being a Chinese male or female pediatric or adolescent subject aged 4 to 16 years with an established diagnosis of asthma, the ability to properly use a mini-wright peak flow meter, nebulizer and MDI with/without a spacer, and accurately complete a diary card with parental assistance if required. Exclusion criteria include severe respiratory dysfunction, history of mechanical ventilation due to respiratory failure, admission to hospital due to respiratory disease within the previous 2 weeks, and clinical or lab evidence of a serious, uncontrolled systemic disease or presence of any disease likely to interfere with the objectives of this study.",
    "The sample is a phase 3 clinical trial for non-small cell lung cancer. The trial is for adult patients aged 18 years or older who have inoperable, locally advanced or metastatic NSCLC. The patients must have received one prior platinum-based chemotherapy regimen for advanced NSCLC, but must have recovered from any treatment-related toxicity. The trial requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and a life expectancy of at least 12 weeks. Patients must also be current cigarette smokers, having smoked more than 100 cigarettes in their lifetime and currently smoking at least one cigarette per day, and not intending to stop during the study. The trial has exclusion criteria, including prior antibody or small molecule therapy against Epidermal growth factor receptor (EGFR), radiotherapy within 28 days prior to enrollment, and having received more than one line of chemotherapy for locally advanced/metastatic NSCLC (first-line maintenance chemotherapy after first-line platinum-based chemotherapy is allowed).",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes mellitus using insulin degludec/liraglutide and a placebo. The trial is looking for subjects with a stable daily dose of sulphonylurea with or without metformin for at least 90 days prior to screening. The inclusion criteria also require a BMI below or equal to 40 kg/m^2 and an HbA1c level between 7.0-9.0%. The exclusion criteria include any use of oral anti-diabetic drugs other than sulphonylurea in monotherapy or in combination with metformin, previous treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, and any insulin regimen. Other exclusion criteria include certain medical conditions such as cardiovascular disorders, proliferative retinopathy, and active diseases of various systems.",
    "The sample is a phase 3 clinical trial for pancreatic cancer. The eligibility criteria include having histologically confirmed ductal adenocarcinoma of the pancreas or other specified types of cancer, complete macroscopic resection, and no evidence of metastases or spread to other organs. Patients must be 18 or older, have a WHO performance status of 0-2, and a life expectancy of more than 3 months. They must not have received neoadjuvant chemotherapy or have any serious medical or psychological conditions that would preclude study treatment. The trial involves the drugs fluorouracil, gemcitabine hydrochloride, and leucovorin calcium.",
    "The sample is a phase 3 clinical trial for chronic constipation. The trial includes participants who have a history of chronic constipation, defined as having 2 or fewer spontaneous bowel movements per week and experiencing symptoms such as hard stools, incomplete evacuation, and straining for at least a quarter of the time for the last 3 months. Participants who have never had spontaneous bowel movements, have functional constipation, or have irritable bowel syndrome with constipation may also be included. Female participants must be postmenopausal, surgically sterile, or practicing a highly effective method of birth control. Exclusion criteria include participants with other diseases or conditions that may affect bowel habits, severe cardiovascular, liver, or lung disease, neurologic or psychiatric disorders, cancer, or impaired renal function.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking for Japanese male or female patients who are 20 years or older and have essential hypertension. The patients must have a sitting diastolic blood pressure (DBP) of 90 mmHg or more despite more than 4 weeks of treatment with antihypertensive drug. The trial is excluding patients with secondary hypertension or hypertensive emergency, as well as those with sitting diastolic blood pressure (DBP) of 110 mmHg or more or sitting systolic blood pressure (SBP) of 180 mmHg or more. The trial is testing the effectiveness of nifedipine (adalat, baya1040) in treating hypertension.",
    "The sample is a phase 3 clinical trial for patients diagnosed with Chronic Phase Philadelphia chromosome positive (CP Ph+) CML who have failed to achieve CCyR after 3-18 months of therapy with imatinib 400 mg. The trial involves the drugs dasatinib and imatinib and includes a list of diseases and their corresponding icd-10 codes. The eligibility criteria include being able to tolerate chronic administration of imatinib at the highest dose received in the past, having an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2, and having adequate hepatic and renal function. The exclusion criteria include previous diagnosis of accelerated/blast crisis CML, T315I mutation, and concurrent malignancies other than CML.",
    "The sample is a phase 3 clinical trial for patients with heart disease, stroke, ischemic heart disease, or myocardial infarction. The trial is testing the effectiveness of aspirin and warfarin in reducing the risk of stroke and death in patients with reduced left ventricular function. The eligibility criteria include having a cardiac EF of 35% or less, a Modified Rankin score of 4 or less, taking ACE inhibitors or angiotensin II receptor blockers, being able to follow an outpatient protocol, and providing informed consent. Exclusion criteria include recent cardiac surgery, angioplasty, or MI, contraindications to aspirin or warfarin, and comorbid conditions that may limit survival to less than five years.",
    "The sample is a record from a clinical trial table that includes information about the phase of the trial, diseases being studied, icd-10 codes of the diseases, drugs being tested, and eligibility criteria for participants. In this particular sample, the trial is in phase 3 and is studying the effects of aspirin on patients with thrombocytopenia and myocardial infarction. The icd-10 codes for these diseases are listed. The eligibility criteria for participants are also listed, including requirements for platelet count, diagnosis of acute coronary syndrome, and ability to give consent. Exclusion criteria are also listed, such as contraindications to aspirin and certain medical conditions.",
    "The sample is a phase 3 clinical trial for patients with chronic obstructive pulmonary disease (COPD). The trial is testing the effectiveness of a combination of drugs, aclidinium bromide/formoterol fumarate, compared to a placebo. The trial includes patients who are current or ex-cigarette smokers with a smoking history of at least 10 pack-years and have a clinical diagnosis of stable COPD according to the Global Initiative for Chronic Lung Disease \"GOLD\" Guidelines. The trial also has specific inclusion and exclusion criteria, including age, pregnancy status, respiratory and cardiovascular conditions, and medication use. Patients must be able to perform repeatable pulmonary function testing for FEV1 according to American Thoracic Society/European Respiratory Society \"ATS/ERS\" 2005 criteria at Screening Visit. The trial aims to determine the safety and efficacy of the drug combination in treating COPD.",
    "The sample is a phase 3 clinical trial for metastatic colorectal cancer. The trial includes patients with adenocarcinoma of the colon or rectum who have progressed during or within 3 months following the last administration of approved standard therapies. Patients with measurable or non-measurable disease and an Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1 are eligible. The trial also requires patients to have a life expectancy of at least 3 months and adequate bone marrow, liver, and renal function. The trial excludes patients with unstable/uncontrolled cardiac disease, history of arterial or venous thrombotic or embolic events, symptomatic metastatic brain or meningeal tumors, evidence or history of bleeding diathesis, interstitial lung disease, and persistent proteinuria >/= grade 3. The trial will test the efficacy of regorafenib (stivarga, bay73-4506) compared to a placebo.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial is testing the effectiveness of two drugs, technosphere\u00ae insulin and technosphere powder, on patients who have been diagnosed with type 2 diabetes for at least 12 months and are currently receiving only metformin or 2 or more OADs as diabetes treatment. The trial has specific eligibility criteria, including a HbA1c level between 7.5% and 10.0%, a BMI of 45 kg/m2 or less, and no previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at the time of initial diagnosis of diabetes. The trial also has exclusion criteria, such as a history of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease, renal disease or dysfunction, and significant cardiovascular dysfunction or history thereof within 12 months of screening.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on patients with type 2 diabetes mellitus and involves the use of three drugs: rosiglitazone, sulfonylurea, and metformin. The eligibility criteria for the trial include having a glycated hemoglobin level between 7.0% and 9.0%, using an oral glucose lowering agent for at least 6 months prior to screening, and having a body mass index greater than 25.0 kg/m2. Exclusion criteria include having a systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 105 mmHg, having required insulin for glycemic control in the past, and having been hospitalized for a major cardiovascular event in the last 3 months. The sample also includes a list of icd-10 codes associated with the disease.",
    "The sample is a phase 3 clinical trial for the treatment of schizophrenia. The trial is looking at the effectiveness of the drug paliperidone er compared to a placebo. The trial is open to patients who have been diagnosed with schizophrenia for at least one year and have had at least one adequate treatment with an antipsychotic. Patients must also have a PANSS score between 60 and 120 and weigh at least 29 kg. Patients who have comorbid disorders such as ADHD are allowed as long as schizophrenia is the primary diagnosis and the comorbid disorders do not require medication. Patients who are pregnant, planning to become pregnant, or nursing are excluded from the trial. Patients with a history of seizure disorder, neuroleptic malignant syndrome, encephalopathic syndrome, tardive dyskinesia, or insulin dependent diabetes mellitus are also excluded. Additionally, patients with any significant or unstable cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease are excluded.",
    "The sample is a phase 3 clinical trial for the treatment of psoriatic arthritis. The trial includes patients who have had plaque psoriasis for at least 12 months, with at least 10% of their total body surface area affected and a PASI score of 12.0 or more. The trial will test the effectiveness of the drug onercept compared to a placebo. The eligibility criteria include being at least 18 years old, having an out-patient status, and being a candidate for phototherapy or systemic therapy. The exclusion criteria include having abnormal liver or renal function, a history of cancer in the preceding 5 years, and a requirement for immunization or allergy desensitization during the study period. The trial also excludes patients with guttate, erythrodermic, or pustular psoriasis as the sole or predominant form of psoriasis, and those with skin conditions other than psoriasis that would interfere with psoriasis disease assessments.",
    "The sample is a phase 3 clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial includes patients who are at least 40 years old and have a clinical history of COPD. The trial excludes patients with other respiratory disorders, poorly controlled COPD, and certain medical conditions. The trial involves the use of two drugs, fluticasone furoate and fluticasone propionate, and requires patients to meet specific eligibility criteria, including spirometry testing and a negative pregnancy test for female patients. The trial also requires patients to comply with study procedures and scheduled visits.",
    "The sample is a record of a clinical trial with a phase 3 designation, focused on pancreatic cancer. The trial includes a list of diseases and their corresponding ICD-10 codes, as well as a list of drugs being tested. The eligibility criteria for patients participating in the trial are also included, such as age, performance status, and medical history. The prior and concurrent therapies that patients have received are also listed, including chemotherapy, radiotherapy, and surgery.",
    "The sample is a phase 3 clinical trial for breast cancer. The trial includes patients with infiltrating primary breast cancer, stage I-IIIA disease, and a resected tumor with free margins. Patients must have node-negative sentinel node or complete axillary clearance, and treatment is scheduled to begin within 10 weeks from the date of surgery. The trial also includes patients with node positivity or node negativity and certain characteristics such as T > 2 cm, grade 3, presence of lymphovascular invasion, Ki 67 > 20%, age 35 years, hormone receptor negativity (<10%), HER2-positive tumor, and estrogen receptor-positive and/or progesterone receptor-positive disease. The trial is open to female patients who are pre- or postmenopausal with an ECOG performance status of 0-1 and suitable for adjuvant chemotherapy. Patients must meet certain criteria such as WBC > 3,000/mcL, ANC > 1,500/mcL, platelet count >100,000/mcL, total bilirubin normal, AST and ALT 2.5 times upper limit of normal, creatinine normal, and cardiac ejection fraction normal as measured by ECHO or MUGA scan. Patients must not be pregnant or nursing, and fertile patients must use effective contraception during and for \u2265 3 months after completion of study therapy. Patients must have no contraindication to anthracycline, cyclophosphamide, fluorouracil, paclitaxel, or trastuzumab (Herceptin\u00ae) treatment and no uncontrolled intercurrent illness. Prior concurrent therapy is not allowed, and no other concurrent investigational agents are allowed.",
    "The sample is a record of a clinical trial with a phase 3 designation. The trial is focused on HIV infection and involves two drugs, half-boosted fosamprenavir and full boosted fosamprenavir. The eligibility criteria for the trial include being willing and able to provide written consent, having HIV-1 infection, and not being pregnant or breastfeeding. Exclusion criteria include having certain medical conditions, taking medication that may interact with the study medication, and having a history of allergy to any of the study drugs or any excipients therein. Other inclusion/exclusion criteria will be evaluated by the physician. The sample also includes the icd-10 codes for the diseases being studied.",
    "The sample is a phase 3 clinical trial for the treatment of depression in patients with bipolar I disorder. The trial includes patients who have had at least one previous manic or mixed episode and no more than six mood episodes in the last year. The patients must be currently experiencing a major depressive episode that started no less than 2 weeks and no more than 12 months prior to the screening visit. The trial involves the use of either armodafinil or a placebo as a treatment. The patients must have been taking at least one of the allowed mood stabilizers for a minimum of 8 weeks prior to the baseline visit and must continue to take the same mood stabilizer(s) during the screening period. The trial has several inclusion and exclusion criteria, including the exclusion of patients with any Axis I disorder apart from bipolar I disorder, current active suicidal ideation, or a history of an eating disorder or obsessive-compulsive disorder within 6 months of the screening visit or during the screening period.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes patients with a weight between 10 kg and 40 kg, with systolic and/or diastolic blood pressure above the 95th percentile based on height-adjusted charts for age and gender. The trial excludes patients with any clinical condition or laboratory abnormality that may interfere with the study or pose a significant risk to the patient. Patients with hypertension secondary to pheochromocytoma, hyperthyroidism, or Cushing's Syndrome are also excluded. Additionally, patients with renal transplant less than 6 months prior to study entry, nephrotic syndrome not in remission, unstable insulin dependent diabetes mellitus, known bleeding, coagulation, or platelet disorder, clinically significant valvular heart disease, clinical diagnosis of heart failure, clinically significant arrhythmia, second or third degree AV block, impaired liver function, known hypersensitivity to ARBs, currently receiving an angiotensin receptor blocker or an angiotensin converting enzyme inhibitor that cannot safely be withdrawn during the study, or unable or unwilling to comply with the study requirements are excluded. The trial includes patients currently receiving other classes of antihypertensive medications, up to 2 concomitant antihypertensive medications are permitted, and doses and dose regimens of concomitant antihypertensive medications must remain unchanged during the 4-week double-blind period of the study. The trial also includes patients who undergo withdrawal of the antihypertensive medication over a 2-week washout period and subsequently meet BP inclusion/exclusion criteria. The trial requires patients to comply with the study requirements including blood sampling and swallowing study drug suspension.",
    "The sample is a phase 3 clinical trial for the treatment of perennial allergic rhinitis. The trial involves testing several drugs, including ciclesonide hfa nasal aerosol and ciclesonide aqueous nasal spray, as well as placebos. The eligibility criteria for participants include having a history of perennial allergic rhinitis and a demonstrated sensitivity to at least one allergen known to induce the condition. Participants must also be in good health and meet several other criteria, such as not having certain medical conditions and not being pregnant or lactating. The trial has several exclusion criteria, such as a history of drug or alcohol abuse, certain medical conditions, and participation in other clinical trials.",
    "The sample is a phase 3 clinical trial for the treatment of gout. The trial includes subjects who have a history or presence of gout as defined by the American College of Rheumatology criteria and have a serum urate level of at least 8.0 mg/dL at the screening visit. The trial involves the use of two drugs, febuxostat and allopurinol. The eligibility criteria include various inclusion and exclusion criteria, such as not being pregnant or breastfeeding, not having a history of xanthinuria, not being intolerant of allopurinol, and not having active liver disease or hepatic dysfunction. The trial also excludes subjects who have previously participated in a clinical study in which febuxostat was administered or have participated in another investigational trial within the 30 days prior to the study.",
    "The sample is a phase 3 clinical trial for the treatment of type 2 diabetes. The trial is looking at the effectiveness of two different insulin treatments in patients who are already receiving insulin injections. The eligibility criteria include being between 18 and 80 years old, having a clinical diagnosis of type 2 diabetes with a certain level of HbA1c, having a BMI below 40, and not smoking. The trial also excludes patients with certain medical conditions or who have taken certain medications within a certain timeframe. The trial requires written informed consent and adherence to certain testing requirements.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus that is insufficiently controlled with a sulfonylurea alone or in combination with metformin. The trial involves the use of lixisenatide, placebo, sulfonylurea, and metformin as drugs. The eligibility criteria for the trial include having type 2 diabetes mellitus for at least 1 year before the screening visit, being between legal age of majority and 75 years old, and having an HbA1c level between 7% and 10% at screening. Exclusion criteria include having a history of hypoglycemia unawareness, having a body mass index less than or equal to 20 kg/m^2, and having a weight change of more than 5 kg during the 3 months preceding the screening visit. Other exclusion criteria include having a history of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, and other major systemic diseases. The trial also excludes patients with conditions that make them non-evaluable for efficacy assessment, such as use of oral or injectable antidiabetic or hypoglycemic agents other than sulfonylurea and metformin, use of systemic glucocorticoids for 1 week or more within 3 months prior to the time of screening, and use of any investigational drug within 3 months prior to the study. The trial also excludes patients with renal impairment, end-stage renal disease, and clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting. Patients who have had an allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past or to metacresol are also excluded from the trial.",
    "The sample is a phase 3 clinical trial for asthma patients. The eligibility criteria include being at least 12 years old, having a known history of moderate to severe persistent, reversible asthma for at least 6 months, and demonstrating a FEV1 of 50% to 80% for predicted normal values. The trial involves the use of two drugs, flutiform and symbicort turbohaler, and requires participants to substitute their pre-study prescribed asthma medication for the duration of the study. The trial also requires participants to attend all study visits, enter information in an electronic diary, and meet certain exclusion criteria, such as having a history of near-fatal or life-threatening asthma within the past year or known history of systemic corticosteroid medication use within 1 month of the screening visit.",
    "The sample is a phase 3 clinical trial for hypertension. The trial includes untreated hypertensive patients with a systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 100 mmHg or higher, as well as treated hypertensive patients with a systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90 mmHg or higher. Patients with insufficient response to 5 mg of amlodipine in the screening period are also included. The inclusion criteria also require patients to have a screening treatment compliance rate of at least 80%. Exclusion criteria include subjects with secondary hypertension, severe hypertension, and malignant hypertension. The trial involves the use of amlodipine as a drug.",
    "The sample is a record of a clinical trial in phase 3 for Parkinson's disease. The disease is identified by the ICD-10 code \"G20\". The drug being tested is called \"parcopa\". The eligibility criteria for the trial includes having stable Parkinson's disease, while exclusion criteria includes having idiopathic PD with Hoehn and Yahr state II or III.",
    "The sample is a phase 3 clinical trial for postmenopausal women aged 40 to 80 years with a diagnosis of vulvar and vaginal atrophy (VVA). The trial is assessing the effectiveness of ospemifene 60mg oral tablet. The inclusion criteria require participants to have completed a previous study without any clinically significant abnormal findings, not have a uterus, and provide written informed consent. The exclusion criteria include having clinically significant abnormal findings at a previous study visit or having any physical or mental condition that may interfere with the subject's ability to comply with the study procedures. The diseases being studied are atrophy and vaginal diseases, and the icd-10 codes associated with these diseases are listed. The eligibility criteria are also provided in detail.",
    "The sample is a phase 3 clinical trial for patients with type 2 diabetes mellitus who have been diagnosed for at least 1 year and are currently under premix insulin therapy, with or without oral anti-diabetic drug (OAD). The trial involves two drugs, insulin human/insuman comb 25 (hr1799) and insulin human/novolin\u00ae 30r. The eligibility criteria include having a signed written informed consent, HbA1c levels between 7% and 10% at screening, and self-monitoring of blood glucose within 3 months prior to screening visit. The exclusion criteria include premix insulin treatment for less than 3 months, treatment with insulins other than premix insulin within 3 months prior to screening visit, and treatment with a stable OAD dose and regimen for less than 3 months prior to screening visit. The sample is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "The sample is a phase 3 clinical trial for individuals with diabetes mellitus type 2 and documented coronary heart disease. The trial is testing the effectiveness of a combination of drugs, including ezetimibe and simvastatin, in lowering LDL cholesterol levels. The eligibility criteria include having controlled diabetes, a certain range of LDL cholesterol levels, and being on a stable regimen of simvastatin. Participants must also meet various health requirements and agree to adhere to the study procedures. The trial excludes individuals with certain medical conditions or who are taking certain medications.",
    "The sample is a phase 3 clinical trial for osteoarthritis knee pain. The trial involves the drugs duloxetine and placebo. The eligibility criteria for the trial include being a male or female outpatient with osteoarthritis knee pain, and not having certain medical conditions or taking certain medications. The exclusion criteria include having certain medical conditions, previous exposure to duloxetine, having a BMI over 40, and daily use of narcotics.",
    "The sample is a phase 3 clinical trial for patients with ovarian or peritoneal cancer. The trial involves the use of several drugs, including paclitaxel, carboplatin, and bibf 1120, as well as a placebo. The eligibility criteria for the trial include a confirmed diagnosis of ovarian or peritoneal cancer, a certain stage of the disease, and a life expectancy of at least 6 months. Patients must also meet certain performance and laboratory criteria, and cannot have certain medical conditions or be pregnant or breastfeeding. The trial also has exclusion criteria, such as a history of certain medical conditions or prior treatment with certain drugs.",
    "The sample is a phase 3 clinical trial for hypertension. The trial is looking at the effectiveness of two drugs, amlodipine/losartan and amlodipine. The eligibility criteria for the trial include being 18 years or older, having a blood pressure within a certain range, and not having certain medical conditions or taking certain medications. The trial also has exclusion criteria, such as having a history of alcohol or drug abuse or being pregnant. The sample includes a list of diseases and their corresponding ICD-10 codes.",
    "The sample is a phase 3 clinical trial for patients with renal failure. The trial involves administering IL-2 receptor antagonist induction therapy, MMF, corticosteroids, and tacrolimus to patients who are receiving a primary or secondary renal allograft from a deceased donor or non-HLA identical living donor. The trial has specific inclusion and exclusion criteria, including being between 18 and 70 years old, having no known contraindications to the study drugs, and having a negative pregnancy test. Patients with certain medical conditions or who are taking certain medications are excluded from the trial. The trial also excludes patients with a history of alcohol or drug abuse, as well as those with certain cardiac, pulmonary, or hepatic disorders. Patients who are unwilling to refrain from consuming grapefruit or grapefruit-containing juices are also excluded. The trial aims to evaluate the safety and efficacy of the study drugs in patients with renal failure.",
    "The sample is a phase 3 clinical trial for the treatment of major depressive disorder. The trial is focused on patients who are currently being treated with selective serotonin reuptake inhibitor (SSRI) monotherapy and are experiencing treatment-emergent sexual dysfunction (TESD). The trial aims to test the efficacy of vortioxetine and escitalopram compared to a placebo. The eligibility criteria include being between 18 and 55 years old, having a stable condition with a Clinical Global Impression Scale-Severity of Illness Scale (CGI-S) score of \u22643, and experiencing TESD. Exclusion criteria include having a history of psychiatric disorders other than major depressive disorder, substance abuse or dependence, neurological disorders, and sexual dysfunction associated with an etiology other than SSRI treatment or current major depressive episode. The trial also excludes individuals who are nonsexually active or anticipate decreasing frequency of sexual activity during the course of the study.",
    "This sample is for a phase 3 clinical trial for the treatment of advanced colorectal cancer. The trial includes patients who have failed previous therapies, including fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and anti-EGFR antibody therapies for K-ras wild-type patients. Patients who had oxaliplatin discontinued due to toxicity are also eligible. Patients must not have had prior exposure to capecitabine in the metastatic colorectal cancer setting, except for limited-course radiosensitizing capecitabine. Patients must have at least one measurable lesion by RECIST criteria. Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe reaction to 5-FU are excluded from the trial."
]